<SEC-DOCUMENT>0001193125-23-086961.txt : 20230331
<SEC-HEADER>0001193125-23-086961.hdr.sgml : 20230331
<ACCEPTANCE-DATETIME>20230331090930
ACCESSION NUMBER:		0001193125-23-086961
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		102
FILED AS OF DATE:		20230331
DATE AS OF CHANGE:		20230331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Surrozen, Inc./DE
		CENTRAL INDEX KEY:			0001824893
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				981556622
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-259496
		FILM NUMBER:		23783595

	BUSINESS ADDRESS:	
		STREET 1:		171 OYSTER POINT BLVD
		STREET 2:		SUITE 400
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-475-2820

	MAIL ADDRESS:	
		STREET 1:		171 OYSTER POINT BLVD
		STREET 2:		SUITE 400
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Consonance-HFW Acquisition Corp.
		DATE OF NAME CHANGE:	20200915
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>d491933dposam.htm
<DESCRIPTION>POS AM
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:srzn="http://Consonance.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>POS AM</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To12_31_2022">true</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2022To12_31_2022">2022</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2022To12_31_2022">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="hidden73306884" contextRef="P01_01_2022To12_31_2022">Surrozen, Inc./DE</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To12_31_2022">0001824893</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden73306899" contextRef="P01_01_2022To12_31_2022">CA</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden73306900" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">CA</ix:nonNumeric><ix:footnote id="FN_253467" xml:lang="en-US">They are included in cash and cash equivalents on the consolidated balance sheets as of December 31, 2022 and 2021.</ix:footnote ><ix:footnote id="FN_253468" xml:lang="en-US">See the definition and discussion of Public Warrants, Private Placement Warrants and PIPE Warrants in Note 11. </ix:footnote ><ix:footnote id="FN_253469" xml:lang="en-US">The change in fair value of the warrant liabilities was recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. </ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="srzn-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_12_2022To12_12_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-12-12</xbrli:startDate> <xbrli:endDate>2022-12-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_12_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2021To08_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-01</xbrli:startDate> <xbrli:endDate>2021-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To10_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:CorporateBondMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:GovernmentBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ForeignBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:ForeignBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LetterOfCreditMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >srzn:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LincolnParkMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >srzn:LincolnParkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:GovernmentBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:CorporateBondMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:GovernmentBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:GovernmentBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:GovernmentBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:CorporateBondMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:CorporateBondMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:CorporateBondMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >srzn:EightYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >srzn:TwoThousandTwentyOneStockPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >srzn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteTaxYearMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >srzn:IndefiniteTaxYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStock1MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >srzn:CommonStock1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStock2MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >srzn:CommonStock2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_GuggenheimSecuritiesLlcMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >srzn:GuggenheimSecuritiesLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:CorporateBondMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:ForeignBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:GovernmentBondsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LetterOfCreditMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >srzn:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:ForeignBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:ForeignBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:ForeignBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:ForeignBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:GovernmentBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:GovernmentBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:GovernmentBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:GovernmentBondsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:CorporateBondMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:CorporateBondMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:CorporateBondMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:CorporateBondMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_WarrantToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >srzn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_UnvestedCommonStockSharesSubjectToRepurchaseMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >srzn:UnvestedCommonStockSharesSubjectToRepurchaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockAwardRSAMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:StockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:StanfordLicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >srzn:StanfordMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_StanfordMemberusgaapRelatedPartyTransactionAxis_UCSFLicenseAndOptionAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >srzn:StanfordMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:UCSFLicenseAndOptionAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >srzn:StanfordMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:DistributedBioSubscriptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FurnitureFixturesAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >srzn:FurnitureFixturesAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FurnitureFixturesAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >srzn:FurnitureFixturesAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_WarrantToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >srzn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_UnvestedCommonStockSharesSubjectToRepurchaseMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >srzn:UnvestedCommonStockSharesSubjectToRepurchaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:CollaborationAndLicenseAgreementWithBiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >srzn:TwoThousandTwentyOneStockPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandFifteenStockPlan1MemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >srzn:TwoThousandFifteenStockPlan1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis" >us-gaap:StockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >srzn:EightYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:EmployeeStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >srzn:TwoThousandTwentyOneStockPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapBalanceSheetLocationAxis_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:CollaborationAndLicenseAgreementWithBiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:AccountsReceivableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:StanfordLicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >srzn:StanfordMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_StanfordMemberusgaapRelatedPartyTransactionAxis_UCSFLicenseAndOptionAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >srzn:StanfordMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:UCSFLicenseAndOptionAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >srzn:StanfordMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:DistributedBioSubscriptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStock1MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >srzn:CommonStock1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStock2MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >srzn:CommonStock2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LincolnParkMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >srzn:LincolnParkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >srzn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_VestedMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >srzn:VestedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_UnvestedMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >srzn:UnvestedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis" >dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2021To08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >srzn:PrivateInvestmentInPublicEntityOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-01</xbrli:startDate> <xbrli:endDate>2021-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_11_2021To08_11_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >srzn:PrivateInvestmentInPublicEntityOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-11</xbrli:startDate> <xbrli:endDate>2021-08-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2021_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2021_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_11_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >srzn:PrivateInvestmentInPublicEntityOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >srzn:PrivateInvestmentInPublicEntityOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2021_SurrozenIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >srzn:SurrozenIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2016_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >srzn:EightYearsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >stpr:CA</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2016-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:CollaborationAndLicenseAgreementWithBiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To10_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >srzn:TwoThousandTwentyOneStockPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2022To11_30_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:CollaborationAndLicenseAgreementWithBiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2016To03_31_2016_MaximumMembersrtRangeAxis_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:StanfordLicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >srzn:StanfordMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-03-01</xbrli:startDate> <xbrli:endDate>2016-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2016To03_31_2016_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:StanfordLicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >srzn:StanfordMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-03-01</xbrli:startDate> <xbrli:endDate>2016-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2018To06_30_2018_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:StanfordLicenseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >srzn:StanfordMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-06-01</xbrli:startDate> <xbrli:endDate>2018-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2016To09_30_2016_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >srzn:DistributedBioSubscriptionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-09-01</xbrli:startDate> <xbrli:endDate>2016-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >srzn:LincolnParkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-01</xbrli:startDate> <xbrli:endDate>2022-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >srzn:LincolnParkMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-01</xbrli:startDate> <xbrli:endDate>2022-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2022To02_28_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-01</xbrli:startDate> <xbrli:endDate>2022-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >srzn:LincolnParkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-01</xbrli:startDate> <xbrli:endDate>2022-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >srzn:LincolnParkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >srzn:LincolnParkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_ClosingSalePriceNotBelow1000PerShareMemberusgaapMeasurementInputTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >srzn:ClosingSalePriceNotBelow1000PerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_ClosingSalePriceNotBelow1200PerShareMemberusgaapMeasurementInputTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >srzn:ClosingSalePriceNotBelow1200PerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_ClosingSalePriceNotBelow1000PerShareMemberusgaapMeasurementInputTypeAxis_LincolnParkMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >srzn:LincolnParkMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >srzn:ClosingSalePriceNotBelow1000PerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_ClosingSalePriceNotBelow1200PerShareMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >srzn:ClosingSalePriceNotBelow1200PerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_27_2022To04_27_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >srzn:LincolnParkMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-27</xbrli:startDate> <xbrli:endDate>2022-04-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >srzn:TwoThousandTwentyOneStockPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2023To01_31_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-31</xbrli:startDate> <xbrli:endDate>2023-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_28_2023To02_28_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-28</xbrli:startDate> <xbrli:endDate>2023-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PIPEWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >srzn:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001824893</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft" > <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqm" > <xbrli:measure>utr:sqm</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Investments" > <xbrli:measure>srzn:Investments</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Employees" > <xbrli:measure>srzn:Employees</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Y" > <xbrli:measure>utr:Y</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_73307291" toRefs="FN_253467"/><ix:relationship fromRefs="Fact_73307292" toRefs="FN_253467"/><ix:relationship fromRefs="Fact_73307293" toRefs="FN_253467"/><ix:relationship fromRefs="Fact_73307294" toRefs="FN_253467"/><ix:relationship fromRefs="Fact_73307316" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307317" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307318" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307319" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307320" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307321" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307322" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307323" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307324" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307325" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307326" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307327" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307328" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307329" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307330" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307331" toRefs="FN_253468"/><ix:relationship fromRefs="Fact_73307374" toRefs="FN_253469"/><ix:relationship fromRefs="Fact_73307375" toRefs="FN_253469"/><ix:relationship fromRefs="Fact_73307376" toRefs="FN_253469"/><ix:relationship fromRefs="Fact_73307377" toRefs="FN_253469"/><ix:relationship fromRefs="Fact_73307378" toRefs="FN_253469"/><ix:relationship fromRefs="Fact_73307379" toRefs="FN_253469"/><ix:relationship fromRefs="Fact_73307380" toRefs="FN_253469"/><ix:relationship fromRefs="Fact_73307381" toRefs="FN_253469"/></ix:resources></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">As filed with the U.S. Securities and Exchange Commission on March&#160;31, 2023. </div></div></div><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-259496</div> </div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">POST-EFFECTIVE </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">AMENDMENT NO. 2 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">TO </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2022To12_31_2022">S-1</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden73306884">SURROZEN, INC.</span> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2022To12_31_2022">2834</ix:nonNumeric></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2022To12_31_2022">98-1556622</ix:nonNumeric></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of<br/>incorporation or organization)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial<br/>Classification Code Number)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer<br/>Identification No.)</div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To12_31_2022">171 Oyster Point Blvd</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2022To12_31_2022">Suite 400</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To12_31_2022">South San Francisco</ix:nonNumeric>, <span style="-sec-ix-hidden:hidden73306899">CA</span> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To12_31_2022">94080</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2022To12_31_2022">650</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2022To12_31_2022">489-9000</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Craig Parker</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">President and Chief Executive Officer </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Surrozen, Inc. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">171 Oyster Point Blvd</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Suite 400</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">South San Francisco</ix:nonNumeric>, <span style="-sec-ix-hidden:hidden73306900">CA</span> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">94080</ix:nonNumeric> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">650</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">489-9000</ix:nonNumeric></div> </div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copy to: </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">John T. McKenna </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cooley LLP </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">3175 Hanover Street </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Palo Alto, California 94304 </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">(650) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">843-5000</div> </div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Approximate date of commencement of proposed sale to the public: </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">As soon as practicable after this Registration Statement is declared effective. </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#160;&#9746; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#9744; </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 15%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 62%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#9746;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">This post-effective amendment will become effective in accordance with the provisions of Section&#160;8(c) of the Securities Act. </div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">EXPLANATORY NOTE </div></div><ix:nonNumeric name="dei:AmendmentDescription" contextRef="P01_01_2022To12_31_2022"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;">This Post-Effective Amendment No.&#160;2 to the Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> (File <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-259496),</div> or the Registration Statement, of Surrozen, Inc., as originally filed with the Securities and Exchange Commission, or the SEC, on September&#160;13, 2021, as amended on November&#160;8, 2021 by Amendment No.1 and declared effective by the SEC on November&#160;9, 2021, as further amended on March&#160;29, 2022 by Post-Effective Amendment No.1 and declared effective on March&#160;29, 2022, is being filed pursuant to the undertakings in Item 17 of the Registration Statement to (i)&#160;include information contained in the Registrant&#8217;s Annual Report on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001824893/000095017023011118/srzn-20221231.htm">Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</span></a> for the fiscal year ended December&#160;31, 2022 that was filed with the SEC on March&#160;31, 2023 and (ii)&#160;update certain other information in the Registration Statement. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No.&#160;2. All applicable registration fees were paid at the time of the original filing of the Registration Statement.</div></div></div></ix:nonNumeric></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">Subject to Completion, Dated March&#160;31, 2023 </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PRELIMINARY PROSPECTUS </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g04a04.jpg" alt="LOGO" />
 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 31,612,348 Shares of Common Stock </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Including up to 7,217,974 Shares of Common Stock Issuable Upon Exercise of Warrants) </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 4,151,323 Warrants to Purchase Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">This prospectus relates to the issuance by us of an aggregate of up to 7,217,974 shares of our common stock, $0.0001 par value per share, or the Common Stock, which consists of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 144,666 shares of Common Stock that are issuable upon the exercise of 144,666 warrants, or the Private Placement Warrants, originally issued in a private placement to the initial stockholder of Consonance Life Sciences, or the Sponsor, in connection with the initial public offering of <span style="white-space:nowrap">Consonance-HFW</span> Acquisition Corp., or Consonance, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 4,006,657 shares of Common Stock that are issuable upon the exercise of 4,006,657 warrants, or the PIPE<span style="font-weight:bold"> </span>Warrants, originally issued connection with a private placement immediately prior to the consummation of the Business Combination, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 3,066,651 shares of Common Stock that are issuable upon the exercise of 3,066,651 warrants, or the Public<span style="font-weight:bold"> </span>Warrants, and, together with the Private Placement Warrants and the PIPE Warrants, the Warrants, originally issued in the initial public offering of Consonance. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We will receive the proceeds from any cash exercise of any Warrants. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">This prospectus also relates to the offer and sale from time to time by the selling securityholders named in this prospectus or their permitted transferees, or the Selling Securityholders, of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 31,612,348 shares of Common Stock consisting of: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 12,020,000 shares of Common Stock issued in a private placement pursuant to subscription agreements, or the Subscription Agreements, entered into on April&#160;15, 2021, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 1,885,000 shares of Common Stock held by the Sponsor following a private placement in connection with the initial public offering of Consonance and subsequent share recapitalization, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 90,000 shares of Common Stock transferred by the Sponsor to the independent directors of <span style="white-space:nowrap">Consonance-HFW</span> Acquisition Corp., </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 144,666 shares of Common Stock issuable upon exercise of the Private Placement Warrants, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 4,006,657 shares of Common Stock issuable upon exercise of the PIPE Warrants, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 1,349,943 shares of Common Stock issuable upon the exercise of stock options, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:2%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 12,116,082 shares of Common Stock and Common Stock issuable upon exercise of Warrants issued to certain former securityholders of Surrozen Operating, Inc. pursuant to the Business Combination Agreement entered into on April&#160;15, 2021. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9.5pt;text-align:left">up to 4,151,323 warrants consisting of 144,666 Private Placement Warrants and 4,006,657 PIPE Warrants. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We will not receive any proceeds from the sale of shares of Common Stock or Warrants by the selling securityholders pursuant to this prospectus. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The selling securityholders may offer, sell or distribute all or a portion of the securities hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any of the proceeds from such sales of the shares of Common Stock or Warrants, except with respect to amounts received by us upon exercise of the Warrants. We will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or &#8220;blue sky&#8221; laws. The selling securityholders will bear all commissions and discounts, if any, attributable to their sale of shares of Common Stock or Warrants. See the section titled &#8220;<span style="font-style:italic">Plan of Distribution.</span>&#8221; </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The Common Stock and Public Warrants are listed on The Nasdaq Capital Market, or Nasdaq, under the symbols &#8220;SRZN&#8221; and &#8220;SRZNW&#8221; respectively. On March&#160;28, 2023, the last reported sales price of our Common Stock was $0.5769 per share and the last reported sales price of our Public Warrants was $0.10 per Public Warrant. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company reporting requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company and a smaller reporting company. We are incorporated in Delaware. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:11.5pt; font-family:Times New Roman"><span style="font-weight:bold">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled </span><span style="font-weight:bold"><span style="font-style:italic">&#8220;</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic"><a href="#toc491933_5">Risk Factors</a></span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">&#8221;</span></span><span style="font-weight:bold"> beginning on page&#160;9 of this prospectus, and under similar headings in any amendments or supplements to this prospectus. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;font-weight:bold;text-align:center">Prospectus dated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023 </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_1">ABOUT THIS PROSPECTUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_2">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_3">FREQUENTLY USED TERMS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_4">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_5">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_6">MARKET AND INDUSTRY DATA</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_7">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_8">DETERMINATION OF OFFERING PRICE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_9">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_10">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_11">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_12">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_13">EXECUTIVE COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_15">PRINCIPAL SECURITYHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_16">SELLING SECURITYHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">154</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_17">DESCRIPTION OF OUR SECURITIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_18">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_19">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_20">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_21">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_22">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc491933_23">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus or any supplement to this prospectus, filed with the Securities and Exchange Commission. Neither we nor the selling securityholders have authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the Securities and Exchange Commission. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The selling securityholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: Neither we nor the selling securityholders, have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference filed with the Securities and Exchange Commission before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in a document incorporated by reference is inconsistent with a statement in another document incorporated by reference having a later date, the statement in the document having the later date modifies or supersedes the earlier statement. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <span style="white-space:nowrap">S-1</span> that we filed with the SEC using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the selling securityholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such selling securityholders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock issuable upon the exercise of any Warrants. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the selling securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the selling securityholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the selling securityholders will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the sections of this prospectus titled &#8220;<span style="font-style:italic">Where You Can Find More Information.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;11, 2021, Legacy Surrozen, Surrozen and Merger Sub (see the section below titled &#8220;<span style="font-style:italic">Frequently Used Terms</span>&#8221; for the meaning of certain capitalized words) consummated the transactions contemplated by the Business Combination Agreement. Prior to the Closing Date, Consonance (i)&#160;changed its jurisdiction of incorporation from Cayman Islands to the State of Delaware by deregistering as an exempted company in the Cayman Islands and domesticating and continuing as a corporation incorporated under the laws of the State of Delaware, and (ii)&#160;changed its name from <span style="white-space:nowrap">Consonance-HFW</span> Acquisition Corp. to Surrozen, Inc., thereafter referred to as Surrozen. Pursuant to the terms of the Business Combination Agreement, a business combination of Legacy Surrozen and Surrozen was effected through the merger of Legacy Surrozen with and into Merger Sub, with Legacy Surrozen surviving as a wholly owned subsidiary of Surrozen. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Surrozen,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to Surrozen, Inc. (f/k/a <span style="white-space:nowrap">Consonance-HFW</span> Acquisition Corp.) and its consolidated subsidiaries (including Legacy Surrozen). References to &#8220;Consonance&#8221; refer to the predecessor company prior to the consummation of the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_2">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the statements contained in this prospectus constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. These forward-looking statements include statements about future financial and operating results of Surrozen; statements about the plans, strategies and objectives of management for future operations of Surrozen; and statements regarding future performance. In some cases, you can identify these forward-looking statements by the use of terminology such as &#8220;outlook,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;approximately,&#8221; &#8220;predicts,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221; &#8220;anticipates&#8221; or the negative version of these words or other comparable words or phrases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements contained in this prospectus reflect Surrozen&#8217;s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. There are no guarantees that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the initiation, cost, timing, progress and results of research and development activities, preclinical or and clinical trials with respect to <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> and potential future drug candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to develop and expand our drug discovery and development capabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain the necessary capital to fund our operations while we conduct clinical trials, seek regulatory approval for our product candidates, and complete the product development process; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to identify, develop and commercialize drug candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the successful development and commercialization of products that compete with our product candidates or receive regulatory approval in advance of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in personnel and availability of qualified personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to manage growth and expand business operations effectively; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effects of macroeconomic conditions, volatile market conditions, and global events, and the actions of U.S. and foreign governments to respond to these events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether the few stockholders who own a large number of shares of our common stock exercise their voting power in a manner that adversely affects the Company or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether we are able to maintain the listing of our Common Stock on Nasdaq; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the increasingly competitive environment in which Surrozen operates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;Surrozen believes&#8221; or &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. Except to the extent required by applicable law, we are under no obligation (and expressly disclaims any such obligation) to update or revise such forward-looking statements whether as a result of new information, future events, or otherwise. For a further discussion of these and other factors that could cause our future results, performance or transactions to differ significantly from those expressed in any forward-looking statement, please see the section titled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; You should not place undue reliance on any forward-looking statements, which are based only on information currently available to us (or to third parties making the forward-looking statements) as of the date of this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_3">FREQUENTLY USED TERMS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Business Combination&#8221; means the transactions contemplated by the Business Combination Agreement, including, among other things, the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Business Combination Agreement&#8221; the Business Combination Agreement, dated as of April&#160;15, 2021, by and among Consonance, Merger Sub and Legacy Surrozen. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Closing&#8221; means the closing of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Closing Date&#8221; means August&#160;11, 2021, the date on which the Closing occurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Consonance&#8221; means <span style="white-space:nowrap">Consonance-HFW</span> Acquisition Corp. (which was <span style="white-space:nowrap">re-named</span> &#8220;Surrozen, Inc.&#8221; in connection with the Domestication). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Consonance IPO&#8221; means Consonance&#8217;s initial public offering, consummated on October&#160;10, 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;DGCL&#8221; means the General Corporation Law of the State of Delaware. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Domestication&#8221; means the continuation of Consonance by way of domestication of Consonance into a Delaware corporation with the ordinary shares of Consonance becoming shares of common stock of the Delaware corporation under the applicable provisions of the Cayman Islands Companies Act (As Revised) and the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Legacy Surrozen&#8221; means Surrozen Operating, Inc., a Delaware corporation, and, unless the context otherwise requires, its consolidated subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Merger&#8221; means the merger of Merger Sub with and into Legacy Surrozen, with Legacy Surrozen continuing as the surviving corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Merger Sub&#8221; means Perseverance Merger Sub Inc., a Delaware corporation and a direct, wholly owned subsidiary of Consonance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;PIPE Financing&#8221; means that certain private placement in the aggregate amount of $120.2&#160;million, consummated immediately prior to the consummation of the Business Combination, pursuant to those certain Subscription Agreements with Consonance, pursuant to which the subscribers purchased 12,020,000 shares of Common Stock at a purchase price of $10.00 per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;PIPE Shares&#8221; means an aggregate of 12,020,000 shares of Common Stock issued to the subscribers in the PIPE Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;PIPE Warrants&#8221; means an aggregate of 4,006,657 warrants issued to the subscribers in the PIPE Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Private Placement Warrants&#8221; means the 144,666 warrants purchased by the Sponsor in connection with the Consonance IPO in a private placement transaction occurring simultaneously with the closing of the Consonance IPO. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Public Warrants&#8221; means the 3,066,651 warrants included as a component of the Consonance units sold in the Consonance IPO, each of which is exercisable, at an exercise price of $11.50, for one share of Common Stock, in accordance with its terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Sponsor&#8221; means Consonance Life Sciences, a Cayman Islands limited liability company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Sponsor Shares&#8221; means the 1,885,000 shares of Common Stock held by the Sponsor following a private placement in connection with the initial public offering of Consonance and subsequent share recapitalization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Surrozen&#8221; means Consonance after the Domestication. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Warrants&#8221; means the PIPE Warrants, the Private Placement Warrants and the Public Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_4">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes thereto and the information set forth in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to transform the treatment of serious disease by fully exploiting the Wnt pathway. We are discovering and developing biologic drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues, for human diseases. Building upon the seminal work of our founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway, we have made breakthrough discoveries that we believe will overcome previous limitations in harnessing the potential of Wnt biology. These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling. As a result of our discoveries, we are pioneering the selective activation of Wnt signaling, designing and engineering Wnt pathway mimetics, and advancing tissue-selective Wnt candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or <span style="white-space:nowrap">R-spondin</span> proteins, which are involved in activation and enhancement of the Wnt pathway, respectively. Given Wnt signaling is essential in tissue maintenance and regeneration throughout the body, we have the potential to target a wide variety of severe diseases, including certain diseases that afflict the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system. In each of these areas, we believe our approach has the potential to change the treatment paradigm for the disease and substantially impact patient outcomes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to exploit the full potential of Wnt signaling by identifying disease states responsive to Wnt modulation, design tissue-selective therapeutics, and advance candidates into clinical development in targeted indications with high unmet need. Our unique approach and platform technologies have led to the discovery and advancement of two lead product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated a Phase 1 clinical trial in the second quarter of 2022 for <span style="white-space:nowrap">SZN-1326,</span> our candidate in development for moderate to severe inflammatory bowel disease, or IBD, with ulcerative colitis, or UC, as our first proposed indication. <span style="white-space:nowrap">SZN-1326,</span> a Fzd5 targeted <span style="white-space:nowrap">bi-specific</span> antibody, is our first development candidate designed using Surrozen&#8217;s SWAP<sup style="font-size:75%; vertical-align:top">&#8482;</sup> technology and targets the <span style="white-space:nowrap">Wnt-signaling</span> pathway in the intestinal epithelium. In preclinical animal models of acute and chronic colitis, <span style="white-space:nowrap">SZN-1326</span> has been shown to transiently activate Wnt signaling in the diseased intestine, stimulate intestinal epithelial regeneration, reduce inflammation and reduce disease activity. In November 2022, we announced that we voluntarily paused enrollment in the single ascending dose, or SAD, portion of our Phase 1 clinical trial evaluating <span style="white-space:nowrap">SZN-1326</span> in healthy volunteers. Following the evaluation of the clinical data and further preclinical work, we will be <span style="white-space:nowrap">re-initiating</span> the Phase 1a clinical trial in healthy volunteers by <span style="white-space:nowrap">mid-2023</span> based on the minimum anticipated biologically effective level (MABEL) and anticipate safety data by the end of 2023. We anticipate initiating a Phase 1b clinical trial in ulcerative colitis patients in 2024 and expect proof of concept data to be potentially available in the second half of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated a Phase 1 clinical trial in the second quarter of 2022 for <span style="white-space:nowrap">SZN-043,</span> our candidate in development for severe alcoholic hepatitis, or AH. <span style="white-space:nowrap">SZN-043,</span> a hepatocyte-specific <span style="white-space:nowrap">R-spondin</span> mimetic bispecific fusion protein targeting ASGR1, is the first development candidate using Surrozen&#8217;s SWEETS<sup style="font-size:75%; vertical-align:top">&#8482;</sup> technology which is designed to mimic the regenerative properties of the protein <span style="white-space:nowrap">R-Spondin</span> by enhancing Wnt signaling in a </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cell-targeted manner. In multiple preclinical animal models of liver injury and fibrosis, <span style="white-space:nowrap">SZN-043</span> has been shown to selectively activate Wnt signaling in the liver, stimulate transient hepatocyte proliferation, improve liver function and reduce fibrosis. We completed enrollment in the second cohort of the <span style="white-space:nowrap">SZN-043</span> Phase 1a single ascending dose clinical trial in 2022 in healthy volunteers. We opened enrollment for the Phase 1a clinical trial in chronic liver disease, enrolled the first patient in the first quarter of 2023 and expect data to be available in the second half of 2023. We anticipate initiating a Phase 1b clinical trial in patients with severe alcoholic hepatitis in 2024 and expect proof of concept data to be potentially available in the second half of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2022, we nominated <span style="white-space:nowrap">SZN-413,</span> a Fzd4 targeted <span style="white-space:nowrap">bi-specific</span> antibody, as a development candidate for the treatment of retinal vascular associated diseases. Fzd4 mediated Wnt signaling is known to play a critical role in retinal vascular integrity and function. Data generated in preclinical models of retinopathy demonstrated <span style="white-space:nowrap">SZN-413</span> stimulated Wnt signaling and was able to induce normal retinal vessel regrowth while suppressing pathological vessel growth. In October 2022, we executed a Collaboration and Licensing Agreement, or CLA, with Boehringer Ingelheim International GmbH, or BI, to research, develop and commercialize Fzd4 <span style="white-space:nowrap">bi-specific</span> antibodies designed using our SWAP technology, including <span style="white-space:nowrap">SZN-413.</span> We anticipate the potential to identify the lead <span style="white-space:nowrap"><span style="white-space:nowrap">Fzd-4-targeted</span></span> Wnt agonist product candidate by the end of 2023, which would trigger a $10.0&#160;million milestone payment to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is located at 171 Oyster Point Blvd., Suite 400, South San Francisco, CA 94080, and our telephone number is <span style="white-space:nowrap">(650)&#160;489-9000.</span> Our corporate website address is<span style="font-style:italic"> www.surrozen.com</span>. Our website and the information contained on, or that can be accessed through, the website is not deemed to be incorporated by reference in, and is not considered part of, this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Implications of Being an Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or JOBS Act, and therefore we intend to take advantage of certain exemptions from various public company reporting requirements that are applicable to other public companies that are not emerging growth companies for as long as we continue to be an emerging growth company, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404(b) of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in this prospectus, our periodic reports and our proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. We will remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal year in which the market value of our Common Stock that is held by <span style="white-space:nowrap">non-affiliates</span> equals or exceeds $700&#160;million as of the end of that year&#8217;s second fiscal quarter, (ii)&#160;the last day of the fiscal year in which we have total annual gross revenue of $1.235&#160;billion or more during such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt in the prior three-year period, (iv)&#160;December&#160;31, 2025, or (v)&#160;the last day of the fiscal year in which we are deemed to be a large accelerated filer. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 171 Oyster Point Blvd, Suite 400, South San Francisco, California&#160;94080 and our telephone number is <span style="white-space:nowrap">(650)&#160;489-9000.</span> Our corporate website address is www.surrozen.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Surrozen and Surrozen&#8217;s subsidiaries own or have rights to trademarks, trade names and service marks that they use in connection with the operation of their business. In addition, their names, logos and website names and addresses are their trademarks or service marks. Other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, in some cases, the trademarks, trade names and service marks referred to in this prospectus are listed without the applicable <sup style="font-size:75%; vertical-align:top">&#174;</sup>, <sup style="font-size:75%; vertical-align:top">&#8482;</sup> and SM symbols, but they will assert, to the fullest extent under applicable law, their rights to these trademarks, trade names and service marks. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">The Offering </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Issuance of Common Stock </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock offered by us </p></td>
<td>7,217,974 shares of Common Stock, including shares of Common Stock issuable upon exercise of the Private Placement Warrants, consisting of (i) 144,666 shares of Common Stock that are issuable upon the exercise of 144,666 Private Placement Warrants (ii)&#160;4,006,657 shares of Common Stock that are issuable upon the exercise of 4,006,657 PIPE Warrants and (iii) 3,066,651 shares of Common Stock that are issuable upon the exercise of 3,066,651 Public Warrants. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock outstanding prior to exercise of&#160;all Warrants </p></td>
<td>30,088,333 shares (as of December&#160;31, 2022). </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock outstanding assuming exercise&#160;of all Warrants </p></td>
<td>37,306,307 shares (based on total shares outstanding as of December&#160;31,&#160;2022). </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Exercise price of Warrants </p></td>
<td>$11.50 per share, subject to adjustment as described herein. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </p></td>
<td>We will receive up to an aggregate of approximately $83.0&#160;million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. We expect to use the net proceeds from the exercise of the Warrants for general corporate purposes. See the section titled &#8220;<span style="font-style:italic">Use of Proceeds</span>.&#8221; </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Resale of Common Stock and Warrants </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock offered by the selling securityholders </p></td>
<td>We are registering the resale by the selling securityholders named in this prospectus, or their permitted transferees, an aggregate of 31,612,348 shares of Common Stock, consisting of: </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:41%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 12,020,000 PIPE Shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:41%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 1,885,000 Sponsor Shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:41%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 90,000 shares of Common Stock transferred by the Sponsor to the independent directors of <span style="white-space:nowrap">Consonance-HFW;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:41%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 144,666 shares of Common Stock issuable upon the exercise of the Private Placement Warrants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:41%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 4,006,657 shares of Common Stock issuable upon exercise of the PIPE Warrants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:41%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 1,349,943 shares of Common Stock issuable upon the exercise of stock options; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:41%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 12,116,082 shares of Common Stock and Common Stock issuable upon exercise of warrants issued to certain former securityholders of Legacy Surrozen pursuant to the Business Combination Agreement. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Warrants offered by the selling securityholders </p></td>
<td>We are registering the resale by the selling securityholders named in this prospectus, or their permitted transferees, an aggregate of 4,151,323 Warrants, consisting of: </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:41%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 144,666 Private Placement Warrants; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:41%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 4,006,657 PIPE Warrants. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Redemption </p></td>
<td>The Public Warrants, PIPE Warrants and Private Placement Warrants are redeemable in certain circumstances. See the section titled &#8220;<span style="font-style:italic">Description of Our Securities&#8212;Warrants.</span>&#8221; </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Lock-Up</span> Agreements </p></td>
<td>Certain of our securityholders are subject to certain restrictions on transfer until the termination of applicable <span style="white-space:nowrap">lock-up</span> periods. See the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions.</span>&#8221; </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the offering </p></td>
<td>The selling securityholders will determine when and how they will dispose of the securities registered for resale under this prospectus. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </p></td>
<td>We will not receive any proceeds from the sale of shares of Common Stock or Warrants by the selling securityholders. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </p></td>
<td>Before investing in our securities, you should carefully read and consider the information set forth in &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page&#160;9. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq ticker symbols </p></td>
<td>&#8220;SRZN&#8221; and &#8220;SRZNW&#8221; </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information concerning the offering, see &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; beginning on page&#160;180. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_5">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing in our securities involves a high degree of risk. Before you make an investment decision with respect to our securities, in addition to the risks and uncertainties discussed above under &#8220;Cautionary Note Regarding Forward-Looking Statements,&#8221; you should carefully consider the risks and uncertainties described below together with all of the other information contained in this prospectus, including our consolidated financial statements and related notes included elsewhere in this prospectus and in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding to invest in our securities. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our securities could decline and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may become material and adversely affect our business. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary of Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Below is a summary of the material factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Our business involves significant risks that may have a material adverse effect on our business, financial condition, results of operations, prospects and stock price. These risks are more fully described below and include, among others: </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are a clinical-stage biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1 clinical trials for <span style="white-space:nowrap">SZN-043</span> in healthy volunteers are ongoing but treatment-related adverse events have been observed, and if these findings continue or worsen, we could require additional capital to complete our clinical trials and development efforts for <span style="white-space:nowrap">SZN-043.</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">None of our products have received regulatory approval; our ability to achieve and sustain profitability depends on obtaining regulatory approval and successfully commercializing product candidates, either alone or with collaborators. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If any current or future product candidate, after it begins clinical trials or receives marketing approval, demonstrates undesirable safety or tolerability side effects or safety concerns, our ability to market and derive revenue from the product candidate could be compromised. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will need substantial additional funds to advance development of product candidates of our Wnt therapeutics platform, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any future equity or debt issuances or other financing transactions may have dilutive or adverse effects on our existing stockholders. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We rely on third parties to conduct our preclinical studies and plan to continue to rely on third parties to conduct clinical trials, and those third parties may not perform satisfactorily. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our clinical development activities could be delayed or otherwise adversely affected for various reasons. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The manufacturing of our product candidates is complex. We and our third-party manufacturers may encounter difficulties in production. If we encounter any such difficulties, our ability to supply our product candidates for clinical trials or, if approved, for commercial sale, could be delayed or halted entirely. </p></td></tr></table> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We face competition from entities that have developed or may develop product candidates for the treatment of the diseases that we may target, including companies developing novel treatments and therapeutic platforms. If these companies develop therapeutics or product candidates more rapidly than we do, or if their therapeutics or product candidates are more effective or have fewer side effects, our ability to develop and successfully commercialize product candidates may be adversely affected. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to maintain proper and effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting and the market price of our common stock may be adversely affected. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our business, operations and clinical development plans and timelines could be adversely affected by the effects of health epidemics, natural disasters and other events on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom it conducts business, including contract manufacturers, CROs, shippers and others. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">To the extent we enter into any other collaborations, we may depend on such collaborations for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collaborations are complex and time-consuming to negotiate and document. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to obtain or protect intellectual property rights related to our technology and current or future product candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Some intellectual property that we have <span style="white-space:nowrap">in-licensed</span> may have been discovered through government funded programs and thus may be subject to federal regulations such as <span style="white-space:nowrap">&#8220;march-in&#8221;</span> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with <span style="white-space:nowrap">non-U.S.</span> manufacturers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Clinical development includes a lengthy and expensive process with an uncertain outcome, we may have negative results and results of earlier studies and trials may not be predictive of future trial results. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have conducted certain of our clinical trials for our product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case its development plans will be delayed, which could materially harm its business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A few stockholders, including one of our directors, may control the voting rights with respect to a large number of shares of our common stock. They could exercise their voting power in a manner that adversely affects the Company or our stockholders. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Business </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are a clinical-stage biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company with a history of losses. Since its inception, we have devoted substantially all of our resources to research and development, preclinical studies, clinical trials, building our management team and building our intellectual property portfolio, and have incurred significant operating losses. Substantially all of our losses have resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with our operations. To date, we have not generated any revenue from product sales, and have not sought or obtained regulatory approval for any product candidate. Furthermore, we do not expect to generate any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials and the regulatory approval process for our current and potential future product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our net losses to increase substantially as our lead product candidates, <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> and <span style="white-space:nowrap">SZN-413,</span> advance through clinical development. However, the amount of our future losses is uncertain. Our ability to achieve or sustain profitability, if ever, will depend on, among other things, successfully developing product candidates, resuming clinical trials for <span style="white-space:nowrap">SZN-1326,</span> continuing clinical trials for <span style="white-space:nowrap">SZN-043,</span> successful development and testing of <span style="white-space:nowrap">SZN-413</span> through our partnership with Boehringer Ingelheim International GmbH, or BI, obtaining regulatory approvals to market and commercialize product candidates, manufacturing any approved products on commercially reasonable terms, entering into potential future alliances, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient funds to finance business activities. If we, or our current and potential future collaborators, are unable to commercialize one or more of our product candidates, or if sales revenue from any product candidate that receives approval is insufficient, we will not achieve or sustain profitability, which could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Phase 1 clinical trials for <span style="white-space:nowrap">SZN-043</span> in healthy volunteers are ongoing but treatment-related adverse events have been observed, and if these findings continue or worsen, we could require additional capital to complete our clinical trials and development efforts for <span style="white-space:nowrap">SZN-043.</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials for <span style="white-space:nowrap">SZN-043</span> are ongoing, but Grade 1 and 2 treatment-related asymptomatic transaminase elevations were present in several subjects dosed with <span style="white-space:nowrap">SZN-043.</span> The transaminase elevations for these subjects resolved spontaneously, and no serious adverse events were observed during the study. We intend to further analyze available clinical data and modify clinical studies as necessary to understand and safely resolve these observations. If these observations continue or worsen, we may need to pause the trials to perform additional <span style="white-space:nowrap">pre-clinical</span> experiments, causing delays in our development plans and requiring additional capital to resume and complete our development efforts and clinical trials for <span style="white-space:nowrap">SZN-043.</span> If we are unable to safely continue the trials for <span style="white-space:nowrap">SZN-043</span> and resolve these observations, development of <span style="white-space:nowrap">SZN-043</span> may be substantially delayed or abandoned and adversely affect our financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">None of our products have received regulatory approval; our ability to achieve and sustain profitability depends on obtaining regulatory approval and successfully commercializing product candidates, either alone or with collaborators. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval for the commercial distribution of our product candidates, we or a collaborator must conduct extensive preclinical studies, followed by clinical trials to demonstrate the safety, purity and potency, or efficacy of our product candidates in humans. There is no guarantee that the U.S. Food and Drug Administration, or the FDA, or other regulatory authorities will permit us to conduct clinical trials. Further, we cannot be certain of the timely completion or outcome of our preclinical studies and cannot predict if the FDA or other regulatory authorities will accept our proposed clinical programs, our clinical protocols or if the outcome of our preclinical studies will ultimately support the further development of our preclinical programs or testing in humans. As a result, we cannot be sure that we will be able to submit Investigational New Drugs, or INDs, or similar applications for our proposed clinical programs on the timeline we expect, if at all, and cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials for any of our product candidates to begin. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the risks of failure inherent in the development of product candidates based on novel approaches, targets and mechanisms of action. There is no guarantee that we will be able to proceed with clinical development of our product candidates or that our product candidates will demonstrate a clinical benefit once we further advance these candidates. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties that we have encountered and that are frequently encountered by clinical stage biopharmaceutical companies such as us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to access the financial resources to continue development of, or to enter into any collaborations for, <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> or any potential future product candidates. This may be exacerbated if </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, a product candidate, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative or inconclusive results from our preclinical or clinical trials (including as described above) or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon any or all of our programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product-related side effects experienced by participants in our clinical trials (such as the asymptomatic transaminase elevations discussed above) or by individuals using drugs or therapeutic antibodies similar to ours, including immunogenicity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in submitting IND applications or comparable foreign applications, or delays or failures to obtain the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conditions imposed by the FDA or other regulatory authorities regarding the scope or design of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in enrolling research subjects in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">high <span style="white-space:nowrap">drop-out</span> rates of research subjects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">chemistry, manufacturing and control, or CMC, challenges associated with manufacturing and scaling up biologic product candidates to ensure consistent quality, stability, purity and potency among different batches used in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">greater-than-anticipated clinical trial costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">poor potency or effectiveness of our product candidates during clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unfavorable FDA or other regulatory authority inspection and review of a clinical trial or manufacturing site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays as a result of the <span style="white-space:nowrap">COVID-19</span> pandemic or events associated with the pandemic; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure of us or Boehringer Ingelheim International GmbH to adequately perform under the Collaboration and License Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays and changes in regulatory requirements, policies and guidelines; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other regulatory authorities interpreting our data differently than it does. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we and our current and potential future collaborator may never receive approval to market and commercialize any product candidate. Even if we or our current and potential future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as were intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or our current and potential future collaborator may be subject to post-marketing testing requirements to maintain regulatory approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> and any future product candidate that is tested in humans may not demonstrate the safety, purity and potency, or efficacy, necessary to become approvable or commercially viable. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may ultimately discover that <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> and <span style="white-space:nowrap">SZN-413</span> do not possess certain properties that we believe are helpful for therapeutic effectiveness and safety. For example, although <span style="white-space:nowrap">SZN-043</span> and <span style="white-space:nowrap">SZN-1326</span> exhibited encouraging results in animal studies, they may not demonstrate the same properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways, as shown by the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
observations of asymptomatic transaminase elevations discussed above. As a result, we may never succeed in developing a marketable product based on any of our current or future product candidates. If <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> or any of our potential future product candidates prove to be ineffective, unsafe or commercially unviable, our entire pipeline could have little, if any, value, which could require us to change our focus and approach to antibody-based discovery and development and materially and adversely affect our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in our efforts to use and expand our Wnt therapeutics platform to build a pipeline of product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to use and expand our Wnt therapeutics platform to discover and develop a portfolio of Wnt product candidates that can facilitate the repair and/or regeneration of damaged tissue for patients suffering from a variety of severe diseases. Although our research and development efforts to date have resulted in the discovery and development of <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> and other potential product candidates, our current product candidates may not be safe or effective therapeutics and we may not be able to develop any successful product candidates. Our platform is evolving and may not reach a state at which building a pipeline of product candidates is possible. Even if we are successful in building its pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. Observations of asymptomatic transaminase elevations in clinical trials of <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043,</span> as announced in November 2022, could also impair our ability to build and expand our Wnt platform if we are unable to successfully resolve those observations. If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although a substantial amount of our efforts will focus on the planned clinical trials and potential approval of our existing product candidates and other potential product candidates we are evaluating, a key element of our strategy is to discover, develop and potentially commercialize additional products beyond our current product candidates to treat various conditions and in a variety of therapeutic areas. We intend to do so by investing in our own drug discovery efforts, exploring potential strategic alliances for the development of new products and <span style="white-space:nowrap">in-licensing</span> technologies. Identifying new investigational medicines requires substantial technical, financial and human resources, whether or not any investigational medicines are ultimately identified. Even if we identify investigational medicines that initially show promise, we may fail to successfully develop and commercialize such products for many reasons, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the research methodology used may not be successful in identifying potential investigational medicines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competitors may develop alternatives that render its investigational medicines obsolete; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">investigational medicines it develops may nevertheless be covered by third parties&#8217; patents or other exclusive rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an investigational medicine may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
through internal research programs, thereby limiting its ability to develop, diversify and expand our product portfolio; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an investigational medicine may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an approved product may not be accepted as safe and effective by trial participants, the medical community or third-party payors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future<span style="font-weight:bold"><span style="font-style:italic"> </span></span>growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market may not be receptive to our current or potential future product candidates, and we may not generate any revenue from the sale or licensing of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if regulatory approval is obtained for a product candidate, including <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043,</span> we may not generate or sustain revenue from sales of approved products. Market acceptance of our current and potential future product candidates, if approved, will depend on, among other factors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of its receipt of any marketing and commercialization approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms of any approvals and the countries in which approvals are obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the safety and efficacy of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of any adverse<span style="font-weight:bold"><span style="font-style:italic"> side effects </span></span>associated with our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">relative convenience and ease of administration of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of its physician education programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of coverage and adequate government and third-party payor reimbursement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the pricing of our products, particularly as compared to alternative treatments; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any product candidate we commercialize fails to achieve market acceptance,<span style="font-weight:bold"><span style="font-style:italic"> </span></span>it could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If any current or future product candidate, after it begins clinical trials or receives marketing approval, demonstrates undesirable safety or tolerability side effects or safety concerns, our ability to market and derive revenue from the product candidate could be compromised. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> or any potential future product candidate could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. While </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we have initiated clinical trials for <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043,</span> we have already experienced findings that have caused us to voluntarily pause clinical trials for <span style="white-space:nowrap">SZN-1326</span> and make adjustments to clinical trials for <span style="white-space:nowrap">SZN-043.</span> It is also likely that there will be side effects associated with the testing or use of our product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these side effects. In such an event, our trials could be suspended (as we have done for <span style="white-space:nowrap">SZN-1326)</span> or terminated and the FDA or other regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. For example, certain researchers have noted that therapeutics targeting the Wnt pathway may lead to tumor formation or proliferation as a result of the downstream impacts of Wnt signaling. To date, we have not observed any such tumor formation with <span style="white-space:nowrap">SZN-1326</span> or <span style="white-space:nowrap">SZN-043</span> in our preclinical toxicology studies and clinical trials, but there can be no guarantee that our current or future product candidates will not result in tumor formation. Any of these occurrences or failure to resolve the findings related to <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043</span> may materially and adversely affect our business and financial condition and impair our ability to generate revenues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, clinical trials by their nature use a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of a product candidate may only be uncovered when a significantly larger number of patients are exposed to the product candidate or when patients are exposed for a longer period of time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any of our current or potential future product candidates receive regulatory approval and we or others identify undesirable side effects caused by one of these products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may withdraw their approval of the product or seize the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be required to recall the product or change the way the product is administered to patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require additional post-marketing safety studies or registries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we could be sued and held liable for harm caused to patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the product may become less competitive; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our reputation may suffer. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need substantial additional funds to advance development of product candidates of our Wnt therapeutics platform, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development of biopharmaceutical product candidates is capital-intensive. If <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> or potential future product candidates advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing and sales capabilities. We have used substantial funds to develop our Wnt therapeutics platform, <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> and other product candidates and we will require significant funds to continue to develop our platform, resume clinical trials for <span style="white-space:nowrap">SZN-1326,</span> continue clinical trials for <span style="white-space:nowrap">SZN-043</span> and conduct further research and development, including preclinical studies and clinical trials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have primarily financed our operations through the sale of equity securities. Until such time as we can generate sufficient revenue from sales of our product candidates, if ever, we expect to finance our operations through public or private equity offerings, debt financings or other capital sources, including government grants, potential collaborations with other companies or other strategic transactions. In February 2022, we entered into a purchase agreement and a registration rights agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, pursuant to which we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $50.0&#160;million of our common stock from time to time over a <span style="white-space:nowrap">36-month</span> period, subject to certain conditions and limitations. We may not be able to receive any or all of the funds from Lincoln Park because of the limitations, restrictions, requirements, events of default and other provisions contained in the purchase agreement that could limit our ability to cause Lincoln Park to purchase our common stock. If our stock price drops, we also may not be able to sell shares to Lincoln Park at all or in amounts sufficient to obtain necessary financing. In December 2022, we entered into a sales agreement with Guggenheim Securities, LLC, or Guggenheim, in connection with a shelf registration statement on Form <span style="white-space:nowrap">S-3</span> filed in December 2022, to issue and sell our common stock up to $23.0&#160;million under the <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> offering. To date we have not sold any shares of common stock under the sales agreement. Given the volatility in the capital markets, we may not be willing or able to raise equity capital through such <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> offering. We may, therefore, need to turn to other sources of funding that may have terms that are not favorable to us, or reduce our business operations given capital constraints. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States, and worldwide. The overall impact of these events on our business may be significantly affected by the actions of U.S. and foreign governments. These events and actions could result in severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to raise additional capital in sufficient amounts, in a timely manner or on terms acceptable to us, we may have to significantly delay, scale back, or discontinue the development of our product pipeline or other research and development initiatives. We also could be required to seek collaborators for our product pipeline and any future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product pipeline and any future product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements and the period for which we expect existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because the length of time and activities associated with successful research and development of product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. The timing and amount of our operating expenditures will depend largely on: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and progress of preclinical and clinical development of <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> and other potential future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and progress of the development of our Wnt therapeutics platform; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the price and pricing structure that we are able to obtain from our third-party contract manufacturers to manufacture our preclinical study and clinical trial materials and supplies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which prices for supplies and materials increase due to inflationary pressures and labor market constraints; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and scope of preclinical and clinical programs we decide to pursue; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain our current licenses, research and development programs and to establish new collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the progress of the development efforts of parties with whom we may in the future enter into collaboration and research and development agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs involved in obtaining, maintaining, enforcing and defending patents and other intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of health epidemics on our business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost and timing of regulatory approvals; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to raise sufficient capital when needed, our business, financial condition and results of operations will be harmed, and we will need to significantly modify our operational plans. We may also have to liquidate assets, and the value we receive for any assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses to date and it is possible we may never generate a profit. We do not expect to realize revenue from product sales or royalties from licensed products for the foreseeable future, if at all, and unless and until our current and potential future product candidates are clinically tested, approved for commercialization and successfully marketed. We expect to continue to incur additional operating losses for the foreseeable future as we continue to develop our product candidates. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to curtail or suspend our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any future equity or debt issuances or other financing transactions may have dilutive or adverse effects on our existing stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of any financing, including our potential financing through Lincoln Park and the <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> offering with Guggenheim, may adversely affect the holdings or the rights of our stockholders, and the issuance of additional securities by us, whether equity or debt, or the market perception that such issuances are likely to occur, could cause the market price of our common stock to decline. To the extent that we raise additional capital through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our current and potential future product candidates, future revenue streams or research programs or to grant licenses on terms that may not be favorable to us. If we raise any additional capital through public or private equity or convertible debt offerings, including through any sales of common stock to Lincoln Park or under the <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> offering with Guggenheim, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional capital raising efforts may divert our management from their <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities, which may adversely affect our ability to develop and commercialize our current and future product candidates, if approved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we intend to focus our efforts on specific research and development programs, including clinical development of <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> and <span style="white-space:nowrap">SZN-413.</span> As a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result, we may forgo or delay pursuit of other opportunities, including with potential future product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial product candidates or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not resume clinical trials for <span style="white-space:nowrap">SZN-1326,</span> we will not see a return on the capital spent to develop <span style="white-space:nowrap">SZN-1326,</span> resulting in adverse effects on our financial condition and ability to pursue other opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaborations, licensing or other royalty arrangements in cases in which we would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures that could result in material changes in the final data. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of its analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, preliminary or topline results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. For example, in November 2022, we reported observations in connection with clinical studies on <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043,</span> and these observations could differ materially from future findings. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim, preliminary or topline data from our clinical studies. Interim, topline or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, topline or interim data and final data could significantly harm our business prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of us in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the topline data that we report differs from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to enter into strategic transactions on acceptable terms, if at all, which could adversely affect our ability to develop and commercialize current and potential future product candidates, impact our cash position, increase our expense, and present significant distractions to our management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases, joint ventures and <span style="white-space:nowrap">out-</span> or <span style="white-space:nowrap">in-licensing</span> of product candidates or technologies. For example, in October 2022, we executed a strategic partnership with BI for the research and development of <span style="white-space:nowrap">SZN-413</span> for the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment of retinal diseases. We will continue to evaluate and, if strategically attractive, seek to enter into collaborations, including with biotechnology or biopharmaceutical companies or hospitals. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. If we are not able to enter into strategic transactions, we may not have access to required liquidity or expertise to further develop our potential future product candidates or our Wnt therapeutics platform. Any such collaboration, or other strategic transaction, may require us to incur <span style="white-space:nowrap">non-recurring</span> or other charges, increase its near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that it believes will complement or augment our existing business, but we may not be able to realize the benefit of acquiring such assets. Conversely, any new collaboration that we enter into may be on terms that are not optimal for us or our product candidates. These transactions would entail numerous operational and financial risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exposure to unknown liabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disruption of our business and diversion of its management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">higher-than-expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to retain key employees of any acquired business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any current or future partnerships and transactions may be subject to the foregoing or other risks and our business could be materially harmed by such transactions. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, to the extent that any current or future collaborators terminate a collaboration agreement, we may be forced to independently develop our current and future product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and maintaining, enforcing and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and materially harm its business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to conduct our preclinical studies and plan to continue to rely on third parties to conduct clinical trials, and those third parties may not perform satisfactorily. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party clinical investigators, contract research organizations, or CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor certain preclinical studies and any clinical trials. Because we intend to rely on these third parties and will not have the ability to conduct certain preclinical studies or clinical trials independently, we will have less control over the timing, quality and other aspects of such preclinical studies and clinical trials than we would have had it conducted them on its own. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
These investigators, CROs and consultants will not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. Some of these third parties may terminate their engagements with us at any time. We also expect to have to negotiate budgets and contracts with CROs, clinical trial sites and contract manufacturing organizations, or CMOs, and may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. If we need to enter into alternative arrangements with, or replace or add any third parties, this would involve substantial cost and require extensive management time and focus, or involve a transition period, and may delay our drug development activities, as well as materially impact our ability to meet our desired clinical development timelines. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties for such drug development activities will reduce our control over these activities. As a result, we will have less direct control over the conduct, timing and completion of preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon its own staff. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, including good laboratory practice, or GLP, good clinical practice, or GCP and current good manufacturing practice, or cGMP, and our reliance on third parties does not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other regulatory authorities require us to comply with GCP standards, regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are reliable and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, European Medicines Agency, or EMA, or other regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials substantially comply with GCP regulations. In addition, our clinical trials must be conducted with product candidates produced under cGMP regulations and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients, may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates FDA regulatory requirements as well as federal or state healthcare laws and regulations or healthcare privacy and security laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, or if these third parties need to be replaced, they will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in its efforts to, successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, its costs could increase and our ability to generate revenue could be delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We and our collaborators may not achieve projected discovery and development milestones and other anticipated key events in the time frames that such collaborators announce, which could have an adverse impact on our business and could cause our stock price to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we expect that we will make public statements regarding the expected timing of certain milestones and key events, such as the commencement and completion of preclinical and <span style="white-space:nowrap">IND-enabling</span> studies in our internal drug discovery programs as well as the commencement and completion of our planned clinical trials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our or any future collaborators&#8217; drug discovery and development programs, the amount of time, effort and resources committed by us and any future collaborators, and the numerous uncertainties inherent in the development of drugs. As a result, there can be no assurance that we or any current or future collaborators&#8217; programs will advance or be completed in the time frames we or they announce or expect. If we or any collaborators fail to achieve one or more of these milestones or other key events as planned, including the milestones in our agreement with BI, our business could be materially adversely affected and the price of common stock could decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical trials are expensive, time-consuming and difficult to design and implement. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our current and potential future product candidates are based on new technologies and discovery approaches, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. In addition, because of the limited number of drug candidates that target the Wnt pathway, the FDA or other regulatory authorities may require us to perform additional testing before commencing or resuming clinical trials and be hesitant to allow us to enroll patients impacted with its targeted disease indications in Phase 1 trials. If we are unable to enroll patients impacted by the targeted disease indications in our current and planned Phase 1 trials, we may continue to be delayed or would be delayed in obtaining potential <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> data in humans, which could extend our development timelines. In addition, costs to treat patients and to treat potential side effects that may result from our product candidates may be significant. Accordingly, our clinical trial costs are likely to be high and could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our clinical development activities could be delayed or otherwise adversely affected for various reasons. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to initiate, resume or continue clinical trials for our current or potential future product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or other regulatory authorities. We cannot predict how difficult it will be to enroll and retain patients for our trials. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the severity of the disease under investigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patient eligibility criteria defined in the clinical trial protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the proximity and availability of clinical trial sites for prospective patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">willingness of physicians to refer their patients to our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain and maintain patient consents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">factors we cannot control that may limit patients, principal investigators or staff or clinical site available, including restrictions related to the <span style="white-space:nowrap">COVID-19</span> pandemic and the conflict between Russia and Ukraine. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our future clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for their clinical trials at such clinical trial sites. Additionally, because some of our clinical trials will be in patients with advanced disease who may experience disease progression or adverse events independent from our product candidates, such patients may be unevaluable for purposes of the trial and, as a result, we may require additional enrollment. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to seek or obtain regulatory approval and commercialize our product candidates on a timely basis, or at all, which would require us to incur additional costs and delay our receipt of any product revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have experienced, and may further experience, delays in our ongoing or future preclinical studies or clinical trials, and we do not know whether preclinical studies or clinical trials will begin on time, resume in a timely manner, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. The commencement or completion of our clinical trials could be substantially delayed or prevented by many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">further discussions with the FDA or comparable foreign regulatory authorities regarding the scope or design of our clinical trials, including the endpoint measures required for regulatory approval and our statistical plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the limited number of, and competition for, suitable study sites and investigators to conduct our clinical trials, many of which may already be engaged in other clinical trial programs with similar patients, including some that may be for the same indication as our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any delay or failure to obtain timely approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to obtain sufficient funds required for a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay or failure to manufacture sufficient quantities or inability to produce quantities of consistent quality, purity and potency of the product candidate for our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a prospective site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other comparable foreign regulatory authorities may require us to submit additional data or impose other requirements before permitting us to initiate a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">slower than expected rates of patient recruitment and enrollment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure of patients to complete the clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to enroll a sufficient number of patients in studies to ensure adequate statistical power to detect statistically significant treatment effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lack of efficacy or failure to measure a statistically significant clinical benefit within the dose range with an acceptable safety margin during clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">termination of our clinical trials by one or more clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to monitor patients adequately during or after treatment by us or our CROs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our CROs or clinical study sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to address any noncompliance with regulatory requirements or safety concerns that arise during the course of a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of, and delays related to, health epidemics such as the <span style="white-space:nowrap">COVID-19</span> pandemic; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the need to suspend, repeat or terminate clinical trials as a result of <span style="white-space:nowrap">non-compliance</span> with regulatory requirements, inconclusive or negative results or unforeseen complications in testing; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the suspension or termination of our clinical trials upon a breach or pursuant to the terms of any agreement with, or for any other reason by, any future strategic collaborator that have responsibility for the clinical development of any of our product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulatory requirements, policies and guidelines may also occur and we may need to significantly modify our clinical development plans to reflect these changes with appropriate regulatory authorities. These changes may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for <span style="white-space:nowrap">re-examination,</span> which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by them, the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any failure or significant delay in commencing or completing clinical trials for our product candidates, any failure to obtain positive results from clinical trials, any safety concerns related to our product candidates, or any requirement to conduct additional clinical trials or other testing of our product candidates beyond those that it currently contemplates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we decide to seek orphan drug designation for one or more of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation for our current or future product candidates that we may develop. If our competitors are able to obtain orphan product exclusivity for their products in specific indications, we may not be able to have competing products approved in those indications by the applicable regulatory authority for a significant period of time. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug or biologic product intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. We may seek orphan drug designation for certain indications for our product candidates in the future. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication for seven years. The FDA may reduce the seven-year exclusivity if the same drug from a competitor demonstrates clinical superiority to the product with orphan exclusivity or if the FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. Even if one of our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates receives orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to conduct, or contract with others to conduct, animal testing in the future, which could harm our research and development activities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain laws and regulations relating to drug development require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted or delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The manufacturing of our product candidates is complex. We and our third-party manufacturers may encounter difficulties in production. If we encounter any such difficulties, our ability to supply our product candidates for clinical trials or, if approved, for commercial sale, could be delayed or halted entirely. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically engineered antibodies have been particularly difficult to manufacture and CMOs have limited experience in the manufacturing of antibodies to selectively activate Wnt signaling. The process of manufacturing our product candidates is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our engineered antibodies are manufactured by culturing cells from a master cell bank. We have one master cell bank for each antibody manufactured in accordance with cGMP standards and regulations, each stored at two sites to reduce risk of loss. It is possible that we could lose multiple cell bank sites and have our manufacturing severely impacted by the need to replace the cell bank sites, and we may fail to have adequate backup should any particular cell bank site be lost in a catastrophic event. Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Furthermore, it is too early to estimate our cost of goods sold. The actual cost to manufacture our product candidates could be greater than we expect because we are early in our development efforts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we may rely on third parties for manufacturing and supply of our product candidates, some of which may be sole source vendors, for preclinical and clinical development materials and commercial supplies, our supply may become limited or interrupted or may not be of satisfactory quantity or quality. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party contract manufacturers for our preclinical and future clinical trial product materials and supplies. We do not produce our product candidates in quantities sufficient for preclinical and clinical development, and we do not currently own manufacturing facilities for producing such supplies. Furthermore, some of our manufacturers represent our sole source of supplies of preclinical and future clinical development materials, including our source for the manufacture of <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043.</span> Although our current contract manufacturer has multiple sites capable of producing our products (both drug substance and drug product), we cannot assure you that its preclinical or future clinical development product supplies and commercial supplies will not be limited or interrupted, especially with respect to our sole source third-party manufacturing and supply collaborators, or will be of satisfactory quality or continue to be available at acceptable prices. In particular, any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. For our current and future sole source third-party manufacturing and supply collaborators, we may be unable to negotiate binding agreements with them or find replacement manufacturers to support our preclinical and future clinical activities at commercially reasonable terms in the event that their services to us become interrupted for any reason. We do not always have arrangements in place for a redundant or second-source supply for our sole source vendors in the event they cease to provide their products or services to us or do not timely provide sufficient quantities to us. Establishing additional or replacement sole source vendors, if required, may not be accomplished quickly. Any delays resulting from manufacturing or supply interruptions associated with our reliance on third-party manufacturing and supply collaborators, including those that are sole source, could impede, delay, limit or prevent our drug development efforts, which could harm our business, result of operations, financial condition and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing process for a product candidate is subject to FDA and other regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. In the event that any of our manufacturers fails to comply with such requirements or to perform their obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, or at all. In some cases, the technical skills or technology required to manufacture our current and future product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect to rely on third-party manufacturers if we receive regulatory approval for any product candidate. We have existing, and may enter into future, manufacturing arrangements with third parties. We will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for any product candidate, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. We or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMPs could adversely affect our business in a number of ways, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an inability to initiate or continue clinical trials of product candidates under development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of the cooperation of a potential future collaborators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subjecting third-party manufacturing facilities or our potential future manufacturing facilities to additional inspections by regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">requirements to cease distribution or to recall batches of product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our third-party manufacturers may be unable to successfully scale manufacturing of <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> or potential future product candidates in sufficient quality and quantity, which would delay or prevent us from developing our current and future product candidates and, if approved, commercializing product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to conduct clinical trials for <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043</span> as well as any potential future product candidates or commercialize, we will need to manufacture large quantities of these product candidates. We may </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue to and currently expect to use third parties for our manufacturing needs. Our manufacturing collaborators may be unable to successfully increase the manufacturing capacity for any current or potential future product candidate in a timely or cost-effective manner, or at all. In addition, quality issues may arise during <span style="white-space:nowrap">scale-up</span> activities. If our manufacturing collaborators are unable to successfully scale the manufacture of any current or potential future product candidate in sufficient quality and quantity, the development, testing, clinical trials and commercialization of that product candidate may be delayed or infeasible and regulatory approval or commercial launch of any potential resulting product may be delayed or not obtained, which could significantly harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current operations are located in the San Francisco Bay Area. Any unplanned event, such as earthquake, flood, fire, explosion, extreme weather condition, medical epidemics, including any potential effects from the current global spread of <span style="white-space:nowrap">COVID-19,</span> power shortage, telecommunication failure, cyberattack or other natural or <span style="white-space:nowrap">man-made</span> accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of its business operations. Natural disasters or pandemics such as the <span style="white-space:nowrap">COVID-19</span> outbreak could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure its investors that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities or the manufacturing facilities of our third-party contract manufacturers are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in methods of product candidate manufacturing or formulation may result in the need to perform new clinical trials, which would require additional costs and cause delay. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As product candidates are developed through preclinical to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of ongoing, planned or future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence product sales and generate revenue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the market opportunities for our current and potential future product candidates, including <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> and <span style="white-space:nowrap">SZN-413,</span> are smaller than we believe they are, our future product revenues may be adversely affected and our business may suffer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our understanding of the number of people who suffer from certain types of moderate to severe IBD, severe AH and retinal vascular associated diseases that <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> and <span style="white-space:nowrap">SZN-413,</span> respectively, may be able to treat are based on estimates. These estimates may prove to be incorrect, and new studies may reduce the estimated incidence or prevalence of these diseases. The number of patients in the United States or elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our current or potential future product candidates or patients may become increasingly difficult to identify and access, all of which would adversely affect our business prospects and financial condition. In particular, the treatable population for our candidates may further be reduced if its estimates of addressable populations are erroneous or <span style="white-space:nowrap">sub-populations</span> of patients do not derive benefit from <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> or <span style="white-space:nowrap">SZN-413.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there are several factors that could contribute to making the actual number of patients who receive our current or potential future product candidates less than the potentially addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face competition from entities that have developed or may develop product candidates for the treatment of the diseases that we may target, including companies developing novel treatments and therapeutic platforms. If these companies develop therapeutics or product candidates more rapidly than we do, or if their therapeutics or product candidates are more effective or have fewer side effects, our ability to develop and successfully commercialize product candidates may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. We face potential competition from many different sources, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing, and commercialization of therapies aimed at treating autoimmune, inflammatory, metabolic, and other diseases, including indications that we are pursuing or may pursue in the future. Any product candidates that we successfully develop and commercialize will compete with current therapies and new therapies that may become available in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy, safety, convenience and price, the level of competition and the availability of coverage and adequate reimbursement from third-party payors. If any of our product candidates are approved and commercialized, it is likely that we will face increased competition as a result of other companies pursuing development of products to address similar diseases. For <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> and our earlier stage research programs, we face competition from approved therapies and potential competition from product candidates in development for the indications we are pursuing or may pursue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and enrolling subjects for our clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. We could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop, including if competitors develop a safer and/or more effective Wnt modulation platform. Our competitors also may obtain FDA or foreign regulatory approval for their products more rapidly than us, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market and materially and adversely impact our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to maintain proper and effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting and the market price of our common stock may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective internal controls are necessary for us to provide reliable financial reports and to protect from fraudulent, illegal or unauthorized transactions. If we cannot provide effective controls and reliable financial reports, our business and operating results could be harmed. We have in the past discovered, and may in the future discover, areas of our internal controls that need improvement. We are required, pursuant to Section&#160;404 of the Sarbanes-Oxley Act, to furnish a report by management on the effectiveness of our internal control over financial reporting. In the future, our independent registered public accounting firm may also need to attest to the effectiveness of our internal control over financial reporting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even though we implemented measures designed to improve our internal control over financial reporting and remediated the control deficiencies that led to the material weakness, we cannot assure that we have identified all, or that we will not in the future have additional, material weaknesses. If material weaknesses or control deficiencies occur again in the future, we are unable to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act in a timely manner, we are unable to assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, we may be unable to report our financial results accurately on a timely basis, which could cause our reported financial results to be materially misstated and result in the loss of investor confidence and cause the market price of our common stock to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Members of our management team have limited experience in managing the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> operations of a public company and, as a result, we may incur additional expenses associated with the management of our company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Members of our management team have limited experience in managing the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> operations of a public company. As a result, we may need to obtain outside assistance from legal, accounting, investor relations, or other professionals that could be more costly than planned. We also plan to hire additional personnel to comply with additional SEC reporting requirements. These compliance costs will make some activities significantly more time-consuming and costly. If we lack cash resources to cover these costs in the future, our failure to comply with reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our potential results of operations, cash flow and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to use net operating loss carryforwards, or NOLs, to offset future taxable income may be subject to certain limitations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our NOLs could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in taxable years beginning before January&#160;1, 2018 are permitted to be carried forward for only 20 taxable years under applicable U.S. federal income tax law. Under current law, NOLs arising in tax years beginning after December&#160;31, 2020 may not be carried back. Moreover, under current law, NOLs generated in taxable years beginning after December&#160;31, 2017 may be carried forward indefinitely, but the deductibility of such NOLs generally will be limited in taxable years beginning after December&#160;31, 2020 to 80% of current year taxable income. As of December&#160;31, 2022, we had NOLs of approximately $139.4&#160;million and $53.0&#160;million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. NOLs generated after 2018 for federal tax reporting purposes of $127.0&#160;million have an indefinite carryforward period. The remaining federal and all state NOLs begin expiring in 2036. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Section&#160;382 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change&#8221; (as defined under Section&#160;382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its <span style="white-space:nowrap">pre-change</span> NOLs to offset future taxable income. A Section&#160;382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders who own at least 5% of our stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. We have determined that we likely had an ownership change in September 2020. As a result of the annual limitations caused by the ownership changes, it was estimated that approximately $1.3&#160;million of federal tax credit and $27.4&#160;million of California NOL will expire unutilized for income tax purposes, and such amounts are excluded from the carryforward balances of December&#160;31, 2022. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, and some of which are outside our control. Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state tax purposes. For these reasons, we may not be able to utilize a material portion of the NOLs reflected on our balance sheet, even if we attain profitability, which could potentially result in increased future tax liability to us and could adversely affect our operating results and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success largely depends on the continued service of key executive management, advisors and other specialized personnel, including Craig Parker, its President and Chief Executive Officer, <span style="white-space:nowrap">Wen-Chen</span> Yeh, our Chief Scientific Officer, and Charles Williams, our Chief Financial Officer. Our senior management may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our employees. The loss of one or more members of the executive team, management team or other key employees or advisors could delay research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of members of senior management or other key employees could impede the achievement of research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing members of senior management and key employees may be difficult and may take an extended period of time because of the limited number of individuals in the industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, <span style="white-space:nowrap">mid-level</span> and senior managers, as well as junior, <span style="white-space:nowrap">mid-level</span> and senior scientific and medical personnel. Competition to hire from this limited candidate pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist in formulating research and development and commercialization strategies. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue its growth strategy will be limited. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may experience difficulties in managing growth and expanding operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited experience in therapeutic development. As our current and potential future product candidates enter and advance through preclinical studies and any clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also experience difficulties in the discovery and development of potential future product candidates using its Wnt therapeutics platform if we are unable to meet demand as it grows our operations. In the future, we also expect to have to manage additional relationships with collaborators, suppliers and other organizations. Our ability to manage operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures and secure adequate facilities for operational needs. We may not be able to implement improvements to management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If any of our product candidates is approved for marketing and commercialization in the future and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no sales, marketing or distribution capabilities or experience. We will need to develop internal sales, marketing and distribution capabilities to commercialize each current and potential future product candidate that gains, if ever, FDA or other regulatory authority approval, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market any approved products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market any approved products or decide to <span style="white-space:nowrap">co-promote</span> products with third parties, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we can make no assurances that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance for any approved product. If we are not successful in commercializing any product approved in the future, either on its own or through third parties, our business and results of operations could be materially and adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our international operations may expose us to business, political, operational and financial risks associated with doing business outside of the United States. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting business internationally. Some of our suppliers are located outside of the United States and we have conducted, and anticipate conducting additional future, clinical trials, including our Phase 1 trials for <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043,</span> outside of the United States. Furthermore, if we or any current or future collaborator succeed in developing any products, we anticipate marketing them in the European Union, or EU, and other jurisdictions in addition to the United States. If approved, we or any future collaborator may hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">multiple, conflicting and changing laws and regulations such as those relating to privacy, data protection and cybersecurity, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">rejection or qualification of foreign clinical trial data by the competent authorities of other countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additional potentially relevant third-party patent rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">complexities and difficulties in obtaining, maintaining, protecting and enforcing our intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in staffing and managing foreign operations; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">complexities associated with managing multiple payor reimbursement regimes, government payors or patient <span style="white-space:nowrap">self-pay</span> systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limits in our ability to penetrate international markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for products and exposure to foreign currency exchange rate fluctuations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">natural disasters, political and economic instability, wars (including the conflict between Russia and Ukraine), terrorism, political unrest, outbreak of disease (including the <span style="white-space:nowrap">COVID-19</span> pandemic), boycotts, trade wars and other significant events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">certain expenses including, among others, expenses for travel, translation and insurance; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or our anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could harm our ongoing international operations and supply chain, as well as any future international expansion and operations and, consequently, our business, financial condition, prospects and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future growth may depend, in part, on our ability to develop and commercialize product candidates in foreign markets for which we may rely on collaborations with third parties. We will not be permitted to market or promote any product candidate before we receive regulatory approval from the applicable regulatory authority in a foreign market, and we may never receive such regulatory approval for any product candidate. To obtain separate regulatory approval in foreign countries, we generally must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of a product candidate, and we cannot predict success in these jurisdictions. If we obtain approval of any current or potential future product candidates and ultimately commercialize any such product candidate in foreign markets, we would be subject to risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business entails a significant risk of product liability, and our inability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we conduct preclinical studies and clinical trials of <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> and other potential future product candidates, we are and will be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of these product candidates. Product liability claims could delay or prevent completion of development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, manufacturing processes and facilities or marketing programs and potentially a recall of products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we or any current or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future collaborators may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, principal investigators, consultants and commercial collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other misconduct by employees, principal investigators, consultants and commercial collaborators. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards We may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business and financial condition, including the imposition of significant criminal, civil and administrative fines or other sanctions, such as monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity obligations, reputational harm and the curtailment or restructuring of our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect and share personal information, health information and other information to develop our products, to operate our business, for clinical trial purposes, for legal and marketing purposes, and for other business-related purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and any potential future collaborators, partners or service providers may be subject to federal, state and foreign data protection laws, regulations and regulatory guidance, the number and scope of which is changing, subject to differing applications and interpretations, and which may be inconsistent among jurisdictions, or in conflict with other rules, laws or contractual obligations. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, such as the Health Insurance Portability and Accountability Act, or HIPAA, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of any future potential collaborators or service providers. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, or other privacy and data security laws. Depending on the facts and circumstances, we could be subject to civil or criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA, or if we otherwise violate applicable privacy and data security laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">International data protection laws, including the EU&#8217;s General Data Protection Regulation, or GDPR, may also apply to health-related and other personal information obtained outside of the United States. The GDPR went into effect on May&#160;25, 2018. The GDPR introduced new data protection requirements in the EU, as well as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential fines for noncompliant companies of up to the greater of &#8364;20&#160;million or 4% of annual global revenue. The regulation imposes numerous requirements for the collection, use and disclosure of personal information, including stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the GDPR includes restrictions on cross-border data transfers. A recent decision by the Court of Justice of the European Union has invalidated the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield Framework, which was one of the primary mechanisms used by U.S. companies to import personal information from Europe in compliance with the GDPR&#8217;s cross-border data transfer restrictions, and raised questions about whether the European Commission&#8217;s Standard Contractual Clauses, or SCCs, one of the primary alternatives to the Privacy Shield, can lawfully be used for personal information transfers from Europe to the United States or most other countries. Similarly, the Swiss Federal Data Protection and Information Commissioner has opined that the <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield is inadequate for transfers of data from Switzerland to the U.S. The United Kingdom, or UK, whose data protection laws are similar to those of the EU, may similarly determine that the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield is not a valid mechanism for lawfully transferring personal information from the UK to the U.S. The European Commission recently proposed updates to the SCCs, and additional regulatory guidance has been released that seeks to impose additional obligations on companies seeking to rely on the SCCs. Given that, at present, there are few, if any, viable alternatives to the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield and the SCCs, any transfers by us or our vendors of personal data from Europe may not comply with European data protection law, which may increase Our exposure to the GDPR&#8217;s heightened sanctions for violations of its cross-border data transfer restrictions and may prohibit the transfer of EU personal data outside of the EU (including clinical trial data), and may adversely impact Our operations, product development, and ability to provide our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GDPR has increased the responsibilities and potential liability in relation to personal data processed subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Further, the exit of the UK from the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the UK. The UK now is considered a &#8220;third country&#8221; under the GDPR and transfers of European personal data to the UK will, unless the UK is determined by the EU to provide adequate protection for personal data, require an adequacy mechanism to render such transfers lawful under the GDPR following the expiration or termination of a grace period that presently is scheduled to last for four months from January&#160;1, 2021, with a potential additional <span style="white-space:nowrap">two-month</span> extension. Aspects of the relationship between the EU and the UK with respect to data protection, including with respect to cross-border data transfers, remain uncertain. Compliance with the GDPR and applicable laws and regulations relating to privacy and data protection of EU Member States and the UK will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change its business practices, and despite those efforts, there is a risk that We may be subject to fines and penalties, litigation, and reputational harm in connection with Our European activities. In addition, failure to comply with GDPR and applicable laws and regulations relating to privacy and data protection of EU Member States and the UK may result in regulators prohibiting Our processing of the personal information of EU data subjects, which could impact Our operations and ability to develop our products and provide its services, including interrupting or ending EU clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act, or the CCPA, on June&#160;28, 2018, which took effect on January&#160;1, 2020 and has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined and can include any of Our current or future employees who may be California residents) and provide such residents new ways to <span style="white-space:nowrap">opt-out</span> of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statutory damages ranging from $100 to $750 per violation, which is expected to increase data breach class action litigation and result in significant exposure to costly legal judgments and settlements. As we expand our operations and trials (both preclinical and clinical), the CCPA may increase compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States. In November 2020, California passed the California Privacy Rights Act, or the CPRA, which amends and expands the CCPA. The CPRA creates obligations relating to consumer data beginning on January&#160;1, 2022, with implementing regulations expected on or before July&#160;1, 2022, and enforcement beginning July&#160;1, 2023. The CPRA has created additional uncertainty and may increase our cost of compliance. Other states are beginning to pass similar laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in its contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Laws and regulations worldwide relating to privacy, data protection and cybersecurity are, and are likely to remain, uncertain for the foreseeable future. While we strive to comply with applicable laws and regulations relating to privacy, data protection and cybersecurity, external and internal privacy and security policies and contractual obligations relating to privacy, data protection and cybersecurity to the extent possible, we may at times fail to do so, or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our personnel, collaborators, partners or vendors do not comply with applicable laws and regulations relating to privacy, data protection and cybersecurity, external and internal privacy and security policies and contractual obligations relating to privacy, data protection and cybersecurity. Actual or perceived failure to comply with any laws and regulations relating to privacy, data protection or cybersecurity in the U.S. or foreign jurisdictions could result in government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect Our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators or service providers obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with applicable laws or regulations, or breached its contractual obligations, even if We are not found liable, could be expensive and time consuming to defend, result in regulatory actions and proceedings, in addition to private claims and litigation, and could result in adverse publicity that could harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also are, or may be asserted to be, subject to the terms of our external and internal privacy and security policies, representations, certifications, publications and frameworks and contractual obligations to third parties related to privacy, data protection, information security and processing. Failure to comply with any of these, or if any of these policies or any of our representations, certifications, publications or frameworks are, in whole or part, found or perceived to be inaccurate, incomplete, deceptive, unfair, or misrepresentative of its actual practices, could result in reputational harm; result in litigation; cause a material adverse impact to business operations or financial results; and otherwise result in other material harm to our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We depend on sophisticated information technology systems and data processing to operate our business. If we experience security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of its proprietary or confidential data, employee data or personal data, we may face costs, significant liabilities, harm to its brand and business disruption. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on information technology systems and data processing that we or our service providers, collaborators, consultants, contractors or partners operate to collect, process, transmit and store electronic information in our <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> operations, including a variety of personal data, such as name, mailing address, email addresses, phone number and clinical trial information. Additionally, we, and our service providers, collaborators, consultants, contractors or partners, do or will collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect and share personal information, health information and other information to host or otherwise process some data and that of users, develop our products, to operate our business, for clinical trial purposes, for legal and marketing purposes, and for other business-related purposes. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Our internal computer systems and data processing and those of our third-party vendors, consultants, collaborators, contractors or partners, including existing and future CROs may be vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy, theft or destruction of intellectual property or other confidential or proprietary information, business interruption or other significant security incidents. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. In addition to traditional computer &#8220;hackers,&#8221; threat actors, software bugs, malicious code (such as viruses and worms), employee theft or misuse, <span style="white-space:nowrap"><span style="white-space:nowrap">denial-of-service</span></span> attacks (such as credential stuffing), phishing and ransomware attacks, sophisticated nation-state and nation-state supported actors now engage in attacks (including advanced persistent threat intrusions). These risks may increase as a result of <span style="white-space:nowrap">COVID-19,</span> owing to an increase in personnel working remotely. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we, our service providers, collaborators, consultants, contractors or partners will be successful in efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data. Any failure by us or our service providers, collaborators, consultants, contractors or partners to detect, prevent, respond to or mitigate security breaches or improper access to, use of, or inappropriate disclosure of any of this information or other confidential or sensitive information, including patients&#8217; personal data, or the perception that any such failure has occurred, could result in claims, litigation, regulatory investigations and other proceedings, significant liability under state, federal and international law, and other financial, legal or reputational harm to us. Further, such failures or perceived failures could result in liability and a material disruption of our development programs and our business operations, which could lead to significant delays or setbacks in research, delays to commercialization of product candidates, lost revenues or other adverse consequences, any of which could have a material adverse effect on its business, results of operations, financial condition, prospects and cashflow. For example, the loss of clinical trial data from completed, ongoing, or future clinical trials could result in delays in our regulatory approval efforts and significantly increase costs to recover or reproduce the data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, applicable laws and regulations relating to privacy, data protection or cybersecurity, external contractual commitments and internal privacy and security policies may require us to notify relevant stakeholders if there has been a security breach, including affected individuals, business partners and regulators. Such disclosures are costly, and the disclosures or any actual or alleged failure to comply with such requirements could lead to a materially adverse impact on the business, including negative publicity, a loss of confidences in our services or security measures by its business partners or breach of contract claims. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages if we fail to comply with applicable data protection laws, privacy policies or other data protection obligations related to information security or security breaches. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research, development and manufacturing involves the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in its facilities that are required for research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing of these materials in its facilities comply with the relevant guidelines of the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to cover ourselves for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. Although we have some environmental liability insurance covering certain facilities, we may not maintain adequate insurance for all environmental liability or toxic tort claims that may be asserted against us in connection with the storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business, operations and clinical development plans and timelines could be adversely affected by the effects of health epidemics, natural disasters and other events on the manufacturing, clinical trial and other business activities performed by us or by third parties with whom it conducts business, including contract manufacturers, CROs, shippers and others. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health epidemics could cause significant disruption in our operations and the operations of third-party manufacturers, CROs and other third parties upon whom we rely. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If relationships with suppliers or other vendors are terminated or scaled back as a result of health epidemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Switching or adding additional suppliers or vendors involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may occur, which could adversely impact our ability to meet desired clinical development and any future commercialization timelines. Although we carefully manage relationships with suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our preclinical studies and future clinical trials may be affected by health epidemics. Clinical site initiation, patient enrollment and activities that require visits to clinical sites, including data monitoring, may be delayed due to concerns among patients about participating in clinical trials during a health epidemics. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. These challenges may also increase the costs of completing our clinical trials. Similarly, if we are unable to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may experience additional restrictions by their institutions, city or state, preclinical studies and future clinical trial operations could be adversely impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">To the extent we enter into any other collaborations, we may depend on such collaborations for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may selectively seek additional third-party collaborators for the development and commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates, including our collaboration with BI, pose many risks to us, including that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or products if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A collaborator with marketing and distribution rights to one or more product candidates or products may not commit sufficient resources to the marketing and distribution of such drugs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Collaborations are complex and time-consuming to negotiate and document. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we decide to collaborate with any other third parties in connection with any of our development programs or product candidates, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development program or the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to obtain or protect intellectual property rights related to our technology and current or future product candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain protection for our owned and <span style="white-space:nowrap">in-licensed</span> intellectual property rights and proprietary technology. We rely on patents and other forms of intellectual property rights, including <span style="white-space:nowrap">in-licenses</span> of intellectual property rights and biologic materials of others, to protect current or future discovery platform, product candidates, methods used to manufacture current or future product candidates, and methods for treating patients using current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own or <span style="white-space:nowrap">in-license</span> patents and patent applications relating to its discovery platform and product candidates. There is no guarantee that any patents covering its discovery platform or product candidates will issue from the patent applications we own or <span style="white-space:nowrap">in-licenses,</span> or, if they do, that the issued claims will provide adequate protection for our discovery platform or product candidates, or any meaningful competitive advantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, complex and time-consuming. Patent license negotiations also can be complex and protracted, with uncertain results. We may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of its research and development output before it is too late to obtain patent protection. The patent applications that our own or <span style="white-space:nowrap">in-licenses</span> may fail to result in issued </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents, and, even if they do issue as patents, such patents may not cover Our current or future technologies or product candidates in the United States or in other countries or provide sufficient protection from competitors. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and our scope can be reinterpreted after issuance. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Even if our owned or <span style="white-space:nowrap">in-licensed</span> patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. our competitors may be able to circumvent our patents by developing similar or alternative product candidates in a <span style="white-space:nowrap">non-infringing</span> manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, although we make reasonable efforts to ensure patentability of its inventions, we cannot guarantee that all of the potentially relevant prior art relating to our owned or <span style="white-space:nowrap">in-licensed</span> patents and patent applications has been found. For example, publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, and in some cases not at all. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our discovery platform, our product candidates, or the use of its technologies. We thus cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or <span style="white-space:nowrap">in-licensed</span> patents or patent applications, or that we or our licensors were the first to file for patent protection of such inventions. There is no assurance that all potentially relevant prior art relating to our owned or <span style="white-space:nowrap">in-licensed</span> patent applications has been found. For this reason, and because there is no guarantee that any prior art search is absolutely correct and comprehensive, we may be unaware of prior art that could be used to invalidate an issued patent or to prevent its owned or <span style="white-space:nowrap">in-licensed</span> patent applications from issuing as patents. Invalidation of any of our patent rights, including <span style="white-space:nowrap">in-licensed</span> patent rights, could materially harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the patent positions of biopharmaceutical companies are generally uncertain because they may involve complex legal and factual considerations that have, in recent years, been the subject of legal development and change. As a result, the issuance, scope, validity, enforceability and commercial value of our pending patent rights is uncertain. The standards applied by the United States Patent and Trademark Office, or the USPTO, and foreign patent offices in granting patents are not always certain and moreover, are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our owned or <span style="white-space:nowrap">in-licensed</span> patent applications or narrow the scope of any patent protection it may obtain from its owned or <span style="white-space:nowrap">in-licensed</span> patent applications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if patents do successfully issue from our owned or <span style="white-space:nowrap">in-licensed</span> patent application, and even if such patents cover our current or any future technologies or product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any current or future technologies or product candidates that it may develop. Likewise, if patent applications we own or have <span style="white-space:nowrap">in-licensed</span> with respect to our development programs and current or future technologies or product candidates fail to issue, if their breadth or strength is threatened, or if they fail to provide meaningful exclusivity, other companies could be dissuaded from collaborating with us to develop current or future technologies or product candidates. Lack of valid and enforceable patent protection could threaten our ability to commercialize current or future products and could prevent us from maintaining exclusivity with respect to the invention or feature claimed in the patent applications. Any failure to obtain or any loss of patent protection could have a material adverse impact on our business and ability to achieve profitability. We may be unable to prevent competitors from entering the market with a product that is similar or identical to <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> or any future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The filing of a patent application or the issuance of a patent is not conclusive as to its ownership, inventorship, scope, patentability, validity or enforceability. Issued patents and patent applications may be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
challenged in the courts and in the patent office in the United States and abroad. For example, our patent applications or patent applications filed by our licensors, or any patents that grant therefrom, may be challenged through third-party submissions, opposition or derivation proceedings. By further example, any issued patents that may result from our owned or <span style="white-space:nowrap">in-licensed</span> patent applications may be challenged through reexamination, inter partes review or post-grant review proceedings before the USPTO, or in declaratory judgment actions or counterclaims. An adverse determination in any such submission, proceeding or litigation could prevent the issuance of, reduce the scope of, invalidate or render unenforceable our owned or <span style="white-space:nowrap">in-licensed</span> patent rights; result in the loss of exclusivity; limit our ability to stop others from using or commercializing similar or identical platforms and product candidates; allow third parties to compete directly with us without payment to us; or result in our inability to manufacture or commercialize product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by any patents that might result from our owned or <span style="white-space:nowrap">in-licensed</span> patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future platforms or product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, future owned and <span style="white-space:nowrap">in-licensed</span> patents and patent applications may be <span style="white-space:nowrap">co-owned</span> with third parties. If we are unable to obtain an exclusive license to any such third-party <span style="white-space:nowrap">co-owners&#8217;</span> interest in such patents or patent application, such <span style="white-space:nowrap">co-owners</span> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We may need the cooperation of any such <span style="white-space:nowrap">co-owners</span> to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business prospects and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <span style="white-space:nowrap">in-licensed</span> patent rights may be subject to a reservation of rights by one or more third parties, such as the U.S. government. In addition, our rights in such inventions may be subject to certain requirements to manufacture product candidates embodying such inventions in the United States. Any exercise by the U.S. government of such rights could harm our competitive position, business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The patent protection and patent prosecution for some of our product candidates may be dependent on third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to our product candidates are controlled by our licensors or collaborators. If any of our licensors or collaborators fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering Our product candidates, we could lose our rights to the intellectual property or exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing product candidates. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">In the future, we may enter into agreements involving licenses or collaborations that provide for access or sharing of intellectual property. If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our current and future product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently license, and in the future may continue to license, from third parties&#8217; certain patents and other intellectual property relating to our current and future product candidates. We have certain obligations to our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
existing licensors, and may owe additional obligations in the future to any additional licensors. If we breach any material obligations, including diligence obligations with respect to development and commercialization of product candidates covered by the intellectual property licensed to us, or uses the licensed intellectual property in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell products that are covered by the licensed intellectual property or enable a competitor to gain access to the licensed intellectual property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise between us and our present and future licensors regarding intellectual property subject to a license agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to sublicense patents and other rights to third parties, including the terms and conditions therefor; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations with respect to the development and commercialization of our product candidates that are covered by the licensed intellectual property, and what activities satisfy those diligence obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to transfer or assign the license; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by any of our licensors and us and our collaborators. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that our licenses in the future prevent or impair our ability to maintain its licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on its business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain of our future agreements with third parties may limit or delay its ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we or our licensors, if any, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on its business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even where we have the right to control patent prosecution of patents and patent applications under license from third parties, it may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to it assuming control over patent prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology acquired or licensed currently or in the future from various third parties is or may be subject to retained rights. Our predecessors or licensors do and may retain certain rights under their agreements with us, including the right to use the underlying technology for <span style="white-space:nowrap">non-commercial</span> academic and research use, to publish </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce its rights to licensed technology in the event of misuse. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical <span style="white-space:nowrap">in-licensed</span> technology, it may be unable to successfully develop, <span style="white-space:nowrap">out-license,</span> market and sell our product candidates, which could prevent or delay new product introductions. Our business strategy depends on the successful development of acquired technologies and licensed technology into commercial product candidates. Therefore, any limitations on its ability to utilize these technologies may impair our ability to develop, <span style="white-space:nowrap">out-license</span> or market and sell our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with our obligations under any license, collaboration or other intellectual property-related agreements, we may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting our current or future technologies or product candidates or we could lose certain rights to grant sublicenses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to an exclusive license agreement with Stanford University covering patents relevant to one or more product candidates, and may need to obtain additional licenses from others to advance our research and development activities or allow the commercialization of our current and future product candidates we may identify and pursue. The license agreements with Stanford and BI impose, and any future license agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. For a more detailed description of the license agreements with Stanford, see the section titled &#8220;<span style="font-style:italic">Business&#8212;Stanford License Agreements.</span>&#8221; If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license. License termination could result in our inability to develop, manufacture and sell products that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Furthermore, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. In certain circumstances, our licensed patent rights are subject to reimbursing licensors for their patent prosecution and maintenance costs. If our licensors and future licensors fail to prosecute, maintain, enforce and defend patents we may license, or lose rights to licensed patents or patent applications, our licensed rights may be reduced or eliminated. In such circumstances, our right to develop and commercialize any of our products or product candidates that is the subject of such licensed rights could be materially adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, our current or future licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that it is infringing, misappropriating or otherwise violating the licensor&#8217;s intellectual property rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products if infringement or misappropriation were found, those amounts could be significant. The amount of future royalty obligations will depend on the technology and intellectual property we use in products that it successfully develops and commercializes, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sublicensing of patent and other rights under our collaborative development relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inventorship and ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the priority of invention of patented technology. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on Our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair its ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <span style="white-space:nowrap">non-provisional</span> filing date. Various extensions may be available. Even so, the life of a patent and the protection it affords are limited. As a result, our owned and <span style="white-space:nowrap">in-licensed</span> patent portfolio provide us with limited rights that may not last for a sufficient period of time to exclude others from commercializing product candidates similar or identical to us. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. For example, given the large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Extensions of patent term may be available, but there is no guarantee that we would have patents eligible for extension, or that we would succeed in obtaining any particular extension&#8212;and no guarantee any such extension would confer patent term for a sufficient period of time to exclude others from commercializing product candidates similar or identical to us. In the United States, depending upon the timing, duration and specifics of FDA marketing approval of product candidates, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved product or approved indication. In the United States, patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval; only one patent may be extended; and extension is available for only those claims covering the approved drug, a method for using it, or a method for manufacturing it. The applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to its patents, or may grant more limited extensions than we request. An extension may not be granted or may be limited where there is, for example, a failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply before expiration of relevant patents, or some other failure to satisfy applicable requirements. If this occurs, our competitors may be able to launch their products earlier by taking advantage of our investment in development and clinical trials along with our clinical and preclinical data. This could have a material adverse effect on our business and ability to achieve profitability. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future technologies or product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States or elsewhere could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The United States has enacted and implemented wide-ranging patent reform legislation. On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law, which could increase the uncertainties and costs surrounding the prosecution of our owned or <span style="white-space:nowrap">in-licensed</span> patent applications and the enforcement or defense of any future owned or <span style="white-space:nowrap">in-licensed</span> issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. patent system from a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-invent&#8221;</span></span> system to a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-file&#8221;</span></span> system. Under a <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-file</span></span> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after March&#160;16, 2013, but before we, could therefore be awarded a patent covering an invention of our even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&#160;file any patent application related to our product candidates or (ii)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. The Leahy-Smith Act also allows third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to challenge the validity of a patent by the USPTO administered post grant proceedings, including derivation, reexamination, inter partes review, post-grant review and interference proceedings. The USPTO developed additional regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and, in particular, the <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-file</span></span> provisions, became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or <span style="white-space:nowrap">in-licensed</span> patent applications and the enforcement or defense of our issued, owned or <span style="white-space:nowrap">in-licensed</span> patents, all of which could have a material adverse impact on our business prospects and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As referenced above, for example, courts in the U.S. continue to refine the heavily <span style="white-space:nowrap"><span style="white-space:nowrap">fact-and-circumstance-dependent</span></span> jurisprudence defining the scope of patent protection available for therapeutics, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This creates uncertainty about our ability to obtain patents in the future and the value of such patents. In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. The United States has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system will likely be introduced by the end of 2023, which would significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will soon have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdiction of the Unitary Patent Court, or UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single <span style="white-space:nowrap">UPC-based</span> revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other companies or organizations may challenge our or our licensors&#8217; patent rights. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may attempt to invalidate our or our licensors&#8217; intellectual property rights via procedures including but not limited to patent infringement lawsuits, interferences, oppositions and inter partes reexamination proceedings before the USPTO, U.S. courts, and foreign patent offices or foreign courts. Even if such rights are not directly challenged, disputes could lead to the weakening of our or our licensors&#8217; intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management, and could have a material and adverse impact on our profitability, financial condition and prospects or ability to successfully compete. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our licensors may find it necessary to pursue claims or to initiate lawsuits to protect or enforce our owned or <span style="white-space:nowrap">in-licensed</span> patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to our owned or <span style="white-space:nowrap">in-licensed</span> patent or other intellectual property rights, even if resolved in our favor, could be substantial, and any litigation or other proceeding would divert our management&#8217;s attention. Such litigation or proceedings could materially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Some of our competitors may be able to more effectively to sustain the costs of complex patent litigation because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and materially limit our ability to continue our operations. Furthermore, because of the substantial amount of discovery required in connection with certain such proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, such announcements could have a material adverse effect on the price of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our licensors were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technology, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, claiming patent-ineligible subject matter, lack of novelty, indefiniteness, lack of written description, <span style="white-space:nowrap">non-enablement,</span> anticipation or obviousness. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome of such invalidity and unenforceability claims is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we or our licensors and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection for one or more of our product candidates or certain aspects of our platform technology. Such a loss of patent protection could have a material adverse effect on our business, financial condition, results of operations and prospects. Patents and other intellectual property rights also will not protect our product candidates and technologies if competitors or third parties design around such product candidates and technologies without legally infringing, misappropriating or violating our owned or <span style="white-space:nowrap">in-licensed</span> patents or other intellectual property rights. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on current or future technologies or product candidates in all countries throughout the world would be prohibitively expensive. Competitors or other third parties may use our technologies in jurisdictions where we have not obtained patent protection to develop our own products and, further, may export infringing product candidates to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These product candidates may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States. Many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, including certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of any owned and <span style="white-space:nowrap">in-licensed</span> patents we may obtain in other countries, or the marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our owned or <span style="white-space:nowrap">in-licensed</span> intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and could divert our efforts and attention from other aspects of our business. Such proceedings could also put any owned or <span style="white-space:nowrap">in-licensed</span> patents at risk of being invalidated or interpreted narrowly, could put our owned or <span style="white-space:nowrap">in-licensed</span> patent applications at risk of not issuing, and could provoke third parties to assert claims against our or out licensors. We or our licensors may not prevail in any lawsuits or other adversarial proceedings that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, we and our licensors&#8217; efforts to enforce such intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or <span style="white-space:nowrap">in-licenses.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of its patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business prospects may be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, upon our ability or the ability of our potential future collaborators to develop, manufacture, market and sell our current or any future product candidates and to use our proprietary technologies without infringing, misappropriating or violating the proprietary and intellectual property rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter partes reexamination proceedings before the USPTO, U.S. courts, foreign patent offices or foreign courts. As the field of antibody-based therapeutics matures, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, there is uncertainty as to when, to whom, and with what claims. Any claims of patent infringement asserted by third parties would be time consuming and could: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">result in costly litigation that may cause negative publicity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">divert the time and attention of our technical personnel and management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cause development delays; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to develop <span style="white-space:nowrap">non-infringing</span> technology, which may not be possible on a cost-effective basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subject us to significant liability to third parties; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be <span style="white-space:nowrap">non-exclusive,</span> which could result in its competitors gaining access to the same technology. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties. Because patent applications can take many years to issue, there may also be currently pending patent applications that may later result in issued patents that our technology or product candidates may infringe. Further, we cannot guarantee that we are aware of all of patents and patent applications potentially relevant to our technology or products. We may not be aware of potentially relevant third-party patents or applications for several reasons. For example, U.S. applications filed before November&#160;29, 2000, and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until a patent issues. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or platform technologies could have been filed by others without its knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover its platform, our product candidates or the use of our technologies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although no third party has asserted a claim of patent infringement against us as of the date hereof, others may hold proprietary rights that could prevent our product candidates from being marketed. We or our licensors, or any future strategic collaborator, may be party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current or any potential future product candidates and technologies, including derivation, reexamination, inter partes review, post-grant review or interference proceedings before the USPTO and similar proceedings in jurisdictions outside of the United States such as opposition proceedings. In some instances, we may be required to indemnify its licensors for the costs associated with any such adversarial proceedings or litigation. Third parties may assert infringement claims against us, our licensors or our strategic collaborators based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation or other adversarial proceedings with us, our licensors or our strategic collaborators to enforce or otherwise assert their patent rights. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a material adverse impact on our ability to utilize our discovery platform or to commercialize our current or any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity by presenting clear and convincing evidence of invalidity. There is no assurance that a court of competent jurisdiction, even if presented with evidence we believe to be clear and convincing, would invalidate the claims of any such U.S. patent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we cannot guarantee that we will be able to successfully settle or otherwise resolve such adversarial proceedings or litigation. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our product candidates. If we, or our licensors, or any future strategic collaborators are found to infringe, misappropriate or violate a third-party patent or other intellectual property rights, We could be required to pay damages, including treble damages and attorney&#8217;s fees, if we are found to have willfully infringed. In addition, we, or our licensors, or any future strategic collaborators may </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
choose to seek, or be required to seek, a license from a third party, which may not be available on commercially reasonable terms, if at all. Even if a license can be obtained on commercially reasonable terms, the rights may be <span style="white-space:nowrap">non-exclusive,</span> which could give our competitors access to the same technology or intellectual property rights licensed to us, and we could be required to make substantial licensing and royalty payments. Parties making claims against we may obtain injunctive or other equitable relief, which could effectively block its ability to further develop and commercialize our current or future product candidates. We could be forced, including by court order, to cease utilizing, developing, manufacturing and commercializing our discovery platform or product candidates deemed to be infringing. We may be forced to redesign current or future technologies or products. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. Any of the foregoing could have a material adverse effect on our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thus, it is possible that one or more third parties will hold patent rights to which we will need a license, which may not be available on reasonable terms or at all. If such third parties refuse to grant us a license to such patent rights on reasonable terms or at all, we may be required to expend significant time and resources to redesign our technology, product candidates or the methods for manufacturing our product candidates, or to develop or license replacement technology, all of which may not be commercially or technically feasible. In such case, we may not be able to market such technology or product candidates and may not be able to perform research and development or other activities covered by these patents. This could have a material adverse effect on our ability to commercialize our product candidates and our business and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common stock to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings or developments in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing product candidates, approved products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights of third parties could adversely affect our ability to commercialize our current or future technologies or product candidates, and we might be required to litigate or obtain licenses from third parties to develop or market our current or future technologies or product candidates, which may not be available on commercially reasonable terms or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the antibody landscape is still evolving, it is difficult to conclusively assess our freedom to operate without infringing, misappropriating or violating third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering antibodies generally or covering portions of antibodies that may be relevant for product candidates that we wish to develop. We are aware of third party patents and patent applications that claim aspects of our current or potential future product candidates and modifications that we may need to apply to our current or potential future product candidates. In particular, we are aware of granted patents that cover certain aspects of the <span style="white-space:nowrap">SZN-1326</span> product candidate and pending patent applications that could result in patents that cover aspects of the <span style="white-space:nowrap">SZN-043</span> product candidate. There are also many issued patents that claim antibodies or portions of antibodies that may be relevant to products we wish to develop. The holders of such patents and patent applications may be able to block or delay our ability to develop and commercialize the applicable product candidates, including <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043,</span> unless we obtain a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all, or it may be <span style="white-space:nowrap">non-exclusive,</span> which could result in our competitors gaining access to the same intellectual property. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitive position may materially suffer if patents issued to third parties or other third-party intellectual property rights cover our current or future technologies product candidates or elements thereof or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize current or future technologies, product candidates unless we successfully pursues litigation to narrow or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our current or future technologies or product candidates. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our current or future technologies or product candidates. If such an infringement claim should successfully be brought, we may be required to pay substantial damages or be forced to abandon our current or future technologies or product candidates or to seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party intellectual property right holders may also actively bring infringement, misappropriation, or other claims alleging violations of intellectual property rights against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our product candidates. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our current or future technologies or product candidates that are held to be infringing, misappropriating or otherwise violating third-party intellectual property rights. We might, if possible, also be forced to redesign current or future technologies or product candidates so that we no longer infringes, misappropriate or violate the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business, which could have a material adverse effect on its financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If, in the future, we develop trade secrets and are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patent protection for certain aspects of our current or future technologies and product candidates, we may in the future consider trade secrets, including confidential and unpatented <span style="white-space:nowrap">know-how,</span> to be important to the maintenance of its competitive position. However, trade secrets and <span style="white-space:nowrap">know-how</span> can be difficult to protect. If we develop trade secrets, we plan to protect trade secrets and confidential and unpatented <span style="white-space:nowrap">know-how,</span> in part, by entering into <span style="white-space:nowrap">non-disclosure</span> and confidentiality agreements with parties who have access to such knowledge, such as its employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants under which they are obligated to maintain confidentiality and to assign their inventions to it. However, we cannot be certain that such agreements have been entered into with all relevant parties, and cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Moreover, individuals with whom we have such agreements may not comply with their terms. Any of these parties may breach such agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for any such breaches. We may also become involved in inventorship disputes relating to inventions and patents developed by our employees or consultants under such agreements. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret, or securing title to an employee- or consultant-developed invention if a dispute arises, is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions disfavor or are unwilling to protect trade secrets. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent that competitor from using the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technology or information to compete with it. If, in the future, any of our trade secrets were to be disclosed to or independently developed by a competitor, its competitive position would be materially and adversely harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of our employees&#8217; or consultants&#8217; former employers or their clients. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees or consultants and our licensors&#8217; employees or consultants were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that one or more of these employees or consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of former employers. Litigation or arbitration may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights or personnel or may be enjoined from using such intellectual property. Any such proceedings and possible aftermath would likely divert significant resources from its core business, including distracting our technical and management personnel from their normal responsibilities. A loss of key research personnel or their work product could limit our ability to commercialize, or prevent it from commercializing, our current or future technologies or product candidates, which could materially harm our business. Even if we are successful in defending against any such claims, litigation or arbitration could result in substantial costs and could be a distraction to management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <span style="white-space:nowrap">in-licensed</span> patents, trade secrets, or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or <span style="white-space:nowrap">in-licensed</span> patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and <span style="white-space:nowrap">in-licenses.</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <span style="white-space:nowrap">in-license,</span> or use these third-party proprietary rights. We may be unable to acquire or <span style="white-space:nowrap">in-license</span> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that We may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow it to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, it may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on its business, financial condition, results of operations, and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and <span style="white-space:nowrap">in-licensed</span> patents or applications and any patent rights it may own or <span style="white-space:nowrap">in-license</span> in the future. The USPTO and various <span style="white-space:nowrap">non-U.S.</span> patent offices require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help it comply with these requirements, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our <span style="white-space:nowrap">in-licensed</span> intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which <span style="white-space:nowrap">non-compliance</span> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical product candidates or platforms, which could have a material adverse effect on our business prospects and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Some intellectual property that we have <span style="white-space:nowrap">in-licensed</span> may have been discovered through government funded programs and thus may be subject to federal regulations such as <span style="white-space:nowrap">&#8220;march-in&#8221;</span> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with <span style="white-space:nowrap">non-U.S.</span> manufacturers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual property rights we have licensed were generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a <span style="white-space:nowrap">non-exclusive,</span> <span style="white-space:nowrap">non-transferable,</span> irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or <span style="white-space:nowrap">non-exclusive</span> licenses to any of these inventions to a third party if we determine that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as <span style="white-space:nowrap">&#8220;march-in</span> rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fails to disclose the invention to the government and fails to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with <span style="white-space:nowrap">non-U.S.</span> product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be forced to stop using these names, which we use for name recognition by potential collaborators or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, it may not be able to compete effectively and our business may be materially adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights do not necessarily address all potential threats to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect its business. The following examples are illustrative: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may be able to make antibodies or portions of antibodies or formulations that are similar to our product candidates, but that are not covered by the claims of any patents that we own, license or control; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we or any strategic collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own license or control; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we or our licensors might not have been the first to file patent applications covering certain of our owned and <span style="white-space:nowrap">in-licensed</span> inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may independently develop the same, similar, or alternative technologies without infringing, misappropriating or violating our owned or <span style="white-space:nowrap">in-licensed</span> intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that our owned or <span style="white-space:nowrap">in-licensed</span> pending patent applications will not lead to issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issued patents that we own, <span style="white-space:nowrap">in-licenses,</span> or controls may not provide us with any competitive advantages, or may be narrowed or held invalid or unenforceable, including as a result of legal challenges; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may choose not to file a patent application in order to maintain certain trade secrets or <span style="white-space:nowrap">know-how,</span> and a third party may subsequently file a patent application covering such trade secrets or <span style="white-space:nowrap">know-how;</span> and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patents of others may have an adverse effect on our business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse impact on our business and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical development includes a lengthy and expensive process with an uncertain outcome, we may have negative results and results of earlier studies and trials may not be predictive of future trial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043</span> have begun clinical development and their risk of failure is high. It is impossible to predict when or if our candidates or any potential future product candidates will prove effective in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety, purity, and potency, or efficacy of that product candidate in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain, particularly in light of recent observations relating to clinical trials for <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043.</span> Failure can occur at any time during the development process. The results of preclinical studies and clinical trials of any of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our current or potential future product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or safety profiles, notwithstanding promising results in earlier trials. We initiated <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> trials of <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043</span> in the third quarter of 2022. We have experienced (as described above), and may further experience, delays in initiating or completing our clinical studies. We do not know whether planned clinical trials will be completed on schedule or at all, or whether planned clinical trials will begin on time, need to be redesigned, will enroll patients on time or be completed on schedule, if at all. Our development programs may be delayed for a variety of reasons, including delays related to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unfavorable findings or observations that cause us to pause or modify our clinical trials, as we have done to some degree with <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA or other regulatory authorities requiring additional data or imposing other requirements before permitting initiation of a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining regulatory approval to commence a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining institutional review board, or IRB, or ethics committee, or EC, approval at each clinical trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recruiting suitable patients to participate in a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">having patients complete a clinical trial or return for post-treatment <span style="white-space:nowrap">follow-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites deviating from trial protocol or dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adding new clinical trial sites; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing sufficient quantities of our product candidates for use in clinical trials. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Furthermore, we expect to rely on CROs, collaborators such as BI and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we expect to enter into agreements governing their committed activities, we may have limited influence over their actual performance. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of current or potential future product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, our collaborators, the IRBs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of any of our current or potential future product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenue from such product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our current or potential future product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> or potential future product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> and any potential future product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. It is possible that none of the product candidates we may develop will obtain the regulatory approvals necessary for us or our potential future collaborators to begin selling them. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA and other regulatory authorities. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating us require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in regulatory policy during the period of product development, clinical trials and FDA regulatory review in the United States and other jurisdictions. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we are seeking approval. Further, we and our potential future collaborators may never receive approval to market and commercialize any product candidate. Even if we or a potential future collaborator obtain regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as it intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a potential future collaborator may be subject to post-marketing testing requirements to maintain regulatory approval. If any of our product candidates prove to be ineffective, unsafe or commercially unviable, we may have to <span style="white-space:nowrap">re-engineer</span> the product candidates, and our entire pipeline could have little, if any, value, which could require us to change our focus and approach to drug discovery and therapeutic development, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also be subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that it will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we succeed in developing any products, we intend to market them in the United States as well as the European Union and other foreign jurisdictions. In order to market and sell our products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that it will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fails to comply with the regulatory requirements in international markets or fails to receive applicable marketing approvals, our target market will be reduced, and our ability to realize the full market potential of our product candidates will be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have conducted certain of our clinical trials for our product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case its development plans will be delayed, which could materially harm its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted and may further conduct clinical trials for our product candidates outside the United States. For example, we have conducted Phase 1 trials of <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043</span> in Australia and New Zealand. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless (i)&#160;those data are applicable to the U.S. population and U.S. medical practice; (ii)&#160;the studies were performed by clinical investigators of recognized competence; and (iii)&#160;the data are considered valid without the need for an <span style="white-space:nowrap">on-site</span> inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an <span style="white-space:nowrap">on-site</span> inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. For studies that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an <span style="white-space:nowrap">on-site</span> inspection if it deems such inspection necessary. For such studies not subject to an IND, the FDA generally does not provide advance comments on the clinical protocols for the studies, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a <span style="white-space:nowrap">non-U.S.</span> clinical trial was inadequate, which could require us to conduct additional clinical trials. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of Our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction or permanently halt our development of our product candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additional foreign regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign exchange fluctuations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with foreign manufacturing, customs, shipment and storage requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cultural differences in medical practice and clinical research; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diminished protection of intellectual property in some countries. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we receive regulatory approval for any of our current or potential future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our current or potential future product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we or our current or potential future collaborators obtain for <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> or any potential future product candidate may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including &#8220;Phase 4&#8221; clinical trials, and surveillance to monitor the safety and efficacy of such product candidate. In addition, if the FDA or any other regulatory authority approves <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> or any of our future product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for such product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and good clinical practices for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product candidate, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product candidate, withdrawal of the product candidate from the market or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters or holds on clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic collaborators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or revocation of product license approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention or refusal to permit the import or export of products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. While physicians may prescribe, in their independent professional medical judgment, products for <span style="white-space:nowrap">off-label</span> uses as the FDA does not regulate the behavior of physicians in their choice of drug treatments, the FDA does restrict manufacturer&#8217;s communications on the subject of <span style="white-space:nowrap">off-label</span> use of their products. Companies may only share truthful and <span style="white-space:nowrap">non-misleading</span> information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other authorities actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses and a company that is found to have improperly promoted <span style="white-space:nowrap">off-label</span> uses may be subject to significant liability including, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of <span style="white-space:nowrap">off-label</span> use and has enjoined </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies from engaging in <span style="white-space:nowrap">off-label</span> promotion. The FDA and other regulatory authorities have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Occurrence of any of the foregoing could have a material and adverse effect on our business and results of operations. The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. Among the provisions of the ACA, of greatest importance to the pharmaceutical and biotechnology industry are the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (and 70% as of January&#160;1, 2019) <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expansion of the entities eligible for discounts under the Public Health program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">implementation of the federal physician payment transparency requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act.&#8221; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been legal and political challenges to certain aspects of the ACA. For example, on June&#160;17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In addition, on August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> cost and creating a new manufacturer discount program. It is unclear how any additional future challenges or the healthcare reform measures of the Biden administration will impact the ACA and our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April&#160;1, 2013 and will remain in effect through 2031, unless additional Congressional action is taken. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. The American Taxpayer Relief Act of 2012 among other things, reduced Medicare payments to several providers, including hospitals and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers. Additionally, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. In addition, the IRA, among other things, (i)&#160;directs the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs and biologics under the law, and (ii)&#160;imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October&#160;14, 2022, directing HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. It is unclear whether this executive order or similar policy initiatives will be implemented in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we or our existing or potential future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our product candidates and may harm our reputation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors, among others, will play a primary role in the prescription and recommendation of any product candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors, providers and customers, among others, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which it obtains marketing approval. Restrictions under applicable federal and state healthcare laws and regulations in the United States and other countries, include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Anti-Kickback Statute, which prohibits, among other things, a person or entity from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease order, arranging for or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, a violation of the Anti-Kickback Statute can form the basis for a violation of the federal False Claims Act (discussed below); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal civil and criminal false claims laws and civil monetary penalties laws, including the federal False Claims Act, which provides for civil whistleblower or qui tam actions, that impose penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a referral made in violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates and covered subcontractors that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal physician payment transparency requirements, sometimes referred to as the &#8220;Sunshine Act&#8221; under the Affordable Care Act, require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, information related to transfers of value made to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests of such physicians and their immediate family members; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">analogous local, state and foreign laws and regulations, such as state anti-kickback and false claims laws that may apply to healthcare items or services reimbursed by third party payors, including private insurers; local, state and foreign transparency laws that require manufacturers to report information related to payments and transfers of value to other healthcare providers and healthcare entities, marketing expenditures, or drug pricing; state laws that require pharmaceutical companies to register certain employees engaged in marketing activities in the location and comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our future business arrangements with third parties comply with applicable healthcare reporting, privacy, data protection, cybersecurity and other laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation in government healthcare programs, integrity obligations, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of <span style="white-space:nowrap">pre-marketing</span> product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, refusal to allow us to enter into supply contracts, including government contracts, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of <span style="white-space:nowrap">non-compliance</span> with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause it to incur significant legal expenses and could divert its management&#8217;s attention from the operation of its business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive marketing and commercialization approval of a product candidate, we will be subject to continuing regulatory requirements, including in relation to adverse patient experiences with the product and clinical results that are reported after a product is made commercially available, both in the United States and any foreign jurisdiction in which it seeks regulatory approval. The FDA and other regulatory authorities have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product candidate from the market. The FDA and other regulatory authorities also have the authority to require a Risk Evaluation and Mitigation Strategy, or a REMS, after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturer and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory authorities, including for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product candidate, manufacturer or facility, including withdrawal of the product candidate from the market. We intend to rely on third-party manufacturers and will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or any of our existing or future collaborators, manufacturers or service providers fails to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, it or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA or other regulatory authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, such as government authorities, private health insurers and health maintenance organizations. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from government healthcare programs, such as Medicare and Medicaid, and private health insurers are critical to new product acceptance. Patients are unlikely to use our future products, if any, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost-containment is a priority in the U.S. healthcare industry and elsewhere. As a result, government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors also may request additional clinical evidence beyond the data required to obtain marketing approval, requiring a company to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our product. Commercial third-party payors often rely upon Medicare coverage policy and payment limitations in setting their reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement for pharmaceutical products in the U.S. can differ significantly from payor to payor. We cannot be sure that coverage and adequate reimbursement will be available for any product that it commercializes and, if reimbursement is available, that the level of reimbursement will be adequate. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize any product candidate for which it obtains marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the regulations that govern regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country. Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay its commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues it is able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup its investment in one or more product candidates, even if our product candidates obtain regulatory approval. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and <span style="white-space:nowrap">non-compliance</span> with such laws can subject us to criminal or civil liability and harm its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of government agencies and government-affiliated hospitals, universities and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad or to obtain necessary permits, licenses and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, its employees, representatives, contractors, collaborators, and agents, even if it does not explicitly authorize or have actual knowledge of such activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas, investigations or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new product candidates and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact its business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new product candidates can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times, and certain regulatory authorities, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on its business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Ownership of Our Shares </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our stock price may be volatile and purchasers of our common stock could incur substantial losses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. As a result of this volatility, investors may not be able to sell their common stock at or above the initial public offering price. The market price for our common stock may be influenced by many factors, including the other risks described in this section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; and the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability, or the ability of our business partners, to advance <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> or potential future product candidates into the clinic; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results of preclinical and clinical studies for <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043,</span> <span style="white-space:nowrap">SZN-413</span> or potential future product candidates, or those of our competitors or current and potential future collaborators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of health epidemics on our business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our future products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of competitive products or technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">introductions and announcements of new products by us, our future commercialization collaborators, or our competitors, and the timing of these introductions or announcements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actions taken by regulatory authorities with respect to our future products, clinical trials, manufacturing process or sales and marketing terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of our efforts to acquire or <span style="white-space:nowrap">in-license</span> additional technologies, products or product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developments concerning any future collaborations, including, but not limited to, those with our sources of manufacturing supply and our commercialization collaborators; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market conditions in the pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements by us or our competitors of significant acquisitions, strategic alliances, joint ventures or capital commitments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability or inability to raise additional capital and the terms on which we raise it; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the recruitment or departure of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the structure of healthcare payment systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuations in the valuation of companies perceived by investors to be comparable to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcement and expectation of additional financing efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">speculation in the press or investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our common stock; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our common stock by us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the concentrated ownership of our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in accounting principles; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">terrorist acts, acts of war or periods of widespread civil unrest; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">natural disasters, public health crises and other calamities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general economic, industry and market conditions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because our management will have flexibility in allocating our cash, you may not agree with how we use them and the cash may not be invested successfully. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently expect to use our current cash to fund the development of <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043</span> through the resumption and continuation of first in human trials and to fund our other ongoing research and discovery programs, as well as for working capital and other general corporate purposes. We may also use a portion of our cash to <span style="white-space:nowrap">in-license,</span> acquire or invest in complementary businesses, technologies, products or assets. However, other than our CLA with BI, we have no current commitments or obligations to do so. Therefore, our management will have flexibility in allocating our cash. Accordingly, you will be relying on the judgment of our management with regard to the allocation of our cash, and you will not have the opportunity, as part of your investment decision, to assess whether the cash is being allocated appropriately. It is possible that the cash will be invested in a way that does not yield a favorable, or any, return for our company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may issue additional shares of Common Stock or other equity securities without your approval, including pursuant to our employee stock plans, our agreement with Lincoln Park and our agreement with Guggenheim, and holders of warrants and options may choose to exercise their warrants and options requiring us to issue shares of Common Stock; all of these actions would dilute your ownership interest and may depress the market price of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant additional capital will be needed in the future to continue our planned operations, including further development of our Wnt therapeutics platform, preparing IND or equivalent filings, conducting preclinical studies and clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock, including shares of common stock sold in this offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;1, 2023, we had Warrants outstanding to purchase an aggregate of 5,907,478 shares of Common Stock and options outstanding which are or will be exercisable into 5,301,567 shares of Common Stock. In addition, pursuant to the 2021 Plan and the 2021 Employee Stock Purchase Plan, or ESPP, we may issue an aggregate of up to 5,234,901 shares of Common Stock for awards granted under the 2021 Plan to our employees, directors and consultants. Additionally, on January&#160;1 of each year continuing through and including January&#160;1, 2031, the number of shares of our common stock reserved for issuance under our 2021 Plan and the ESPP will automatically increase by 5% and 1%, respectively, of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also issue additional shares of Common Stock or other equity securities of equal or senior rank in the future in connection with, among other things, future acquisitions or repayment of outstanding indebtedness, without stockholder approval, in a number of circumstances. The issuance of additional shares or other equity securities of equal or senior rank would have the following effects: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">existing stockholders&#8217; proportionate ownership interest in us will decrease; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amount of cash available per share, including for payment of dividends in the future, may decrease; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relative voting strength of each previously outstanding Common Stock may be diminished; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the market price of the Common Stock may decline. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A few stockholders, including one of our directors, may control the voting rights with respect to a large number of shares of our common stock. They could exercise their voting power in a manner that adversely affects the Company or our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;1, 2023, our officers and directors control 35.4&#160;percent of our common stock, of which The Column Group (managed by one of our directors, Tim Kutzkey) controls 31.1&#160;percent of our common stock. Acting together, they could significantly influence any matter requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combinations. Furthermore, The Regents of the University of California controls 6.9% of our common stock, SymBiosis II, LLC controls 6.5% of our common stock and BML Investment Partners, L.P. controls 5.5% of our common stock. Combined, all of the foregoing stockholders control over 50% of our common stock, and acting together, they could determine the outcome of any matter requiring approval by a majority of stockholders, including the election of directors and the approval of mergers or other business combinations. The interests of this group may not always coincide with our interests or the interests of other stockholders and may cause, prevent or delay a change in control. This significant concentration of share ownership may adversely affect the trading price of our common stock because many investors perceive disadvantages to owning stock in companies with controlling stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may delay or prevent an acquisition of our company or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a prohibition on actions by our stockholders by written consent; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a requirement that special meetings of stockholders, which our company is not obligated to call more than once per calendar year, be called only by the chairman of our board of directors, our chief executive officer, or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">division of our board of directors into three classes, serving staggered terms of three years each; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, as amended, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America, will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and, to the extent enforceable, the federal district courts of the United States of America, will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any derivative claim or cause of action brought on our behalf; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any claim or cause of action for breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any claim or cause of action against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, or DGCL, our certificate of incorporation or our bylaws; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">claim or cause of action seeking to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any claim or cause of action against us or any of our current or former directors, officers or other employees that is governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Securities Act, or the Securities Exchange Act of 1934, as amended, or the Exchange Act, or any claim for which the U.S. federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. The enforceability of similar exclusive federal forum provisions in other companies&#8217; organizational documents has been challenged in legal proceedings, and while the Delaware Supreme Court and certain other state courts have ruled that this type of exclusive federal forum provision is facially valid under Delaware law, there is uncertainty as to whether other courts would enforce such provisions and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If any other court of competent jurisdiction were to find either exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and Bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as permitted by Section&#160;145 of the DGCL, the Bylaws and our indemnification agreements that we entered into with our directors and officers provide that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we will not be obligated pursuant to our Bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rights conferred in the Bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not retroactively amend our Bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There can be no assurance that we will be able to comply with the continued listing standards of Nasdaq. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on the Nasdaq. To maintain that listing, we must satisfy minimum financial and other requirements including, without limitation, a requirement that our closing bid price be at least $1.00 per share. If Nasdaq delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face significant material adverse consequences including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a limited availability of market quotations for our securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced liquidity for our securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination that our Common Stock is a &#8220;penny stock&#8221; which will require brokers trading in our Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a decreased ability to issue additional securities or obtain additional financing in the future. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Because Common Stock and Public Warrants are listed on Nasdaq, they are covered securities. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. While we are not aware of a state, other than the State of Idaho, having used these powers to prohibit or restrict the sale of securities issued by blank check companies, certain state securities regulators view blank check companies unfavorably and might use these powers, or threaten to use these powers, to hinder the sale of securities of blank check companies in their states. Further, if we were no longer listed on Nasdaq, our securities would not be covered securities and we would be subject to regulation in each state in which we offer our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our securities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;4, 2023, we received a written notice from Nasdaq notifying us that on January&#160;3, 2023, the average closing price of our common stock over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2), or the Minimum Bid Requirement. We have 180 calendar days to regain compliance with the Minimum Bid Requirement, or the Grace Period, subject to a potential 180 calendar day extension, as described below. To regain compliance, the closing bid price of our common stock must be at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period. If we do not achieve compliance with the Minimum Bid Requirement by July&#160;3, 2023, the end of the Grace Period, we may be eligible for an additional 180 calendar day period to regain compliance. To qualify, we would be required to meet the continued listing requirement for the market value of our publicly held shares and all other Nasdaq initial listing standards, with the exception of the bid price requirement, and would need to provide written notice of our intention to cure the deficiency during the second compliance period. However, if it appears to Nasdaq staff that we will not be able to cure the deficiency, or if we do not meet the other listing standards, Nasdaq could provide notice that our common stock will be subject to delisting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such a delisting would likely have a negative effect on the price of the securities and would impair your ability to sell or purchase the securities when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our securities to become listed again, stabilize the market price or improve the liquidity of our securities, prevent our securities from dropping below the Nasdaq minimum share price requirement or prevent future <span style="white-space:nowrap">non-compliance</span> with Nasdaq&#8217;s listing requirements. Additionally, if our securities are not listed on, or become delisted from, Nasdaq for any reason, and are quoted on the OTC Bulletin Board, an inter-dealer automated quotation system for equity securities that is not a national securities exchange, the liquidity and price of our securities may be more limited than if we were quoted or listed on Nasdaq or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We qualify as an emerging growth company as well as a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies or smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#8220;emerging growth company&#8221; within the meaning of the Securities Act, as modified by the JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies for as long as we continue to be an emerging growth company, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payments not previously approved. As a result, our stockholders may not have access to certain information they may deem important. We will remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal year in which the market value of our Common Stock that is held by <span style="white-space:nowrap">non-affiliates</span> equals or exceeds $700&#160;million as of the end of that year&#8217;s second fiscal quarter, (ii)&#160;the last day of the fiscal year in which we have total annual gross revenue of $1.235&#160;billion or more during such fiscal year (as indexed for inflation), (iii) the date on which we have issued more than $1&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt in the prior three-year period or (iv)&#160;December&#160;31, 2025. Investors may find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&#160;107 of the JOBS Act also provides that an emerging growth company can take advantage of the exemption from complying with new or revised accounting standards provided in Section&#160;7(a)(2)(B) of the Securities Act as long as we are an emerging growth company. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to opt out of such extended transition period and, therefore, we may not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accountant standards used. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we qualify as a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <span style="white-space:nowrap">S-K.</span> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $250&#160;million as of the end of that year&#8217;s second fiscal quarter, or (ii)&#160;our annual revenues exceeded $100&#160;million during such completed fiscal year and the market value of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> equals or exceeds $700&#160;million as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A significant portion of our total outstanding shares of Common Stock are restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of Common Stock to drop significantly, even if our business is doing well. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our Common Stock that are currently restricted from immediate resale may be sold into the market in the near future. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of Common Stock. We are unable to predict the effect that sales may have on the prevailing market price of Common Stock and Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent our Warrants are exercised, additional shares of Common Stock will be issued, which will result in dilution to the holders of Common Stock and increase the number of shares eligible for resale in the public market. Sales, or the potential sales, of substantial numbers of shares in the public market by the selling securityholders, subject to certain restrictions on transfer until the termination of applicable <span style="white-space:nowrap">lock-up</span> periods, could increase the volatility of the market price of Common Stock or adversely affect the market price of Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There is no guarantee that the Warrants will be in the money, and they may expire worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price for the Warrants is $11.50 per share of Common Stock. There is no guarantee that the Warrants will be in the money prior to their expiration, and as such, the Warrants may expire worthless. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may amend the terms of the Public Warrants in a manner that may be adverse to holders with the approval by the holders of at least 50% of the then-outstanding Public Warrants. As a result, the exercise price of your Public Warrants could be increased, the exercise period could be shortened and the number of shares of our common stock purchasable upon exercise of a Public Warrant could be decreased, all without your approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Public Warrants are issued in registered form under a warrant agreement by and between Continental Stock Transfer&#160;&amp; Trust Company, as the warrant agent, and us, dated as of November&#160;18, 2020, or the Warrant Agreement. The Warrant Agreement provides that the terms of the Public Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then-outstanding Public Warrants to make any change that adversely affects the interests of the registered holders of Public Warrants. Accordingly, we may amend the terms of the Public Warrants in a manner adverse to a holder if holders of at least 50% of the then-outstanding Public Warrants approve of such amendment. Although our ability to amend the terms of the Public Warrants with the consent of at least 50% of the then-outstanding Public Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the Public Warrants, convert the Public Warrants into cash or stock (at a ratio different than initially provided), shorten the exercise period or decrease the number of shares of our common stock purchasable upon exercise of a Public Warrant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may redeem unexpired Public Warrants prior to their exercise at a time that is disadvantageous to holders, thereby making such Public Warrants worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the ability to redeem outstanding Public Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per Public Warrant, provided that the last reported sales price of our Common Stock equals or exceeds $18 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 <span style="white-space:nowrap">trading-day</span> period ending on the third trading day prior to the date on which we give proper notice of such redemption and provided certain other conditions are met. If and when the Public Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding Public Warrants could force you (a)&#160;to exercise your Public Warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so, (b)&#160;to sell your Public Warrants at the then-current market price when you might otherwise wish to hold your Public Warrants or (c)&#160;to accept the nominal redemption price which, at the time the outstanding Public Warrants are called for redemption, is likely to be substantially less than the market value of your Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may redeem your Public Warrants after they become exercisable for a number of shares of Common Stock determined based on the redemption date and the fair market value of our Common Stock. Any such redemption may have similar consequences to a cash redemption described above. In addition, such redemption may occur at a time when the Public Warrants are <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;out-of-the-money,&#8221;</span></span></span> in which case, you would lose any potential embedded value from a subsequent increase in the value of our Common Stock had your Public Warrants remained outstanding. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_6">MARKET AND INDUSTRY DATA </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain industry data and market data included in this prospectus were obtained from independent third-party surveys, market research, publicly available information, reports of governmental agencies and industry publications and surveys. All of management&#8217;s estimates presented herein are based upon management&#8217;s review of independent third-party surveys and industry publications prepared by a number of sources and other publicly available information. All of the market data used in this prospectus involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We believe that the information from these industry publications and surveys included in this prospectus is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_7">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares of Common Stock and Warrants offered by the selling securityholders pursuant to this prospectus will be sold by the selling securityholders for their respective accounts. We will not receive any of the proceeds from these sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will receive up to an aggregate of approximately $83.0&#160;million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. We expect to use the net proceeds from the exercise of the Warrants for general corporate purposes. We will have broad discretion over the use of proceeds from the exercise of the Warrants. There is no assurance that the holders of the Warrants will elect to exercise any or all of such Warrants. To the extent that the Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of the Warrants will decrease. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_8">DETERMINATION OF OFFERING PRICE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering price of the shares of Common Stock underlying the Warrants offered hereby is determined by reference to the exercise price of the Warrants of $11.50 per share. The Public Warrants are listed on Nasdaq under the symbol &#8220;SRZNW.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot currently determine the price or prices at which shares of Common Stock or Warrants may be sold by the selling securityholders under this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_9">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Market Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on Nasdaq under the symbols &#8220;SRZN&#8221; and &#8220;SRZNW&#8221;, respectively. Prior to the consummation of the Business Combination, Consonance&#8217;s Class&#160;A ordinary shares, units and the Public Warrants were listed on Nasdaq under the symbols &#8220;CHFW,&#8221; &#8220;CHFW.U&#8221; and &#8220;CHFW.W,&#8221; respectively. As of March&#160;1, 2023, there were 73 holders of record of the Common Stock and 26 holders of record of our Warrants. We currently do not intend to list the Private Placement Warrants or PIPE Warrants offered hereby on any stock exchange or stock market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on shares of Common Stock. We anticipate that we will retain all of our future earnings, if any, to fund the development and growth of our business. Any future determination to declare and pay dividends on Surrozen&#8217;s capital stock will be made at the sole discretion of our board of directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_10">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion and analysis should be read in conjunction with our audited consolidated financial statements and related notes included elsewhere in this prospectus. This discussion includes both historical information and forward-looking statements that involve risks, uncertainties and assumptions. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the sections titled &#8220;Item 1A. Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; included elsewhere in this prospectus. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless otherwise indicated, the terms &#8220;Surrozen,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; refer to Surrozen Operating, Inc., or Legacy Surrozen, prior to its Business Combination with <span style="white-space:nowrap">Consonance-HFW</span> Acquisition Corp. and Surrozen, Inc., formerly known as <span style="white-space:nowrap">Consonance-HFW</span> Acquisition Corp., together with its consolidated subsidiaries after giving effect to the Business Combination.</span><span style="font-weight:bold"> </span><span style="font-style:italic"> </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are discovering and developing biologic drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues, for human diseases. Building upon the seminal work of our founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway, we have made breakthrough discoveries that we believe will overcome previous limitations in harnessing the potential of Wnt biology. These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling. As a result of our discoveries, we are pioneering the selective activation of Wnt signaling, designing and engineering Wnt pathway mimetics, and advancing tissue-selective Wnt candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or <span style="white-space:nowrap">R-spondin</span> proteins, which are involved in activation and enhancement of the Wnt pathway, respectively. Given Wnt signaling is essential in tissue maintenance and regeneration throughout the body, we have the potential to target a wide variety of severe diseases, including certain diseases that afflict the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system. In each of these areas, we believe our approach has the potential to change the treatment paradigm for the disease and substantially impact patient outcomes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to exploit the full potential of Wnt signaling by identifying disease states responsive to Wnt modulation, design tissue-selective therapeutics, and advance candidates into clinical development in targeted indications with high unmet need. Our unique approach and platform technologies have led to the discovery and advancement of two lead product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated a Phase 1 clinical trial in the second quarter of 2022 for <span style="white-space:nowrap">SZN-1326,</span> our candidate in development for moderate to severe inflammatory bowel disease, or IBD, with ulcerative colitis, or UC, as our first proposed indication. <span style="white-space:nowrap">SZN-1326,</span> a Fzd5 targeted <span style="white-space:nowrap">bi-specific</span> antibody, is the first development candidate designed using Surrozen&#8217;s SWAP technology and targets the <span style="white-space:nowrap">Wnt-signaling</span> pathway in the intestinal epithelium. In preclinical animal models of acute and chronic colitis, <span style="white-space:nowrap">SZN-1326</span> has been shown to transiently activate Wnt signaling in the diseased intestine, stimulate intestinal epithelial regeneration, reduce inflammation and reduce disease activity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2022, we announced that we voluntarily paused enrollment in the single ascending dose, or SAD, portion of our Phase 1 clinical trial evaluating <span style="white-space:nowrap">SZN-1326</span> in healthy volunteers. Following the evaluation of the clinical data and further preclinical work, we will be <span style="white-space:nowrap">re-initiating</span> the Phase 1a clinical trial in healthy volunteers by <span style="white-space:nowrap">mid-2023</span> based on the minimum anticipated biologically effective level (MABEL) and anticipate safety data by the end of 2023. We anticipate initiating a Phase 1b clinical trial in ulcerative colitis patients in 2024 and expect proof of concept data to be potentially available in the second half of 2024. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated a Phase 1 clinical trial in the second quarter of 2022 for <span style="white-space:nowrap">SZN-043,</span> our candidate in development for severe alcoholic hepatitis, or AH. <span style="white-space:nowrap">SZN-043,</span> a hepatocyte-specific <span style="white-space:nowrap">R-spondin</span> mimetic bispecific fusion protein targeting ASGR1, is the first development candidate using Surrozen&#8217;s SWEETS technology which is designed to mimic the regenerative properties of the protein <span style="white-space:nowrap">R-Spondin</span> by enhancing Wnt signaling in a cell-targeted manner. In multiple preclinical animal models of liver injury and fibrosis, <span style="white-space:nowrap">SZN-043</span> has been shown to selectively activate Wnt signaling in the liver, stimulate transient hepatocyte proliferation, improve liver function and reduce fibrosis. We completed enrollment in the second cohort of the <span style="white-space:nowrap">SZN-043</span> Phase 1a single ascending dose clinical trial in healthy volunteers in 2022. We opened enrollment for the Phase 1a clinical trial in chronic liver disease and enrolled the first patient in the first quarter of 2023. We anticipate initiating a Phase 1b clinical trial in 2024 in patients with severe alcoholic hepatitis with proof of concept data expected to be potentially available in the second half of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2022, we nominated <span style="white-space:nowrap">SZN-413,</span> a Fzd4 targeted <span style="white-space:nowrap">bi-specific</span> antibody, as a development candidate for the treatment of retinal vascular associated diseases. Fzd4 mediated Wnt signaling is known to play a critical role in retinal vascular integrity and function. Data generated in preclinical models of retinopathy demonstrated <span style="white-space:nowrap">SZN-413</span> stimulated Wnt signaling and was able to induce normal retinal vessel regrowth while suppressing pathological vessel growth. In October 2022, we executed a Collaboration and Licensing Agreement, or CLA, with Boehringer Ingelheim International GmbH, or BI, to research, develop and commercialize Fzd4 <span style="white-space:nowrap">bi-specific</span> antibodies designed using our SWAP technology, including <span style="white-space:nowrap">SZN-413.</span> We anticipate the potential to identify the lead <span style="white-space:nowrap"><span style="white-space:nowrap">Fzd-4-targeted</span></span> Wnt agonist product candidate by the end of 2023, which would trigger a $10.0&#160;million milestone payment to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart below represents a summary of our wholly owned product candidates: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g66a66.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By leveraging our scientific capabilities and approach, we have identified multiple potential tissue types to explore. In our most advanced research programs, we are developing potential therapeutics for ocular diseases such as <span style="white-space:nowrap">age-related</span> macular degeneration, or AMD, and diabetic retinopathy. Genetic studies in the literature have identified that the Wnt signaling pathway is critical for maintenance of healthy retinal blood vessels. We have shown that activation of <span style="white-space:nowrap">Wnt-pathway</span> signaling can potentially reverse vascular damage through a mechanism that is distinct from the mechanisms of currently approved therapeutics that target angiogenesis. We also have identified the potential for regeneration of retinal pigment epithelium, or RPE, an important cell type in the retina. RPE cells are required for maintenance and viability of photoreceptors and as such are a potential target for the treatment of dry AMD. We are also assessing the potential to drive tissue repair in diseases resulting in tissue injury to organs including lacrimal gland and cornea. The chart below represents a summary of our wholly-owned research programs: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g66b66.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2022, we entered into a securities purchase agreement with entities affiliated with Consonance Capital Management LP, collectively the Consonance Entities. Pursuant to the agreement, we </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
repurchased and canceled 5.4&#160;million shares of common stock and warrants to purchase 1.3&#160;million shares of common stock from the Consonance Entities for an aggregate purchase price of approximately $2.7&#160;million. Following the repurchase, the Consonance Entities no longer hold any shares of common stock or warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2023, we implemented a restructuring plan approved by the Board of Directors to reduce our overall workforce by approximately 25%. We expect to substantially complete the workforce reduction by the end of first quarter of 2023 and estimate to incur <span style="white-space:nowrap">one-time</span> restructuring charges of approximately $1.2&#160;million, including employee severance, benefits and related costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in 2015, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, developing and optimizing our Wnt therapeutics platform, identifying potential product candidates, undertaking research and development activities, engaging in strategic transactions, establishing and enhancing our intellectual property portfolio, and providing general and administrative support for these operations. We have incurred net losses since inception. For the years ended December&#160;31, 2022 and 2021, we incurred net losses of $36.0&#160;million and $54.6&#160;million. As of December&#160;31, 2022, we had an accumulated deficit of $178.7&#160;million and cash, cash equivalents and marketable securities of $75.8&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur losses for the foreseeable future and expect to incur increased expenses as we expand our pipeline and advance our product candidates through clinical development and regulatory submissions. Specifically, in the near term we expect to incur substantial expenses relating to our Phase 1 clinical trials, the development and validation of our manufacturing processes, and other research and development activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Impact of Inflation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inflation has increased and is expected to continue to increase for the near future. Inflation generally affects us by increasing our labor costs, research and clinical trial costs. While we do not believe that inflation has had a material effect on our financial condition and results of operations during the periods presented, it may result in increased costs in the foreseeable future and adversely affect our business and financial condition. In addition, inflation may cause us to experience greater uncertainty in general economic conditions and additional volatility in the market price of our common stock, which are already subject to the effects of rising interest rates and the ongoing war in Ukraine. If these conditions worsen or do not improve, our ability to raise capital and our shareholders&#8217; ability to sell their shares will be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property and Licensing Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, our patent portfolio consisted of over 20 pending patent application families, including 15 families that have entered national phase in the United States and other countries, three families with pending Patent Cooperation Treaty, or PCT, applications, which have also been filed in certain <span style="white-space:nowrap">non-PCT</span> countries (e.g., Taiwan), and five families with pending U.S. provisional applications. These patent applications are directed to, for example, the SWAP and SWEETS platforms, the parental constructs of our two lead product candidate molecules, <span style="white-space:nowrap">SZN-043</span> and <span style="white-space:nowrap">SZN-1326,</span> the recently <span style="white-space:nowrap">out-licensed</span> <span style="white-space:nowrap">SZN-413,</span> as well as methods of treating disorders of the liver, intestine, retina, cornea, lacrimal gland, and kidney. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2022, we executed the CLA with Boehringer Ingelheim International GmbH, or BI, to research, develop and commercialize Fzd4 <span style="white-space:nowrap">bi-specific</span> antibodies designed using the Company&#8217;s SWAP technology, including <span style="white-space:nowrap">SZN-413,</span> as described in Note 7 of the footnotes to the financial statements of this prospectus. We and BI are conducting partnership research focused on <span style="white-space:nowrap">SZN-413</span> during a <span style="white-space:nowrap">one-year</span> period, which BI has the right to extend by up to six months. We granted BI an exclusive, royalty-bearing, worldwide, sublicensable license, under our applicable patents and know-how, to develop, manufacture and commercialize, for all uses, one lead and two back-up Fzd4 bi-specific antibodies selected by BI and their derivatives. After an initial period of joint </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research, BI shall be responsible for all further research, preclinical and clinical development, manufacturing, regulatory approvals, and commercialization of licensed products at its expense. For five years after the effective date of the CLA, we are prohibited from preclinically and clinically developing or commercializing Fzd4 bi-specific antibodies for any diseases of the eye, and BI is prohibited from clinically developing or commercializing licensed products for any purpose other than diseases of the eye. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have entered into patent and research license arrangements with third-parties, as described in Note 8 of the footnotes to the financial statements of this Report. The license agreements require milestone payments upon the achievement of certain regulatory and developmental stages. In addition, we will be required to pay royalties on sales of certain licensed products. As of December&#160;31, 2022, we have incurred nominal fees and milestone payments under our license agreements. Upon the achievement of further regulatory and developmental milestones and the sale of licensed products, we may incur significant fees and royalties under these licenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Components of Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Collaboration and License Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had not generated any revenue prior to the execution of the CLA in October 2022. Under the terms of the CLA, BI paid a <span style="white-space:nowrap">non-refundable</span> upfront payment of $12.5&#160;million less any applicable withholding tax, and we are eligible to receive success-based milestone payments up to $587.0&#160;million and <span style="white-space:nowrap">mid-single</span> digit to <span style="white-space:nowrap">low-double</span> digit royalties on net sales of the licensed products should any reach commercialization. We received $10.5&#160;million of the upfront payment from BI in November 2022 and expect to receive the refund of the associated withholding tax of $2.0&#160;million in 2023. The <span style="white-space:nowrap">non-refundable</span> upfront payment of $12.5&#160;million was recognized as collaboration and license revenue for the year ended December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to generate any revenue from the sale of our products unless and until we obtain regulatory clearance or approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We classify operating expenses into two main categories: (i)&#160;research and development expenses and (ii)&#160;general and administrative expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have focused significant resources on our research and development activities. Our research and development expenses consist of external and internal expenses incurred in connection with our research activities and development programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">External expenses include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs incurred under agreements with third parties, including CROs and other third parties conducting research and development activities on our behalf; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs of laboratory supplies and acquiring, developing and manufacturing drug candidate materials; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">license and sublicense costs under our license agreements made for intellectual property used in research and development activities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal expenses include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">personnel-related costs, including salaries, bonuses, benefits and stock-based compensation for individuals involved in our research and product development activities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">facilities, depreciation, and other allocated costs, which include rent and insurance. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We track external expenses that are directly attributable to our clinical development candidates. We allocate internal expenses to our clinical development candidates on a program-specific basis. The internal expenses for early-stage research and discovery programs are not allocated as our internal resources, employees and infrastructure are typically deployed across multiple programs. As such, we do not provide financial information regarding the costs incurred for early-stage research and discovery programs on a program-specific basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our research and development expenses will increase for the foreseeable future as we identify and develop product candidates, in particular as we seek to continue clinical trials and pursue regulatory approval and commercialization for <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> or any future product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates, many of which are outside of our control, including those associated with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability, and the ability of our primary business partners, to hire and retain key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and progress of preclinical and clinical development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and scope of preclinical and clinical programs we decide to pursue; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain our current research and development programs and to establish new ones; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing an appropriate safety profile with <span style="white-space:nowrap">IND-enabling</span> studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of sites and patients included in the clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the countries in which the clinical trials are conducted; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">per patient trial costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successful patient enrollment in, and the initiation of, clinical trials, as well as drop out or discontinuation rates, particularly in light of the lingering effects of the <span style="white-space:nowrap">COVID-19</span> pandemic, the availability of alternate treatments and the limited pool of eligible patients in certain disease areas; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the FDA or any comparable foreign regulatory authority; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of trials required for regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing, receipt and terms of any regulatory approvals from applicable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to establish new licensing or collaboration arrangements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the performance of our current and future business partners, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant and changing government regulation and regulatory guidance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of any business interruptions to our operations or to those of the third parties with whom we work, particularly in light of the conflict between Russia and Ukraine and the current <span style="white-space:nowrap">COVID-19</span> pandemic environment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of inflation on our expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">launching commercial sales of our drug candidates, if approved, whether alone or in collaboration with others; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of products that may compete with our product candidates or other market developments; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintaining a continued acceptable safety profile of the drug candidates following approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes in the outcome of any of these variables could mean a significant change in the costs and timing associated with the development of our drug candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel-related costs, including salaries, bonuses, benefits and stock-based compensation expense for personnel in executive, finance, human resources, business and corporate development, legal, information technology and other administrative functions. General and administrative expenses also include legal, audit, tax and other consulting fees, investor relations services, insurance costs, and facility costs not otherwise included in research and development expenses, and costs associated with compliance with the rules and regulations of the SEC and Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative expenses will increase for the foreseeable future to support our continued research and development activities and to reflect increased costs of operating as a public company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income consists primarily of interest earned on our cash equivalents and marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Income (Expense), Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense), net primarily consists of the gain on the change in fair value of warrant liabilities and the transaction costs allocated to the warrant liabilities assumed in the Business Combination occurred in August 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the years ended December&#160;31, 2022 and 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes results of operations for the periods presented (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:61%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$</span><br /><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%</span><br /><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and license revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,164</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56,839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54,391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(44,339</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(54,391</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-18</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">709</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(329</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,883</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36,004</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(54,648</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-34</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Percentage is not meaningful </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses for the periods presented (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:60%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$</span><br /><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%</span><br /><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SZN-1326</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,827</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,483</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,656</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-39</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SZN-043</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,702</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discovery and preclinical stage programs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,061</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,164</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">-8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease of $5.7&#160;million, or 39%, in <span style="white-space:nowrap">SZN-1326</span> program expenses for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021, is primarily due to the completion of manufacturing drug substance. The increase of $0.4&#160;million, or 4%, in <span style="white-space:nowrap">SZN-043</span> program expenses for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021, is primarily due to the decrease in the government grant from the National Institute of Health awarded in September 2020. The increase of $2.1&#160;million, or 14% in discovery and preclinical stage program expenses for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021, is primarily due to the increase in personnel-related expenses as a result of a higher headcount. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase of $5.6&#160;million, or 39%, in general and administrative expenses for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021, is primarily attributable to a $3.7&#160;million increase in personnel-related expenses, including a $1.3&#160;million increase in stock-based compensation expense, due to an increase in headcount, a $1.1&#160;million increase in facility-related costs and other expenses including rent and insurance and a $0.5&#160;million increase in information technology costs to support our growth and operations as a public company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase of $0.7&#160;million in interest income for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021, is due to the increase in interest rates on our money market funds and marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Income (Expense), Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase of $7.9&#160;million in other income (expense), net, for the year ended December&#160;31, 2022, compared to the year ended December&#160;31, 2021, is primarily attributable to a $7.8&#160;million increase in gain on the change in fair value of warrant liabilities and a $0.4&#160;million decrease in expense related to the warrant liabilities issued in connection with the Business Combination consummated in August 2011, offset by a $0.3&#160;million increase in expenses related to the commitment shares issued to Lincoln Park under the Equity Purchase Agreement in February 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have only generated collaboration and license revenue under the CLA with BI. We incurred significant net operating losses and negative cash flows from operations. Historically, we have financed our operations primarily through the sales of our equity securities and the payment received under our collaboration and license agreement. We anticipate that we will continue to incur net losses for the foreseeable future because of additional costs and expenses related to our research and development activities, including </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased expenses from pipeline advancement and advancement of our product candidates into and through clinical developments and associated regulatory submissions, and increased general and administrative expenses as we scale our organization as a public company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a purchase agreement and a registration rights agreement with Lincoln Park in February 2022, pursuant to which Lincoln Park is obligated to purchase up to $50.0&#160;million of our common stock from time to time at our sole discretion over a <span style="white-space:nowrap">36-month</span> period commencing on April&#160;27, 2022. To date we have not sold any shares of common stock under the purchase agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We executed the CLA in October 2022 and received $10.5&#160;million of the <span style="white-space:nowrap">non-refundable</span> upfront payment from BI in November 2022. The associated withholding tax of $2.0&#160;million is expected to be refunded to us in 2023. In addition, we will be eligible to receive success-based milestone payments up to $587.0&#160;million plus <span style="white-space:nowrap">mid-single</span> digit to <span style="white-space:nowrap">low-double</span> digit royalties on net sales of the licensed products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into an <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> sales agreement with Guggenheim Securities, LLC, in connection with a shelf registration statement on Form <span style="white-space:nowrap">S-3</span> filed in December 2022, under which we may issue and sell up to $23.0&#160;million of our common stock. To date we have not sold any shares of common stock under the sales agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we had cash, cash equivalents and marketable securities of $75.8&#160;million and accumulated deficit of $178.7&#160;million. We believe, based on our current operating plan, that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next 12 months from the date of this Report. Our ability to continue as a going concern is dependent upon our ability to successfully secure sources of financing and ultimately achieve profitable operations. Insufficient liquidity may require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Funding Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have only generated revenue from our partnership with BI in connection with the CLA executed in October 2022. We have not generated and do not expect to generate any revenue from sales of our products unless and until we obtain regulatory approval and commercialize one of our product candidates, and we do not know when, or if, that will occur. We will continue to require substantial additional capital to develop our products candidates and fund operations for the foreseeable future. Since our inception in 2015, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, developing and optimizing our Wnt therapeutics platform, identifying potential product candidates, undertaking research and development activities, engaging in strategic transactions, establishing and enhancing our intellectual property portfolio, and providing general and administrative support for these operations. We expect our expenses to continue to increase in connection with our ongoing activities as we continue to advance our product candidates through clinical development and regulatory approval. In addition, we will continue to incur additional costs associated with operating as a public company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our cash, cash equivalents and marketable securities will provide the capital needed to fund our operations for at least the next 12 months from the date of this prospectus. We expect that in the long-term we will need to raise additional capital through public or private equity offerings, debt financings or other capital sources, including government grants, potential collaborations with other companies or other strategic transactions as we do not expect sales of common stock to Lincoln Park or under the <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> offering with Guggenheim and revenue derived from the CLA to be sufficient to provide all necessary financing until we are able to generate revenue on our own. There can be no assurance that sufficient funds will be available to us at all or on attractive terms when needed from these sources. If we are unable to obtain additional funding from these or other sources when needed, it may be necessary to significantly reduce expenses through reductions in staff and delaying, scaling back operations, or stopping certain research and development programs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, rate of progress, results and costs of researching and developing our lead product candidates or any future product candidates, conducting preclinical and clinical studies, in particular our current ongoing clinical studies of <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome, costs, and timing involved in obtaining regulatory approvals for our lead product candidates or our other product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the achievement of milestones that trigger payments to us and the timing, receipt and amount of royalties under the CLA and any collaboration and license agreement we may enter in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and scope of clinical programs we decide to pursue; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of acquiring, licensing, or investing in product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with securing and establishing commercialization; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense, and enforcement of any patents or other intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need and ability to retain key management and hire scientific, technical, business, and medical personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing products and product candidates and other market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing, receipt, and amount of sales from <span style="white-space:nowrap">SZN-1326,</span> <span style="white-space:nowrap">SZN-043</span> and any other product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the economic and other terms, timing of, and success of any collaboration, licensing, or other arrangements which we may enter in the future; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effects of the disruptions to and volatility in the credit and financial markets in the U.S. and worldwide from the conflict between Russia and Ukraine and the <span style="white-space:nowrap">COVID-19</span> pandemic. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any future financing through sales of equity securities, including sales of common stock to Lincoln Park and under the <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> offering with Guggenheim, will cause our stockholders to experience dilution. If we raise additional capital through debt financing, we may be subject to covenants that restrict our operations including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments, and engage in certain merger, consolidation, or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others our rights to any of our current or future product candidates or discovery programs in certain territories or indications that we would prefer to develop and commercialize ourselves. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary of Cash Flows </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the primary sources and uses of cash, cash equivalents and restricted cash for the periods presented below (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(44,145</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(48,813</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(77,708</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,565</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">124,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash, cash equivalents and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,401</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,891</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Used in Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities of $44.1&#160;million for the year ended December&#160;31, 2022 was primarily due to the use of funds in our operations and the resulting net loss of $36.0&#160;million and a net change of $8.4&#160;million in our net operating assets and liabilities, partially offset by $0.3&#160;million in <span style="white-space:nowrap">non-cash</span> charges. The net change in our operating assets and liabilities was primarily due to an increase in accounts receivable and a net decrease in accounts payable and accrued and other liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities of $48.8&#160;million for the year ended December&#160;31, 2021 was primarily due to the use of funds in our operations and the resulting net loss of $54.6&#160;million and a net change of $0.2&#160;million in our net operating assets and liabilities, partially offset by $6.0&#160;million in <span style="white-space:nowrap">non-cash</span> charges. The net change in our operating assets and liabilities was primarily due to a net increase in prepaid expenses, accounts payable and accrued and other liabilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Provided by (Used in) Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by investing activities of $38.3&#160;million for the year ended December&#160;31, 2022 consisted primarily of $68.6&#160;million of proceeds from the maturities of marketable securities, partially offset by $29.6&#160;million of cash used for the purchase of marketable securities and $0.8&#160;million of cash used for the purchase of property and equipment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in investing activities of $77.7&#160;million for the year ended December&#160;31, 2021 consisted primarily of $91.7&#160;million of cash used for the purchase of marketable securities and $1.3&#160;million of cash used for the purchase of property and equipment, partially offset by $15.3&#160;million of proceeds from the sale and maturities of marketable securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash (Used in) Provided by Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in financing activities of $2.6&#160;million for the year ended December&#160;31, 2022 consisted primarily of $2.7&#160;million of cash used for the repurchase of common stock and warrants, partially offset by $0.1&#160;million of proceeds from the issuance of common stock under the employee stock purchase plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities of $124.6&#160;million for the year ended December&#160;31, 2021 consisted primarily of $124.2&#160;million of net proceeds from the Business Combination and PIPE Financing and $0.4&#160;million of proceeds from the exercise of options. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Obligations and Commitments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we have lease obligations primarily consisting of one operating lease for our facility. The lease expires in April 2025. Under the terms of our operating leases, we had lease obligations consisting of $6.2&#160;million in payments through 2025 as of December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to license or subscription agreements pursuant to which we have <span style="white-space:nowrap">in-licensed</span> various intellectual property rights. The license agreements obligate us to make certain milestone payments related to achievement of specified events, as well as royalties in the low single-digit percentages based on sales of licensed products. The payment obligations under the license agreements are contingent upon future events, such as our achievement of specified milestones or generating product sales. As of December&#160;31, 2022, we were unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with third-party vendors for preclinical research studies, clinical trials, research supplies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination on notice, and may or may not include cancellation fees. Given that the amount and timing related to such payments are uncertain, they are not considered to be contractual obligations. As of December&#160;31, 2022, we had not accrued for any termination or cancellation charges as these were not considered probable. In February 2023, we cancelled certain studies with our contract manufacturing organization and incurred a cancellation fee equal to 50% of the contract price of the studies plus any raw materials and handling fees that have been incurred. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies, Significant Judgments and Use of Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in the notes to our consolidated financial statements included elsewhere in this prospectus, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue Recognition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue in accordance with ASC 606, <span style="font-style:italic">Revenue from Contracts with Customers (Topic 606)</span>,<span style="font-style:italic"> </span>when our customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for these goods or services. To determine revenue recognition for the arrangement that is within the scope of ASC 606, we perform the following five steps: (i)&#160;identify the contract with the customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration that we are entitled to in exchange for the goods or services transferred to the customer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At contract inception, we assess the goods or services promised within the contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revenue for the amount of the transaction price that is allocated to the respective performance obligations when or as the performance obligations are satisfied. We constrain the estimate of the transaction price up to the amount (the variable consideration constraint) that a significant reversal of recognized revenue is not probable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record accounts receivable for amounts billed to the customer for which we have an unconditional right to consideration. We assess accounts receivable for impairment and, to date, no impairment losses have been recorded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Licenses of Intellectual Property:</span> If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from <span style="white-space:nowrap">non-refundable</span> upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <span style="white-space:nowrap">non-refundable</span> upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Milestone Payments:</span> At contract inception, we use the most likely amount method to evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received or the underlying activity has been completed. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we <span style="white-space:nowrap">re-evaluate</span> the probability of achievement of such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <span style="white-space:nowrap">catch-up</span> basis, which would affect revenue in the period of adjustment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Royalties:</span> We recognize sales-based royalties as revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalties that have been allocated have been satisfied (or partially satisfied). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The incremental costs of obtaining a customer contract are expensed as and when incurred if the amortization period of the asset that would have been recognized is one year or less. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs consist of external and internal expenses directly attributable to the conduct of research and development programs. The external expenses include the costs of services provided by outside contractors, clinical research organizations and contract manufacturing organizations. The internal expenses include the costs of salaries, bonus, payroll taxes, stock-based compensation, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, and the facility costs for laboratory space used for research and development activities, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into and may continue to enter into license agreements to access and utilize certain technology. In each case, we evaluate if the license agreement results in the acquisition of an asset or a business. To date, none of our license agreements has been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expense when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Accrued Research and Development Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record accruals for estimated costs of research, preclinical, clinical and manufacturing development, within accrued expenses which are significant components of research and development expenses. A substantial portion of our ongoing research and development activities is conducted by third-party service providers. We accrue the costs under agreements with these third parties as incurred. We estimate the amounts incurred in each period based on the information available and our knowledge of the nature of the contractual activities generating such costs. Clinical trial contract expenses are accrued based on units of activity. Payments made to third parties under these arrangements in advance of the performance of the related services are recorded as prepaid expenses until the services are rendered. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust accrued expenses or prepaid expenses accordingly, which impacts research and development expenses. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Warrant Liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for all outstanding warrants as liabilities and record at fair value. At the end of each reporting period, changes in fair value during the period are recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. The fair values of the Public Warrants and Private Placement Warrants were determined based on the listed trading price of Public Warrants. The fair value of the PIPE Warrants was initially recorded using a binomial lattice model in 2021. The significant unobservable input used in the fair value measurement of the PIPE Warrants was the expected volatility. The expected volatility was implied from the market price of the Public Warrants. A binomial lattice model methodology was also used in estimating the fair value of the Public Warrants for periods where no observable traded price was available, using the same expected volatility as was used in measuring the fair value of the PIPE Warrants. Given the adequate history of the market data of the Public Warrants as of December&#160;31, 2022 and 2021, the PIPE Warrants were remeasured at December&#160;31, 2022 and 2021 based on the listed trading price of the Public Warrants. We will continue to adjust the warrant liabilities for changes in the fair value until the earlier of a) the exercise or expiration of the warrants or b) the redemption of the warrants, at which time such warrants will be reclassified to additional <span style="white-space:nowrap">paid-in</span> capital. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock-Based Compensation Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize stock-based compensation expense for all stock-based awards. Stock-based compensation costs are estimated at the grant date based on the fair value of the equity and recognized as expense, net of actual forfeitures when occur, on a straight-line basis over the requisite service period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We calculate the fair value of options using the Black-Scholes option-pricing model, which requires the use of various highly subjective assumptions as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Fair Value of Common Stock&#8212;See the subsection titled &#8220;Common Stock Valuations&#8221; below. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expected Term&#8212;We have opted to use the &#8220;simplified method&#8221; for estimating the expected term of options, whereby the expected term equals the arithmetic average of the <span style="white-space:nowrap">mid-point</span> between the vesting date and the end of contractual term of the option (generally ten years). The expected term for nonemployee awards is calculated based on the remaining contractual life to measure the remaining life of an award. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expected Volatility&#8212;Due to our limited operating history and a lack of sufficient company-specific historical and implied volatility data, we have based our estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock becomes available. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Risk-Free Interest Rate&#8212;The risk-free rate assumption is based on the U.S. Treasury zero coupon issued in effect at the time of grant with maturities similar to the expected term of our options. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Expected Dividend Yield&#8212;We have not issued any dividends in our history and do not expect to pay dividends on our common stock over the life of the options and therefore have estimated the dividend yield to be zero. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will continue to use judgment in evaluating the expected volatility, expected terms and interest rates utilized for our stock-based compensation expense calculations on a prospective basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2022 and 2021, stock-based compensation expense was $4.5&#160;million and $2.3&#160;million, respectively. As of December&#160;31, 2022, we had $9.9&#160;million of total unrecognized stock-based compensation costs, which we expect to recognize over an estimated weighted-average period of 2.5 years. We expect to continue to grant options and other stock-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Common Stock Valuations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the absence of a public trading market of our common stock prior to the Business Combination, and in accordance with the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation, or the Practice Aid, our board of directors exercised reasonable judgment and considered numerous and subjective factors to determine the best estimate of fair value of our common stock prior to the Business Combination, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">relevant precedent transactions involving our capital stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">contemporaneous valuations performed by third-party specialists; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">rights, preferences, and privileges of our redeemable convertible preferred stock relative to those of our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual operating and financial performance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">current business conditions and financial projections; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">likelihood of achieving a liquidity event, such as an initial public offering or a sale of our business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the lack of marketability of our common stock, and the illiquidity of stock-based awards involving securities in a private company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market multiples of comparable publicly-traded companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">stage of development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">industry information such as market size and growth; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. and global capital and macroeconomic conditions. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, we considered the following methods: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Option Pricing Method, or OPM. </span>Under the OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are inferred by analyzing these options. This method is appropriate to use when the range of possible future outcomes is so difficult to predict that estimates would be highly speculative, and dissolution or liquidation is not imminent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Probability-Weighted Expected Return Method, or PWERM</span>. The PWERM is a scenario-based analysis that estimates value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For valuations performed beginning in 2021, prior to the Business Combination, in accordance with the Practice Aid, we used a hybrid approach of the OPM and the PWERM methods to determine the estimated fair value of our common stock as a result of the increasing likelihood of the occurrence of certain discrete events, such as a potential initial public offering, improving market conditions and receptivity of the market to initial public offerings. The enterprise value determined under the OPM and PWERM methods was weighted according to our board of directors&#8217; estimate of the probability of the occurrence of a certain discrete event as of the valuation date. The resulting equity value for the common stock was then divided by the number of shares of common stock outstanding at the date of the valuation to derive a per share value on a <span style="white-space:nowrap">non-marketable</span> basis. In order to determine the fair value of our common stock on a marketable basis, we then applied a discount for lack of marketability which we derived based on inputs including a company-specific volatility rate, a term equal to the expected time to a future liquidity event and a risk-free rate equal to the yield on treasuries of similar duration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Application of these approaches involves the use of estimates, judgment and assumptions that are highly complex and subjective, such as those regarding our expected future revenue, expenses, cash flows, discount rates, market multiples, the selection of comparable companies and the probability of future events. Changes in any or all of these estimates and assumptions, or the relationships between those assumptions, impact our valuations as of each valuation date and may have a material impact on the valuation of common stock. The assumptions underlying these valuations represent our management&#8217;s best estimate, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of the Business Combination, the fair value of our common stock has been determined based on the quoted market price of our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is not likely to be realized and, accordingly, has provided a full valuation allowance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is more likely than not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (i)&#160;the factors underlying the sustainability assertion have changed and (ii)&#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. Our unrecognized tax benefits, if recognized, would not have an impact on our effective tax rate assuming we continue to maintain a full valuation allowance position. We do not expect our unrecognized tax benefits to change significantly over the next 12 months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards, or NOLs, in the event of an ownership change for tax purposes, as defined in Section&#160;382 of the Internal Revenue Code. We completed an assessment of the available NOLs under Section&#160;382 and determined that we underwent an ownership change in September 2020 and as a result, NOLs attributable to the <span style="white-space:nowrap">pre-ownership</span> change are subject to a substantial annual limitation under Section&#160;382 of the Internal Revenue Code. As a result of the annual limitations caused by the ownership change, it was estimated that approximately $1.3&#160;million of federal tax credit and $27.4&#160;million of California NOL will expire unutilized for income tax purposes, and such amounts are excluded from the carryforward balances of December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company Status </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. The JOBS Act permits companies with EGC status to take advantage of an extended transition period to comply with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. We have elected to use this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date the Company (i)&#160;is no longer an EGC or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company effective dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we intend to rely on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an EGC, we intend to rely on such exemptions, we are not required to, among other things: (i)&#160;provide an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act; (ii)&#160;provide all of the compensation disclosure that may be required of <span style="white-space:nowrap">non-emerging</span> growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act; (iii)&#160;comply with any requirement that may be adopted by the Public Company Accounting Oversight Board; and (iv)&#160;disclose certain executive compensation-related items such as the correlation between executive compensation and performance and comparisons of the Chief Executive Officer&#8217;s compensation to median employee compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an EGC under the JOBS Act until the earliest of (i)&#160;the last day of the fiscal year (a)&#160;of 2025, (b) the year in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;the year in which we are deemed to be a large accelerated filer; or (ii)&#160;the date on which we have issued more than $1&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note&#160;2 to our consolidated financial statements included in this prospectus for more information about recent accounting pronouncements, the timing of their adoption and our assessment, to the extent they have been made, of their potential impact on our financial condition and results of operations and cash flows. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_11">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our mission is to transform the treatment of serious disease by fully exploiting the Wnt pathway. We are discovering and developing biologic drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues, for human diseases. Building upon the seminal work of our founders and scientific advisors who discovered the Wnt gene and key regulators of the Wnt pathway, we have made breakthrough discoveries that we believe will overcome previous limitations in harnessing the potential of Wnt biology. These breakthroughs enable us to rapidly and flexibly design tissue-targeted therapeutics that modulate Wnt signaling. As a result of our discoveries, we are pioneering the selective activation of Wnt signaling, designing and engineering Wnt pathway mimetics, and advancing tissue-selective Wnt candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or <span style="white-space:nowrap">R-spondin</span> proteins, which are involved in activation and enhancement of the Wnt pathway, respectively. Given Wnt signaling is essential in tissue maintenance and regeneration throughout the body, we have the potential to target a wide variety of severe diseases, including certain diseases that afflict the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system. In each of these areas, we believe our approach has the potential to change the treatment paradigm for the disease and substantially impact patient outcomes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to exploit the full potential of Wnt signaling by identifying disease states responsive to Wnt modulation, design tissue-selective therapeutics, and advance candidates into clinical development in targeted indications with high unmet need. Our unique approach and platform technologies have led to the discovery and advancement of two lead product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated a Phase 1 clinical trial in the second quarter of 2022 for <span style="white-space:nowrap">SZN-1326,</span> our candidate in development for moderate to severe inflammatory bowel disease, or IBD, with ulcerative colitis, or UC, as our first proposed indication. <span style="white-space:nowrap">SZN-1326,</span> a Fzd5 targeted <span style="white-space:nowrap">bi-specific</span> antibody, is our first development candidate designed using Surrozen&#8217;s SWAP<sup style="font-size:75%; vertical-align:top">&#8482;</sup> technology and targets the <span style="white-space:nowrap">Wnt-signaling</span> pathway in the intestinal epithelium. In preclinical animal models of acute and chronic colitis, <span style="white-space:nowrap">SZN-1326</span> has been shown to transiently activate Wnt signaling in the diseased intestine, stimulate intestinal epithelial regeneration, reduce inflammation and reduce disease activity. In November 2022, we announced that we voluntarily paused enrollment in the single ascending dose, or SAD, portion of our Phase 1 clinical trial evaluating <span style="white-space:nowrap">SZN-1326</span> in healthy volunteers. Following the evaluation of the clinical data and further preclinical work, we will be <span style="white-space:nowrap">re-initiating</span> the Phase 1a clinical trial in healthy volunteers by <span style="white-space:nowrap">mid-2023</span> based on the minimum anticipated biologically effective level (MABEL) and anticipate safety data by the end of 2023. We anticipate initiating a Phase 1b clinical trial in ulcerative colitis patients in 2024 and expect proof of concept data to be potentially available in the second half of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initiated a Phase 1 clinical trial in the second quarter of 2022 for <span style="white-space:nowrap">SZN-043,</span> our candidate in development for severe alcoholic hepatitis, or AH. <span style="white-space:nowrap">SZN-043,</span> a hepatocyte-specific <span style="white-space:nowrap">R-spondin</span> mimetic bispecific fusion protein targeting ASGR1, is the first development candidate using Surrozen&#8217;s SWEETS<sup style="font-size:75%; vertical-align:top">&#8482;</sup> technology which is designed to mimic the regenerative properties of the protein <span style="white-space:nowrap">R-Spondin</span> by enhancing Wnt signaling in a cell-targeted manner. In multiple preclinical animal models of liver injury and fibrosis, <span style="white-space:nowrap">SZN-043</span> has been shown to selectively activate Wnt signaling in the liver, stimulate transient hepatocyte proliferation, improve liver function and reduce fibrosis. We completed enrollment in the second cohort of the <span style="white-space:nowrap">SZN-043</span> Phase 1a single ascending dose clinical trial in 2022 in healthy volunteers. We opened enrollment for the Phase 1a clinical trial in chronic liver disease, enrolled the first patient in the first quarter of 2023 and expect data to be available in the second half of 2023. We anticipate initiating a Phase 1b clinical trial in patients with severe alcoholic hepatitis in 2024 and expect proof of concept data to be potentially available in the second half of 2024. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2022, we nominated <span style="white-space:nowrap">SZN-413,</span> a Fzd4 targeted <span style="white-space:nowrap">bi-specific</span> antibody, as a development candidate for the treatment of retinal vascular associated diseases. Fzd4 mediated Wnt signaling is known to play a critical role in retinal vascular integrity and function. Data generated in preclinical models of retinopathy demonstrated <span style="white-space:nowrap">SZN-413</span> stimulated Wnt signaling and was able to induce normal retinal vessel regrowth while suppressing pathological vessel growth. In October 2022, we executed a Collaboration and Licensing Agreement, or CLA, with Boehringer Ingelheim International GmbH, or BI, to research, develop and commercialize Fzd4 <span style="white-space:nowrap">bi-specific</span> antibodies designed using our SWAP technology, including <span style="white-space:nowrap">SZN-413.</span> We anticipate the potential to identify the lead <span style="white-space:nowrap"><span style="white-space:nowrap">Fzd-4-targeted</span></span> Wnt agonist product candidate by the end of 2023, which would trigger a $10.0&#160;million milestone payment to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Fundamental Importance of the Wnt Pathway and Our Founders&#8217; Roles in Its Discovery </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Wnt pathway holds significant therapeutic promise in view of its ability to regulate stem cell renewal, proliferation and differentiation, and its central role in tissue regeneration. Over the past 30 years our founders and advisors have helped establish the fundamental importance of the Wnt pathway in tissue regeneration. Each has been on the forefront of the Wnt signaling pathway research, and their discoveries are the foundation of our approach to therapeutic development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wnt proteins exert a wide variety of effects on target cells during development. Fundamentally, Wnts are growth stimulatory factors that promote cell proliferation. Compared to other growth factors, two distinctive aspects of Wnt proteins are their lack of specificity and their ability to give shape to growing tissues while inducing cells to proliferate, acting in the process as directional growth factors. Wnt signals can instruct new cells in such a way that organized body plans are generated. Moreover, Wnt proteins employ a number of receptor isoforms and <span style="white-space:nowrap">sub-families,</span> generating an array of combinatorial Wnt signaling critical for correctly shaping tissues during development, maintaining tissue architecture in adult life and repairing tissue injury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Roel Nusse and Dr.&#160;Harold Varmus discovered the first Wnt gene in 1982. Wnt signaling has now been shown to be critical to many essential normal functions. Dr.&#160;Nusse is a founder of our company and a member of our Scientific Advisory Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Past Limitations in Targeting the Wnt Pathway for Drug Discovery </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although modulation of Wnt signaling has held significant promise for decades, a number of characteristics of Wnt signaling have created obstacles to conventional protein therapeutic approaches. The key obstacles to drug development targeting the Wnt signaling pathway are described below: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Potent Pathway Activation:</span> While the activity of naturally occurring Wnt pathway agonists is well established, previous attempts to engineer synthetic Wnt and <span style="white-space:nowrap">R-spondin</span> ligands have not resulted in selective, potent activation of Wnt signaling. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Selectivity:</span> Naturally occurring Wnt ligands are not selective in their interactions. The same lack of selectivity is observed with naturally occurring <span style="white-space:nowrap">R-spondin</span> ligands and their interactions with the cell surface receptors. Moreover, components of the Wnt signaling pathway, which can be targeted with small molecules, are widely expressed and therefore cannot be selectively targeted. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Manufacturing:</span> Wnt ligands are highly hydrophobic, making them difficult to express, solubilize and purify and therefore difficult to manufacture. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Wnt Therapeutics Platform </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Scientific Capabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our breakthrough discoveries and technologies will enable us to overcome the challenges facing drug developers targeting the Wnt pathway. We believe we are potentially the first developer to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacture synthetic, soluble Wnt mimetics. To date, we have developed potent, selective and manufacturable Wnt and <span style="white-space:nowrap">R-spondin</span> mimetics that are designed to replicate the role of naturally occurring Wnt and <span style="white-space:nowrap">R-spondin</span> proteins. In pursuit of our goal to develop a portfolio of Wnt product candidates that can repair tissue damage and regenerate functional tissues for patients, we are continuing to expand our platform through the development of novel technologies and capabilities required to research, develop, manufacture and ultimately commercialize therapeutic products that address unmet medical needs. Our core capabilities are described below: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Wnt Biology Expertise:</span> We have established a deep understanding of the Wnt pathway and its role in disease biology and have invested significantly in our people and technologies that enable us to selectively modulate Wnt signaling. Our research and development organization is led by world-class scientists. We have partnered with key thought leaders in the field, including those on our Scientific Advisory Board, and have developed significant expertise in various areas of biology relevant to the Wnt signaling pathway. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proprietary Antibody Discovery and Research Technologies:</span> We have developed proprietary antibody discovery capabilities that have led to the discovery of two initial antibody technologies that enable us to potently and selectively modulate the Wnt pathway. Our SWAP (Surrozen Wnt signal Activating Protein) technology enables the design and development of <span style="white-space:nowrap">Wnt-mimetics,</span> and our SWEETS (Surrozen Wnt signal Enhancers Engineered for Tissue Specificity) technology enables the design and development of <span style="white-space:nowrap">R-spondin</span> mimetics. Importantly, our approach provides a flexible and robust platform that has generated multiple antibodies that possess either tissue or cell selectivity based on preclinical studies. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Additional Novel Wnt Modulating Technologies:</span> We have developed and filed patent applications for additional Wnt modulating antibody technologies, and are committed to continuously integrating new insights, tools, technologies and capabilities to apply to additional diseases and areas. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Genetic Mapping of Wnt Signaling:</span> The role of Wnt signaling in disease and the differential expression of genes involved in Wnt signaling have not been well characterized across many disease states. We isolate RNA for gene expression to identify potential deficiencies in Wnt signaling in specific diseases. Through our genetic mapping, we have increased our understanding of Wnt biology in numerous diseases and Wnts&#8217; involvement in diseases that had previously not been well-characterized. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Protein Science Capabilities:</span> We have invested in building capabilities in key areas of antibody discovery which include:<span style="font-style:italic"> in vitro</span> and<span style="font-style:italic"> in vivo</span> binder discovery, antibody optimization including humanization, structural biology, cell line construction, upstream and downstream process development and purification, bioanalytical characterization, developability assessments including stability and formulatability. These capabilities enable discovery of novel structures and sequences and optimization for pharmacokinetics, potency, selectivity, manufacturability and other drug-like properties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Scientific Approach </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By combining our Wnt biology expertise with our proprietary technologies and capabilities, we have been able to establish a broad array of therapeutic opportunities. Our approach includes: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Identifying and characterizing areas where Wnt biology is critical to tissue structure and function. To date, we have investigated the importance of Wnt signaling in over 20 different tissue types and have prioritized multiple tissue types for further exploration, with a plan to continue to expand our efforts. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Prioritizing disease opportunities where there is significant evidence based on our proprietary model systems and tool compounds that Wnt activation could play a role in tissue repair in severe disease. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Focusing efforts and investments in diseases where the strength of our capabilities can potentially address key limitations of existing therapeutic approaches. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Seeking to limit or eliminate the potential oncogenic risk from Wnt pathway activation through our selective activation in the target disease tissue, we focus on severe disease and limited treatment exposure, and mimicking a physiologic repair process that is self-limiting. In preclinical studies, we have observed that the predominant response to Wnt signaling is in diseased tissue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Technologies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our two initial proprietary technologies, SWAP and SWEETS, enable us to potently and selectively modulate Wnt signaling through the generation of Wnt and <span style="white-space:nowrap">R-spondin</span> mimetics. Using these technologies, we design and develop antibodies that modulate Wnt signaling. Product candidates generated by these technologies have demonstrated the ability to repair tissue damage in multiple preclinical models including colitis and liver injury. We have developed specific candidate molecules for each disease area based on the associated tissue biology, the role of Wnt signaling in disease versus normal tissue, and a functional assessment of our candidate molecules. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our SWAP and SWEETS technologies focus on key regulators of Wnt signaling, Wnt proteins and <span style="white-space:nowrap">R-spondins.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Wnt Activation: SWAP (Surrozen Wnt signal Activating Protein) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. They are bispecific full-length human (IgG) antibodies that, like Wnt proteins, directly activate the <span style="white-space:nowrap">Wnt-signaling</span> pathway in target tissue by binding to two of its natural <span style="white-space:nowrap">co-receptors,</span> Fzd and Lrp. With our SWAP technology, we combine Fzd and Lrp antibody-binding domains into bispecific antibodies to selectively activate Wnt signaling. We have generated and validated a broad library of SWAPs that have successfully activated <span style="white-space:nowrap">Wnt-signaling.</span> Our product candidates, <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-413,</span> utilize our SWAP technology and are designed to activate the Wnt pathway in injured tissue where certain Fzd receptors are expressed and the natural Wnt ligand is disturbed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key characteristics of our SWAP technology include: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Potency:</span> Our Wnt mimetics are multivalent, designed to bind one or more Fzd receptors and one or more Lrp receptors. We demonstrated that the ability to bind to one or more receptors leads to highly potent Wnt signal activation as compared to a protein that can only bind to one Lrp receptor and one Fzd receptor. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Selectivity:</span> Our antibody-based proteins are capable of selective binding to individual Fzd and Lrp receptor isoforms and selective isoform binding has the potential to confer tissue selectivity. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Manufacturability:</span> Our antibody platform is designed to produce molecules with properties suitable for manufacturing and to overcome the challenges of Wnt protein derivates. Unlike our antibodies, Wnt proteins are highly hydrophobic, making them difficult to express, solubilize and purify. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Christopher Garcia, a Howard Hughes Medical Institute Investigator and one of our founders, enabled our SWAP approach through the discovery of surrogate Wnt agonists. His surrogate ligands were water soluble, consisted of two domains and provided the building blocks for our SWAP technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent discoveries made at Surrozen improved on the potency and selectivity of the surrogate ligands discovered by Dr.&#160;Garcia. Our technology allows for targeting of Fzd and Lrp receptors, and we believe we can identify an optimized ratio of Fzds and Lrps required to activate Wnt signaling. We have also discovered that binding two different Fzds together with Lrp leads to efficient Wnt signal activation. Figure 1 below compares </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
natural Wnt signaling to how our SWAP product candidates engage receptors on the cell surface to trigger Wnt signal activation. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g81a81.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 1. Like endogenous Wnt (left side), our SWAP technology activates Wnt signaling by binding specific Fzd and Lrp receptors (right side) </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Wnt Amplification: SWEETS (Surrozen Wnt signal Enhancer Engineered for Tissue Specificity) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SWEETS molecules are designed to amplify the body&#8217;s response to naturally occurring Wnt proteins. They are antibody-based molecules that, like <span style="white-space:nowrap">R-spondin,</span> enhance Wnt signaling by stabilizing Fzd receptors. Our SWEETS molecules are designed to modify the specificity of <span style="white-space:nowrap">R-spondin</span> activity such that it can be directed to a cell surface antigen of our choosing. Our SWEETS molecules consist of a full-length antibody fusion protein in which an antibody-binding domain of one of these antigens is combined with an <span style="white-space:nowrap">R-spondin</span> derivative. <span style="white-space:nowrap">SZN-043</span> is our initial product candidate to utilize our SWEETS technology and is designed to selectively amplify the Wnt pathway in hepatocytes, the most abundant type of liver cell. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">R-spondin</span> may be beneficial in adult tissue repair, particularly in situations where naturally occurring Wnt ligands are present but signaling is insufficient to repair tissue damage. One major challenge facing drug developers targeting the Wnt pathway in harnessing <span style="white-space:nowrap">R-spondin-based</span> Wnt amplification has been limiting <span style="white-space:nowrap">R-spondin&#8217;s</span> effects to a specific tissue of interest, which we believe we have overcome through: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Reducing <span style="white-space:nowrap">non-specific</span> binding.</span> Naturally occurring <span style="white-space:nowrap">R-spondins</span> are dependent on E3 ligases and leucine-rich repeat-containing <span style="white-space:nowrap">G-protein</span> coupled receptors, or LGRs, for activity. LGRs are widely expressed and result in <span style="white-space:nowrap">R-spondins</span> enhancing Wnt signaling in a broad variety of tissues. Based on preclinical studies, we have been able to eliminate the requirement for LGR binding through substitution of binding to different cell surface receptors; and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Targeting specific cell types.</span> We have designed multiple antibodies targeted to several cell surface receptors. Based on preclinical studies, these antibodies have demonstrated specificity to multiple tissues and cell lineages. The engineered antibodies specifically upregulated <span style="white-space:nowrap">Wnt-signaling</span> with greater tissue specificity than <span style="white-space:nowrap">non-targeted</span> controls and stimulated proliferation </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure 2 below illustrates the effect of Fzd (and Lrp) stabilization on promoting Wnt signaling. On the left side of the image, unbound E3 ligases induce internalization and ubiquitination of Fzd receptors, leading to disruption of Wnt signaling. With our SWEETS technology, we have demonstrated tissue-targeted binding and sequestration of E3 ligases leading to the stabilization of Fzd and Lrp and promotion of Wnt signaling. With our SWEETS technology, we have been able to affect tissue-targeted binding and inhibition of E3 ligase promoted degradation of Fzd, leading to the promotion of Wnt signaling. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g82a82.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 2. Our SWEETS technology leads to amplification of the Wnt signaling pathway by inhibition of Fzd degradation by the E3 ligase/proteasome pathway. Specificity of SWEETS binding is driven by an antigen-binding domain that can be targeted to specific cell surface protein </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Product Candidates and Research Programs </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that both our SWAP and SWEETS technologies have the potential to generate a portfolio of product candidates that can harness the tissue repair activity of the Wnt pathway for a broad spectrum of severe diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The chart below represents a summary of our wholly owned product candidates: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g82b82.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 3. Lead programs </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our first product candidate, <span style="white-space:nowrap">SZN-1326,</span> is being developed as a novel treatment for moderate to severe IBD, with UC as our first proposed indication, and utilizes our proprietary SWAP technology to activate Wnt signaling. Wnt signaling plays a critical role in intestinal epithelial turnover and normal function. Abnormal signaling has been observed in patients with IBD and restoration of normal signaling is believed to play a role in the repair of damaged intestinal epithelial cells in IBD. <span style="white-space:nowrap">SZN-1326</span> targets Fzd 5, Fzd 8 and Lrp 6 to activate Wnt signaling. We have observed that Fzd 5, Fzd 8 and Lrp 6 are expressed in the large bowel epithelium of UC tissue samples and that Fzd 5 is the most abundant, representing an attractive target for our therapeutic approach. IBD affects an estimated two </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
million patients in the United States and is caused by damage to the intestinal barrier and an enhanced inflammatory response, which further exacerbates tissue damage. <span style="white-space:nowrap">SZN-1326</span> is designed to activate <span style="white-space:nowrap">Wnt-pathway</span> signaling in intestinal epithelial cells. In multiple mouse models of IBD<span style="font-style:italic">,</span> <span style="white-space:nowrap">SZN-1326</span> stimulated intestinal epithelial regeneration, characterized by restoration of the intestinal barrier and reduced histology severity score, lower levels of inflammatory cytokines and reduced disease activity. We will be <span style="white-space:nowrap">re-initiating</span> the Phase 1a clinical trial by <span style="white-space:nowrap">mid-2023</span> based on the minimum anticipated biologically effective level (MABEL) and anticipate safety data by the end of 2023. We anticipate initiating a Phase 1b clinical trial in ulcerative colitis patients in 2024 and expect proof of concept data to be potentially available in the second half of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second product candidate, <span style="white-space:nowrap">SZN-043,</span> is being developed as a novel treatment for severe liver diseases, including severe AH, and utilizes our proprietary SWEETS technology. Severe AH is a disease with a <span style="white-space:nowrap">90-day</span> mortality rate of 30% and has an estimated incidence of approximately 130,000 patients in the United States annually. In severe AH, damage to hepatocytes due to excessive alcohol use leads to jaundice, inflammation, impaired blood coagulation and increased risk of infections that may impact other organs such as the kidneys, brain and gastrointestinal system. We have designed <span style="white-space:nowrap">SZN-043</span> to modulate naturally occurring Wnt signaling that is specifically targeted to hepatocytes. We have shown in preclinical models of liver injury that <span style="white-space:nowrap">SZN-043</span> selectively and transiently stimulates hepatocyte proliferation, and restores liver function as measured by plasma ammonia. The selectivity of <span style="white-space:nowrap">SZN-043</span> is achieved through the inclusion of an antibody binding domain selective for ASGR1 that is solely expressed on hepatocytes. We completed enrollment in the second cohort of the <span style="white-space:nowrap">SZN-043</span> Phase 1a single ascending dose clinical trial in healthy volunteers in 2022. We opened enrollment for the Phase 1a clinical trial in chronic liver disease, enrolled the first patient in the first quarter of 2023 and expect data to be available in the second half of 2023. We anticipate initiating a Phase 1b clinical trial in patients with severe alcoholic hepatitis in 2024 and expect proof of concept data to be potentially available in the second half of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third product candidate, <span style="white-space:nowrap">SZN-413,</span> a Fzd4 targeted <span style="white-space:nowrap">bi-specific</span> antibody, is being developed as a novel treatment for retinal vascular-associated diseases and utilizes our proprietary SWAP technology to activate Wnt signaling. <span style="white-space:nowrap">Fzd4-mediated</span> Wnt signaling is known to play a critical role in retinal vascular integrity and function, and data with <span style="white-space:nowrap">Fzd4-specific</span> Surrozen Wnt modulating tool molecules have shown that selectively activating Wnt signaling can rescue a disease phenotype in a norrin knockout model. Data evaluating <span style="white-space:nowrap">SZN-413</span> in preclinical models of retinopathy demonstrated that activation of Wnt signaling increased tight unction protein expression in retinal vascular endothelial cells and significantly reduced avascular area and pathological neovascular tuft formation in an oxygen-induced retinopathy mouse model. In October 2022, we executed a CLA with BI to research, develop and commercialize Fzd4 <span style="white-space:nowrap">bi-specific</span> antibodies designed using our SWAP technology, including <span style="white-space:nowrap">SZN-413.</span> We anticipate the potential to identify the lead <span style="white-space:nowrap"><span style="white-space:nowrap">Fzd-4-targeted</span></span> Wnt agonist product candidate by the end of 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Research Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that both our SWAP and SWEETS technologies have the potential to generate a portfolio of product candidates that can harness the tissue regenerative activity of the Wnt pathway and potentially bring therapeutic benefit to patients suffering from a broad spectrum of diseases. Our goal in each of these programs is to activate the natural ability of tissues in the body to heal themselves by increasing the Wnt signaling pathway in a localized, transient, and, we believe, safe manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By leveraging our scientific capabilities and approach, we have identified multiple potential tissue types to explore. We are currently focused on developing potential therapeutics for ocular diseases such as dry eye and fuch&#8217;s endothelial dystrophy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of our more advanced preclinical programs targets the lacrimal gland. Tear-producing lacrimal glands rely on Wnt signaling for maintenance of function. Restoration of lacrimal gland function through activation of Wnt signaling is a potential therapeutic approach to treat dry eye, including dry eye associated with Sjogren&#8217;s </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Disease. Preclinical data demonstrated that our <span style="white-space:nowrap">Wnt-modulating</span> molecules activated Wnt signaling in the lacrimal gland and increased tear production in a mouse <span style="white-space:nowrap">IL-1a</span> lacrimal gland injury model. The chart below represents a summary of our research programs: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g83a83.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 4. Our current Research Programs </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our People </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our people are the most important strength of our company. We have assembled a diverse group of experienced executives, scientists, engineers and operators that consist of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Experienced Company Builders.</span> Craig Parker, our President and Chief Executive Officer, has extensive experience in the science and business of building companies in the biotechnology industry. He was previously Senior Vice President of Corporate Development at Jazz Pharmaceuticals and held similar executive positions at Geron Corporation, Human Genome Sciences (acquired by GSK), Proteolix (acquired by Onyx) and Immunex (acquired by Amgen). He is a member of the Scientific Advisory Board of the Life Sciences Institute at the University of Michigan and previously served as a director of Xcyte Therapies and vTv Therapeutics. Our Chief Financial Officer, Charles Williams, has extensive experience at multiple public companies across various leadership positions in strategy, operations, finance and corporate development, and was previously at Jazz Pharmaceuticals, MAP Pharmaceuticals (acquired by Allergan) and CV Therapeutics (acquired by Gilead). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Accomplished Scientific Leadership.</span> Our team consists of discovery scientists along with a team of drug developers experienced in advancing drug product candidates through the drug development process. Our Chief Scientific Officer, <span style="white-space:nowrap">Wen-Chen</span> Yeh, MD, PhD, was previously at Amgen, where he led research teams in a variety of disease indications including inflammation, diabetes, dyslipidemia and cardiovascular disease. At Amgen, Dr.&#160;Yeh helped advance multiple programs towards clinical trials. Our Senior Vice President of Biology, Yang Li, Ph.D., was previously at Amgen, where he advanced multiple programs into the clinic in a variety of disease indications. Collectively, our scientific team are authors or <span style="white-space:nowrap">co-authors</span> on over 200 scientific publications. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Founders and Scientific Advisory Board</span><span style="font-weight:bold"><span style="font-style:italic">.</span></span> We are supported by our founders and Scientific Advisory Board which includes world class researchers who have made seminal discoveries in Wnt biology and have successfully collaborated prior to their involvement with our company. Dr.&#160;Varmus, a member of our Scientific Advisory Board, is a <span style="white-space:nowrap">co-recipient</span> of the 1989 Nobel Prize in Physiology or Medicine for studies on the genetic basis of cancer. Dr.&#160;Nusse was recently awarded the 2017 Breakthrough Prize in Life Sciences and the 2020 Canada Gairdner International Award for Biomedical Research for his continued pioneering work on the Wnt signaling pathway. Our <span style="white-space:nowrap">Co-Founder,</span> Dr.&#160;Hans Clever, was awarded the 2013 Breakthrough Prize in Life Sciences for his work describing the role of Wnt signaling in tissue stem cells and cancer. </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Board of Directors and Investors with Shared Long-Term Vision</span><span style="font-weight:bold"><span style="font-style:italic">.</span></span> Our board of directors is composed of renowned company builders, operators, leaders, scientists, drug developers and investors with experience across a diverse array of companies. This team is supported by investors who share our long-term vision around building the leading company in Wnt biology, including The Column Group, a recognized leader in early-stage biotechnology venture investing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to develop a portfolio of product candidates that can repair tissue damage and regenerate functional tissues for a variety of diseases. Consistent throughout our strategy is our goal to activate Wnt </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
signaling only within targeted diseased tissue, focusing on severe diseases, and mimicking the self-limiting physiologic repair process. We plan to achieve this goal by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Continuing to build on our pioneering research, insights and intellectual property in Wnt pathway modulation.</span></span> Our scientific capabilities and approaches are built upon the groundbreaking work of our academic <span style="white-space:nowrap">co-founders</span> and have been developed further by our experienced team. We consider ourselves to be pioneers in the selective modulation of the Wnt signaling pathway and intend to utilize our proprietary insights into Wnt biology and our proprietary technologies to further advance our research and exploration of its therapeutic potential. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Developing <span style="white-space:nowrap">SZN-1326</span> for the treatment of moderate to severe IBD</span></span>. We have shown that <span style="white-space:nowrap">SZN-1326</span> leads to rapid repair of tissue damage and functional improvements in mouse models of IBD. We intend to initially develop <span style="white-space:nowrap">SZN-1326</span> in patients with moderate to severe UC and then expand into the treatment of other intestinal diseases including CD. We will be <span style="white-space:nowrap">re-initiating</span> the Phase 1a clinical trial in healthy volunteers by <span style="white-space:nowrap">mid-2023.</span> We anticipate initiating a Phase 1b clinical trial in ulcerative colitis patients in 2024. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Developing <span style="white-space:nowrap">SZN-043</span> for the treatment of liver disease.</span></span> We have shown that <span style="white-space:nowrap">SZN-043</span> selectively stimulates hepatocyte proliferation and leads to improvement of liver function in multiple animal models of liver injury. We intend to develop SZN-043 in patients with severe AH. We believe that the mechanism of <span style="white-space:nowrap">SZN-043</span> has the potential to bring therapeutic benefit to patients with liver disease beyond our initial indication of severe AH. We opened enrollment for the Phase 1a clinical trial in chronic liver disease patients, enrolled the first patient in the first quarter of 2023 and expect data to be available in the second half of 2023. We anticipate initiating a Phase 1b clinical trial in patients with severe alcoholic hepatitis in 2024. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Developing novel product candidates and expanding our platform technologies to further our leading position in developing the Wnt signaling pathway modulators</span></span><span style="font-weight:bold">.</span> Wnt signaling is critical in tissue regeneration throughout the body, including in intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas and central nervous system. Our research suggests that SWAP and SWEETS will provide us with the opportunity to generate specific modulators of Wnt signaling. We have generated libraries of Wnt and <span style="white-space:nowrap">R-spondin</span> receptor binders that have helped us create a broad portfolio of product candidates. We have developed and filed patent applications for additional Wnt modulating antibody technologies and are committed to continuously applying new insights, tools, technologies and capabilities to additional diseases and areas and adding to our platform technologies and pipeline. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Pursuing strategic alliances to maximize the full potential of our pipeline.</span></span> The importance of the Wnt signaling pathway and the potential therapeutic applications of Wnt pathway mimetics are expected to provide us with an abundance of product candidates. We believe this generates an exciting opportunity to enter into strategic alliances to accelerate product development and maximize commercial potential. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Wnt Signaling Pathway&#8212;A Central Regulator of Tissue Regeneration </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As gatekeepers for the maintenance of stem cells and functions, prior attempts at modulating Wnt signaling were hampered by an absence of drug-like properties. Through our technologies, we can modulate Wnt signaling with antibodies, which could open the door for the development of a new classes of drugs with the ability to repair and regenerate damaged tissues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Signaling through the Wnt pathway can stimulate cell proliferation as well as control cell differentiation and movement. <span style="white-space:nowrap"><span style="white-space:nowrap">Cell-to-cell</span></span> communication is needed during embryonic development, and Wnt signaling is essential for development to proceed properly. In both embryonic stem cells and pluripotent stem cells, the Wnt pathway has a dual role in both promoting stem cell renewal and differentiation of certain cell types. In adults, Wnt has a critical role in promoting proliferation and stem cell renewal in multiple tissues. Maintenance of the intestinal surface or epithelium homeostasis, for example, is dependent on Wnt signaling. Wnt signaling is also important for bone formation, retina development and function, liver regeneration and renewal of cells in the lung and pancreas among other tissues. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that several characteristics of the Wnt signaling pathway make this pathway attractive for drug development: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Broad potential for therapeutic intervention</span></span><span style="font-style:italic">.</span> Signaling through the Wnt pathway is critical in cell fate determination in tissues throughout the body. Aberrant Wnt signaling underlies a broad range of pathologies in humans. In some cases, such as in certain rare bone diseases, mutations in the Wnt signaling pathway are the cause of the disease. Mutations in Wnt signal pathway components are also associated with retina vessel disorders such as Norrie disease and familial exudative vitreoretinopathy, or FEVR, tooth development disorders, and metabolic diseases including diabetes. Preclinical model studies have shown that Wnt signaling is instrumental for liver regeneration, intestine epithelium turnover and injury repair, and plays a role in maintaining residential stem cells in many more adult tissues including lung, kidney, cochlea, skin and the central nervous system. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Common activation mechanism across Wnt proteins.</span></span> There are 19 Wnt protein genes in the human genome and the genomes of other mammals. Most Wnt proteins bind interchangeably to the 10 different Fzd receptors with little discrimination. Genetic knockouts in mice have shown that individual Wnt protein genes have distinct functions. The differences in biological functions likely arise from discrete localized expression and the relative insolubility of Wnt proteins which limits migration from the site of synthesis. On the other hand, when it comes to biochemical signaling, the different Wnt proteins have very similar activities upon target cells. This, in turn, implies that the same therapeutic approach could be used to address multiple diseases. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Multiple modulators of activity.</span></span> Multiple modulators of the Wnt signaling pathway have been identified that activate, amplify, dampen or inhibit the pathway&#8217;s activity and limit the potential consequences of either over-activation or inhibition of Wnt signaling. These modulators can serve both as direct targets for therapeutic intervention and as examples of how novel therapeutics could be developed that mimic their action. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The low solubility of Wnt proteins due to the required fatty acid modification limits the ability of natural Wnt proteins themselves to be developed as therapeutic agents. The lack of solubility of Wnt proteins makes them difficult to purify; difficult to formulate into an easily administered drug; and difficult to deliver to various tissues in the body. In contrast, we have developed technologies enabling us to develop activators and amplifiers of Wnt signaling which avoid the low solubility of natural Wnt proteins. These technologies trigger the Wnt pathway to act in a transient manner by mimicking the binding of Wnt proteins and other regulators of the pathway. Our goal is to use our technologies to develop therapeutics that can modulate the naturally occurring Wnt response and promote healing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Wnt Therapeutics Platform </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have discovered two proprietary technologies of modulators of Wnt signaling: SWAP and SWEETS. We have designed and continue to design antibodies that modulate the Wnt signaling pathway by acting as mimetics of either Wnt protein or one of its regulators, <span style="white-space:nowrap">R-spondin.</span> Product candidates generated by our technologies have demonstrated the ability to repair tissue damage in multiple preclinical models including IBD and liver injuries. We were able to select a specific candidate molecule and technology for each disease area based on tissue biology, profile of Wnt signaling in disease versus normal, and functional test of molecules. We are advancing two of these candidates, <span style="white-space:nowrap">SZN-1326</span> and <span style="white-space:nowrap">SZN-043,</span> into clinical development. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Wnt Activation: SWAP </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Wnt pathway is equipped with binding sites for two receptors found on the surface of cells that can be triggered by Wnt protein. Binding to just one of these two receptors does not cause activation of the Wnt pathway. But when Wnt protein simultaneously binds to both receptors, this pair of interactions activates several intracellular signaling pathways, as can be seen in Figure 5 below. The two Wnt receptors are called frizzled, or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Fzd, and <span style="white-space:nowrap">low-density</span> lipoprotein receptor-related protein 5 or 6, or Lrp 5/6. Fzd is an integral membrane protein that binds to Wnt protein, in part, through the fatty acid posttranslational modification on the Wnt protein. The second receptor, Lrp 5/6, contains an intracellular domain that is chemically modified by <span style="white-space:nowrap">Wnt-protein-induced</span> receptor dimerization to initiate the Wnt signaling pathway cascade in cells. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g86a86.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 5. Like endogenous Wnt (left side), our SWAP technology activates Wnt signaling by binding specific Fzd and Lrp receptors (right side) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Published work by Dr.&#160;Christopher Garcia, one of our founders and Scientific Advisory Board members, showed that Wnt signaling could be induced by identifying <span style="white-space:nowrap">non-Wnt</span> proteins capable of selectively binding to Fzd and Lrp and linking these binding domains together. These <span style="white-space:nowrap">non-Wnt</span> proteins led to an activation of Wnt signaling that in many ways was indistinguishable from that induced by Wnt itself. Furthermore, these <span style="white-space:nowrap">non-Wnt</span> proteins were soluble and did not require posttranslational modification with fatty acid for activity. These observations revealed the opportunity to develop <span style="white-space:nowrap">Wnt-mimetic</span> therapeutics freed from the burden of containing a fatty acid, which decreases their solubility. There was no apparent restriction on the type of interacting domains that could be used to create these molecules. Several categories of molecules, including domains from natural proteins, artificial protein binding domains, and antibodies were all found to be able to function as binding domains for Fzd or Lrp. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have focused our efforts on developing antibody-binding domains that independently bind to Fzd and to Lrp. Antibody-binding domains provide a potential advantage over other binding domains due to the ability to identify domains with high potency and with high specificity, in addition to the maturing manufacturing process. We have identified antibody-binding domains capable of distinguishing individual Fzd family members, providing an opportunity to selectively activate Wnt signaling in cells expressing specific Fzd receptors&#8212;a property that naturally occurring Wnt proteins do not have. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our SWAP technology, we created multivalent bispecific antibodies that bring together two different sets of antibody-binding domains&#8212;one set that binds to Fzd and another set that binds to Lrp. We found that certain recombinant proteins containing these two antibody-binding domains were able to simultaneously bind both Fzd and Lrp, however, inducing the simple bimolecular interaction of one Fzd and one Lrp was, in most cases, insufficient to induce Wnt signaling, as can be observed in Figure 6. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Figure 6 below, in an assay measuring protein concentration <span style="white-space:nowrap">(x-axis)</span> against Wnt pathway activation (as measured by relative light units, or RLU, <span style="white-space:nowrap">y-axis),</span> we have demonstrated that a simple bivalent antibody containing a single Fzd binding domain (F1) (the blue line) and a single Lrp binding domain (L2) (the red line) did not significantly induce the Wnt signaling pathway. At similar concentrations, naturally-occurring Wnt (Wnt3a) (the green line) demonstrated pathway activation. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g87a87.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 6. A simple bivalent antibody containing a single Fzd binding domain (F1) and a single Lrp binding domain (L2) did not significantly induce the Wnt signaling pathway. At similar concentrations, naturally-occurring Wnt (Wnt3a) demonstrated pathway activation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, multivalent antibodies that contained multiple binding domains, either two <span style="white-space:nowrap">Fzd-binding</span> domains with one Lrp binding domain (the blue line in Figure 7 below) or two of each binding domain (the light green line), led to activation of the Wnt signaling pathway at concentrations that were 100 times or lower than required for activation by Wnt3a (the dark green line), as can be observed in Figure 7. For comparison, an antibody with a single Fzd binding domain (the red line) did not demonstrate significant activity. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g87b87.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 7. Multivalent antibodies with two Fzd binding domains (F3) and at least one Lrp binding domain (L2) led to more potent activation of the Wnt signaling pathway. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a series of product candidates based on the SWAP technology, which combines binding domains for specific Fzd receptors and binding domains for specific Lrp receptors. Our current SWAP lead product candidate, <span style="white-space:nowrap">SZN-1326,</span> is being evaluated for its ability to treat moderate to severe IBD. <span style="white-space:nowrap">SZN-413</span> is another SWAP project candidate for the treatment of retinal vascular associated diseases. In addition, we are developing other product candidates, including for the potential treatment of ocular diseases. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Wnt Amplification: SWEETS </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have designed our SWEETS technology for those diseases that are characterized by the presence of naturally occurring Wnt, yet with insufficient Wnt signaling for specific cells. This technology allows us to target Wnt pathway activation to specific cells in the body. For this, our SWEETS technology couples the regulation of the Wnt pathway to the binding of cell-specific surface antigens. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">R-spondins</span> are a family of four proteins that amplify Wnt pathway signals by reducing the destruction of Fzd by internalization and degradation. Proteins that are destined for degradation, such as Fzd, are normally tagged by E3 ligases. <span style="white-space:nowrap">R-spondin</span> prevents E3 ligase from tagging Fzd, thereby increasing the amount of time that Fzd remains on the cell surface. This results in an increased activation of the Wnt signaling pathway. Importantly, <span style="white-space:nowrap">R-spondin</span> does not directly cause signaling through the Wnt pathway, but rather it extends or amplifies the signaling that arises from already-present naturally occurring Wnt protein. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wild type <span style="white-space:nowrap">R-spondin</span> activity requires binding to two cell surface proteins: the E3 ligases and a member of a family of membrane proteins, referred to as LGR <span style="white-space:nowrap">4-6.</span> We have shown that derivatives of <span style="white-space:nowrap">R-spondin</span> can be generated that couple its E3 binding domain to an antigen-binding domain that recognizes a specific cell surface protein of our choosing resulting in <span style="white-space:nowrap">R-spondin</span> like activity. This technology creates <span style="white-space:nowrap">R-spondin</span> mimetics that can be targeted to specific cells in the body that express the chosen cell surface protein, which is illustrated in the Figure 8 below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g88a88.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 8. Our SWEETS technology leads to amplification of the Wnt signaling pathway by inhibition of Fzd degradation by the E3 ligase/proteasome pathway. Specificity of SWEETS binding is driven by an antigen-binding domain that can be targeted to specific cell surface proteins. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-concept</span></span> experiment conducted internally, an antibody-binding domain recognizing a cell surface protein was fused to a <span style="white-space:nowrap">R-spondin</span> protein in which the binding site for LGR <span style="white-space:nowrap">4-6</span> had been inactivated. This recombinant antibody <span style="white-space:nowrap">R-spondin</span> construct (the red line in &#8220;Target Cell&#8221; in Figure 9 below) stimulated the Wnt signaling pathway in cells that expressed the cell surface protein and was inactive in cells lacking the cell surface protein (the red line in <span style="white-space:nowrap">&#8220;Non-Target</span> Cell&#8221;). Wild-type <span style="white-space:nowrap">R-spondin</span> did not exhibit this selectivity and led to the Wnt </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
signaling pathway amplification in both types of cells (the black lines in the figure below). A <span style="white-space:nowrap">non-cell</span> surface targeted molecule serving as a negative control (the blue lines in the figure below) did not demonstrate any activity. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g88b88.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 9. Cell specificity of <span style="white-space:nowrap">R-spondin</span> was altered by inactivating the LGR <span style="white-space:nowrap">4-6</span> binding site and adding an antigen-binding domain for a specific cell surface protein. SWEETS shown in red. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">SZN-1326:</span> a SWAP Product Candidate for the Treatment of moderate to severe IBD </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our first product candidate, <span style="white-space:nowrap">SZN-1326,</span> is being developed as a novel treatment for moderate to severe IBD, with UC as our first proposed indication, and utilizes our proprietary SWAP technology to activate Wnt signaling. Wnt signaling plays a critical role in intestinal epithelial turnover and normal function. Abnormal signaling has been observed in patients with IBD and restoration of normal signaling is expected to play a role in the repair of intestinal epithelial cells in IBD. <span style="white-space:nowrap">SZN-1326</span> targets Fzd 5, Fzd 8, and Lrp 6 to activate Wnt signaling. We have observed that Fzd 5, Fzd 8, and Lrp 6 are expressed in the large bowel epithelium UC tissue samples and that Fzd 5 is the most abundant Fzd, representing an attractive target for our therapeutic approach. We have shown that <span style="white-space:nowrap">SZN-1326</span> has several simultaneous beneficial effects in that it: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">activates the Wnt signaling pathway in intestinal stem cells resulting in proliferation and differentiation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restores intestinal barrier function and tissue architecture; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreases inflammation; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduces disease activity in mouse models of moderate to severe IBD. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be <span style="white-space:nowrap">re-initiating</span> the Phase 1a clinical trial by <span style="white-space:nowrap">mid-2023</span> based on the minimum anticipated biologically effective level (MABEL) and anticipate safety data by the end of 2023. We anticipate initiating a Phase 1b clinical trial in ulcerative colitis patients in 2024 and expect proof of concept data to be potentially available in the second half of 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ulcerative Colitis Disease Background </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UC is a form of IBD characterized by inflammation and ulcers in the large intestine. The hallmark clinical symptoms of UC are diarrhea, bloody stool, and urgency to defecate, and its clinical course is marked by exacerbations and remissions, which may occur spontaneously or in response to dietary changes, alterations in treatment regimens, other illnesses or stress. In UC, inflammation is continuous throughout the large bowel and lacks healthy patches distributed adjacent to the inflamed tissue. The extent of disease is variable but starts at the left side (the rectum) and can involve the whole, large intestine. UC is limited to the inner most layer of the intestinal wall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UC can be debilitating with frequent diarrhea, bloody stools, weight loss, dehydration, and anemia. Intestinal complications from severe and chronic inflammation can become life-threatening. Patients with active </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disease are more likely to suffer psychological conditions such as anxiety and depression and are more likely to have impaired social interactions. Persistent UC is associated with an increased risk of developing colon cancer. It is estimated that there are two million individuals in the United States with IBD, of which roughly half have UC. An even higher number of individuals in Europe are estimated to have UC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UC is typically treated with anti-inflammatory drugs. The typical treatment regimen begins with fairly mild and locally-delivered drugs and progresses to stronger systemic immunosuppressive drugs that are only prescribed for patients with moderate to severe disease. First-line therapy for patients with mild disease consists of locally delivered or oral <span style="white-space:nowrap">5-aminosalicylates</span> such as mesalamine and sulfasalazine, or corticosteroids. This is done with the intent of inducing remission and transitioning patients to drugs such as <span style="white-space:nowrap">5-aminosalicylates</span> for maintenance. Patients with moderate to severe disease will usually be treated first-line with anti-inflammatory biologics such as infliximab, adalimumab, and golimumab. Infliximab, adalimumab, and golimumab are antibodies directed against tumor necrosis factor alpha, or TNF&#945;, an inflammatory cytokine secreted during acute inflammation. However, over time, many patients lose responsiveness to these <span style="white-space:nowrap">anti-TNF</span> antibodies and approximately 20% do not initially respond to this treatment. Patients <span style="white-space:nowrap">non-responsive</span> to <span style="white-space:nowrap">anti-TNF&#945;</span> antibody therapy are instead treated with other approved biologics such as ustekinumab, an inhibitor of interleukin 12 and interleukin 23, and vedolizumab, an integrin inhibitor or with a JAK inhibitor, tofacitinib, an oral anti-inflammatory. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the availability of a number of approved drugs and validated drug targets, many patients with moderate to severe UC have an inadequate or slow response to therapy, lose responsiveness, or cannot tolerate existing treatments. For example, up to 20% of patients do not respond to <span style="white-space:nowrap">anti-TNF</span> antibodies and 10% to 15% lose responsiveness every year despite initial benefit. Overall, it is estimated that less than half of moderate to severe UC patients are in clinical remission. Approximately 70% of patients with active disease in a given year will have another episode in the following year. Once a patient has successfully been treated and is in remission, the longer the patient is in remission, the less likely he or she is to experience a <span style="white-space:nowrap">flare-up</span> in the following year. A potential factor driving longer-term remissions is the repair of the intestinal barrier and absence of any inflammatory activity in the large intestine gut wall. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Crohn&#8217;s Disease Background </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Crohn&#8217;s disease, or CD, is a chronic inflammatory disease that most commonly affects the end of the small intestine and the beginning of the large intestine, although it may involve any part of the gastrointestinal tract. Like UC, CD is a type of IBD and many of the symptoms and demographics overlap. In addition to the potential of CD developing in other segments of the intestine, CD differs from UC in that there can be normal healthy tissue between patches of diseased tissue. CD can also occur in all layers of the intestinal wall unlike UC which is limited to the inner most layer. It is estimated that there are approximately 1&#160;million individuals in the United States and approximately 1.1&#160;million individuals in Europe with CD. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The treatment paradigm for CD is very similar to that of UC. Currently approved therapies are mostly anti-inflammatory agents. It is estimated that 60% of patients have moderate to severe disease and will eventually require surgery to treat complications such as fistulas (abnormal connections between body parts), life-threatening bleeding, and intestinal obstructions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Wnt Signaling Pathway and its Role in IBD </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the two most common forms of IBD, UC and CD, are treated with anti-inflammatory agents, the root cause of these diseases has been proposed to be an impaired intestinal barrier that occurs due to initial damages by genetic, environmental, inflammatory or other factors. This impairment is thought to allow bacteria to penetrate through the intestinal epithelium, leading both to immune cell activation and to an inflammatory reaction that exacerbates the damage. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intestinal epithelium is one of the fastest proliferating tissues in adults, being largely made anew every four to five days. The wall of the small intestine is made up of villi, finger-like projections that extend into the lumen of the intestine, which greatly increase the surface area available for nutrient absorption. The cells at the tips of these villi are continuously shed and are replenished by cells that originate from stem cells located at the base of the villus, called the intestinal crypts. The colon (large intestine) wall is made up of a lining of columnar epithelial cells with pouches called colonic crypts. Similar to the small intestine villi, the stem cells are located at the base of colonic crypts, as shown in Figure 10, below. The Wnt signaling pathway is critical for the renewal and proliferation of these stem cells. Inactivation of the Wnt signaling pathway blocks stem cell proliferation and differentiation causing a rapid loss of intestinal epithelial cells in mice. Figure 10 below illustrates how the Wnt signaling pathway potentially stimulates stem cell renewal and proliferation in colonic crypts leading to increased turnover of epithelial cells. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g90a90.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 10. Wnt signaling pathway stimulates stem cell renewal and proliferation leading to increased synthesis and turnover of epithelial cells </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is direct evidence linking dysregulation in the Wnt signaling pathway to the development of moderate to severe IBD in patients and deficiency in the Wnt signaling pathway has been associated not only with the reduced turnover of stem cells in the intestinal crypt but also with a reduced production of cells that secrete anti-bacterial proteins. It has been proposed that transient elevations in the Wnt signaling pathway may be beneficial in wound healing and evidence from mouse IBD models provide further support for treatment with a Wnt signal activator. The Wnt protein inhibitor Dkk1 is induced by inflammatory cytokines in colitis and, in mice, blocking Dkk1 function resulted in elevated Wnt signaling and the promotion of wound repair. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Solution: <span style="white-space:nowrap">SZN-1326</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate, <span style="white-space:nowrap">SZN-1326,</span> is a Wnt protein mimetic based on our SWAP technology, for the treatment of moderate to severe IBD. Our goal for <span style="white-space:nowrap">SZN-1326</span> was to create a Wnt protein mimetic that could specifically support the proliferation and differentiation of stem cells in the damaged intestinal or colonic crypts of patients with moderate to severe IBD. We believe that treatment with <span style="white-space:nowrap">SZN-1326</span> has the potential to accelerate the repair of the intestinal barrier, which can result in a reduction of bacteria penetrating through the intestinal epithelium and a reduction of immune cell activation and inflammation, thereby treating IBD. Figure 11 below demonstrates how <span style="white-space:nowrap">SZN-1326</span> potentially binds to Fzd5/8 and Lrp6 on intestinal stem cells to activate Wnt signaling. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g91a09.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 11: <span style="white-space:nowrap">SZN-1326</span> binds to Fzd5/8 and Lrp6 on intestinal stem cells to activate Wnt signaling </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Selective Wnt Pathway Activation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SZN-1326</span> is a bispecific antibody targeting Fzd5/8 and Lrp6. Fzd5 was reported to be highly expressed in intestinal mucosal cells from IBD patients. Our research found that Fzd5, was also highly expressed in a mouse model of colitis induced by dextran sodium sulfate, or DSS, as shown in Figure 12. In this model, DSS exposure leads to disruption of the intestinal barrier resulting in an inflammatory response similar to that seen in IBD </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patients. We identified <span style="white-space:nowrap">SZN-1326</span> through testing of multiple SWAP antibodies both in na&#239;ve and injured intestinal tissue and in DSS models. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g92a09.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 12. Fzd5 is highly expressed in intestinal tissue from a DSS mouse model </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have shown that <span style="white-space:nowrap">SZN-1326</span> can stimulate Wnt signal activation in <span style="white-space:nowrap">DSS-injured</span> intestine epithelial cells as measured by the expression of<span style="font-style:italic"> Axin2</span>, a downstream target gene in the Wnt pathway. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restoration of Epithelial Tight Junctions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mice exposed to DSS for seven days led to the breakdown of the intestinal barrier, which can be readily visualized in stained cross sections of the colon, as shown in Figure 13. In the absence of DSS, there is an intact intestinal wall and the crypts are tightly packed to form a continuous structure. Exposure to DSS followed by treatment with a negative control antibody, <span style="white-space:nowrap">anti-GFP,</span> resulted in several effects: a breakdown of the intestinal wall; shrinkage of the crypts; and the creation of multiple discontinuous segments by day ten. However, <span style="white-space:nowrap">DSS-exposed</span> mice treated with <span style="white-space:nowrap">SZN-1326,</span> administered on days four and seven, led to a dose-dependent repair </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of this damage, with a dose of 1 mg/kg or higher restoring most of the damage visible by histology. Similar results were observed in a chronic model of DSS, as can be seen in Figure 13. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g92b09.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 13. <span style="white-space:nowrap">SZN-1326</span> administration led to the restoration of the intestinal epithelium in a DSS model </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of epithelial repair as measured by histology with <span style="white-space:nowrap">SZN-1326</span> was greater than what we obtained in additional experiments with cyclosporine, an <span style="white-space:nowrap">anti-TNF</span> antibody or an anti-IL12/23 antibody. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Histologic staining showed that treatment with <span style="white-space:nowrap">SZN-1326</span> led to the restoration of tight junctions, the <span style="white-space:nowrap"><span style="white-space:nowrap">cell-to-cell</span></span> structures that create the intestinal barrier that prevents the free flow of material. In healthy intestinal tissue, the zonula occludens 1 protein, or <span style="white-space:nowrap">ZO-1,</span> a component of tight junctions, was found as a continuous layer along the intestinal wall. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In <span style="white-space:nowrap">DSS-damaged</span> intestinal tissue, no such barrier was observed. Treatment with <span style="white-space:nowrap">SZN-1326</span> restored <span style="white-space:nowrap">ZO-1</span> localization as a continuous layer along the intestinal wall, as can be observed in Figure 14. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g93a09.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 14. <span style="white-space:nowrap">SZN-1326</span> restored <span style="white-space:nowrap">ZO-1</span> localization (green) and reestablishment of the intestinal barrier in a DSS mouse model. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Inflammation Reduction </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The breakdown of the intestinal barrier triggers an inflammatory response that leads to further tissue damage. Disease modification in IBD can be measured by the levels of inflammatory cytokines present in the injured tissue and in serum. In the mouse DSS model, treatment with <span style="white-space:nowrap">SZN-1326</span> administration led to a significant dose-dependent decrease in a number of inflammatory cytokines such as TNF&#945;, <span style="white-space:nowrap">interleukin-6,</span> or <span style="white-space:nowrap">IL-6,</span> and <span style="white-space:nowrap">interleukin-8,</span> or <span style="white-space:nowrap">IL-8.</span> Reductions in cytokine levels were observed both in colon tissue and in serum, as can be seen in Figure 15 below. We believe that these results suggest that <span style="white-space:nowrap">SZN-1326</span> not only has the potential of directly repairing the epithelium but also, as a result, of reducing inflammation. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g93b09.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 15. <span style="white-space:nowrap">SZN-1326</span> administration led to significant reductions in cytokine levels in a DSS mouse model. (* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the description of the preclinical studies above and throughout, a <span style="white-space:nowrap">p-value</span> represents the probability that random chance caused the result. For example, a <span style="white-space:nowrap">p-value</span> of 0.001 means that there is a 0.1% probability that the difference between the control group and the treatment group is purely due to random chance. A <span style="white-space:nowrap">p-value</span> of less than or equal to 0.05 is a commonly used threshold for identifying statistically significant outcomes. The FDA&#8217;s evidentiary standard of efficacy when evaluating the results of a clinical trial generally relies on a <span style="white-space:nowrap">p-value</span> of less than or equal to 0.05. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Functional Improvement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most importantly, <span style="white-space:nowrap">SZN-1326</span> administration led to an improvement in the disease activity index, or DAI, in the DSS model. The DAI is a composite score composed of body weight change, diarrhea, and bloody stools that is frequently used to quantify disease severity. <span style="white-space:nowrap">SZN-1326</span> treatments led to a dose dependent decrease in DAI which was superior to that which we observed with cyclosporine, an <span style="white-space:nowrap">anti-TNF</span> antibody, or an anti-IL12/23 antibody in acute and chronic DS models, respectively. Figure 16 below demonstrates that <span style="white-space:nowrap">SZN-1326</span> administration led to improvements in DAI in an acute DSS model. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g94a09.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 16. <span style="white-space:nowrap">SZN-1326</span> administration led to improvement in the disease activity index in an acute DSS model. (* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001) </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical Development of <span style="white-space:nowrap">SZN-1326</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to <span style="white-space:nowrap">re-initiate</span> the Phase 1a clinical trial by <span style="white-space:nowrap">mid-2023.</span> Our trial focuses on assessing safety and tolerability as well as on obtaining human pharmacokinetic data in healthy volunteers. We intend to conduct a multiple ascending dose trial in patients with moderate to severe UC in 2024 with the goal of assessing safety, tolerability, pharmacokinetics and initial signs of clinical activity through the effects on stool frequency, rectal bleeding, cytokines, biomarkers, and endoscopic and histological changes in the colon. We anticipate that later stage trials would include the induction of clinical and histological remission, either alone or in combination with anti-inflammatory drugs. Based both on the mechanism of action of <span style="white-space:nowrap">SZN-1326</span> and our preclinical results, we believe that dosing of <span style="white-space:nowrap">SZN-1326</span> for several weeks has the potential to demonstrate durable remissions. If we obtain initial signs of efficacy in UC, we anticipate also initiating clinical development in CD. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">SZN-043,</span> a SWEETS product candidate for the treatment of severe liver diseases </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SZN-043</span> is our product candidate in development for severe alcoholic hepatitis, or AH. <span style="white-space:nowrap">SZN-043,</span> a hepatocyte-specific <span style="white-space:nowrap">R-spondin</span> mimetic bispecific fusion protein targeting ASGR1, is the first development </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidate using Surrozen&#8217;s SWEETS<sup style="font-size:75%; vertical-align:top">&#8482;</sup> technology which is designed to mimic the regenerative properties of the protein <span style="white-space:nowrap">R-Spondin</span> by enhancing Wnt signaling in a cell-targeted manner. We have shown that <span style="white-space:nowrap">SZN-043</span> activates Wnt signaling in hepatocytes and contributes both to increasing hepatocyte proliferation and to restoring liver function. We opened enrollment for the Phase 1a clinical trial in chronic liver disease patients, enrolled the first patient in the first quarter of 2023 and expect data to be available in the second half of 2023. We anticipate initiating a Phase 1b clinical trial in patients with severe alcoholic hepatitis in 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Severe Alcoholic Hepatitis Background </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AH is inflammation of the liver caused by excessive alcohol ingestion. AH is most likely to occur in people who drink heavily over many years; however, the relationship between drinking and alcoholic hepatitis is complex. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not all heavy drinkers develop alcoholic hepatitis, and the disease can occur in people who drink only moderately. AH is characterized by the rapid onset of jaundice, malaise, anorexia, liver enlargement and a systemic inflammatory response syndrome, or SIRS. AH is characterized by impaired hepatocyte proliferation. In these patients, higher Wnt signaling and hepatocyte proliferation have been associated with better outcomes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many patients with severe AH require inpatient hospitalization due to the high risk of developing renal failure, liver failure, infections and the effects of alcohol withdrawal. AH is treated with anti-inflammatory drugs such as glucocorticoids, typically prednisolone. Glucocorticoid treatment requires close monitoring because of the increased risk of infections, glucose intolerance and gastrointestinal bleeding. For patients who respond to glucocorticoids, the duration of treatment is typically 28 days. Mortality rates after one to six months among patients treated with glucocorticoids in clinical trials ranged from approximately 20% to 40%. The effectiveness of glucocorticoid treatment is controversial. A 2017 meta-analysis of 15 randomized trials found that glucocorticoid treatment did not significantly lower mortality rates compared to placebo. In addition, only 25% to 45% of patients are eligible for glucocorticoid therapy due to other comorbidities. Those not qualifying include patients with infections, poorly controlled diabetes mellitus, renal failure, and active gastrointestinal bleeding. Although levels of TNF&#945; are highly elevated in AH, treatment with <span style="white-space:nowrap">anti-TNF&#945;</span> antibodies has not been determined to be effective. The overall <span style="white-space:nowrap">30-day</span> mortality rate in patients hospitalized with AH is approximately 15% and the <span style="white-space:nowrap">90-day</span> rate is approximately 30%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are an estimated 130,000 unique <span style="white-space:nowrap">AH-related</span> hospitalizations annually in the United States. Alcoholism affects an estimated 8% of the U.S. population and between 10% and 35% of alcoholics have characteristics consistent with the development of AH. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Solution: <span style="white-space:nowrap">SZN-043</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SZN-043,</span> a tissue-selective <span style="white-space:nowrap">R-spondin</span> mimetic based on our SWEETS technology, for the treatment of severe liver disease. Our goal was to create a molecule that could stimulate liver regeneration by amplifying the effect of naturally occurring Wnt proteins. <span style="white-space:nowrap">SZN-043</span> is a bispecific antibody that mimics the stimulatory effect of <span style="white-space:nowrap">R-spondin</span> specifically on hepatocytes through targeting of asialoglycoprotein receptor 1, or ASGR1. Liver regeneration has been shown to be an important predictor and biomarker for disease severity, response to corticosteroids and patient survival in those with severe AH. We believe that the regenerative </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capacity that <span style="white-space:nowrap">SZN-043</span> has shown in preclinical models will potentially improve the outcome of patients with severe AH. Figure 17 below describes the proposed mechanism of action of <span style="white-space:nowrap">SZN-043.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g95a09.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 17. In liver injury, <span style="white-space:nowrap">SZN-043</span> amplifies the regenerative activity of endogenous Wnts by stabilizing their Fzd receptors on hepatocytes </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Selective Wnt Pathway Activation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to <span style="white-space:nowrap">R-spondin,</span> <span style="white-space:nowrap">SZN-043</span> leads to an amplification of Wnt signaling by inhibiting internalization and degradation of Fzd. However, an important difference from <span style="white-space:nowrap">R-spondin</span> is that <span style="white-space:nowrap">SZN-043</span> requires binding to ASGR1, a protein that is exclusively expressed on hepatocytes, for activity. A single dose of <span style="white-space:nowrap">SZN-043</span> at 10 mg/kg led to the amplification of the Wnt signaling pathway, as measured by<span style="font-style:italic"> Axin2</span> expression, a common indicator of Wnt signaling activity, in mouse liver, but not in any of the other tissues analyzed. In a similar experiment, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">R-spondin</span> at 10 mg/kg led to Wnt pathway activation in multiple tissues including liver, lung, stomach, intestines, and pancreas, as can be seen in Figure 18 below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g96a09.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Figure 18. <span style="white-space:nowrap">R-spondin</span> <span style="white-space:nowrap">(R-spo2)</span> significantly increased</span><span style="font-weight:bold"><span style="font-style:italic"> Axin2</span></span><span style="font-weight:bold"> expression in many tissues, whereas <span style="white-space:nowrap">SZN-043</span> only increases</span><span style="font-weight:bold"><span style="font-style:italic"> Axin2</span></span><span style="font-weight:bold"> expression in the liver. (* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001) </span></p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Hepatocyte Proliferation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mice treated with a single dose of <span style="white-space:nowrap">SZN-043</span> had significantly increased proliferation of hepatocytes at 48 hours as measured by <span style="white-space:nowrap">Ki-67</span> expression (green signal in Figure 19 below), a nuclear protein that is associated with, and used as, a cellular marker of proliferation. Treatment with <span style="white-space:nowrap">SZN-043</span> led to an increased number of hepatocytes that express hepatocyte nuclear factor 4&#945;, or HNF4&#945; (red signal in Figure 19, below), a master regulator of hepatic differentiation that is critical to the regulation of liver differentiation and development. In Figure 19, a yellow signal results from the merging of a green and red signal, indicating that the proliferating cells are hepatocytes. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g96b09.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 19. <span style="white-space:nowrap">SZN-043</span> led to increased proliferation and differentiation of hepatocytes in mice. (* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Functional Improvement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">High levels of ammonia in the blood, a condition known as hyperammonemia, is believed to contribute to the pathogenesis of hepatic encephalopathy and a sign of severe liver disease. Ammonia levels have been shown to predict mortality in patients with acute hepatitis. Acute liver failure patients who have decreased ammonia levels have improved survival. Measurement of ammonia levels is a standard clinical test used to screen for liver function and follow progression of liver disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Elevated ammonia levels are also observed in a mouse model of AH. In this model, AH is induced by seven weeks of a binge ethanol diet. After seven weeks, the ethanol diet is suspended, and liver injury is assessed. Treatment with <span style="white-space:nowrap">SZN-043</span> significantly lowered ammonia levels in this model by day three, as shown in Figure&#160;20. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g97a09.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Figure 20. <span style="white-space:nowrap">SZN-043</span> treatment significantly reduced ammonia levels in an alcoholic hepatitis mouse model. (* p &lt; 0.05, ** p &lt; 0.01, *** p &lt; 0.001, **** p &lt; 0.0001) </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical Development of <span style="white-space:nowrap">SZN-043</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We completed enrollment in the second cohort of the <span style="white-space:nowrap">SZN-043</span> Phase 1a single ascending dose clinical trial in healthy volunteers in 2022. We opened enrollment for the Phase 1a clinical trial in chronic liver disease patients, enrolled the first patient in the first quarter of 2023 and expect data to be available in the second half of 2023. This single ascending dose Phase 1a study assesses pharmacokinetics, safety and tolerability, and pharmacodynamic markers. We anticipate conducting a clinical trial in patients with severe AH in 2024 with the primary endpoints of safety and pharmacokinetics and exploratory efficacy endpoints consisting of the Lille and MELD scores. The Lille model is a highly predictive measure of likelihood of death at three and six months calculated by taking into account patient age, renal insufficiency, albumin, prothrombin time, bilirubin, and evolution of bilirubin at day seven. The MELD score is a separate prognostic scoring system that is used to predict the three-month mortality due to liver disease based on laboratory parameters such as creatinine, bilirubin, and INR measurements. Based on our estimates of the prevalence of severe AH, we are exploring whether <span style="white-space:nowrap">SZN-043</span> may qualify for orphan drug designation or fast track designation or both, which may accelerate its path towards potential regulatory approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
internally or licensed from third parties. We also rely on <span style="white-space:nowrap">know-how,</span> continuing technological innovation and <span style="white-space:nowrap">in-licensing</span> opportunities to develop, strengthen and maintain our proprietary position in our field and other fields that are or may be important for the development of our business. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Collaboration and Licensing Arrangements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Collaboration and License Agreement with Boehringer Ingelheim International GmbH </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2022, we executed the CLA with BI to research, develop and commercialize Fzd4 <span style="white-space:nowrap">bi-specific</span> antibodies designed using the Company&#8217;s SWAP technology, including <span style="white-space:nowrap">SZN-413.</span> We and BI are conducting collaborative research focused on <span style="white-space:nowrap">SZN-413</span> during a <span style="white-space:nowrap">one-year</span> period, which BI has the right to extend by up to six months. We granted BI an exclusive, royalty-bearing, worldwide, sublicensable license, under our applicable patents and <span style="white-space:nowrap">know-how,</span> to develop, manufacture and commercialize, for all uses, one lead and two back-up Fzd4 bi-specific antibodies selected by BI and their derivatives. After the end of the collaborative research, BI shall be responsible for all further research, preclinical and clinical development, manufacturing, regulatory approvals, and commercialization of licensed products at its expense. Unless terminated earlier, or expiring on account of BI not selecting at least one Fzd4 bi-specific antibody within sixty days after the end of the collaborative research, the CLA will remain effective, on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> basis, until the expiration of BI&#8217;s royalty obligations. Under the terms of the CLA, BI paid a <span style="white-space:nowrap">non-refundable</span> upfront payment of $12.5&#160;million less applicable withholding tax, and we are eligible to receive success-based milestone payments up to a total of $586&#160;million and <span style="white-space:nowrap">mid-single</span> digit to <span style="white-space:nowrap">low-double</span> digit royalties on net sales of the licensed products should any reach commercialization. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stanford License Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, we entered into a license agreement with Stanford University, or the 2016 Stanford Agreement, which was amended in July 2016, October 2016 and January 2021, pursuant to which we obtained a worldwide, exclusive, sublicensable license under certain patents, rights, or licensed patents and technology related to our engineered Wnt surrogate molecules to make, use, import, offer to sell and sell products that are claimed by the licensed patents or that use or incorporate such technology, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases. The 2016 Stanford Agreement covers two patent families and any patents that grant from these families are predicted to expire in 2035 and 2037, absent any patent term adjustments or extensions. In consideration for this license, we paid Stanford a nominal upfront fee and issued an aggregate of 42,451 shares of our common stock to Stanford, the University of Washington and two <span style="white-space:nowrap">co-inventors</span> of the licensed patents. In addition, we agreed to pay Stanford nominal annual license maintenance fees which are creditable against earned royalties owed to Stanford for the same year, an aggregate of up to $0.9&#160;million for the achievement of specified development and regulatory milestones, and an aggregate of up to $5.0&#160;million for the achievement of specified sales milestones. Stanford is also entitled to receive royalties from us equal to a very low single digit percentage of our and our sublicensees&#8217; net sales of licensed products that are covered by a valid claim of a licensed patent. Our obligation to pay royalties will continue, on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis, until the <span style="white-space:nowrap"><span style="white-space:nowrap">last-to-expire</span></span> valid claim of a licensed patent covering a licensed product in the country of manufacture or sale. Additionally, we agreed to pay Stanford a <span style="white-space:nowrap">sub-teen</span> double digit percentage of certain consideration we receive as a result of granting sublicenses to the licensed patents. However, we and Stanford may be able to negotiate a lower <span style="white-space:nowrap">non-royalty</span> sublicense percentage based on the then-current value of the licensed patents for each sublicense product. If we are acquired, we agreed to pay a <span style="white-space:nowrap">one-time</span> change of control fee in the low six figures. Stanford retains the right under the 2016 Stanford Agreement, on behalf of itself, Stanford Hospital and Clinics, the University of Washington and all other <span style="white-space:nowrap">non-profit</span> research institutions, to practice the licensed patents and technology for any <span style="white-space:nowrap">non-profit</span> purpose. The licensed patents and technology are additionally subject to a non-exclusive, irrevocable, worldwide license held by the Howard Hughes Medical Institute to practice the licensed patents and technology for its research purposes, but with no right to assign or sublicense. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, we entered into another license agreement with Stanford, or the 2018 Stanford Agreement, pursuant to which we obtained from Stanford, a worldwide, exclusive, sublicensable license under certain patent rights related to our surrogate <span style="white-space:nowrap">R-spondin</span> proteins, or licensed patents, to make, use, import, offer to sell and sell products that are claimed by the licensed patents, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases, or the exclusive field. The 2018 Stanford Agreement covers one patent family, and any patents that grant from this family are predicted to expire in 2038, absent any patent term adjustment or extension. Additionally, Stanford granted us a worldwide, <span style="white-space:nowrap">non-exclusive,</span> sublicensable license under the licensed patents to make and use licensed products for research and development purposes in furtherance of the exclusive field and a worldwide, <span style="white-space:nowrap">non-exclusive</span> license to make, use and import, but not to offer to sell or sell, licensed products in any other field of use. In consideration of these licenses, we paid Stanford a nominal upfront fee. We also agreed to pay Stanford nominal annual license maintenance fees which are creditable against earned royalties owed to Stanford for the same year, and an aggregate of up to $0.4&#160;million for the achievement of specified development and regulatory milestones. Stanford is also entitled to receive royalties from us equal to a <span style="white-space:nowrap">sub-single</span> digit percentage of our and our sublicensees&#8217; net sales of licensed products that are covered by a valid claim of a licensed patent. Our obligation to pay royalties will continue, on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis, until the <span style="white-space:nowrap"><span style="white-space:nowrap">last-to-expire</span></span> valid claim of a licensed patent covering a licensed product in the country of manufacture or sale. Additionally, we agreed to pay Stanford a <span style="white-space:nowrap">one-time</span> payment in the low six figures for each sublicense of the licensed patents that we grant to a third party and, if we are acquired, a <span style="white-space:nowrap">one-time</span> nominal change of control fee. Stanford retains the right under the 2018 Stanford Agreement, on behalf of itself, Stanford Health Care, Lucile Packard Children&#8217;s Hospital at Stanford, and all other <span style="white-space:nowrap">non-profit</span> research institutions, to practice the licensed patents for any <span style="white-space:nowrap">non-profit</span> purpose. The licensed patents are additionally subject to a <span style="white-space:nowrap">non-exclusive,</span> irrevocable, worldwide license held by the Howard Hughes Medical Institute to exercise any intellectual property rights with respect to the licensed patents for research purposes, including the right to sublicense to <span style="white-space:nowrap">non-profit</span> and governmental entities but with no other rights to assign or sublicense. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under each of the 2016 Stanford Agreement and the 2018 Stanford Agreement, or Stanford Agreements, we agreed to use commercially reasonable efforts to develop and commercialize licensed products and we agreed to achieve certain funding and development milestones by certain dates. Unless earlier terminated, each Stanford Agreement will continue until the expiration of the patents licensed under such Stanford Agreement. We may terminate either Stanford Agreement at any time for any reason by providing at least 30 days&#8217; written notice to Stanford. Stanford may terminate either Stanford Agreement if we breach certain provisions of that Stanford Agreement and fail to remedy such breach within 90 days after written notice of the breach by Stanford. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">UCSF License and Option Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September and October 2016, we entered into two license and option agreements with UCSF, or the UCSF Agreements, pursuant to which we obtained exclusive licenses from UCSF for internal research and antibody discovery purposes and an option to negotiate with UCSF to obtain an exclusive license under UCSF&#8217;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from our use of such library, or licensed products. Our <span style="white-space:nowrap">SZN-1326</span> candidate comprises a VHH domain isolated from the licensed UCSF single domain antibody library. In consideration for the license and option rights under each UCSF Agreement, we paid UCSF a nominal option issue fee and agreed to pay UCSF a nominal annual option maintenance fee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2020, we amended and restated the UCSF Agreements to provide <span style="white-space:nowrap">non-exclusive</span> licenses to make and use a certain human Fab na&#239;ve phage display library and to make and use a certain phage display llama VHH single domain antibody library for internal research and antibody discovery purposes and an option to negotiate with UCSF to obtain a <span style="white-space:nowrap">non-exclusive</span> license under UCSF&#8217;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from our use of such library, or licensed products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, we exercised the option under the UCSF Agreements and entered into a <span style="white-space:nowrap">non-exclusive</span> commercial license agreement to make and use licensed products derived from the phage display llama VHH </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
single domain antibody library. Under the commercial license agreement, the Company paid UCSF a nominal license issue fee and agreed to pay a nominal annual license maintenance fee, five- to <span style="white-space:nowrap">six-digit</span> payments per licensed product upon achievement of a regulatory milestone, nominal minimum annual royalties, and earned royalties equal to a <span style="white-space:nowrap">sub-single</span> digit percentage of the Company&#8217;s and the Company&#8217;s sublicensees&#8217; net sales of licensed products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, each UCSF Agreement will continue until four years from its execution date and we may exercise the option to negotiate a commercial license at any time during that term. Additionally, we may extend each UCSF Agreement for an additional four years by paying UCSF a nominal term extension fee. We may terminate either UCSF Agreement at any time for any reason by providing at least 60 days&#8217; written notice to UCSF. UCSF may terminate either UCSF Agreement if UCSF reasonably believes we are in material breach of such UCSF Agreement and we fail to remedy such breach within 60 days after written notice of such breach given by UCSF. Additionally, the UCSF Agreements will automatically terminate in the event of our bankruptcy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Distributed Bio Subscription Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2016, we entered into, and in January 2019 we amended, an antibody library subscription agreement with Distributed Bio, Inc., or Distributed Bio (Distributed Bio has since been acquired by Charles River Laboratories International, Inc.). In this antibody library subscription agreement, or the Distributed Bio Agreement, we obtained from Distributed Bio a <span style="white-space:nowrap">non-exclusive</span> license to use Distributed Bio&#8217;s antibody library to identify antibodies directed to an unlimited number of our proprietary targets and to make, use, sell, offer for sale, import and exploit products incorporating the antibodies that we identify, or licensed products. Our <span style="white-space:nowrap">SZN-1326</span> candidate incorporates a binding component isolated from the Distributed Bio antibody library. In consideration for the rights granted to us under the Distributed Bio Agreement, we paid Distributed Bio a nominal upfront fee and an additional nominal fee upon entering into the amendment. We agreed to pay Distributed Bio an annual fee in the low six figures after the first three years. Additionally, we agreed to pay Distributed Bio an aggregate of $5.9&#160;million for each licensed product that achieves specified development, regulatory and commercial milestones and royalties equal to a very low single digit percentage of our and our sublicensees&#8217; net sales of licensed products. Our obligation to pay royalties will end for each licensed product ten years after its first commercial sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the Distributed Bio Agreement will continue for an initial four-year term and will thereafter automatically renew for additional <span style="white-space:nowrap">one-year</span> terms. We may terminate the Distributed Bio Agreement for convenience at any time by providing written notice to Distributed Bio. We and Distributed Bio may terminate the Distributed Bio Agreement for the other party&#8217;s material breach and failure to cure such breach within 60 days after notice of such breach. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patents and Other Proprietary Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, our patent portfolio consisted of over 20 pending patent application families, including 15 families that have entered national phase in the United States and other countries, three families with pending Patent Cooperation Treaty, or PCT, applications, some of which have also been filed in certain <span style="white-space:nowrap">non-PCT</span> countries (e.g., Taiwan), and five families with pending U.S. provisional applications. These patent applications are directed to, for example, the SWAP and SWEETS platforms, the parental constructs of our two lead product candidate molecules, <span style="white-space:nowrap">SZN-043</span> and <span style="white-space:nowrap">SZN-1326,</span> the recently <span style="white-space:nowrap">out-licensed</span> <span style="white-space:nowrap">SZN-413,</span> as well as methods of treating disorders of the liver, intestine, retina, cornea, and lacrimal gland. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SWAP Platform Technology </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we solely own or exclusively license 15 patent families related to our SWAP platform. These patent families are directed to compositions of matter and/or methods of use, and relate to Wnt mimetics that bind to both a FZD receptor and an LRP receptor, and binding domains and uses thereof. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Any patents that issue from these patent families are predicted to expire between 2035 and 2042 absent any patent term adjustment or extension. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have exclusively licensed two patent families from The Board of Trustees of the Leland Stanford Junior University, or Stanford, related to our SWAP platform. One patent family has been allowed or granted in Australia, Europe, Japan and the United States and is pending in the United States, Australia, Canada, and Japan, and any patents that grant from this patent family are predicted to expire in 2035 absent any patent term adjustment or extension. The other patent family is pending in the United States, and any patents that grant from this patent family are predicted to expire in 2037 absent any patent term adjustment or extension. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exclusively owned patent families related to our SWAP platform include six patent families related to compositions of matter and/or methods of use relevant to <span style="white-space:nowrap">SZN-1326.</span> Two of these patent families are filed in the United States, Australia, Canada, China, Europe, Hong Kong and Japan, and any patents that grant from these patent families are predicted to expire in 2038 absent any patent term adjustment or extension. One is filed in the United States, Australia, Canada, China, Europe, Hong Kong, India, and Japan, and any patents that grant from these patent families are predicted to expire in 2038 absent any patent term adjustment or extension. One application is filed in the United States, Australia, Canada, China, Europe, India, and Japan, and any patents that grant from these applications are predicted to expire in 2039 absent any patent term adjustment or extension. One application is filed in the United States, Australia, Canada, China, Europe, India, Japan, and the Republic of Korea, and any patents that grant from these applications are predicted to expire in 2040 absent any patent term adjustment or extension. Another has been filed as a PCT application and a Taiwan application, and any patents that grant from these applications are predicted to expire in 2042. Other exclusively owned patent families related to the SWAP program are directed to compositions of matter and/or methods of use relevant to potential future product candidates. They include: one patent family filed in the United States, Australia, Canada, China, Europe, Hong Kong, India, Japan, and the Republic of Korea; one patent family filed in the United States, Australia, Canada, Europe, and Japan; one patent family filed in the United States, Australia, Canada, China, Europe, and Japan; one pending PCT application and corresponding pending applications also filed in the United States, Lebanon, Taiwan, and Argentina; one pending PCT application; and two provisional applications. Any patents that grant from these patent families related to the SWAP program are predicted to expire between 2040 and 2043 absent any patent term adjustment or extension. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">SWEETS Platform Technology </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we solely own or exclusively license five patent families related to our SWEETS platform. These patent families are directed to compositions of matter and methods of use of SWEETS molecules, and relate to tissue-selective <span style="white-space:nowrap">R-spondin</span> mimetics and binding domains and uses thereof. Any patents that grant from these patent families are predicted to expire between 2038 and 2041 absent any patent term adjustment or extension. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have exclusively licensed one patent family from Stanford related to our SWEETS platform. This patent family is filed in the United States, Australia, Canada, China, Europe, Hong Kong, India, and Japan, and any patents that grant from this patent family are predicted to expire in 2038 absent any patent term adjustment or extension. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our solely owned patent families related to our SWEETS platform include three patent families related to compositions of matter and/or methods of use relevant to <span style="white-space:nowrap">SZN-043.</span> Two of these patent families have been filed in the United States, Australia, Canada, China, Europe, Hong Kong, India, and Japan, and any patents that grant from these patent families are predicted to expire in 2038 or 2039 absent any patent term adjustment or extension. The other patent family directed to <span style="white-space:nowrap">SZN-043</span> composition of matter and methods of use was filed as PCT and Taiwan patent applications, and any patents that grant from national stage applications resulting from these applications are predicted to expire in 2041 absent any patent term adjustment or extension. We also filed a US provisional application encompassing antibodies that bind to components of <span style="white-space:nowrap">SZN-043</span> and method of use related to quantification of and release assays for SZN-043. Any patents that grant from any related national </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stage applications are predicted to expire in 2043. We plan on filing additional applications on any improvements or modifications of <span style="white-space:nowrap">SZN-043</span> and methods of use thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The actual term of any patent that may issue from the above-described patent applications claiming one of our product candidates could be longer than described above due to patent term adjustment or patent term extension, if available, or shorter if we are required to file terminal disclaimers. The term of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a <span style="white-space:nowrap">non-provisional</span> patent application in the applicable country. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20 years from the earliest effective <span style="white-space:nowrap">non-provisional</span> filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we may rely upon trade secrets and <span style="white-space:nowrap">know-how</span> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with selected consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <span style="white-space:nowrap">know-how</span> and inventions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our product candidates or processes, obtain licenses, or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future product candidates may have an adverse impact on us. If third parties have prepared and filed patent applications prior to March&#160;16, 2013 in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO, to determine priority of invention. For more information, please see the section titled &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to Our Intellectual Property</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property. We face potential competition from many different sources, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
establish collaborative arrangements for the research, development, manufacturing, and commercialization of therapies aimed at treating autoimmune, inflammatory, metabolic, and other diseases. Any product candidates that we successfully develop and commercialize will compete with current therapies and new therapies that may become available in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of our product candidates, if approved, are likely to be their efficacy, safety, convenience and price, the level of competition and the availability of coverage and adequate reimbursement from third-party payors. If any of our product candidates are approved and successfully commercialized, it is likely that we will face increased competition as a result of other companies pursuing development of products to address similar diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to <span style="white-space:nowrap">SZN-1326,</span> there are no <span style="white-space:nowrap">FDA-approved</span> therapeutics targeted towards the Wnt signaling pathway for the treatment of IBD. There are currently oral and biologic therapeutics approved for the treatment of IBD marketed by Johnson&#160;&amp; Johnson, Amgen Inc., Abbvie Inc., Takeda, Bristol Myers Squibb and Pfizer Inc., in addition to other major pharmaceutical companies, against which our product candidate may compete, if approved. In addition, we are aware of product candidates under development targeting epithelial barrier repair for the treatment of IBD, including from Applied Molecular Transport <span style="white-space:nowrap">(AMT-126)</span> in Phase 1. Other epithelial barrier repair programs include <span style="white-space:nowrap">TP-317</span> by Thetis Pharmaceuticals, an oral therapeutic designed to deliver Resolvin E1 to the gastrointestinal tract in Phase 1. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are aware of product candidates under development for AH and liver failure. Durect Corp is investigating <span style="white-space:nowrap">DUR-928</span> in a Phase 2/3 clinical trial in patients with severe AH, Intercept is investigating <span style="white-space:nowrap">INT-787</span> in a Phase 2a clinical trial in subjects with severe AH and Akaza Bioscience is preparing to investigate resatorvid <span style="white-space:nowrap">(TAK-242)</span> in a Phase 2 clinical trial of subjects with grade 1 or 2 <span style="white-space:nowrap"><span style="white-space:nowrap">acute-on-chronic</span></span> liver failure (ACLF). Evive has completed a Phase 1b study with <span style="white-space:nowrap">F-652</span> a recombinant fusion protein containing human interleukin 22 <span style="white-space:nowrap">(IL-22)</span> in alcoholic hepatitis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our earlier stage research programs, we are aware of one <span style="white-space:nowrap">FDA-approved</span> treatment targeting the Wnt pathway. Evenity (romosozumab) is a humanized monoclonal antibody targeting sclerostin and currently marketed by Amgen Inc. and UCB for postmenopausal osteoporosis. Ankasa Regenerative Therapeutics, Inc. is developing a liposomal formulation of recombinant human Wnt3A protein, that is applied ex vivo, to harvested autologous bone grafts (autograft) to enhance the osteogenic properties of the autograft prior to reimplantation in orthopedic surgeries. Frequency Therapeutics is developing a therapeutic product focused on the underlying cause of sensorineural hearing loss by activating progenitor cells to regenerate hair cells. AntlerA Therapeutics is a preclinical stage company developing Wnt antibody-like molecules (ANTs) that activate specific Fzd receptor complexes and are designed to control tissue stem cells and promote tissue repair and rejuvenation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information on the competitive risks we face, please see the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to Our Business&#8212;We face competition from entities that have developed or may develop product candidates for the treatment of the diseases that we may target...</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local level and in other countries and jurisdictions including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, such as our product candidates and any future product candidates. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Regulatory Approval in the United States </span></span>In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, or PHSA, and other federal, state, local and foreign statutes and regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations, including studies conducted in accordance with the FDA&#8217;s Good Laboratory Practice, or GLP, requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an institutional review board, or IRB, or independent ethics committee at each clinical trial site before each clinical trial may be commenced; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, Good Clinical Practice (GCP) requirements and other clinical trial-related regulations to establish the safety, purity and potency of the product candidate for each proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation and submission to the FDA of a biologics license application, or BLA, after completion of all clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">payment of any user fees for FDA review of the BLA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination by the FDA within 60 days of its receipt of a BLA to accept the application for review; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA Advisory Committee review, if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of one or more FDA <span style="white-space:nowrap">pre-approval</span> inspections of the manufacturing facility or facilities where the biologic, or components thereof, will be produced to assess compliance with current cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, strength, quality and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in support of the BLA to assure compliance with GCPs and integrity of the clinical data; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preclinical Studies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any biological product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Clinical Trials </span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the trial sponsor&#8217;s control. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations; (ii)&#160;in compliance with GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii)&#160;under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, clinical trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Disclosure of the results of these clinical trials can be delayed in certain circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well- designed and well-conducted foreign clinical trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of BLA submission and approval, clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, which may overlap or be combined: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the safety, dosage tolerance, absorption, metabolism and distribution of the product candidate in humans, the side effects associated with increasing doses, and, if possible, early evidence of effectiveness. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 2 clinical trials generally involve studies conducted in a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide statistically significant evidence of clinical efficacy of the product for its intended use, further evaluate its safety and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including non-compliance with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biologic does not undergo unacceptable deterioration over their shelf life. <span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">FDA Review Processes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by independent investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, purity and potency of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of preparing and submitting a BLA is substantial. Under the Prescription Drug User Fee Act, or PDUFA, each BLA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a <span style="white-space:nowrap">non-orphan</span> indication. The applicant under an approved BLA is also subject to an annual program fee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews a submitted BLA to determine if it is substantially complete before the FDA accepts it for filing and may request additional information from the sponsor. The FDA must make a decision on accepting a BLA for filing within 60 days of receipt, and may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission. In this event, the BLA must be resubmitted with any additional information requested. Once the submission is accepted for filing, the FDA begins an <span style="white-space:nowrap">in-depth</span> review of the BLA. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. Under the goals agreed to by the FDA under the PDUFA, the FDA has ten months, from the filing date, in which to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process can be extended by FDA requests for additional information or clarification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will typically conduct a <span style="white-space:nowrap">pre-approval</span> inspection of the manufacturing facilities for the new product to determine whether such facilities comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may audit data from clinical trials to ensure compliance with GCP requirements and the integrity of the data supporting safety, purity, and potency of the product candidate. Additionally, the FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it generally considers such recommendations carefully when making decisions on approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product is produced, it will issue either an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the BLA and may require additional clinical data, additional pivotal clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing in order for FDA to reconsider the application. If a CRL is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months from receipt, depending on the type of information included. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may require a REMS to help ensure that the benefits of the biologic outweigh the potential risks to patients. A REMS is a safety strategy implemented to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure a product&#8217;s safe use, or ETASU. An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <span style="white-space:nowrap">pre-</span> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. <span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Orphan Drug Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee. In addition, if a product that has orphan designation subsequently receives the first FDA </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because healthcare professionals are free to prescribe products for <span style="white-space:nowrap">off-label</span> uses, the competitor&#8217;s product could be used for the orphan indication despite another product&#8217;s orphan exclusivity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A designated orphan drug many not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA offers a number of expedited development and review programs for qualifying product candidates intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. For example, fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and where preclinical or clinical data demonstrate the potential to address unmet medical needs for the disease condition. Fast track designation applies to combination of the product and the specific indication for which it is being studied. The sponsor of a biological product candidate can request the FDA to designate the candidate for a specific indication for fast track status concurrent with, or after, the submission of the IND for the candidate. The FDA must determine if the biologic candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#8217;s request. The sponsor of a fast track product has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new biologic candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the biologic candidate. The FDA must determine if the biological product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#8217;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner. The designation also includes all of the fast track program features, including eligibility for rolling review of BLA submissions if the relevant criteria are met. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the <span style="white-space:nowrap">60-day</span> filing date (as compared to ten months under standard review). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accelerated approval may be granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit. The accelerated approval pathway is contingent on a sponsor&#8217;s agreement to conduct additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval, but may expedite the development or approval process. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Additional Controls for Biologics </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval. <span style="font-weight:bold"><span style="font-style:italic"> </span></span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pediatric Information </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act (PREA), BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA generally does not apply to any biological product for an indication for which orphan designation has been granted. PREA applies to BLAs for orphan-designated biologics if the biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA has determined is substantially relevant to the growth or progression of a pediatric cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Best Pharmaceuticals for Children Act (BPCA) provides a <span style="white-space:nowrap">six-month</span> extension of any exclusivity&#8212;patent or <span style="white-space:nowrap">non-patent&#8212;for</span> a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the use of a new biologic in the pediatric population may produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers. <span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. Once a BLA is approved, a product will be subject to certain additional post-approval requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may require post-marketing testing, known as Phase 4 testing, may impose a REMS and/or post-market surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Manufacturers are subject to periodic unannounced inspections by the FDA, including those focused on manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning or other enforcement-related letters or holds on post-approval clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">mandated modification of promotional materials and labeling and the issuance of corrective information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such <span style="white-space:nowrap">off-label</span> uses are common across medical specialties. Physicians may believe that such <span style="white-space:nowrap">off-label</span> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of <span style="white-space:nowrap">off-label</span> use of their products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Biosimilars and Reference Product Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Affordable Care Act, signed into law in 2010, includes a subtitle called The Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an <span style="white-space:nowrap">FDA-licensed</span> reference biological product. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BPCIA an application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. During this <span style="white-space:nowrap">12-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales and distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Other Healthcare Laws and Regulations and Legislative Reform </span><span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare Laws and Regulations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, physicians, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. Our current and future operations are subject to regulation by various federal, state, and local authorities in addition to the FDA, including but not limited to CMS, HHS (including the Office of Inspector General, Office for Civil Rights and the Health Resources and Services Administration), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. The healthcare laws that may affect our ability to operate include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Federal civil and criminal false claims laws, such as the False Claims Act, which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Drug manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. For example, pharmaceutical companies have been prosecuted under the False Claims Act in connection with their alleged <span style="white-space:nowrap">off-label</span> promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Health Insurance Portability and Accountability Act, or HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, which impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Affordable Care Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments and other transfers of value provided to physicians, as defined by such law, and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members. Effective January&#160;1, 2022, these reporting obligations will extend to include payments and transfers of value made to certain <span style="white-space:nowrap">non-physician</span> providers such as physician assistants and nurse practitioners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by <span style="white-space:nowrap">non-governmental</span> third-party payors, including private insurers, and state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales representatives; state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes; and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
health information privacy and data breach notification laws which govern the collection, use, disclosure and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not <span style="white-space:nowrap">pre-empted</span> by HIPAA, thus requiring additional compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of these laws or any other current or future healthcare laws that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <span style="white-space:nowrap">non-compliance</span> with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. <span style="font-weight:bold"><span style="font-style:italic"> </span></span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legislative Reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the U.S. Congress enacted the Affordable Care Act, which included changes to the coverage and reimbursement of drug products under government healthcare programs such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must pay to the federal government; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70%, effective as of 2019) <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">created a licensure framework for <span style="white-space:nowrap">follow-on</span> biologic products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There remain judicial and congressional challenges to certain aspects of the Affordable Care Act. It is unclear how efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act. It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results of operations, financial condition and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop. Moreover, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Further, it is possible that additional governmental action is taken in response to health epidemics. We expect that additional state and federal healthcare reform measures will be adopted in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Employees </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;1, 2023, we had 74 full-time employees, with 50 in research and development and 24 in general and administrative functions. None of our employees are represented by a labor union or covered by collective bargaining agreements, and we have not experienced any work stoppages. We consider our relationship with our employees to be good. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our total compensation package helps us attract and retain our employees. We offer our employees flexible benefits to meet the individual health and wellness needs of our employees, including competitive pay, equity grants, medical benefits, leave programs, and a 401(k) savings plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our human capital objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Strategic Talent and Culture Vision </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to being a great place to work for enterprising pioneers. We embody these shared values or principles in our work and daily interactions: collaborate, lead, innovate, motivate, and be brave, open and nurturing. These core principles are incorporated in all our people practices including hiring, performance management, and career development. We strive to foster an environment for our employees where: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we bravely explore and innovate together, with passion for the work and honesty towards each other; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">flexibility in skills, resilience, and adaptability to change are valued; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diversity, equity, and inclusion are embraced, and everyone makes a difference; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the workplace is fun, supportive and rewarding; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patients are at the heart of what we do. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know how much culture matters to the quality of our work experience, so we are committed to do all we can to strengthen our culture. Our inclusive and pioneering culture creates a sense of belonging, impact, adventure and fun. Our values are not just words on the wall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Leadership is something that we promote at all levels, encouraging employees to expand their comfort zones through team adventures and enthusiastically celebrate our accomplishments together. Through Surrozen Leadership Academy, we provide training to all employees on various leadership topics that support the long-term growth of the organization. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employee Engagement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our engagement strategy focuses on creating a workplace that is reflective of our core values. We believe that strong employee engagement helps enable higher retention and better business performance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employee feedback is gathered through regular conversations with our employees, managers, and through engagement surveys. Feedback informs and shapes our future employee-focused initiatives. Feedback has been incorporated into changes in our compensation, benefits, employee development programs and other culture programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Diversity, Equity, and Inclusion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe a diverse workforce and culture of inclusion is essential. To that end, we recently formed IDEA, a committee focused on diversity, equity, and inclusion. The committee is committed to making Surrozen a safe space for all employees, where everyone can voice their opinions without fear. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IDEA&#8217;s mission is for everyone to feel they belong at Surrozen, and that they are acknowledged, appreciated, and given opportunities for development. IDEA is committed to raising awareness, spotlighting cultural and heritage events, and celebrating all our multi-faceted backgrounds. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;1, 2023, 47% of all employees were female, and 40% or our managerial employees were female. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g491933g11a02.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employee Wellness and Safety </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is our goal to provide a safe and healthy workplace for all employees and to eliminate occupational injuries and illnesses. Every employee is obligated to always comply with the requirements of our Injury and Illness Prevention Program. In addition, we provide information to employees about workplace safety and health issues through bulletin board postings, memos, training, and online or other written communications. All employees and managers complete workplace harassment and sexual harassment training that includes details on how to report any violation of these policies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the <span style="white-space:nowrap">COVID-19</span> pandemic, we have taken caution and adhered to local safety guidelines. We have also created policies and practices to ensure the safety of employees within the office, including increasing cleaning procedures, encouraging employees who are able to work from home to do so and implementing mask mandates, social distancing, and additional safety measures as appropriate. We require all U.S. employees to be vaccinated, boosted, and provide optional PCR based testing on a weekly basis for all <span style="white-space:nowrap">on-site</span> employees. For any employee who contracts <span style="white-space:nowrap">COVID-19,</span> we provide full pay for their entire recovery and quarantine time, regardless of the guidelines of their home country. We provide sick leave for any affected employee at 100% of their salary or average hourly wages. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, we support a flexible workforce. We offer a variety of work arrangements including remote working, hybrid (virtual and <span style="white-space:nowrap">on-site)</span> and completely <span style="white-space:nowrap">on-site.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an additional benefit for all employees, we provide flu shots for our employees and their families. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Code of Conduct </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to maintaining the highest standards of business conduct and ethics. Our Code of Business Conduct and Ethics reflects the business practices and principles of behavior that support this commitment. We expect every employee, officer and director to read and understand our Code of Business Conduct and Ethics and its application to the performance of his or her business responsibilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located in South San Francisco, California, pursuant to a lease that expires in 2025. We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_12">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the names, ages, and positions of our current executive officers and directors: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:49%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:46%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Age</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position(s)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="font-style:italic">Executive Officers</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig Parker</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">61</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">President, Chief Executive Officer and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Williams</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">43</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geertrui (Trudy) Vanhove, M.D., Ph.D.<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">57</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Medical Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Wen-Chen</span> Yeh, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">59</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Scientific Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Directors</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tim Kutzkey, Ph.D.<sup style="font-size:75%; vertical-align:top">(1)(3)(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">47</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director, Chairman of the Board</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Berkenblit, M.D.<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">53</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Y. Chai<sup style="font-size:75%; vertical-align:top">(1)(3)(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Woodhouse, Ph.D.<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">52</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Haak-Frendscho, Ph.D.<sup style="font-size:75%; vertical-align:top">(2)(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">66</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mace Rothenberg, M.D.<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">66</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Shao-Lee</span> Lin, M.D., Ph.D.<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="right">56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the audit committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the compensation committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the nominating and corporate governance committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Chair of the audit committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Chair of the compensation committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Chair of the nominating and corporate governance committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Vanhove will terminate her employment with us on March&#160;31, 2023. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Craig Parker</span> has served as our President and Chief Executive Officer since March 2018 and as a member of our board of directors since April 2018. From August 2014 to March 2018, Mr.&#160;Parker served as Senior Vice President of Corporate Development at Jazz Pharmaceuticals plc, a biopharmaceutical company. From 2012 to 2014, Mr.&#160;Parker served as Executive Vice President of Corporate Development and Scientific Affairs at Geron Corporation and from 2011 to 2012 as Senior Vice President of Strategy and Corporate Development at Human Genome Sciences, or HGS, until its acquisition by GlaxoSmithKline plc. Prior to HGS, Mr.&#160;Parker worked in various positions at J.P. Morgan and other Wall Street financial institutions. Mr.&#160;Parker served on the board of directors of vTv Therapeutics, a biopharmaceutical company, from July 2015 to February 2019. Mr.&#160;Parker is a member of the Scientific Advisory Board and chairs the Leadership Council of the Life Sciences Institute, University of Michigan and has been a member since 2005. Mr.&#160;Parker received a A.B. in biological sciences from the University of Chicago, an M.B.A. from the University of Michigan and attended the Georgetown University School of Medicine. We believe that Mr.&#160;Parker&#8217;s extensive scientific, business and leadership experience in both public and privately-held companies in the life sciences industry provide him with the qualifications and skills to serve on our board of directors and as our President and Chief Executive Officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Charles Williams</span> has served as our Chief Financial Officer since November 2020. From 2013 to November 2020, he served as Head of Corporate Development at Jazz Pharmaceuticals plc. From 2008 to 2013, he served as Director of Corporate and Business Development at MAP Pharmaceuticals, Inc., a biopharmaceutical company acquired by Allergan, Inc. Prior to MAP, Mr.&#160;Williams held various roles related to business development, finance and strategic planning at CV Therapeutics, Inc., a biopharmaceutical company acquired by Gilead Sciences, Inc. Mr.&#160;Williams received a B.A. in economics from Cornell University. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Geertrui (Trudy) Vanhove, M.D., Ph.D.</span> has served as our Chief Medical Officer since April 2019. From June 2012 to October 2015, she served as Vice President, Medical Affairs and, from October 2015 to April 2019, she served as Vice President, Head of Search and Evaluation at Jazz Pharmaceuticals plc. From 2011 to 2012, she served as Vice President, Medical Affairs at Depomed, Inc., a pharmaceutical company. Prior to this, Dr.&#160;Vanhove held positions of increasing responsibility from 2006 to 2011 in Clinical Development at NeurogesX, Inc., a biopharmaceutical company. Prior to NeurogesX, Dr.&#160;Vanhove served as Medical Director at XOMA (US) LLC and Abbott Laboratories. Dr.&#160;Vanhove also served on the board of Insys Therapeutics from April 2018 to February 2020. Dr.&#160;Vanhove received an M.D. and a Ph.D. in pharmacology from the Catholic University in Leuven, Belgium and completed a fellowship in clinical pharmacology at Stanford University. Dr.&#160;Vanhove also received an M.B.A. from St. Mary&#8217;s College of California. Dr.&#160;Vanhove will terminate her employment with us on March&#160;31, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Wen-Chen</span> Yeh, M.D., Ph.D.</span> has served as our Chief Scientific Officer since May 2016. From December 2006 to April 2016, he held various positions of increasing responsibility at Amgen Inc., or Amgen, a biopharmaceutical company, as an Associate Director, Director of Research and Scientific Executive Director. Prior to Amgen, Dr.&#160;Yeh served as a professor and led a research laboratory at the University of Toronto. Dr.&#160;Yeh received an M.D. from the National Taiwan University and a Ph.D. from The Johns Hopkins University. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Tim Kutzkey, Ph.D.</span> has served on our board of directors since April 2016, Chairman of our board of directors since August 2021, chair of our board of directors&#8217; Nominating and Corporate Governance Committee since August 2021 and served as our interim Chief Executive Officer from inception to April 2018. Dr.&#160;Kutzkey serves as Managing Partner of The Column Group, LLC, a venture capital partnership, where he has served in various roles since 2007. Prior to The Column Group, Dr.&#160;Kutzkey served as a scientist at Kai Pharmaceuticals, Inc. Dr.&#160;Kutzkey also serves on the board of directors of Kallyope Inc., Nura Bio Inc., Neurona Therapeutics Inc., Synthekine Inc., Plexium, Inc., Cajal Neuroscience Inc. and Carmot Therapeutics, all biotechnology companies. Dr.&#160;Kutzkey obtained a Ph.D. in molecular and cell biology from the University of California, Berkeley and completed his undergraduate degree in biological sciences from Stanford University. We believe that Dr.&#160;Kutzkey&#8217;s scientific training and experience as a director of other publicly traded and privately held biopharmaceutical companies provide him with the qualifications and skills to serve as a director of our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anna Berkenblit, M.D.</span> has served on our board of directors since August 2018, and on our Board of Directors&#8217; compensation committee since August 2021. Dr.&#160;Berkenblit has served as the Senior Vice President and Chief Medical Officer at ImunnoGen, Inc., a biotechnology company, since April 2015. Prior to ImmunoGen, Dr.&#160;Berkenblit served as Senior Vice President Head of Clinical Development at H3, Biomedicine Inc., a developer of targeted anti-cancer compounders, from 2013 to 2015. From 2011 to 2013, she served as Head of Clinical Research at AVEO Pharmaceuticals, Inc., a biopharmaceutical company, where she led the clinical development of oncology product candidates spanning early testing to registration trials. From January 2007 to September 2011, Dr.&#160;Berkenblit held various positions of increasing responsibility at Pfizer Inc., a biopharmaceutical company. Dr.&#160;Berkenblit received an M.D. from Harvard Medical School and an M.M.S. degree in the Clinical Investigator Training Program of Harvard/MIT Health Sciences and Technology. We believe that Dr.&#160;Berkenblit&#8217;s extensive leadership and scientific experience, especially in the clinical development of biopharmaceuticals, provide her with the qualifications and skills to serve as a director of our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Christopher Y. Chai.</span> has served on our board of directors since April 2021 and Chair of our board of directors&#8217; Audit Committee since August 2021. Mr.&#160;Chai has served as a venture partner at SR One since January 2021, where he works with portfolio companies on their engagement with Wall Street and their overall financing strategy and execution. Prior to joining SR One, Mr.&#160;Chai served as Chief Financial Officer of Principia Biopharma Inc. from 2013 to 2020, where he led the company from an early-stage private venture-backed </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company to its acquisition by Sanofi S.A. Mr.&#160;Chai previously served as Chief Financial Officer at MAP Pharmaceuticals, Inc. (acquired by Allergan, Inc.) and Vice President, Treasury and Investor Relations at CV Therapeutics, Inc. (acquired by Gilead Sciences, Inc.). Mr.&#160;Chai received his B.S. in Operations Research and Industrial Engineering from Cornell University. We believe that Mr.&#160;Chai&#8217;s extensive financial and executive experience provide him with the qualifications and skills to serve as a director of our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">David J. Woodhouse, Ph.D.</span> has served on our board of directors since September 2020. Dr.&#160;Woodhouse has served as the Chief Executive Officer and director of NGM Biopharmaceuticals, Inc., or NGM, since September 2018. Dr.&#160;Woodhouse also served as Chief Financial Officer from March 2015 until September 2018 and acting Chief Financial Officer from September 2018 until June 2020 at NGM. From 2002 to 2015, he was an investment banker at Goldman Sachs&#160;&amp; Co. LLC, most recently as a managing director in the healthcare investment banking group and <span style="white-space:nowrap">co-head</span> of biotechnology investment banking. Earlier in his career, Dr.&#160;Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr.&#160;Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine. We believe that Dr.&#160;Woodhouse&#8217;s extensive financial and executive experience provide him with the qualifications and skills to serve as a director of our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mary Haak-Frendscho, Ph.D.</span> has served on our board of directors since March 2021 and Chair of our board of directors&#8217; Compensation Committee since August 2021. Dr.&#160;Haak-Frendscho has served as the president and chief executive officer of Spotlight Therapeutics, Inc., a privately held biotechnology company, since January 2019. Prior to Spotlight, from January 2017 to January 2019, she was a venture partner with Versant Ventures and, from January 2016 to January 2019, she served as the chief executive officer of Blueline Bioscience, Versant&#8217;s vehicle for new company creation in Canada. Earlier, Dr.&#160;Haak-Frendscho established and served as the chair of Compugen USA, Inc. from 2012 to 2016, was the chief executive officer of Igenica Biotherapeutics from 2012 to 2014, and was the founding president and chief scientific officer of Takeda San Francisco from 2008 to 2012. She received her B.S. from the University of Michigan, M.L.A. from Washington University, M.S. from SUNY-Stony Brook, C.S.E.P. from Columbia University Graduate School of Business, and Ph.D. from the University of Wisconsin. We believe that Dr.&#160;Haak-Frendscho&#8217;s scientific training, work experience, and experience as a director of other biopharmaceutical companies provide her with the qualifications and skills to serve as a director of our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mace Rothenberg, M.D.</span> has served on our board of directors since April 2021. Dr.&#160;Rothenberg served as chief medical officer of Pfizer Inc., a biopharmaceutical company from January 2019 to January 2021, where he led Pfizer&#8217;s Worldwide Medical&#160;&amp; Safety organization that is responsible for ensuring that patients, physicians, and regulatory agencies are provided with information on the safe and appropriate use of Pfizer medications. From January 2019 to March 2021, Dr.&#160;Rothenberg also served as a member of Pfizer&#8217;s Portfolio Strategy and Investment Committee, Worldwide Research, Development, and Medical Leadership Team, and Blueprint Leaders Forum. Prior to becoming Pfizer&#8217;s chief medical officer, Dr.&#160;Rothenberg led Pfizer&#8217;s oncology clinical drug development efforts. During his ten years in this role, Dr.&#160;Rothenberg&#8217;s organization obtained FDA approval for eleven cancer medicines. He received his B.A. from the University of Pennsylvania and his M.D. from the New York University School of Medicine. Dr.&#160;Rothenberg received his post-graduate training in Internal Medicine at Vanderbilt University and in Medical Oncology at the National Cancer Institute. In addition, Dr.&#160;Rothenberg currently serves as a member of the board for Tango Therapeutics and Aulos Bioscience, both biopharmaceutical companies. We believe that Dr.&#160;Rothenberg&#8217;s scientific training, work experience, and experience as a director of other biopharmaceutical companies provide him with the qualifications and skills to serve as a director of our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Shao-Lee</span> Lin, M.D., Ph.D.</span> has served on our board of directors since January 2021. Dr.&#160;Lin <span style="white-space:nowrap">co-founded</span> and serves as the Chief Executive Officer of ACELYRIN, INC. formed in July 2020. From January 2018 to January 2020, she served as Executive Vice President, Research and Development and Chief Scientific Officer at Horizon Pharma plc, a biopharmaceutical company. From April 2015 to December 2017, she served as a corporate officer </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Vice President, Therapeutic Areas, Development Excellence and International Development at Abbvie Inc., a biopharmaceutical company. Prior to Abbvie, Dr.&#160;Lin served as Vice President, Inflammation and Respiratory Development at Gilead from August 2012 to February 2015 and served in various roles of increasing responsibility at Amgen from April 2004 to August 2012, Dr.&#160;Lin served on the board of directors of Principia Biopharma Inc., a biopharmaceutical company, from April 2019 until it was acquired in September 2020 Dr.&#160;Lin has also been faculty as a Clinical Scholar at The Rockefeller University and adjunct faculty at the medical schools of Cornell University, The University of California, Los Angeles, Stanford University and Northwestern University. Dr.&#160;Lin received her bachelor&#8217;s degree in chemical engineering and biochemistry from Rice University and holds an M.D. and Ph.D. from The Johns Hopkins University School of Medicine. We believe that Dr.&#160;Lin&#8217;s scientific training, work experience, and experience as a director of other publicly traded biopharmaceutical companies provide her with the qualifications and skills to serve as a director of our company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our executive officers or directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Composition of Our Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our board of directors, which currently consists of eight directors. Each director will continue to serve until the election and qualification of his or her successor, or until his or her earlier death, resignation or removal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may establish the authorized number of directors from time to time by resolution. In accordance with our amended and restated certificate of incorporation our board of directors will be divided into three classes with staggered three-year terms. At each annual general meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors are divided among the three classes as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;I directors are Anna Berkenblit, M.D. and Tim Kutzkey, Ph.D., and their terms will expire at our annual meeting of stockholders to be held in 2025; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;II directors are <span style="white-space:nowrap">Shao-Lee</span> Lin, M.D., Ph.D., Mace Rothenberg, M.D. and David J. Woodhouse, Ph.D., and their terms will expire at our annual meeting of stockholders to be held in 2023; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;III directors are Christopher Y. Chai, Mary Haak-Frendscho, Ph.D. and Craig Parker, and their terms will expire at our annual meeting of stockholders to be held in 2024. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <span style="white-space:nowrap">one-third</span> of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning his or her background, employment and affiliations, our board of directors has determined that no director, except for Craig Parker, has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of our directors, except for Craig Parker, is &#8220;independent&#8221; as that term is defined under the applicable listing standards. In making these determinations, our board of directors considered the current and prior relationships that each <span style="white-space:nowrap">non-employee</span> director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our shares held by each <span style="white-space:nowrap">non-employee</span> director and the transactions described in the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions, and Director Independence.</span>&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Role of the Board on Risk Oversight </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the key functions of the board of directors is the informed oversight of our risk management process. The board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of the board that address risks inherent in their respective areas of oversight. In particular, the board is responsible for monitoring and assessing strategic risk exposure and the audit committee has the responsibility to consider and discuss our major financial risk exposures and the steps its management will take to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee will also monitor compliance with legal and regulatory requirements. The compensation committee assesses and monitors whether our compensation plans, policies and programs comply with applicable legal and regulatory requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Committees of Our Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has an audit committee, a compensation committee, and a nominating and corporate governance committee. The composition and responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Our board of directors may establish other committees as it deems necessary or appropriate from time to time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee consists of the following members: Christopher Y. Chai, David J. Woodhouse, Ph.D. and Tim Kutzkey, Ph.D. Our board of directors has determined that each member of the audit committee satisfies the independence requirements under the Nasdaq listing standards and Rule <span style="white-space:nowrap">10A-3(b)(1)</span> of the Exchange Act. The chair of our audit committee is Christopher Y. Chai. Our board of directors has determined that Christopher Y. Chai is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. Each member of our audit committee can read and understand fundamental financial statements in accordance with applicable listing standards. In arriving at these determinations, our board of directors has examined each audit committee member&#8217;s scope of experience and the nature of his or her employment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of the audit committee is to discharge the responsibilities of our board of directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial statement audits, and to oversee our independent registered public accounting firm. Specific responsibilities of our audit committee include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">helping our board of directors oversee our corporate accounting and financial reporting processes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">managing and/or assessing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and <span style="white-space:nowrap">year-end</span> operating results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, approving and disapproving related party transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing our policies on risk assessment and risk management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, with our independent registered public accounting firm, our internal quality control procedures, any material issues with such procedures and any steps taken to deal with such issues; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">pre-approving</span> audit and permissible <span style="white-space:nowrap">non-audit</span> services to be performed by the independent registered public accounting firm. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee operates under a written charter that satisfies the applicable listing standards of Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors has a compensation committee, which consists of the following members: Mary Haak-Frendscho, Ph.D., Anna Berkenblit, M.D. and <span style="white-space:nowrap">Shao-Lee</span> Lin, M.D., Ph.D. The chair of our compensation committee is Mary Haak-Frendscho, Ph.D. Our board of directors has determined that each member of the compensation committee satisfies the independence requirements under the listing standards of Nasdaq and is a <span style="white-space:nowrap">&#8220;non-employee</span> director&#8221; as defined in Rule <span style="white-space:nowrap">16b-3</span> promulgated under the Exchange Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary purpose of our compensation committee is to discharge the responsibilities of our board of directors in overseeing our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specific responsibilities of our compensation committee include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to our board of directors the compensation of our chief executive officer and other executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to our board of directors the compensation of our directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">administering our equity incentive plans and other benefit programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, adopting, amending and terminating incentive compensation and equity plans, severance agreements, profit sharing plans, bonus plans, <span style="white-space:nowrap"><span style="white-space:nowrap">change-of-control</span></span> protections and any other compensatory arrangements for our executive officers and other senior management; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and establishing general policies relating to compensation and benefits of our employees, including our overall compensation philosophy. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee operates under a written charter that satisfies the applicable listing standards of Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors continues to have a nominating and corporate governance committee, which consists of the following members: Tim Kutzkey, Ph.D., Christopher Y. Chai and Mace Rothenberg, M.D. The chair of our nominating and corporate governance committee is Tim Kutzkey, Ph.D. Our board of directors has determined that each member of the nominating and corporate governance committee satisfies the independence requirements under the listing standards of Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specific responsibilities of our nominating and corporate governance committee include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders, to serve on our board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">considering and making recommendations to our board of directors regarding the composition and chairpersonship of the board of directors and committees of our board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing developments in corporate governance practices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and making recommendations to our board of directors regarding corporate governance guidelines and matters; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing periodic evaluations of the board of directors&#8217; performance, including committees of the board of directors. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee operates under a written charter that satisfies the applicable listing standards of Nasdaq. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Compensation Committee Interlocks and Insider Participation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of the compensation committee is currently or has been at any time one of our officers or employees. None of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee. Additionally, none of the members who serves or served on the compensation committee of our Board of Directors had any relationship as set forth in Item 404 of Regulation <span style="white-space:nowrap">S-K</span> under the Securities Act of 1933, as amended. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Business Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We adopted a Code of Business Conduct and Ethics, or Code of Ethics, applicable to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, in accordance with applicable federal securities laws. The Code of Ethics codifies the business and ethical principles that govern all aspects of our business. The Code of Ethics is available on our website at www.surrozen.com. If we make any substantive amendments to the Code of Ethics or grant any waiver from a provision of the Code of Ethics to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Delinquent Section&#160;16(a) Reports </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;16(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, requires our executive officers, directors and persons who beneficially own more than 10% of a registered class of our equity securities to file with the Securities and Exchange Commission initial reports of ownership and reports of changes in ownership of our shares of common stock and other equity securities. These executive officers, directors, and greater than 10% beneficial owners are required by SEC regulation to furnish us with copies of all Section&#160;16(a) forms filed by such reporting persons. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reviewed all forms provided to us or filed with the SEC. Based on that review and on written information given to us by our executive officers and directors, we believe that all Section&#160;16(a) filings during fiscal year 2022 were filed on a timely basis and that all directors, executive officers and 10% beneficial owners have fully complied with such requirements during the past fiscal year, other than three reports on Form 4 filed by <span style="white-space:nowrap">Wen-Chen</span> Yeh on October&#160;12, 2022, by Charles Williams and Geertrui Vanhove on October&#160;13, 2022, which were filed late. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We previously provided cash and equity-based compensation to certain of our <span style="white-space:nowrap">non-employee</span> directors. In addition, all <span style="white-space:nowrap">non-employee</span> directors are entitled to reimbursement of direct expenses incurred in connection with attending meetings of the board of directors or committees thereof. Our board of directors has approved a policy providing for annual <span style="white-space:nowrap">non-employee</span> director compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the compensation earned by or paid to our <span style="white-space:nowrap">non-employee</span> directors during the year ended December&#160;31, 2022. Craig Parker, our President and Chief Executive Officer, is also a member of our board of directors, but did not receive any additional compensation for service as a director. The compensation earned by or paid to Mr.&#160;Parker as a named executive officer of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Surrozen for the fiscal year ended December&#160;31, 2022 is set forth under &#8220;<span style="font-style:italic">Executive Compensation&#8212;Summary Compensation Table</span>.&#8221; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:54%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees&#160;Earned<br />or Paid in<br />Cash<br />$</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br />Awards<br />($)<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Berkenblit, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tim Kutzkey, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">80,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119,526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Shao-Lee</span> Lin, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Woodhouse, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">81,526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Haak-Frendscho, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mace Rothenberg, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Y. Chai</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported represent the aggregate grant date fair value of the option awards granted during the fiscal year ended December&#160;31, 2022 under Surrozen&#8217;s 2021 Plan, computed in accordance with Financial Accounting Standard Board Accounting Standards Codification, Topic 718, or ASC Topic 718. The assumptions used in calculating the grant-date fair value of the stock options reported in this column are set forth in the notes to Surrozen&#8217;s consolidated financial statements included elsewhere in this prospectus. This amount does not reflect the actual economic value that may be realized by the <span style="white-space:nowrap">non-employee</span> director. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The option awards were granted on June&#160;7, 2022 and fully vest on the <span style="white-space:nowrap">one-year</span> anniversary of the grant date. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_13">EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, our named executive officers consisted of our chief executive officer, chief financial officer and the next most highly compensated executive officer: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Craig Parker, our President and Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Charles Williams, our Chief Financial Officer; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">Wen-Chen</span> Yeh, M.D., Ph.D., our Chief Scientific Officer. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents all of the compensation awarded to our named executive officers during the fiscal years ended December&#160;31, 2022 and 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Bonus<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards<br />($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-Equity</span><br />Incentive Plan<br />Compensation<br />($)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation<br />($)<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig Parker</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">558,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">793,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">195,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,547,094</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">President and Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">495,750</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">3,470,726</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">246,150</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">4,212,626</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Williams</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">423,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">268,174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">139,689</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">831,663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">374,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">104,321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">156,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">635,236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Wen-Chen</span> Yeh, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">428,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">269,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145,656</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">843,860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Scientific Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">376,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">216,043</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">151,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">744,073</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts disclosed represent the aggregate grant date fair value of the stock options granted to our named executive officers during the fiscal year ended December&#160;31, 2022 under our 2021 Plan, computed in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options are set forth in the notes to our audited financial statements included elsewhere in this prospectus. This amount does not reflect the actual economic value that may be realized by the named executive officer. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts disclosed represent the applicable named executive officer&#8217;s total performance-based bonus earned for the fiscal year indicated, as described in this section below under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-Equity</span> Incentive Plan Compensation</span>.&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts comprised of 401(k) plan matching contributions. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Arrangements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements or offer letters with each of our named executive officers setting forth the terms and conditions of such executive&#8217;s employment with us. The employment agreements or offer letters generally will provide for <span style="white-space:nowrap">at-will</span> employment and set forth the executive officer&#8217;s initial base salary. Each of our named executive officers has executed our standard confidential information and invention assignment agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee has also adopted severance terms whereby executive officers shall receive certain benefits if their employment is terminated without cause or in connection with a <span style="white-space:nowrap"><span style="white-space:nowrap">change-in-control</span></span> of the Company. If terminated <span style="white-space:nowrap"><span style="white-space:nowrap">not-for-cause,</span></span> the named executive officers will receive nine months base salary (12 months for Mr.&#160;Parker) and nine months of continued benefits (12 months for Mr.&#160;Parker) but no acceleration of equity vesting requirements. If terminated in connection with a <span style="white-space:nowrap"><span style="white-space:nowrap">change-in-control</span></span> of the Company, i.e., at any time within the <span style="white-space:nowrap">12-month</span> period beginning three months prior to the <span style="white-space:nowrap"><span style="white-space:nowrap">change-in-control,</span></span> the named executive officers will receive 12 months base salary (18 months for Mr.&#160;Parker), 100% of their target bonus (1.5 times the target bonus for Mr.&#160;Parker), 12 months continuation of benefits (18 months for Mr.&#160;Parker) and acceleration of all existing equity vesting requirements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Equity</span> Incentive Plan Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to base salaries, our named executive officers are eligible to receive annual performance-based cash bonuses under our Annual Cash Bonus Plan, or Bonus Plan. The compensation committee established the Bonus Plan to incentivize our employees and reward them upon the achievement of corporate performance goals. With respect to the performance-based cash bonuses of the named executive officers for 2022 and 2021, the Bonus Plan targets the amount of the bonus at 50% of base salary for our chief executive officer and 40% for other executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual amounts paid under the Annual Cash Bonus Plan generally depend on the extent to which (i)&#160;we achieve our corporate performance goals, and (ii)&#160;the employee achieves his or her individual goals that were established at the beginning of the year. After the end of each year, the board of directors determines the level or percentage at which the Company has achieved its corporate goals for the past year and sets the corporate performance goals for the next year. Corporate performance goals include stretch goals that reflect our desired progress and outcomes relating to the development of our product candidates and adherence to established budgets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When determining the actual payout amount of our chief executive officer&#8217;s performance-based cash bonus for 2022 and 2021, the compensation committee weighted 100% of its decision on the extent to which the Company achieved its corporate performance goals. When determining the actual payout amount of the performance-based cash bonus for our other executives, the compensation committee weighted 50% of its decision on the Company&#8217;s attainment of corporate performance goals and 50% on the attainment of individual performance goals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended December&#160;31, 2022, our board of directors determined that the Company had achieved 70% of its corporate performance goals, so Mr.&#160;Parker received 70% of his targeted bonus. Mr.&#160;Williams and Dr.&#160;Yeh received 85% and 83% of their targeted bonus amounts, respectively, based on the 70% achievement of our 2022 corporate performance goals and 100% and 95% achievement of their personal goals, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the fiscal year ended December&#160;31, 2021, our board of directors determined that the Company had achieved 90% of its corporate performance goals, so Mr.&#160;Parker received 90% of his targeted bonus. Mr.&#160;Williams and Dr.&#160;Yeh received 94% and 90% of their targeted bonus amounts, respectively, based on our 90% achievement of our 2021 corporate performance goals and 98% and 90% achievement of their personal goals, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All performance-based cash bonuses are generally paid within a few months after the year to which they relate, upon final determination by the compensation committee. The performance-based cash bonuses paid to our named executive officers for the fiscal years ended December&#160;31, 2022 and 2021, as determined by the compensation committee based on the guidelines above, are set forth above in the &#8220;<span style="font-style:italic">Summary Compensation Table</span>&#8221; in the column titled &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-Equity</span> Incentive Plan Compensation</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards as of December&#160;31, 2022 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of December&#160;31, 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option Awards<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Vesting<br />Commencement<br />Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options<br />Exercisable<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options<br />Unexercisable<br />(#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Exercise<br />Price<br />Per<br />Share<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Expiration<br />Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig Parker</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">04/11/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/19/2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">316,167</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">04/10/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">02/07/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,397</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">02/06/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/01/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84,791</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">285,209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/01/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/10/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,329</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">182,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">02/22/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/10/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/12/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61,111</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122,224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/12/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Williams</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/01/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,645</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96,355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/01/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/10/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/30/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91,482</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/13/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/10/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/12/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,865</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,732</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/12/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Wen-Chen</span> Yeh, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">02/07/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,599</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/31/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">02/13/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,615</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,514</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">02/12/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/01/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,645</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96,355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/01/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">07/01/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/21/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">438</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">07/01/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/10/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,832</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">02/22/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each of the equity awards granted prior to August&#160;12, 2021 was granted under the 2015 Plan. Each of the equity awards granted on August&#160;12, 2021 or later were granted under the 2021 Plan. The 2015 Plan and 2021 Plan are described below under &#8220;<span style="font-style:italic">Employee Benefit and Stock Plans</span>.&#8221; </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares subject to the option award vest over a four-year period, with 25% of the total number of shares subject to the option vesting on the <span style="white-space:nowrap">one-year</span> anniversary of the vesting commencement date, and the balance of the shares vesting in 36 equal monthly installments thereafter, subject to continued service through each such vesting date. 100% of the unvested shares subject to the option will immediately become fully vested in the event that, upon or following a change in control, the holder&#8217;s employment is terminated without cause or the holder resigns for good reason. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares subject to the option award vest over a four-year period, with 25% of the total number of shares subject to the option vesting on the <span style="white-space:nowrap">one-year</span> anniversary of the vesting commencement date, and the balance of the shares vesting in 36 equal monthly installments thereafter, subject to continued service through each such vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The shares subject to the option award vest over a four-year period in 48 equal monthly installments measured from the vesting commencement date, subject to continued service through each such vesting date. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Compensation and Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in our employee benefit plans, including our 401(k) plan, medical, dental, vision, life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as generally all of our other full-time exempt employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers did not participate in, or earn any benefits under, any nonqualified deferred compensation plan sponsored by us during the fiscal years ended December&#160;31, 2022 and 2021. The Surrozen </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors may elect to provide our officers and other employees with nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stock Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to August&#160;12, 2021, grants of equity awards were provided to our named executive officers under our 2015 Equity Incentive Plan, or the 2015 Plan. On August&#160;12, 2021, we adopted the Surrozen, Inc. 2021 Equity Incentive Plan, or the 2021 Plan, which replaces and supersedes the 2015 Plan, except with respect to awards previously granted. The 2021 Plan authorizes us to grant equity and cash incentive awards to officers, directors, employees, and eligible service providers. A description of our stock plans can be found in Note 12 &#8220;<span style="font-style:italic">Stock-Based Compensation Plan</span>&#8221;<span style="font-style:italic"> </span>of the consolidated financial statements in this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitations of Liability and Indemnification Matters </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation limits the liability of our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except liability for: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes us to indemnify our directors, officers, employees and other agents to the fullest extent permitted by Delaware law. The Bylaws provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and agents. The Bylaws also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors and executive officers. With certain exceptions, these agreements provide for indemnification for related expenses including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by any of these individuals in connection with any action, proceeding or investigation. We believe that the Certificate of Incorporation and Bylaws provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain customary directors&#8217; and officers&#8217; liability insurance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our Certificate of Incorporation and Bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#8217;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for directors, executive officers or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Rule <span style="white-space:nowrap">10b5-1</span> Sales Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers may adopt written plans, known as Rule <span style="white-space:nowrap">10b5-1</span> plans, in which they will contract with a broker to buy or sell shares of common stock on a periodic basis. Under a Rule <span style="white-space:nowrap">10b5-1</span> plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, without further direction from them. The director or executive officer may amend a Rule <span style="white-space:nowrap">10b5-1</span> plan in some circumstances and may terminate a plan at any time. Our directors and executive officers also may buy or sell additional shares outside of a Rule <span style="white-space:nowrap">10b5-1</span> plan when they are not in possession of material nonpublic information, subject to compliance with the terms of our insider trading policy. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_14">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than compensation arrangements for Surrozen&#8217;s directors and executive officers, which are described elsewhere in this prospectus, described below are transactions since January&#160;1, 2021 and each currently proposed transaction in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amounts involved exceeded or will exceed $120,000; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any of Surrozen directors, executive officers or holders of more than 5% of Surrozen outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity and other compensation, termination, change in control and other arrangements are described in the sections titled &#8220;<span style="font-style:italic">Executive Compensation</span>&#8221;<span style="font-style:italic"> </span>and &#8220;<span style="font-style:italic">Director Compensation</span>.&#8221; Described below are certain other transactions with Surrozen directors, executive officers and stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Investors&#8217; Rights Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Closing, that certain Registration and Shareholder Rights Agreement, dated November&#160;18, 2020, was terminated, and Surrozen, the Sponsor and certain stockholders of Surrozen, or the Investors, entered into the Investors&#8217; Rights Agreement, dated August&#160;11, 2021, the form of which is attached as an exhibit to the registration statement of which this prospectus is a part, and pursuant to which the Investors, subject to certain conditions, will be entitled to registration rights. The Investors include our officers and directors and certain significant stockholders, namely, The Column Group III, L.P., The Column Group <span style="white-space:nowrap">III-A,</span> L.P., The Regents of the University of California and the Sponsor. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Indemnification Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation contains provisions limiting the liability of directors, and the Certificate of Incorporation provides that Surrozen indemnify each of Surrozen&#8217;s directors and officers to the fullest extent permitted under Delaware law. The Certificate of Incorporation also provides Surrozen&#8217;s board of directors with discretion to indemnify Surrozen&#8217;s employees and other agents when determined appropriate by the board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Surrozen has entered into an indemnification agreement with each of Surrozen&#8217;s directors and executive officers, which requires Surrozen to indemnify them. For more information regarding these agreements, see the section titled &#8220;<span style="font-style:italic">Surrozen&#8217;s Executive Compensation&#8212;Limitations of Liability and Indemnification Matters</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">UCSF License and Option Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, Surrozen entered into a <span style="white-space:nowrap">non-exclusive</span> commercial license agreement The Regents of the University of California, or UCSF, a holder of more than 5% of Surrozen&#8217;s capital stock to make and use licensed products identified from the phage display llama VHH single domain antibody library. Under the commercial license agreement, Surrozen paid UCSF a nominal license issue fee. Surrozen agreed to pay a nominal annual license maintenance fee, low five-digit payment per licensed product upon achievement of a regulatory milestone, nominal annual minimum royalties, and earned royalties equal to a <span style="white-space:nowrap">sub-single</span> digit percentage of Surrozen&#8217;s and Surrozen&#8217;s sublicensees&#8217; net sales of licensed products. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a more detailed description of the UCSF Agreements, see the section titled &#8220;<span style="font-style:italic">Business&#8212;UCSF License and Option Agreements</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Securities Repurchase </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2022, Surrozen entered into a securities purchase agreement with entities affiliated with Consonance Capital Management LP, collectively the Consonance Entities. Pursuant to the agreement, on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&#160;15, 2022, we repurchased an aggregate of 5,382,499 shares of our common stock and warrants to purchase an aggregate 1,310,496 shares of our common stock from the Consonance Entities for an aggregate purchase price of approximately $2.7&#160;million. The shares of common stock were returned to authorized and unissued status and the warrants were cancelled. Following the repurchase, the Consonance Entities no longer hold any shares of Surrozen common stock or warrants to purchase Surrozen common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Policies and Procedures for Related Person Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Surrozen board of directors has adopted a related person transaction policy setting forth the policies and procedures for the identification, review, and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation <span style="white-space:nowrap">S-K</span> under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which Surrozen and a related person were or will be participants and the amount involved exceeds $120,000, including purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness and guarantees of indebtedness. In reviewing and approving any such transactions, the Surrozen audit committee will consider all relevant facts and circumstances as appropriate, such as the purpose of the transaction, the availability of other sources of comparable products or services, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction, management&#8217;s recommendation with respect to the proposed related person transaction, and the extent of the related person&#8217;s interest in the transaction.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_15">PRINCIPAL SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our common stock by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each beneficial owner of more than 5% of our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our executive officers and directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our executive officers and directors as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as noted by footnote, and subject to community property laws where applicable, based on the information provided to us, we believe that the persons and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially owned by them. The beneficial ownership percentages set forth in the table below are based on 30,079,441 shares of common stock outstanding as of March&#160;1, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:69%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Address of Beneficial Owners <sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares<br />Beneficially<br />Owned<sup style="font-size:75%; vertical-align:top"> (2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage<br />of Total<br />Voting<br />Power</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Directors and Executive Officers:</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig Parker<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">775,803</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Wen-Chen</span> Yeh <sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">333,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Williams <sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168,653</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geertrui (Trudy) Vanhove <sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">233,299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Berkenblit <sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tim Kutzkey <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,414,795</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Shao-Lee</span> Lin <sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Woodhouse <sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Haak-Frendscho <sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mace Rothenberg <sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Y. Chai<sup style="font-size:75%; vertical-align:top"> (8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">All directors and executive officers as a group (11 persons) <sup style="font-size:75%; vertical-align:top">(9)</sup></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,136,523</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Five Percent Holders:</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with the Column Group <sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,414,795</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Regents of the University of California <sup style="font-size:75%; vertical-align:top">(11)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,081,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with SymBiosis II, LLC <sup style="font-size:75%; vertical-align:top">(12)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,964,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BML Investment Partners, L.P.<sup style="font-size:75%; vertical-align:top">(13)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,669,037</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1% beneficial ownership </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise noted, the business address of each of the directors and officers is 171 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that the individual or entity has the right to acquire, such as through the exercise of warrants or stock options or the vesting of restricted stock units, within 60 days. Shares subject to warrants or options that are currently exercisable or exercisable within 60 days or subject to restricted stock units that vest within 60 days are considered outstanding and beneficially owned by the person holding such warrants, options or restricted stock units for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes: (a) (i) 4,343,245 shares held by The Column Group III, LP (&#8220;TCG III&#8221;) and (ii) 4,904,884 shares held by The Column Group <span style="white-space:nowrap">III-A,</span> LP (&#8220;TCG <span style="white-space:nowrap">III-A&#8221;),</span> (b) (i) 78,272 shares underlying warrants held by TCG </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
III, and (ii) 88,394 shares underlying warrants held by TCG <span style="white-space:nowrap">III-A,</span> LP. The Column Group III GP, LP (&#8220;TCG III GP&#8221;), is the general partner of each of TCG III and TCG <span style="white-space:nowrap">III-A.</span> Dr.&#160;Kutzkey, David Goeddel and Peter Svennilson are the Managing Partners of TCG III GP and as such may each be deemed to share voting and investment power with respect to the securities held by each of TCG III and TCG <span style="white-space:nowrap">III-A</span> and disclaims beneficial ownership of the securities except to the extent of his pecuniary interests therein. The address for the entities listed herein is 1 Letterman Drive, Building D, Suite <span style="white-space:nowrap">DM-900,</span> San Francisco, CA 94129. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 9,578 shares of common stock and 766,225 shares of common stock issuable pursuant to stock options that have vested or will vest and become exercisable within 60 days of March&#160;1, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 229,138 shares of common stock and 104,061 shares of common stock issuable pursuant to stock options that have vested or will vest and become exercisable within 60 days of March&#160;1, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 9,578 shares of common stock and 159,075 shares of common stock issuable pursuant to stock options that have vested or will vest and become exercisable within 60 days of March&#160;1, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 32,412 shares of common stock and 200,887 shares of common stock issuable pursuant to stock options that have vested or will vest and become exercisable within 60 days of March&#160;1, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 35,129 shares of common stock subject to restricted stock awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of Craig Parker, Geertrui Vanhove, <span style="white-space:nowrap">Wen-Chen</span> Yeh, Charles Williams, Anna Berkenblit, Christopher Chai, Tim Kutzkey, <span style="white-space:nowrap">Shao-Lee</span> Lin, David Woodhouse, Mary Haak-Frendscho and Mace Rothenberg. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes: (a) (i) 4,343,245 shares held by The Column Group III, LP (&#8220;TCG III&#8221;) and (ii) 4,904,884 shares held by The Column Group <span style="white-space:nowrap">III-A,</span> LP (&#8220;TCG <span style="white-space:nowrap">III-A&#8221;),</span> (b) (i) 78,272 shares underlying warrants held by TCG III, and (ii) 88,394 shares underlying warrants held by TCG <span style="white-space:nowrap">III-A,</span> LP based on information set forth in a Schedule 13D/A filed with the SEC on February&#160;13, 2023. The Column Group III GP, LP (&#8220;TCG III GP&#8221;), is the general partner of each of TCG III and TCG <span style="white-space:nowrap">III-A.</span> Dr.&#160;Kutzkey, David Goeddel and Peter Svennilson are the Managing Partners of TCG III GP and as such may each be deemed to share voting and investment power with respect to the securities held by each of TCG III and TCG <span style="white-space:nowrap">III-A</span> and disclaims beneficial ownership of the securities except to the extent of his pecuniary interests therein. The address for the entities listed herein is 1 Letterman Drive, Building D, Suite <span style="white-space:nowrap">DM-900,</span> San Francisco, CA 94129. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes: (a) 1,998,120 shares of common stock held by The Regents of the University of California (&#8220;UC&#8221;), and (b) 83,333 shares of common stock underlying warrants held by UC based on information set forth in a Schedule 13G/A filed with the SEC on Februay 2, 2023. The address for UC is 1111 Franklin Street, 6th Floor, Oakland, CA 94607. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 1,964,082 shares of common stock held by SymBiosis II, LLC (&#8220;SymBiosis&#8221;) based on information set forth in a Schedule 13G filed with the SEC on May&#160;10, 2022. The address for SymBiosis is 609 SW 8th St., Suite 365, Bentonville, AR 72712. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 1,669,037 shares of common stock held by BML Investment Partners, L.P. (&#8220;BML&#8221;) based on information set forth in a Schedule 13G filed with the SEC on February&#160;2, 2023. The address for BML is 65 E Cedar, Suite 2, Zionsville, IN 46077. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_16">SELLING SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale by the selling securityholders from time to time of up to 31,612,348 shares of Common Stock (including 4,006,657 shares of Common Stock that may be issued upon exercise of the PIPE Warrants and 1,349,943 shares of Common Stock issuable upon the exercise of stock options) and up to 4,006,657 PIPE Warrants. The selling securityholders may from time to time offer and sell any or all of the Common Stock and PIPE Warrants set forth below pursuant to this prospectus and any accompanying prospectus supplement. As used in this prospectus, the term &#8220;selling securityholders&#8221; includes the persons listed in the table below, together with any additional selling securityholders listed in a subsequent amendment to this prospectus, and their pledgees, donees, transferees, assignees, successors, designees and others who later come to hold any of the selling securityholders&#8217; interests in the Common Stock or PIPE Warrants other than through a public sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the selling securityholders listed below entered into a <span style="white-space:nowrap">lock-up</span> agreement with us with respect to certain of the shares of Common Stock that may be sold by it from time to time pursuant to the registration statement of which this prospectus forms part. Such restrictions began at Closing and end on the earliest to occur of (i) 365 days after the date of the Closing; (ii)&#160;the first day after the date on which the closing price of the Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any <span style="white-space:nowrap">30-trading</span> day period commencing at least 150 days after the date of the Closing; or (iii)&#160;the date on which Surrozen completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of Consonance&#8217;s public shareholders having the right to exchange their Common Stock for cash, securities or other property. See the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the footnotes below, the following table sets forth, based on written representations from the selling securityholders, certain information as of August&#160;11, 2021 regarding the beneficial ownership of our Common Stock and Warrants by the selling securityholders and the shares of Common Stock and Warrants being offered by the selling securityholders. The applicable percentage ownership of Common Stock is based on approximately 35,027,407 shares of Common Stock outstanding as of August&#160;11, 2021. Information with respect to shares of Common Stock and Warrants owned beneficially after the offering assumes the sale of all of the shares of Common Stock or Warrants. The selling securityholders may offer and sell some, all or none of their shares of Common Stock or Warrants, as applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the selling securityholders have sole voting and investment power with respect to all shares of Common Stock and Warrants that they beneficially own, subject to applicable community property laws. Except as otherwise described below, based on the information provided to us by the selling securityholders, no selling securityholder is a broker-dealer or an affiliate of a broker dealer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth in the footnotes below, up to 3,066,651 shares of Common Stock issuable upon exercise of the Public Warrants and up to 144,666 shares of Common Stock issuable upon exercise of the Private Placement Warrants are not included in the table below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section titled &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; for further information regarding the selling securityholder&#8217;s method of distributing these shares </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares of Common Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Warrants to Purchase Common Stock</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name of Selling <br />Securityholder</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br />Beneficially<br />Owned<br />Prior to<br />Offering**</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br />Registered<br />for Sale<br />Hereby</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br />Beneficially<br />Owned<br />After<br />Offering</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent<br />Owned<br />After<br />Offering</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br />Beneficially<br />Owned<br />Prior to<br />Offering</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br />Registered<br />for Sale<br />Hereby</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<br />Beneficially<br />Owned<br />After<br />Offering</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent<br />Owned<br />After<br />Offering</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">PIPE:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyeska Master Fund, L.P.(1)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">666,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors LP(2)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,333,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">833,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">833,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BEMAP Master Fund Ltd(3)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">169,486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bespoke Alpha MAC MIM LP(4)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Banner LLC(5)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">683,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">512,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">170,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prelude Structured Alternatives Master Fund Ltd.(6)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">73,843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,614</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,614</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swiftcurrent Master Fund Ltd.(7)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">843,876</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">626,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consonance Capital</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Master Account LP(8)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,331,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,748,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">582,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">582,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consonance Capital Opportunity Master Fund, LP(9)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,730,562</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,297,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">432,640</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">432,640</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">P Consonance Opportunities Ltd.(10)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">601,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">450,828</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DS Liquid Div RVA MON LLC(11)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">148,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">49,365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Empery Asset Master, LTD(12)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">551,909</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">413,932</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Empery Tax Efficient III, LP(13)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">223,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">167,460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,820</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Empery Tax Efficient, LP(14)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">158,144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HHLR Fund, L.P.(15)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,548,533</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,161,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">387,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">387,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hartford HealthCare Corporation Defined Benefit Master Trust(16)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">440,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">330,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hartford HealthCare Endowment, LLC(17)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">440,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">330,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harvard Management Private Equity Corporation(18)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">934,915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">325,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">501,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">108,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">108,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Monashee Pure Alpha SPV I LP(19)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">108,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">81,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Monashee Solitario Fund LP(20)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136,365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,091</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,091</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NS Investment Co., Ltd.(21)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">617,963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">351,287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SFL SPV I LLC(22)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29.793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Spur Ventures V, LP(23)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">367,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200,741</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SymBiosis II, LLC(24)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,302,594</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">450,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">702,594</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tech Opportunities LLC(25)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">400,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Column Group III, LP(26)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,421,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,343,245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Column Group <span style="white-space:nowrap">III-A,</span> LP(27)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,993,278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,904,884</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Regents of the University of California(28)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,081,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,998,120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Trustees of Columbia University in the City of New York(29)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">752,283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">618,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">YHG Investment, L.P.(30)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,866</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Officers of Surrozen and Affiliated Entities:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig Parker(31)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">410,577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">885,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Geertrui (Trudy) Vanhove, M.D., Ph.D.(32)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">94,910</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">217,564</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Wen-Chen</span> Yeh, M.D., Ph.D.(33)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">252,492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">298,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Williams(34)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">190,245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Berkenblit, M.D.(35)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tim Kutzkey, Ph.D.(35)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,414,795</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,414,795</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Shao-Lee</span> Lin, M.D., Ph.D.(35)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David J. Woodhouse, Ph.D.(35)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Haak-Frendscho, Ph.D.(35)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mace Rothenberg, M.D.(35)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Y. Chai(35)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Othe Holder of Registration Rights pursuant to the Registration Agreement</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consonance Life Sciences(36)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,029,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,885,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">144,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">144,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Haqq(37)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald Santel(37)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jennifer Jarrett(37)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than one percent </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes shares of common stock issuable upon exercise of the warrants listed in this table in the columns under the heading &#8220;Warrants to Purchase Common Stock.&#8221; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Alyeska Investment Group, L.P., the investment manager of the selling securityholder, has voting and investment control of the shares held by the selling securityholder. The address for the selling securityholder 77 W. Wacker, Suite 700, Chicago, Illinois 60601. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes (i) 184,777 shares of common stock and 61,592 shares of common stock issuable upon the exercise of warrants held directly by 667, L.P. (&#8220;667&#8221;) and (ii) 2,315,223 shares of common stock and 771,741 shares of common stock issuable upon the exercise of warrants held directly by Baker Brothers Life Sciences, L.P. (&#8220;Life Sciences&#8221;, and together with 667, the &#8220;BBA Funds&#8221;). Baker Bros. Advisors LP (&#8220;BBA&#8221;) is the investment adviser to the BBA Funds and has the sole voting and investment power with respect to the securities held by the BBA Funds and thus may be deemed to beneficially own such securities. Baker Bros. Advisors (GP) LLC (&#8220;BBA GP&#8221;) is the sole general partner of BBA and thus may be deemed to beneficially own the securities held by the BBA Funds. The managing members of BBA GP are Julian C. Baker and Felix J. Baker, who may be deemed to beneficially own the securities held by the BBA Funds. Felix J. Baker, BBA and BBA GP disclaim beneficial ownership of all shares held by the BBA Funds, except to the extent of their indirect pecuniary interest therein. The business address of BBA, BBA GP, Julian C. Baker and Felix J. Baker is 860 Washington Street, 3rd Floor, New York, NY 10014. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each of DS Liquid Div RVA MON LLC (&#8220;DS&#8221;), BEMAP Master Fund Ltd. (&#8220;BEMAP&#8221;), Monashee Solitario Fund LP (&#8220;Solitario&#8221;), Monashee Pure Alpha SVP I LLP (&#8220;Pure Alpha&#8221;), SFL SPV I LLC (&#8220;SFL&#8221;) and Bespoke Alpha MAC MIM LP (&#8220;Bespoke&#8221;) is managed by Monashee Investment Management, LLC (&#8220;Monashee&#8221;). Jeff Muller is CCO of Monashee Investment Management, LLC and has voting and dispositive power and, may be deemed to have beneficial ownership of such shares held by DS, BEMAP, Solitario, Pure Alpha, SFL and Bespoke. Jeff Muller, however, disclaims any beneficial ownership of the shares held by these entities. The business address of DS, BEMAP, Solitario, Pure Alpha, SFL, Bespoke, Monashee and Mr.&#160;Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 2nd Floor, Boston, MA 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each of DS Liquid Div RVA MON LLC (&#8220;DS&#8221;), BEMAP Master Fund Ltd. (&#8220;BEMAP&#8221;), Monashee Solitario Fund LP (&#8220;Solitario&#8221;), Monashee Pure Alpha SVP I LLP (&#8220;Pure Alpha&#8221;), SFL SPV I LLC (&#8220;SFL&#8221;) and Bespoke Alpha MAC MIM LP (&#8220;Bespoke&#8221;) is managed by Monashee Investment Management, LLC (&#8220;Monashee&#8221;). Jeff Muller is CCO of Monashee Investment Management, LLC and has voting and dispositive power and, may be deemed to have beneficial ownership of such shares held by DS, BEMAP, Solitario, Pure Alpha, SFL and Bespoke. Jeff Muller, however, disclaims any beneficial ownership of the shares held by these entities. The business address of DS, BEMAP, Solitario, Pure Alpha, SFL, Bespoke, Monashee and Mr.&#160;Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 2nd Floor, Boston, MA 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Managing Member of Banner LLC is Alabaster Ltd., a Bermuda Company Limited. The three directors of Alabaster Ltd. are John R. B. Richmond, Lorinda Gazzard and Ian Hilton. Consists of 512,500 shares of common stock and 170,833 warrants held of record by Banner LLC. The address for Banner LLC is Rose Bank Centre, 11 Bermudiana Road Pembroke, HM 08 Bermuda. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Prelude Structure Alternatives Master Fund Ltd. may be deemed to have voting and dispositive power over the securities held by the selling securityholder. The address for the selling securityholder is c/o Bridger Capital LLC, 90 Park Ave, 40th Floor, New York, New York 10019. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Swiftcurrent Master Fund Ltd. may be deemed to have voting and dispositive power over the securities held by the selling securityholder. The address for the selling securityholder is c/o Bridger Capital LLC, 90 Park Ave, 40th Floor, New York, New York 10019. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents securities held directly by Consonance Capital Master Account, LP (the &#8220;Master Account&#8221;). Consonance Capital Management LP (&#8220;Consonance Management&#8221;) is an indirect beneficial owner of the securities held by Master Account. Consonance Management is the investment adviser of Master Account, and pursuant to an investment advisory agreement, Consonance Management exercises voting and investment power over the securities of the Issuer held by Master Account. Consonance Capman GP LLC (&#8220;Capman&#8221;) is the general partner of Consonance Management. Mitchell Blutt is the manager and member of Capman. The address of Master Account, Consonance Management, Capman and Dr.&#160;Blutt is 1370 Avenue of the Americas, Suite 3301, New York, NY 10019. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents securities held directly by Consonance Capital Opportunity Master Fund, LP (&#8220;Consonance Opportunity Master&#8221;). Consonance Management is an indirect beneficial owner of the securities held by Consonance Opportunity Master. Consonance Management is the investment adviser of Consonance Opportunity Master, and pursuant to an investment advisory agreement, Consonance Management exercises voting and investment power over the securities of the Issuer held by Consonance Opportunity Master. Capman is the general partner of Consonance Management. Mitchell Blutt is the manager and member of Capman. The address of Consonance Opportunity Master, Consonance Management, Capman and Dr.&#160;Blutt is 1370 Avenue of the Americas, Suite 3301, New York, NY 10019. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents securities held directly by P Consonance Opportunities Ltd., a certain managed account (the &#8220;Managed Account&#8221;). Consonance Management is an indirect beneficial owner of the securities held by the Managed Account. Consonance Management is the investment adviser of the Managed Account and exercises voting and investment power over the securities of the Issuer held by the Managed Account. Capman is the general partner of Consonance Management. Mitchell Blutt is the manager and member of Capman. The address of the Managed Account, Consonance Management, Capman and Dr.&#160;Blutt is 1370 Avenue of the Americas, Suite 3301, New York, NY 10019. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each of DS Liquid Div RVA MON LLC (&#8220;DS&#8221;), BEMAP Master Fund Ltd. (&#8220;BEMAP&#8221;), Monashee Solitario Fund LP (&#8220;Solitario&#8221;), Monashee Pure Alpha SVP I LLP (&#8220;Pure Alpha&#8221;), SFL SPV I LLC (&#8220;SFL&#8221;) and Bespoke Alpha MAC MIM LP (&#8220;Bespoke&#8221;) is managed by Monashee Investment Management, LLC (&#8220;Monashee&#8221;). Jeff Muller is CCO of Monashee Investment Management, LLC and has voting and dispositive power and, may be deemed to have beneficial ownership of such shares held by DS, BEMAP, Solitario, Pure Alpha, SFL and Bespoke. Jeff Muller, however, disclaims any beneficial ownership of the shares held by these entities. The business address of DS, BEMAP, Solitario, Pure Alpha, SFL, Bespoke, Monashee and Mr.&#160;Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 2nd Floor, Boston, MA 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Empery Asset Management LP, the authorized agent of Empery Asset Master Ltd (&#8220;EAM&#8221;), has discretionary authority to vote and dispose of the shares held by EAM and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have investment discretion and voting power over the shares held by EAM. EAM, Mr.&#160;Hoe and Mr.&#160;Lane each disclaim any beneficial ownership of these shares. The address for the selling securityholder is c/o Empery Asset Management, LP, 1 Rockefeller Plaza, Suite 1205, New York, NY 10020. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Empery Asset Management LP, the authorized agent of Empery Tax Efficient III, LP (&#8220;ETE III&#8221;), has discretionary authority to vote and dispose of the shares held by ETE III and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have investment discretion and voting power over the shares held by ETE III. ETE III, Mr.&#160;Hoe and Mr.&#160;Lane each disclaim any beneficial ownership of these shares. The address for the selling securityholder is c/o Empery Asset Management, LP, 1 Rockefeller Plaza, Suite 1205, New York, NY 10020. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Empery Asset Management LP, the authorized agent of Empery Tax Efficient, LP (&#8220;ETE&#8221;), has discretionary authority to vote and dispose of the shares held by ETE and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also to be deemed to have investment discretion and voting power over the shares held by ETE. ETE, Mr.&#160;Hoe and Mr.&#160;Lane each disclaim any beneficial ownership of these shares. The address for the selling securityholder is c/o Empery Asset Management, LP, 1 Rockefeller Plaza, Suite 1205, New York, NY 10020. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents shares directly held by HHLR Fund, L.P. (&#8220;HHLR Fund&#8221;), an exempted limited partnership organized under the laws of the Cayman Islands. HHLR Advisors, Ltd. (&#8220;HHLR&#8221;), an exempted Cayman Islands company, acts as sole management company of HHLR Fund and is deemed to be the beneficial owner of, and to control the voting power of, the ordinary shares held by HHLR Fund. The business address of each of HHLR Fund and HHLR is Suite 2202, 22nd Floor, Two International Finance Centre, 8 Finance Street, Central Hong Kong. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">David Holmgren serves as Chief Investment Officer of the selling stockholder and may be deemed to have voting and dispositive power over the securities held by the selling securityholder. Mr.&#160;David Holmgren disclaims any beneficial ownership of the shares. The address for the selling securityholder is 80 Seymour Street, Hartford, Connecticut 06102. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(17)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">David Holmgren serves as Chief Investment Officer of the selling stockholder and may be deemed to have voting and dispositive power over the securities held by the selling securityholder. Mr.&#160;David Holmgren disclaims any beneficial ownership of the shares. The address for the selling securityholder is 80 Seymour Street, Hartford, Connecticut 06102. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(18)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Harvard Management Private Equity Corporation may be deemed to have voting and dispositive power over the securities held by the selling securityholder. The address for the selling securityholder is 600 Atlantic Avenue, Boston, Massachusetts 02210. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(19)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each of DS Liquid Div RVA MON LLC (&#8220;DS&#8221;), BEMAP Master Fund Ltd. (&#8220;BEMAP&#8221;), Monashee Solitario Fund LP (&#8220;Solitario&#8221;), Monashee Pure Alpha SVP I LLP (&#8220;Pure Alpha&#8221;), SFL SPV I LLC (&#8220;SFL&#8221;) and Bespoke Alpha MAC MIM LP (&#8220;Bespoke&#8221;) is managed by Monashee Investment Management, LLC (&#8220;Monashee&#8221;). Jeff Muller is CCO of Monashee Investment Management, LLC and has voting and dispositive power and, may be deemed to have beneficial ownership of such shares held by DS, BEMAP, Solitario, Pure Alpha, SFL and Bespoke. Jeff Muller, however, disclaims any beneficial ownership of the shares held by these entities. The business address of DS, BEMAP, Solitario, Pure Alpha, SFL, Bespoke, Monashee and Mr.&#160;Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 2nd Floor, Boston, MA 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(20)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each of DS Liquid Div RVA MON LLC (&#8220;DS&#8221;), BEMAP Master Fund Ltd. (&#8220;BEMAP&#8221;), Monashee Solitario Fund LP (&#8220;Solitario&#8221;), Monashee Pure Alpha SVP I LLP (&#8220;Pure Alpha&#8221;), SFL SPV I LLC (&#8220;SFL&#8221;) and Bespoke Alpha MAC MIM LP (&#8220;Bespoke&#8221;) is managed by Monashee Investment Management, LLC (&#8220;Monashee&#8221;). Jeff Muller is CCO of Monashee Investment Management, LLC and has voting and dispositive power and, may be deemed to have beneficial ownership of such shares held by DS, BEMAP, Solitario, Pure Alpha, SFL and Bespoke. Jeff Muller, however, disclaims any beneficial ownership of the shares held by these entities. The business address of DS, BEMAP, Solitario, Pure Alpha, SFL, Bespoke, Monashee and Mr.&#160;Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 2nd Floor, Boston, MA 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(21)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">NS Investment Co., Ltd. is a general partner of, and is affiliated with, Meritz NS Global Bio Fund, which is governed by its fund manager Taekyoung Sohn. As such, Taekyoung Sohn has voting and investment discretion of the shares held by Meritz NS Global Bio Fund and may be deemed to have voting and dispositive power over the securities held by the selling securityholder. Taekyoung Sohn disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. The address for the selling securityholder is Suite 203, 50 Seosomunno11gil, Junggu, Seoul 04515, Republic of Korea. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(22)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each of DS Liquid Div RVA MON LLC (&#8220;DS&#8221;), BEMAP Master Fund Ltd. (&#8220;BEMAP&#8221;), Monashee Solitario Fund LP (&#8220;Solitario&#8221;), Monashee Pure Alpha SVP I LLP (&#8220;Pure Alpha&#8221;), SFL SPV I LLC (&#8220;SFL&#8221;) and Bespoke Alpha MAC MIM LP (&#8220;Bespoke&#8221;) is managed by Monashee Investment Management, LLC (&#8220;Monashee&#8221;). Jeff Muller is CCO of Monashee Investment Management, LLC and has voting and dispositive power and, may be deemed to have beneficial ownership of such shares held by DS, BEMAP, Solitario, Pure Alpha, SFL and Bespoke. Jeff Muller, however, disclaims any beneficial ownership of the shares held by these entities. The business address of DS, BEMAP, Solitario, Pure Alpha, SFL, Bespoke, Monashee and Mr.&#160;Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 2nd Floor, Boston, MA 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(23)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Spur Capital Management V, LLC (&#8220;SCM V GP&#8221;) is the general partner of the stockholder. Paul D. Fetsch, Paul A. Gompers, Joan C. Heidorn, and C. Bradford Kelly are the Members of SCM V GP and as such may each be deemed to have voting and dispositive power over the securities held by the securityholder. Each of Paul D. Fetsch, Paul A. Gompers, Joan C. Heidorn, and C. Bradford Kelly disclaims beneficial ownership of the securities except to the extent of his/her pecuniary interests therein may be deemed to have voting and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
dispositive power over the securities held by the securityholder. The address for the securityholder is 2370 Nowata Place, Bartlesville, Oklahoma 74006. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(24)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">SymBiosis II, LLC is governed by SymBiosis Capital Partners, LLC. Chidozie Ugwumba, as Managing Partner of SymBiosis Capital Partners, LLC. As such, Chidozie Ugwumba has voting and investment discretion of the shares held by SymBiosis Capital Partners, LLC and may be deemed to have voting and dispositive power over the securities held by the selling securityholder. Chidozie Ugwumba disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(25)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Hudson Bay Capital Management LP, the investment manager of Tech Opportunities LLC, has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Each of Tech Opportunities LLC and Sander Gerber disclaims beneficial ownership over these securities. The address for the securityholder is c/o Hudson Bay Capital Management LP, 28 Havemeyer Place, 2nd Floor, Greenwich CT 06830. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(26)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Column Group III GP, LP (&#8220;TCG III GP LP&#8221;) is the general partner of the selling securityholder and may be deemed to have voting, investment and dispositive power with respect to the securities held by the selling securityholder. Peter Svennilson, David Goeddel and Tim Kutzkey, a member of the board of directors, are the managing partners of TCG III GP LP (the &#8220;Managing Partners&#8221;) and may each be deemed to share voting, investment and dispositive power with respect to the securities held by the selling securityholder. TCG III GP LP and each of the Managing Partners disclaim beneficial ownership of the securities held by the selling securityholder, except to the extent of their respective pecuniary interest therein. The address for the selling securityholder is 1 Letterman Dr, Building D, Suite <span style="white-space:nowrap">DM-900,</span> San Francisco, California 94129. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(27)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Column Group III GP, LP (&#8220;TCG III GP LP&#8221;) is the general partner of the selling securityholder and may be deemed to have voting, investment and dispositive power with respect to the securities held by the selling securityholder. Peter Svennilson, David Goeddel and Tim Kutzkey, a member of the board of directors, are the managing partners of TCG III GP LP (the &#8220;Managing Partners&#8221;) and may each be deemed to share voting, investment and dispositive power with respect to the securities held by the selling securityholder. TCG III GP LP and each of the Managing Partners disclaim beneficial ownership of the securities held by the selling securityholder, except to the extent of their respective pecuniary interest therein. The address for the selling securityholder is 1 Letterman Dr, Building D, Suite <span style="white-space:nowrap">DM-900,</span> San Francisco, California 94129. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(28)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Regents of the University of California may be deemed to have voting and dispositive power over the securities held by the selling securityholder. The address for the selling securityholder is c/o Office of the Chief Investment Officer, 1111 Franklin Street, Oakland, California 94607. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(29)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Trustees of Columbia University in the City of New York may be deemed to have voting and dispositive power over the securities held by the selling securityholder. The address for the selling securityholder is 405 Lexington Avenue, 63rd Floor, New York, New York 10174. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(30)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents shares directly held by YHG Investment, L.P. (&#8220;YHG&#8221;), an exempted limited partnership organized under the laws of the Cayman Islands. HHLR Advisors, Ltd. (&#8220;HHLR&#8221;), an exempted Cayman Islands company, acts as the sole general partner of YHG, and is deemed to be the beneficial owner of, and to control the voting power of, the ordinary shares held by YHG. The business address of each of YHG and HHLR is Suite 2202, 22nd Floor, Two International Finance Centre, 8 Finance Street, Central Hong Kong. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(31)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Parker is our President and Chief Executive Officer. Consists of 885,928 shares of Common Stock issuable pursuant to stock options exercisable. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(32)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Vanhove is our Chief Medical Officer. Consists of 22,834 shares of Common Stock and 194,730 shares of Common Stock issuable pursuant to stock options exercisable. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(33)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Yeh is our Chief Scientific Officer. Consists of (a) 219,560 shares of Common Stock subject to restricted stock awards and (b) 79,040 shares of Common Stock issuable pursuant to stock options exercisable. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(34)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Williams is our Chief Financial Officer. Consists of 190,245 shares of Common Stock issuable pursuant to stock options exercisable. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(35)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Drs. Berkenblit, Kutzkey, Lin, Woodhouse, Haak-Frendscho and Rothenberg and Mr.&#160;Chai are members of our board of directors. With respect to Drs. Berkenblit, Lin, Woodhouse, Haak-Frendscho and Mr.&#160;Chai, consists of 35,129 shares of Common Stock subject to restricted stock awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(36)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consonance Life Sciences is governed by a board of managers consisting of Mitchell J. Blutt, Benny Soffer and Kevin Livingston. As such, Mitchell J. Blutt, Benny Soffer and Kevin Livingston may be deemed to have voting and dispositive power over the securities held by the selling securityholder and may be deemed to have shared beneficial ownership of the shares held by the selling security holders. Each of Mitchell J. Blutt, Benny Soffer and Kevin Livingston disclaims beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. The address for the selling securityholder is 1 Palmer Square, Ste 305, Princeton, New Jersey 08540. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(37)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 30,000 shares of Common Stock. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_17">DESCRIPTION OF OUR SECURITIES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following is a summary of the rights of our securities. This summary is qualified by reference to the complete text of our certificate of incorporation and bylaws filed as exhibits to the registration statement of which this prospectus forms a part. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized and Outstanding Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">500,000,000 shares of Common Stock, $0.0001 par value per share; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">10,000,000 shares of undesignated Preferred Stock, $0.0001 par value per share. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, there were 30,088,333 shares of Common Stock issued and outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Preemptive or Similar Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock will not be entitled to preemptive rights, and are not subject to conversion, redemption or sinking fund provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Right to Receive Liquidation Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we become subject to a liquidation, dissolution or <span style="white-space:nowrap">winding-up,</span> the assets legally available for distribution to the stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Fully Paid and <span style="white-space:nowrap">Non-Assessable</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the outstanding shares of our common stock are fully paid and <span style="white-space:nowrap">non-assessable.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions. The number of authorized shares of preferred stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of our company entitled to vote thereon, without a separate vote of the holders of the preferred stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of preferred stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with financings, possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring, discouraging or preventing a change in control of our company, may adversely affect the market price of our common stock and the voting and other rights of the holders of common stock, and may reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. As of December&#160;31, 2022, we have no shares of preferred stock issued and outstanding. We have no present plans to issue any shares of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Public Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole Public Warrant entitles the registered holder to purchase one share of our common stock at a price of $11.50 per share, subject to adjustment as discussed below, provided that we have an effective registration statement under the Securities Act covering the common stock issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or we permit holders to exercise their Public Warrants on a cashless basis) and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Pursuant to that certain warrant agreement, dated as of November&#160;18, 2020, by and between us and Continental Stock Transfer&#160;&amp; Trust Company, or the Continental Warrant Agreement, a Public Warrant holder may exercise its Public Warrants only for a whole number of common stock. This means only a whole Public Warrant may be exercised at a given time by a Public Warrant holder. No fractional Public Warrants will be issued upon separation of the shares and only whole Public Warrants will trade. Accordingly, unless you purchase at least three shares, you will not be able to receive or trade a whole Public Warrant. The Public Warrants will expire on August&#160;12, 2026 at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not be obligated to deliver any common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act with respect to the common stock underlying the Public Warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration, or a valid exemption from registration is available. No Public Warrant will be exercisable and we will not be obligated to issue a common stock upon exercise of a Public Warrant unless the common stock issuable upon such Public Warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the Public Warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a Public Warrant, the holder of such Public Warrant will not be entitled to exercise such Public Warrant and such Public Warrant may have no value and expire worthless. In no event will we be required to net cash settle any Public Warrant. In the event that a registration statement is not effective for the exercised Public Warrants, the purchaser of a share containing such Public Warrant will have paid the full purchase price for the share solely for the common stock underlying such unit. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will use our commercially reasonable efforts to maintain the effectiveness of a registration statement covering the common stock issuable upon exercise of the Public Warrants and a current prospectus relating to those common stock until the Public Warrants expire or are redeemed, as specified in the Continental Warrant Agreement; provided that if our common stock are at the time of any exercise of a Public Warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, we may, at our option, require holders of Public Warrants who exercise their Public Warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so appoint, we will not be required to file or maintain in effect a registration statement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption of Public Warrants for cash when the price per Common Stock equals or exceeds $18.00</span>. Once the Public Warrants become exercisable, we may call the Public Warrants for redemption (except as described herein with respect to the private placement Public Warrants): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in whole and not in part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at a price of $0.01 per Public Warrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon not less than 30 days&#8217; prior written notice of redemption to each Public Warrant holder; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for share <span style="white-space:nowrap">sub-divisions,</span> share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <span style="white-space:nowrap">30-trading</span> day period ending on the third trading day prior to the date on which notice of the redemption is given to the Public Warrant holders, or the Reference Value. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not redeem the Public Warrants as described above unless a registration statement under the Securities Act covering the issuance of the common stock issuable upon exercise of the Public Warrants is then effective and a current prospectus relating to those shares is available throughout the <span style="white-space:nowrap">30-day</span> redemption period. If and when the Public Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. As a result, we may redeem the Public Warrants as set forth above even if the holders are otherwise unable to exercise the Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established the last of the redemption criteria discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the Public Warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the Public Warrants, each Public Warrant holder will be entitled to exercise his, her or its Public Warrant prior to the scheduled redemption date. However, the price of our common stock may fall below the $18.00 redemption trigger price (as adjusted for share <span style="white-space:nowrap">sub-divisions,</span> share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) Public Warrant exercise price after the redemption notice is issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption of Public Warrants for Common Stock when the price per Common Stock equals or exceeds $10.00. </span>Once the Public Warrants become exercisable, we may redeem the outstanding Public Warrants: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in whole and not in part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at $0.10 per Public Warrant upon a minimum of 30 days&#8217; prior written notice of redemption; provided that during such 30 day period holders will be able to exercise their Public Warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the &#8220;fair market value&#8221; of our Common Stock (as defined below) except as otherwise described below; provided, further, that if the Public Warrants are not exercised on a cashless basis or otherwise during such 30 day period, we shall redeem such Public Warrants for $0.10 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the Reference Value (as defined above under &#8220;<span style="font-style:italic">Redemption of Public Warrants for Cash When the Price per Common Stock Equals or Exceeds $18.00</span>&#8221;) equals or exceeds $10.00 per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like) on the trading day before we send the notice of redemption to the Public Warrant holders; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the Reference Value is less than $18.00 per share (as adjusted for share subdivisions, share dividends, reorganizations, recapitalizations and the like), the private placement Public Warrants must </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The numbers in the table below represent the number of common stock that a Public Warrant holder will receive upon exercise in connection with a redemption by us pursuant to this redemption feature, based on the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;fair market value&#8221; of our common stock on the corresponding redemption date (assuming holders elect to exercise their Public Warrants and such Public Warrants are not redeemed for $0.10 per Public Warrant), determined based on volume-weighted average price of our common stock as reported during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of Public Warrants, and the number of months that the corresponding redemption date precedes the expiration date of the Public Warrants, each as set forth in the table below. We will provide our Public Warrant holders with the final fair market value no later than one business day after the <span style="white-space:nowrap">10-trading</span> day period described above ends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The share prices set forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable upon exercise of a Public Warrant or the exercise price of the Public Warrant is adjusted as set forth under the heading &#8220;&#8212;Anti-dilution Adjustments&#8221; below. If the number of shares issuable upon exercise of a Public Warrant is adjusted, the adjusted share prices in the column headings will equal the share prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the exercise price of the Public Warrant after such adjustment and the denominator of which is the price of the Public Warrant immediately prior to such adjustment. In such an event, the number of shares in the table below shall be adjusted by multiplying such share amounts by a fraction, the numerator of which is the number of shares deliverable upon exercise of a Public Warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise of a Public Warrant as so adjusted. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" rowspan="2" align="center"><span style="font-weight:bold">Redemption date (period to<br />expiration of Public Warrants)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="34" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fair market value of Common Stock</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"></span>&#8804;<span style="font-weight:bold"></span><span style="font-weight:bold">$10.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$11.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$12.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$13.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$14.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$15.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$16.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$17.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"></span>&#8805;<span style="font-weight:bold"></span><span style="font-weight:bold">$18.00</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">60 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">57 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.294</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">54 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.307</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">51 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.287</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">48 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.263</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">45 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">42 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.294</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.312</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">39 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.246</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.290</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.325</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">36 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.239</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.263</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.305</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.353</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">33 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.352</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.224</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.313</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.230</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.312</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.305</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.099</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.219</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.331</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.243</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">0 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is between two values in the table or the redemption date is between two redemption dates in the table, the number of common stock to be issued for each Public Warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365 or <span style="white-space:nowrap">366-day</span> year, as applicable. For example, if the volume-weighted average price of our common stock as reported during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of the Public Warrants is $11.00 per share, and at such time there are 57 months until the expiration of the Public Warrants, holders may choose to, in connection with this redemption feature, exercise their Public Warrants for 0.277 common stock for each whole </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Public Warrant. For an example where the exact fair market value and redemption date are not as set forth in the table above, if the volume-weighted average price of our common stock as reported during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of the Public Warrants is $13.50 per share, and at such time there are 38 months until the expiration of the Public Warrants, holders may choose to, in connection with this redemption feature, exercise their Public Warrants for 0.298 common stock for each whole Public Warrant. In no event will the Public Warrants be exercisable in connection with this redemption feature for more than 0.361 common stock per Public Warrant (subject to adjustment). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This redemption feature is structured to allow for all of the outstanding Public Warrants to be redeemed when our common stock are trading at or above $10.00 per share, which may be at a time when the trading price of our common stock is below the exercise price of the Public Warrants. We have established this redemption feature to provide us with the flexibility to redeem the Public Warrants without the Public Warrants having to reach the $18.00 per share threshold set forth above under &#8220;&#8212;Redemption of Public Warrants for cash when the price per Common Stock equals or exceeds $18.00.&#8221; Holders choosing to exercise their Public Warrants in connection with a redemption pursuant to this feature will, in effect, receive a number of shares for their Public Warrants based on an option pricing model with a fixed volatility input as of the date of any applicable prospectus. This redemption right provides us with an additional mechanism by which to redeem all of the outstanding Public Warrants, and therefore have certainty as to our capital structure as the Public Warrants would no longer be outstanding and would have been exercised or redeemed. We will be required to pay the applicable redemption price to Public Warrant holders if we choose to exercise this redemption right and it will allow us to quickly proceed with a redemption of the Public Warrants if we determine it is in our best interest to do so. As such, we would redeem the Public Warrants in this manner when we believe it is in our best interest to update our capital structure to remove the Public Warrants and pay the redemption price to the Public Warrant holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As stated above, we can redeem the Public Warrants when our common stock are trading at a price starting at $10.00, which is below the exercise price of $11.50, because it will provide certainty with respect to our capital structure and cash position while providing Public Warrant holders with the opportunity to exercise their Public Warrants on a cashless basis for the applicable number of shares. If we choose to redeem the Public Warrants when our common stock are trading at a price below the exercise price of the Public Warrants, this could result in the Public Warrant holders receiving fewer common stock than they would have received if they had chosen to wait to exercise their Public Warrants for common stock if and when such common stock were trading at a price higher than the exercise price of $11.50. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional common stock will be issued upon exercise and only whole Public Warrants will trade. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, we will round down to the nearest whole number of the number of common stock to be issued to the holder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of a Public Warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such Public Warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the Public Warrant agent&#8217;s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder) of our common stock issued and outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-dilution adjustments. </span>If the number of outstanding common stock is increased by a capitalization or share dividend payable in common stock, or by a <span style="white-space:nowrap">sub-divisions</span> of ordinary shares or other similar event, then, on the effective date of such capitalization or share dividend, <span style="white-space:nowrap">sub-divisions</span> or similar event, the number of common stock issuable on exercise of each Public Warrant will be increased in proportion to such increase in the outstanding ordinary shares. A rights offering made to all or substantially all holders of ordinary shares entitling holders to purchase common stock at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed a share dividend of a number of common stock equal to the product of (i)&#160;the number of common stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for common stock) and (ii)&#160;one minus the quotient of (x)&#160;the price </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
per common stock paid in such rights offering and (y)&#160;the historical fair market value. For these purposes, (i)&#160;if the rights offering is for securities convertible into or exercisable for common stock, in determining the price payable for common stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#8220;historical fair market value&#8221; means the volume-weighted average price of common stock as reported during the 10 trading day period ending on the trading day prior to the first date on which our common stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of outstanding common stock is decreased by a consolidation, combination, reverse share <span style="white-space:nowrap">sub-division</span> or reclassification of common stock or other similar event, then, on the effective date of such consolidation, combination, reverse share <span style="white-space:nowrap">sub-division,</span> reclassification or similar event, the number of common stock issuable on exercise of each Public Warrant will be decreased in proportion to such decrease in outstanding common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the number of common stock purchasable upon the exercise of the Public Warrants is adjusted, as described above, the Public Warrant exercise price will be adjusted by multiplying the Public Warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of common stock purchasable upon the exercise of the Public Warrants immediately prior to such adjustment and (y)&#160;the denominator of which will be the number of common stock so purchasable immediately thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of any reclassification or reorganization of the outstanding common stock (other than those described above or that solely affects the par value of such common stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our issued and outstanding common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the Public Warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Public Warrants and in lieu of our common stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of common stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Public Warrants would have received if such holder had exercised their Public Warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of common stock in such a transaction is payable in the form of common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the Public Warrant properly exercises the Public Warrant within thirty days following public disclosure of such transaction, the Public Warrant exercise price will be reduced as specified in the Continental Warrant Agreement based on the Black-Scholes value (as defined in the Continental Warrant Agreement) of the Public Warrant. The purpose of such exercise price reduction is to provide additional value to holders of the Public Warrants when an extraordinary transaction occurs during the exercise period of the Public Warrants pursuant to which the holders of the Public Warrants otherwise do not receive the full potential value of the Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrants will be issued in registered form under a warrant agreement between Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, and us. The Continental Warrant Agreement provides that the terms of the Public Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, including to conform the provisions of the Continental Warrant Agreement to the description of the terms of the Public Warrants and the Continental Warrant Agreement set forth herein, but requires the approval by the holders of at least 50% of the then outstanding Public Warrants to make any change that adversely affects the interests of the registered holders. You should review a copy of the Continental Warrant Agreement, which is filed as an exhibit to the report to which this exhibit is attached, for a complete description of the terms and conditions applicable to the Public Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrant holders do not have the rights or privileges of holders of ordinary shares and any voting rights until they exercise their Public Warrants and receive common stock. After the issuance of common stock upon exercise of the Public Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed that, subject to applicable law, any action, proceeding or claim against us arising out of or relating in any way to the Continental Warrant Agreement will be brought and enforced in the courts of the State of New York or the U.S. District Court for the Southern District of New York, and we irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or claim. This provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any claim for which the federal district courts of the U.S. of America are the sole and exclusive forum. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants (including the common stock issuable upon exercise of the Private Placement Warrants) will not be redeemable so long as they are held by Consonance Life Sciences, a Cayman Islands limited liability company, or the Sponsor, or its permitted transferees. The Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. If the Private Placement Warrants are held by holders other than our Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by us in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. Any amendment to the terms of the Private Placement Warrants or any provision of the Continental Warrant Agreement with respect to the Private Placement Warrants will require a vote of holders of at least 50% of the number of the then outstanding Private Placement Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If holders of the Private Placement Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering his, her or its warrants for that number of common stock equal to the quotient obtained by dividing (x)&#160;the product of the number of common stock underlying the warrants, multiplied by the excess of the &#8220;historical fair market value&#8221; (defined below) over the exercise price of the warrants by (y)&#160;the historical fair market value. The &#8220;historical fair market value&#8221; will mean the average reported closing price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent. The reason that we have agreed that these warrants will be exercisable on a cashless basis so long as they are held by the Sponsor and permitted transferees is because, as they remained affiliated with us, their ability to sell our securities in the open market is limited. We expect to have policies in place that restrict insiders from selling our securities except during specific periods of time. Even during such periods of time when insiders will be permitted to sell our securities, an insider cannot trade in our securities if he or she is in possession of material <span style="white-space:nowrap">non-public</span> information. Accordingly, unlike public shareholders who could exercise their warrants and sell the common stock received upon such exercise freely in the open market in order to recoup the cost of such exercise, the insiders could be significantly restricted from selling such securities. As a result, we believe that allowing the holders to exercise such warrants on a cashless basis is appropriate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">PIPE Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PIPE Warrants (including the common stock issuable upon exercise of the PIPE Warrants) are the same in all respects as the Public Warrants as described above under &#8220;Public Warrants,&#8221; except that the PIPE Warrants were not redeemable prior to August&#160;11, 2022. The PIPE Warrants will be issued pursuant to that certain amended and restated warrant agreement between Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, and us, dated as of March&#160;31, 2023. A copy of such warrant agreement is filed as an exhibit to our Annual Report on Form <span style="white-space:nowrap">10-K</span> to which this exhibit is attached. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Provisions of Delaware Law and Our Charter Documents </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Section&#160;203 of the Delaware General Corporation Law </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&#160;203 of the DGCL, which generally prohibits a publicly held Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (1)&#160;by persons who are directors and also officers and (2)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In general, Section&#160;203 defines a &#8220;business combination&#8221; to include the following: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any merger or consolidation involving the corporation and the interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&#160;203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its amended and restated certificate of incorporation or amended and restated bylaws resulting from a stockholders&#8217; amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certificate of Incorporation and Bylaws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation and Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our management team, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Board of Directors Vacancies</span>. The Certificate of Incorporation and Bylaws authorize only the board of directors to fill vacant and newly created directorships, unless the board of directors determines by resolution that such vacancies or newly created directorships be filled by the stockholders, or as otherwise provided by law. In addition, the number of directors constituting our board of directors is </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
permitted to be set only by a resolution adopted by the board of directors. These provisions prevent a stockholder from increasing the size of the board of directors and then gaining control of the board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Classified Board</span>. The Certificate of Incorporation and Bylaws provide that the board of directors is divided into three classes of directors for a period of time following August&#160;11, 2021. Beginning at the 2026 annual meeting of stockholders, all directors will be elected to <span style="white-space:nowrap">one-year</span> terms and the board of directors will cease to be classified. The existence of a classified board of directors could discourage a third-party from making a tender offer or otherwise attempting to obtain control of our company as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Directors Removed Only for Cause</span>. The Certificate of Incorporation provides that stockholders may remove directors only for cause while the board of directors remains classified. Beginning at the 2026 annual meeting of stockholders, directors may be removed with or without cause by the stockholders. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Supermajority Requirements for Amendments of The Certificate of Incorporation and Bylaws</span>. The Certificate of Incorporation further provides that the affirmative vote of holders of at least <span style="white-space:nowrap">two-thirds</span> of the voting power of all of the then outstanding shares of voting stock will be required to amend certain provisions of the Certificate of Incorporation, including provisions relating to the classified board, the size of the board, removal of directors, special meetings, the liability of directors and indemnification. The affirmative vote of holders of at least <span style="white-space:nowrap">two-thirds</span> of the voting power of all of the then outstanding shares of voting stock will be required to amend or repeal the Bylaws, although the Bylaws may be amended by a simple majority vote of our board of directors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Stockholder Action; Special Meeting of Stockholders</span>. The Certificate of Incorporation and Bylaws provide that special meetings of stockholders may be called only by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the board of directors for adoption), the chairperson of the board of directors, or any chief executive officer, thus prohibiting a stockholder from calling a special meeting. The Certificate of Incorporation provides that the stockholders may not take action by written consent, but may only take action at annual or special meetings of stockholders. As a result, holders of capital stock would not be able to amend the Bylaws or remove directors without holding a meeting of stockholders called in accordance with the Bylaws. These provisions might delay the ability of stockholders to force consideration of a proposal or for stockholders to take any action, including the removal of directors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Notice Requirements for Stockholder Proposals and Director Nominations</span>. The Bylaws provide advance notice procedures for stockholders seeking to bring business before the annual meeting of stockholders or to nominate candidates for election as directors at the annual meeting of stockholders. The Bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice. These provisions might preclude stockholders from bringing matters before the annual meeting of stockholders or from making nominations for directors at the annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our Company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">No Cumulative Voting</span>. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation&#8217;s certificate of incorporation provides otherwise. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Issuance of Undesignated Preferred Stock</span>. Our board of directors will have the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated Preferred Stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of Preferred Stock will enable our board of </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
directors to render more difficult or to discourage an attempt to obtain control of our company by means of a merger, tender offer, proxy contest, or other means. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Choice of Forum </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders; (iii)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers, or other employees, arising out of or pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws; (iv)&#160;any action or proceeding to interpret, apply, enforce, or determine the validity of the Certificate of Incorporation or the Bylaws; (v)&#160;any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&#160;any action asserting a claim against us or any of our directors, officers, or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, the Certificate of Incorporation and the Bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of the Certificate of Incorporation and the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation or bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find either exclusive forum provision contained in the Certificate of Incorporation or the Bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could seriously harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Opportunity Doctrine </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. The Certificate of Incorporation, to the extent permitted by the DGCL, renounces any interest or expectancy that we have in, or right to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to a member of our board of directors who is not our employee, or any partner, member, director, stockholder, employee or agent of such member, other than one of our employees. Notwithstanding the foregoing, the Certificate of Incorporation does not renounce our interest in any business opportunity that is expressly offered to a director solely in their capacity as a director. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exchange Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock and Public Warrants are listed on the Nasdaq Capital Market under the symbols &#8220;SRZN&#8221; and &#8220;SRZNW,&#8221; respectively. The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on the Nasdaq Capital Market or any securities market or other exchange of the preferred stock covered by such prospectus supplement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent for our securities is Continental Stock Transfer&#160;&amp; Trust Company. The transfer agent&#8217;s address is One State Street Plaza, 30th Floor New York, New York 10004. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_18">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of material U.S. federal income tax considerations generally applicable to the ownership and disposition of our Common Stock and the purchase, exercise, disposition and lapse of our Warrants. The Common Stock and the Warrants are collectively referred to herein as our securities. All prospective holders of our securities should consult their tax advisors with respect to the U.S. federal, state, local and <span style="white-space:nowrap">non-U.S.</span> tax consequences of the purchase, ownership and disposition of our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating to the purchase, ownership and disposition of our securities. This summary is based upon current provisions of the Code, existing U.S. Treasury Regulations promulgated thereunder, published administrative pronouncements and rulings of the U.S. Internal Revenue Service, or the IRS, and judicial decisions, all as in effect as of the date of this prospectus. These authorities are subject to change and differing interpretation, possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to holders described in this discussion. There can be no assurance that a court or the IRS will not challenge one or more of the tax consequences described herein, and we have not obtained, nor do we intend to obtain, a ruling with respect to the U.S. federal income tax consequences to a holder of the purchase, ownership or disposition of our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We assume in this discussion that a holder holds our securities as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular holder in light of that holder&#8217;s individual circumstances, nor does it address the special tax accounting rules under Section&#160;451(b) of the Code, any alternative minimum, Medicare contribution, estate or gift tax consequences, or any aspects of U.S. state, local or <span style="white-space:nowrap">non-U.S.</span> taxes or any <span style="white-space:nowrap">non-income</span> U.S. federal tax laws. This discussion also does not address consequences relevant to holders subject to special tax rules, such as holders that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below), corporations that accumulate earnings to avoid U.S. federal income tax, <span style="white-space:nowrap">tax-exempt</span> organizations, governmental organizations, banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities, commodities or currencies, regulated investment companies or real estate investment trusts, persons that have a &#8220;functional currency&#8221; other than the U.S. dollar, <span style="white-space:nowrap">tax-</span> qualified retirement plans, holders who hold or receive our securities pursuant to the exercise of employee stock options or otherwise as compensation, holders holding our securities as part of a hedge, straddle or other risk reduction strategy, conversion transaction or other integrated investment, holders deemed to sell our securities under the constructive sale provisions of the Code, passive foreign investment companies, controlled foreign corporations, and certain former U.S. citizens or long-term residents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, this discussion does not address the tax treatment of partnerships (or entities or arrangements that are treated as partnerships for U.S. federal income tax purposes) or persons that hold our securities through such partnerships. If a partnership, including any entity or arrangement treated as a partnership for U.S. federal income tax purposes, holds our securities, the U.S. federal income tax treatment of a partner in such partnership will generally depend upon the status of the partner and the activities of the partnership. Such partners and partnerships should consult their tax advisors regarding the tax consequences of the purchase, ownership and disposition of our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a &#8220;U.S. Holder&#8221; means a beneficial owner of our securities (other than a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes) that is, for U.S. federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation, or an entity treated as a corporation for U.S. federal income tax purposes, created or organized in the United States or under the laws of the United States or of any state thereof or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust if (a)&#160;a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons have the authority to control all of the trust&#8217;s substantial decisions or (b)&#160;the trust has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For purposes of this discussion, a <span style="white-space:nowrap">&#8220;non-U.S.</span> Holder&#8221; is a beneficial owner of our securities that is neither a U.S. Holder nor a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Tax Considerations Applicable to U.S. Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to U.S. Holders of shares of our Common Stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in our Common Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Common Stock and will be treated as described under &#8220;&#8212;Tax Considerations Applicable to U.S. Holders&#8212;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S. Holder that is a taxable corporation will generally qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a <span style="white-space:nowrap">non-corporate</span> U.S. Holder will generally constitute &#8220;qualified dividends&#8221; that will be subject to tax at long-term capital gains rates. If the holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and <span style="white-space:nowrap">non-corporate</span> holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified dividend income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Common Stock. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Common Stock so disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (2)&#160;the U.S. Holder&#8217;s adjusted tax basis in its Common Stock so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its Common Stock will generally equal the U.S. Holder&#8217;s acquisition cost for such Common Stock (or, in the case of Common Stock received upon exercise of a Warrant, the U.S. Holder&#8217;s initial basis for such Common Stock, as discussed below), less any prior distributions treated as a return of capital. Long-term capital gains recognized by <span style="white-space:nowrap">non-corporate</span> U.S. Holders are generally eligible for reduced rates of tax. If the U.S. Holder&#8217;s holding period for the Common Stock so disposed of is one year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax rates. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exercise of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as discussed below with respect to the cashless exercise of a Warrant, a U.S. Holder generally will not recognize taxable gain or loss upon the exercise of a Warrant for cash. The U.S. Holder&#8217;s initial tax basis in the share of our Common Stock received upon exercise of the Warrant will generally be an amount equal to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sum of the U.S. Holder&#8217;s acquisition cost of the Warrant and the exercise price of such Warrant. It is unclear whether a U.S. Holder&#8217;s holding period for the Common Stock received upon exercise of the Warrant would commence on the date of exercise of the Warrant or the day following the date of exercise of the Warrant; however, in either case the holding period will not include the period during which the U.S. Holder held the Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain circumstances, the Warrants may be exercised on a cashless basis. The U.S. federal income tax treatment of an exercise of a warrant on a cashless basis is not clear, and could differ from the consequences described above. It is possible that a cashless exercise could be a taxable event. U.S. holders are urged to consult their tax advisors as to the consequences of an exercise of a Warrant on a cashless basis, including with respect to their holding period and tax basis in the Common Stock received upon exercise of the Warrant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sale, Exchange, Redemption or Expiration of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a sale, exchange (other than by exercise), redemption, or expiration of a Warrant, a U.S. Holder will recognize taxable gain or loss in an amount equal to the difference between (1)&#160;the amount realized upon such disposition or expiration and (2)&#160;the U.S. Holder&#8217;s adjusted tax basis in the Warrant. A U.S. Holder&#8217;s adjusted tax basis in its Warrants will generally equal the U.S. Holder&#8217;s acquisition cost, increased by the amount of any constructive distributions included in income by such U.S. Holder (as described below under &#8220;<span style="font-style:italic">Tax Considerations Applicable to U.S. Holders&#8212;Possible Constructive Distributions</span>&#8221;). Such gain or loss generally will be treated as long-term capital gain or loss if the Warrant is held by the U.S. Holder for more than one year at the time of such disposition or expiration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a Warrant is allowed to lapse unexercised, a U.S. Holder will generally recognize a capital loss equal to such holder&#8217;s adjusted tax basis in the Warrant. Any such loss generally will be a capital loss and will be long-term capital loss if the Warrant is held for more than one year. Because the term of the Warrants is more than one year, a U.S. Holder&#8217;s capital loss will be treated as a long-term capital loss. The deductibility of capital losses is subject to certain limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Possible Constructive Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each Warrant provide for an adjustment to the number of shares of Common Stock for which the Warrant may be exercised or to the exercise price of the Warrant in certain events, as discussed in the section of this prospectus captioned &#8220;<span style="font-style:italic">Description of our Securities&#8212;Redeemable Warrants</span>.&#8221; An adjustment which has the effect of preventing dilution generally should not be a taxable event. Nevertheless, a U.S. Holder of Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Common Stock that would be obtained upon exercise or an adjustment to the exercise price of the Warrant) as a result of a distribution of cash to the holders of shares of our Common Stock which is taxable to such holders as a distribution. Such constructive distribution would be subject to tax as described above under &#8220;<span style="font-style:italic">Tax Considerations Applicable to U.S. Holders&#8212;Taxation of Distributions</span>&#8221; in the same manner as if such U.S. Holder received a cash distribution from us on Common Stock equal to the fair market value of such increased interest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Information Reporting and Backup Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, information reporting requirements may apply to dividends paid to a U.S. Holder and to the proceeds of the sale or other disposition of our shares of Common Stock and Warrants, unless the U.S. Holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. Holder fails to provide a taxpayer identification number (or furnishes an incorrect taxpayer identification number) or a certification of exempt status, or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. Taxpayers should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Tax Considerations Applicable to <span style="white-space:nowrap">Non-U.S.</span> Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, any distributions (including constructive distributions) we make to a <span style="white-space:nowrap">non-U.S.</span> Holder of shares on our Common Stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the <span style="white-space:nowrap">non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <span style="white-space:nowrap">non-U.S.</span> Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <span style="white-space:nowrap">W-8BEN</span> or <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E,</span></span> as applicable). In the case of any constructive dividend (as described below under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders&#8212;Possible Constructive Distributions</span>&#8221;), it is possible that this tax would be withheld from any amount owed to a <span style="white-space:nowrap">non-U.S.</span> Holder by the applicable withholding agent, including cash distributions on other property or sale proceeds from Warrants or other property subsequently paid or credited to such holder. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <span style="white-space:nowrap">non-U.S.</span> Holder&#8217;s adjusted tax basis in its shares of our Common Stock and, to the extent such distribution exceeds the <span style="white-space:nowrap">non-U.S.</span> Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of the Common Stock, which will be treated as described under &#8220;<span style="font-style:italic">&#8212;Tax Considerations Applicable to <span style="white-space:nowrap">Non-U.S.</span> Holders&#8212;Gain on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock and Warrants</span>&#8221; below. In addition, if we determine that we are likely to be classified as a &#8220;United States real property holding corporation&#8221; (see &#8220;<span style="font-style:italic">Tax Considerations Applicable to <span style="white-space:nowrap">Non-U.S.</span> Holders&#8212;Gain on Sale, Exchange or Other Taxable Disposition of Common Stock and Warrants</span>&#8221; below), we will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a <span style="white-space:nowrap">non-U.S.</span> Holder that are effectively connected with such <span style="white-space:nowrap">non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States (or if a tax treaty applies are attributable to a U.S. permanent establishment or fixed base maintained by the <span style="white-space:nowrap">non-U.S.</span> Holder) will generally not be subject to U.S. withholding tax, provided such <span style="white-space:nowrap">non-U.S.</span> Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form <span style="white-space:nowrap">W-8ECI).</span> Instead, such dividends generally will be subject to U.S. federal income tax, net of certain deductions, at the same individual or corporate rates applicable to U.S. Holders. If the <span style="white-space:nowrap">non-U.S.</span> Holder is a corporation, dividends that are effectively connected income may also be subject to a &#8220;branch profits tax&#8221; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exercise of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal income tax treatment of a <span style="white-space:nowrap">non-U.S.</span> Holder&#8217;s exercise of a Warrant will generally correspond to the U.S. federal income tax treatment of the exercise of a Warrant by a U.S. Holder, as described under &#8220;<span style="font-style:italic">&#8212;Tax Considerations Applicable to U.S. Holders&#8212;Exercise of a Warrant</span>&#8221; above, although to the extent a cashless exercise results in a taxable exchange, the tax consequences to the <span style="white-space:nowrap">non-U.S.</span> Holder would be the same as those described below in<span style="font-style:italic"> &#8220;&#8212;Tax Considerations Applicable to <span style="white-space:nowrap">Non-U.S.</span> Holders&#8212;Gain on Sale, Exchange or Other Taxable Disposition of Common Stock and Warrants</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain on Sale, Exchange or Other Taxable Disposition of Common Stock and Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">non-U.S.</span> Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our Common Stock or Warrants or an expiration or redemption of our Warrants, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the gain is effectively connected with the conduct of a trade or business by the <span style="white-space:nowrap">non-U.S.</span> Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the <span style="white-space:nowrap">non-U.S.</span> Holder); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the <span style="white-space:nowrap">non-U.S.</span> Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are or have been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <span style="white-space:nowrap">non-U.S.</span> Holder held our Common Stock or Warrants and, in the case where shares of our Common Stock are regularly traded on an established securities market, the <span style="white-space:nowrap">non-U.S.</span> Holder has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period preceding the disposition or such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s holding period for the shares of our Common Stock. These rules may be modified as applied to the Warrants. There can be no assurance that our Common Stock will be treated as regularly traded or not regularly traded on an established securities market for this purpose. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the <span style="white-space:nowrap">non-U.S.</span> Holder were a U.S. resident. Any gains described in the first bullet point above of a <span style="white-space:nowrap">non-U.S.</span> Holder that is a foreign corporation may also be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate (or lower applicable treaty rate). Gain described in the second bullet point above will generally be subject to a flat 30% U.S. federal income tax. <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a <span style="white-space:nowrap">non-U.S.</span> Holder and applicable exceptions are not available, gain recognized by such holder on the sale, exchange or other disposition of our Common Stock or Warrants, as applicable, will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our Common Stock or Warrants from such holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. We will be classified as a United States real property holding corporation if the fair market value of our &#8220;United States real property interests&#8221; equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes. We do not believe we currently are or will become a United States real property holding corporation, however there can be no assurance in this regard. <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors regarding the application of these rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Possible Constructive Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each Warrant provide for an adjustment to the number of shares of Common Stock for which the Warrant may be exercised or to the exercise price of the Warrant in certain events, as discussed in the section of this prospectus captioned &#8220;<span style="font-style:italic">Description of our Securities&#8212;Warrants</span>.&#8221; An adjustment which has the effect of preventing dilution generally should not be a taxable event. Nevertheless, a <span style="white-space:nowrap">non-U.S.</span> Holder of Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Common Stock that would be obtained upon exercise or an adjustment to the exercise price of the Warrant) as a result of a distribution of cash to the holders of shares of our Common Stock which is taxable to such holders as a distribution. A <span style="white-space:nowrap">non-U.S.</span> Holder would be subject to U.S. federal income tax withholding as described above under &#8220;<span style="font-style:italic">Tax Considerations Applicable to <span style="white-space:nowrap">Non-U.S.</span> Holders&#8212;Taxation of Distributions</span>&#8221; under that section in the same manner as if such <span style="white-space:nowrap">non-U.S.</span> Holder received a cash distribution from us on Common Stock equal to the fair market value of such increased interest. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Foreign Account Tax Compliance Act </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of the Code and Treasury Regulations and administrative guidance promulgated thereunder commonly referred as the Foreign Account Tax Compliance Act, or FATCA generally impose withholding at a rate of 30% in certain circumstances on dividends (including constructive dividends) in respect of our securities which are held by or through certain foreign financial institutions (including investment funds), unless any such institution (1)&#160;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <span style="white-space:nowrap">non-U.S.</span> entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (2)&#160;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Accordingly, the entity through which our securities are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of our securities held by an investor that is a <span style="white-space:nowrap">non-financial</span> <span style="white-space:nowrap">non-U.S.</span> entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (1)&#160;certifies to us or the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (2)&#160;provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221; which will in turn be provided to the U.S. Department of Treasury. Withholding under FATCA was scheduled to apply to payments of gross proceeds from the sale or other disposition of property that produces U.S.-source interest or dividends, however, the IRS released proposed regulations that, if finalized in their proposed form, would eliminate the obligation to withhold on such gross proceeds. Although these proposed Treasury Regulations are not final, taxpayers generally may rely on them until final Treasury Regulations are issued. Prospective investors should consult their tax advisors regarding the possible implications of FATCA on their investment in our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Information Reporting and Backup Withholding. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of our Common Stock and Warrants. A <span style="white-space:nowrap">non-U.S.</span> Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a <span style="white-space:nowrap">non-U.S.</span> Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">178 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_19">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the issuance by us of up to 7,217,974 shares of Common Stock, consisting of (i) 144,666 shares of Common Stock that are issuable upon the exercise of 144,666 Private Placement Warrants (ii) 4,006,657 shares of Common Stock that are issuable upon the exercise of 4,006,657 PIPE Warrants and (iii) 3,066,651 shares of Common Stock that are issuable upon the exercise of 3,066,651 Public Warrants. We are also registering the resale by the selling securityholders or their permitted transferees from time to time of (i)&#160;up to 31,612,348 shares of Common Stock (including up to 4,006,657 shares of Common Stock that may be issued upon exercise of the PIPE Warrants, up to 144,666 shares of Common Stock that may be issued upon exercise of the Private Placement Warrants) and up to 4,151,323 Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay all fees and expenses incident to the registration of the securities to be offered and sold pursuant to this prospectus. The selling securityholders will bear all commissions and discounts, if any, attributable to their sale of securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of the securities by the selling securityholders. We will receive proceeds from Warrants exercised in the event that such Warrants are exercised for cash under certain conditions. The aggregate proceeds to the selling securityholders will be the purchase price of the securities less any discounts and commissions borne by such selling securityholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock beneficially owned by the selling securityholders covered by this prospectus may be offered and sold from time to time by the selling securityholders. The term &#8220;selling securityholders&#8221; includes donees, pledgees, transferees or other successors in interest selling securities received after the date of this prospectus from a selling securityholder as a gift, pledge, partnership distribution or other transfer. The selling securityholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. The selling securityholders may sell their securities by one or more of, or a combination of, the following methods: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokerage transactions and transactions in which the broker solicits purchasers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> distribution in accordance with the rules of Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through trading plans entered into by a selling securityholder pursuant to Rule <span style="white-space:nowrap">10b5-1</span> under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">short sales; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">distribution to employees, members, limited partners or stockholders of the selling securityholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through the writing or settlement of options or other hedging transaction, whether through an options exchange or otherwise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by pledge to secured debts and other obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delayed delivery arrangements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">to or through underwriters or broker-dealers; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">179 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in &#8220;at the market&#8221; offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in privately negotiated transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in options transactions; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any other method permitted pursuant to applicable law. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any securities that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a selling securityholder that is an entity may elect to make a pro rata <span style="white-space:nowrap">in-kind</span> distribution of securities to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or stockholders would thereby receive freely tradeable securities pursuant to the distribution through a registration statement. To the extent a distributee is our affiliate (or to the extent otherwise required by law), we may, at our option, file a prospectus supplement in order to permit the distributees to use the prospectus to resell the securities acquired in the distribution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the securities or otherwise, the selling securityholders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of the securities in the course of hedging the positions they assume with selling securityholders. The selling securityholders may also sell the securities short and redeliver the securities to close out such short positions. The selling securityholders may also enter into option or other transactions with broker-dealers or other financial institutions that require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The selling securityholders may also pledge securities to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution, may effect sales of the pledged securities pursuant to this prospectus (as supplemented or amended to reflect such transaction). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In effecting sales, broker-dealers or agents engaged by the selling securityholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the selling securityholders in amounts to be negotiated immediately prior to the sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In offering the securities covered by this prospectus, the selling securityholders and any broker-dealers who execute sales for the selling securityholders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any profits realized by the selling securityholders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, the securities must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states, the securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the selling securityholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of securities in the market and to the activities of the selling securityholders and their affiliates. In addition, we will make copies of this prospectus available to the selling securityholders for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">180 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the securities against certain liabilities, including liabilities arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time a particular offer of securities is made, if required, a prospectus supplement will be distributed that will set forth the number of securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of Public Warrants being exercised. The warrant holders do not have the rights or privileges of holders of Common Stock and any voting rights until they exercise their warrants and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the Public Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Warrants (including the Combined Company Common Stock issuable upon exercise of the Private Warrants) will not, subject to certain limited exceptions, be transferred, assigned or sold by our Sponsor until the earliest to occur of (i) 365 days after the date of the Closing, (ii)&#160;the first day after the date on which the closing price of the Combined Company Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any <span style="white-space:nowrap">30-trading</span> day period commencing at least 150 days after the date of the Closing, or (iii)&#160;the date on which Consonance completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of Consonance&#8217;s public stockholders having the right to exchange their Combined Company Common Stock for cash, securities or other property; and they will not be redeemable by us so long as they are held by our Sponsor or its permitted transferees. Otherwise, the Private Warrants have terms and provisions that are identical to those of the Public Warrants sold as part of the Public Units in the Consonance IPO, including as to exercise price, exercisability and exercise period. If the Private Warrants are held by holders other than our Sponsor or its permitted transferees, the Private Warrants will be redeemable by us and exercisable by the holders on the same basis as the Public Warrants included in the Public Units sold in the Consonance IPO. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If holders of the Private Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering their warrants for that number of shares of Combined Company Common Stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Combined Company Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#8220;fair market value&#8221; (defined below) by (y)&#160;the fair market value. The &#8220;fair market value&#8221; shall mean the average reported last sale price of the Combined Company Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent. The reason that we agreed that these warrants will be exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees is because it was not known at the time of issuance whether they would be affiliated with us following the Business Combination. If they remain affiliated with us, their ability to sell our securities in the open market will be significantly limited. We expect to have policies in place that prohibit insiders from selling our securities except during specific periods of time. Even during such periods of time when insiders will be permitted to sell our securities, an insider cannot trade in our securities if such insider is in possession of material <span style="white-space:nowrap">non-public</span> information. Accordingly, unlike Public Stockholders who could sell the shares of Combined Company Common Stock issuable upon exercise of the Public Warrants freely in the open market, the insiders could be significantly restricted from doing so. As a result, we believe that allowing the holders to exercise such warrants on a cashless basis is appropriate. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">181 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the selling securityholders against certain liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the Warrants or shares of Common Stock offered by this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the selling securityholders to keep the registration statement of which this prospectus constitutes a part effective until such time as all of the securities covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement or such securities have been withdrawn or, in the case of shares issued pursuant to the Subscription Agreements, until two years from the effective date of this registration statement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">182 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_20">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered hereby will be passed upon for us by Cooley LLP. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_21">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Surrozen, Inc. at December&#160;31, 2022 and 2021, and for the years then ended, appearing in this prospectus and Registration Statement have been audited by Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc491933_22">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <span style="white-space:nowrap">S-1</span> under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus, which constitutes part of the registration statement, does not contain all of the information in the registration statement and its exhibits. For further information with respect to Surrozen and the securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. You can read our SEC filings, including the registration statement, over the internet at the SEC&#8217;s website at <span style="font-style:italic">www.sec.gov</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the information reporting requirements of the Exchange Act, and we file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for review at the SEC&#8217;s website at www.sec.gov. We also maintain a website at www.surrozen.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">183 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="srzn-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div id="toc491933_23" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:95%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin491933_1">Report of Independent Registered Public Accounting Firm (PCAOB ID:42)</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin491933_2">Consolidated Balance Sheets</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin491933_3">Consolidated Statements of Operations and Comprehensive Loss</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin491933_4">Consolidated Statements of Stockholders&#8217; Equity</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin491933_5">Consolidated Statements of Cash Flows</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><a href="#fin491933_6">Notes to the Consolidated Financial Statements</a></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-1 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin491933_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Stockholders and the Board of Directors of Surrozen, Inc.</div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Surrozen, Inc. (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for the years ended December&#160;31, 2022 and 2021, and the related notes (collectively referred to as &#8220;the consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for the years ended December&#160;31, 2022 and 2021, in conformity with U.S. generally accepted accounting principles.</div></div><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion</div></div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP</div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2020.</div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">San Francisco, California</div></div><div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, 202</div>3 </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;;text-indent: 0px;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center;text-indent: 0px;">F-2 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div id="fin491933_2" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Balance Sheets </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,091</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,978</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,148</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,760</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,489</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,338</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,305</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">105,189</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,268</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,655</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">827</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">89,435</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">137,174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities and stockholders&#8217; equity</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">658</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,718</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,662</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,226</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,193</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,732</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,573</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, noncurrent portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,376</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrant liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:WarrantLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:WarrantLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,434</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,474</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and contingencies (Note 6 and Note&#160;14)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; equity:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,000</ix:nonFraction></ix:nonFraction> shares authorized;<ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"> no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">500,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2022 and 2021; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,088</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,034</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and 2021, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in-capital</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">254,892</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">252,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">241</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,653</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">142,649</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">76,001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">109,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders&#8217; equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">89,435</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">137,174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div id="fin491933_3" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Operations and Comprehensive Loss </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Collaboration and license revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,013</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,177</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,826</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,214</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">56,839</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,391</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44,339</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">54,391</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense), net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">54,648</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized loss on marketable securities, net of tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">54,767</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.04</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">2.21</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">34,722</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,689</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div id="fin491933_4" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Stockholders&#8217; Equity </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:49%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/> capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> other<br/> comprehensive<br/> loss</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2020, after effect of Business Combination</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">18,257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,292</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs and warrant liabilities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">16,441</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">114,463</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">114,465</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercises of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclassification to liability for early exercised stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vesting of early exercised stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">207</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">207</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repurchase of early exercised stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:RepurchaseOfEarlyExercisedStockOptionsShares" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock granted</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">193</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted stock forfeited</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">54,648</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">54,648</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,034</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">252,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">142,649</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">109,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock under Equity Purchase Agreement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:IssuanceOfCommonStockUnderEquityPurchaseAgreement" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:Issuanceofcommonstockvalueunderequitypurchaseagreement" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">273</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:Issuanceofcommonstockvalueunderequitypurchaseagreement" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">273</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock under employee stock purchase plan</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repurchase of early exercised stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:RepurchaseOfEarlyExercisedStockOptionsShares" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repurchase and cancellation of common stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:RepurchaseAndCancellationOfCommonStock" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="3" sign="-" format="ixt:num-dot-decimal">5,382</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,606</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,607</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vesting of early exercised stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,088</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">254,892</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">241</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,653</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">76,001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div id="fin491933_5" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Cash Flows </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">54,648</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,955</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,066</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> operating lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of premium on marketable securities, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeAmortizationOfPremium" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">108</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeAmortizationOfPremium" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of warrant liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,890</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other expense related to the commitment shares issued to Lincoln Park</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">273</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs allocated to warrants in connection with Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,978</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,296</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">379</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">510</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">857</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,782</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,789</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,061</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44,145</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">48,813</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Investing activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">728</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,269</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">91,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from sales of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:ProceedsFromSaleOfMarketableSecurities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:ProceedsFromSaleOfMarketableSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from maturities of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,637</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net cash provided by (used in) investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,309</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">77,708</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Financing activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">124,220</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock upon exercise of stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">411</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock upon employee stock plan purchases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repurchase and cancellation of common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,607</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repurchase of warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfWarrants" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repurchase of early exercised stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:RepurchaseOfEarlyExcercisedStockOptions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:RepurchaseOfEarlyExcercisedStockOptions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net cash (used in) provided by financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">124,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net decrease in cash, cash equivalents and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,401</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash at beginning of year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash at end of year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,095</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental disclosure of noncash investing and financing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of redeemable convertible preferred stock into common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133,097</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumption of warrant liabilities in Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AssumptionOfWarrantLiabilitiesInBusinessCombination" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AssumptionOfWarrantLiabilitiesInBusinessCombination" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,372</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transaction costs in Business Combination included in accounts payable and accrued liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,792</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment included in accounts payable and accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vesting of early exercises of stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:VestingOfEarlyExercisesOfStockOptions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:VestingOfEarlyExercisesOfStockOptions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">207</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclassification to liability for early exercised stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:ReclassificationToLiabilityForEarlyExercisedStockOptions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:ReclassificationToLiabilityForEarlyExercisedStockOptions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increase in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and lease liabilities due to lease extension</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">The following table presents a reconciliation of the Company&#8217;s cash, cash equivalents and restricted cash in the Company&#8217;s consolidated balance sheets: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#160;&#160;<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,091</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash, cash equivalents and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,095</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements </div></div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div id="fin491933_6" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div><ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 1. Organization and Business </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Surrozen, Inc., or the Company, formerly known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Consonance-HFW</div> Acquisition Corp., or Consonance, is a clinical stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The Company, a Delaware corporation, is located in South San Francisco, California, and it operates and manages its business as one operating segment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consonance was a blank check company incorporated as a Cayman Islands exempted company on August&#160;21, 2020. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On August&#160;11, 2021, Consonance consummated a business combination, or the Business Combination, among Consonance, Perseverance Merger Sub Inc., a subsidiary of Consonance, and Surrozen, Inc., or Legacy Surrozen, a Delaware company incorporated on August&#160;12, 2015. Upon closing of the Business Combination, Consonance became a Delaware corporation and was renamed to Surrozen, Inc., Legacy Surrozen, was renamed to Surrozen Operating, Inc., and Legacy Surrozen continued as a wholly-owned subsidiary of the Company. See Note 3, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recapitalization&#8221;</div></div> for additional details. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Surrozen Netherlands, B.V. was incorporated in May 2022 and is located in Rotterdam, Netherlands as a wholly-owned subsidiary of Surrozen Operating, Inc. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred net operating losses each period since inception. During the years ended December&#160;31, 2022 and 2021, the Company incurred a net loss of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">36.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">54.6</ix:nonFraction>&#160;million, respectively. During the years ended December&#160;31, 2022 and 2021, the Company used $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">44.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">48.8</ix:nonFraction>&#160;million of cash in operations. As of December&#160;31, 2022, the Company had cash, cash equivalents and marketable securities of $<ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.8</ix:nonFraction>&#160;million and an accumulated deficit of approximately $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">178.7</ix:nonFraction>&#160;million. The Company expects operating expenses to continue to increase in connection with its ongoing clinical studies and anticipates the need to raise additional capital to continue to execute its long-range business plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management believes that the existing cash, cash equivalents and marketable securities are sufficient for the Company to continue operating activities for at least the next 12 months from the date of issuance of its consolidated financial statements. However, if the Company&#8217;s anticipated cash burn is greater than anticipated, the Company could use its capital resources sooner than expected which may result in the need to reduce future planned expenditures and/or raise additional capital to continue to fund the operations. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307158"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 2. Summary of Significant Accounting Policies </div></div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307177"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, as determined by the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, and pursuant to the regulations of the U.S. Securities and Exchange Commission, or SEC. The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany transactions and balances have been eliminated. </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7 </div></ix:exclude></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73307177" continuedAt="TextSelectionAppend_73307177_1"><ix:continuation id="TextSelection_73307158" continuedAt="TextSelectionAppend_73307158_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_1" continuedAt="TextSelectionAppend_73307158_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_2" continuedAt="TextSelectionAppend_73307158_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307158_3" continuedAt="TextSelectionAppend_73307158_4"><ix:continuation id="TextSelectionAppend_73307177_1"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination discussed in Note 1 was accounted for as a reverse recapitalization with Legacy Surrozen as the accounting acquirer and Consonance as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the consolidated financial statements represents the accounts of Legacy Surrozen at their historical cost as if Legacy Surrozen is the predecessor to the Company. The consolidated financial statements following the closing of the Business Combination reflect the results of the combined entity&#8217;s operations. All issued and outstanding common stock and stock awards of Legacy Surrozen and per share amounts contained in the consolidated financial statements for the periods presented prior to the closing of the Business Combination on August&#160;11, 2021 have been retroactively restated to reflect the exchange ratio established in the Business Combination. See Note 3, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recapitalization&#8221;</div></div> for additional details. </div></ix:continuation><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, revenue recognition, certain accruals for research and development activities, the fair value of common stock prior to the Business Combination, initial fair value of the PIPE Warrants and stock-based compensation expense. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could materially differ from those estimates. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist of cash, cash equivalents and marketable securities. The Company&#8217;s cash is held by one financial institution that may at times exceed federally insured limits. However, the Company&#8217;s exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company believes it is not exposed to significant credit risk on cash. The Company&#8217;s policy is to invest cash in institutional money market funds and marketable securities with high credit quality to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and marketable securities in a variety of securities, including money market funds, U.S. government bonds, U.S. government agency debt securities, foreign bonds, commercial paper and corporate debt securities. The Company has not experienced any losses on its cash equivalents and marketable securities. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash equivalents relate to securities having an original maturity of three months or less at the time of purchase. As of December&#160;31, 2022 and 2021, cash and cash equivalents consisted of bank deposits, money market funds and U.S. government agency debt securities. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of each of December&#160;31, 2022 and 2021, the Company had $<ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021_LetterOfCreditMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022_LetterOfCreditMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction></ix:nonFraction>&#160;million of restricted cash in the form of a letter of credit for the Company&#8217;s facility lease. The restricted cash is classified as a noncurrent asset as the Company is required to maintain the letter of credit for the benefit of the landlord until the end of the lease term in April 2025. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-8</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73307158_4" continuedAt="TextSelectionAppend_73307158_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_5" continuedAt="TextSelectionAppend_73307158_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_6" continuedAt="TextSelectionAppend_73307158_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307158_7" continuedAt="TextSelectionAppend_73307158_8"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:MarketableSecuritiesPolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company invests its excess cash in marketable U.S. government bonds, foreign bonds, commercial paper and corporate debt securities. All marketable securities have been classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company does not buy or hold securities principally for the purpose of selling them in the near future. The Company&#8217;s policy is focused on the preservation of capital, liquidity, and return. From time to time, the Company may sell certain securities, but the objectives are generally not to generate profits on short-term differences in price. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Short-term marketable securities have maturities less than or equal to one year as of the balance sheet date. Long-term marketable securities have maturities greater than one year as of the balance sheet date. These marketable securities are carried at estimated fair value with unrealized holding gains and losses included in accumulated other comprehensive loss in stockholders&#8217; equity until realized. Gains and losses on marketable security transactions are reported on the specific-identification method. Interest income is recognized in the consolidated statements of operations and comprehensive loss when earned. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company periodically evaluates its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities for impairment. When the fair value of a marketable security is below its amortized cost basis, the amortized cost is reduced to its fair value if it is more likely than not that the Company is required to sell the impaired security before recovery of its amortized cost, or the Company has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost basis over the fair value of the security. An allowance for credit losses for the excess of amortized cost basis over the expected cash flows, if any, is recorded in other income (expense), net on the consolidated statements of operations. Impairment losses that are not credit-related are included in accumulated other comprehensive loss in stockholders&#8217; equity. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div><ix:nonNumeric name="srzn:PropertyPlantAndEquipmentUsefulLivesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, including leasehold improvements, are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Estimated useful life</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Shorter of useful life of asset or lease term</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">3 years</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture, fixtures and equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2022To12_31_2022_FurnitureFixturesAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">3</ix:nonNumeric>-</div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2022To12_31_2022_FurnitureFixturesAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8</div> years</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2022To12_31_2022_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">3 years</ix:nonNumeric></td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the period realized. Maintenance and repairs are expensed as incurred. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307184"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Material leases with a term longer than one year are recognized as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use,</div></div> or ROU, assets and lease liabilities in the Company&#8217;s consolidated balance sheets. The Company determines the lease classification and measurement of its ROU assets and lease liabilities at the lease commencement date and thereafter if modified. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-9</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_73307184" continuedAt="TextSelectionAppend_73307184_1"><ix:continuation id="TextSelectionAppend_73307158_8" continuedAt="TextSelectionAppend_73307158_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_9" continuedAt="TextSelectionAppend_73307158_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_10" continuedAt="TextSelectionAppend_73307158_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307158_11" continuedAt="TextSelectionAppend_73307158_12"><ix:continuation id="TextSelectionAppend_73307184_1"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses its incremental borrowing rate, based on the information available at the commencement date, to determine the present value of lease payments if the rate implicit in the lease is not readily available. The ROU asset is based on the measurement of the lease liability and is adjusted for lease incentives provided by the landlord. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. </div></ix:continuation><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. The Company has not identified any such impairment losses to date. </div></ix:nonNumeric><ix:nonNumeric name="srzn:WarrantLiabilityPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Public Warrants, Private Placement Warrants and PIPE Warrants were classified as liabilities (see Note 11). At the end of each reporting period, any changes in fair value during the period are recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> Private Placement Warrants were outstanding as of December&#160;31, 2022 as a result of the repurchase of <ix:nonFraction name="srzn:ClassOfWarrantsRepurchased" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction>&#160;million warrants in December 2022 (see Note 9). The Company will continue to adjust the warrant liabilities pertaining to the outstanding warrants for changes in the fair value until the earlier of a) the exercise or expiration of the warrants or b) the redemption of the warrants, at which time such warrants will be reclassified to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. </div></ix:nonNumeric><ix:nonNumeric name="srzn:RevenueRecognitionsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307187"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue in accordance with ASC 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers (Topic 606)</div></div>,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for these goods or services. To determine revenue recognition for the arrangement that is within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract with the customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At contract inception, the Company assesses the goods or services promised within the contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligations when or as the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the variable consideration constraint) that a significant reversal of recognized revenue is not probable. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses accounts receivable for impairment and, to date, no impairment losses have been recorded. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-10</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_73307187" continuedAt="TextSelectionAppend_73307187_1"><ix:continuation id="TextSelectionAppend_73307158_12" continuedAt="TextSelectionAppend_73307158_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_13" continuedAt="TextSelectionAppend_73307158_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_14" continuedAt="TextSelectionAppend_73307158_15"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307158_15" continuedAt="TextSelectionAppend_73307158_16"><ix:continuation id="TextSelectionAppend_73307187_1"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a collaboration and license agreement with BI to which the Company licensed certain rights to its intellectual property (see Note 7) that is determined within the scope of ASC 606. The terms of the CLA include payment to the Company of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment, development, regulatory and commercial milestone payments and royalties on net sales of licensed products. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licenses of Intellectual Property: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone Payments:</div></div> At contract inception, the Company using the most likely amount method evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received or the underlying activity has been completed. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenue in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties:</div></div> The Company recognizes sales-based royalties as revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalties that have been allocated have been satisfied (or partially satisfied). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The incremental costs of obtaining a customer contract are expensed as and when incurred if the amortization period of the asset that would have been recognized is one year or less. </div></ix:continuation><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307188"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs consist of external and internal expenses directly attributable to the conduct of research and development programs. The external expenses include the costs of services provided by outside contractors, clinical research organizations and contract manufacturing organizations. The internal expenses include the costs of salaries, bonus, payroll taxes, stock-based compensation, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, and the allocated facility-related costs, such as rent, utilities, insurance, repairs and maintenance, and general support services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into and may continue to enter into licensing or subscription arrangements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company&#8217;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-11</ix:exclude></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_73307188" continuedAt="TextSelectionAppend_73307188_1"><ix:continuation id="TextSelectionAppend_73307158_16" continuedAt="TextSelectionAppend_73307158_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_17" continuedAt="TextSelectionAppend_73307158_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_18" continuedAt="TextSelectionAppend_73307158_19"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307158_19" continuedAt="TextSelectionAppend_73307158_20"><ix:continuation id="TextSelectionAppend_73307188_1"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects. </div></ix:continuation><ix:nonNumeric name="srzn:AccruedResearchAndDevelopmentExpensesPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records accruals for estimated costs of research, preclinical, clinical, and manufacturing development, which are significant components of research and development expenses, within accrued and other liabilities in the accompanying consolidated balance sheets. A substantial portion of the Company&#8217;s ongoing research and development activities is conducted by third-party service providers. The Company accrues the costs under agreements with these third parties as incurred. The Company estimates the amounts incurred in each period based on the information available and its knowledge of the nature of the contractual activities generating such costs. Clinical trial contract expenses are accrued based on units of activity. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. For the years ended December&#160;31, 2022 and 2021, the Company has not experienced any material differences between accrued costs and actual costs incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts accrued expenses or prepaid expenses accordingly, which impacts research and development expenses. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307190"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes stock-based compensation expense for all stock-based awards. For stock option awards, stock-based compensation cost is estimated at the grant date based on the fair value of the equity for financial reporting purposes and is recognized as expense on a straight-line basis over the requisite service period. Under the Company&#8217;s employee stock purchase plan, stock-based compensation cost is measured at the beginning of the offering period and recognized on a straight-line basis over the offering period. Forfeitures are accounted for as they occur. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has elected to calculate the fair value of awards using the Black-Scholes option pricing model, or the Black-Scholes Model. The Black-Scholes Model requires the use of various assumptions including common stock valuation, expected option life and expected stock price volatility. The Company estimates the expected term for stock options using the simplified method as the midpoint between the vesting date and the contractual expiration date of the award as the Company has limited historical exercise information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. Due to the limited trading history of the Company&#8217;s stock, the Company estimates the volatility using volatilities of a group of public companies in a comparable industry, stage of life cycle, and size. The interest rate is derived from the U.S. Treasury instruments with maturities similar to the expected term of the options. The Company has not declared nor expects to declare dividends. Therefore, there is no dividend impact on the valuation of options. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, the fair value of common stock was determined considering numerous objective and subjective factors and requires judgment. These objective and subjective factors include, but are not limited to: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">relevant precedent transactions involving the Company&#8217;s capital stock; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">contemporaneous valuations performed by third-party specialists; </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_73307190" continuedAt="TextSelectionAppend_73307190_1"><ix:continuation id="TextSelectionAppend_73307158_20" continuedAt="TextSelectionAppend_73307158_21"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_21" continuedAt="TextSelectionAppend_73307158_22"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_22" continuedAt="TextSelectionAppend_73307158_23"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307158_23" continuedAt="TextSelectionAppend_73307158_24"><ix:continuation id="TextSelectionAppend_73307190_1"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">rights, preferences, and privileges of the Company&#8217;s redeemable convertible preferred stock relative to those of the Company&#8217;s common stock; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">actual operating and financial performance; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">current business conditions and financial projections; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company&#8217;s business; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the lack of marketability of the Company&#8217;s common stock, and the illiquidity of stock-based awards involving securities in a private company; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">market multiples of comparable publicly traded companies; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">stage of development; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">industry information such as market size and growth; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">U.S. and global capital and macroeconomic conditions. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of the Business Combination, the fair value of our common stock has been determined based on the quoted market price of our common stock.</div></ix:continuation><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s comprehensive loss consists of unrealized losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing the net loss attributable to common stock by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities. Since the Company was in a loss position for the periods presented, basic net loss per share is the same as diluted net loss per share as the effects of the potentially dilutive securities are antidilutive<ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307196">. The following table presents the potential common stock outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_73307196"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">3,896</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">1,794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_RestrictedStockAwardRSAMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested common stock subject to repurchase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_UnvestedCommonStockSharesSubjectToRepurchaseMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_UnvestedCommonStockSharesSubjectToRepurchaseMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_WarrantToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">5,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_WarrantToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">7,218</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">9,930</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">9,248</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307193"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-13</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div></div><ix:continuation id="TextSelection_73307193" continuedAt="TextSelectionAppend_73307193_1"><ix:continuation id="TextSelectionAppend_73307158_24" continuedAt="TextSelectionAppend_73307158_25"><div></div></ix:continuation></ix:continuation></div><div><div style="background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_73307193_1" continuedAt="TextSelectionAppend_73307193_2"><ix:continuation id="TextSelectionAppend_73307158_25" continuedAt="TextSelectionAppend_73307158_26"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_26" continuedAt="TextSelectionAppend_73307158_27"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307158_27" continuedAt="TextSelectionAppend_73307158_28"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307158_28"><ix:continuation id="TextSelectionAppend_73307193_2"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is more likely than not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&#160;the factors underlying the sustainability assertion have changed and (ii)&#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits require significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits. </div></ix:continuation><ix:nonNumeric name="srzn:EmergingGrowthCompanyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div></ix:nonNumeric></ix:continuation><ix:nonNumeric name="srzn:RecapitalizationNoteDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307159"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 3. Recapitalization </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;11, 2021, Consonance consummated the Business Combination (see Note 1). Immediately after the consummation of the Business Combination, certain investors subscribed for and purchased an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_11_2021To08_11_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction>&#160;million units, each consisting of one share of the Company&#8217;s common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one redeemable warrant, for a purchase price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn08_11_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per unit through a private investment in public entity financing, or PIPE Financing. In connection with the Business Combination and PIPE Financing, Legacy Surrozen received the aggregate cash consideration of $<ix:nonFraction name="srzn:ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" contextRef="P08_01_2021To08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">128.8</ix:nonFraction>&#160;million, after deducting the transaction fees incurred by Consonance. The cash consideration was comprised of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P08_01_2021To08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.6</ix:nonFraction>&#160;million in proceeds from issuance of common stock upon the closing of the Business Combination and $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P08_01_2021To08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">120.2</ix:nonFraction>&#160;million in proceeds from the PIPE Financing. The Company incurred transaction costs of $<ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="PAsOn08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.3</ix:nonFraction>&#160;million, consisting of legal, accounting and other professional services directly related to the Business Combination, $<ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="PAsOn08_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million of which were allocated to the warrant liabilities assumed and recognized as other expenses when incurred. The remaining $<ix:nonFraction name="srzn:BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" contextRef="PAsOn08_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.9</ix:nonFraction>&#160;million were recorded as a reduction of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital in the consolidated balance sheet. Legacy Surrozen was deemed the accounting acquirer in the Business Combination and the Business Combination was accounted for as a reverse recapitalization based on the following predominant factors: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Legacy Surrozen&#8217;s stockholders have the greatest voting interest in the Company; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company&#8217;s board and senior management are primarily composed of individuals associated with Legacy Surrozen; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Legacy Surrozen is the larger entity based on historical operating activity and has the larger employee base at the time of the Business Combination. </div></td></tr></table><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-14 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73307159" continuedAt="TextSelectionAppend_73307159_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307159_1" continuedAt="TextSelectionAppend_73307159_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307159_2" continuedAt="TextSelectionAppend_73307159_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307159_3"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, for accounting purposes, the reverse recapitalization was treated as the equivalent of Legacy Surrozen issuing stock for the net assets of Consonance, accompanied by a recapitalization. The net assets of Consonance are stated at historical cost, with <ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn08_31_2021_SurrozenIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> goodwill or other intangible assets recorded. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the business combination agreement, upon the closing of the Business Combination, (i)&#160;each share of redeemable convertible preferred stock of Legacy Surrozen (on an as converted to common stock basis) and each share of common stock of Legacy Surrozen, whether vested or unvested, was converted into <ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="P08_01_2021To08_31_2021" unitRef="Unit_pure" decimals="9" scale="0" format="ixt:num-dot-decimal">0.175648535</ix:nonFraction> shares of the Company&#8217;s common stock and (ii)&#160;each outstanding option to purchase common stock of Legacy Surrozen was converted into an option to purchase shares of the Company&#8217;s common stock based on an exchange ratio of <ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="9" scale="0" format="ixt:num-dot-decimal">0.175648535</ix:nonFraction>, or the Exchange Ratio, with corresponding adjustments to the exercise price. All issued and outstanding common stock, preferred stock and stock awards of Legacy Surrozen and corresponding capital amounts contained in the consolidated financial statements for the periods presented prior to the closing of the Business Combination have been retroactively restated to reflect the conversion. </div></ix:continuation><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307160"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 4. Fair Value Measurement </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records its financial assets and liabilities at fair value. The carrying amount of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable, restricted cash, accounts payable, and accrued and other liabilities, approximate their fair value due to their short-term maturities. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value as follows: </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 2&#8212;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div><ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307197"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,802</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,802</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government agency debt securities<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,982</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,982</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,130</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,324</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(2)</div>:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-15</ix:exclude> </div></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73307197" continuedAt="TextSelectionAppend_73307197_1"><ix:continuation id="TextSelection_73307160" continuedAt="TextSelectionAppend_73307160_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307160_1" continuedAt="TextSelectionAppend_73307160_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307160_2" continuedAt="TextSelectionAppend_73307160_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307160_3" continuedAt="TextSelectionAppend_73307160_4"><ix:continuation id="TextSelectionAppend_73307197_1"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:61%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307294">32,310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_73307293">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_73307292">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307291">32,310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,480</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,480</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,082</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,082</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,717</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,717</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,310</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,415</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,725</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(2)</div>:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307331">3,527</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_73307330">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_73307329">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307328">3,527</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_73307327">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307326">166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_73307325">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307324">166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_73307323">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307322">4,608</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_73307321">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307320">4,608</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307319">3,527</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307318">4,774</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="Fact_73307317">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_73307316">8,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">They are included in cash and cash equivalents on the consolidated balance sheets as of December&#160;31, 2022 and 2021. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">See the definition and discussion of Public Warrants, Private Placement Warrants and PIPE Warrants in Note 11. </div></td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Corporate bonds, commercial paper, foreign bonds, government bonds and government agency debt securities are classified as Level&#160;2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrants are classified as Level&#160;1 due to the use of an observable market quote in an active market. The Private Placement Warrants are classified as Level&#160;2 due to the use of observable market data for identical or similar liabilities. The fair value of each Private Placement Warrant was determined to be consistent with that of a Public Warrant because the Private Warrants are also subject to the make-whole redemption feature, which allows the Company to redeem both types of warrants on similar terms when the stock price is in the range of $<ix:nonFraction name="srzn:StockPriceToRedeemsWarrants" contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">10</ix:nonFraction> to $<ix:nonFraction name="srzn:StockPriceToRedeemsWarrants" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:num-dot-decimal">18</ix:nonFraction> per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PIPE Warrants were initially recorded in 2021 at fair value using a binomial lattice model. The PIPE Warrants were classified as Level&#160;3 at issuance because the fair value was measured based on significant inputs that are unobservable in the market. The significant unobservable input used in the fair value measurement of the PIPE Warrants is the expected volatility. The expected volatility was implied from the market price of the Company&#8217;s Public Warrants. The expected term was based on the remaining contractual term of the PIPE Warrants, and the risk-free interest rate was based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the expected term. The dividend rate is based on the historical rate, which the Company anticipated remaining at zero. <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307198">The key inputs into the binomial lattice model for the PIPE Warrants at the initial measurement were as follows: </ix:nonNumeric></div><ix:continuation id="TextSelection_73307198"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">August&#160;11,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn08_11_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_Y" decimals="2" scale="0" format="ixt:num-dot-decimal">5.01</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn08_11_2021_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">18.90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn08_11_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.81</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn08_11_2021_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-16</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73307160_4" continuedAt="TextSelectionAppend_73307160_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307160_5" continuedAt="TextSelectionAppend_73307160_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307160_6" continuedAt="TextSelectionAppend_73307160_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307160_7" continuedAt="TextSelectionAppend_73307160_8"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the adequate history of the market data of the Public Warrants as of December&#160;31, 2022 and 2021, the PIPE Warrants were remeasured at December&#160;31, 2022 and 2021 based on the observable market quote of the Public Warrants and are classified as Level&#160;2. The valuation technique was changed since the fair value of the Public Warrant is equally or more representative of the fair value of the PIPE Warrants. The fair value of each PIPE Warrant was determined to be consistent with that of a Public Warrant because the PIPE Warrants are also subject to the make-whole redemption feature, which allows the Company to redeem both types of warrants on similar terms. There were <ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn12_31_2022_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> changes to the valuation methods utilized, and there were <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> transfers of financial instruments for the year ended December&#160;31, 2022. </div><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s warrant liabilities for the years ended December&#160;31, 2022 and 2021 (in thousands):</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Public<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/> Placement<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Warrant<br/> Liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance, December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2020_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2020_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2020_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumption in Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" contextRef="P01_01_2021To12_31_2021_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,557</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" contextRef="P01_01_2021To12_31_2021_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">168</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" contextRef="P01_01_2021To12_31_2021_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,647</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,372</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value upon remeasurement<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2021To12_31_2021_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_73307381">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2021To12_31_2021_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_73307380">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2021To12_31_2021_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_73307379">39</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_73307378">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance, December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2021_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,527</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2021_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2021_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,608</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value upon remeasurement<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_73307377">3,354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_73307376">157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2022To12_31_2022_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_73307375">4,379</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="Fact_73307374">7,890</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repurchase (Note 9)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:ProceedsFromRepurchaseOfWarrants" contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:ProceedsFromRepurchaseOfWarrants" contextRef="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:ProceedsFromRepurchaseOfWarrants" contextRef="P01_01_2022To12_31_2022_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:ProceedsFromRepurchaseOfWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance, December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The change in fair value of the warrant liabilities was recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. </div></td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables provide the Company&#8217;s marketable securities by security type (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,817</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,023</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">221</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,802</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,389</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">242</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,148</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,136</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,920</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,725</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,717</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,760</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,082</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,588</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,573</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,753</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">98</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,655</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-17</ix:exclude></div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_73307160_8" continuedAt="TextSelectionAppend_73307160_9"><div></div></ix:continuation></div><div><div style="background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_73307160_9" continuedAt="TextSelectionAppend_73307160_10"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307160_10" continuedAt="TextSelectionAppend_73307160_11"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307160_11" continuedAt="TextSelectionAppend_73307160_12"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307160_12"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table indicates the length of the time that individual securities have been in a continuous unrealized loss position (dollars in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:47%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Investments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Investments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_Investments" decimals="0" scale="0" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,719</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_Investments" decimals="0" scale="0" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_Investments" decimals="0" scale="0" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">221</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_Investments" decimals="0" scale="0" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,082</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn12_31_2022_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_Investments" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_Investments" decimals="0" scale="0" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,717</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn12_31_2022" unitRef="Unit_Investments" decimals="0" scale="0" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">242</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="PAsOn12_31_2021" unitRef="Unit_Investments" decimals="0" scale="0" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,371</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and 2021, all short-term marketable securities had maturities of one year or less. All long-term marketable securities as of December&#160;31, 2021 had maturities of greater than one year but less than two years. There have been no significant realized gains or losses on the marketable securities during the years ended December&#160;31, 2022 and 2021. The Company periodically reviews the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investments for credit losses. All investments with unrealized losses have been in a loss position for less than 12 months. The Company determined that the unrealized loss was primarily attributed to changes in current market interest rates and not to credit quality. The Company does not intend to sell the marketable securities that are in an unrealized loss position, nor is it more likely than not that the Company will be required to sell the marketable securities before the recovery of the amortized cost basis, which may be at maturity. As a result, the Company did <ix:nonFraction name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognize any allowance for credit losses as of December&#160;31, 2022. </div></ix:continuation><ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307161"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 5. Balance Sheet Components </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,515</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,881</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">299</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">309</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">93</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,985</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,335</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,355</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,541</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expenses for the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.1</ix:nonFraction>&#160;million, respectively. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-18</ix:exclude></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73307161" continuedAt="TextSelectionAppend_73307161_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307161_1" continuedAt="TextSelectionAppend_73307161_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307161_2" continuedAt="TextSelectionAppend_73307161_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307161_3"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div></ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued and Other Liabilities </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other liabilities consist of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued payroll and related expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,964</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,887</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,666</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">638</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liability for early exercised stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,848</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,662</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 6. Leases </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2016, the Company entered into a lease agreement for office and lab space, which consists of approximately <ix:nonFraction name="us-gaap:AreaOfRealEstateProperty" contextRef="PAsOn08_31_2016_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis" unitRef="Unit_sqft" decimals="INF" scale="0" format="ixt:num-dot-decimal">32,813</ix:nonFraction> square feet of rental space in South San Francisco, California. The office space lease is classified as an operating lease. The initial lease term commenced in May 2017 and ends in <ix:nonNumeric name="srzn:OperatingLeaseMonthOfExpiryOfLease" contextRef="P01_01_2022To12_31_2022_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis" format="ixt:date-monthname-year-en">April 2025</ix:nonNumeric>, with rent payments escalating each year. The Company has options to extend the lease for additional years, but the exercise of the option was not reasonably certain. In connection with the lease, the Company maintains a letter of credit for the benefit of the landlord in the amount of $<ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn12_31_2022_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million, which is recorded as restricted cash in the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the Company entered into a lease agreement for a term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn01_31_2020" format="ixt-sec:durmonth">18</ix:nonNumeric> months commencing June 2020 for approximately <ix:nonFraction name="us-gaap:AreaOfRealEstateProperty" contextRef="PAsOn01_31_2020" unitRef="Unit_sqm" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,478</ix:nonFraction> square feet of office space. This office space lease, which was classified as an operating lease, was amended in September 2021 and expired in June 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The operating lease expense for the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction>&#160;million. </div> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aggregate future minimum rental payments under the operating leases as of December&#160;31, 2022, were as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,596</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,670</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">891</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,602</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="srzn:ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents supplemental information related to the Company&#8217;s operating facility leases: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,743</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,856</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear">2.33</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">3.25</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">8.48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">8.43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-19 </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div> <ix:nonNumeric name="srzn:CollaborationAndLicenseAgreementsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Note 7. Collaboration and License Agreements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration and License Agreement with Boehringer Ingelheim International GmbH </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2022, the Company executed the CLA with BI to research, develop and commercialize Fzd4 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibodies designed using the Company&#8217;s SWAP<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#8482;</div> technology, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SZN-413.</div> The Company and BI are conducting partnership research focused on SZN-413 during a one-year period, which BI has the right to extend by up to six months. The Company granted BI an exclusive, royalty-bearing, worldwide, sublicensable license, under the applicable patents and know-how, to develop, manufacture and commercialize, for all uses, one lead and two back-up Fzd4 bi-specific antibodies selected by BI and their derivatives. After an initial period of joint research, BI shall be responsible for all further research, preclinical and clinical development, manufacturing, regulatory approvals, and commercialization of licensed products at its expense. Unless terminated earlier, or expiring on account of BI not selecting at least one Fzd4 bi-specific antibody within sixty days after the end of the partnership research, the CLA will remain effective, on a country-by-country and product-by-product basis, until the expiration of BI&#8217;s royalty obligations. BI has the right to terminate the CLA for any reason after a specified notice period. Each party has the right to terminate the CLA on account of the other party&#8217;s bankruptcy or material, uncured breach. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the CLA, BI agreed to pay a non-refundable upfront payment of&#160;</div>$<ix:nonFraction name="srzn:NonRefundableUpfrontPaymentReceived" contextRef="P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.5</ix:nonFraction>&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million less any applicable withholding tax, success-based milestone payments up to a total of</div> $<ix:nonFraction name="srzn:SuccessBasedMilestonePayments" contextRef="P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">587.0</ix:nonFraction>&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million and mid-single digit to low-double digit royalties on net sales of the licensed products should any reach commercialization. The royalty payments will be subject to reduction due to patent expiration, generic competition and payments made under certain licenses for third-party intellectual property. The Company received</div> $<ix:nonFraction name="srzn:UpfrontPayment" contextRef="P11_01_2022To11_30_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.5</ix:nonFraction>&#160;million of the upfront payment from BI in November 2022. The associated withholding tax of $<ix:nonFraction name="srzn:AssociatedWithholdingTax" contextRef="P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction>&#160;million is expected to be refunded to the Company in 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the CLA is within the scope of ASC 606. The Company evaluated the promised goods and services and determined that the license to the Company&#8217;s intellectual property granted to BI represented one performance obligation for the purposes of conducting the partnership research and further development on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SZN-413.</div> The transaction price was determined to be $<ix:nonFraction name="srzn:TransactionPrice" contextRef="P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.5</ix:nonFraction>&#160;million, which is the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment. Variable consideration related to future milestones was fully constrained because the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based royalties, the Company determined that the license is the predominant item to which the royalties relate to. Accordingly, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all the royalty has been allocated has been satisfied (or partially satisfied). The Company will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. During the year ended December&#160;31, 2022, the Company recognized the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment of $<ix:nonFraction name="srzn:NonRefundableUpfrontPaymentReceived" contextRef="P01_01_2022To12_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.5</ix:nonFraction>&#160;million as collaboration and license revenue at a point in time upon delivery of the license. The associated withholding tax of $<ix:nonFraction name="srzn:AssociatedWithholdingTax" contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapBalanceSheetLocationAxis_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction>&#160;million to be refunded was recognized as accounts receivable as of December&#160;31, 2022. </div> </ix:nonNumeric><ix:nonNumeric name="srzn:LicenseAgreementsDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307164"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Note 8. License Agreements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stanford License Agreements </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the Company entered into a license agreement with Stanford University, or the 2016 Stanford Agreement, which was amended in July 2016, October 2016 and January 2021, pursuant to which the Company obtained from Stanford a worldwide, exclusive, sublicensable license under certain patents, rights, or licensed patents and technology related to its engineered Wnt surrogate molecules to make, use, import, offer to sell and sell products that are claimed by the licensed patents or that use or incorporate such technology, or </div> <ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-20</div></div></div></ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;;text-indent: 0px;"></div></ix:exclude> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_73307164" continuedAt="TextSelectionAppend_73307164_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);;text-indent: 0px;"/></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_73307164_1" continuedAt="TextSelectionAppend_73307164_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;text-indent: 0px;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307164_2" continuedAt="TextSelectionAppend_73307164_3"><ix:exclude><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SURROZEN, INC. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the Consolidated Financial Statements </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;;text-indent: 0px;">licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases. The Company agreed to pay Stanford (i)&#160;nominal annual license maintenance fees which are creditable against earned royalties owed to Stanford for the same year, (ii)&#160;an aggregate of up to $<ix:nonFraction name="srzn:PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" contextRef="P03_01_2016To03_31_2016_MaximumMembersrtRangeAxis_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction>&#160;million for the achievement of specified development and regulatory milestones, and (iii)&#160;an aggregate of up to $<ix:nonFraction name="srzn:PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" contextRef="P03_01_2016To03_31_2016_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction>&#160;<div style="display:inline;">million for achievement of specified sales milestones. Stanford is also entitled to receive royalties from the Company equal to a very low single digit percentage of the Company&#8217;s and its sublicensees&#8217; net sales of licensed products that are covered by a valid claim of a licensed patent. Additionally, the Company agreed to pay Stanford a sub-teen double digit percentage of certain consideration the Company receives as a result of granting sublicenses to the licensed patents. However, the Company and Stanford may be able to negotiate a lower non-royalty sublicense percentage based on then-current value of the licensed patents for each sublicense product. If the Company is acquired, it agreed to pay a one-time change of control fee in the low six figures. Stanford retains the right under the 2016 Stanford Agreement, on behalf of itself, Stanford Hospital and Clinics, the University of Washington and all other non-profit research institutions, to practice the licensed patents and technology for any non-profit purpose. The licensed patents and technology are additionally subject to a non-exclusive, irrevocable, worldwide license held by the Howard Hughes Medical Institute to practice the licensed patents and technology for its research purposes, but with no right to assign or sublicense.&#160;</div></div></ix:continuation></div></div> </div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307164_3" continuedAt="TextSelectionAppend_73307164_4"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"></div> </ix:exclude> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2018, the Company entered into another license agreement with Stanford, or the 2018 Stanford Agreement, pursuant to which the Company obtained from Stanford a worldwide, exclusive, sublicensable license under certain patent rights related to its surrogate </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">R-spondin</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> proteins, or the licensed patents, to make, use, import, offer to sell and sell products that are claimed by the licensed patents, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases, or the exclusive field. Additionally, Stanford granted the Company a worldwide, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> sublicensable license under the licensed patents to make and use licensed products for research and development purposes in furtherance of the exclusive field and a worldwide, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> license to make, use and import, but not to offer to sell or sell licensed products in any other field of use. The Company agreed to pay Stanford an aggregate of up to $</div><ix:nonFraction name="srzn:PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" contextRef="P06_01_2018To06_30_2018_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the achievement of specified development and regulatory milestones. Stanford is also entitled to receive royalties from the Company equal to a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-single</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> digit percentage of the Company&#8217;s and its sublicensees&#8217; net sales of licensed products. Additionally, Stanford is entitled to receive a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> payment in the low six figures for each sublicense of the licensed patents that the Company grants to a third party and, if the Company is acquired, a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> nominal change of control fee.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, the Company incurred research and development expenses of approximately $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million under the Stanford Agreements, pertaining to the sublicense fee in connection with the upfront payment received from BI. For the year ended December&#160;31, 2021, the Company incurred research and development expenses of approximately $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million under the Stanford Agreements. <ix:nonFraction name="srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones" contextRef="P01_01_2022To12_31_2022_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction> milestones have been achieved as of December&#160;31, 2022. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UCSF License and Option Agreements </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September and October 2016, the Company entered into two separate license and option agreements with The Regents of the University of California, or the UCSF Agreements, pursuant to which the Company obtained exclusive licenses from UCSF for internal research and antibody discovery purposes and an option to negotiate with UCSF to obtain an exclusive license under UCSF&#8217;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from the Company&#8217;s use of such library, or licensed products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In January 2020, the Company amended and restated the UCSF Agreements to provide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> licenses to make and use a certain human Fab na&#239;ve phage display library and to make and use a certain phage display llama VHH single domain antibody library for internal research and antibody discovery purposes and an </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-21</ix:exclude> </div> </ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73307164_4" continuedAt="TextSelectionAppend_73307164_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307164_5" continuedAt="TextSelectionAppend_73307164_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307164_6" continuedAt="TextSelectionAppend_73307164_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307164_7"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div> </ix:exclude> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">option to negotiate with UCSF to obtain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> commercial license under UCSF&#8217;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from the Company&#8217;s use of such library, or licensed products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In March 2022, the Company exercised the option under the UCSF Agreements and entered into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> commercial license agreement to make and use licensed products derived from the phage display llama VHH single domain antibody library. Under the commercial license agreement, the Company paid UCSF a nominal license issue fee and agreed to pay a nominal annual license maintenance fee, five- to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-digit</div> payments per licensed product upon achievement of a regulatory milestone, nominal minimum annual royalties and earned royalties equal to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-single</div> digit percentage of the Company&#8217;s and the Company&#8217;s sublicensees&#8217; net sales of licensed products. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, the Company incurred research and development expenses of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022_StanfordMemberusgaapRelatedPartyTransactionAxis_UCSFLicenseAndOptionAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million under the UCSF Agreements as a result of the CLA. For the year ended December&#160;31, 2021, the Company incurred research and development expenses of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021_StanfordMemberusgaapRelatedPartyTransactionAxis_UCSFLicenseAndOptionAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,000</ix:nonFraction> under the UCSF Agreements.<ix:nonFraction name="srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones" contextRef="P01_01_2022To12_31_2022_StanfordMemberusgaapRelatedPartyTransactionAxis_UCSFLicenseAndOptionAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"> No</ix:nonFraction> milestones have been achieved as of December&#160;31, 2022. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distributed Bio Subscription Agreement </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2016, the Company entered into, and in January 2019 the Company amended, an antibody library subscription agreement with Charles River Laboratories International, Inc., formerly known as Distributed Bio, or the Distributed Bio Agreement, in which the Company obtained from Distributed Bio a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license to use Distributed Bio&#8217;s antibody library to identify antibodies directed to an unlimited number of the Company&#8217;s proprietary targets and to make, use, sell, offer for sale, import and exploit products incorporating the antibodies that the Company identifies, or licensed products. In consideration for the rights granted to the Company under the Distributed Bio Agreement, the Company paid Distributed Bio a nominal upfront fee and an additional nominal fee upon entering into the amendment. The Company agreed to pay Distributed Bio an annual fee in the low six figures after the first three years. Additionally, the Company agreed to pay Distributed Bio an aggregate of $<ix:nonFraction name="srzn:PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" contextRef="P09_01_2016To09_30_2016_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.9</ix:nonFraction>&#160;million for each licensed product that achieves specified development, regulatory and commercial milestones and royalties equal to a very low single digit percentage of the Company&#8217;s and its sublicensees&#8217; net sales of licensed products. The Company&#8217;s obligation to pay royalties will end for each licensed product ten years after its first commercial sale. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2022 and 2021, the Company incurred research and development expenses of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million under the Distributed Bio Agreement, including the milestone payment of $<ix:nonFraction name="srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones" contextRef="P01_01_2022To12_31_2022_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones" contextRef="P01_01_2021To12_31_2021_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,000</ix:nonFraction>, respectively, as the Company achieved milestones with regard to the Phase 1 clinical trial for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SZN-1326.</div></div> </ix:continuation><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307166"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 9. Related Party Transactions </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Repurchase of Common Stock and Common Stock Warrants </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2022, the Company entered into a securities purchase agreement with entities affiliated with Consonance Capital Management LP, collectively the Consonance Entities. Pursuant to the agreement, the Company repurchased <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="P12_12_2022To12_12_2022" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">5.4</ix:nonFraction>&#160;million shares of common stock and warrants to purchase <ix:nonFraction name="srzn:ClassOfWarrantsRepurchased" contextRef="PAsOn12_12_2022" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction>&#160;million shares of common stock from the Consonance Entities for an aggregate purchase price of approximately $<ix:nonFraction name="srzn:CommonStockTotalPurchasePrice" contextRef="P12_12_2022To12_12_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.7</ix:nonFraction>&#160;million, or the Repurchase. Following the Repurchase, the Consonance Entities no longer hold any shares of common stock or warrants. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock repurchased were constructively retired and the common stock warrants repurchased were subsequently canceled. The total purchase price was allocated to the repurchase of common stock warrants based on the fair value of the warrants remeasured on the repurchase date, resulting in the</div> <ix:exclude><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-22 </div></div></div></ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_73307166" continuedAt="TextSelectionAppend_73307166_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_73307166_1" continuedAt="TextSelectionAppend_73307166_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307166_2"><ix:exclude><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SURROZEN, INC. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to the Consolidated Financial Statements </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;">derecognition of warrant liabilities of $<ix:nonFraction name="srzn:WarrantLiability" contextRef="PAsOn12_12_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million. The remaining $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P12_12_2022To12_12_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction>&#160;million allocated to the repurchase of common stock was recorded as a reduction of equity on the consolidated balance sheets. <br/><br/></div></ix:continuation></div></div> </div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;">Note 10. Stockholders&#8217; Equity</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2022, the Company entered into the Equity Purchase Agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, pursuant to which Lincoln Park is obligated to purchase up to $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">50.0</ix:nonFraction>&#160;million of the Company&#8217;s common stock with a maximum of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">7.0</ix:nonFraction>&#160;million shares from time to time at the Company&#8217;s sole discretion over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="srzn:CommonStockPurchaseCommitmentPeriod" contextRef="P04_27_2022To04_27_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">36-month</ix:nonNumeric></div> period commencing on April&#160;27, 2022. The Company also entered into a registration rights agreement with Lincoln Park pursuant to which the Company filed with the SEC the registration statement to register for resale under the Securities Act of 1933, as amended, the shares of common stock that have been or may be issued to Lincoln Park under the Equity Purchase Agreement. The registration statement was effective on April&#160;5, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the Equity Purchase Agreement, the Company issued <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million shares of common stock to Lincoln Park with the fair value of $<ix:nonFraction name="us-gaap:CommonStockOtherValueOutstanding" contextRef="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million as consideration for Lincoln Park&#8217;s commitment to purchase the Company&#8217;s common stock, which was included in other income (expense), net on the consolidated statements of operations and comprehensive loss. In the event that the Company sells its common stock under the Equity Purchase Agreement for an aggregate price equal to or greater than $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.0</ix:nonFraction>&#160;million, the Company shall pay an additional commitment fee of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million in cash to Lincoln Park. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As contemplated by the Equity Purchase Agreement, and so long as the closing price of the Company&#8217;s common stock exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.00</ix:nonFraction> per share, the Company may direct Lincoln Park, at its sole discretion, to purchase up to <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> shares of its common stock, or the Regular Purchase Share Limit, on any business day at a purchase price per share equal to the lower of: (i)&#160;the lowest price of the Company&#8217;s common stock on the applicable purchase date and (ii)&#160;the average of the three lowest closing prices of the Company&#8217;s common stock during the ten consecutive business days preceding such purchase date. <ix:nonNumeric name="us-gaap:SaleOfStockDescriptionOfTransaction" contextRef="P01_01_2022To12_31_2022_LincolnParkMemberdeiLegalEntityAxis">The Regular Purchase Share Limit may be increased to up to <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn02_28_2022_ClosingSalePriceNotBelow1000PerShareMemberusgaapMeasurementInputTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,000</ix:nonFraction> shares and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn02_28_2022_ClosingSalePriceNotBelow1200PerShareMemberusgaapMeasurementInputTypeAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,000</ix:nonFraction> shares if the closing price of the Company&#8217;s common stock is not below $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_28_2022_ClosingSalePriceNotBelow1000PerShareMemberusgaapMeasurementInputTypeAxis_LincolnParkMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per share and $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_28_2022_ClosingSalePriceNotBelow1200PerShareMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.00</ix:nonFraction> per share, respectively. Any single purchase of the Company&#8217;s common stock shall not exceed $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P02_01_2022To02_28_2022_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction> million.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may also direct Lincoln Park to purchase additional shares no less than the Regular Purchase Share Limit and no greater than <ix:nonFraction name="srzn:PurchaseOfAdditionalShares" contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million shares at a <ix:nonNumeric name="srzn:PurchasePricePerShareOfAdditionalShares" contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis">purchase price per share equal to 96% of the lower of (i) the closing price of the Company&#8217;s common stock on the purchase date and (ii) the volume weighted average price of the Company&#8217;s common stock on the purchase date.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company has <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_LincolnParkMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction>t sold any shares of common stock under the Equity Purchase Agreement. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-the-Market</div></div> Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> filed in December 2022, the Company entered into a sales agreement with Guggenheim Securities, LLC to issue and sell the Company&#8217;s common stock up to $<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022_GuggenheimSecuritiesLlcMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.0</ix:nonFraction>&#160;million, or the 2022 ATM. The compensation payable to Guggenheim is equal to <ix:nonFraction name="srzn:CompensationPayable" contextRef="PAsOn12_31_2022_GuggenheimSecuritiesLlcMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.0</ix:nonFraction>% of the gross sales price of any shares sold through it pursuant to the sales agreement. As of December&#160;31, 2022, the Company has <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_LincolnParkMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction>t sold any shares of common stock under the 2022 ATM. </div></ix:nonNumeric><ix:nonNumeric name="srzn:CommonStockWarrantsDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307170"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 11. Common Stock Warrants </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, Legacy Surrozen, as the accounting acquirer, was deemed to assume <ix:nonFraction name="srzn:BusinessCombinationInitialWarrantsIssued" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.1</ix:nonFraction>&#160;million warrants held by Consonance&#8217;s stockholders, or the Public Warrants, and <ix:nonFraction name="srzn:AssumedWarrants" contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million warrants </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-23</ix:exclude> </div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_73307170" continuedAt="TextSelectionAppend_73307170_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307170_1" continuedAt="TextSelectionAppend_73307170_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307170_2" continuedAt="TextSelectionAppend_73307170_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307170_3" continuedAt="TextSelectionAppend_73307170_4"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div> </ix:exclude> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">held by Consonance&#8217;s sponsor, or the Private Placement Warrants. In addition, immediately after the consummation of the Business Combination, certain investors subscribed for and purchased an aggregate of <ix:nonFraction name="srzn:ClassOfWarrantOrRightIssued" contextRef="PAsOn12_31_2021_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction>&#160;million units in the PIPE Financing, consisting of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2021_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction>&#160;million warrants, or the PIPE Warrants. In conjunction with the Repurchase (see Note 9), the Company repurchased <ix:nonFraction name="srzn:ClassOfWarrantsRepurchased" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million Public Warrants, <ix:nonFraction name="srzn:ClassOfWarrantsRepurchased" contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>&#160;million Private Placement Warrants and <ix:nonFraction name="srzn:ClassOfWarrantsRepurchased" contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction>&#160;million PIPE Warrants. <ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307207">As of December&#160;31, 2022, the following common stock warrants were outstanding (in thousands, except per share amounts): </ix:nonNumeric></div> <ix:continuation id="TextSelection_73307207"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:49%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Type</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price&#160;per<br/> Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="srzn:ClassOfWarrantOrRightClassification" contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">Liability</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en">August 12, 2026</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">2,733</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="srzn:ClassOfWarrantOrRightClassification" contextRef="P01_01_2022To12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis">Liability</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en">August 12, 2026</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">3,174</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="3" format="ixt:num-dot-decimal">5,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:continuation> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Public Warrants </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole Public Warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share, at any time commencing on November&#160;23, 2021 and terminating at the earlier of <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="PAsOn12_31_2022" format="ixt:date-monthname-day-year-en">August 12, 2026</ix:nonNumeric> or upon redemption or liquidation. The exercise price and number of shares issuable upon exercise of the Public Warrants may be adjusted in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. The Company would not be obligated to deliver any shares of common stock pursuant to the exercise of a Public Warrant and would have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act with respect to the common stock underlying the Public Warrants is then effective. The registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> to register for resale under the Securities Act of 1933, as amended, was effective in November 2021. The Company will use its commercially reasonable efforts to maintain the effectiveness of the registration statement until the expiration or redemption of the Public Warrants. If the Company fails to have maintained an effective registration statement, the Public Warrant holders have the right to exercise the Public Warrants on a cashless basis until such time as there is an effective registration statement. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the outstanding Public Warrants at a price of $<ix:nonFraction name="srzn:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="P01_01_2022To12_31_2022_CommonStock1MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction> per warrant if the closing price of common stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2022_CommonStock1MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share capitalizations, reorganizations, recapitalizations and similar transaction). Additionally, the Company may redeem the outstanding Public Warrants at a price of $<ix:nonFraction name="srzn:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" contextRef="P01_01_2022To12_31_2022_CommonStock2MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction> per warrant if the closing price of common stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2022_CommonStock2MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share capitalizations, reorganizations, recapitalizations and similar transaction). Notice of redemption shall be mailed to the Public Warrant holders no less than <ix:nonNumeric name="srzn:WarrantNoticePeriodPriorToRedemptionDate" contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">30</ix:nonNumeric> days prior to the redemption date, or the Redemption Period. If the closing price of common stock equals or exceeds $<ix:nonFraction name="srzn:WarrantRedemptionConditionMinimumSharePriceScenarioOne" contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per share and is less than $<ix:nonFraction name="srzn:WarrantRedemptionConditionMinimumSharePriceScenarioTwo" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share, during the Redemption Period, the Public Warrant holders may elect to exercise their Public Warrants on a cashless basis based on a make-whole table. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no event will the Company be required to net cash settle the Public Warrants. The Public Warrant holders do not have the rights or privileges of common stockholders and any voting rights until they exercise their Public Warrants and receive common stock. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Placement Warrants </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants (including the common stock issuable upon exercise of the Private Placement Warrants) will not be redeemable so long as they are held by Consonance Life Sciences, a Cayman </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-24</ix:exclude> </div> </ix:continuation></div></div> <ix:continuation id="TextSelectionAppend_73307170_4" continuedAt="TextSelectionAppend_73307170_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_73307170_5" continuedAt="TextSelectionAppend_73307170_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307170_6" continuedAt="TextSelectionAppend_73307170_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307170_7"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Islands limited liability company, or the Sponsor, or its permitted transferees. The Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. There were no Private Placement Warrants outstanding as of December&#160;31, 2022. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PIPE Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole PIPE Warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share, at any time commencing on November&#160;23, 2021 and terminating on <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt:date-monthname-day-year-en">August 12, 2026</ix:nonNumeric>. The PIPE Warrants are the same in all respects as the Public Warrants except that the PIPE Warrants were not redeemable before August&#160;12, 2022. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Classification </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrants, Private Placement Warrants and PIPE Warrants are not considered indexed to the Company&#8217;s common stock as certain provisions of the warrant agreements could change the settlement amount of these warrants. As a result, they are classified as liabilities and recorded at fair value with subsequent change in their respective fair value recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. See Note 4 for the discussion of warrant valuations. </div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307171"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 12. Stock-Based Compensation Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains the 2021 Equity Incentive Plan, or the 2021 Plan, which provides for the granting of stock awards to employees, directors and consultants. Options granted under the 2021 Plan may be either incentive stock options or nonqualified stock options to purchase common stock. Options granted under the 2021 Plan expire no later than <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant. <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" contextRef="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis">Options under the 2021 Plan generally vest over four years.</ix:nonNumeric> As of December&#160;31, 2022, there were <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">3.7</ix:nonFraction>&#160;million shares of common stock available for issuance under the 2021 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Legacy Surrozen maintained the 2015 Stock Plan, or the 2015 Plan, which provided for the granting of options to purchase shares of common stock to officers, employees, directors, consultants and key persons who provide services to the Company. Options under the 2015 Plan have a term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2022To12_31_2022_TwoThousandFifteenStockPlan1MemberusgaapPlanNameAxis" format="ixt-sec:duryear">10</ix:nonNumeric> years and generally vested over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="srzn:CliffVestingPeriod" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:durwordsen">one-year</ix:nonNumeric></div> cliff vesting. In conjunction with the Business Combination, options and the corresponding exercise price under the 2015 Plan were converted into the awards under the 2021 Equity Incentive Plan based on the Exchange Ratio. Each converted option is subject to the same terms and conditions as were applicable to the corresponding options under the 2015 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted the 2021 Employee Stock Purchase Plan, or the ESPP, in August 2021. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction name="srzn:PercentageOfDiscountPayrollDeductions" contextRef="P01_01_2022To12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction>% of their eligible compensation, subject to plan limitations. An offering period under the ESPP consists of four <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> purchase periods, unless otherwise determined by the Company. <ix:nonNumeric name="srzn:CommonStockTradingDiscription" contextRef="P01_01_2022To12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis">The eligible employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the purchase day.</ix:nonNumeric> As of December&#160;31, 2022, there were <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million shares of common stock available for issuance under the ESPP. During the year ended December&#160;31, 2022, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million shares were issued under the ESPP. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-25</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73307171" continuedAt="TextSelectionAppend_73307171_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307171_1" continuedAt="TextSelectionAppend_73307171_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307171_2" continuedAt="TextSelectionAppend_73307171_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307171_3" continuedAt="TextSelectionAppend_73307171_4"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Option Exchange </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2022, the Company&#8217;s Compensation Committee authorized and approved a stock option exchange whereby certain outstanding stock options held by <ix:nonFraction name="dei:EntityNumberOfEmployees" contextRef="PAsOn10_31_2022" unitRef="Unit_Employees" decimals="0" scale="0" format="ixt:num-dot-decimal">59</ix:nonFraction> employees were exchanged for stock options on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis with an exercise price at the current market price on the date of the exchange. As a result of this exchange, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn10_31_2022" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction>&#160;million outstanding stock options, with a weighted average exercise price of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="P10_01_2022To10_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">8.81</ix:nonFraction> per share, were exchanged for <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn10_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction>&#160;million new stock options under the 2021 Plan with an exercise price of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" contextRef="P10_01_2022To10_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.16</ix:nonFraction> per share. The vesting terms and expiration dates of the new stock options remain unchanged from the original stock options. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The option exchange was treated as an option modification for accounting purposes and resulted in the incremental expense of $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million. $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="P01_01_2022To12_31_2022_VestedMemberusgaapVestingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million of the total incremental expense associated with the vested options was recognized on the modification date. The remaining $<ix:nonFraction name="us-gaap:StockOptionPlanExpense" contextRef="P01_01_2022To12_31_2022_UnvestedMemberusgaapVestingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>&#160;million associated with the unvested options as of the modification date will be recognized over the remainder of the original requisite service period. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of option activity is set forth below (shares in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:47%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> Remaining<br/> Contractual&#160;Life<br/> (In years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value<br/> (In&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding &#8211; December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">8.43</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">79</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.77</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding &#8211; December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,896</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">8.44</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable &#8211; December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,430</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">7.48</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest is the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock at December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intrinsic value of options exercised during the year ended December&#160;31, 2021 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction>&#160;million. <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction> options were exercised during the year ended December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&#160;31, 2022 and 2021, the Company granted options with a weighted-average grant-date fair value of $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.28</ix:nonFraction> per share and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.36</ix:nonFraction> per share, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Awards </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s RSA activity (shares in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSAs, unvested at December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.39</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSAs, unvested at December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-26</ix:exclude> </div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_73307171_4" continuedAt="TextSelectionAppend_73307171_5"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_73307171_5" continuedAt="TextSelectionAppend_73307171_6"><div><div style="background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307171_6"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div> </ix:exclude> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of RSAs vested during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="P01_01_2021To12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million, respectively. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Options </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of options is estimated at the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" format="ixt-sec:duryear">6.00</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" format="ixt-sec:duryear">6.01</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">81.07</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">71.23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.03</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded in the consolidated statements of operations and comprehensive loss related to options and RSAs was as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,612</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">736</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, there was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.9</ix:nonFraction>&#160;million of stock-based compensation expense to be recognized over a weighted-average period of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">2.5</ix:nonNumeric> years. </div> </ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307172"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 13. Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> provision for income taxes was recorded for the years ended December&#160;31, 2022 and 2021. The Company has incurred net operating losses for all the periods presented. The Company accounts for income taxes in accordance with the asset and liability method, which requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is not likely to be realized and, accordingly, has provided a full valuation allowance. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-27</ix:exclude> </div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_73307172" continuedAt="TextSelectionAppend_73307172_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307172_1" continuedAt="TextSelectionAppend_73307172_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307172_2" continuedAt="TextSelectionAppend_73307172_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307172_3" continuedAt="TextSelectionAppend_73307172_4"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div> </ix:exclude> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#8217;s net deferred tax assets consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,985</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,826</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Section&#160;174 capitalized expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:DeferredTaxAssetsCapitalizedExpenses" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,812</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:DeferredTaxAssetsCapitalizedExpenses" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,775</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:DeferredTaxAssetsLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,096</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:DeferredTaxAssetsLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,521</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrual and reserves</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">590</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee retention credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:DeferredTaxAssetsEmployeeRetentionCredits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:DeferredTaxAssetsEmployeeRetentionCredits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">201</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized intangible costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:DeferredTaxAssetsCapitalizedIntangibleAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">176</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:DeferredTaxAssetsCapitalizedIntangibleAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">66</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,867</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,202</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="srzn:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">962</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,202</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total net deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net valuation allowance increased by $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.7</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022 and 2021. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had net operating loss, or NOL, carryforwards of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">139.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">53.0</ix:nonFraction>&#160;million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. NOL carryforwards generated after 2018 for federal tax reporting purposes of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteTaxYearMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">127.0</ix:nonFraction>&#160;million have an indefinite carryforward period. The remaining federal and state net operating loss carryforwards begin expiring in <ix:nonNumeric name="srzn:TaxCreditCarryForwardsExpirationStartYear" contextRef="P01_01_2022To12_31_2022">2036</ix:nonNumeric>. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had research and development credit carryforwards of approximately $<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.8</ix:nonFraction>&#160;million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. The federal credit carryforwards begin expiring in <ix:nonNumeric name="srzn:TaxCreditCarryForwardsExpirationStartYear" contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">2036</ix:nonNumeric> and the state credits carry forward <ix:nonNumeric name="srzn:StateTaxCreditCarryForwardsExpiration" contextRef="P01_01_2022To12_31_2022_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">indefinitely</ix:nonNumeric>. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning January&#160;1, 2022, the Tax Cuts and Jobs Act, or the Tax Act, eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code, or the IRC, Section&#160;174. The capitalized expenses are amortized over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:CapitalizedContractCostAmortizationPeriod" contextRef="PAsOn01_01_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" format="ixt-sec:durwordsen">5-year</ix:nonNumeric></div> period for domestic expenses and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:CapitalizedContractCostAmortizationPeriod" contextRef="PAsOn01_01_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" format="ixt-sec:durwordsen">15-year</ix:nonNumeric></div> period for foreign expenses. As a result of this provision of the Tax Act, deferred tax assets related to capitalized research expenses increased by $<ix:nonFraction name="srzn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" contextRef="PAsOn01_01_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.7</ix:nonFraction>&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section&#160;382 of the Internal </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-28</ix:exclude> </div> </ix:continuation></div><ix:continuation id="TextSelectionAppend_73307172_4" continuedAt="TextSelectionAppend_73307172_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307172_5" continuedAt="TextSelectionAppend_73307172_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307172_6" continuedAt="TextSelectionAppend_73307172_7"><ix:exclude> <div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307172_7" continuedAt="TextSelectionAppend_73307172_8"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:exclude><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue Code. As a result of such ownership changes, the Company&#8217;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be limited and may expire unutilized. Such impairment of tax losses and tax credits would reduce the deferred tax asset and corresponding valuation allowance, as a result of the limitation. The Company completed an assessment of the available NOLs under Section&#160;382 and determined that the Company underwent an ownership change in September 2020. As a result of the annual limitations caused by the ownership change, it was estimated the approximately $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction>&#160;million of federal tax credit and $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.4</ix:nonFraction>&#160;million of California NOL will expire unrealized for income tax purposes, and such amounts are excluded from the carryforward balances as of December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. <ix:nonNumeric name="us-gaap:IncomeTaxExaminationDescription" contextRef="P01_01_2022To12_31_2022">An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</ix:nonNumeric> The unrecognized tax benefits, if recognized, would not have an impact on the Company&#8217;s effective tax rate assuming the Company continues to maintain a full valuation allowance position. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. </div><ix:nonNumeric name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the Company&#8217;s unrecognized tax benefits is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at beginning of the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">974</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">921</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions based on tax positions related to current year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">654</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">480</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reductions based on tax positions of prior year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at end of the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">974</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S. federal and California tax jurisdictions. As of the date these financial statements were issued, the Company is not under examination by any income tax authority. The federal and state income tax returns from December&#160;31, 2016 to December&#160;31, 2021 remain subject to examination. </div><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the statutory U.S. federal tax rate to the Company&#8217;s effective tax rate is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">2.78</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.72</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.70</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">2.26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">26.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">16.92</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">NOL and tax credits limited under 382</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain on warrant liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="srzn:EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">0.57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;21, 2020, the Consolidated Appropriations Act, 2021, or the Appropriations Act, was signed into law which expanded and extended some of CARES Act provisions, including the expansion of the employee retention credits. The Company claimed employee retention credits of $<ix:nonFraction name="srzn:ReinsuranceRetentionsPolicyAmountRetained" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="srzn:ReinsuranceRetentionsPolicyAmountRetained" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million for the 2021 and 2020 tax years. The Company will recognize the benefit of those credits as the refunds are received. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-29</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73307172_8" continuedAt="TextSelectionAppend_73307172_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307172_9" continuedAt="TextSelectionAppend_73307172_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307172_10" continuedAt="TextSelectionAppend_73307172_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307172_11"><ix:exclude><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div></ix:exclude><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inflation Reduction Act of 2022, or the IRA, which was signed into law in August 2022, includes several provisions that are specifically applicable to corporations. Among other changes, it created a new corporate alternative minimum tax based on adjusted financial statement income and imposes a 1% excise tax on corporate stock repurchases. The effective date of these provisions is January&#160;1, 2023. The Company is evaluating how the enactment of the IRA will have an impact on its consolidated financial statements but does not expect that the provisions of the IRA will have a material impact for the year ended December&#160;31, 2022. </div></ix:continuation><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 14. Commitments and Contingencies </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i)&#160;the Company&#8217;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship with the Company, (ii)&#160;contracts under which the Company must indemnify directors and certain officers for liabilities arising out of their relationship with the Company, (iii)&#160;contracts under which the Company may be required to indemnify customers or partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights and (iv)&#160;procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts the Company may have to modify the accused infringing intellectual property and/or refund amounts received. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains director and officer insurance, which may cover certain liabilities arising from the Company&#8217;s obligation to indemnify its directors and certain officers. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the date of the consolidated financial statements were issued, the Company has not incurred any material costs or accrued any liabilities related to indemnification obligations. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result, the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Management is not aware of any pending or threatened litigation. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73307174"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 15. 401(k) Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted a 401(k) retirement savings plan, or the 401(k) Plan for all eligible employees. Each participant may contribute <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> or post- tax compensation, up to annual statutory limits. The 401(k) Plan also </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-30</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73307174" continuedAt="TextSelectionAppend_73307174_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307174_1" continuedAt="TextSelectionAppend_73307174_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73307174_2" continuedAt="TextSelectionAppend_73307174_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73307174_3"><ix:exclude> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SURROZEN, INC. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to the Consolidated Financial Statements </div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> </ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">permits the Company to make discretionary and matching contributions, subject to established limits and a vesting schedule. Each year, the Company may, at its sole discretion, make contributions to the plan. For the years ended December&#160;31, 2022 and 2021, the Company&#8217;s contributions were $<ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million and nominal, respectively. </div> </ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 16. Subsequent Events </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2023, the Company implemented a restructuring plan approved by the board of directors to reduce its overall workforce by approximately <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P01_31_2023To01_31_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>%. The Company expects to substantially complete the workforce reduction by the end of the first quarter of 2023 and estimates to incur <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> restructuring charges of approximately $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_31_2023To01_31_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction>&#160;million, including employee severance, benefits and related costs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2023, the Company cancelled certain studies with its contract manufacturing organization and incurred a cancellation fee equal to <ix:nonFraction name="srzn:PercentOfContractPrice" contextRef="P02_28_2023To02_28_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the contract price of the studies plus any raw materials and handling fees that have been incurred. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;10, 2023, Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or FDIC, as a receiver. On March&#160;12, 2023, the U.S. Department of the Treasury, Federal Reserve, and FDIC jointly announced that the FDIC would complete its resolution of SVB in a manner that fully protects all depositors. The Company has access to its full deposits with SVB and does not anticipate any disruption to its ongoing operations. The Company is working on replacing the letter of credit issued by SVB as required by the landlord and transferring substantially all of its cash deposits at SVB to a different financial institution. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2023, we entered into an amended and restated warrant agreement with Continental Stock Transfer&#160;&amp; Trust Company as warrant agent, or the PIPE Warrant Agreement. PIPE Warrants may be converted into Public Warrants on transfer pursuant to the terms of the PIPE Warrant Agreement. To the date of the consolidated financial statements were issued, no PIPE Warrants were converted into Public Warrants </div> </ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-31 </div> </div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;13.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Expenses of Issuance and Distribution. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the sale of the securities being registered. All amounts shown are estimates except for the SEC registration fee. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#8217; fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">314,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">767,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Discounts, concessions, commissions and similar selling expenses attributable to the sale of shares of Common Stock covered by this prospectus will be borne by the selling securityholders. We will pay all expenses (other than discounts, concessions, commissions and similar selling expenses) relating to the registration of the shares with the SEC, as estimated in the table above. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;14.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Indemnification of Directors and Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent of the Registrant. The DGCL provides that Section&#160;145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaws, agreement, vote of stockholders or disinterested directors or otherwise. The Registrant&#8217;s Certificate of Incorporation and Bylaws provide for indemnification by the Registrant of its directors and officers to the fullest extent permitted by the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102(b)(7) of the DGCL permits a corporation to provide in its Certificate of Incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (1)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (2)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&#160;for unlawful payments of dividends or unlawful stock repurchases redemptions or other distributions or (4)&#160;for any transaction from which the director derived an improper personal benefit. The Registrant&#8217;s Certificate of Incorporation provides for such limitation of liability to the fullest extent permitted by the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant has entered into indemnification agreements with each of its directors and executive officers to provide contractual indemnification in addition to the indemnification provided in our Certificate of Incorporation. Each indemnification agreement provides for indemnification and advancements by the Registrant of certain expenses and costs relating to claims, suits or proceedings arising from his or her service to the Registrant or, at our request, service to other entities, as officers or directors to the maximum extent permitted by applicable law. We believe that these provisions and agreements are necessary to attract qualified directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant also maintains standard policies of insurance under which coverage is provided (1)&#160;to its directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
while acting in their capacity as directors and officers of the Registrant, and (2)&#160;to the Registrant with respect to payments which may be made by the Registrant to such officers and directors pursuant to any indemnification provision contained in the Registrant&#8217;s Certificate of Incorporation and Bylaws or otherwise as a matter of law. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;15.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Recent Sales of Unregistered Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following list sets forth information regarding all unregistered securities sold by us since January&#160;1, 2020: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In July 2021, we issued an aggregate of 144,666 private placement warrants to Consonance Acquisition Partners LLC at a price of $11.50 per private placement warrant, generating gross proceeds of $144,666. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In April 2021, concurrently with the closing of the Business Combination, the PIPE Investors purchased from us an aggregate of 12,020,000&#160;million shares of our Common Stock at a price of $10.00 per share, for an aggregate purchase price equal to $120.2&#160;million. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe each of these transactions was exempt from registration under the Securities Act in reliance on Section&#160;4(a)(2) of the Securities Act (and Regulation D promulgated thereunder) as transactions by an issuer not involving any public offering or Rule 701 promulgated under Section&#160;3(b) of the Securities Act as transactions by an issuer under benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;16.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Exhibits and Financial Statement Schedules. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits. The exhibits listed below are filed as part of this registration statement. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:46%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="8" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Incorporated by Reference</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit <br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Schedule/<br />Form</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">File No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312521117200/d41318dex21.htm">Business Combination Agreement, dated as of April<span style="text-decoration:underline"></span>&#160;15, 2021, by and among CHFW, Perseverance Merger Sub Inc., and Surrozen, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">2.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">April&#160;15,&#160;2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312521249342/d184950dex31.htm">Certificate of Incorporation of the Company. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">August&#160;17,&#160;2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312521249342/d184950dex32.htm">Bylaws of the Company. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">August&#160;17, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000110465920114246/tm2030948d4_ex4-3.htm">Specimen Warrant Certificate. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-1/A</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-249394</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">October&#160;13, 2020</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000110465920129281/tm2037076d1_ex4-1.htm">Warrant Agreement, dated as of November<span style="text-decoration:underline"></span>&#160;18, 2020, by and between <span style="white-space:nowrap">Consonance-HFW</span> Acquisition Corp. and Continental Stock Transfer<span style="text-decoration:underline"></span>&#160;&amp; Trust Company. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">November&#160;25,&#160;2020</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000110465920113567/tm2030948d3_ex4-1.htm">Specimen Unit Certificate</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-1</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-249394</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">October&#160;9, 2020</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000110465920114246/tm2030948d4_ex4-2.htm">Specimen Ordinary Share Certificate</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-1/A</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-249394</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">October&#160;13, 2020</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521249342/d184950dex45.htm">Certificate of Corporate Domestication of <span style="white-space:nowrap">Consonance-HFW</span> Acquisition Corp.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">4.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">August&#160;17, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:43%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="8" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Incorporated by Reference</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit <br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Schedule/<br />Form</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">File No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000095017023011118/srzn-ex4_6.htm">Amended and Restated Warrant Agreement, dated as of March&#160;31, 2023, by and between Surrozen, Inc. and Continental Stock Transfer&#160;&amp; Trust Company. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">4.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">March&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000095017023011118/srzn-ex4_7.htm">Description of Securities.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">4.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">March&#160;31,&#160;2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521323016/d223535dex51.htm">Opinion of Cooley LLP. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-1/A</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-259496</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">November&#160;8,&#160;2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312521117200/d41318dex102.htm">Form of Subscription Agreement. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">April&#160;15, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312521117200/d41318dex103.htm">Form of Company Stockholder Support Agreement. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">April&#160;15, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312521117200/d41318dex104.htm">Form of CHFW Shareholder Support Agreement. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">April&#160;15, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.4#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312521249342/d184950dex105.htm">Investors&#8217; Rights Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;11, 2021, by and among Surrozen, Inc., Consonance Life Sciences, and certain other investors. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">August&#160;17, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.5#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312521249342/d184950dex106.htm">Surrozen, Inc. 2021 Equity Incentive Plan and forms of agreement thereunder. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">August&#160;17, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.6#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312521249342/d184950dex107.htm">Surrozen, Inc. 2021 Employee Stock Purchase Plan. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">August&#160;17,&#160;2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.7#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312521249342/d184950dex108.htm">Form of Indemnification Agreement. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">August&#160;17, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.8&#8224;&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521198826/d40894dex109.htm">Amended and Restated License and Option Agreement for Llama Single Domain Antibody Phage Library, dated as of January<span style="text-decoration:underline"></span>&#160;17, 2020, by and between Regents of the University of California and Surrozen, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-4/A</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-256146</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.9</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">June&#160;24,&#160;2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.9&#8224;&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521198826/d40894dex1010.htm">Amended and Restated License and Option Agreement for Human Na&#239;ve Fab Library, dated as of January<span style="text-decoration:underline"></span>&#160;17, 2020, by and between Surrozen, Inc. and Regents of the University of California. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-4/A</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-256146</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">June&#160;24, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.10&#8224;&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521198826/d40894dex1011.htm">Antibody Library Subscription Agreement, dated as of September<span style="text-decoration:underline"></span>&#160;30, 2016, by and between Distributed Bio, Inc. and Surrozen, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-4/A</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-256146</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.11</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">June&#160;24, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.11&#8224;&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521198826/d40894dex1012.htm">First Amendment to the Antibody Library Subscription Agreement, dated as of September<span style="text-decoration:underline"></span>&#160;30, 2016, by and between Distributed Bio, Inc. and Surrozen, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-4/A</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-256146</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">10.12</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">June&#160;24, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:44%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Incorporated by Reference</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit <br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Schedule/<br />Form</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">File No.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.12&#8224;&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521198826/d40894dex1013.htm">Exclusive (Equity) Agreement, dated as of March<span style="text-decoration:underline"></span>&#160;23, 2016, by and between the Board of Trustees of the Leland Stanford Junior University and Surrozen, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-4/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-256146</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">10.13</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">June&#160;24, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.13&#8224;&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521198826/d40894dex1014.htm">Amendment No.<span style="text-decoration:underline"></span>&#160;1 the Exclusive (Equity) Agreement, dated as of July<span style="text-decoration:underline"></span>&#160;5, 2016, by and between the Board of Trustees of the Leland Stanford Junior University and Surrozen, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-4/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-256146</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">10.14</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">June&#160;24, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.14&#8224;&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521198826/d40894dex1015.htm">Amendment No.<span style="text-decoration:underline"></span>&#160;2 to the Exclusive (Equity) Agreement, dated as of October<span style="text-decoration:underline"></span>&#160;7, 2016, by and between the Board of Trustees of the Leland Stanford Junior University and Surrozen, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-4/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-256146</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">10.15</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">June&#160;24, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.15&#8224;&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521198826/d40894dex1016.htm">Amendment No.<span style="text-decoration:underline"></span>&#160;3 to the Exclusive (Equity) Agreement, dated as of January<span style="text-decoration:underline"></span>&#160;19, 2021, by and between the Board of Trustees of the Leland Stanford Junior University and Surrozen, Inc. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-4/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-256146</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">10.16</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">June&#160;24, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.16&#8224;&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521198826/d40894dex1017.htm">Exclusive License Agreement, dated as of June<span style="text-decoration:underline"></span>&#160;6, 2018, by and between Surrozen, Inc. and The Board of Trustees of the Leland Stanford Junior University. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-4/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-256146</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">10.17</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">June&#160;24, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.17</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000095017022001988/srzn-ex10_1.htm">Purchase Agreement by and between the Company and Lincoln Park Capital Fund, LLC, dated February<span style="text-decoration:underline"></span>&#160;18, 2022. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">10.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">February&#160;24, 2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.18</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000095017022001988/srzn-ex10_2.htm">Registration Rights Agreement by and between the Company and Lincoln Park Capital Fund, LLC, dated February<span style="text-decoration:underline"></span>&#160;18, 2022.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">10.2</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">February&#160;24,&#160;2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.19</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000095017022004787/srzn-ex10_20.htm">Lease Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;4, 2016, by and between Surrozen, Inc. and HCP Oyster Point III LLC. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">10.20</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">March&#160;28,&#160;2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.20</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000095017022025096/srzn-ex10_1.htm">Collaboration and License Agreement, dated as of September<span style="text-decoration:underline"></span>&#160;30, 2022, by and between Boehringer Ingelheim International GmbH and Surrozen Operating, Inc.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">10-Q</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">10.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">November&#160;14, 2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.21</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000119312522301907/d419980dex12.htm">Sales Agreement, dated as of December<span style="text-decoration:underline"></span>&#160;9, 2022, by and between the Company and Guggenheim Securities, LLC.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-3</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-268745</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">1.2</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">December&#160;9, 2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1824893/000095017022004787/srzn-ex21_1.htm">List of Subsidiaries. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">001-39635</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">21.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">March&#160;28,&#160;2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d491933dex231.htm">Consent of Ernst&#160;&amp; Young LLP. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:43%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Incorporated by Reference</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit <br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Schedule/<br />Form</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">File No.</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Exhibit</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Filing Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001824893/000119312521323016/d223535dex51.htm">Consent of Cooley LLP (included in Exhibit<span style="text-decoration:underline"></span>&#160;5.1). </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-1/A</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-259496</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">5.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">November&#160;8, 2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;24.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001824893/000119312521271554/d223535ds1.htm#sig">Power of Attorney (included on the signature page of Registration <span style="white-space:nowrap">Statement&#160;S-1).</span> </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">S-1</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">333-259496</span></td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">24.1</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">September&#160;13,&#160;2021</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Label Linkbase Document.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation <span style="white-space:nowrap">S-K.</span> The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">&#8224;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation SK. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">&#094;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain portions of this exhibit (indicated by asterisks) have been excluded pursuant to Item 601(b)(10) of Regulation <span style="white-space:nowrap">S-K</span> because they are both not material and are the type that the Company treats as private or confidential. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan or arrangement. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(b)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Financial Statement Schedules. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;17.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Undertakings. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td align="left" style="vertical-align:top">
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or our securities provided by or on behalf of the undersigned registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the undersigned pursuant to the foregoing provisions, or otherwise, the undersigned has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the undersigned of expenses incurred or paid by a director, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
officer or controlling person of the undersigned in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the undersigned will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the Company has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of South San Francisco, State of California, on this 31st day of March, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:100%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">SURROZEN, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ <span style="font-style:italic">Craig Parker</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Craig Parker</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No.2 to the Registration Statement on Form <span style="white-space:nowrap">S-1</span> has been signed by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:30%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:54%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:14%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Craig Parker</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Craig Parker</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer and Director</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(Principal Executive Officer)</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March&#160;31, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Charles Williams</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Charles Williams</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(Principal&#160;Financial&#160;Officer&#160;and&#160;Principal&#160;Accounting&#160;Officer)</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March&#160;31, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Tim Kutzkey, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chair of the Board of Directors</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March&#160;31, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Anna Berkenblit, M.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March&#160;31, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Christopher Y. Chai</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March&#160;31, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Mary Haak-Frendscho, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March&#160;31, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Mace Rothenberg, M.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March&#160;31, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="white-space:nowrap">Shao-Lee</span> Lin, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March&#160;31, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">David J. Woodhouse, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">March&#160;31, 2023</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:11%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:88%"></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">*&#160;By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Craig Parker</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Craig Parker</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-style:italic"><span style="white-space:nowrap"><span style="white-space:nowrap">Attorney-in-Fact</span></span></span></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d491933dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 23.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Consent of Independent Registered Public Accounting Firm </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated March&nbsp;31, 2023, in the Post-Effective
Amendment No.&nbsp;2 to the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-1</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-259496)</FONT> and related Prospectus of Surrozen, Inc. for the registration of common stock and
warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco,
California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>srzn-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 31-March-2023 [06:09:59] {PM}-->
<schema targetNamespace="http://Consonance.com/20221231" elementFormDefault="qualified" xmlns:srzn="http://Consonance.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3">
<annotation>
<appinfo>
<link:roleType roleURI="http://Consonance.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>1001 - Document -  Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement -  Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement -  Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement -  Consolidated Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
<link:definition>1005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
<link:definition>1007 - Disclosure -  Organization and Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1008 - Disclosure -  Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/Recapitalization" id="Recapitalization">
<link:definition>1009 - Disclosure -  Recapitalization</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurement" id="FairValueMeasurement">
<link:definition>1010 - Disclosure -  Fair Value Measurement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/BalanceSheetComponents" id="BalanceSheetComponents">
<link:definition>1011 - Disclosure -  Balance Sheet Components</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/Leases" id="Leases">
<link:definition>1012 - Disclosure -  Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/CollaborationAndLicenseAgreement" id="CollaborationAndLicenseAgreement">
<link:definition>1013 - Disclosure -  Collaboration and License Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/LicenseAgreement" id="LicenseAgreement">
<link:definition>1014 - Disclosure -  License Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1015 - Disclosure -  Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1016 - Disclosure -  Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/CommonStockWarrants" id="CommonStockWarrants">
<link:definition>1017 - Disclosure -  Common Stock Warrants</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockBasedCompensationPlan" id="StockBasedCompensationPlan">
<link:definition>1018 - Disclosure -  Stock Based Compensation Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1019 - Disclosure -  Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1020 - Disclosure -  Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/KPlan" id="KPlan">
<link:definition>1021 - Disclosure -  401(K) Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1022 - Disclosure -  Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1023 - Disclosure -  Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1024 - Disclosure -  Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementTables" id="FairValueMeasurementTables">
<link:definition>1025 - Disclosure -  Fair Value Measurement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/BalanceSheetComponentsTables" id="BalanceSheetComponentsTables">
<link:definition>1026 - Disclosure -  Balance Sheet Components (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/LeasesTables" id="LeasesTables">
<link:definition>1027 - Disclosure -  Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/CommonStockWarrantsTables" id="CommonStockWarrantsTables">
<link:definition>1028 - Disclosure -  Common Stock Warrants (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockBasedCompensationPlanTables" id="StockBasedCompensationPlanTables">
<link:definition>1029 - Disclosure -  Stock Based Compensation Plan (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1030 - Disclosure -  Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails" id="OrganizationAndBusinessAdditionalInformationDetails">
<link:definition>1031 - Disclosure -  Organization and Business - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1032 - Disclosure -  Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails">
<link:definition>1033 - Disclosure -  Summary of Significant Accounting Policies - Summary of Property and Equipment Useful Lives (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
<link:definition>1034 - Disclosure -  Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/RecapitalizationAdditionalInformationDetails" id="RecapitalizationAdditionalInformationDetails">
<link:definition>1035 - Disclosure -  Recapitalization - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
<link:definition>1036 - Disclosure - Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details))</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails" id="FairValueMeasurementAdditionalInformationDetails">
<link:definition>1037 - Disclosure -  Fair Value Measurement - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails" id="FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails">
<link:definition>1038 - Disclosure -  Fair Value Measurement - Schedule of Measurement of PIPE Warrants with Binomial Lattice Model (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails" id="FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails">
<link:definition>1039 - Disclosure - Fair Value Measurement - Summary of Changes in Fair Value of Warrant Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails" id="FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails">
<link:definition>1040 - Disclosure -  Fair Value Measurement - Schedule of Marketable Securities by Security Type (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails" id="FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails">
<link:definition>1041 - Disclosure -  Fair Value Measurement - Schedule of Individual Securities Unrealized Loss Position (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" id="BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail">
<link:definition>1042 - Disclosure -  Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/BalanceSheetComponentsAdditionalInformationDetail" id="BalanceSheetComponentsAdditionalInformationDetail">
<link:definition>1043 - Disclosure -  Balance Sheet Components - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" id="BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail">
<link:definition>1044 - Disclosure -  Balance Sheet Components - Schedule of Accrued Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/LeasesAdditionalInformationDetails" id="LeasesAdditionalInformationDetails">
<link:definition>1045 - Disclosure -  Leases - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails" id="LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails">
<link:definition>1046 - Disclosure -  Leases - Summary Of Lessee, Operating Lease, Liability, Maturity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails" id="LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails">
<link:definition>1047 - Disclosure -  Leases - Schedule of Supplemental Information Related to Operating Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails" id="CollaborationAndLicenseAgreementAdditionalInformationDetails">
<link:definition>1048 - Disclosure -  Collaboration and License Agreement (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails" id="LicenseAgreementsAdditionalInformationDetails">
<link:definition>1049 - Disclosure -  License Agreements - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails" id="RelatedPartyTransactionsAdditionalInformationDetails">
<link:definition>1050 - Disclosure -  Related Party Transactions (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails" id="StockholdersEquityAdditionalInformationDetails">
<link:definition>1051 - Disclosure -  Stockholders' Equity (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails" id="CommonStockWarrantsAdditionalInformationDetails">
<link:definition>1052 - Disclosure -  Common Stock Warrants - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/CommonStockWarrantsDetails" id="CommonStockWarrantsDetails">
<link:definition>1053 - Disclosure -  Common Stock Warrants - (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails" id="StockBasedCompensationPlanAdditionalInformationDetails">
<link:definition>1054 - Disclosure -  Stock Based Compensation Plan - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails" id="StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails">
<link:definition>1055 - Disclosure -  Stock Based Compensation Plan - Summary of Stock Option Activity for Company's Stock Option Plans (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails" id="StockBasedCompensationPlanSummaryOfRsaActivityDetails">
<link:definition>1056 - Disclosure -  Stock Based Compensation Plan - Summary of RSA Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails" id="StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails">
<link:definition>1057 - Disclosure -  Stock Based Compensation Plan- Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Options (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails" id="StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails">
<link:definition>1058 - Disclosure -  Stock Based Compensation Plan - Schedule of Stock-Based Compensation Expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1059 - Disclosure -  Income Taxes - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" id="IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails">
<link:definition>1060 - Disclosure -  Income Taxes - Summary of Net Deferred Tax Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/IncomeTaxesSummaryOfTaxBenefitsDetail" id="IncomeTaxesSummaryOfTaxBenefitsDetail">
<link:definition>1061 - Disclosure -  Income Taxes - Summary of Tax Benefits (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" id="IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail">
<link:definition>1062 - Disclosure -  Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate TO Effective Income Tax Rate (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/KPlanAdditionalInformationDetails" id="KPlanAdditionalInformationDetails">
<link:definition>1063 - Disclosure -  401(K) Plan Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
<link:definition>1064 - Disclosure -  Subsequent Events (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="srzn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
<import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
<element name="DocumentDocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_DocumentDocumentAndEntityInformationAbstract" substitutionGroup="xbrli:item" />
<element name="WarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_WarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Issuanceofcommonstockvalueunderequitypurchaseagreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfCommonStockUnderEquityPurchaseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement" substitutionGroup="xbrli:item" />
<element name="RepurchaseOfEarlyExercisedStockOptionsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_RepurchaseOfEarlyExercisedStockOptionsShares" substitutionGroup="xbrli:item" />
<element name="RepurchaseAndCancellationOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_RepurchaseAndCancellationOfCommonStock" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromSaleOfMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_ProceedsFromSaleOfMarketableSecurities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepurchaseOfEarlyExcercisedStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_RepurchaseOfEarlyExcercisedStockOptions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AssumptionOfWarrantLiabilitiesInBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="VestingOfEarlyExercisesOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_VestingOfEarlyExercisesOfStockOptions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReclassificationToLiabilityForEarlyExercisedStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract" substitutionGroup="xbrli:item" />
<element name="RecapitalizationNoteAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_RecapitalizationNoteAbstract" substitutionGroup="xbrli:item" />
<element name="RecapitalizationNoteDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_RecapitalizationNoteDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="CollaborationAndLicenseAgreementsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_CollaborationAndLicenseAgreementsTextBlock" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_LicenseAgreementsAbstract" substitutionGroup="xbrli:item" />
<element name="LicenseAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_LicenseAgreementsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockWarrantsDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_CommonStockWarrantsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="WarrantLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_WarrantLiabilityPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="RevenueRecognitionsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_RevenueRecognitionsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="AccruedResearchAndDevelopmentExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="EmergingGrowthCompanyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_EmergingGrowthCompanyPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_PrivatePlacementWarrantsMember" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsRepurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_ClassOfWarrantsRepurchased" substitutionGroup="xbrli:item" />
<element name="FurnitureFixturesAndEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_FurnitureFixturesAndEquipmentMember" substitutionGroup="xbrli:item" />
<element name="RestrictedStockAwardRSAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_RestrictedStockAwardRSAMember" substitutionGroup="xbrli:item" />
<element name="UnvestedCommonStockSharesSubjectToRepurchaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember" substitutionGroup="xbrli:item" />
<element name="WarrantToPurchaseCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_WarrantToPurchaseCommonStockMember" substitutionGroup="xbrli:item" />
<element name="AccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_AccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrivateInvestmentInPublicEntityOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_PrivateInvestmentInPublicEntityOfferingMember" substitutionGroup="xbrli:item" />
<element name="SurrozenIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_SurrozenIncMember" substitutionGroup="xbrli:item" />
<element name="CorporateBondMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_CorporateBondMember" substitutionGroup="xbrli:item" />
<element name="GovernmentBondsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_GovernmentBondsMember" substitutionGroup="xbrli:item" />
<element name="ForeignBondsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_ForeignBondsMember" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_PublicWarrantsMember" substitutionGroup="xbrli:item" />
<element name="PIPEWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_PIPEWarrantsMember" substitutionGroup="xbrli:item" />
<element name="StockPriceToRedeemsWarrants" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_StockPriceToRedeemsWarrants" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromRepurchaseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_ProceedsFromRepurchaseOfWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LabEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_LabEquipmentMember" substitutionGroup="xbrli:item" />
<element name="AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EightYearsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_EightYearsMember" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseMonthOfExpiryOfLease" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_OperatingLeaseMonthOfExpiryOfLease" substitutionGroup="xbrli:item" />
<element name="SuccessBasedMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_SuccessBasedMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_UpfrontPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AssociatedWithholdingTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_AssociatedWithholdingTax" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TransactionPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_TransactionPrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonRefundableUpfrontPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_NonRefundableUpfrontPaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CollaborationAndLicenseAgreementWithBiMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_CollaborationAndLicenseAgreementWithBiMember" substitutionGroup="xbrli:item" />
<element name="UCSFLicenseAndOptionAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_UCSFLicenseAndOptionAgreementsMember" substitutionGroup="xbrli:item" />
<element name="DistributedBioSubscriptionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_DistributedBioSubscriptionAgreementMember" substitutionGroup="xbrli:item" />
<element name="StanfordLicenseAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_StanfordLicenseAgreementsMember" substitutionGroup="xbrli:item" />
<element name="StanfordMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_StanfordMember" substitutionGroup="xbrli:item" />
<element name="PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsForMilestoneAgreementOnAchievementOfMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CommonStockTotalPurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_CommonStockTotalPurchasePrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CommonStockPurchaseCommitmentPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_CommonStockPurchaseCommitmentPeriod" substitutionGroup="xbrli:item" />
<element name="PurchaseOfAdditionalShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_PurchaseOfAdditionalShares" substitutionGroup="xbrli:item" />
<element name="PurchasePricePerShareOfAdditionalShares" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_PurchasePricePerShareOfAdditionalShares" substitutionGroup="xbrli:item" />
<element name="CompensationPayable" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_CompensationPayable" substitutionGroup="xbrli:item" />
<element name="GuggenheimSecuritiesLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_GuggenheimSecuritiesLlcMember" substitutionGroup="xbrli:item" />
<element name="LincolnParkMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_LincolnParkMember" substitutionGroup="xbrli:item" />
<element name="ClosingSalePriceNotBelow1200PerShareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_ClosingSalePriceNotBelow1200PerShareMember" substitutionGroup="xbrli:item" />
<element name="ClosingSalePriceNotBelow1000PerShareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_ClosingSalePriceNotBelow1000PerShareMember" substitutionGroup="xbrli:item" />
<element name="CommonStock1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_CommonStock1Member" substitutionGroup="xbrli:item" />
<element name="CommonStock2Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_CommonStock2Member" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationInitialWarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_BusinessCombinationInitialWarrantsIssued" substitutionGroup="xbrli:item" />
<element name="AssumedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_AssumedWarrants" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_ClassOfWarrantOrRightIssued" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" substitutionGroup="xbrli:item" />
<element name="WarrantNoticePeriodPriorToRedemptionDate" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_WarrantNoticePeriodPriorToRedemptionDate" substitutionGroup="xbrli:item" />
<element name="WarrantRedemptionConditionMinimumSharePriceScenarioOne" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne" substitutionGroup="xbrli:item" />
<element name="WarrantRedemptionConditionMinimumSharePriceScenarioTwo" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightClassification" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_ClassOfWarrantOrRightClassification" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyOneStockPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_TwoThousandTwentyOneStockPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandFifteenStockPlan1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_TwoThousandFifteenStockPlan1Member" substitutionGroup="xbrli:item" />
<element name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_EmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="VestedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_VestedMember" substitutionGroup="xbrli:item" />
<element name="UnvestedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_UnvestedMember" substitutionGroup="xbrli:item" />
<element name="CliffVestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_CliffVestingPeriod" substitutionGroup="xbrli:item" />
<element name="CommonStockTradingDiscription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_CommonStockTradingDiscription" substitutionGroup="xbrli:item" />
<element name="PercentageOfDiscountPayrollDeductions" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_PercentageOfDiscountPayrollDeductions" substitutionGroup="xbrli:item" />
<element name="IndefiniteTaxYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="srzn_IndefiniteTaxYearMember" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryForwardsExpirationStartYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_TaxCreditCarryForwardsExpirationStartYear" substitutionGroup="xbrli:item" />
<element name="StateTaxCreditCarryForwardsExpiration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_StateTaxCreditCarryForwardsExpiration" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReinsuranceRetentionsPolicyAmountRetained" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_ReinsuranceRetentionsPolicyAmountRetained" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_DeferredTaxLiabilitiesRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_DeferredTaxAssetsLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsEmployeeRetentionCredits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_DeferredTaxAssetsEmployeeRetentionCredits" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsCapitalizedIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_DeferredTaxAssetsCapitalizedIntangibleAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsCapitalizedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="srzn_DeferredTaxAssetsCapitalizedExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" substitutionGroup="xbrli:item" />
<element name="PercentOfContractPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="srzn_PercentOfContractPrice" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>srzn-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 31-March-2023 [06:09:59] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://Consonance.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://Consonance.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" roleURI="http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" roleURI="http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails" roleURI="http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" roleURI="http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" roleURI="http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" />
<calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantLiability" xlink:label="loc_SRZN_WarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_SRZN_WarrantLiability" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="23" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromSaleOfMarketableSecurities" xlink:label="loc_SRZN_ProceedsFromSaleOfMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_SRZN_ProceedsFromSaleOfMarketableSecurities" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RepurchaseOfEarlyExcercisedStockOptions" xlink:label="loc_SRZN_RepurchaseOfEarlyExcercisedStockOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SRZN_RepurchaseOfEarlyExcercisedStockOptions" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" xlink:label="loc_SRZN_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SRZN_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" xlink:label="loc_SRZN_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SRZN_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationAndAmortization" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" xlink:label="loc_SRZN_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SRZN_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="27" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_RestrictedCash" use="optional" order="29" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" xlink:label="loc_SRZN_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_SRZN_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsCapitalizedExpenses" xlink:label="loc_SRZN_DeferredTaxAssetsCapitalizedExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SRZN_DeferredTaxAssetsCapitalizedExpenses" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_SRZN_DeferredTaxAssetsLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SRZN_DeferredTaxAssetsLeaseLiabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsEmployeeRetentionCredits" xlink:label="loc_SRZN_DeferredTaxAssetsEmployeeRetentionCredits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SRZN_DeferredTaxAssetsEmployeeRetentionCredits" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsCapitalizedIntangibleAssets" xlink:label="loc_SRZN_DeferredTaxAssetsCapitalizedIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SRZN_DeferredTaxAssetsCapitalizedIntangibleAssets" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxLiabilities" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_SRZN_DeferredTaxLiabilitiesRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_SRZN_DeferredTaxLiabilitiesRightOfUseAssets" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="17" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" xlink:label="loc_SRZN_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SRZN_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" use="optional" order="8" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>srzn-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 31-March-2023 [06:09:59] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#DocumentAndEntityInformation" roleURI="http://Consonance.com/role/DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#OrganizationAndBusinessAdditionalInformationDetails" roleURI="http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#RecapitalizationAdditionalInformationDetails" roleURI="http://Consonance.com/role/RecapitalizationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementAdditionalInformationDetails" roleURI="http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails" roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails" roleURI="http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails" roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails" roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" roleURI="http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LeasesAdditionalInformationDetails" roleURI="http://Consonance.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CollaborationAndLicenseAgreementAdditionalInformationDetails" roleURI="http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LicenseAgreementsAdditionalInformationDetails" roleURI="http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockholdersEquityAdditionalInformationDetails" roleURI="http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CommonStockWarrantsAdditionalInformationDetails" roleURI="http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CommonStockWarrantsDetails" roleURI="http://Consonance.com/role/CommonStockWarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanAdditionalInformationDetails" roleURI="http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails" roleURI="http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanSummaryOfRsaActivityDetails" roleURI="http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails" roleURI="http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails" roleURI="http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://Consonance.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://Consonance.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#OrganizationAndBusiness" roleURI="http://Consonance.com/role/OrganizationAndBusiness" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#Recapitalization" roleURI="http://Consonance.com/role/Recapitalization" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurement" roleURI="http://Consonance.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponents" roleURI="http://Consonance.com/role/BalanceSheetComponents" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#Leases" roleURI="http://Consonance.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CollaborationAndLicenseAgreement" roleURI="http://Consonance.com/role/CollaborationAndLicenseAgreement" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LicenseAgreement" roleURI="http://Consonance.com/role/LicenseAgreement" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#RelatedPartyTransactions" roleURI="http://Consonance.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockholdersEquity" roleURI="http://Consonance.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CommonStockWarrants" roleURI="http://Consonance.com/role/CommonStockWarrants" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlan" roleURI="http://Consonance.com/role/StockBasedCompensationPlan" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxes" roleURI="http://Consonance.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CommitmentsAndContingencies" roleURI="http://Consonance.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#KPlan" roleURI="http://Consonance.com/role/KPlan" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SubsequentEvents" roleURI="http://Consonance.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementTables" roleURI="http://Consonance.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesTables" roleURI="http://Consonance.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CommonStockWarrantsTables" roleURI="http://Consonance.com/role/CommonStockWarrantsTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanTables" roleURI="http://Consonance.com/role/StockBasedCompensationPlanTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponentsAdditionalInformationDetail" roleURI="http://Consonance.com/role/BalanceSheetComponentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" roleURI="http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails" roleURI="http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails" roleURI="http://Consonance.com/role/LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" roleURI="http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesSummaryOfTaxBenefitsDetail" roleURI="http://Consonance.com/role/IncomeTaxesSummaryOfTaxBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" roleURI="http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LeasesTables" roleURI="http://Consonance.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#KPlanAdditionalInformationDetails" roleURI="http://Consonance.com/role/KPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponentsTables" roleURI="http://Consonance.com/role/BalanceSheetComponentsTables" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_109" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_AmendmentFlag_108" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_DocumentFiscalPeriodFocus_113" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityRegistrantName_115" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityCentralIndexKey_116" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityFilerCategory_118" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntitySmallBusiness_119" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityEmergingGrowthCompany_120" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityExTransitionPeriod_121" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityTaxIdentificationNumber_130" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityAddressAddressLine1_131" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityAddressAddressLine2_132" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityAddressCityOrTown_133" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityAddressStateOrProvince_134" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityAddressPostalZipCode_135" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_CityAreaCode_136" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_LocalPhoneNumber_137" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityIncorporationStateCountryCode_141" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_DocumentFiscalYearFocus_112" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_DocumentInformationTable_102" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_102" xlink:to="loc_us-gaap_StatementClassOfStockAxis_106" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_106" xlink:to="loc_us-gaap_ClassOfStockDomain_105" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_105_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_106" xlink:to="loc_us-gaap_ClassOfStockDomain_105_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_102" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1060" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1060" xlink:to="loc_dei_AddressTypeDomain_1061" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1061_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1060" xlink:to="loc_dei_AddressTypeDomain_1061_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1061" xlink:to="loc_dei_BusinessContactMember_1062" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_DocumentType_104" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityPrimarySicNumber_1059" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_ContactPersonnelName_1063" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_AmendmentDescription_1064" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_227" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockholdersEquity_218" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StatementTable_213" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_213" xlink:to="loc_us-gaap_StatementClassOfStockAxis_211" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_211" xlink:to="loc_us-gaap_ClassOfStockDomain_217" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_217_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_211" xlink:to="loc_us-gaap_ClassOfStockDomain_217_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_213" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_220" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_220" xlink:to="loc_us-gaap_EquityComponentDomain_215" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_215_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_220" xlink:to="loc_us-gaap_EquityComponentDomain_215_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_215" xlink:to="loc_us-gaap_CommonStockMember_219" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_215" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_223" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_215" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_226" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_215" xlink:to="loc_us-gaap_RetainedEarningsMember_229" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_213" xlink:to="loc_srt_RestatementAxis_224" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_224" xlink:to="loc_srt_RestatementDomain_212" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_212_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_224" xlink:to="loc_srt_RestatementDomain_212_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_231" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_232" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_233" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" xlink:label="loc_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions_234" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" xlink:label="loc_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue_235" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_SharesIssued_228" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_230" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_247" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_248" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_249" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_ProfitLoss_250" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement" xlink:label="loc_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement_237" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement" xlink:label="loc_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement_238" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_239" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_240" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RepurchaseOfEarlyExercisedStockOptionsShares" xlink:label="loc_srzn_RepurchaseOfEarlyExercisedStockOptionsShares_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_RepurchaseOfEarlyExercisedStockOptionsShares_241" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_242" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RepurchaseAndCancellationOfCommonStock" xlink:label="loc_srzn_RepurchaseAndCancellationOfCommonStock_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_RepurchaseAndCancellationOfCommonStock_243" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_245" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" xlink:to="loc_us-gaap_NetIncomeLoss_437" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_439" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_443" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_446" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_434" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_434" xlink:to="loc_us-gaap_EquityComponentDomain_429" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_429_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_434" xlink:to="loc_us-gaap_EquityComponentDomain_429_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_436" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_436" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_433" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_433_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_436" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_433_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_438" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_438" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_426" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_426_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_438" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_426_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" xlink:to="loc_dei_LegalEntityAxis_424" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_424" xlink:to="loc_dei_EntityDomain_427" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_427_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_424" xlink:to="loc_dei_EntityDomain_427_default" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_458" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_458" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_452" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_458" xlink:to="loc_us-gaap_StatementTable_453" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_453" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_449" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_449" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_450" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_450_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_449" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_450_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_450" xlink:to="loc_us-gaap_LetterOfCreditMember_455" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_453" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_456" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_456" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_454" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_454_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_456" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_454_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivatePlacementWarrantsMember" xlink:label="loc_srzn_PrivatePlacementWarrantsMember_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_454" xlink:to="loc_srzn_PrivatePlacementWarrantsMember_451" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_458" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_457" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantsRepurchased" xlink:label="loc_srzn_ClassOfWarrantsRepurchased_459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_458" xlink:to="loc_srzn_ClassOfWarrantsRepurchased_459" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_472" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_465" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_472" xlink:to="loc_us-gaap_StatementTable_466" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_462" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_466" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_462" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_462" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_462" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_468" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" xlink:to="loc_us-gaap_ComputerEquipmentMember_471" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_FurnitureFixturesAndEquipmentMember" xlink:label="loc_srzn_FurnitureFixturesAndEquipmentMember_473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" xlink:to="loc_srzn_FurnitureFixturesAndEquipmentMember_473" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_474" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_466" xlink:to="loc_srt_RangeAxis_469" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_469" xlink:to="loc_srt_RangeMember_463" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_463_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_469" xlink:to="loc_srt_RangeMember_463_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_463" xlink:to="loc_srt_MinimumMember_464" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_463" xlink:to="loc_srt_MaximumMember_470" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AccountingPoliciesLineItems" xlink:label="loc_srzn_AccountingPoliciesLineItems_483" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srzn_AccountingPoliciesLineItems_483" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_480" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_480" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_480" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" xlink:to="loc_us-gaap_EmployeeStockOptionMember_479" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RestrictedStockAwardRSAMember" xlink:label="loc_srzn_RestrictedStockAwardRSAMember_482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" xlink:to="loc_srzn_RestrictedStockAwardRSAMember_482" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember" xlink:label="loc_srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember_484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" xlink:to="loc_srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember_484" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantToPurchaseCommonStockMember" xlink:label="loc_srzn_WarrantToPurchaseCommonStockMember_485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" xlink:to="loc_srzn_WarrantToPurchaseCommonStockMember_485" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srzn_AccountingPoliciesLineItems_483" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_481" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/RecapitalizationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" xlink:label="loc_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering_498" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_499" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_500" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_501" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" xlink:label="loc_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital_502" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_Goodwill_505" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_506" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_493" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_494" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_494" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_489" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_489" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_489" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivateInvestmentInPublicEntityOfferingMember" xlink:label="loc_srzn_PrivateInvestmentInPublicEntityOfferingMember_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492" xlink:to="loc_srzn_PrivateInvestmentInPublicEntityOfferingMember_490" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_494" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_495" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_495" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_495" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_SurrozenIncMember" xlink:label="loc_srzn_SurrozenIncMember_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" xlink:to="loc_srzn_SurrozenIncMember_491" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_496" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_528" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_528" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_523" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_523" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_527" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_528" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_520" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_520" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_520" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_521" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_525" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_516" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_524" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_524" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_524" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_us-gaap_CommercialPaperMember_518" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CorporateBondMember" xlink:label="loc_srzn_CorporateBondMember_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_CorporateBondMember_522" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_GovernmentBondsMember" xlink:label="loc_srzn_GovernmentBondsMember_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_GovernmentBondsMember_526" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_529" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ForeignBondsMember" xlink:label="loc_srzn_ForeignBondsMember_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_ForeignBondsMember_530" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PublicWarrantsMember" xlink:label="loc_srzn_PublicWarrantsMember_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_PublicWarrantsMember_531" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivatePlacementWarrantsMember" xlink:label="loc_srzn_PrivatePlacementWarrantsMember_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_PrivatePlacementWarrantsMember_532" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_PIPEWarrantsMember_533" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_us-gaap_MoneyMarketFundsMember_511" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_514" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_514" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_515" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_515_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_514" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_515_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_515" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_517" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_528" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_513" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_513" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_519" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_556" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_557" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_558" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_550" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_550" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_543" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_543_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_550" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_543_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember_542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_543" xlink:to="loc_srzn_PIPEWarrantsMember_542" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_552" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_552" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_547" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_547_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_552" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_547_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_547" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_546" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" xlink:to="loc_srt_RangeAxis_545" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_545" xlink:to="loc_srt_RangeMember_540" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_540_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_545" xlink:to="loc_srt_RangeMember_540_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_540" xlink:to="loc_srt_MaximumMember_548" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_540" xlink:to="loc_srt_MinimumMember_541" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StockPriceToRedeemsWarrants" xlink:label="loc_srzn_StockPriceToRedeemsWarrants_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" xlink:to="loc_srzn_StockPriceToRedeemsWarrants_544" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_566" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_566" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_561" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_561" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_563" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_563" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_565" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_565_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_563" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_565_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_565" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_564" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_565" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_567" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_565" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_569" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_566" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_562" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_575" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" xlink:label="loc_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" xlink:to="loc_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination_578" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_581" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromRepurchaseOfWarrants" xlink:label="loc_srzn_ProceedsFromRepurchaseOfWarrants_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" xlink:to="loc_srzn_ProceedsFromRepurchaseOfWarrants_583" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_572" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_572" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_576" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_576" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_576" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PublicWarrantsMember" xlink:label="loc_srzn_PublicWarrantsMember_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574" xlink:to="loc_srzn_PublicWarrantsMember_573" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivatePlacementWarrantsMember" xlink:label="loc_srzn_PrivatePlacementWarrantsMember_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574" xlink:to="loc_srzn_PrivatePlacementWarrantsMember_577" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574" xlink:to="loc_srzn_PIPEWarrantsMember_580" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:label="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_596" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_598" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_599" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xlink:label="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent_600" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_601" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_602" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_587" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_587" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_591" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_591" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_591" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_GovernmentBondsMember" xlink:label="loc_srzn_GovernmentBondsMember_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" xlink:to="loc_srzn_GovernmentBondsMember_597" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" xlink:to="loc_us-gaap_CommercialPaperMember_588" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CorporateBondMember" xlink:label="loc_srzn_CorporateBondMember_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" xlink:to="loc_srzn_CorporateBondMember_592" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ForeignBondsMember" xlink:label="loc_srzn_ForeignBondsMember_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" xlink:to="loc_srzn_ForeignBondsMember_595" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_590" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_593" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_611" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_611" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_614" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_611" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_605" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_605" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_608" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_608" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_608" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CorporateBondMember" xlink:label="loc_srzn_CorporateBondMember_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607" xlink:to="loc_srzn_CorporateBondMember_606" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_GovernmentBondsMember" xlink:label="loc_srzn_GovernmentBondsMember_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607" xlink:to="loc_srzn_GovernmentBondsMember_610" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ForeignBondsMember" xlink:label="loc_srzn_ForeignBondsMember_613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607" xlink:to="loc_srzn_ForeignBondsMember_613" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_611" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_609" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_611" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_612" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_622" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_625" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_617" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_618" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_618" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_619" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_619" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_619" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LabEquipmentMember" xlink:label="loc_srzn_LabEquipmentMember_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" xlink:to="loc_srzn_LabEquipmentMember_624" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_626" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" xlink:to="loc_us-gaap_ComputerEquipmentMember_627" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_621" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_OperatingLeaseMonthOfExpiryOfLease" xlink:label="loc_srzn_OperatingLeaseMonthOfExpiryOfLease_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_srzn_OperatingLeaseMonthOfExpiryOfLease_650" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_655" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_656" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_us-gaap_OperatingLeaseExpense_658" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_644" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_645" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_645" xlink:to="loc_us-gaap_LeaseContractualTermAxis_651" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_651" xlink:to="loc_us-gaap_LeaseContractualTermDomain_648" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_648_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_651" xlink:to="loc_us-gaap_LeaseContractualTermDomain_648_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EightYearsMember" xlink:label="loc_srzn_EightYearsMember_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_648" xlink:to="loc_srzn_EightYearsMember_642" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_645" xlink:to="loc_srt_StatementGeographicalAxis_646" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_646" xlink:to="loc_srt_SegmentGeographicalDomain_647" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_647_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_646" xlink:to="loc_srt_SegmentGeographicalDomain_647_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="loc_stpr_CA_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_647" xlink:to="loc_stpr_CA_643" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_689" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_SuccessBasedMilestonePayments" xlink:label="loc_srzn_SuccessBasedMilestonePayments_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_srzn_SuccessBasedMilestonePayments_685" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UpfrontPayment" xlink:label="loc_srzn_UpfrontPayment_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_srzn_UpfrontPayment_688" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AssociatedWithholdingTax" xlink:label="loc_srzn_AssociatedWithholdingTax_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_srzn_AssociatedWithholdingTax_690" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TransactionPrice" xlink:label="loc_srzn_TransactionPrice_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_srzn_TransactionPrice_692" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_NonRefundableUpfrontPaymentReceived" xlink:label="loc_srzn_NonRefundableUpfrontPaymentReceived_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_srzn_NonRefundableUpfrontPaymentReceived_680" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_us-gaap_StatementTable_678" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_678" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_684" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_684" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_679" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_679_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_684" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_679_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_678" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_687" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_687" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_683" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_683_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_687" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_683_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_683" xlink:to="loc_us-gaap_AccountsReceivableMember_677" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_678" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_675" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_675" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_682" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_682_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_675" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_682_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CollaborationAndLicenseAgreementWithBiMember" xlink:label="loc_srzn_CollaborationAndLicenseAgreementWithBiMember_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_682" xlink:to="loc_srzn_CollaborationAndLicenseAgreementWithBiMember_676" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_711" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" xlink:label="loc_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones_710" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" xlink:label="loc_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones_712" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_714" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones" xlink:label="loc_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones_715" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_StatementTable_703" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_703" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_704" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_704" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_704" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UCSFLicenseAndOptionAgreementsMember" xlink:label="loc_srzn_UCSFLicenseAndOptionAgreementsMember_706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702" xlink:to="loc_srzn_UCSFLicenseAndOptionAgreementsMember_706" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DistributedBioSubscriptionAgreementMember" xlink:label="loc_srzn_DistributedBioSubscriptionAgreementMember_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702" xlink:to="loc_srzn_DistributedBioSubscriptionAgreementMember_709" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StanfordLicenseAgreementsMember" xlink:label="loc_srzn_StanfordLicenseAgreementsMember_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702" xlink:to="loc_srzn_StanfordLicenseAgreementsMember_698" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_703" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_708" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_708" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_699" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_699_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_708" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_699_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StanfordMember" xlink:label="loc_srzn_StanfordMember_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_699" xlink:to="loc_srzn_StanfordMember_701" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_703" xlink:to="loc_srt_RangeAxis_695" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_695" xlink:to="loc_srt_RangeMember_696" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_696_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_695" xlink:to="loc_srt_RangeMember_696_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_696" xlink:to="loc_srt_MaximumMember_697" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_726" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantsRepurchased" xlink:label="loc_srzn_ClassOfWarrantsRepurchased_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_srzn_ClassOfWarrantsRepurchased_725" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_728" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockTotalPurchasePrice" xlink:label="loc_srzn_CommonStockTotalPurchasePrice_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_srzn_CommonStockTotalPurchasePrice_729" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantLiability" xlink:label="loc_srzn_WarrantLiability_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_srzn_WarrantLiability_730" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_721" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_721" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_723" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_723" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_723" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_722" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_761" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_StatementTable_739" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_srt_RangeAxis_734" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_734" xlink:to="loc_srt_RangeMember_736" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_736_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_734" xlink:to="loc_srt_RangeMember_736_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_736" xlink:to="loc_srt_MaximumMember_737" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_736" xlink:to="loc_srt_MinimumMember_748" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_TypeOfArrangementAxis_756" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_756" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_735" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_735_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_756" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_735_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_759" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_759" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_745" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_745_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_759" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_745_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_dei_LegalEntityAxis_747" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_747" xlink:to="loc_dei_EntityDomain_738" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_738_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_747" xlink:to="loc_dei_EntityDomain_738_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_GuggenheimSecuritiesLlcMember" xlink:label="loc_srzn_GuggenheimSecuritiesLlcMember_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_738" xlink:to="loc_srzn_GuggenheimSecuritiesLlcMember_755" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LincolnParkMember" xlink:label="loc_srzn_LincolnParkMember_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_738" xlink:to="loc_srzn_LincolnParkMember_746" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_752" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_752" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_744" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_744_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_752" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_744_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClosingSalePriceNotBelow1200PerShareMember" xlink:label="loc_srzn_ClosingSalePriceNotBelow1200PerShareMember_758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_744" xlink:to="loc_srzn_ClosingSalePriceNotBelow1200PerShareMember_758" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClosingSalePriceNotBelow1000PerShareMember" xlink:label="loc_srzn_ClosingSalePriceNotBelow1000PerShareMember_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_744" xlink:to="loc_srzn_ClosingSalePriceNotBelow1000PerShareMember_750" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockPurchaseCommitmentPeriod" xlink:label="loc_srzn_CommonStockPurchaseCommitmentPeriod_753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_srzn_CommonStockPurchaseCommitmentPeriod_753" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherValueOutstanding" xlink:label="loc_us-gaap_CommonStockOtherValueOutstanding_757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_CommonStockOtherValueOutstanding_757" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_760" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_SharePrice_762" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_763" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_764" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PurchaseOfAdditionalShares" xlink:label="loc_srzn_PurchaseOfAdditionalShares_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_srzn_PurchaseOfAdditionalShares_765" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PurchasePricePerShareOfAdditionalShares" xlink:label="loc_srzn_PurchasePricePerShareOfAdditionalShares_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_srzn_PurchasePricePerShareOfAdditionalShares_766" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_CommonStockValue_767" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CompensationPayable" xlink:label="loc_srzn_CompensationPayable_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_srzn_CompensationPayable_768" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_770" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_742" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_CommonStockSharesIssued_749" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_789" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_782" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_BusinessCombinationInitialWarrantsIssued" xlink:label="loc_srzn_BusinessCombinationInitialWarrantsIssued_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_BusinessCombinationInitialWarrantsIssued_787" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AssumedWarrants" xlink:label="loc_srzn_AssumedWarrants_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_AssumedWarrants_791" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantOrRightIssued" xlink:label="loc_srzn_ClassOfWarrantOrRightIssued_793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_ClassOfWarrantOrRightIssued_793" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_794" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_796" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_797" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_SharePrice_798" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantNoticePeriodPriorToRedemptionDate" xlink:label="loc_srzn_WarrantNoticePeriodPriorToRedemptionDate_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_WarrantNoticePeriodPriorToRedemptionDate_799" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantsRepurchased" xlink:label="loc_srzn_ClassOfWarrantsRepurchased_801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_ClassOfWarrantsRepurchased_801" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne" xlink:label="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne_804" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:label="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_805" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_807" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_StatementTable_779" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_779" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_785" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_785" xlink:to="loc_us-gaap_EquityComponentDomain_781" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_781_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_785" xlink:to="loc_us-gaap_EquityComponentDomain_781_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_781" xlink:to="loc_us-gaap_CommonStockMember_783" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStock1Member" xlink:label="loc_srzn_CommonStock1Member_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_781" xlink:to="loc_srzn_CommonStock1Member_788" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStock2Member" xlink:label="loc_srzn_CommonStock2Member_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_781" xlink:to="loc_srzn_CommonStock2Member_792" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_779" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_778" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_778" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_784" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_784_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_778" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_784_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PublicWarrantsMember" xlink:label="loc_srzn_PublicWarrantsMember_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_784" xlink:to="loc_srzn_PublicWarrantsMember_780" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivatePlacementWarrantsMember" xlink:label="loc_srzn_PrivatePlacementWarrantsMember_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_784" xlink:to="loc_srzn_PrivatePlacementWarrantsMember_786" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_784" xlink:to="loc_srzn_PIPEWarrantsMember_790" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/CommonStockWarrantsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantOrRightClassification" xlink:label="loc_srzn_ClassOfWarrantOrRightClassification_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_srzn_ClassOfWarrantOrRightClassification_811" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_812" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_812" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_810" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_810" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_814" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_814_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_810" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_814_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PublicWarrantsMember" xlink:label="loc_srzn_PublicWarrantsMember_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_814" xlink:to="loc_srzn_PublicWarrantsMember_813" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_814" xlink:to="loc_srzn_PIPEWarrantsMember_817" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_816" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_818" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_819" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_820" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_843" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_850" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CliffVestingPeriod" xlink:label="loc_srzn_CliffVestingPeriod_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_srzn_CliffVestingPeriod_853" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_us-gaap_PlanNameAxis_844" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_844" xlink:to="loc_us-gaap_PlanNameDomain_846" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_846_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_844" xlink:to="loc_us-gaap_PlanNameDomain_846_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TwoThousandTwentyOneStockPlanMember" xlink:label="loc_srzn_TwoThousandTwentyOneStockPlanMember_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_846" xlink:to="loc_srzn_TwoThousandTwentyOneStockPlanMember_847" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TwoThousandFifteenStockPlan1Member" xlink:label="loc_srzn_TwoThousandFifteenStockPlan1Member_834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_846" xlink:to="loc_srzn_TwoThousandFifteenStockPlan1Member_834" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_851" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_851" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_839" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_839_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_851" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_839_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EmployeeStockPurchasePlanMember" xlink:label="loc_srzn_EmployeeStockPurchasePlanMember_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_839" xlink:to="loc_srzn_EmployeeStockPurchasePlanMember_848" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_839" xlink:to="loc_us-gaap_EmployeeStockMember_835" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_srt_RangeAxis_854" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_854" xlink:to="loc_srt_RangeMember_837" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_837_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_854" xlink:to="loc_srt_RangeMember_837_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_837" xlink:to="loc_srt_MaximumMember_838" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_us-gaap_AwardTypeAxis_856" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_842" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_842_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_842_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RestrictedStockAwardRSAMember" xlink:label="loc_srzn_RestrictedStockAwardRSAMember_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_842" xlink:to="loc_srzn_RestrictedStockAwardRSAMember_841" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_us-gaap_VestingAxis_858" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_858" xlink:to="loc_us-gaap_VestingDomain_840" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_840_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_858" xlink:to="loc_us-gaap_VestingDomain_840_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_VestedMember" xlink:label="loc_srzn_VestedMember_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_840" xlink:to="loc_srzn_VestedMember_845" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UnvestedMember" xlink:label="loc_srzn_UnvestedMember_852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_840" xlink:to="loc_srzn_UnvestedMember_852" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockTradingDiscription" xlink:label="loc_srzn_CommonStockTradingDiscription_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_srzn_CommonStockTradingDiscription_866" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_CommonStockSharesIssued_867" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_868" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees" xlink:label="loc_dei_EntityNumberOfEmployees_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_dei_EntityNumberOfEmployees_869" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_870" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_StockOptionPlanExpense_871" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_857" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_859" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_861" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_862" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_863" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_864" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PercentageOfDiscountPayrollDeductions" xlink:label="loc_srzn_PercentageOfDiscountPayrollDeductions_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_srzn_PercentageOfDiscountPayrollDeductions_865" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_855" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_877" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_874" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_874" xlink:to="loc_srt_RestatementAxis_878" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_878" xlink:to="loc_srt_RestatementDomain_875" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_875_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_878" xlink:to="loc_srt_RestatementDomain_875_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_888" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_890" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_883" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_884" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_886" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_893" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_894" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_896" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_898" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_900" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_901" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909" xlink:to="loc_us-gaap_AwardTypeAxis_918" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_918" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_918" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RestrictedStockAwardRSAMember" xlink:label="loc_srzn_RestrictedStockAwardRSAMember_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913" xlink:to="loc_srzn_RestrictedStockAwardRSAMember_912" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909" xlink:to="loc_srt_RestatementAxis_915" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_915" xlink:to="loc_srt_RestatementDomain_910" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_910_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_915" xlink:to="loc_srt_RestatementDomain_910_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_914" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_924" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_927" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_921" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_940" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_942" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_944" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932" xlink:to="loc_srt_RangeAxis_937" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_937" xlink:to="loc_srt_RangeMember_933" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_933_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_937" xlink:to="loc_srt_RangeMember_933_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_941" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_941" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_938" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_938_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_941" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_938_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_938" xlink:to="loc_us-gaap_StockOptionMember_934" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_936" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_954" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_954" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_951" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_951" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_948" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_948_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_951" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_948_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_948" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_950" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_948" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_953" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_954" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_949" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_954" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_952" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_954" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_955" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TaxCreditCarryForwardsExpirationStartYear" xlink:label="loc_srzn_TaxCreditCarryForwardsExpirationStartYear_973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_srzn_TaxCreditCarryForwardsExpirationStartYear_973" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_977" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StateTaxCreditCarryForwardsExpiration" xlink:label="loc_srzn_StateTaxCreditCarryForwardsExpiration_979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_srzn_StateTaxCreditCarryForwardsExpiration_979" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_981" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" xlink:label="loc_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease_983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease_983" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription_984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_IncomeTaxExaminationDescription_984" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_OperatingLossCarryforwards_985" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ReinsuranceRetentionsPolicyAmountRetained" xlink:label="loc_srzn_ReinsuranceRetentionsPolicyAmountRetained_989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_srzn_ReinsuranceRetentionsPolicyAmountRetained_989" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_990" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_991" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_964" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_us-gaap_TaxPeriodAxis_971" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_971" xlink:to="loc_us-gaap_TaxPeriodDomain_960" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_960_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_971" xlink:to="loc_us-gaap_TaxPeriodDomain_960_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IndefiniteTaxYearMember" xlink:label="loc_srzn_IndefiniteTaxYearMember_966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_960" xlink:to="loc_srzn_IndefiniteTaxYearMember_966" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_976" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_976" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_967" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_967_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_976" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_967_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_967" xlink:to="loc_us-gaap_ResearchMember_968" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_srt_RangeAxis_978" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_978" xlink:to="loc_srt_RangeMember_962" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_962_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_978" xlink:to="loc_srt_RangeMember_962_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_980" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_980" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_969" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_969_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_980" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_969_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_958" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_958" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_970" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_970_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_958" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_970_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_970" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_972" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_970" xlink:to="loc_us-gaap_DomesticCountryMember_959" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_961" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1052" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1052" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1040" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1052" xlink:to="loc_us-gaap_SubsequentEventTable_1043" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1043" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1044" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1044" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1046" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1046_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1044" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1046_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1046" xlink:to="loc_us-gaap_SubsequentEventMember_1038" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1043" xlink:to="loc_dei_LegalEntityAxis_1048" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1048" xlink:to="loc_dei_EntityDomain_1042" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1042_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1048" xlink:to="loc_dei_EntityDomain_1042_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1043" xlink:to="loc_srt_RangeAxis_1050" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1050" xlink:to="loc_srt_RangeMember_1039" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1039_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1050" xlink:to="loc_srt_RangeMember_1039_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1052" xlink:to="loc_us-gaap_RestructuringCharges_1047" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PercentOfContractPrice" xlink:label="loc_srzn_PercentOfContractPrice_1065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1052" xlink:to="loc_srzn_PercentOfContractPrice_1065" use="optional" order="14" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>srzn-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 31-March-2023 [06:09:59] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_srzn_DocumentDocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_DocumentDocumentAndEntityInformationAbstract" xml:lang="en-US">Document Document And Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_DocumentDocumentAndEntityInformationAbstract" xlink:to="lab_srzn_DocumentDocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_DocumentDocumentAndEntityInformationAbstract" xml:lang="en-US">Document Document And Entity Information [Abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription" xml:lang="en-US">Amendment Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xml:lang="en-US">Marketable Securities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xml:lang="en-US">Short-term marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xml:lang="en-US">Marketable Securities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xml:lang="en-US">Long-term marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted Cash, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Lease liabilities, current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liabilities, noncurrent portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantLiability" xlink:label="loc_srzn_WarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_WarrantLiability" xml:lang="en-US">Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_WarrantLiability" xml:lang="en-US">Warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_WarrantLiability" xlink:to="lab_srzn_WarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_WarrantLiability" xml:lang="en-US">Warrant liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 6 and Note 14)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2022 and 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value, 500,000 shares authorized as of December 31, 2022 and 2021; 30,088 and 35,034 shares issued and outstanding as of December 31, 2022 and 2021, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in-capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at the beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at the end</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common shares, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common shares, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common shares, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common shares, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Collaboration and license revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income (expense), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized loss on marketable securities, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share attributable to common stockholders, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share attributable to common Stockholders, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Issuance of common stock upon Business Combination and PIPE Financing, net of issuance costs and warrant liabilities, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercises of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercises of stock options, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" xlink:label="loc_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" xml:lang="en-US">Adjustment to additional paid in capital reclassification of early exercised stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" xml:lang="en-US">Reclassification to liability for early exercised stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" xlink:to="lab_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" xml:lang="en-US">Adjustment to additional paid in capital reclassification of early exercised stock options.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" xlink:label="loc_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" xml:lang="en-US">Adjustment to additional paid in capital early exercise of stock options value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" xml:lang="en-US">Vesting of early exercised stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" xlink:to="lab_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" xml:lang="en-US">Adjustment to additional paid in capital early exercise of stock options value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance at the beginning (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Balance at the end (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs and warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US">Restricted stock forfeited, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement" xlink:label="loc_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement" xml:lang="en-US">IssuanceOfCommonStockValueUnderEquityPurchaseAgreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement" xml:lang="en-US">Issuance of common stock under Equity Purchase Agreement(Value)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement" xlink:to="lab_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement" xml:lang="en-US">Issuance of common stock value under equity purchase agreement.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement" xlink:label="loc_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement" xml:lang="en-US">Issuance of common stock under Equity Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement" xml:lang="en-US">Issuance of common stock under Equity Purchase Agreement (Share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement" xlink:to="lab_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement" xml:lang="en-US">Issuance of common stock under Equity Purchase Agreement</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (Share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RepurchaseOfEarlyExercisedStockOptionsShares" xlink:label="loc_srzn_RepurchaseOfEarlyExercisedStockOptionsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_RepurchaseOfEarlyExercisedStockOptionsShares" xml:lang="en-US">Repurchase Of Early Exercised Stock Options Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_srzn_RepurchaseOfEarlyExercisedStockOptionsShares" xml:lang="en-US">Repurchase of early exercised stock options, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_RepurchaseOfEarlyExercisedStockOptionsShares" xlink:to="lab_srzn_RepurchaseOfEarlyExercisedStockOptionsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_RepurchaseOfEarlyExercisedStockOptionsShares" xml:lang="en-US">Repurchase of early exercised stock options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Repurchase and cancelation of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RepurchaseAndCancellationOfCommonStock" xlink:label="loc_srzn_RepurchaseAndCancellationOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_RepurchaseAndCancellationOfCommonStock" xml:lang="en-US">Repurchase and cancellation of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_RepurchaseAndCancellationOfCommonStock" xml:lang="en-US">Repurchase and cancellation of common stock (Share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_RepurchaseAndCancellationOfCommonStock" xlink:to="lab_srzn_RepurchaseAndCancellationOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_RepurchaseAndCancellationOfCommonStock" xml:lang="en-US">Repurchase and cancellation of common stock</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Restricted stock granted, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Non-cash operating lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xml:lang="en-US">Investment Income, Amortization of Premium</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xml:lang="en-US">Amortization of premium on marketable securities, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" xlink:label="loc_srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" xml:lang="en-US">Issuance of common stock as a commitment fee under Equity Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" xml:lang="en-US">Other expense related to the commitment shares issued to Lincoln Park</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" xlink:to="lab_srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" xml:lang="en-US">Issuance of common stock as a commitment fee under Equity Purchase Agreement</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xml:lang="en-US">Business Combination, Acquisition Related Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xml:lang="en-US">Transaction costs allocated to warrants in connection with Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in Operation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Purchases of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromSaleOfMarketableSecurities" xlink:label="loc_srzn_ProceedsFromSaleOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ProceedsFromSaleOfMarketableSecurities" xml:lang="en-US">Proceeds From Sale Of Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ProceedsFromSaleOfMarketableSecurities" xml:lang="en-US">Proceeds from sales of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ProceedsFromSaleOfMarketableSecurities" xlink:to="lab_srzn_ProceedsFromSaleOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ProceedsFromSaleOfMarketableSecurities" xml:lang="en-US">Proceeds From Sale Of Marketable Securities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from maturities of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" xlink:label="loc_srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" xlink:to="lab_srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" xlink:label="loc_srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" xml:lang="en-US">Proceeds from issuance of common stock upon employee stock plan purchases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" xlink:to="lab_srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" xml:lang="en-US">Proceeds from issuance of common stock upon employee stock plan purchases</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xml:lang="en-US">Payments for Repurchase of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xml:lang="en-US">Repurchase of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RepurchaseOfEarlyExcercisedStockOptions" xlink:label="loc_srzn_RepurchaseOfEarlyExcercisedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_RepurchaseOfEarlyExcercisedStockOptions" xml:lang="en-US">Repurchase Of Early Excercised Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_srzn_RepurchaseOfEarlyExcercisedStockOptions" xml:lang="en-US">Repurchase of early exercised stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_RepurchaseOfEarlyExcercisedStockOptions" xlink:to="lab_srzn_RepurchaseOfEarlyExcercisedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_RepurchaseOfEarlyExcercisedStockOptions" xml:lang="en-US">Repurchase of early excercised stock options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of redeemable convertible preferred stock into common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination" xlink:label="loc_srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination" xml:lang="en-US">Assumption Of Warrant Liabilities In Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination" xml:lang="en-US">Assumption of warrant liabilities in Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination" xlink:to="lab_srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination" xml:lang="en-US">Assumption of warrant liabilities in business combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Transaction costs in Business Combination included in accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Payments to Acquire Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_VestingOfEarlyExercisesOfStockOptions" xlink:label="loc_srzn_VestingOfEarlyExercisesOfStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_VestingOfEarlyExercisesOfStockOptions" xml:lang="en-US">Vesting Of Early Exercises Of Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_VestingOfEarlyExercisesOfStockOptions" xml:lang="en-US">Vesting of early exercises of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_VestingOfEarlyExercisesOfStockOptions" xlink:to="lab_srzn_VestingOfEarlyExercisesOfStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_VestingOfEarlyExercisesOfStockOptions" xml:lang="en-US">Vesting of early exercises of stock options.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions" xlink:label="loc_srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions" xml:lang="en-US">Reclassification To Liability For Early Exercised Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions" xml:lang="en-US">Reclassification to liability for early exercised stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions" xlink:to="lab_srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions" xml:lang="en-US">Reclassification to liability for early exercised stock options.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" xlink:label="loc_srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" xml:lang="en-US">Increase in right-of-use assets and lease liabilities due to lease extension</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" xml:lang="en-US">Increase in right-of-use assets and lease liabilities due to lease extension</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" xlink:to="lab_srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" xml:lang="en-US">Increase in right-of-use assets and lease liabilities due to lease extension</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract" xlink:label="loc_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash To Consolidated Balance Sheets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash To Consolidated Balance Sheets Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract" xlink:to="lab_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract" xml:lang="en-US">Reconciliation of cash,cash equivalents and restricted cash to consolidated balance sheets abstract.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Organization and Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RecapitalizationNoteAbstract" xlink:label="loc_srzn_RecapitalizationNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_RecapitalizationNoteAbstract" xml:lang="en-US">Recapitalization Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_RecapitalizationNoteAbstract" xlink:to="lab_srzn_RecapitalizationNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_RecapitalizationNoteAbstract" xml:lang="en-US">Recapitalization</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RecapitalizationNoteDisclosureTextBlock" xlink:label="loc_srzn_RecapitalizationNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_RecapitalizationNoteDisclosureTextBlock" xml:lang="en-US">Recapitalization Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_RecapitalizationNoteDisclosureTextBlock" xml:lang="en-US">Recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_RecapitalizationNoteDisclosureTextBlock" xlink:to="lab_srzn_RecapitalizationNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_RecapitalizationNoteDisclosureTextBlock" xml:lang="en-US">The entire disclosure for recapitalization.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Balance Sheet Components</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CollaborationAndLicenseAgreementsTextBlock" xlink:label="loc_srzn_CollaborationAndLicenseAgreementsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CollaborationAndLicenseAgreementsTextBlock" xml:lang="en-US">Collaboration and License Agreements [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_CollaborationAndLicenseAgreementsTextBlock" xml:lang="en-US">Collaboration and License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CollaborationAndLicenseAgreementsTextBlock" xlink:to="lab_srzn_CollaborationAndLicenseAgreementsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CollaborationAndLicenseAgreementsTextBlock" xml:lang="en-US">The entire disclosure for collaboration and license agreements.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LicenseAgreementsAbstract" xlink:label="loc_srzn_LicenseAgreementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_LicenseAgreementsAbstract" xml:lang="en-US">License Agreements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_LicenseAgreementsAbstract" xlink:to="lab_srzn_LicenseAgreementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_LicenseAgreementsAbstract" xml:lang="en-US">License Agreements Abstract.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LicenseAgreementsDisclosureTextBlock" xlink:label="loc_srzn_LicenseAgreementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_LicenseAgreementsDisclosureTextBlock" xml:lang="en-US">License Agreements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_LicenseAgreementsDisclosureTextBlock" xml:lang="en-US">License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_LicenseAgreementsDisclosureTextBlock" xlink:to="lab_srzn_LicenseAgreementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_LicenseAgreementsDisclosureTextBlock" xml:lang="en-US">License agreements disclosure [Text Block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockWarrantsDisclosureTextBlock" xlink:label="loc_srzn_CommonStockWarrantsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CommonStockWarrantsDisclosureTextBlock" xml:lang="en-US">Common Stock Warrants Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_CommonStockWarrantsDisclosureTextBlock" xml:lang="en-US">Common Stock Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CommonStockWarrantsDisclosureTextBlock" xlink:to="lab_srzn_CommonStockWarrantsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CommonStockWarrantsDisclosureTextBlock" xml:lang="en-US">The entire disclosure for common stock warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock-Based Compensation Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Retirement Benefits [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">401(K) Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US">Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantLiabilityPolicyTextBlock" xlink:label="loc_srzn_WarrantLiabilityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Warrant Liability Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Warrant Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_WarrantLiabilityPolicyTextBlock" xlink:to="lab_srzn_WarrantLiabilityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">warrant liability[Policy text block].</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RevenueRecognitionsPolicyTextBlock" xlink:label="loc_srzn_RevenueRecognitionsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_RevenueRecognitionsPolicyTextBlock" xml:lang="en-US">Revenue Recognitions [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_RevenueRecognitionsPolicyTextBlock" xml:lang="en-US">Revenue Recognitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_RevenueRecognitionsPolicyTextBlock" xlink:to="lab_srzn_RevenueRecognitionsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_RevenueRecognitionsPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for revenue recognitions.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="loc_srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xml:lang="en-US">Accrued Research And Development Expenses Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xml:lang="en-US">Accrued Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="lab_srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xml:lang="en-US">Accrued research and development expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_srzn_EmergingGrowthCompanyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_EmergingGrowthCompanyPolicyTextBlock" xml:lang="en-US">Emerging Growth Company Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_EmergingGrowthCompanyPolicyTextBlock" xml:lang="en-US">Emerging Growth Company Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_EmergingGrowthCompanyPolicyTextBlock" xlink:to="lab_srzn_EmergingGrowthCompanyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_EmergingGrowthCompanyPolicyTextBlock" xml:lang="en-US">Represents the accounting policy on Emerging Growth Company.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Property Plant And Equipment Useful Lives Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Summary of Property and Equipment Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="lab_srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xml:lang="en-US">Property plant and equipment useful lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Summary of Changes in Fair Value of Warrant Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xml:lang="en-US">Schedule of Marketable Securities by Security Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xml:lang="en-US">Schedule of Unrealized Loss on Investments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xml:lang="en-US">Schedule Of Unrealized Loss On Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued and Other Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of Lessee, Operating Lease, Liability, Maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule Of Supplemental Information Related To Operating Leases Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Supplemental Information Related to Operating Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="lab_srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of supplemental information related to operating leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Common Stock Warrants Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of stock option activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Summary of RSA Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate TO Effective Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Summary of Net Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xml:lang="en-US">Summary of Unrecognized Tax Benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xml:lang="en-US">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xml:lang="en-US">Subsidiary Sale Of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash, cash equivalents and marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivatePlacementWarrantsMember" xlink:label="loc_srzn_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PrivatePlacementWarrantsMember" xlink:to="lab_srzn_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PrivatePlacementWarrantsMember" xml:lang="en-US">Private placement warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Common Stock Warrants Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantsRepurchased" xlink:label="loc_srzn_ClassOfWarrantsRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ClassOfWarrantsRepurchased" xml:lang="en-US">Class of Warrants Repurchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ClassOfWarrantsRepurchased" xml:lang="en-US">Class of warrants repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ClassOfWarrantsRepurchased" xlink:to="lab_srzn_ClassOfWarrantsRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ClassOfWarrantsRepurchased" xml:lang="en-US">Class of warrants repurchased.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_FurnitureFixturesAndEquipmentMember" xlink:label="loc_srzn_FurnitureFixturesAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_FurnitureFixturesAndEquipmentMember" xml:lang="en-US">Furniture Fixtures And Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_FurnitureFixturesAndEquipmentMember" xml:lang="en-US">Furniture Fixtures And Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_FurnitureFixturesAndEquipmentMember" xlink:to="lab_srzn_FurnitureFixturesAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_FurnitureFixturesAndEquipmentMember" xml:lang="en-US">Furniture Fixtures and Equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xml:lang="en-US">Other Machinery and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Options Outstanding [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RestrictedStockAwardRSAMember" xlink:label="loc_srzn_RestrictedStockAwardRSAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_RestrictedStockAwardRSAMember" xml:lang="en-US">Restricted Stock Award R S A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_RestrictedStockAwardRSAMember" xml:lang="en-US">RSA [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_RestrictedStockAwardRSAMember" xlink:to="lab_srzn_RestrictedStockAwardRSAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_RestrictedStockAwardRSAMember" xml:lang="en-US">Restricted Stock Award R S A.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember" xlink:label="loc_srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember" xml:lang="en-US">Unvested Common Stock Shares Subject To Repurchase [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember" xml:lang="en-US">Unvested common stock subject to repurchase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember" xlink:to="lab_srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember" xml:lang="en-US">Unvested Common Stock Shares Subject To Repurchase.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantToPurchaseCommonStockMember" xlink:label="loc_srzn_WarrantToPurchaseCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_WarrantToPurchaseCommonStockMember" xml:lang="en-US">Warrant To Purchase Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_WarrantToPurchaseCommonStockMember" xml:lang="en-US">Warrants To Purchase Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_WarrantToPurchaseCommonStockMember" xlink:to="lab_srzn_WarrantToPurchaseCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_WarrantToPurchaseCommonStockMember" xml:lang="en-US">Warrant To Purchase Common Stock.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AccountingPoliciesLineItems" xlink:label="loc_srzn_AccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AccountingPoliciesLineItems" xml:lang="en-US">Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AccountingPoliciesLineItems" xlink:to="lab_srzn_AccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AccountingPoliciesLineItems" xml:lang="en-US">Accounting policies.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" xlink:label="loc_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" xml:lang="en-US">Proceeds From Cash Acquired Through Acquisition And Private Investment In Public Entity Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" xml:lang="en-US">Proceeds from cash acquired through acquisition and PIPE offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" xlink:to="lab_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" xml:lang="en-US">Proceeds from cash acquired through acquisition and private investment in public entity offering.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from issuance of units upon PIPE Financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xml:lang="en-US">Business Acquisition, Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xml:lang="en-US">Transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" xlink:label="loc_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" xml:lang="en-US">Business Acquisition Remaining Cost Of Acquired Entity Recorded as a Reduction of Additional Paid-in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" xml:lang="en-US">Reduction Of Additional Paid In Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" xlink:to="lab_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" xml:lang="en-US">Business Acquisition Remaining Cost Of Acquired Entity Recorded as a Reduction of Additional Paid-in Capital</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Share issued, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Series C redeemable convertible preferred stock, net of issuance costs, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares issued, price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivateInvestmentInPublicEntityOfferingMember" xlink:label="loc_srzn_PrivateInvestmentInPublicEntityOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PrivateInvestmentInPublicEntityOfferingMember" xml:lang="en-US">Private Investment In Public Entity Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_PrivateInvestmentInPublicEntityOfferingMember" xml:lang="en-US">Private Investment In Public Entity Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PrivateInvestmentInPublicEntityOfferingMember" xlink:to="lab_srzn_PrivateInvestmentInPublicEntityOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PrivateInvestmentInPublicEntityOfferingMember" xml:lang="en-US">Private investment in public entity offering member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_SurrozenIncMember" xlink:label="loc_srzn_SurrozenIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_SurrozenIncMember" xml:lang="en-US">Surrozen Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_SurrozenIncMember" xml:lang="en-US">Surrozen Inc</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_SurrozenIncMember" xlink:to="lab_srzn_SurrozenIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_SurrozenIncMember" xml:lang="en-US">Surrozen Inc Member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CorporateBondMember" xlink:label="loc_srzn_CorporateBondMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CorporateBondMember" xml:lang="en-US">Corporate Bond [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_CorporateBondMember" xml:lang="en-US">Corporate Bond</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CorporateBondMember" xlink:to="lab_srzn_CorporateBondMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CorporateBondMember" xml:lang="en-US">Corporate bonds.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_GovernmentBondsMember" xlink:label="loc_srzn_GovernmentBondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_GovernmentBondsMember" xml:lang="en-US">Government bonds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_GovernmentBondsMember" xml:lang="en-US">Government Bonds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_GovernmentBondsMember" xlink:to="lab_srzn_GovernmentBondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_GovernmentBondsMember" xml:lang="en-US">Government bonds [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xml:lang="en-US">Government agency debt securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ForeignBondsMember" xlink:label="loc_srzn_ForeignBondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ForeignBondsMember" xml:lang="en-US">Foreign bonds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ForeignBondsMember" xml:lang="en-US">Foreign Bonds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ForeignBondsMember" xlink:to="lab_srzn_ForeignBondsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ForeignBondsMember" xml:lang="en-US">Foreign bonds [Member]</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PublicWarrantsMember" xlink:label="loc_srzn_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_PublicWarrantsMember" xml:lang="en-US">Public Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PublicWarrantsMember" xlink:to="lab_srzn_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PublicWarrantsMember" xml:lang="en-US">Public warrants.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PIPEWarrantsMember" xml:lang="en-US">P I P E Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_PIPEWarrantsMember" xml:lang="en-US">P I P E Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PIPEWarrantsMember" xlink:to="lab_srzn_PIPEWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PIPEWarrantsMember" xml:lang="en-US">PIPE warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities(2):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xml:lang="en-US">Measurement Input, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xml:lang="en-US">Dividend Yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xml:lang="en-US">Transfers of financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xml:lang="en-US">Alternative Investment, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xml:lang="en-US">Alternative Investment, Measurement Input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StockPriceToRedeemsWarrants" xlink:label="loc_srzn_StockPriceToRedeemsWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_StockPriceToRedeemsWarrants" xml:lang="en-US">Stock Price to Redeems Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_StockPriceToRedeemsWarrants" xml:lang="en-US">Stock price to redeem warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_StockPriceToRedeemsWarrants" xlink:to="lab_srzn_StockPriceToRedeemsWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_StockPriceToRedeemsWarrants" xml:lang="en-US">Stock Price to Redeems Warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Expected Term (Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Expected Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US">Warrants, Measurement Input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xml:lang="en-US">Balance, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xml:lang="en-US">Balance, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" xlink:label="loc_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Assumption In Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" xml:lang="en-US">Assumption in Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" xlink:to="lab_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis assumption in business combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Change in fair value upon remeasurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromRepurchaseOfWarrants" xlink:label="loc_srzn_ProceedsFromRepurchaseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ProceedsFromRepurchaseOfWarrants" xml:lang="en-US">Proceeds From Repurchase Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_srzn_ProceedsFromRepurchaseOfWarrants" xml:lang="en-US">Repurchase (Note 9)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ProceedsFromRepurchaseOfWarrants" xlink:to="lab_srzn_ProceedsFromRepurchaseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ProceedsFromRepurchaseOfWarrants" xml:lang="en-US">Proceeds from repurchase of warrants.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:label="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xml:lang="en-US">Gross Unrealized Gains, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax, Current</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Gross Unrealized Gains, Non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xml:lang="en-US">Gross Unrealized Losses, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax, Current</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xlink:label="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xml:lang="en-US">Gross Unrealized Gains, Non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xlink:to="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xml:lang="en-US">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-sale, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xml:lang="en-US">Fair Value, Non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xml:lang="en-US">Amortized Cost Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xml:lang="en-US">Amortized Cost, Non-current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xml:lang="en-US">Less then 12 Months, Unrealized Losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xml:lang="en-US">Number Of Positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xml:lang="en-US">Less then 12 Months, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property Plant And Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LabEquipmentMember" xlink:label="loc_srzn_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_LabEquipmentMember" xml:lang="en-US">Lab equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_LabEquipmentMember" xlink:to="lab_srzn_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_LabEquipmentMember" xml:lang="en-US">Lab equipment..</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and office equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" xlink:label="loc_srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" xml:lang="en-US">Accrued Research And Development Expenses Current And Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" xml:lang="en-US">Accrued research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" xlink:to="lab_srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" xml:lang="en-US">Accrued research and development expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xml:lang="en-US">Accrued professional service fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Other Employee-related Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Liability for early exercised stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Other Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xml:lang="en-US">Accrued Employee Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xml:lang="en-US">Accrued payroll and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee Lease Description [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EightYearsMember" xlink:label="loc_srzn_EightYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_EightYearsMember" xml:lang="en-US">Eight Years [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_EightYearsMember" xml:lang="en-US">Eight Years [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_EightYearsMember" xlink:to="lab_srzn_EightYearsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_EightYearsMember" xml:lang="en-US">Eight years.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee Lease Description [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_OperatingLeaseMonthOfExpiryOfLease" xlink:label="loc_srzn_OperatingLeaseMonthOfExpiryOfLease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_OperatingLeaseMonthOfExpiryOfLease" xml:lang="en-US">Operating Lease Month Of Expiry Of Lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_OperatingLeaseMonthOfExpiryOfLease" xml:lang="en-US">Operating lease month of expiry of lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_OperatingLeaseMonthOfExpiryOfLease" xlink:to="lab_srzn_OperatingLeaseMonthOfExpiryOfLease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_OperatingLeaseMonthOfExpiryOfLease" xml:lang="en-US">Operating lease month Of expiry of lease.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Operating lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xml:lang="en-US">Area of Real Estate Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xml:lang="en-US">Area of real estate property</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="loc_stpr_CA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_stpr_CA" xml:lang="en-US">CALIFORNIA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_stpr_CA" xml:lang="en-US">CALIFORNIA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Year ending December 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Year ending December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Year ending December 31, 2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: Imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted-average remaining lease term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted-average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_SuccessBasedMilestonePayments" xlink:label="loc_srzn_SuccessBasedMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_SuccessBasedMilestonePayments" xml:lang="en-US">Success-based milestone payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_SuccessBasedMilestonePayments" xml:lang="en-US">Success-based milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_SuccessBasedMilestonePayments" xlink:to="lab_srzn_SuccessBasedMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_SuccessBasedMilestonePayments" xml:lang="en-US">Success-based milestone payments</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UpfrontPayment" xlink:label="loc_srzn_UpfrontPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_UpfrontPayment" xml:lang="en-US">Upfront Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_UpfrontPayment" xml:lang="en-US">Upfront Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_UpfrontPayment" xlink:to="lab_srzn_UpfrontPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_UpfrontPayment" xml:lang="en-US">Upfront payment.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AssociatedWithholdingTax" xlink:label="loc_srzn_AssociatedWithholdingTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AssociatedWithholdingTax" xml:lang="en-US">Associated Withholding Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_AssociatedWithholdingTax" xml:lang="en-US">Associated withholding tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AssociatedWithholdingTax" xlink:to="lab_srzn_AssociatedWithholdingTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AssociatedWithholdingTax" xml:lang="en-US">Associated withholding tax.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TransactionPrice" xlink:label="loc_srzn_TransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_TransactionPrice" xml:lang="en-US">Transaction price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_TransactionPrice" xml:lang="en-US">Transaction price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_TransactionPrice" xlink:to="lab_srzn_TransactionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_TransactionPrice" xml:lang="en-US">Transaction price</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_NonRefundableUpfrontPaymentReceived" xlink:label="loc_srzn_NonRefundableUpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_NonRefundableUpfrontPaymentReceived" xml:lang="en-US">Non-refundable upfront payment received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_NonRefundableUpfrontPaymentReceived" xml:lang="en-US">Non-refundable upfront payment received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_NonRefundableUpfrontPaymentReceived" xlink:to="lab_srzn_NonRefundableUpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_NonRefundableUpfrontPaymentReceived" xml:lang="en-US">Non-refundable upfront payment received</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CollaborationAndLicenseAgreementWithBiMember" xlink:label="loc_srzn_CollaborationAndLicenseAgreementWithBiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CollaborationAndLicenseAgreementWithBiMember" xml:lang="en-US">Collaboration and License Agreement with BI [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_CollaborationAndLicenseAgreementWithBiMember" xml:lang="en-US">Collaboration and License Agreement with BI [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CollaborationAndLicenseAgreementWithBiMember" xlink:to="lab_srzn_CollaborationAndLicenseAgreementWithBiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CollaborationAndLicenseAgreementWithBiMember" xml:lang="en-US">Collaboration and License Agreement with BI [Member]</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UCSFLicenseAndOptionAgreementsMember" xlink:label="loc_srzn_UCSFLicenseAndOptionAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_UCSFLicenseAndOptionAgreementsMember" xml:lang="en-US">U C S F License And Option Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_UCSFLicenseAndOptionAgreementsMember" xml:lang="en-US">U C S F License And Option Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_UCSFLicenseAndOptionAgreementsMember" xlink:to="lab_srzn_UCSFLicenseAndOptionAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_UCSFLicenseAndOptionAgreementsMember" xml:lang="en-US">UCSF License And Option Agreements Member.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DistributedBioSubscriptionAgreementMember" xlink:label="loc_srzn_DistributedBioSubscriptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_DistributedBioSubscriptionAgreementMember" xml:lang="en-US">Distributed Bio Subscription Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_DistributedBioSubscriptionAgreementMember" xml:lang="en-US">Distributed Bio Subscription Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_DistributedBioSubscriptionAgreementMember" xlink:to="lab_srzn_DistributedBioSubscriptionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_DistributedBioSubscriptionAgreementMember" xml:lang="en-US">Distributed Bio Subscription Agreement Member.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StanfordLicenseAgreementsMember" xlink:label="loc_srzn_StanfordLicenseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_StanfordLicenseAgreementsMember" xml:lang="en-US">Stanford License Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_StanfordLicenseAgreementsMember" xml:lang="en-US">Stanford License Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_StanfordLicenseAgreementsMember" xlink:to="lab_srzn_StanfordLicenseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_StanfordLicenseAgreementsMember" xml:lang="en-US">Stanford License Agreements member.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StanfordMember" xlink:label="loc_srzn_StanfordMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_StanfordMember" xml:lang="en-US">Stanford [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_StanfordMember" xml:lang="en-US">Stanford [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_StanfordMember" xlink:to="lab_srzn_StanfordMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_StanfordMember" xml:lang="en-US">Stanford Member.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" xlink:label="loc_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" xml:lang="en-US">Payments For Milestone Agreement Or Earned Royalties On Achievement Of Milestones</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" xml:lang="en-US">Payments for milestone agreement or earned royalties on achievement of milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" xlink:to="lab_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" xml:lang="en-US">Payments for milestone agreement or earned royalties on achievement of milestones.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" xlink:label="loc_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" xml:lang="en-US">Payments For Achievement Of Specified Development And Regulatory Milestones</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" xml:lang="en-US">Payments for achievement of specified development and regulatory milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" xlink:to="lab_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" xml:lang="en-US">Payments for achievement of specified development and regulatory milestones.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones" xlink:label="loc_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones" xml:lang="en-US">Payments For Milestone Agreement On Achievement Of Milestones</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones" xml:lang="en-US">Payments for milestone agreement on achievement of milestones</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones" xlink:to="lab_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones" xml:lang="en-US">Payments for milestone agreement on achievement of milestones.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Repurchase of warrants or repurchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockTotalPurchasePrice" xlink:label="loc_srzn_CommonStockTotalPurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CommonStockTotalPurchasePrice" xml:lang="en-US">Common Stock total purchase price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_CommonStockTotalPurchasePrice" xml:lang="en-US">Common stock purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CommonStockTotalPurchasePrice" xlink:to="lab_srzn_CommonStockTotalPurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CommonStockTotalPurchasePrice" xml:lang="en-US">Common Stock total purchase price</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xml:lang="en-US">Share repurchased, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockPurchaseCommitmentPeriod" xlink:label="loc_srzn_CommonStockPurchaseCommitmentPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CommonStockPurchaseCommitmentPeriod" xml:lang="en-US">Common Stock Purchase Commitment Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srzn_CommonStockPurchaseCommitmentPeriod" xml:lang="en-US">Stock Issuance period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CommonStockPurchaseCommitmentPeriod" xlink:to="lab_srzn_CommonStockPurchaseCommitmentPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CommonStockPurchaseCommitmentPeriod" xml:lang="en-US">Common stock purchase commitment period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherValueOutstanding" xlink:label="loc_us-gaap_CommonStockOtherValueOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockOtherValueOutstanding" xml:lang="en-US">Common Stock, Other Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockOtherValueOutstanding" xml:lang="en-US">Common stock with the fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherValueOutstanding" xlink:to="lab_us-gaap_CommonStockOtherValueOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Common stock purchase commitment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Common stock per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Issuance of common stock Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sole discretion purchase common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Description of common stock closing sale transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_us-gaap_SaleOfStockDescriptionOfTransaction" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PurchaseOfAdditionalShares" xlink:label="loc_srzn_PurchaseOfAdditionalShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PurchaseOfAdditionalShares" xml:lang="en-US">Purchase of additional shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PurchaseOfAdditionalShares" xlink:to="lab_srzn_PurchaseOfAdditionalShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PurchaseOfAdditionalShares" xml:lang="en-US">Purchase of additional shares</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PurchasePricePerShareOfAdditionalShares" xlink:label="loc_srzn_PurchasePricePerShareOfAdditionalShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PurchasePricePerShareOfAdditionalShares" xml:lang="en-US">Purchase Price Per Share of Additional Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_PurchasePricePerShareOfAdditionalShares" xml:lang="en-US">Purchase price of additional shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PurchasePricePerShareOfAdditionalShares" xlink:to="lab_srzn_PurchasePricePerShareOfAdditionalShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PurchasePricePerShareOfAdditionalShares" xml:lang="en-US">Purchase price per share of additional shares.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CompensationPayable" xlink:label="loc_srzn_CompensationPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CompensationPayable" xml:lang="en-US">Compensation payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_CompensationPayable" xml:lang="en-US">Compensation payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CompensationPayable" xlink:to="lab_srzn_CompensationPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CompensationPayable" xml:lang="en-US">Compensation payable</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of stock, consideration received on transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_GuggenheimSecuritiesLlcMember" xlink:label="loc_srzn_GuggenheimSecuritiesLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_GuggenheimSecuritiesLlcMember" xml:lang="en-US">Guggenheim Securities, LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_GuggenheimSecuritiesLlcMember" xlink:to="lab_srzn_GuggenheimSecuritiesLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_GuggenheimSecuritiesLlcMember" xml:lang="en-US">Guggenheim Securities, LLC [Member]</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LincolnParkMember" xlink:label="loc_srzn_LincolnParkMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_LincolnParkMember" xml:lang="en-US">Lincoln Park [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_LincolnParkMember" xlink:to="lab_srzn_LincolnParkMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_LincolnParkMember" xml:lang="en-US">Lincoln Park [Member]</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClosingSalePriceNotBelow1200PerShareMember" xlink:label="loc_srzn_ClosingSalePriceNotBelow1200PerShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ClosingSalePriceNotBelow1200PerShareMember" xml:lang="en-US">Closing Sale Price Not Below 1200 Per Share [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ClosingSalePriceNotBelow1200PerShareMember" xlink:to="lab_srzn_ClosingSalePriceNotBelow1200PerShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ClosingSalePriceNotBelow1200PerShareMember" xml:lang="en-US">Closing sale price not below 1200 Per share.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClosingSalePriceNotBelow1000PerShareMember" xlink:label="loc_srzn_ClosingSalePriceNotBelow1000PerShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ClosingSalePriceNotBelow1000PerShareMember" xml:lang="en-US">Closing Sale Price Not Below 10.00 per Share [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ClosingSalePriceNotBelow1000PerShareMember" xlink:to="lab_srzn_ClosingSalePriceNotBelow1000PerShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ClosingSalePriceNotBelow1000PerShareMember" xml:lang="en-US">Closing sale price not below 10.00 per share .</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStock1Member" xlink:label="loc_srzn_CommonStock1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CommonStock1Member" xml:lang="en-US">Common Stock1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_CommonStock1Member" xml:lang="en-US">Common Stock, Closing Price equals or Exceeds $18 Per Share [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CommonStock1Member" xlink:to="lab_srzn_CommonStock1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CommonStock1Member" xml:lang="en-US">Common Stock, 1.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStock2Member" xlink:label="loc_srzn_CommonStock2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CommonStock2Member" xml:lang="en-US">Common Stock2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_CommonStock2Member" xml:lang="en-US">Common Stock, Closing Price equals or Exceeds $10 Per Share [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CommonStock2Member" xlink:to="lab_srzn_CommonStock2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CommonStock2Member" xml:lang="en-US">Common Stock, 2.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_BusinessCombinationInitialWarrantsIssued" xlink:label="loc_srzn_BusinessCombinationInitialWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_BusinessCombinationInitialWarrantsIssued" xml:lang="en-US">Business Combination Initial Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_BusinessCombinationInitialWarrantsIssued" xml:lang="en-US">Common stock warrants issued as part of business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_BusinessCombinationInitialWarrantsIssued" xlink:to="lab_srzn_BusinessCombinationInitialWarrantsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_BusinessCombinationInitialWarrantsIssued" xml:lang="en-US">Business Combination Initial Warrants Issued.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AssumedWarrants" xlink:label="loc_srzn_AssumedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_AssumedWarrants" xml:lang="en-US">Assumed Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_AssumedWarrants" xml:lang="en-US">Common stock warrants assumed as part of business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_AssumedWarrants" xlink:to="lab_srzn_AssumedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_AssumedWarrants" xml:lang="en-US">Assumed warrants.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantOrRightIssued" xlink:label="loc_srzn_ClassOfWarrantOrRightIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ClassOfWarrantOrRightIssued" xml:lang="en-US">Class Of Warrant Or Right Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ClassOfWarrantOrRightIssued" xml:lang="en-US">Common stock warrants issued as part of business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ClassOfWarrantOrRightIssued" xlink:to="lab_srzn_ClassOfWarrantOrRightIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ClassOfWarrantOrRightIssued" xml:lang="en-US">Class of warrant or right issued.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Common Stock Warrants Expiration Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xml:lang="en-US">Class Of Warrant Or Right Redemption Price Of Warrants Or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xml:lang="en-US">Redemption Price Per Public Warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="lab_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xml:lang="en-US">Class Of Warrant Or Right Redemption Price Of Warrants Or Rights.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantNoticePeriodPriorToRedemptionDate" xlink:label="loc_srzn_WarrantNoticePeriodPriorToRedemptionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_WarrantNoticePeriodPriorToRedemptionDate" xml:lang="en-US">Warrant Notice Period Prior To Redemption Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_WarrantNoticePeriodPriorToRedemptionDate" xml:lang="en-US">Warrant Redemption Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_WarrantNoticePeriodPriorToRedemptionDate" xlink:to="lab_srzn_WarrantNoticePeriodPriorToRedemptionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_WarrantNoticePeriodPriorToRedemptionDate" xml:lang="en-US">Redemption Period.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne" xlink:label="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne" xml:lang="en-US">Warrant Redemption Condition Minimum Share Price Scenario One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne" xml:lang="en-US">Warrant Redemption Condition Minimum Share Price Scenario One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne" xlink:to="lab_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne" xml:lang="en-US">Warrant Redemption Condition Minimum Share Price Scenario One</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:label="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xml:lang="en-US">Warrant Redemption Condition Minimum Share Price Scenario Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xml:lang="en-US">Warrant Redemption Condition Minimum Share Price Scenario Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:to="lab_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xml:lang="en-US">WarrantRedemptionConditionMinimumSharePriceScenarioTwo</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Common stock warrants exercise price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class Of Warrant Or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class Of Warrant Or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantOrRightClassification" xlink:label="loc_srzn_ClassOfWarrantOrRightClassification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ClassOfWarrantOrRightClassification" xml:lang="en-US">Class Of Warrant Or Right Classification</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ClassOfWarrantOrRightClassification" xml:lang="en-US">Common Stock Warrant Classification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ClassOfWarrantOrRightClassification" xlink:to="lab_srzn_ClassOfWarrantOrRightClassification" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ClassOfWarrantOrRightClassification" xml:lang="en-US">Class of Warrant or Right Classification.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Common Stock Warrants Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TwoThousandTwentyOneStockPlanMember" xlink:label="loc_srzn_TwoThousandTwentyOneStockPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_TwoThousandTwentyOneStockPlanMember" xml:lang="en-US">Two Thousand Twenty One Equity Incentive Stock Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_TwoThousandTwentyOneStockPlanMember" xml:lang="en-US">2021 Stock Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_TwoThousandTwentyOneStockPlanMember" xlink:to="lab_srzn_TwoThousandTwentyOneStockPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_TwoThousandTwentyOneStockPlanMember" xml:lang="en-US">Two Thousand Twenty One Equity Incentive Plan [Member]</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TwoThousandFifteenStockPlan1Member" xlink:label="loc_srzn_TwoThousandFifteenStockPlan1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_TwoThousandFifteenStockPlan1Member" xml:lang="en-US">Two thousand fifteen stock plan 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_TwoThousandFifteenStockPlan1Member" xml:lang="en-US">2015 stock plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_TwoThousandFifteenStockPlan1Member" xlink:to="lab_srzn_TwoThousandFifteenStockPlan1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_TwoThousandFifteenStockPlan1Member" xml:lang="en-US">Two thousand fifteen stock plan 1 [Member]</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EmployeeStockPurchasePlanMember" xlink:label="loc_srzn_EmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee stock purchase plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_EmployeeStockPurchasePlanMember" xlink:to="lab_srzn_EmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_EmployeeStockPurchasePlanMember" xml:lang="en-US">Employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember" xml:lang="en-US">Employee Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockMember" xml:lang="en-US">Employee Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_VestedMember" xlink:label="loc_srzn_VestedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_VestedMember" xml:lang="en-US">vested member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_VestedMember" xlink:to="lab_srzn_VestedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_VestedMember" xml:lang="en-US">vested member</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UnvestedMember" xlink:label="loc_srzn_UnvestedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_UnvestedMember" xml:lang="en-US">unvested member</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_UnvestedMember" xlink:to="lab_srzn_UnvestedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_UnvestedMember" xml:lang="en-US">unvested member</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vesting Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CliffVestingPeriod" xlink:label="loc_srzn_CliffVestingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CliffVestingPeriod" xml:lang="en-US">Cliff vesting period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_CliffVestingPeriod" xml:lang="en-US">Cliff vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CliffVestingPeriod" xlink:to="lab_srzn_CliffVestingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CliffVestingPeriod" xml:lang="en-US">Cliff vesting period.</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockTradingDiscription" xlink:label="loc_srzn_CommonStockTradingDiscription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_CommonStockTradingDiscription" xml:lang="en-US">Common Stock Trading Discription</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_CommonStockTradingDiscription" xml:lang="en-US">Common stock trading description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_CommonStockTradingDiscription" xlink:to="lab_srzn_CommonStockTradingDiscription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_CommonStockTradingDiscription" xml:lang="en-US">Common Stock Trading Discription</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock options outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options Outstanding Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options Outstanding Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees" xlink:label="loc_dei_EntityNumberOfEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityNumberOfEmployees" xml:lang="en-US">Entity Number of Employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityNumberOfEmployees" xml:lang="en-US">Number of employees held stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionPlanExpense" xml:lang="en-US">Stock or Unit Option Plan Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockOptionPlanExpense" xml:lang="en-US">Incremental expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense" xlink:to="lab_us-gaap_StockOptionPlanExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Shares reserved for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Intrinsic value of options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value/shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xml:lang="en-US">Fair value of RSAs vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized stock based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted-average period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PercentageOfDiscountPayrollDeductions" xlink:label="loc_srzn_PercentageOfDiscountPayrollDeductions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PercentageOfDiscountPayrollDeductions" xml:lang="en-US">Percentage of discount payroll deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PercentageOfDiscountPayrollDeductions" xlink:to="lab_srzn_PercentageOfDiscountPayrollDeductions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PercentageOfDiscountPayrollDeductions" xml:lang="en-US">Percentage of discount payroll deductions</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Plan Modification, Description and Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xml:lang="en-US">Description of modification of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Options outstanding and exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of options Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Number of Options Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Options outstanding and exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life (In Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life, exercisable (In Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Shares RSAs, unvested, Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value RSAs, Unvested Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value RSAs, Unvested Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value RSAs, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Number of Shares RSAs, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xml:lang="en-US">Derivative Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xml:lang="en-US">Derivative Contract [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Equity Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockOptionMember" xml:lang="en-US">Stock Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Total stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IndefiniteTaxYearMember" xlink:label="loc_srzn_IndefiniteTaxYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_IndefiniteTaxYearMember" xml:lang="en-US">Indefinite Tax Year [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_IndefiniteTaxYearMember" xml:lang="en-US">Indefinite Tax Year [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_IndefiniteTaxYearMember" xlink:to="lab_srzn_IndefiniteTaxYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_IndefiniteTaxYearMember" xml:lang="en-US">Indefinite Tax Year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xml:lang="en-US">Unusual or Infrequent Item, or Both</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xml:lang="en-US">Unusual or Infrequent Item, or Both</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TaxCreditCarryForwardsExpirationStartYear" xlink:label="loc_srzn_TaxCreditCarryForwardsExpirationStartYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_TaxCreditCarryForwardsExpirationStartYear" xml:lang="en-US">Tax Credit Carry Forwards Expiration Start Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_TaxCreditCarryForwardsExpirationStartYear" xml:lang="en-US">Tax credit carry forwards expiration start year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_TaxCreditCarryForwardsExpirationStartYear" xlink:to="lab_srzn_TaxCreditCarryForwardsExpirationStartYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_TaxCreditCarryForwardsExpirationStartYear" xml:lang="en-US">Tax credit carry forwards expiration start year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StateTaxCreditCarryForwardsExpiration" xlink:label="loc_srzn_StateTaxCreditCarryForwardsExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_StateTaxCreditCarryForwardsExpiration" xml:lang="en-US">State Tax Credit Carry Forwards Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_StateTaxCreditCarryForwardsExpiration" xml:lang="en-US">Tax credit carry forwards expiration start year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_StateTaxCreditCarryForwardsExpiration" xlink:to="lab_srzn_StateTaxCreditCarryForwardsExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_StateTaxCreditCarryForwardsExpiration" xml:lang="en-US">State tax credit carry forwards expiration.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xml:lang="en-US">Capitalized Contract Cost, Amortization Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xml:lang="en-US">Capitalized expenses, amortization period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" xlink:label="loc_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" xml:lang="en-US">Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs Increase Decrease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" xml:lang="en-US">Deferred tax assets, deferred expense, capitalized research and development costs increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" xlink:to="lab_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" xml:lang="en-US">Deferred tax assets deferred expense capitalized research and development costs increase decrease.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationDescription" xml:lang="en-US">Income Tax Examination, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationDescription" xml:lang="en-US">Uncertain income tax position, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationDescription" xlink:to="lab_us-gaap_IncomeTaxExaminationDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ReinsuranceRetentionsPolicyAmountRetained" xlink:label="loc_srzn_ReinsuranceRetentionsPolicyAmountRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_ReinsuranceRetentionsPolicyAmountRetained" xml:lang="en-US">Reinsurance Retentions Policy Amount Retained</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_ReinsuranceRetentionsPolicyAmountRetained" xml:lang="en-US">Reinsurance Retention Policy Amount Retained</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_ReinsuranceRetentionsPolicyAmountRetained" xlink:to="lab_srzn_ReinsuranceRetentionsPolicyAmountRetained" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_ReinsuranceRetentionsPolicyAmountRetained" xml:lang="en-US">Reinsurance Retentions Policy Amount Retained</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Net valuation allowance increased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carry forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Gross deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_srzn_DeferredTaxLiabilitiesRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_srzn_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_srzn_DeferredTaxLiabilitiesRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Deferred tax liabilities right of use assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Total net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_srzn_DeferredTaxAssetsLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_srzn_DeferredTaxAssetsLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Deferred tax assets lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xml:lang="en-US">Accrual and reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsEmployeeRetentionCredits" xlink:label="loc_srzn_DeferredTaxAssetsEmployeeRetentionCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_DeferredTaxAssetsEmployeeRetentionCredits" xml:lang="en-US">Deferred Tax Assets, Employee retention credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_srzn_DeferredTaxAssetsEmployeeRetentionCredits" xml:lang="en-US">Employee retention credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_DeferredTaxAssetsEmployeeRetentionCredits" xlink:to="lab_srzn_DeferredTaxAssetsEmployeeRetentionCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_DeferredTaxAssetsEmployeeRetentionCredits" xml:lang="en-US">Deferred Tax Assets, Employee retention credits</label>
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsCapitalizedIntangibleAssets" xlink:label="loc_srzn_DeferredTaxAssetsCapitalizedIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_DeferredTaxAssetsCapitalizedIntangibleAssets" xml:lang="en-US">Deferred Tax Assets Capitalized Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_DeferredTaxAssetsCapitalizedIntangibleAssets" xml:lang="en-US">Capitalized intangible costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_DeferredTaxAssetsCapitalizedIntangibleAssets" xlink:to="lab_srzn_DeferredTaxAssetsCapitalizedIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_DeferredTaxAssetsCapitalizedIntangibleAssets" xml:lang="en-US">Deferred tax assets capitalized intangible assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Gross deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsCapitalizedExpenses" xlink:label="loc_srzn_DeferredTaxAssetsCapitalizedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_DeferredTaxAssetsCapitalizedExpenses" xml:lang="en-US">Deferred Tax Assets Capitalized Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_DeferredTaxAssetsCapitalizedExpenses" xml:lang="en-US">Section 174 capitalized expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_DeferredTaxAssetsCapitalizedExpenses" xlink:to="lab_srzn_DeferredTaxAssetsCapitalizedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_DeferredTaxAssetsCapitalizedExpenses" xml:lang="en-US">Deferred tax assets capitalized expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Less valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Balance at beginning of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Balance at end of the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Additions based on tax positions related to current year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Reductions based on tax positions of prior year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xml:lang="en-US">Tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xml:lang="en-US">NOL and tax credits limited under 382</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" xlink:label="loc_srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" xml:lang="en-US">Effective Income Tax Rate Reconciliation Gain on warrant liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" xml:lang="en-US">Gain on warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" xlink:to="lab_srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" xml:lang="en-US">Effective income tax rate reconciliation gain on warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xml:lang="en-US">Company's Contributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Workforce reduction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PercentOfContractPrice" xlink:label="loc_srzn_PercentOfContractPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srzn_PercentOfContractPrice" xml:lang="en-US">Percent Of Contract Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srzn_PercentOfContractPrice" xml:lang="en-US">Percent of Contract Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srzn_PercentOfContractPrice" xlink:to="lab_srzn_PercentOfContractPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_srzn_PercentOfContractPrice" xml:lang="en-US">Percent of contract price.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>srzn-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 31-March-2023 [06:09:59] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#DocumentAndEntityInformation" roleURI="http://Consonance.com/role/DocumentAndEntityInformation" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://Consonance.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://Consonance.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#OrganizationAndBusiness" roleURI="http://Consonance.com/role/OrganizationAndBusiness" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#Recapitalization" roleURI="http://Consonance.com/role/Recapitalization" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurement" roleURI="http://Consonance.com/role/FairValueMeasurement" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponents" roleURI="http://Consonance.com/role/BalanceSheetComponents" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#Leases" roleURI="http://Consonance.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CollaborationAndLicenseAgreement" roleURI="http://Consonance.com/role/CollaborationAndLicenseAgreement" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LicenseAgreement" roleURI="http://Consonance.com/role/LicenseAgreement" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#RelatedPartyTransactions" roleURI="http://Consonance.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockholdersEquity" roleURI="http://Consonance.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CommonStockWarrants" roleURI="http://Consonance.com/role/CommonStockWarrants" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlan" roleURI="http://Consonance.com/role/StockBasedCompensationPlan" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxes" roleURI="http://Consonance.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CommitmentsAndContingencies" roleURI="http://Consonance.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#KPlan" roleURI="http://Consonance.com/role/KPlan" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SubsequentEvents" roleURI="http://Consonance.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementTables" roleURI="http://Consonance.com/role/FairValueMeasurementTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponentsTables" roleURI="http://Consonance.com/role/BalanceSheetComponentsTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LeasesTables" roleURI="http://Consonance.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CommonStockWarrantsTables" roleURI="http://Consonance.com/role/CommonStockWarrantsTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanTables" roleURI="http://Consonance.com/role/StockBasedCompensationPlanTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesTables" roleURI="http://Consonance.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#OrganizationAndBusinessAdditionalInformationDetails" roleURI="http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#RecapitalizationAdditionalInformationDetails" roleURI="http://Consonance.com/role/RecapitalizationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementAdditionalInformationDetails" roleURI="http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails" roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails" roleURI="http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails" roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails" roleURI="http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" roleURI="http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponentsAdditionalInformationDetail" roleURI="http://Consonance.com/role/BalanceSheetComponentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" roleURI="http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LeasesAdditionalInformationDetails" roleURI="http://Consonance.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails" roleURI="http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails" roleURI="http://Consonance.com/role/LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CollaborationAndLicenseAgreementAdditionalInformationDetails" roleURI="http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#LicenseAgreementsAdditionalInformationDetails" roleURI="http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockholdersEquityAdditionalInformationDetails" roleURI="http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CommonStockWarrantsAdditionalInformationDetails" roleURI="http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#CommonStockWarrantsDetails" roleURI="http://Consonance.com/role/CommonStockWarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanAdditionalInformationDetails" roleURI="http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails" roleURI="http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanSummaryOfRsaActivityDetails" roleURI="http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails" roleURI="http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails" roleURI="http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" roleURI="http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesSummaryOfTaxBenefitsDetail" roleURI="http://Consonance.com/role/IncomeTaxesSummaryOfTaxBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" roleURI="http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#KPlanAdditionalInformationDetails" roleURI="http://Consonance.com/role/KPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="srzn-20221231.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails" />
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DocumentDocumentAndEntityInformationAbstract" xlink:label="loc_srzn_DocumentDocumentAndEntityInformationAbstract_101" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srzn_DocumentDocumentAndEntityInformationAbstract_101" xlink:to="loc_dei_DocumentInformationTable_102" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_102" xlink:to="loc_us-gaap_StatementClassOfStockAxis_106" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_106" xlink:to="loc_us-gaap_ClassOfStockDomain_105" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_102" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1060" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1060" xlink:to="loc_dei_AddressTypeDomain_1061" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1061" xlink:to="loc_dei_BusinessContactMember_1062" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_102" xlink:to="loc_dei_DocumentInformationLineItems_109" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_DocumentType_104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_AmendmentFlag_108" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_DocumentFiscalYearFocus_112" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_DocumentFiscalPeriodFocus_113" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityRegistrantName_115" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityCentralIndexKey_116" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityFilerCategory_118" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntitySmallBusiness_119" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityEmergingGrowthCompany_120" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityExTransitionPeriod_121" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityTaxIdentificationNumber_130" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityAddressAddressLine1_131" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityAddressAddressLine2_132" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityAddressCityOrTown_133" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityAddressStateOrProvince_134" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityAddressPostalZipCode_135" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_CityAreaCode_136" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_LocalPhoneNumber_137" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityIncorporationStateCountryCode_141" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_EntityPrimarySicNumber_1059" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_ContactPersonnelName_1063" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_109" xlink:to="loc_dei_AmendmentDescription_1064" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_148" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_148" xlink:to="loc_us-gaap_AssetsAbstract_149" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_149" xlink:to="loc_us-gaap_AssetsCurrentAbstract_151" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_153" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_159" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_165" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_171" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_AssetsCurrent_175" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_149" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_157" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_149" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_163" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_149" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_169" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_149" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_174" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_149" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_178" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_148" xlink:to="loc_us-gaap_Assets_155" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_148" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_161" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_161" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_152" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_AccountsPayableCurrent_154" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_160" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_152" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_166" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_161" xlink:to="loc_us-gaap_LiabilitiesCurrent_158" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_161" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_164" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantLiability" xlink:label="loc_srzn_WarrantLiability_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_161" xlink:to="loc_srzn_WarrantLiability_170" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_148" xlink:to="loc_us-gaap_Liabilities_167" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_148" xlink:to="loc_us-gaap_CommitmentsAndContingencies_172" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_148" xlink:to="loc_us-gaap_StockholdersEquityAbstract_176" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_176" xlink:to="loc_us-gaap_PreferredStockValue_150" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_176" xlink:to="loc_us-gaap_CommonStockValue_156" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_176" xlink:to="loc_us-gaap_AdditionalPaidInCapital_162" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_176" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_168" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_176" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_173" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_176" xlink:to="loc_us-gaap_StockholdersEquity_177" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_148" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_179" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_181" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_181" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_182" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_181" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_183" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_181" xlink:to="loc_us-gaap_PreferredStockSharesIssued_184" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_181" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_185" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_181" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_186" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_181" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_187" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_181" xlink:to="loc_us-gaap_CommonStockSharesIssued_188" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_181" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_189" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_191" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_RevenuesAbstract_192" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_192" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_194" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_OperatingExpensesAbstract_195" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_195" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_193" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_195" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_196" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_195" xlink:to="loc_us-gaap_OperatingExpenses_199" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_OperatingIncomeLoss_198" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_InvestmentIncomeInterest_200" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_201" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_NetIncomeLoss_202" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_203" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_204" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_EarningsPerShareBasic_205" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_EarningsPerShareDiluted_206" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_207" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_191" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_208" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_210" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_210" xlink:to="loc_us-gaap_StatementTable_213" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_213" xlink:to="loc_us-gaap_StatementClassOfStockAxis_211" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_211" xlink:to="loc_us-gaap_ClassOfStockDomain_217" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_213" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_220" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_220" xlink:to="loc_us-gaap_EquityComponentDomain_215" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_215" xlink:to="loc_us-gaap_CommonStockMember_219" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_215" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_223" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_215" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_226" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_215" xlink:to="loc_us-gaap_RetainedEarningsMember_229" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_213" xlink:to="loc_srt_RestatementAxis_224" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_224" xlink:to="loc_srt_RestatementDomain_212" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_213" xlink:to="loc_us-gaap_StatementLineItems_227" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockholdersEquity_218" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_SharesIssued_228" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_230" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_231" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_232" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_233" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions" xlink:label="loc_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions_234" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue" xlink:label="loc_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue_235" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RepurchaseOfEarlyExercisedStockOptionsShares" xlink:label="loc_srzn_RepurchaseOfEarlyExercisedStockOptionsShares_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_RepurchaseOfEarlyExercisedStockOptionsShares_241" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement" xlink:label="loc_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement_237" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement" xlink:label="loc_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement_238" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_239" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_240" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_242" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RepurchaseAndCancellationOfCommonStock" xlink:label="loc_srzn_RepurchaseAndCancellationOfCommonStock_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_srzn_RepurchaseAndCancellationOfCommonStock_243" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_245" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_247" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_248" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_249" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_ProfitLoss_250" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_StockholdersEquity_251" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_227" xlink:to="loc_us-gaap_SharesIssued_254" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_264" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_264" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_266" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_266" xlink:to="loc_us-gaap_ProfitLoss_267" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_266" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_275" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_275" xlink:to="loc_us-gaap_DepreciationAndAmortization_269" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_275" xlink:to="loc_us-gaap_ShareBasedCompensation_277" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_275" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_285" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_275" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_293" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_275" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_299" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement" xlink:label="loc_srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_275" xlink:to="loc_srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement_304" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_275" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_309" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_266" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_283" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_283" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_272" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_283" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_280" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_283" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_288" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_283" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_295" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_283" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_301" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_283" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_306" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_266" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_291" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_264" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_274" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_274" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_268" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_274" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_276" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromSaleOfMarketableSecurities" xlink:label="loc_srzn_ProceedsFromSaleOfMarketableSecurities_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_274" xlink:to="loc_srzn_ProceedsFromSaleOfMarketableSecurities_284" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_274" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_292" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_298" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_264" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_282" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_282" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_265" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions" xlink:label="loc_srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_282" xlink:to="loc_srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions_273" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases" xlink:label="loc_srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_282" xlink:to="loc_srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases_281" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_282" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_289" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_282" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_296" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RepurchaseOfEarlyExcercisedStockOptions" xlink:label="loc_srzn_RepurchaseOfEarlyExcercisedStockOptions_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_282" xlink:to="loc_srzn_RepurchaseOfEarlyExcercisedStockOptions_302" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_282" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_307" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_264" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_290" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_264" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_297" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_264" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_303" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_264" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_308" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_308" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_270" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination" xlink:label="loc_srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_308" xlink:to="loc_srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination_278" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_308" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_286" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_308" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_294" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_VestingOfEarlyExercisesOfStockOptions" xlink:label="loc_srzn_VestingOfEarlyExercisesOfStockOptions_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_308" xlink:to="loc_srzn_VestingOfEarlyExercisesOfStockOptions_300" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions" xlink:label="loc_srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_308" xlink:to="loc_srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions_305" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension" xlink:label="loc_srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_308" xlink:to="loc_srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension_310" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract" xlink:label="loc_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_264" xlink:to="loc_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract_311" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract_311" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_271" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract_311" xlink:to="loc_us-gaap_RestrictedCash_279" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract_311" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_287" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/OrganizationAndBusiness">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_313" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_313" xlink:to="loc_us-gaap_NatureOfOperations_314" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_316" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_316" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_317" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/Recapitalization">
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RecapitalizationNoteAbstract" xlink:label="loc_srzn_RecapitalizationNoteAbstract_319" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RecapitalizationNoteDisclosureTextBlock" xlink:label="loc_srzn_RecapitalizationNoteDisclosureTextBlock_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srzn_RecapitalizationNoteAbstract_319" xlink:to="loc_srzn_RecapitalizationNoteDisclosureTextBlock_320" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_322" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_322" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_323" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheetComponents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_325" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_325" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_326" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_328" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_328" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_329" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/CollaborationAndLicenseAgreement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_331" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CollaborationAndLicenseAgreementsTextBlock" xlink:label="loc_srzn_CollaborationAndLicenseAgreementsTextBlock_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_331" xlink:to="loc_srzn_CollaborationAndLicenseAgreementsTextBlock_332" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/LicenseAgreement">
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LicenseAgreementsAbstract" xlink:label="loc_srzn_LicenseAgreementsAbstract_334" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LicenseAgreementsDisclosureTextBlock" xlink:label="loc_srzn_LicenseAgreementsDisclosureTextBlock_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srzn_LicenseAgreementsAbstract_334" xlink:to="loc_srzn_LicenseAgreementsDisclosureTextBlock_335" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_337" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_337" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_338" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_340" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_340" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_341" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/CommonStockWarrants">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_343" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockWarrantsDisclosureTextBlock" xlink:label="loc_srzn_CommonStockWarrantsDisclosureTextBlock_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_343" xlink:to="loc_srzn_CommonStockWarrantsDisclosureTextBlock_344" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_349" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_349" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_350" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_352" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_352" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_355" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_355" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/KPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_358" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_358" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_359" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_361" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_361" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_362" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_364" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_UseOfEstimates_366" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_368" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_369" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_370" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_371" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_372" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_373" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_374" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantLiabilityPolicyTextBlock" xlink:label="loc_srzn_WarrantLiabilityPolicyTextBlock_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_srzn_WarrantLiabilityPolicyTextBlock_375" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RevenueRecognitionsPolicyTextBlock" xlink:label="loc_srzn_RevenueRecognitionsPolicyTextBlock_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_srzn_RevenueRecognitionsPolicyTextBlock_376" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_378" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="loc_srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_379" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_380" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_381" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_382" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_383" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EmergingGrowthCompanyPolicyTextBlock" xlink:label="loc_srzn_EmergingGrowthCompanyPolicyTextBlock_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_364" xlink:to="loc_srzn_EmergingGrowthCompanyPolicyTextBlock_384" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_387" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_387" xlink:to="loc_srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock_388" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_387" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_389" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_391" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_391" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_392" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_391" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_393" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_391" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_394" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_391" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_395" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_391" xlink:to="loc_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock_396" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheetComponentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_398" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_398" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_401" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_398" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_402" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_404" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_404" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_405" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="loc_srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_404" xlink:to="loc_srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock_406" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/CommonStockWarrantsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_408" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_408" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_409" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_411" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_411" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_412" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_411" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_413" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_411" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_414" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_411" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_415" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_417" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_417" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_418" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_417" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_419" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_417" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_420" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_422" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_422" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" xlink:to="loc_dei_LegalEntityAxis_424" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_424" xlink:to="loc_dei_EntityDomain_427" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_434" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_434" xlink:to="loc_us-gaap_EquityComponentDomain_429" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_436" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_436" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_433" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_438" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_438" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_426" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_431" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" xlink:to="loc_us-gaap_NetIncomeLoss_437" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_439" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_443" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_440" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_446" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_448" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448" xlink:to="loc_us-gaap_StatementTable_453" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_453" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_449" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_449" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_450" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_450" xlink:to="loc_us-gaap_LetterOfCreditMember_455" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_453" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_456" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_456" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_454" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivatePlacementWarrantsMember" xlink:label="loc_srzn_PrivatePlacementWarrantsMember_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_454" xlink:to="loc_srzn_PrivatePlacementWarrantsMember_451" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_453" xlink:to="loc_us-gaap_StatementLineItems_458" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_458" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_452" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_458" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_457" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantsRepurchased" xlink:label="loc_srzn_ClassOfWarrantsRepurchased_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_458" xlink:to="loc_srzn_ClassOfWarrantsRepurchased_459" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_461" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_461" xlink:to="loc_us-gaap_StatementTable_466" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_466" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_462" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_462" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_468" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" xlink:to="loc_us-gaap_ComputerEquipmentMember_471" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_FurnitureFixturesAndEquipmentMember" xlink:label="loc_srzn_FurnitureFixturesAndEquipmentMember_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" xlink:to="loc_srzn_FurnitureFixturesAndEquipmentMember_473" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherMachineryAndEquipmentMember" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_467" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_474" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_466" xlink:to="loc_srt_RangeAxis_469" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_469" xlink:to="loc_srt_RangeMember_463" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_463" xlink:to="loc_srt_MinimumMember_464" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_463" xlink:to="loc_srt_MaximumMember_470" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_466" xlink:to="loc_us-gaap_StatementLineItems_472" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_472" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_465" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_476" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_476" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_480" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_480" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" xlink:to="loc_us-gaap_EmployeeStockOptionMember_479" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RestrictedStockAwardRSAMember" xlink:label="loc_srzn_RestrictedStockAwardRSAMember_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" xlink:to="loc_srzn_RestrictedStockAwardRSAMember_482" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember" xlink:label="loc_srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" xlink:to="loc_srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember_484" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantToPurchaseCommonStockMember" xlink:label="loc_srzn_WarrantToPurchaseCommonStockMember_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_477" xlink:to="loc_srzn_WarrantToPurchaseCommonStockMember_485" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AccountingPoliciesLineItems" xlink:label="loc_srzn_AccountingPoliciesLineItems_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_478" xlink:to="loc_srzn_AccountingPoliciesLineItems_483" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srzn_AccountingPoliciesLineItems_483" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_481" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/RecapitalizationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RecapitalizationNoteAbstract" xlink:label="loc_srzn_RecapitalizationNoteAbstract_487" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srzn_RecapitalizationNoteAbstract_487" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_494" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_489" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_489" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivateInvestmentInPublicEntityOfferingMember" xlink:label="loc_srzn_PrivateInvestmentInPublicEntityOfferingMember_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_492" xlink:to="loc_srzn_PrivateInvestmentInPublicEntityOfferingMember_490" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_494" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_495" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_495" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_SurrozenIncMember" xlink:label="loc_srzn_SurrozenIncMember_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_488" xlink:to="loc_srzn_SurrozenIncMember_491" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_494" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_493" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_496" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering" xlink:label="loc_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering_498" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_499" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_500" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_501" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital" xlink:label="loc_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital_502" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_Goodwill_505" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_497" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_506" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_508" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_508" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_514" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_514" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_515" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_515" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_517" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_520" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_520" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_516" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_521" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_510" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_525" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_524" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_524" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_us-gaap_MoneyMarketFundsMember_511" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_us-gaap_CommercialPaperMember_518" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CorporateBondMember" xlink:label="loc_srzn_CorporateBondMember_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_CorporateBondMember_522" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_GovernmentBondsMember" xlink:label="loc_srzn_GovernmentBondsMember_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_GovernmentBondsMember_526" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_529" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ForeignBondsMember" xlink:label="loc_srzn_ForeignBondsMember_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_ForeignBondsMember_530" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PublicWarrantsMember" xlink:label="loc_srzn_PublicWarrantsMember_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_PublicWarrantsMember_531" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivatePlacementWarrantsMember" xlink:label="loc_srzn_PrivatePlacementWarrantsMember_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_PrivatePlacementWarrantsMember_532" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512" xlink:to="loc_srzn_PIPEWarrantsMember_533" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_509" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_528" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_528" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_513" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_513" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_519" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_528" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_523" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_523" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_527" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_538" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_538" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" xlink:to="loc_srt_RangeAxis_545" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_545" xlink:to="loc_srt_RangeMember_540" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_540" xlink:to="loc_srt_MinimumMember_541" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_540" xlink:to="loc_srt_MaximumMember_548" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_550" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_550" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_543" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_543" xlink:to="loc_srzn_PIPEWarrantsMember_542" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_552" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_552" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_547" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_547" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_546" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_539" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StockPriceToRedeemsWarrants" xlink:label="loc_srzn_StockPriceToRedeemsWarrants_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" xlink:to="loc_srzn_StockPriceToRedeemsWarrants_544" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_556" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_557" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_554" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_558" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_560" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_560" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_561" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_561" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_563" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_563" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_565" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_565" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_564" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_565" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_567" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_565" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_569" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_561" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_566" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_566" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_562" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_571" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_571" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_572" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_572" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_576" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_576" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PublicWarrantsMember" xlink:label="loc_srzn_PublicWarrantsMember_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574" xlink:to="loc_srzn_PublicWarrantsMember_573" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivatePlacementWarrantsMember" xlink:label="loc_srzn_PrivatePlacementWarrantsMember_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574" xlink:to="loc_srzn_PrivatePlacementWarrantsMember_577" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_574" xlink:to="loc_srzn_PIPEWarrantsMember_580" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_572" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_575" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination" xlink:label="loc_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" xlink:to="loc_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination_578" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_581" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ProceedsFromRepurchaseOfWarrants" xlink:label="loc_srzn_ProceedsFromRepurchaseOfWarrants_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" xlink:to="loc_srzn_ProceedsFromRepurchaseOfWarrants_583" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_579" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_584" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_586" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_586" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_587" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_587" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_591" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_591" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" xlink:to="loc_us-gaap_CommercialPaperMember_588" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CorporateBondMember" xlink:label="loc_srzn_CorporateBondMember_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" xlink:to="loc_srzn_CorporateBondMember_592" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ForeignBondsMember" xlink:label="loc_srzn_ForeignBondsMember_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" xlink:to="loc_srzn_ForeignBondsMember_595" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_GovernmentBondsMember" xlink:label="loc_srzn_GovernmentBondsMember_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_589" xlink:to="loc_srzn_GovernmentBondsMember_597" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_587" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_590" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_593" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:label="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_596" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_598" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_599" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xlink:label="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent_600" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_601" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_594" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_602" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_604" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_604" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_605" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_605" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_608" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_608" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CorporateBondMember" xlink:label="loc_srzn_CorporateBondMember_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607" xlink:to="loc_srzn_CorporateBondMember_606" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_GovernmentBondsMember" xlink:label="loc_srzn_GovernmentBondsMember_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607" xlink:to="loc_srzn_GovernmentBondsMember_610" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ForeignBondsMember" xlink:label="loc_srzn_ForeignBondsMember_613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_607" xlink:to="loc_srzn_ForeignBondsMember_613" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_605" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_611" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_611" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_609" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_611" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_612" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_611" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_614" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_616" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_616" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_618" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_618" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_619" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_619" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_621" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LabEquipmentMember" xlink:label="loc_srzn_LabEquipmentMember_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" xlink:to="loc_srzn_LabEquipmentMember_624" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_626" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_620" xlink:to="loc_us-gaap_ComputerEquipmentMember_627" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_618" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_617" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_622" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_623" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_625" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheetComponentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_629" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_629" xlink:to="loc_us-gaap_DepreciationAndAmortization_630" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_633" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_633" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent_634" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent" xlink:label="loc_srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_633" xlink:to="loc_srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent_635" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_633" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_636" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_633" xlink:to="loc_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent_637" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_633" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_638" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_633" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_639" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_641" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_641" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_645" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_645" xlink:to="loc_srt_StatementGeographicalAxis_646" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_646" xlink:to="loc_srt_SegmentGeographicalDomain_647" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="loc_stpr_CA_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_647" xlink:to="loc_stpr_CA_643" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_645" xlink:to="loc_us-gaap_LeaseContractualTermAxis_651" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_651" xlink:to="loc_us-gaap_LeaseContractualTermDomain_648" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EightYearsMember" xlink:label="loc_srzn_EightYearsMember_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_648" xlink:to="loc_srzn_EightYearsMember_642" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_645" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_644" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_OperatingLeaseMonthOfExpiryOfLease" xlink:label="loc_srzn_OperatingLeaseMonthOfExpiryOfLease_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_srzn_OperatingLeaseMonthOfExpiryOfLease_650" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_655" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_656" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_654" xlink:to="loc_us-gaap_OperatingLeaseExpense_658" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_660" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_660" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_661" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_660" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_662" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_660" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_663" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_660" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_665" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_660" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_666" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_660" xlink:to="loc_us-gaap_OperatingLeaseLiability_667" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_669" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669" xlink:to="loc_us-gaap_OperatingLeasePayments_670" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_671" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_669" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_672" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_674" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_674" xlink:to="loc_us-gaap_StatementTable_678" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_678" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_675" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_675" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_682" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CollaborationAndLicenseAgreementWithBiMember" xlink:label="loc_srzn_CollaborationAndLicenseAgreementWithBiMember_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_682" xlink:to="loc_srzn_CollaborationAndLicenseAgreementWithBiMember_676" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_678" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_684" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_684" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_679" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_678" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_687" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_687" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_683" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_683" xlink:to="loc_us-gaap_AccountsReceivableMember_677" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_678" xlink:to="loc_us-gaap_StatementLineItems_689" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_NonRefundableUpfrontPaymentReceived" xlink:label="loc_srzn_NonRefundableUpfrontPaymentReceived_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_srzn_NonRefundableUpfrontPaymentReceived_680" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_SuccessBasedMilestonePayments" xlink:label="loc_srzn_SuccessBasedMilestonePayments_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_srzn_SuccessBasedMilestonePayments_685" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UpfrontPayment" xlink:label="loc_srzn_UpfrontPayment_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_srzn_UpfrontPayment_688" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AssociatedWithholdingTax" xlink:label="loc_srzn_AssociatedWithholdingTax_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_srzn_AssociatedWithholdingTax_690" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TransactionPrice" xlink:label="loc_srzn_TransactionPrice_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_689" xlink:to="loc_srzn_TransactionPrice_692" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LicenseAgreementsAbstract" xlink:label="loc_srzn_LicenseAgreementsAbstract_694" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srzn_LicenseAgreementsAbstract_694" xlink:to="loc_us-gaap_StatementTable_703" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_703" xlink:to="loc_srt_RangeAxis_695" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_695" xlink:to="loc_srt_RangeMember_696" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_696" xlink:to="loc_srt_MaximumMember_697" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_703" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_704" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_704" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StanfordLicenseAgreementsMember" xlink:label="loc_srzn_StanfordLicenseAgreementsMember_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702" xlink:to="loc_srzn_StanfordLicenseAgreementsMember_698" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UCSFLicenseAndOptionAgreementsMember" xlink:label="loc_srzn_UCSFLicenseAndOptionAgreementsMember_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702" xlink:to="loc_srzn_UCSFLicenseAndOptionAgreementsMember_706" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DistributedBioSubscriptionAgreementMember" xlink:label="loc_srzn_DistributedBioSubscriptionAgreementMember_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_702" xlink:to="loc_srzn_DistributedBioSubscriptionAgreementMember_709" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_703" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_708" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_708" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_699" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StanfordMember" xlink:label="loc_srzn_StanfordMember_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_699" xlink:to="loc_srzn_StanfordMember_701" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_703" xlink:to="loc_us-gaap_StatementLineItems_711" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones" xlink:label="loc_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones_710" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones" xlink:label="loc_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones_712" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_714" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones" xlink:label="loc_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_711" xlink:to="loc_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones_715" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_718" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_718" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_721" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_721" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_723" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_723" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_720" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_721" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_726" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_722" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantsRepurchased" xlink:label="loc_srzn_ClassOfWarrantsRepurchased_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_srzn_ClassOfWarrantsRepurchased_725" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_728" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockTotalPurchasePrice" xlink:label="loc_srzn_CommonStockTotalPurchasePrice_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_srzn_CommonStockTotalPurchasePrice_729" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantLiability" xlink:label="loc_srzn_WarrantLiability_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_726" xlink:to="loc_srzn_WarrantLiability_730" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_733" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_733" xlink:to="loc_us-gaap_StatementTable_739" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_srt_RangeAxis_734" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_734" xlink:to="loc_srt_RangeMember_736" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_736" xlink:to="loc_srt_MaximumMember_737" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_736" xlink:to="loc_srt_MinimumMember_748" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_dei_LegalEntityAxis_747" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_747" xlink:to="loc_dei_EntityDomain_738" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_LincolnParkMember" xlink:label="loc_srzn_LincolnParkMember_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_738" xlink:to="loc_srzn_LincolnParkMember_746" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_GuggenheimSecuritiesLlcMember" xlink:label="loc_srzn_GuggenheimSecuritiesLlcMember_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_738" xlink:to="loc_srzn_GuggenheimSecuritiesLlcMember_755" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_752" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_752" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_744" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClosingSalePriceNotBelow1000PerShareMember" xlink:label="loc_srzn_ClosingSalePriceNotBelow1000PerShareMember_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_744" xlink:to="loc_srzn_ClosingSalePriceNotBelow1000PerShareMember_750" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClosingSalePriceNotBelow1200PerShareMember" xlink:label="loc_srzn_ClosingSalePriceNotBelow1200PerShareMember_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_744" xlink:to="loc_srzn_ClosingSalePriceNotBelow1200PerShareMember_758" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_TypeOfArrangementAxis_756" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_756" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_735" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_759" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_759" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_745" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_739" xlink:to="loc_us-gaap_StatementLineItems_761" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_742" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_CommonStockSharesIssued_749" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockPurchaseCommitmentPeriod" xlink:label="loc_srzn_CommonStockPurchaseCommitmentPeriod_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_srzn_CommonStockPurchaseCommitmentPeriod_753" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherValueOutstanding" xlink:label="loc_us-gaap_CommonStockOtherValueOutstanding_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_CommonStockOtherValueOutstanding_757" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_760" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_SharePrice_762" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_763" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_764" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PurchaseOfAdditionalShares" xlink:label="loc_srzn_PurchaseOfAdditionalShares_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_srzn_PurchaseOfAdditionalShares_765" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PurchasePricePerShareOfAdditionalShares" xlink:label="loc_srzn_PurchasePricePerShareOfAdditionalShares_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_srzn_PurchasePricePerShareOfAdditionalShares_766" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_CommonStockValue_767" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CompensationPayable" xlink:label="loc_srzn_CompensationPayable_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_srzn_CompensationPayable_768" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_761" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_770" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_777" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_777" xlink:to="loc_us-gaap_StatementTable_779" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_779" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_778" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_778" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_784" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PublicWarrantsMember" xlink:label="loc_srzn_PublicWarrantsMember_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_784" xlink:to="loc_srzn_PublicWarrantsMember_780" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PrivatePlacementWarrantsMember" xlink:label="loc_srzn_PrivatePlacementWarrantsMember_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_784" xlink:to="loc_srzn_PrivatePlacementWarrantsMember_786" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_784" xlink:to="loc_srzn_PIPEWarrantsMember_790" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_779" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_785" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_785" xlink:to="loc_us-gaap_EquityComponentDomain_781" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_781" xlink:to="loc_us-gaap_CommonStockMember_783" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStock1Member" xlink:label="loc_srzn_CommonStock1Member_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_781" xlink:to="loc_srzn_CommonStock1Member_788" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStock2Member" xlink:label="loc_srzn_CommonStock2Member_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_781" xlink:to="loc_srzn_CommonStock2Member_792" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_779" xlink:to="loc_us-gaap_StatementLineItems_789" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_782" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_BusinessCombinationInitialWarrantsIssued" xlink:label="loc_srzn_BusinessCombinationInitialWarrantsIssued_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_BusinessCombinationInitialWarrantsIssued_787" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_AssumedWarrants" xlink:label="loc_srzn_AssumedWarrants_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_AssumedWarrants_791" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantOrRightIssued" xlink:label="loc_srzn_ClassOfWarrantOrRightIssued_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_ClassOfWarrantOrRightIssued_793" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_794" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_796" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_797" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_SharePrice_798" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantNoticePeriodPriorToRedemptionDate" xlink:label="loc_srzn_WarrantNoticePeriodPriorToRedemptionDate_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_WarrantNoticePeriodPriorToRedemptionDate_799" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantsRepurchased" xlink:label="loc_srzn_ClassOfWarrantsRepurchased_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_ClassOfWarrantsRepurchased_801" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne" xlink:label="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne_804" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo" xlink:label="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo_805" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_789" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_807" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/CommonStockWarrantsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_809" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_809" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_812" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_812" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_810" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_810" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_814" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PublicWarrantsMember" xlink:label="loc_srzn_PublicWarrantsMember_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_814" xlink:to="loc_srzn_PublicWarrantsMember_813" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PIPEWarrantsMember" xlink:label="loc_srzn_PIPEWarrantsMember_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_814" xlink:to="loc_srzn_PIPEWarrantsMember_817" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_812" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ClassOfWarrantOrRightClassification" xlink:label="loc_srzn_ClassOfWarrantOrRightClassification_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_srzn_ClassOfWarrantOrRightClassification_811" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_816" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_818" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_819" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_815" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_820" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_833" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_833" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_us-gaap_PlanNameAxis_844" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_844" xlink:to="loc_us-gaap_PlanNameDomain_846" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TwoThousandFifteenStockPlan1Member" xlink:label="loc_srzn_TwoThousandFifteenStockPlan1Member_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_846" xlink:to="loc_srzn_TwoThousandFifteenStockPlan1Member_834" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TwoThousandTwentyOneStockPlanMember" xlink:label="loc_srzn_TwoThousandTwentyOneStockPlanMember_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_846" xlink:to="loc_srzn_TwoThousandTwentyOneStockPlanMember_847" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_851" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_851" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_839" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_839" xlink:to="loc_us-gaap_EmployeeStockMember_835" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EmployeeStockPurchasePlanMember" xlink:label="loc_srzn_EmployeeStockPurchasePlanMember_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_839" xlink:to="loc_srzn_EmployeeStockPurchasePlanMember_848" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_srt_RangeAxis_854" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_854" xlink:to="loc_srt_RangeMember_837" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_837" xlink:to="loc_srt_MaximumMember_838" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_us-gaap_AwardTypeAxis_856" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_842" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RestrictedStockAwardRSAMember" xlink:label="loc_srzn_RestrictedStockAwardRSAMember_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_842" xlink:to="loc_srzn_RestrictedStockAwardRSAMember_841" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_us-gaap_VestingAxis_858" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_858" xlink:to="loc_us-gaap_VestingDomain_840" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_VestedMember" xlink:label="loc_srzn_VestedMember_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_840" xlink:to="loc_srzn_VestedMember_845" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_UnvestedMember" xlink:label="loc_srzn_UnvestedMember_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_840" xlink:to="loc_srzn_UnvestedMember_852" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_843" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_850" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CliffVestingPeriod" xlink:label="loc_srzn_CliffVestingPeriod_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_srzn_CliffVestingPeriod_853" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_855" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_857" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_859" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_861" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_862" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_863" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_864" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PercentageOfDiscountPayrollDeductions" xlink:label="loc_srzn_PercentageOfDiscountPayrollDeductions_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_srzn_PercentageOfDiscountPayrollDeductions_865" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_CommonStockTradingDiscription" xlink:label="loc_srzn_CommonStockTradingDiscription_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_srzn_CommonStockTradingDiscription_866" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_CommonStockSharesIssued_867" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_868" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityNumberOfEmployees" xlink:label="loc_dei_EntityNumberOfEmployees_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_dei_EntityNumberOfEmployees_869" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_870" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaap_StockOptionPlanExpense_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_860" xlink:to="loc_us-gaap_StockOptionPlanExpense_871" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_873" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_873" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_874" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_874" xlink:to="loc_srt_RestatementAxis_878" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_878" xlink:to="loc_srt_RestatementDomain_875" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_874" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_877" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_883" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_884" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_886" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_887" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_888" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_890" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_893" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_894" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_896" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_897" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_898" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_900" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_881" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_901" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_908" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_908" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909" xlink:to="loc_srt_RestatementAxis_915" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_915" xlink:to="loc_srt_RestatementDomain_910" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909" xlink:to="loc_us-gaap_AwardTypeAxis_918" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_918" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_RestrictedStockAwardRSAMember" xlink:label="loc_srzn_RestrictedStockAwardRSAMember_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_913" xlink:to="loc_srzn_RestrictedStockAwardRSAMember_912" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_909" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_914" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_921" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_923" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_924" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_927" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_920" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_929" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_931" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_931" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932" xlink:to="loc_srt_RangeAxis_937" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_937" xlink:to="loc_srt_RangeMember_933" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_941" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_941" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_938" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_938" xlink:to="loc_us-gaap_StockOptionMember_934" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_932" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_936" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_940" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_942" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_943" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_944" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_946" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_946" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_951" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_951" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_948" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_948" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_950" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_948" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_953" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_947" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_954" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_954" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_949" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_954" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_952" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_954" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_955" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_957" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_957" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_964" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_958" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_958" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_970" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_970" xlink:to="loc_us-gaap_DomesticCountryMember_959" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_970" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_972" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_us-gaap_TaxPeriodAxis_971" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_971" xlink:to="loc_us-gaap_TaxPeriodDomain_960" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_IndefiniteTaxYearMember" xlink:label="loc_srzn_IndefiniteTaxYearMember_966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_960" xlink:to="loc_srzn_IndefiniteTaxYearMember_966" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_976" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_976" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_967" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_967" xlink:to="loc_us-gaap_ResearchMember_968" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_srt_RangeAxis_978" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_978" xlink:to="loc_srt_RangeMember_962" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_980" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_980" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_969" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_964" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_961" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_TaxCreditCarryForwardsExpirationStartYear" xlink:label="loc_srzn_TaxCreditCarryForwardsExpirationStartYear_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_srzn_TaxCreditCarryForwardsExpirationStartYear_973" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_977" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_StateTaxCreditCarryForwardsExpiration" xlink:label="loc_srzn_StateTaxCreditCarryForwardsExpiration_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_srzn_StateTaxCreditCarryForwardsExpiration_979" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_981" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease" xlink:label="loc_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease_983" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription_984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_IncomeTaxExaminationDescription_984" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_OperatingLossCarryforwards_985" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_ReinsuranceRetentionsPolicyAmountRetained" xlink:label="loc_srzn_ReinsuranceRetentionsPolicyAmountRetained_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_srzn_ReinsuranceRetentionsPolicyAmountRetained_989" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_990" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_982" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_991" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_993" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_994" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsCapitalizedExpenses" xlink:label="loc_srzn_DeferredTaxAssetsCapitalizedExpenses_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_srzn_DeferredTaxAssetsCapitalizedExpenses_997" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1000" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_srzn_DeferredTaxAssetsLeaseLiabilities_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_srzn_DeferredTaxAssetsLeaseLiabilities_1003" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1006" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsEmployeeRetentionCredits" xlink:label="loc_srzn_DeferredTaxAssetsEmployeeRetentionCredits_1008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_srzn_DeferredTaxAssetsEmployeeRetentionCredits_1008" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxAssetsCapitalizedIntangibleAssets" xlink:label="loc_srzn_DeferredTaxAssetsCapitalizedIntangibleAssets_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_srzn_DeferredTaxAssetsCapitalizedIntangibleAssets_1009" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1010" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1011" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1012" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_996" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1013" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_999" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1002" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_993" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1005" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_srzn_DeferredTaxLiabilitiesRightOfUseAssets_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1005" xlink:to="loc_srzn_DeferredTaxLiabilitiesRightOfUseAssets_995" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1005" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_998" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1005" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_1001" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1005" xlink:to="loc_us-gaap_DeferredTaxLiabilities_1004" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_993" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1007" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/IncomeTaxesSummaryOfTaxBenefitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1015" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1015" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1016" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1015" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1017" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1015" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1018" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1015" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1019" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1021" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1021" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1022" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1021" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1023" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1021" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1024" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1021" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_1025" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1021" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1026" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_1027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1021" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_1027" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities" xlink:label="loc_srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities_1028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1021" xlink:to="loc_srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities_1028" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1021" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_1030" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1021" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1031" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/KPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1033" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1033" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_1035" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1037" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1037" xlink:to="loc_us-gaap_SubsequentEventTable_1043" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1043" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1044" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1044" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1046" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1046" xlink:to="loc_us-gaap_SubsequentEventMember_1038" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1043" xlink:to="loc_dei_LegalEntityAxis_1048" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1048" xlink:to="loc_dei_EntityDomain_1042" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1043" xlink:to="loc_srt_RangeAxis_1050" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1050" xlink:to="loc_srt_RangeMember_1039" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1043" xlink:to="loc_us-gaap_SubsequentEventLineItems_1052" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1052" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_1040" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_1047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1052" xlink:to="loc_us-gaap_RestructuringCharges_1047" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="srzn-20221231.xsd#srzn_PercentOfContractPrice" xlink:label="loc_srzn_PercentOfContractPrice_1065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1052" xlink:to="loc_srzn_PercentOfContractPrice_1065" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g491933g04a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g04a04.jpg
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M(C$8)#(Y04-1=K?_Q  = 0$  @(# 0$             !P@"!@$#!0D$_\0
M/!$  @$$ 0($ P4%!P0#     0(#  0%$082(0<3,4$4(E$(,F%Q\!5"@9&A
M(R0S4K'!T4-BX?$64X+_V@ , P$  A$#$0 _ -_'BE/%*BCR7YQ\3>'T:B0Y
M%[RI&N"B!<F1U8+-?FKU,"XRM."8:@UL:8N4F)EU&65'APCH#+RDH(*9RK&?
M/9Q/'LUG'*XO'7%T >EIE41VZ'UU)<RF.!&UWZ6D#$>@->9D<QC,4O5?WD-N
M2.I8R2\[COW2",/,XV"-JA7?8D51AR"[Q+QOZ?IND>N>F3S-EV5) 5R-V/>Z
MX W9RY2<-P%&LT>GG%2,5$#*:4T<3:+LV_\ :@O$+>KD1]A^6S8[AG@;C,7B
MY^5^)-VB8^SMWO\ ]E6TTB0BUA0R&;(W482>0R ?V-G9%&<^6#<2-*;<5+\1
M?M#YG(YV+@GA1:&7+75ZF*?-W$$4TK7\L@A^'Q-K*7MHQ Y*W&0OUDB3IF*6
M\:1+=M*=R[\+>K8:I7GG]R7/V_R_N,<F<78[DY<MMW&&23ET<EG55)$$GW]<
MT@-YL^)"MA0-=<L61) -$BRPAFL1<>YC+<@YZ]SC>%X*#CW#K>0PQ8['1VN,
MANE3127,W2&+]HWD@Z)6MVDGCMR48(\@:ZEEGBW$,)P-+;+\VSMSRSG-P@GG
MS.6FNLI+9/(-/;X&UF,HQEE$>N%+E(X)[E0X9XX2EG!)32/<WUK[[DQ("H\G
MZA6[$:Z@<>$VI'V'5#KY+R\-CBBR]^B8*L2!93F4MC"1LZ82\ZM#*&LO+2WG
M2,AP3E>-1I9\1/+$HV9+-HKT #U+);/),JJ.[,\:J!LDZ!-279\MX_>L$BR,
M4<A[!+E9+79]@'G1(V)]@KDGTUNK/!R&"V&"A7V21266R!B1W$/,$,/(2XR^
MP\VI3;K+K:DN-N-J4AQ"DJ2K*<XSYJ1!!(((()!!&B".Q!![@@]B#Z5L0((!
M!!! ((.P0>X(([$$>AKW><5S3Q2GBE/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q
M2GBE/%*>*4\4IXI3Q2GBE/%*>*4\4K);VZ]_1FNYZT\9."TU'OVN&(,K^RN1
M#* Y8&O23"G!92L:G8?03&R,R"]A8<K>S&BXZ-):)%K 99R1[)'31PGPV6ZC
MAR_(HV$#A9;3%GJ1I4.F2:]((9(V&F2V4AG4@S,J[B>,>4<W-N\N.PSJ94+1
MW%_V98W!TT=L""K.IV&G.U4@B,,=2+GAU7P&YK<L*%LWF-8:Y9)#4]5BI[8M
M\W9M^P2316P6:^TLZ=;JQLU^1M&P9DIL0D+$L&,3 #R#*P9:Q1S[2FTS!9YO
MC=CGL'QDRPK/>Y"RL4Q]C$I%ND\R(!,(^B&U3I;[C,LI5@Z1./6)N0V6?_\
MBG)N301R'X##Y*^2]NG;<L\-M(R/&7ZI)V60 E@#'M2K2*15QG0?6JO8>=Z3
MYE SDA2=+[!L]/0ZC&?CL3LA5*DZL9.<>U+S=7M-DRE6,>J&\.93Z*QC.-F^
MT1?7%OX>""U)6*^SF-M+P*0!\*L5Y>*IT?NFZM+4:]-Z'IVJ!OLN8N&X\4C=
M7Z!IL?Q[+WU@TGS-\=)-8V+,I/\ U/@KZ]/4>^NH^O>J7N=MEVSS [)>0S$5
M$V"\;"NW(JW:OUY4H]E\V7=C*Q:B]?Z^JD<(OV_$H&!AHH-W&4C#H?06>5\&
M%DNXTKCL5E@^*8PR/%;VUOBX;RZG8A4#S0BZN9F/??5)([#U)!51OL*LKFI+
MK*\@O@B/+/-?RVT$2[9NF.4P0QJ#K6D10?0 ]3'7<U(.Z]"':)2*C_+GN/@M
MF;9#R;)5VE;&U[9[=&MI;RXMG^/@6/)4V8GT]F JJJP$NN9PEAMW]YQYMOXD
M<0N)_(&3:$ENE);BUNH8'.];\UHNF-?^Z?R@!ZD5^Z;A/(X8O--B) !U-'#/
M!)*OX>6LFW/X1=9^FZ_G\#NUWE[UJ7U&NK!BU6_3\',KB;[QNV>N6C2JPIDG
MVRB*5F;85,:OM0:LOK6 R)B -+<<S8:X<3]N6'ER/AN$Y7;&ZB\F"^DCZ[;*
MVG0ZS;&T^(\L^7>0MV^8MYJK_A2J-JV.%Y-E>/SBWD\V6U1^F?'W)=3'H_,(
M>L=5M*#LE0OEL=^9&QTP[ KBSRETUS'TS6-Z:,LR+#3;&VI@D4A+0MAJ=A%;
M97+U"WQ*'R%0UFA5OM(-#R\^,2.\)*Q)DE"2,;)&5JS&'OL%?S8[(1>5/$=A
MALQ31$GHG@<@>9#( 2K:!!#(ZI(KHLX8W)6F5M([RRD$D,@T0>TD3C77%*FR
M4D0GN.X((92R,K&1'GEU^^GBE/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/
M%*>*4\4IXI3Q2GBE/%*>*5GC^H([&Y?B=HN(X[:BGGH?>7(F)E$2,[&%?;R^
MO=/L.JBYZ<!=;5@F/G;L;DJIUJ192ET,,*X28)8,S$Q1'DG>&G%DS61?*7L8
M?'8MTZ8W&TNKXCKCC8>C1VZ],TJGLS- C!HW<5HO.,^^+LDL;5RE[?JW4ZG3
MP6H/2[J?4/,VXHV]@)6!5U4U1MT7]1X',BT.\F.0L(Z1QIUY/*CJY4B_E':W
M1?8M3#Y,<7A/L=>UY5LN-?R5QI;;5AF%M5AEY\8.TL"R%XA\U;!0C$XR0#+7
M4?7+.-$V%L^P'7V%U-H^5L$Q)N8@,T).F\-XNN5D_:%\F\= _3'$>PNYUT2I
M]_(CV/,UH2-J,$@2 :R>1]ZKEZMVSNM:IQ4+#3FP.OK;]]J\<&.Q&! BE2HV
MFZ7#0@8WV\> #&F%R#Z &1\-H%!8^W0R( 0E41\<$N,GQ'-)WD>''<OQ23LQ
M+LWDLN1N7D8[9F=$5>HMO;G9+,"-[Y3 F7QF=XA B)+D^)Y9(%&D56N(7L+9
M44:5521^K7H HUH*:Q.<#^3SG$'EUJ3<,L@P>"K%G>K^Q8[##V"\TFR#DUBX
MH6#[4NOGPT>>_-  .80I<S$ MKRA2?5-U^=XE.7\2RV&0H9KJV6XQ\A<=(O;
M9EN;,]>R%262-89'&]0RR$;W5!?#W*/PGF>&SKJZPVETUODHNGYS872/:7H,
M?4&:2&*5IXXSK^WAC!UJK/IC1L!Q,^HTT#LTA )FDN5E[LNW=36<?++]>EY_
M>VO;K7"0XV0:RN->,!W!:638\85U:VX:>J9S:&\2@655M6_FS'A?D[(AX\CA
M((K"_@8%9HDQEU;R;D0@.H-E"5<L!_:13J?N-5S_ (6''\[Q]XK))89:5[RS
MG0AHI6O[>5!Y;KM&'Q,JLA4G^SDB8?>!K:#Y U2Y5,_;7U*ZX[ M;2ESI<7"
MT_E?3H9YVA7UIEB/:O;,>.MP?7&Q"48:2?#R/LP) 6 W+I],D'&BA77(1V9A
MY+>N%\TNN,W203N\^&GD'Q-L26-N6.C=6H[E9%]9(U^6=00P\P1NFI\GXQ;Y
MRW::)$BR<2'R)^R^<%':WG(^\C>B.VVA/<'H+JV1OJ8YWWOK3YA$4K:>9BNZ
M@NML3JOD;1IS! BJ3,Q<P_!,WMZ.<]5 6+6<RHM,XA++CYM958HCX7#EQ9 ,
MU\TXY;<KP8N+/RY;ZW@^,Q=Q'IOB(W02&V#C[T5W'TF/OI9O*?87K#1?QC-3
M\>RIANNN.UFE^&R$,@(\EU8H)ROJLEN^^OL2T9D71;H*]CPR\R0RT0.ZV^.^
MVAYA]EQ+K+S+J<+:=:=1E2'&W$*2M#B%92M.<*3G.,XSY5L@@D$$$$@@C1!'
M8@@]P0?45/8((!!!!&P1W!!]"#[@U[/.*YIXI3Q2GBE/%*>*4\4IXI3Q2GBE
M/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2NM'[,]F6_G+VG;<B*P\N7)F=W1?&C
M48"WLJ"P!5;$/JRMHC\I^3+0-ELK9UI5C'JK)=D+>RA"G,M(M=Q.T@X]P^R>
M8!%CQ[Y:]8#3=4T1O)2_U:*$K#O_ "Q*/;=5\Y#<2YGDETL9+%[Q<?:J3V"Q
M2"VC"_022=4NO\TA/O78J<>='TOC7H_5NAM>BI%J.JZ9#5&*5\3;)$DY'#)_
M)STBEK&&US%DEW#[!-$)Q_NI:3-)5_<[GRL&3R$^5R%YD;D[GO+B2=^Y(4.?
MDC7?<)$@6*,>R(H]JGBPLXL?9VUE -16T*1+VT6*CYG;_ND?J=S[LQ/O683M
M<Y+R7"/O%X<<DY7[[.O6^/%/J=ZPU[R$$T">V1NBLWYH85&/<077(V>#MX "
M,I21- QF<NI^5?MEOAN)7D'A]G<4G3\5^U)Y[;>AJYCM+"6V);]U97B:!G/I
M&S]NU1WR7(-A^8XG(/OR/@(HIM=]P/<7<<X ]S&KB55WW95[]ZKR[M>(*N./
M)5[>&OF!I#CYRF=+V71[#"J077XZWS*&IFYUIDX5:P\#2!9^+I5LL_""37)]
M($1]RBNR+C,N^%7,/VS@(\3>.RYC *EA<QRDK++:Q;CM+CI8AB41!:S[VXFA
M+R:\] 8$\5N#_L?D,N5LH@V)S[R7UN\8ZHX;N4^9>6^UVH#2.;F #2&&81Q[
M\E]<L</K\/V.<2@.#4[:1JWS0XG'*W3U\[)D31PS95=/PS,E:D5+F+3E#H2(
M]EJ/94_EEB"%KLW@)8>K'D%ZUS7'#BW('Y;;P&7CV? L.6V<:EEBDN-QKD1&
MN_EEZB9#K9G,R%^J_'3N/ ,K)G\"O$KJ8Q9S"!KSBUU(W29H8!YAQQ=B-M!T
M_P!D-]K81,$Z+$]6OWB#R#8Y.<?:#M=^*>K-O,"*K6TZ.:RZ)*Z\V[3C'JWL
MRBRT>3G!P!->MT=)C"M'MLE%1*HV3RTED]G*JZY[%-ALI=6(<30*RS65RI#)
M=V%PHFL[F-A\K+- Z,2I*A^M-[4U87#9)<KCK>\Z3%*P:*[@8$/;7D#&*ZMW
M4_,K13*Z@, 2G2VM,*DOYX]>I6#_ .I8XI16IN6E&Y"U6-;CH/DS4CW[,T*R
MAL=6T-;*B(>Q26&V$H:'5.U>9I1I'O;P[(3+$]*.NOD%$Y;L;X39:2_PEUC)
M&+R8B=!%LDM\'=^9)$NSO?ES1W"COI8S&@  &X.\2+-<?E+:_C 6/)1.9!V
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MIV>VYN.X2OW1P=> 0P26TJWWV<!JE5P<VXBOUM,-F:)2%$&FH5P29'WZ;/\
M(?T]!^595>J?EQQ,+YM[[[1NU3<<U7.2]ALTD'H_6+V@^1MYC-?1TE%(C7K>
M#(4K4]OKX(-8J"Q=7ZRB')QZ6B(D*RR\T)^2)@);+M^OK^M5VNIZ0B:*^YZA
MLG?XGZ]_Y#VK4KI[N8XI\K>36D.-G#^<LVYI2ZFWR?VU:)#4VW-=UW6.LZ7K
M6VS;$ODS951I!)]@G]C(U]5HT02-DXU,9,S;YQ8)[4.R:KJ*$ DZ'L.X.S_
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M=Q;R]+>7-&C%6 *G"-ROXC\A^N'>L80Y(3L<''3WYS3&\:K@R,!GD1[N"0B
MY =2OPEMC&LH;L%9((40(YEQ;*I.!,"DC_H5P[FG&?%#CTRB*WE>6V^'SO'[
MSHFDMS*O1(KQL!\192G9MKM5"N-!A#<))%'\N>=\ Y=X.\H@9I;J&.&Z^*XY
MR>P$D$5V(FZXGBE0GX6_A70N[)W+QMLJ9[22*>6V[C[]0[*PM4"@N2NF"[C9
MHT9MA5^UE*1<,Y8<M(PW@B9ILNT/&Q\D[[?F-,A9MB,(?=7]E7HIA"&<PSR3
M[-$,]Y)<<6SJ6-I*Y88[*PS3BVZCOH@OH6:62)=],:3P-*J@>9<S,2U3[Q/[
M7,]M816O,^.29&]A14.5PL\%L;PJ .NYQUPJ0PS-KJEDMKE8'=CY5I;H M1-
MY[]T.Q.6M EM+:UH2=/:KL2F&K>49._R&\7./%(:+9AR#10HR,KD"02TRY*Q
M@#4H;)I&:%>G$11$C%F[CX=>!>,X;D8<[E<C^V\Q;=1LD2W^&Q]C*ZE#.L;R
M2RW5RJEA#+(8HXNLNMN9EBFCT/Q5^T?E^?8FXXWA<4./8*\*KD))+KXO)Y&%
M'$BVSR)%##9VKNJF>&(3RS!%1KH0/-!)SK]/AQWMDQN;8?)B1C2PZ#3:7)ZY
MKTF^TXR//W>SG0IDBQ&NJQ["V:W78]_$QA'Z8)L4)C"\J^9"-?\ M)\FLX<'
MC.*12I)D;Z^BREU"I#/;6%I'.D32@=T:ZNI5\G?WDMI^P'23M'V2^(7]QR++
M\TFADBQ6.QL^'LYF4JEWD[V6VDF6%B-2+96D+?$:^[)>6P!)ZP*7.YK:U3Y,
M]INY'Z::J5IU3DZ;J5^=AE,%Y+_IW!QT-?)$!2UH#?3&V5%ECX]W[A0A[<<*
M0V_\9:,8\?PQP-^..8JPCC O+T3W@24,J0I<R-+$\Y +(BP>5))I>I2Q0*SZ
M!F3Q-Y/B\5>Y?-7LI^!QZQ6Y\KH,MQ+$BQF"W#,J/-+<%XH@6"=NMV6,,PD!
MR[YN;VY\V>DZN@:[)U[5==(B:WIOCY25R,^MPH<9J$@R)A8@S9]ZNK@>$1X9
M2H]@6.9=?&@8J/R=*OR4L\.\-\!X>6-WD9[F&?)2123Y?D-_Y5LJ1[,LR0!G
M,=A8J07=?,+R,%>>:3RXECJKSGQ@Y'XH9.SQD%C<08U;B.#"<9QWG7;23OJ&
M!Y_+19<CD'!$<;>2J1!F2V@B\R8RZ4^H[K"9X<58C<6WP0B^1M\A\ K 2L<X
M;5%3+4T2[5@#&%O#%V>66T.];9@1Q8[*6&*]$.K"'DY&>J[XO>)PYC>+AL*[
MIQO'S%Q*0\;9>[3J47<B, R6L0+"SA<!F+-<3 .T4=O</P2\)FX18G/9^*,\
MKR4'08 4E3"64A5S91R*722\F*HU]/&Q1>E;6!C&DTMS=;Y"=3[3Q2GBE/%*
M>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*>*5^&V/K/
M7VWZ?+T#:%.K][IDZS\,I7;+&CR<<1[?7+)"&WT*4*<(O/S 2(:V)"/)2@H$
MD<AMMU/H8O*Y+"7T&2Q-]<X^^MVZH;JUE:*5?\RDJ=/&X^62)PT4J$I(C(2I
M\O,87$\AQ]QB<YCK3*8ZZ7IGL[V%)X7UW5P'!,<L9T\4T926%PLD3HZAA1'N
M[Z>C0MOE2Y?1VWKIIMLMU;_\8L,,QM&M ^Y?JD2'?)FJM:!!$H_M2J8L%D*P
MK^]3ZT^C>+"X#[2W(K&%(.086QSA10OQ=M.V(NY-#[\ZI;WEH[D]R(+:U0^G
M2#WJKO)?LD<5R$\EQQGD.2XZLC%_@KNV3.640)[1V[/<V%]'&/0&YN[V0>I8
MCM7\'1_T\&J:M9!)S?&[Y_:\,$^A]-)J-6SKB-DLM+]?MIRP*LMFG2(\A/\
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:>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g491933g11a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g11a02.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1>(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %VR^698X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!H0"#
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             !Q0  ! L    & &< ,0 Q
M &$ ,  R     0                         !              0+   !
MQ0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MQ0    !29VAT;&]N9P  ! L    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   <4     4F=H=&QO;F<
M  0+     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M&K],SV,WL?\ I:V;_1MKV?I*[$K<OZUTY+MN-7;CV&AK
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\%+!%R0F8J&QT>$8*#-R\24G-41S@I+_Q  < 0$  @,! 0$
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M'<-O=W,WQ';O;K,L375YMC^5Y7G=S?L^+4-IN.(TEZ8?I;C7TU0T[>%J:L]
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MZ>.J>Y[?6FAVCV2VK6]>,S<OMI?N&=[H6NX9.Y@5G;Q-NH=O-&G!G;W37_\
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M?[1Q2'.>9,;/GZSGZ^*J%L^DAT?VKI_RCIKI[1G9VYR#>:LW]M%2K-[BC,L
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M^"0!SXY_:D'E4NI:3(&^61_:%YE,/VJ/PYP*RF _W]XW?-56FR1HE)]54%0
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M)+HMWW<N^PSL1+N><-5>[#GYG!&/8VA7>(YGFJ._D;24N?XYA(5RD@@D*$2
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M (K SX5SMY>M\3>J*VSQ<&(W^^> 38B8,U>_1A]33KMW4ZN=A\*W ZC,PO\
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M[5'2III2FE*:4II2FE*:4II2FE*:4KB==0VE162 !)(\CY^.9CF(\?C2JW7
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M 8',B)\B//CS\3J)18G(_IF'8B"(\?1BI 06#.-W:)W6<^TL129B H <@#Y
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M$0QF+50<;,_9<.T^<1]MJB203!$#MG@>0 %<$B203)'F1/N$B3!O+'RAN_\
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M(CE79E,W$9K=+Z=9_P#G@Z9O;W ;H6<B$R8+%8(@3! ' @\@DSSKY?4+K?\
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MT[[3J.H+NUMM5N@D1B<_;&-W:.YVHV6J&DE5+=O<),5%"RH$1Q[FWTN2K_\
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MW*-H@)!.#8W(FNR:>M;U/3]/JZ=]M_=IS<V+<$VF&%1V(7<C,UFRV51<;]T
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MO/4_4=3_ %L[F7.W7,5N!;5UK^TFW[+-07*+]!B-74L7^\-(D,J<R'*7;S<
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MVS623ZK=PN23:%:G\2_%W3>B6?@:/X>OU6M;J?+IWV7W:+8VAWEJMB]^!/\
M*[93VO2/0=7U*XUM;OTM'2NM[6\;#5;AEL[@MN!M90;9OB[>O<?TN]&6Q'2C
MA%+@VR&W5FQ"U*8IT7:ZH83697E553E2OXCEF25+:KK>ZMQU;KJ$5%2:*A"S
M3VNDH*1#%.UP[U#U?U3U74OOZG6ONT[E[+6Z.T?S",]HX@@F,UT+1Z/HNCL-
M/1TDN(+KBU^;>$NROB54>7-;>T>.,) "6DF>W@@'QP#^"01P0$S!YY)^(+8[
M=RTY2-B=A=C]@YK.WO&-]G;;;D@Q/^F*XU8Q!E@#MX!*(*I/CN"8)(B#//\
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MF3[*U:4E1Y[5%#J6G 2?<I/!]TZ\3XAZ8ZSHM:VT;D-*XML)9LU;6Z(RHBL
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M#-T3,L8@5.XS^S94M+4=7FYE6\ILU-)T]7C]*5* 6%U6=X'3O>D"96H((#@
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M;""/WSQ',9.3//UKZ=15Z:4II2FE*:4II2O@K@ VHQ,B"(//VY )CS\1/D\
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M6Z%A=:J%MRI" GNQG?)AKB_JFJ:OJ76WERV7=1<VH#W6\)R$$2_2)VI '*3
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M?[HX^GM'\/:X'DL(B9B/:HQ /,)\S)D29_!T]_D-Y.W&VV-L_F)X^U7FZ?\
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MS\+^X!GXT^P"A\L\CM#%S_=3 T,;L;[IE7B(X/!.^^*G">>5*2.)6KW$+X'
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MSXWD_P!'Z-%[D_*R8S&^<JQC^[LN*)6WM*6R/4Y 45*)X '')$#CQ*0#'*B
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MR*/'V+JEVKQ]%<BQ7BW*O>.W55ER*R?Q>ZIQO)+.JWWZVIN%=%S:+ZBKF_\
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ML#*B'/X*I0G6J>L_!_HWJMMNH:+H]187=E]@6BW(O?@'-A*2A,(#7N^G^O\
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M_7.ZWJ=-@%5NL^T7 ^-O)RU\F6_5(Z#<2HUU-WZN]B'V4)[E_P!W=P['F;X
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M"Z;@)B,/RQ!Q+#!'E6',9\N>X$6'YLRD+LL#$_0C&6Z@@J/A1\2)YY$P>3/
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M*#LDFZ1+N<OT'&0G(OVVS/S.!EP=JFZ9"X ?E9M(28@<'SY'!$$DDP!\'@&
M>.!$Z.[.R,3'+M.?KOMF0:K,!S"2LW8C,1N=N(2U=D7-2D'[\R #!\1X\G[<
M^9'^;@@HC\SS[NW._,1MMQ4[26'MP%HVBA$[9NW&9)(&IH]W(G]W=(X'=\\
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MB*"#W9.U6W&?<'&>',>9)G0CK&Z.]I^K[:>^;2;OV,UULK5?KL>R"A0TU?\
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MNN858'Y=E4D@S%?)<NH=R7/<A;*"_*.,#RYC8F9KV88OB5PRAU!91Z%O[_\
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MB8DD$PVSL"$A6J:GXNFZEFK9<7VO:+9< ;2(1=%JO<-T8F))I$1!(CM,D_\
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M@X$^FGM/8KM\]H"NTJXA,R  I7/<.#,<PV$MXW6W1FT<YX-HF8_3FLEEX_\
M4VVV6<RCA,FY'-=;O59],/I'ZL$U];NIM/:V<QK&NQ&Y.%]V(9XE: 4LOU5Z
MM;;:;X&>U7;39-1WRFX3VT[<%3GM^E?$7JOI3;^#U&I;IV)=^#<W7&H6O_3N
M^:.VX.V9(%^M?!U7I/0]8O<%DX[K;21<=P@_E%39F)G->=CJ%_LW^[.-/5]U
MZ;=X<<S^TA3CM+BFY].YB&4,4Z0 FG:R.T4]QQN]U2N5)?J[?B#!,!;;7+FN
MA^F?\1^DO;+?4>F_!6\+K[#\0LMDF_$9MWVC$25JGJ'PIU(M_2=4ZI:*6IV-
MP1\L,3,09SM%=.6Z_P!.KK?V3?JDY]TS[JLT=&%K?OF,XZ_GN.H823%0N_8.
MK(K4U3N) 4E594L/#O0E;;:NX#=>E^)?1>NMGI^MT\V_+;J?(LRC%R,Y&0$F
M/->#J^D^HZ M_3:L1W-UA,!#>2#)\I$R+F5*T\N%NN%GJ%45VH:NUUS8)>H;
MC2/T56TGN[1ZM/5(;<020I/:IM*@H$J2D<Z]'3UNGUGY.HTDF [[5G!$3O[;
MH5\=Y?82Z-Z_+DTKC"W)O#Y>XQEN,5\0(B4]JN)(24D@)(B8*CVGY,$&0)$\
M9FV9"^UN-BVX5B  W[O$\X-ZJ7LDZ6M"]L7:5QNCA 0GP/O$01D#W$!(*20)
M3R09( )"E$0)':>TJ@R3.K!=8EU^G?IVD-UUXVVVDLMRK@C=P#G8JMQ?=;=;
M;I:MRD Z5V=H9"=F$MEDVS%>C_\ L_N179VNZBL!117)^DJJ7!LPMBVZ2H=I
ME5-'47VQ7A"'@RXV'DIK+*5(84IQQ*/<"A*HUKUWJ^D(O_'TGL%?GM8($4Q(
M))Q[Y6I_PO5:ENE9;HZC=):6EMV^2!RSV\ &("2#TXV_ \HN:B46\TR5E/\
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M@#D\8[2T)<W&9<F6-XPXYC,RUEN;EBW%CF-MCY<*+EQA]BKTI:$,CL"0)@J
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M$B^RY)R0J 5GT.GZC4 MZ?68N&>R^>;OF @9A;6%,Q*M;[[/_2?Z_MZ'J3^
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KF/N  )( !49/Y,1)_,<:C^VU9(#@_O\ 6?/O4=*FFE*:4II2FE*:4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g491933g66a66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g66a66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1*Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $IZ^1V8X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q :/@@P         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          $+   $\0    8 9P V #8 80 V #8    !
M          $             !/$   $+                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   $+     %)G:'1L;VYG   $\0    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   !"P    !29VAT;&]N9P  !/$    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     ,X0DE-! P     "$H    !
MH    "(   '@   _P   ""X &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B
M90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.
M#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,
M# P,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M1U=EEI>EM>$X0F)C9&=V\2A(9H2%HX:FQ?_$ !T! 0$  P$! 0$!
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MO1;9DIEW=KI3+_984TC8Z%7[]5JZJH\=%8I0>9K6!8W)B]BR*E821)1I6XI
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M&6!S'UF3?0[&:F&CV::-5P%!^19!LJCV)UC4T-]TF[6$!XO@!*1"U*"E00)
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M3:! 92%+2E/ 01(2H<6PP9&/$SL20G(#341X;Q$1X  ;M== T#APUU[<<8D
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MN_@&O#3CX].&.R%1'H?^K)YC<;=-LY\:\P.).>\MH@S"SQ<Q$Q(.<>$Y,XH
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MI0      Q\FI142I1)4HDDG)).237]4;;0TA#3:0AMM*4(0D0E*4@!*0!@
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M*84IA2F%*84J(E?WV'^RZ7X&]PJ'EY_<=O?::'A6JASJ&<2H&.8QA DS*ID
M3&$P@5,CPI"% 1T*4I0*4-"E "@ 85:X]!-/5,Q\.3'Y[A2G033U3+_#DO\
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M3 X]9 ]9, 5,>$Q]7X5K[:-JG9.IT])UFS;1F7L)/0S@[.5B'^:K-%]'/$A
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MR+MH;%_* ?U466/C'-ACIIIVA,ZA^@:8H[#]LP03V<UF!.561"<C]()03@G
M G;8 S#VET+/[ZV6,X<;^K'V\]JL&NV9L:%7EA/M.Y7D*H_(=$_GK,R\Z3HY
MB3G-1EQ!310BB?+-\]\X!=Q2E'&1[$]L5$</9S5MB?S=FX3F1Z0<; $1,;Y'
M*@[2Z%!_?6SP1,K;Y_Y0WQ&3Y#(,WWZM#8PX?JHLL1#3_.PQZM^F@R^[P?\
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M1V+ +OVHLKM0XZYMM $-_#0)@ #V@'MT'&0[$]L$B#V=U8'?T[%TJSM/"V1
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M[+B(:ZZ?X;NUWZ?\L*4Z"9^J9?X<E^S^N_IQXX4IT&S$1#OJ7U#B 3LQJ'C
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MG*E>.'DES9W:#AL9?E^"F\:^3!IRV0ZW\H-WKB5JEM:484P41,+$B08 (!!
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MPK,[,$>W?SUCZ3DW:2CV,@9= '47$4QB 1@3)G,9(P(!.8S'4UFO@)1W:%(
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M6ZX '?S;>/-&W!]%WCA4.01X5Q8S\&5BS*:8C"F*T;@8HO6Q1*((D 0$!5U
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MBCO9$4#F!\XY0=K>T9TJZT1S5;Q[3;U32[EMVZ?6I9:F$@*44]V9A2#*5!*
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M"E,*4PI41*_OL/\ 9=+\#>X5#R\_'QZ?V>>Q&DGA3G*$%*J 0QBE4(I$<A0
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M6_+^^0WROA5J-DW$@]3;IIP,J )/F3@_*5AM!30<IJ*<G25$>7R"F$NN@:Z
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M]*//K?E_?8;Y6PK*K=PX,[!,'-9DEP24!8@*A!*@14@?.*D!25,!5"" "0X
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MR]GU?75>E'GK!+^^0VO_ !?3X\*M4Z4>?6_+^^0WROA4ST^O]E6KA=^^<QA
MAG[9-"0(Y6<.58SFR)D;N4Q^=;R#A8QC&5*!0*F/6)M #05-XP/(_CR/MZ3S
#K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g491933g66b66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g66b66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[0^B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #X:^.70X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q :."#(         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          "A   $[     8 9P V #8 8@ V #8    !
M          $             !.P   "A                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   "A     %)G:'1L;VYG   $[     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    H0    !29VAT;&]N9P  !.P    #=7)L5$585     $
M  !N=6QL5$585     $       !-<V=E5$585     $       9A;'1486=4
M15A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'14
M15A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI
M9VX    '9&5F875L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( $X"8 ,!$0 "$0$#$0'_Q  >  $  00# 0$
M             00%!@<" P@)"O_$ %(0   & 0(!!0D)#0<$ 04   $" P0%
M!@ '$2$($A8Q01,4%5%55F&3E1@D)45E<8'3\ D7(C5$=9&QM<'1U-4C,S14
MA:'Q)D:4X4)#9+3$Q?_$ !L! 0$  P$! 0             ! @,%! 8'_\0
M.1$  00! @,%!@8" 00#     0 " P01!1(3(3$&%$%1\")A<9&AT14R@;'!
MX0<C\20E0F(6,U/_V@ , P$  A$#$0 _ /W::N:I5#1'3&^:O7]T[8TK3>KR
M]PM+Q@Q<2;UM"0;11[(+-8YJ4SEZN1!(XIMD"BHJ8 *0!$<]="E/J5VK0JM:
MZQ;FCKPM>X,:9)'!K0YYY-&3S<>0',KRW;<-"I8NV"X058GS2EC2]X9&-SMK
M&\W' Y-',GD%HK27ER\FK5^F7"]1M]+1(?3VPQ=6O+;6.,?:12]4FIZ*9SE?
M:S,=?4H55N2P0[]I(PCDIE&\FV5$S150R:A2=._V:UC3[->J^KWJ2W$^:L[3
MWMOQSQQO='*Z-]4R \*1CF2 X+'#F.BYE'M'I%^M/:99[K'6E9#8&H,=1DA?
M(T/B$C+(C($K'!\9YA[3D+>0ZQZ2!9HJECJAI[TPGH<EAA*MTRKW2"8@%&IW
MZ<U&1'A'O]]%*,4E'B<@U05:G:)G<%5%$ACAS?P^_P "2SW*WW>*3@RS]WEX
M,<N[;PWR;-C9-WL['$.W<L9Y+I=_H\:.OWRKWB6/C1P<>+BR18W<1D>[>YFW
MVMP!;CGG"LIN4-H&2I.[\?6S2<M'830UQ]<!U"J?1AI80 1\!N9WPMX,1EQ*
M G".4<E=B0!."(D#G9L&DZH;#:HTZ\;+X^,VN*L_&=$>DHCV;S'_ .X&W/+.
M5J.K:6('6CJ-'NS)."ZQWJ#@ME__ "=)OV"3_P!"=WN5\#6#28TO'0!=3M/S
M3LNS;2$5#%N->-*24>\AWMA:/F# ) 73MDZ@8Z0FF[I!)1!:*9.GZ:AFJ"JI
M=7<+W#?+W.UPHW.8^3N\NQCVR-B<U[MFUKFRO;&6D@B1P81N("V]_H\1D7?*
MW$D:U\<?'CWO8Z-TK7M;NRYKHVND#@""QKG9P"1HB?Y=7)?KUXTZIKG5BF.V
M.I<7J-)0^H4=;J>ZTSBEM,#U1.Q0UBN'2%-E&3BRERA4XN-*1RLY.JH586W]
MCW;IQ]FM:EK6[ HV&NIOJ-DJ/KV&W'BZ)S#)%7X1<^("O(7O): ,$;N>.=+V
MCT>*Q4A-VNYEQMHQVF6*[J;'5.%Q(Y9^*&MD)E8UC "2<@[3C.6<H3E4Z5\F
MFOT6Q7\MRFF^I5J2IM)CM-Z9.:BSU@G%J],6DB4="5=L^D'3?P%!2<@+ENBJ
MGW%N)@$0, YITG0[VLRV8:O=XW4X#8LON68J<448EC@)?).YC&NXLK&;20<G
MW+=JNM4](BKS6A8D;;F%>NRG7EMRR2&-\H#8X0Y[@8XW.R >0\E<].>5+R>M
M5ZS2;72=7:-(1VH<"TLE39O9^/AI^2B7C*6D2+&K<NNRG6JJ+2 GE73=TP26
M:EA)85B$+'NA3UV]%U6C-9@L4++7U)70SN;$Z6)CVNC80)HPZ)P+I8@TM>0>
M(S'Y@LZFLZ7=BKS5[U9S;439H&NE9'*YCFR.!,3RV1I#8I206@CAOS^4XO@\
MH700M.4U#'6O2@*$E,FKJET^^#5.BI)\O$T(:?\ "O@L)8I?PQCA==]@3^T[
MES/PLU_A.J=X[I^&W^]&,3"OW2?CF(C(DX7#W\,^#]NW/+.5L_%=,[OWK\1I
M=V$G"-CO4'!$H.#&9=^P/_\ 4NS[ER;\H/0=V5N=KK3I4X(ZC'<TV,AJ!5%2
MKP["*/.OI5(22H@I&LX5-26=/B[MD(XAGJJI6Y14P[2M4;G=IUYNU[8SFI.,
M2/?PFL.8^3W2?ZPT^T7^R!GD@U337 %NH4R',=(TBS"<QM9Q'/'M\V-C!D<[
MHU@+B0WFN)^4-H&G58Z\J:V:3ITN77DFL5;5-0JF2MR3F'3,M+-F,T:6".=N
M(Q(AE'Z"#@ZK1,.>N0A=AQ^$ZIQWU1IMXV8PPOKBI.9F"0XC+HA'O:'GDPD8
M<>F4_%=,X+;)U"D*[R]K)S:A$+W1C,@;)OV$L'-X!RT=<+L3Y0.A"T99YM'6
MC2I:&I248O<)5+4"J*1U60FBE-#K6!Z25,VATY4IBC''?J(%>\X ;"H([9/P
MK4]\,?X=>$EDO%=AJSA\YCY2")ICS(6?^>P';XX0:III9-*-0I&.N&&Q(+4)
M9")/_K,K@_$8?_XEQ&[H,E;&@+! VN%C+)5YJ*L=>FF:4A#SL'(-)6(E6*Y>
M<@\CI)BJNS>-5B\4UVZRB1PXE,.>26*6"1\,T<D,L;BV2*5CHY&.'5KV. <U
MP\00"O7%+%/&R6&1DL4C0Z.2-[7QO:>CF/:2US3X$$@J[YK6Q,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$7GSE8:.R_*$Y-&N>AT#+1T#-:K:96RBQDS+)N58R,>V&*7CT'KY-F4[L[
M5 ZP'5*W*982 /, 3;!G5T._'I6L:;J,K'R1TKD%E\;-N]S8GAQ#=Q#=QQRW
M'&>JYNLTI-2TK4*$3VLDMU9J['O+@QKI&%H+BT%P'/GM!/DOC]9_N-]\;552
MG4'4RF'K]<UZK>OM/0MSJ_A8;#)/M)7FF5^I6H=[BGI[4_BHA5P63TKLA'<E
M+0$6J\K4BR69'27)]]#_ ) JNG%BW3L<6;3)M+L&!E0PPL;>%RK8J57M$#9)
M -EZ(L8R5X;,QX>"%\'-V#LMK]VJW(!'#J,.I0"9]H2S2.IOJVJ]JRPF=T;"
M1)2EW/?&TNC>TMP1>HS[D9J)&W2!4J][TUTFI!^3N]T/OSJDFU%M5JMS5UI%
M.Z>Q3<&FH,G*QT<6E3%@<O:S<(N1B[2K5VR-:DR+$77<9J=V[J/K2\>K;O6O
MQ5FI56V!4@@@<V]%:D)=58Q[Q9CB:V:!['P\8F9N,!JW,[$66V(^#9JTZQTQ
M^GV70=ZFL3A]*2LS(LO>T&"25SHYF/9(Z$")X))<L5KOW(WE!U71]SI_6]4M
M)J],SUSTT4U"6:/M6Y*'U*I&FVFMNT_AS2*\K)+3%,FVBMB8R3>+HJL0T>1\
M46OR<ZNR% Z.^7MYI4^H-M34KTT<4%SNH<R@Q]2S<N06Y UL;1'8C=PG,=)9
M$CFO?Q61!P.?-#V'U2&DZM'<IQOEL5#:P^Z]EJO4J35HRYSWF2N]O$:\1U]C
M'!O#=)M(V[,T@^Y$253HNK57OEYI,M9;QR*=/^2G3-1(:NO'-EH,I6ZS=JY9
M;/$+RY4W3.+GV]DBT56,<_;/'<<P<QSQ<J)TASQW^WC)[5">K5LQPU>T5G6[
M%225C8;+)9J\T,+Q&2'/B=$\ASV.:U[@]H)RO?2[$OAKWXK$]9TUK0J^CP6F
M1O=-6?%%/')*UT@!:R02,!:UP<YK7-):#SRQ_P#<W-1]1H_24FJS7DNL%M+=
M%N4EI2TK^FNG\U'U!S)ZMZ<:>T2EW@8V;1=_]11*]1E7\\_!))=!F_C(^)%4
M\>=TMYV]KZE1]\TG:TX7M0TB\Z6Y:C?8:RC<M6;%;?&YHX+VSL;"S)!<U[I,
M!X VN[*6K3*0NMT=II4=5IMBJ5GM@+[M2M6@L;9&N_VL="]TK\!P:6-8'%A)
MW1JGR Y'5[1/D-:,6RZ]SC.3+/T61U&D:Y.VZJ3-OCJKH[9=.'S:GV2NNXZP
MP;I_*339Z5R9\S4-$I.VBRNZXIGY]'M0S3]1[2ZA7K>WK,5IE-DL5>>.N^?4
M(;;#8AF#XI&L9&YI :_VRT@8&1T+O9I]^AV>HS3X9I,M=]IT4L\#YF0T9:KA
M!+"6R,+GO!&7-!9D$^!P"S?<IM.Y*P<H=O44J90J5J+R1:;R8=&1C()>3M6C
MO@-&^(S\TQD)(QUC-;"2U,"2IF<FG+32+>23DWHF>BJ;U1=MK38=)[P;-FQ4
MUZQK.H;I6QP7^(:QBC<UF '1<%W#W,X<9+"QOL@#SR=C:IFU,P"O7@LZ-7TJ
MCMC+YJ7"X_$<"_F62\5O$Q)OE&\//M9/SAY3G(%Y0FFE6K$DG5J[9[7J/K#"
M2UD'DWZ7WR0TQTRJ6FW)DLVB+1H:D0,3;K:M:=:4[0Y+-6M&J.(J$<QS1-:1
MBU4F,FI]?HO:C2KDTT9GE@@J:?)'#^+W:S+MRQ<UF#47.[S))! (=.X(X<!G
M:^1KG%K7@N:/DM8[-:I4AA<(HY9K=Z-TWX55LOJ5*]/2IJ+6]W9%--Q]1XN9
M)Q 6QNC;[3';7GV)I']SWU2EM%]8[Q%PVG_)TUQUQY-7)[TOTUC9:%)>Y_0!
M+3BB]$;=5)*=E6;]RJRN$4!8]^M'J+R;=)THI)E=23 A3?/W^U5)FH:?6?);
MU;3=,UC5;MQ[).[1:H;EGCP31Q1N:-U>0E[0\"-Q:!'M8XD]ZCV9NOHW[3(Z
MNF:AJ6DZ74J,D9WB33FU*_ G@?(]KG!L\?LN+"7@./$W/8%:=*ON1MYK(TU/
M4.Z:77&,AN4IK=K_ #->5C+5.1"J>K/)U::41T(V-;C2CN2?URY(](%9>64$
MS]FW1?HHLI$Y6;;9>[>5IN\&K6NUY)-'TW2XY0^")X-'577GR.X&P,9-7/"X
M<?Y7.+27,&YVNEV(LQ-K-MV*D[8=6U'4WQD3RL/?M,[HR,<</+W0V/\ 9OD/
M-K6O #SM%H2^X]6F%TN94>'?:*R#HO)AT*T;ED%D;S3FDCJ7I-JA/:A.M4T)
MZE@QG6LR565:+5^2=)R3GO\ 9J-YABZC5S)9E_\ /H)+K[,C=1:TZQJ5]CAW
M6PYM.]3BJBDZ*P7QN9B-PD8US0&N!C>'MRH>P\S*?=X3IQ)TFC2<T]X@:;=2
MW-9-L2UVLD#P9&[)'!SG%I$C"TX7V'Y,VFUUT>T"TGTPU&N$??[Q1Z;%U^S7
M&*A6]?CYZ39D."CQI$M4D$FZ12&3;@J***ST41?.DDW+E8@? ZQ;K7]4O7*E
M=]6M9L/EAKOD,KXF.QAKI'$DG.3C)#<[6G:T+[G2:D]'3:=2U.VS8KP-CEG8
MP1MD<W/,,:&@8&!G:"XC>X!SBMYYS5T$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81=2[A!JD9=RLDW1
M)L)UEU"))$ 1 H"910Q2%W$0 -Q#<1 .L<R:USW!K&N<X]&M!<X^/(#)/+R4
M)#02X@ =22 !\2>2I&TM%/%^]6DG'NG7<!==[-GK9=?O4%10%SW%)0RG< 7
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M @8 ,40,4P )3 (" @(;@("' 0$.("' 0R$$$@C!'(@]0?(J]>BD1  $1'8
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MB?5FM'>TRUC )&OB:'R@DDL!P1J6FZ+\N>2&I2NJ++5)U'U[7;3R\=$HK6F
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M[$0+)!8L,LN<X8R^.2.24-A<<F.,N#F#JUN5ZHSY-=M,(F$3"+2O*1J-BO\
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MSRMD.J:HN0%=9&$4:-Y, 9&<#SRJA5,_OC[_ "65:4ZLS6H]MO$7(4^5IL9
M5[3N;AF5@")--O$;FC:'9WRZL'.3D:+-1M%,"MD.[-WK1T61;O$><1,PE?7K
MU_6]\(F$3")A%9IW_"-OSS7_ -N1_P!O1U]6#]OW_7UY=46GM6M3+-0K)36B
M",-!TJ8!ST@OUB@[).PD9)%DXAE&5UZI7'#5.J&F6[Y\X;6NQK#7V[ADFQ7(
M*SE/<BP>$Y8VE\]9G%?:,K"5HC8T*[TE,$"XA""XLZ])2DI'O&==24&S6MW@
MR&:HSL?&R+TLY&231DK'!(.&)%9_=O:5C($8A#VXP&@%K HJ"$!W=%NI592\
M0Q#Q SX3HI3M5CF\HUDTXP\.S/-0[&4?LGKARBT(L@4Y6E-96NG4N<JEP@+!
M;D*T]".D#U-1]!QMWFW\%37TG'L+0\?NBS*\<L\>(0+:87K<>8CJQ$C0YY2$
M7.^:T7RHSVJ4DRAZE)432-2DFL,>Y/+,K;)QMECF4C+2$-)D<.(<7D0W>&48
M0CF( 9E5N#+PJQ5=)JID7:?E55-FE+R$Q3[Q"5]F.I#6"L$@V@#,KE-:7S;F
M GX"O-F<^ZDO"CY\T<]'DI5G&$F4FKL[<X%;F$2GGZ]?9=5@UTM$+J3=($(%
MPZK=%K$=9'T5%4"Z6&R3!7%3DK*\8M[?'/$:!7Y-(616C&-G5P7DU0!%JH95
MZS'"JMMNY:&DU3>=[=QGIQ 7CU)*0B/ )6;Z-B8:IS,U+PYI.=CEIQ.-)<X=
MAX,B$7DX_DR2+2-C'8L%C8Y^C_2?LLKU,U<NT%.6.$H%3;V,U6I5(M4PNHQF
MIA^@2^W=Y7FSMC7(04I2;;5FN5JWV>6B(XPR\N+>+C(H45U'!\)[L\_K\5B9
M.4>Y7;QD9 'B]0;7/-*@6MMJ; +-(^=DYAUJ$XFT4RVNZ0IHD8N&T]F>_P!C
M//XYU!RC)9FX5E'BY(] BZ Y8])(\@XLE;M4HZ?5Y":E%VA*U'*1AR4R<NDF
M56O2-IZ0G:1K&N2K%Y),6DG"MYTB<$28=/2JF(177W6M,;V&CU>8J=P@IF\-
MJM(H1\BK4AD(:(O4VY@J;)24:TM#I^[),.6JSIZV@6\P[K<<0SRQHQB91#"+
MI9<IM[8X=M/UO3"X-XQ"L,M37Y)M*$<2LSI:M&V%=:5J,57K%)N7EB<2L.QB
M8^$E0CESA,-7YTA;%<=P(LSH6N!+W8Z6V:Q#=I7-0*1;[)7W9)F!FWJ,G1+'
M!0\VQ=O:O-3T"NV>L[3%.V -GQ7K!PPE6<JBDZ,FW;$6_P#")A$PB81,(K/*
M?XJ#_.P_LR2PB\6ZD")KS9N=N.TD<H"(B/X()I@4 W$1      Z@  VX< *#
MQYYY^A^GKGDK". AZ/%\W8/TX]>O7\JH''Q^C< ](?I_0&P\.W")P#<?TX3
M\DZO1Z #[?3P[<)@=<<_-/FVX?-P_AU"'#JQZ]>OBF!Y>AT3LZNKJ_=MMO\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g491933g81a81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g81a81.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1J^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &J*^:!@X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q 8L            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          (A   #&     8 9P X #$ 80 X #$    !
M          $              Q@   (A                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   (A     %)G:'1L;VYG   #&     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   "(0    !29VAT;&]N9P   Q@    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     ,X0DE-! P     $$X    !
MH    &X   '@  #.0   $#( &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B
M90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.
M#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( &X H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$!
M 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'
M" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"
M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#
MTW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W
M$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P
M,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S
M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ /54DDDE*22224I))))2DDDDE*22224I)0LMJJ;NM>UC28!<0!/A
MJF&102 +&$N,-&X:F-T#^S[DE-?JUME6!:^MQ8[VC<.0'.:QW_1<L5V1D558
M=C+7AWO_ #B9_3$;7AQ]_P"[[EL]0SJJNG6Y-6S(9 :!(<P[B*_=M^DWWK$;
MG#&KP+_3K?(M]I;Q-W^"U_1O;^8I<8TVO7_N5DCKO6G_ '3U"222B7J22224
MI))))3__T/54DDDE*22224I))))2DDDDE*22224AR,9F1Z>\N'IN#QM@&1_*
MC<W_ *VJK>BXC2"UUC2"""'<$"-W'_5+06=U'K>+@VB@M=;>6EY8V &L'^$N
M>\M;6Q( G9$IQB+D:#7ZN,%F&>D4VLIR;PTTL=N,D.:YOJ/ ?M]3T]GJ/6*[
M#RK:,&NS;0RAMSK;G&6[19ZQ]/:/TSO2&^OTM_J*5=&3E=0R,^L'+^TO(QBT
M?0:"&39N'Z/9'V5EG_!Y-BW,_ O'3JF53;9C 2SG<(AVUKOW?S&_];5BA#AB
M)#4ZW^C*M?[K7$Y3XY&!T^6OTH<7I_O<7S^AO8>;BYU7K8M@MKDM)$B".Q:Z
M'(ZY'IMK^CYE]CP6U90 IPYAV\.][?TFUM?I;MM3'N_2U75?N+I.G]1QNH4>
MMCDP"6O8X0YKARRQO[RBR0$3Z;,>A9,67B $ZCDUN/E^D/\ I-I))),95)))
M)*?_T?54DDDE*220KLBJG^<.T03,'LDIH==R.H55TU8(V&YQ%N3H?28T;WN#
M'?G; ]#Z3G'U!C/+WA\EEECR]\@:M>=&_1]WL]BN9U8N=143M%AL:3W&ZNP+
M Q+_ +-U;'Q2YEV4;37Z5;@Z  [UKK"W^:;4P?S=GZ7>JV>7,>]@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                     /_A/HEH='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB
M861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#8N,"UC
M,# U(#<Y+C$V-#4Y,"P@,C R,"\Q,B\P.2TQ,3HU-SHT-" @(" @(" @(CX*
M(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM
M;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@
M(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIP:&]T
M;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@
M(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%=O<F0@9F]R($UI
M8W)O<V]F=" S-C4\+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'AM<#I#<F5A
M=&]R5&]O;#Y-:6-R;W-O9G3"KB!7;W)D(&9O<B!-:6-R;W-O9G0@,S8U/"]X
M;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(S
M+3 S+3,P5# R.C$P.C4P*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @
M(" @/'AM<#I-;V1I9GE$871E/C(P,C,M,#,M,S!4,#(Z,C4Z,S$K,#4Z,S \
M+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR
M,#(S+3 S+3,P5# R.C(U.C,Q*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H
M;W Z8F)E,S$Y8C<M86(T,2UA,31C+3ED-3@M868S8C5E,3 W834Q/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.F9F,#@W9#EF+6%E8C4M.3DT,BUB,SEA+3!B-&,X9#@Y-&5A-CPO>&UP
M34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#YU=6ED.D4Q,C9%,S8Q+4,V,#8M-$,Q,"U"1C(Q+3<Q0C<Y.#4U.4$X
M-3PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z9&)F
M9#EA.6$M,&-F-BUA9#1F+3AF8S@M939D.6)D9C9D-# W/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 S
M+3,P5# R.C(U.C(P*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N
M,2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F1C.6$P.#%E+3@S-#$M
M,F$T-BUA8S4R+6$Q,#0S-V$U-#,W,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP,RTS,%0P,CHR-3HS
M,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C$@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L
M:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T
M179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.F9F,#@W9#EF+6%E8C4M.3DT,BUB,SEA+3!B-&,X9#@Y-&5A-CPO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C R,RTP,RTS,%0P,CHR-3HS,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO
M=&]S:&]P(#(R+C$@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX
M;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z9&,Y83 X,64M
M.#,T,2TR830V+6%C-3(M83$P-#,W834T,S<R/"]S=%)E9CII;G-T86YC94E$
M/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YU=6ED.D4Q,C9%,S8Q
M+4,V,#8M-$,Q,"U"1C(Q+3<Q0C<Y.#4U.4$X-3PO<W12968Z9&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED
M.D4Q,C9%,S8Q+4,V,#8M-$,Q,"U"1C(Q+3<Q0C<Y.#4U.4$X-3PO<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&
M<F]M/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^1&5L=&$\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @
M(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @
M(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-
M;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\
M+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M/#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_;
M $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 5T!^P,!$0 "$0$#$0'_Q  >
M  $  @$% 0$              0D( @4&!PH$ __$ &80  $# P,# @,% @8)
M#P8)#0$" Q$$!2$ !C$'$D$(41,B80D4%7&!,I$6(T)4H;$7,S12D[+!T_ 8
M)"4G-4-$4V)C<G/1TN$9.(*2Y/$F*#9&1V1F=Y6C1597971U@X>4HL/B_\0
M'0$!  $% 0$!              $"!08'" ,$"?_$ %41  $# P($ P8$! ,%
M!04!$0$"$2$  S$$004246$&<8$'$R*1H? (,K'!%!5"T2/A\18E,U)B%R0U
M-G(F-$13@A@G0U1S.%62HK*S149D=(.TPO_:  P# 0 "$0,1 #\ ]_&E*:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2H)@3$_35*B0'%*Z/ZX=;]L
M]%-M-7B]L5-SNUUJ%6[;&VK<6/Q+<%R#:W76FUO+#5';J&F0JLO-UJ>VEMU
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M0 1!',_8@NU5L5-T'W9\*<E*FPF 9'SK2)'S1,GV_*,3L76,C2Z\L"/=W/S
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M\+!(3GK!Q+>K:X\?$"U8<C!<9W\MX[-54KMS ;)6HA,@DJ)@)2XVM1YS 23
MY,>)ULS7I4K0Z]24JY1:5+$Q&!G<EN^2:U_85[O6Z%"E.HW;; %QF>X<?.7&
MU>@3[3YUO_4Q6-Q /<UU(V,M"H .:*[H6H=T'Y4.*[B,@$CD@#1_@5[GB+D
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MPE:X4/XFR@*98!*7^%*G4^W]3!W+$@L!(Z2\%>,#QM*$ZU;:PH)0A:0">4S
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M4?I:Z=WE35FV?2T2^N%]MSOW.IZA]7WZ5"K[;;C5TR6UU6V]GMNIME#9B_\
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MPY4U5G-2X:RM?=;\_99Q_4\+XGJ?"'$UK]S<OWQH4K45H-@W%FVE)+ED,F"
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MMD)+)2'6E0 <GE) 9+X:(C]"_"7X9? / .-)\7:=2-2FU>M:KA>BO+5=%OF
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M83_:W:>S(<J;71+)[5U]1<E'O%%3EK4WM&X];3>5P;0W1[M2DWKRK2A)05?
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M0H;$ABZ6:#R![4_#2?"O&4ZW1HU%W2<6O*-RX575IT@N\UQ00IR+02IT@I4
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MII55-*4TI7X5+Z:9AQ]844M@*4$@%42 8!4D><Y$"3GC5*E<J2IB6V&<U!+
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M<NDM%+7[K88J*BC>O%)5V:S[=55TKCK-33T5WO=QHS=ET[R"AYVST=QH@I)
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M6[4]VMKKCK*W&>]#])4M+*'J*NI7DMU5#6TZAV/4E4RR^VJ.YL @E4URN?\
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M7VK8 2+@( WYD(6?.5'?Z5RMXGTZ--QSB%JV $INAFW)MH48VDGY]7)SN @
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M]J94U['I$WTJC==:8J;GLFAJRTOL34TU7NVUIJ*1:>X%QIY@*2MMP%IQ)[7
M4D@V'PW[G^9VC=( @N050DN82#V=LAVP*XM_$I>U%CV0^(UZ6ZJU<*0A90HH
M/NU\D$P#S<JFDCX1S,""?*\7WNY+B7TH#?<A"/XP)2A)[U0(4F0J%!0SW)"@
MI/8"-Q+U=I*[>F18]XBXWO%-;?E+@DN0K<N .[9K\;;2[AM7;R[J4W4H6BPZ
MKH%IC[PE"0%IR[*#*Y@Y/P@U:K<[_>C]D9MQDO/IH3UJ784K+Q4'K.-VW*M_
M#2D.$FG%0TBJ[" @.MI@?*%#"D:?2J\8ZBV"A%L(NJ *5$)6BV%)) #RMTP[
M,2S5WHKC&HU/X-M L:N[:LVM7H]'<U',LE?\)Q/^'N6#R@K8WT+L\K"W)D()
M-56FI93#:F'G6TF<*2%82I8@%P&9"5#@]V1D3K+2J^L%M6BWS!@5)7G#PCMY
M8?=^%;-[3H6FXE"D&V1<9*E(6"'4DI"20/B*3*@<J9W>USJ7>:]W[*OH0E59
M5_<E=8:BRO,.NK4G\&MUVWI6T%"XB5C[M0OT[3S+("@@LM)0!V(*<%L6TI\1
M\12I2+MWDYDJ ("[Q"!\+A+.$@!V G:*[N\2\4U5S\(WA#57M3>%NYQ=&FN*
M7<N*4=,OB/$6MW2 5+";;."%.4_U%C53HJ7R$J+JEK#SC(I^[E!2%$]JAV=A
M6E*NT*)! 5!^:-AJU>GMH6%V$HL^[0!?(2 %K*F22D\_,0E4E/+!'-":X+3S
M*4E2=1<-XA039-RX5%:0E16I#%'NE*97*%GX@%E EK3^O%^N;_V87I,15556
MZS4]27[6MHO**G:#;U'U)I+13+^8)+5 S1TC5.V##::5@I2DMI P3AM@GQ-K
M'(M7;15=))!"0M/*7Y>8$'WB 1OS8+$CN;VI\8U1_"I[*.:_>3:U%SA>GU".
M8\VHLV.'\17:0KD;F^*Q;NCG/*%6P6)2!552WJ=20%-.J$X:,1V@$ @=_D$B
M22840!!)&?!5XCW9U%L)_P"8.SDLTH?IY?KPJ-<"0>4PHD!: 00'/,2"I4<Q
MF?S$!CS-;7ZMKI75?V>7H4-;7U+B;HTP7EU+RW?O"K;L^XTMN:J"2HN&E8!2
MVIP+2@J ;,3&O/#Z/<\=XB3;YOX4A:\0DK45+DAV$L) =DUWQ[=>(:K4_AT]
MF%ZYK5B]Q(6DK)4MKGNM)[NTE1Y8 25(2X@.!!BJ!#Q6I/WIP*0TTZEY+@40
MAL#@CM5/<5$2$E13/$R<T]^BY:OVDZ=OXUU:-3(!O*()=)"G2R6)]YR98!PU
M<,V2VIL$ZA9_A;B#?"UW3[K3HYN;G2I)"E*60RD!1*4D$C)M:]=EYN55Z0/0
M(U75E=4L73IO0WFL0I];AJ;M2[$VO24M>^I2PI;[5-75S*7%%2RBJ>S*R#B?
MAJT$\7XMR+MVA8-RTZ@?S)O(/*" IV(+%F^$MM7;GXD.)W[GL-]BZ_?W-3;X
MCIN"ZU2RI2E7+J_#-XH6OG 42U]?.5DE3J=WJIAUUI+#A'QU)#3I!4L2#VKD
MI"5F#S! "A/!R=9Q=-R]:N6KM^V+:DJMK 2J4*2 H'_#,,3N.Q)KA;3:LHU%
MB[;6M%ZW<1<M701;7;NHN<]M2%6B2%A?Y3!02\&1:I]H?N*]77HYZ(W:JM?>
M-VZ1,WRM2ZLJ0Y>ZJQ[;8>JE(4OM-4FF>+7QE!1[7EI"S\1P*P[PA:TJ>)\4
M]ZE"TV3<-HJ&>0 I/Y20%,.B@\G<=R?BOU^JO>"/9&B]?O&U>X(I2[B5*)N:
M@:;2*4A0)!*^6Z/\1:6^+E?\PJK5;RF$UB6ZE3O;3._<E(6L*^,@!:%(*DI4
MA2%]I"AVE,2""-9+J+Z=9H+:KFF%J\D\UU!"1R$@B2A12HEC@JG(VKBOAMY&
MAXQ9"-7<-NW<2FWJ NZ2K_$LD*0DIYD%(YIY$D##$FO;STDJ*BKZ:;#JZFH5
M4OU>S=KU3SRUK6XZ[466C>==<6OYE+=6LN*4J5*4I14>XF-):L)3JM0E( Y;
MRP0.H4?N(K]X.!J6O@_"[BUE9N</T:PHERKFT]L\SF?BS,]J[&U\]76FE*:4
MK;Z[A(_+_''C_3Z>=5)P?O\ I57G<PK_ -*?_P!ZCK7DU^T_<6CUH=5(4K_<
M[86 0$C_ .!=E.3VGB >)F1]#M+PO_X-IR&_/?A]N=3  %NOZBOR0_%^6]M'
M$@S_ .Z^"N(2#_W&S))& WSCJ*Z'])+Q/JE].J)4I1ZJ[44K Y%<4I $Y(^$
M,P<'Q$Z]N)@?RWB<0=+< ^4CMMW.<8US[#E*/M;]GJ07/^TO"5*<, 3JTIA)
M9R @$*;<.U=G?:*.*1ZU.NB01!ONW\D<_P#P'VT.WVD03SYY(UX>'Q_NRV6<
M>Y0^6P&/S81VD36:?BK4WMI\1AV_P.'D="3IDACG8;L68$$$/Q7T,J4?5OZ=
M5DDJ&_G9$@)'^Q%\,9)D23Y,\F00=>W'KI'!]2D8%VV,[!1<=23#$L"8\[5^
M&]O^VOP 2)5>XJ!EA_N7B*F#J,'8AW+EAFGK><_^-SZ@T]PC^'KA,"9!L5E)
M)C. 1  R.3)Q/!KI3PS1$1_A'=IYU-'[,_RGY_Q(,?;3XX!/_P 9H-B2'X/P
M\DPV'#=9!<UR+[/(G_5G=",D@;@OXXQ\NS=P("E*(@S)G!@XQD:\?$ETKX3?
M#C*2WHO'2"Q;'TJ^?A.!_P"VSPV6(;3<2!Y0<C3  EP,N0XEV (<@=7^JU:D
M^ISKN 0!_91WF?Y7[7XHLCN !A).)@3\JI.0/NX-/"$S_7:CR4L0?[/@B*P/
MVV.GVL>.6Q_M'Q-6\$WEGXDC8J:69N4N2X&1'V8!1_JUNDZ0.;#OGWP!LJZG
MV  S&1)GR)&K?Q__ ,'XYL!Q0SU)U4CS,$^7>=L_A,Y1[8N"!+D_R'B3Y!3R
M\.6Q/1C#9)+R XQ-ZYN'^S=UCX!_LK=10F209_AA>1B1$D@]H*B2,@*S%TT5
MXC1:5+EAI['T0GSZR&EJT?[4P3[1_&FS^(N)LY(?_'43D 27:23E*5,0,V_L
MFU*_U7="">X'IQO0S[#[WMXB),PJ22?)@B-67Q1<]YPY6S*^<I'7Y 8'TW]^
M#%/+[5+\I+\%U9<; N0Q@R""2?S&6%5_[[=7_#W?OLG=^[1@>%;@JIX@F)$Y
M,8G5\X4#_ 6 6<K2-G_X2B,?N 2/0#G?VB/_ +=>,N5R!Q[B8( #@'7$D07A
M4G<%M@*LE^R&<6?4EO8$&$]#MQP#."+UM $>WM[$Y,DSK&_%##A/" ""?YA<
MQM_BWB?38>7D_3WX+2H^T/Q,5 A(\ Z@!P0(XEP8,'[)!]>I-57U3A%34*#8
MS5UQ,$]Q"JVJG ,R3!)F1B",@Y8F\H(2 7(0'] !^A8AF,\U<E>(P3XBXZ2F
M#QKBN2Q8Z_42SN'8.>9_RL=C;]]C&HKZ[]6%#_\ 52Q&1'_RFH29(!///CV&
M=8?XQ45Z2P22XNJ9\AAACD3OL:[0_ V!_M+XY;_\R\+(E,G^)U0GE>>N6:"S
MU@/ZL\^JOU)R>.M&](__ +EJ1[1D#Q'USK-/#7_@?#>HL1\D_O7[B>!@_AU6
MS+T)V'_WK4.7;SG-8_D'W_<,>/<>/W9&K[^O;Z-_K64EB-OF'C#2QQ+N3MM7
MK&^RVSZ&.@1__9>]_83_ +9N]@#_ )(G !.M#^)__,.O_P#6G_\ <VOE]BN8
M?%\>(N)"7]\,O'^#9<3Y@OOOBK"M6:L:II2FE*:4JH+[9<E/IKVJ1(_VVMO2
M<Y_V!W2(Y\B?I(@^^LE\*_\ BMJ6<%OIC9WSF-JY._&0W_8_?A__ &@X,3W_
M ,34"3OTG'4UYHG''BE$F0JJ*5 CMPI3H!,!.,P#!.9 P3K9MMO?W^UA1?8R
M#O#G#>9Z5^3KW%6@"2Q(<&&!) E+.(@_F)(Z$U:MU\6K_P E9Z35C!/5R[JB
M29/=U85QDD21S'F"1K%>#+*?$?%3E] L>OOM*V\8Z/U8UV][5/\ \E+V0$%B
M>+:%3DDE_P"3<<=PRB99MM^J3505N_%$F4D'M.9F(!F!/:1W?,<3CB=97:O%
MT)!DW$N 0)*Q$AY!EH/E%</+!"5.Y#**5L7#);+RD$.'ZP[/5KGJT);^SF]
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MR\Q.PFV/[3QQ;=I]'B4X[_3W;053"DRC;,D$C)E.8[C!(!X.L/\ #%PIU'$
M\_Q6H<;$?$&9]V^DO7;'XP5E.B]E89W\)Z<$X(>S99BQ.0!#DN6;:J%3CA#W
M>HG^.,I_O4AA9Y_.1E2B"(.1&LLTJRM@"(MWR&/_ $7 3E]AD8D":XTX4_\
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MQJJ5#BDO@ D N.01F)2#PJ202 D&($#GC69ZV="H$.?>Z5P2P@7M@1C+."8
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M>ZUQ+JVJ;J=M5Q:&4I==4E->2 T@J3W.*#B>T2))/D2?IXC_ .&<3[:6Z3G
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M[QU:VU_,]P<>;6/I_P#6,G(_?K'DE@ <XP=R?[9Q6. OBG]EK;7'W+<&>/\
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MD%B6<'NTSTZL*[G]N"G_  W>R%G)_B;B02"2 A*PK?+D,3D2PJK29#?(274
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M0?:V6JQM^UMQ4N/,_#IG"=L7&13/E1#^% &!]3(&L=X,7XWXB (!&E$A\<A
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M.O+C*^;0+((FX@ @="6CR'JS $,#>_PG*YO;5X8 ! 3;UA<" 3:MD DQ 9B
MV=\=>^J!Y(]2'6U/=,=2=V&$J[AV"XN2J (@@8)"A( DR!J>'K*.$N.5A<ML
M2'V,!FR27EX,AJP3VVA"?:CXU91)_P!H-<2DJ)^'^(OEV+A@ D]&Y<DSW3]G
M2^ESU9].0L_)^ [URH$#M.TKB$DK^4 C$9)!$G*HUY<;2@\.O62?@UFJ3=N[
M*"S<7=(1!Y05C!?X8#L"-D_A(6H^V+A:C_3POC#$@R$Z%24O R#RMD%))DD5
MC7UJ?2.LG5R"85U/W]/;/:.[=EX5(R20%'B< XF,?9I+B5::P26(MI1!$"V
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MJ,_,DC_D@S@^Y&N>?%)-OQ'KDI 8K!GI[A#M(Q.'\NG,'C%(/B36Y'Q".AY
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M/F*B7(*D\R2&_*TM/,"W2 2 _6K-?7>X4=%/18&B.X=*:=L]BA* =O;$X2"
M((,*CO!Y)$:Q7PZ4F[J7+$*6P>("-R#(#>;GHU=S?BRY_P#8?V+,)_DMUR"R
MA_W;22 "'WV('J*K$?=_BG DI)71O#,R4GY2 E,#^5 D$3DZR<+"EWR2?A+P
M1!<S+@[_ /3#"'KAS3![]@.#S:BT E_S)%R83RJZ#R+ER2]GGVBSR/POTJ**
MP2CH;1E7:4@I4MO;1(AM23,DX43@9!X-C\.A(OZQG)-V]$/^9;#Y3B9\Z[2_
M%XM2])[*@IN6WX0T0< EC_ :;N)#!V+$ YQ58:G4A#Q0LS\5V3,C%(53':08
M )^;NQ/RF)-Z7=-NPN['-:0OE<1\2BB9<P6 !#9KC7@P0GBG"0"X_F6A>29_
MB[:BZ@[LRCTR"#BK.?M0EI/5?HX4K"C_ &#[?W=OPR.Y6Z-PDR4@9@09!"1$
MB.+'X>Y+=G5:< <BM2=2Y,FX D9CX?A$9=YVKL?\8T:[V=*<_P#E.T.O_P 1
MJ&/1F<DD$!]@2*K7MKA356T2 57FF)40"915TT=L_*(295*51.")C5\64_P>
MJV_P4C: >9P(#^LN,G-<A< (_G/!6S_':11>!S#46^5I$ $*.P)[M7LE9>8#
M#!#S>$(_EMB/D XGM P ,8Q$$#6H=4$K-P-'\2H;?_,4 7+;'S%?OGIO_<].
M^0FT>O\ 2,[;["7->3;UH5J4>L'U*)2H$#J5209*L?P!V3 2?FD$#D3](.-=
M!>#[+< T/*[%"B=__OBQ^@&?/$5U/X(_\ TW_I$^@ST^FWF<:S<%"2E0"H49
MQ@!)$3@S[Y,^^LG]T8APX=PP8G[\]ISF <EW,P"Y=U.Q>>Q'9QBO3C]FK4-*
M]&72LK6A*E7CJE\I<">W_;9WN#"2J1YY!$D\3 Y_\6_^9-0@LP4K(V]U9[^N
MVTUS)XV_\R7&E@J.IAW#.Y\\Y'7/,NLS)<:'_P#-'C@CYO!,?T\\XJ+8_7!;
ML.\MY1#YK$.C'/\ GOY3].]"ZQ_QC>((EU,'V_E^V/&.- A)8_$^(^;=P#![
MO FG7?R'[/ZMEJA3S(G^-;D00/B)P8^J_P!<CSB<#10Y+-U2<LF3+R69\]?(
M ]J LM$B>;Z;'H7 W\X>J#?M@*IM'5/H4XVMLG^QYO<*[5 @#^%%D )@P8R?
MF)\Y)UMGV;O<TVK)$\]C#L?@.T#;(GYO6[?9.";7%-_AMN.W-U<'9A'ENU1O
MX@/[Z8^AY)G, Y..,$^<9VC[HS&<_#D?+/[=*VY\3X('ZL9;L#)_1ZN=^QTJ
MFW+WZCBMU*4IM71\ J*.34]3I@JA1$F>V8YP!\NM3>T<<BM/$BTMX/\ \RWT
M/K]")K2WM5#*M&1\%M\;!(B<O/V6SD^T7?:_U)N_ VXVLB\[%6.U22L%.\;,
M)!"N\"%1 ,3 \SK"_#ZVU06<BV$B6!#J(B6E1!<[N) KAC\47-_V/^)@ X&C
ML$,[GXM27@N';#.#,@UYKFW.TD# 4XX@P1Y_E2! /RB,*,0(/S3LBZ4JN6UD
MGF0E*DDR'#@%LD,9 +=^GXXE08L&^%/,Q@_$IR2P"8V+NX;>K**IQI7V5^WP
MM0*SUKJ5=H5GM-[NQ!(!2H0  DS (&8)UC2KB3XAO7W:XRT$;92DP-I>?V>N
MWTDI_!VM #BWQ:_>1@D>^\27"MRGD=DW%?E8!@26%5HN.!+4)*@ ATSRDI^$
M\D083D=\D\A7B(C(1=!6<9=B=PQZD1G;S>N&U+(6 H%BD_$D%E) (8&"XYDN
M4@J!V(D69[^=2/LR>BQ*@3_9D7YE8"J_J&0>2H DG,# $9UC=NX$\7UQW*U
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MUELHN@LP2E12.4-\)EG+L<=N[?;C; _#M['N4\XY""Q?F'(HDI(V8<QDF'G
MK/4XE2W%]Q)/CB#"@0"J3)X!)/,< :OEJX4^^M);DM6!;3$D!1:06^0& W2N
M%2>92%NIRL$N&8A3,.:78LY<YWY:LK]9+Z1Z6/0I"DE7]C*F0KM4DD [0VBH
MCY3 F5 P)@8D2=8[P<@:[5JR2FXXQFZCZQN(]6KMG\0BF]A7L)#!_P"7:  N
M[MP-W!!D,_Y7ZAP *K)??#C#J@DA9:69(!A10> 3,)*22""DR21/.3<XZCY8
M(?JV8A^F:XFMW.:Y;*00H7$$= KF_*65!27>&,@L7-6<^NYTIZ2>BY:%A2O[
M$K"5 =I 4;'M$&4@@@P??M!X!QK%^"J-GB/$.1@+B5\Y)?80,Y?,P^37<'XJ
M"W@/V4*=3IT-X!FD_P OT(.",;;@C!-5C*>5\"3\Q4E\*&3$A!! _; $E7,3
MS(@G)KBDFU>07'*D ;$L%/+-._8&0S5Q3H@5:[3)(8?Q&G!>2$FX@@MD!BX,
M!]@"#7L*Z;O4XZ>[%"WFDG^!FUB/F2#_ +@6WV4"8F)(QGD&=:JUZ$G5WR,A
M:B1G^HX$#8,17[Y>'(X%P4=."\(__P!"P_G7,G'Z;X:P*ADDH4F"I)D09$*.
M8!)&/!B(U\:D) )EP1.SP-^H($9CHXO=91;),[.VJ??;UGD#P?P^GD?IJ@8'
MD*5UYN^TVVIOU6\_;Z)Y\M4J5//TK#RUI0R D*6XPM?R D) ,'N.!&?4*  #
M'_)SBC^OEZ?Z[?WXK^!6GN@6JV3!_P" TO*1(,*IR(P#P(CB,Z6UA[S MRB(
MD<H[MY _I-4VX1K#@^\L2.X0):1&?+RKR[?:9)I:/U?=2*=AA+#*+/L3L:IV
MVVV1\39]J5E" AL*Q$I3B3S(.L_X*I^&Z8)+ +N%B6W([EN@PPC%?D3^+=('
MM>UAZ\*X>_PGE<VB?B!#%1R[$AG.171WI)+-5ZH?3ZTMOO9<ZF;52I#H;4E2
M#<E2E252@C$=JPJ?  D'WXB%?R[B()#FQ=$!W)MGR(ZN T2"X;7GL)^+VK^"
M% .$^(.%F2 4A6LMEPEPY!8#F)S$PKLK[0AMBB]9/6*E9:0TVFY;=4A+*4--
MI!V7M\F$ )0DE*0"$A)4#G$1X<*4I'#U*)@)1@E\ ,8 Z,0VP,5FOXKD#_MH
M\02P58TB@S)GW7,>H<R)8EU%B'(X9Z*4-57JWZ"-.H0XVO>Z IMQ*5)6$;<O
M,RE2%),E(!"A!@=H3_)GB2U7.#7+27!-]2B\);WJU[<V #_2S@3UQ[\./*?;
M3X&_*1_-[B0P+D)TNH0H_E$B 7. " ) ^GUN):I/5MUX:;:0VVG>B/AM-)2A
MM*/P.S)^&A([0 5@F$B>,"3/IPXJ/#],@%C;M!"B3!4_.X(G"F)(!)!C%>WX
MFN8>V_QX4@ ?S#1 !\C^5:%)$9=4P#M!!8\E^SY0S4^L7HRTZTV\TY=;X%MN
M(2XE23M"]R"VL%("N 5)5@09X'EQ=91H%.7)NI *>I2H.\,W0=1F7OOX3@?^
MVOPW 86]85 ?T_"A@S @$A@2(W_I ZT]5Y;9]3O7EE* A+?4O=;:$H"0E*/O
MY6E  2 A("Y(2E(YQ G7U:-3<-]R845H5GX2P/=^:-@W7>L"]N"6]JGC<#E
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MP^)PT,4GFM8]6](PU]GEZ%:IMEEIU]#9==0VVEQTG:->M7>ZEL..?,!!=6Y
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M]:W;[)?BL\54 2 $ %,AW?+=';JQ8Q5$?XAB.X\CQG]\_OR0(UNGE!EG^_\
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M8Q7XY$<B4J"200@I4GXA*B0[,GF^(AY_.DDDU:[<5M#[(7;7SI[D==*KO1W
M+2!N&ZHE:09 "AV'Y4_,"#\VK):4W&+I) )-QI#%R3\+NY+P9<-ES7=3!7X/
M4VT@K5_.-4H6T@E92KQ!=6E7);YE%"D%*DE(',@A0+'F%3X5(([@?F$"$B05
M X(QXF8\0J9C5R.H"5\I4 8^%P%"7A/YG([.888-<+BRH7&7:6[N I"AAV <
M"!N "D!P07:K9.HJ#_Y*/H2I /<>M-2)3F3]_P!^@   A69@)D&"8G5H"O\
M>-]2B$PDE2G #')*F('*0[@"0XF.Z/%*2K\&WA)*0HJ/B&X2D20]_4@%D\V5
M @$02"7)$U-#O2QW J_MR2%=D@E*5DY*2D%(\)$3DC61^^L^])-VU_PKCNM
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M*7%%20@J'QJ+)+MA7Y3+@!W+037<_MR2H_AT]D]H)4;R+'*;02?>!9T]UDE
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MM6K/H]5I_P"/U3,3L 1\3,KE\R 00)[AW/Z'>W#V9<?1^'_P9I]%9N:W5^%
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M$DA3AN:*H9:^+4+0TPG[Q4+?%*U24Z%.53U4:E%.*1FG$+54J?46$,=J'C4
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MV5U"[4T_LZT4-3>%H0C%KMEWL2J"K>64H8;K*:H)6T5J1;]'JK!U5]E,%VU
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MW>7\O.HD!B\/@NQB7 [-]%[4ZF^EKMY=Q(_+SDJ:,@O&0.@8&LR_@@A*%)(
M,I!$B,),$F> (GB.1!GQ2E*"2D,52HB'.)\H_P MOG0M=OF*#RA8()<CF!!)
MYAO#B&#F'VX5:NFFT++O/<G4*EM3J]Y;KI:"W7.\UM757!ZGM5J;0W1VFT-5
MCK]-9K2HH-354-N:IFJJXO.UCG<\DJ,A(2 $L '8 0'=\BH20W* $AG#DC/U
MS.7;:N<%$D I)/$P/),Y.<E4GGF?).I=OOZ^?^=4Y)).'9R[=.QQUG,[Z82"
M$F/(A6"2D))@&2KF<CW@_*8;?ZS)_1A_K4LP=FG(V'H6G,-,8-.SN$I'=^A
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MV%:*:\[CJ$52VTJJZ6WU5?;F7J6D+R5UCGWQ"V&TK(:7 !CG[3]_?W,MS9(
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M6^YVQ=DK::AN#-Q<M-2E3]90LW%A=!7V:YW2BKZ1RDJ&3\9+S3R'.]MYAI4
MA<<8@%C,#.8CY;_.%QL/KT$MC;J8R#FNUON[9)) "B%)*T@=W:H@D#N"@)*4
M@@ )4$PI)DDO>=OK_E5(4T 1OB>HP,SU/>OC;L]K:J/OC=OH6ZN3W53=(RBH
M6%$%04^$_&^8 A2D.(5GY%(E7<YI, '#_M@SGS;=A0*P\MW;J(W&?(;;-]?W
M<01W$C,$@2)GV@8!CCCZR2YST\Y^6WIU]<N;,!SG_+!$SF-J!@9E9).9(_\
M']=.><?7]_EY--1S%FG#'H9?&W3RC%2EA*2#*A"2D]I*>Y)(/8H ]JD#,)*>
M53.!J?>=LQD&/V^CCM0EWC)<R^[CZSYS%?(Q9[72NJJ*:WT5-5$A7WRFI*=B
MK4J!W%VH;;"W2I0*I5D%1R=/>=ND.?/]XZB8-4L/\V&_HW;%?6*='N9,]Q))
M*B5$RHK*B820E(F$I$#!@.=VB)C=X^<#YL(>:B7],=A,?7/]Z@4__+/[A/\
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MHRP8P6!Z9?H**SP9]OF)G)/(/@ @<#CVT#%SM+&3UEB"X?NXAXH8@9@X8O\
MKC??UH)5,]T<F.9$S$3[^9\Q]#L,GJ,B'Z R3MV:13KB7&V6+3 WV;:)#I$F
M# D2)B3],C,3[20,Q.I(.Y((!/3=1+-#XA\;U,&0.@ZM@#9R[%G!V@$T/O))
M(!$\"> ) F9R )C/.D@N2\&6);MYC=VR7J"0S##X>3B<']6PPBH\@CN'GVS\
MHC,>/,^?.F27[C8!NH[A^9W=NKO4[ @=,N3N)8X)C !W:*&2, S[^V?I@\<9
M.!B=023O/1SYMW()[$%P 88 S@@R,@=,ER8!=GP1EIK4(@GR9C@\"8)[@#$8
MY.?UTP7+2H]M\G=G^1'F\&0PP [.3^T;O@&#3@) $ \C^D*,P,#'T,F3C54
MF<X F<D?.6@3/:,CRSY8'GG]! $Z8)SVICE,XF9QD\3CD#V\13(R"\$M.">Y
MS)V#[9J8.^Q'79AL,Q@$D.]!S\H/;,0)F#!$\3G]PS!D1);."0!,GON=B,EV
MB@[OUB ^!LV0SX^1KJCJ[U?V_P!(MO,W.Y4]=?-P7FM9L>R]DV1I%3N;>>YJ
MIN*2Q66B6M)6XZI2:BJKG(H[90-5596N(2VE"J79\$_/(ZX+;C!<O4@$]AO)
M&#L&B78;;@9/.=J5.Y*[;-CK=X6JAL6Z:RTT53?;-;*Y=SM]JN;K*%U=!37%
MQBG76-TSJE-"H+#7Q.PJ"8[29#D -$Y=G?Y]@7W;K0@ F3!!ZDP[YV8[>;UO
MP,'.)B1*22!(/L![YC,P-&^D@C$!X( WST)&[N??.[2'*B6AR_[B#0YD8F1X
MD<P 3_E(CD#(TWV!@D29.\[]!.2TU&\AQ(!=G9QMME_-U&@(B23.1X$3)G'O
MXGS$3SH08GR/=MLF<O#ERTB@,X.-CCN7B 6F-CO72%9UA_@UU99Z;;[LHVU:
M]U)I1TOWM]Z^\6#=MR^ I5SVI<*AYFG38MW,.-/5-MMKZGF+U;$EVAJEUC:Z
M4P3+&1VB,MZ3$,8>!50$.D &6WW:/[X[2:[Q*8 ,Y@C(^80LHA8R KN3/:%&
M 09SJ7 C#]W@CKW<-Y EZ@OW+1A@X,  $3GO.!FH[>1&)CZCSG)CC !\F=2Y
M:8B.[Y,!^I.V">IB''GLWHQP6\@/2@SF2<^#C\^9 \D'(_*9,0\F!EIE4D[G
M!.\=*F"  &=Y<20(Z#?H/-Z@8'([LR#,3^T"?R$Q&)G]6T#8,00[B/U<<V^!
M+5'=RSR>KERP9NA:>K= ^DR"/F_RG),<XB#).)TRYPQYIP"-G[OYAF:IQ$&&
MC#'.S0Q)/4] 14Y@_P!]/Z8&0)XDQF//G!(]6!>#)8G$'I!;I!Z 1DL\2=MV
M[9PX&<1)K43G B28P1/O!]L\QG/.-1AW;'F'ZD8!P-F.Q!HV"',L[EPTP(V<
MC/3.=&!SSC@Q[$XR0.23@^\P)9<9^(=68%HV#N )9N[/.)G!> [EQF'Q/<%Y
M) E(P??)$R/?,Y,9P(S!)CD3+;8 <'H'D2"P?JX9A4 R-Y,$"7;'0^L-F6J,
M3W3))Q[R<^#F?J8'O[R-@Q@].D9QOL-BY_JH^<2)F-C'1FW/9ABA! 3G@GV
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M9'["Y&# [5<\Q.<".03X@2&<,^6(>"V3WS+ERSU &^S$26D"!F6+?2N24?\
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MS+9)9$=8!+DLX$3L/(^3 0!^U!\8/O$<DXD><G*A^>A(+2T 'R<'L8.P#-B
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M3$9  F<'F,$EIW);T9H)#N1NP,4C;H3C;<'M W<.0":CWB?8?*>?>,QR,G@
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M( , R H$Y$ C$X'M_?8_34QN["">A.7><A\-V!FH#NX[LX;'E\M@,.T4QC!
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MIVG*EA"V$EPT)AX=SZLS9ZN>A^E>A&-F;<ME^V&R<XRS9M2"?/DR!R8D8 S
M\D0,'57E_P#48P0'R'ZMN9RY:@N&#@=!T+D9QU+OVHH@\DG,R,''&($2))QX
MY(C3U@!G()!#/(<]0S^C&";MF&>1+06G#=G\WF1!@QP!CV'F3.,G\O:=,F<O
MB0<P.WFYV J9P##'. .O7=C #C!(C2 )G/,*]Q/&1'M@$=O,$Z0Y<@D1ONV
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M@S)YB0#Q)Y T<$O$/L'(ZSELR-RP<5)<!I)^%NH/1MHZ3'=JTNI"T+2L!:'
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M-R9=B3A^IGT@,:AW'0$E@X'0=)G<]#BIX)"3&1,CP/I$D>1YS^FH9G?, ,[
M]VW'9WJ6)$$8>>DXDL#@XQ.:@D GB) QP#F<8B#$XC]>*E9 PS3]',X'78QO
M03.7"H?'EF3/F/6HX&!!/M$9/(!))$ Q'U]B!'6=R>_1)C#$E]^HJ)CIT=G8
M G+=OHT 5.)X.1/M,3'/!Q/N(YYU!/?&V&,] Q.X(;!P6J0__*)@CU!G)9ML
M8R[4@^TDCG.(/D1"3 )'.9U4P )S@RGN'+G/SQ\Z@.3$9 97:-W/G+P!@"L;
M.MGJ<VST(J2-U[ ZMWBS,V^AN-;NW:6RDWK:E!^(UYMM)05U]=O5N8I[@:U3
M+?W53+JR:NC2#W/H2JDG#]!OM#1(<@=QB*J2 7+]1@-W\@7V9I#[UO&U>OE+
MNNAL]:GI1UPV^+SO*CV6Q2;EZ?+L];1KK;<]<QN>Y,KN]2BAVE2-H125EY=>
M6&J]UJG31K<40AS'J9,L^PC>>^Y;.] G.&(,X\X.#]$_2N^P! /N D*/\K]J
M#_>B2A4$"#VD@2"!+R2T$G?JY+2)9@9CU:H(.-PS #H6W$C)=V<U$A29R04E
M28'*<YG*8)!((\SX,!N9 V>.H;!&&Z><8=Y.Y?J&<8@9!EFZLU:B(*L0$@DP
M"($$DGZ8\D?4&)U#=R ?ED9DQ,]#$S4#;<LT@&!);]I+@P1BI"3 ,&$DR8D3
M$Y,1 !YP(C4]@SDOV#]F:) 8_4"FY,^;;;'(DLY/G.16F(B 22"H&?RF?!$R
M3!^O!C4@/(8-&3VZ,TQ W,=3M :<AN\29/6?(O-)*2)CB2>8]L^2">,G,&<D
MH8G?<=0X]9#!Q#N7ERST+L,8R(VEM]F9F@![A)G.>?!.!^Z)/(G$Z@[.2X+]
M1Z$G=CNYP1 I]'R,>6S!H,^?E*5'W)(!D"#QR8$?0^^)$D:B'W( $_3![[>>
MQ#&B#)+,7<9\O+#3-:3."!D&<B08D D01[8'O])U4.D$2&)8@.9F(9\..U.\
MX@=<1EV9QZ=8$XF8,P3&!'DDYX.0<8$F)QJ!!$"<'(CH""2^8+EPQ#U)P9W$
M%W)/4X#?)PQV)@B#(R(Q]#@) /DIB..)]]2QAMV+S+YP7W:6/E)HXP0Q'DQZ
M[-L^\ME@*F0$DC*9(@1$S"OS@X,<& 1(U$2^9=CAB PG!$3Z!J@%S'4,^3EB
M3(<;X>7>M(S!\3YCG(_4X,R1D&)P !<^1ZGS=B<=A,;0#)'*(=C#ENSAP\Y'
M3MN/QJZ6EK:9^AK66ZBEK6'::IIZA"'&7Z>H2XRZR\% @M/)467.X@*0M2%
M@D$X;& P]7!@8.Y=_P!*3U#N.I.Q!GSP #G,MUUT?Z4[3Z+=/MO].MELK18-
MO_B I7ZGX*ZRH=N=RK+K4OU;S24]SKM16.I ("TLI;8D!L)-+07@]#]@#/\
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M$S,^^9C]P)C39P\=VC.27  VD2#--^W0,9VPPR>T1TK62,1(/@&)'OF<CR8
MP?<:-D1UC<C8N[2V8[34;.V.I@O$8.TL^*_,C('[C^R 2<>>"1,P<9)\B 6
MZ!L=6+]"Y]&;<,]1!RT[@L8AH9F&/KY:I@&.0!(/!)$&>>1R<2/.,",LQF!V
M)!&"(+CR[5 ;H1D$]_HS=IVG>#C&8))F.9)'_)E0P0"0)!XC4Y$D]WP[M+2
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M4 <=MX!,/.7B!MESU(C'N1PF8X@C$" )Q($^1QJ,[$CL Y/W)8$]78&I$,'
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M5)+X,E@6Z_O+;X&9K<?X [)-5<*U>T=M_?+K2"@N-4FR6W[S7T213 4E6_\
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M(B=2Y:'8[,,F,L7EW=CB7-0&?N\']V>&]4Q@M3W!_,3Q^OLG,8_+()B,P#S
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M)\T9F/1C@[.[_* [  ^9@8.$@D" ,_K)/MXCQ[<Z0^6@L0PZ@$?+L']'C9I
M=C+C8MNV_?J[57WZS+CMNX]2?35L;>5DWANO:3][ZA;RW=MC8]JW->[S=K;9
M=K"T6Q"K;M(_B[MO3?;T7WBVH,TZD-N+<0V"32=AT$^>?H[>E5I.=P\/$/#1
M\NXC>NFNE_57;71FQ]8NOFP;)?+1T"W9<]F; Z0[)WGNJKMK6XNI2;A<K)N'
M<#:MQ7"^O['V^U7MU#%Y?KOXUFDM5VN;5 Z:1+#D8G;?['ECY5)F"VT9S#R,
MY R,%J[IL?K2K:.T=;:O<]GV+O2HZ3=.K3U+I+CT9W95[DVY?J"Z5]19G=M5
ME;<K<P[9KW:+I3=U=5.HJ:5RTOHN:*9M+2FE3S$3OUC<Y+Q#G#%OE5)2/2=C
M&7+_ %P03A@:W*R>J#J$=\4^VK]0=&[IM^W=,W^L?4#=NQ-V[AOU-L39MM2X
MJX;?J*9%K=I[MN>Y-!-58:IVOM--64M)7.LT#_92ATY_U'IOM#=".U3R3..F
MW5O*3T\IK9^EWK6N&_\ ?72RU/T'3!S;/6*[7"V62Q;6WVYN'J=L9(L]PO\
M8Z_J!9&J%-KIV;A;+<IBYM6ZJ_V"N=134E0_4K68.>W>,R\[?<U/*!U^9#=6
M8O+EA.\S7X[<]7/5J\6?IMU$J>EFS&>E?4'K4QTBHZVEWE=ZC>-8FY[QN^U+
M?N:V69=@9H!34SMK=75VY^M<K*W[K4U%(::G+92<R6$QUF.LG&_[U#;/ ^G8
M@ ,#.X<>4;5U"]>2MOWCJ%6;5H^EUSVETPW>[L^Z6.^;^70=4=\U%JN=':=T
M7/8^VZ&AK:=F@M==45E+;Q=''G[T]::];#=.U\,D^,>68^X!!=A4<NQ) /H#
M)8#IU;=XP]=ZT?6OJCNKK?U!Z<[&V-M2MV3TPNFP6=W[WONY*V@K$4FY]O-[
MAN]#:;+36^I%POE'2O-_=#455NL[7:[]]N!60E,E3["1T8_KM0)[D9AP=F[#
MS/D.]=7[3]7^Z;]U5Z<[.J[)TNJ;1U*W7N+:[-GVAOUS=>^ME(L]JN5WI+MN
MFHM-%5;+K6G6K<*>Y4EBO54+95U2&G*YU3+R=1S'L?,?KU]>@Z5)2&W?<^6[
M%AB!L'W$UP/9W67JP=A>M'JAU&I-M7W9NW[GOK;MJV[;-S[E2&[KM+;5NVXY
MMS;KJ+;2/6_;UVJ:VJ<?NU*ZS?\ ^$56\^Q3LH0@-/\ 3[/]OWH6'+VQ+1'5
MLB!ZO7:]'U8W_:TTW2+H/T^V?4.](NDNS+[O1[>VZ]Q,6BRUEVL'XA9^GEFJ
MF;?=+U=[P+72JK*G<%WJ33T[*F$UR'*M;JDGQV^]_P!.KMEJ,))ZGOB 8W$^
M7G-::'U3]0>H5=T;LW1_IYMBY7;JGT<N_5>Y?PUW-<++0[,IZ"[T&WZ9JJJ+
M7:;DY=*=^YN5R&T,,TE54-IIU(53I2\Z3EFVCZ='QZ4Y0^^7Z]Y\R#\LO7>W
MIWZJW3K1TKL>_+W8:7;5VJKAN.S72U4%<NYVYJY;7OUPL%:_;+@XTPY5VRKJ
M*%3E(M;*' GX@5W !1D-EL0VQW+GR=X9JI(EA W<B X:-GC,DYZGNX\]W$<Y
M(X@">>8' R(/T-3 MLSAI)] SX).(C&T%P"(+R\>?EL8ZNSTCZ0($GQ$F< ^
M!SSYYD NV0)AH>?Z@7[=>LPZ$1MYL!)V$MO^A-2)">8!S(' \',)^D@ \_35
M+S&,,<=#N8]>F6J8\R"<9.^X?S=)$;36DR!)\CQP0,  GCGQ/!(C,U#+1#X,
MP,0'Z&0[A\L!!#R,0[P0^\G]VGUIVB1)&8 4 0(((QF/'L><>(2Q 9W]0Y>5
M,Q.V=ADTC/3JS';$-]3+ON9$ DD$C,>>8F#DR>9R/Z1ID$@@8+- \W?HT /T
M:F2V>AWG[=CB0X-0//U(CG((,Y./8Y$J@&-0<!I?=F(W^0,EBPD%HJ6ZO@1E
MV8"(,O#MYU,'/O@#@8 \ G,$B<F!I+EMVD ^3QA\L1]6=T$0\$]WR0VS>9Z/
M40<@"/(([3[3Q&<\XD1CW9D@='GSW=OD7^)X<U +8EST8R_23Y @ M4P.<DY
M)C QSD"(\SB8B8SH9F-G=QL"YZX:/,!S0';OYSA@"W67.(.[QYGD$0#, ?\
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MV>W;<M-YJZM%@MR[*U<MIW>XO-+VU<ZNRK_#JEQ=+<&FT!RIITHJ73\.&/\
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M!R)J"<GSB)!5/RX\Y&(,&/:=5/#'+C/=]A),8.<F*IW@MY1)V';N[-4X\IP
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M':9(GM/)':J0?8XTR>[2Y#,PW=_W(=]W;.<9^?-U!&VP Q'203!))^OL<DG
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MN,1M!J/ ,]Q^@5 _7GCS!DD<@3J9S!RP=ST+L)@',[%S%3UR#N<#]>I&(@2
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MGOD9/B.8!D?L\YB1!$&(G1W$[9?H3D;M(!;(:H&6:?-C@9V$R,D$-41^I]C
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M-SO4X)D8_5I&)!#[.&(88@@Y_7D3) )_.3X(Q,# $FIQ!8089WSL& ;Z9 ;
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M3Q &9 (SF K85IDXR.5 DYD1 B,Q(\3$@#@:G#-^DY@%]GV<;R6)H6D-TWB
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M .9\R!*O&%<Q^43]=4A@';J1.V#W<RS#I+ M5G>,/@EI!Z1W.!U:H) ([8D
M>9&"#_1$_O)^LF2Q[L'SAB9_3=V'6&@D=1L8=X?U#[=S4@2 <$3!YXGDQ]3R
M9$Y!!,F"[L7/GYLX$>FYR8)H&F._T)8MA\,.I=V%3/F9]L9@@0!.3''M, ^-
M3DMT)Z8;!;N2 0Y<G!@MH#$MU\W!>, RS"9!>H).#/=,8_,S.3]/Z,G&( =Y
M($O$=</T?Z=:E3!H!Q\A#8ZC/G#&8)^5>,%*H(@B.Q7L,< 'R)Y$:DB.H_I?
M9FAX@S\H+U!G(D"<CU/4R)C."*Y'2?W+3_\ 4M_X@U0<G>3/6O48'D*V:LG[
MR_X *."1,-I' DP>)D1!&I#P&,P._7U'R@$XGS(DEXC9SY%_+>9 .2WS9!F?
M&)(QS['/RG,D\&2,Q5)@.Q'0 D#KVD"#M+.2!(R[GL^3N';</ @D99B  *H.
M2#D"1W R,XB/,I$R<'42(/5YP1O$N20^\R&R66;.&P7V/5@Y;9@'.U1VF1,D
M\ $0<29S$CR?ZS!F7@B'8.YDEO/;IVZF(;=R9+-'^CX$?03),'F/SQ[&.3@D
M9B1XR<Z,3+L1U=^C.[&1\R<8(%NA!S /4NP8A@=_]-/,3P>#(..,\29X'_*X
MQ&I<&"!AY.Y?.#&YSO.:8=CV?KZ@G_0>E:^Z)!()$9@21'$$8P,3YCW(,2PR
M"<SB7!W/;(, 4ZM@ MDX9Q'626AB?,:! $9$R9/;GD=N1$YSG Q$R3&6,02,
M.^^,G/3,G,,=<);+[8,B6WZ#HU:I &,B.1Y@<X/!, YD<C U/YMAC]?+NY9_
M,!P:'X3ON_\ :1,'HTO-1*8'<3(,XC.<&) D208,8^IDQ(#SL,#:)\V:7(F1
M@[&(<=26;]0W40^TUJQQB09':0#DG'' @$C]GW(&H W @B'$1USL\]3#4?,]
M7E^@S#@].@EVJ!CZ?LP"3!D D>X]P"/U,P6<$'8/DR&C]!#L\N14[OZDB6=Q
MZ_\ 41#P&84*AF#VG]/ QS[P,C@YC3],XB'PQ(8.78AMIHV[@@!O(XD09P'!
MB#$A$@YQYS/[/@R0<S[F,YY&JG![%YP7!8&=A'8?,&H:69X^$R.\=?\ 2H!&
M<Y[3$#).<X .3CG&? !U!Z00SEE;[F9=S&0>CT D;%P&(>#UP_R]14XB!X,X
M)S/ P,#SP$G\M0#!RPS+9'VS].[5)@[8V#P#W(F&@DAO6HD@X()X'Z\9!B3R
M#&,F0(F<E]F)Z=1)$Q,N2>F:@X8@Y8'/FPALB&'?%/'Y&501(';SYS]8$^T:
M$DPY,-(W;,!Y&-\D]"^0>1Y/@N0&C=WCTD!(GYOH/'OD&! B3)@?F3B"=B78
M0V,8,]0"P=L#9I[@9[R9VZQ!R^2.L3$DF3Q@\#S'$")DYS$GG4Y<L.Y<[-TA
M]QM&,5#L!O'0,\^;M^YP8J08R(X\0,09DD^(@<3F1.H (?HYB2" 8#LPD9)Q
M+-D3 [3T(>88[YP6=GI.#&9D9\XF!B1C@YGWSH>C,"2[$3M +X8L.I&[4'9M
MLDP\9!'4/^F:'@D01VDC,\^^ 0?IQB.(E(B6!'9S&TN9! /3&14YZ/@OCYN^
M!ECYX;3@P#$ X(.#SSSGCS.?ST<=)WR8:7;LPR)RU0?1H? S+/G(+=@&=Q4S
M$$F)G!&8DP8C!Q!,<2)U/*<,X!!& ^TB<CKT[FA+]!U$SDOY.79\Y>*D_,3
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MSCCDB9]XU+ $"'!$@=CG9H#X.?,P_FS;MV!#MECD;-T:D>Y\B8C/ D2,1F,
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M_>V*CE3T^I_O3\+H/YN/\([_ -_1SU^4?I]C.:<J>GS)/[T_"Z'^;C_"._\
M?TYCU^Q]SUWIRIZ?K4?A=!_-Q_A'1_\ [/Z-.8N[_?W_ &Q3E3T^I_O4_A=
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g491933g82a82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g82a82.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %GR^5U8X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q 8K^W@         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          %A   #2     8 9P X #( 80 X #(    !
M          $              T@   %A                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %A     %)G:'1L;VYG   #2     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   !80    !29VAT;&]N9P   T@    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     ,X0DE-! P     #"@    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ /54DDDE*22224I))))2DE&NQMC=S9CS!:?N="DDI22222E(>0''
M'M#7;'%C@UY,08^EN_-VHBI=6R<>G#?7=8*G9(=347 F7O!:W1@>[;^^B!9
M""0 2=&ETD..5418"UN,-S0^=WZ2R'-;^>W_ (5;2YCI[SA9>+=G.;CL;C-Q
MP7'=
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MI"-4JETR<EI$ZG09B&5EQE$J)'D)960 5M)>;6&UD  J0 < #/ TA'.
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M"C$**"% H6I(EK2JC_?#@;AF<1:RA?E=+$7$8^W]I;OCS2PGXO[*K-#G0A(
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MB%/G4NU:2Y'^,$-3BVVUUFJR)$&@4*(I:#,N&MTB,%>7\4I':8N5,7,P\B2
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M;*U'5.ERR%&6I1;2I21I30I"E J(2Y&K<=FN1X"9F/3.7X@9=-3),J5,"/\
MMSI@(E*EE!U-*F$K%=1 4D'56,7EK[W[P>'/=(EJZ[HC7!85><I%Q6M4[EK-
M3HE88I,A#%1H\AFH29$:32ZC$\M-%J:F.IJ-*A5*GKC-N@'>.(Z7Z3ZQZ7E*
MRS#(DXJ3*4$31)0E1G% +**:ZG8W-7!L7\G*Z]ZU\.^N3^]NH\5B\)+Q8,[
M+5/4B=(0M23+TK6I!2I.I((30@+0HJ4"GZEMK]PJ'NG8=M7_ &O+1,H%V4N%
M5:<^@I\P,RF2MQB0A*E!F5%>2[%E,$];$AAUES#C:AKR3C<OFY7F&+P<].E<
MF8H%-QJ!I7<$&A# ABYK'T*RK-,/G.58#,\(L*DXR3+FI4DI-%I!8Z26(L02
M#0[1<=&.E..W2,?=CC^S7%CL[7OO&K2$-(0TA#2$-(0TA#2$-(0TA&TXYT8
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M"BJN2A77)74YM%IJXS=5H=7="!,5%:F2(R9=.G2"N9AEQ3\1]]]KR?(2RH^
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M &1G ZAG."0.#R-:4+$GU>OZ^?\ 2/2P#) NP9GIZ.UN*1NZ15&VX1C')[\
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M): SJ4$MR 64X?8V-:TCJ>GO$SHGJC,<1E'3W4F6YKF&&8S<-A5S#,2%*6E
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M3$]NVD(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(T+. #_P!H?AD]_7M]QT-
M3P"?D/SB"6;N0/G%MMSMPK<VULRX+UNV:85#MJFOU*H/MH#CY0$E+,6(SE*G
MYDQ[IB1V4J2I;[K2 <KUT>=YW@>G,DQ.>9L4)PV'25**DA52E1"!J;[S!+;N
M]H[/)LFQO4><X/),K0J9B\7,2A"=12+_ !*)MI0C5,4IW !:K",%C_C?MQW>
MX;GM;#6J[0$-&&BFOFEMUU]@)EI;K$E]=+^ CUMY4H.+90AQ@/A*%U5P*,AO
MQJ/VG.C5]02D2^@LO&$$_P M69'+L%]I2DFDT34H4;@G[_\ *&#1[03^S/U'
M)Z8FRU>(.92<;Y 4G(\+C,;-R:8L!_**1-$O2ER 2EG#4I&;BT]V[;O/9E6[
MEH.HDT"1:U<N&GI<;^&<;52&9Y?I\QCS6?AY4.9"=A36B^@-/-.CXDI ?/LC
MIK/<LZFR; 9[DZTS,NQTI:\.4@)2#*FS,/.3H'PI\N=)FRR X=)XCQIU#D.9
M=,YQC\BS>2,-F.7SDR\1+3,$U/\ %ER\1*F"8"RA.D3I<X$&TS8T%,6IN=6;
MCNVVJ9&JE"J=-JE >K%6-.CI\Z#U_/3WTRX=PU6,8U0*FFH#D5$VFON1IT-^
M>U45M,-9 0-*2+EW^GYN_P!*,!T]O5Z5O5_7UXK0B_HU)R <8R,X]M4Q,3I"
M&D(CG/X<#Z_L^[_=I$5?9F^O](P_[RONKW3O=QQ:G7175I*W!U*"6HS+32.I
M6%*0PE+2&TD="6VDM].!U#OI'_I3:XM<4/&^_/>/./6F(F_OV:DJ4R%+TU4V
MDJ]@XH0^U!S%1WS-E/;3;2LNNNJ:0BXT-I4ZM2&O+J+##*PE2R.IEA2VFLCI
M;;6H) SC5C#C3--;N*OSMZ;;@G<.W;]08B<OI/*PZAJT/4VJ!1ZD T% ;AQ]
M[5M;-=:LK>,1I*V"++C+RVI8ZUNS9+:B,*Y/EE2%+6%+*3TA24CHU7,'^H3\
M+_$!6UJ'8TH['=Q%SI ZLDS;_5*2/LLUP%* 10DD$[FKN7KL&(MYM_,<BWY:
M"HSKC+B+DI"&W$*4E;:#4&4E*.DH"0<%'4D));*VUE:%*2+N.8(30/I]:!R;
M$-5Z[W],8Z:Q$U/46$"5K4?M(2E3DDI\X;4%U$ L"P(+AX[3=24\K<B]7777
M%OJN*<E;CJ^M90TZXPVC)!^1MIIIM"#E*$-H2GM\UN0/X$P#E(<"I("@S7%@
M=[T85'(ZOGS3GV*)*@!, #FC)7-TEB. >S6XBK=R:G)>VYV99<DO.-)MZKAM
M#CBU)2IJH)90L?, %)9;# P!TM -I 2 -6<, "3N7K;?AJ"GJ".#'=]4XR:O
M(\@E+FJ2F;AP5$D@ HEKX(+D )JW!I'&VYJ4B-MSO,B/->80NAVSUAMUP=:G
MJZ_&=Z0% )*HJULK4D94V4I)(2D!.JH4>I(+OL0[GFNYO44BWTSB52^FLZT8
ME:?@+@++I"IJ 6K1P2S?D&I7:^4IK<:Q2SEI7YRTX ME8/2[)2V\D$K(2'&U
M=/2D)3CN%<ZNS@3+8T=)N"YI7V-CS\XZ;IC&349_DQU*+XE&DFKA4\@WY=VI
M3>H;B;CS7).X%YNNJ+JU7564.+6"I2@B8ZA.2%#*0WAM"5Y#3:6D)!#:2*\*
M-*2 ;$L/0  FNY#"A:M(XW5&+FS,[QRE*5\.8S@"YH4^78 AF<LXI2M ^4#8
MEYY_:BR''UJ<<%$8;ZUDE12VMQ" 5$E6$I2$I!) 2!]==1B6\];$FI?@%P&_
M7>D>A\A6M>4X$K))^SRZG_X_E0?F6>+N:LQV\-(1PI=/B3O*^+CQY(9>1(93
M(CLOAEYO)0\T'4+Z'4GE+@^9)[8."$(L;?U;KEH5Z&+0M.!58T.E3*_72*:R
MT0T*I$0ZTW44RXJH<I^"NK.,.1:;6WG)8CLK@H8=4\$11RU#;WO];D#UH7,4
M55MW&:.B9-5MK1G$T&56#(B1I3'Q0J,=V329S,5V10XD6%/74&X]0GR)#C27
MK7DMU$NJD,.PM/Q_7X[>^]G'UIV_7X/%84&_%W36J5'F[=LQV*JTQ&ES)CT*
M3*I4FJTFIS'8)0F$H38ROL.;"DS%2(S:GOA8R6'@IDK1#L6<!K"U+O\ E[%M
MV\T>/3>NO["6%;4;;AB#0;GOR<_0T7##@1$RZ'0:%&:ER!3VU-J9^(*9,>'"
M,AF1%BH>6]\(IY#)1W.2X&7F.((G'4B4 2"[J*E, [ZF<*+ @OO4QL'PXZ=P
M>?9VI..2%RD!!4D@GS"22 HW(37@EA5@0<8'A=\4.Z.WV[=#C5&XZI<=N7U<
MU)I-WTNL27JBM[[;JKC"JU3I#KOQ,*I1)U5>F=+#R(+J77FU0\J#B,GS;*L*
M<+JE2DH,I)\LB@)*7*3<,=(H02P-1&X^L_#KIU&23\3@?+P^.EJ4R4#0Z0%T
M(2 X# 7! < B@'8^+GQ.;F7]NC=5JQ*_4[>LNR;IJM$HE I$EZGA]^ANSZ+*
MJ]2EQG$S),V8XN4I#8D(A-PW/)^# ?D%VWE&5X48=,V9+0M<V4E140&&HADI
M!#)9+@T)+NYHU/0?AOD:^GL'C\9Y>(Q6(F%PI.HI#3%!G>OP@%MR [ &/0MA
M^.K<F%X6[^J-8?:J^XUJUZ@6A;ERS(J5^;&NV.^855JD5I+4>5/I IE84<(0
MS*>1!6^C_+*5UT_)I1S7#R4C_3S5)5,2Y TB8A*M)>@98H#1B7M&&9KT!AD]
M6R<)ADA.&F+3-6A*B'0B;*3,#L" 1-38D'24A@1'BO;CQ6;V[<WV]>\:\:S7
MG*I4$2[II%;E_%TRX8BILB7)8=A@,M0907-EOPY=.$(QYCI><2Y&*F1WF-R7
M *D%'E"6$)9"DBKM2]#W=PX%HV%GWA_T]+R#^#AI*<:A)TK2A*5@A+ N+AC4
M5!%"#2/J#H5115Z+2:JTA;;53IL*H-MN )6VW,CMR$(6$@)"T)<"5=(QD''&
MM<J1Y:E(I\"BFEOA)%.U(\JSY1D3YTA7WI,V9*/JA92?PCM=1%J&D(:0AI"-
M.<$Y( X S[G']F3_ .&H!<D<?YB"6_+:/'_BS\2EA[#VO#8N:WHM[5JZ%RHM
M#LR0W!<8J 8;3\1/JRIS$AF)1H?F-"3(2Q+D+=<0Q&@2EK46M4>*'B3T_P"'
MV5C%9]@T9@,0J;+P>#5*ESAB)TN5YBI9$P,$D,DD DD@-0F-H^&/AOU%X@9M
MY.1XD9>C!&3/Q>8^>J1,PDN9-$M"\.$*3-FS@=2M*!\.D$D/7'-X-_%[M]9M
MTILV[]N+?M,WC<$)%.O:C,T_^:I#]+IE'BP:T@T^+,C0I[M/#[DZ++?;8G3B
MT]3V(JQ+&F_#;]H3HWJ#/).5'I+!=/8K&8R5A\)/PN P<G7,GZ4HUF4E*[EM
M8!#'<!XW3XG_ +/_ %AE.2KS>7UEF?5V%R["3L3BY>;XW$JFX>7)#S#A1B9B
MTK2D!32T:5J(8?$XC+]N!?;]HN6<U&D0(XN:X$T=4B?\.IM"3!ER W';?JM)
M,F4Y*:8:0Q'7+F.,^>J+3ICJ4-*]=HF2IL@SI3:34$4 =W/%A8VJ&%X\AE$R
M7.$M9/H:N*?1C0AO=B[:B\ZQ>C%RS*D]3)4*!<3U/HD^EPWX<>HTQ-,ILSXE
M*7ZA4%+2W)G/1"7'&);#L=R/.@PI(7':))(!.X!^8>G;UK%:J*(9F)%>Q/'8
M.]/Z7=U,(XTL L\\GK04I_K+2>I"3DC() R,X(R#P=4J4$Z7_F4E(]2:<\1(
M *D@G2-0+@LS%_R[^D?&9XQ:L_4/%!OH]-<=FS1N57HRI#JENK4Q"+<&&T7'
M%EQ+;$5EID-M+;3Y:.DI)/5K=^2(D8?+Y*BR J1+^$ "X!8![TX8V! I'Q7\
M?LPQF(\5NJY4_$39BI.;8E*#YBUG1+G+3)EN22D) 9DZ:(&H*(2I-UO$/<51
ME>%7P11:A/ES8+5M[F"#">?<<::33;BCTRFDA:NI2H%-;;A1CU ,L)6TTE"5
MD:ZK*)<D=29@0R23.)4S?SI?9P]10[V:D;0\:,TS"9X%>#HQ&)FS9:LNPI,E
M<U7QJ3@9B914H,5>6E()%!\!8 ECR_"S5YT;P\^.-$&5(B,IV:MM4AB.ZXQY
MIF7#-I<HA#:NE#LBGJ<A.EL-EV,M3+Q<2XH*X^<"2<PP1(!;$3"Y#LSE[V"G
M)<$GM1K'@EF^:(\+/&Z7+QD^6C"]#8I2$HFK"?-,K$!:DL2$K*3_ ":0Y)4D
MK)4NPOA@J[D+Q![((@KD0:@C<^T&HTF.KR76A(J[$1[R^@!*4N15NL.)<2X%
M,NJ8 #*@@]IG*)*\OFS 4E*I#+20X^%)*: /]Y0-:5)C6/@GG&8#Q1Z.")\^
M7BL7U!@L*J<)BM2T39\E$U$PDMIT"I4%*+)10%C'B@JLA?B#WJ55''9\F1N7
M>41R7+<=><+$.L*@,M*RI* B/&3'C-)">DL,^2[YB%N=5WIX29N! 0L RT2_
MA;=<M2F)#O\ <]N'I%7CGF&8+\4.K539JYTS"]09AETJ:J;->6C#SU:$R_B9
M"I8("2D,6TJU!1!O=XG+@JTCP]>"!B;.ES8R-IKE,2._(?>9:5"N&/1V'BDN
M)6I],-F/'#BG#AI'EX#:RG749))D+S/'42D^;-<@"NEYEPX9PSL"SBSOLOQJ
MSW,\1X5^"LF;BYTW[7TSALP(7.FD*7*P\R6)I*%()6A"D@$T<APQ(C;\/5RU
M.!X8_&Q3Z=,D18;EF[;.2(K+SK2'79]X/4N:"EM:0E4JG%<!]QOH<=A*1$=4
MIIIH)KSB1*/4.#*B%.9#*-0 4!F%FXN;L6)(O>#N=YC+\%/&&7+Q,^5+&6SB
M9(41_$4F1*6200Y4A2D@@#2E00[(2UM_!U67HOBF\/RX[RX;C>Y=O1B\TXXA
M:H\MUV+*;=6A:/,0]&*FWDJR%>8YTAL="1R\_E2DY?,"=)*@200+!*62'^[R
M& %.7C6?@1G6.E^+'1B).)FR4XCJ'+\/B3+G3$B=)F8@ZE3B"D3@M)"2F9J^
M)2U)T@I$43OY653][]W)LH/5&9)W*OKXF7/>>D/N_#7!-8BDNK<\Q*&F&PTV
MAI;: PAII2"RA#1O9&E*LJF S @(\K2$_P"TH6)@4S/5FU.[ <D<;QHS6?,\
M4NL9@6J>K"=2YJE'G39JM$F7BDF7Y'QNA "$%2)7EI51,P+ TJ][^,BXJW.\
M 7@!BRJB_)9J]/\ BJFEUQ2OCY-OV6B+252W M*WTP&:K+#"%' >+4C/GLLN
M-X[T\B2>I\<S :)ZTT J[\$ D#ZV:_VX_9-QIQ70W3>8XR3]NFGPVR0*FS )
MI2M1R:69VI8<JH?B%:G>L8Q+%K=2MB^;&N2B2%0:M;]ZVC6:9+: 2Y&GT^X*
M<_'<24=*2D.I <0XE0>8+T9TJCR'VW,XSQ,N=D^*U %/D*(! -AM6C%V[F/3
M_4^#P^)Z;Q,\I22)$Q0)'% ;^U-F:P$?=4R.EI ]>D$\8R3R3CG&2<XSQK0=
M-J"/*Y#$CN?QC<TB(:0AI"&D(:0AI"&D(I^1==LQ'W8LROT>%)84E+S$RHQ(
MSK:E-MNI"T//((*FW4* /)"LC@'2#QM?GG9_^E5N?Z[IO_$Z0?\ K8_KVO#\
M\[0SC\Z;=S[?;5.^_P#ZSI$./\T_7ZYA^>=H?Z56Y_KJF_\ $Z0?U^1@;SL\
M?^U5N?Z[IOKC_P#B?K_S@Z1,#>=H#O=5N?Z[IO\ Q.D0]6K\BWSM#\]+/[?G
M5;GM_GJF^OU^)Q^/8>ND3&E=Y6@0/_.FW3A0/%;II[9/_6<?\Y^NC.0+DE@.
M2=H@FA/^T$DD$  7+M;DQX?_ "AUS6[,\+5[L4ZNTB5)<K5EGRHE1B/.N(;N
MRDJ  :>*E=*BD@<X)&!K2?[016/"OJ$A2DLN4E)"B-)^,D @T8 DLP8%S&[_
M -G7#B=XM]-!4H3$MBUJ!0%#3]F6$E3@AG(2E[%0%"1'SD*FCH/2L_*E73TD
M\<*_1]$G/J/P()!/R?1*F)F?>4-1JQ(H6N 6(YN1O0!OJZG!I3\ EI"?]FA.
MFIMI ;Z.U&(:/H9_)NW+1(?A?H,>JUVEPW&[PO=*(\VJ1&'&V57*^XE(:>>0
MI"%*6XOIZ0#UES&',GZN?LYO_P"$W3"7*C+E9LX)<)'[YS(DAZ!R2?4@WK'R
MJ_:7DB3XO]2A" A"OW&!I2$A2OW#E3_= !+-9W8Q[Z1=EEC.+EMH'I*3FL4S
M]$\D<R<=)[D?7G/&MWI!T [&@.W+/:@(IM&BB"#4$'AF^@']MXWOSSM#M^=5
MN#C_ -]TT=N,?])[_3O],:F*7]?D8?GG9_\ I5;A^ZMTTGMGL).>VD3$_GE:
M'^E5N>W^>Z9Z8'_6?J-(A_7Y'^D0;SL\?^U5NY^E:II_9_C)'W:D FP)]! V
M/8/&(/>28V]N;?3S#Z7FW:M*+;C*_,0O##!2I"DD@YSPI/=7 .<Z[=)9(8D!
MJU8.*?I^^T>9>L5:L]QY!*AHFE#%PQF&H&Q;85V,51?M3B.;4;.MQY+#KT=J
MZA+:;6%/-*55DK"7V^H+0H(]%I!X2.V :9899(-"4@-3Y$>UC>N\=MU',/\
MTQTP 2->&"E@/\;R"05BFIBY<NUS41HVMG0V;(WF;D/L,//V1';BH>6A#CKK
M=26I260HA2EA'4<#)QU*[9S"RH8A)<WM6[./<[-O6IBKIEOW;U8D #3D&M(&
MRCA@Z@*LIV<W<CM%OK!E-,WS9SLAYMJ.U=%&<>?>6E+;;(J$8K6XXI72AM("
MBHJ4$CDJQDG5>+/PL2QTO4]J5]0Y&SC>,<Z5_P#UG(S_ +LYDI)=E*&O#G2K
ME)*B2FM2=S7L]UZC'>W#O%Z+(;?8<N.INLO,.H<0ZVJ0\4K0MM2DE!)^4YP3
MU $%"M7);B0@ 7O["Q %;BU[T$4]53%'/LS^)Q^\)NFI) "G2*V'Q/IM]7J?
M<.I0GMOMG&F)4=V1&MZL(DMLNH6MAPU9(Z7DI5E"@<@I5SD*&.#JRFDT,P=Z
M>B:ML0:[[>\9%U9,2K).GP&*DRY;@&H.D_#04<>@N.T;5@SX+>W^]K#TF.R^
M];=M&(RXZVAUY3-PI4Z6$+4E2RD+RKH!X5D^NHG7O=0NW^VGI5FH[WV>GIDH
M&2]5)(2R<+J2" P#RS0'=-W!W?F*5VSG,L[@6*Y(?2TTS<=+6\\\I"&4-HEM
M%3BW5$)2E(&"M1 QQGWDZBD!S]UJGTY!_+\QTW2JGZ@R0&H.(10EP6G%MPS"
MH;BG$1N%*;5?EY+96VMM=U5UUMQM04A:'*@^M"DK2<$*0I)!!(P1@ZNR2Q _
MXBCMM=P=P*,YYCB=3J_\]S/20W[PG$4YTN13?YT:@C)=L/=%N0MJ[-CSK@HT
M5YJD)2XU*JD)E:%%YPA*@X^,*[X'![\=]=;BZ3C8/Z5+E^YVCT5TH2K(< HD
MJ(E)2HN202' /=A["]A%X!>=H'M=5N_ZZIH[??)UQHR*'YYVA_I5;G^NZ;_Q
M.D0_K\C#\]+//_M5;O\ KJG?\3_SQ[C2)C2N[[-7^G=%N*_H\UJG>O=/$GU]
M1^T:>D10\_4#^A_/YQM_G79/^DEM#]+G[9IH[]/4,_$COA/4/7I2#^B,(,.*
M6W["WL*^\:DW;98)*;FMK)X)%:IF3DY.3\3ZD9.>Y&3VTB*/8N'V/^/T -HQ
M)?E4JS1ZO1MF/LJJT^?Y59O0+$*6Q(Z JFT+ 4&EJP"0 <C P.??*>F$D3IZ
MB"$E,MCL6\S[I!=P2FU0X=G8[J\%T/G.*40X*)0#C=*EZJ'AZ^W:,5&VJ@UN
M3MZXZL-MHOJSU.*40$X1<%.4HYXXQW'KZ GC679B <(L .=(8 .7*56W?>E3
MP0\>@.H)4M>3YN3+0HIP,\I*DI)!$R6Q#@L4@D:G>XWCM-ZG6W=Y-VGF'$.L
M.[FWVXVZTI/E.(7<M2Z5-E/!ST_B0!W &HRP-@<."&(ER4D$ $$)3J!%Q6_)
MO%KI@!/3'3+!(U9-,F+(8%2]<\:U?[EL '-69CS5%!>CCPZ;HMJ=92^K=':1
M:6BI/G*0FF;@)64H)"B@%0R4\<'OTY'%GI_\UP[!D^3-=K.9^&/I8'VX$='G
M*6ZQZ=*0VOI_,U+:FM8.**5*;[ROX:2E1!4- 9B*6(5C#Q/(#+N<)S@%M76
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M)M=TKN>W4)#BU_;U-24M EQ6)3!"6TI^8K).  <J(& DYU<F 3$#50U^C_\
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MPQYTJ&FK_P"-A24DI$A$1PI:E>24J& 4MCYQJ=0- 4EJ5J!VL*,3N'IS'?\
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M&U9/ P#W&/3&0!G.>03@X]0AL*CTHS$, ';@\%B0^Y>3C^B0>/51P,<''OW
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MUPP?8,Y%.Y'PWM4\G!_8YF,PV%S#,)>!PLR<@S%3)'FI2"H S2I,N8KX6 *
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MV?=_<1%L;R;17G<M0L^U=P[/N"YJ<E#C]&I=?I<V8ZPME+WQ,%#$IP5*,&E
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ML1!F(I[7L6X:]&K$_##&?EP<^I/ /&.#]<<Y]OK!!#7H0* <N/?D'=G)<1(
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MU<[ATX<X&1\V1DXR<CWQ!(( ;@E^P;;\FM%:00Y-*=O7V/K[][^%O! *2,
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MIJY!],XX(QC&.>XQC@8[8SWU-_1J5+4!'9ASQ;<120U@=N 1N&;>_P#2E-6
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M)#V2PP_E) CO.MN$@I2G)SJEE>:))!$VGPD-0!P0[ D $U-H2VG2C-E+ES$
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M$2FW$*!CE2"E*R@II"R+(#MV/<@N:@?1GK%U2,//.N:CRE"FFP5W^%P=0_W
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M9W-M[?,.T4LW<.SFSTJS\5>H-*1/4<Y_'!(X[<D8]ASGWP#GC4\UM<$ACMR
MP+<;!@1 V%!47#T9S^%.[.32 ./3.<' (R?4_4_VYQSSJ&J7J0*,XK6UJ4)I
M[4<0VV )-Z\;5((_._,'D $@=/Z6., G((!)Y/H!@CZY.%*U-1^5R!5MP34O
M5P[JTH#6CO>S584%#MWLT+(#;F00>@XXP/TD$^I]CR,_AZN-Z%B;E@:,7:I
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MC((Q]1WY+NSD LU@&<"I-J@4W<UWC''#S"U/-FO6[35T8AZ/8AF%A2.3\I(
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M/;N,Z7'S:M0[N][EK\WO$]_FV] 0WXT9@ 6%H GY1Q@*!']($G(Q@YR".3G
M5C@@'.I]2>16H)K8.U*\_>+<1M3T/! [G\O^(O?;>;#Q3YF5="PM/", ]ACY
M/Z()2D  A*E $K"%(BA#[O3\?B-^0X M4M$@T[-7G@M5AL[]B!:-9''JKYBK
M/2VDA1P"?D0D]73D=>.HH4I'"<:CUJ[5>U2].]_T8'U9JCNX<,0SLP' V-A$
M_*,)*1P.!P<J/S9^<'/S!#A)_36E.>!C1B6H[UI3^HW;9N.3TH=[\!MV +EG
MX+7O$#U"B,8(("0D%)^;&4!)("AD\DJP.K(2D"?A9V)-O3B[]@+_ #$/B%'
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M9Q] >.,CG'M_9CEM0N:CD-P-Z4;O9S2)=R"1\-.+_05-_JQ :2.201C'(//
M.>W&2/;CGD9U M4!J[&M1<AK?3BT"2[7=W[7<!W8;OQZ&-)/?'ID'G@>@/\
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M+N52;4LBBUIAB V_'D6I;M1E5RIP&?)F.PJ49$U<R(O"Y)-7?O[=OU7O!A<
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MU4X$2H-Q9"9<9$MA$@1Y:&)##<ID+2H(>;CRY+*7 .H-O+2,A1&H8_>IR'8
MU(8BS[T_$Q(84J*#4:[AQ:S$M:KUCK&+0MB,B$B+0:9%137&'J<&(K3282X\
M=B(PJ,E*>EE+,6)%BM(2DMM,1F&VT)2V # ,_8^HH[>_=^UXER6_)[O0;CB]
M#6L=+5]LK%K<:H0YU!BM(JDIN;,>@E4.2J6U*5.2\'V"D@*EN/OO,D*C252)
M0D-/(DO(69Q3A[&O+.;"SD"PYB-1!:I[$ T/- Y[/O4T+[_^#NR'(E-AO6[
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M<\=L#& << ]^\&E3L6:]ZN"27]6#UL691OS>E!9J5<^W<.2P<'N .,*[C';
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M1Y*F&U2&%/("'?)>4V5M)=2 AT-J;+B $J)QI45[F_<&MV)(XW'S BQ)K\@
M:"[M?<;1O=0/'5WQZ'O[X_V<^O!YR/L>;5MN-W=M^;0O5V%@#]!O04)>CG:
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MS]K/"U6<>MMG8%V:EZW>L,IS^F0/N(Q[C';OZ8Y/<G.H%'9W-0[4LYK2M>X
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M#&AM<AMG=GH&9C0<G\3$4<V-*&O'?G?C9H93G]+/KC"ASD8QQV^_MCMZE0<
M%QSOO4V#7<5LSP?FK,VUOK]03#*<\*/U."?7.<=/MZX!&!QJ"Y&U2]P;M8TJ
MX(MS7>)IRU"+%]_4!WK7Y/$]8[=7''H<GGL0, '''4#G'L2<"XN0.!\ZV)9R
M:&AKLSJ4 J32OT;^[M[1!*202>><\$ \G)Q@]SP>PQ[ZD5H PO6XV:W8.X+$
M&Y8Q!9KN>'/%#[</O8,1#*<_I$CZYX]\8!P<\ \ 9[>F@VJ6V]W=W#7=JFU
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M31O<_.*-*2M3I%N!P(W&H\?*_P"09[I_]$C^KC^K[$ZDDLD.6 IVJ8( !4P
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:'''EH]__ .G1R+%HAAP/E&_@>P_8-(F/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g491933g82b82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g82b82.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1*L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $I"^1U(X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q 8L!J@         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          #(   #M@    8 9P X #( 8@ X #(    !
M          $              [8   #(                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   #(     %)G:'1L;VYG   #M@    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    R     !29VAT;&]N9P   [8    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     ,X0DE-! P     "#P    !
MH    "(   '@   _P   ""  &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B
M90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.
M#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MGA2F%*84IA2F%*84KI3<(JJKH)GZ2K84RKET,'5F53!5,!$0 #=),P&^=$0
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MBZ0<OCW6M@,D:I?D]_\ KR,8]Y[<#-<?3:S8+KT<T<R0,8>F<Q;S:P$Y@*!
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M@E -.?SNFW/I=P:!KW@'+73NVTUQ'+)VR<G?Z<^TDY[,TP!L<@#L[^[!VYC
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MK[\$'0+4+N>]GTAUFN9&EE6"[N8(C(WSF6*.157)R2 ,9).*A0\&-P? (#Z
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M@.G/209Q>Q[_ .[6_P"S\]E0/P*?@] P-*N=_P#M*]_;<_'G50\&-P>@&GH
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M-.PF?[?)AMIM+27]:U\GY:X4QXY]WW><U'/HU!HZAE4EGQS=JHDZ*\@\<)B
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M(#KJ(  :Z!KMH(?;[PV'$Y/T8]E3@X))Y[;DY[Q@CEWC?';XUQ4*4Q3@< ,
ME, @(:AR'4!#EH/M<O* @& )Y;G)W&>>>_.V_C4 *"&4 8YDC.._LWSW#N.P
M[/W1<'[MT_X7<@'CUPN[=+Y2T@ZSERJ===8XP3(!.JJJ<ZBA]"@ F.(F'O$=
MQ'X3Z8Q1P]*^D,42+'&FKWRHB *JCKW("J % W.PP!W5]#Z [/HVF,[%F-E;
M%F8DDDQC).=_>2:V1QYJNQ3"E,*5:O\ ZQ>:?N1Q_,GPJ#R.>ZNN,]38_P#B
M+3^83PJ:OL*4PI3"E,*4PI3"E0K /JK/>==A_P /1_+O[L*=ON^WSY%36%*8
M4IA2F%*84IA2H6P[0SW_ "4ONN$@PJ#R^GNY;U,EY![0?>PJ:KA2F%*84IA2
MF%*84J(G?4Q?^%9_AS;"E:#\9>36=N<^9^2T)E>]5AZXUH>=X6:POKMFI3ZY
M7;+(#EPTH\VJ7*JRUJ3E[3&"-@?5AG*N31P VE0ZYFJJ"V%*U/E+/X07*J79
M46D1&;5]"$LMP*]N$]7X:?@KU$/9ZY0A+*X=/(^7DV[EJV85*R1$,C:*6R8%
MF42L8JW1ZTHWA7;[_LJ/HS[#R^O;UUE1E=./>MYHY4UZ7)>+M2/1S5$;5*-J
M!38=U/P]MJ>4TS:AFIEE /X2+@<NYR>S+CVS,J-*D7<? $03N4]8(M"/FGGS
MY]5/$'GR[OLSGL]>VU<\V)WC0I>;F=1,NG&;<Q7)B[.Y[+ANC2JO;ZZI,(96
MY0L\O*$F\D&Z!J]E'9;2EFJMF#-).V\M!3$8R7&=K_:Q%)Q3'V>'?]_+LKV'
M$W9^."'G[\_R;"72J\>YR9AHQK'5>'F/$X:P0UND,S[? #Z%[;8;%,PEBC:;
M ^($AI)M'0LU+O4X=RZZE_&//GSZJ>_GX^<?1W5-9VV3C2#);+"0J5(C'>9#
M2JP-@L$S673Y63-F1Z55Q5EHYUEH\9M632N-KJ,+U";^V2Y5G:R$4ZARE*#Y
M-3]_U]_V?=6N&;D?QTN9H&+67S>EH^F6H6C:V5:"A(=_F#77K$7S&-L<5!)-
MHE>$)/V,\*_<PD5$R:41!-'CB1(LP=R"KSYV^WM/A4Y^_P ^=J@%+IX0F=LD
M-%IU[.:L52J3N6CYXBG UULB[=U"]4:(4A"/T(!Q)R-'N]:EY>:N@KV:Z2:\
M2P4>KN:>_92M?(\^>=*WKX&+1Q16FAV9YQ2-3L[0G+PX1C5U6E*Z]8/%Z^R<
M7.'3,$)76DO!0MI4>L*Y(LHYX@:.3!$+1:RIIS*S?S[?/O[JC;/B?L^C[:WA
MPJ:84J%F/T6%_EA#\&=84K'.?=!NF9V4EUH^7>8\GE+=YV*%"M9@Q4:PF5J_
M*(KHNFYW<1)I*M).(?B@,9-L#=4JZB'CU%NY:N#)KDM64\-M=V\]Q:K>6\<@
M::W9BADCP0P1QC@D /%&W8P&!FJE]!-<VLT,%PUM,Z$13*.+@D!!4NO:AQAQ
MVJ2,'-?'>;\&5Q82;//NZU?-OAXR5SDSERRK632X9$Y<VF@T%]4FUP)8[E<+
M*3M&1E5\QK/' XK[61C6R"<+&OGI&K@RRJ2Z/M(^E&DJ=.MYK+4+VQL+J:\7
MX?/%<3)(Z%(H(AZ*?!XVPY5R>-E!8'&#Y.3H[JK+>S17=C:WEU EK_!8YHH&
MB# R22#?\M(HQQ(H(#,H*@Y.9XS@MXIYO)_+#(:X/N%.DY89-9J\/%_H$'DY
M6\SX\S>,R?S+B;A8(B44MDM,%=K3D0Q<),W0%*LM-NE'<HX.FHH;%"76]+BO
MKG4;9=5N+F]M+^VN'O7M\YO('B1D^#J"!$[!N'EPK@!=\V1HVIRV=O87)TV.
MVM;BSGB6U2XXB;:59).,RD@F4!@2<GB;B))WJ'H?@C*S5>(;B N3K,NZQV1>
M9["OKY<T3+J]7;+BW99R"%KM=RL59:6.K2$<=3+Y6P7*>DX6!([,FW6D>J5;
M #%LJ.R[Z8S76F:9:FSMWO+)YS<74\,<R70ECBA61HV&.NX84XY,<38)R0V
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MX[X6C^/A2GH@@_LO'?"T/Q\*5#S\[#'B'I22K QA*EH4KI$3#HND(@  ?7D
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MAXY9M@>32"\:86LRBJDO,)LD5#-'Z!!,NFV3=JC/AVX_?Y[?::\B'%'+SLE
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MZLK+Y[#'V>0EB93V>*JZ\TY@ACHUS+4:\RL$A$VU)NO,QD1&)J)RCT!=J26
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MI0R$A<;\*JO"O9@8Y8%:19I<0W'=E4A8&MOGLSJ[%VO,:584.<>9:9=&E8N
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M4?[?G?D_/]'B-M_Y2W\N%*CFKJ41?2;@]?D13>*M3H@5Q$B8 1:)HGZ8#(@
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6!'HH/%E3")E"@ %3'<=1$  1PI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g491933g83a83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g83a83.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[0^B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #X:^.70X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q :."#(         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          "A   $[     8 9P X #, 80 X #,    !
M          $             !.P   "A                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   "A     %)G:'1L;VYG   $[     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    H0    !29VAT;&]N9P  !.P    #=7)L5$585     $
M  !N=6QL5$585     $       !-<V=E5$585     $       9A;'1486=4
M15A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'14
M15A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI
M9VX    '9&5F875L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( $X"8 ,!$0 "$0$#$0'_Q  >  $  00# 0$
M             00%!@<" P@)"O_$ %(0   & 0(!!0D)#0<$ 04   $" P0%
M!@ '$2$($A8Q01,4%5%55F&3E1@D)45E<8'3\ D7(C5$=9&QM<'1U-4C,S14
MA:'Q)D:4X4)#9+3$Q?_$ !L! 0$  P$! 0             ! @,%! 8'_\0
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M)#02X@ =22 !\2>2I&TM%/%^]6DG'NG7<!==[-GK9=?O4%10%SW%)0RG< 7
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M @8 ,40,4P )3 (" @(;@("' 0$.("' 0R$$$@C!'(@]0?(J]>BD1  $1'8
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MB?5FM'>TRUC )&OB:'R@DDL!P1J6FZ+\N>2&I2NJ++5)U'U[7;3R\=$HK6F
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M[$0+)!8L,LN<X8R^.2.24-A<<F.,N#F#JUN5ZHSY-=M,(F$3"+2O*1J-BO\
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MSRMD.J:HN0%=9&$4:-Y, 9&<#SRJA5,_OC[_ "65:4ZLS6H]MO$7(4^5IL9
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MQYYY^A^GKGDK". AZ/%\W8/TX]>O7\JH''Q^C< ](?I_0&P\.W")P#<?TX3
M\DZO1Z #[?3P[<)@=<<_-/FVX?-P_AU"'#JQZ]>OBF!Y>AT3LZNKJ_=MMO\
M-X_1@^1\>2)V=76&PAOU?;JX!QX81.'6&W_KK_7QPF!Y( !X@W]'Z0_=A%/5
M\WH_AA%&W > =7'^'5Q_1]&$3AOMMV>+Q;?Q'YOIPB#_ ,^+;M]/5U;?3@>O
M[PB;>C@/7_L'5\V$4_\ '[_H_P",)@>2CAXMPXCPV'?K_7O_ .\*8'D$^< X
M_P -A'T]@=6%5(!MA$_1_P"OMOA%&P?1U;=@=@[;!Z1W_1\Q$^CZ/H[>S]V$
MP/+W_KYIL'B_3]'8/5U!PPB  !V!OQ'LW^P;[815+,PE=M3%$2F*Y0,4Q1V$
MI@5+S3 (?A (<!W .'CPGKR]>]?1C"#F K-)?C"O?G-U^Q)7[=?_ *(KSA$P
MB81,(F$3")A$PB81,(F$3")A$PBLT]^+@_.,+U?GJ/\ %A0]#\"NFTUB%NE=
MF:I8FJCV#GV#B,E&J3MXP569N2\Q4B3V/7:OFBNVPIN&CA!PB<"G25(<H& J
MM7>YVTM4E(V:>L;5,2D8XKKM-W.ZC:ASJCYQ3[ M::FI.!+6AX2P!6IUTZ?0
M:<V5^E&F=+I-2)HG[F!%D%9T<H%0=Q[R"C)) 8894L"S=V:S2L57&TT@FVD8
MZN1$I+O(R B5444DTXJ):M(]J5-,K5LB5-,"D7"$T5TTKJ,<A#UI-FE$RE:F
MH\@2$JL#>2J%=)5*\Y 5WRHJ#'P)"L2IJB=)< [NY(LX_M<(L<)R:M&TI!K)
M)5=VBHT50=),T;1;$HA1^U92<8UE74(G-EB'LNVC)B2C4)1VR7?(L'(M4URH
MIHE3(LRGM*J38X6M03^.?-6U,*V+4W\'/S]<L%=!K&FAR!$V6!DXZ?:%5BS&
M8/2)R()R#4PI/B."#MA%AQ.3;I BT9M&U>E61V"K59M),+E=&$Z"K9"S-3J*
M6%I8$9M8[]M<K.A+'5?G-+)3#HLB+G^R[F3&/UYK(6>BFF#"(;0#>J- AFCR
M+?I1JSJ0<M1<0U*;:=Q_=DW+M4'"*--:-X0[9?NC=PB05W"2KLZBYG]#Y=$Z
M>O-7&B:64O3=257JK*41<S3:'92+J7LEDLSM9C7DGC>#8IN;)*RJ[9C$MGSE
MLQ:-3HMT4#%3!/8A-B+8>$3")A$PBLL]_@VWYZK_ .W8_P"W\,>O7KYHL;N>
MFE5OZK(UH).O&C,@I*P[2V6F'KTNW%PBZ[UL==AYAC"61J*R!.<VG6#]$Z0J
MMCD,U7714(L<<:#:8NX>WUMU"R3FKW=%\C.55>U6M6KI>$I,TT_7@:\>:&(J
MSQS,'/*G>UMG%.R/S"Y2634$1%Z]>OY15+_1+3F0?/GQHB28!+0!:Q-1L+9[
M1 P$[#)0:];;-IVN0TPQ@IA1E!.#QC%W(Q[AXS:IM2-UTQ9,A;D5V=:74YS8
MXBV$;2\;.P\?%1";N#L]F@4I.)@W#AU#Q5D8PTNQ86B.C'#QZJR9V%M)(("_
M?D(0$GSLBQ%;)G173FPVIQ<)J&>R,H]=P4B_8N+'91J\E)5@$0KTE*4TDN2I
MRDA#&;ME8YY(0SE=JX;-G*1RN&Z*J9%CEIT*@[$KIY$(!%1]&I&H3[5)W JQ
MKR2E)6WK2DS8&RK6:=2_<XN//8IZ1E91J:-?&>%%..;*,&7/3$BRF8TPBEK'
M+7RON9.(O4@P1;@X5LES&GOG;"/<QT4O9J+%6>'K]B29(.3$YCMN1R<A4Q([
M251052(L(IG)JT^J=(H-2YDIW_0VDFFTL]:F[#19=TXL3XDM:"&<U2:CWI82
M;E2).5:^Y?/8Y))I'(\U4S!NL4BS.PZ3PMCM;RTK3%GBU9:I1U2FFU<L,S67
M$@W@9Y:P5I^2<KS^,G6+R&<R5@:[-)!-"28SKMK(I.$DD"E(L B.334&DK85
MGXB$*OT9+36M??6BO62K+0"UP?.YU6\-K.M9Y&TV"1O=E/-3:3Z/5D6;]=L_
M3>&=O57!%B)N2DBC?5YN*MZ\/1W3>"A7%0CAMK-=6CPE6/7#:>N56EV;UB3@
M9%PYDIEW*351D[.5U+O@1F".",7S,GKUZ_E;[7TKIBLY V)!K+Q<M7HV)A6J
M\%:+- I2,- K*.(6(LC2'EV32U1D8NNZ49LK&A)MTN_I!,$^Y2#U-<B[(S2V
MDPK!M'0\8ZB465);:=L5HR:G&,@PJ;(RAV<>QDVLBE(LW#510RK>5;N4Y9%4
M"J)O2G(40(K'4]%ZG3+2TLT*>3WCH*Q13!G(R+Z95+(7.P,K%<[)(3,PZ?S4
MM-V)W#P*#AR_>J][-8HJ+8"$=+%PBV[A$PB81,(F$5GE/\5!?G8?V9)81:AM
M.BPV">D9E"?!H616!P=LJP%P*2HD(4X%5*[2 Q!,7G$ 4RB0#<T>=L!A*>?Q
M]>N:Q_W/SCSG1]E'_G\*I[GYQYSH^RC_ ,_A$]S\X\YT?91_Y_")[GYQMMTH
M2[?BI3]S_P"P81/<_./.A'V4?T__ '_I^W'"*/<_+^="/LH_#LX>_P#A]'B^
M?<BGW/[CSG1]E'^C\OPB>Y^<><Z/TQ1Q_P#W\(GN?G'#_JA'A\E*?S_IPB>Y
M_<>="/LH_P#/X1 Y/SCSH1]E'_G\(GN?G'G.CP^2C_S^$5$30M<\@Y8=)$@%
MNT:.A5\&'$# Z5>) 3F]_<.9WISN=SAYW/VV#F[B15GN?G'G0D'^E''];\<(
MI]S^X\Z$?91_Y_")[GYQYSH^RC_S^$3W/SCSH1]E*?K[_P"'[L(@\GY<>NSH
M^GX+4#</%_C_ )^O?KPB>Y^<>="/LH_CW['_ /SVX1/<_N/.='V4?^?PB>Y^
M7\YT?92G7_Y_V^;AA$]S^X\YT?91_P"?PB>Y_<>="/LH_P#/X15#30(R3ILJ
MO92J()+)**II1@D4.0AP,8A#G>G*0QP 2@<2' N_.YIMMA?#UZYHO1V$5FDO
MQA7OSFZ_8DMA%><(F$3")A$PB81,(F$3")A$PB81,(F$5FGOQ>'9\(PO[:C\
MA_D?NH>A^!]>*AQ"01A7=.H]CN/=%W"ZR9"@'6HJJHH;8"@'X1SG$0  W$P[
M955CU==:;V]JX>5.0J=G9LW1V3MU7Y&-F6[5Z0I3J-'"\<X<)HN2$.0YD%3%
M5*4Q3"4 $!PF/'^3^W19!T;@?)3+U)>SJPICX_,IT;@?)++U)<*IT;@?)3+U
M)<(G1N!\DLO4EPB=&X'R2R]27")T;@?)++U)<(G1N!\DLO4EPB=&X$/BIEZD
MN$3HW ^267J2X1.C<#Y)9>I+A,>'\G]^J=&X'R2R]27"*T35>A$VK<Q(MF41
MEX(@B"0!N1298IG+P[#$,8I@[0$0'AD/\C]QY^O+FG]^/FJ&P2&F-348(VF5
MI]:5EE%$HM*>E8N'4DE4S)$428$D'+<SM1,SA IR-P4,4RZ13  J$ :BR4*Y
M CQ"*9" AP$$2\0'T^(0PBH&C"GO7<DQ9(PSI]#+H-99HW,@LXC'+IF@_;(/
MT"&,=JJX8NF[M%-<I#*-ETEB )#E,)%VGB:HF]0C3M8@DBY;.7C9@8R!7CAF
MS4:HNW2+43@LJV:K/6:3A<A#)HJ.VQ%#%,ND!B*RP;_3.SN'[2MRE/L#J+5,
MC)MH25BY5Q'+$4.D9)\BQ<KJ-%2JD.F8C@J9@4*<@@!BB $62#7($ XQ3$ #
M<>*)=@X<1X^@/HPB@M=@#E Q8MB8IP Q3%2*)3%$ $# (;@("&P@("("&PAA
M%/1N!\E,O%_<E[/^,(J"/84Z6*[/&(PT@1@_>13TS(Z#DK23CU10?Q[@43'!
M%XS7 4G+8_-504 2*$*;AA%7]&X'R2R]27[?Q[<(G1N!\DLO4EPICX_,^'K]
M?%.C<#Y*9=O_ -$O;A5.C<#Y*9>I+A$Z-P/DIEZDN$QZR?#U^OBG1N!\DLO4
MAA,>LE.C<#Y*9>I+MV=G5V81.C<#Q^"F7'K_ +$N$QZR?1_5.C<#Y)9>I+A$
MZ-P/DEEZDN$QZR5:I*OPA',*!8MF 'E!*<.XEV,7P;(&V$![.<4H_.4![,*?
M/Y_W[O#[K45IU$KM>G7\*A2VCWP>J""CA1R1OW14"%,IS$@:K""91,!0,)Q,
M;83<T $ PGW.>?[<_=T_X./_ 'W83S"8?^>'\A]NOKZR>NI\/7/ZY3[[L'YA
M,-O'X0#;_P# PJGWW80>NA,.'5\(!_(<,*8]9/KT?U??=A!_["C_ *'X?N8;
M83W>'Q.?77Q_J/ON0?;0F'M#T=OO#;].$QY?4G^_EX_O/WW83S"8<?E ./;_
M )#T850=783S"8>T  .(\=@[P[-M_3]&$]>BGWW83S!8>T _W]X?QPIC]\]3
MZQ[NB??=A!_["8=O'O\ #YAZV'7OO^C??"J??=A/,%A_YX?O8>/Q?J'">NJ?
M?=A/,)A_YX?R&%#ZYX]?RI#5V#W#G4)CS0Z]I -P ?$ L-M^OCXP^D"8Z?<^
MC[L]/HMVQ$7 23XSQ*):D;O*_!ODDCI%YR97BDDI^$ "(<_F\PIA 1XDX#P#
M&/7DGS\^OV/TZ+).C<#Y)9>I+A,?'YE.C<#Y)9>I+A,?'YG[J>CD#Y*9>I+]
MNS"JCHW ^2F7J2X1.C<#Y)9>I+A%/1R!'XI9>I+A,>LE1T;@?)++U)<(@5N!
M#?:*9<=P_N2]N$4A7((.J*9>+^Y+_OX_IPBCHW ^267J2X3'K)4C7((>N*9>
MI+_MXL(HZ-P/DEEZDN$5HD:]"%?P)2Q;,I59)R4X B4 .4L-*' HAV@!B%-M
MXR@/7A.G_)5WZ-P/DIEXO[D/U=6$3HW ^267J2X4Q\?F?NG1N"'KBF7J2^C^
M ?1PZL*IT;@?)++U(81.C<#Y)9>I+A%(UR!'KBF7J2]F$4=&X'R2R]27")T;
M@?)3+U)<(G1N!\DLNT/[DO;A$Z-P/DEEZDN$3HW ^267J2X3'VZGU^O5.C<#
MY)9>I+A$Z-P/DIEZD,(G1N!\E,O4EPBM<Q!P[5HDX0CFJ*R4G"BFH1( .0PS
M+ -RB'4/$0^D<*'H<^2QW6NIS%ZTIO-2@2H*RLW!K-6S)VY%FSEBE517<P3U
MV4B@M64^T17A7;@4SE2;/U3G(<A3%$JO.U\B-1K-%0:U4TBU HT2RA;M#KTZ
MJW.HT29)>',56D]/+@YD*E<F["1J=;.UL$:HT=/US)KN6+Y6KRC1NB#<IX^_
MS^8'QZGE^W)<V6D&K+\C%:VV2[NY:3UCBE;<YA]1K!"QA],8ZF*I.D(1A%3K
M!*&BY.V\YTX:QJ#6<7!QS53E:I(D1>OK\?7EX)CUZ\<<LK (+3WE11=TK#^4
MF;H^C(.,8)P2"%C1D(Q1"%<VY)W7K\Z>ZAQH+GLS12 %U934^[3@I*,56\C&
MR44L8Y/7UY>L_$>6[^3!!:NPK2^'U29S<:C*3$!(5F+FYQQ.*L -6V2%E1:*
MOKUJ(_;LAL"+DZ!7-C$KHHA((QT=WVHU(5]>N0]>*]3X1,(F$3")A$PB81,(
MK+._X-M^>J_^W(_]6$6F]1--[);]6M-['&2AX.#K53O3.7D$XNMS(N'<M.Z?
M/&$.9G8&;\Z!)!M"2:AI&.03<M>]0(#I$RZ95"+SPM7.4P_CH>&<1%Y09U*M
MHQ%K<M[_ !#.0U)!+5ZJR\VG5)!I9"R#"0E=-8^98Q,W+KUV11"1<1)'L2N;
MOH"GF>?/E]3@^/G]U>$-']0$+%/76M--2*JK+773T[2*4U&5<R:5$9Z6M:Y9
MDY5JZM,O7YJPH2B9$22,\O,OA?1\>[;/S-F_=CD^YQX^?R^8\!D9PMK<G:D6
M6'@PD=0X.71M4"]GH*M6"T3DA+6J5J<VUJ+R3>S+5Q=;XQAGDE-UY$KEA&6!
M>.7/%$F&,?"!+N(U,JO,BVG%TAJ/7Y"3@4-#)'2&!U*>O]79.Q5B-//OY5^_
M>5" 06KDL]D7U6?V$\#+3K>Q'8%>>#VT0C&O5I%8J93]/#T/M^O3QO3>E:[W
M E(MKYKJ X>:E0,],VVMR%UDH*H:=,KPI//8N+9&B+Q RK>R4VO/:_ /8][3
MK%#R[AAW=J:"D3/WQB #P^/ASS]??\O#DKU!Z3ZN)4646CF^H]<EX;3O2:NU
M>IO=47W= 5B9)V76!K%KMK9)13>?M$$FI&UJP2CT0AC.HA>*<01VBYV\\<^'
M3'PSS]>Y,9SD=>OO_7K[E@-DA=:PGF%29QVKH&G*MK=-:;U9KJR=G.TL0D-,
MX^@REZL W 49]O 3KJ?D2M'4W;%&$-+H1ZC*4304:H57UZ]?RLFF]*=1Z7#6
M.VNKQ,T)S)7C6*>MMJ6OKIA4(Z)?0[N2H$R:OFF"0C5![?6$"LY29QR<R[1D
M9&-D3*,9!PU$H?''7]/L?Y7JW0$UPD--XRV7TSY&U:@.7EZD(5XZ<N$ZJUL1
MRN82J,4W'-[T;P,$6-9+H))(D/)$?NSI@LY5,8JMTX1,(F$3")A$PB81,(F$
M5GE/\5!_G8?V9)81>+-1P$+S9MP^,U!#AQV%-,0'Z0'</0.%!CGCS/S^7W\L
M\EA7V_CA5/MZ>'_/^^$3K_7]OI^?")A%'5VA]/7MV_N\0!]&V$4X1/M]OM^[
M&/OZ]=>:(/'MVPB=6W5^K]&$3J^WV#"*/X@'#Y^'\1^G")Z0^;]'\..$7NBG
M;@E'@/#:FU3@/6 \R1[.O(.@!ZX&46<Y43")A$PB81,(F$3")A$PB81,(K-)
M?C"O?G-U^Q);"*\X1,(F$3")A$PB81,(F$3")A$PB81,(K-/?BX/SC"_MF/R
M'^1^X1<5I1VFHJ0K)N<J:AB 8SY4AC 4VP&$@,#@41#81*!S  \ ,.VXU8[N
M>,>>/TS]BNL9=X'Y U[?C!7L';R=X]OHX^C"!V?#RQ^HRH\+O-A'O!MPV^,%
M>W_3L*Y/(8YG/CRY>_'E[D\+O. ]X->.^WP@KV=>_P '84SS(QTQGGY_I\/K
MY<WA=YN(=X-MPW^,%>S_ $["N>6<=<8Y^9\>7W09=X'6P;>T%?$ ^3O3A <_
M+/U(_A/"[WA[P:[#U?""O7OMY._?A3/7ET&3\L\O04>&'G^0;>T%?Z=A9<_1
M^7A_Q[UR\+/=M^\6O9\8*]NWR=Z<+$N&<8\_IG/[+B,P\X>\&W'Y05\>WD[T
M85R>?(<O?XXSY>\>NL^%WG5W@VWV ?Q@KV[?)WI#"9\?>1\LY_8J1EGH?D+7
MM^,%>P-_)V% X'/7D0/GR4>&'FP"+!KQ^4%>SK^+OMZ,*@Y)'EU_7I_?\J@D
MGK]XW13*S:$$C^,=[F?K#N5C(M79R;!'<!4(@)"CU 8P"/ !P@.21Y8^JKQE
MW@?D#;V@KX@'R=Z<)G/3Z_$CW^(09=X B'>#;</E!7^G80'(!\_[3PN\_P @
MVZ@'\8*]0[?)WI#'G[ON!_*9]WB1U\LY\/<?IT\ R[T-MV#7CXI!7^G!A0.)
MS@=/,_T5UJ2;A9,R:L8R53$2\Y-5Z<Y#"40.7<IHTQ1YIB@8!$!V, "'$ PK
MSSC \^OD1[O?E=HRST/R!KVC^,%>H-ODWKX]7^_B+$/SX>0Z^)S].77Z*/"[
MS8![P:\0$0^$%>S_ $["RSU'D0/GT_O^5Q-*.@.4XQS,3@4Q0/W\ISRD,("8
MH&\&[@4PD*)B@( (E*([B ;% <C('C@9_3W*%9)PLF=-:,9*ICMSDU'IU"&V
M-N'.(>-$H[&* AN [" "''J)NR0,<C_ !Z?J/'JN82[S;@P:@ ?*"OB$?)WB
M#"N<8SU/W _GR3PN]_!]X-?POE!7T?)OIPIN_-R_+]>N?V3PN]VW[P:[<?C!
M7?AOO\7>C"%W,C'3'UQ]T\+O. =X->( /XP5[?\ 3L)N/,@<AGQ\OT*#+O #
M<6#7L^,%>W?;XN]'']^%0<\OC],9_= EW@[^\&W -_Q@K_3L*$D> YG Y_OR
M^Z@9AX&X=X-MPW^,%?Z=A4'(!\QE<@EGH_D+7V@KX@'R=Z0QY^[[@?RH78SR
M]<_Y'R^2#+/0_(&NP"(?C!7?JWZO!WB].$#@<=>8S]<?O]%Q\,//\@V]H*_T
M["R5$[>OG*T<H5FT*#-[WR<#/UA$Y1:.FW-+M'<!YS@IMQX;%'M$ PH3CK]/
MAGW>15N?Q,-*N3/9*IP+UVH!2G<.% 56.4A=B =0T7SC<TH;!N(B   ;[ &%
M@2,GD>7CG'/./#]_)6_HS5O,BM\>/67YO)GBX86>,= /+J>GAX?\<^N2I&L5
M??8:16NT>LOS\?@OT=7$. 86(((R!X@#F?A^G(]1SZ_$ST8JYO\ LBM?2)0X
M; /9%]?']8;[83(&>O7SSYCGD^X_3]./1FK!PZ$5O@(]7,Z^KR7\_P WZBH\
MQY#&2?KUQ]<^*Y!6*N.PA2*UU[!OS=]]N/Q7XOTCQ].,#R]#I\E"<9R#G&>1
M/G^GC[NGR4!6JOU!2:WQ'M$H_P#\L<*GH2?+S/R_OZ(%9JX@.U(K7#KXE =N
M/5M%]G8'#Q=6$) (ZY/(<SCRY\_X/FG1BKCM_P!$5KCL'67JW';CX+]&XX3.
M">7(9/4^ 'AT\>7\)T8JP\.A%:#@'4)?_EM\EAVC]NK"9 Y^'/J<_ESX'X>Y
M K%6W#:D5OC^#UE]'R7U<?TX0GD<CH,]>O7^0?=CY*!K-6 =NA%;X;AUE^;A
M\%^+"<R.G7PR>G7R^GERZ<ER+6JP4Q3EI-; W. 0'\ >)1X"(#%B' >SB'HP
MF>O+\HY\_/GR\SYYPKV@Z>I22[LC%D5%9BQ9II%?K%%,6BKT^X $;S ()71"
MD NPAS!W#;FX5)QGW#/Z<_LKGX6>CU,&O'?;>05#JX<?@T?1X^WQ<2A<!GET
MQG]>?[9]=("7>CM[P:\?E!7Q@'D[TX0NP2,=/?[B?+R!]=)\+O.'O%MQ !_&
M"O4(@ ?%WIXX3=UY="1\@2?VY?P@2ST1V[Q:]OQ@KV;?)WIPH78YXY<O'SS[
MO<N/AAYP]X-N/R@KXQ#R=Z,++)Y\NAQU]P/E[UR&6>AO[P:\/E!7Q;^3O%A0
M.SX=?VSCYY\/+Q\%Q"8>".W>#;B.P?""O].PJ3C)\AE3X7>;B'>#;AO\8*]G
M^G83)QG'7&.?F?'ER^JGPL]V >\6O';XP5[>KXN^;[=98[^9&.F?'R]'Z>?*
M EW@_D#;J$?Q@KU .WD["I./#QQU\2,^73UA!EWH!OW@UZM_Q@KU</D[TX0.
MR<8\<?O]E(RST-Q[P:\!V'X05]'5\'>D/%A0.R0,=1GK[S[O(?Q[U0.WC]PY
MBURLVA2LGBJYRC(+;G!6.>-2E+M&[ (&=%.(B.W-*(!N(AA7=UY= 3\C@JO&
M6>@.W>+7L^,%>T=O)V$W9&0.62/?R&?OX_U R[P/R!M[05\0#Y.].%0<Y]WW
M(_A/"[W</>#7C\H*^(!\G>D,*;NN1T^Y'N\D&8>!UL&O;U2"H]HAY.#Q85!S
MT^O+P!]_@5/A9[Q]XM>'R@KXM_)V%CO&1RZ]/G@9^J>%WG'W@U_!Z_A!7T_)
MWHPKN_+R_-[_ (>[WJ/"[WC[P:_@]?P@KZ?DWT83=^7E^;^ONI"6>B&_>#78
M1V#X05\>WD[QX0N .,=!D_+/KHH&7>!^0-O:"OC$/)WC#"H.<\OAS]V?+EU'
MFI"6>B&X,&OTR"O].'"A=CEC_CG]?=]5Q\,//\@V]H*_T["RY^CX_+Z_12$N
M\$-^\&VW'XP5WW !'R=^_"Q)P<8Y_'S.!X?/^5(R[P-_>#7AMO\ ""O;_IV$
MW9Q@=<]3Y?H5Q\,/-M^\&W9\8*]8[_)WHPKGGCX_(8^ZI7KI[())-0:M4@.]
MCE3*"^5.)2-I!HZ/L3O G.,8B1BE 3E#GB&Y@#<0>O7KF@.<CUXC]P?I^G__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g491933g86a86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g86a86.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1K\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &N"^:( X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q ;"@7X         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T#\@      "@  ________   X0DE-! T
M  0   !:.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             #0P  !,0    & &< .  V
M &$ .  V     0                         !              3$   #
M0P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M0P    !29VAT;&]N9P  !,0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   T,     4F=H=&QO;F<
M  3$     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MZNJFG?=^F]-5N8GS RX(XHWC,C[I OT_U@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M_^$^B6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E
M9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z
M>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O
M8F4@6$U0($-O<F4@-BXP+6,P,#4@-SDN,38T-3DP+" R,#(P+S$R+S Y+3$Q
M.C4W.C0T(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @(" @
M(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+R(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @
M(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P
M:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^36EC<F]S
M;V9TPJX@5V]R9"!F;W(@36EC<F]S;V9T(#,V-3PO<&1F.E!R;V1U8V5R/@H@
M(" @(" @(" \>&UP.D-R96%T;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@9F]R
M($UI8W)O<V]F=" S-C4\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,C,M,#,M,S!4,#(Z,3 Z-3 K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,RTP,RTS
M,%0P,CHT-#HP-BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,C,M,#,M,S!4,#(Z-#0Z,#8K,#4Z,S \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/F%D
M;V)E.F1O8VED.G!H;W1O<VAO<#HR,#,S.#=A-2TV.#5A+3DT-#,M.6)B.2UE
M,C$U9#@Y-#<T968\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I);G-T86YC94E$/GAM<"YI:60Z.#@R.31B,&(M-V0U,BUC,30R+3@Q,&8M
M,6(Q,V8R-C$W,CAE/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP
M34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z13$R-D4S-C$M0S8P-BTT0S$P
M+4)&,C$M-S%"-SDX-34Y03@U/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#IA-C,Y-34Y8BUA,C1A+6$R-&8M8C@S,2TU,#ED9#,X
M9C8S,V8\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C,M,#,M,S!4,#(Z,S Z-#DK,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<" R,BXQ("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z,&4S8S=B-3(M.3EC-2UB,S1F+6(T,S8M-#5D8C$Y,34Y,3 Y/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(S+3 S+3,P5# R.C0T.C V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @,C(N,2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A
M=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T
M.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O
M;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @
M=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.#@R.31B,&(M-V0U,BUC,30R+3@Q
M,&8M,6(Q,V8R-C$W,CAE/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 S+3,P5# R.C0T.C V*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C(N,2 H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M>&UP+FEI9#HP93-C-V(U,BTY.6,U+6(S-&8M8C0S-BTT-61B,3DQ-3DQ,#D\
M+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N
M=$E$/G5U:60Z13$R-D4S-C$M0S8P-BTT0S$P+4)&,C$M-S%"-SDX-34Y03@U
M/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/G5U:60Z13$R-D4S-C$M0S8P-BTT0S$P+4)&,C$M-S%"
M-SDX-34Y03@U/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y$
M96QT83PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F
M/"]D8SIF;W)M870^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\
M+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!
M9 (( P$1  (1 0,1 ?_$ !X  0 " 04! 0             !"0@"!08'"@0#
M_\0 :!   0,# P($ P4!# 0'"@07 0(#! 41(0 &,0=!"!)180D3<105(H&1
MH187(R0R0E)CE+'!TC/1T_ 8)28T<^'Q)S=#155B<G2"DC5$1E:$E;*SU2@V
M.%-D976BM4=4=GB3HZ34XO_$ !X! 0$  @,! 0$!           !!@@"!0<#
M"00*_\0 41$  0,"! 4!!04%!04' 08' 0(1(0 Q P1!404&$F%Q@0<3(I&A
M"#*QT? 4(T+!X146)%+Q)28S-&(7-39#1%-R9#=48W2"LB=6<Z*SM,+_V@ ,
M P$  A$#$0 _ /?QI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*X)U%ZA;3Z9[3JF[MX55BF4>F)8^:I2'9,J4_(DM1HE/IT"*V_,J-2G2
M'6XT&!$8>D29+C;:&S<D?3 R^9SN*G*Y%",;,K4$IPU%D[JZS_" @*()8.+W
MKY8^+A9?"5C8YZ<) !)@:@)9X+J*?-5I;Z\<_5"HB;(Z>[.VCM*ELL2'HKF_
M$53==:EL(0IQ"YE)VU7MM4ZC2U?+L68^X-Q(2' HN^8>09_E^1$I3@KS><!Q
M^DK. @?N4*"3 Q"X*Q9@Q*22!#C$\SS$O%3CC+HZ E#(.(ERK]X@, 6N#H3(
M@-!RNZH=8MY;8\,%'ZO[?C4']V%5V_TLJ26*I3YM0H$:1OFL[1I]46Y#BU>F
M37&8L>NS78;(K#:UNLM!;SR0M+N&Y#(X>9XLGAV)BKPD*S&/AJ4@=3!!)#D@
ML7<SW(=J[W-YO$RW#QFB.I8P<(E@Y=0 ,"9C6X8UCGL;QT[KIDEEGJOLZCU*
MEN.M"9N?IVU584JFMV2E<A[9-8FUV5-B1OQO/N4S=$RJ+:NB#1IKZ VYE/%.
M1<<!:N%YOWIP$A:QB=(7B)#DH1TAE6A(U_BFNLRG,"'0,?#+8HE820E%I+V$
MS,"7@O99M[<%$W11*7N#;U3@UBBUB#'J5+J5.D-R84V#+;2]'DQWVR4.-NM+
M2L$<7L0""!@RT*P<16#BI5A8N&X7A+!0M#%CU(5\29WO62(Q$8B$XB%)6A;=
M*DD%)?8@D$]JWK4KG32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*56+\0"
M?*.[>BNW2^[]TOTKJ3N=R$'%)8=K=!D;$H]+G.("DI4_"IV[:]'840?*FHOD
M$*"2,ZY&P</W^:6<)*E@)"<0PI!+DMK\0@LU@=*Q;F4KZ,)L103).&'98"A!
MEH,@?H8'STAR'+0KA<=\$@6_E-*OVL.3<@6YSKTI3N@D_=*B2VV%B2SR;1_(
MFL/_ (5$.2R8M=>'!BS;ZAGTJR;K( / CM@"Q2-F>':WN/W2=/@/U_U>NO&.
M%,>9$D2#F\PQ[ J@]Y_35GO%?^YRW_L9=_F\?B>SU7(#:UN<CGZ#T[C!R?-D
M*N"0?9@% .@ E2F7HR0WCO _&V#H4D(0Y_@&GDW2XWU^IFS+P$U"9,Z5;PI+
MS[CL';75&OTFCM*4I0AP*A0MJ;J?B->;(;-9W#5Y*$("6VD20TA"4M@J\CYS
MR^%A\:)PP ,;*I4LI#%1)*22?0=-W O9LTY=QUXO#\1*O_*S:TH#_P (Z3!8
M-)@'4P*SM& !Z:Q<!@!L&K(*:M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4JK_ .( @?N]Z'.%!QM3K"R7;*\H6Y5ND#K3/GPCYCC<>4ZANY6M#+RTI*&W
M5(SWD5SCYP@$IZ,.= 74'OX%FVFL4YEZ&P/B 60H ,"53]" "9]*P7EXBR?^
M@>_:A0_Q][>AM;7H^(IAY"Q\\-?Y?FUZPY2PA*B7DI#0X_>""=;$ 6#07O8_
MUH<\O@(VR^VI*@=D>'DH(LI*A^Z3IV$JN"1GS!22,>6Y&3KQCA(/]X4'_P"K
MS)VU4VP<V\ZWK/\ BA?@RHDX.7C>Q/9FW[571S;D9Q<_W]O2^O8O?! L2"MG
M?2))[_IZP889*<,N&&&(;R!X&FNTF:LM\ B4HZ<]17$_R7NKE36"0H>8M;&Z
M>QW?(2D)6D.MJ;*D%20XVZV5!;;B4^6<Z+0OC* A25].40"4RWQ.1<VU_E-9
MGRVA2,AC.(5G%%,$ PDN[2'<.'<[6K//6)UD=-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI70GB#Z)4WK5LP4I<QVE;EHDU%9VC76(S,I=,K"67XA:F1E
MEM4VB5&+*?B5F"E]EQV*O[1#>C5*)!E1_P"_A?%<?@N8&:P@O&1U!.)EPP]X
MA9"" !T_=ZNL/;I(L2#_  Y_(8.?P58:P$K ?#Q !U)4"X8EX,I(LRCK-5 =
M4>F_4;I!:+U$V?/A19;[].INXMN(<W/MJLRVZ74*JM-.73&G:Y##5-I=0EOM
MUZA49;3,20M'SV6@^[ZE@<R<,S_N$X6:P\#%5U'%P<P%)7ACW2PHI*62IB1(
M)OY-8+FN"YW#/2I *#C( 6E[ D]3R/X0+;GN,_\ JE1ZRUX#J/2)-%J*ZG0^
MEG1YVITEJFS'ZM3QM=S9<^MB536VG9R7Z1&ITR1,:3&+L8175NH ;6!YSPS$
MP</F'KQ,U@)RPS..1BGJ(/WI+*8@N" W\2?7+.(868Q.#JP\/!7B8WN\)/0A
MM&N%;A][:Q6%'3/H7U:ZP-QY6VMMO;:VT_*D1I&]=XMFGPF/L,QR#46Z;MX.
MHW-5JE$DQI+"69-/HU*6\TKS5I*4 .YOG^9^'9=&.A"QF,4O[LX3]#:.3(+B
M==M6QO)\*SV93A]>"<!(/2L8GWT@-(8D$C1V!(,BKB.E/3&@])=DT396WG)3
ML*E,O+D39OR55"K52?*>J%6K-1<::;;7/JM1D/S)(9;9C-*=^1$8CQ&H\=GS
M+,YA><S"\UB$]6(GI:8#N&-W%FMV)FLWRV51E<##P$$D89?J+.I4.20 [[^O
M:NRM?*OZ::4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4J#P<VP<^GO^6E/U^G
MKA._-_;4Z<;8J^[=ZUN-0=NT2,)-0J4HK*4)+B&VFF&6$+DRYLE];4:# AM/
MS*A,>8A0H\F4\VPOE@8&8SF*,OEL):\0D %(=VE3"Y@%[@!R8!KXX^/A9?#5
MC8R@G#0Q43H"0!J-2/6TM5/_ (CO%=/ZWP(5 VELZ+MV@TFJSZG#KV\9#LJN
M3VYNUMR[3<MMFE*9CTQIV#N61+9,ROR)@4EMB;3HZEOQVL]X9R5^[&9S^9]T
MH!382$ XH6$%0ZB4N$PHD-=@36(9[FC#25C!RZE=*71B&0"5I2[.4V,$VN0:
MSBZP]2Z^[X,Y_4M$.E-5C>72W:$F;"<9DOTF$[U(8V_2ZH83*9D>6XU 1N.8
M[3T.S?.IQF.J4MU"' O#N&9#!S'&!D58^*C".9QT%7NL,V)8ET"(8[NV@K)<
MQG,9'#DYO"0@K5@8:RA:U(#J'41"I!?7P#-8I=!/&>_TTH\+:'4O;+4F@)JU
M8G.;OV<])DO4S[_K51K<AV?M&6R[/<IT!ZH*9+E'J]6J"V&TK;ICKB7"G,>(
M<AXJ</$Q\AFOVD80*S@K0E*RUP E+ 7V)/TQ_)<SX96</-X2< J/2"%%:;P7
M47=X8*86 :K9=M[@I&Z:'2=P4&HQJQ1JU3XU4I=6@NMR(%0@3&T/19<20TI;
M3S#[3B5MJ;4H>7D@VO@F+AKPL1>%B)*%H44J2;I(-B]99A8B<7#0M"@M*TA0
M4&D;AH;^E;[KYU]*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*BX]1Z\]O72E+CBXOZ7TI
M4Z4II2H/!^AYX_/2AL?]/KI54_Q+MPU&)(Z([82^I-$JKW4#=,V$E92F75]I
M)V=2Z*MU((2XW"9WI5I#3:[H$P1I/E^=%86WG/(&7]YG<YBAPO!2"%!P0%E2
M2Q=P#T@N- !(OB'-RUIRN%AA:@G$)"DA1 7TJ21U &6)<.#,W%5E&KJ*7"H%
M/\&JQ)X_#BP_:#VP;\#7J:\$X;XD!12M)+#J/P*<$W_TK 0M01BCJ+!"?AZB
MW_$01!($L7 T]*MJZH.%SX;FT93ZOF+5T4Z%RE$BUW;;!>45CT4O)"0+#\*0
M!SXWP!SS=DTDDA?$<PD@F"",4,H:B]WT\5Z=G D\"!4 2,MEV=BWPN\SH'M.
MIJI,5M&#Y[X'/.;XOR,\6[DXO?7L^$DIP<%8++7@GK4[*6/>X@'4;JM8DV;8
M5Y:>E5P"Q+ RQ[/JVU7$?#GK,V?T8W73GY3CM/V_U0K<"C,*6M2:= J5"VMN
M*3"CA2U^2,:Q6JK-0V@I;0N:ZE"$H"0/'.=,%&#QHJ0A.&,7+#%4$I"0I9*@
M5D  %18.6>9KTWE?$6OA?QK4LHQU)1U*4>E'PLD.[)F ( =MJL(UB=ZR2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*PZ\:'6?=?1K8VR9.V*M'V>UO7J-0=F;AZE3Z$K<5/Z<;
M?J+<I^?N5VEJ2N))EI3&$:"U44+@K<=<#B5O".VM0V.E=2T*O]8D[9ZL5KIM
MXE=O=>]@IZ/;GJNV=Y-HV!,WEL?JO3X4F=38GV':E&31JG2)D1LS#$W!3TOP
MI*8\,1GXJW%+5QO/S[L##/O<'Q-<5W3XK-^*3X,8&V9H#>^X_1K>?7*K)BTU
M:8FV.HU4HNS8-*=2[#?9AFO;HJ=5EJ53T0)<1G;Y3&>$=U]M*@8ZO),1<O.O
M\MQ%=@5;Q!;BIE9\1W4UNH/U'ISTSE4OH]THV?&9B+;Z@]9W%,)J;C<]$7[Z
M?6O<M:HFSHT.'-=IRF(U1J'V-V6T%I58F?/:P[,]P=)+M7-_"QU&ZCO;"ZM4
M/KM7VJ[O_H[OVOT?<U<AP*?36I-$_<Y1-W4N8Q&I4.GQFXXA5*7%C+3%#KK4
M1"W777%*6I4!TU+GZMJ'\.):=ZQ-C=5/$-1_#?T_\154\1<JI;PWA5Z)(HW1
M6J[0Z;BD;O;KN\?NJ'M.BOT?;U+W>[/D[>D,3VY$>;(?C@+E2DI82MYE2!O>
M;E]=+>/I(>WYDK5':+B2AQ3*"M!()0LH'F22  2E5P2 !<8 &H;'P:Y53E\5
M1UQC=/AY>2?*@47K&T5'LXN9TG4D$C))2VX1_P"@3>PUZ+[.AU9S/W/^&0F(
MD+<C26#@;"L%YS/2G)%P!U8AFUA\HV_,BK,U$^4^9PD^7-C^$>@ /;@&^"3Q
MQKUA6&L)7\)^YB08,H+S]6<L^LU@.(M*DL"[*02P@ *%A>"1+3\JNXZOJ#7P
MUJ I(LEOH9T8-\62$Q]CYP<6 -R+"UP.UO#>7P?[X9--O]IYC281BZ !W=F_
M%Y]8SQ']A%5Q^R8,C;I_K5(XJ!('\-R+\X&>Y'/>W_9?V_+X!7E,H5 @^Y:7
M$>]Q=-)?T%>1^^Z5*2D@@DMY#.+ :-;=YO='\+J2[)Z5=5%+45(;ZL/LMDD^
M7&PMBJ-KW )*KFW-P2->/<_)Z>,X:?\ +E$ 1;XC<W>.UJ]/Y/4%\/Q5!G]\
M$JU 4$!P;6>1%ZL[' OZ#6#UEM3I2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2L;NN*.N\6I;2J_3
M+;VU.H>SH[E4A=0>F-=F4FA5/<4.:TC[KJ-!W'68<JEQGZ4^E8F4VI!N+46%
MH3YPM*G$JXF))C;5[-!G4P/6*Z=Z!^'W<M'ZE]7.K6Y=@;1Z.P.HNUJ7LZ'T
MJV?58M;90F(Y,=J6ZMRR:3&A[=17IR9:(S+-#:=9;C"69$A3[ZGGU4@_+?\
M-H[QX:NB]F>#WJ]M?PC[^VS(73I?7NMUC94[:=JO3W8-#I?2;<E(7T[V^U4W
MUFE?)A4ZF5*I)6L_+^UUY]$H&2'[J&6;YW[_ (@:_4 CL-/A&W)6V.B/2&NU
M6LT7I/TKVY,W]N/=6TMQ,T3=F\^OE6JC[ZJFQ)C%RLTR-29%4W%76JH0R')5
M0;BQT.!AEV*IO<ZC8V9C;\ITKZJ=X<.I'3&1XM:+LA^O[PH76'I)36]EUO>F
M]FJWN1[J&QMS<FUI5/K-3J\A-1+7V292WXM1DI1!CQ8[<)MU2HR4)?JWZ-1F
ML-+6!W,1YCTD/WET-\*G1KIEM;I].'2K8T;J-0=J[>BUC=*:'3I5:<W+$I,6
M/6:FW55(?<$R54&Y+JIL9U+C@<)#GE5;2N0W&LUE0!86' P-*52U\7!]<:?X
M>GP"&RWU8;4K( 7YNFZT@D8!4CYI2._D6;$(-O2?9FA6+Q#/X24_$G!3B%V8
MAUF#N(;^4M@7/1",MD\4E+#%6@!SU=3'39@9_I5/7WN;*_E"X_I'GS)X!/<7
M_4)!]?8BD*0MF=EH9R"_NURSF U]_+UYO[T##6HN 0@!K.5H@@E@(+FX+ 3-
M7\=94N2/AAP'8Z5?P70#I,^I-P"&XL+9CCQ!! *4(94LDF]L9XUK_P %)PN<
M\LM?_E\4Q^HB6*AB)'F5!S:YKV'/$#EM2B?A&1PE&98)!,1?0>E[T#(JILFR
MB+WQYR.#CO8#W/L!G6P(P%9?!P,+$*3B82/=*2DE1Z@M:G'W2Q"P"2+OL]>,
MX6(E6'[T*'0M2E)!)20EX@0/J[;U>Y\*!XO=&NIKA!LOJ_+(4+D'R;"V$"+]
MRDI(N.;@\W \/]HJ%87'L-)(/5D\-0 T^)5X#&+&SW:O5^2/BX3B+ @YS$G=
MT)#AH+#M_*K3]8'69TTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E0 !>P N;FPM<^I]]*5-@0
M00"#>X[&_-Q[]]*5'E3@6%AQ@8Q;'IC&.VE*%*38D D<$@&WTTHPV[>FU2 !
M@  9P,<FY_4Y/OI2OD5)%B"DY5Y 4^<V)/EN;H38 ]Q=([J SJ!R[L+ZOOH0
M'CS\JBCT,2"0=AU#U(MWVU:L2_&-X9(7B<Z9(V^U5H]"WAMFHM;CV+69#"Y,
M2+6T19E/ETZJHCD27:'7J?-?A5%,=1<BNHA5=IF3*I<5H]UP#CF:Y?XD,UA+
M'N5H&%B88/2I23<@D$.'"@.DEA!8J%=1QKA&#QG)G 5\&,A7O,+$;KZ%BX*0
M4D@AT_>U$0&\V75KHOUBZ'/2X?4GI[N/;[K:G8E.JS=.F5K:E:FI8>?8:H^Y
MZ9'?I<MR6S'>>9ANN1:PVRV[]LID)YIQIOWCA?'^#\4]TO S>&C,+PE>]P\5
M8P^D%!ZB2KI'5U=(8 N"6):?'\YP+BF3QE(QLOBG!4L8:<3#25R5!0/2G[J>
ME!NH,6=JM'ZC]0/$/)\":MICHO56MK1^CNQJ5)K3U.I\=QO;<>%MYJ94F$IW
M^_4WEL4UA^=Y4;96ZX$):?@L6<0SX[D48>'S><3$S&73@X?$,7%&+[SX5=*B
M"D0-"[DM-C%>G\0"E<KC#PL''Q<1>43@E PR"A@D!1DDO*F8$2VM5N]%_#GU
MLZ^5&)%Z>=/J^NAO.*:E;[W' E;;V/3 T^EF27JQ4V8[]2?BW4'(%"AU2=\Y
M(94RA/S7FO7>-<W<#R"<SC*S*,3-*^/#1A+ZVZDCI!4 4A09W( <I>X->9\+
MY8XEGEX.$<#$P\)* E6+B)*&+DMTDR&4&G2PT]+GAJZ%4+PY=)Z'T^I$X526
MP[)J>Y*XMA$1W<.YJD4KJ=55%2X^(K*OE,PZ?"#SQ@TF'!A+?DKCJD.^!<7X
MEC<<XEB\14KK"TE*4]7W4 ACU=+F&T#N# M[#PO(8?",A@Y($? Q*F;J4;E@
M2VPF&[&L@$2O.4^5 \I4E)45$6*B+63Y"3R+$^4&XR ;ZZUU=72R2 SGJFW^
M4)(]''HXKLP>H!206UZ@4M\[]MZ^O7.K32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*5\4J5]GN2MI"4#SN%P*/E:2"I:CY5"UDI41@X%[=C\U*4DX:4H*E8N,G"2
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M  R4)9A6>?@<Z8.;FJ$WK#76@8%)<F4/8[3S96E^HI48M>W"A*OPJ#" _MZ
M\BP"E5RUT.1G#Y)[2>/X6:Q</A&4).7PL08V8D@JQT)Q,,X:FN@>\)*3<A)8
M=(KWOV/<N9C#R:N/<0P\-.9Q$JP\J4(#)PE*0KK!@N0@ $*U5:K2/*/+Y !9
M22. 1Q;(XMGCCMZ:\G8,S!MM/E7NSF^MW._=M?'I55_C;Z4/;6K+/5G;\8IH
MU==C4W=T>,P0W#KJ@&*96W2WAINKL(:IDQU82TFH1*:H*,FI2%*]=]FW,.#@
MXIX-G5$X>(2<HZC&*KH3T!R0$_"&2  Q4P>:U_\ ;'RWFL/ 1S1PW!PUXF39
M.>PQA!7O<)94D+4.GXBGK<J(<,"5$EA@C2M]5?:]9H^ZJ ^VW7-MU-FK4POK
M4(\EQI*FI%.F!LJ6J#5:>]*IDX)/G$66MQD_:$,G7JO&>7L#BG#<?*XX2<92
MU+"NCJ]UB3\: 0>D@ 2&)F;OX-P7FS%X#Q#)9O*+<IS?[[#7BPO#4$J4E:4J
M'4D]2DD$  " X#5Y^,+8-3H&X4]?Z9M,[<Z4]<JY6:G1D0PRND[?WS'<?=WA
MM-+@?^U!:IK50J<=V5!I;<R8WN*/2:>U2:7'+G>>R_FE&6R/$.6.)XAQ>(\"
MQ ,4XN)U^^RI().$I?4%>[0>D=+@ #5J\X]O_LYQ5\2X9SWRWE2>#\TD?MF%
MAH4?V;BY)P\)& G##X2<;& *U(2 5%4@ BK7_AZ5C8?@F\/W[Y_B+W;$V'4/
M$+7&:]M.AR(54J=4.TJ!2DQ*(MRFT:)4):9DUV;4:N^$MI^PP:O2HD\LS4O,
M#Q+VI\71SIS?C)X5AC$1D$>Y0RTI"RD+"PE1^%:DBX<GX20 !.Q?L6PN#^Q#
MV<9;,\]<6P.#XO'LRK-X&7.6Q%!(6E)0A:<!"EC$4#]XI'4I6&E2BHL<]-K_
M !(/"+NZ>U3(O5R!2)K[P:9_=+M_=>VH;A+GRT$U.N4JGTMAMPV^6Y(F,H7@
M()Q?SK&Y<XS@)2K$R2TA2NE(Z@M2E,2R4CI)+ F'):!7J'"O;][*.+9A.5R_
M.7"T8RL1.&$YK#S>43[Q3LA2\?"2E*E-'416;M"J<&JP&JE J$"H4^:VW)A3
M8$Q$R+)C.I*T/-2&W'&7&UI_$A3+BT%-C?748F&K"6<-:5HQ$EEH6GI4E3LS
M7^?UKU[+9C!S."G,8&-E\?+XJ4XF#CY?%][A8F&H=06E9@@@N""4D2+UO@((
MN""/4&XU\Z_HO:ITI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E<3WSNNC;&VI7-X;CG1:90-M4Z96:U49I
M4(L*FT^,[)ER7U(2M26VFFRHE*'%7 "4*40D_7 P59C&PL##258F,M.'AA(<
M]:K>-9%?Q<2XAE.$Y#-\2S^(C!R62R^+F<UBXB@E&'@822M:UDO\*0'+ GL:
M\F7B]\8F_?$]NJ6[(F2J'TJAS -K;%9DR(\9^,R\I4>N;E89=^34*W)+)DMM
MOAZ-1TJ0Q"_C/VR9*]=Y?X+@\.3AH.&3GRC'4K.?"E&$,'W96ER8?WR;.Y<)
MM7Y,^W'VY\Q^T+BV:R>2SV/P[E;+YE>4R_#,MC8R3Q)U##P,7-)PL3#ZUGW>
M)[I)ZDX:,0!+$K-<HV]L':OALV?M#=_4'9.W^HG6CJ70?W6;/V#O%#LO9?3'
M9#SR447<^]J%%D,KW'N/<3J'7*%M]V5%CQ8T6<N7(I\ZFK^T=KP?A>;YSS^+
ME,GBXG#^'Y;%4C-Y["'QYG'0WO>@N"YPU8:79GEV,>C<I\C\N>R+EOAW,_./
M#<+C_-G&L##SO#N%YT)Q<OP# QD]65Q,T@=:,7%6H%1^(J2ED!*5)*CR=[Q>
M=>:[38NQJ32>FI@5ZOT5#>U-L; B[<?W!54/AC;]#CR*=56BI+]<>@283-71
M565SXT-$Y2Z<9C+N1\8]D_ LGE<?BJ>+\0P3D,+]MPL3,+!4K'P'^\4!QU%)
M"=&*=@3Z+RK[<N:.(9K*<)RW+/+B>&\1XG@<-Q\GD\OT9S&R^,$A1Q!\*&)4
MHI47 !#J"B2;$>K?3[9@H72[PP]$Z72=A[A17H^X]X;3H<5$K;R]W5.DTQ,M
M59J#,6EO;@J5-9F3MR5FMPWE"G0*2Y-G4<SZG0X+/DW">/\ $.&\0Q>8N)8*
M^,!C@X6+G#UJ".HA'NB2HHZ$I'2XV @.=D>/<L\(XWPH\I\(5A<&Q5$YG&RN
M2 0E*EH)7[UNE*TNH^\"5$D D@F#N^WOAT;\>JT9K=_46@1Z$)"/M:MLP*B[
M6)<2[A6B&[4ODQ:5)*4)2E]UJJAI2B?D++:/F99G_:_B8^27@Y/AON,PM!0C
M&*Q^Z=@HA)=W3U)%OO.S.*P#A?L!5A9K#5G^+9;$RF"M&(<+!P%#$Q4I4&3U
MP 5$,2Q #PH&K6-F;2HVQ]MT3:FWH2*=1:!38]*IT1 !+<:(TTRVIQTDK>><
M""X\\X2X^ZM;KI+BE'7B^/CXN9QL7'QE%6)BXBL11.A423:-=-HK8S)Y/+Y#
M+8&4RN$,' R^$G"0A+,0D !7EAK,DF37*M?*OZJXOO+:5%WSMFL[4W#$$VCU
MV$Y GQ_,4*4TYE+C3B?Q-2&' AZ.^BSC#[;3S2D.-I6/ME\?&RF8P<U@+Z,;
M!6%H4-""_P#I7\N=R>!Q#*X^3S2/>8&/AJP\1&X4-+,;3I?2JN]P_#AW.JK2
MSM?JG 9H2W%&$W7]M29-4B,DGR-R9=.J\6-4G4IM=Y$.F)41_H[J4$>MY/VN
M9G RWN\UD$XV,  K%Z@#BJ2WQ$-8QN?A=B[UK_Q/V!Y?-9Q6-D>-_L. K$4I
M&#_9V6Q3A))<(&(2%+:0ZDA_^EGKC?1C86S:/3.I/AIZP0(.]-U3J_*W%M7;
MU<9CQJ''WU H4N/%?VU*?@516TZQ.C0XFY*%N9U?VF9!K<.138[=5@56*YBG
M&>.<1XMQ \P9;#5PM.(A."K$R1Z4J2&!"PD]2H!ZW >7=WK/N7.5N$\M\,RW
M+7$E8?&TC$5F\GD\]TJQ.M"BM.)@P489&(.K#^,%)(@$.:[8WC'ZYT6FR=H5
M7;W2TQJ-6:R@;9W?T].YIVVJD_-*=Q4.6_4JJTE+*J]&G39<2)$@H:J4B5]D
M\D%$./']EX-[(.7LSP_+9S^V<_BG,X2,V<7+8@<8^8 <A1#.@K)4 7*006DU
MK)S1[=^.9;B.<X5GN7. ^[R6;S&4P\'B>1&;Q\KE\$+]V3@J^!:5*0A/4DJZ
M86.HI#]:[JV;M+KSM7=F]]A;+H'3SJET[I W3OO8&T?M#.R]_;&C/-L5K>>Q
M*(^B1(VS6-KN2XBMR[7CU"?$D4YZ-/@+>J4@Q#T7'."<1Y/XA@Y?.9K$XAP[
M-*]SD.(8K/EL=0ZD#$)/WAAIQ "P!<R&^+R?G'DKEGVH\M<4YQY/X8CE[F;@
M:/VWCO!,GB%&6XYDL *.9SV3RR$].77A]:2L(4%KPTM[M:T"OJ\&_C1WKX9]
MTTV%4ILVN=&ZC+1'K^T7Y$F4SM^,^^H2=P[586XZF'-AK<7*FTUA+<2LH^>%
M(3/4Q*:QWF'@6%Q%&*,%\'/@X9_:5 ?ORI'6&2D74  "6[&S8Q["/;QQ_D#C
M.1X7QO.YCBG*.=6C+XN2Q\7'7_9*%](Q,;+C$Q,0H1@@J5B80'3B@$D=03T^
ML/:U=IFZ-OTG<=%F1ZA1ZW!C5.E3HA\T>73YC*'HDEE?E3YVWF5(<0H  I4.
M]]>48V&K!Q5X2@0O#/2L*OU#[S^M?JWD,W@9_)Y;/93$1C97-X.'F<KBX9="
M\OC(&)A*0=4J0H$=B PK?]?*OZZ:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*_)QT-6\R5$>52BH% 2D)*
M18E:TY/FN+ X"KD6%U' O 8DJ/W0VA9RYT8&QM7%]S[ZVGLNCS]Q;LKE-V[0
M*7'<E5&M5F=#IU-AL-(*UN2)4N0RA "1WR20!<D \T86)BK&'A8:L1:B $H'
M47/BOXL[Q+(<-RV)G,_F\#*93"0O$Q<SF,1&#A8:$ E2EJQ"E@ 'L:P%W1\5
MGPB;>J#\*%N?=6Z68RE-O5+;6T*F]3/FHN%H:EU55(3)";7#\1+\5P6++[@-
M]=_A\J<8Q$'$5@*P4A)7^\7T=0_Z8+R^TN(:O">(?:=]D.1SJ\EA<Q+XEB(Z
MP5\+R&;SF"Z"RDC%2A*%D%Q\!4"WPDBLG>@OBEZ1^)&E56J=+ZC6YOW$_ CU
MF!6MO5*@3X"ZFEY<!Q3=2::CRXTI$:0IN53I,R/=EUI3J7T%K759[A^9X?B#
M"S(PPHB"C%P\06=B4J)"NQ +PQ->I<F\]\N<^9',Y_ES-9C,X64Q,/"S",SD
MLWD<9"L0.DC#S>%A=:&!/5AE2?A+$D5D5K^*LQII2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*QE\8O2S</6GPX=3.FNU9T>!N#<5+@KICLQY<
M>%(D46L4^OIILU]M*U-1*L*6:9(<^6ZEMJ6IQ;3J$J;5V?!\[@</XEE<UF&]
MUAX@ZB0Y#QU)'^8!R+-=PU8![4N5<[SMR!S/ROP_&]QG.+<.Q,# Q"L8:>M*
MD8J4+4;(Q588PEL#\*S\)#BO-1T9\*^\VZZCJ1UAVXUM7HETNAQ.H74RK5>I
MT*:W4]M4H-5U.W*33*;4Y\VJU'=3,9FEQH1CQU%J:\A;S<SY421Z/F^,8?$\
M,\/X9C#,YGB..,'"P\L5G'P_>LA!4"E/2%.LXI25MT(8'3\].1_LX\U<$YIR
M_,?/G"L#AG+'+25<8XCF,UF,'$P\]@<,4G%]SE<+"*SBKQ5(PTK]_P#LZ>C$
M/[PDA*NG>I_6JM]6^H>[^I.Y5)9JN[*JJ<BG-*06:)2&&&(5 V[%4@_\UHM&
M8APD+;"42GFWYQ!=EN+7L]RARG@\O<#RN01AA6:1@IQ<[B)<KQ,QBI"L1E*0
ME3I"0"DM #$@@#$O:'[1E<Y<P\0XC^UX?N<;.+P\'!25#+8.#@MAY7!PF )"
M<M[@J*4 '&.(D ](4K-/P-[28@1]Q^*#<\ 2Z9L60_LSI!1YC*E,[KZLUF*Y
M'=JK:5@%VF;*I[KYDRF4NAB5)J<QEUJ;MQ:$^4^U+B&+F<[E>2N$8JE*S2T9
MWB^.%-@Y;)(92L!2\/J/OU#J4,,H"2Z 5_%&P?L$Y?P\AP_/>T[C."I)P<LO
MA/ <HM+_ +3CJ6I SB<%?0ED+/2,0*ZP J.I#5E-&KM1IQ:JT2IO?NGA5-S<
M\>NJ\R9+NZ5/.SWZH]Y?+YT5"8\^F;&NEB13Y+]+="H3RT'I<;@>45PS]AP\
M/#.$C!9"L0@.$X?2@DA)^*QM<.&85Z#D^/YC#XL>)?M:TYDXKK2I3=3XCK2P
M)<*#CI.C W-73[#KBMU[3VQNI;28R]P;=I%8<C)65AA=4@1YJF@2E)/RU/%-
MSS:XQDZ_9K#]QF<Q@?\ M8R\-X=T$@@-IM)>\6K:;(X_[7E<GFW;W^6P\5A9
MEI20X8,9V[7%<SU\*_MII2FE*XYNBL&A;?K5:4%*12*;4:BXAL74MJ%%=DJ2
MD6N5%#2@FW\XC/(U]<N@8N/A81CWF(G##NSJ+ E@6 -[QW+5_/F\0X.6S&*E
MWP<)6)#.0F6#D268>=G:DZ9N>IUQ^57ZE4)"-S5>HQ]R2*Q%*DR8E=;>9FP)
M,!:PI3::(\Q#8I"%+6F/$I\6-9325).P60X)@9;A_P"Q8F7PU82T+!4I+I9:
M)(4!<N3HQ&]:I\4YASF;XOB9Y.<Q1FL',8:\HE*K8:%@J0L=7P]3$!*7#020
MYK%CQN[08K$&@^*/:L!B'"W1/C;)ZW42G-NEO;/5*#'88INX"VD$1J3O.FBG
MA#SA0ER4J@K(>J=>?6YW/LOS^)PKB.;Y#XICK]UA8F)Q'A>8Q"5','%07RZ5
M*(^'#1U+8"/=DI<  X'[>>!)XKP?)>TK@N40G&QL/!X;QW!PT@#*%"T@9O$"
M 3\:^D8B^KJ"5#^)P<&>G_6&K],]];:W[0"U(J>UZDF4*<^OY<2NTMYER'6=
MMU'"TKI]=I$F;3):7$*#'VA,QM'SX;%O6^9.7,+F+@_$."YI/Q*1^ZQD3B(Q
M<)*L7"Q,$EKK2$DE204DB7K7'D?VB_W0XYD.)HQDG+#,(P<W@XH5[G-<.QEI
MP\ZK#2"?>X7NBL#J0E16P*7#CL'?GAKWTZXK?_2W;YW-T:WU KV_.GNX(=8H
M,;[OVE&DM2JE1:["G5*%4(%=V.9K&WZ]%$%8<J4&0BGB1Y5,,ZS*XYE\KB(P
M>+XB,IQ+(XHRV/@8@(4O"RB3@8*@P+J6GI*@2 #()O63<Q?9VYSY@XYF.-\@
M\+P^+\D<Q8Z^)\'XQE<W@IR^6P,ZI*UY?%1B*1BX9RRE'#(1A*2H(5\3NE'J
M=\*O3*N=&_#]TQZ9[EJ::M7]I[?3 JTMIYR1&1,=E29KL"$\\$N.P*9]J%-@
M+4AHF)%9_@&/] WY7Q+-(SN>S.91T]&+BJ*>D,&=@_??1[17Z2^SSES-<I<D
M\M\NYW&.8S?"N&8&6S&*5^\!Q0"I:4+NK#PRKW>&2$J*$I=*3 R#U_#69TTI
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*5PK?^[:'L7:U:WAN6:U3:!MFDU*O5B>\KRMQJ=2XRI4ITV2LJ\K
M:+A 25+( 0E:_*A7+#P\7'QL/ PL/K.*>EW^Z7#.""X+D7&M==Q;B64X/P[-
M\5S^,G R/#<OC9[-XJWZ$9?+8:L3$4II+)!( !/^4=35Y(_%AXK=^>)_?,RI
M5>3+I6PJ/)EL[&V*IQ?V*FPFUJ2U5ZN@.(;F[DEQ?*[*GOH<-.:==@02EE,E
M<SV/@W!LCPW*86,K"_>A",5>8)!92A'P]+=+@@CJ ^%W>OR+]MWMKYE]J',6
M9RN%CJR?+.!F\;!X5P_+I5A=> 3T#,9D)6E\=825D*P@<(.@".I6=7ALZ&]-
M_#CL[:G5/J]LU._NM^\:?$W+LCIW451DTO8VVGT!5-K6X/M$29'@U:6VI#BJ
M@_"FU&,XL4JCP":;5I[FN7MW^T#P'V<9?W>>SV)C9I15^SY'+8BL$XZ0#U8@
M4$8PP<,68H67ZE""0/T(^R1]D5&+PS*\V<?X5A8?%<TC QL;,9U&#CY?A.!B
M$*PL+"RRDH&-F58/N\3%6<0*PBV&5)(ZUYK;=\9N[Z34&Y%:Z>;5FT<!E+T;
M:TF?3:M&C(<)/V5507*@51]ID@(9?%&0\4*4J2R $G3KA'VSLGF>+(P..<#R
M^%PO%QD8>%Q'+8N/FL0>\Q&2,1*L% 0I /QKZP$AU%/P])_0SB'V?LM@875P
MCB^,<T4%QC93!&!CX@1\"4IP<7"_9T%4.OWY2"-@]C>P]_4'J-MRE[IVS):F
MT>K-N.1GT+5YVU,J6U(BR65M-NQJA#D(7%GP9"&WX<EIYAU(<;4G6ZW ^.<.
MYCX;D^+\(S",WP_.Y=&/A8Z% RL G#*;@I=B207#=(-> <4X5GN#9S,</XC@
MC+YO+8Z\'$PBIRR7Z5@L 0L,0 [!3N1?FVNWKKZ:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4K;*PP9%.E(NG#+RCYT%8L&7. '&\W(L22!FZ3R&
MHM!!D./Q'SGQ7%3$,0E0V4"08):"&/?Z51;UHV)N;??@?Z[0MI,RY53HE)Z/
M;M?@04..R*A2-H(IVX:O#;C-'YDEP4NG2Y#,9 *GG(R&4MN*6EM6=^SSB64X
M5SMP7.9M.%AX"EXF!UD#I&:QO=HRSIAAUNZG^&Y>O(?;-P#.<;]F7-7#>#IQ
M,/.X_#\12$82U].(C#!Q%X9!462M*0"E[206-4.=)]E[LZU=1ME],-DH7*W#
MO>MLTF&^$%^) C.I5)J->G(;5?[NH5*9E5F:KYB2MB&M"%A]QM*MV>9^8\MR
MEP'-<>S@PL3]BP O,(P\?_BX^93TX6"A70J0.E;C#5"V*0Q-?EGR1R7Q'G;F
M[A?*N!AIPL[CYE&7S11@C%P\DC)](Q5XI2I'O",%(4M17AGXPDE0 4J[O=58
MVO1/W,=,>GQ2STRZ+4E6R=GJ1Y$_N@K+02G>F^YP9(8DU&OUU,MMB>D+#[ F
MU%AT-5M:!KSRGPO-XO[?QSBI.+GN*J.:Q!B)(4,OC$JP<%*BI12#@'"<MHEP
MX &]'-_,'#.')R/*/!"G#X9P/"1D</#PF"1F,$)]_CJ8 +?'.(>E]5$*8E^4
M](-F5#K%OVC;)A*>8ISZQ/W-46?.54W;<)UE52<2XD)^5+G^=%*IJ_F>9J?-
M:EJ;>CQ9*4N<>)X/ N#@0,UBJ4G"PPIBD+"@@E1!Z@D$0R79A-<?9YP+$YHX
M^3BA2LE@%.(O,,2%'#6%*0$1TE1<=3JO:":O/H]'B4.GPZ7 ;;8@P&&HL..R
MCY;4>+';2TPPVD*4 VTVE*$"]@D 6QK7!17B+7B8B^M:\5>*2P$J>-;/?>8)
MK<+"PL/ PT86$.G#PT)PTI@L$@ - :!85NNK7TII2FE*^.7":FL/QGPE;,AM
MQEUM:/.A;;B5H6A220%)4E:@I)P1@XN-$NDI(+%.)U@CT@3!B^\M7%: M*T*
ME*T%!'G4[^-:HPZU[%F=&=^U/:2PM=$?)J6TYC@6/M6WWW5)9C+<65A<NCK2
MNF2;.?-6AB',=0VJ>WYMB^2N.(X]PWW&*$XF8P@0H=;$)0 &8I>1/S!EWU%]
MHG \3ECCASB$J3D\4!>&OI)3U?>2(40Z3X9W,&N([0W/M60_N'874-O[5TJZ
MO43]P?4*.7TM)I:)3JCMS>44N-J;CS]LU5QI2IP2ER%#D?>:EJ%'CMJ^_-7"
MLR<+ X[D2<#BW!\3"Q\'%0DDXV",1",;!("DE/7@J7\0*I_@DO\ Q\G<P<-S
M*LYRQQG$1F>!\Q86+DLS@XH(& O%PU>Y6@D*"C[].&!]SIZNOJ=)%4L];.G&
MZ^@/5#>/2O>C3AJFSZB6FJJ4%+%>H3S29=#W-!\WG'V.LTIQJ6I*5.(A2ERH
M"G%/0WTI]XY.YBRO-'!,OQK+JP\+'0@C-IQ<4$93%P@$K"XP_>=0LWNH,%3!
M](_:9R5Q+D#G3-\%7ACHR9"N!8F*@'"7P[-+Z<-*,/XCF.M2@.GK1TGJ*AU
MI%RG1;9&Y=F>"/I4C=<63 F[JV-XC]YP*7-2XAZ%0-SS=L3Z(5,N)2IH5*G+
M8K1;M<&ID+2VX%(3IK[2^(Y/B'.W&,YE,/!*/?G#*DD*"L3#2$XB@R0 Z@?A
M @"Y:OTZ]A/ <_P#V6\L<-XJE:,W^S+S6)E<8K5@X"<WB''0G#2%I(0L*]Z4
M%^A2R')<GT)1&0PR&QY+ J/X$%"<G^BI;AOZGS9[ "PUY_O:3H&_1[U[0D,
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MV"Y3'(LMQQ*OM#"J<\[!+3P6@1%J8 #9\NE<*^1GIGL[]UL[?,V@4N?NF2Y
M^S5N9%:DU&GQJ9#$6%"A2G6_G1XD5QVHRHK(6L1I-8K#K"FQ4Y:%JC?R8;-^
MOU#=@:5:XEO;:</?&T]S;0JJ4.4S=%$K&WZBVHJ"7*?6*?*ITEM7E%_Q,2EI
M(%OKV/+#4K#Q<+%265A8B<0$;I+B(D[N&-J^F#B+P<;"QD%E86(E8(=_A]9.
MV@+'2O$7N3HKU.VEU#D] J]LFNU3J4Q5QLMG;Z*7)93NI3]1308&X8$B:TS
M.SMPK?C3(^Y7GT4./ EH-0FQWX\EIKW3*<=X=C\-3FL3'PPE.&5K0MNOJ0.H
MI* 5.2Q!3+NP!M6S.6YGX)B\%P\UCYO"(Z!U8)4CW@9/Q)*2II#@#J(EC5QG
MBO\ @U[I\2U.Z/;_ -K]2=I[4ZY4GIML39/6RJ;DA5:71>IM8VQMN#2U;U=J
M-*CO51G=++<55/>ERX#YK].:ICDMRFOTT?;,4Y:]HF9X!A9CAJL)6-PM.;Q\
MYDDX?0<?"QL5*@,-844)]S\04P6H@NP(9M5^.</P<_G\SC94X>'A*S.+B !P
MZ5'X0&"F(!#2S $$AJLI\#/@0Z<^";IPYMF@O,[JWWN)+$KJ%U'D0E0:ENBH
MLW+,2%#6_,51-L4Q)+=)H+,V2VRI3\Z4]*J4V;*>Q7F;F7B/-.<5FL^H)2&3
MA8&&6PT( 80 '69ZC+B'8!N66RF%ED (<K(92C8AW'R-;9XZ $T>B) P.FW6
MH 7["#LOU_W&L=2.D!(# ,!))8?KO_*OJNZ?7^6M9Y3($.IPW(-1BLS8;X"7
MXLEM+K#R4K"TI=:6"A:0I*5!*@1< VQJUS%AIVV[>E;!/V)LZJ51%;J6VZ1.
MJJ(2*<F=*B-OOFGMKDNHA+4X%!R*EV9*<##@4U\R0ZOR^9:B5&'S=_6OWVUL
MW:FSF),;:NWJ1M]F8MAR6BE06(?VI<6.B)%5)4RA*GS%B-M1(OS%*$>(TS%9
M"&&FVTJM<ETI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E?D\Z&D%1*$V!-
MW%>1.!<W4>, GZ _411($,^G42 ?4 _A4/S)L-SM5>%<ZI=4^NN[)6V>E<B;
M2-ILL_:F7Z=4'=O/2Z(Y*7#C[DW)NV$Q-K5%AUEUB:O:6W=KMLU^J1F3/J$R
M'&$N/1>8]V2D%<E'4>D%02IS\),"S'2^E1/4 ZLOF$88)PSB%"2DX@+_  _&
MZD=)!*A+PUJFM=+>OG3*$[NO;N^MPUX0 J3.BTS<^\ZO4&X[2%.2'6=H[YJ.
MYJ#NOY83>1&*J95WV HT;SU%3;:XD))^-12"X!2.H]BQ:>TZWBN:1+8@42H?
MNTX7Q$G3J)*0GY^6M61_0;K..J.WY3=39@Q=S;>:IIK @..FFU.F59AYZ@[F
MI*'0IYJGUMN+.0N$ZXZ]3*G3ZE +\MB/&G2XLI2KI2M!+LQ/21+,0T&-[]JX
M**TE95@8V$G#4K#)Q0$NI!Z5=("B"GJ?I4X<,=6KOM^2VQ'=?4ML!MI3I\ZP
ME/E2";J4<I2;95:P%SFVGT\Q\]J%20.KJ '^8NWF');835?>X>J?53KCO"3M
M?I3(ET7;+++DA,BG555"=G45,A<1C=6X-V1(LVKT.G5QR/*.T*'M=IFNU2-'
M-2G3&8AJ$>D<U(*0Y4B68 NH@@%V:!^MVF(4AAAXN#BJ4D'H2<0,"-24!(.X
M?J L]?C6.E/B!Z;P#N?;>^=P;B>BM_:YL.E;IWI6*BS'20I?V;:N^*CN>@;M
M*4)29##@I%6<94\BC^>HN,M.<&E/Q(2'DJ)$18,YOVD54%2PI/21BLZ$C[IN
MX*C (N-P:R(Z$];AU/H[L:J,P(^XZ0U379ZX#RON^LTNKM/*HNYJ1'>4N1&I
M]85$FLK@.N2'J748,Z"J1,898J$KZ*0G^!86&=P"Q,N ;. Q;8N]GXA:P_O,
M#'P@%G"*EI2WO!TD@$*+H9:?CU),,*[[D33&;4XXBR4.*2I0\Y0$)3Y_.5>4
M #R]\I\Q"21DCY. SP2X N=6MN&)V[Z_1B&=)/5]T(^,EW9Q'3(8O:\AJK_W
M%U5ZG];=VRML=*ILNC;82E;S4JG3U[>D3Z*93L)C=&XMVL19%7V_2ZN^Q)3M
M>B[90WN2KQXJJF[,C0?MK%.YJ2!A#$1B89+@%*B4L_H[W;<Q>OE@XF%B8JTX
MF*,!" H'WF'C>\.(F%(2@(Z2'#=16VL DUJK723K_P!-X;NY:!ORO[A<AH,J
M?&I.ZMY5.H--73\Q</:^_:INK;>['D* +D=]%(J+S(6*:L37&HT@D J 4H)!
M+$FP_5O6QK[)]T!B'%7[L!)((05O( Z@)(G0'T8UD1T$ZT*ZIT>5#J;4&/N:
MALP79[L N-4RNTRI-J<I6YJ.P\MU^-!J1:EQY%/D.NR:75(,Z$MV2PB)-F%H
M*%,2DAG=)<WVB/77Y\'2 &Q<+$49 05VFY4A(ZK INY.@KOJ6\$(+?X276G;
M#SI"K!(!*4D@J%U 7'!M?D:^:E 74D.[=19_'\_PVY1J0+1K.PUM6"/@L?#2
MMY^8&SFTND0N,V*:?NM*A;DE-TA1M^&X\V"-<ATD."\WECX) $:Z=Z+"T'J.
M&L8)9*,103\6( ZTL"8 *2#J"[ 5EMU0Z9;1ZR;"W%TXW_2X]9VENVFO4FN4
MI\NI3(C.D%"X\J.[&F09T5U#<RG5&!(C3Z=/9CS84AF3':<3],OCXV6Q48^"
MHX6-AJ"DJ27*2#!>'L/P+BOOE<SCY/'P\SE\0X6+A%TJ$L=-MGJFG??P[_#C
MT*WSL2?1(NZ-]ORT5&L,)ZCUR/N*#29=+W7LR/ 7"I$"FT>BR%0V*K*;BS*U
M3JK46E%J0)QEMI?.0X_-'',[@+PU8J48/NBA91ETRA22E3J$@J'4Y$.04I$O
MDW$><^9.,9<8.+G$#!2 A7N$#!!0  4J* >HE,*<N\W+F\>*$-.):0II*/,4
MH;"D)*?*A1\C: ;GRB]Q862";6%QBZ2 3\845%VZG.K@:EFO>"]8B3\3]842
M3U.2^L!PY-GU@UN>N=6FE*:4II2FE*VBO5RG;<I%2KE5EQX5-I,*34:A+DN?
M+9BP8;*Y,N2\NQ*6H\=MQYQ5B A!)L,AW) &Y( FTD@2:XE:$_?6$"9+EO(
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M:1#EU&<_'BP($*1/FR9#ORFHT6*TM^2^ZL@A#+++:G'%FP2D%1L!KB5,H E
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M;27(DI#4A#$YB7&9XK9*RE*T+0[!0)!/I9_#O7.2.KHQ$)/W1BI"%MIU)"E
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M:8KM$^<Z[(%%JU/1*6J2A[R^&\6X?B<+XCF,EB*ZO=XA5A&'5EU#JPB6@EB
MH[NU:V\=X1B\#XGF>'XI"O=K4K!(+O@$DX1.I/24@F[O#365VOX*ZBFE*:4K
M#GQQ^)=_PL=!*]U$I,>!4-Y5"JTW9^P:74FW'*=+W77$RW(\FI(9=8==IU"I
M4"J[FG142(CE1BT5ZF-3(3LQN8SVG!>&KXMQ++Y,*Z$%7O,=0;J&70W64DV4
M; L6.A +]YR[P;$X[Q3+Y%!Z4%7O,PIV*<!)^,@V!V)CM7DKWSU3ZJ]3-R.[
MSW]U0W_N/=3SWST55W=E=IR*2X)34YMO;=-HLZFTO:L2+,88DQ8NW85,0P\P
MV^"N0DNGV[+<#X3E<!.!A9#+>['^?"1B*4?\RUJ!*B=R0-&TK9#)\K<!RF C
M+(X9E5H!!"L3#2M9(;XBLRY_A(#.S.&:Z+X5OC3ZD;OZBCPW]7-R5#>[<W;E
M7KW37>=><^\-ULO[<::=K.S=Q5IQLSMP-O4I]RNT&L59UZKQF:16*=4)\YEV
MF"+YUS?RYE<@A'$\CAHP$8F.48^$D1\85T*PY/2'#*%K :UY+SWRGEN&9='%
MLCA(P,+$QO=XV&DGI'6IL,X8=DR0"!#6J^:K3DTZ$]-6/X.*T_(<58GRML,N
M.J-@"3<((' !()U@?2I7PH(2I12D$@$.I21J1O7E.*OW:3B$.G#1B8BI8 8:
M%++GN$D :OO!\B7B9\9?5WK_ +ZJU5&YJCM;945VLTW:^V=O2U4],;;U5,=A
M]JL3XP:FU695XT"&]5&I#RH##@3&AQFTL*<>]?X3RYD,IEL-6/@#'QL;#PRH
MXKJ ^'X^E+#I#EQ<E@9$U^2_M3^TMS_QSF3B Y<XKFN7N"Y//8^7R>5R:T8>
M8_<8G05YO&4A2L1>+T]11 PG.$)2M[;OAH>-#J'UDC;MZ7]5:DUN'<>S*,C=
M5)W<J/&8J%4VVF0(50AUM,5IB.]4Z9)=@F/-:C(<G0Y?\:2J3%<D2\0YHX%@
M9#&P<7(H]SA9A83[MP1U. HI=C)/X7O6VGV8O;5QSVC<*XOP[FG&1FN(\"&'
MC)XFE &+F<HM.(Z,?#3TI]]@J2D!:1^\2I)4ZG>I?Q,>,SJGX@NI-2KT7=-0
MVQLV%(JM(V;2-N2':8VC:TV3'*I-4D17$O5297FZ?3YM11(=7!06V(<=@LL+
M>?RSAG+O#,GET8F+D\/'QC@)5B'$975BJ 4I*0PAR1+F07!K57VI?:-YSYAY
MNS:^5^-YG@O!>&9O%RF33EC[A6*G"QE89S.80W7C'%Z$XH00 @.D%B:M>^&G
MXPNHO6./O?I?U'K*-P[EV?2(NYJ!N:1&88GU6@HG-TVJ0ZR(S3,=V72UN051
MIJ4H=FQY81*07XKCTC%>:N"8>3Q\/,91"<+"QRE#  I!4'!2D,PT<@L6:#6U
M'V9/;/QOVB<-XYP?F-?[9QC@>'E,W@Y_$(PEX^4Q%K1BC'2&2K$'2%)6"'2O
MX@Z356OB>\:W5WKIU$JU0A[OJ>U-C42LU$[#V_M]PTE<6(&Y5.BU"J2X@1-F
M5BI4J2ZN>A^0J)'1+=@L1@U\UQ_*.#< RV3PO\1E\/,JQ482B,8)6Z#]]:0J
MR7;I/;735OVJ_:1YXXUS9Q)'+W%LWR_P+AN=S&%D,ID"<+%Q$9970V=Q@E1Q
M<3&(*U.D(0#TI2\U9W\+GQ<;QZDQMR]&.HM215JEL#:-/JVT:ZN.TW.E[5IB
MV:3+H]22RVVEU^B%VE)B5$I+TV-+#<L*DQ5296,\U<"R^16C.Y1&'A9?'Q1A
M*""!T*4P3?0J=@[#4APVT7V8O;5Q?VA9'BG!N9L4YCBG",#]LPLSTI3BX^3'
MP*3C%(!5B8*BD>]*![T$'[TFKKQ4>,OJOUZZC56?#W'4-K[*HDJOT+:%#V_+
M?IBON"5+89D2*Q.BK:EU&37$TV#)FL+?5 :0B-&89M'6ZYE7"^6<ADLMAJS6
M C,9K$PTJ65$%*4XB0H) %H+Z!R3J*U;]L'VD.?N)\TY_(\O<4S/+W#.%Y_,
MY7+X634D+S*,OCK0,QF,12"5XF(  P)2D!(#,M-6E_#*\9W4?JY)W9TLZMU4
M;BJVUJ*QN*@[L<ALM52914S6:9.I];^Q,LQI#\"3/@.0YR&$R)+#SS4EMQZ/
M]I=Q?FK@65X>G"SN4 P\#&Q!@G!ZG",=<I"9#!3.QU5>MG_LQ>VWC?M#RO%^
M"\T*_:N)\%R^6S".*)PQAKS.6QL?&PU^^PTNE2L$8:$)4F5N21 >L'Q0>-WJ
M_P!>.HE3>HF[:MM;I_0MQU!S8]$VZ_\ =*T16!/I<;<=1J41:)TBKUBFR'W9
M4=4H4^"S+-/BL.#[3(DY-PCEK(Y+)(QLWE\#%S.)@X>(0M(4>O$0%$%%^I!)
M!+Z=JUE]K/VE/:!Q?G'BF4Y:XYG> \#X;G<YD.'X>2.'AG-HR>8Q,OAY[&Q5
M(ZVS*4>]."MA@A24NM1439'\+KQ:;VZC(K70;?LI-;?V3M)K<&S-P*:2S/5M
MRBOT^BRZ)5RVE*)2X"YE+-.FE(E/QI#Z)Q<=BB3(Q;FO@:<AB86;R8&&G,*"
M5))"D?$6^$,&=X?N]JV2^R[[;.*>T++\2Y6YD*\[Q7@>3_;L+/*/NUYC*HQ!
MA*&,5 %6(@J00IG6E3F7JM?Q7>,CJKU\ZEU^5!W'4]J[*H<FO[?VEMRA2'J4
M^*&^\S#F2JS-C+;E3YM<;I[,B7%>>,-AM3,1F*A;+S\K)N#<OY+*9+"7F<##
MQEYDI4M6*D8@90N$W 'PA]/ +:X^UK[1_.W&.<>)Y3EOBV;X#PCA.:QLGEL'
M*'HQ<=.!B)P\3&QUJ04KQ5E*E)2'*4%D_$_59Q\,KQH[YZH3=S]'>J575N.L
M;=VTC<NUMR2(K4>IS*3$F1*55*35S&#3,EZG2*A2WH-0^0V_(8E269SCCL=J
M0]C'-/ <'AQ1G<LC#P\MC8HPE=)#)4IAA$D.W6Y >P23N^R7V8/;GQ;G[*\3
MY;YKQ59KC'!\FGB&5X@<-.'BY_+KQ1A8V%C!">D+RRAAD8I+X@QPX)27K<\6
M'C>ZQ];NHU88I.[JAM+I]M7<M0;V51=N/&E/+%.<G4EK<50JL9+52EU.J0WI
M2@V)*($&'-,%IAQ27I<K*N$\M\/RF5PE9G!1F,SBH!Q%J/4,,*2#TI%A!<:R
MJP8#6_VT?:1Y]SW-O%>$<N<4Q^7^#\)XAF,M@8>3"!C9G]EQ\1'[1BXQ0M2E
MXK!)0_1AA'2Q+DV+_"M\6^^>HLVH] -_S$UN1M#9S=7V3N)QAIJH-[>H\J'2
M9- JZFPVW,^[D5"CFD3 VE]4)UYB4I:XB'7\8YKX#@<.3A9S*@86!F%.,'J!
M*6(26'\(*NHL79WEWK8W[+GMIX[[0L//\N<R*.;XCPC*)Q\#BN(R<;,8!Q%A
M:<RD$#$Q<,'#",1(92 RB%";N4'S(2;A5TI/F& ;@&X'8'D:PDW-;CB0"[N!
M._>M6E6FE*_)[_1GZC^__?'?4/\ ,?U^GZ>E><;XSKRF>KW1=+9\OGZ=ULDV
MO<G<$8@GZ&_)MGMW]&Y)"59+/(4 I'[0I72\.Y!?=P)-K>*_.'[<F(O#XOR*
MI!*5GA.<2%,Y89KX0+V( ,/:6O3++DNKCR"OS*_"[<DDJ!4BQ( ]1^'@7&<6
MUG "$'"2E*4I4@H4D, I"0I721JQ)(8D.3O6BV1S.,<YEDG$Q"E6;P%K%PI8
MS&&KJ*1<NA(<M $L*MG^*,Y_ ^$,C)/0Q-R2+J4IO;"_,H]P?+YB+\\D'6'\
MKK*</CBDD@_MZD#0]/4L%)O!L9!G6MU?M@D*R'LH< J'+J2"0/X\'+*,GO)<
M,2'#%JJ;FRG!$G)5YC^ E/!"5K!NJQN<@_BM<9-\9.7HZ?W?2& 0I-F#(!
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MKK>W4@N'SUZF)O<6S.B*%QR+*5YA<8)N+=LGS*HS+"59-3W, *2TEA\(;T#
MN36JO*6,1S%RV>I14GC_  T)5;I!SN7&@<?>,E@ 6TJRWXMSZ6O%=M\M!24_
MO+;$-DV("ANOJ,+Y)O8$ G)/EO8YOBW+!_V=CI+%*EXH*9^[U)'3>(=HM:MK
M_MF8@P_:!RTI'4E0Y:P93,?M^=#RZ2Q#G4@.Q::Q(<QQ4V#=3EOM\*Q)%B5R
M6@2JQ!SYB2>3>YN"#K+L;I3@8R4@-[G$# M 06 !%@0&#MW!!%:D<L8V(OF3
M@"BLEN+Y ASJK-X;J:'))>TW+R39U\6Q:4^)7:I2DA;W1?:+[BA8?-6JO;N!
M4?Q9)*4W%O0D&UM8OR<LIX=CD$SFL8*E_NJ(2"9'P@D#7N'>ML?MJ*(YVY:
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MWQ%8G!O9,2;<OX_2!#=65X5H[WM +%Y%5<.OH5!?_%W&+'-T/ $*L<?G:]B
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M ,2*]_\ \H_K^5N^HRA,&?T'<SZ?B].SG?2+=G_1>M)Z@;Z4"E54H]E @_\
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MB#]VO_\ +8Y\_ H:/XFM<N1"!SERLMVZ>/<,+@ F,WANHA@SD3(# RSMG/\
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M_4ZZVK5SFK#']Y>/ DJ!XOG[Z@9I8!U!9KWDN9+V@?"%!<\3.YKDD_O/;I&
M#_\ *G8HOP>3<8QBVL>YB/O.'@$ !&:P3]';T!&V_G:_[%R0GGCF%0)?^P<,
M-L/VP2^Y(O8;5Z3_ )&1_*N1V'K?M@@WY%P"<^AUABOO*\G\:_4E?WE__)7X
MFYKD&UVO)6X*B3<?:+7  L8<CT (Y[X].=2N#S;>?'Z'U=FK>-X ?;8MQ?\
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M "M6(I84DJ *B7=)"27(&H)9R27,.3J9[._LR<\\8YCX?_;W!\UP#@F!F?\
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M_*Q\4A9"%)Q&4>DC#4V))8^[4 2%])^ BQ(@BJ,OBJ>#W?>_*[2O$+TZAJW
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M-$Y<B!!HT=5G)<BONTV1%8G?AB1XC,R8J0M;$=B5VF-G<GE<MC-B*5F,1!2
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M7PASTA1+N'-YNX()$,QJD?HQ\.CQ>]:MZ*V=3>F4S93,1U/W[NO?<NG4O;]
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MLA,%^/#:>><I\:&C[4MJ3-?BQ^OXGG<-:<OE\(O[K%&(M3!U%W 47<A,W#@
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M^95Y-+%0;H]0IM9J22*Q5MK59R'-II-:/E?J^U]QQ'=N5>>55"1(BON2T2)
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M4L,SO!;S8^C^A8^*@3>P-RY9[D;?G,G6LO\ Y:225=S>Z47!!R"DC"DF]PH
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MB0*GR^_< \W!].]^/7\6;:XQHTZOW]"PM.SC6C7\$VBW:UQV&]/(?4?2YO\
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M/]QN#8!#"09+!C?Y-K)%W\G^FY#,UM"3#.(,"U#R!COQBUL@6R3V[$=['M=
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MV$TOD '-L]Q;%\\^X/?%^1IM'AM):2\P#M$O+@QER/PL+,^C@$:6&M+FV .
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M7;4^ 2/743>"?RC@&WTR<#)[X]<_2W.G:Q["^Y8=I!8?, T[FS1O#>=8;N[
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M\IEN4PV\VU)8793$A"7 AUI5RAP+0K(U6,&23-H!/:S%X.\,]H;D2UHV'=I
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MM0L'B;$Z6(VB9;?Q7S-U&"]+>@(F1ES64I<>AAYM4IM"P%!:V$K^:E!N++*
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M(U;P"[$MZAQ%M#I\G+2UV<_A+ZN7<3,.Q<4L>;W-A:^#:]\C^\\^@OI=Y+V
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MP;EE[-I\4^5<296Z_MFOG;8GH*5'[''K\*G+D/H!,:*J1((4VTX-<23O#1:
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MTY'U_HG'^]\DV]LVT)(DM+./5HN-)>T7(!HP)8>CWD>1JS!V=S J#;ZFUP;
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MC)GNL-QG)H8;3+7%;6IQ$=4@)#JV$N*+B6E*4A*B5)"2M14;4,&=[CL8#QZ
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M$HC#\>5%A4I"Z*F!+BU*'6(<RG.4E<)^F2XM9I\.K1Y$!R.XW4HZ)0(<3DP
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M(^KZO!DP3NY8![HX#;SX:-F(F[SW(^PL1CN+=\@=CW_(&W:N!]=2&/T+P78
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MBPN!<#N#H&(^Z[%Q8 ![$_."*&-8)\W ),COYISQ@'O<&_L;W[FP -N?SK^
M^[W$WV9F/<,8 J,W?LUHU^M[LY#&OUB_\^B\'^$<R/\ U63CW_7M^0XJ:>Q^
MAL-1&EF L]N:1*;ZP3JQTT_KX?ZJD+OH_P"BQ[?B4+D7SS88[^QT2/YR7:WR
MN9?QYJBW>S^NEG%GAF,SI\%A;VO[C_L(^@_HXU=+/H-9<2;-<L^\B23PD.T'
MMLQM+MO>SO2UA<<VQ>Y.;<VYOCCCMC34@3)OU1:?+P[:3>E[GNPBSVA@TGO:
M]1[8MF]B;#U[7 )[Y -P<"VAGT!#-86T]';<Z!JHB=VEI)O#QZ&[ B2")N+D
M8OF_-S;-L#/<6_(]['B S-,07-X&GY2Y%&MLT QL[.2WFUR+!YM[ GM?F^,C
MDC]O;(QJEF-G+ZL2Y@]Q>;> X$&A+EFML'CY-]346L/SQQ>_;)Q?G-KD<Y&H
M003H^Q<Z:N'UC4[LX";RPUT'<@.UF]; TR+$<<<XMFQOG%C_ +VL4D6#-L+E
MYAV87[AA-2+%WW8N^S/)>/ST6''(Q:XQQP#GC)][]LZ!G.GJ .PAV/U</#3;
MM]6))D;'>!M?M47S>_Y$XO\ _P#-KDY&;^EZ]X#:0SC<00P,^')!,T _0T[1
MJ7U[![@3D"^>,\?6]CWYO[^NC%)!V)_!]AH&U#Z:4@^8;\&N;::L* 6S;D_]
MGI@<&XN3GMB WAW9V$!MX+@!H?>Q8T/8VU^<WU+F($:FAMDD<\7L?R'.>_H>
MY]*#\G#Z6EV&T.T@ .[U&+L+SV[?IVNS;R.X-OI8=B2"/R MZ6^NIYB& ,!]
M_1S)UD.8%V.CN6)U9QI^B'-B=)XR3Z$V_,7L#?T].>YMIWETWAV+DQ,MWBYO
M5&S O:1X-Y#WT+L.U2/8@=[#/IR?<<8%NV!JR\$>C, "2T7<D-#F8%3R#+R;
M^1XU#D;Z5/.1CL<<V_3_ ')N+WU&+6TCI+P08O;YO(!D5']?.Y 'T;\/!TW%
M[_E<]B.!8F_UXOSWOJO(9C$,6 @Q=]6#LQMK5:-=VDQJ79F,;CR0*F^>.]K_
M -P-_?C@ $>NH2&80X9NTL]RY<ZBX=Q>LX)[/;=G80 UNY!U$!>^3W[C)QW^
MMKWN2?:Q&K+@,()B'T+W:TL(=XAZD2SCU=KB=6EC$;EV+N>^,< VSFQ)MFW/
M.!V\VA!D=WM#F^CW=I)9H::1MIYU#?ULSF?X1 )N>#@7-S];^WL ,W-C@ZER
M3N('RV>UV@V(FU9@V@-X^H+.YAR6@CSJMW%LCZ@7)Y%^3^VP/;5+F&/4 ]RV
M[B3,7U)F:X@_+\8W8B-CH6U-1S90SWMQ?GOC-\<BV<V.AT5&C$[OKHS/;615
MD.#H"_T;;5M](@52YO#<G0Q[JCXL-_=:>B^^NIK374VF[#VQ7*/M6I2MK4>3
MMG;-"V>B@JWHBITND[>J=7W"]'1(^=+0ZRZ_#E(<#C\?S_/^GT\$>MW]:^FV
MS2]V>08TEI&MV-=P[:ZU;U\.&RNC'ASW-N3IK1^J;73^I;UW3NGK+N^<C:FU
M*!+W-56=N[43*IJX]1W)N!EIQ-'BLQIC,:+3=N2IRWY45;'EKLT"/KYJ$=3D
M&-!W:&+PY.P.E<Z@>,+=%<V!T3JE/H^Q*%N/JUN[>NRY>X]T5J:WTLVY,V!(
MJC52JC=98$:15F-R-P&E;0@"7$74G9)97.!CAV0ZC_5A?^9DW?4W:C";]VV.
MC"6C:VK5MB?&1OFA[%W[U W52NF,S;M W\UT=V-6-N5BMQJ'U"WT_.CMC<S%
M8K(73J)T\I4-RH&MR!,KLMF91JDTS-\K#?V@Y_'Z_K\=S0I#B]W,DZAN^C>C
MDQ/ZTCQFU]C;O7IZLO\ 2?>=5Z6=+V>HVWMR=+:Q5JILFJRYKDVG1]K5<SGQ
M.C52%6F:>S(3&DH7/I\\/LM0'4#YQSN=_P"3_P!:K"/+>6<D>"7>UK6KFE!\
M1?5G;F_MH4+K;M3I]M_;6]>D6Z^J+$O9M8KM2JVU(FRJ53JO6D;I35(3$5UI
MV))6E@4M);8E$QOM<U+/SW4ZF[F>S_C\B>]I!'PO!&XU'I&Y!,2]<!Z?>-NL
M[RWETK^:YTAD[1ZL[J.V(6S-L;JFUCK#LMFJ1YKVW*UN^"E:Z0&'3&9;K<*'
M&:50USFFG)TU]"TI.7'T:+^*$#XF[7FUA?P9@!G#5V#L+Q"=8MZ0^HN_SL[I
MS!Z2;$W+U9H<*I3]TRJ-N'=B=DRJI"V^N%)J@1M?;\)Z7#C,UNN5ZIIC)^?,
M,6!%1 :?J)R=?G_,_G:JPTVTU&\N_P!3,Z5Q[I9XI.HN^>I"^G#SO1?<,JM=
M,-R;[H5:Z?U?<U4HNU:O1Y,>'"HF[ZA,8^16J=)E36$/UG;B&T.AF2F,PL$+
M-ZC9X_3?*XKB4[!IW%NWI+>>U=-;5ZB]3Y_@SWWU(ZI0]I=0J3U<WJH;2VQ.
MJF]"^\-\=5E[0?V_4'T5.')@[9A1_D/[3I= GQUQZ>V$2WO.ZME$:'TD?KYQ
MXJDL0D78 V]&+/YV$@:C(3>?7;JI'D]7&^B6T.G\G8GASB+IF[)V^*G78TS<
M58H= 17ZUM?9[=&;,: =OT-<1IRI5QQQM^IK:CMQ5L!R2ZW8P-_6S[O _)Z1
MTR\Z &Y9[NYT+GL-:F5XC.JV^][[6VGT3VGL-YK<'A[VOUQG5+J-4J] 8V^K
M==0>13J+(30V9+TY\T]KS&.TS&27%*FFI,QHBHLMV_%HWO\ JVK-88OW#=G9
MH%H)'R=GKOCP\]4I_6KHWLCJ=4Z,UM^H[EAU S:9%>5*AM2Z;6JG1'GX3[H#
MJX$QVEKEPPX"XB,^VVM;BD_,<Y)<L 6$_GXC0P9OMP/2"8!9NUO.KMN"/G7=
M(O\ 2Q[?KFZ;_I^S5 U.O2='?5@TZQK9B9J>KZ39I8.^['4"[Z5 [B]B>X]3
M<COR,VR<<>U+;/HQ\6D0!$EBP)W>3_.9]=;D,='OI3]._>XL1;_VN";G\N-1
M[$;%R-QJ;O<7L;BXJS(GL&'Z23L+U!L>;D>O/U/)(MC@ 'Z$6/J3_F:QWL6-
MW$V@O8"G8:MVT'@&SR3> "]"/2V.UKY[>GUQ:U[]]"(#0-079_$_=DG2)=B!
M00Y=WL"&&^KM;6>QJ1CT!L/U[W]<VSSG!N=1C+Q <7=OELX8P':H^SF3HT6A
MK$ZPQ>1%2#;DY[CT)[6(OGT/'TT#L8#")EG+7#:79_K1@6W\- N3+?Z%YJ 0
M2>.WO[\\>G'!O]2CY$L_^5C, 69PVI+S-"X%V[6G4&=CJ+-NU1BW%L6R.Y.+
MD9 O>W ^F-/F()<%BS1 -GL"TL! FEY%YV</K<;=R;F7)$\DV/%K ]B>3^AQ
M<&QOV%M4.)) ML"8$!X8?B*XEAW\^>V[;V+=Z'/'I;DBV20;^H(XM<$GWNWF
M'+OH68ZEX=O2[%J2'LUCV.T,/72Y% +"_P"ML>MAQ<8&.,@>M]<239P;[_33
ML&AC(FES&XNQ]2=229$_1J@V[6L%"]B+&PR3ZD9(MZWSG5@V3I(!W<[-L1W8
M"U)_B/AYU[P'9I[O4WM:][\=Q<GVP".WMC0S8%A!VTAW;P6T%[BSN-"-8$DZ
ML9=GWBF/6U[CG-SQWP>3:U[WX-]"27 .H#B+ N3).SF8 ?2N($B._EV:#>=K
MS.M/<_0Y]"<6Q<>ELGC.;H:6N!=[#3YW)('RJVL38G:"/4O:/5Q>IL2>?>P_
M[+VYOGCZX$;M!V@6NS$]5G9KL+4<3<^M^Y@R+C3NXF"!R"?3!   /^'%K'&A
M:9U!N>W;0/W$AHH"6 (C1QN(8W^(_P!(BF?4GWR,'V&;C'/Z^BSZ""UW=I8F
MW<B3L8#Z$O+BX[]WT(\'6;9Q<6Q<6X]+_ML,6/?N+B'?M( L0[PS;@:O: &N
M^[E[V ]'NQUTJ#^0Q;@>_-^V,<#W.J0+'4!IC4O 9@QD 7+W>GSN;N\$6D27
MD.\7FF,^]CGN.+?]1[GWU-- 9&Q)=I]"?Q)V@_.TL=]=I(T%.,CO<WO<>U_0
M>MO0=N 9XU@$1(M-[7[FUC5V<P&B)&LC:6<V,=V>+ Y_$.;7X-N!GZ_F3?06
M#W#P["&)T<0'NSL=V?F):U[6<:6D0P8"H'!(O?O?R\\YXXX[6' !OJ7<ZRSL
M&UOJ9:T.)%4PPT.FX=H\L_<W<,*U8MG\[Y [$7^OKSG7(P+B8.S, VI\:D2&
M<FIK&CL-7<D0^FM@-1OI .;C(L!].W !'K?W"K<:C"1VAV?S=H'S <0:%X[E
MV[F\&[VU +CS^\4?QV+D?Z1?;D_99/OSR?I^NA@ >1IHUV_ =B7-5/WA!WG9
MC]+ %_Q8?54?].CU^4/_ *I9_:18]P,B^;0$L1H[DV:S3Y[>NU4SE]OGWTM.
MI$2UCM_&;X_(WXMFU_;N3C.J=SWOV'I,,]]P"!7&]AMNP@^!N=&FXJ0<7(SW
M%CG.<@&W'(]??5-H?T%B '<!FD")9G&E&TAB07<=YEGU>T[6J+Y%SS>UNWUY
M[XMZ@8.;1YEHM8'5GL7$6\@&"#0X?OK_ "B/Q()T(^ZO8X]K#U'N1C'H!;5>
M;0"S#5S.@<#:SD7%&\V?32=_,Z2&>P\&_P!/2WXK WY]/T]] 3+FTC35B=-#
M8W<>IA#/:8?2VLWTCTJ;WL.+Y%[BP%CZ&YO<$=AZZ>MV,P;$W@"]Q()GO#]!
MJ)UWV:SD_EI((N1Z6%N>0+<'MF]^PX-QJ#NUB(NX#DN'??5C80]7;L7[,\W;
M6&#"\V82;_7VM8WP?2UR,'C!M?4=GB^YV>-PPANIYU!HT2P$3)NSV/;8AP0X
MJ><'-[V]Q8&XP/V=^,<5SV+V)\MI)+,\!5BT"EI!9F?22]W,-:8;5RU#8 _6
MY_0"V,_K<?3G1X,O^.J9N-=W(:6 % '(%N_S+CY-'\Z "V"+'ZYO[7QW'<XY
MP1H#H'ARPT@C4?BQ+V)FH7N?U'U](#PSU'?@9)!^N;8QS8=\W'MHSWAX@:,X
M@/<R1)UB]<O#L&-]KZ/ @&T1)J;BY'![W]><#GGZ7/&3JB-="-P#>-'<.T"S
M/4;^D@'I;R8T!E@[VIC&>PM<X[VN3Q?];>U]& ?ZN(<39SH\B/\ +4DC_771
M]@6+$W.M1C&>/07^@OGN/J< YYAW9VM;L9,N 1H29D@WY;Z&TD['2-P+,+B'
M9FYMZC  %KFU_?%^>.;$6(MS&@(@D*8&P&OJ+@V@U(O>-0XT=S#3J"3(>7J;
M7YSW!O9/;..+9MR><Z-!8&W<6T%W> Q+N-(99B;>A-WL;>0&^=+#...;#US@
MX[Y'<6P.-0P&.CL\" ':QFS/)+EJ:AS>7?T#W$:[ FB?SX%O:WJ/4$=N"1<X
M&N3M>P$0&(;O8D:'2-7HK4ZN7&H,O:&[ZM3-[V-B?;]H%K>ES?BQ!(%N+.=2
M[P'@ZO #P[18:-3LX!&X?Y7O&EI&K@,6XS;Z_AYMP1[7YM[V@TTVAR7@A]+Z
M#>Y$UW+W<%]P.I^W;7Y12X!R2+>N>+B_:]^#W/;&=<BXES#7?U>\&^FHN&J2
M= Q/8>@?;M9YI88X)L/3CCT/O:XMG@C&HT& ([.([]I;4O\ $+4<@P3?8R=7
M#^A](-8JJ\+-%D]$.J_1NH[GD35]6=U[OWG5MUFD--RH5>W36V:Y$E-4W[Q=
M1)^XW85-88"YS)EMP$J6ICYJP)T_.7D:%K;F&DO5>1M+=[N',2_Q%AVL*_/>
M7ASW95M\TGJ9LOJZ=F[U_>XIO37=T^?L&D[SINYZ92Y3U0B5F-2:I6(:*+N!
MF?+FNLS52JK&2P\U#>AR&VUE\!W%VB;VNW?Y.+BG5=T[P[>6U'?>3#$5C=UQ
MZ+[RF;VZ8[;KD?K?NKI?L#8M4>IF_-@-[=WEO&N=2J[/#-7>WO0]QI?H[4./
M2&4NTAZ/MM]49R8Y$:JD2*%PXW&N3@ .XEB^P'T'@7V=Z[!V7T"ZG]2^B<7;
M75#=-<VEN/9_5Q&^^BU9J6W=I.[HVS1MN2/^1YWSMW;JH^TJE-=0[534Z3#D
M,H3&GQV7933R%LHH'RWCON1M4*F.EAK\@(FYFUK&_8=?\,.XMZ=.=_[)WSUE
MJ^X*IU%G;2<JU6C;4IU#V_1J5M6M4^L"C;7V=#JCC-,:JX@EBK3)=:J<R4MU
M#[KBT1F8PK:/>#&C_6T->WD# +6%^H!S:1#2J]]7-ZY[N_H#1-\=29>^*_5Y
M#M)E]%=S=%QM2/#;CM1J=NZI-2JU7(E53(+C-0<I[#=*89;@)0TS=]3RU^1"
M+TS!T.D!W;TO\4LPJ/\ -PTN3K+"9G27U>N+=)_#YO3I[*VBQ7.ME5W=M;I]
M1G*'M#:T+9U'VBR_&1 -,IKV]JC3ZC.E[ND4>#\M-/#8H49$EIN9(C/R$A>A
M2UR([&0_;U?4!O2]5V3=@==&V] \':];6KPG0%>&-SPX'?-14'Y"JF_O8T2*
MX]*K1WJ=\_;9^WG9SD2;$D5(-L5&GN5%(FQ0H"0P5CR\6_UNP[L]'N2 "&[$
MG\9G1KAXK?=I^'JMT[J#7.I6]^ILC=^XJSTI7TICL4[:5.VC1]NTIVK.59R5
MMN!&J=67#0X\6E*8G2:E)5(#[KE27%7'@1+TV9BX/HVL2>WR:PJ=0=VU<EW>
M"P[03&\.+UQS;_A3ET[I%TSZ.UGJ2NN4'IAU(VEO2CR&MG0Z0[/H>SJBNL4W
M:5188K4A#Q=JBA*E5Q2U/.A"4_=_G ?T8M=AW82+Q)+/_+052J7:6T)@1-M8
M8=RXEJ^3<OA,J]6J_5*#0NLM<VGTOZT[B=W1U&V' VO2I56G5*I0XE/W(U0M
M[2)Z9%#@;EC0F$5&,[1*HX@!28;\=LK;4:9B[AH&PDM.DT>WPO  E]CMINT&
M*[+H/0*!MO>O4W>-)KWV->^.GFT>F^W*4Q2$-Q-B4':%%G4R&W <%0^95&G)
M<Q-2##B8'R/D-Q ZM)^>*$P[BVMKM?T_)W>IU:2S^IN6:S2.Q ]!SGH_TXA]
M(>F.R>FM/GKJL79M"BT9-3>C(A.5)YKSNR9RXB7I*8JYDEQR061)?+?G\I=<
M*2M4#B-V=O,-,W!CMWI!.L@L238]SH X.TES%=D$W%@/<C(L,G-KVOZ<F^KL
M0[DAR 6:\0\-,NX/>H#&D.!(U8;R&U, >&J.+\^N21;VXL;G)MWQQ@KG<2S"
M3$?)@+!B-6+(VVT>7+Z@C6"[B^C:N<'%\V],#BXL;CD_E]#=[ ABP+F-Y:V@
MB'H_?4.;ZN3H0YEG>_:H!]3<' /&<^A_2P%[9Q:Z^_U>X(+2=2T@D0"-7B^H
M])O>SM+::M/(/KD@&W(QZVM?]OOI#;V)+.Y/G8/!N;B] []Q%BX%]BSO>]:2
M3B_.;6-KF^1Z6XP1FWKC5^]W?Z=BTFPNU@QI ?\ !GTO=A+ZF]HJ;)%AD_M[
M'MR+V)QR?II#7*I) A_J"XU@7N-A?QXBQBT AVFP[M0\ <'!L>187-[GGZC_
M %B-I9PY;M;0.]H+$SY;FXD#0?21=VU#CL5N#>V;]K&Y-LC@VL">#QF^J9.[
MR(!F(<NSOX$=Q49B06AWDA]MG&H D_*I/]W)-N+\@VMP+D9^N -!WN+-:R1H
MY=VD,?DP6_5[W!VD5'89XX_%:X&.<<_LO>_;4  #O8F09:1]683XU%74Q)>&
MU-]3;Q.VM,6M?FW-[WR,BXY''&3@<7>3'2\ZR"P\LSW;<,:&"[2'M:&[?,?Z
M4[6! OWL+6XL.QM@?2W?00>VX,>)VT<02QN#1C+ASMJ[O]7)809(M3UQ].0!
MBP [BV>V,G@YEPQ.Y8 F>VC7V^3&A_3M9W/5J2[0W:2]",$\G-A8=^W8_G>_
MUXU>GML8.DOK#F =A#Z@>[ P2>UFN?(M+1!H#Z>F#V OZ>;D9';@VXT ?4.9
MU@2[D;P[E]YI(T,%H(<F#LY%F<'2:F]^1Z9]?2UL\WL.^+\C5?PS,2'.@#F6
M(\[1JS6)O!%F+ML-RS,]/4YS;M?OP0">",V_6XOJ6,@/_4ZV$BX&I+C2>N[-
M'F2VA[[--0!;RYY%AR<>QM;]1FUM')L=07(UG9QJ!V@-%7>&:XD/9H=SOYDD
MVJ;$7%QR0"3DGMFQN> ,=NXU=9WZMY^3Q (+';8SP=&^DW/DDVUAXBXO_B#8
M<7)P?<GV]K@D&8?1VT)?0BTR8L#>DE[QZD: :=A_**'D<C!^G?/%A@#F_?'?
M4,,;!W9[V+W<O$N6])Y=GFSM(D!OJ= 3$N6J<9N<CD?MX]O4"]_TTL'T+Q<7
MAN\$.YB7<BH"Y8#5S =K-LUBS-OO4')XM:QN;CL38X-K\C.+@\Z-9G=H<"6=
M]_K(AH,6SC28#DC3<6) [S+77Y-[ ?X'BQL/86!X.=(\P=79DV<$0+=Y>SUQ
M9_)MZM+_ ,BUP1!I@]\GW_;8DX-^#[<'5+MO,B^CB ;$SZ/J *Q>[;$Q9@SD
M"WH!VI:WNH#/<_K8&]N.+^]KZC7"F>SN'N-'C5R9E]ZI,@AP#+6#_P Q .O9
MJ_6+8SHA%C_".&]^/XK)'^K_ '.H;?,!HLSF"?JQD7%JEP1?P7T!;^@'\J^N
MI#^&3S;Y0N>W\M>/S'Z?GJ:&WSG334!OF?-%&>^@9VV\&[7!A]Z^ X/L?V$D
M =^,_E^@USM#%Y$[.!8;W)%S9WKB&+?KN7)#:0+2+34'-L@BW?OD6X_OL>>#
M>VN-C))#-Z1#@F-6F"-W%]&+QV9[N.YDD6T:0-[V/:UK@V(/J?7L2,VSSKD)
M #N8UUF0[G<EVL&#&H8)<,#VO8M'@>'+EYI<X)OV]1;FY(SZ>@ OSWU)<%P]
MS*= .S#87ESW(-(W=H?PUCO\I>ENY]A;F_&<WY-O?&3;5B 0&OI#F6-@'[N(
M8O GAQK^5NSSWL!-1^AY /%NP -N38\?W6T<]F ((U.[2;:L9WLU;RY8Z$.=
MQ#2;R);>IOCOB_ZW'K8XX/ YO8:26!=Q(.Q-@=W:^\7J-M\G<G=KM&_D$TR.
M,=SG!SGMQ^ECFW!*Q%NY'IY:\NP: SE[!^3 ,>X'Y"53XA; M;@$V%K8^GU-
M\6!]+C0!G)8"PBTV?;0DL"=P2YWU+SK?;\!#EVTBG-P0 /[R?7MG N"2#8V[
M:AEV($P"=W?=M7F=A#K:OW =F8QX';M:1/:YO;WP<=\6]_7L1;C5T,LWYO!#
M#4:,2S'4!<0)[[G6_P#+N]/7/&+CF_TMWXMGVR+%/=K3J?4!RP9HF-9;1-Q-
MA?0^LV%WTC!XN.;]NX[<Y.+^MQR=0W8CNVI/9G9V9K-%V- (?8ZAPS>9:2TZ
M=Z>IM<XL2.>#R/[[  _0Z%@;D,[V<VVT(D/&U'>Y$]S#?3\2?)J1D@\8R/V_
MGSVM;W[74$"6:\O9Y=PT@@2Q>'IHU]7T_D7L"\S L\8!&0"<'B^<W&!W]; X
MX[I<L"^A!TF#K>38ZDP]28^8NQ(W>($0XL*6MQP !_=<W_O%A?O?&C$EXTGZ
M$3(L9NXB]-&<ZGZ1&Y\L ?- ;C!%R<7_ %..^,_4YMP))T]"[ ,)#6_BC1F$
MU;1%M+ZP_P"/9KBI/IC/ XO;L>3;/86 O?',G1[^#$"[LT^-=*>;:DNTL7#-
MIN7+B'J"!QVMSZ8_FC%^1QS<#C H!#V=B]G$!B/+MW\T&_<'5C+D$N0/70/&
MHG(%C?ZCC'KZV()O^E]-7 [^FOF]RQT,T =Y%[-K+6^@#W?2F<D"PSR+8 X&
M0 /0&W)P+9$QMH0Y:!'DQ )[,[FFK7EO))U_F0^DD4'L"+\ )]QR.>]CQCCL
M='_$0 SES!&X M;5WO9]9DEW#:'R_>0-Z=_7C ^N"?3GU[7 ]#]QN-X\7;1R
MQ(+S:->_X,9!]-PSML+SG/;)_,#%P,GWX(]>0=  \MY&D@V9B"XDQM %"VEH
M+'UU^88-IJ[1CL<'N>#VXOGL+$XM<YY:AXAF.@]""VDVER:;F'!N"9]69X<?
M1[!V-\V]^1>X((/'O['G1S$F'</81!,7MKVF*,YAF+:/I,3\K"-&-!Z=QF^;
M9'UN<W[=O7.CD@".T.TB!?U>X^J+][6]3$.+-#EPP#4L<9M:Y-O2]R>,V'J.
M<W]3W)M%YD-WWT_RNS4T:=PX\VG5_FPFAM86) MZ6].";<C];GTT9[6#7^\V
M["X^L7JNQEB9.\S?O:T0/(#/'Z XQ]"/;G&+8O<W2PT)8 MKM8O_ -3!V<6E
MCO<!W#NX/I?8N?2F#@<?MSR";G/-[9_%SJ$P0#9^\&X$;B[>HM28)%V;Y18=
MPP[$$5!/:_:WX;X-^!@@>G(YR.-4AHB[&P'K<P3)+&VK$#X.X>2>^D:M-MGJ
M0+6]/IDDWY]^,XN;^H&I8%MFL6(,W?0.;#4684<2X>=]M!V-H)8;M0@?SLYN
M+#F_;M?BQ%SQWP-" 'TV%SK)T\-:.[@^CR 'VF=X?6!>-@_(7 (MG\L<@'GZ
M\C2[7 <M=IT+6<.P&AVDK?/P8>Q_,7 @L:GZX M;G%N#?%ORXSGT-#EP^K&6
M!TD6ERTNQU#9O)9M6<6W@ OXW@<6SR; V[=QV],X%Q@#C0Q!'W@Y[ 6:;]O
MI?OH^[[P"7/9R'DW WO>_L .Y_Q)&+=NV1JZ&20XE@2]Y\. 06M!TI!VU+Z,
M/J+.#)W!>F>00.P%\8YMVQ<$\VM:_I&DGPP< $-.H< 1L?G1G8=RY8D]GUGT
M\:EFUP3<=LCO@VM>W-\YQS8Z,0+#>6=R+,_T8N1M "28.QL6#2QM]& -P*BP
M(M]2".PO:_. 3V]<6N#I&Y(:07 >YUDF8.NL-0P7AK"Q@-OVU;;>ISFPL;D>
M@[V-LV'Y<^Q-Z #^!,[VG=])>X8D4)(VL" 1#1KKM.UW -+ _P!X%K\$WO<
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M1ZZA&IAX ,6$&X'IHY$VJN\/_.)?1]R7(<7%J7-B;&PM[\W^@QZ]QSD8H.C
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MK^F@!Y>E^U^PM^8/<X/L>;_34[[EBY8C\->QZ0 2-*:"Y9_D]R-/G.X:HOD
MD 8YL;#W!!-_K;L<WMH^E]-')+B[:.2Y9B2"[O5;4;ESX+Z$"S0">S-48R;W
M%_4^ELC)/8$YO<'CE<@'Q&LN7;27NT%F-HY&C S-QLQ/8%H?S!K4#; \ON;V
M [ GN;XXO]2,ZI-VW<. VK&6N)#S#]Z;.\?,CM<?#.VT4N/7V)N!;'?D$WN1
M;]@O>"1H6O9FDB(8Z/# [NR\?227@-JP'S+3I3S#.1C'IQZ<GV_+ T@'6&!
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MEN_;VQJ%VU9[1#;-<%Y+#231/WM7<_AJ&[3-[/6]OPV9"PMP.>9*0D%#KC>
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MZBITC;O<WWO3[LB_UW]H?_SZ.;/^KOY[TZ4[?4_G3[LB_P!=_:'_ //HY/\
MH/T\7O3I&WU/C?:*?=D7C^&MZ?:'_P#::/?O^O3TITCO\S^=/NR+Z/?VA_\
MSZ.?T!^OZ.+&G2-OJ?S["GW9%]'O[0__ )]"2?\ 0;O^-.D=_F?SI]V1?Z[^
MT/\ ^?4ITC;M<VVO7Z-0([3B74!PJ1?R^=YU:02E2+A*UE-_*M20;8"CJDDW
+\_K^>]4) D"O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g491933g87a87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g87a87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1M^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &V*^<! X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q :Y=$(         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          (U   $7P    8 9P X #< 80 X #<    !
M          $             !%\   (U                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   (U     %)G:'1L;VYG   $7P    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   "-0    !29VAT;&]N9P  !%\    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     ,X0DE-! P     $0T    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,E:!D3A">)BQMM?P)":A)T98P2@S-%)7<H:(LM'A_\0 '@$! 0 " P$! 0$
M          $%!@(#! <("0K_Q  [$0 ! P($! ,%!P0" P$!   !  (1 P0%
M$B$Q!D%1\!-A<2*!D:&Q!Q0RP='A\0@5(T)28A8D<H(S_]H # ,!  (1 Q$
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M3R.V#2MGV9S7XJK2*DPA2X+4EG9E1DS65-K%)-YE11XZ;*IB"8^D1)(,;]=
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MC\XNKF[O[JK>W]U5O+RN[-6NJY#J]4G<U7@ /))F<K===]5E6-;38UC!#6B
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MVC\NWC3JJ&%(IR&BX*B_'#E#O*YQ>U+CL#8G";?]3UY43RP07 JSWC:^Q"6
MI7CUI$24)*3,DV.K/L(J5;5R-;G;R4M+-O@MS'137,0H3&Z]?QHYHSVUM&;F
MW3N'4]AU(KJ3=&WM:RNNX1A);4OD7%:TL"$$A]YPVM$K>M.W!<5@6F(>BDL;
M%JX^,SBWLLBT&0<$GJ1WKU/0ZJV#>G/C>E:Y2;BT;1-I>/335;U77=2RC1SS
M V+<*-=;B[V56Y*>=+U^/BK%%LG<1!'8IM7"I$ 43.Y2(JJ=0W12=[=/+?7W
M^\*ZG87D$T!QS-2*1R6V=7HC;+V@5NY;")K2E[1NU ID?*]1J]XLT] UFQIZ
MPU=)V!M*(5JU;2D:\R>,F#M15^?[ND%D23]?Y^'E.RJA>N86CZ#N#5.E)BXP
MOXHVW [$L,/()3]7+ 0;+7#6F/)(EI>NY]HZBG$RWO$4K64R,':<L5M(B9=J
M""'S1/3I[_+33SWA::?WS8-C<A^5VFY*$B&$/Q]EM,1\%+LCO!DYQ/9NK65]
MD5)<BRZK1,T>_<G8,OD2)E,V( K_ !5>U3$_?OOY:!6L\H>6?,+CW9K+L;^1
M32?\URF[2U3K1)&Q['G?YP^X4-C3M'JKRU:HK=<C)6F,%(NT7<82N46W2:5L
MNBM9E7?HK;>2@P=E?55 YE\SY70VI=IV+7#>JMKWK;97'?7$E*;Q@[S3M,Q
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MY9Q%.5G#9M()1\M)-G9V:RS1RFFX*C\ RK=9,BICI']/AKXE96U7P:]PRB^
M?;,:'7S^/\+PW6)8?9OR75W1HN D>(]K9)TT!=\^GO J/JC<6K]W5US;]2;
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ML^V<RIAM9]QD\,N@936YUFP?P$$09!!'0:?-!]FE?[P',OJ++?.'D$'-X?\
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M!LU67<G(F@D0QU3J& I")E*(G,<1$  I2@(F$1   !$1  '(X@ EQ#0W4DF
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MK")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81;3F]!1,/OU_
M/^/MD) $G0!%%+Y0MW7IO1*)Q#T:HX0Y"<Q; KK>LNVZ9G!J/KAN#9;;&QI
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M759VK6\MG M<0=&@Z $D:YC5]7=49A&' OO;OVJCVZFVH@0YVG-PV!UDR#(
M-R_%GC+KWBSJ6$UC02N'S9/XLS9;5+J@]L]^N4OZ'-AO-ME1+\65L$^]%1RX
M<J&$C=#Y:/:E38LVJ26/O[VIB-8UJCR<LMI"?9ITQ(8Q@T :UL &,Q !)DDG
M)8=84["B*3 /: =4,:OJF"][B=RYTGE$Q&BN5SQK(IA$PB81,(O@=LW4/\0Z
M1#'_ ".(?M![=>P_D/0==AT.$0C9!/\ L)$+^T)^P#H?4(="(#]0]O;V'^R
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M$B(TVY<O3Y+,#83OS6N5$PB81:"( ( (@ F'H $0 1'KOH _,>O?V_+"+7L
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M7#]Q69AX N[L!I<'W! #F"H02_*) $$<]3"UKA^UQ6O4K8KCE&DZ]=-O;9R
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M!^@?Y81.@ZZZ#KOOKKV[[[[_ (]^_P#'WPBUPBT,'J 0_4!#OH!Z[_</L/\
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M##U_K%Z[ZZ[[#L0#OZ=]_D'>% 9$]5M^93$QB=']12F-UT'N!0[]A[Z]Q_9
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M70L36;6S#)+;9U#,1_FRRX3:0]JAYN-C95HN)&LHQ;2#;YCX:9P0=(E62!0
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M?*O%)]\NY@%$UV=[[_9.Y6<Y"M4F$6PCT#&.WCV;5BV4.)3&4;M6Z2*)S&*
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MXC[B/OV/OV.$&W\_GK\5Z7"J81,(F$3")A$PB81,(F$3")A$PB81,(F$6AC
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M-#SZDF4_H(_'2(]FJ/(,PC[B(\S^7@=B/Y]%W6!0_@4  /R ,1Z_$\E-!H
M.0 T'QD_$]>I6[^@F\=O0@%4Y!@(^X&_GE\MS"!NO8P%-N<2"("'?0E$!'Z@
M/8XB1!]K4F3^+76)$:>07($ GV6EI$&F02PCG.N;7G#AY<H#X)O'>;U>NK<A
M#>L1]0?SR^6A.P[]0%[3W*0>@-[@(#ZA_P!8Q@$0$! C4Q.623EGIR/3V@?B
MH'. (S$SIK!(:-F Q(:-.<Z:DB9V?T$7CH_NAR##_P#>AR]_^>[!Q'F3\/R
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M;[)KR?R+V@LZ^[BYH(X#6!@JWF#NGPO!<JP@%CF@92Z)>"7/T\ZA>->8B-3
M"H<X:9O8DG((RGY9A!V =#>7-7ZCX(O'281$U0Y!B(_4?YZ'+T._\"[L*4/\
M #_/+\MMO)3Y#RGY:S^G):?T$7CH#W"H<@P$/<!_GH\OAZ'\AZ'=@@/7[P$/
MU <)YZ@[C7\MO<1"WCX)O'<(@(U7D&/0>P?SR>6?0#ZA,)PZW( ^H1$??O\
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MC\K=F62C_FD%U8B5*R8DE8E5E)$8LR.BMDB*Z3")A$PB81!$  1'Z '8_P
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CF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g491933g87b87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g87b87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1\^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'R*^>7 X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q ;&EO(         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          **   $,     8 9P X #< 8@ X #<    !
M          $             !#    **                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   **     %)G:'1L;VYG   $,     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   "B@    !29VAT;&]N9P  !#     #=7)L5$585     $
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M!!$       $! #A"24T$%       !     ,X0DE-! P     %,X    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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M7]Q6</ P\%CZ\.IM#+';W,9HW=M;7NV_F^RMB<L<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( 1,!Q0,!$0 "$0$#$0'_Q  ?  $  0,% 0$
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M<G.B8XHG3XQQ;PIB6&Q0LH*S&<6^\N?][SMFD8P-+<N< N)+NIL 6@ BXO\
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M'OY9 $P!(#&]S"81SL.!8.,$HQ1BKJ*QH<7"2I=F>";W WL-A8= OH+ ,&.
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M(&](J% WM[#V ]B/0![A[CW[=?4/Q .\*+BU^5K^BT^:;AZ^UDP^&7U*")@
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MX%)6L<^F;70N:Z1K+9K2LDD@<6YAF%\VOF5<H0R0B8$S)B(="8""41#OOH3
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MFS^*#5LV:@LLJY6!NBDA\5=8WK675!,I?B+*G'UJJG[.H8?4<PB/>$TU_/\
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M<AT%9[_38/8M%N>O[.T)(5N\U6P4^P,5  2/82RQ3N&E&IP'V]+AB]72'OV
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MZWJ.)FF4#+:YMR=HMU7=OY36LS-P+"%MB0R;VUU.PP1[,X5M<5.3$YO#6M:
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MZ]!/4!_2'J ! #=!WT/N(=_M'W_?A0 !LOK"E,(F$3")A$PB81,(F$3")A%
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MLF35,3??4^&W2(!U5/4LJ?U*KJ*KJ*JGYK+756(U-365TSIZVHF=/5O<[/\
M^1,3+):0M:7_ !.Y_A_#I99(,9&&QQ-RQ,:&QMY@"]]@!:^VF@TZ >\RE2F$
M3"*V/FCL]/2_%#D+M0[PK%:CZCO<Y'+&."9CS2-=D$H%LD;L!%P\FEF#5N0H
M@9598B13%$X&"PQ24PX?5R#\387ANMOB<,K?S()\ 5C\6F^[X97RC\3:63N]
M;?U" &:V.YT];G2ZHUXMM7*Z?X$<8Z<[:J,Y-;5=>M\VU7*)7#:>V"1>]S39
MSZA$3.&DC8G#58PF-]] 2 /1 SQP2'N<-IFVL7-=([GJ]Q.OC:P]%XX#3_=L
M(HHR '.C,SK"QO*<WQ?]NNFAT4@.9599,(F$3")A$PB81,(F$3")A$PB8183
M];\BVF8+S]7D4.)NFJXP:[+MW%^V[G=N2P]YAIZK6B8I-KW]*3\H^:TV*.]5
M9*1-@=*,&4HZU^04%I]S*N'#=\]^_?\ $<M.FFA^FZJ[P=Y/[EH/G%M^JM]\
M'],:&L'+1A;UZE-U>FP3.ZQE:IU8V!>:[<H[9,!-SM=O;79+*KR3?9LM!.E&
MEDN;9A(D<19J\ZB%XY^GR_77Y:)ROO\ OZ\Q^7@LP(H@)2B'T$ $/W"'MDJ5
MKA$PB81,(F$5NG*;B[I;F1IRQZ W]"2EDUG;W$"\G(.'L]@I[YXK6;!&V:(,
MG/5:0BIQF5O,Q3!PH#.00!P1(6R_Q&ZRJ2A/\>_?)03\I?$UXO?&CH:\<X]?
M\37>T+QQS6J-ZIU0V-O?<<[57-C"[UN'BW[R.L-EM$.LM$NI1.4:@_K\LB+E
MHD0S80-ZRD62\CZ?@I>DH$+\)/TD+T(%+Z Z* AT'10]@Z  Z#VPGFMW")A$
MPB81,(F$3"*!SPH_UK^:#_.[\E?]DK&%%[W\#93QX4IA$PB81,(F$3")A$PB
M81,(F$3")A$PBL=YU;8E-9Z<D(JI%.[V-M688:OU['ME/@NQG;,1=FH_25^B
M9HUJ==VDH;T)"[!DBL<$U^C:5QIBTF&834-@<75.*O9A=%&P.SB9^;OY3KJ(
MXR S*  ]S<QL[30NT7'9<%X?=3T30_&,>J(,#P=H=9XK*YQ:V5EB".X:'2..
MUV@'=58XRZ1C=!ZAJ.MV((G7AV)'$T]13 #2U@?'!W,RJYS@<QU7CY544B^L
M009D;M@$?@@;,MP[@T>"X53T+ <PM+,ZX+WSORF21[B+EYME)%@&!K6@6"S7
M"?#\/"^ T&#PZ_=HOZTARF2>ID)?4U$KFAH=)+*]Y+@UHRD  6TKA8I1A!PD
ME,RKINQBXEHK(R+UVJ5%JT8LRBX=N7"RATTTD4&Z:BJBJAR)IE*)U#E(!A#/
M=V^9T<$<;Y9*B6*GBC8TO<^2>1L48#1\3KO>+@:D7 (.JV(]20T-^,DZ !GQ
MDWY6#;WU\BH>/&-".N0^R>2OD0MT6NU/ONV+:_T<B^3.1Y#:*UE)*PD>HW2<
M^I2.2M$O&MG4BS!%J9:7K[J2Z50?(F#JG:(]F"8?P[P#33M)P.C%=C@A+,DN
M.8E&U\@?8.#C2QDMA+KEC)0QQ<6DG%X9>:2LKG_'WTQ9 9+YA TES<NP+7$W
M-\Q!#1<$%3.I)%2+Z2=]?41$>Q$1$1$1'H.Q$1$1_P"[H/;.3PPL@8(V7RBY
MNXW<7$W<YQL+N<;DG:^P T66)N23SZ;+<SU4)A%H81 .P^OM]?WA_P"'T_;A
M%#UYJYQQ,\2JUH"-6$MAY2\@=&:/C6[4QROEF\W?8R>D_E@!0G9#-*]\F[[-
MZ3MWQTA /B@.8#B-Y^YMIHP'2SU$,;6DVN+N/*QU>UK;CKJ-;#7.))"ZABIA
M^.MJ88 !<'5Q>+$7YL%QKK:^EU+36XQO"0L7#,T2-V43',(UH@0H%!%NR:IM
MDDP*4 *4I$TR%*4I2@'0@  '09FH(Q%#%&+V9&QNN^C0/!;!&P1QQQMME9$Q
M@  %LHML-.FEA8!=[GJJTPB81,(F$3")A$PB81,(F$3")A%^4]R[U-L#>OE6
MY8:=U= K638>R.=O(BJ5"#3=,XX9":F-Y7-*/35D)-RSC(UL'Q 6<R4D[;,&
M#8BKMZX0;I**%@;G7?6W3D?0GV5 V'D%/#PFW]1KUY$O";Q?JUU)MVU<,]3\
MEZ9M+;;)I,(PTE;[KIS8DF;7%?=S\;&2TY6=.L8%G3XJP?*IQ4D!UCQ)?DBH
MKN&W\[E3UY?I]?>ZS?P]P ?S ,E%KA$PB81,(F$4?OD^L=&IO"[;]PV1R.W#
MQ0IE:;U24E]V:#7%';<$=*Z0"49 4LA6$D=U*7F7684OY,&O3MM/.&ZCAHBH
MJY2(L4G:TCQ$V1QEDW^T/+GY@-CK7382>FC\'-G?8@[ZOVQ8X:O:F--DM,R5
M;<^J*7;S-4G4K8Y?*4],9"/:)S"UC.C!*%'+3IIT_+3Y+.S0_P"A1]Q-_1)_
M>'KLWW ]QZ]NQ^H]>W?T]L*5NX1,(F$3")A$PB810.>%'^M?S0?YW?DK_LE8
MPBGCPB81,(F$3")A$PB81,(F$3")A$PB81=3+2"$6S>R#MV@Q9LFQG+IV[61
M;M&K=$#*+N'#A;TI))))E,=0ZARD(0HF,)0 1RA\C&->Y[V1-8W,Z24Y8P/^
MSB0   23?2^Z\Y'B)KI7.:&M!+N\.6-C1<E[G @@ 7+KFV@\E& A((\H^;R*
MT:]93.KN+5:^UF\FT6*\C)?:-Y:M31ZK1PB86CQ*+CT2+$4167*U?1 E'HSK
MU9S7O(^)^,(W-,-3A?#5.^1DT1[R*?$:L,#&-<WX7&%S6R @D7I[.S!PMR9D
MPXP[1HG1=U4X)P)3.E;+&<\-7C>+QL#&QOU:[[E3@/:;YHIK 6#BI4"E J7M
MWV"8>_8C[E+V _40^OOG2VM#0+#D![NNNCE?U43/EOVA;XWCQ7^.VMW0_P J
MO,+8=;X_UE%!42.F4!8W!E+S."BF9%4\6A"HI5Z57%PV39IVE%PHX3 "D4Z#
MV543)L;EQW%([X9PMATV-U;GEK0ZH@!^YQ V-Y'3&-[&L^)W=N++N 6/Q66U
M*R*(EDT\S8+M-R6N)SZ.N  P/).GP[GFI'M.ZSK.G-94'5U0:)LJ[K^FUZHP
MZ!/NF%E!1K9@"ZQ?4/J<.CH"Y=*F[.JZ564.8QU#".DXCB%1B^*XEBM4\OGQ
M"JFJI"XDGO)7ET@L=@SX(VM&C6M&@OK>Q1LABBB8,HC8& 6M8 "WF3:]_'=5
M-RV5:81,(M##T41^G0#D';KSMY:A%##S.$-H^3'QI:>:E*\;4%QN?D=;VQP,
MHDP:UFK(PM DU4!]28G-<0<H,W1@ Z"J2@(]J*% =>KOZ^,83$T9LA-0_72S
M""TV.FCFZ:;D!:SB3N_QG!Z=FAA,U2;VL,H :3?HZS>0!(.JF4:% "G$._O'
M[#L1$>@[*'?8CT/8"'Y_G^&;"+:VZF_GS6R-'XCR+B1T].GD/!<O)5281,(F
M$3")A$PB81,(F$3")A$PBL.@?&GPPK/*B6YIPFD8!CR+EW,K)N;N24L:K<D_
M/,W$=.VAG6%Y8]4C[3+L7CU"0GV<*C(.1?OW!U@>/GKIR4?3W^73GU\==-^-
M/A9H/D'<.46K-&5VK;JNZDTM*VMO)V)XWCE[,LLYLKBKUN1EG=:J;B>677+(
MKUR+C3G:N74<W^7CG#AJL2W7;Y6Z<]?T(\E?@     ?0 Z#]P84IA$PB81,(
MF$467F1U!NW>/!BWT;CQJ]SN3;#/:W'*_P!>URVL-<JAK4VUAOW76P9V,-8;
M8_CH.+3/!UR0.JY>KG]*13 W:/G(I,UR@Z6]>7ES%[;>[*$;5K7R?T[R \B^
M?]J\!C"X;.WHAJ:'I;N6YI<?!E-"PM#UK$ZYM8U6=/ R0R<AL L.REY:79P=
M;E63%L6ME<2#)9VX<DYVU\[:'KTU\M-5F!IF Y"'*'13D*8 Z$.@, " =" "
M'L/T$ $/Q !]L*5]X1.P_,,(G8#]! <(G8?F'UZ_O_+]^$3L/S#W^G[<(G8=
M]=AW^7X_PPB810.>%'^M?S0?YW?DK_LE8PBGCPB81,(F$3")A$PB81,(F$3"
M)A$PB811@>4?=Y];:6)K^+<.D+!MQ16$!=H=0BK&LQXIK61P)B>Y2O$5VL/T
M'7?VD)N_Z,0SF/:=C;\-P@4%.&B?%;QN<XVM!"6N>6ZZ9B]K7.']I(WL5Q_M
MGXH_T'A9U# Z9E;CCS1LEA#B:>D !JY20T@.?&13QYB/CF#FWRD&DGB,GJV_
MU;L.IMFIF=LBKBE-SZRHB*LFPE&;9O!/"G$/6"23>+78?  132.R.X$ ,Y-F
M.[**B!V'XA2!G]6.>*I+A;XP696Y3:Y(<UXL 1:Y!N2L1V!5%-+PM74HAEBQ
M&/%'555),'9ZAKV@P2!S@'/;W3>[ )<V\=Q^*RF35,)&RA@#L2H', "/78E3
M$0 1]^O<.N_?K]N=;E+NZD+/Q]V\LO\ \LIRWMXV7>!N-+ZC0;GP4+E&!+EQ
MY7KY=UB+OM5<#:$&MZD8Q3*Q3K?6QD3K6^2;&.4[=RXK]=3>5^22*9)RPEHF
M!>HG$HD,?K%6^/A7LRPVCB</]2XWK175!:Z[VX%AH_\ %.A^*.>J,$C'BP<V
M21KLP)MB(A]XQ2:0V?'219&7%V"63X7V&P<UMQL?Q'4#133D3*0    ! .NP
M* =]?N^@?D'?\?<<Y3H'6MJ;NOYD7^9U/4ZZK++[RI$PB81;*_\ T*GT_P G
M\1Z#ZA^( /7[\;;^_'T0FP)\#O\ OR\^2ASXS%+N7RQ\W]OJ*%?P?'O5VI>+
M],<B!5D"/Y9-;85_1:J]J DYCY]/Y5V!3)&Z>>DZ9A$Y\UNB!J,<KIP1W=$P
MTK-0X$R.:XD$7 (R$&Q! -C?EK- !4<0XK-E)%%34=+&\ZMS2M>^3(ZQ!N6'
M/E((-@]MS=3(@ !]  /W  ?ZLV1;,M<(F$3")A$PB81,(F$3")A$PB"(![B/
M0?F.$7S\0GM]\GOWU]X/?KZ]>_OUV'?7TPBU 0'OH0'KZ]" ]?OPBU$0 .Q$
M  /J(^P!_?A%\"HF4!$5"  !V(B8H  ?F(B/L'L/\,(@J)AWV<@==]]F*'70
M"(]^_MT "(]_0 $?P'"+4#D$?2!BB(AZ@ # (^GV]^N^^O</?Z>X?F&$7UA$
MPB81,(F$3"+;6.!$E#F,!0*43"8?H ![B(_L_/OH/S$ PBQ@N/\ Y=-T;;\B
M>]-22O)KB'":/TOMKD[6T.-[[7^T8[D]>*'H2 M[<LS4KTHV7U1*R"M@@1L2
MT86=)8%Z?$R\D,$BV%-4"CTWWM^^A\OT7E--^:3FC3*;8]Q\LM=: <:[W;P&
MW=SUXI06JU+BSL%9C-4R+%I$ZIVP]FWCI"2<V./L=9DE9^"(3Y8RCE,I2.%S
M,(Y[]\_R"GWY+DF\N/D$T/0M\ZHY)TOC98N7CNF\/KWQE>:Y;7./U.HES0O9
M];05>V>UE)A29%WK&Q)+.'RT&\^#/M$%42O_ (8)RK@HTMOH-#[&UN?3P7K5
MO*+Y!V-0?\27<!QG5\C*//F&X4M[RE'WA/CF2O3^H#[U9;@7@Q>*VI10*:W>
M1JD$@N19%]\L\/%_%$8A1Z>_?^%)V/OZZ?->,1\N7D1W51]'Z=X_TGC+7^8;
M**YKSW)62V TNSW4"2'""ZM*/*QVMF,;,)SJ;G:LJ\;BV4F7BB, )A1%=-NJ
MK(1[7WK^R=?R]^_+F9E-,>2WC)8>)W%?DKR(W7H[C&IR<U5#WZO0.W-L4[7;
M1]+)Q4*O=HBJ.KU,P:EB;565FF;5XLS^85:MI&(6>_#^TFIEB*P_P1V^J; M
MWE^O-$LT!=*5;_*[R#LE4MU4F(^P5FS5Z9B:F_B)VOSL2X=QDQ#RC%=%Y'24
M>Z<,WK59)PV6424(<2+(%PB81,(F$3")A$PB81,(F$3")A$PB^3'*0.S#U["
M/T$?8.N_8 $?Q#^.$]^_FHP?( 1;:%IT+QJBTDE5=N7 96R//A]NXNB4=,\S
M8#-3E#X[==V*21D1$4TU3,S)B*@B"1^:\>-.)U.!X!& 'XC/)4F7NF.=#3T;
M<\X!<,X$K"3E LXQ .!!L>4=I0&-5/#'!D3F$X]B#ZJNLR-TD6%808JBIOFM
M(UM2\QL81=I,3M#<@R$5.JPL"R22AX>.B&WR:+9((YFVCS&02(5-(%$VJ"0>
MHA2]@)C'$GN!!$!S?:6CIJ:$1TU-!31F-H#J>*.%Y:&@-+Q&T .M;07L1KMI
MU&&FIZ5@BIH(86!C TQQL8\M#1E!RC+8"V4--NHO=>+Y#;FKN@='[4W#8U"C
M%ZZHEALYFYS"F:2>1T:NI%Q""IDSD!W,R?R<6T]13 9R]1 P="(#G\ PR7'<
M7PW"*:YDKZNEI@ZQ 8R>0-?*21^&.,/D<!<M:PFVUZIY.XADG<;,C:XEPW:6
MM)%@+DDFUK#?FK+O$WJ2<UYQ4@[]>Q,YVKR5LMDY&[$D5$115<2>S%TI**1,
MD<RBC<C:NDAO6U]?PT7RSTZ*2153E#:^TW%::OXK=AU !'AG#=&S <-8P#N^
MXP_)%/;+=IS5)<<[0WO QIL;&UEAD#XJ<OE;DEG?W[A>^DH#FZ\K"PMN.:D]
MS0ED4PB81,(NFL4LS@8":G)%RFS80\6^E'SM41!)JS8-E'3ERJ(>X)H(I'5.
M(>X%*(A[Y1([)&]Y-@UCG$[6#6DD^EE1(]L;'R.(#6,<\DWL UI/+7EY==+J
M)/PK03I_Q;M.^IQ)4+9RIWSNC><ZY7*83K)2]R>UZ'(@HI_2&8HQ=>0,Q^ZB
MD""_:*0$.4Y\#PZRU&9W'-+5S32/=U+'ENVMM<QL3\-R-]%K_#$;G8<:UXM)
M75$\K]C<B0M)O<FUP38G0EP.M[3"YL*V-,(F$3")A$PB81,(F$3")A$PBI#R
M!<3K31&Z'577EFMF;:JV XKCF!.Z3G&\\C5952'6AE&/^/$E4I$K8\>9E_C9
M794A;?TP$PGOW[\E&C;=9[(UMQ97"V;&V=7]E6ALC)4F=K6W^:VP(P+0AK>4
M-%LKY+R%YNFQ:ZHO).)-TPKE:E*]5+9>4*?#3,38W?R<&Z*+=  -]O>NWO:4
MG4TI-S>LZ!,6>+F8.S2M)J<G8H.QF9&L$--OX"/=2L5.&C6[2--,1\@JY:29
MHYJV8&?HN#-&Z* D3*0>]+>QT^I5&>4MNVI58K7!=??K1'U^;V0A$[0ME$UU
M(;5NU.HY:1=9=I*P%*C86T.GXR5_BZ15Y1\G5+']DPU@D7AF3$J?ZP0I#[OH
M/FHQYA_R/M.K+-=-I4W=$[NV=T;J.9T]%PU#WQ7HJN74],D5MGUJ,B=-(/VV
MI]JI;75>1K6U7\R46XJ TA9U.SU;8SY42:#GN=KC7EYZ6\^MU[*PZ*WW,:QY
M];/4:G_6R7J'*2+U97VU-VX&XW$U)Z?4BJB:E6QAM<863@G,RZ>M*M&U/4J$
MBX>'1&#GQ?I$<JQ;ZWUU^71 +#\OEI^BOQXNZ*O&H9"_3%KGZV:/N:553A*'
M2%;ZK2ZB:NI3A)&:CQV#:K+(_;]R-,,PL!HU"#BQ;5J$*#-V]*\D74H/._RU
M\[#E:RN^PI3")A$PB81,(MI=,545$R^GU'*(!ZO\GO\ ;[&]O[APBQRZ#X4]
MX,^3D#+;1Y!:PN'#_5V]>0?(;5E.C==.&7(B2M/(:!M\-+TW8FT5D@3>U&IJ
M7-\Y8.TG,L[L!6#)H^C(MFC&-X0@]^_X"\EIKP5[X4K]OUERFY04/8>K:)PJ
MV_P4XHIZ\U])0%EJ6N-MR39XOL#982COY.1N=<:0U>C&$'$O9"*>-F!%7$RD
MZ367D"+?:>%#E9L[6^];#R9Y3ZOL?+*=J/%JB\=]FZ\H,M&T;7$3PZMXW[64
MU<J]))M5[)/72SF47NZ3=I]GQ)5W"D4$NW52BVY1]3:^OOZ:KTO_ .#]R_<Z
MZ>[I?\F--G\D"_-V)YM([)1H,\/'X)J#UF;3,=JA6M&(2T?J:6@JK^N9(S&8
M^T#E;BV.9,LOA+>_'KK?\[^J\NMX5>7&MM?:)N'';E1J6O\ +N!CN6D+R'V!
M>]=S$EKC8\=S/MK.Z;&5J$*R*\D*^^HDPT2-33.F((3JR*+N4)!M3+PRI3[]
M^^G12OZV\:?$R&XR\:.->Z]'Z:Y*Q'&+6L9KZCSNZ=4TN_+M% BX1G:IV':6
MZ*GDZXXN3Z!CY&::Q2B2:PLHQLL=PG&,S)D4?G@BI]3U];?+[1:'68"F4JG^
M5WD'6ZG4:K$,("M5FO0T34V$1!0$'%H-8V(B(MB@@SCXY@V0:,VJ*2#=%-(A
M2@3K[MH%D#81,(F$3")A$PB81,(F$3")A$PB81==(+"B"/WR$ YQ((G$0$1Z
M W11Z_\ E*<1[$/H ]] .><CBW);F]H)Y!NI<3X6!U&H4Z:?\LP !V<-2X7V
MOH+7TW47?'%=3>W+G??(-^"[^L:V*&FM8KJ%$&8D8G.XMCQHJ F25.L\-Z$U
MT?48S1Z**@^X"GS3A^5^-\2XYC[VND@PX.P[#F.N UH<X2D#,YI=8%W_ *2-
M+AL5R+A1O^XN/.)^*WD24>#L_P!N8,_5T5XW..)OB^&P>9W=V'M/Q,%B38%2
MH(=?!3](>D/0'0>_8?L'O\?S_;]/;.FMME;;;*+>5M/R77/-0T^4Z86W#/<1
M^#M=7?'D>2N]:_.;&8,3'34'16L523]^4>N$B*F8)*.%8URQ55*)7"L"];B@
ML4HD'I_9G$<*@XGXUD9&Z' ,#J8\)=(_*XX[B9,-&-06NC9"7M+07.R/T818
M.QN(N[W[M0@$NJWMD>?[600',]K]<V=^33*"VQL7-)"F AX=*%:L8]D@T9QS
M!FDR:LVB8(H-4&Y?AMT&R)$TTDFZ*(%232(4A4B$(0H>D@9RT,>)7/,CI \2
M.>^5Q=,Z1\SI02ZUB/ZCP3>^C=[7&2LT'0 -#6M;I8Z  WU/0\S>]SKMW>>J
M)A$PB811J>6S<+K4? W>RT(HX"W[&@H_3=':-# 1_(6;:LTRI94(_P"\!CNV
ML3*2TJ0J8&.*<>H($.(!UA\=J!!ATP!<))OZ,>4 G,2,U[D:%H<+B^O)87'Y
MW08949#:28"",#4ESWM!Z6^ N%];&VA *NPXP:@CM"<?=,Z=BR-P:ZWUQ5*D
M99 HE^<>14,R;RDBH'0 +B4DR.Y)T;L?6Y=*G[['+RA@%-2P0@6[N)OG\0#G
M>&KKG3Z65_0P?=J2G@L!W<3!I>URT%QUVN;FPT5>\O%=IA$PB81,(F$3")A$
MPB81,(F$7D;]>J;K*EVC86PK#%5.CTN%?6.TV6<=)LHF$A8I$SI[(O7*H@5-
M)NDF)P OJ54/Z$D2*+'3(:0'.(:T%SG$  ;DE4N<&@N<;-:+DG8>_?-8RNS?
MTGC3T9<G49J'BCL[;&N6;PR!;[.WBNZS=2K<H]?:5?ITA7;+(.(]R4/6S+.2
M5>>N45!,LS:&Z*7:J+@KB*OIOO<% \1%H<PO.4R-.MV  Z>=CSVU6NU7%>!T
M<X@FK6F0%P>& N#"#J'&PO;GEO:UKWN#,]P.\B/'SG]092W::?3<=8:N\81N
MQ-;6]FVB[Q0I:11,JS3EX]N[=M7D5(@DY&(L40Y=PTK\F\2173?,G[)KK=52
MU5%//354$D,U/*(GQO #C<@%[==6 :DZ'0V!6;I:JGJX8:BFE9+%/'WC9&[
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M%\H<>2ZGA;J533_''7U.D43(V,T>M/7 S@@'<+V6RK#./RN%3F.9=1B5ZC&
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M?I6R:6(_=4Z%GJR2L,G\&T9*.:\T:? +'*1S%^FNP.#$C5N1%NY241%,@$,
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M.!P?4R-&CY&@N;&-R6M^$D@ 7?O<:3LLTRHMD4B%]!$B?#(3VZ*4@B4H!U[
M'0!T ?0/;\,Y(22277S$DF^IN3K?U68OFUM8'8= -!^7R7)PB81,(M!'KZ_0
M [[_  __ -PBC \C',J3T-7(C2>DVJ=QY>[^%:H:.U^U."CM@M*-SL76RIXH
MHJM(RLU(17>B\E5$&3MTR534$8]G,NXW!8QB!@B%+2D/K*HY&6%W0QF[7.=K
M\-R+MS"QOFO9JP&-XN:%C8*4=[B%0X4T-.!<]U,!GJ;'3^D20W4"[;D@!RJ]
MP6XGU[AKQ_KFK&DB2:N$@)[=M6[>I55W>=GV!%!S;;$Y</O_ "@LFH])\C&
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M&R*D7A]O_CZO+MH1%/;+@U^K1*@7]9(8RKTTPO1ZZ#4KEL*L<82RK3XAWB:
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MHR<K#1IH9BQI\A8FLS=$7<GZYUK)33-"I)%JYWI4Y%V5R"JZ?RJ+TI]^_?\
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M*DV8Q[)!%JU03*5-)%(A"%*4 *!%!YX5! FVO,^F80]8^7+DFMZ0]Q AVM9
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MQTB(B.QN9?8^_P!W?[<"]C[CT'ZCCT'Y!V/7YCA2@?HM_CI#_P!XW,W\?_B
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M (?\_EA%K_-;_'1_:+S,_P!(!O\ ]_\ YC_ZNL(G\UO\=/\ :-S,#]W(!O\
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MZ>]-TZ^_?U_)9N&G:<[UWJ/5FOW[A%X^HVN*/3GKMN4Y$'3NLUF+A'+A J@
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M(^W[1$1'\Q$<(M<(F$3")A$PBTZ#\@_@&$0"E >P*4!#Z"   A]1_P!8B/\
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MT189ME(6V24>6::0?*C)R#WTH>E[]_/\U'\?GOO;WRTLN-N;5\\UIW+CC$O
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3)A$PB81,(F$3")A$PB81,(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g491933g88a88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g88a88.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1::4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %GZ^5U@X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q ;$O 8         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T#\@      "@  ________   X0DE-! T
M  0   !:.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             "4P  !7D    & &< .  X
M &$ .  X     0                         !              5Y   "
M4P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M4P    !29VAT;&]N9P  !7D    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   E,     4F=H=&QO;F<
M  5Y     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MQZZ*GP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #\ E(# 1$
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MK:&, \'! VV/';5'B&A*,%@= (_Y\[DN&')(KRU'VCK](**\;B%+]Y7Y)%P
M:J HW+O05+&A:,'[VKQ8OJ_6@HX;O^^ .VYNRL9R..^!V^7OF64RD*R;"+(]
M_P!@AE.1LD/0@<@N.QM&/YBH_P!2FH-4&:H$,"XJ34UN&U @BV\;N?L]Y)E>
M&&U'B5%*KEZD!L$DA#8ZBW3A"0=@D*\Y &!E1VUJ#JH!.?XQ &E(1(4U_>4%
MZBYJ2=(>K69GC8W31?*)!=_\2<D=@%!AW !9^7XC)+J+U4M+IA&H[ER+J\J?
M<52^Y[;M^VZ%5+EN.X*FF+(GO1:51:/&E37TQ*?$E3ITMQ#4&!$86],E,A38
M7CT7TEOL??\ M%+VQXANF5UOT>) J53@S:S3KVJ @UZBU"A3:6KIS4Z91[VI
MU=C5-J.Y2*K;\ZKP4S(,M*'"PXJ6P78J"]I$OM]_?]N1'XT^);I([:-JWPQ7
M)DBW;QM>\;SHLMJE3"X;7L*EOU>Z:U/86A#E-@TV.RB.IZ:&4N5"7 @(S*F,
M-K1#^?P_:\?BC>)FQ'+7N*\YUN=4Z!;-M4!NXY56N;IG=5O1:A ?>CLQ6Z&J
MJP8OWS.EJE,KBPH(=??:6'4)*%)*D'JWW]T/PC]+WB*MF+0*G<DRPNML*!2'
M8K<MF9T=OJ+4"W)CU"4N7&@/4I$B5 I[%-?75)S"5Q:<78B)3K:Y<=+B!/8G
MR;<MS_:.HC>*SIG)MJB73]T]3&(EUS:? LJG2>F=W,5^^7JG3':U&=L^B*IO
MQ]>@)I##M2DU2(T:9$BI"Y$MM3C2%HE_O[]?@8NUT\ZD6QU/H"+BM9RI*B)G
M5&E3X=7I,^AUBC5FD2W8-3H]9I-48C3J=4H,IEQI^,\SD )=0I;+K+CB$5YI
M"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(
M:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI
M"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"-"_VI4]47K7
M8B0K#:^G2  %''G1<]="CL2 HA;9P #@(SYLHQM[PP"3@,U)9OZO@R':R<.L
M$@U# L#P2'8QK/KM93C<K2Y *9Q4D*(<:2VL.Q V<<;&(^RUFB;ULO\ 45#R
M-],',DX'-TT,E60<;!/?(P,[8W>)R0,NRS2ES^>4?=NITDU(O8'E_A%/1$P*
MS'&#4X&"00"7"?>NSTM7RNT8"=5*K\-U-ZE,(44AOJ'>P SD@&Z*J<D\G(5D
M9VQC?WS')99.284:"2<-+TITJ)-$D$;DOL/2,5S2:V88QE53-6QU?I]XUH2P
M% S7+=CZ /LYG ]X3.GCPQ_EJGU"7Y@ /,3U+O$%6W.<8SWQCMMI'JW_ />3
M,!_I1ADGD$)F!CW&\;<Z<8Y-A""""%%P QLY<4))N7K0FIK5'B;M.H735;#4
MCIKU$NN'0E5RI4^].D=Z0[4ZB6+<3T5B%$-.8J-9MN'4:/6Z<]4HE44NJ3&X
MSC<03*-)C/*D1L>B]M]V/Q'I%B*YT1Z]7;9_AUAW0Y(DW$FL]3+.ZIUJ=.I$
MBX:-T=O]P2ID6MU*CJBTZLW=+M:W:+;4^IT5EYHW%.$]I3C<=R:M$/?L'LSN
M7:W^Y?<4Z9WP^=48/2KQ-146L_(K,R)U"Z/=$+;ICU*5(3TIO'J)6[JGU6#\
M94(L"$]66KK1'=@R)4$II5E4:,XA'D;2I$W[!@2"/OU%:<14=X6!>5;Z%718
M]O6+XDY"JG=W2B/.I'42]+0K=R&T*/=U,J]RO6).:O6H4NEN0J-39"5-S:C!
M4]4ETQ;#3S;#A;0J]N?7BK'SVONQB[_W1>9\-_6.C6S;76DWI5[;O.EVQ2NL
M=U4.X+ME5.JVLU3:<NE5B+<M;I,6D?%/!<1B958JH\YFH/NM-,NMN.H@TH 6
MV8,+[WXV%CN2(Z?K5TT4FB=%K9:Z:=0;IIEA45R'1KOZ/WE#M7J)T^K=+H5/
MH%.-*8G5:WH4VC5ZF&?#JF*M*#)C0T2*3(C/%YE$VYK?=B=_C>C6+ /%]?#S
M2.H5%Z4V_"ZI29,R\OB:X_*?J:Z5(KR:4_6Z@[;D:YIU#98I-2N:';ZJ;$KU
M0IZ%19=29D.M.OI(><0'W]N6\HO;I$PTA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$-(0TA#2$-(0TA#2$4K5KUMJ@SHU-J]23#F3)=&@Q6UQY:Q(E5^548E+9
M;6TRX@J>=I,\NJ\WIQ&(ZI4Q<>.I+A1']_E2/QT[J18=572V8%V4.1)K3\>+
M3(29S*9\J7*ILZL1X8@+4F8W+<I=-J$T17F6WPQ"DJ4VGT5A*)?^/OF*U!!&
M1QI")TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$1D#],\'C_'
M;G4$@5,(M9U3ZV=+.BU$37NIUY4NTZ<^\J-#^-3+D3:C*2V'E1:52J=&F56K
M2D,_Y=R-384M]MA+C[C:66G7$=W+\OQN:SAA\OPT[%35+3+"9:"P4IM(4I6E
M"07'O*4$]Z&+1G.>Y3T_A#C<WQ^'P.'26USEG4H\)EH"YJCV2A7EN,!>K]-\
M,?VA5%A4OIWU4ID3JC9S-2J%MS#3*O3:TBF251VJM%J5I7#&H-7JUL2I**9\
M7/AQ_-3*BW3EL5!"),FGU/*Y"NH>@,;*F9CEV(EX7$.A6$4E*TS5 ^\4JDJF
M)*D>\:'_ #$L'<8JC-.F.O\ !8B7D^9X3%8S"FL]&N7/DIL"J1/1*GF6MDLK
MV>@@@A1!$85^&GI]>W0'JWU+8J?5>W[(D4JE+M5RN4&@5>^8E=#=SR(LMF/#
M?LZ6[ 3$FVZ^77WXT9TI<9]$RHSJ\<G5G4V7=09;@42<'BY,Z3C#-F2]824(
M)%22K01LP<]@T=SIS(L?DV-Q2YD_"39$W"HE(FA!.J8'<$ :G# NH /R+49T
MI\%EX=?^HM\RZYU$H%#MF!<4VI5ZNQ&*E-NVLLU:O5Q/Q=)H4JD4R!3GJB*9
M+D.3:J^#2S,A2%6[.8=0R;WB.O<+E^4R</@,-B3/1AD21/4=0D%DIUI2GWBI
M!%"A)!!+L*BT*Z,Q6(S*9B\9BI(D&<J:N5+2H&;+<J(4H#2E!<.5J#4NVF-N
MMB>*#P5](:-;/2"UNK]FTRDVO3X5OTU4=^JU*@MACU$./S[VCP95M.2Y4DR)
M=3J$NMA3TUZ1)E.^HZM1Q"=TWU1C9*LYG97C)TK$Z9AQ6E+S4K<H(E%0G, ]
MI;!P]Q%W1UMT3E^*E9&G/LNDXE#2T89$Q4R6A5E).(EH7ADJ!_6%3AI+!3$@
M1FA3ZK3JM$BSZ;+9G09K+<F'+C$N1I4=Y(6S(CO)'IO,NH4E;;K:E-N(4E:5
M%)!.-*2I"EH6E2%H44K2L%*DJ%P4J +CL+TN#&9)F(6$J0M$Q*@%)7+4)B%)
M5925H*D*!Y"B([#G5(+Q7#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(18_J99MI72\*M=%4G4B%%HI@S/-/@PJ:VR
MQ7:95VYSRY33S34MI$.=3DRTN-K;I58K$=!0J2I]CJS\;A<-+GS)\Z7+1AQJ
MFJF*3+"4-J5,!F%"2E"74IB5,"R2IA%4N3-G39<J5+6J=-"E)0$E2B$O16EV
M=_=8FW I^"R;=Z:U"X(EV697Z57%PI,P2E42?0ZK3U29<V^*FDK5%9=7'D,R
M^H5?]-V,_'=#+YC*4IA<EN1ULOSG*\V"SE>-P^8"42)IPLZ5,$HB^ME4K0 5
M<AP*MS8K!8O %'YS#SL*)H!EB?+F(UN2'3J2Q>Y-+-4UB_#3X=4Z@-N(++BF
MR5A.%>4)(4DI4K*5>;;.#E*L@8WNA HQ!<.6_P I?]*G 96[5IO'52K5J#*3
MI5I]X?JI^I)!+I\V/:/OJ(JAI"&D(:0AI"&D(:0AI"&D(X>HD<Y&5>49X)YV
M.<8'?2(>W?\ AXCU4[['\(R22D#'ONK_ '_+0L Y(^?\0>K,?.C?6"74J!4,
MA( .3C&^<8.?ESQOSS@"X!%00X\K_2))9SL-]CY1(<"CMO\ /*<;_P#ZV?W:
M@%_W&XA'/4PCB5 8!_I$ <;D^V3^[GVSI$.':Q[_ 'OMS$*<2CD^W<#DX')&
MH>K,?-J<WB7 N6CB'FRI203E._'/T]]"H)N6?F(>I#&E_P!OC_O6/QU&;'IT
M2749+R&(T**[)DNNN(:998CH6\ZZZXM24(0A"2I:U*2E*4DJ4$@D2AUD)0E2
MU*4$A*1[RB2 R02 27W].]$R8B4E4V8L2T(EK6I2RR$)0-2BHU9@*FU(\G'C
M#\53/B&ZU5RYH,IQ=CVZ7[8L&.MSS1?N2$^$R[B2VM9;1(NJ8P*FXH-M/HIC
M-$AR%+>@+4OV/X:=$'IW(OS6, E8S'R4XZ;,6E)ER)(*E2T(6=*Q,$I2=8TA
M(F:TA:D@*/S5\:_%25U=UFG+L+/4,HP$V=EN$&O2G%9BD:4ITRU+2TZ8%&45
M%*B@RG2"XC)'P\V?<_2>W(M=G2(]*KO5RU*?7*@Q&1)A7=:=E)JAG6U1#/;+
M<FD2KW+#%TU=,22EU=%BT6FS(<.2TB7-P;J#&IZQSU02I:\JZ;7,EX%<R7+T
MXS$SO=Q(F E04@'V@EO=JI C<70>5S>@NEY"L0D2^I^J<$C'9MB9DQ0Q>38+
M#K2<)A5( "4&>%( T+5JEAU:5!*8VR^$BB6A6K KZ*I;E-KM7BWQ4VJE6JS3
MX55G3_BJ=1I\)UV7+9=>6IB$_'AO%;CCDB1$>J+ZC(G.E6E^L<N1E>=*P:0!
M+FX9.)EI2S(02H:%T'^)[IHD*2S *-H]-]$9S,SO()>*FA17*Q"L+,*O_,4G
M23-1=Y?O4)TD $D QC=UUJ$*V^N]U2;&0]:+]OL4&.J+2%_=U+J5P,4FE5@U
M"=3J>8C4V$XP]0:<]2I*_A7#2Y4HMH<J"GSDO3'3<G'9.,3/"E*GB8J64:5+
MEA"2TLZ@PFK4Q2$D AW*:@X;UOUECLISC\M@YBDC HE3%8=BH9@5J2B9AU!P
M/R_LIDQ4Q3*4#*04H/ZDZA/$/8U5Z<UREWH]'I*;5ZK/5^O4<4+UDTNW[BB5
M1TW=9 9D1F5P%T6=):G4F&"_$^XZK"BTZ;4VZ?)F+WOX9Y[/Q^#5T]B7F9GD
M\Y*4R%I0?:X!25 3BZF)DB7[Y*7&I-"[#Q_XV=-R^F\;@^J\F2B5D74DQ253
M,/-FKD8'-,>1,S"4HZ$F7[,RI*4!*2@$K *0DJC:U]E5XGV[UMRH>'ZX:DA5
M;L*&[6+']=:BY/L=V6E,FEH=4I7JO6I4YJ8K+1]+TZ%/H\:*TXFFR7$:=\8>
MCQD^;C-\&F8<'FDQ4W6$@2A.U+]HP2-/LU4T,YU!14!OZ(_#CXF8;JK(!TY/
MG*./Z?D(PZ$XA8.)G85 $N6J9[\PJGI4%&8-11[-4HI425!.Y-)R <YSWUI^
M/30??O\ 6)TB8:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D
M(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0A
MI"&D(:0AI"&D(:0C3CXI^IU1N_J54;33(4;4LJHB!$@!U2XT^OQFD/5*K2D9
M"'7H,IQ=)AMR$._!JI\B5%<;5/6AOYJ?BK\5<VQ?5.'Z+RC,)DK(LH!7C1A9
MGY;$3\RE(,U>'GSY8*C+2E@J67"DZ@4@%SZP\'.B</A<F&>8G"RYF.S20C$R
MIF(0)GY>3^:,DRI05I_ZJ$B9K#$ @:2 5*L=:EZUFP;@A7=;;RV*I3WDJ?;2
MZM#=7I_G29E%G'S>1V%/9"V1ZJ5_!R5-3F"W(80M.@O"KQ2S[HKJS+L7(S;$
M2<MGXU/Y[#S9YFRILJ8E2#+65O[JUJ2 IG26(M&TNK>DLOZDRC%83&X:2I:<
M-,_*342DIF2)J 5R2G2L%03,0D:00% D5!+[V;3K<"Y:%1KAI;Z)--KE(@5:
M!)0H*2_#J$9F7%=!22DAQAY"@4DIWRDD'.OLKE..DYG@L+F>&8X;,L/*QDL@
MN!K0D,DL'3W\KT,>!,3AYF$Q$_"S@T["SIDB8]#J2H@@IV+BOTBIM7.."&D(
M_,_+C14+=DR(\=IM*UK<?>0RA"&TE2U*6X4I"4 %2U$X2D$G8:AR7"027:@/
M^WHX?YQ2I24U4I*1RHA-KU)V$4[3[XM"J2FH-/N>WYTUY?D:BPJM"DR%J()"
M4,M/+<4HI!5@)S@$\;ZDI6EM26[U;TI\?CV'5E9A@9R@B3B\/-62P2B:A2B>
M  23%5Z1W(:0AI"&D(XK.$*.VR5'?C8$[[C;WW&W?2(- ;6WMZ]HU2>.WQSU
MSHC4V>E73F"U'ONH4INIU2ZJM3A(IUOPI/E5$;H426DPZQ6O2*);SLYB12Z8
MT[##\6I+E/1XF29)DB<R4J9,64R9:F6A)"EJ]W>HT@*9S5V+-0C9_AUT#*ZL
MFS)^/QDE&%D$?\O+F#VLXL2 *@I#Z22') +B@,:ED>-+Q,MU,U='6N]Q-4H*
M"5SHSE+\WF\V4T%4,T()R<*:-.]!2<(]/TLH.8HZ>RH)*3A)<T 5*BL*!I4J
M2H%[GM2C1Z 7X4='!$B7-RU:3[J%@3UJUI"2ZBHU<J 8LXM5R(VY>![QW2>M
MLQ[I;U,9@,]1V*<]/H58A(1"@7E#I[174FW8*0&85P0F3\<]&@H$*H0VIDR(
MQ";A28[>'9_DB\N Q.$*IDE;^XIQ[%3I"05NHE*G9S5V#N1&B/$?PX_X57,S
M#+T3%9,M924*)6<.2H:4:_\ ,%:C4I!]VKO2S;?VH4BQNM'52A7I:3UT]/Z1
M>M=H]H/6ZJFPZ]2(E D?<*TJ3-<8A5>%6)%.E5SUGJA&FP9$]Z*U\33U0V8'
M<E]+*Q&"PL^3B):<3-DIF3$3"6:8-0"2*^Z&<LRGLX(-TE>$6*S+(LHS# 3$
MR<3C)*)ZDS@$R$HF)U)!F!1((20%.@->M7NE'^UWZ)*\P?Z:=5V$A(*"VQ9;
M_F))R"/Y7L^7 P<[Y).!@#/7_P"$LR8-,PQ/_P!:Q_\ \$^D==7@IU0DD"?@
MEL?U(65(5W2JFH'8L*;58=-TP^T@=ZP^)KIU85(M8VYTXN5JL4)2ZT\S(N%^
MX%TZ34:)4WQ"==A4]A4FF&BBG1GZF%JK*)[\YD,&.U3B^GIN$RR?C%3#[5$[
M1[() 'LR0"=9(+A1!9FM6\49_P"%6+Z9Z8Q699CB)&(Q^#EX#$SI6%_Q94J3
MB5A"U>U!#F4Y(.@!5J7BC?&;]H5=-L7A6>EG1.?#HL^VY"Z;==[J9@U60W64
M!!ET>W8TQ$JFI735?YG59\^'*4F8)$.*S$?@JEO=C)>GDXJ2,1BRK06]G* ;
M6*^\5.D@&A#?J ]YA2+IX?\ A8C-\#(S;/DS),K%+*\/APE_:24^\B8M95+*
M4KH4A(<C>I2->=*\9_B8H]2-6A=:+O>EEU+BVJG,CUFG+*3^)'W/58\RE)9=
M!*5(1"2I/F)94VK!&3'I_*52RA6#0/==*PI86DLP)5J#D;Z@1=VI&V<=X7=(
M3Y"4)P"9 2$H]K*6H*!5[NH^][VZB"WF]MP'AS\1<SQI]%NJ_36X8R;9OM5G
M5:U*S5Z6U)31)T>ZJ%4Z3'K-'6Z^\Y%GPY#R$U&E+F+7&=7#ELOJ9G-H:P?&
M85&2YOEN(EK]O)P^,E8DRU @S)<N8-4M:AJ9)(HH O6E'/F'Q6\/3D S'*9.
M,2O"YME^)PTC$(F)7/PYG25RPLR@IM8*J(UAR =56CSV](.A%YQ^KUUQ^H]H
M-U.T/#]5J=4.IE/541!H]U$5Q-(MRV:#5GT^2IP+VJ32C!E1(\@OV[&GOA@+
M 0/575'7^%S3I/+L+D6(1.S#.@C+I&#D$JG866H>SF3U@ %)EJ"@E*M.H:3J
M:D?)3HOP>S#)_$'.<?UQE\S#]/\ 2.*7GV*Q&*=$G,%B:HY=.P:Z)Q,V<4H$
MV4"R%)4 KW3&R$7A<E^W49#K:ZM==Y5IH&-3FTI^+J4Q3$&!3(#8+28\6"PF
M'2Z<"MM$:##BM+4GTW9",:1EV&Z4R*4N8%#"X6658J<J6->(Q6E14I0UG0E4
MP*( *A=G#1MM6<XOK7J?\O*)1C,WQB5S9;E"48'#I$N7@6*::1I*U.%!0"=/
M.\CH5TX:Z7]/*7;:@E=66XNHW%,0' F=79:&DSI#8<2E0C-I99A04E*0B!%C
M-@#RD:\XYWFB\ZS3$XR8HKU*(ED@^[+!=*!R #4\Q[!Z;RA&19/AL B6$*EH
M!F-_GF$ *6:.Y(-*T%XPL\;_ $XDT62SUBHS2A$E+IM!O)M#:DI1+*1#H-?=
M4E./\KY6J#/=7ZBU)50DH4AJ.XDYWX;9U*1B9N58N:XQ"PO!RU!D2YX(0$.2
M7"@I2AW!#"D:R\7\BGG+T=18$(1B,MEJ]O,+DJE*2H*60 ?>2'2QH7!N#&MJ
M[8SG5BPK@Z*MP6:C/OFJTBH6!*?JL:F(M;J?#=:IU)J[+DIIR)\/<E)==LRM
MQWGHB9,.5!2S,BR&&I V/F4C'=)9SA^J<#JDSY15)S1<E)F(7E^*T@B8@CW0
MG2=*DH47-&H^@\ K!=;=+YGX?X[$2%R<VDZ^G9F(44IPO4R]4V0#-!)0F?+D
MK 2['0I!NH&A?LF^C_4&K>*"I7G5*=.MRB=%X-ST:Z&ZFV["?=NZ>U4+8-J!
MI\-+>>IKR*G+K);#S5.D08,>4EI^?%SR^-75N48WI7+LMRV?A<3-Q,N5/D&5
M,"SA<.H'< $+UDC2HI6*T>]I_##X:]49-UWGF=9M@\9EN#RH3\OGF>A4M&8X
MZ4KV*YB0LNJ0=*9B9@<+(2DU  ]2+"VRA"4+2HI2 H)5YL* !QD9X^>#C&PX
MUYA$Q)(2X*B VP/WY1[]% 12A(+%VN6-*$=X^^N2*H:0AI"&D(:0AI"&D(:0
MAI"&D(:0AI"&D(^,A[T&RYCS8_HY )P"=LD#MN2< 9.H*@+W- &N;MVH#\(5
M< )*NR:J]!1_)XM7<'7+I':53-&NSJ=T[M>K#T@:7<%Z6]2*BE;J/.AI4.=/
M9?#CB2%M(\F7$'S)R-=E&$Q2Y?M$X><1OI05 %G%1=^:=GJUCQ?4N08&?^6Q
MN=95@Y[@&1BL?AI$Y-0"%2YDU*@HE20E+5U!R"0#<:BU:'7:;%JU/DQ)L"<V
M'X4V!+9G0ID5>[,F++CK6P^P\@A;;C:U)4D@@D'7 I*DDI4DI4*%*@Q!X(B\
MRYDN<A,V4K7*6 J6OW66@ATK24J4DI4"Z2%$$5CM-1%<-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$>>;J-+EL=1^H+,T*1*3U!O3U_4QZ@6;BJBBHX&Q4% CVSC]KS'7Q4\</
M;I\5.M\-/04+_P"(\7CQJ%?:*P8E%*=Q*,O2H(%-1<%RT?0_H'#RST=TXM*P
MI!R3 L$L/?$T.]191(()V-A%'_>*% ^92B,'_M#<#*?Z.<<'Z;<:U" LOIJO
M0LR@-YX2HR"1Q[4(*@]0XWC.)F%=-; I4:AAI(42>0X8C<'O&\GPPJ?/0SI9
M\227/Y"V^MKOB$Y":73M^,& 8N,;<XVX^Y7A<C$2O#_H^1BTJ3B9.09>)NJA
M*ILI,PT%!LW M'SAZW"/^,>I3+*2A6:S_P!-@02"!V=_(@B,@-9_&+1U57JD
M>CTVHU::\(\&E0Y$^8\I)4$18K*I$AP@ D);:0M1(!.PP#C!E*5+4A*;J4!4
M/0^O+6?R,<4Z<C#RIDZ861+EKF*:X" 2>; .0SD6M&L.Z[YO'KO><:APW76:
M;/GF-1*(VI3$:+' 4I4^IA("9<EMAM<N2X[GT$ LPPE2?,O(I$N3A,.J8M ,
MP"ZAJ#@\$\@TH-^(T=C<[Q_5V:C+L$N9(P_M%)&@E!4@&ZB"*L-57H&3O&=G
M3[HG9-BQ(*F:-$GUR&XU(579S29,TS1@N/PU/%P0$<I;:B!I"$Y \Q4I2K'/
MQ"YZ@I>F@LE(3SV/P<^;VVSE60X'*I,M$J4A<Y+%<Y0=>K<I4?>32K)+5W)>
M+RZX(OL-(0TA#2$00% @[@@@CY$8.D+WBQ?7SH=976[IG<UBW138[J:K#4BE
MU0QF7Y]OU@N),"MTMQU!4Q+@2"AW+9'K,!Z*Z'8[[K+G:P.,FY=B9>)E+6#+
M6"4DDI4DT*2/])!(/%[B+MDN<XO(<=AL=A%J29$T*4A)]U25NA8*;'W5*+;;
M,:QX_NH5N7)TNOBZ.GEYQ54^YK1J\BCU9@J44*>9"'8\N,HC+T&HPGHM2@/@
M?YQ"F1G@<.:W-@ITK&X>7B<,H%$Q+L;I4 =0(+$%*@016L>Z<CSB1G^48+&8
M:8G$!<A)F3$4*%D5EFE% @N['W3N3%Z/!M6JH/%1T&11%/*GN]1*,T4L)*WC
M37TR&*X?*!DLIH;E2,HX 3']12CL-6_J"6C^DXU4\I"1(.@ !*C-U),L7J":
MMN[@T,8OXE(E#HO.$3G#RP92IJBM(FI("4M9S8"]"*[=AXT.EU?Z'>(GJ';M
M7A/1:1<MP5>]K+G9"HE2MFXZC)J;"(CB0 IVCOR7J/4&CY'69$/U%)+$F,X_
MPY!B)&899A0-"L3(DHE3T,DK2I%-3W*2 -)J #S;K^&.?Y=GG3N PAG)_,X+
M###S\+.4%)]I)"4E8EEFES"RDV #V81BT*V!LI9V X4<_N!S@<X./TU?ORQ#
M )#;!O,!S=A?EF?:-DR]"4I EI  8!(9(%AI2U UAL#W,;"?LU^F=;ZE>(J@
MWHW#DBT^E*9EPUJJ%M:8KE:E4V73K7HK;ZO(CXY=4EMUI;6'/+!I+Q<"/784
MO$>J<9+E9<A'M09F,F(*Y)+S$U!6H@$*2D'2DVJ7#@4TUXP]09=@^GYV2X>9
M*3B\?B\'AT2I898R[#3 K5/%2L I&HD@*L:1@C<5<J2[BN)RMK=^^GJ]6G:R
M7L!\UARIREU0R0D;234%23)_I!XK21D8UD^%E 2)(E)'LT2)2D,S>\!] ':]
M-JF-E9&9 RC*S(!G X'#I6E*_<0R0WLT@>[W(-K[Q5W2V@Q;XN@1:O/?I5H4
M"G2[IOJO1T>J]1;1HWI_>3T5"O*'JO4I$F';]NP_,E<ZY*Q2(@(0\YKBQPGB
M6B3AY?M<1BY@PTB2D>\N;,-%.*Z)825S&%4@U9C&*>*'6^5^'?2.<9_FLU$L
M83"S52Y2UZ"9Y03* :JM"JE(J:"A8&[U4ZU]2;EJL&!;%RW3:-*7,9H]E].^
MGMR5VW:'1F9<M,:CT"CTJWYM+9J-7>4Y'CR*K+;?JM>JCIE3WW7Y)0-LX#H?
MIKIW)58C.\+*QF(E23.QV-GCVB)BE(U)3))'NL?= =@78 &GP<ZH\7O$#KSK
M)4W 9[C$S,VS)4C"8/#3U>RER5+24*$I*SI4$D:C38$#;9A0*(AVP.F_0?J!
M5XU2MJW+GI3W4*Z?.\Y<0NEZ94T5I%,N%A3/GH]HL5,6=$J4IM4UQ%"76)$^
M;28Z:5.T;,R[&2SC.J,DEIP*E39L[!X=*?\ H8'#K,HS$H)83)@DE:5)+>^%
M,YIZ:P>8X.;)ROH_J>9_5A*0B5C<5/.HKS">#,$I,P?^3(,Y*-)?_$05EK1L
MSZ:>$KHGTPJ\:YK;MR>NX&&S\-4:W6ZE6G:>74 .? ,3GWHD-X#+:9;#"9J6
MU+;3*\CBPK#\SZKSW-I!PN,Q\V9AG<RA[J5$64L"Y-SL222(V+D?0?3'3\Y&
M*R_+D)Q:=9&(G*,V<#,JMEJ#U+U;5L203&3&.WSSMM_#'^OYZQMAY>5'\^?*
M,RCI+BMNBW71JC;]PP&*I1JM&?AU&G2DA<:7%DM.,NLO((_$A2'%$;@I6$+2
M0M"2.25,7(F(FR5&7,EJ"D+30I(+@CUCKXK"X?&X>=A<5*3.P\^6J5-E+ *%
MH510(-"XI7:T:X.O7A#Z)=-+,FWI:R;@I=?B52F+MRFSKDJE3ILNK*J##D>G
M(8DN.2UX:3(DL.RICT>"J,),\.4EF>P[F^"ZHZHS<HR:7B$SI6(EJEX@*DI4
M584:?::UFI( &@@@I=1N01K3,NA.B,A$W.U8 252@GV2!-4)*,4E3X:;*E
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M%16D^I(2I.4]'9IA\ISS#SL2'ESTJP@XU3V N;T:Q<$\1@_B%E>,S3IK%R\
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ME:X8KAI"&D(:0AI"&D(:0AI"&D(IN\+@3:EL5ZY5QG)C="I-1JSD1GS>M)1
MA/RBPR$-/.+>=]((:;:9==<<4E#;:U*"2A%MI/6JDTB.C[ZH]<<FNTLU5J/0
MZ7.G(<80JHJ=;":I%H54C2$0:/5ZMZ=7H]*$F'2JD*6JH/1DM.HBOK\OOM%V
M*'.?J=(IM1DQ_A'YT*+,=B>?U3$7)8;?5%+OIL^JJ.7/24X6FBLH)+;9)2$
M7&WI\ODT8I]1$^;Q5=)-L^6F1"!YO*3BWNLVV3D=R1@:@U&C0%!9 *B0\L Z
M@H"Y+@)H7 )(B"*A8)U()*4[+*AH()%@ 27.XXCI?$_X8+=ZI*3>,&X8-AW3
M3J<IB76Z@V'*%4Z;%4'4-UT!;+D=V WZWP549D)^"B.RT2HTR.W'0QY_\9?
M')?%N5^93/.4Y^A/LD9C*E^T,Y * GVR4^\I@@(2ZJ:B;@/MGPU\4<UZ&G'
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M%>F'5?)OQI_&!XL9'XC]39+E.:IP^"RK-)^%DRY8  1(F+EZ2 D)"CIU'0-
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M/'6TE$MR$9"81=8,HM)D,*7V,;EN)P9 F(4 P.L?I)JX?;8-N;/%VSKI+/\
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M2DFI#QB20% !62, 8.3D<<\\;@XR,#!R =9" DI8@$&]+W#,/@POQ&T5I25
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M6HO'12EC\,'BBIR#_P 09"#^H^ZB=A0'%@?]3#]1)6Y)C'+P_P HKZ_=!4'
M ZR]-FA@X4$_RQHX\H*<*VW_ !$DYS@Y&KAC4(_*8Y1?WL.I2O?6Q4&)]URD
M7_2D)%.8U%X/SE3O$_H.7,#I3U)EI!2 DN,2A2:H"5%E"Y)!<IJ+UOXS)?I^
M*GQ!-E6W\Y%:"BK\9P'&E$94%*!\RE'(P<'<X&-=?+?_  K ,5)"4S"E()#'
M6Q) +*8"R@H [ DQD'XA)\Q'C#UY*"AI5FDF8HK2E9U*P.$*CK4E2R2:@)(9
MB P<"Z]0D*'V:5%\N?2/BZGI*?,<%0Z<S$!9//"NQ&W.N):B>J HGWOZ;+:@
M>QM1A\+L6WC/L:N8C\)F4$$G1XA%24L0Q]CB4.14&BE"NRG9ZBV'@Q?1,\7'
M0!#A)]3J#300VI3.0*>\/PJ:4A2#^!(!201@[!1)UV,S=&0XZ4"?9KD@J"E*
M4[8B<H%U$J =2G8@E[Z=(C!/ /&3)_C)T4E2P K-9:2$2Y:' PRE,\M"%!3I
M"G2H4!>L6GZQR?3ZQ=8"?Q$]4NH8).%*RF\:T ?,K/&,<@G'F.NS@YBYN"P8
MF+)"9* !^D,D::E+ ^Z *N7J:EXP?Q.FJ_[1NMBHN5=29M+)T(*F1C9J4"H-
M0 !J)"BQ),92]5W /L_O","DJ#G4OKLHH\Z_*#_*>J(\W[0((0E \J1C8G_M
M'5IP4U<O/\SG2U--$N2RJ%Q[M"D@I-2?/9W:-Z=>E0_#/X1D5'];SJ80Z@!,
M,_')"@!1TI- 0P#D-4Q\OLXG [XQ.G2> JA7L<I4I)/GL&X/-CRD?M $$9P!
MN -M59^I7]-(U*($Y*V)+!1Q2'/!HHAK#>M8MWX5SJ\7<OV"LASD*8D:BG+P
MEV!8$@E]+!C6H$8-/2D_Y8_A(1+\H\Q 4"E21@_12U\G<$G)&"+Y(6K1(]XA
M\.2?]-4ERUG.E)MM[MS'G_J&<5Y]G:ULM2\WS J4I@HE.+FI%@-W! 9WU*=@
M8VP>)H#_ .Y:^"-[)*W.IS *E**LI%H=9?* %**1CS''EQSSWUBN0^]U=F0+
MG7A,2A1=G25R%$$BU4@O0A@ =H^]/X0/>Z(Z%47)7T1@@HG<##26H[#T;SL8
MU-#(4D?]HI"@/F<'!S^$@'(*<$'!3@XUL<(3^72@ @)0 D J)&D4#N5&FY).
MYCVI_P##ZW94M)2@[I"OU!P:@LQ)K8N&:/8]X"SGP7^&$_\ Y%K#_7[CBY_?
MK06=?^+YE4G_ )W$5-3_ -55X\H=0@#/<W L,QQ8W-IZ]S4^L9;:MD6>&D(:
M0AI"&D(:0AI"&D(MW6NI%+HE5E4AVEUB;(AI84^["33/029#0>0C,RIPW2H-
MJ2I1#11@CRK4<@(1UG\[=))Q]P7'^8H(_C7?\9T^_O[_ &A#^=ND[?\ F_<>
M_P#W:%M]?^7=(0/5NDC_ .@+C_)-"_V[I"'\[=)_T!<?]FA?+_W[\QI")_G;
MI/\ H"X_TH/^W=0_GO\ +[I"(_G;I/\ H"X_TH/S_P#?N.VCT>O[P@>K=)'_
M -3]Q_I0?G_[^[=_J/?4_?W_ 'A#^=RD_P"@+CYQ^S0O]N_[](1K]^TAOJ%<
M'A\#$:FU2$M%\VTZIR?]VI;PW'JH !B5&8LE17L/( /*?,1MGS]^)8__ ++,
MZ2D*"ES<(DD!@L">A@HN"H F@JSFSO'H?\,$@SO%3+E-J3+P\YP0]5()&FA#
M@)+NQK1P[:#OCE# SN!CGW(SW[_GOC&W/R[F8916HG<B][4>FS^E1Y?5#\N"
M215_NS%K6[=HW6?9<7G%MSIKU0;ETRI3S*ZF-/(<I_W:IM 9M*A-E"S-J,)8
M7D^9)0A2"G!"PK*1])/PHH?P]Q"6)(SW&'WKA,O"2E@$5("=)TU8%K7CYL?B
MXD%/7>4+# #I?!.URV+GC9+;BY=G#4<[1OYW*3_[/W'[<4';CG_EWY_ZM>H?
MOZ_Q\Q'D^.7\[=*/_P! 7'^8H(_C7=0_G=OMGIYPB/YVZ3M_R!<6_P J#_MW
M/^/IH_G\#_$(?SMTG_0%Q_3%!SV_]^]L[_Z]3"'\[=)SC[@N/]*#C]?OW&D(
MH[J%U.IU2L.\8+-#K[+LNVJTRAQY-%])"ET]\!3@9K3KOD['TVG%XSY4*(QK
MDE?]1'=35#BO,6S.BV4YB;-A)U;-[AJ_UC4\7LXPL9.5#Z.'(!&0!^U@G=.0
MHC.KZG_IJ((<)+%R""XM\Q9^\>4 HIF2RDD S2;D!C-2Q?XL>SAXO1UTK[->
MN"UIL9B7%;18%L1PF7Z"7' TU*"7DB/(D)2VX%!24N*0ZDY2MM)3OU<.^@T(
M=1(%15PYM79S=N8SCQ$7JQF4%S3*I -:LP/G_!>]#'Z>F-=9@].>M=.<8DNN
M56AVZAIYKT%,1S&G5)PJE%V0TZ$J'X4%AIXE>?.$)'F'%B"?:2F)!"@4D.PI
M[Q#.Q((M6*^D%MTQU>*N<-):H8,)G)W>@ V[5L:S)+2V'%'SH;=2XL(.ZDHP
M=@HA)40-PI0 '?79)GA3) "7H7_]/UJS['BT8=E#?U7+ZL?S4NY87%:C;SWY
MO>7Q 5AJK]4;CJ+,>1%;D-4=2697HI=2&Z-!:)4([TAK!4T5@I=5^$I\P2H*
M2FF0?\ 5IK8UM[UB#1C]/,1D_B H*S[&$,-4O#4I73)0#1Z@-WI<;1-L7%'3
MT6ZEV\&92I:[CM"I*D!+!AM,.26F&T.+,A,@O.+B._A1%6D)""M:?.G$*+ST
M$L6"P"34$BX<79)'QJU^?"3C_P &=1(3J23G&$_2P(I*-:@L=)L]2+U:WMGS
MDP[JMB4ZE;J(]Q4=Y2&R@K6EJI1EE#8<4VWYE!.$A:VT^;]I0'XM<LQQ+6]
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M\8W(FM;'?Y;#;ZCWU4Z:U9^Q]:,Q?O\ 6 #5;MY!]NV_^P$! K)&U/;R,?\
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M[*RVC<\$A"00,G./,#P#QGY:^.F-D!4T%9 *A-(!)<I.*Q!=Q0/6[6W,?;3
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M*C@#_)D$D#!')'-6:$#))H):B:%RWOK(KLSWKZ,(P;\/A/\ VP=$C<YC;])
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MY8OZ%XU)BKC(_&H>;()"@#ND^_SWP.V,<:VW-P[(4.$%P ^S4VIRUX]KD?\
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MW[,CTJK2(*:HQ2JD_9-"9@5%ZF+D14U%J%+6U)7!5)C)EH:5',AD.>=/N_\
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M,HZO!1TUG"BD!L#-K:X'9O6X[1['PR3PG88 /F[>_MC'.3C(_/6D5);27-$
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MX;/LWQN-RW%9=AYF)DKE8R<J?+3B52TA,A:$S=,Q)5730L6C.3KMX,NMU-\
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MS#,F+F9UB$Z%G4E)PV$ESD>R2PT**AJHX*@+ 1\XOQ8X5$OQ"R;#((EE?3&
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M*G*(N"[% -0$@%BH@:AS+Q8P,[KS"=2RY"E9#E<A>68A821B,5+Q)(5,DRR
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MF6J%((CNU"I!QMV:T^Q'IKS(1,.9Y)T[A\3)&+QZIZL.HL@2 ?=61J2)A]X
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M=<"#59$5I#C<!@W?T^JJGIBBM/IQQ#H52D%9\R?-$"<%U3055+852 &) 84
M9][#]XK63.<3"[,:@ T)+T">:O?UC(D,#RX*58(((.""DD9!WQN=L'L2/EJ%
M  D)2 X)( K7R&Y^=VJ327!!_P!+ 4]T,#0)+AV_S,3\08QUM:UJ]&\0_4:X
M9-&G1Z!.HS35.K#C*4PICKM"Z:Q?1CNA?F6XE^AU-MX%"0#$425)+:E5ABC2
M0"D@'20#Z[L_G7?M62ZA,(!F!B[,15RPLXXV/FT9!3(GGB2D);4M;D9]M",
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M!#4Y1>:E38<>%50AY3L6H1'VVG42POL*%Z;V-*%FK0/O$@FHJY%!:[5[LU
M[4';Y_\ DL]'!L*#=A'N>K'5K)/.=KUP/[N,]M*!Q[U-N [[$CS>Y:T1J/84
MV [@?QY1=6R[ MVP*2JB6O"GPZ<N6_.6W/KU=N*294A#+3I^\;CJ56J*F2F.
MV&X_Q2([!#BFF$./OK<, [LWQNQ#7]' <7N6DDD7- #\_(;LS/YQ5OHJP0//
MQ\N>-]^.V<< ]N9=B+5-PQ(=AR2]]R*U<FD,=P?(T^P[/6]KTMG;_2R%0>H5
MV=0VJG4I$RZX[++E*=1$3!IY1#HL-U<9UME$IQ3Z:#$6I+SBDM+<?\F0X B
M2Y%6<T)]T.2"2=_W/>\DN !9P"S.;;;;M%S?2)_[?S! QL-LY^@W(_72_P!*
MW<FW=@&#E_D(BHOPX9G:MF< 5)(#_"L6=NGH%TVO.N3+CN"CW!(JT\1A+>I_
M4#J%0HCGPD9F$P$4R@W/3:6RH1H[0>6Q#9,A[SR'_/(>==<G30NXW9PP_DN*
M?5X/;?9R*CN];/1C3BSVTO#P5]#KUI*:)4J7>3$!4^!-E-L]2NH$U$UJ"_\
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MG&WY\@Z[3@CD!BS%G[FNP+T +OY62H9Z$[GCRNX<&M:#B)S@'DY[>VVV<[\
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M2*H5.(0TPMMF?6(\-QU2T1VGFZW/_P ^D0HE1CTI^J49FH].HHX8@*9P'"J
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MR?"W/,KF_F/^)9_4V3SL*D%)E##R\)/DF84LZDZE*=F910QJ0=G']'&!D)&
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MQC;1^:,XO6G)?NSD[T O BK"H85;9KC>A=VXJ]8#<9Y[XW&_._/;')(XQVU
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M-Z\"U6;FFS6$/,G]D*&2%$;C<)QYBG<;)R"3P,^V-'#-:E#S5M@*4)JYWN!
MC>]7N3W8TJ2-Q2E>8DG)4.X )QN %9.=L@@@;#Y$;)WTJ=RQ;YN[!QO1JDU,
M &8MO8TV^(N2]A2KB';/SQOW! SGG/'(R!@;XYCB@>OF&Y'Q-=N&#35Z&S.S
M-O8A@ 7LX-3Q$$@8W!P,DA6 !D GG/E&<>;<=OH-VVXL^SUH-_\ Z6:C1'.P
M-J/2[?2[/0VNR/,I!(R,)*2H>89&1E.<C(W!('F!R-AJ0UA2PO1SRWZN6/\
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M]XG([9'.<8Y)[\D$^^0!L-*%A1[]GJ2Y!)M^UH,6>A9F-;49G#$?W?:)//\
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MJT(%Z/0 W['9HD#?]DYWW_7C!R-LD\?KH&=R&J!1W!O9K;48TH^\%[ N!6K
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M;YY<\;4W-7HS I=W-!<VB3:E^:E]N[L6 -G-&K$>V3L=]P=ML[$Y&,9SN?8
M;Z7?L'2"0>._ ML.]XJ*-REZUV-!>XJUQO$C?')V^G.=_??Y;8S@\:'R&FCL
M7/)%RSD,]'85@0;FIL 0:[;L_._<7@.XSW/Y=S[\9[]^^^   9]Z $T#5+]W
M:E*_(SM0V#]]@WG]@L28Q@#/ .^1O@'Z @[[#]"-SJ7[ ;.7!MS<</< AQ#?
M<DUN"'=S:AH!ZBUHD@X[YWV^OR_NSW.ZNZ^Q+-NYH#1C38NX=S38D&LX#-5N
M]WNX>G(%6@>Y&3C;D8VQOG()QOR><C;.HW)I3NX#]VJ*L0SU=W),.!V>@J23
M1N'#>G-!$C '& <CN3WW.>,^YX^6!IM2SL36H8^5A<<VH6A<UJ6[,_#!W]+D
MU:ICB<C<')VR,<X&/D3N1]/R T(V>HK7>Y)#TWK46)8Q(9B2&!)J]K%J<-QQ
M81.=\;<'8G?.<_P^NWY: _44=B*D<ON7J[MM4PU"?FU&'?DGRWN2T,G)Y'8G
MC8'O\CG;_&):M18$6H&LY)#TW-.UV;<\#E^PJ#1B']>6_.,[[9YW.3G88WWW
M[\Z#?RWH&+5 8T?9F.PVB"U=OG4.VYIQ=K<DN^/;CC\LX/89P,#/Y9TN^[AP
M6W(;RV%JO1S6)^0=C7Z'R-6?DAFA\R,'&X&YSO@Y'?![<9&>VH=P7L*@,S@.
M_HX?S&VP7!% ]VH+$7XWKS=JQL>X X!!XQSQC8'&,[;\[XT' IR1\W/8M:@!
M-XEZUJ7L0-ZBE;U>]6>K&&2$CY<@8R,'^! ]^#DYU-&+48_%SN78BC.7%#R(
MAB]:N]=JA^'>KLUR*1. 3N.-O\9YVQ\N<$]HK7@.268N1:GSXW#"%K/5F[@6
MXN78W/ >K.P5]<]]M]OX;\#<\:'=B[-Z,[;>CU?<@4("K,U-SSS4<VNW>L3C
MZ=\'OQ@YQQN,9!'MMH:N]RPWI8EZ>O8.YLX6H]*G]A7S-&JYOM:"_;!K5V]0
MNC%QL2*<+=Z<W%=5T5J%+?DHFS*K-LJLVI;JJ<RU#>9<$5RX*F],=?EQ5L,^
MG\.W)6XM"!%F>A/:IMMY#X6H\ZF=VJW>GQ8AGW=S\,>[T\/O4JJFY:K2&[2E
M7)6.LET]0Z55DWS>-F5RVXKUG4JQ+)J-)N2BV_56S/IM"I\EJY;:JEN5:C5.
M+45Q(U0;5&2Z_2WW;=FJWGY1+MW#6\ZDFIH26#\TI4H/AZZHPNH=BUUJI6;'
MI](@]-HE\7)3*G5X:KT@632_//I52Z3R:!4K)5-D7.N34K;NJCU>VJC;<1]
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MNJ<CVW <5^'[YKTAI]M*DD*ATMF;,4?51#8E\V<9C(RN1-,L)5/F,I"ZZP0
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M*1R .,8YQLD#LGR@8(P-MML; #?2G#'?XWK05 !O=N8GR- 2:N 3YBI._-(
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M?G4VWM1J6MVJ*\.&)9F@-@SN>Y/-JC?@[[O$8'&#[[@XP<'Y?[O;&=#M4,S
MW.Y-!1]B?*L0#5]]N79NY[M8VXB>3QS@8QM[\>^_..V-CJ 2&;NUK/<"K&[D
M]R\2U*V?CY/1PVP.[U:((.,@'Y$# !&V^V.^.V1CG R'UKP>X!JHEPU'^)H/
M?CTVJ!1KOY^L3CN-SN1G@9_+8?\ #N=*ML+79SY7:];7>CEU'W%&I6@NYH]
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C#X*)D'T&P4J2H$#!"D$*2=NX*0?RWT@PX^[_ &(_5I$Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g491933g88b88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g88b88.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %E*^5Q0X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q :/]]H         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          %=   $X     8 9P X #@ 8@ X #@    !
M          $             !.    %=                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %=     %)G:'1L;VYG   $X     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   !70    !29VAT;&]N9P  !.     #=7)L5$585     $
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M!!$       $! #A"24T$%       !     ,X0DE-! P     "_X    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ ._=T*TDEO4\QA]VV'M(&[^2YGYOYF]*WH ?J,W*:XAH)]0Q[&,J
M'M^CN=Z>ZUW^$]:__K>LJG4L+[;2RD@%N\.?+GMT /T?0=6YSOZ_L3@==37D
M@C0T+/B::MG0WON?:WJ.77Z@:TULL 8-K6US
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     /_A/HEH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME
M="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^
M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L]
M(D%D;V)E(%A-4"!#;W)E(#8N,"UC,# U(#<Y+C$V-#4Y,"P@,C R,"\Q,B\P
M.2TQ,3HU-SHT-" @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(@H@
M(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @
M>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@
M(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/DUI
M8W)O<V]F=,*N(%=O<F0@9F]R($UI8W)O<V]F=" S-C4\+W!D9CI0<F]D=6-E
M<CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y-:6-R;W-O9G3"KB!7;W)D
M(&9O<B!-:6-R;W-O9G0@,S8U/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @
M(#QX;7 Z0W)E871E1&%T93XR,#(S+3 S+3,P5# R.C$P.C4P*S U.C,P/"]X
M;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C,M
M,#,M,S!4,#(Z,S8Z-3@K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @
M(" \>&UP.DUE=&%D871A1&%T93XR,#(S+3 S+3,P5# R.C,V.C4X*S U.C,P
M/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)
M1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z,69F-&0P838M-3$V,RUB,31B+6$W
M,S8M-68Q.#,U835D93(R/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C8Y-3=C-C@S+38Q9CDM,C8T-BTY
M9F-A+3DU9F9E,C=D-#AC,3PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @
M/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.D4Q,C9%,S8Q+4,V,#8M
M-$,Q,"U"1C(Q+3<Q0C<Y.#4U.4$X-3PO>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z8V-B8V,W93<M9C-E.2UA-S0P+6)E83$M-C,S
M,V-C,F1C-#@R/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(S+3 S+3,P5# R.C,V.C4Q*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @,C(N,2 H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C)B,30Q8S Q+3=F9#8M96,T82UA8S1A+6-B-SED,3 U,&4X,#PO
M<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H
M96X^,C R,RTP,RTS,%0P,CHS-CHU."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO
M=&]S:&]P(#(R+C$@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N
M9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C8Y-3=C-C@S+38Q9CDM,C8T
M-BTY9F-A+3DU9F9E,C=D-#AC,3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,RTP,RTS,%0P,CHS-CHU."LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C$@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-
M.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC
M94E$/GAM<"YI:60Z,F(Q-#%C,#$M-V9D-BUE8S1A+6%C-&$M8V(W.60Q,#4P
M93@P/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C
M=6UE;G1)1#YU=6ED.D4Q,C9%,S8Q+4,V,#8M-$,Q,"U"1C(Q+3<Q0C<Y.#4U
M.4$X-3PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#YU=6ED.D4Q,C9%,S8Q+4,V,#8M-$,Q,"U"1C(Q
M+3<Q0C<Y.#4U.4$X-3PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @
M(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \9&,Z8W)E871O
M<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D^1&5L=&$\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O
M97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D
M93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( *@"5P,!$0 "$0$#$0'_Q  >  $  00# 0$             "04&!P@"
M P0!"O_$ $L0  $$ @(! P(% 00&! T#!04" P0& 0< "!$)$B$3,105%D%1
M82)Q@9$7&",RH? 90E+!"B0E*3,T.5AXF+&VT1K3X3AH<GGQ_\0 '0$!  $%
M 0$!              $" P0%!P8("?_$ $ 1  $# @0$ P8% P0" 00#  $
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MX42\6*ZZ@W?VJ&R;5"AQ9"%Q?"8KDYAX8Q->(,JC9I?P_B,5.*@A@B>0Z$7
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M;@V  NXLMN,KMQJ4PK&75U!75SVVCAF>UFP#BUKG"UR+V#2#ROMNL:];M_\
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M 66J/=+IIVFV'NCL15M+4/8@S679@QIHS:K")OVGGM56"Q4I\ T3LU[#6D7
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M+,L0V3:VW'39I$!=IE9SM3)24$&'U&+D2U_YKC,AD<P@^ ^)HISE> 0&FXS
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MG%>>PJ>E%+BM#4/$1Q&G,0J=;QV>7@::AKB=3?GIM9>AQ>CJ)*K#ZVG:Z7\
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M=6*4:>!PQ)5]<NLVROQ"8$[+,P EHJY"R @\"Z5 W+KQID-<*A)-U@KD>^Y
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MHV"EE934A@86BSXWE^6[KWN["=PZ9=S-S;7NU?W#N?:$:EZ_T4-(ZG.T:TR
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MA$6 T6-LI:*&CK<.AB%)AXG92XCX@JHXZE].:B,O\5X!9*US0XAA T6V30V
M\/5 4TTZ-6TN.MEM"&D89>:REQE.&LIQAM:%*1G&/;A7N5[O.,YSG/BJ(966
MA>'@6;[CB1R_5?;3YGST7B)73OD?+/+X\DA)=+*,\ER1L^Y)/2UM]#JM8JQT
M;ZM4\:<#@=<98'V6GF=?&&)MKNA=4FGV*NQZ>2KZ'3!^=(BP7*U%A!(K<1QC
M\!!AQ61ZXN6<*Q<[W//JJ=-]Q\_L/+Y_!8OLFN.B5=C%;40?>$23USENQ+)4
MK=M%JS2KTJU;A*& ^N2]*+9L2R[5CM&Y5V.J4!]S$.).L3)L7'#-H0V_=.0
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M7U*9\/PC[1\:Q#&*;"L?PLTOX_-^#F,;HP;:AKK@7;:X#FDN!M<67T1[;_\
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M+TU=H0KG63P=W0]N!V?8FO9^PM?D-58_0,F!4==V8!DB=09M$JX3ZF(6^S7
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M]L/!>"</_EV,8'DAIL4DR?A6/S,UA=/XT//PR,H-SNYO.Y.Z]EG%&,8C4U^
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M;EWRZK>[H1H^J=;NH&AM(TBO[%JU7U_26A8JO;;6"<V,)3+)D3$R);%5F1+
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M$>I9IZT67J_K>MA+%J^&]N3NBU?:$$J^QC%=JMN%B-3B3K0>- "5VN@S$O\
M'XP&'P6XL=,IH;BWSYVZ#ROO9?J8X4IPB<(G")PB<(G"*T-@7>N:THUPV)<"
M3 >IT2LG+?9RTI?LCC:_7!LDN8GNJ_[$0?#D/YQ\Y5]/VIQE6<8R4'SYZ?/1
M:M]#:0;"Z-QM.[PI$+:'9RVV#LGL:-/0M)0//V@J)-I=&GJ<_M^_5NJX5"U<
MVG/E/TZ:E:?E:O)2MT^$3A%Y9<A,=K*U9\8QC*O/]K[)\9SCRA*U?./GX3G/
MC&?CQYY!( ))LUH)<Z^P W.VG4G0>ME(U(%KZ.)T.P%R=.8&S3;,;-N+K2O3
MK"MV;WO^]GI"I5&UZV:TGIM&4Y7#EO1"3.=N7F'A?PI9>S#(U(@2T8\9&TZ6
M_&6J,9>^IHJ%KZ^ODQ.1XDIX?$@H &D6+C:HEN3?7)&UM@!9H+20;GH..Y^&
M^%<+X3:/#KL7=2\1\0,NW,(71/.!T,P )O'35%15S1N-VRU;(WM#J>[MTXD=
M<?"TJ6A:<Y3AOVMJ1E*$^<82O*G'/?G&,^,*\)^,?.,Y^>;T7.KCF<2238"^
MIM8#:P\RN>  "PO8&S;DDAFF5I)W+3F][2X(%A;7U\E2G")PB<(G")PB<(G"
M+&%[TGIS:4R 0V=J?6FQ9PJ.]$%S+U1*O;90V*^ZE]Z- DGQ9!Z)'=>0EUUF
M.MMMQW&'%)RK&/!%? $ #JP<;7JT'%U\ &AL#A ,(/B"A J!%;2S%@C1T%IB
M'!A164):CQ8S+;#+24MM(0A.,<(JOPB<(G"*-C3W_M5N\?\ \)71+_[V[A<(
MI)^$3A$X1.$3A$X1.$3A$X1.$6 ^P79G475^MAK=N0M: E>/V ;51L^LZTV;
MLM:K 9E,0 PZ7!UE3KC/&.&"4J()$/%(T.,3,S80>"]()S8L1XBUHZID!_8?
M?V_>WD9,U^HCU0^KNBWR,(@/R]2M:3W3FV;5$&%HT,@)E6S<Q<O4BT>3"B2W
M8NH:[F6WG,=CVE \QOKY??3S\SI?4J1/A2G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB9^V?^?\_Z?SPBT5LG=ZOUG=MUU.]4"IN* 57*[7"8)S&)5HV1.L-"
M"GJDU(.MA:FRD8UM6G28C[5H?FOKKNT43!\)%-0LF47_ ']-+[Z:#S^X733>
M]%7M$FT.S*590H\7!Q,K<-+#1ZPVEUVF4&V11OX"NO%&0Q20_=%AFFR+[8M3
MX]$G)E+$MGR3O[]>[^2M>U]S;Q6:8 LZ:SIXRX=B"K,\T!VA/,JK].)4TK;7
M)9,+$K*;.0<BJ&XB_CJT)-N.CERK D'] ;(A+*>^]^^:^5WN/ML_7MJWB!I&
M(8H]$B[9D";$T8L%=$SG=9[(<ID:*Z5L5;8BG%6(! /6U$BK,$$BG ;@">A$
MPA"?43E_B_\ '[*1="O<E*LX\9SC&<X_C/[X^?&?C/\ .,9_ICA%RX1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X11&>LS_P#T\]>/_P#83T5_S_U@*M_W_?\ CA%+
MGPB<(G")PB<(G")PBC^[I/O;9M6C^F@N,J8QO:SNW;<:F\X^F,ZZ:8( K+>H
MT[*?.4M;$MDVB:L3'7C'X\7:[ IM>$0)"FBB_?[WO;J?2WQW]9;0TTVTVG"&
MVT)0A"<>$I2G&,)3C^F,8QC'"#OOOS79PI7%6<XQYPGS]_/SC'CQC_OX4=/7
M7Y%:K]K=@6"OTH50M>O,IVQN$WC7E!]V/JJ#R"$1Z38KH^SC&?</HM98*6>2
MI>,MNOP84''E^<PG.NQ&H,'X>/\ _E.?#E',.9J="",HN= ;FS="0O8\%X93
M5==-BN*,?^18%&,0Q-[1_P"7PW7HZ-I-AFK*ML4);<$Q>+8&Q69]6Z_KVKJ+
M5:'5(_X6OU4 -"C6U9][RF83.&LORGU9RN3,DN8=ES)+N5.R94E]YU:G'%*S
M?HZ=E+31P1BT;,V0;6#C?:YL3SU-^O308QBM3CF*U^+5CS)4XA4R54CCL#(3
M9C  T-C8VS8V@6:T!H  TR'S*6N3A$X1?,JQCXSGY\>?'].07 &W.U]=OFB^
M)7A6//V^?'C/W_R^/OQ<<R->AN.N_47U\U -^1'KHN7)4IPB<(G")PBI)XX*
MK0<G8#DZ,,#!8$PH5(S'4LQ8 X?'<ES9DEU6<);8C1F7'WEY^$-H4K/QC.<$
M[[[^ZU"!>HATRL<NFCQN]ZP@A?)9^!7H!8;::]-3,K.<I+1K%%L  6]2WO>G
M+8INYH *L#F6V@&";KK2%$^%OE^Q*^"?42Z9'&J,^.WQ5<M['(F1535.@V<3
MF1-!+&MSD&TE0,)5/9?6:"(#3;A@#"L2CH+]/2"F#(S\43OO3ZKV5+U NGUY
MF:Z@5?>56*S=K6&?5:/$1"L<:22/#Y("$J&19FA(SE9:(S;94HE=G6A(:#:9
M-MJS-;D%5V$/B:18@T]G&?55[QYQGSC_ %2NB6/./MY_6W<+/CS_ '?/"*2?
MA$X1.$3A$X1.$3A$X1.$3A%^9'_PGO6>WMC=9^NJ=2;AD:O(C-_!8CX<>9V:
M-,7XK8'1D*M0Q$370$W@E*I4YB3L)_)M4+(P?6IA4#F8:B1XCA.?R_?OXJ=G
MIOJV%I3JIU[U5!<A2,4G45##$",!99V,</(KH^19;']8_%A'I#]EL+Y0]+E'
M(D<S+ED7Y15EN>](3@G??]ELKPB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+
MYG'G&<>?'G&<>?WQY_?^_A%;4JIUIU#*I $)(Q#,JL43$@5!<Q%/..N.NF6,
M*8REDJXZ\ZZH@TE$O+SKSF7<Y=5C@"^@4&P&I YDGH#<[?3E<VV48G9+U(NK
MO4N[DJ.-I[]XV/&9CMV@7K8/7!Z@F$18OX4=9K%/>&Q&Y>8+<)+(J,HG-AQV
M8:946&REC// <1^TGASAR8TL\DU36,=9\%,UKC&;VL]Y(#7:@VL=C<#1?2GL
MF_TK^TOVMX>W',-BHL$X?ES"FQ'&#,PU;A<9J:G8S-+&7#)GS-L3F:'MS$73
MU*[@=2NX#4ZGU.B!ZG:X<U=L(ZQNM0J\:=(DLYPI5M$MC4SP)UV+)RCZI:'(
M66@K<:<G1XN76<YV?"_&F"<6-E&&SN;40B\E)498YP+ ES&AQSL&MW#H=!<7
M\W[7?]/_ !_[&GP3<2T4=7A%7(8J;&\-,DU%X@/NQ5.9C7T\KP+M806NS6#R
M0X*1] 0/@<\);&#$"YOXQ4F W!BXA2E$'G94];\3#7X9Y4V5)?DR\N-KQ)>>
M>=?]ZW59SZSG:W?GW?R7#P0;&][[=#\.JK./C'C_ )_[^%*<(G")PB<(G")P
MB<(G")PB<(HE^[_>_;'5[9-@#4:N:BV+7ZMHVX[2L]2D%+9$V!2H@>J7T@$V
M'>C;.6JG7: 8NX&L4T;56(A2[6<8]L&\AYT /K<Y%44?3S[_ 'TVW6DQKUI-
MQUG]29FZJU)8$Z^#[2KAIL&;M$5V_P!THX?N"7&;1H*W)Q+$72"5=568EDCR
MTV K"=OV$Q;6M5=2V=*?C_/IS&G=^:U>L]N:C2+4R0UCIRX)UI%V76;$NHF[
M2SC8]HJTGN"T%V7K1#Y$OB!IH?CJHQ^M$D7K,5@KOKV(MA916F'+"[^_]OYZ
M0-N>O6]Q]=^^2QUWB[Q9W3UXZBT2^UJ>O9]B]3+3U8;MNL*;<3&B#4;KSW.;
MUX0LL6_OM% =73;T 6"8.L6"R22KTU\D.&RB[(W\?)*>_/Z?LOU#<(G")PB<
M(G")PBIIDN,KXDF=-3H@P.&'S"I4E/?;BP1PT?'<ESI\R2\I+4>)#BLO29,A
MU26V66G'5J2A"LX(M$NE\ AML_L[NU9HI&*]V$4'":1$EHTJ)*K/5RBO%$ZP
M?5"FH:D02&UR9BR;E*H<98E8&W.J B*%2*LC#9/CU[^'^5O_ ,(G"*B6$Z,K
M@@B9,3X@L8+@S") C.>1&A08,",Y*E2Y<AW*6F(\=EI;S[KCB$MM(6XI6$IS
MRB21D+'2R.:R.-I?(YQ  :T7))/V[-V""6JFBIZ>.2:::2.&.*)I?(^25[8V
M-8QMW.<7.   OJH_^L%UI?:7:M^[#0[563S==A/Z^U'51-@&&"E4UV\4>P6O
M1X7#FNO!3.VC89$J*T189E1JC6Z]':_#2Y)YA[SN#5<.,SU6(&3Q8VO,5)"<
MMHXVN</'T]X.F(_2X !C6@$@KIO&V%5_!>$4'!SJ>H@?(8:[B"K+'-AKJY\;
M)X</IY1[LL%#$X%Y#G'\4^3,&N8 )%66U-)]JG,N?&,8\I2GVXQCYQ_9^,_/
M_P".>E^']_-<LYN/(N) &S1I9H\AYZZKNX4IPB\STEIA6,.N(1[DX]ON\^<J
MSG.,?/VPGS\9S^V<XY;=(&N#=2YQ#6@-<XYG7#2[*#9I+3=QL!;?5#H,QT:#
M8DD#7>VI%S;8<U&KZE/<JV]5M6U=K5PADYM?:UC54*,AZ"\5C#WF&4ND2B1+
M&/>9G-N21XX6)PO"91$DPMU+K+"F7>A^S/A.EXRQJKIZ^H;#AV$TYJL4E!RM
MCC#WQ@9W%H!$C'!_O#*!?JN?>T7BN?A;"::6AC\2NQ*H--1:9CF:UKWG( XN
ML' , !S.)&4VLM&N@W?OMH2[$@>OG;ZO&LR]ECC,^CF;)04ZYL@R8)@D2B&G
M!4,2%@%J]-:#DH+,I U$V&280A<^8RMUM/O./_9SPQ0\/38_PEB,%33X=- R
MOACG;41,9);-()0]Y;,2X.,6@((TUN/&<$<=<15&-0X3Q)256:O9,:2HE@%.
M\/;<LB="&1GPP 09+.=FV(U"_01B;\>Y6$83Y\>?[6,9S_CCSC]_OC]N<!#V
M&]G-T\[>[?W3KU%BNYW&4.+FBX&AOH[G?38:[VT!*[V9.'<^,8\><><9QG'M
MSC^F?/SG]O'CXSP'L.H>PWO9H/O&VFWK>W7D4OJ18D-M=P%F&XOH2=>GJO3C
M/GE0-Q>UO)2G)1.$5LW,8;,U2Q"JT:8KEB(!2D,#89(AH_'!&)4&1'&F'@;\
MF$P8;&S'69BQCTV(U-0RJ.Y(90YE>"@_#X\_+<:]%#/%]'-)S%5QM'L05MLA
M:'4[F*5_7$>M%MV28-Q+;(J]A,%CMVOI<#<8=]L!DM9S4*=-'V(.X.JPP!5@
MHF&WA\?AWWY)KL!WR_?2_2]KZ=>?1C#&$P$W+L1;#CMDGB<;Q>&T"N $[0!T
M;&L4:N%@F6"DY&N)%48U!2F#)0>DXY:__+BWXHE9&)D9'Q[[W_Q9?['37?U'
MP(TOY<E<&NO2%BTBR4*TDNQ%GL9$==*+8]J)SKVM!F-E"M/'^O\ 8].!1:81
M"0YK]^K3>M&M6[&7AO'57**[:4+A!)!>"Z(E->8'?PZ>G3GI=7474%1TMZF_
M?RN4Z7=9L ]UYZ77>>[>]C7[9I-!JPW?MSDBT.,;$LEH+" 2%16\C:R+FQ*Z
M']SV!0N'A][ZA+;>7?P_A2\<*4X1.$3A$X1.$3A$X1.$7S.<8_?'[_?/C[?\
M_/"*.V%(9[0=VESFUO2]1=%<3Q4=:<9P'M7;/8U95%+NLKQ[FYW^@K3-A<#O
M8RIR,FV[G)QO#9NC.?ARCU',VMT',^MOJ 5(G]N%*<(G")PB<(NB0ZIE'O2G
MW>//G'S^V//QX_Q^_P#') N=P/51KR:7'D&V!/EJ;?'Z+ZR[AUMM>,XQE:,*
MRG&?/CSCSG']^/./O\^/GQ\\'0D7O8[]?-3L;$%KANTV)&X()&AL1:X-OF%W
M<A$X1=2G<8QYQ_/[X_\ YQX_Q_;_  Y3F&NH:1_WT"&XY$_^NOV1+F5XSG&/
MMX^,XSY_;^/C/W_;C-89KM<T[%AO\^G+T47-[6((WN/L?MU7;RI2G")PB<(G
M")PBH=ES+2!+K@(2Y.;'3'83:O.,+F-L+7%3G.,X\84^E"<_./OCY\>>4N+P
MQY9^L,>6^N4_?KRW5R$1F>G$P!A\>$R@WL6"5A=>VMK \_+GI^-+JGT@VEW?
MM6U#\^V8I::^?FNVNUV$+*.O%[T9(2YI<.VQ@H*?_'C\97+*K??SF.B5 CM-
M+<D>&ODK >!\4XVQ/'JJIJ32?AZIS9)96EYDG=.X&.Q((#6@D$#D ;+]I/:-
M_J-X0]@'#G &"83@7YY+BF!4M;1X;13QT$-/A388X(:AM2(Y(6OEJ9+!CHQ=
MC9+:N:YN3A'5G:O2KO\ =9*K&/IL\JR7"M2ZS;P(^2'C' 9&<L-? KPUV82>
MCY%AWY?YPPY+>;_+I4.<M3>'<LL[:BX3Q;@3C? :=E4)8JXE_P"(8UUC#9\<
M[7@6LYL;BYE]#F'*Y/D<>]L_"'M^_P!./M+QBOPRGPO$^'J2KCFP>>L@JI:>
MNB\.;#:F*3(TN9+,V-ARM#P]CVM<#EM^NJ,YE#3?N4E2O&,?[V,>%9^5)SG.
M<)QE.?C&//GQ]^?4&8<WMT#;N/\ R&P.^F:U^?U7Y!AI LUI>=[7!()%R !L
M&WL- O5]7/MQG&,95E7CV_&,_P 8_P"MG'_'[?W?,%UQ=EG<QK8'XV)^GU50
MOKH1;?37[_*Y'R7U#OE64JQA.<8]WCSC.?'G&,?&,Y_G[^?\. X_\FY=+Z'-
M^P.GHIY7&U[#ST)\^G5=N,XS]LXSYQY_PY5NHYVYCO\ 9?>$3A$X1.$3A$X1
M.$3A%B0_H32=IN;FQK%J369S8#HJ2!<O)>AU0G<%@9@R4&F@U66<)?-*$3!,
MV8+E#LS<Q) V9+@.-*BRY+3I%V1=%:7@.!7(&IM:0EURJ3Z( S$H=6CY"TDK
MA6"=/%?2%(_+ZL1PMS$VOQ?I"97U'?KQ'/J*\E%N^^>V]]EQ@Z'TL+2#2-U-
MK4?FLUHK3*VJ#0ZI#S7Z@<RM1JK!<QA+615<+J=>R3!P?H#)^7G<R8SGU%^2
M6^]_M\[6^6G6\8?JV5&L43JYUEJU+KP.IU@-Z@712(&KE:$#@((3%SV$K+N8
MPP0*C0Q\&/EUUQW#$:.TWAQQQ?CRO.>$VN>FOTYG4_'HIE>%*XY4G'[XQGVY
M5CSG'VQ^^?XQ_7/C']>%%QM?E?X;+BTYAQ/NPI"L?RA258^WGXRE2L>/X^?/
M]/WRL1O]K=]^B!P(NTA_FT@C[KFK/A.<X^<XQG/CY_;'],9S_EC.?Z<*>^BZ
M\+7G./[.,8SGY_WL^,?/\)_RSGV_OYQCQQ\;Z=.?=^O)1[W0:?\ ^AMU'7T^
M5UR6O"$JSYQY3CSG&<X^W]?.<>/.,9\><XQ\??XSPI4:&YK'GNML4CU=U]/>
M=Z^T@RPCMYL<<\A(2Y.C7&)7^J962/U,-DYEI]\=[>LV!EZ)7:,F1KV8XFP7
M62T#7&I.PWM\/W('.RMYV%P!D:RX.C@XG07!T.4:];^2DF@L,1(<2)%998C1
MF6XT=B,TVU&88CHPTTRRTUX:9::0A+;;3>$H0E.$(2E*<8PTU(.GK=5 [#0[
MV+1I8?9=SCR$)RK*T8PGY7E6<8PE./OGSG.,?'^/G]L9Y!.PN 20!?F3L-Q<
MGI=22 "2;!MRX] .9Z#G?:WS5%-6$=7QDLR6(#APF P_,G$9\MJ%!A0H[7U7
MI4J7)<;CQV&D_P!MU]]QIEIO^VXM"<95RB26.%KGRO;&R/1[WD!N8"^0:WS%
MH<=G6RE7::"HJYH:>DIYJNHJ7-93T]-$Z6>5SW-8P1PMN^9SGN:T-8,UW7M9
MI4<>T<W3OS7;+0]?$BFONNDP.9@3-FXBR6B6XS4B)*@0!].@ONC9N-8"9^&Y
MIRPY7%3>5,9#@UO E32,SS5>V3B"*2DAD-+ASP0*IY+/QC[$-B8+$F*Y$CB#
M>0 !CK$E=CP*6F]C^*46,XO0PXIQS2S1OCX?%12R1\-1O:":K$ILDU/^<.C<
M8X*!V<T9<9:EADC\(9GZS]=K?J>]VN[6VP:[(NF=9:XUL.&:[HD^E1&H5!)W
M BV8,)GV,\H@6)?JKZ#KK28R6VH36%?44KW<V&&8;)0RR/<^E#3!% R*EB=&
MW^F][S*_.YY+GE]K@M!Z:"VAXUXUP_B/#Z6@H*7&(LF+5V-54N+XG1XB_P#%
MXA#"R>*F=34=*^*G#H\S(WN>UNH8 <Q.ZF?/[>/MG[X_?SCQ^^/Z_P#/WW![
M)VMI?Z;+FRZ\/(\>?>WG'GQC.%8QCSY\>/.<Y\_X?W?QYH$K' N8]CF@VN'"
MUQN,UR"?(6MS*6(W%BJ-8+(&JH<E8+&4&@P@B(]/)EBLV- &#X,="G'Y<^?+
M=8BPHS*$*4[(DNM,MIQE2W,)QG.*F">61D,-/-+-*]L<4<,3JA\KW;,9'%=^
M8FP!<&L%]7:$)< 7<1;UL?K>YYZ7TY!00=V-9;M]44G0)/5"Q9U_JC5+%O;9
MVY;3MSI(+;YJUO5MI.=?"Z\+EG+%4JPFN.Y3=B46)7#T@FM-1DE(C,J>YV/@
M[B#"/9L,0;Q-0#$,6Q-E$YN#T[:6JJ\,@A_$7?7.=GCII9G393 USW1B(.E+
M'N\,:7$:6?$?";35+X&1N)D+02)/@'-N "+$W)-R 1O*@<ZSUN]@.OR;XILK
M;=!G*G: )A3/XZ*Z=! 4!"CDA$U.'IK!)&5R6G7,M2&B$<62S[I$-;;G,Z3'
MZBCFQTT$SXJ;&I*J.HC#3$74L]3)5-@)C#01&9G1M<SW<H -W9G&O$L%H\5?
MA<E;$U\N$RMGIG$-<6R!H!<0YI!+LH+MB"!98"[QZ]M8\MKGL+K($X;V;J%T
MP(JJ(8!LQ(B#;W%C"; 1EQT(7-F-C8;*T0&(J641Y!!\A)=>:CJ9QZSV?5.&
MRSU?#V-8BZBP'$FPRU#!*Z[YJ2[XVG.XL#9"0)"6YW-:&@WM;FGM<.+X/AE/
MQ3PYA,^*\08<]T%*RBA$M1'%5G)),Z&SFO;"[WF#+[I<7N(;F)U$<[7=[=-5
MK:1J^ZREW%-0U^3NZL'1#,*.$80\F/ )+GU=J1$FQ&'%29) +GZ9/\NA29*I
M$1IO+JO>XQPC[+L2.$G \9$'BXS34%4QCO\ [8B1]5,UL[ [,QK8VQN.9I<7
M!S"<H/*.$_:)[9,(K,2@XMP#$J^&/"9,2-3+34S32,+H(Z?-)2-; 7^(^0RQ
MEN9L48D:\>^6XXZK=[NYA'L-HNE[=0!O-.WQ,(P71HNIY 3Z#-@B8IR9B%)8
M7E1""$%&:_.)3969T!QF:0&LD<&PQ.,SJ\9X;X"Q#!.+)^'WR4.)\'UII3/5
M/)IL8:?#(DI0\M,CBQYB)ALTS-=:S#9O88*CVA<.8UP=!Q#-38M1<<X8W&:1
ME&&Y\/H9<SHV5+8V_P!&9K U[VS;MOH#9Q_10TK"FTJQX\9QG[8\8\XSG&<8
MQ_3/G'G]_O\ OSB;79VAVNO7?33Y::>2ZN+?\=N2[.5*4X1.$3A$X1.$4;&G
MO_:K=X__ (2NB7_WMW"X123\(G")PB<(G")PB<(G")PBT_[:;[/:T#5O6.H8
MT.Q=E-WODJKI>N/M+F#PLAEAG]1;9N[3&?="UKJD?,:LEGDO*9R9DX$4P0X[
M8K2'C/%'?Q[L1^VE\K=>M* .ONI*KJ\#/GG%B&9I*RVTRI#MAOEYL9"38+SL
M"S2D8Q^,LEWM9(M93,C/]G,TBXRSAN.RRTV4K-7")PB<(N"E^WSG*DXPGSY\
M^?/C"4Y_G&//G/S_ #C.,??SR1KI;7EW_A03;F+#]5^6FB\6)S>75(]WPE6$
M>,-/9\*SC'RIQ*<M8QYS_P!KX^V<XSY\2&WOE+21O9[=O_6][]VYJDOL?>#V
M@V&L4@%SL<]BP@@@CU&JB ]3#OKLGKB>H^G-(5V$;V?>Q,RS/3Y82=9'0@-J
M>^-@-"JW!SETR7*RAQ9:<+2['@P1DAY^,]EYKV\QX^XUK.'I:+#,'HS78K6L
M=(R,"1[61@D:-B+7.>;$!M["QN-1;ZU_TT^P7AKVH0\1<4<?XP<%X/X;GI*5
M\@JH:/\ $UE0WQ'-EJ906QT[&/B:"TL>Y\EP]N0@^7TU>_6T.P5JMVD=Z5N*
M(V55 2;5 *QP)&LN%0K4J$.(Q3-=FY2H24@2"8>4P\TEB,2@$'%IB,.1,.2G
M ?&U=Q#/683C6'_EV+4#6/<W+-&'Q$6O(R8N<V4$',,UC<$-%B%F_P"IC_3]
MPW[,\-X?XV]GV-?G?!>-5DV&O+ZJFK'4E:,[X8Z2I@MX],6-?'FD,KVNA(=,
M[.+3*8=QXQ_95_NXS^V?/Q]\9]W]K']<>?/^/.EYFW #@;[>8Y$>HU7Q_KT-
MQH1IH;D$?"Q79C/QYSG'SCS_ !\?YYY*"_/L>?GU7YW/4%W;W5VCVJ)]7>HZ
MKD.9US3 5NMR*.9@50V;<.PA<YN?+LI(D)3%$1&C8H?&'P2,5<X@@HN1B6TS
M]./W_P!G&!\$T/"HXEXTDI9C/B=500"HC,L,;:9I>T")H+W3>Z72.==C6.9^
MD YN#\>XSQ=5<2_D7##*N-L%%3U4K*5YBFD=,&W<Z0N#&0CQ&M:#J2QYLXD%
MNT?I7]CM];*#;FTSV.:)2=FZ L8<&0,&?H+.2HAW!?+(T_)B+S!($Q3H61]$
MI&<4@L,DP9N9$M>79;WD?:KPYPY@N(83BO#=53_E>/P22TE/ '&*/((R2&7+
MV-=G-FNR%I:YKFZ6;Z7V8X_CF)T>)X9CK99ZW!961SU$IM/=[I!X<A.A>PL!
M)LZX-PX@-<Z77$G.<8\Y;QY\>58]V4>,Y_GSX^?&?'E7Q^_Q\\Y5G;;,)(PV
MUR21IZW>+?$+J=QI8YCY-=:^VA(M]?7J?1AQ.<8SC/G^?'CX_P".<?\ '/'B
M-<+L/B#D6Z@_%38\P1ZKLY<1.$3A$X1<5HPM*D9\^%8\9\>//_'&<?YXSPGP
MOZK!NN-#5+55JV.=IF90T;L^SMWFPUW_ ,54'9NKD%$ O8A3*8J'($BP(C#I
M):*VYF&X3B.DF&69,V=F1ATE!2T,E1)2QB'\4\R3,8&ACI#N^V4D.=NXAPN=
M3<W6]QGB7&<?I<&I,6J75K,"P^+"L/EF+G3-H()99H*:9Y?:2.)\O].S6EK6
M1M_XW.G?J$TI(&NB.Q%=78V]EZR:R+HY83,PU"HS%MGM0[E:5"\Q),(I.*"?
MH!'GRT>6S!A8^K%3$4N7(<]][..&\ XBXTPF/B&"&:-GXOPS,[+ERTDKFL8Y
MQ:6AV0#0ZBX&ILN1^U[VC<8\#^RGB:BX1GGIF8O48<[$F4D+7OF8VM@#9)7!
MKG^#37,K@TB[B"XD"RB/1N+M&.PS?W-A[C;'O*:FL6"4]:&JZXVZO&$+2IQI
M%8=CR5N-H;1F,N&Y[D(PTK"DXS]:.X=]FLTK\'9AW#KZIS"S\+$^"2M&5I)M
M:;\0'M_62'"PU=J;KX%=Q;[4&-AQS\[XTIX9Y08,2E_&LP5TTH:UKB7Q"F=0
MAS2PQDN+G/ 9(RS@:UV<]1#N?*J>F=4T^&Q3;;MD<Q*B6NL#)B;K9VIMHFTL
M-"$LSX<B*,DFIT7$AR6$8?G*:EP?R]^!EWWXYS@WLVX'I\3XEQ7$Y?Q>%<.2
M3>)1SO:::-T4<<[I+Q%LSGL8YT3&.F .=S7!Y#2OHVA]HW''$&#\(866FFQ;
M'GP4CJBE9)!/B<M2^JIJ>2C=(7,A@DFA#I'AKR0YLC7M:?#.!:5W3[7]6ML:
M_E%-[F^Q>J[A+&//++N6F>"L<9PA$&6H567[N)@V&!8JM/F+'._EZL#<$XJ1
M\MOZN)X^%1A>&^S7VG\(XIC?#6'18768<:J OIW&(M? V4M;4-<Z6-\+\ES8
M1R"1MLS0-?5<389[3_8UQ9AW#W&4\_XBJI::NFH:NHDK&O@J986QOIG2RB2.
M0L?<C,\%CP]HL;']? N3F9!BRO&4XD,-O80M.4N(PZG"TI7C.<YQE.%>,XS\
MXSC//E]H<TO8^V9DCV^[>Q <0+7)Y;Z[KO['B1K)6@AKXV.&;]6K03?8;WY=
M54.5JM.$3A$X1.$3A$X1.$3A$X142RV0#3J^:M=I,#:]6JX+G&SYXQ,8'B0H
M87&=FDRI2?*<:C0AX^$P]+F2I#K;,>.TXZXM*$YSPBAK]4[9^O\ <74CK!L'
M5]N!7JE'O4(Z/Y#V:N3V20D@H?V-KXP@TQ)84K'UQY.%-&SXSF$2(4^'*AR6
MFY$=UM#OOI\5&]_EIH>NFO0CXJ:_A2M,.^6S=KZ?ZL[:V'IB$Z2VA6 0V;4X
M,2OOV=R3.>L 8=)0V"82\]/Q^!ES7,--I4II./K_ !EK*\5Q!KYV,>[PX7%H
M?(=V-+O><3L0UOO$6&WR]=P'AN'8OQ-AV'8J":6HBJ3,T3QTV=\=/+)#$V>5
MCV1B69K&%SVN%G=";08]5/64[1D:7:,[1U]IC8MB"W&:'G$K1OK5'5V>!5!B
MCTO Y-,NRY!&>^W*S*6\4SEM+;KRA:TI>'N(3O<2P[AF'&*REPS'Z[$L-AJ(
M8VUT6'-,3&.IC)*1+^)B;4.$@:&&)K&_U/")=D<]>VXCX'X=H\,P&KK,7PO@
MK%\0PZIGKL GEJL=>RKCKC#36J,*IYQ30R4P#I&S"20.:9 TAUEL&8];.\P8
M[R7NN^AY"W&W&VV1??729R2XI2<IPEF*&"3WY"LYSC"$M-*RK.?'QYYC20</
ML8]S,3QB1[6.<&#":8%[V@EL8+<7<6EQ ;FRFU[VY'RK.$L$>X-=QYPED-L_
MB.XAB9E_Y9GR8!&&BQL3F:  27"UUJYUR]2_U/;7NI]4KK?:]YT&>HJL%21%
M+9UZ.C-RI:'!D]K:;U3ECWAH6$KPN6ZU"CD$*1E;V'%(;SD5L'",6$<-5='C
M6,5=?B#*AV+TC<*#C0N9J"YKI8!%X)O$X/GF%0;R,+!9IZKQ)P!PA%'Q32-_
MVKPY38.[!/\ ;?$1XGFQ23&654375LC\.I&U=2]TER^ ,HJ?PA[C_$)NMT-Y
M;-]67=TP=5X'4EW3FF)<)3%YCZZ['4V%N2W-NJPE885M.0$<8UL EM?[$M/J
MU3=O:VDY_3UQJTI:)>+!CX9<PM_,<:SD?_T]/EN1>QR8H]]@;"[6$G4V 7+/
M]GX ]S&?_(?#L8<Y@+OP'$UVMSMSDWP6VC"2";DF_NZ%1T=@1WJ7U+<NIP?7
MSK]O'K9IV@@:A 'Z8T9LDX?U5AT9:U%"$^P&:I$"5TW.M&'W\6.0='F24E2U
M23DB;E^1F3=HJ?@:6CQIF(8EQ)^9TS:=^%146'PT\-6TR-\82"I=*V5[&N<X
M@U-("R,D%[GM8>L</8%P?%A_#L4.*>S/'Z6JDQL<4XIC6)5.&8EAT=.S+AHP
MS#JL4-8[Q)!%G>V"KS^(\^'$UCW"?BM;J[V$6&7)O2^A O<EOWI*=GAB\I_V
M?M4O+0S5\Y365?"LM)2M259]OQSS[I('Q1"G97M>YSP]M73T\3&L%RT>)!75
M)&E@#X;@[].@-QS!_#OL_AGJA-Q](Y@D_HPX=PW555FY['^K4UM#&T ?IWOI
MH!OH]ZC)_P!4@_J4.G5&J85'5'N0J3*?T!MRV739,N*H:78<B3(#-&I3+=<P
MM]+L]U$F>O$]D?A45<=;CJ-MPV,.;CE >(8W28,9'_B?PLL3:B,Y'9)3^*8R
M'PVG1]B9;$9&DYEZGAFG]G--'BIPO&(*SB*&BD?@\G'&#P4G#7XD31"\PIL2
MJ99:DPF0TT4@?3N=K*QV56WU:TMW@N>I]>G.R6GU[P-#DRYT2G]@>RYRGCQ,
MIHO,7"G6'50W2%A@E2J&_I+@KO%AN2H\=$=Z''$X4F*W;FX?X,J:ZOJY\=XC
M;1U6(SU-%AM1A5%54\$4;BR!P\+$( ]V1QNXFQN3D:=L7C3CIV%XG)AW!=%P
MM@\HHZ+\WXDX89-^+KL4?3N%8:*JG?,S#J?.YX9'A%/0QY+"3Q) 'B0RU; [
MV!Z>;<KW6'1,26,KQ-0EB/V6LQ-QF1$'/_@&A8:/UW8_'24.-M8BC,2X+<Q:
M4Q%2F$N^].VIJ#@@U-*VHQW$FTOXB!CVRX)20011ND#7O\5V*O,=F.(S97AH
M.8,N+KB\\U99\K6BIG)<\N<YTKY'.U>Z<R-#I<SM7/<XO#CODNTZ3=#^Q/JN
M;,9V<G:^AJ,^Z&_1V0+^X,V[KGA+A-%B4;2#9#:PORK@TC,(9F<IU(A0/*HC
M:'"&":OP?O.,L!]EF%NPU^$<15]1'4LG$QPL8=C9 B,;8S+(:S#FTY==P:W^
ML76<XY &AVDPR?%I1,*FGCB E<YADCR7!)]UI8UNC>0(.]\W);^OG?40G^4Q
M]<=/*ZGPKV/2]N[HM2F\YSC&,KB1=+U-#RD8QYSC!./[LI5E*O[?]GPDS.!F
M B/$.*:DN8X -PK#86AVGZRS$ZLV.P_2;WL'&RV[!5YAG\ -YY<]]CMF=;IR
MY 7M:T;*-$>KZ>[I.V4WN5JFZ*GGD/32=(L 8QK<&&31&82FZWIZ[%YAN;E5
M@0YC+=A9?RV;D23S2'(>&6.>[;C?LFBX%CH8L%_%8ZR#)''6TCX*N6H;59BZ
M:KC:R-C1%L&NNYF5A.=Q<M8*?%78F7.F::(:D:9G'+R-G 7-_P!+]AM86,E(
M;H]KPR9@6?>UTV=V<L8I]F8-8W388$W7X><WG#S4L-INI!ZIJ./+C/?[:$2F
MT\J<@*]J6#&<X6M?/CQ96Q0/I<'HZ# (BW)+^6P/CJG->US3&_$9YIZMT;V$
MMDBBG9 XDET=[6VI@9?5SW : %P(WO<V N;\^FA\]T8T&/%:0S':;CM-X2A#
M;#;33:4(1A"$);0C"$(3C&/"$)1C&/CQXSG&?-92\YG%P)>7.MN^]R6O+LQ+
M27%Q#2V[KD[D&\VS=FCY6UZZ6U[WLO4A&$>[QG.?<KW?.$X\?&,>,>U*?CX\
M_/G/G.?GQXQBMHM?4D7]T6: P  96Y6@Y;@N]XN==Q&;*&M:_?7<G[DKJ=C-
M.YSE>//GVXS\)SY\?[N,YRG.?C/SCY\XS]LXY.5N8/+07-! )O<7WL00I!(-
MVDM.UQ:]NFH.G?5>60+B3&7&'L8=8>2XV\RMN,\R\TZA3;K+K;S#K:VUI4I*
ML93[LXSE.5>W*DY,:(W-<R[2TN(#7. S/=F+]'7S WRF^ESIM:G<.#K.:\CQ
M&N:PB1EK&)_NZQ.'ZFZ$];*FLU*OL/CY30H>B6(C/P1$O \=^)%0)/X;$B -
M=_">Z%#>1#B-.QX_TT+:BQFU8REAO";GBRVD:9'F.4M<^/,0QS@#[S@VQ>XD
MEQ+RZSB<MAHK?@L#HW@6DB:YD,EFE\,;C_XHB01'$!9H8T 90 ;D75Q(3A"<
M)3]L?;XQC[Y\_MC&/OG^.4*X!;1<N%*<(G")PB<(L5W3>&HM=72@:ZO.Q:G5
M;QM.9+@:\JYLQ#@F;?,@N0F93 2$\ZAV4MN22&PDYPG"'IY&! 94Y,EL,.%'
M[;Z?OM_"TKT\I/\ TJO>+/G'C/4OHEC&?/WS^M^X/QC^OSCXXY_+TY]GX*5)
M,M7L0I7QCVX\_/V_QX) U) ',DV ]2= EP-3L-3Z?58DO6^=-:R*0P>Q-K:Y
MHQHA$00@BK?<J]7"$T>Y)=B(G1(9@E#D2(JY++T9+[3;C>9#+K6%96VM.+U-
MA^+UL,DU'AE;5Q0R^%-4T]/+)3PV&<F5S&N#;L(L"0=0=E=9"]]B"T!VV8@$
MGH+N'V/PNLH,D(LA#;C#J'4.I2MM3:TK2XA2?>E:%)SE*D*3_:2K&<X5CQG'
MQG&>8(J8W.>UI#G,<6EM\IS-_4/> &FYN=O/14.8YK@UPM>^O_$6ZG;DK0O6
MSM?ZR!_J;8EQK='KF);$%1RUF1P$3B;)]WX:'D@3E18F)4C*%X88R[]5WV+P
MVA64Y\95+%55TS*>CI9ZJ=Y(;%3,\>0VN2?#B+GD- +G$ V:+FPN1<B@DF)$
M>5UA<B]C\S8 >>WFNRD;'I&R0D:SZ_M5?NU9F.RF(M@JI6 <#2'X3[D66PP3
M&RI,-YV+*:=CR$(=RME]M;3B4K3G'*:B.HHZF6EJXI8*F*V>EGIY*>5H<+@G
MQLO+7;4$?&)(I(GACV%IM?,7 L\K$;WU\A8@ZJZI9"-"CORY3S<6-&:<?DR)
M*DML,,-(4XZZ\XI:4--MH3E;CBU80A"5*5G&,><63([3W7-U LUOBN<3H&M;
M&7.S$D6.4C2UKD*EL;GN#& />XV:UIU)/P/RYK&M%WKIO9\V:.UOM/7M^G#H
MR9I")3;A7[-)@0G'?H-2YK <E,=C1W'?]FA]U*&EN9]B595\<SZVAQ'#VPR5
MN'UM''."8I:NEFIXY+ '*QTS8\[B#F#6W]T$FP"J=#(QI<X  /R'4&S[$Y3:
MX!L+V)59O&S]?ZW%/&[]>:=1Q#+2WG2MOL8>NCFF6\9RMUR67G0V$H0E*\J5
MESVXPG.5*QC&>80>2"X"X:+DV)%N@+,]R;Z:?#I:=HTD$;@#GJ;6N--.5[J*
M;9_K/=<Y.X*GU>ZO' &\.PFQR35;JLZ=(-UO1%>,SFU.09=OVFP')-DV'VL?
M5&A:$-LY(](PR/;E"<2OQ\?.=A^)?E;L9CH9Y,-8[*^H$4P9&0;/+SX): ";
M6)!!:ZX&BRC0U-PUH8YQC\7*'#-DM>^Y%^@/U&IW:ZZ]<6M7&+5M;95QE;?[
M';)CCF-A[9GC6Q,5D./4\Z)USK6LXD38^OM5UMUUY8FL0)<B>3(/2K+;R]@L
MY"847K1.QQ+HGQS,(:6Y' /9[MR'YRW<DY0&@BQNL:UR6EAC<VU\Y!!)O8M-
MK:#??EYK.-^W+JO5B!J]D;$I% 08S)2)5=+0%K*22H>&<R\0,EYT/$S\+B1'
MS)Q'^IEC#S67/;AQ'G-IJ:LK2YE'2S5+V .>V&-\Q:RQ.8^"V0@:?\@!H3LK
MT=--,"8VAS00W,"+9S<M9J1J0"0!JKN!64-91<$V"(PC(8G#C$!985*8GC"4
M"8PW)BS8$V,ZY'EQ9+#K;T>0PM;3S3B%MJ4E6,YQG2!KWQV.:-Q9(TD,<Q[=
MV.:_*X.&QTMYWN!:<Q\;GLD:8WL.5S76N3U;8FXZ']M51KKL6GZZKQBW7FQA
MZE5J_!_,31^PS&18@7#]Z6LR9Y&2ZB-%9^JM#?U'58Q[U)QCSE2?-<&>IFCI
M8(W2U<SLD-,PYY9'VN UL8>3>^FER0=-%7!3S5,K8H&E[S_QRD#;G(;,;:QO
M<BUKG0A8UHO9W1NRPA.S4+;.O+?7@\_\M*F:Y:!146,GXC-3,Q")%B7B-$?S
M$?9D_3=5AQ++B'<IRA6,YNUE'B6&S-AQ*@K*.62//%%-25$8< 2"_P 8L+7
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M(HORM[9P]QEFHO#+76+AFCS$2N)>7L/NFM]!3OKH\1_%5;9F,#<C9G%I+6@
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MC/GR\VE]*\(<SYS[E)QC*O.?=Y\Y\P6APL1<7O\ %7(Y'PN+HSE) !.AN!J
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M_56V=H];[9U](N59G5RUTH9$U]1[;48GY+3=HAR6)P[94BV0<3C\V1%;S[(
MM0MZ.)G,12\'*2#++S50WV!&NA%QJ+?S\45J]>^L6S=?=N^P.^;U5M#BJO>
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MLA/;_KRX+CEHU\E3V)I@8#'0A=)OY8Z6G&PIVQA70M;&5:7830DN!K%B,"K
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MN?47;SLGLF^%V2; D9468U5M0= /7%8E#VZE?:FYL2J0+0?LF^ %LB'%54F
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M#Z]:U.@J/%-6&[W0+O=X:(.,,BP1_4NPMO\ 7MREYE&W\,3K94ZDY(M,N?\
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M6W9$Q<@HM\NFATM;X>>_D;*^8-#I R5%FCJA6H$V"N&Y"EPP8V-*B.#AI +
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MDX.0"3#60BPR$^)&FJ9S)8C393#3J6GW4J*5DB!1:4*A1!HNI5P:.'@L5>!
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($X1.$3A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g491933g90a90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g90a90.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1V^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ':*^=88X0DE-! 0      !$< @   @  ' )0  5$96QT80 X0DE-!"4
M     !#C?*;(JC_4;-3S<Z3Z+->M.$))300Z      #_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    . $$ 4 !. "  +0 @ %$ 5 !! "  +0 @ #$
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q :/WK          IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M            /X   #A"24T$#0      !    %HX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          (X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          .K   $9P    8 9P Y #  80 Y #     !
M          $             !&<   .K                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   .K     %)G:'1L;VYG   $9P    9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #JP    !29VAT;&]N9P  !&<    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     ,X0DE-! P     $TT    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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MJO/_  [_ .":3Z@/-<!Z)'M3
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M='>TMM$8)29B<G:WX?$V4R<T0T15<X*2DY2R.$;2TRA%5EAC9&5F=:+#_\0
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MP;[?72'<'F/>_E]8H%U2W<6_U(A\P_G>G7T_12'<&_B$<@NF5WR9OMC_ ,B
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M6S!W(9VN-1O<;Q>'TJE>O,WQZ>" ;YW#\,1 0^T/3O4.GF.MQUMO[>T.X/\
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MEN'Z!DX!@%#9^!0'UW[#OOZ9]0J'',0\M;"_(/JQOOIS#PR</_*#@0SS8V$
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M!/1N%.SO$^(J1==+GRJ.E[TRT+JAE$U0EIF9Y9( 6@I(1F'A*QE!<$ QXFK
M5:@+YE<+>4\YY9:%CXMS-/DT2-Q<JRI4X](RJD2@7"*SDR**J;DR:'E3**%
M=AX"X^PKCM$Y&')$J?(*C.I5J!J):4A*N_7+8+$I1*@E1 !4A8!)28\GB_@_
M$N%2B955$N9(F,)<^7_HK)470%OE*PSE+DLI+Z@1)ELZH:?7><$8&Z(QX],
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MM[/OY/L#"+.OJ^(ZPX+VT\CY.747?LHB.BXA)-1Z_E9)446+4JCA1!HU(JJ
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M)(220P8WY>?Z:_*)2H9@ 7+^7R-GL-[7T<B-HHG)ON ?#.<8V'? =^^ SG(
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MGH619WI.2R"8)N8UE%O$U8IF1<A0.BYFY% $1(4Y%#1C:2.F/,0*^VYI"@2
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M-VMLQ V'U NX\HFP.QTWL=#=VWU!ZZ,\/&+Z&#ITQ]G7]7PH4MN+['7EU L
M'?H[" /OZ/N_/?4VO#QB=P'[ Z#U[_\ 7X4RJU/U8\W?71OT@"-+MJ-KC0[W
M.D6U><VM!VI<$PT*H9U&Q3MT@)4O',FHBF)RN/  Y!7!MCQQ1YB@J"9D\@!A
MQK_%59-P[AS%JV5)5/F2*4K1*0M2%+>9+0H!: 5@A*RI@1^$O9S'L</4DNNQ
MK#Z2<4IESZ@(4I9L/ M0)Z. Y((C7&^;LWJ;R1<D.JXD55'AGBCI1PX7.4!
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M(0I"(JUU_(IJ[_5I?']VI*D(D>+_ !;'?T%I_9TZ0CO4A&*_&;"A*\/]W."
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M]!"#L/25@Z<W<_DI(EP-F#BX7(H@]?F0:-H^PXI,SJ9838J\Z5W+<C1D9_J
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M\=LH Y#M_(!CON8!S@,>'PHL&EGI&@G%0.YS.^[6(U:]G,;7Q_+R8A1L#>E
M)878IOKU_P G3(^MKC0H4A'@W0C+.+<G$(%<&TXM%/TH=R;\!O**-52,%E,[
M>&DZ,D<^0$.4HY*(9 846'70><(U,6(PN#3S0"";Z::+ZE6%Q$,6EB0FO^H*
M6E#IY?CV%<7E"-]5;@A+IDHMZSU4N95JK*W);AFREU"FR!5=NS!=$D<M4UGM
MRUOUZ[7](CH6\OM]OOZ<I.7XR9BWQ0AKJUJBHN*MWB>G+2N!U8%OM;WO&/M$
M]E.]$FM\1#VS3MHJ<N%XO<;1O')P5OSEPPR2A3,&CE111M* DFY(8!B^[@;\
M@YYVA8\CS^GGRVLXU>.-RZB<35AP@1UW7SJRFVN#53AB:-+H0L2W7%UHL=3;
M$GWVK-JV=$(VD6-DR6]/,D2,6 Q$O,PKKE;*#)*%*U6IF,@RPDOF6I*GV =B
M+BYM;K$^1!-VY6??YZ?,Z19MSZH<<\?;>EXQ,1K:XFFBSV4+++VBR!.[+62U
MA>Q,4SO^U8O2N95C;M/I>DTFIA)_<]AMB-W!5F+1><*JW&I08D @CF"_VBA9
M*= #YE] "&N1J>C>@B^+\LSB+NBVV5\W1?>NPI0W&B\*A:5GVM$(O[3T;MW4
MF]8B(N*(C&5G25Q7&U5@',0]0=/"2S!Q%@P<^1=M43.%*8A*C?,&86ZZ."22
MQ<@7^<>_+)<74SJ =)OJ+K+;MJSVJO$9; MHNR;5\K;E@VA;#BYM+YJ-?RME
M/7"#BXKD:I03.9?KNVDFP<^RHU$'8)NJ16#ZZ7\_;GD\>-9-\\;4[JOI$-UG
MNBU+;<VWHVYF8IS8TVK;UPI2UJME=4PGC1.G4JU@+I;3Z[Y%O[=O>S&\&=HT
M,G"O&C@Y1>_9_P _2*%*4" D N#J^K_7R^1TB/YN-XQ+ST2GHVYKDUPEI:].
M'!_>;Z/1M6*A92W-1+7U2C&C.TH48ZTFDBF[GK(\RZD81XH^F)DR!GC)1 3I
M(@B4EPY:Y8,_IKO?;:VT;,+P,)^%F\#B_N:4$^BEQF&1O-@,5=CT1LUYES<<
M:,7""QF51R:1;#$1@HNA5(+)MCPBHJ=Q:_E^1B>XO\6QW]!:?V=.D3'>I"(A
MU^$2Z):K"!N7_0*YPSWP,2ZR ?,,ACOG ;[#*3E4#JT5)0J8I*$$!2E !WY]
M"(TQ6CJD[@(>/+$VDUDW%HQB\FE*21+8(\BV@+D\TJP>NVYWP"X=K&(T;-@,
M[,8Q033,?[X-V2KO3-*@4E)+-_, [7(;[GEL([5AW8[-JL,P;$*G&Y%.O&I<
MB;(D)D3%=VF>A,Q*9BAF\20;FR3;2+E7XD]73@H9D2 0(83"0SDPN13SD2@=
M--HS X;;X,0PX'IORX2ZJ0E:DJSA25$'0AP2#LX&K,"[:QO$G]GFCTJ.(:D'
M0]U3(N1J1F2JSW%SM<ZQ\-/-3[TOC72TVUZ#%//+6Y<Z\,M%-UH\S=T# I7!
MW15SNP>IJLO,II$24:"@;WQ\40+BZ9TF;13%RRHJ"E#Q-E>_(/HGY><:SQKV
M2X1P?@$_&Y>.U=0))4%2IU,D726+=VA)U#.+$;L8]7[HL;GX%>*P +L;12]1
M^. C3CC?T  'TP&<!@:P5?@+G;3TZ6)9P>HUCBP5F"% DA0206()!RD%MK6+
MZ.W2,PHL_P#FJ-Z!E@T'OG^0(.?7I@P=^G8:H+79G -O30L6 #@$[D=!%N_Z
M$-:Y>_F>?Y1W!..XCZCT$>N?3L(!U$-O3-6 /S=]2#II;9M-.6D5:$;NVUF(
M &]P+:@/N7BO,/3'SQOC.V?CG'IL&^,U-O-_KOSW^P;32 2;NQ ZW8?K>^YW
MTAS&Z\NP9VSWWVZ]!V#IWR(XZP=2.FN_F USIIR'(14X(V=KD=&:Q;Z;@#<"
M G'J.V_81V#/;;MGIT[ .=JD$!R; /<?8^N[<_,TERDY=;#S;376UPP%Q<->
M(/N:V7%X:U6A&IW)-6F5I9\@Z4D+=60;2#SQI9,I&KEPX1<D%HD#<ZB294>8
M%5E3>( &$ ]&@3,1+FS"$!-OQEGN";Z;DOIMK&%.7*"T 9RHN%,' L6:SAS9
MB_II$KGT46*50Q-7]3 R(E#EE8O)!+@,E-[- !-MD><IL".,#64*E$T'N#*G
ME) 5+E+0J8[M8/HDLXU9R#%"D+0 I:%)06(44J9B-=#>VQ^UX"U"A#QY+KMK
M^$W4Y=RSBGB13/G=N+Q[]=."">59*-VZ'M,B*\8JH(NUF:#%P9FZ:).0< D*
MM;3$D=ZE,LEV0[KO]+6?0=+12&6"I$V6M((=(?.[N"7.CCD8SZX01SP\:> (
MYPVFB[F W+BXI8 )S!L/('N^@8P&P!5"M3[\OI:',.[>^0\_7RC)6J80I"%(
M0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0$0#J(!\Z0AD!Z#FD(4A
M"D(4A"D/?OZ0I"*9#U#;KN&V.OV4A%:0A2$4R&<9#IG'ZOW[]N@TA%:0A2$*
M0A2$*0A2$*0BAAP4P^@"._38,[TA$7:QK&1T\NDP' N8]$F<X'*CYNE@!R >
M\!Q 0W'</A7DXV?^%U@LQDS'YZ>^@CV^&90FX]AZ"2 :B620VH<O<'DUFW$0
MUPQ.3G/=J)C\WXE4W'?(C)E$.H (B4 $=L[[XZ5KO!BTJE5:7)*5);1M2YWY
MMKSU<QNG:9),NJPZ8 ?%**#NP2!T!V)<VZ",MZWB.80I"(JU+U -8I;77.+9
M)A)W!)MI=ZY*'ALXF#LF[KT?'3,HNV1(NJC:QFI%EE2HMRK'<*[)@4U!5XPC
M8@DG4^3:7M[:*5J*4Y@ 3F2+ON_*^W]C$,)\6<9(VW.34!8EP/'\#;LO.O(:
M9?P5MN$58J2N6+*P4"3D@?+*N5K4EW!SL(QZ5BT*T6>@D#O"%<2Y<<B'Z[?9
M[^1O:_87XJ8N":/AN:T[D3DV@W$]+&QK"-<.%(F%N*[(-<[<&5Q2Z#X8MU Q
M<5)/T'2;=Q(W%".2-&#:2%!DA=S>SCJVG+GS.@:T>-K!K4*=C:<7LEI^V=-W
M,E.74:'O^VQ6E+?7LAB\<DD6B!WR"L'*)\CA5A<#1O+/F;14JC.(>&>"F2VN
MQ0=P7'TVM]QYWBH '<#]?MKJ^D=)MQ0W&N[2@ MV&+<#;4*6CI),5G_EBZ;)
MW*]M.W[D0R(F++RL\1.,%NJ?RJBT-<IVX 1HD4MYF -[ZV-N1V] _P!XMJ)
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MI\HAW49"GN ATR< -C?&=\[AB @ 6>P>_-K%B>1/GH !?44EV!O=W<:MJ0&
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M"\/.GXY-D$IXN_I]))4<B [@.V<9VR(;[5W$(3+9"/"A"$H0@?A2E*0$@;V
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M3F=.&#KS!T[=&:MN0E9EH1>3%HU\>1;+MD&A7,NL9-@LY*V3,]<BV:*J.E5
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MO"R@ $_AW#AGL^@C9377H^<X4A"D(4A"D(4A"D(4A"D(4A"D(BK77\BFKO\
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MR)3F3*?-H^*\*Q#$Y&'4E6J:9^'&M3,"$A($M14LJ44L#D2IPV4#1E,8P*C
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M.P]B4O/Q35'\38?,%QH"4OILUOK&.'"4^QK$Q3$P@*\%-H8' !_))KB3;X(
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M*.54B0ZA) L+\HI$TYN!5F1.1A;=@ETTX]Q8RT;X1&5MLC)(&9&1354<&(0
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M2.?#730Y>[>_E]#[DGI7IU-KR#J7LV D'4LM%N))PYCT#+/',&U,PB'*J@%
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M7&FI<1]$]HO99PU@/"4_&<+FU)KI"*+OC4*44M,\ $H.+*<N&) 2&N"(V_\
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MMJR$^94[C:&A9!%WXX2+LRRAP#PT$4TA%9P84O$$,M"4+E3,Z4KRD@9D@MR
M!<-IIJ(^B\.[)\#K<*P.N1B.)S/WG+I9]6F738;-E4IFI2I<M"YP[Q,M#D)2
M6)  VB_S:_ZPKCS)WC'MBB&#>SK;CL!@,'*0SWSP 4!]0,;;!ASG/EIJ94A:
MPBEG I)"ERE% 4Q/C 2H?BU'1HZ9)[$N"D@"?)K*@   S,16A*@ !:1+/=R4
MJNTJ6E,N7^! "4I \NS;^O6[=<;/1NZY5)QNWA+F.R26C8A@*2HQX$$X*QC!
MF<PBB94@D4,H %$IPP*8#5_OD3*&;.4@2)847R@)*CF+E92^=1U*CXBIR7N8
MTWM [-^$N'>&!B>$2YU-62ZA2$R*E07*G!*B+I*0%I<>&RLP94<_N@JHEX,-
M?E4S "A+,0.4P  @!@GX8Q1P.2XYB@.!*(" "4?=$:\-]2"X8$;6<,VKA@+Z
M'4O9_F\JS$:#4D  )!8Z6#,=!II<1F,@<#(I#G&4DQWP&?=#XC]='!&MP VI
M#C?78:VZAXR@7LY< >]ST+Z><?7F+TR&WQJ7#,+'2X=[6)UV.G5M-9Z;#9C]
M.=MA](9#U#[0H"S Z 6M9P;D6?KIJ[M$PYBCOS /U@-'&H)LQ9@2 '! :P#;
MOSYQ#CZMS^WS\M8"<H=1#T[?$/W^WTH5!F!.X&K;:Z=0!IZ11-+(-R/*QU#C
MG?UM]8Z"XH2T]9K=G;B=-HZ,5M%XQ1?O@\-F=P24%59L#@Y>3QBD51.9(#<X
ME.0V,9&LW"P,LP%MK#<$ZD-L>I:Y+/'G5ES+.Q=B=1X3]P;.+CRB>%->=)A^
M]FNVVR"."E SA$ QL&0$P<NP;]>@; &P5ZK VRCS;RY_1@W7EB6ZZ\_?Z=(@
M;4*^(J34NQRPOZUW< ^AGQ$(H)4IG8<\ #9JQ:PY(CE%R,TD:0)+IS:2BS9V
MX8*L53)-%VY@X.4 OLSZ>5]+Z:;B)'FW/RC-S@[_ /L[V!_L3W4<C_VDENHA
MMGUQL Y -JMJ_$?3["(C)NJ80I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0I"%(0
MI"*&QRFR. P.1] QN/U4TA&"_&_;JKZQK<N9%R[43MFXDR.FX',=L=K-)&:D
M7<(]!.@\0;)-U1V)YE5,1*5<XA\Q_M/X/65?!^&XS3SIJ9. XA*FU$I,U29<
MXU"DRY*IR$EIAES0A4LJ!"%'.DA0!CM/8;B,JDXKG8?.2E\2HYR9:U =XDH2
M3D0HW2E2<^9(L6!&A$:U'#MW))GCFY5EG,@HDT03!=595598WAMD$"G/R)\R
MZ@\A0*80$Q2&4.4 $/AI&-XEB=3A^&4J%HJ*NIIZ:6N4I25YYTU"$D+207=0
M(U+L!>\?5$S#*3#D5F(U!0N3(IY\]:9B4K3DERU+4X+N&3>['>-M.L=FO'_#
M?)VTF=\I(P5F1#T2D5,=T]=6N$:^7;KG(;F< Y".535*)A%83XW#8?T>[0^'
MZO%>R;$<+1,F(K:7 Z$)1+4H9E24R%S$* +Y2):G#$$@V#L?BK@_&*;#^/Z#
M$IDJ4JEG8E5*4%(20!/5-1+6P&4*2I:65L!:\:EBS)_+%3!0XD%(44B^*J")
M"J@3(II^,"11,)15!02\WC'\8H%4(4]?FTO'\05*FX>$K 2N92(1F5E3-392
MT)+A*G#YDL?*X/VNG")$V<B<9A2 F75K4G\2D!UA*U"Y0&T58!VYQMDX?+.>
M'X:8> D5WK12YH2X%2G*N<CAFTN)S)'9J,E, 9N)&+ELLB4/P% \0"@8PU^C
MO9A@6(2.R##,(JYTX5E3A=>53%S%F8?B9<[NG6HE1"<R<O2VF5OC'CS&*:K[
M0<0Q2CERE4\JOILJ D!"OA3)3,S)8I9:D+"BS%P[QJ>!9U N7D*Y(JFZB7CZ
M/=I'443Y73-91LNFLF0Q"*^&Y2 X$,'AJ 42J%.100#\]:[%,1X9Q'&<(FH7
M4*H<0FK/>$K(4)BPF9XB?$G\0.H+D.2\?8M!(I<=PW#,4EIERQ.I))D)2E+2
MR4I),O* $-HZ #L&9SL@X%HATE:]ZW"L9<&TS<A&[1-0YO!.,:Q1!PZ13_ Y
MSJO!;+*E .;RB:>Y4B8^U_V8**N3POB^+U9F9<5Q$3I25J41:7XE,20]V??T
MCYE[=:NEF<24%%3IEIF46']W4J0E*53)IF%BL@ K4E(_$IRQ]!+/& T.[X>[
M\!,"\[0UKR@"8!$"DB;P@)%8^VX"1!LJ8#9Y28YC )0$*^L\#FB5B^'D_P ]
M0)8'/.E0MY:^C;QPU0MMYEK?,?,;QC#P:L2N=6;BE )[T9IXZ9\Q1, $+.7+
M!KIE,.X??#6ZH/+S9$"#L;!N7:N,"!2TJ;/\2M77_2OZ.?K:(%E*!Y];:ZD;
M_P"(V#7_ !/MVR[KA@(F8\M;4[&%YQ,7=_&.6V"G)]\+S"H&Y/>R " "( %:
M"EW#/=G;D^[><9^'3DT^(T-02QDU<A:3H01-0;'4.0':[1IEX3F2CK7S2\_*
M;D9+7#(*EW*8@)V?-$(90IL"'(JNF4Q3AS%4. 8SD0QZ63W<VN)8E9D,2WAR
M]Z% $N0"X?=]>8^R>V*I0OLWF3$K),X82UWS DDE1N25-J-P"><;R0#<1_.Q
MM\@QO\?U=*OQ\4@<M"S<O2*TB8H8,E$,B&P[@(@(?'(;_92$8;V:/EOI D!O
M<+=MY$R?.<#=4R/OXR(@.=^HX$>O<#R.O(\H1-FA1@-IC"" <O\ G2\0$N<X
M$+UN+.<[Y$=QSOD=]Z0B7:0A2$*0A2$4,."F'K@!''KM4C4-SB#H?(QJV^Z!
MNRI3VG3<QA#EC)UQ@,=#N8<@@7Y@B/P$.V=JXUVJKR##22<H6EP]B<Y(M^KC
M5[1]1?LYTQG2>*%IU$[#TD[Y64Z2VB2?Q:\VC%SASDB(:XZ:&*;E,I=#1OOW
M!RFN@!?F8R@%QZ&, B.1K1^"J@KXDH&)!^)RN[%BA=B1=DO<:7]8ZOVM4^3@
M;'@0Z10@@,X![^2' (#'J&( /E&^PHY /L']_P!-?38T'O[6^\? \5J80I"%
M(0I"%(0I"%(0I"%(0I"(QUK:/'^CVJC&/9NI!^]T\O)HR8L6ZSMX\=.;?D$6
M[9JU;D57<.%E3E310034554,4B9#',!10BTX_B!T]18LT56&JY%46C=)0G\
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M$MY2TM:MVPMT6Z]:HR80SV.<(OD#.$DVH.TW*+I$B*I%2K^*HHF!EDU&(E2
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M;NX5XUJBYAIT6;:V7S)6/<1L69-4#(13L[IZW8US4T!DG)F,[Q905* %DE#
MAB'S:W=@#I%G%T<%2L.J5825*K5359BI<SP),BF5+$K,HI*<XGY]2+!RE\WJ
MZH27%8G,ZGELA"[VR:=RVVTM%&,B+%<6RCI^H6V1F9N#<OF3V>?WL#I6XP78
M21'S5%FD/DX@SD(T[NS)^%"4":U@HJ8JS%94I@6ME9M&).A9P,?"Y7"H31_&
M*2H?"S53 I4P*^)/>$)6$@)3*'A8@I46=S=H^MC3C6^3UVTQO>\X>1DCM5=)
M%KGN4&4?%(*K0=B\0L=)O'48V<<C-=NO<UN(R*3=$B8/95 R2")#F1;Y"YM*
M:>;*EAEM, <D_B7)4GQ$#1*5,^Q&X>,Z?B?#TOAZOHJ A*A-K^X02I2LLRLX
M<F )4I*2H/*J@EP&2E0;PF-I*>?#( XR!0 <;AD P._? AUV^0=*\G3WSOT]
M\]8YVX.EQ'.D(4A"D(4A%G7[>3:P;6D;I=1,O.D8J1S=*'@2QQI>2>2TJPAH
M]DQ"6D8F-!9=](MR<[V19MDR<YU5R 4,H>_?TB,/X:;U_P#W9==O_F=$OVZR
MTA$PL9TB]OMYZ98N;4*HP(^?QUQ+QB+N%YT@55;2KA@_D(DJS7/AN5&<D]9E
M.4X)NE2EYAD)*R$I!4I1RA(<DDV  %W.EH@J !)L!<DV ;77ESTBQK7G],6,
MW<:D+>EMOI:_+F9SKMFG<<,Z44EDK8MNSF[:,;(+>,":D;:<<8$/OZJCPSI4
MIP*J1).X:.I0,RJ28A*05*44*   <J-FL&Z 7L7,6DSY"B$IF2R26 "A<N;>
M;V_S>5S& A1,8<  9$?0/W]-_2K477#/M$3/I[2YE?(W2_OFW&=Q1T"[M%9B
MZN.';IH-'$FTE%RN6BRY7"3Y-TS2( J'(5-,RB9D!.;G+?32U:T!2),U4O\
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MCL'7<,_6)J?BNXJ%EUU=.BI&CA"TH6!MH%I%O\<-FT\ZDG3J6>7F4RS)4=O
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M@&_]KFR Y'YU]QX<OO*"A6=54DG77_32]O/76^\?CIBZ.ZQ?%9;-DQ&L'_\
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MIMO%$H&,!14\/G$H&$ $V $0 !'39BC,G39FRUE0;9R2U[[QM\E'=RI:+^!
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MXF$M'H*"*[=JDN/BTB"+-;:VUC%MGN2]K,2!.^8<UUPB0F ]X67&+J/&R %
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M$D @'0!KMJ-&8VC*P/$Y^(R9AG("52EY2Q#/Z&[WN'^3/D+7B1[L4 I2_@@
M;B.VP9'KM\<4@WOW]XK2$*0A2$*0CB8<?7T^([B(=\8 ,[AOVR/2"[.-M>@W
M/M_*(?\ MU]_*,+YW5#7 ]Q7"E;RUB-X1C<,Q%QZ4C!R;U^#6+D5XXAW#E&>
M9HG67\L98X%;I$3%7D*!@)DV[T& 83/I)4ZK[_OIB H"6I %[N<R%.!?=VU
M,:;4\2SZ6MJ*<R@J3)5=1<W)L&#$L "X!%_2,B=([GG+PL&&G;D28(SBR\PR
MD2QB:R+ Z\1-2$4"[9%PLY61(Y39$<"D=PL*9U#D!02@ !JV(4LNCK)U/*S"
M6@@I"B"IE)"@Y3;?8#DVYV>@J55E+*J%(R&9F+.#8*(!U.H#L;C</$DUA1F0
MI"%(0I"."O\ )J;9]P^P]!]T=AJE99"SR2H_(&) <@'0D L'-^F_E'XI;ZD4
MWE]7F\*83IO;MN1V01$V3%<S+Y4,@( 8!'GW$<B'?8:^%,>FF?CN-SD*=",2
MJ):SH2KO5%F)=08BX]2-_P!Q^!*/X;@OA"2I(2:;AW"I:@^F>BDE+-SYZ@AN
M<6J9PF &'/*&#8'/3;J/3IG.-]MM^_D)6Q!+ ."2>0U._+DVHWC;52@0[%K%
MBS$ OOT!^EQ'ZHON<\@5_P (^E'*H)S-4;H;*9_F^'>%P!R] _!'D#'8 QOC
M;[.[.YB)G">%J1M+4DV:X5UNS&QO^GXX_M"4BZ+M>XPE+#*F5TNH;49)\A"T
M*#%K\AIHPVSEK=HXQ"D(UY<9>H.L=OZAZ565I#/:A1TK=-A:Q3+6'TZMZT)Z
M0G;OMA&SRV4A.#>,>[81]JIR4PJ2>>IKL12:.!,HZ3 I3D,_I>*%,+D W;<V
MWMSU%M?I'C#Q@:RVT-VPET:66F[E-/I31K3&;FBWP,0PD]8]5X"P'23,[(D#
M)IQ5G14I=,P,A.ED'9@:L8U&/:/5WC@S0+IS7;0>?+[^[02H*) )=GT9KLWF
MXZCTB)+[XJ]09^?=O<2EDO-/M)N-:&O6W[.NX)"!E;VT<3TK4B;EMN>=V^1%
MUY-*;>C$OY&VA7BW;F4;KQZRK1RG4,3GV.5@1>[ZZ68'K%,PD92-RQO>]OF.
MG]X\U7BEUETTU+U+GIJ'?7XG,WOICH]I?:#6Z;HD(F-4F=*6VI:TS)6[;MA2
M;MS+O8]JY=/I"'C'L@O+2"L0@D$,T*^"4N$)!U'T<#< /HW2]KQ$HE5SJVK<
MG'GR?GSUB=1XV-0%57[AQI%&6?$6KH7"ZPZ@+W]=4U$REI/IZ1O>WF%K!!1-
ME3<U,*+W%:C5)%=M'(OSQ<@*X19W_@1[A%WU.OO:XB,HOC:UYU)N#2B)L>Q+
M)MQY*ZKZMZ5WO"7=-7-&-9.3L?3-M?$>HQ?2EB-;BMU$S21!P9"1MY&54E&"
M<8=F+1Z=RF@=WT;]7Z^_EZ>F'&W=#"W-*;.F+3=3=]ZEPNF,M89YBYR2<A=[
M*[+UN:#U$=OW[2VHA/\ \&D3;SR;6\M&(G>12L7XZ;0%5ER(7<WMR:X\N?L1
M._"=Q:W/Q*/9!P_TCF[(M)W;;6Z[-NEV,Z=C,,%Y9>,4B7R\O:]OQYY]ND#6
M06"V7UQ0P)K.&I9(5F2AU4#;?5MNOYN!TMO&1FNOY%-7?ZM+X_NU)4B8D>+_
M !;'?T%I_9TZ0CO4A$.\0GY#]5?]QKB'KC;V<L'H;8,_FCZ8JJ43WTO37FVX
MZ'E;UBE?X5;6U]_YY7C63IFC))65:BI;UFXXIT6PMD(ZWX=^C!(2<@2*9G4>
M/T%5TRO7IP0*1$Z[E4I'*AFY&:2B@=:I5R!148-%*6132G69B@J81+!4K*"U
M]7ME)&[@<FQ#_OM78_\ >9NPL<QN_7SLQL=8G8EEWL &Y]5)PYAS@PP]O)\I
MA$1Y0*DP H  8# " !L  !0J36T:2WP$FUKSE'1A_4P)U_,W,8C\R.1<"Q<N
M+W._4FVIB%[YB)R'OFUC3-SNKE(LSERMP?-&;0S)4K(3@='R"2 *&43(*9O,
M 8H 81 N0 U>%Q8N3/X9K4HEBGN7RYE9K$AR268.S%B[OM&W<'J*L5E J=FN
MS 7;5ALU['T!,8A\>OB#PR704J@IG6U$X>&_-S<ONK<1>E)%2#RX$2G*(D,7
MH<HB40'(!7$J9"OB$ #0)U.S /J221?F^S1U9;(S9K@E_/38;!O(!ASC,03F
MQCU#&?YO?&,_(,#W]?66OJ'<^NA(>VEP3KJ&U$97G>W+Y\_E% ,;UVWR(=]]
MM@W$.N!  _0.1U \@ = 6'0WO=W8;N;8207Z/=C\K!CY;?(QRYA$0#.!QD/7
MX!G&<=<AMT^68OXCMIR#'>S/MM<;1.K#\)VU)9M ;'FXO<-%.<P[9$.@B.0V
M# >G7;8!^6=QJ68.6T(  U=[;$7>PZBP%CW8N+A[Z?(WLP<VLYN2SG. COW$
M=@ <@(AMT[;B.W7;;.:I8'*V@7+4=;9%A2C8ZL+ 'YM %C?_ )KL_H6;?6W)
MK&(EN72R0U$U2M9W#7*I;$I&VY((G=F8-I-LY:N) AB(G:+D)X:B:I%!\9-Q
M[Y5"D%,.03&[3V?U4J3@^+E:.]3.Q$3DH?*\LH* 2=0<UV9QEOK&H<58M-PV
M=(3)EI)4 7.I%G9SL]P>>PB1B\,EY^\*VKKHXB.>1&V89L0H9_F#X2Z@ &!_
M"4$XCT$-@#;E8E39631Y3H%&8I3=&(#ORV=G:-3/%=2Y9 =AH !<VN["VYOR
M!-XCJ;X?8V)/<1BZA3;J8:1\HHY2&/>,F3Q44DI218,GGEDXGS;A(R3E\TCS
MB[.4?-.2J"DH9*9E8J;3K1W*4H4A0!!25!02H)*DN^7\02J[7 -[URN*:Y4U
M"4RTG,M.:X 91\3&PS 79[\F!;9=P5&$W#O9^0QROKG*4-O=*6XI+ >Z  ./
M7O7'*FU1.;3O%MY/Z1O8F&:E,PABM*21:Q*1N(RMJQ$PI"%(0I"%(0I"%(0I
M"%(0I"%(0I".'.7?KMGL/8PE'XCN ].V]1F#/K<CJX+$?,0B"M2],Y.]YNSI
MZ%GT8"0LD]YNV+A9A[1 S^YK5DK;:JG3(]9F32C5GR<F=,A^=?RP-P,W%45B
M>GAN))HI%;2JI1,EUB*9):9ER]S5HJ%, "ZE@*%VLKH$G7L8P,XK68;72:PT
ML_"TXD9"D2Q->?742J($AV:6%"8S',H,8B#AYTIM_32?F LO4TM]1,C9=IHR
MD2N\@W;MO(6^\D8V-GDG,*#0J3*1;I/XQ4CUFZ=K*Q(IGE%E&RB9/1QK%9^(
M29!JZ,T:I,ZH2%%"T^!D*F J62DD!2%>$@$*\*4BT>#PIPY1X)53O@,7^.E5
M.&T:YJ0M"U*J*=<Q%/4'(S">RY:R02"@9ED@Q/NM_P"3UQ_O9II_Q+M&M<C?
MXEJD(4A"D(4A"D(4A&*VHHYU-E\". MBU0'J&_G+FS@1V -RYZ8ZCMD:W/ ;
M8?-)!O,F: W#)Y:[_P"1&A\4G_>I WRILSELROU!\G=R(];1 ?\ 3'4D,Y_S
M;8XX'.0'GNP1Z[]P^ Y]<XP^)?Q4)M_H*;_W!^FK-&=PH_=5G_YD^HRZ[>[1
MDG6L1MT*0A2$*0A2$*0B@AG'UY^0@/UU!-CT#_?](@@N.0=_E[]O&%1P$)&Z
M1# 8O&[P+N("/+<\F&W;; = $=LUTG#_ /N=$#<F0CY%+A_0[Z^;B.58PE0K
M<2+"RQ<=21;3</9VVB>=#.;^#B-YAR/MF[L?+Z6S>/3]5:=CG_U.H\I7S$M
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MREDW_:KQ#36"=(>3*W<(P-WE8SAX@Y CXMXC[5;^9D3G/4DN$CD_W_2WI!]
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MY<\R/6.()$#HF3]?V (8#ZJIR)_H1[_],0ZOZB/(_J\15K?^3US_ +V::?\
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M0 D%B2!81L>$_M$\:\.%&&JET.(8=AR114E/42\A132/!+09J!WBBD .2JY
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MZ])NZ[=*B1S;3-^YTS0<PQS).2\TIJ/.P$RNFY4:M7!T)>,9-"(>,W;+))
MG;(*&,)]5'&N,8K7X>N33KIZ6=-EA4DAE)_B$'.=W2-GMOH8]Q> T%)2U(FS
M)<^<A4XRYDLN D4Z9B ;W\:B"WA<6!TC.A,1$-^P%^T2 /PKMJ= =RD$^;1H
M)U(V!+>4?2JH0I"%(0I"%(0I"%(0I"%(1$NM_P"3US_O9II_Q+M&D(EJD(4A
M"D(4A"D(4A%! !Z@ _,,]A#]0B'R$0I"+1N"Q;7N-L@B_BD$EV:[EW&R<<96
M*F(AZ\.=1T]B)>-4:R,:[<**'.Y6:.4A="=0CH%DU5"'0BSR+:AV,9)-V1SJ
M9;).<%)%L1FROJ+1((FYWC #M(FZTR$SSK118F7 B8$3B9=TMD41IY>_D/;@
M6B^[9NVW[O8G?V_(I/T$%CM7:?(LW>Q[Q, %5A*1SM-O(Q4@B!B^/'R;1H^1
MY@\5N3(90!]^['7:T7)2)A2$?)99)NDHLNH1))(ACJ**&*0A"$*)CF.8P@4I
M2E*)C&,(   (B( %(?G[]_I$5+ZFK3YA::8PPWDJ*P-SW*LY]F6&R/GWSA<
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M% Q3%'82B @(" @(@(#L-(1%.N22:>B>KH)ID('\&=[A@A"E# 6U)  >Z ;
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M2<P=FU!!V8D$&/3\C;;R^HZ[_G%ZI(I()D1023122*4B:21"IIID(7E(0A"
M!2%*4 *4I0 "E#   55!H^E(0I"%(0I"%(0I"*"&0$/4!#[0Q2$83_=!I (W
M@PXB%\F)XFG<JQ$Y1 N0E56K$2CD,>\"_@B'\X%!W#OK/&LP(X3XB40^?!,3
MEBXUF4,^5FW=B7;4GE'7_P!GNG^)[;NRV4UAQM@<Q0RNR9%9+K#:PTDE+N "
M<S6RG\3@*!C81W#H!< &XAC.=PQD!V <#U"OB#122Y5<?+D[F_TUZQ_0"F2
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M;E:,M06#?8<C\-NP?'X;=1P/P"L,KN0S7YG](I"'#O[_ ,VU^4/&+N&X;AT
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M..?/DS"*B(!]?<=PV$ Z9]!SGTWWH]WTZ#^^G,:M]G3F=S]@-ARMN_6FXYV
M>N<X#ZNO3IOD1R&-J:_*[GI8_I<AVT! B':W,ZAAO?<FU^MCR)BNV=N^_;U'
MU'\X<Y /EFJ5J* 5MF*6( YA0(9G!;D/I%:"A*DF8"4.Z@-2-&)+G<=6#1YC
MMS(0ZXS$/)NX>2433CC.VAD2G5:G5.H5 ?'*H!%3'.=)NNB0SA$Z_,1)4I!
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M>0CPT\08<$XG,GS?A9.&UYH)LR8S&:4RB@):ZBI4Y"4I S$EHLBYN+G2*!A
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M"D$.[J>QME+A-[[ -K&M?22^QL3533"\SL7,.R7DHX5%W)6O))63=IC0SEX
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M& YL>OV>OJ/S .FV]'<'DY 9W8Z[%]CSU/2&_P#AOT_** J?(@)\>N-]A#J
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MTH+FY@DISJRR@'L E*CXF4^@<![!Q&LUV/\ PBERJ62C/*4J4K*D%0RD@DL
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M!#@V(,=<K!D0W.1HV(<3 83E13*<3!@0$3 4##N =1'IO5>=6F93::F*!)E
MN$)!U<!B_..R4A2_@E N<!ML&VP;?*J8N;D[G6_*.5(0I"%(0I"%(0I"%(0I
M"*#T'Y#^^](1^;W[J'"V?J#Q]<,.GE_.7;>TKELV%M6969/@9/HM:\[UN""@
MI4BYRJ)II-)U6,>/2*%\)TQ9*MU1 AA.GQ7CRFPS$N,L$PS%9K4DZAJ$$%3)
ME+G!4I$X/9*I:U!:5ABZ0H,Q(_1G]EK%N(>%_P!GOM8XLX4%%^^\&Q48BA55
M)[U:I&&4.&5\^2I"2E4R6JF15)$LJRJ6M82"HL</''!;8EMV)I_<UV+7.,S8
M]L:DSO%'#MWZ;8+>=&LR?OK26,C1\H8T4I+M6$?%.CF,LHLZ=D(!@.H3E\%7
M9S@^'TM+4XA-).%2*J;Q"A*_$F8I"U8=+RZI,\F6D(U6[W<1TE/[4'%F.\0X
M[A6 3::7(XFKL(HNRV;/PQ:162$XK24'$DZ>2XGKIDJJ9M.LD9$!*0,P+=6Y
M^$?2PEHKWE:"ESNV]E<,BMU:F1[Z5046A-7I?26W=4K*FR\C0BH6?<K.:EH]
MLQ.F!22=J2+(7HJN"#5%9P5PU)I*G$I29ZY&&80KXR5XB55<R4F?3SE* LI:
M%J!9LO=Z%A$X/^T%VD+Q.7PSC%91T^,8OVB?N+AO$:?"%3:2?@5+BLW!<9IY
MLE2C+G8C03)$JI2J80<E6A1<Y@+:L^)TLM'4;@&N^Q[-D+9G=2+]L:\YE^\O
M*3N!HP3@==7%E*QC-F\8()>7>M(5*45=K'\TV65613 Z1\AA2Z3 J'%N#)V'
MT$VEJ*^BIZD3.\4R9BIRY:RM)0GO%+E!:2LL-04Z"-AK\3[0>(>&_P!HG!>)
M.,Y>-8-P?@W$&#4](.&J/#U8@#PU)KD5?QDM>>7\/.F.$("R3XN\"5%_V6-Q
M PJXSL) WZ_@ .-^W0/JVVQ7TR0V7_I?YD^_[Z?CT/YN8F*!ZD!//Y]2YWCL
MU$3"D(UM<:-H3[_4?3&][&L:Y-1K^MN-/$0MF2VE+K4#2>?CY>[(5S)A)W6@
M9!#2B[H<D:608WFZD6":;$2M2D?@99L5$$BSVOO9F>_K]0>48^S3#BFTY8Z\
MM-/E];O/S_%8>9FY(ULR=P$::13EKS#^)GM,W$-8MQN)H7MQMXR)N].V8NX7
ML%&-(<J\9$%6>.G:*%:AK6.G37<:.3U-C%RSDIQMNX124:W=JXUGK>TWX>WK
M)"W=.&K:+NNZ[DU(F;?U%7E(2YK(=299&'L19I-3T$@$0:*>)H2LG&M&B9&P
M(E UUU%K[:<M?(:1/SB"X@[EX8.*&PCRE[S&HK*Y-7+.TJGKF19P%TW/:":+
M<]M/&L@QCH"-74DV;R0C(FX6K-FW55(@J17G0%<U)U%_OS'^ ]K^3U]6:W^?
M;Q!5^R-ZV_I99Z?"?HMJ;HD@>Y82&UB=(:-SUMWD,:UM.XABE&<6VLZY;BNU
M!E<R;%I<-SP%J7%XQGS0J4DHP=2;UI<3^-.A!27##9MB-?>YB%?@)W"A<.^X
M/D+V'GRCSC61K7<&I=A7/>%JW7.33BX^!26NFYFUE3D3'NW5J/\ 5=:]959D
MXC6PQ!8(\K&N;B:K(-!@%)1L61;,#+II5*0/XCMJ<NG+;D-=.46U$@RP";IO
MRU5N-=4]6;H3N*JB+L15KK^135W^K2^/[M25(1(\7^+8[^@M/[.G2$=ZD(4A
M'ES<-&W%$24%,-$GT7+LG,>_:+% R;AJ[2.BLF8! <<Q#CRF .8AL'((&* @
MB" 0Q#@Z^_.-0$U9-SZ>:A!H?<MQ/H^S#'=O[5E$S>65N2WE'1UFT,B[32+S
M2!5%%F[I)1?P6ZI#%30+XS)0-NX?Q%4PFEF64D%,M;EV'A!!?DSEGU2.NKXU
MALNFD3JJ0E/>35+6KPAPJ82IB6YDD ]"3$MVQ?$+!VEXJT8SB6C9RRC(2*BC
MJK+2+I\Q:N213<J[=NHK*LG3A1C*J) HW2>(.O%52%%0B6V+DJFS,JB5$C*5
M3+^%)RA6I&7*'2"Q(8D,YC0LR[%SLX!N2H.4L5;*<*UO;D(NQPZ1MN&E+YNP
MP$<1\8ZD%T$^99&(9))J+FCH], ^^.5" "+EP >,_=&\-,J:(HH$PZBH332E
MJ_\ !2V9(+)4SL2&^3Z<WO%M:Q)IU+46U45$$$!R6N"SN.A=A9C&K:XKPU5>
MWS'7E.2319E+RL?#KVZE&LT8UA%RKQ!(C9FHFBF^\TVYDEC.UW"YW#A$X*@9
M%0B:/.J['I/$5.:&;H'4$'\.8 LIE/=SJ!:/*PJLXMX;Q2AQ>;-[RCFI_C86
M9BNX$MP5J$H'*5!+D*4DJ%KO'73U<N T^W.K:2!+,>/V[1"2!ZM[73;NG"39
M&24;BU\KX)E5B*F;%,*I$#<XK&,40'7A@=&*=:I-6)F("6H_"J5F2E83X04$
MV3F\K:!M=NE]K&.)QV5)J<&0GA*LJ)5-15B)(_>*3/6):5SIW^JR5+"B2P %
MX]%[K7%-9MQ'_1^;4BF;Q2.7N /+%9$=HK"U5.1N*GFE6";D!3.^Y1'PRJ.2
M-SIICF)/#*C(D5$RNE*J%J1WU++4,Z$DISB6D$D+9\O_ #,W*,W$NVO#*'%J
MJ@&%U91229M)(KTR5S*--:I!13U-8@)*9DJ7.R3)R5$YI:5 EC%EL);4V0:K
MSTI*J.H:4;+)OH!FS:HE91,@@JDHK%*)H ].\CDU@62,NZ4,Z5;&2.4GCD.W
MO3*G!J>=*ID2UBHD+3F7-0<I4#;O21XD;*>Q=SL3HLOB+CJKGUU94XY*J<#K
M)<U!IZ:DF2UID3 0L4A2,LB;D+2U)8A6X.EP6A"P,/;S5T1^QBCI*^4.Z.NV
M1:+N$P-X27B*J)D51723\VV.17)FQ2K!D,<W(>UO@BE[19%/15L[$Z/$\,ES
M%X=54BYDM*9:TJ EA:1X9)*@Z00/2.M]BW'5'V2_$FEE29N%XE.[W$::>@&<
M I69<Q*+?Q23J03<FP>/96FC%<NV"A#^T&S<'942E$$UF^!PNU5(<P.$"CRB
M<R8"9+G2,HF!5$SG^(.,.Q/M X3I/BIM"G%<-S3%HJ\/2)\^7+!LJI6@%25
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M.3#D:^DP2V50\8RYFT<AR!T<\H_().Q!=.4H"CJHI4/&HFZE$"Y-VW;7T3&
MH9'I_CTZX#[1I%<8>V+Q0R%V6]<FKLM:4%:7#M".+V12U#EKQ76N1=M9$H^A
M7,XK9S6VS(I1$O*QKQI%(-[B=3"N&AO9JBCY-$J(/L<_;W]+B[^Z?C%T/2B_
M:2\A=S=Y],6=@*VNOIU?*-\H79)V\[NF)B%[)5M\ET%5F8)FN_B%2Q9V\@D
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M;1:FM>HR[2*AM.U)+VD+I56\YSRTH$Z[;6Q$^ O#0ZLB8B"CUW+SJ!WB('3
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M1,4$A!# D*(>@E 0]>X>M(A@S,&Y-;Y14  .@ 'R  ]?\1^T:1+#E%# (@(
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M=+)1E%(NA2JK7HY*:H)"-"D$L[O'GWBVXI%FNH V^I>J4HOJ:L2/4:.;'6A
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M=22P\0;HT0PCP><44B<$66A.I7+SB43O;=7BTQ'  414DS,R%)D/PC>Z.0_
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MBIY(X#SGM+XLG8%@T^31STHQ&?*'PYS)"Y03,EE<P!PH,APE3?B5;2.:\?\
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M5+EV<7"74[EM@2^>Y2\H &1' 8#;&VW;MTVKI&I?H1HVK?IRC>OI'*IA%!$
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MH=""#<7&SVCK\F;+J94J?)4F9)G(3,EJ !!0I(*5)/)0;TMTCVR$*0I2E*
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M  P4I0+VKZCEH$M*)20R):$(1T"4A(&KV ;\X^RY,B73295/)82I,M$N6 "
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*A2$*0A2$*0C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g491933g91a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g91a09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2!>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ($*^@E@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!GU.]@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             #,    U4    & &< .0 Q
M &$ ,  Y     0                         !              -5   #
M,                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M,     !29VAT;&]N9P   U4    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   S      4F=H=&QO;F<
M  -5     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MS3N'Z-V_:L7J.#7E]7S,FFTUVRVMP>):=HV>W:0YO\TKO2,%V-B9UK[&6V7
M5 M:06F-OIRX^YFZSV_01X<56/F_:O,IU1VV=S$:6XM+3R*V@_(!&3 0("=!
M8\I?<VJ^VAA=: ][7.=+""21M/J@.?\ \9LV*U]7+>GV]':'$V,KN>SWM_.C
MU/HB?S/<@YW1+W]0OLIO:UMC_4+;&N)&X#Z):?TC=_\ F*U]5\.K 9EXK'NL
M<+=SB1#>/3_1MEW^C_.3Y2Q\( EZNRXSSR%2'ZL:]/\ !;X/22V0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%18R87$7(X&1)*&Q&"4S0E+P)B<T0\'Q"E-BA9+1_\0 '@$!  $% 0$! 0
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MQ:1;Z_TFXT^M3J4*CJ;A!$@__4#^H![2L=95LW9X];V.>[*V<'%<ML"K+O\
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M2@D@+#:)QW2EDM<HD"T+7$(]R_Y;45SVL&QY&YZEIQ$F@0X$;CVM\QZG<<2
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MU68( )$7$&\&X]N(ON-^0=1JXS$XB34<X S!#C)$B(N8<9),7FW+8^#<AR+
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MR68YKK&Y5E!BROVP]99N//J5(%C#TUT*ICM(&F>L3NG1756'K93^#S+',HG
M$N)>X:GL EH<227  00Z;R8  GD75F28FCCFU\MP-2HUWG(IM.@..\- BYN-
M]P)M LC9S9O=2TQ3%J*JQPS8U72U-6:_NU/0TRK#A! 98KK :V1QJK/^&]M
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MFZG.<Y]IA4K'9[RHO08IRN:C.%8V4Y]^.-^T^O:W?99^T1-$31$T1-$7CF2
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MPYC#1G$Z6H]HFE1B(7J=YT*PKT15:+ !T"8%@>3'?O/!DR::U 8;$.H2#YW
M$@>8 D!P%X)$1M_J&T*Z;('NJ^5'1513Q9 5<AG17*A O8J>Y&BE JKSTF&B
MO$Y&O15:BM=4]Q\,OD2/RF9(B; WB+Q>)MV"@CS:=Q:6G8_EWW^>_?A??8/(
MS@R*?2-JXY8<^/%0LNJA2F@@OC!F2/<2+<D1@+ ,ON1XD?HG%:PP^_&"@YSV
MCV#IW&Z*@H>&V'@7:T GN3Y1-X_,Z+^HG2NJ,!2%&GB?Q#C5#B&T7/<X1(,:
M"3I ;-P "+; SE/U'JD3;RGOD15=BNY^S^0M>G'6,,3<K%XTTJ*O/AE=,F.)
M]G"[C7<M547>/4VY/V+#]HD+0C?CGY<GZ?6\+/J?"<)PG">$XX3^GCQ_MXT1
M<Z(FB)HB:(H=^HL]=)N*R"-UO#N*RLFS_>09$6#!/&L#HUH)=B^SKSH6*E29
MRA4%C%A@L?<'AE>8'1IO5!HN=1:8+P+F ?2#S8 BW OV6[=(U,5@S5Q?AMJ4
M*A-!C' %NLF=8801J(W> '"#?DTJO$X<"$)51[APHXE>I?<*J,"UJJA^&J=%
M=RJDZ6]Q5[G2BNXUK0:QK0"-H$@ R(B;[$P?7<1"WO54-W-\Q&IWJ\PYTD;G
ML>W,*QMT[6CQK";O(K6EK;E]=';[*#8 "0<RTEF9!K(?<4$@@$E3Y8 ..P3N
MP(IB]*M8YJV^+JX>E0<XTZ)(!OX;=1(Y-MR3>3[]E[X:C7Q6+HT0Y[ X@>5Y
M AQ'8@.: +B_IZXI],&6DO,_!!LH-'&O*ZRA,;%IX<@57*H<C@6Q5<"!-DSF
MU<^KDTTMC[. 2.LN"*+'.G1.( ,]*XAM?,&00(?#1'Y6D._*/],?^(!M!$6%
M'7N4_@,O#A4>#X4:@8)C3();&J9&\B2>6K;*)K6#8UB(C6M1$1J(B(B?9$3A
M$3^B?&NO+A(V$=OOY]_5=]%*:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+4MZWH#Z
M?<6BRT[@Q**P@3:*SF&*@  M.Q6V-#WG*Y!C9*#!O0,.5&]$QH8C'J>< 1>0
M=>86J<QI5F#RAH! !%X:;Q]"3%[+O?PLQF%.68C#5ZFF:CB 2 " 2#ZZKB+7
M [2KYV!K9%7M7C@Y3##6>^[OAL.QP'I%R3)+?((+'B>YRL<.#9@1$Y<J^?H$
MU&HL973T8<!TD1,.]8);VB8&QWX4YH]E7-L4^G 93:&-#0-(+;%P:+-+HN1]
M3>,TDX5J>$5O"\(J\([S\<+X5%_'*>/OQRFKYT7L ))@B!VB#[D@ BX]R;)L
M$F#),$D]B)!MQZF3$SP52]CS5,3-A"FT]E%M3U,V'66%@ =<%[G$2:^N@UL)
MY8#%="BGEE+(6-(8*&U@VF[R(S/=/^ W$!I:W60[2Z 71)L#L #>UQ:RU+JZ
ME5."P]8?E%4M<T -MLTG9SA).YBUM)F<P>IT/>]/VZ3FN5CXN)2[,"M7A6'J
MB LX[FJG*HK"Q&.;TKSRU..?&MT^4\Q[77/#:)[Q]_W_ '@+.T<B% $J>$((
M9$1?*\/8UR>>5^R_E?[Z*5]=$31$T1-$4#MZJP0-RYKZU8\A\^%#G6D>5C)\
MDE!FF*6(G9DD8QD*,:#5A]A'6000I!)AE"@GA:F@]0TM.9AP.L.PX?H=+FAQ
M)V;MN/2#)DFRZ#TQ7=4RXTJFH4V8HAL$B+[P"-R8$"\ 6@E7&%&N&Q$3I7H:
MG3PC.E.E%XXXX1$YXZ?"IPB+XX1<13NUI($EH)D&Q)]H^0(O,]QN;B09W;/E
M),SV)DR20-SZF)*P=ZC(QS;8S2A$4H:ZZQRQG-$U[D97Q;J(Z5*+T?6@(0U6
M:=W\K!1WN)P)'.3'YG2U8=\@1!/%O3U''$SMPK[*JC&X_#M>;O<.8-SWF!<P
MT"/T(&/?1_3O/NP+)FM(^-[E:,7#G-$]U#C>2S+ KF=/9(R/,R.NCB,C^KW2
M3@=*.CO<KHJAIQVLB1KLT@V #CY9D  G:(@1LO/XHXUKLN;AVD%U.J:1??4Y
MNIHASID@Z3:2#-^ MOPT5!L14X7I3E/]/^OY_KKLJX"/HN^B)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(H&^K7,Z;%4I1R:F=,EV9@TS!TXJ8T^S0H[.>\,T5VIJ
MEE56QX9C%E3:^69)$X$2O/&D'.DC0.ML91I!C'L!>6@!Y;Y@TSLYVPD[@=H
ML%TSX>99B,6*KZ51[:8<9:'.#)!N2&G?@;7,NU1:T<-(3-<7J,GK<RR^+#MH
M;)/M9 </;*@26N>*=63$%C)1-FULX<FOFM&0K&RXIV-*]J=2Z]0;XM!M5E>H
MUI:TP'$<2;6F]C( L3!L5M==KJ&(J4C2'B%Q:7$7(!T@&3)L)$F0  5<I\8G
M$!R;*+Z>J)RL>8^O'#DL1RI[>8RHKZF0Z.5'=)VQ)4.0\?*-E,3E5]A3>/\
M,<YY:!,%UB?TN;6O;;8.5IB:A+/P],!M1QLY@TF""(#A$1,=MQ$V65MJ\DI9
MF2@K(.W.,T1F5TPI[FI#5Q)S&PFQQ,0P!0QS5]QWVL<II"2 JYCY(NDHW.VS
M)L71Q-9C1A</3(;I-1E&FU[B(NYS6AVXG>9)W(MH6?X''87#A]7'XS$4@XD4
MJU>L]C9))TLJ/T@B^P$PKX]1J([T^[Q\M1?_ )99@YJ<)X5*&8K51..$5J\*
MG'PJ)QK;R()'8PM/:9 )Y ,GU[K+U2O-76JJJO-?#7E?E?\ AQ^5_KJ%*]^B
M)HB:(FB+7_OGO+>8SN9.P=^#8I/$\57+J;*\J)63>_K[ A&,L)2A6#%HQ1KL
M=C7BB2"SCO94GL%;[4XUCW5/)\%BZ9K5A3?4-CXE)E1[1O <\%P;!D!MA('>
M-ZZ;R YC@/Q%+,,30C$D5&4*SZ=P0;AC@#&VQO:QF<-BLLL&UZIG<Z,YY7E6
M/$K*I8,9C^E6PZ\,Z)+E1H<96N$!DF;.-T*U'R%5%5<)4Z1RNJY[O'Q=,N<7
M%M+%4V,82Z=+&:#I:W9K9L/9=.I87#8>E3H.I5ZSJ3&TW5':WFHY@#2\O,AQ
M<;R>Y.Q)-&R_<.;A>*W5_DV:RYU/#C<RP2J*AF+(&961QP10DCQ62#S9)A@&
MPKE&YQD81!B8\C?(="4,74929B:SF:M+6NJ:G&PNX^5I,?F=$& !V5UA<!AL
M9B&,HX7$,JRUH<P.!U<#4 7"-[$ _P"T2%D'T8[I8OFU^$%1%@.C6-);)0!#
M5PJ&7BLFF-5%NZ*71599%0)9[)T>P99PB-(1C_;E:2.:*1V29TKANGW0*;"\
M0 XL:20X.@@BY,B"3%]R"%I?Q+RO%83#TWNJ5](Q#0]M2H7:W?Z7N<8<XF[2
M729'!F=CD_):2GDP8%G8PX,NQ.L6O!,FPXIITA&*10PQ29 B2S=#7O[$=I)"
MC8\C1*-CG-]%Q_4/O]_3?F#O95%+.$JL:IV-(0#Y(Q/<UIG1A.$TIT$KD)VA
M..!I"=/2QQA-<J.(Q%?S^OTW4R.?[?46_7]POJ*9&,"/(&5CQ2D&L=['L>TJ
M%9W!N&YCG-(UPT4K7#<]JB12(JL17:(#/[??[+THO*(J)RCDY3X_'*??SS_3
MG_;SHDC])^7>-UXX=C#G]QT*0&4P;F-<6.49AHI8X90T5XGO:BDCR '8BJBO
M"416HHR#<XDWC[^^_N%[=%*:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M2WK>.=^\NWPC,1(@,
M/SD<57(B]^22;MV][4;PK6H,!R=LB\%>DF6-&J(:N)R7X@D_BJ0N/(( /H"1
M')VM[@R!;N_PI#1E^)(_-K/F(O\ F/-X%XBP]MQ7O3-$FQ]L5)+ZD%.RW,Y]
M> CSO4%>?))X6=+3!8@V394>78L0;B"("8(HR/1RHRTR1I;@"7W@$@.\T"21
MN+ F(W$#>")R74#Z;LYK"FUK--.G^4!HU!K07"(@R23<2[BY*D(Y5Z..$5JI
MY3X:J<^.>$\(O'/*(JIY7CA/&3-V@'\I M8@W![$'80(\W:RP@ #BZ/,"0'&
M[A(,B3<<S%K@$DJS]GZNRD9K#+7BFUCWDFR9=K%JI-E63*\16&D5?[N^V+&&
MV:J1T26M4R5,8".C2M]H!6W_ $[0Q!Q?B#6U@<21?3 B #,0 0=K3!@&1K74
MV*HC"NHNTO).SG29),N]"#( !,^;<V,@/4P10^GO=OE>5)@=W$X1.E".FPW0
MD9T]3?#W'1O;ZN7(O0GU*BZZ&N:VM%AQ';^G&WM'&;X8^S$BAXX[48 ^.%3C
MH$UO'"^4^/A?.BE>C1$T1-$31%J9]3^X=O,W5OL9C-M UM*^/&59=!AT2 IJ
MT4.YL',O[&2'.F0V@M 2WW% &5$@ .<(8)%[DB1G,'0:[#ZS))%X>[\O8M:-
M$R(&MP))&T0NQ?#_ ">G5R]V(;B\."_%2ZB_'8RE5U$SI;0HQAW'@"H02?*2
M9*L%;1Z\JKFJJJKE\(OGY\HU?Z^5Z>/'*+QPJW36M    @ 6$$"(]"!: NIO
MP3VN<QNK2"0WS.@ $:8!M V@S(WA1^]35B]^U%@U7*K4O<>5W2CG-;S9A8QS
M^GJ1K4(YBHJ_2U>'?*<ZO\J8S_$:8T@CPW.@M%W:'&3ZVL3Z7NLKT_1+<>T"
M0X/<##C)L;'Y@\B?DJA^F9<2P[P,AN$Q($MUQ#B%17L5;*9CCID[A5>J*T,+
M'H7TM8PK?>,>KB-:YC9ZF8TTZ3I.K0UQ-C(U.TF;&9)O8'3<#=:I\;<,TY73
MJ@-#FUAKV!<0\QJ@?^3I<9, "=ENLS3 ,JO\BB6U-94,0!4PV/./:QBSIU?!
MQC+'Y+9BJ8[XIXIGY.%\>&=SCURU4ZFI+H1)YX(HP])_M]_T[+Y>@WCD6,F;
M^D1;@<?,K%[MA,^DH"5(S-H;@5++@1;0>2YE+)3RY,>F#9= )!QQ;^%E)L>A
M3;,=H"-^S&LKA*X,U\HYYD?S[_9^FRF]]O2+??R5TT&SF50<I'?7.4FLXD+,
M"7-76$NIYJ^MI@TV?P*V-65C*J""ND1VY;3U1XYI-FTE;CD:2RQ8]L2NBR;_
M -./3YCO?ZW4 $>Q]R>.;>O:++Q%VCW+,7&Y7\<EB3*>WG6%L:#DV1I$R24.
M7CUA6W5C5V,.R %9)ZN[@SL6JSUE9#JLD)"';646KC0SDC:8[D"8^XF1L2;J
MY,(VKR#$\AH9JWC'45/5S83ZP%E9N#(<1)4:O8^O]M%CG-7U[J^(VTE22(<%
M>(9Z<LL5;9592/O<^US\UGG12FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+5CZQ\LVBGY(&@LR
MWEI?P+6%%<_&KG'**=59#/KF]G'8-UDEG##,L+VB> Q,>APYS6(R'/80$T85
M!C<PZ#QG4@;C:>DTZ8_*X"'  28().Y$D1V,S.[]+=55<AIU*;6DAY)TSY3V
M!$Q D.G<;7NK4QCU"X%C==78VF&9WC\*ICQJB$ 6.FNX@HL0+!1^;"GESE,C
MQM:A)94>AR(A#&[KBO)CC\/>IJ%/1A\MIN8+0S$-:TB/]LP";&(,>ALLH_JG
M*,15?5Q%;%"L^?$<:E0FYDPX._*#-I@#M-LFX[O=@N87%;C%)836Y)=,XJJB
MWBMQR;.5Z%1[80LED58)D@2 *_V4=YICFC>444K!O<W%5>E<_P .7>+A'-BS
M@8TMTV-S @$1(L1!BTJ]_P =RHM%1M:6@ B#OVVN2Z;N,WD=XD'M'A><XGDL
MB3<,5*2RJ5C2TXJH#16##", \>'13I82R)1#'=)+)1J11\CCD:PCQ.O\BR['
MX/&8D8@N%/PP0S413:XP26MG2".2(XX6I]19MDV/P=%N$94&(%=P<\#<:C(<
MZ[M(N6S?O-RKJ]3*]W9RWJ>5ZLDR/;C%$:BJJD9DNXN*4LEO/RJ>TF2'.YYY
M:UW/.MHM'!V]CV[[GW^:U/;T ^]UG_\ MJ4_1-$31$T1-$4#_4[L'F^Z63U]
MIB5/ML5HZ&95EO,H!=2<AKI#[(DT!*^*.UKL?4< KFSHDJ;$M)'O>X(H%B-0
M1\AA<33H@LK"NYCH.C#$-<8&Q!DR18D0;R""2NA=$=5X+I]M=F+Q&;MI.JZW
M4\,R@_"F"9\0U=3VR26S2:'!L0X&ZUR9UFE=MUE=E@MY,_<LDI)!HEC"QH@<
MD(!P&]1"R'TA9*1RHU4<2O.T%G&4C6R*^.KF-79<%E>,Q5-E6CAZQI5&AU,5
M&U&.##&F0^[B0?S D._,"973F?%+HDL:7Y[3I5' .J4GT!XE-T'6QY\Y+FGR
MDZB0>2%CK(]P<3S''K6CLL=S.SJK$3X1&IC=G7E<17M0<B*ZX%!< \,[AR 2
M2,%V3#:5KO\ +ZDRN&Z<SAM=M2GX--T2WSP\-D^4G3_MLYI)$2.ZM*OQL^'&
M <'T<VK/Q%)VFLZGEV)+75&R'$/9 <TG5YFBX-A$1F7T!5>W%+NQCE8^^MZF
M[ ?*+;&Z[)@#'89GDTB@E5,]C)U6(M#&;38XDN0.H9,'82%&:5[<2U\Q28[J
M7 9I0IE^*HM\-H#'/8 *8#3;29)(+B;ANY%HLM#ZW^+W3W6U!F4Y2<0_$N+:
M_BU6U:;'TVS=M-Y+@'220\B+ -$+?(%Z-"%'+]2L8WCE7NY5/E?EWGA557?A
M>>%\:T4'4 8B1,=ES68B8!/86]8@6 ^4!?1Y&C:CG\MY5$1..5Y7E>.&\\\(
MBJO'*(B*O/":E3,?LNS7(Y$<GPOGS\_Z\<_[?*?"\+HBYT3[^_O^::(G/GC^
MBKSX^W']>?O^./'E4\<D31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T16SF+)C\9OFP$F.F?LUFZ&RNERH,XDT<5
MY(8XTJ&4,D!2'8P;2!(PB*[PY&J[DH,\?\6/U6"8]AGMBP&&U;<HK/VBT@!M
MK^U@Y/*+-K2Y+%4+HV23K.*DUT['ZZX+:2*Z?(+6_O-0-$K"C0.FUOK._'L
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MX[3+R@SHA<<H#R)7=.6EK"2'O?U.(4D$!"/?T^5<Y[G.55Y557GRO*Z]#AV
MF&M$$B;6WWL)N8]8'&\&7&7$F9$$DR+]S[_+8<KS9=F+9./3A"1ASI7O-$8^
M**<C)X2.)"D,C%5&$-'DM8<2/()!D:TBE%T=QL/HZYUM#IVU#4# @B#,B!Y1
M'L(41#2 2 =Q( VO( B^Y];A;(?TULWE95&W-AVF8YA/FTRXS70<)RW+&9"&
MLKX@9A9>2T45S8GMXEI86*UDJ375,2F*ZIACB3+)[226\UZHH'#5,,64:=/6
MYSG/I4A2-0%Q$/@38 ?F)-XMN[UIP9  #6S M .]HM>_ @SW*FKOTULUVR^-
MIQ_W_OI@KGCX16K%Q"/=[@'ZV_\ ]/C$F#54151Y1_E-:XO0[$_K]_SMR5G]
MJ<(B)\(B)\JOV_*^5_NOG\^=%(V'\]_FN=$31$T1-$6IS]2/%<H(+"\KJMT*
M_&:!33J*[Q#,,W9C^*VKV-L)@K"MIC9#C8[N^..::LF,%(LYL>J%&9$@QPNG
M2';ET7C<)1Q%>C5R\8K6]Q.(_#BM5H&X(8]S7N8)NT,@ CL+:EU-2J%E.HVL
M^DUMW 5',!V(,2T'WFVPW6K^@NH\:EK 1!CC1V0Q*P0HBP <D8CRD%$1[_;M
M.1SS*)7/=_F+UO*O+W=@:R/^R2*< M),.TS:>28@']+V6A&HS=VIQ,W-RYQY
M-M]S-S-Y)5%W(S*PJMOLVLZZ6Z'85N*WLN%+8YR/C2P5DET:2-[5:K7QB-89
MJHYJ(X;4ZN%5%]</1U5VAS0Z3>;S)N1,R=R;6 GWC\1IIU-+BV[C8Q:^Y! M
MOQ/>ZBEZ+=RI.V^_^UL6)-F-KL@S_!IAQ@F&$CK>%DM4RRL'/5KD4MYC<V[A
M74@KV%L #CBD2#,1PB>75F#_ !65XQD:F4<*886@M!8V6Z6R0TM($0 9Y!49
M+C*K<=0JBH_5^)%(O+W!WAEP&@D'5H(DZ0[1 ["WZ]]Q(E_8W.#QH-7-MZ:)
M-L;*W6*J/8"4!M?$J@2QBRK&GCC$!.N)*R7#NH\>17Q2&II!7QR)\U,U!C0;
MN@2=S(W))O;E=K,3(@ ;&X$6F.!/'O%X*Q;>!W_2NCUPYUS<R(TO&KJ'-8+"
M:^-+L:Q<;N+:ER8@TKBQZ<5Q&LH59_#HUGV(3O!82RQ(BGGU_P!?3]NW"B9'
M(L ;FUOG?D_4QLKJ0F\YR2(8[7*H,4L#V]1;%JMNG3 %MY5U6GLLFB-$026.
M,C)39!20J*"L"9%&D"[#:2OW&. FW.Q_2V\V'[D;222NMZ#?2L&>71VDR2%+
M*14^TE"QB3(/7FMLS*;+A*\4=%MFU1L-'55+#0ZD<N)*;+J2ADE&-]_?_/T3
MYVDF]C$#N-@?0;S*],Z;O0RKIF0274FZ3";&:TK:[$ 5]AF3:^>2!7Y>*412
MP0*0-:QO\*%B@/92I;GD#6!;IVGM'SWDV^0V'=3/ZG^T"_I//U5J&'O>04JQ
M9(NSY!$K^Q#+V<888CH]S,?$<6K'/'0LLBTMU95TJ4V 8+60:RS+639<($(K
MY_V/<>OZ>E@H&X,$?*9]S)@'F8,R9F5*?'R3BT=22S:]MDZOB_N#2$&5[9R!
M:V6UY0C$$KDD(1%( 0@/XZ@C8)6-1[JH?=Y58T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1<*B.3AR(J+]E3GY3C_
M **J:(NJ#&GPQJ?"^&HGPJN3X3_U.<O]U5?E=%$#](^7KW^?KW75P NXZA#7
MA55.6-\*[GJ7X^5Y7G\\^=$@;QZ_/OZ(@ (G2@1(U55W3T-XZG+RJ\<<<JOE
M5XYY\Z*5TD-(@"K'X:9HB*)%X1BD1CNVU_Q]/5Q^$1.?*:*D[6M<=QZ<$+\/
M^]^U6;@WJRRKR:%(I"6-^D;,7VDIL.Q@V,4 8-F 892(64^=!K0&IID-31):
M3VV/?)!9WW]SRK'8*I@Z;:&*PP>*; X#2#.D$SM!!WGD6$[>/@M<?%+,20!>
M"X"(F1!VL)$^HG99S;DXP#&(1'-$!C!B8SJZ&B&SH8U%3E4Z&<)TN1'I]T^5
M7T+FG<@@S,'UWL1^EHNJ(=>#:21-^T3/;VW![JEY%E_-?!$KG.61*@B0?L"7
M+RC%:%.=B5 I,)EGTQ %(L"9/@P9C K%G3(T0IBMH+7:3YK1;S%HN($O$Z.)
M(F/<!3:=R2;& 3^7<Q_3Y1<K?Q^F;MYB]1M-+W2I[FARLNY,L_[=>P-L*7;6
MUKJ6DE/K)./3HU/8W K,0[Z%-G#G#M)T4[2@*"7*8HRZY/U)B*[\>,/7U@4B
M0UAJNJ-;<'RET&[7"'$"TB! 7K3.XOMV ^<";GF"?7A2NW"?^Y;[;!42_6.K
MC[IYY)8BJK6I48]58A#<]%5$:Y39X1XW(BK_ )+T14Y7G!?R^OH?W7IM/?B=
MKDP/E_PI!-_E;_9/Z_;\ZE2N=$31$T1-$6JW]4# MR+W;2FS+$P8Y8T.!RYT
MV^K)=546&3/=?3JBMC3Z>5?5MA6AKZ^*LR3:UR)&-8F#6=)R. Q [AT1BL'0
MS=V&K/Q+3B:9EM*I4:PN\T2&DD7)(@6)!L;G6NI*.+JX8.I##Z& @ZV-)-HD
M@@ P")DWD^D:0*C("#A)&,YXI$*0>+(&KV.>(R$<_H,X)9$=AW!<(A11C%C#
M<5!QB.$-JZ[E292%.GH$M:T07 ET 0-6KS:N;B9'LN657.:]X<0'!Q!B- -P
M6M#26MN;?22%Z+*QC6M;.JIRN-"LH4J!*$I&)WHLN.4$AJ*BO<U'B>\:*B=2
M*J\-1>5;ZM+6&6AK2!O$&W(.\VN059.JNEXU$-)[D@B1[1[&!>0(VBAM%MGN
M'&W4I*Z-4V,N=3DGQL8D5I&D-E-Q8#+48X*F;&>6P68X)'SK#@(W5IP(4RMC
MO0KK?-Z^&9EN/;C<90P]2I@W&A3<X-=5ECB"X$RXD\S-Q*]\OI8S\5A:N$PV
M)Q%'\6TXAS0YS&>8%T:?RM$=@V+;!?NIKNHT"&8X6".6(!QQM5SFL(\35(-'
MN^HC6O56H]_+GHB.555>=?,$02+&"1+?RF#N-K%=]!#@'01(F#N ;P5ZNP'I
M5G:'TJO*MZ&\<\\\\<?//G^_G1('8??]..RY[(N.GMLZ45%XZ6\<M1$1>../
M"-3C\<)^$T2!VXCY=D40G-1CAL<U%54:K45J*O/*\*G'*\KS^>5Y^5T2!V'T
M7*B&J\JQB^>4Y:B\+QQRB*G"+QXY3SQS^=$@=@B"&U7*T;&JY>IRHU$Y=Y7E
M>$\KRJKS\\JJZ) [!=D1$3A$1$\^$^/*\K_ST4KG1$T1-$31$T1-$31$T1-$
M31$7QHFRZ*1K>.>?*\?"^.?/+E^$3^J^-%$@??/;W_XW1"-5RM3E51415X\<
MK^'+PB\?=$7GSXY713]_<KLBHO/'/A>%Y14_U3GCE/ZIX7SQSHD_U1%1>>/L
MO'^NB+G1$T1-$31$T1-$31$T1-$31$T1-$5H9W)N8V*W[\<>5N0?L=NM+V1A
M,5MDD(B0S"!)*&-), [F%#%D&$"01K1F,(;G$:^_O^R@[CWB/?\ IZVCU 6
M95GN5']Q5XNS-OV&;7R5C3LC@S+2ZBEL0Y)5R;$=K(GCL8;*:9 QV]@5E@TU
MA(#?RP@CQHL0,>H@^DQZDS'N!<_JHD\N$SM:_IWWD6_=52-D^\\D2E!5]"QS
M-E$B3*I(IY$AUGC<?]A"8]JJNJPQ)U\KL@Z.N42J)*!']HP"3I^_O]82P,:C
M/OVDF>!^EA&RI3=P=UHL2WGV44\4-;52[B![K%2Q@71QU4LYJB>5+GKQTD.Y
MCCK:ICAGF7@+&MD, 1&2G.??W]/L*.8DS(M-C?V VX'ZD2O589)O@"R82' $
MD>WN:1'0[*OF-A8[72(-=.D0!SJN+/)-,Y;"QC6=G.-"A5LK')(DD"2RK&D?
M?W;W_3NJB=K\=ONTG87,CU67-V\B=BFVN7WS93XCX%%,4<X;VL=%*87MA2T>
MJMX6.\R2.I%Y1!JJ(KNG5MBGN91<6DM,;@P?D>_SGL"O?#T_%JL9N"9(@W N
M?;GNM%F*9XNY.5NBY5C>-6.-Y)&M#Q*VTH8<N="08EEU[IYY;I*33R(2RW6H
MY#2C284(HW$4;T-@*6+Q6&DT,17I=S1J.9)[^4WN;SO-XDK<W,:&!@: ($MB
M&^@($#OZV[*X\C].FR&1"<Q^&MJG*J]$B@F2:4XG-$8;'#+#,U%1.YU]@PR1
M5(T97!>0(UUF*74N9TM+_P ?C:K6#S-=B*K@($;%Y$\1;Z[V3L!AZQ__  ]!
MAO<4V R2)<2 +DWU=S-]Q\,.]+_IDJ#V-7N#@.5[D0;N(K*WV^<9-66M.&.5
MWO1PZRCE5D:P8\AP/9*G2%F,\C>XC4<5^;'6.=$#36+6@ V?)<#$:BX&\3:1
M<G876-KY.'$^&&-.ITV L9[&UO<?4+;YZ:=H=KMG-LJRBVBQJXQ3$;HY<K94
M7TVQG6H)]T&*^0LQ]I,GR '[8 -( <AP&N8KF?S*JV];&5\PJ#$8ESGU"!YG
MF7#T:9, 'B8C@;+#%GADL$>4EI(YTF/GLNT9/W?U/VKU8C@X/LG4QQO14<C9
MVX.:VAY+'+QU-(R%M_ <GU?RR%\>$5*%3O\ +>Y''Z[_ &5('12FB)HB:(FB
M+"^_6'X#FNV624&Y6*ES/$)C(1+6@C/,&2=(EC%EQI8Y$>7!/"_;)0163YPI
M<=\,<1\I")VE:ZAV9XC)S^/P[7FI3V>PAKVCF'"" T7WYF;7-RRCFU1F"K/:
MQM8Z07&!)/87DGLM7-OZ0/3UN+%A1<(Q.RVUJ:PBF?-QG-;JUOK,<AQ7CA6
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MA2O2V5$5$7E.>$\^5X^.?'*_*<_/W7\HDM :"!,'<6C?TM;F_P#)/#8#8-/
MM/O:)D[7'ILJ7;K^ZB<)S;!0"KWM4T+NR'")-ER58PD6*,Y6R5'%*L)0@,:8
M1I8PVE<![=>M.'P&@2+"Q,Q(N!\H/SV*LJ[Q0!(VY@AL6$02>;D@&P/Y5N9V
M^@WU=AV.P\EDP)5Q'J8899JQDH<)>T)K -"V:P<M>B,T+"OD#&5YFO<]C57C
M6U4Q%-@[,:/T"TFH9JU#P7N(^;B9^_\ G&.U*?N6ZGJ)R+I^@>8XAA$1_//,
M7$L#I;0[$\JB*VZR^X5R-1J(Y?/+N>*UY^P]9XG^O=2!T4IHB:(FB)HBM',#
M BXW>RY'9Z 5TXBI)BFFQE4<>2YC9,..CC2@.<B(2./AQFKVVJCW)Q;XLD86
MN0 ^*;C!N.VUQ;86,?)5T!_[B@X.=3=XS!K:2UP\T;^UQQ/SF$6)6,F=;62G
M;VT& 81C",,"$UT8Q6E]K5,YE15<I&N+[]ZRQ,2.%>6<*G+I8ZO5?38UCVU'
MA^D  O!<7"P!)Y/J=UV7#-?3H@5'NJ:F!S'O=J.E^Q%R!N-C)C>!*R&GW7CY
M3CX3XY^_^G'/E?*>->SJCB3YC%X&XWM$1^W%R3MZ-IM !TB8&HD7)C?;<F>R
MUT[ZU[*K<C.8T]W^1D5-79-&15Z6+#=5+CTUG<>U&.6/+J7..UJJT 9</J7J
M(J:T[.J1.88=[O,##FET& '>@X[7B3M-^A],5L/5RS&4S5 \+4U[)&F0.;GD
MWD#D'DK:/Z6)9#[85L,Z%:>K2 PK3O5QU=:453>D(1JM8K%=)LY#5:_E[7L=
M\=2(G7^EZP?EA$F:=7P]P2 T"!^60!,1&PMM?Y[ZTI"GGE5S(%.IJJ,B8(<2
M)]23))@;W)*DOK95JB:(FB)HB:(FB)HB:(FB)HBZN=TM5RHJHGE43CGC\^51
M/'ROGXT11_W&]1>&839'Q*F!99[N(T+2)A6)C#*EUZ$5$$?)[8Y0TN)PR<]3
M"W<V/*D,175\*<_I&[T92>_\K2>9@QO' /TWL5Z,I5*GY&D@R)'IN >_%KRH
MX7EOO)N2TB9MF1,&QTZ.1V#[8S9,&4\2\< O=P# CW\UWRP[,=CXN'GK&YTH
M:M>E_0P6SJNUY:8 B;#O['8QQL<CA\$T!OC?G.[7"8[6V&U_3L3*Z8YA.+XD
M$@L<HJ^H0[D?+D1HS5FS2JJ<GL)YE+/GR'N^MYYLF0<CTZGD<]5=J^;3IL@,
M:(!L00 #ZD7$]]R=ED&TV4S%,,:!L W?O!/)YO%^;*Y5$JKRO/*)QYYYX3X\
MKY1%\IY_IQQSSKUN!:=MK6,<F1(/._>RJ%1[O*7F)($'<?S+;1<>]EQVE1?"
M+Y\)X7[*ORGCY^//V3[\)J"3-Q[#RS-X/._$&W;:9#W 3J]>XO&W+8W),S;;
MAV%^Z+\>.%_KQRGA./'*\_")SJ+\S:8-KP8F/2>\&+J-4W)F8WDQ;8GFVP%_
M2(3M+PB(O''"\<>$\>>.//"+PG/Y7A?/G4R>Q()X+>=]OJ-O4\*#$B2!8F)_
M\@09(]-IV%AR7;7\NY^.%Y7Y_/''PGE?QX^_C02#NZ#8&?4?K-K"W!.XDG>P
M,3$2)YYF;6MN)G:"[/**J\\\?A>?A%\?///GRJ<?Z>=+V/%@+BY!.YN+Q'-S
M8@J)O ,&YB-@380>P/<6$F=B["\\IU<?^7E%3S\^&_"KX1/OX^Z_:/E$@F 1
M!MMS:#%C;> IUN;,.Y@D$DW-R1MP#<=P9LN4%PB?/CC[>?/W7E$^RIYY_LJ:
MJ.OU_2UQWBX$C[M(JNO+[1-R;_\ _5R=MB+_ #Z]KQS]7#OLB>./G^OCE/A?
MNBKY7SJF_/SG3!$=Q_38CW(N)D3(N+D_.QM:#!DS&W"LBUVZQJ?:,OXD>;C.
M5#1J!R_#YLC&,G$H_J:A+6I?&)81V*B<0K1)L!W"(:,5GTIX5:#' GPVET#=
MMQWX ($\[&!'?P?AZ-0 D4PZ[=0 ) _TS[WM8D@S( B\:7=[>S;T@AY"(>\^
M)BX0DR &NQO<V#&:G"$=";[;%,P(-%^M(JXM.(U.1QI\GI:3'OP;Q,6@#TW(
M$W$1?:?:XO85,#?R.D&\[CVBVW(DQW(4K=NMV\#W2@'F8;=-GF@%;'N:>6 ]
M;D./S'*K?8Y!0V#(]I3RT5A$:.9&&T[1O+&></!'6;F.88=(.]_7M86[?T5A
M48ZDX->() (]021_([_O99*U"H31$T1-$31$T1-$31$T1-$7S<$3T1',:Y&K
MRB*G*(J+SRB+_7S_ 'T40.P7'8#SSVA\\JO\J>%<BHJIX\*J.<BJG"JCG)\.
M7DI4+?6#E^-5F(KB=RL:*$T(V33+Z8XA!8]#J3@C!-'@1W-)82YY9I88(;E;
M'.!DUI>\=(L8_M2P+L>#1#=4PT0)))DCF00.=MIA;?T?D-?-L:'TG. :X"!?
M42+MGAI&\C8$CTUP8%BE=9XX.YVSM,2EXY9'EG8,=588J99K9#A36R0,;9/C
M2QO"^.Z+)BQB,51JWI"QJ)98KI1U-QIFM48\1J!]8-B)!M FXM?9=$QG3E7#
M/\%X+'2 0 ;6L9 @S?\ 4$BTU@]5FL(9EF8R0Z,17(6GG5]DCFHK?#!E- DJ
MK^51J.C-Z%0?EWVQ/^ 9C)#74G 2UNHB_8F_:QM:\W)FS_Z?S$$1X(!V_,2=
MC<P),7M>WH2,T;<[0[POOL2SG%[+'9<0=O2SYT&FS8*$6FBS@%GT]J^&.+(:
MQP62'6%<@[%R2))XSQR%8)J&Y9BJ+PX@ C=H)@EMB8%KD2/2X%EHV98D,J8R
MAB\)5HFDQ[&.#' :F2SQ&DZ3#BT$.Y%Y((6W$;D0(W+RJ=L:^$Y7RB?9/[^>
M/]-9P;#V"U&0;B8-Q.\&]_O=8$]-R+.P.XRQWU.SK<K=++6%5%1QH%AGM[%I
M2>55'#_8H%8R.]/#HPP*WAO")*CD^G'J8/;Y[F9]%(#12FB)HB:(FB+YO"(B
M<$&UZ<JO#D14Y5'(OS^4<Y%_**J?&G!'#@01P0;D'W3D'EI#FGLX;$>HX*@_
MFF.U^V=GEV;7M[M]BN.)8V<M6&<&DEFBF?(FL&Z:3W\NWL%$PCA5@(<<DF4Q
MXHJN:(8WZH.F<5B<9B#AZ#0VK6J/:&#\P>^9V(&[23MW(V6\X+JC!TL-AZ.(
MJ8E]6E293>201K:(,&UI'))B\+ ,CU+5)F*^CP/.;9&H-[7SX]!C0'H5SVHK
MFW=Y'G-1C6*KF) <1O4SD*NZN,K2^'><U8)\.FTCRZI#@">9]#>!!X, SD']
M696UH(=5<8N(F#$6 @1Y8C>9N-EA#='>JILZ@60;D[;8)44='+@OB6N59E:V
M,J(>QF!B>U% QK&'DENEJL<1*W]R=!GO5@9K#Q1NUD/_ $E=B"Q^(K!]1L0#
M)#3R&ZHL+QVX!!"MZ76QPPK-PC'4J58N+],M-0$GS/%Y+A'!W,=U.;T;;VT&
MYL6[IX ("6:0H.7LN*6W_=:3*J.S<M4"TK^J#7R*PE>>L;53*>4,LBO>,372
MYABRB#OZO3+>G*-*BT@BH)?#2"ZH!!+I)$D"9&_L0M.S3,JN98LU7!P8!I9(
MG2V;-!]A\MN IUZMECTT1-$31$T1-$31$T1-$5M9;EV.830V6295<P:*DJ@*
M>=96$AD:.%JJC1LZWN1Q#&(K0@CA:^1(,]@8XR%>QJR 28 DH 7'2W>W]?VY
M_FH6Y)N=N1O%WX6.$O-I]LY"\):$9[#=+,H;D16.@!,BOV[II@%0K#G&_,#H
MY48/&C"ZBWM'"@D%YXDB#;B_*R%'+WN#7O<0#_IN!S>W>)WM)[%?+&\-QW$:
M[]LQZJCU<5Q7R#()KRR)TLJ\R)UC-.I)ME/DNZGR)U@>1+D/<YYC$?R[618Q
MK!I8(L8( !!W)$S%[S-A*R=.DVDT-: -)XB\G>1OO$<F+1,W D=K?"*J,5$7
MCA>$Y_LG_)..?NO"HB5F"3Y0;1SZ"+6CZ3WV59DB[C)WD#;?F#,""((CA<]A
M%YX5W"IXY:O'GSSQQSS^/]_">-57F "(FTW(WCZ3M)$VC<0 &B\$$W[ ['TC
M@[6D'LG8^WU<?*JO*_/A>./_ #<<?CA--P+$'B! CD6))YVN1?9)N;B/>2(V
MB1 XWF_,H@4Y1?*HJ<_"\?A>?S\<+^53E.%74 WC;?:3&XL+B9[1SW0BT[\[
MQZ]Q87B9B4[/'/'*JOS_ +ISPGE43SS_ %5>?&DFQB8F+$=C)O>T\W%S*G>0
M2 .P(/I$0(,@7,G@+MV&K\JJKSPB\<<<>5^Z^?E/"\>$\\)QIJ-_;UD\;[2-
MR2."+;!%A!Y(.T<FX)F+P!8;$2973LIRGSRY45>.$^4^?GG\^47X^4^-))$0
M('J1QMOVG^<(;$>8SP!O<\VVVCVMPN>RB?\ J^%5?E.>/NJ^/LO]U7[)H''[
MVDF1OR"9WFU]B4(!]/2\VW@;1%OG:910^/EWGE$5..?LBIPJ<\)QSS\^415U
M,DR8B/\ GB#(OZ1,Q<F( @;@^I]@3>(N-N8@;0["+X\ISPGGY_/'POX3[_E5
MX5.%@$F 038[]YL9_3T /JJC YC?;V/\S,QVL3"(%JK\N7QPOX_"_P!?'//U
M*GS_ +-4QR#N.YO)@2=SQVL.U,;P?8QM%HFW8@CUOZ\]A%\\JG/CX\I\^>$_
MJJ+_ '3G4@DF1<@<Q//M:\?N-E!:T;]P01/82.?4Q^N\=/;M3SPO/"IPO/E.
M4\*O'GE57CY1/"IQQQJ"21\[B\;&TR(]A<VN;JJ(ML+Q$'D18S]>+F-E9U]@
M<"VL8V35,ZSQ'.:T?:J<XQHZ0,ABL8O4V%+>X4B)?TQ'^9%%D$.QJBIU.6(V
M0@S#\:E&G4F6-+H/FCUWD;"Y(@;[CE>%6C3>"7,:70 TD2=R8!WY,WB\@\+)
M&&>H6\QB; Q;?4-?6$FRPP*/=*F"4&#WYC$8*+$R".<ABX)?REX:P$Z3*Q^?
M)=VJZY225E6+&5<.YAL#$<V[SW]+6M?:ZQ%;#OIF6MEL ][3%K["#S,]U,,9
M&%:CQN1S51%1S5145%\HJ*BJBHJ?"HNK56P,\$7BZ[Z*4T1-$31$T1-$31$T
M1-$31%HK_4ZS"0+*8V-@.7L^WH(4IO'R^O!:W;XRO\\HXUY3GZ7>&N"+I3PU
MR;?TQ1!>7D F7$3Q!#1Z6AWRF;[_ $;\%<M:["8C%NIL+@YT$C4?S0"3N(&K
MF([R0,5>E.5(C[7'(]2M!*RJ_D1.ZCF-4+$AP2/C\M1.R25 DN<K>>2]3E_S
M%<C?;.6M;CMKPP.VNXB3-SP[>9FP[+>L^92?F>)#&-;X=%A$ 6>6DD@"1>1<
MD;>DJ2W[JYO2O4[A%54=U<KY1S?I\_2OU*B+]D<O*<:QY8TS^TVW[>XYMN%@
MA2:1L# [-,P))OO?MP/65Y]GLBK6[\XL^X-+B =>2@0)L<L1S9=G(":MJ*N4
M:H]U.6+(D%[:P9 8<-&,&2RL#2H[J]]MBP!0(:! /FCB)DWN"=^1, 1NM/ZW
MP=8Y/6JM9AB2T@N<UNH,TF?,1)=L=S-PV+K;-G^1CP[;W,LM(]&LQ?#\@R!7
MIX3_ +GII4].E.%_G4"(UJ-7GE$1.>-8-<$ L!:P M;TL!QO'R]Q1-DL=+B6
MS^V&.'3IE5&!8K"F-1%1/?#IHCISE1R([J=,<=SE<B*JK]2<IH@%Y[^LSZ_0
M"+[<!90T4IHB:(FB)HB:(OS^^MVHPS;;U&6]U4YTR1?Y+(J<DM<')77LB?52
M+"<Y\ZQ+EDNGDT0JN4",:4.A/D;9%?$:@JVC!'9&*+>.F\4YV#<W\,V:=8TQ
MB(:):TQH))UD^S0-K@W5N1+G03^8R!<DDBP,&+6]"?2%A_\ Q'$[ZD*]6JBJ
MBM<CD7GI5.%ZG(J.;YZDXZDX^/A-Z%%KH<6@S!_+ )B]P3ZV%N8X5.H222?6
M;]]S?<G87F?51B]5693+3"\99%D.6%'S.(>S9RY$4:U%R*,Y[4&Y.D<LS/J5
M[$ZU8B(XBL:OM3ITQI&D"-XY-YY%QQ[':256TN\.JX3(!MRW<<&QMV.]]I,F
M_P!'G<I(>^=OA,V2U07&+9-7T,;K$-629[Z7,3 8U(Z*9S/X8R28T?N^@8Y<
MMZ,<K.7:=UM1U8&C6 O3K!L@BS2'M#;\";-!LHH/<YC=3B9 )G:8 %^]_G^@
M_3&U>IJ.X5.41>%3A4Y3GA4^RI]T_.N<*X^_JN=$31$T1-$31$T1-$6-MS]T
ML7VJQPE[D)I!Y)SCKJ#':L7N\BRJ]D\^RH<=K4<TL^RE.17*U%9'B1FFFSSQ
MH,>1('+07$ ;G[XDJ6@N.D7/S^Y]-U#Y*?*]Q[^!GV[J@):P2^]P_;R#)69B
M6WB/;R&0Y7,:S),V0;NB;E$AGMH;T6/C<>%%ZY4W)X>@UK6O< '7F>^H@;[6
MC8WY$DK)X:@&07-!,$ZB#?>)VOL+=A,W60>R[EJKPJIX:GX\>$1.51J(B(B-
M:O"(B-1$XU=@,/ @\QMZ_8]H61DQY3 L +@&)M$<WY OP0G;Y5>%7E..KGGS
MSU>/QRB(OAOPB^$5/BJ0+"/38VXXXGGTL(2/4B-[F-[SVVXVFQ(*=GG[_"^%
M5%5?]?MS\]7]?'")I(C;OL>\[VFWJ?W2^^J 8W%P=MMN;D;&RY47]_'V3GC^
MOV^_A/"_]-"9W'T@?=OVMS,['<\D[QZ[S'?>^QX7'9_OY^R\KYX__M^$_NJ(
MOW^=)[#Y&XYC]X[]C>%%SNX>AGD@=A,3>WI8HH4=RO*\\I^?SXYY^$^%7[^$
M^WE4^WT']$C< D>NJ;]CVW%M[>DGCM>?OY1.$1%\?G[\\?/RB^>./SI/:/H#
M_+B!P#<J;FQD3R#;@[[7D[F! WA.RB\HO*<\_/CCG^7CX_JG'W5$Y\*ND^@^
M8'>>P]?2^P4 'N;@]Q!VF/4;3<QN+KGL\\\^/NGSPGPOGQ\HO^GV3A?"2# X
MWV-^/:8GU]".ZYDSP8@V'N>_R]0>W/97IY3^W'/Q\HJ^57XX3[^>41?RL [S
M&W;WCV^0N1[E3<0=1M!,$P-I'<P1>]OI)P%Z554Y^7*G**GQY:BHO"<KXY7S
MY^>.>)D>EHX%X^1N?VWDJ#/K<D[FVUK1;C__ &%ICAH%>GCJ_IRG3^.5Y5>5
M3E4X_I^/C28.P!N.#<;0.#;N>^VZ)GS&]P#V(O>(,3L#_;M[=?GA/*HO**GP
MBHG'SY^>.?[_ --1/S-]X^7?MMM%ARFUMA8[FVT@=YFQM?V"X["_/QROPB\K
MQSRG"?953[(J_*(O">-3(WM &Q B=C].YO:ZD@S<D$DR9OW&_P Y []K![?X
MX1?PG^B^$X14^?/]$3GA>>4U$CMR;;1^GV;D=UQ-^ -R9F;[R)-MK<'D$"]5
M\*OV_P#-YY7GE4\^/CGQY3ROQSI,=M^P];&TGZ_KM!D[$]C!W[$=I-C:QGL5
MY9U3!M8,RMLX<:PKYX"1IM?- .5$E1BMZ"@D1SM>$PBM56O8]CFN:O"IY75%
M0!^XD#D@;7W[D [" 5YN -B-QM> .U[W,^@N)*M+%LQR+T]/#%F'N,IV,:1@
MS#=[BUR;:8"*C?=1R/[T[(=OXS&_\1"12W>+1N#15L:<#XT#'UZ#0=5-H: T
M3?DC>..-I]EC,50AP<QH:--PT  N!<3OWL/93PJ[2MNZZ%;U$Z)9U=E&#-@6
M$&0*5#FQ) VE!)BR0.>$X##<T@BB>YCV.1S7*U475B1%BK'[^_O>R]^B)HB:
M(FB)HB:(FB)HB:(M(7KEVAL\VSZ\*Z>8(9MI79!7VE?"DWJUX5HX-)-JK:K@
MF6;7D$RM%.C2)(APY+71^TXCFS$;FLJSS!9>=#Z[ _S M+FC<DB"0>9%P!>3
M,7^D/A-G="ADYPS VE6+GM<:YT:Y<2"TN\I$QR8!)((@K&N*KC^*8_2XO43!
MMB54$$0##2!,FG>-KN](E@16/63).XLD[NR-5,8BN3ERN6Z?C:&*J.JNQ%)[
MR=4FHTGOR1%H %[6VLN@5,.:]6I6=4HUJE0D.=JF1S)U$EH%@;1\X%U$MNV-
MY$5SU[?+&L3K>[IY<UK&]3&];^.&L<Y'.=PB*G/4GNW0X0QT^LVXW/-C^IO=
M6SL*:3P[%.P]*E:Q(L 2-[3WV,7%@L_>BR-CF09_:S9[<ABY)C= Z1"B3UK(
M-1:1[B<D>=+C4PJ:.;OTC@UPDE!NKL0$M0CD& 9$8?&YB7M$"-#KD:2#+>[I
M,R)@B#ZW*XU\4!C< S"T1B*-7!XNHYXJ8<R0UY):UYU.GROV(;R=,$1-?U0'
M*_9NTQP"N]UG]]@^VX>E>7*/.LQHL<LWM1557N%33K(_"*JJT3E\^=89<<^M
MOJ>U[?/:?92%$-@AC$-$:,;&#8U$X1K&-1K41/LB-1$1/QHIW7?1$T1-$31$
MT1-$6@O]4[ ;*EW!QO<%VZQQ0,TK[ZH_@+)YUZ>KA+C4*H)&_AW'J.(.KFU9
M9DQMA:?O(Y4XMM*B,9+D09$@,'=^D<P;3%7#5<-0+=>IKW:-1(,-<2]S1,$D
M"3 DQW\*D"38=YF\^T^ABW"U:BSQ"#&1Q"M<YC7.ZTZ'H]4:J]Q%>_H>KE5'
M(KW*UZ*CG^$5>DSAZ[6&G5:PAOFT$!I($$@W[Q.P XA6WEX%9Y=&P);<["-Q
M(M-K#NK8S*>#.,=M<;=,((LD0Y "B<CR1Y,*0*5#.1B=;NPR4(7?^EK7"4@T
M?UKTHBG3=)JT"+0'&#S<WWC?TN.(N:='%/$,P>(<QQ_,6&'7WB #(XDR=]Y$
MK?TK=H=P6^I'%LE&,+J[%9UED&3W,=Q8M7%J%P?)<:@UD$]F."6YL;2?D1V+
M%@Q#N@QD?**1@@%(_4>L\;A#@J>'IN8Y[R"6M!(UZI)M> .3W,38+W&$Q%.F
M75<)B*%-@(#RTB=@#M D'<0#OLOU:!<CQ,<U55KDY15^5157_?\ HJ<HJ>45
M4\ZY8)B^_*@$$ C8KZ:E2FB)HB:(FB)HBQON?N=CVUF,2LBO5DR"^XC5M)1U
MPFR;K)KZ>_M5>/T</K:Z586)_P#+9]0P1A--,F'C0XLJ0&6M+B .5+6EQTC?
MZ_I_Q]+J'L8$I]R/=C>NWIHN:W!$I*2#(LPLQK;^NLGJ6)A^+/EO"%]M+"+I
MOL@5!V636 B1XZ,K(T*"#(4:;*;0YX!(!,QZVO8P+;1^H*R-'#BFUKW;F21,
M;$Q>UA$&)-A:0LJH!J<=*>$1%3IXXXX^GRG'+>%X;T\M<U$<URL5%U=M?J;+
M0(.H =XM(M&\^G)! *O-0(!%VR+\  _I'M[7,CGL=7*-Y5W/Y7CQ_?\ EY\\
M\<JB<\(GQI=H@0!,#TBXBY-^Q]H@J6N@0) (D?/<\P!R;;CB)C5L5ENX>49C
MOW$S*( -10;FNJ,7[,T$DE;%%04TG]H()C^!HVK/369#A1P"6EA;B16=MG50
M'.-9S;P-,#M8&_>^KD^GJIEQJ/ETD"2.! ['UOP.T6*DJ@DX\\_GE$5/PB_?
MX\(GX3Y\KKT:2?>3Q/UV/H+".1<*#4()AVQO>YV!WCC;G:.51[NXI<=ADL[Z
MWKJ.N&YC7SK:=&KHC2/5&#8Z5**$*/(Y%:QBD1RJOA$3G4EP;8R2+F!Q]D#E
M5S(DO$S82?D?F)X^LRJNT:.1')U*B^6_*(J?+>.>.4\_'#53SSPJ+PU2)$?/
MO)$;\G;M!D]FHS8F-R1L";^H'S$&>V_/9^55%5$\+X7GRO//SPGCGA%_ORW[
M+\6V&PMMO?\ ;Y<%4ZW2+C:=[&2;;=_3B(3LIS_*J>4^R>%7^W*?*K]2?UTF
M;6,C:U[WV)MO:."FL[S)%^; 2>1O&T]^T!<H!%\]*^?SSQ\>5YY5/'X^?OU<
MZ3];B.)$WDP8',&W[M1$^8D"9@^:2;6[SS%R.)5(9<4QK>3CX[6N?=PXL>=*
MI_>1_P!R!#DN>.-++7H7W8XIGB*,,AXF *\91L(YXR(V-41(WW(VO,'VM[^^
MZK#@;%Y#MN+$\]MMK1/S55:Q7)RB+\_[\(B<^/'*_=>//">$XXTU28!B9W^Y
M]^)%I@S026@ZB77)FT7  ['VO'<+"_J+R+)L-V2W)R;$4XOJO&)YXDI3# M8
MWMM;+MVN)SUEKH9#2XX1H\A98XXVI];U;Y5G. &DP9%P=P8[ \@\ 0O.I4<
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MU/'Q\55+GU*]5SC5=+G/-Q)$& (-_F-C!OE:.5L93;IHL:!6T@-:+,G\NUX
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M?@Q))VWF ??E4Q^-5#[V/D9:R$N11:^331[EP!_N8JJ5(!*D5J3.GN^S+*B
M.H'/4;#,ZD:-[R\@0;CUXW -^^Q^9WCA ]QW)/8;>;>UAW$1M/:":MV6=; /
M5JF,K^V![D4ID&Y4(K1/:KWHSC_,3IX1%Z7>?&J7%I\I%K'TV].-K;&_L:7O
M(,.N =C<@D3$2!Z<W]879P6M54\\(U/NO'"\=*>>'>$_/PB<\*G"ZJ!$#MQ:
M\WG;T]/W4ASM@9%P(D3$$S,P#SZ_545F/X_#O)60LKZ^/D%M$A4\BU:,*3YE
M? +(D0H'N/YW1@&D2#CCL<UBE(XRM<YG<9$M-SN!O<>L"=R)Y[J'DAUP) W)
MVB\6( ]OZ@*M*%K$^_EJ.\I^?E.>E$<OW\*K>?*+X7AJ)[7MV@QS>=^-_G /
MM3=+9)F)@V, Q8"\6-KQ)Y@QC#=#,++!J6GL:F/7RC6&1PZB0*Q9*()(A:ZT
MF&>'VQXSQRG)!:(1'$>(2O5[Q'1G0^EY=(@D1>T<FWI'$F.YBZH?4#6DS$P;
M"!9P@&).]_+)XO:,H$"UC^.556K]OY>>51..41$5R(G/EW"N545$7A##J!F_
M%]_T,GB1 /' "] \D-,2.YC?V.T@F]P($18KY]I>$5.?*I]E7GGA?ZJJ??[\
M<\K]T2O4.;;_ ,^; 'UG@CL3-XX.QN9M FT3'OO8BZI=[++5T=S: 8PAZVIL
M9X6&1RB<6%#/)$TJ-5B]ISQM1[4<U5:[PJ)QQ0]Q$0=_KP#-[\"1R8N5YU7Z
M&$R1!L9[=A>^Y@;#T@BBX#>3<KP^AR"R!$CS;..=\D4 9F0VE!-DQ7=AASR3
ML8O81[6E.5S>OA2O5$74M<8=,DR3&UA^P]).^PV2F[4!<ELQL)GM<'>\6;ZD
M;KWY9AU/G&.6^+W\=\BKM ((O9(X,R*<3V2(MC7R&(KXUE7R0"FP)0E0T:6
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M^G]%3[+\)_KY^WC7J7NV)B>+<WM ]^=C\U[M#;$- MP!($<[CD"9BQ]U KU
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M_P".%\?K%[D>\EH1KF-(T2%_CL[^.A"*1!H5J<(INXC51$*CD[B4M+!@:S8
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M2A4?/;[76]3H14:Y.AS%YZEFG7+JU1KSY?#(O ,-<XW.TQL!$V$67IAZ+V_
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M-HTNH<8RIXA<!3'E:(  <(NX3<3?F!<!<QZWQE*AU!7;4:7.\-C@3J&D:J@
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M:9'Y'"#)F!;O8VNCT<Y?8WT^;!MY9YDZJB7%82;*>CY5A&[U%9TQY143F04
MY=S"0Q7/.1(SBD>0A3/38NA,4^L*S'OU. ,DP9V<2.UYG;@25J7Q(RYF$?1?
M29X=$N!8T:B-/F:!))<;WB?E$+8+KI"Y2FB)HBCGZD.N_P =Q#:\;E:NZ^XF
M+8E.1O5UNQNO))S;+$^ES?\ (EXWB=I5&<KF\.L6,3ZB#ZGW]_51N8[7_I-O
MY^OM(<+4:(;6HC6HQJ-1K4:B-1.&HC4Y1J(G"(B+PB?'C1!M_:/TX6&O4<UJ
M[ [VIY5R[49^B(G/S_#%FJ>>>$^WX\<ZN,*2,11(XJ-/S&RUOK%H?TKU(V)U
M9)F;3N/_ ,G5Y!VO<#WW"_'[Z-2-+ZAMN$1S?$?,5<JKQPO\ 9,O'+O*JO"\
M_'QR[GA$7;WUG^%6!?RP20+@-9^@%@;Q,6W'Y3? NC'Q.P3;>7 YZ2"02V<K
MQ?E,@EQD>:XF)<3&E<^B=4?ZJ=@V/;RJYQ 7I=XY<D";TH_E4X5KF(G**B(Y
M43PJ\:IJ53X-8V,OIM/'_P .F;?.][Q]%7\#J0/Q@Z>U S^/S-P]0,+BCYCO
M&MC72/*"&B^P\WHT>J^J+T^C=PJ_XG8@U[45//,SCA.GQ]:*O3PY.$5'*G/*
MIY5ZLTZTFVIFD&#8LIQL!<&2;1!($!6_PCHN;\9NFXN#U3C&%K1$,!?((O(<
M]VL.U B1.Y5N;(.1/4=LY]7'&_&VZJSEO"(N?4K>%1%7AR\*COE.?'/"<I[N
MQ+S2Q+2ZT4@=N&-)(]03W!@25C.AVD_&#I[4/R]8X4M$^4#_ !H4VBQ$N+&@
M;&#I (DE5_$GN;ZM\4:J*JIZFJ-O2Y>%ZTW3A-1.GJ1.6JUZ*JIX\I\HB)!K
MD4J[0?*!0&D6B&MU F"3<[#8D;V*R67-=_ZYT/*?+U\US0;_ )\\!#@-1,.&
MH@D 02+ D-MJ^,G_ &CKU'*B=._5OU+RU41%W#/U>47A47ZDY1>/E/A%U+JY
M;AZ[08:&T3ICLV\S>-S>;QO%K?-*3_\ UIQ)T$$=9GD1YLR:0ZQFY-B+3:#=
M>SU!2&-]2&[S6N1%;N_E_P!2-1>E$RF6JMY\HOA%7QRO*JOG[^5=[33;O^6E
M,DB1(DSV-I]X]HZYID?&'.!P>J:9!@F)KTR!,[^;B]R3*\/ZOSVIZ]-U6+RC
MOX<VG5?*_P Z;8XMQRK5\<H-W'V7A/'*(B=E^&T.Z<IP+-Q6-F;_ /YAXB_N
M!R3?@K^@OX7 MZ:P F0:!,;B[SL-M_>)L39;R_T"^A?1]FK>I7<>H7+55.7+
MT\X'MJK>57GA57ZE15\-Y5>$7A>3?$QH/5-20/+A<+ID"1_ENV.YWY[>BYY\
M1?\ ^O 184F0+C<"\;3._H#?O3/UO^AF*[$.\\NRC,VJJ*Y?'[-2N5R\?9/'
MU<_?Y1>GG7\E<&LQI-HILN+1<@3Q>([S'$D?G;_&>W5TUTB6[MSW%SO(!P0!
M( F2!&]HF"(A:>Y;VN]&./KPJ)_VI,L3J5R?5_\ *7#G=#>I>/"M5R_*]#7(
MO&LKXI;486F :5,$&\;BXY!-H[FR^6L;3:/@+DX#""[X@8PEU_S'*6DGLV&@
M$G<,!F";=H147T97A&MY5OJCQY$7J1R)SM+DG#>>41$<U45.4Y5'?/GA:A4B
MLX@P2P"8OR+]O6XB/14X/4[X%8\.:'$==8*!+8@Y=7=IF&AP/J)ATQ-EY<?.
MK_2/N>J)U(F_NT?E.7(SC#-S^6KXY\N=TJK4\K\)X75%2J&O)%B6-U&Q)DQ,
M386]! )LKG(FAWP+ZMENK7U5E#Y -G##8IND@?F+8N!L";67.(E3_LK;XO=]
M]VMFVIY5?J=6[@O7CA?I3ACO/A.I%1$Y<J:]/')=ACJN'@"P!'[$[23ZQ-EX
M=.T7'X+=<.+"=?460C<F3X=<0T G203 $ 6%@22/)MR5/\ ?5&C>51T78Y%X
M1$<B_P"(AWN147RJ*G"<KXY\N_F7B78ESJ[7%QMB71V#@&_L2/:T1$IT52 ^
M$GQ1:6$R[IXZHN0<>]T&^P(DZA<R3N8K6SI6IZ?O5TKTX7^&-F^&KY5$_P 4
M8@VHB<KX16\*B*JJO"KYXUYU,0Y]=H>Z8Q#CP!)#'$RW:1R;>FE>WP]ID?#'
MXLB/+^ R-H!OI/\ BA :+R8)DW)[$G><_P"BOTD]1>X;?YN-GYZM1$5OT_Q9
MC".5$1?/EZ<KPB(KDZ>$7A<=G-9]:CYW%P&+I 7X%-VYW^IGOLNL_P &%+3U
M?U0XD">G&0T" !^-PQ!CG423<;FQ$@+5G^JNJ+^H;ZGE8JJW^)\+7A'.7XVE
MV_:Y$1%55=UM>G2J=7A?Z)KOGPY\W265.-SIQ,$C_P#R7Q,Q&Y/OZW7[5?#Y
MT],X&YM5Q !B!_W3OM83R5^C#]"5$3T,-5/A=X]P_P _^0&.C1.%XXZ48C>/
MCZ>>5YY7B?7T_P#5&83:[(':QG]9]]UR3KUSG]1XK69+6-:#86#ZMK1,>O\
MQN8UIJTU?F@__D6(WV/I%5$^OWN^/*\JG#4%M(K?//SSU<(GGY_IKKWPC/\
M[W.Q.^"P_;BK5WGTGU75_A8 <1GDWTX*@YHO^;Q7WMRHE_H)\-]8>;*_JZ5V
M'RA.5Y<C5?F6!-8BK]NIRN7A//AW''C6>^+0G*<MIF['XV7-_P!Q;2.DR-HO
ML1)O?=9GXI$#+,(_5#CB-.P%M&]M[@#L;DF1:G?J1/1OK4WY7GA?WB@54:JK
MRW^#L?7RJ?G\<>55$\^=<OPE0T\#AP")<UW8W:XM!@DW '! M"_"K^)5CC\9
M<\(EKR,N)TN(U#\'0@DC:Y=Q<]UBGU,*JY?@3R<)QZ?=A'(J+PG/^%6-N1R<
M*O5RJ\ISRGTKPWE%Y]VXJHRI7#70'4'D@09)<!O!^H, '<S;%?&[#@]2]/O<
M-#W=+],4P)():W -\HV,AQ=^:?RR6BTWCNWEUG@F\VQ&95)EC6V,;-^F>\@E
MY5OMY]5@..3 2'=*\KTE8A.$X:Y$^A$3C5OB-%;+VTWMU'6]UYN?RM-C8AP$
M=[[FRW[.,_=TO\8/AQG%-YP]/#=,](BH1 U8:M@FT*U-Y>TDMT/)[[NL0%^R
M#"LAKLNQ/&\KJ'*ZKRBAI\CKE5R.Y@WM?'M(KN4_FZ@RFKU)]+OEOWUJSYF]
MR+$[3&WT$#O*_37#5*=:BRM2(-*LQE6F09#F5&A[7@\AP,@['A73JE>Z:(FB
M)HBU<^N$DJ-D.+W!A&-65JRZR?+8$KQ5ZSX,.?#D2W"$Y@(<F34F@LD&<,23
M3Q@];GD:W7+.NZ57$8BF&,/^41HWD'29)&V\W)B_)NNX?"FI0P^'KE^);2J5
MY#G&)<&N'!$"P!$ ?UJNPE);T>W-8RZ$:)/N)MID"PY"(TT2'9S3R*J,=J#$
M\$D55[-LF.1G>CR>['*KBA(]]CE5 TL)X3Q#W GB\DF\'2=_L[Y#/<13Q.;/
MJT8T'RO<).K2 -CM)DV+9)'I&9W?2BKPG'/*^41554Y1$Y5$Y\*OV7^BKJ\@
MQ!@[BQOWCYQ([$01"L),W.P/;VYWWNK9V>IJ_(<UB2)4X5E^S"6]+6RK$]B8
M1^^-::=#EUC(U4O9.UZ]LLB6I1$&J1$1K3)E.G\-3JXYM5[M3V&Q)/<0  6M
MO @1) *U7JO'XBCA30IR*-006Z:9!W+AYF.< >=)L3OLLY^HSJ/@6.U#/I6^
MW>V-JGM7CE\9N[6'64X/UJO*E@5TH2HJJJM>[Y^4Z"N;&X''Z[@]I'ZQZ\'/
MNBJ31$T1-$31$T1-$31$T10DW7@VU;N%.LI,0;8ED\,L5C7V$B#'?'C=$,8;
M01A'1\V.&*SW)([V#6.X#VB57%1NCY\W%T\8U[:+#K)%-^LSX9L)$D;7, D1
MN-ET/IK$4?\ "JE-M8MTUBVJWPJ3O,3<ZG-U&\@#5W Y7M:YS6,5WERHG6K4
M5&\\(BJB*KO'/'"<JK?NO"ZP1:0XA\,+206B\<P+R1>QDSWVG;&N;H:6RX:1
M!L"X';VM8\1L+K$>^=)(NMO; D41I$FGG5]V( 6*\JBAF[5CVA-Y<4B5,B?V
MV-17D*K&":XJM:ZQS+#.Q.!JTV^>(<UH-M0-C+;F#%C(N>"%D,FQ'X7,J=0N
M-(.):7&#+'-@2(-CS8'<F!94;T9"D#OY-NB(D&RLR5T.3]2,F>PHY\B2<+UY
M&:,T\@8.X-W2DJ/(8KE<U[=7G0;*M![Q580Z7!YB))$'MMV &U]RK+XHXC#X
MG!TA1<TNHU&L+I!Y%MX!$D\[BX$+:"Q55C5555>$Y5?E==77#5VT1-$4?<@_
M[_\ 4IMW5.^N+@>V6=YE('QRC+7*[C'L2H9*KSRQS*R%F0!>.7(<SDX1B*A1
MR?L1 M?Y[?,\*06BE6IEE/#R6DN\;M([)=3?54VFL(Y5X%(AV4=\2=&>J.8K
M6%B&(SESD:[J<U5\\+Z4R6.:\"7-(('\[@R+<>_"M<7AL/C:&(P.,!_"8W#5
ML/6()'EKL?2<"6D.$AT6+?0K1AM=Z(MH_2)Z@KC+]QIV:76*5\2T;MI--4LE
M8\(605\JNEQK636 ),GVT*LLS5\80A!4;U)/EC:Q]?(+D:V8ZFAK"0YUZI(%
MR(B0 -FAK; 1 )$DKYTZ(_ATZ2Z*ZHQ74[L3F>.<UF,PV78-C#4I-I8ZFZE4
MJ%P::KW,I/?1$N%]3B'.TD75Z1?T[\ QG?*7OA#-FIL"Q2T/,VHH<FBQ(4V;
M)F19L99TMT5W>G5]1'.PE01>VR:8T4\F08M?*8JKF \,-83+Q+P8<W4T -O$
MSI :(@$;@D&?3HW^&WI+HWK!W5M#,\SQ;L)4KU,LRVLT-%-V,I'67U0&&H*(
MK/IM:XQY 7ZB)-!HO0?M-Z5O5(#=3)Y.<3=M*:Q)E.VHXM>.944UXX#70ZJ_
MF0VOL)J4<R1.)40@M%).*+4FF2+ ++58L5,=KHQ'F< 'SMJ;8&S1$M#0+C:2
M-PYTW_#CT7TIUF[K6EB\VQ%;"XRKC,MR9K75*=*OBVRYYJ@/?4%!QTTVN-B
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MQ;:=4PLKCPW1!ME5H9 9+4U'"_Q%= ]&Y\.DLPS>EBL3BJU.C6\-S/"P%2L
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M*#0RE2QV(:Q@)(8S633:)),-IE@W.UR3)6&SZ@W#9SF5!@AE/%/:UHL&B&V
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M"GTOEE*#X!</]WC53(B.:EA( $C:UN)<U&YMEAF45%+<9&&OQ*E<$)Z^IH8
MA I!UYE%(E JJ&#'APQ*/O$'"ZEB)&8,1RN*1FM4H9Y4&:,=C<SJ5:9.IU,L
M8 "[S02UHF#^D B)*G&]-8=^6U:N"R[1B 265#B*[M7F$_Y=2HYEQ!L#;@0%
M/2'(#+B19<9_<CRHP) "=+F]83":03^EZ-<WJ8YKNES4<G/#D145-;VUP>UK
MFF6N:'-/<.$@_0KFKFN8YS'"'-):X;PYI@B18W"QGNKMI&W$I(@(LZ5C^545
MF*_PW+ZYHW6.*Y#%&1@9X1%<T<VOEA(:MNZ8SO:7%3+E0I+41[2BJ4??W]RK
M2PG>=XK>/MYN]$A8%N4-$C0PD*5N*YZ@U1C;C +J3P&P'*:B%D8Y)*/(Z8CU
M!,AE T4Z04>LR+_H>('OWX6?6F&YSFM=RK417)P[PBJK47E4X7RBIX5?*+HI
ME?31$T1-$31$T1?,I6"8KWO1C&JG4Y>.$15Z?*K\>?'/YT$EP:!+CP-_O^5U
M#G!HU.( &Y*T ;H^IW>@.[V=U.![^8_E6UN2Y5;LQ\U7:;=Y-<P*9*Y\V37C
MJSXM(E5$."6=["*5Z,(04:.K),P[)9Q=+Z?R++,PP],XC U&XAE*GKJFMB&-
M+N3I;4:R9$D#81(@B=#QV=YE@L75.&Q[A2\=[J086>1H=J;!+9M(%S>US$*/
M8@WT)7OIL^RJ$IW*5P)I*FV@(Y[T*J#BRH'_  PE=X:" 2((8U00D8)K6IMC
MLARXC34H&6C3(J51L ))#Y_6(F2MFR_XO=796]@9B3F%*P?0=0PX=MMX@I!X
MM$G5JONJ=D^XV5XS6.9EF0[;6M%.4547^*12,86:><C1>P<X1["O.20KG,:T
M8&N1$1/;JK"$;9CI?"$E^'Q%2DYIF 2[0=[%VHD"^Y CDK?,!_$+FF&J4_Q6
M48(L:6@4Z5:K0Q+2(AM2I5>^D:@Y+ &DS#8LMI_Z=N/XK:4EOEL+V]7D..+)
MPR?A]?%0%?B0YAXMNY02V&**[;D4<=?9@M!MCH,321"1 S&SG%YQU+0Q."S
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M$UY;@?=/*(EC/]Q77($FQY;"D (Q2S92GD-DG8@U.[CZ+R^E2&&!P]2FX,8
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M7.I1-$6/-V<*%N-MMF>$D+[=^0T4R'"EIX=!M6-233V#5^6OK[4$*8QR>6O
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MF28 WWL._/%X1;K[P&N+6"+;B\E@EU,QS"NZ'BA79[!\-!UXU.AX#3QU>C'
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MSX$R7 F1RC-%DE&Y%T03S^G_ "?OZG5%^I_1Y%691M]N *#*?BCL8D8S87
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M4<?6K4[T)"(G6+AOJ*+33+O0-%K$FY!O,P!>_P"J]6X6P&D"3/>! VD7$S>
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MRG2W2+*)2F@DKP23+.F]QXX[>I)1T5/K75V<PQIK5,0,35;6JL\-]5KR'N9
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M<DFPM;:8"!7P@#1>LLF5)>,(F-7PJO>G+E1J(KE1%*)^?;U4;W91N-ORQ(6
MLM=MMJI*]-AN9.B$@9MET$CE:^/MO1SQM/1UDL:+_P#&V0Q0RR12-+C](52"
MN OOW_3[LGW/UWVGVX_;/>%8/C.WN.P<5Q*K%4TT#N.& ;B&.>0<BFESI\T[
MB3+&RG'<^1/L9QSS9L@A#23E(]7:)'S^_2%=NBE-$31$T1-$31$T1-$31%'7
M>RWW@IH@Y^%I'_AYL9RVI:JJ;.RFO*CE<Z2P4U\N))KVB1%*L.M)817HK^@@
M'$/&O,"S".);B"]KC^0Z@&][RVQB;$Q([[WV"IX2HXMQ1>+C3H?HD3&Y:Z_H
M+DVB%KDW4W6O*C$[#))$NSS XEC#$"VN9TJK$V5)&!TZ3&:1T,$*(CW'.R-%
MC,<U$1SXS7../<LORO#UZ].D6TVTW $NT^:\&-1)&H@6DD;DS$#9F82BULEC
M2+0;$[ "9'Z\<GE11@^I7/:XXSNA8G-C$>U/VB!62JP\I5Y5L>MD#L9KQR2*
MC&!0L.:Y[UX[*_?9JN189M,Z*K@YLG42TBVTV$B]P(VW'%Z*-+2!H;Q'E#C
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MQ1C%<^NMSITHB4\\B,1QWJCG+62V!G-YXC)."-TE=>Q6 K8<N<&EU$$@/BX
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MPT63 )U-81B,\MUC:^=U:S'L92I!KY$N!?8VL):WY%I6/KY[4J,-.G2IZ2"
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MI@N%2G! 8_40!Q!#FP0+ W D0W:<C0S3$T2)=K C\X+MB(_U-XD"/?=13O\
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B-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g491933g92a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g92a09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1;(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %JR^6 0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!QX=<0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             ">0  !Q0    & &< .0 R
M &$ ,  Y     0                         !              <4   "
M>0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M>0    !29VAT;&]N9P  !Q0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   GD     4F=H=&QO;F<
M  <4     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M]DS<9^&^]]7K0W=22UXU!]KX=M5)_0ZV%@=U
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ U )@ P$1  (1 0,1 ?_$ !X
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MUA==:?US]:?TU_3GYMU3F-,LO:25I?ZC/">IO.>"K:)S,:CPF6C6H:'IZ.U
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M"9B^_16I<7K#3Z/U6[A\PZI6JZEPF'RC?T\*=JR6/73=:+'V+M2TN%GM_?\
M;7"/U7_9E_35KW3'GG#Z^3KC6VK/J6ROC3,^7?+6H-52?DW-W/#6<PVI/%"<
M3E,?CJ&GM+X30.;P..R.#TKIO3.+THRX%FUE<)D7Y'(G:7_._P#M_P <-3=_
MRKOYOMP*UO[)WZ6T:8R>F6-\DVRRVI_JGU#<U+<U@INK3H_6ICUX_P"I32$9
MH,,DYTQY'%->ZV226I=.Y6I1R6EM28:U1J&E<+/:NWV^?M_/CLM_V4WTG_[0
M]-^0]/XK6FAV:4\M>$_.>$T=HO6%O#Z#J^4_I^\9O\.^-M4QIQE6X,'0\;'4
MTME,8BTC#YBIB<;;NT#R?OKUUJ/[_OY?W?/"_9WN_P"W'Q_Q3)?_ +,?Z?T>
M$J7TYXO.^5,-X;P/EW2OF716C*>LJUNIH'/Z,\FAYBT_@=)6,W@LO9K:/H^1
M4U\ZK#91F6<FM75IVM>KZ8EF&-^%7^_]_P CX<X\ &?_ +'SZ5-2^/<!XYRE
M_P JSCM,9CZJ,MB,U2UM7QNHDH^L^KE$?4%I]MS'X"M3=I_5[\Q=MU4,H%D\
M$P@KX?*U,>'LI7S_ 'V_XX6;OXR?\?W^..W4_P#9(_37JZQ:M9?4?ER77-*?
M2MHVS-;4^F4PS#_1EFXU)X(VWT0<!:PF=EN4SCP&(U(ZPRKDULQH)I+7"S\?
MM_WXM_\ 37],V@OI:TOKK2/CR_J:_B_(7F#R7YPSQZHR&/R-P=<^6]0-U5K9
ME)V/Q.'4C%W=0V;F0IX^4,''Q:.I68%-5>NE<+/=_E]_O_9Q8KTN'XSTN%QG
MI<+C/2X7&>EPN,]+A<9Z7"XSTN%QGI<+C/2X7&>EPN,]+A<9Z7"XSTN%QGI<
M+C/2X7&>EPN,]+A<9Z7"XSTN%QGI<+C/2X7&>EPN,]+A<9Z7"XSTN%QGI<+C
M/2X7&>EPN,]+A<9Z7"XSTN%QGI<+C/2X7&>EPN,]+A<9Z7"XSTN%QGI<+C/2
MX7&>EPN,]+A<9Z7"XSTN%QGI<+C/2X7&>EPN,]+A<9Z7"XSTN%QGI<+C/2X7
M&>EPN,]+A<9Z7"XSTN%QGI<+B.R__HG*?_1UW_[LWTN%Q'W=6Z7QKF5\AJ+!
MTGJF(<BWE:-9RIF/CFISP8,S\;1(Q,Q,3&_J<=/4F#'3U)6U[8LC\I@,/?A9
M_O\ O[<#ECR[XKJ& 6O(^A:YMWZA?JS J)L1 %/6++XD6PL7,[1\08S\P43)
MCD>?D+#D.=F!=PY77E%^TC31_P"<<*K_ *\<T^:?$,.]M/E#Q]%B"6$UYUCI
MZ'032$%#U?J/.281B(1M]\E$#OOZ3R/J(#+T_G(V+[^7UHV1JTZM,NK+\67N
M</7YVVSOMM>_;@C'76B2,%CJ_3,L9MUK_7<7S/E$D,"/NMRF8B9C:)WB)F/Q
MZ&:',(R_R^N 6KI3H/*U@.]UPW&ZQK+2-3_K6J-/5MHWGOS..5\?/S^Y8'X^
M)^?]/3&AKR!CH:LAV8Z<D3[U7[7PN.2/(&A)C>-::4F-HG>-08F8VGYB=_=_
MB8^8G\3_ !ZD\OS'_P"[ZSY_TIX^<APN.A^MM&UI$;&J].)DHW&&YO&K*8B.
M6\0=F)VX[S_PB=M_4/H\P[<OJIYZ)?\ '^_"XUHUWHFR'96U?IFPO<A[$YS&
M-"2 I X@PLD,R)"0E&^\$)1/S$[/]'6[Z.J?>$O^.W"_W_VXD5:DT\XI!.=Q
M#3B8B17D:AE$E$S$3 NF=YB)V^/G;U%A,_5"1>UB6><AP_3*KIKS37&QV>PE
M>)*QF,8B(_,NO5E1&\;QOS:.V\?QZ1"<L1A*3X!?Z"_RX9QN)^./"M1Z?<8K
M3G,0UA% ""\C4,Y,IV@8$727*9^(C;??X]/]+5+O2U .[!KA<2/NZLN]O%E$
MOC\I[5]L?:)_*^7./M(2_'X*)_$QZC35TUY[<+C8+DEOQ:LMIVG8QG:=YC;\
M_P!8F/\ C$Q_'IJ?'"XC;6>PE(I"YF,94(9XR-F_524% P<C(L:,Q,!,%\Q_
MEF)_'IR,U0A) M06CYQBN_\ WX7]GV\_GC14U1IO(69IT,_AKMN)VFM4R5.Q
M8C\QM*4N-D3O$QMQ_,?UG;U)T]2(2EISC%+),9$7?92G;A.-^_ KE_,/BC 9
M-F%S?DO0&'S*28#<3E-88#'Y)9)-:VBRE;OJL@2V-4!B2HD38 SM)Q$ST^5Y
MS5!T>4YC6)%Q=+2U-02ZL8P<6A>V=\EKCJ1Y3\:6! T>0-%N%A< )6J,(P3+
M8BXC(7IY3Q$BVC>=HF8^/3O*\W%Z9\IS,)&\9:.I%/N,1-QR;(]^&ZCR>.,K
M^5/&5NTVC5\AZ(L74#S?41JG"-LI#D0<FH"\3%CS PW(8CF,C_FB8].\IS1$
MD\KS!'RZ.H!^6-?WCA6>3]^)9&MM&VCE=;5>G++!VD@1F\:XQB?F)(5V2D8F
M/F.6V\?,;^H/+\P%_0UJ_P#X<_\ <.'_ +_WXYX\@Z#DS7&M-*RQ1FMH1J#%
M22S7/%@,B+<R!@7VF)[$,_$Q$^G_ ,OS'_[#6_\ ^4__ /7A<=M?5^E+DS%3
M4N!M3$;S%?+47S$?UF%O*8]#83CB4)1?")_4.%2[%\=;<_@D1!.S.+4,\=B9
M?J@,\MH'Y)L1]TE''Y^=XV_/I$9.T9-[4+?[<.B91_9^_P#3CDG5VE(8"9U+
M@8<W>5J_5Z'8R(F8F5AW\CVF)B>,3M,3$_CT_P!/4_\ V<__ /"7_'$;/ZG[
M>?'YX\QK'24G*XU/@)9#>B0C+T).'P'9*9'W'*&]?[G7,<^'W[<?GT_TM:__
M &=7[]#_ .?Y</NT7^S_ '_?P\97UEI*VR55=3Z?L-&9@E(S&/:P9B=I@@78
M(HVF8WWB-MXW_/II:>I']4)Q_P#THR/ZAPMOSQ.JLUWK!R7I:I@P:V+8!@8S
M^" AF1(9_B8F8GU&GP_M_?AX:S^_Q_R<>Y<H?RU<;1O\F,?&^V_Y_&_QO^/2
MI\/[</9YXXKV7Q.,&#R63Q] "B9$KMRO5$HB8B9@G,")B)F(F8G:-XWVW](C
M*7Z8LGX%S^!X5\1G]\M)<>?]Y\!PW$>?ZO0X\CB)".7N..YQ,2,;[EO&V^\>
MB?1UO_V.KY_]N>WG;A<3->_2M+!M6W6LJ9,B#$/6X#(9*"@#61"4C(E!0,S,
M2,Q.TQ/H;&1O%*WL2N&9 @H+V?[QL[^'B+O:JTWC+TXW(9O&T\A"UMFG8M*7
M8A;H*5'*B*"@60!R$S&Q0)3'XG9R$TZB+6V"RZM+X>_[IXYAUMI$RD!U)AR(
M9F)B+R)VF"D)B=CV^"B8G^FW]/2Z)_\ 1+S^EV\[<+CS;USHZC*!NZEPU6;/
M'V\/OH5+^<3(PKF<=DE$3,0._P 1,^GAI:DU(0G)"TC%:#NT;<+CS4UWHV^J
MRZEJ7#VE5)*++474L!$AO)]A"4P,#$3,SOM$1,[[1,^E+2U8=/5IS&== Q3J
MZOTUCOPN.&/)OCXE->.L=/2I"TN<?ZG7X+78,EH,RY_:+C$A7,[<YCX_,>I?
MY?F&PT-1D-(1<(6WCL9<<+^_[_OOQVVM>:,HS4BYJ;#UIOL%5*'75 5IAQ)"
M"(F=VD4#,Q 1.\1O^/48Z>I,FPA*1IYU$%Z-@O&,H9K/#HFXGWQ_7C8&M](M
MO3C%:CP[,C"!M31"\@K?MSF1%W1!2R5E,3 GQXS/\_/IW1UHG4Z4R.W4Q0ZG
M:.3=O!=\(%V%^Q?'+7\BZ%MY"YBJ^J\&W)8^3&]2"^B;%65QR9#E\^2Y ?DH
M+;:/G\>E+1UX$93TIPC)J$D:D_&/]^Y5\-\=S<\<:/\ :;X^F8B-8Z?*2YR/
M'(H+E"Y.&%'$IW ) A(XW&#&0F8+XE_H<P9=#4#RQ:_NRO[KB/4>?Y/[;;_'
M'3?\A:(Q85V9'5.%IA;4;ZQ6+RE]R5QR8U<%.Y+ ?N,XCB(Q)3,1$S#1T=:=
M].E.55=16E[)6.WWOB5)N5Q(5=6::NUO>4\YC;-7:"]PFTMBN)?Y2YC,QQ+_
M +)?Y9_B9]-/3U-.3&<)1D;QD(G;;A;A(V=FM^_]/W[<:WZQTM5KMMV,]C$U
MD"1->RRL%+@1DIDS*8$=A&9^9C\>E'3U)I&&G.4I-1B#<EP!\KPG!?8XA%^4
M_'CV"I&L, YA.!$ &2K\I<P.Q:XB3VY&'W1$S$S$Q,1M,>BO)\[$5Y/F,"XT
MW8W<UPS(,J;U^7/]..S(>1M"XE@IR6K,%2<:"LBJQD*ZSE *[C;L1Q^V*H[)
M+\</N_'J$.7YK4!TN6UIVD:C!NW =\WC??'#,HQ:DA?G']F=]N-&.\G^/<O4
M]]C-8Z?O4^8!-BOD4,7R;MUQR$IWD^0[?UW_ #ZE/E>:TYFGJ<MJPF[PG!)'
MSTU>::P;<(G%VD/YQ^^W]WMQU:J\@:-T1[6-59^CA9NBXZHW";!/"O =QK%2
MF3(J[ @YVB!DQCYF8CU#2T-?F)=.AHSUI=S3+Z7_ .7@^7\AQ+@=#S;XK;QZ
M]9XPY.9$(%=W<ICCO$;U(_'(=YG:/F/GT5Y/FHBRT)E7;BBM\WL>>'!<'!"G
MR#HYX":<[6:)[[2"K1_B=IB>->>,[_Q.V^T[;Q$[5T1IP\+I?#_?]/OQ-KSV
M':N6C?3"Q"623(-,0$#)\Y[0#[>(R6_XVB?Z3ZC8M=\]GMO]ZX;^_P!^.1^K
MM-5PECLS26N DY.63(P(SM,S(C,?'\Q^=OG;:8]*Z\_LO]#AR*['Q_=\<^1U
MOI3$,ZLGG<=19U+=QLNE4]3N4J9]P;<6<2X3OL4B4#O,3$$A">I?1&4J>EH6
MI9Q]\.-^%3AK#\_WGX[]N!]OF#QF@3-VM,$ +$C,ILG/$0B2+XA4S,P,3,#'
MW%M]L3Z-_D^;[<OJO_ZK^>U'Y=\-<-WKO_>WG?M]N.0?-_B<G#7'76"[2_RB
M;VKWV* F8DTC&T%/&9WVY?;^?2_R?-__ +MJ_@'QE1HR^>&4"UH\N/[^//;B
M8K>4?'MN2BMJ[#.D?@H"S,S&T;S,Q(1/';YY;;3\_/Q/J$N7UXXEI:@A:,6S
MA"-4C?S_ +<2JM:Z5>Q:E9NF9MVZHB6;'OQV@3E<!,ERCC'+<IWB-Y$M@R]I
M<L&3.-M_VOB0+L7QUW-3X&@,%<R== ROMB2AD\E[\>0\5ERC?XG;?:?42<9)
M$D*M!Y>$178OB K>3_']P"97U7B6  \C+N,($8F(F2[%C,;3,<HF-QWB9B(]
M'='5C75IR+VLWOQYX9*:<)V[\;U^1M"M6;E:IP[5J[.PEVA/AU;=G,1B2':)
M@HWB.0_<.X[SZBZ>H;PD?C^_/"O^Z?[_ +^3B/?Y:\<5O]_J[%A$D B6]@P,
MF3L$+,$$+-Y^)ZY+C,3!;3$[.:6H_P #_P!OY?/"XUK\P^,FV*=1>L\+-F^'
M943+FBUT;S'& ),2+8F)W2S@X?Y"/473U E)@D8ON:<>+QWI^/EX5?W_ ,^.
M"_(ZAPN)IU+^0R5.I3ON17IV;#H6BPZRLVUUK;,2.[5 ; F=H(1F8GTHQE-Z
M8192>T17&^#B4(3U'IA%E+>C>C=_''?-^D,1,VD1!1$Q,L':8+;C,3OM,3R'
M;^N\>FZ9;=+?BGB/^RC]QI_GQY#)8\W%7&Y7EX1!$KM&&0,[;%PF8F0^8CE$
M2,3\3.\3Z?IE5],J\TU^]<+_ '_VXZ(>F9F(:$S&T_!1^)_$_P#Q_P"/\[1"
M7C]K=OP<-9Y_?''KL7MOS';_ /NCTN'XSM7OMV!OMOMR'?;?;?\ /]?C_CZ>
MGP\+C)8N/R81_P 2'_W^FI\<*SS_ &;\9V+G\&'_ -J/^']?3TFXG#6/<XR6
MKCYDQC_QC?YG;\?G\_Z>FX?C(8N?P83_ ,"B?_Q]*GQPUGDXUG:KJ,5L<L&'
MO( 1Q!% Q$E(Q,[S$1/YC_A^8GT]22R*GG-?R'A[[?W_ '\<!^3\CZ*PKNC+
MZCQ>.9L4P-NS"9(0$B,HAD#,B,"<[Q&T\#VWXSL2'+Z^H7#1G/->TO.*.V<^
M#^EEAH:TX]4-.4HA;(,&:S^>/2/(VA;+ZU9.J\&;[BC?47&01RL)78]JQBHD
MHY NS^P91,P#?L*8G:)D\KS0*\OJ@-2]BUBRZ'<\U_/B+IS-XI_7>MOVVX_,
MKY&T/A+M;'975&&Q]ZZ/*I6N75(*P,BTH-9%/$@V2R9,9F(XSO\ QNVGRW,Z
MI)AR^K(AF:04B71:75^'Y.SPC3U)?I@KXVS^>.;*^4= 8+)JP^:U;I_&Y)]&
MOD4T[64K*L,IV38M-D5&<'-=K5,6IVT@PPD0F2^WT^GRO-:I>ER^KJ H]$)-
M5^JZ/X3+X[\2=#6CHO,2TIFC&71+5KV$\>U=QR80XGF9;&YK3V1OXF[7R%)N
M/R(KLU60U)DM#09 F/Q,B42,[?B8F/X]!E&4),)Q8R-Q$?LWP+BEGG[3N2US
M4UGI[$Y:<?:G(3%B[CRA5JI5#K8U G+)?-AM*;5*PQ#%$*+S5@,P/ ]SD>8_
MR1H<Q+!"/4F_6=01$I&EB@VW36+X-HR^G.*QC,DD>F1&497MU#CLN=DX^=FG
ML)1U'-K*8TZEJBVU8K5L@NX9,N!AG/P]T7U*X-%(D.-W%JR>!P2&<%L)JP[_
M $N==+3^I,E>IT3Z4E73*(E+[:IH!'%4.YN?Y0T-0TM.].1 EJLDG"M6/U(D
M&)TW&,P]JTQ1J1TD]:TI4Q^/OXXARBK#5JMV&TA*SE"&O8.R5.I-@&N1!DXT
MIZ!62E -5<K2D FQ'G)3Z-5 A'K@#?3[ZMD8ZNEB-2O*N[?&?+K9K87$.F-1
M BX4,7)?Y9KN;XG6EAE=";:YBSB)IP&50NS2D,?:<D$%:1-&0]SCZIM.V L$
M#BO(5H[W=:Z>KRLCJG /I:TI0^G/4C:Q7W1&?LZJ[@TYKAHSMZ;DM2NK;Z<_
M; =\!CO@D%N9R]R0:MEVI9<PE6C7:KO7"&S%@3386$NA_: C/225QV&%AX#$
M%633T],!=*6F!.-A -^HE&HK5%"[+\\$Z7%MV+8C\=MD26$\+VX:FEO'NHLG
M6HY&P,A5J77U'NR-=*[58;BXLXY[ZD5JE6,>M]6M3Y$N6(&!(^]KV6#Q^:]5
MY?1-33TY,IR@TQFUU=24.:E4I/AV'BR:;-"F]S;MA,X*[A9MNW1G;T=@U566
M]1Z@3+_VQD:*TS#&<)B8 0'9@\2">,DP60Q.TEV=@Y4/4N<5ARVE(FT2=59%
MM9B24*Q>0W=DXG],!9.PJX>V^#L65QMKVM(854NQF(9?GJ5R8Z)%7%79$G"^
M0'Q6/)@ES(V1,;P0SR@DH>I\RAK:\-%MZ0BN7,JZ+JFK&OSMQ"].."/6OP8K
M;%9PM;^>/7]]M2394ZA6QE0,BD2K50D)LLJ"M5>O:F>1[H-/)4.-_P"X4+:Q
MRF,@C3R&ET_ZD]36G!!F2D0ZK>KVJ,LO83OC?B9,38"JW''8NO<YJ^]]N /)
MW\I8R5:M9;=R5EP-FVR&BE-*8X\5*778U3I@Y E'WC)H!\GQ8@A*_P O#1TX
M'^G"$NUQ@R1"FPLO.-S\WQ&1&74W2QH^:P]L=G?QL[%VD=+ZFO9&A:KT[*YA
MOW$ -*7HF>4#-=SA(1B9F -A5T1SYL,)@C]5.8YSEX:6K#KME%Z-.F4XRO$G
M4! H1M[VM<-TEV])3;MDR?:_AW:W,\72#&6.BH^U/1<4JL1O5(M(2 8%BVE*
MX[8B.(LF0@63O(B(Q(SSQ,=C>['?S5WWIWJJNG?BLHK6UM&U#5MUXVKSO3CL
M I6V0= 03(C@:QF5R0R1D)0,3P,1F9,)B!B9DHG[XCTL(5>]4C>0[XO;'??B
M$K2QKSFOLYQ7ASVWKBLWF0&KU/C8J\:Z3:EMATBUT3:)*#4Z0WXAU)ZI#?[%
MFKL&(/?UL>F-PUMU(1HIVZ@3!FRS%8:7>YG4:<;O>5UNYV4M3LH]C?'"Z\89
M!4^4,4EE@RL.R%=1RVRQKW-[E//L*4J"8(YCBF1 AE4DV#DA ;?JL)_Y$]OM
M*0,1([6&V4S@K\EOE*NTOO> Q9CSL??!P%>=\0FOY"U):NXO&Y>C[VU<O*##
MRNX(6P5*%LN#7A5Q5-&/ATNAHL7-E@LA@CVRO2=9_P IIZ4-74TV,6,1F]/Z
MGVQ.KV]]L;WNG#CCXON77X:S5_\ &#BOY58M"IF.48-:L>NI(P"4@Q;6%,.F
M ,;HKXA84*"$E$)+GL7/KJ-'5=*'3K3)$3W,IGN-\,G-9VIL;:X%K0926(U=
MX**(U=;F1O8-MZ.(2G5?4N5EY"_89,6VV:D3 -82V,6TZCFPF;L#UN=!!76N
M 5P4+U@H#B[JZ\)Z<_I0Q*%$KN EC[;!+JFVJ>!1A,RF]@?;Q;XJ_.+IX>N(
MTA8SJGZ@BZNE4 P8;#/JKT?:U"$#@1G]_84B,/?&Y/(5*D:\I5'.ZOJ1RJ<O
M.#J3Z24>D5G*>Y=(1BK(BH-=W<YIJ#U- 7FLT6&?.^,]C'#%K8K06GTDW)9!
M>2M'7$H0MBK/>YP@8P!F;%]A3O,[**#(>D3@9D_67/FO5>89?3A* 208C'I[
MTY#'5>+&^]5Q9A],CF0)\+=GV^,Y-O+QJ=Y%=3BY5P5:KC:B!BO##&1M[E$1
MS,6##Y EMVXS\F$$( )S"HA'TQG[^9UYZTC*QE+H^4_ASL%;=^),O$07?IK;
M.^"[Q=]\O')DWWK=7%S:?EFQ<FQ%Y@JEB=H (%=.!B!:D60(L:L+/^4QX$H#
MB9QCH:4I$32N!<273N [N"W;;]N(JHKASCMW_#YV?QFY#$8+4]E:ZN(QUH(I
MV(E-]BC$P7#H=%@A01/:P>R.('$560)#(Q'$9C/F^6TUGJ2@@2):<?<REBNB
MB05Y*%KOLQ&1^H"]OT_[??OYX8M?PWD6I;:U9GO9TZL]V^ZE*)I$(! HJS)E
M9)03(# B8[=(J&2F1IS]8KI_RVDQ)'36H]<V6<%BXR[51>S?#]-4GE*\7W+:
M#^5_N=F.S?CO2P6*.E,:&>RB@9*8LE^TYZYKKZ45TBUDM,G"Z(O2@A%10+R=
ML(@U)<UK1=36E*&GA5M#>GI+GLT49V\\.%U&0#N67CM[D;I_#G.>"_Q[YD1J
MRW.,9675(+84P$5V*[E0TH!),K/G[5PV83,1(,_S-X=8SZ'S7*SY5AUYCJ%P
M06,AWR*;?9Q?:^(3TV/54*8M2J49=KW%'L;UW[AP\'U6D)[DP0;$##0*>Q>\
M3$R \?@3_@IY;'QGC$Q,36ZK[;%;?.=QO^Z[\ )%XH_!_3X*O<PV!7"I\NX<
M\SI@NF52ZN%D(E[!7!\Q61(&#'=C2-,<4!'[D2<#,3'JSR6J:/,PD_I5$2S/
M= RAM6=ZXE'-[V5BOO;W^/\ OCBDMAV15:K51Y4W&3JUH(K!,\B-;0&"B3X&
M5BPHXD"-I$+P- J2;)ZXEH.E)_7&(2AJ"$4P,9105(V55=6;[<,7)"VC#L4B
M7Y^<%;>$>/H+XS6X,!B/<"4'VOB8./N@H>Q9P4Q&TR)P4<AW':(^Z=_7$Z\N
MJ>M(E<6<JSBML':FZV,O$=0J<1!3IL\/CQ?S=-\53^J/75;">1:6 4^WBW7L
M/CIOY6HEUI_49VC0M2:RR:$ M3R:UQ144,"9F)\09N>B<CJ<QH:FM"$-8TM0
MK1U)FG%<&_4=6%QG\5?#:DHW&,GI&7N<^V/2M^W-W1C/NVJ^%IXC+-9!+;EX
M[-AEO(2>,NNCB]M9? R8WMCL. (!E(R, $'8F1^X9D_K;RVE*.GI:<=.1 CK
M0@/3!E$>\1E6XE[T";-H,UU)33I1("=3@H[895U715O#D\H^/+N=NXF_.9&G
MBEIY.F9 #)YQL92 R)@8_? 2N& )3/V"<;QG<CZA'DW4Z=)GJ:Q&,)!:5U'2
MP!9$NH7"%%IC@O2SD,;J-V766@O:]FK\.]WPO<C>76=A]-Z9RU).'--IE^VJ
MQ 6.VJ8%;&RR1882P>[D<@4<P2N"7,M[+NAI:LHZW-\]I:O64Z$&$XZ>GTR_
MTTBE=-](])LI5;2U&)'IBCM:KA-S<5NKK'?(8A<?H^]J/+?I=,@9IO'9JFX$
M%9LN>%3'1V5:]NO#2D7G?<5LW.%,'CWU @8A,K99YCU'2Y/E^MC(YC6T=3>,
MHCJ3 ZHK1&-1P8JELO"TB4F&Z#G-=C?JW^>D4+$>)[R,ZOEM0XK%TGV@3A:K
MCM7$#//'/,%U<<]1**3B)L1#W#(]<UX,S(0^X,_T7KT=#7YC4A%=9_\ ;U 3
M7BMTC>;+.JJP]KX+S LHG51$%+07\4+3VVSY..[P]B"G(:BSMG+1<K4%IQ]6
MRX7*.ZE%>4-]IWPQAK]P7& 8XRGF4DS:8!;>N<S&6CH\KIQ^E/5_UIZ>&46+
M1&71[50Q'.$ V.%HQJQM,.:<W=WXJAK?;MP<9;&TJVG]4W\/*TY5V,:5B_'%
M0R8;B#"8.[)A6WW3,;1,SQWB"F,CEM76_P QRFAKLF'UH],'JI%LJ%*_>FL\
M2U2#HSE C=C8 I&[R(]ZW_<X16FVSDXQJ$8AX_J5W$(BZ6X57(HX_'V;(UC9
MC^=BL]B L7"[NHWC C]ZW;]CSLG1T]==0#2^K9TRJ/6L=.\,1B]( M)VKBII
M@S%!%A5YO ID[VJT?FKX)?)=OW&HSI)OE4L8[$)QZK /L$H;&0MIJ0-M"_O)
M;:@/8P (FL N41 @QHT_0S5CR[/5C'5CK:EQ*]T8:0LYQG+]-]42L2:P/:?-
M=?7[,>TVD1#=_P#-]L=N"'QOG5XG3NK;5:U#Z&/O92GC17.W:!D@JZE"(' \
MW2\J\09@(E,SPF=O53U+3^KSG)PVGKZ<9:L4J45<C9M6<V7X<</H_P#M3DKT
MQFD1R#7@;HS>&K&UQQ,Y'.V-2>*,Q:NHD+J%7D7E1V$P(FH\9&8F!.#GC%B%
MC!2N2VB=P&9A'3.5]4Y;0)LM/4G#4C*9C$CVL78)#8@.^;X4Z=*4J 8IG%/8
M^"3OD#/AX1^DZ-Q^I<30':U,V:KSKH6*QKQ0QX(.Q;>($3;-EK%UJ_(P22Z2
M24L3?V,Z'F=;3CR?,3BNFRT-33)2DQ9:DI1Z2,6I1",99H&\NUTB,F4:5+'*
M-AN[UBK!R^'CI\MPFWJ7-UVS)+J8AM,0/B!%;*14%=1O,0:\O]WU<1&.9$4$
M(D4E]&E7)\I&2W/7M[XC*[4+P9!+Q[2ZX?FJG-0$C"G:BHN?PU^=\9XVZ1MV
M<)H#!6$PB(?FL<TQI/!D+63 5 V5IBR0%,3(0III.),A9NPCGT/G(FOZKS(6
M0.6UH09=492GEC)L&\UUUL9=C@>G4='KV!+8]UH:*S]J;S^&E]<4BK)Z >/5
M)1C-2+:#"D>:RMX.1G:0(> LXRTX$I /NB"F.!9'^%0OG9 ,B.DQ&-WU$HN4
M^>WC[\79;;@#=M'SW^WX_JL=%>4<5G:M7!Y2AD+EO&W"H,ONVJIK-.JNS":Y
MOZ[EXYIJ3:LKJ+L/KU;>.?:151=KM:/U'TW5Y;791FL9P=4@.(BVLF.(9ZBY
M=(TA=6GAT,#9=JHLS9VRU??!CMQ8S5FHPT)I7%6Z(2EV3JQ)M7*^"'K"(8D)
M@(GM4UO%H[=D ,P4$S>(Q.3Y6?.\P$62"]:M5G.Z;(MI?CANHCU=5!4@QBTQ
M87O8W6]\5PN>6M?-&Q-"5(C.@>.(6J*6.1$,;!U"<)"QW6-A4D$P*P>Z&0#.
MOUTFGZ+Z:3J<IZNIID&9IK&)U;DL5)SO'J\OG@$66928_3!;#)>W_P FK%W[
MG;C4O5FILM5K4[N2 !YRHKBQ(H%XQ,1-@4!,(AHP<*;)AM]I$O9AK$LN0Y+3
ME(T^6E*E2#*%T;-*%M&%7!C)4XR6/MF!1=Q:=Z>V?Y[^.-YS8S95DMR;,E8:
ML:5#*76*>CB G[VJBB61JWBM8R*K12B8&$E!*V@8@U##2T(LHD=*'5U," :G
M514I)'JDI9;G.]/$H4*UUV;2%3[;N=KZJ_/!'B*VE</7R 9MN/I66)):P8R,
M@TVE/2FQ[8QL/3W(JPUB#AP/8;9 I#[?5/F=7FM6<(Z)K:L'W2C"4HC N^ID
MQ#&*:97MP6NO39UIPZ3I(L099+EL=3X<OC%<15 L7"[-G(V<?<>Q?[E<<7[Q
M"E"T@EE>0QJS$S0 D:(X$@R!G/8#YRGHUT_3A,CL2GKP)2DF1C*9(K(6=[L.
M*U/3$E*#EPQ$RCVW0.^3QGCKN!I]_>^O3I9 ?8UYK17L7Z/9+ 69A(JI=8MX
M$$PR2*LM-B6&N94:QE>NPC EJ:1;&;K1TY@71TZ@LB/_ $@W+ [O"Z-.'N(E
MXV*?=BB57L'C&SCCH71U+4:3-,/S0.>:&C3O5IOT@ UH8T$VMZH[5VC.S6J>
M1L%O$%J(9$$X<LC#FX<KJ1BH,92AJR#:7M*5S5YQGB49&T>JC!3)[[V"45_/
M]K$X>WOIM=34>HJ99&G(F!A,-?,,DO=)(8GI6 P0B$%9$N8LV"!F ]<UK:5:
MTY<OIZAI$O\ 3>B5B;5+IVKN(?M?!A"5M;7E#[]Q'&.V+WX&BTUXT"X>5.]4
M)T')L"!@:RV%,'+92RWU0<$':?V&L0+:(V)HC;CS7J<M$T73DQE[C4E"4IQ1
M0C]1,#3:(</_ *=W*\/FRS?!N55X_P"_FWF-!C)HQF'?EI4OL<S'U4L4+%LC
MD5J!7*0,(1V[$Q?$!ADA$3,2..CZCTDI<Q(5;A+593RX ZI.]]OOYX==)#]/
M;^%S6.X8^5_WX$LKJK2$F<CIG&6+5@3):%3%IEN.+BD@"J-@26P0):9DN+(D
M5<R:,#Z.<GS4CJES.I'RLIF>Y5G?>\'>B^&&">V$5P9"OO:!=?)?CB'OU, ]
ME>WD=,NQ^=A,0O$4V3#&*2[W%:V;ED7"3[8W,C3P@R!WX@O0S2YG_4TX\U&7
M+A>I*5RC*2HQ7W$J*:STKX7AI5?Z*4=GI$,;7YP_';&7;YWO%_L*TEDJK%5;
M$OTK:HBRT?5W,PUDA7,H9"[H*4;&FMLLK$I)VI6Z4+ [7I,:YPBC(-/4ZMQ0
MJW-N:R;E]N-+T"$-3U&$)H1EIZHN^Q_R??B"\M^3LCH/PG.J$<ZNH[&*JCC:
MHD!-6Q]:6=Y?MM@>E $==TI97"Y-,6+:HC66ER7)QYSU".E=:)-=2;1$!WM3
M"[EWT]6R"5^4Y:&IZEJ<M(=30-2<^MZHLO<O1>\1S%K!MP@_I=\X:DS3_P!"
MU>Z;06+^:62LF1.R.,8BX2T#7N';O3:J,_W4+R#\?D4"*@9BU2;!KW?5O3H\
MLLM/^$C(E':<4LQ1D&[C959R\='ZYZ1RARVAS?)Z1R[]&!,A.<H]4,2900+O
M%Q&W*V<?1ZLP2"!%FYQ/W#$S!#M&^T[3,1$Q&\[_ )WY?B=_7,3,W6'';/W_
M -_MB^.(1ZLMAFZ:7)@QE;JJK;%5QO&)'Y*9_I,;S_QF/_?O\QM^?D=X\2"]
MB[L+K*7V42OP*M=ZCZ3X<3>:Y6R#()7+DG$<)#_)U$4[1._.60!S/_9X\/4Y
MB$02JO9_G?W[-7CA8;W:6K&.]^=RL;-><\2NWS]LE$?,1/QOQB2C^DQ\[;_U
MC\;Q^)&+XSCQFS^S[&+X<*# ?[7WP??][#C8M9'O,%.T3\_/\Q,[1M_/Q_'Q
M^9V_.WII2(X[[_\ GAZJL'<,;%5WK'\[,\>X1)C*Y&/F=XB=]YX[3$[[C&WQ
M&T;[[_$1\1ZAU9'XS\;_  _\_;;A"";5WQ_?Y?ZY./SK*9V&-I_.V_S&_P S
MMO\ C:(^/G;XWC^8](3=/)L>,W]["NWG>Y/3OCX$[YQ04[G_ #QRE3-C9LP;
M"DEK7(F;&!,*-A@2URR5J.),X88KY-_9WG9<SZF3 2J[E?-#V+L"ONWVX&A_
M#656_FRGS3G%>.(RYA O+;7OUJM^JPBV"Q7GFM<[3$04RTH,)$8 P()VVG[3
MDI$QJ4V2E&8?PM6Y[8PB+=]_&5#58(DDR7TJ6]W';#V79.UK+4/AO2F7BFU:
M&5'8Q[+50EB+Y0QT.&QTB<PP0>#7=JQ;O,L@@(#&-[FAZCS&B2C&=QU"D7'D
M5V0\Y[XXL1UI-DO=;8R52[\_?/P.U97.I_%UG+#&(R-,LII.A0FPAO SR*;<
M#TP5,6*LM1:6IL[IB+"7J[(*.P XV-+GXZ77J:?5#7U9=.H?PU9N#4A[-7%.
MYN73UXZ?1(PBR0LN1:1KN+0OWX"?J6T3F<KXDQ69QV+OWLUHZ*A758R%GEHT
M^MJUVW*K$I@Y&U40JK;909')RIORF$W K$)/2>=_RW.K.(:>K*5$EZ;;_P"F
MTNWMEZ=P#C2]&>5YGG]7E^;UC1TN;TM2F1)T_JX8XI!Q0H4RQW%]>!=3*U=X
M2J9=0)$XJZAQ]DT0H ?>QSK=&[8)23-:7.LUVFZO!D59TL0V1<#%AF>K0=+G
M]:-J)&8JM$HB1SF@=_Y&W&;S_+O*<WK:"2&"-2C**$BS$@43(A2(EB*':CQO
M#76?V;()L77O2P!4:!LMK-6_W<$Z"*0(1*%RL5%*0B.9L<8DCT3Y;1N!-,!N
M'?J SU7^,X-G@3%-.,[_ (?MFP[M_I5[^3M5(O(^&#':SU#2PNG,?B+6GYK7
ML\C"8_(8AS;.397%V7%U4:F'SBS=3C(6@H8RN<5\I4F#6^,J4]-Z;K3GRVE]
M>4Y$_J:>DZLB<?9%(P@U<5D])U,BQ,'2<69R-7EV6IK,IQ!C&2> .UW5%W7;
M/?79H8LGR[O;;L-,CLNL!;#D1+[KH%S::9@;#9'B,C!3P;! +!4.II:NLPCI
ML(1C%P5EK%WNJ&.^:KC.ETQ22_F]ML=AWV_#Y9'3>FGLLI2%:64;HI)*/;P^
MKL+1D#.PF(!P ,J972^9@V!#8,G&D87-<Q#I92E+JT[N/5[!/U5%R.%WWW*O
MAH"2.AI1J62L-]Z;&BL._;+TS)X_1OZ73HXM3LC,+)S&F'2,2PG-@P*8CD/;
M+ 9!<)G9,P<".V!I1U.<_P SJ:NO+_+RD]&FNT:$;I=QQWWW<G&,*(1*/U*.
M9"WW"_E:JU+W_'ZKS=U;:#[[*U8I4:AJ!-@F,F)X!7"5@I J$8$2!D"J)@U+
M9//E,Y#E82)FC]1[]2!#/Z^UIXS=UX0SJ2>T3-B&<[[['_'WN&HZ3S^:[#&M
M:DK, ,&N80%0Y.&2X6F$6;;+"U+-T2'7,;3 +Y=AOJ<WRW+C4H,X#B(>Z061
MVQO6_P G"24R[PV5?[GC<_[WPP+/C3))IUZ_ZE1J4[9V_>':LC4OH73;5_3A
M8RJ\61#AFQV+4SC$UXX@,%(#G'JT):C+_+ZLY6=/1( <W8Q7L9LV;SM#Z6>[
M6,XLR=SP=GQWX)\%HC3EAR!R&JJ^2) !6*:ZG2-6O!KD!6*U]2A["@%IF>B(
M69E!"/ :O,\[K[QTOH$E0E?4C\W$)52X;_?B3'%5*25BRVL;F=_Z/<0)<Q5\
M>>/%)#V0YG*;FQ:DCUM87$?L,%"PF,WDI8,LYS,M[CB3$9J:+S7,ZK$FQ@9U
M-2:L819)13G-WOODVM16GV].%]WN<&_;\;F[;P'_ .UW.6KOZ9B:]'3X<6'*
M8"FD4QV)3 2IJCL 9 1BX^S814Z&2J%"0W7TLTX?4U=2;:1B:4>MZKO)X>F5
MOFN[Q"H38J+G*KV&WL?L;T&;ME^(_)&=UN=NIE*D=*E.GW$!(. U&E<K%B5*
M38']X@!H*24&$2,,@A@:G.\KI\M*)#49,BV,@C.-AB4<5>'OASP*< C*054@
M VJK=\O9WS]N'*Q44P%<K)JYF.IAP)%$#$,<3]Y$).> ##-I.9G?>)DI*I%O
MXK?YNP//?N^<<"3/SBCQ6#;8[U\7BFJY^=\>'(,BOC)U:^.;6 XL;VVR^XEP
M08+)<]:(5!B]@1LU?'?88C6]*U)FHPV-0GU(TU"#+%[*E6B^,IQ)/]../XA^
M,I@K%;_:M\EJ+QO@\:O7VF\C7Z!M.U'2>2U?+Q42%.Y,-<=4#$N6D />9A3"
MY1'7OH>J<QJRY7Z<G!I1[9?=*^_YVW5/'#QP(+5X[M=(IC8_%-?%<:_J*QVI
MK'D' W-+KQ;&.RM_"9_]3JF<5,/D:YF%['S7NUK#LBE]1#H%H.K"(1 )AC%F
M(?2(:+H3EK28FG>IID7]<^JB#8U8J5NWXMD;7VON7\O] ^;^,5GL9K*Z:BU@
MU+JV3HVW4HRM:JA:\BMQBSW7*5$V!5P;"3:@"0NU,0U_ 61T&ERVASDH3U&1
M&<&1HSD/1TT 4![DO-W=E7PI[>TN\;7O=M=L9^U-4-=NF\06K<S0QR75,?D<
MG<942RTT$+2XQ-HBTGK5++#MO<M&0F6?MJVDI2,&YC7CR>A+#/3TP8G@Q8=.
MYXR^>[8P7=\;UC]HB;>/MG:T&3\=9C%Z'L8JLSLO$]@P5<":+UE,K&*\]4KF
M">U< (C!SV"R!F8ZRYG2YW3U.>-?5*AEWJB44B.YCJS7S=5P>@A5"5X^R)LE
M5ON=JJN W >*,JZHTL]<C%BD^A3+8+KL,E1 DG9G VO^UA3$*_"IAD1L1%:Y
MKU/EXZQ]#3^HM968578C.)>;WR47@X:,3MAM/;='G]AW?&SW)W8G0^B"AV7L
M/S.0%8N0)L-TD \=N@S%L[P1R?. $I'>(9N42-*&OSOJ*FC'Z.C%W@,8F$;N
M2.$,/=LX.=)=CL"-=\VE'SY7&U ^+WE<XQ0!B<=CZ-139Z1R(H>P&.)2T0"&
MA;V%[K A]H+3VG,E'(Y.9'HTI39:VOJ:S+&I+3DQZ2MWJC+:);\7\\*4PS&(
MJU6 =NQ6'_GYJ>TCJO6.1STU'7V1054EMJ42ZFI9%&T@85I!10KDP.4B0E S
MP@9B)&IZAR7*\IRGUCJ=5U#3TXRD*L_'2%?F^VU9A!ZI2L2/2O8I[9_V_#BW
MCIUMJ56I<TC"IS!SCZJ'+FI#G*.Y84L%NQ\'# 7W.,O^L]Q$(L@63 CP*7)\
MGJ0TO\Q/1O5[,O<:<+.I JI=-EMENV>)8B=1(E_\3]5^!O&-P'OFS"Q9CK+\
MTBAANMURFD1A:$$FM74]4@).$N:WVU,%IDWN @:,&?*>$3HNM#Z$G5@?1DH7
M76%&1,?![<^=^&B6]5;[4"=-CDR'>ZD'XIX<6D\5A?'%.,OD7)3E)63(M.VB
M)=*Y (YF2N5>":V%1 G#-HA80N8@<+F.<UN?U(QT=.>J:(PAHZ:D2/>:+)7^
M$1"FJ7/$G3H1:)KF6=K-[/&V*_DM?07D9&I[ES&.>MP0<5T6E@RN1M$MIKQ$
MD)G!")F+($"#B0SOQWBMJZ>MH2B:T?ILCJ(/ZA>RI5TW0=RR[X!/2C$&'ND&
M;,&;L#;<[J-\'V?P(9*K8JC,Q[D!@#+F8C91)&DR""B!&9*0)HR!E!<2DA*9
MA$A^'-)C=/OG:@\W?;@,9,7-4>-^]N-KS?CQ>>*I6?#F4/4C7V663&[P*O2-
M4"8R)P3I%P-; 5_VYD[$%!"L!&5% R/K4_\ 56'+QT8:4&5="R%NCI51*7.?
MDQ@X*$!^I&0W;T]R[[456!\U]^+::?QGZ74QF/Y2PJBU QN\SV.&))S.6VY2
MQLF<[_,R4[S$;1ZRY-QE165JME1=\[??M7G@.HW/J7?.7Y?O7[5_/BB/U#8B
MMG?/R,7>L)14LZ<PQ-V+BZ10O(E,&<%$PLY..L-QCFHV3!,&N0]1Z/K.AZ-S
M7,1CU2T]?VU>%T\M;-'91S]Q9S.D*H[%X;QBZ[.7Q6;X):>0T]XJPE<K\51,
M1E..49@?6LN(PPI&#)LE/,EK@#&841GO$S!948<YZIS.ITPE*4@ZEWMA&)5;
M7@K+WMQP250&TC&K%,#2W+)8=ZIKQ=\*#5/F>KK'3.7Q3PR5.R]KXP]H5PM+
MZ<1$/D>J :D9,6@7N( AYB0'$BZ(W.6]!U^4YB&N.GJ.G%ZXI?T^K(-5'J::
M<A7=:81UB0PICU54O^NK'I\!>=W.W<$:>8Q6&HMJX6OB<M^J38Q:\>%:+]]F
M-MXZR+?<6D_:3&7CEC+#K+G>W8]9J7(K4O2GR[J:O7KSUHPA".LSE-Z5CJQ*
MZ4Z0E$Z0Z+ND0V&T+C+8(-]3@ZO-M=5;EYOAZ8JL7CKQ[?RU]_/4&05-@^\B
MLE:N-:E3ADM@(1["4E,B)1Q$H'KEA3'-<TOK'J1I:>F1Y>"$8.(]$5.K?N>6
MVL]JN1)Z7+];7U"V5_IMO8NZK:ER>. S2.*S>8NQA\@]J'Y(&9'/RD&$U=:T
MP')8RXS[!AB5""TURF$H%S&NECH#U?Y_7Y?DM-U(1ZXZ<NCEO^B<^F7M(F;Z
M>J0V!1^(:;*<@E3(!:M*P&XXS]R[N\<&VJ\]2HOIZ/P?-.)FNI#9I5P7<LM9
M!KL)$MQ0D*B22R#KM=( P!!:FP79F<GR,N:T]3GM;J-:4OJ:9JR'IZ6@3"1N
M-_\ Z*9<634F08Z=*]*U1<F[10,-YH,YXF="KH83QSFK>HA*K7RMIZ:@,$S;
M./==DNPDGLTXD)K(#@L6%#I -N)' O427->J0>4SJ:1I,'3]I#4A8KN5)SYJ
M)VXCIR#3?:PC+JZE<_%%)8;X<5M5<>]#:?TA!9'(X7*?J;,8ILXNHP"(,> P
M0Q73,O@ 2*FC!'*B[ 6U3&3M(@O5.8YYAIZ/,:/^6-2:3D76O-E9-E;B4_<?
M=OB>AIQZAC/JC :&K0*+Q5F'!?V'A)7<DZ_DLYD^B(L-S=N$(F 8R^NFQ>)I
M@9+:K:O1L6R&Q!"9FRYS'[A,QZ30TXZ'*Z&F:A&N7C&6I(]L9R;ET[5*HQII
MSO>3BM)9LUH53'V^]MV]U/BN#W6Z;ND_'%;1U:1;9NT)R=\H^U;#QU?W=94.
MABG(DK8J@V00PI-SM(-ES YWI\H<]ZIK<YJO5IZ<^B"U8,@!Q34;E5#@SY)K
M!IZ.EI"X*7NOE-NI?^QOQ/\ B.:=O1NHBR=5E3&0+50-LPL.B$!64M=EJY<M
MQR!.!YIY 7:4!)3!0-?UJ,H\_HRTV]3Z?L=.S,I+&4?%646]_N-IK+38R.J/
M46&Z;5>:P>.UUWXY=/:CQV,3@;^"TJ&,I7LL"8NF=9K'^X.0HV4TA F= L4<
MN>PPDP89!M _8W,<EK:L]?2U^9E+4T>7-=TS:%"],BLLN]5M:=N&@Q8E1Z62
MVN;Z7>.?Y5WQ1OFO/'>.UAJ6Y.-R]*I?R45;;Z/.!;-])*<8C]RQ!ADRRCFV
M37*IA/Q\1%GTWU/4Y3E-&<N59Z.G*4OK-](2^.JV^HZ<E-+=9%J:/U(R"5RD
M&#%$4NK']\Y:.W WF:^E=/Z;H:6F7D]F0Q;VO75A*6W%&Z;3HCL)C&#>$06N
M0&(DC8&PENRWR\N9YOF-;U"[TC3FU+,NB0],8].QNN]?-XA(CT?2;JHC339>
M;"KLJT\T75SWUT0^<OXVZQGHBEJCW1$),3*YG$  3&\ IO:T'"\N1 E-@!6<
MLB1!_@^B?.JA4-&KR74C(9_O[<$U08Y+SC?'[)?%<M"NHX#-QJ7)XI26%1<K
M&JQZP>SWD(X U[KY6V/4QJZ-ZP#);#90I*I):!0G4]0TW5@\KR^HRG.=ZDI,
M5=*3[XE!1EB;48[MJ+05@+N,=Z^+MK+;_+C1?UQE'6*17YMY&A4N\[-*[9X1
M5G(=;7BJJ;YD7W06@EFD&5S?,3^Z4,GU+2Y+1"1H]&BRB1$CE2R3>,CYM[5F
M^$LHI(A*95Q+=T.R-[]C-&YGC\=G)OHKSU7,<I]H&G#& /77<DR,Z[45'RZ5
M#(=*N"52U;)YK$-O5C3Y?Z*PTX',2C O5"UG6.NVFG>NU[-<1$9#*PEAVQ9W
MQN%G\WOPP=-X?4&HJM7'T@;^F**5ILW%DZW9:MH6*C99P@98H&-6R"%Y,,A&
M2.8(BR^<YC2Y1^KJS^IK-=>GI>T)6[#U^!RM>7;BP:4)0F190J,4G-&&[X-]
MG>F^Z\,7#>%<W5NC8=J"Z-:V8396_)M0M1@N F:R3NP0K; K9,B 0R.XFP1_
M>6/S/KNA+!RNFO>72LI%[/N!.^ OY[GTPR,Y2GO*FCM:%8IN\]]MKG:'@K X
M^Q?S63SD7:V/]E#46+$67CVRM5+:%3N^.1PL"8YH@WY)82$\*>KZ]SFKI?1Y
M72AI$VF6G%)YLJV24Y7'E.)_3@T363U$ADGM>R4%53OOP8'JG06)LA2Q&(18
M:(SW5P&Q<*V1!RDY.O(UE]DR2^$%,P4SQ@=ACU3CR7J&N=<]26E$DR=64JN[
M_4?9Q0=Q.(38P7)*UKI*#[[COVV^>T7DM>X:HFU:QND)M44N.)+VOQ"U2:PA
MEDKI'QYE GR49]D0H 48R(VM/TS7E*,=3U&&G*<@C&3J29]3BCKZ<X3"%X.!
M_4C*SH:!1N[JT3N;?+2=\\,''Y&CG]-HRU"O-8+2C%R "0D!*"X\9@1.%20S
M$R<042$QSD8W+(YC3GH<SJZ>K,U)Z6I]-_5TO3DQU?-[_P ^)Z0.13JCD[9K
M:\U^?]N*T3CL;ALA?H6[].<JZ_5N*NOKA?254[@'81:A\,8D'C!)L,W%R&DF
M5GW&0QU7U9:^CI:T-)T^7TM*49Q@$66I&"^UD--XDYQ=9SP& =4B:7%HZ[K'
MBD<;/;]^.O$5;=_-5Y47O*=(#?<'3N,BM5MVC<L5JIY*ZJO9A( !K,VE89(M
MG]POMB0Z_-:?+Z,"6G'3UY]+'ZFO<X00S+3")U%V%!3&Q3B4=.Y2D;&T8N$Q
MC-A9_+;Y.4:.RI=Z#&[7Q>[[*)O,16&GS;897B(I$#6,K56S0:]K^=N%-9,1
MM 'FO/\ +]46,(:NO%7VDB4G[W3;MBD,9NWE!_ABQ[>Z1;^Q9\N#XX[\?C]+
M8>L+T7$YBQ54!U:==$-;,(B0Y$(2;&\&L*%R?8,,DRYKGDR :^MSG-]4.B7*
M1FN=3-BV]%4%E]+FFK&N)$2*,7JD?PE.^'(]LW^-N ;)YA3+MPGOVM9DSK;(
M*>^KC$RSL (2;P(B,9]QN4*(0@ F1GAZT-'DM33TXI$='0"6I&=IJ2E=3E2+
MU(8&JL*W1LU4Z0H!'?-GD<UG&^;\&7U0Y:]IOZ9_&3=*UF, LMH#'I&S7D8I
MXC^ZF5([%RBU(C(5:M<3=7LJ4%<A[FB$UY"3>C:9J^H\VZDXQ8\MS>KEZ3J)
MP.F/Q[E(VJT*[.Y_ADT'U;0_S"FD0U&5(2?;0#D&W>G9X4_D/4:K57QSI-D%
M>S^"3IH\]9C$R5!CI2_(WX4X[:D+=2:-.&+5<R\5K-@*-BJ'85JOL>G:2ZG-
MZD?_ &)NM"#U9HDPBRJ/>G/3'JI2OTMK_*_3ASW-,OIZ+JZTM&,=6'UHR&73
M!&",95=47=V5PDZP6M-^1J=Q:+& 3G<I7NV7L1 K99;2R.):=9E5S*H6Q.V6
MXG7BG3 ZKA8HX$6:W,Z9J\BQ)?6>7 9$K>A8S2DM"L5)5ZA'8O\ I7,NOR<C
MF/>ST->,-*69Z4R1TLV^EZD&B)0-VWQ]6](96EJ72M#4.,:FCS4T[ZE37L0N
MTE3$7:[+"6O2+:MQ1BXDD4R=>5$?WMCUP6M_IZKIML>H(WBQR-(81'-THXXX
M[FN7U>7YIT-2B5$L'3C4IC3?SWWLVHX1GF;R]D,7H5P8&I=?F;%.2L4,<(+S
M!)5("958:Q:P3<W")M!!""["Q$XEL'&GZ?Z:Z^N.I..GIC[92S#OO65CLEF2
M\\7N1Y;2>8TXZTB$<R93IB_%7>/G:S;A2?3GYR<S(V<#J)MA=\[K$Y'%9.$%
M?Q\,M,"E?IV4T:?N,;UG-29M2^RM*J?:9-)Y'<]7]*= CJPD3TV/MG&^F21M
MBEO3+%T4=@XU/4^3CK:/UM#2A"&G'$].+&.H&/<*K)PM,<WBC'T%RUNMBL7;
MR5EHIK4:S;3W3_E%2@EA3^(VWB/B/ZS^?S,\OICJ:A$%9I$C9EP537SO^U\<
MO",YSC"KDR(IG.:P]^WV[_%>\']1&#?D2JW(5%=CG3#JTBP:JTFM+ >46#(2
M4)1>9-A=<QK-DH42UBYNEJ^FR,C:5OBU&0=S.0Z5V+;>-G5]%YB.DZA%R6#3
M>]X[Y\7CYXLM1NT[:4VD-6P7+$QD#$XD#'?>)&?G>)C;\;1,;[3\>LF4)141
MPTX3^O&,DA213%1'?#6_C'';U#);E,S,S^(F/B)CXCYWB8GY_P!/^'J/$5Q3
MME[WVO;?;X^SQZZ0B(VDHWC;;>/C>/G?X_I^?_'Y^?2XC;=?O_VSWLS>/!Q^
M2I8P13OL,;SO\S\Q$[_$;[Q^-OG\;?'QZ7#YK.^P["_A\GQX/GC= 3M(0,[Q
M,SM\EOO'Y';?YWG\S&VT[[_/J1ERM1\4UN_[>'^G#;6 E^6K[69WVQAX2'E+
MR-<\>NIV8Q*[F(BNZ[?L"\RN""6 MB:M2%P,P,-%SK1.F53 ("LXK$NK:?(\
MG_G)2A'4C&6T.K(RI07&':K^6^Y].!+2E.75U1: JG[F]G@\]L\;-(^0].ZS
M0M $E5BQ7*(0P@;6MK9!08KEFY,A@P?!+P$F@%@4PZ$OD9<QRNORLI1U8OM:
M91-G'<Q\WXJOB,M)C_J1M=HV[)2]-4YQ;_80Z T)CO'FA\[@L0?'%NN:JS%*
MH*80K'JR]FW>FDA<-;'37-Q"HHE<'&[!2GL((H<WK3U];KU*9=$(J7[B$2))
M7=2NK *M%'%GG>=U>?UOKZ\F>M]/3TYSE^J3IP(1&L/1$(F-C-\(K6% 4>1L
MOF1OK]E&977OU['-4*=(0%<$LED0;9N64DKG'2(M8N)B&+$-'1E?)D#2&8=<
M)/P@R>]5=T*M4);P*-H5C&<[F-GR]_\ I!VK(5J +6&L@[)WJN1R.;0_ TY$
M8Q;L;C\BY05[%BTZ<M<:=8_=(@P<%2*2]^*W([YGHSBD80C..G"<=;534D0=
M33621B1[ULUU.[3@I]$-NI#,6\Y5*[#@KPGVXJA9=C].M9B\D,4M5XXTMU!A
M[ERK[JAD;UCME[:HU4RJG>95>%<2$QM!78RNZ4+)'KMM#ZG-$W1U-.6C,)6*
MA'HJ)+=ZBI%EG>[WJZG1*0G4"UTXZ89NRY;.V_;!MQ8/QCK5X914IJ'NL'HG
MW%'=8I:D8ARD#O(35:326V5H.>L9B) ]FXWJG+!I393B-P1)6REU'M&GJ=Q/
MFW:^'@BD<J"49L.U;XK;OCL<,[5.(T5D>RPS-[T]Q;C;(1!WK<&I9.@^L $1
M0^&UF%8]J!#,2OE)289')Z_.Z3TZ>E?4BZ<CVU86HJ76V?+>Q-C?ZA*&[V3L
MY6J[O?YKC1C-8:"QC!QU2GWU%FZ46;YD=V.(J".15U*1R64  )DN,%,\2,G<
MIES/)^IZO5KS)0>FHZ8A DU4JR[=7E<_;@L-33#I+OMX>U;VU@[=^_ CE_)N
M<N&08YM=&)K&4PU)[("!LUUPAAUP/V[W18(@7%%^PS+7,@A 3L\OZ7H1TXNM
M&<]24?<2H(2;5C=][1:[WCAV=DF,C9HINSMCS]_%5=\<?NLMF05*FVRL_M20
M$=EZR-C![.A9E66]0/A?%@G(FL]_G[50>.GR_*$LD8+F3M"KKYR+L-5G8X$]
M30QO;S1BGOGP!>W:CAFZ?HKT97;GLL!SEK[$0O'B0 %@BD Y&N9+J$X'M.)*
M.ULLE1@J3:61SDY^HZAR^E)>6TKD:D5!<V"]E>G9PWM?$H7 DR=G8_4]MGL;
MMM49VX&K>:QUS4EE^:.Q5&^+1KL58:IB$]9%*Z9@8,AVPDQEY<LA03*X$FOA
MT6X<K..A&&E& 0Q(%N4L7*J[F*^,8XB2%H$^6MNVV7MFJS:\::V"RNI@Z<-3
M76Q8.-;+G#MNV@48LE[7RJ39 FR39$G^\WE+ +<YAM3FM#DYZ;KS9:K!D:$4
MZ=-P6ECU'Z3<J2WB^)D9)96:$5VP^-_V^=JX<.+R^'\6XUM92YBZQ"ZZF1(-
M-3>0-8$KX%+GL;*SL1V_ Q6"-O@O6,_7]0U]6< D4SJZC#IC02_:_:N'-<-J
M:;[:KI)=[O._YPY_KL.33>K:F>P=6UD;%:I;8HV,4PP3(B+"A;N#BB9Y!UD0
M;D,\HB1X3&]/],F-EC4JO#FS.2_.YYWX#/35]I)-MO/FG- V>/PL)K_27]X<
M(M2YB;*SW0/*"2Y=C8C1V%RX09BHTL(HE9@L9. -C(M<OKRTM2.I!+C>7<LI
MQ]G-"/Q1P,:4JI?R:W^_<3+3GO2,\9>/LG5US7O1 U58AW*S6-/'KZRG9A21
M"<G:@5KX1#)&1YQLI,"=OF^?^KHNET$IRB/4T Y[BN^=L;9."C[%L5LH<I_(
M,;;'$/Y2N8RQJ76@4*"+V?I)MH<VS582*B'(7&XV'HFB=U9$#::6N^6?? $
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M <6"P6N<:8YK"(NZ>JRT^7+Z?HK K'425]VUA@S?BW;B4).PN!K&S^U^?O\
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M?%(#@?O?!-I?75E#'9>"=0M&N*XDXI&%36Y+6#&JEJ8BM CO/$Y4/(F%ORD
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M:85Z:%\$5F2**R5PH% LA@ECR">0\%A(3"OYELB-#6Y_0T T?3SZDI/1+5U
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MN<=.8LR!%2JD4]-O\,A!+L>GSG@ER7CK7-,D$\:^2L/GW"YR-&"IP\%*$#0
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MNO[_ *\"SC\_M3\_\_;Q7'R;CAH9FS:<E?Z+D>P+5F W*ME3)/"6B(D,IM"
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M@Y5M[%!XK@@;Y.G):HW6U?GN]DQ;<]=U/CUX>S2P=6,;BFB(?J@D(OL%QD!
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M"EM?37;97B]8655EEZ</;KJQY.9:8%2UD@4?(+*>.?ZZ'^E^I=2$9,IT U#
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MOD_?;@5SNI[^IG5Z66&V-?\ >ZCKA;@9&LQ"2HLA*E"M:F6ZPS8DTU3KUG-
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M=YX)'F0HD%!O6:K:[?--E>,UP1J\VTHO,MG;.LU?%P*BE^W;@(%4"M5>.E2
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M\NHT59KQ;5-NL#8$DUO7H0UN5C.2PU=.RI+<B%7:C*2F19>X,>6?.QY'G/\
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MC'3U E[?I =+;U905673=*2<&++1[Y)R].Y;7T9&J)'1TM/4.J1-!"*)5/\
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M58-/;%_BZ_WKP\)#4VF<-JDEV*-<ZN9K2JM8;?9:L7$"\DPFC1+OLTAD4MN
M'0;:P-DA)I#!Q.QR.MK\JOMO2GG4@OMK'NQNG?9 \[2F AN'ANKO8:V-_P!O
ME1M/'VJ=EH7\9>KYEKFBI[*[&%=JIYS7*I83,D --92A)P#XE8I""+L(=Z>K
MI:T82TM2,]*,!H6Z+NQWVMQXP9XA$D75^YLRF';L9[9Q6W'+DM/T\9!A#%O9
M=G=D.4PE ;.:S2=;G!$XJ1-0R3*8!AI2O>.0R^CS'U8A$>DQ%<7FK.Y3%-C
M=B^'D^WX"Q,75;+_ #Q5;V&"?2M.,Z-;%'>]N1@==)0N5K"5]AIH2NN'/L@X
MA4!$2TF"LA&2EXD'F]3_ "L):KIRE$%E*RKL-QNG=1W=N!]#-S-A5EVT_OEM
M\XI,XX9RO&EZLAR\AF$XQC634D6V)7WH" 8:S@U/*6A*FE,RL3@!9,P*SE99
MSZKIZA%TM'ZT\2J4<8!>U-=J;O!7!M/0KVNO*[4Z4#NIFMBKV:Q\<-C":,P>
ME-/6,ZJ1R+EIF7RA;'N Q2QA,9$J60PL!AHI2N!DS@CGY*?6-S?-ZW.:L(,G
M3.M*=@:[6XQG\A;8DZ&*ATAYSFJ_>64>QX,G%2M19M9:BMY')F]IVKO+&UW6
M[,5%H4!&4)%1+0AEHYCY/L&5BR5R&TP?5:?+:<.7T]+1 .CKU-4HGJRVS>>D
M-K1[4X>*XR92DQ_4M55YJ^U6C6''\N-EK4]?/S:FPPZS7%036?N@1HMH6R?
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M,9+#15>=1"$W:++.'RJK^0LP:,1E<@2[E5.0N7:Y?I@P+P<UR!SF@Z,PTYQ
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MWMA8=OW"CKUD7G+X.-&-OT+M:S8EH$YF,D\H=B 4XSZ"$#1Y@C"W3A$UH/\
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ME<=-XT6<I[12VJNV R&.K7ES=I_K'.HVVK)*A5<MGEO4YPY<GS&K]=ZFXSE
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MKM:@DRLP6@JY]AF$+]KP(0%" ED$>Q@^222[$+Y&6A'T73A3K:D!C?4E)8Y
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MN:[:HTT5)"II8%.+"OD;_N_;0RTEN/L#":) %<$A%.Q= TLEJS=3L3#0E*+
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MBK(X&]8M7:][&*1DJ=&O>EP8<<A5*:^YR/JT=32ARW,R9ZPRZ9RC4I.4+B+
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M$9:6MHD90=.4JG],)6RE"V#74+6"[O9J'75K67TW9W,YD!7G*E0,3J1.!O\
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MLIQ@QCM^*[?SVX7FH_&+[;+]S&4X6_*ERR:%N4GW#H%2PR"")L"%Y:DJ!O\
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M$8^9V_)3.\S+AM^):8B8VG_RG_E_\?C_ (^EPO[_ +_EQ^#&WYV_X_\ Y_\
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M':_[:\_W]\<=%SS/H&AE?T:UD;Z[VW+KC!9EB^._^;W"Z1(VB(F9_<_ S/\
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MJ"Q*T<#'[E:FH9D%F22MMLVZZZPB5<;O(0GS',:W-SUYZL9E:.G+^"463;N
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M8.PF<Y:D\CCVG5L8^DLSA(J,YNUYL"!J44V>4F FWD:YY<2" BGJ\SS/,_\
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M0<T M-MGQ>ZKMYO1KC$TM=Z;+4&+R,)OXPEN13E!O"PR )2Q,!(86OK&($S
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M,)+2A<-4R,WEM/0>:CI<T$--6+&#<EV;+NG[EG<VX).3T=4),[.J-@+7\/\
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M5NGD) 3-S&V$KF8?[F(/G_O2,N(=;H6M4#/5/!41/VP9?3.=-6$>6FI=I/N
MG>[W;WR^0X#J:<U]L:-VJ+-^V[V;W%#&R(S=.U8Q-I7%8..R]9BAD#;K4W"Y
MC;[Z\2M_&;BF4UL7+6->86&,X*GAT/+:A#6C-J/31.4\PFB$>A=O:QN06(V7
MQ7U+8=*O5%ZH[-QCE/MN(I9E:MX[=!94]*7Z\'WRE\(!O[IL,IE<I4,A_NW
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MOSFZX%]"(LHK4969L]KB[KQYRY'B T:YF'U!D$PSN%;$2+SARD,@U(8J*J1
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M.^]^'Y)Z02T9Q2@ZHE5V.H__ %LOQC@ T-?R&&UL0W;2!7;MI0@O:Q7A-5(
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MTE,JX\J$!,779-@KK*HKIATG-V"*:U="9B1!IC%?F^8T].+]?5(112164IZ
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M@UF_QX Q7!'C/%:<GEZ5O%54A^IO3C5"^O87AC.723722J[F%9.M468=>Q.
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MMWZGN53V,_C)7"UHJ#(J0^V6-ZW-Z=L_RIXX-#:R;G]*9O0[7JM6**FOI/:
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M2RC*\GYC>SON8O\ G?!QH+3>;H:CP\MQCZ6/6^+<NLY1=AY$1# (;6 #GM;
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M]"L5C\E5K93-6256 T6<LU!6K!&FL;JYV5H]NHVO/A4*5*!8&W]I<")1ZO\
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MI3$WRNN[# 4O782MPE68>)NNLUJULFR:QBQ7V:MJ^!8ST^>T'Z,XRU-&7NG
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M:E&#TQ0E44S9%"*9IP]V[\<'.0M/3CUT$I;#+%;W*2A4P)H<RM4LP%9I@^R
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M!?RF_P#YW[%?'CBI?F!J\UB<9J^NICJCII-;8JUI<"W4T&FRCMD)!90L%VE
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M,)"]%Q+ZD_C7!2;7LT\4M6?T]?4P5)4/CLI0&;NK^*57;DLN6.6(8H'TJMG
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M #CJW$Z4U3IFG@6+TPY&3R&*Q*K%+->0,7HWQ=Y U&%)Z]<Y2WIO3F*P?E?
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MF$[ T%7"'H/1^4/H:L]682(:G1U73'H,BX;1O:ZWO'%?4F]9&-71:@T6E _
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M\6WMW[JKJW-;F,?#W._WKM1Q^$SCMO.V\3^9V^/C?\_Q^-_Z?C;Y],W9BAO
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MQ$QO,?Q'+^=OF#04# N]MO?%9_;OQ%CU);XI'<W_ '?VKMC)9BM_[HY")_\
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M^N\M]2&IJ:>NRA+J*@?L7*J[#16:#NNP.:1O:\)^/Y^..C _27J>AE:PY9^
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MAQ9TM]1=[[./'SPS*P*0SB_.=S;8K\=^/.)\ WFY:SJ'4J:MNZU2$+K5[<3
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.._P"CKO\ ]V;Z7"X__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g491933g92b09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g92b09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[3(N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ,A*^$H&#A"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M   !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&X#J.
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  \!U'  $  0#P'4
M<  0 !.$))300F       .             #^    X0DE- _(       H  /
M_______P  .$))300-       $    6CA"24T$&0      !    !XX0DE- _
M,       D           $ .$))32<0       *  $          3A"24T#]0
M      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M   0!:    !@       0 U     0 M    !@       3A"24T#^       <
M  _____________________________P/H     /____________________
M________\#Z     #_____________________________ ^@     ______
M_______________________P/H   X0DE-! @      !     !   "0    D
M      .$))301$       0     @   D    )      #A"24T$'@      !
M     X0DE-!!H      T$    &              -(   #7P    8 9P Y #
M( 8@ P #D    !                          $              U\
M-(                      $                         $     $
M    !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M   %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M-(     %)G:'1L;VYG   #7P    9S;&EC97-6;$QS     4]B:F,    !
M     %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&
M]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T
M=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M@       P    "/_         X0DE-!!$       $! #A"24T$%       !
M    ,X0DE-! P     )[<    !    H    )P   '@  $D@   )YL &  !_]
MC_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0
MP1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,#
MP,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,#
MP1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( )P H ,!(@ "$0
M$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!
M$% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0
M "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1
M:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F
M9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R
M$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C
M7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK
M;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /1>NTY]W2[:^GEPR"ZLD,
M?Z;W5ML8_*IIO_ ,#=?C-NIIM]GIV/_G:OYU83Z/KG52_[%ZM=0:P48UEM%]
MS=WVJQQLR\O?ZKV7?LZK(]2VS9A?:OLMF5E^ED+HG9X:YS?3)VDB9'8PF_:
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M[BZ!86[60^=&MW7/\ 3=NV?IO_ %&H[\BB7;GEA<6ML$$.\6N_P=F[=['I&
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M:Q[BT0=VZUS6_V%5KQ [#=?87:.8QKHE
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0'_P  1" %0 5D# 1$  A$! Q$!_\0 '@   00" P$
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M&;WL^^?A.Z<-QG56F-Y$Y9Y2YIU9N.XBX7XDHP[[D'>VU36/NK^>NAM;2CI
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M=SWG_B$)O'5)?QZ"722$E6=785%/=%9D6DMK((J,0YPD$IK#;]^_[_?>C?U
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M^O[]>$-U^%^_H;V^7L:^=<:.3[4BDX.#YUN^41.6^;(Z_P"TTL>XCQUEN/\
MB3'4FII-)9\;";3*Y.G! Y'M)N2ZQY%>?6U^R/7,ZNZN]#7UI>*KJ\!UK(M_
MTX*.Q '8WO\ /Y#W]_>QWKA\C?;$\'MX:U_)5WQ%S[G>0\=WDZOND3]VJQQ]
M'/SG><]:$&.US.*SU36ZHW*&_':E2[(6VDU<->P>ILF.>Z9 6')8^GR_&OY]
MN%WNOD3?T _EZ]O;@D^Z#WZ,=WO]3SSB:/C#ECBK6]W6]Q67Y&S7+=%4Y^[
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M8Q\OY> [DW[3+^KU%MG9RW>/59S[\YW7?N?3P_$$E(OG0T;PEO(U97I).R1
M51B]5X3_ &^G^O?Z\=NV^RPV]GIY+_\ =>R\<#_MA,E]INHCLW:O?]T\YBF9
M2;BI94/9_"$B=B&1:!>M6R)/)> KE5_9*_G?Y5_3@LGV[4/D?R_4@W?;;@9.
M^QW%MUP_FN=N\%07G(FNW^B^T0XA[Z_#\W"7#,W,-QQ3<XC$%XV*3D3C273Y
MZUY!Q*QN-@TL>.G(NPFW%99#4MD+76C'!_EN/7^7R[>OY<)?H=K'N/R'K?S
MXF[[&K+\[V7(7?\ >\1S;5[:-.\)RUQ/8Y;3;[A^YX"MMDS"\9I1W]G3<1Z2
MPM-'E\556%A!FLB1=6)]C;UE,A=@9+;-LFL*_7]_E_4\+?8?OO\ ]N^_X#B]
M3LO!PNQP<+L<'"['!PNQP<+L<'"['!PNQP<+L<'"['!PNQP<+L<'"['!PNQP
M<+L<'"['!PNQP<+L<'"['!PNQP<+L<'"['!PNQP<+L<'"['!PNQP<+L<'"['
M!PNQP<+L<'"['!PNQP<+L<'"['!PNQP<+L<'"['!PNQP<+L<'"['!PNQP<+L
M<'"['!PNQP<+L<'"['!P.>[Y4UV=UMI1U,6<]&!'7N:ZQK;(PI[BPH2I'+(-
M>5T2,:Z16M8D"JB-55D=U5&H37Y?]M_2Z/[V)^?^G[W_ 'MPTTYMY 7_ $+'
M?G_8*Z_D3^%B]5_6B?3ZKT[>0Q]1V&_?8U>^VP/X]O4<+MM\_P /7Y_3Z;_*
MBOW;>0%^4>._]!7?\GOK$ZK^KL:B#1KUW]*]#W[7WX*'IW_U]@!9^A/??C"\
MV\@(JIY>.]E_V"N_^-G[?YOS[ >QZ [_ #_,;?H=S^7!_2^_?MVV][_EW'"_
M=NY _P!;QWM_\A7:_P G36=/Y_E^M.QJ[?/T LCV!WV)^G?@V_IZ?UV_$?T2
M\V\@?ZWCNO7W1:*[_P"-G]/?V_%-9[;=B?TL>OTO^9O9:VO>J[_/8>V_K^GK
ML5^[=R G^AX[Y^_]@KKIT_'K][.RACOM>UB@=_EZ[^^^Q]#7";>G;Z_SV'U[
M=OQX7[MW('O^]XWI_P" KKV_7_"SV7^GR]U Q/M]/?>MM_ZB_7T!M\_S_3L?
MS_3UX2\W<@)_H>._)?@5U^7T^]GYI[=?Y.QJ-=OJ*.PW[^UU^ [WMP&OWN#^
M@_/UX7[MO('^M8Y5]OE17?\ QL_I^/8U;^E;W>WT^@O8D_B!M8*]C^]S^8!K
MZ>O&?W;M_P!.JQXY/_F*ZZ?G[KK/YOS3\>QJ;;:[]AZ]Z[^WJ:]]P-PU^I'>
MQM^ _G^&_&/W;>0.G_.L=_Z"N_V_]=GT]OY>R:_;?WV]/7U]/V>#;]??M]35
M?B.%^[=R!_K6._\ 05W_ ,;/Z=>WK5_,?6C7Y=P0?7M0/"<9_=MY _UK'_MH
MKI/_ ,V+^W\^R%ZO<?(#?\]^WM[]Z].% &W]?RK8GZ[']>,?NW<@?ZUCU3WZ
MK\!NO;IU^GWL]_E].RV:WH'Z[ ;=_P _?U_#@_ ^WU/[^OMZ\9_=MW_^MX_Y
MK_J%=?+]7WL14[)J)[#ZD@^MT*&^^V_Z<'X?J/E\OT]+W[&U^[;R!UZ>5COV
MT5VB]?;_ +K/;Z]C4?8#>@?3M[V+W%;?KM90_KN!W]CV]K]>_P"&/W;N0/I'
MCNOO[+177OT]_;^%J?3^GU0#'<D;#\^]>Y]1V_VL-;5_V_0?+]>,_NV\@?ZU
MCO\ T%=_\;/V?A[^ZIV-1NJ^FWO[[_6Z[4?8\'M_7O\ IM^/'RO-^_1JJL6.
MZHBJB? KOWZ)U^?WL]OP_G1/P"6'M5#O_(;]_E9^N_ *^?YU^M'\]N"ASEA/
M;Y^BM26QL(LZ>LL)F0^+RF2FA0$R-C1ZN>C&OE<C$<YSD:B=7*O55]\)QN>Q
MP<:32W+,YG;[0R0N)BH::SN91F/:R0B*K#F-E@C>_JUDDK('1L<Y%:U[D5R=
M$7L<'T_?SW]N*ED^V1X7Z)XN,N1>O3W7S*%$Z_)?]/KT1%1>BJONGO[=C?\
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MX+[I[^R)XE3^9%_G]_H<'$5:3A/C37&:RPTF:$MK'8# B65L8C9;4 >M#]$
MR@L'HI.?<*SQD-?4RB2..DE,>Y9'KV.#C$_"V +2="JTPI"S]S9EI/:&JA)?
M(E0M)K'R^&5J^&PK5\F-J.3T;WNG&6.5/&IP<=ZEXDP-'+,2E)#<ES34)*E:
M5&Z F S-5$%)4&B36C2'!'#@C11>K&2*=[F-E<Y)$3H<'#7'[O'%XZ%P,K;R
M0":FT=!75!.MTA=)FJO65Q53?C92G+LYJW/H;7FD"M< .Q1H9%B%\EB(WL<%
M_P!?;]_]_<\2(7B<\;)BY9QIW/P):'9E&%3,],3\#.SWFD^!R>L_L78$Q(R9
MO1'O;+U\;$53@X=GNK?FJ]/DOX)\DZ=4Z^WA]OHB>W3Y]C@X2)\U_7^*(J=4
MZ].G3\T7Y>R]C@X77I]/;\%_DZIUZ]5^?XHOXJGNAP<93K\U1?;\_P#LOE\_
MG[]>J]%Z]?ET^1P<83ZI^'O[I\^B^_\ WOT1?I[?/L<'"Z?CUZ=$Z=??V^GO
M[].ONB)_.J?,X.%\U_M57Y]>B]53JOS]OGT^7S5.J]?Q[(37O^ O@ )["_W_
M +\7(?8T=?W7>7^O^YQ7?/V7WTX7TZ_+Z^WRZ^_S[ (/[_?OZT?EP41W%=OU
M^7[W_7T/=EX.&54_QXU_O_J5DUZ?5??0?3\/?VZ_KZ>_8]?R^GK^S^'">HV]
M]_\ O[[57>N^QX>O8X7A=C@X78X.%V.#CCDECB1'2/1B*O1%=U]UZ*O3VZ_A
MU_4B]D8T"?0;FR!0]]_PX0L!5FK-#YGV'OQJS;NMKQY2SC@PA(6JZ4DN>.""
M%K>JN?--*Z..*-&IU5[W-:U.JJJIUZ>(GZS%(JD?:ECN1B#VH*!9)V %[\.+
M%*Y4)%+(6J@D;L=^Q\H)J]KK\=]A\T/?'[LF5>;#=\W<>LGKE<AD-;>#WDL#
MFN1BLDBI)+%[)6N<C70_I2MZ*YS43JB7,/(.>9 7I\KS5U_=:7'>)6[[KU&2
MQ0N]0^5WQ:X_(.<Y-F+ F=>X;9 1ZGST1Z[$7MPSX^_]W3IW(R#F"FD59)(_
M$VEU:L187PLF=XDH_ Z.)\\3994>D4:O:CWMZ.\,M_"W/5!_Y%@:!HRXW\0-
M#_U@;G2Q -$@;#B8OA#Q(^XY5/7U5F&VWE%$^]#TXDO%=Z/N_<AE_#L?S%Q]
M=V2*_P ==%?A"6'2-&+*C0#YQBWK&DC%>K(WHQ')XD3KU[5V3R?G&(JOD<OR
MHD)%R?#.\=$&O.C%19V!U&Z- \0LKD'.L('XGEF9'5>;H2%=SL245P 1V)(%
M[=]N)WA)AG]XIHI4Z-7K&O7HCD1S57])51'(J+UZ=.BI[^_M6JX8$CT.D['8
M[;$$ @T1L+^O%2002#W!(/R/L=SN/4;'Y<=GM[X3A=C@X78X.%V.#A=C@X78
MX.%V.#A=C@X78X.&?Q]_$;(_WO57_J<7\OZ_K\^QP?U/8WZ\/#L<'#6W,4<V
M)V$,K&R12Y?01RQNZ^&2-]26U['].BJU[55KD147PJO147W[!['@X@M.YEW7
M53]+A?'JOU7RCTZ^_P _T3D3^1$['!^_;_?Z_P"G"_J,>ZY_N+8__P U8?CU
M_N_L<'&/ZC/NMJJM_<6Q_7Y_\ZL/Q_'UWT7\%]NQ^_W^7!QG^HQ[KG^XMC__
M #5A_P#[_P#^CY_/L<'"_J,NZXGO^XMCT^7OY=A]/E_I_P#_ $_7L<''S)W-
M.ZW&QSUX7QR(WHJJZ,]$3W1/=5/]O^%?U]O+'2I.VW_4V@;D#=CL/KP;>IH?
M2_T'&IL>ZCW1:<60VVXJX]JP86HX@RP)(#%A:OOXI"2+..&-JJG1%?(B=?9%
M5>RQAY2%2,R,Q "Q?:,3Z4%%G<[4#[UQ[2.21@L:NY:PBI&[,Q]10W[;U6XL
M<#'KK+[+S&'Q55J/Q&0<20P,.&A;?:MDICFND4)T^8EM1V&>4U'('),PI?''
M^\?OL7F7<'AKQ!E)(\7*LA41=6K(*8Q(NBX2>2-^G[. !88?P\6D7(>;Y"L8
ML&7R]]8"[WOL2"-O?MZ[[<1_-RW]E$),\<G/9R*2)C99%^X7)JLC8YTC6.E5
MM4^2-%2-55'QITZLZHGF,5TY?!O/W%KAJ;L#_FL0757I)R #5]P?Y;36\(^(
M!'K&*C+[=9 ;KU%D WVOOVVWIS9S:?94ZDZ&OKXN,!)9Y5@BGO:C:9JODG:]
M6.A^*: :KJVR1N16R->:CHW]&2-8Y[&K'G\*^(($9WY9,^E0Q6&2":32>QZ<
M,KR$'T(7L">P/#$OAKG<2AFP)B/4 *6'_P H?5^0/Z'@F*#N[=R;5Q#DY?!\
M4Z,0F-LT!%';_%8I6.7]%T<@%L0QR.5%1OOT_#JG:AFARH'Z<N+/"X^\,B.6
M#2.QW9#Y@?3;_P"+:C53XN1C,4R,>>)QW5H7M1[G;L?<6.'A#W-^ZU*C^G#&
M-=T?T16Q6*(OLGXV"KUZ]>O3I[=.J(O7LVM[W5]C7I7H=SOO?I\_<Q['O_,;
M]ZW ]..5.YEW7%5S?W%<@B(J=56*Q3JJHB^R^N]TZ>RJB^R]45.O7LM;W^_R
M[>O!_O\ O\1PF]S#NNM:J+PSD7_I.7J^([JGB<KD;^B:U.C.OA:JHKD:B=7*
MO55*'?\ ?X>WSKOZ\''U_49=US_<6R'_ )JP7^?U_7LO!POZC'NN?[BV/^G^
MA6'T_P#'^R5^_K7].#A+W,NZ[[_\Q;'IU3_6K#__ '^RU^[/!QT9>YOW96(J
M-X9Q[$ZJKOWDU5Z?EU-7I[I[>ZHOUZ=G $[_ ,^VU7?;W_H1VXCMK%50];]=
M_8=AVKTXT,G=&[L[T<X3B3&RM;+/"KF#D/\ #-!(^">-50IR>."9CXI6_P!L
MR1BL?T5%[2HTB;NHO_7^8OT_$<,-/(E4["R!VOY]O7;\.^X/#CXPX=XWXNWX
MQ>!R%1EI;BEN0K&2JBD@4P<::K)@A(1TKTD9%-TECZIU:]%Z*GB=XC)AC1 Z
M#3N%T@V*(L$V2=6]'T[?C[@GDD<HY#4MW_%]#6U>O:]_S*7M!XF<,JJ_CSK_
M ,ZK)JGLOO\ Q@Z_R=?Z>R=CU_+_ %_'][>O">Q^;#W]?R]/F1VVX>O8X7A=
MC@X78X.*K^^5]H#/P]<2<;\.#5-_R +&Z72W=T/9&YK(-56)$ HE6Y);;03^
M?$Y0_4CBUD#F$%>MD=Z'MKN1>&4Y@BY?,))8L1F40QP/''-D?>)?7)8CA !%
MZ6+D%5TCS<=-\(?V?9'.\8\SYB)<;!*%L:%0!D91 )#BSY82:(H%W'8J*)JO
MM^_AWT]1FD#FY9(JWW%7+ 2^JRN0K+,%9W2SOG *I0#2(#((%DKW%>OB= V"
M.6 !#W^H9N5\/>&H,MB.7QR)!*"HDR<J1)* 4+(DS1AD8TX4(02Q#-I!!WV'
M_9OR#X:&=H<IYGMM)U%8V5M(!)>J/<%EW)!U50X&JT+T>I$,,V%S>[*YZP.8
M?K-0;>Q$S3^!EBYI!A!9RR^!BO3U3?)E1CF1S(Y[_#9=6.&2,8Z0XL0U#1CX
MR0LBC>-?*JJ06(!*D,";(( XV/+_  _R_#5$AQ(T;05<Z22P%A20-*K78@61
M0)!/?&9%"J&RTA%8+U9&Z6!\<"HYRF+,U)6RR2DK+"^8=H[!!WJ+)X6/EC:1
MYT3?&5--/IG$CE2:(9KK0%L4 A! )8L1J7TM-)XGQ<MPX&J-8XVW#J% "DD:
MANMK8:R=KU&O4\<QC9$>XIA\P#"89D1C[%A"*T;S%ZQJH[W12RQ^;&R9CFNC
M;Y\D+6](TG;CMM*&(2E66ZCTGSD=QJ *@T2M42%!]=+LCPQ*S&8J2#H9;706
M(/H;-;';<; CV;=I3B6C&1V8KD+459)38GSUEEY*/\*R$%*YA+9'?UO.D<DC
M1T<$Z/RGC/DA9,AR9L=B8;T!PJQ$+)%JTW2I16@-2V!J\X-A@#Q#EP,+,CC,
MF2FIHRS3:B7H$**\U$"].X.QL[@<3!QIWD>\CPE-ZKCOD_43UC2F,EH-#)#=
M9]6#K'$]K*FUA-$ AE8QQ,I=8P0V=J,C9T=*]LD7-P.2\T\N=R_&28IM+CL\
M<F]D6Z,I=@6*Z7!6MSLHK-9O@#EN>*8=2-E-2L@25B2QU*\02Z+  L"=J.RK
MQ:%P-]K#'9V@.8Y^Q1.9*,F8,+N,HV:TS4C9416%754SU)M-'&Y\<<Y Y)\3
M6R,+>,- KDAQ/,_ LB1/D\ESER@D3,^!ELL4Y:S2PSD!7.QJT%[K99=1YGXB
M_LVR<!C)RUWECU>5)-[  M2PTTQ)-7L:H$&KN&R^JI==5A7^=NJR]I;-K9@+
M*J/A/ (B:KV.4<H:60>9J.:K'*QR+XD5'-147M@62:)S%-#)!,N\L4JL'0$>
MQ (W[6 *O8;7S/(QIL:0Q3PS03(/M(I!6B]P:H$?C?U]G9V.&.%V.#A=C@X7
M8X.%V.#A=C@X78X.&?Q]_$;(_+^+U5\OE_T'%_1?S[(.P^G!_4_S_E[?+AX=
MEX.&SM5Z8W6JONB9F^54_55%]C@X<R?+]7M_)V. ?U[_ %_=?+A=C@XXD@B;
M,\A(VI.^-D+Y??QNBC<][&*O7^U:Z1[FI]%>[\>QP<<O8X. J[V/?3XP[K08
MH^D]5I-O9!3GYC"43I7W!JL6<2.RMI6,<)1YQ9FSCNMK%_[Z5&\>N#L"XI(H
MM!R'PYG<^=S!IAQ(GT9&=,P$4;D@F*)1YI\@*01"I\H(+LBD'B\Y)X?SN=S$
M0Z4QD)$DO\>H4=*)=MWW.P&UD [TI\G_ &EW.F].'=G-G?8420$4":MQPE0%
M&5:'DHY&""% :>Z66" E@ Q8^DE^*$QP'P#5<KY:MG1,'P=RW%1UGQ8LUQ([
M*V3U'"Q1@D:JD@B()4NX>'R+:EGV?CJ^#X#Y;A0K\:()R5,G6G+* I.D*2'$
M8\Q%'3WV)H[,8;AKOI<\R,.,Q7).K%22%D5URM,&+!"3$1..9./)NK8@IT7F
M-E8Q*J9WI296LBA9XH&)*;FWASE2%5R\+&)U,8N7"2RM+I4_!QJ"PL;.-P"2
M6(-ROB?"?*9!'\5B0NBA3&DB9;L2-0+)$OD4K04LH)(HD]^&W==VC<XFR"S6
MLY>X1S-VC5GBSMSS-526M0T@Z;SB7 >N,94,',";%,CD0)Q;49 B0QD3MD1<
MXBS(C/B\NYKD1;W-%RJ0(^E%\IDT(9&*N2MT^DV225'#L?B3D3-.WPF2U1+H
M8PM$) "PUQ1FM2G[H8$73#B=<G]GOJ[@EK;CE:ELH)49"PC A/TOEC?O,4<Y
MH;#*OP^<[SVQS11]&-'C:<JQL=*-49'BR&-0R<OFC8,UC+<0>8$DA&*N+!(L
M'>V)0 FBUD>,<2(,L..43I!ZRE 4L;_Z;KU LM56.]<3+C?LL,B:00'>\IZH
M^I#8Z8V'[HAY][D3P^&9IA5P>'&,^*:65TL0ZQ/>V5I+)'$3^*LR?'>5&@>#
M#A1V['XB211VM2%B5[L>Y(V*D!15+G>.]*(Z<JQ&9KZ<C9!(0UWH0K=C:BR]
MS5"CPX-]]F%B\Y""=B^2+O(6[Y6& 2:96&"&VD->22Z'U-,\&*N:R 620DHA
M+"!_B'%=(ILS6S,87CC,FU)EX<<Z$:6$.NTC)%L1*AU&Z5=.FB?:@(.%X[;*
MM>9<O@DA5J8X]%U0&B6!6R/;<$'T(H<-.I,^T&[J\<-@(A>]R S&SS3ND*V^
M=(KY/$]7$@!VPSJ%@*0/2<P<2D>K'QJVSL6Q^B9,?_"G.[653B3MY5*:<:57
M!  !:)NJSEM@6EOL40:7XG3XG@WQ)(/A,J#%S&4#HS@XTI.K_,C=B X8L0$T
MO;*38!6B%XU^U4!M3!:O?8'TA",%^(3T-E$"8-Y[163$#UFA(;4EAP%DK QW
MWOBM">C$@J9)Y!X9ZK*\$-$C28N<74LW36>(,*!:E,D"JX8* :.(4466F-&J
M/._L]RHD,F'D#(7^$D JXW-@J3Z+=@%1O9&_!ET7?A[N]\6"''L[.K6SD5@1
M&CQ^KS8+T1D\B.EL+BE""&1[!27,4DB!'M@F<U52-Z-SLOASG$2N1B]4INZ0
MY&/*Z[U2I'*S,=QL@;N.,O-X9YQ!&)'QD9-KZ>1!(VYH *KEB38[ GU/MP4M
M%?U6C!'LZ2Q!MZPJ/S!;*M,&."*8B^%70$BRRQ2-Z]>JM<J=45.O5%1*9DEC
M9EFC:%EV:.0%74C_ *@>WXT?UXHY(Y89#'+&\;J-PZU_O?Z;<;OLG'CA=C@X
M^'L:]%ZHB]4Z>_7Z+U3Y?@OO^OL<(5![_GZ\:8H5&?VJ(BN5R^R(B*Y??Q?G
M^:JBN1>OS1>TF-AZ;;=KWV]?PWWV'N1Z0ID('XDW\_K[5VX:,,21[&@<GR4&
M]1$7W5%=&"J^_1%1/WM>J>__ %/Y]GLAKA'_ ,7M\A9OUWV_#VX;Q!4I'?R>
MO?V_TXDKM XLN&54I_#G7K_\E9/\/;WT">_MU_D^?S^:+V.$LV-O>_P_K^Q[
M/17-;TZKTZKT3]?]/E^*^R>ZIV0D @'NQH;$[T3Z#;8$[T.%_P!.(UY4Y1PO
M$.1M-OR#?"Y_/UD,:S%%1S3.FFDE2(80(,6 @VP-*F>D4 84$Q$B]5:Q&H]R
M2,3#R,_)3%Q8S--(#I05I739+R,Q"HHJBSLHL4#=\3,#E^7S/)BP\.!IYIF*
MJ I*K0LM(1LB*-RSTI[ D[<4E]X;[1'5<IA6.5XD;;X'"R.+K#-;)%\/V^BC
M:C(R9*.125BR]<L<LCF$#O*O$C&GFEGJ)(9Q4W_*_"T?+VBFY@T.?FA0XAW^
M#@+6562, F=QI IOLK8 "4,K<=I\+?V;8F-IS.=R-)E0R:TQHJ.(5J@SBB9*
M]0]1W5;[BNB[+#CK%^(SM)5)X[."T,5\!;X_"A/G'2CC21SNF*6%3!%KVMEE
MB806LDZ1O?J(M;RV@9;4HZ*-2!K*D+J<$ +JTOK- D( M@=3@@DC&@ ?9,85
M12M&.JM0:*@ #=F%70%;#29^FOM;(M'G<W=:BX.57O)'K'+%! ?.\48V:Y9(
M*)2SFSOB=XR97>5&[TR02S-8]9$I2)A))/%C0H/NE_O,@#,O1IC,J*&V6B:+
M6HL<>,CF./RO&ZF7D1!F>E\ZJ=(!.E03J(V + ?IP287=UA %FK=/R1'EK0P
M"<9(WY^V*K(;X1*\6JIR-*<9FZXNQN)[!2(HH!YZR0> M)+:%PD<,U6<\RLL
MT.&<B-) VTD:R&!BQ>48X6>54B5--DA@Q!$;:B1E)O&^F62*# :0*A!=YU3[
MQNTTNP< ;AB"Y/EJ@!P_=S3\"]TF'*+J,75]X'DC15-:^;&W&W?F3Q"S1G6:
M36N7J*"TBIO2@.&;$#:75CX_.8@ ;WQ.>GGET/-/$CY @R9.484$DFG+3$$Z
M%%8QW'/-+$9"S]W2-:HZV&P.1S?$_.>:)DO!D2\JQ1'TP\:]7KLIHZ'D #;B
MM:! 3:[T21OD^U8Y<HP6U_$7&W#O%M"&3.$-4YKCV*UM1!@HUG&+)MK&Q)#L
M8S'LD&+G02%\XZR&0%LF>JLU</\ 9ARQB#S+F',\Z9E1FFR,S1'(68 QA%02
M(5!#*"YTM2,".^.R3'.6>63F6<Q %3YLA9*)/:, :3Z;#M=FN)0ROVL>_P!)
MDRK+EKCSA'DRL$CJQ;7,%T"T5A.98VI@X\8)T\UC7DR1AA-N9U<'&.(*R5SW
M2.:V5869_9EAP973Y9G<UP9)3(T62LJS1HL42EF**$D2V<Q !R7<C877#,$6
M.D0DBR<W"E4@_99$CMYBH4%9:4K1U7=D"R0#N[SN]+W#^20S&[?N^\C\0%LF
M!&/V''!=3>5M ^T0IM6<36AV:@%P%/"-\MD6>N%D],Y!TD<J2]J<^$/%^&\8
MP><\NYI&=97%YA%)!+.(])F5)BJ-&RB1"VMQ6H:J!KC08OB#Q/RY^I%SMLI$
MZ9:+.1K9&I0H>,NP![$ZAO=TO=A<K=W>DAQ</*/$_(&<Y6XELR(((- BOK;R
MDM)IG"Q4FTIV&H=2V#+ >4 ?J.QT9[(HY1QYW0#S^,3F<\68^!G8F1R_/A%O
M#0=)(P+,N'*4T31%2&+7NEE2RDL.E\B\7Q<[_P#1_,L0XO,*)2&16^"R@-VD
M$I4+)0W9;#@ TND&AY^*;3*6 1N8V>AS!506EF#!G[DL5'V2MA1222%9!(Z2
M3][8R;PS)$LI+FD+-*4V&U23'F1TGQ8LE95Z3-D1*72/S;*JDJ!5D@U8"^4*
MJDZ/)\/X&<AZD,2G00YC6-X)P00%82]1](]M0-@ [ 6>W#?VJ'.>0>M9RGEJ
MSE4*2;PC6M>QF4T 0T;6MGCDD@ 95E212IU6&8")%>CFR6/B='&W-\Q\%<IG
M0G G;EHTDM$P.1"SL;!%L774+\P)[FH^Y/..9_V4X651Y?,V+.'96TN)(J-D
M6LA+K7HJN4H7I!LD^L/]JEP!HIA1M75;7CV25B*83;4C;BJ'D:QKY'K89TL\
MJ2)K.KUD^%1N9$SS961L5BNR^3X(YL@/PTF)EH!05,F2&<V2!0E5%!]*#[DT
MMW0PO,?[-.?8%O%+C9::;!B4H7-L"*D(6Q0[M6XX/;CWF3BSE"O:=Q_O<SK8
M6L:Z9M-:0%%"^-7=&FA>)IP+U5KFK&8/!(CVN8K4<U6IF\C S.7Z8\S%R,9J
M( F5RIKO4Q&AP/\ J#;[>_&+S.6Y^ Q7,Q)H"-B6C.BQ79U!3UV\V_I?$EME
MC=X?"JKXO=/T7?5.OOU3V_;T]_;Y]HNI=M[U=JW!]=B-N(1%&CZ?C^HVXY.W
MKA.%V.#A=C@X9W'OMA<C]?X/57X+_I.+ZHB)_(G\OS['?MP?7Y_O]_IP\>QP
M<-G:_P 3=;_>S??[U%_A[]C@X<W8X!_7^?"['!QA'(JN3HOZ*HB]45$7JB.]
ME5.CDZ+T54Z]%ZHONG8X.(-[R7*,'#G"'*7(:V(-:=F,3=6%-/8C3&".T,@L
MH>:'F#@_?2VF7Y%>-Z:-S7S>8L:/8CE>V9RK"',N;\NP&4R)E944<Z*54MBA
MM64=3#2-$.IK-@>Q[<6'*L*3F',,3$CC,C32T$4@%@BZWHDBJ7U_GVX\?6SW
M?)/(FG)W?)UU<;?66@M=3F6UTZ(H@&MA;(]*,:G'%$BJ@&$EFI"##$J%3*7'
M',V'QQN^A8\? Q<=<+ET:86)$\LJ10#2DCKI F,I8]5BB("QV4%?+=$?0W).
M5Q<LB2)8,9YHHX^FQ%+#+E6&#5W<U9)NJ!8CN+B/LO.[G1V%7>\W[.I"DEDM
MV4V*",!;/&X.IDEDOK54G8L#G$V:11AGLD(EB]%:.C:U)WHO-_&O.'1X.6XT
MLE%1)DLF]F4 11V"" L9+.I !!0=QQB_[1>>Y<$T?)<5DC 0/E.-)!9B L8(
M-!G)UD5Z#N0 'C]K1SUJ^.^(L-2Y*>O"S.ILS_BHJ"D3B:N.@CJ;L+(ML*:_
MS]@)2757'=R&6% >^=[*::@?"LERSR#^S/E$',N:YTF5'([X="&0N(WQNHW2
M^+6.2&:.5XG:,(DJ!59^KN(J/.^48O5DDD;>96,=,&MG^_I!U+3:5+ VV]=N
M*+,#W<>?N0J@SD( R#%S!9BM,RE_I]?G\E7Z4L0Q0B<75W]O<TWP[2N\XJVC
MK)6%P/JW&K&1YUG"7<=AS?$?(\&>/ :,YJMDR+DQ8V+/.\.I PRI(4BEZL!
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MCP6LDCF/7'U4(DTH[3!6!4+$(@0IL.#(D6=6:41H@99 J "B*WJCM8(75I[
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M0OE3NJ2:-.@?$1XT!(C61T*=1WI%4VQ+6-)/R[*BG >,H]%@@B/E\U!&IZ!
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M8W6J/:38U](0\ :7I;:_D/,,0B0986:;*9LD6RU(QI7.46=J==FM4-*&DIR
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M+R;4GC4X&+SS; -*6:EM;*:6$>O:17FGUB0O)E(;7NO+&!Y!I*V:B5I-8)/
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M$R%.B2$BE1["QIA9IZ\M\15MR+EIR%DQLN2&>2.",\R@RH9VE6*9&9%@.K0
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M"_,\J ]=UR+7'0 .=!LE0Q+;-L=SL-B-N)IXUS96HJL3Y543(U>2 JRL#/\
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MR!UB][3(J-6U@P[:=)_A TD@DV1W)[ @DV.W$R156,@;50%&R*%U>]][^0W
M .PZ=[[?28JP R.=&%M;^R?8Z6RFOQSO14F4LV@T14=5)4M 9,XJ4(^%$4N0
MT2>1BECJ(2TA+CPYAQY8ER9BZ11L(HNFR!I9UU2!CK#$ '2UT+ -$-0;5^%.
M6MEF7,G+K!"1#$4(U2S AV:R#1TGV[G;<[@;I,O3U5=< *0 #1EG$5DQ,0MC
M<FB3'LK]16 E)XEE&1U^+(@Z3="WAF63AR9"HS9VZZ')=GBD*LSA.H 2D2,$
M+0.Z%=FJ-@35C6B6%4HO&[A>3(9(XPYR5T2K'(5"O'&720DL"&)A/F7[II;
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M(7F*V2L*9$,7050:4.JKJ41ZR".)387+8&3XC#6<II;6$9RR[+U,EE8:6)(
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MF+H>K%%>+  NK(RV5EB6,;+I#HSDL12*^G<TU3XJY[#R?EL^6(T:16Z,+!E
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M'FEJMJ-4DAT)(=?<5CY6OJH9S*J)U=.Z?48IGP>E'%G28/+.H4FPK24)&"H
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M1X&.&81Q0S*%>28L\JLNO4JJHF-.F,\G7D9W,114.BTB92>GI%JP8TQ-%@&
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M?KUZ_)?>1G[8\24*9]^Q.R$@W_4>WJ#Q%CW;5ON#\MK]1OZ^U#Z57$[^)?\
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M!MT(\.S/6P=5=!"IG*64LC4&<.79228Y$\=$=)A2&&05-!-MI+FE.I04U*&
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MTZ(C_P"N!"7O%+9XF3,_M7,O.6<\YCRO)BFBR'E@5AU<.=C)!/&#>AE8D+1
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M-2VGK+B%1XQ*ISH1PQV>E</*&63%+\0)9;D5\T(H[24F1H4CXY&"UT% %T"
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M^N^D7_R/E]_QZ_PF7]G\J_@IP?IOV'8?I>_K9]31XW>>J?@-%44OGJ3\+KQ
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M>P-':S6]\9_=.WJ)_&,K\?=D'7_^POM\_?Z=%^?MV3_#?+":*2#YAO\ <?\
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M-";%_=[W=;5[;BCN-_?CN?NSZ=#Q:M=M"ED>)(>#7*57>N,!A5C9C11%9YY
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M1CODG7I76*>_Y+\6^77V_'I[_3L?\*</:N:9-C__ %(?7L;;U%G>J[=^%/\
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M?AUC[?1$]K;ZI[^_ZTZJB=C_ (4X??\ O3(W[?9IOV]"1[_+V['@_P"*.?\
M^&P6#5:V]OK]=OEQC^KMY85?\Y<CT_\ !UE[_P#]6Z)T_!%]^O8_X481_P#S
M7*W]HHR!]/-=$C<T*^EC@_XI9F]X&."-J+O=_C6W[WXRO?NY71%_L-CT^J*M
M?8KT1?JO2V_#Y>Z>_P D5>RG^RG"WKFF3?H.D@&QW'?<_0>X-=N$_P"*>:>W
M+\?O0\[V?PWJOG_+C']7?RMUZK48_P"O^IUCT_)/:V3Z_DOX*G7Y)_PJQ/\
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MVQ[^@-[@\)>_?RLORI\?U]T_SNL?ITZ?*V]U7JGR^GUZ=C_A3AU_[4R=M_\
M+C/H>^H]OKZ^E"^#_BEG77]W8X.U#6Y)W]J- C>_P[UQ+'!O>QY%Y+Y.SF.O
M ,V+5VCK#U<H 9D92(+7%%QI%)*?.QBK+ U'*Z-R.8KD1.JHY,]XH\!XOA_E
M,O,8^833,LV/&J2(BJ>I)3 $$WJ!';M1KC0^&/'.1S[FL/+Y,2.$/#DRED+$
M_9H"M@V!1O5ZB_H>+#_-;_KR_P CO_8[<UL>P_7^O'1MO^L_D?Z\1KS-_$0_
MVZHAE?U^7]TM3Z]/;W7^;Z=>UGR7_P!J8=&KE/X^1O\ 0?G7UX@\X_\ 9N7_
M /LCN;H>9?;>[[?*]^ QC5/%[(J+T_-57Y?JZ=?Q3Z?EVZH/S'KV!^O;Z; >
M_P"'*Y02#Z^;M7U .W?8=SMZ;\<R*O5$Z=43V^OZE7Z]4^GU14]D3LOX]_\
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MO8['?W!W[^GS!K?U_P!+K=[W! .]%30^M#:_?;MZ;\+Y>_1>B^R]$Z=>OO\
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M_%>3O_RD&];:W'OOV[_(?CWX7_"^/_\ S4VVWW%_+[W;]./G]R-B?*TTR?\
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MD <>X/#?+^:0/S+#QL;1/F-+#$LAC1,+#DH%E8M(TF0J%7"Z1;Z@ND;][/\
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M4P"BG>AV;#Q.2^#\1XY!\3S)X4.RJ):>2K.[$+U _D#Z@ "Q]X#[P?-'&NV
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MGCD2*,!<_&DCDGFB5T+1SPJ=$NJ/3)U2$8,&D(THJ"LS,092PJ^,\\\:EE*
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MKYWCQM;-'YL<C&(;/"-/XXO$V=&*M/F<I,D R8F5V=6CZ93SL%;0ZA038\K
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MW$9-./&:4"7;&B+ICZB-\L=SZ6,X0PL>XN&H8VO+0 8>:62=@\[H!I;%%O\
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MJFR-,DG88Z6'MYCSI8<F;($D$9S(EC5)$R!)CIKGF15Z4;QM8F/4"L&ZD:J
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M+/;CS^Y_O!;#BBU$I.*9VW>[T0M@9?MJD]0#8 6%>CY "Q1?*//(@5]E935
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M659YBZXMIHK63%1OD9X+&5@];/"0;@I,K-U3F2-8Y#DOCG&+/JCCC9ECD4*
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M>36!=QH[ 8F"GC! A8E3&:.=&RXI%R#KA6L5669P713'C!I&:4@Q:YDBT)%
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M16UU"RP(+#XL3-2U[6VP\MH+#&R&!Y!)1;V01P,!@$&\YXB/8Y(460E\SWP
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MV_3HO3W5+'-KXO;\?;\/P7\YN>M8T)H7K/OL"O8?+;U_F>&8V^T/< [#MOV
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MU)<#F32BDU+N@9[#!%)'FE@:\F1TI3'E:X)!E)!DX$J9D&3&9$DW(M0#(I
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MP1M9XDPGB/5V=Z$7R);55H34TEC3M1S6V]N0^-[QXF6)-A$0,836C&SLBO8
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MW\W;/ZS[K^3?TX:X;H*?PMT'R_SHSGOU^JD:)5^O]/V)T<]?R_UX3V%DU?\
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M#J7WH\>=OO$<L5W>0Y.%Y)OLRN8VVSM*Y^N&S5P0="BUP+:&C^" VF>+(+G
MKAH9ICJ>U2NLVUQ2(RF::*<_NO(.5S<AP)<**<9&)C))\*9X!&URN)I1,T>0
MJJ'=BH66/6G42NJ5=!H?^5AQL?!QU-1D@/KW,3!F,I( !<EB2NFP*U'8CARZ
MK>W.4(\RZ+S_ "?=VA4=>-G.0<580WFAX]M(ZN7/V=;90AS.&<,/6AC-D&L(
MKT9S?(A+L*7U@L#&+APY:L8H\CED$*,S3X69&T&/G1&03I+&SC4'9V/F5H7W
M9E28JY]21RQ="-)8\B20Z@44VR%@@"%1W 8L591Y=SWH&#]FEP:G)G+W)3M/
MA0C.$XL%=8RQ"E%/DKI;NUT-%,E+)=R""QWR,ES,]N]?/,GID0("67UJ+YF5
M\=<WCPN7<O7'S)%YPV7%F(^I%DZ$44US+ '<P"IQ%V59?,]%2!PQSS-R<" !
M'B$H<F, DE-,3:RZD E'UZ 198T *)(A3[0/C/N[<$:\G$\1;Q60YRWJ!]GP
MI6%I%'%97(7C***D?1$L+L0*0FC,C,L+="WBDVXL-G5V*10DW/@;.YYS>$97
M,<0,)\::3&YQ*NJHX6I57[9&5'F$RZ%C*!EC;IO'J965R),WE^/FY,+Q2RS1
M0PI$#60CML^VJE!#W0%#3L=](VB6>4N\GK-KEN,ZB"[BMH*@(5FBM)J*GK5:
M2 17O"*F.=I([)\-7!X[0^9J6:1L9)8"K/"+?O'E0YF+@Y?,Y3CF'KLXQXQ/
M++8D60.H3H%-4AJ-%\EDK&Q!:0NE\9LJ&).NDSPLK[Z=!HD:1VV)L@;5LM F
M0N[)LZF>ZW7&VXP.1Y'H-*)L^3:G/GL3#V,?(_'E4?;U$=0?4%UU;GPWA0V0
M1008S(SAP/"2DQ4<;GUWB+%E6'%S\3-RL";';#Y;+,A.8AY?GNL<A=)$>6=P
MS(ZN[$H\@*TMU)72RPNC!=3O+UM*_>$J!BR@OW8J4H>4!B?8QE<4V2W-T_8B
MUL^6LK6 6)<K5V%?O:JXU]N,IAEG',_95FLJB+/Q-4J<C-VM3 2.98'Q6;?2
M1CV<$V5@X@Q'<9449;3ER+)A2PXD+A$B8?"OC2:*.D+.DI5ECC,=MJ8F$>1G
MK4A4H273;IO(RT)4*V?+>FB%)!L"P.-KB.1L_P  <LNVF9DO +3(Y6,_),+K
MJ0)EAO[N8>.UM) 9'!C?"0G$$5M6'(#.%85+981IJTHCTD+.9R_)\0<K7$F$
M,J9664RFCDG<Q8$*DQ1+(NMA(]"25UD61)2K,'5=1>+8^.,F')#I 8"A0L L
MCR,XD^9(4*T9LD.3JH4>/G6\C\=<QQ ;C=9IUCS.RQ"!M,[Q\!2Y'/[U7+H[
M,:[O*PJ @G+I22!V%AJ6X *7/Z&31P&D)57"$EH8W+^9\I=\/"G$7*FB9DR\
MZ27)FP?\F,Q0.FE,KJ:D3'^.99\<0LJ&2+RGQ$<7IHMB6)"?LI'O)-:%4EMQ
MI()(?6"M 4P(7C=X%U^F*4[6HC&G7R76;%?"PHR@Q-76VD-/6263Q4(:%Z@Z
MX47XNLE:%!# 1710RV$BRP.;- <X0898E,<0Y<FK2F1F221F641AZZA"1!NF
M [$TY(2AH.31-'BR9DJ*W6=VQ80&72I &D[ %44!_(220000 .+G_L].[@[R
M9>\ENZB2&SM("@^+P"WRND%IYY"8K#8O'?$/' 3?P2QA4S',\QE-"0>V21EV
MU(.9>*^;;_W%BS@QQ.LF>RBB90%*8UJ262$@O(;HRD+0Z1+8[QASH,PP,>ED
M>"LR2,G1OVAJ[U+]XWV)4"J/%DTS^N@HFN5%<^_KW>Z?)?/^G1/Q]E7Y_5?P
M[9'-%X,S"JTA3L#9)'?ZW_/N-SSB*M00$^4 [UVMMO4]P37\AW(?P_\ >_\
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M90X)+*)VL+&I):.Q*=Q&30>(O$;8"KBXK Y QU$:>71BQL]%SIW&01Y!&6)
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/_P#SVJ="^WZG^O$CC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g491933g93a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g93a09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1LH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &PR^:20X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!NA4>@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             "HP  !@H    & &< .0 S
M &$ ,  Y     0                         !              8*   "
MHP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MHP    !29VAT;&]N9P  !@H    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   J,     4F=H=&QO;F<
M  8*     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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ME9,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                          #_
MX4'W:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G
M:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX
M;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B
M92!835 @0V]R92 Y+C M8S P,2 W.2XQ-&5C8C0R+" R,#(R+S$R+S R+3$Y
M.C$R.C0T(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @
M(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @
M(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @(" @
M(" @(" @('AM;&YS.G!D9G@](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F>"\Q
M+C,O(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B"B @(" @(" @(" @('AM;&YS.G1I
M9F8](FAT=' Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C O(@H@(" @(" @(" @
M("!X;6QN<SIE>&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(S+3 S+3,P5# R.C,U.C(Q
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C,M,#,M,S!4,#(Z,34Z,C0K,#4Z,S \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(S+3 S+3,P5# R.C,U
M.C(Q*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.D-R
M96%T;W)4;V]L/D%C<F]B870@4$1&36%K97(@,C(@9F]R(%=O<F0\+WAM<#I#
M<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z
M9&]C:60Z<&AO=&]S:&]P.F%F,3,Y9C1F+3<R9&$M,3<T92TX.3<T+3$U-V5B
M93,W860T-#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN
M<W1A;F-E240^>&UP+FEI9#ID-C@W86%B,2UB,V(Y+6$S-# M.6-E,"TQ96)B
M9&4V-&1F-C0\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33IS
M=6)J96-T/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @
M/')D9CIL:3XQ/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]X;7!-33IS=6)J96-T/@H@(" @(" @(" \>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T
M:6]N+W!D9B!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HU8C4R-V5B92TP,&(U+3%E-#4M83)D."UF-&-F8C5E83<T.30\
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C,M,#,M,S!4,#(Z,C0Z-3(K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<" R-"XR("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z9F4Y
M,&8R9F8M8V8U-RTQ,31C+6$X-S M,V(U.30Y,3-E.#<X/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 S
M+3,P5# R.C,U.C(Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C0N
M,B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M
M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E
M9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA
M9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z9#8X-V%A8C$M8C-B.2UA,S0P+3EC93 M,65B
M8F1E-C1D9C8T/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(S+3 S+3,P5# R.C,U.C(Q*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @,C0N,B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C@S8C-C
M,S<S+6(S9C$M-#@Y,RUB.61A+3 T-S8Y-# S9&$T,3PO>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#YX;7 N:6ED.F9E.3!F,F9F+6-F-3<M,3$T8RUA.#<P+3-B-3DT
M.3$S93@W.#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F
M.F1O8W5M96YT240^=75I9#HX,V(S8S,W,RUB,V8Q+30X.3,M8CED82TP-#<V
M.30P,V1A-#$\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HX,V(S8S,W,RUB,V8Q+30X.3,M
M8CED82TP-#<V.30P,V1A-#$\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/&1C.F9O
M<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QP9&8Z4')O
M9'5C97(^061O8F4@4$1&($QI8G)A<GD@,C(N,RXY.#PO<&1F.E!R;V1U8V5R
M/@H@(" @(" @(" \<&1F>#I3;W5R8V5-;V1I9FEE9#Y$.C(P,C,P,S(Y,C R
M-30R/"]P9&9X.E-O=7)C94UO9&EF:65D/@H@(" @(" @(" \<&1F>#I#;VUP
M86YY+SX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S
M:&]P.D-O;&]R36]D93X*(" @(" @(" @/'1I9F8Z3W)I96YT871I;VX^,3PO
M=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L=71I;VX^
M,C0T,38U,"\Q,# P,#PO=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @/'1I
M9F8Z65)E<V]L=71I;VX^,C0T,38U,"\Q,# P,#PO=&EF9CI94F5S;VQU=&EO
M;CX*(" @(" @(" @/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI297-O
M;'5T:6]N56YI=#X*(" @(" @(" @/&5X:68Z0V]L;W)3<&%C93XV-34S-3PO
M97AI9CI#;VQO<E-P86-E/@H@(" @(" @(" \97AI9CI0:7AE;%A$:6UE;G-I
M;VX^,34T-CPO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF
M.E!I>&5L641I;65N<VEO;CXV-S4\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( 0D"8 ,!$0 "$0$#$0'_Q  ?   !! $%
M 0              !08'" 0! @,)"@O_Q !5$  " @(! P,"! 0#! 4( !<!
M @,$!1$&!Q(A !,Q""()%$%1"A4R818C<1="@9$:)%*AL1@H,S=8P>'P&2<X
M2&+1)31#9WC2UR9'5W*"B)>GM_'_Q  = 0 !! ,! 0              ! 4&
M!P(#" $)_\0 11$  @(! P(% 08$!00! P + 0(#$00%$B$ ,083(D%180<4
M,G&!\"-"D:$5L<'1X20S4O$60V)R%S22""6"4V.BM/+_V@ , P$  A$#$0 _
M /?QZ.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'
M1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T=
M'HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='5!/Q'^HO5'IST'X*_2#J)ENE/+N
MH7U3_21T7GY[@<#PGDF>X_Q7K+]0O3[IQS&SA,7U$XQS+A[Y9^-<BR<./LYG
MC66@IV9([*UFDC0@/[_?/1U4#J=U@^NGZ;.=]7OIDXEU$?ZM^HO/OHVZQ_4!
M]*?*NH'!.G/%NI&-ZG](.0\4XOG.GW+Z'2_"=.^F_,<3EX^HG%LUPBY_A3B-
MYLUC\KQS.V\E3M4\A7/G\N/S_?Y_EUY_;\_Z_E]..*['IB4?J;ZU9[Z1>K?*
MOIH^IGKS]2W6?AW/^B^/ZN<'ZA?3ITBXK]6OTQ\+S/)Z$/648+Z>,-TJZ94^
M0<]J<$;D&?Z<<>YEQ7EV.SF5X[../Y?GE-31MG/M_OVY[>_Z]>?%_7YX)[4?
MROGO^5UUV8?0UU.XMU9Z'IRCB7U-<C^JS'Q<LS^)M=0.<</X9T]ZA\=R=$U/
MS_3GJ#P;A/ >EU/B_*^)SRE;F,S/3_C/(XZM^D<G2G!KW[9UZ/>Q1_K?UZN+
MZ.O>CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z
M.CH]'1T>CHZ/1T='HZ.CT='1Z.CKKS_$:Z@=6>%<#^G3 ]'NJ.=Z.Y[K']9'
M0#HCR#GG%^/< Y+R/%\)ZA9/-T^21X3']3>(<ZXA'D9X:D @N9#C.0:L5)B5
M2S;.CJI74?K5]=W03E'U._2KPKFD_P!575R#Z/W^J+Z9NH/)^ ]/,%U2BM8G
MJ7!TRZ@\%Y1Q?@6&X#TMYQGL13R.)Y?TK:IQGB:<BRK6>)\EKW8DCR$AUY[<
M\?/-?T/UZ;$_U.=6<O\ 2#RSF7TX?5-U[^ICE/&NMO33CW7>]DOIUZ4X_P"K
MWZ9>G=VY5CZL8_'?3AA^D/ :&6Y_@J(?(XC \QZ5<ER'\EL9G)X>KS88G'Q3
M'7E=O:@WQ[UR.;K\J/Y==F?T4=1^+=5>@^'Y=P_ZE[_U886?-YZC'U7SO'.%
M</Y8MBC;$5CB/-.*<$X9T[Q/'N5<5<_R[*XJ[P;B^<KD0G*XJ.=Q+,=9?L]6
MU]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/
M1T='HZ.CT='1Z.CH]'1T>CHZ/1T=:;'[CQ\^?CX_^V/^8]'1UJ"#Y!V/W'HZ
M.CT='6FQ\[&O'G8_4Z'_ #/@?N?1T='<H&R0!\;V-;_;T='0&4ZT0=C8T0=@
MZT1KY!V//QY'HZ.M?1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'
M1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.JM?5_].&1^J+I/B>G^$ZB
M2=*^2<8ZM]&.LW$^;+Q6IS>#%\LZ(]3.-=3^-QY#B]W+8*OF,9=S'&:E3(56
MRU)C6ED*2DCL8//[_?\ ?CHZA;C/T/\ /Z_)>H?63GGU5\]YA]3W,.FE7I+P
M_K1BN =.>+83HOP>IR"ORV?"],ND]C$<FXTE?E/)J=#)\^M<QR'+<QRE,;B:
M$>5P]'$XV"J=>$=JK@^_O['_ #/YGIN\:^@[J]@N2=4>M$WUC<HF^J3J;C.F
M'%;'5_%]%^E^*X=B.GO26SR^]QWI\G2&U#F*62P>7R'/>3Y/EF4M<OCY=?OM
MAA@.2<7QV'3&V3HKY ]_KWY]_K_O].K#_2S],8^G2EU7S&>Z@Y3JOU5Z\=3)
M.K/5WJ'D./83AU3.\ICXAQ7@.)J<>X7QQ3B>+<=P7#^%\>Q-"@+67REF:O;R
MF9SN5R%Z693KW]CJU/HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>
MCHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CJIGUA?3/F?J?X/TZ
MP/%^J$G2'F'2KKATVZ[\-YG_ (,H\_IU^4=-+>0MXNCE.+9#,X"#(XVV^0D_
M,*,K5D4Q1E2REE)T=1-QKZ(>?XK)]5>J^>^JSGN>^JCJ?Q/A_ JO7RKT_P"G
M&)Q_37@/!>36>78;I_TZZ2V\3G>*8_AF;SU_*7^>ULY=S_*.82Y29I.78V3&
M<>DPQUY1OZ?'U]OW[?Y-WB?T)=8.'Y#JYU4Q7UB\GB^I_K3R#II>YIU?AZ,]
M,X>$7.(])..\@XSPWIK_ +&98[55>*15.59S*Y._!S>OS2]R*2A<CY74Q5!,
M'(=%?O\ ?Y#]GJP_TH?3!4^F/B_46M;YWF^J'4'K-U8Y/UNZM]0LUB,)QH<G
MZA<JH83#W)\/Q/CE>OA>*\?Q^$XW@\3B<-5:_92&BUS)Y;*Y.W;NRG7O5I_1
MT='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='
M1Z.CH]'1T>CHZ/1T='HZ.CT='71=]2GU4]</IZ_$@Y'R[(<XR-_Z,NEG1GZ6
M<3]0/3:S5Q[X/@.+^I3J5]0?$J?U)U+BU1EX)^G?,NGG!,5SA!:EH1]->0Y_
M./##)QJ)F/W^_P!\]>5_F?[DWV_4?3I\]#?KCZFXWA?#NGV/X=G/J4^H#K-]
M5/XCW'^G6#M\OP7!L)A^D?TS?5GU.XE8SG+.<9''Y"#$<4X)Q*[TSX1@J^+X
M_P CY!E\AE\+3BQTD,>3RE,^E_UX_P!O@_3H^?;WL?LV?^._5[_IB^I6M]37
M3'FG*&X;G.FG,>G?4#J-T<ZF]/<_;QN3RG".I?3?*6<1R/#QY["6+6#Y%BY4
M..S?'^0XF;\ME<'EL=;DKT;4D]&N?O\ ?[_RZ.]_%<?K_8_T^.]]=+'2KJ-]
M3O1_Z!_I4_$2E^JCK3U3R'*LQT%7KYT6ZK6>$<KZ?<]XCUGZP\=Z39JMT]6E
MPG#\PZ?\TXY)S*EG^)7\=RB[CK<V)?#9W$9>MD>^N$^_/^O]_P"]_P!NBO@#
M\_Z5QQ[_ %]NK&=,^IW4GC7UN<IX1]6?6;ZCNEG-^8=<.I>,^EG@SXGA"_1'
MU[Z0G#Y:7IKPKC7+,5P+-VZ_5?#8*NG).7\?YASOB'4W(<TP]]./IF>+.<.#
MKRO8<BJKW[_)]JNORX/2A^'MU4ZAKU=L]+_J[ZS?4OQ[ZT;?$.:9'FOT^=6L
M3PFC]/O-*F.Y=CY+'4OZ3<SQ7@-'$<BX/Q:A)C\35IX#J)DN2XG!\A[NIW&&
MSB5\K7/W_E^_WQYVY %42:X-B_W1NC^5]=VGHZSZ/1T='HZ.CT='1Z.CH]'1
MT>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1TW.7\OXMT_
MXMG^;\WY!B.*<0XKB;N=Y+R7/WZ^+PN"PV-@>S?RF4R-N2*M2I5*\;S3V)Y$
MCC1268>CH_UZKU@/K@^D?E' >5=4<']073.WP#@G(N,<4YOR>3D,%"AP[D'-
M<CBL3Q''\J3(K4M\>/)+^<Q,6&LY>O3IWX[L5JO8>H))T.B_;]_O_CY'4,=5
M?Q0?H^X!]/?,/J-XKU;XGU;X3POGG$^FN77IUF*F<MU^7\MRV(J5,795'2.B
MT6$RC\LCGO/7K9/CU.6WB)[S6*263KRS[#FO?V_.O:Z[?(^>IVZ<?4;ANJ75
MBWPSAUGA6<X3)T9X+U>P')\?RV^>9Y2GS7EG->-0->Z=7>+T9,/Q5DXA)-AN
M62\DGGS&2_FV)?CU X@7+Q^_W_;HYXX_,?L_L?7@QWUJ^JCGO'NNV(^F+Z?>
ME&"ZP=9I^G*]8.8MS/J%-TNZ:]+NFUO/S\4X[EN8\LH</ZA\@NY[FO(\=G:'
M$>+<9X7E+-JMQW.Y;-7\'C*$5BZ=%_7WKM]..?\ >^]=1WU>^K3ZF>E''_IP
MP=[Z=>E9ZX_4+]1-WH)C>)W.O^9/2W&04^E'4KJNG.X.I6+Z+Y'E%O'W<;TX
MMXN'!Y#I;ALI7R%T_F62K7BM73X[\FN.>B_K[$]CV_=_4_YX_4SZKOJMX1U*
M^G#H+AOI_P"@_(>N'6SIU]0'4GDF.N_45S?"=-.)8GHCR'IEB:U#!<VC^G?+
M\BY/DN44>J&'N2MD>!\6I82W2R%,SY.!:]Z8Z+KOV_?[[=65^D/ZCL;]6?T]
M< Z]XOB^2X5'S+_%%#(<3RE^EEK. Y%P?F/(. <KQD6;QG_W-SV.K<GXOETQ
M&?QX2GF\3^2RD$4"VO8B.@7[_P"5?ZGJRGHZ]Z/1T='HZ.CT='1Z.CH]'1T>
MCHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CJ@?5_P"K?JGA/JC/
MTJ=#.DG3?G_.L-T4P'7CDDO5;K?9Z-IE>)\BYCRGAM7#],J.-Z9=3<CS7/8R
MWQ#(VN4V[=;CO'>+IE>*5\AE9)^01BL?E^GUZ\/OS_;_ #^?[=,?ZF?JU^J_
MH!SCIM@L3T!Z"<_Q'6OK-P[I#T?PU7ZAN>8SJQR^?D/MY#D6=L<*C^G7+<;Q
M&,Z>\3I\HYQS&[)SZSB<7Q;C5JT^4:]<I8Z8Z![?Z\?^J^/[^_31Z>_B=Q<I
MZQ?6MT7Y/TF;B&=^F/&]7^0]*<K+RX9+%_4+QWH8E?']39*;0X"NW"N0<0Y!
MF>%1YSCLHY'8@P'4'B^=K6+D+VXHCH-\5[_V^I[_ !7Z]QWZOYT,ZK3]8^@'
M2/K=+@C@9.J723@75$\;@MG+-AFYMP_%<J;!PW_RM%\FV..3_(1W#1HM>>'W
M_P I6$HB0'L?;H)(!_MV_P!^W;WOZ#JMOTR?6#U&^H#D_P!5O$<_].G(>DW*
M/ISSG"<9@^&<FYKQ7)\QYM5Y_P!+,9U.XRV>AQ$DO%>!YS)T\OCZ<N$?EO)(
M,,]I!F<O3N5[U&J?/19^GUKZ=Z'/;L??O[T.F[TJ^L3KCRGK7U6^GSGWT_\
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M5,R;1LE,>0$H^Z%BU"SZ4D9K Y-CK0-0Q22H<D@60 20/EO@?4T.FW9_B/\
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MD(MD FK'8=_Z5^OM?7ID4#=S7S7Y?6_<=:#^)5_!_8D+]1?*R02"/]@O7/\
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M#*\2Q^L*=K!BEC:6#$#JJDG\2E^$%'ON^HGEH"^6;_8'UU[0-$[)_P!GV@-
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M0>+XYEP]&T75-=PTT;5]/?2AF8V9!I^=)DKJ$0QK,^-!%D1W(C"BI:8 1N0
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M#867<;"@L:6Z/5*:DR8VNZE)&98,/,R,LELB(QHF02MH<B1JE4%2D05K1:4
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MO(_V3G_A^_\ ;T=>?W_?]^*[?7\NM#_$O_C-;U_Y5N&'[?\ F]_3@=D[^?\
MZ4^A_P##T?O]_O\ +KW]_OMUK_TE_P#&:U_]5;AM_P#Y/GTW_P#Z)_UV-'^X
M\?IZ.O+_ '^_\^W6G_27_P 9O?GZK,,-G0_\WSZ;]_\ ?TG^/[_KX\>?1U[U
MK_TE_P#&:/Q]5N'^?._I[^G#_P#1-^WQO7R-_P!SKSX_?^WYGOUI_P!)?_&;
M_3ZK<-X^=_3Y]-_QL_\ XIO!\'>_C_GZ/W^_Z]%]_P"GSWK_ 'Y[='_27_QF
MC_\ 76X;>Q\?3Y]-Y\?_ -IOG_P_7T=>]:_])?\ QF]>?JKPX^ ?_-\^F_\
MXG_U3GQO_N&_CT=%^W[_ .>M#_$O_C-_^U7A_P!?CZ?/IP\Z)_\ Q3G6O'G]
M?'C9.CH_?[_?Y] _B7_QF_U^JS#_ /#Z?/IO^?U'_JG_ '\#X\^/VV='/O\
ML='_ $E_\9O_ -J[#?H?_J?/IO\ C]=ZZ3G]->?C_GZ.O+Z!_$O_ (S?_M68
M;1'S_P"3Y].'@^/_ ,4^CY/QO]_]/7G_ !_?C^G^W7O1_P!)?_&;_7ZK<-\_
M!^GSZ;]Z_?\ ]4^OWV1XUY_37KW]_'^_1U[(OX;[Z]/JF_$$^EOKEU.^J[J/
M6ZD\SX7U^GX+QW*5.%\&X1%2XRG3K@^>6@V.X%QOC.-MNN5S&1L?G+=2>ZPG
M$1L>Q%#%'Y?M^_?_ &Z*YO\ 3JIW\7)"9?I2^D^%&$?N?4GD5+$GM7?3/DRE
MFULZ (_N/D>?3UX?@;)U3'B#!5:MS,651'=ON((-%05[]V'STERMHA?=04W9
M)  )(YYXXY^G7C2Z6FK4LY>0PV+->E"JQV5B4I[:Q^XZ("P8]YVX;M8LNM,%
M/GI[P4V)!DY<NR7)@Q(S&'4!U544EHU+'U"_=BS<&V%$"'L@<U%)N))5'-!0
M"W%$+3!31LB^QY'>O'*LW@;O+,G>B%FO3GLRRJKIWL94++V:!W&LC*O:?! [
MRQ'CU2?C[/P\O/RSAI.OG,UJ0/2 [KM.X4* [@ FZ!-+TY?=9Y4+14_"J20!
M;;?41[E>+%WR#?TY[53&92..Y8DEBR>1K3V@E!0F/KDP:QU=$T[N)F51:8D^
MT'4[[A)VUGA8&;,7CQL<R1HS%B]EE /K8GF]HLUVX[<"DGG20NL8!*0%4?<!
MN?:?637:B&*WP0!1)-],#.8R2I+#2MP)!>KQP6&E1N^.9)XXYHBK+VJX[) &
M8=P[@=,PT?6]8;:0&0 )Z6!NMP- =C[DBZ(/STZX<V_?(KW$QV@'G8>W /S7
M:ZY[>W6906E+ D3$MDY)E""552MV ?9N3?B4L=:*]N@#W;)TCDQIQ*; 6%0;
M;WY[G\B.??FQ^?LL\L=[01$0;-^H$$#@5^&K^O _,)W-KV9RDMF7**IR2F&!
MXHZ]>K&(XE$:*D-:.* J8SL,%U(#WDG>_2_&@QH-,\K$ME.2TC6[R6QXNV9A
M[GB_:C==;M,CA13Y+%D()4EF8DEBS>IB6JR>">.WMRTXZD&/ G>?VV;6@"%
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M*'BHXUC "TH ' 4#A0/;@?D#74YP\2/%QH,9$1(H$1(XXT"1QK& J*BB@BJ
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M1Q;W@D*'SU:!O,,FVPNXE;:Z) ZB7IA/QG#<*'%N08/&-D5SMJ=LI9]FT<Q
MA6&O3GK3MV)'&$/M,D2@][LW:1OULU"1Y]0&0DLPB:*(LJ!A]WOER&4CGU$L
M"?@<]^IGXFQ-9RL\ZCIF=.(EPDB7%C/EF%SND>:.11YC,X9007JDI;[=71S(
MZ:\DZ?>_!TBXAF;<E(8W'<9Q6,KT^0R9&%$ADM41 1--364"4F!9'(4B,@.S
M^FO/PI=*U&-<3Q!-EXLL,>9]]#OY4<<Q)^[9 (J/(BK:PN@&!-\#JG--F\1X
M>O&++\2:E@!)O.R,[*G=].6)CN6+(,HVB<CT ,R@L>]#:?2S^$3Q:OPW\#[Z
MU,+6K6*):C]7ERQC[4,\$V.LV.AF-5Z;+: E<5S7[&DUIGV/.F(L3P]F29N$
M\DC!RLQ02 K4BB-""-OI[$$U_E774WAK/.I:<,EGBEN5D2:%E=)HE1 N1:DJ
MOF@@@#L"!QVZ^;SVG?D$?Z^?@_'D;^?G9\'6C\^G_J0^P]^W;_?CWY^HXKH(
M( \:'C9^!_?1\?IL['CQ_P CH_S_ 'WY^O;K37_('XUKQ_;7SO?_ !^-#T=!
M-?T)]O;]_E\]&Q^_]_CX_L#X_8@[_P"/ZCT=['Z'H'Z<\\>_R>_Y=!)/Q\?I
M\>/V_?8WO9U_<>!OUY^7S_[_ +?Z=>]OW^_^.M!X^-:UOP1Y(^?)\$>/) WY
M^/7O7GTL^_S[_P!OR^/T/1X^?G7Z_'QXWY.OD[!\@#QZ\_V_/_+O^G1^_P#U
MW_+VKV]N@:&_GYV?]1_[CK1)/Z?)\GU[^_W?]NCG]^WY\_Y=:Z^1KYWKR3OP
M=_Z;_8GY&Q^_HZ!?'[_?Z\_EUI\@D_'@@>/^/^A))WYW^@^/)T?Y?K?[_P#=
M]:Z']B!^@\_I\?.OV/['QX!&R='?_P!D'FN?;_?@][Z#K^_].O@;T?W_ $'_
M '>1X_4$Z/WW^/\ ;_/XZT']OC7QK6OV^?U_O_W:((.CZ^_S7^GO^7Y=:^#\
MCR/(']Q^WQO_ (;&@/CT?O\ ?]>COVZ!_8GP"/'CS^_GQ^FM>0/'QZ.CYX^!
M^G_%GH.M^!Y_36O[ _\ C\G>O/\ Q.CXK]C^_P"_?K36]_KOQ_KK_EO]2""/
M]2/ #^_V.CM_P#_3Z>W]^!UK\? &M[_MK0\C]O\ Y/QZ.@?[_OCX_=]'G9UK
M]-[_ ''P?T\D_'CSKY'CT='QW]_V?CZ<CK:WG6O'R-?M^GZ;\;\'Q\^/@CT=
M>]:Z)/G?[:)_3Y)\;!^2/T ^!^FC]_O]\=>?Z5^?^AJP">>:(ZUT3O\ 3]M'
M]/\ E_\ 'YUH>CH/ [?Y?K[CZ_UZ!L?ZCY.M_/D_J/['^_SY)\'[_P!/]NC_
M %]C_E^[Z "=#^^]:.OWT/W.S\>/CXWOT?Z?N_\ 3^O1^_W^?'Z^YXZ^B%_!
MX>?H=^IS_P#*LL?_ .HNFO[Z/_,?Z>C]_3]_L^W7O4S_ ,45QK&<E^ESZ=:>
M01E$'77(V*\R:]RO*G ,\KLA.P"8^]#L:[2='?S:?V3Z3B:IJ6L09 9?*TN,
MPNG!C RX2Q!)XM5*GGGMQ=],^L-4,:D6)7(<71K:.0W<&Z%CKQ.TJ-:O@,XF
M(N3E4K?E6$B@(QIP"NC+V_;[A1$#:'E0/G?J\M-T[%P=)U*'39IA&H?<'_"U
M&V*M9-DL;'<<=J Z9XH%QWB39=NT@+-N8,]?-6HJ[KO[59ZID_%LSD,O_*X:
M%B2_8G=$@5?O8]Q/=OP H#!BQ(71/D'XHW-\+ZAJ>H^5'&WG2RLMD$W;%N/F
M]W;Z_(/3SCY8CC*OW4>ICP 17)/Y&['S5&QU:CI[TGNX>HT_(TAFFFJO6JUR
M2TE5Y045C)W:+1:4:4=HV?)4D>KC\)_9])HV,SZC$KOD1M$BL C":12B,>3P
M&&X@\'@7W/3%D9D33R/"REBX=R%+*$NW6S8):R031^.>FGU-Z?FK^1XY"([N
M3*B?"R$P5GB667_K%"Q9E*135I542U?<F459E<CL6>7=4_:1X'A\-:BF7CS!
MERD,F7"J/0=K"2"KH<$'\P>W9)B9:XLPR8V*8DID\Z)@6(:Q4@"@\ ^QY-4"
M1759Y8I('>*17AGKN\<L;;#QNC%2&\[VK J1K8U\_IZK)EW;0JD6MFS5@^]G
MM\ &NI&6$K(8ZDBG4,C 6& [$ GC@]R.YL>_2=D<A9=DEED,A]M83(Y[V$:]
MRIYUL]BZ \G077@#UI;= #Y9 W_B([=Z_P! /<\<'I?%$L2A%X )/T%_W]R?
M?N;LT>FK9[7B>9W>1W!&FT'!/D,#\=NCK6MG?SY'I-O8[MP))7@_'?FOBB?I
M_HJ!L@W\_ ^35"_CW/Y?(X,6TD-V-E!*$]LG[%7^U1X/D]W:!^NO/Z'UE 2D
MJL/8\]O?V(/UZR/8^_'Q_G\\_3].GFKPK/)&N_<50[@GPH;?:!^@'@^!X!))
M\[].EQ+(X5:>MS6>%;G@C\@.WN/IQJ )':Q?_'%_WX^">L-X UB.Q'*O:.XL
MA<]K'P=]O[C?R0-:(_4^DDL(D;<L@!/)((][)XL?7VOGD7T$ J5*D$V.:(X^
MO]SV_3BLAE0Q=W?VLQ'W)\CSLZ^/G1'C]SK9T/6P)'Y07>"QX)[\>X)(->X[
M>PLCK6E#T$<;2.+_ *\<$?K_ '[<#Y% ZK(S2Z\&4GN5-:\:T2 /VUK^_K4O
ME0V$6S9M^PYY_/\ XL5UG'&BDD*!?M7?ZV?[G@=N>>LH6H)45DF5AY_<$D$@
M_(!&B#\_(\^?!]+&EC=%(EW';RM'V-<<=A]/>_<&LMC? ^/R^O[_ +&NL&6:
M>LZ6(7+0NZJSHP.CL[!WIM$;!UO_ )Z(09$)"[_QINVA@!0/Q1Y]_CO7O?6+
M1J;+^IJX^.3^ZXOBNW/4V\3Y93S$B4\O 7>'#R8^@L+LCF64J@M32&3P@#-[
MH0!B"@4J ?46RL PG? ^T/D++*S"QM Y4#:>_!L^P/OU',_#GQT,F,0"\PDD
M+ $!0"VP"C?L>>+%GGI%;'SR6UKR7I>R>6-84E,@$"2LOMCN?R5=60(5UW+Y
M!^[U,]"TR#.GQXD=8_/>)&D%=RW/R>W\M"C76@S"0+Z*D4;7/'))JZO@ \\7
M\_'5IL/T3X3C, N5S(N9:_[2'\M '[6;L#L$1&'@[;2D;.QO^W6>G?9_X=TS
M2%SLQ<C,E:,,8X@&/F%>44$&@:^%H'W]D;YTXR&QH40!>6DF)(*BK*J& 'Q_
M,201?%](N%DXY6GRM;*Y3*<9I4HHI,#B8*\W?;9IHTDB6TC!J4T4;/.C.LBN
M8RC,I8=L*74Y,/6X<2?'F@T60D1+#((LK%VH2 &8J02P4* #WJP"#TGS-2U!
M)X$7#CG@E&V1S22P^D[6HLH*EZ# 'L>":Z<..K8GEXIB+'328>ADFFDR&5N-
M9OWF2*=8A,C*6$,;$&,$MW&0[[0I]3;"3 UMX/)Q9/N./F,TN7FY!ERIV"2*
M%D!'"HPI=MV7)[ GI?',\:%Q)O)0*D:IZ4=33@78W , 237P+[Q/U=ZA++0J
M<0Q<8IU:3=EU4*@$P$".$$ : 8%V\D:(&SY AOCGQ>(L'&T;$5,:/%L,JGAF
M3YJS9)X]O43P0#TMP\)%EF>R\DM%VJMBW85:YLBN;/ ')!(6&ZEVW+CY75I"
M6A>'PQ ,?;YT!L;UL:^3X.]^?548WB2:,.';<LVZ,"^[.U4M?S<U[ \>U=82
M*()Z#FBP!/?<#^($&N#VL]K[>Y</37,YS%\FHC&K/,LTHCGK)W,I5_!=_@+V
M@@EBP'_%M&8^#M4U6#4XQ#YCIN!V!7M2Y%\D!3NODCCG@_*V4Q/&$ #*_#"P
M0 1W%&A57SW/')XZMQD./5;%/,J*\<T]VO$2'._;FLN4  WVJ>[YU\E=DGY]
M7+DZ7')#J#>6LDDT<;42/1-,Y5:%@"S0XOD?ETV>;ZD#FX_4"I-[PHL6:YXN
M^W!XZ:>?LY3B?%(8:TJ)(CQTI"N@%B([6/;W:[@2$/;O;=QUH#;)J>3F:+HH
M".(RI,4@ [1A2";%GO8('Q8-=QV#(SK'9 7@@TH) !  /"CU#\P#U]*GI'8E
MI?@J=,K<3F.S5_#%XA:BE TT5FK]+>.L0R ^=-'-$K@_(*AAVZV.1-2V3R90
ME4NN3)*'4<DA][&J^.YK^XX,FA5),)4=08WQ]K!N0RLNTJ1WY!YX^>!U\RVG
M]3/4?(8FOB,MEILM0QX+Q0-8;8F33.;#$N9A*"R/&^^Z-BH((/="9O#&$)BT
M&Z)Y2%_ #:G@!> PH 4=WP?85 SX&\.8V3+FPX$.+D3-NDD"CGN!M7@*5LD%
M5L$V*OJN/-\S?SK3UYX:D,ZR2I-)[I>:5)I?<99I!))WJH8JA\LBA5\!="38
MN",#T$M:TIC(X1E!6@  !P.2#1(-6>TRP(XHP&0R;"J[:7T< +P*X8C\7I[\
MV>F#5PE^Y+_+(^WV)61DFC02,&9 HC&B"Z  $:'<2/V/E7)*D:EV.V@31L>D
M$USV!^I_UZ7M,JC?7/8@\&@:[=OGGY]SUA9OBU['1):026:LG:GYA4;L[T)5
ME# =C>5).NTH02=^2!)D<E;"N #L)&ZCV-?7XZ\BR8IBRJP#J>4)]0';D=^D
M^2:O)%4KI7*V%*A2'76@P+D,&/RH(^=[_0'QZ5.Z&,"J87S8X^EW7S5_\]*#
M_D..0?TL?7]D]=G'X<M?C)ZNX?-Y'$4#+P.Q/R/)W[$EJQ:MX6YC[6'_ )55
MQ\$<RRV8KMJ.[WM"P"KN2:.-2?59?:.N:^C38V-D2Q_?X3CQ* J*F2C+(L[.
MQ6E*_P /@V"#6XD#JG/M>RY<30S&YDEQ-0?'Q1A_PDB$D.7#ER2RRR%=JOCQ
M/&!NLG^5CQU2KKERU^5]3^H60BDDKT;W-^2Y3#XII9"E)+F1E=>V/;(C")80
MND&PB#3 */4RT3%7$TO C(5YA@XR2R@*&D*1TUF^;)+<GNQ[D]6-X8P!I^@Z
M1B-L,V/I6GXKNHK?Y.,%8!AS2N2!=#WYL]1A7MW+4_NW.XS.(T!C0N_:&==G
ML+$;<.-M\L/ 'C;GM"J0H  OOVY^+X['\O:NGAE55H;0 3W( 'SS[5P*[?Y]
M6OZ4\%Y#PS(<:ZP\GIW^/<<Q&4I6<5/8KSULCEYP?>A.&AE1'L*[QJ%M1!HH
M6'>S:0:BNL:A!F1SZ1B%<F>5"LP5D:*)01N$QL@$*"2I[\ GD PO6]2P=6AS
M_#>#-C9F=DXL\<\:2*Z8T141O]Y:,D15N/\ #<[GL!5]^KC<AR?4OZY+^+X/
M<P>/IXO&Y@Y&GSG,UXILWB<--(:]>/+Y*&*.5J:I)$ME);#(LBA8HPX[##L9
M=.\%K+F0R%G:$H^!C;Q \P!=O)A)*^8Q#%/+C5FY9C7(KK$P]#^RC&GU9]1R
M\G+S((\=],68MB9.3&JAY81(2XD!7;&[VJ(:! /-?>KWT1<EZ;97&<>QF<X_
MS?,YW+IB<+C>.F:>W>1U5DOQ(&9/RSS/^7[V;?N*Z.1[+#U(=*\:XVH0MD38
M^1@PQPF61\D;/+VW<;J0"&4<D=JHBU-]2OP[]I^!KL.7E9&+DZ;C8,33YF3D
MLGW>-P2IB611_$)0>8M [A5 MP.T'Z6/PLN+\0H\?YSUM:7*YHFO<3A%%4%"
MG/)]T<65<=YM3*Q#21QF*.,J0TD@)7U4'B[[7Y\J;)TSP\(TC574Y\Q(4JM[
MC&;[#V/(8FJ-<5_XH^TC5=366#2O-T[2WD,"Y42LVIY49.T/$A&W$CDO@N&F
M"4W\-J'7:[R1^#=).GEBO%+6X9@:M-Z=6S2K1Q"E*ZL(G[8X74RB1N\,Z,"X
M/=X)W36F?XMXDUU)I4&HSI(LTL4S5&T8-$ %E"I0J@10/TXK7/1<7".-!]YD
MS,\M'$Z[ILO(R2N\M-)R[-2TS%@0HVH1QU7+AE/A?43A27\[EJV:X;'G99+)
MYG9L7[F7RF)<R56%R]<6C%%.26C@K1)%[;>S(#M^VPM4FSM,SA!AXCIG28JK
M&=/CB2#'QYCM=C%'&9',9 )9B6L6E$ &*)#J6GYLLV1E+IN3& S1XIDBF*R0
MF1L5"JJZLZ.5:3S-X-,Y8;#U+G&..\=Y5E:_(N2</Q50XM#1XZDQK7*U+&H>
MR"O5,;-27:QM)JM&R1H1&LC!#J.:KF9NFX9PM.U*:628&7-=59)WF8@R2R6!
M*"20IWL"31VB^=FDNN9F9397FQX$CQ%8VDD7$DD0.!"59U\X1#>6)4ABSL0:
M(ZERORGBTU>:*MD\>D,<C5 HM1)$DD1,81 6 5@X[2@(8$? !]1&71]825))
M<:=W8>;?E,SE6IBS4+(V^JP.?S!'4EBU?1VC>**>&)% C"%A&M54?EJVT415
M4 "H#"P>8-ZFY3&4\GQG+FS=3*X:?*V\=<QEIE,]>E3-V?&YJ.**1OY;D$A2
MLMA21%*4<G0WZG/A_$G?%U#':-3C9*P)/!/$*225_+$^,S,!YT1)D>,CU=AR
M.HKF90FR(_(?&=HG6-<HSDRJGG((B5113@OL25)1<32A@005Z)^9?5)S+EW4
MWJY(^#J<FR_/,!:XIAZ.0=#A\#6H3_FI4]NZ(H99JM6O+^6E""47',T;O*P/
MJ]L#PQA8.E:6JS/AXN!,D\GE[A+,'&Q2?+MO6[[I%)HC@TO'72F)X&PHM)\.
M3RYLT$FG9RZMFY42DSYV3D*J *R;BL6XHFWD")57CGJ@^3ZAY:QA3A+5J6&S
M!+,KLLFT[I'+*$D73Z"KV$=S+H*  /F?PZ5 N0,E5#(RKM##V"@$E3Z1[$<
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M %U\GX.CZ]K^?[<<?[^W1H#?]SX'@$'R-C?_ !UY_7X]>?J/WVZ/S'<<CO\
MIT#Y\Z^/D?KLGXT=_IO]][_4^C]_^_\ B^C]G^WT^/W\:[^?&QX_36_W_P!?
M'Q^_QY] Y_?;Z'Z]>? %CD_TY_,?E].WQUH->/&CXUL_Z'0UK>]G?]_!_3U[
MUZ??GZG]*]_;V_S%=^M=:&O^X?V_OXT?[D_(!_<>O/W[GY]OW\>PZ+'?C@]^
M*_/N:_SYZ/ )\>2?^7Q\GYU\$[^ =#8'KWH^!0K^PK_GH\Z^-?'G>_\ CO\
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M9>5(%5=^]BJX(^/[7]!TDS]S,ZKWJ5\MM2='1 \>3LC>P?G9/Z#UXQ/J !!
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M>]9LV);,S]\TKL[M\]Q/ZG9/GQVC9^!\D@GTL  %+P!Q0]OI_3^W3D!M 50
M *'?CG\_CCO_ ,+>/EO9-&JF9U7P"P4OI$'>5.RY1=J".WM'< &/P#X0 ;]R
M1P."3?M5?/(/R/CK!MD:ER%H'DV 3WKO6X_/]!\=.>[3GBB1H&DL.A5(;$*>
MPKP]P#,T1'>Q0A]=VU/SVZ/K?'AY3+O.._E]R"I]-W1OXJC=&ND\63"[M&=J
M%CZ@YO:31!4BA=>POF^">G?TLZ=\WZH\LQ7&\+@YLOG>8Y&/"XJ2Z&6E^9GD
M L6))7[0JUHY&D?14)VJ%#L0I:-1S<73<:7(R)1!#B1F66J!"*.!1]F/!)X
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M!)@[<-2W#!7@N5Y&B,,:$"15U[C]@^T%B!LG7VG>UWZF6%AQ8$ABBCCV3H
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M'SX/J\? XGR/#N4IVH%25U*L%;U%S\V#78<W8K@$=6)BKLE"[@R[P$8$$[6
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M$@/\ZDE0*/OV-CFB*))Z<V+P6.CZ@IF<_B+& QF0I.N,RL@KUJV1O2(-21%
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MO!'[?OK0T/\ N\^M!<V>_ (%\\_[=)'E8FA;<?-\7[]^?W[GI9KU.X+]HVH
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M\ UQSQ_<]^ >L,Q$#[%K:6%6>3\C@]U[?F.WL?JI=)U#_@A=.8M'_-_"XXE
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M'/''7B,YARF>W*Z8RZ5D$9/9"-@=A(8;!^X;!&P1K] -GU>VOZ[)F3DXV2P
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M^8J11PX6W6_+I#:F:1'FJY)W2.5X6A5DJR&0F&=U#%805$/\1?9OJF@E\J.
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M^//.OV@^-FD:8SY'E8T(,B L/*AC)"D4J^HE>0QY+!>YX+Q,F%IV,69TBC@
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MCW_7ZCF[KL;[>SDKT.XCM&S\DJI/@D#>Q_R.A_IOX](WE 'Q?%$UP?F^WO\
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M-M]1NZ O;9L"R!G\+R%O'T>0\EANQM1J1 RPRN-2V!&L@*[\@CO8[\C; :
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M9D3U\8+F!P]'_$;PV98?R]N.**1X:YCD=6F5Y8B\L*!V,46I!V,=W-JKXX7
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MX (\:.OG_F?D:0MB \Q40>=I(LW\&J%V>]?G[=>;WWLR,#0-+W-BC];]JO\
MO[8ZUS".Y)4[%8*L2^7 'ZEM[[-?WWL>1X &B.1EDVE6 !J_:[^G_ XL^_2E
M9V(VNI4GNQ''>OZG\A]!? S%/N=P*CQXV//@^=_V'GS^G_#T]0WD!D47Z;/Y
M=^!W]CVJQV'/618**+4#_2_W^^.L&UBX+*_>O:QV05T/N/ZG]?/Z>-$ ^M$N
MG%D5]R\C=5\CB_Y;]O8_VZS$P)( O^WY_P!_R_7I!;!2U2LT$A+QZ(\$@ 'R
M!XWY&QL'X\?H/3:V+)'ZA?'-FC_;_P!>_P"?6P,"11_MW_J.EV&3W8TG4?YJ
MJ58$Z)UX9?(^2?\ D=_MZVV)$L5N%W\GM]1VHV/?WJ^L)$$BLANF'!HV#VXX
MX^I]['>N-4N03G3/[+)H$N.WM(_8CN!(\;UXW^Y](')LBN0?ZGFK/(O]^W2/
MRI8_Q'S0.XOV( H T:%#W]N:!ZSC9MU LT%A^Q/N$D<K(T:J2RN"-,.UO._!
M&S^_K)\<LFYD#*5W-^'\)7GC\KXJ^W'OUK54=BCQE7]@PL-55SV-V!7^W6],
MGDI9C-+/[TLH/^:23)(KD-_F!QW-Y&R2?)&SZTMB*H"@!$[JM 5^A_/M5_%<
M5F5CC4^DJ%!X]A7;V_N *!-=/6/E.2@A2*W5J2$QMV+)64@+V%%)^\%2""5(
M/AM-Y\^L$TQB;0L >],3WKY)H?I^7T96QHY79T$A&XW3=^03[?3Z\'KBQ'(\
M)063\[5LI)//&99()@=Q#N]T(&([68E>SSKQY'I8)]1Q %AE90!Z;)';M\^]
MW5<_/?HFT_*FVE&6E' 8$$=B!P!W[FQW' Z^JAT=-:U^"STQL56ECI6?PRN(
M2U6=0+$=*?Z7<>]<N8RP,T<+1DLNP9$\:\:ST_=)J& 9B-\F=B>8X%;2V1&6
M9>.X-LO'+;;^>I!&LB8*I+ZY8\;:2#W8)1 [=R*/ X-V.>OG=<,P&)QW$+T'
M(K RF)>B6IY;(.9KAFL+*/:G0[/8.Y1"0/M57WH 'UW?I&!!CZ/(,^2/*P98
M5:/*R::<+(&C=&W [ AV>40U@L;''4(SIY)<R-<<.D\9V21KPK%=K*WI(#;@
M2&L5QWKJNF:Q7$\/3KW<&(QEZ=QI$D64DNH=@8S_ -H."JZ/R%?]F/JL-1AT
M;!QDGQ"#DPR\,*Y4,>. +!! %FA1_5VED$"EYXD"4NU M/N/!Y!NAR?Z<V:Z
MPTY#F.97*5?%TK$F?8BEC:]2)I)KMR9E"15X8PS=[('[ JAV^X@J%(]0[Q+X
MU3&QH\YW6 8X;[QD-M18XU!)V@LH\Q@OHXH]C0/37GYN/B0+DF08^-$)'GFE
M:,K$@6V#;F (JSM8BR %OJ[,O2O)= N U\]SNM0M<ORLLF+RN .?PUW/8N]D
M*Y.//\CKV)[T,<JF-9))(U:&23MD :16]+?LL^V'PGK+9>G86+K&5J,F^:+/
M;")P\A:VK'%.WI4O,-H4 LY!(4JI'5>:)XQ3Q'K^5I..LHPX[GQ<QL)H87"%
M5E\UKW G<"BNJ[J?U$JQ5EV.J^#H8+'XO(XA:F:AJU4GCR4!,\]N566)(1[>
M]1A@K;8 '[5!\'U>1\4XF-C(F9%-'GI# K8TT7EEIF6J%WN6Q98JMDT.+(GG
M^$R2R&2.1'QVD9A+&Q8;0238'<V-O<@=R?;I0X'@^.2X[D-[D]=[V="26*F(
M".WM12@R1-65 " VT[V TOW=VP!HT;3H"F3+FPK-F2.\TN-(@<P0N!)&(8R#
M_P!P'A@=P8; 5HWYFSRQ-&F+*4@M5\X-2LQ8J0S=Z##D&P"68U=]+,&&X5C3
M7N97#Y*"OG<7BLAAY[,L126O5LO4R4C".9C 'G1@(YE2:11WA K*WK'3LKPW
MFY.3%C[9'A6))VG27R4>/@QK(WI$B,5^\"S9L"UOIKBUE\Z7,QL/(&1)IV0<
M;*CB7F.9U5@&)51* H)4H752*+60 O<D7@LN#LUN.26EOD+96M$9?8]OM!T_
M=_EZ ^-[<-L$GX]/LZ09&'D8T!A/\!I F/0]2BP:4!2K 4?8C]*$:=9DDF+^
M6\@C;S+JF/*G=VYHBNQX^>DCI]QC'9ZNKR6FJ92BH[U#*8I,< &LENP!GD=@
M\3$:[05\$$Z2Z1'$<;'R?+VS11M &C?DJ2KD..QW60Q/-**JK*G/F<2/&G_;
M?:264E:Y7T&Q5  U=7WX-=.KF_26SQ3 <(ZRTK4&$Q?46YGZ>"@I6P;N.KX&
MXM.S9M0(O="MV1)^V02L-O"A[#H&.)E8F3XDREPY)\;[O$L&1E1P*,:'(5V$
MZ3!EV#SU6EL<MZ^_42T?QF-6U[6/"\<$TBZ-%%(\LNTK.[;3Y,9+%U,!90OF
M *X1O++ 'J+>$XEN:5.74\_)D,ID+#35>*>[DSCS0RC.9(<G)#(LHR%9XHYT
M>-M@M-W@_P"[Z:9M&\0^(5)AUYH(L7/8R8^7&Y6>&B58;5<J*/HI:_%VH O/
MB2/5,271YM*E1((Y1)J6.$0//"0=T*.2H#@%;!(X4>Y'2QC*N3Z?\AM_E;..
MK85(Z>)R5ZUC8KT8N1JOYF6G7L(\*M*(A$YDBE9DV0%+ ^H[D_9+#J&2)/$>
M;>!#.TKOC.T0G64?PULKN !(4G: +-T;(9FT(>(<./\ Q)ITRUR,B1(86IO)
MW'9&[J:W1*&H DD>Y!HS%>ZO<XY1E+W*K]ZH>+C&8[B$,$%>.K8L5*42Q]TK
M>>RE/99[,U5"L32]KK'I%"R#[.OLQ\-> <[5\[P\K186I$4)R99VE$B^9-YK
M!2JES)$@_$4"BJH,WZ7]GNC:+Y2E9\S+AF.5$9VW"!AO,0 7TEXHRB(VT[1R
M2S>H1_)U;J])<;GK<BYN7'<SSL\=]*Z-'!8K8JG&*5.2<2"2U6DMVI?S->0+
M&0(7+C>RT>(<30H_&^;F^)=/Q]6TS_#XX,%63S),'-5U\]2C-$H,ETK;CM#
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MJRO<4D:22,ZO PV1$L2H-E6.W=R HH <75JL^".550K(SV"IB(&TD\A@2#0
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M^8R'.J5G)X*>Q::NT<!$<M]#_F%@S[8K]H#D?#%M[(!D'A_6]2REEFU:-\C
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MRI<3$\ D@CFC6;GV$P5.AC.08:.;+9:[-8NYS\G$7CCF>?NALNA(6*+[F([
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MQK :*[%5;L'8M623?)':K%]ZKJ>^'\#R\]";FN6R5B/(#(*JQRC3.Z*'$BJ
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MD"^02!V#;R_0?E="V:]48_(Q15JMB6:OD*,21K;@2:.&4368R+*^XJ/ =.)
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M9 H9/,8;:8V2#0YO.-,[&=Y*>:*$.5#,Q9P%%,@))!V*2W''/>[#/YG4SD>
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MP;:QKL!?\I[6.YKFP*7,5-FTC>7/U#>!@9L=%;E("2L0-Q@LH+A68A2&=B%
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M+*<?.A:#( LQE2O%6:!LCGV/Y\5Q9_A[Q+#JJ*C[8,IE,AQF-N(PVW?R;/-
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M.5:,AI"5\L,X"E^Y!LUZAQ8YNAR.SAJ7_2Q-*Q!8#<@:0@EP;;TGFBI]@38
M'XCT[:>/XM[\U"IE\E@I1)' U\L)J;CO"?FK%6%&L)VA@YAB!^X]P9 OK<T6
MI.HD;%CR%1!*T:, P' W <[OQ < FSQ?/3$V1EJ@>2%<H&W*'EU%FPI8\_B
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M>;RP)('-=J_._P _<=.HRDV CO0-'N1[< \=Q[_E9OK;_AN!P/;,K>1O42:
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MH-\^/49T[5Y\1X)7#.8V1PNX+P!ZE/L;J@1VL^W'3XBQM'Y8!*/$ ".-H]B
M0#S=_0CM1HVDXUS#A_.YH+&0HUS!#<KC\O;TSH52,'?VD@'M8^/)!\#QKU:^
M!K>C^()0^;C0J1+'Y2S,&(;RU4!S2@KN4\4."+-7TUOA9N# /NF0S AMQ4$=
MW<GCU%7]0_6JYYZ;62R.-XEU#LY?"XN,5Z:I=IJ @0M$Y4*00-C3:51]V@?T
MV?4;S<C%TCQ'-EX6-&88@KH@)5+V!9 ON++,4VV1QW/'6Q8I)\)1/*09!4AK
MU !RWMW;:!O]C1ZL3Q<YODE',9WE].+&T,K3O-6D95DA6QMXTB *G4HC"LBJ
M \94=OW,=SO2,G,UC!RY,V%8<7-4C'2,L'6&FC9Q9+W2JP) O\5<\1+(CP9S
M6'-/NBF!,B[H3(R!&Y/I##=NH"AS1L$'JGO*^JO)8<<_&+5I3C,?D+E-865U
MD6-[+.(61UVKI"0#W^2AWY)/JK-2\3ZA'C-I4LH&/#*^.^Y2)71'.Q)21OM
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MS&?;6J?<T==OVD=W:#M@-@M\GX ].>5EB",*RAII&"PQ%;,KV."%%FAR3V[
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M@22QT/@#?=HI<W4,#3=HRF<N]$1I8*K=;F)5JW$>E3W%D?1JS,O),GDXBQD
M@R2.?0018H@@$@<D7[C@W0Q>*<@SN;R$UCL5JTFY64*%6,ANW:G6R "!VG>]
MD[_95C9"9<#S *L0(6+;N#5R=K63N- -8JMU$=NDNF9D[Y30EUF'J,A"G:A%
M!=K %>QX!)NB0?;IX\ELMC\3;R$@C,U:"62(!!,BS*-Q B0D%0_R0.X?=H;]
M8R3""&>:F98()9F4<,RQ(SLH '=@I L_'/;I_P ET2%G95?: %! H,Q")^,U
M09K)-=N:'/5%^J=$VL%@.0,E3\S:O9NK>DC'9:DEB..L!IHN_?MQQW(UAD[$
M1E3L4ETE)^;7VAZC+F^+=6:63*9IITS0DT4$4*-G*T[)%Y(LG<!99FL$F^>F
MWP?,4U//Q!O$4?E31 L6&V0NM+7HMV1N  10)H$=5[>012?![6'C8V?@?I\[
MWO7G]?.O4. M?;<._/'<^]_'^7'?JU5Y ]S7][ [5\_Y]9*G85OWT=_I^A_^
M?/K WR/I_O\ OV_/KTW^_P#CO_;\^O<W_"P^?I+^HL[^?J1D/_\ BWI^N_\
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MLE88TNFY>E^=D&0JCA0S(S,RBBW-5W[=^]V1UH8B6')3),:;%.TEJ/"DD^U
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MCIV'F:0<3"5<>(EBA"BT:-S2R$#?ZEJ[]0! ]0 Z8)<N6#++S@2DJH(-E3N
MLA3QQM)J^*]NH_Y5>;A#+Q+D&=_FL$5943'0S&>*MJ/L>,1Z( C#=J[TVB57
MP/4;U'+71HTTW-SCF0OCK6.J@&-:9=K"MX4 ;E#'\!4T*!Z701QY>[+AA$#A
MF+.UT_\ Y$42INZ;:#1%7SP_NDF)XQRZ),58QZA3E3<ORC_*]S'F)%FQ\<_A
M'>6  R ,I@VI<:'=ZSTW%T77M*S],943(0M.PC4&3&:92N/,K6&<*JFT!6[V
MFC1ZCGB9Y91+BQ94:9#0DQ&PQ5U7<'\JQ9Y!N^4)[W73-X\^#N9KEF*R+V(&
MBFN/BJ]8M.L,<MNRM:$R%C[FXXT!;>R3MM [+5X4Q<*LG1-2=Y\F"/9$6,E,
M!)-&[(JEQYAV(0&)!Y!''6$ D33=,2;^+)]VCFG9D"J\ED6RD^A5((:B39L<
M7U(N'O\ ,#1I<8Q>+2I#"+%IKAC>.2Z%5DCK2LP0-$5(5U[B) %C(&SN;XL>
M;&D.&<&%(8(]XER 'B,D;EH%$84;9 X20O98;05KANM\NGZ3(A:8),#*)UA!
M5F204?-/+%@**K_*.QNA2CPHX^K>S\.=-&MGCJ+^5FM%(\Z%2Z/# 06217[%
M"H>TH3LJI/I3@E1/D"=,9,^1@)%B958P!5:-UCO=M8%N06Y LV>L\_"CR!AS
MHV08<4EHG+,%\TMM8.308"N U=^..>HXI9>[@[9P.1B_+4,GFEFT\8C:.)7=
MW!7^I-C8"_:3W;\A0"UX^;/IN7]QR(EACS,Z1XG8! D;L6;LVVFV*%O\-DV1
M8+K+C19<(GBD+R08JJX%MN=12V6%[E))-5?(-UUR9_)&]S"=[6*K6L"]5:>.
M21V=89(3)VS*60]JOW;$7CR3]Q!\^9LKG6BN7APY."T"0Q,Y5P)0Q=I+VD$G
M=MVC\PW/6R"$C3U,4SPSB0R/M!!*D; I4D&@ &X[$40>G9)8N\&P,63P% 6+
M.8,B6:D?8^/,7C\OJJ!M90"7:3Y(!4C]2YYEZ3BR3:?A"61I(R88?,6)2P/J
M"*3ML$!B@4L:+?R@(X0,Z94RIBJ(K!7?:7.VA6ZNYHMZK"\@ &P?7G^$]D,Q
ME?P6_JKNY&,1Y23'?5)$D")H!DZ.XY*BH- .74J1H#9.CO1/KE+[6GR\OQUI
M0R\9<>67!TV/RE+$,CYTP4%6MKDL\ T=O ]7$IT5(%TS.C1]\8FR4#DCMY-7
MP HH][JN>:'7DXZ&X!&X16&0I>SD<B&CNQ20 .FD[@&&AK6B"!K98D !3KI_
MPOB' T+3XC!]VD$9>5&4HUEV"[AWL(% OV([7S"<TQQRE%?<D:*M[@P)V@D'
MN#W-GDGZUP[^4P?X1GBDQ]2-<OE)A6"..\P59%4E*NF"1EHS&Q=0WW-W%6/G
MU(@Q< UNI@H[<B_62220  2?J/4#TFAVR7(&X8$DD62 *4 =A;[19[W['NA<
MSY)QG$X^GC.2V(HYYJY[)I2C21R,@55+-HAR20')W]H++^GI+E9V%A@',GBA
MCG9E42\!QS8 ]7'([CN?ITJQL?(F9F@5FV7PO- 51N^]7\WS8YZZY.HW(*M3
M)V[&(R,TU>7N!["RJ.Z0A>Q@P4C[3V_VWY&M>N>_%FLXF'E3OBYA,4K2>7?)
M/J-<!J  !'UXYXKJ5"25HHHMRHX7:X4AANX]Q1%<_-D@\CJ$X\1E\O--/%7L
MS1RB6PEAT<Q,%!<#O\@%EVJCS]VA^C$4UEZB)YF\QO-EDD!#*U6"11/+$'O=
M@T"!8 ZW>?!"J*SKO'I90=S<FR2?>NYYY /%D=6#Z"<4SD.>66&G#/=FGKU8
M:TOW$)-WLT[E59%BC[5:0E@X1@>TJ3VVQ]FS9ZZO$<7%3)12=I,?H1  "\LV
MX@5;'L6 7@WTQZGJ$=A SNA1UD,?# @6H'O9-+S2VU'GJ_N!XK8X]R3^89V>
MG"![QJM%IDL3^T%"1]P!* RLP;L5CH *%.QTE#CR>=D9+F-Y)@@ C5U,48"V
M"S$DV01Q5BB:/ 8OONZ&-'7R@#_.R<DD  4W>V4615@@#OTC]:N;IQC!02Q;
M:[[\<S2I&S^RBLI&@HTV]^//VA3O0(/ILU_5GT; ;(3_ +DCB.,UN4407)7F
M_3P+H<D^W3AIN+'ES;).$5 [+V)Y.SD'ON%WSV/8F^J>Y'ZE>2YJ5\4[BO7:
M-XVLQGL+*5T#,G:H[>WR"&.]ZUOU5&J?:;FQJ\"K!"VUE9D4JY#+W)).PU[K
M]*^CM/I^/CMOA4R%2MB0VH/R *HW5V>W%>W3-P]-;XNYO*WX:N-B83/:[@SS
M/.[Z6.+_ /",S@!= !%)+E0!ZJ;.\1Y,TVS'17>9@2PL[A(02 >=IYK=[$\
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MR1H$GM7?:/&]   'MUY]6 X"'8B[(TM4112J/R'%FKL\GJ0:;BIBXRIL5)"
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M]>MB:?D-(I=MJMR15$>Y )JA1[?%?7KZ?_1*V\_X+_2G(QHJV)/PT.$9")&
M=1,WTP8NW&C+)N-T#@!DDW&Z K)M2WJ120 8KX]D;8&B)!(('EE:ON./?W[\
MCJ9-$K:<\+DA6Q7C8@E31C*FBG(N_P"7D7QSU\J7FW,<GRCD=W+<BL^]<DE2
MNS.0.Y:R+!'$@!(6.%(Q%%'%_EI$JJ@"@>G;PQCX&E10^:H6,[B!S_$,A))H
M'OS;-W)-'IHP-+BQ<:.+ %(%)0630)+$V?4S.22SFRQHDWWV\9DII=>69G22
M./W*:*Y'?,IVB?:02"0/!_;R#YW</AN3#>61U_AMM5L>,2$AD]@ 3;=^;_\
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M$<D\D%67['>1@CF&$RN$#%@O>X\!B#ZE4/BF;3]%.BSO$D,\ICC:1O6%:F*
MM9"EP#QR#9'!-I-5FPL+(AR\H^6^X0QG<::0<!R "25!KD=@#\=6)X3B<=P[
MI)GHY6-[F5DVX?Y?$]>80B4>["]U@LDL<\==@\P21(TD(A5"Z[6:>$I"W@_4
MIHXA.V1][B1#33S0*AB2?(0*IB,FYY-E! JKM + =,<>3DZWJ<;2*(M*0*F,
M[EDFF%_Q9;+5<E!%5;(]1]@1%7%.;\IQU"E@H*5(7<I9LID,DJM%D;@NRK[
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MXJR(D+(^8C;&8-(3M610K* JAY%OAN .QZ86,YEGZF?$5JQ=N8^G3L5,3#9
M7\LEB9GA*: T K?K]W8!OX/IJQ/$&4,TH99\B+&BD@QEE_\ I;W8J$H#C:PV
MD=P%))Z<%FQSO4*&WT7(50\K(>&8  L"M"_>B3RU]6:Z<5>(_P"'WM\FG-#)
MV;J1U^Z(AW]R<=S]ZKH@(-E?V)(&QXLSPVNEC3UFS_*CR)L@H#,3&3[QJE5>
MYK+'D+7J(');]0FRVE QU=HA'ZE7;6XAB=U^ZU0'<W5$\">N.7>.XSE,V%XW
M^4;#W:RR9/\ I!FD2)B[1RN>XC>NY>X@@D]HT#ZEV.^$D[X>)'!'($;)E,)
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M+*W,A/#-%<P.4(A169@LJV.US!$PU/V.H*$]VQK8UOU"L#%R<')DF=*FT_(
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M,,: )LGNQ)( )X KLW>%8C%Q8_)I=&1@S3>U)7H5HW:-A.6['[=-]@![F*Z
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M-_ WYTUZ_P"*GQE:T2;'I]Z,#&>1ZS3;3P #N=5]R+';IO3]*C@B!C5D4(H
MLD[5L+P>.:%C=S0(-CFM-_J3DZYBLX,^S6L3RRB&16<0/W]P0(I[==K*I/>?
MN!(_1C4DWB6:.2(XC$12R,X3DTQ:U"*#R "%-U3 A;XM6D;&0I*Y(3D@U1!)
MV^H@G@"B!0!)JP >K8='>49+J$RVL]/%5K86!JYE*)7-MXX_<>0@DD1*/Z64
MEN[N 0!0?5S^#]7U'6W.1F2J$TZ,1*0@C?(D>@TC"N455-T1S5@V3TU:CC18
MJ!(4)2<[6+?*$76X\(;(45N[GL.I.K4[O(EN6$L00\1QMF24V&]O_KCU^[O0
M%BH4JNV9N[Y7M^"=R5I)M1E=C) NE1/>X*KG*\G_ +@9F_[<*2 DN.25 ^:0
MB-<):&XY<RDD58A\PVM"@#(010XH$GWLU=ZE=;:ZV[&/X_522C79ZQ+V&D#!
M=H6)!V@9U8=J%XSK^K9(6JO%OCQ9"^-B7'"BNJ(S"Y2FY=Q"_@!H*H!=0!>Z
MV-.V#IRQ1[G+#)DMO5R%OO9;EC=FS7;VJNJX\CMRYE*D]'NC[C[DT$9[2LTA
M[^_8_P!1^^AX'=K?KFW4\R3/G\R6V:0M*0O9"Y8[3= 435<T>YH]+</9CR2C
M(&Z]P4\&QS9 :KL?K=$GXSJ6)?,I5I9&*?WXTCC2V S ACH$J1Y"G0V3H]NR
M=@^C3-+FGR(D6-G4NK5&0S"C>YNX]N=I/SVOK1+D&,L^,;!);RP>1R/RX/?V
M_+M5O^E'!*W :L^1F<'*W*G^7*%V8XB0P[@0-@$@L$[OUT?&_767@+P[%X9Q
M7R<PHF7D8SNC$V4B)5RSV$+$G8-L=G:I'%@],N;ERY;1P4%J0/,RNMC:*VC=
MR#R>:X86>.GUE;F,Q&#GR>6RM:2Q&[SU8I.T2RRL69 00H8JWB%=]RANT@:/
MJ0ZG/@86ER9^HZBF08A)EXVXQJQD)W(NS\3!"2(P=H1;7N.=2QF:<"**1,9
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MEBZ\[!K;NTT;-=IIV=C0B62>!64*?: /,F1I$W@[4\_&R(_OVBY,\D<B2E@
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MN<++D.E0LV0"[L-TCJ%=F4A2T<866CL7<1&0#VZD.8S38F)OA'WJ=FVMM(
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M!)(.U;!- ]KLGIUT["R\>9/,>-H1'^ /90FC16A1%D T01P>U].OISTEPO\
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M.RP(#$MLMOG3/FER<M_,(\EMQV#<2I)LU8(H7QR#[U=CI,D?+<K0-5NJKL
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M_,")(H4FF:32 "A/MU\9Y&@:5CZ/A0.\NH9"#)D.PK'& -A W[A';$L^TFP
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M'I"$TJJ/P_0T2>3R2>=U4%SII4%S.XW%W:7O5YIT#0")6EC#DGW7,B'L7P/
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M8UK9[?'D,F-J:YTF-BO4:>03L-@*54+0LB[%@L* (L?1T5C*VQJ5=K(Q'\U
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MB-:+]JTCS:%G'8,EE$D3E&$0#Q3&.20@&K 4,RCCU6 *XQQ@L6?$5M$:G52
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MJ/G&-(F9Q*C(ZJD+(I!92-S$E1Z0@O<#TFDFE3.Q\9 5Q7 WO0(8R G<'.X
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M[11-@EBHJSS8LT3TOQ49,&?SG$C>6^]U "D" ;JK@BA5@=NP /7E!H4K7'^
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M$T;,\E&6\L<6E98O;<E4"@ _<O<NA\E@K';_ #$]8U?*S-0&AZ=)"?.F@QI
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M\$J!7328W</ \BKBP -+)&Z@2FF/EDKZ2%7@@<$@? ZL!EL90P'#)9<E(O\
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M3ZXSS<YGU;?CS-(K$%Y YW V2:-V:Y%?/<]@7'#:]32($LLL#B0 TH8 ;78
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MLCD:.O>$LB,TQB[_ +P[:)V#L@_KZA,,<\VFZQ-G2S1!8Q:I*R1Y#RRJSLR
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M2!C[AEC9D!4%#LG0\CPWRT>'_#V NI94.?"LF5*K>0*1]LC[@IW -5GDL#5
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M,^4PAFE\N/REN%88^2"X.Q7! (0FS=KUYC199;*BW%DDO8P'HW,+XL6"5])
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M6 2P1B57]:JFP@[VY(LE0".3W(^+X#FQM=8Q+<->"J)U5DC]L)(L*KL&0J
MVBV@#H? /SZ]8\A=S,%][XOGL/I7/Y]NE!-@'L2 6'P:[?W(/Y=0SSGE]W.&
MUQK EU2SJ'\W"LAG>7<BD0@:5CM.X+Y+*!HZ<;KWQWXWP/"NFY*M.$S&QY2C
M+=Q<&W6EK<@!:]P)'"AF[MV5JV-@H\LCJS)P%;V(!8,Q_#L!JN+)!)XOJ-\'
MP23$3U[>2BJ9V[6M31YLY:X]+CV"+!!7&8R2Q/'/<)D9[6*I2O8B6,PR$6)!
M!ZX9\:?:+F:W--C8DF6L1HPRPRDR9!;_ +A,0]:\FO70!-DU?4<S=9;4&F4R
MS8$,D:'',$9DS)@02\D4/+1(0*65]JG>&'I%B)><<+M7N3X#D^9Y+CN5<<R&
M;HXV]9H"Y47#+[RJF,-2[#7EKTX*2!:DD$0IF%5BAU+'(OIQ^RZ73\CQ+A:5
MKN-+BR&;$!7(E0)D)+DQ!W9K(XC8DI9--Q=CJ4:!J.)Y+8&+@S:=/'$',$XC
M+SA0=^4TL3&-Y)G(9D9O,5NX(((E[-<8XSTDM9KE]:_02KFJO\JXY"MI9)X:
MZ?EI,E;8*"TAE+"E70.QE0V?<4+&A>4?;+H.FXGCK"TO28HH,2"+'U#,ABL1
M0/-L"@$@AM[ NP!)16!:ATP:EEY&MYSZ% DABPY%R)I:.PL5#*%D)*L5W!CM
M-A@ .; PNA61J\CY?8Y![T4D$$4^YED4?Y\L7VB5'82(Q"S.SE2O>>TGNUN[
M?L2PXE3.DCC&Z%,HAA7_ &\W*C="*XMD1R0!N7D-1('3_'C' \G"<%?+1R >
MQ_#R6%J;[ WS7P>IQL<C?%Y.YDKMB9*67FGBQM0RQF"1H6AC-N16;:0M)#&5
M=-'L8ZT#KUT$9%C*K++Y?F.L4:R4O*@ A/<[SZA?%D'@L>M:X,64S3R0F8I*
M9$5OPEU!C60HQ'X!P" >;*C@'J'.J/4- ]/AL5^-:UD$7;U?;3322=VBBCQ[
M7NMV:V&':S?]C=8?:;XL30].GPHY!&^9CR)*\;;I8T9''EH%!IV"VQ()%[>!
M=N38[0XH94W@!E"4$!4"RQ!8=RU+?'.X$FB%'&\6/)^&\0XM%;GJXJQDN0<K
MYODORY6.CQWBE:+MG6P[!;$@@ELBI4 4O:FBB[6,H[/FSJ^IM)JV?GL'DD98
MX<-9&W2&65_+VOP:((7<Y)](+]E(,*BS!IVHZOJCQ1-E(F!IND8A96;(SM0#
MMM$8M@BA%:1J 4 VUU?L5_AI>2XWE?TY_4G?P@LIA*'U&1X;$5K<L4\]/'8S
MI'TZJUHI7BB@A$TB()9C!%&C2R/I?DF=>'\&? TR%,DQF;()RG,:L/5-R>6+
M&N. S$@=R3WN+P'I\^GZ,5RRCY61DRY&1)$"L<DTK;VD"DD@TWE@$EMJ6>_5
M>?XNBN]CZ2_I72(=TA^HW)!$4?<Q;IGR90@_0;+#Y^-_\#,-%Q'RLJ2.,;G6
M(M&FVP6+*@'<5PS$GVHFN>I5G,J1JS<#=1/N% +$CYH+V]^1Q9Z\6'3CI+U+
MGP4')9Z=B7@E+EF(X[DA#;20)E<I7DMPTXHTD+!Y*D4SS#0[%"^'+>+2\/ZG
M+B>+= \$:AF+-E:@JY?W""7>ZXJ!FXI5V JCV6(]*7V-]0?/\1Z=!K$.BB63
M[Y/AMF0*$+1F$!BK.PL!F=14=V0&/8-TR^NW)\EE^4RX&>M!0H\=U3JUX .[
M0"_=,>Q-R,-;4]W:/][SX?/M0U7+S=1_PXPQXV/IQ$,2)ZF1$M A:A3UR:L$
M,H!H67K3XH(8(Y ?.DF_C&0BB[NMFQS2@WQ=G^;XZ8V'Z@<CQ%/$XPVOSF(P
M=R>WC\3<"S48K%DDV7$+?I.3N100'TI)/:/5 9WAB+-RIYBC)DY9"/,HVNW(
MV]SQ?'-T.WN>L)\+&E?(FC01S9L<:9<\+&.258J$2[@#L*@+;"RWJNKX?E)^
M0<S_ "^:Y;8E@XG!:B#(O^15CKH.T"I5C[$4HJ!&D12Q\$][  V=X*^S_&TY
MX=5RXA#CJR)+,4W2$&BSH^X$/8'LP]1XL]:(=.Q\4B2% )RK%YI"6F?W8%_2
M2M@ $G@BQP>+)<9QL7)8H<WCHH*N#P$#S<=QK1$QSVX![8OR0)$NYW()4OW$
M'3?<3OUTCI6)_BR)J.)&L&FZ8I.EXA4R)+DQ)_\ K$D8V@R.P!+$LP)6@0.-
M&5.F/MB=_,FRF!FG)V[8B2-J'DA5#G: :J[([=01G*7+\ODLKFN38Z]*@JV'
MBGG'V0P-(ZR&,.D?A6VD<;(/;B[?N?0+5UK'^,32Y>=J&-DR#R)) \P*QK&&
M8.R@J/2AW(D>T*% &ZN>EDLD,!$&.08]C)M4AD!8&1F8@J=P)Y!HD"]W4%R>
MVMUZT<4S5S("T8F)5F&B2ZQZ0@: 'QH#8UX]5(,V;*?RHY'AA=A<:,1&[L0+
MD4$6MT0!V( ![];(WD&/;.-S#E:H=[! 8]P*[GZ=Q74W<?Z'9'+WJ=JY=@QN
M'F1)II9G^^)"@E '<R @@G3=WVCP0Q.S:6A?9YE32PR9.1'#AL!(V1*?+""M
MX!#/S8_#ZAR+-CGI/)E+C1MYB^<XY58C3.X( 4\$"J.X@]_;V%PN.SM4X];P
MR5":4$<4=:U(IEEEAJ ]DT09A%]Q8FNY64)N1V4R"/LN335RYL=L.-)(-.T]
M5V99B667/2'>X6 R'RHXRQ1DE\N5B5>.@*(B>>TTVJ8[)-Y*-(CSJ#^-SQY)
M=2'5$%&1OYR=J[0"37BEU72EDLOBN87I+.*,UBK66U $<-$\D:;C@B+!'[0/
MN7[=_<2/'JNO_G\6'D9F!KD\F7AN9(U6= A4H6"&T4T+ )!XX[GJ138N/Q]Q
MQRLZFY)4 HC@R V1OL]R>;)[$6(-GY=7J9?(SV>.4I(I#8BQ\TJR>]#!)(X5
MTF4A)0L;GLD6/QX4']/7.?B*+'U/5<J?&>7'QC,7C2(G:XX__&Q=-=#VL ]\
MWQ//5/N^08199U7B^>QY!4CL01SS7 OI[\$K/GK:4L*OM4B>^5.UE"$E=B0L
MY[GD/<P<-_N^5^T#U,O!GA'_ !+*A:.,NR%61I%#;N1:62M!JLV"1M''26?'
M<EGDI7C6S(P#FK6P"/<\#OZ:/MP;7<<K\?X_9QU6P(*EJ*56DE"A6)!#%-^&
M*@E06#> #]I(]=/Z5!H^C&#&F6*#4$)N0@* S+^#=9&VB 6)'-@]KZ39"SRQ
ML85!AVK2Q@65%6P:QR19VT2P-V6-=2D^"XOR/*_XIR<T'99BG2C45C'[,->0
M55LRH-@.S*\HB*GW J.S%3VAQ&%INLY$F6\;SG' Q5#,X1E WLX5=A(MF0&V
M "@\&NH\,^26;/TP(T*XY42R65,GG1EF56*D !0.Q)O=5<CJ:JLM''4*$PD2
M2M=@@B69U[79 $5 Q[NU45.V-5";UV@?KMSQ\:+'B&-CPB*.&RJK="R2QLVS
M$FR6O\_:D&/AXNF4L#-&DTA>17.XS2-P"68BJNMM&[4?FE\FY%0Q=><TH(;7
M:4B2$*/RSLP[MERC /'X+-HD;3]6'K>L;E=S7N'MNI[]A\ &^;[#D\7TLCS(
M#E-C!CN15=G )10;])8 VP"W7)(91[\5LY'#D(K%WE69RU*O2KJQ:+WD9@RC
M2(B"7;*O<%3[>]G+ ^1KU%M1@R<+*R-;U#4H,73\.$E8Z9E386*J22@9K[<!
MF8_A%4'C$E5F:-+<-Z6! '<BW/)X/"J -IH"R:NE5W!<@ZN\MMM7L2NH=U_-
M.K+1H4HV9Q-8.Q'!$D ,DDI=4T"[2!?N]<;_ &B>/#D:AF9&1DM.LC5C0J_E
MNP!!5PFU@030"C\*]BQX+W-J4&DP*[(4A%"& "Y22*58XC>Z1VH!;LW^G3CK
MT,OD./<@X(.2QKQ#A36LG/8K0_\ 5LA9CCCBD-5@(9)Q=:$"JTY8L_:?;4,Y
M%,R3HN7CZB<5GS<\A55GYB5B:9A3 % UL!M%77(LZY),'%R</4WPW&?J=1(L
MC4R*QW7(#:H\>X>8JJ"%/+'BX\XWR='LQ<7P^+KTL=E#7@NVI&>>ZYC9N^=R
MS*BGRS^TJ]@T@4@[+V!X7T1<_7,!LYS(%R!P8P(T5^5H%N:H=^">]&B%6=B+
M(Z94\K&2*0-%_+&@) J@+)][W#@4;XZM%Q&IA8I)</@ZD=F_&=Y#(6P".W?9
M+V,49AV^>P+I5 # :('KKKPLNE/++HVB8<$N9 1]]R)E!CCC8;6\OT&F^""2
M".!QTADF5=\DC;$6R50$,Q))#6>X)YV\66H$<]-WEF)JX+._R:QF%2AGO;DO
M1TE4_DYE,BUKH]Q9%]RM-.[B6/VS&'F$:;8^JL^U_P .8NES)EK+C3YSQDE%
M1KCB]18E3Z;W%:;<"-WX>2 DS F1"-0$1,J5&$8[?.C_ )@ H(VFA?XB"I%'
M=N#MZ89;*U&M8C*Y.=7R,OY/,FQ52".06!-+1LU/;B1Q#-46O(A />LNPX*%
M?6[[%O%C-F'PSE2QPXV?#*T<!\PN#Y;1@PR*@5&8DJ077@6/8]-TY0.OE+LB
M= R$\@-8W*?8'CGY(I?J],IR?-<+R]7%S0Q9&O:+)565%"^TJ^''O*R*FBB%
MRPV\B!M;WZMC7?&>=X)S(,/483F8,S%<><[HR(U]*C<H=B0!R"QY4FB>^B)@
MZS,X*R*W!#!E8_(#+0&T\G@]KOOU]$[@Y:?\&[B]@D O^&UC9"J$ =LOTS0R
MA0ZD@Z)[.\ JR[8 !M>N/M3R5S/$>H:@E^5-K67DA5X)AGS/O"HC50"DA=P4
M@J": ('5O:=_^H8A/OCQD=N;4<^P_P">_7S#:V9Q.>Z5TZ/),N97H5IZF&IH
M[/)5LP.657^T*@E#PA/E=?<QWO73&-G8>I^%\:+4,QG\O'*8D*-N*.-I/F.
MI]5J%;D@K7X1TW>68\MFBC4+(;R7+;2U>E:[^I67D&@02>>_4=<CX1G>.8G!
M\ER;1?DKJP"(P-N161>Z)9AW EE0*/<4>/"Z^-Q_5-"R]*Q<'6LMS'C34X\I
MR0QJE+J&'X=RDL1;<#@=L86B,L\,37*C*94"D;&<@A@30:S]?;@=<. BRO,F
MR&.JR3W<C,AEBA$2A3'"O:IEE,B=H(T"#\:!T=^O-(GEUU,O'Q7.1D%F$2+'
M2@*#L+'<2VX#U#BOSL]+G*Q1L)G 4*+8U7-"A5]SW!NC[MSTFIPS(QT<E8RD
M-C'SUHIY:7NIJ"X*TG996*3N"[B;M78[@Q< : '<U-X?G?%S?\1C>&5A,<=@
M3Y,FU@6*\@"FX(L\7R!QUIM8VM3QM XH;-U$!@.:8 T?3P3P>D/$9.:*[C4C
ML?DC',*\UE"0?8ED4.S =O<%4]Q^?!UL?'IFTC6F;)T_')&.Z.<65C)=K_*P
M3:+)K;=BN;L'K(1*KF3\09002>*)'!'(!%T#V- 5?/5Y)N9X;@?3*#B<.2?)
M9.Y?DFH63+VV\8U]$>:S2=1*IA=-L\,@*ENX]_D=M^SZKB:%X<7 QLZ67/G+
MK'-'(%DQ6R!Y@FB]#^F,-Z4)MB[C=M.PQC(Q)LG.?)E B@"A/4H;S&%@!E)J
MP>;V$4J^YXJ@N(RN=RUC*M8-7'M<1YKC2=K0I+(%##^DMK8T 0#L $ ]WJL,
M?$S<N=\B68)$TRN77AE5CV%"^]&_<$+0-'I\Q(FV!Y#_ !7YX/+%:'%"NW'/
M'ZV"_,?P+)5<?G.>\>Y-%9;!RNJ%_P#.DN+%&&E9V,Q]O[00 1*"=;(V-R/&
MT'(3&U'7L#-#M@2*FUF),H0=P+] Y '<GV!HCKV3+B7)BQ)$??D(Q6Z93M%[
M211(["P1M&T'VIG<!YFD'-[F;SLBS/EHK,<Z-&&BGLV=B-6 !55#'P2I4? U
M^L8\.^(XGU_+R\PAY,A9%DB9+C>1U==N[:%X+$FU()[=N=F5#_!5!<?"@,*X
M",A6J((JJNR3P"?F2.+0T.+\CFOY6SDI*N4ARK1<>Q-NY0L5S[4GLY*Y8C6.
M+\H@=9FK1NS35R48?(](,O.S,76CB.DN-I\TN.[,6)$RM,K.D:  !G4@)ZB0
MQ4@<+U$-;?+SB^+!$B!,B!FEG19T98Y ?X*,4VNVTE) 6*/S1((-C[$W%>4X
MBSAN'.] "E-8R%J2,1VY9# A>%&F0,P0CW?<5^YB?';V@FY,W3?#WB>"'!TP
MG&? \W4$GB62"<3&$IL:0@.Z,#_%#,4X%#NP;9\)UR(9,PLQA*[ D@!1I-M/
MZ10HIV7U&^:VCJ,>@,T?".J$4EIW,.3EFQ$$\SJ0+$VPTLK$$*"WCO9MANU?
M\PDLL4\#YL>!X@?$R#_^M>?@0OO!=\A2) )+"T95C])!)L 6;OI;F/\ >\<1
M;Z,4AD)Y]?EAU*\$^Q9@6^*KGJ4N4]),/ROF^7Y#.\QPV,SE1<JT ;\K;AG:
M,SU?=4J)7C)]XC[@1L: ._4ZS/"VFZUKN1DRR*6Q)L6:> +1?S(/6C,K K90
ML6I@2Q  8$C7#JN-C1QXA6)\KR6EC7>IDB42&-)63:2T9([<=J/'/3"YSPN/
MI=F+>4X<))\)#D()#&KK.T=>41-,H).^U20K^"3MCVCX#+K.BS>&)O\ %M,5
MEQ!-$^W>6,!)7>K%C84G@;@;4[2>_2_&RTS(9DE<&8K3"]@:K <,-RBP>0J@
M V .L_.5+76""',V.+QT,1AWK4YC45:XE:9@OYE^U$9YI.XQHH) +C1/:N]T
MPE\8I#F_<A%BP.(F9)%,DI9AYC(2H9PHH!*(&[DDV3LP7Q\&%HAD>8TQ+*"I
M"+LW*%H$@60=Q)Y (H<$;<IBZF,LGBE""Q3Q<)B%^%59KRN DT: KKM[B?<9
MD8LV]?W.6IP0XLYT7#2:+!N Y>U?-R.%$B!2-M !MWI<@@T>PKWS9YT3(F"F
M5ED0,A(B" D4I.UE/ !+"AQ0Z;)Q+<SY1A\=-*(HZ%R3'*MB-U<TX9/:$TRO
M(C]Y36E;[5\[9B/+<N--K>J8F)*[5 [8J^8A#C&QR0"RE@=YC7@7P3R20;6H
MXQ,.69E(9@92017F/WY4$;7-7[B[[<!K=5NDF6P7(XJ>+#.,E"\0C<AC%7C"
MM[XW(6",@0%2#VL""=DCTV>*/"DN)J$*X;M+'DHVQ;+,$C-L6&X415'D@BCR
M3UJQI4ST$LA"-&R+("?2#[;3Q[DV!7-FQ1MV]&N,Y;%TLG)+D88*U/)5UD@:
M&1DR-L["U8YTCD6.5(I6G;9T8UTQ&U!5>$YIM/SH=-@G!D?)227&0^ATB:F9
MY '\NO-](VG?9XI>FW7]3Q8'Q=-A@?*RI4G+&)]OW6 %6DD<'TD@$5&2I-?B
M%"WQG3>X%?RG)>-XVKG,3=BF?.17Q#;CH6F;O+X]8G64,S[8GN4AV/:L>^WU
M+M1270\K+U;2<>/.Q)3(V:)665,7(#DD0;-LBAF-NELH+5=$ 9:=-!JV.F)D
MR2Q3PV(;#H[QHNSLRE6W;;[@M1([UUP<4SO(^<4;:7XWEGA,C8-+4OMX>A!/
MIIE*R1D133.J,R#R&0;D/V^D'A^*;4CJ>3]UO.R&#Q2R[SA1J5(*D'=LD'&U
M$!_\BPHGK(Z7IVB3+)CJ(?O!K)97+Y$H6V4 /PJ@EMWJH$@4;%1QFN95\-Q6
MQQG%5_9YA4LR->L5XQ(O9[FBXC VP8,J:8@!71M$H06K+U>'$TAM)@A,6JQS
MM]XE158$*[AJ8$,P8%4VG: !O!-UT^#$,^6,EW#XK0KY49)-?AK<M[0!3,2#
MN);FJ'4J6).2Y_I9%FLJ(HVK15*Q(E"&**I%',#[/:H,A24J=[/@@'YU*)9<
M[/\ "1ER51)(Q')N#[=T$04!R*"[S97:.X - GIN1<?'UK9$S;9$8;0+_B.;
MK<+(0;..W)KGCJ/\[E,@^ DY%Q&M9M?F:4.*S$DZM^6DCKJ4E6 ZW&8B68NB
M2'MU]I/IASLO(; ;4=)BR91-BQX.H/(H:)O+4*RQDAB@7W<*>.P')Z7QHB3&
M#*\IRDK38L2.5D()].[D DDV>X)[@D\>S_\  XMG+_@?_5"T&X9)+'U15"9"
MQ]N?_8U@XBY;M5B$=@^]#[?/@[ Y^\4R?>O&?AM(_P"'(3H\#6Q]#OJ<H1K
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M.[L!5BZAG>(/&.LZ&^0V/I.AXFG>9CI&!]^R<Z-\C?+*>5ABB4*L2&F=BSL
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M:23.TDDS'R_VZ-K^$?L(R\O3\+/=?+DRL 9*9$]AD=VH0!=]EFV*RWM_$:
MLVGH^DIAPH9&,DVP#SI0#D(I/,>X7_#')"@*$ %%MP7IS])^#S<]XUG^(25Y
MA-+DL=WV).SV\?&JS.9UA^R1[$L\=>$:D0K%)+)OL20BF?M(PY_!VMX.0Y:+
M(CQS(P8D.)!:*JM0VA-K/9'+4 H(]4;\4ZH=$U#'SE>1&,,@\GN9=IC!0-0
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MAO2;.X68YHVGY$F5J<NI/"\DV5(NEQEO,>'&QE2.3,C)8L#/.;%'^'6U=H
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M02+LWS72B/'!7REC#JHWN6;A6)8U_,25HF@: X^@93\E3,66RF:M6K4A*O\
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M_&TTM([&,29&=$VYY6E5P@%\.C*1OX_F !JV[=<E?-/+QZ#/4I+T]&61WY!
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M,TTT)F-D ^U'[1!<[V2O:"%7;)Y\^?3EB>%95S),[/U!LB0[6!CM2)!]6Y
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M3E]A6,<<DDI 6*/M!"P*VRJJ %&CL=OC1]1'7M5S&RYHX,V6?RSY?FLU;B@
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MJ)+,K2]DGW(LL8^Y@&!,992 &\2O(T-O!F1&F7LR<'(6.-,E_P "*)5,BER
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M?391YN*^0@39DML9TDF8*1>U@MTK-MO\5=3[+Q<C,PURS"?O((4QIZB8;*T
MI(=K(8WRHL6:!ZP,AU7I0=3\E F5%:I#4DBJWZ\B^RG<$$8E<?80N]EQK1^X
M_P!)/HE\3X\7B2:*3*5<5<<P1S1;)(@S*"&<V5($MG=9(]/!4$=;%TLG3$0Q
M$SR.)GCDW!BNXA@/=24 &TCO0')LSMPOK7R2CQ+,<FQV6XO!;5),9/)D:,%K
M(T:11(1<I1V9C CF-6>*4UY&A[A*FG575UQ=9FS]+DSAF8^,8)&$L:QJ-J(R
MJ6<N[$-(I,B   @T/?J$ZSX+P=4U#&ARY]5./$RN,:#)^[Q3.I9BLHCC5F0
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M.7+K#&K*NT"[4+V -&R;)%U2\$>W45U*LUR588'4S6'$42NP3W&;] 6^T^=
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MLF?38)A SLZ3N'+.AL2%=]$&@U@@T#8OMUN"X\\<)F5)8R=\5@D43M!*T+X
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MBPO^?C\=[BQF25%<)%/&C=SK&-H=J2R@-ZDFC^$\+3M.P,W+99IM4C@AU)X
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M3H^3O+3_ !CXFTIS)@:SF8[$;6V."K#B@592IJN#5CFN_6,F#BS*$EA211R
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MV 00=$2&#Q)D0&-ONF'*R*%WS+([, #08B0=B21MVCFJKI)DX*Y*LIFFC5@
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ML2223L#?]CH?=_\ S;W^NSLGP(*HDFR2?PBP3>TT "/;FR039)-]>W[4./\
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M<H-$#\2KV/L!1%CJ*^*?#DGB73X, 9TNGK#J,6;*$C3(QLR&!Q*F%DQ2LK/
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AHZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g491933g93b09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g93b09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1GN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &=*^9A X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!R3ST0
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             # 0  !P,    & &< .0 S
M &( ,  Y     0                         !              <#   #
M 0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M 0    !29VAT;&]N9P  !P,    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   P$     4F=H=&QO;F<
M  <#     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MLV>HB8F'U*F_?D=0.33M(-1J8SWG\_U*M@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJE!2BM4^B>(E&IU;>K:27]IC)ADI@W8%QZTF I4E(-U+UUI\/FFD?._=U/E
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MK$CF.<7-6Y/8.19W=-VC5RTRJ"S/8WI,O+E^'W*/<_[27<W<<4;>[E7F6/\
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M-'3ULP*^=,X&.E)$C!NNZ24D'P,Q9Q;(J\E)+M(YHZ=HM0/[3@T=Y,#XIQY
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M(N',R98I&'YEU<:+1,X8?RDYR?79,*?,6W'BZPPN0L>!#SM8"X0,ZX1D\99
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M0:\OS_'QXRA$'Z]?2UEDZDC/RMC?#D6J[@3  D=N%6R7E" ^,WF)-G)O$ \
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M_;"W3C^JSCGT_P#*^(#UY#@>.G';GI\]/'KKA'E94]WQZD9Q\RML?54743D
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MQ!F/XO[+:^@B B*R?(>O'V<!V >G/77;,=_(\3_R];O_ (MU[]21?CC[9_\
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M#QC'+R[UJR=.6D2U69MW,FY00.HA'MW$@X:,$%WBI2MTEGKMLT344*=PX11
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MY)-K;GP?3^.>3E=CV;830?Q*1?-'\7KI@/J4VW%-PK0XFY--KB 9.]!W29,
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M#U>P,/BVJ#:_N^L]9 )W13?3876!D34:(%Y/ $C[%I!W9]YP86""-XO#B+F
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M(_J'X3#?Q52N\?/OZ<#]X=M537P^[7Z:\H7D;DA_JOV@.0#I%FX$W'3X,Q
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MR8/ CP/[JL;!R =Q#L'/ISQ\N<<>E&!V>I38G:6'B3?^*KS;,W(O&E[RMSA
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M62/(V-]X>0:C)5)[D?;5'MY0[$QW;7$>4%%T?<9!M(%\)%<T&3-XS-2IF\7
M 0YC!R8 #7*[$VK5V)M*AM*C395J8<5@UE3>W#ZZC4H.WMUS76;4<1#A[P&E
MEP/:;85'M+L7&;$Q%:KAZ.-]1O5J+6NJ-]GQ%+$MW=\.:)?1:#O-/N[T"8(A
MN_V?;PFEUK-<;7[!#^N3%?MDG-W1/%U\1:UN5A'M3;UZ"<19\Q^^/EK4VG+
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M/69/+>3&UTN\/=KC%QT3N!VZQ,&I$U64J+6SJHM8.R,JK"D9O[M7$HZ(208
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M81ZB(].O7YZA (@@$',&X/@BY\)?D'Z U8'#*PY#@BX$A!  $A1 ! 0 2@(
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M),>3K.SYSG?H!\#9U<9&O1]+F4WRLA(N))2NSKX>'P^^'?\ /3Z+W)[>=O\
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MB:(FB)HB:(FB+Y'[5%ZS<M'*";ELY140<-UB@=)9!4HIJI*$'DIR'(8Q3D,
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MYD0CZF"RL;'NWKQDU$OT>\CRV[F1?JE$I .(N3>,Y@ H%SH.P'92',_0V$W
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M,/T?T'Z$Q74?G\,)U'J/WZ\K]I/VEVQF/X5Q7?\ RAWQ7N_L</\ 0KL\#?\
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MP/0.>?3GIZCW06S MO$2)&HR/*WWZ^&W/<7D;SC, RYVH)O.I!O)XSSFCLS
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MDD#*+<%%W91^2WA[^X$A_E%,Z(I0*+HI#PHJFF(@)@ YRE'@..1ZB';D.?D
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M[CR&4J[WLQ.1W];6NP_U36G3MS_2:8[=NG\G/Z.*](7[);9_X%+C_MF=_P!
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MK?=D^?G;:SPD-'1Y:W=]I$BL1Q'OG;E<SHC[<]%D23,FN0$S)J*F,8! Q"@
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M,>29<!! S"UW$O9?^T.<7B2QRGM7LAK?%52&NCV._"AM^*BE7;#,V""BGI9
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M>)F;F2.*A3"9,G=^SGI!V'LK8NS]GXFEM!U?"4?5533H433=O5:I=N$UVET
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MKY)3?5UYJ[3[2P^U^T6U]J8056X;&[1KXJ@*S&MJBE4K%[=]C7/:'[INT.<
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M,DR< Z>F]W=,74HFY06\)B#Y2J93\&*/AZASJ%B"2  1))@#F2; <UH>"6/
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M,^"[KZ+>S/:'9W;/9V+Q^P]JX/#4J..]96Q.!Q-*E3-3#/IL+GOIM#=XF 3
M%IAMQ3OM5\_8.R3C7%\?CS+V.+P_C[M)/'[.I7&"L+IDT4@%T".72$4^=*(-
MSK'*D154I"&./@ PCTUQ7H6Q^ P&V=L.Q^.P>"95V93ITG8S%4,*VK4&)8\L
MIFO48'N#6EQ#9( DQ99:]*^"QV-P.QVX+ XS&FEC:SZHPF%KXDTF.HAH<\4&
M/<P%T ;T WO )&"XMLK*KMPP3G8L[YH@W=.F9'B)W2#5ZHY29N5D"F%1%!XH
MR>D;JG(4BYVCHB9C&05 GHK]TG9QIEW:#8=C_P!K[/ !OH<1,3K\]<+CL_MX
MAH&P]L@Q$'9>/$Y?VJ$ <3/>3*V1O9X[E]O%'VIT2N7/.&*:G8&<G=#NX6QW
MRM0LLU(YM\R[;&7CY&1;NDBN&RR+A$QTR@HBJFJ7DARB/DWTHXK#8SMKM/$X
M/$T,70=2V>&5L+7IXBD_<P&%8_=J4G/8=U[',< <VD9KT3Z.\)BL'V5P5'&8
M:OA:S:^.<:6)HU:%0!^+K/8=VJUKKL<"+9.&A"T_-W+UM);F-R]LCE#/JM(9
MMRY8F-E9HKNJ^]KZ]SGI%"<:S"!#QZ\0M'G*^3D$USLS-!!P584>#ZS=V:[2
M]GJ'9S9%"OMS9=&O2P&#;4HU<=A65*;V8=@<U['U0YKVNEKFN <"""!DL+=H
M.S?:&MMS:=:CL7:=6E4QN*=3JT\%B'4ZC75WN:6U&L+2UPN'-):00X2)(NU[
M.N38TK>WMOM=Q<&JM8A,AMWTU8["DM#0<4R+$RI#/)*5D4V[%BV QR%%9TNB
MGXE"EY$3 !N-[<;?V)C.RVU</A=K[.Q5>K2IMIT</C*%>HXMJM<6AM)[C( )
MOG$9V&\[(;!VUA.TFRJ^+V5M##4:5<NJ5<1A:M)C&!D22]C6Q)$Q)$CC)S<?
MJ@[->(<S;&*_5,0Y,I.4K0AG_'\NM6\=6.+ND\C$-:OD-!W)K1%<<R4@E'MU
MW;-%=XHW*V25<MTSJE.LF4^'?1UB\-@NT'M&,KTL+0. Q3#5Q%1M*FU]1] L
M:Y[RUH+@T@21E&:]&8ICGTX:-X[P,"]H<)\R.KK2?"HW$70,0I]P%[[N#H6?
MT6G_ 'OW45#) Y%N,=YHMQ6(9/SO!Y?FE,0#";D SO\ NBV#:-M[*_\ K\,8
MS_[SOC/4V7'^HK?[,S?2WAPSL+C4P0MV+]3Y9NP_AO8M8*GE[)M'Q;:%\_7R
M81KF1+)%4N>6B756Q\U:RB<18W,=(*1SERQ>H-WI4!;++-'*:2AS(J^'!/I%
MQ.'Q?:,UL+7I8BE[%A&>MHO;487-;4WAO,):2)$Q:X6^PK2UA!$03].'GEJ3
M[LD+9"K5GKES@HVSU&=B;-7)AN#J)G8)^UE(B2;"<R8.&,@S56:ND1.0Y/,1
M5.3Q%,7GD!#715NE[NB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(N! #!P(
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G;O0 9<#&1@Q)F;V^:+]BE*4! I0* CR(%   1'N/ >H\==?5%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g491933g94a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g94a09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1Z@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'H2^>!(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!PQFZ
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             "XP   O0    & &< .0 T
M &$ ,  Y     0                         !              +T   "
MXP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MXP    !29VAT;&]N9P   O0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   N,     4F=H=&QO;F<
M  +T     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M+7,L?BM:0Y[R?7]<75_HZ_39<RS'V4^_TO\ "6V5_HUT%E55H L8UX:X/:'
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MX?Z?_P"WF*M99/UE_H%'_A_I_P#[>8JUDE*22224YWU@_P"1\K^J/^H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                          #_X4'V:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60]
M(E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS
M.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 Y
M+C M8S P,2 W.2XQ-&5C8C0R+" R,#(R+S$R+S R+3$Y.C$R.C0T(" @(" @
M(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS
M.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS
M=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS
M.G!D9G@](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F>"\Q+C,O(@H@(" @(" @
M(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO
M=&]S:&]P+S$N,"\B"B @(" @(" @(" @('AM;&YS.G1I9F8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO=&EF9B\Q+C O(@H@(" @(" @(" @("!X;6QN<SIE>&EF
M/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(^"B @(" @(" @(#QX
M;7 Z36]D:69Y1&%T93XR,#(S+3 S+3,P5# R.C,T.C,Y*S U.C,P/"]X;7 Z
M36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C,M,#,M
M,S!4,#(Z,34Z,C0K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \
M>&UP.DUE=&%D871A1&%T93XR,#(S+3 S+3,P5# R.C,T.C,Y*S U.C,P/"]X
M;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%C
M<F]B870@4$1&36%K97(@,C(@9F]R(%=O<F0\+WAM<#I#<F5A=&]R5&]O;#X*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S
M:&]P.F1A,S-D.3 R+3-C,&,M-3<T."UB86(W+64V960V-#(W9&,S,#PO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#IB,C-F-3AF."TV-3-B+68W-#8M.#4W8BTT9&8S-3AF-C@U8C4\+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33IS=6)J96-T/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3XQ/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-
M33IS=6)J96-T/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T
M:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W!D9B!T;R!A
M<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU961B
M-60V,RTP8C%C+3<R-#<M8C P-"UA-C5C,C9E,CDQ93 \+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#,M
M,S!4,#(Z,C@Z,C@K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R-"XR
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z-&%E8V0X,F4M9#ED."UC
M.#0Q+3AF-#$M-C-A.#0R9F%A9#<Y/"]S=$5V=#II;G-T86YC94E$/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 S+3,P5# R.C,T.C,Y
M*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C0N,B H5VEN9&]W<RD\
M+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC
M;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO
M=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI
M8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%
M=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z8C(S9C4X9C@M-C4S8BUF-S0V+3@U-V(M-&1F,S4X9C8X-6(U/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(S+3 S+3,P5# R.C,T.C,Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @,C0N,B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C@S8C-C,S<S+6(S9C$M-#@Y
M,RUB.61A+3 T-S8Y-# S9&$T,3PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.C1A96-D.#)E+60Y9#@M8S@T,2TX9C0Q+38S83@T,F9A860W.3PO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M=75I9#HX,V(S8S,W,RUB,V8Q+30X.3,M8CED82TP-#<V.30P,V1A-#$\+W-T
M4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^=75I9#HX,V(S8S,W,RUB,V8Q+30X.3,M8CED82TP-#<V.30P
M,V1A-#$\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X
M;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E
M<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@
M4$1&($QI8G)A<GD@,C(N,RXY.#PO<&1F.E!R;V1U8V5R/@H@(" @(" @(" \
M<&1F>#I3;W5R8V5-;V1I9FEE9#Y$.C(P,C,P,S(Y,C R-30R/"]P9&9X.E-O
M=7)C94UO9&EF:65D/@H@(" @(" @(" \<&1F>#I#;VUP86YY+SX*(" @(" @
M(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D
M93X*(" @(" @(" @/'1I9F8Z3W)I96YT871I;VX^,3PO=&EF9CI/<FEE;G1A
M=&EO;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L=71I;VX^,C8X-# R,"\Q,# P
M,#PO=&EF9CI84F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I
M;VX^,C8X-# R,"\Q,# P,#PO=&EF9CI94F5S;VQU=&EO;CX*(" @(" @(" @
M/'1I9F8Z4F5S;VQU=&EO;E5N:70^,CPO=&EF9CI297-O;'5T:6]N56YI=#X*
M(" @(" @(" @/&5X:68Z0V]L;W)3<&%C93XV-34S-3PO97AI9CI#;VQO<E-P
M86-E/@H@(" @(" @(" \97AI9CI0:7AE;%A$:6UE;G-I;VX^-S4V/"]E>&EF
M.E!I>&5L6$1I;65N<VEO;CX*(" @(" @(" @/&5X:68Z4&EX96Q91&EM96YS
M:6]N/C<S.3PO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^
M_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_\  $0@!" $. P$1  (1 0,1 ?_$ !\  0 " @(# 0$            (
M"0<* 08" P4+!/_$ &T0  $!!P,!! ,%#@X,"0L%  $% @,$!@<1(0 (,4$)
M$E%A$W&!%!46D;$*%QDB)C(S-C<Y<G:A\!@C)2<H.$99E[6XP='7)"DU0D53
M5F)WF.'Q-$1'4E5F9W6"0U=88VAS>(6&AY6BI:>RMO_$ !P! 0 !!0$!
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M31$(!Y /KT1+#PU$#@/4B:E$T1>I^"7+UD$ EVT ;!H ED@?2G!S;&H<"6N
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MG E0K;'C/>8;9Q],R1GBQ%CJ#D<C8V.7?RXHJI*C56J6ES_-\ F3>M0,#"3
MIP\+"N(L,.G$.ZBGC+MAABUV666&0&0<@#-^==%=G.RFP,1L+9=;%;+PM2M4
MPE.HZIN$.<:DD%QF"2' D18@#DN.>U_;GM9A.TNV\+@MMX_#4*.T\53IT65
M*+:;7C<#&QO ""-"1<R2NB155:D*#MERH3BN1;#$1#QC+#V*9:9$1!O6'\,\
M%P#WW+UVP\8N;,MLW )L=>X.R79QAFGLG"-M!.X9(-C)O:YM$1>UUC%3MWVO
MQ%(4ZVWMHU *K*P#JK8%2F06$" 9#@#)R(R(LOZ16>K/6>U_-O\ C><#K=GQ
M)Z\BY%['5)['=F--D8;2?1@V\2?@%7_\0NVP /Z1[1-Q_.MSRM8\,ARU%I<[
M5YRFZ;G\Y,S0MQRVQ!.T)N#:CGX>F':?^^WI67=@"&7C+MRTW86)9=C^](UJ
M?RD['V;LJILGYOP5+#-JC$;_ )H;N\ZE!+BW7=:=T1F2;%;V\C':';>W?GX[
M8VCB,<["G .PYKN#BPU3B6EK3 @$LF3E Z*:S.66;\V%_B\\ZUF,A' +>BYU
M*)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBK+VF?? NU<_T@;1/Y*DF?
MGG1%9IHB:(FB)HB:(N#P?4?SZZ(M2*L6*OU8Y^Z9/V?"\UJ_EQR?.P(XS U\
M<L^[J->"GV>OU^WV6NL<]1USZN3F^,9M?G-B+8TRSTOQBWMUO;HGCK?DG!MP
M;#CPSX\GP-CFP)/5[_'+6.'1,^ ]G'U]?B;W:]D[]J-8_P :);ZWM^I$5^>;
MGQ)T'C\.[A90K;FOK6O4?DT-@3P!14R51;+52)W!P/A&K6.0!WHQ[U&<$V\,
MYY%NJ>S#B>S^QW:G9N#-M?U0D03PO8\.$+@[MN([7=H/[UQ<<)\X0)@1Q%X]
M=UT3!M<^ P+7QD$BWJN0;];ZR#Q\??ZEBU@<X, </58QK G/N0BXN+FQOP+]
M;?DP>E[G&-$C._JZG/3C(C6- IO;-FN\]GO!!]'+I/@<K( Y'0"U@+LL^!SI
M;RM3.Q0,@-H1K?S=*>L&_'KDNC?()!':,B9(V63/_/C"(&40=-94]V/K&?P6
M?D&M/C(3P"Z-7D38$^&=2B]?IG5^[Z1B]RS;O"_>9'>:9M?ZX @EGD Y&BB1
MX]_3FCM\Y>@%T]=O 666KL-LM#NMCO,'Z4G#3.6?$9&-(/!2O9HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(JS-IGWP'M6_P ?]HG\E23=$5F>B)HB:(FB)HB:
M(M2"L0)J_5BP_P"4R?KWZCX6*V/Y^?5;&GBZG*(X?AE>-?80 L<DBP\KV(MZ
M_'I<9SF]C?.HO^'#U7T,93D4\>.7XG5<XO@FS5Q?K?F_Q'QN 3<BVG3CK.GN
MXY>^5'XV5VG9._:C6/!'U42WSC_!$7Q;%NGGSJ45MS?UK7X)^0ZAV1Z'W(J8
MZH#]<B=\D$S&J@7-R+13V^,9M;DW/@-=4=EOL_L?(_LS!:?[H1.MCK%N)&7!
M_;B_:[M#,C]J8P1S;6=<6SO?K!!71N;^7C<$BWJZ>!X'MUD' \8Z>_ND9F-%
MBN=H-LKYZ9WTF9$W[T&>OTN;BP^,C)XL2.2/_%=QSGO'J/><ICU!2.NG&^6?
MCF;V4WMFI)>SW?%W<O&US;#2P+WSR #S:QL+#6EO*U]+8QY;0X#^;I$DQ',"
MXYFRZ,\@AEO:(FTC99X_QXSX7T-^A,]V?K6?P1\FM0#(= NC5Y'@_P W/\_R
M'4HHROMJE-'ZJI++U2GGW8IJT[*[\,SFM.X=U$3TF!*4W4/#B(#MS#I[@MOD
M1V ?>Z+>-/V&FR&&68L1%B.&80F>7</;'M]B[M3*ALF4G4%)2EB)F5\_4T27
M4!^PNS$HK,.Z@)9@S IQAG,:]>,.(EZYL8U^P.]$O&&6K.P"RU47$YGQQ^],
M_:LR:B1Q1-$31$T1-$31$T1-$31$T1-$31$T1-$59FTR_P!$![5OP^'^T2W^
MJI)M_P _S!%9GHB:(FB)HB:(AX.B'(_'+O6I#6/[K]5Q;FID_<6)Q-2MQBXO
MB^/C!U'CVGQ^:D^/'O\ $8YXZGG'GCX@";&^0<7X.GJ,>RYZ]/7Q4(03ZCU(
MX\\8/-[X-R>@.GK_ #]65\M,[D*?5IRTCC^.JNU[)V_P1K%?GX3RWX7_ +D1
M>3;Q]?Y-3X^]1[SFK;6_K6OP3\AU#LCT/N3QX\>I4QU0^Z3/&<&8U7D\?V8\
MSXW\Q?Z7C&NJ>RWV?V-;_-F"O&?ZD:]!?F2N#^W /Z6]H23_ )UQDS?^>=<7
MX9&X([UT:_ASXFY !OC-SYWY!L;7R<@C33AXTY:K%M.&DY\0/@==>J V)[S1
M)9#1%\W)&+=.O%[ 8-^#'01E[#?XQUGFJ=1)T,&VL=;BW]*??-[9K?TT^?\
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M;Y[]6.OZYL^@#_ZL5L9Z9MZAQ:XU'PS[[^/Q!3Q[_!_-8\'7!O<VR,CIX7'
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M+'!M?@\DXQ;G!-N>=.OLGQW9*1G86DWF8XYY3I&8,B-9O[-K%]/A'^+ET&X
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MCP;\>!]NN:!D.GC-=!.$@CC[]/:M"?M<A?M$MR>#_=R3B+^)II)7-QT&",V
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MHO:U]%.7CB/@#/JLL<CP(X\KW%[<'( L./6?.,K_ !ZG7CEI;A"C3QXTX?!
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M1[N^^7?DM";M<A;M$MR=[_W>D[CK^MG)(]?/0<'' UU9Y-OLCL?^PK?]\^/
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M<@;?*AWO>_VR2%C/2_2WR8UKY4@#V;9NW_:&'S%\GSG;06]ZN86/E+(RAXS
M_A-X@$S;IFM]77/:]A-$31%69M,^^!=JY^/^T3^2I)N?YO9HBLST1-$31$T1
M-$7!X/J.B'(K4BK$/UWZL<_=,G[ &2#-BL?$'FXR/*][:>+^WQWIP\2L<FY
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M)[P-3RD&.Y3>V;7]//9N#^E2\#GH6ECNWYR!]+8YQBPQK2_E:^EL;0#YPO\
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M)-^,2!/6UC).9Y\HM-S9L2'L^7_Q4O&Q/^<LB][7L  3?U$8L-+^5O/8T?\
M$.1D4J))\9B<Y"Z-\@GT>T0C39<1>1OXP?#*3UR4^&?K&;9^D'R?GUUI_2>6
M?Y+HU:B&]G]M;7.P_=XK$D6!O9S:_MZ^SG7;?D_OV*[-Z?L]L2+?O'\) \!<
MB=J/M1VCC(;7Q1D'(AQC.,YY>T*+747-A\=B!D6-[&_](UE_( ].(S]T6[Y7
MB:B3 ]<$"X@S!G[PAN,'D6\K >!^(\'QYOH--/;QT\<4,C.Y%N! D9&W '(\
M<Y5S/8X9J!60C_)&7>M_\,1?F3UZ];GI;6B_+I]3[$_O'$CE;"\L])^,K:GD
ME^O=I$:[+&N7^%TH$WSU!,R= 5?TWAVUY,GY,^ ^0:YI&0Z!= G*_$>\<5H2
M]KEGM$MR-Q_AV3@#U-Z:243;BUR21D>J]M=6>3;[(['_ /IZVD'^4.SGV+EG
MMY?M7M<01&*81G(&Y:.)$Y&XFU@57"<\Y&" /,_$;G&<6S>]]9][?Q\1[N*P
M\Z @6T$#20!!)()SN;77/F;^T]+'ID<=,7M>V+:CQX\>Y1FZ^0)(N<QE)$R1
M(=GPSS5_WS/-^V;K5X_.+?8.;?5W*0 Z6^,_EN=.^63ZIV-_>;O7\G=[K@\R
MMK^27ZWVGQ^;IO)SKT\R8/=GQ)))6WVSP/4/DUSNWZ(\:^)70*_.T[?7[Y_7
M#/\ @&EO/-_G:RMBV,8OQGP -M=.=@_LEL;CN8[I_+\1TN;?C9>/B/WM6W\8
MT_W8Y\XF.&9%J;V;]WD7\;&UST\L^/4\&X)S)N4F<K6$1)UZYSPDF,K /X2=
M+V^-X'$+DXO>Y!YM?U^.<YL,VO>X U-@#,'IF1(OSO!GC.F<VRGU:B=9/&.!
M%Y$ +8&^9L2/H@RYW1:^WNH7(R?JDD(WOZ^G]&M;>5'=_1RG /UAAS['B)/2
MXGOM:]A?Y2RUH?\ ^TW%S[SJM]77/:]A-$77_A9*OPB^"'PFE_X6>]7O[\%_
M?E.^$7O'[I$'[\^\GNGWR]ZO=A$)[X^YO<?ND^@]-Z7Z307) N6_2 N6Q ,Q
ME!(%^(XJ"0T,+C J3N$V#XSW2;.C6%77M,^^!=JW_G3_ +12/.VU23 2/(8R
M/'XRGAX\?GP5FFB2./+OX)HB7'B-$31$T21G-N*X:P#FV#F]ORZ(3&:U(ZQ,
MDU?JP+-7^>;/PMW3?$UJX(-Q<&^+9(/0V&HR^_QD!XN5.@,_G DB9'#6>5EC
MHAJPL#?'%Q>]P.,^!Z8'3@/7:T6S%];SU//FG?SY<+<^EH&NG 9/-FO.P-AX
MW+.+XQ89ZBY!#2.7?[?49]B6\>WVY>U7:=D[?X(UBO?[9Y; OU'O1%_'S_M(
ML3/CQ^2@_EX\:PK;FK=UJ]K6-[\<:@Y&>"%4QU0:8-1YV+)!O,BJ18W!9,6]
MSW@<FQ9L<WO?@#O=5=F7-_1_9$%H V=A&DR+.;3 +3<P00003(RZ<&]MC_C9
MV@-S^U<9&L@U3<'4',$6.? KHHY!9[W-QR1; OGC.+@6L+DG7N[S?Z38ZCK[
MK_!8P)C)QRBQ)OJ?=W&Y*Y%A:]LLG/ATX%_ 9P<\&X.DB]\B-<]3J.,9Q;+1
M0 ;6S$<#%^_NT.ITFWLV:9#^>P6@#Z&7S8M"]F6E@M'QLS<!HG&<W%M:8\K)
MWG;&#;D?+I O&]3I!I,7 <00.,$<5T;Y!3;M'-O1V9G&C\87<S <TDS:1U,^
M&2 [9)( # )).   2?4!R=:?M$FPB\Y :R3[9[UT:M0_>L>]NMKH0.\#/:D0
M1=H'O!T;BY(L;@C@$8X(MVWV !_0OLWG!V93/K>\^HV,\P<H7(O:?=':7M$=
M?GK'B3!MYT;OO,?PD"!F5%T@CD'%^0;$@G/J _+R+7UE\$Z>J21D9^Z<[KPM
MX?T@2+9S)DQW7@<R+1*6OFUL>!L<7O<_$3XYS<V<LS,:S:T=]HU$9*;$Y@&+
MP<[2)DVX&=;WO%RW8YM,L5 K'WV@QWI2ET M$,]XA7C+@=ZUR; XS[<ZT5Y=
M2&[&V&20)VE7:V2(<YV%,-'%QT&<2MI^20@[>VD 9(V2TD3H,72EQ!Z"\:QG
M=7]MD>B:M8_2'GCC'/QZYJ%@.0701R_._*U[\M%H3]KF .T1W)>!7)-:9S@@
MTSDJQ'0 ^(\ ;XUU;Y-FN'9#8I+3NNP]4M)! <//NNTV!' @E<L=N_M3MF]_
ME+6N;G'ZL&#G!UM<")(R5<(O>P'3H+FP'M\[<\>5]9X;$ \9(F#'JZ?'GA_#
M(2+F0?:)'/,Y&,[<6L#;UWZ>OF]SXD\&QXL9$G+AIK]_101()!)-\LI(!',:
MYDG/0J_[YGE+/Z)JM(N!>A;T '!)^'<I7QU]G@>@UISRRQ\T['&HVD21J&G#
MOOQ RO:]M%MCR2?6VTQ_PZ,H!BO3F.(!MJ)]NWX,,@G L/DUSNVS1-K=/R70
M.>2_.T[?,W[3ZN0Z>\%+ 2"< TTE8LW-L=ZUQ8"_=-NIUTWV!^R6QR+C=QLD
M92<=B#>.(D]%X^((\[5@@G?$Y:,%B._U*F]DLV(:(QD@]!DC!\1F_769"UI@
MR=8O_6[Q$6Y$JR(U.LP9@F.G&)Y:E<WQBU^I)\!?/7^@>' JG41,R?2! '">
M<6MZH"&,\SK?IQ'6P! Z"%L#?,V1_M@ZX6BR+;>ZA"]Q;,R2$!UQ?-K\^LC6
MMO*G/Z-L)N!CJ$EIM$.%S?F/9JKV&_E-/*2*@$7D[O.<Q.LV]>^KKGM>PN+@
MD@$$CD7%QZQTT15/5?[->.K1N_6JYK]1&Y9I],$JPD''1].%F<J>[@X13@Y-
M:DAW)Z-5"55).C$JFSUGT<ZQ$)!QKF+>S2'T.\@'D+$-QK+"@8=V(<?UAK-J
MM:#,-%:IA7N)O=S?DT,(%M]RBJ7/\V&Q$M-3>ONFF:^Z*0_A:\5OU@L"6-BP
M7H2^QKVRHLPS5-:35_>^ES).[Q&?S>MIN].OD"JS+$R^F.T5&BEY2A9M=1ZQ
M$)B.YATJ >J43%-02=#N(*%]##NP[T4KLA[)NAK(N=P._P!P+_MZMQU[9\)W
M!_/PT\>/P]Z>/&:^8Y[+;;O$O_<T-N4WVOXCTT5#&'<[]]PK;X/X NQ'.?0N
MY[:>E[!EZZ9BW?=[\.T\=A\RP6F=6R\"X!(D@D&8AP:3>Q <0VTPZ00+J2"+
M&Q$>T2/6+CDHC;J^S=39'G7:8YIEN"WRL2G,>XY)1:Z1"MOLK@Z=P5(FY!GJ
M)CHMS$+=1(1Y#OA-[F48</D</U3^RF'#MUZ!\^;8%[=X4[FJX.=3ICZ3VL-,
M/<#8 --2\V(!O!"08+C9C8!=GZ1R:!J2+B.F=E*=]V9NV1Q&J4!$;I-[\/%H
MT %58AW_ &@=>W,0E)S0[WN]3</)_9>P,$&;->ZXIEU#D$$/#J6N!!,Y.+""
M<G"Q%\R+ \'6/I2J23O;L&2T/&5VDQ(Y9>V,BOM0'95[?U6#AU!,W';\U& B
MW3$1"1T%OSW$1D'%0[P!IV]AHEQ/3UR_<MBS3#QVVTPT#=EH@ZJ@BQ!:1:,M
M,\A&?#A;) 0;B#?W9KVQ7924&@X>(BXK<1OXAH:'=/'\3$/]]^XMRX<N73);
M>O7SUY/#+MTZ=L!IMX\;:9889#331#(P) $G(#QFJ@"2 !)-AQNL#1/8R=G@
MJLN)BB:K;D(]B9E5\Z<+;W>O5B)875R+?/'L0X<*#<YO':FJQ$2T];>N73U[
M%O'Y;+;);+6ALYK/XG%P:T&"2SZ0:!<Q!F 8@\(5(,B1E -KB#E?FHU[D.Q8
MV\N/G+P>W68-S\T*;G<_19"KHGP&[.J*Y&2U0U55XSYY*DIP;^< _16H-)9<
M/Q&.F&%1PPR7D$Z;/?U#'"HT/:9!'JDFQTD1U&MY0F,[<!J>@ZSRLI!O.QC[
M-V'@GZD_JKN$=)T-'/$Q^H/=Z]4V(%RJ.V2VVFO(QJ<V8=VH,,,M-M03;P1+
M++)+3H,LFT;UP#(WBX-)UW PF!<Y/&8!@3S0D"1F0W>(&8!F,XSBU^'%9&D+
MLCMFB&TL)E,JZ[OTQX'SEZN)TE[Z*VPKUE\RRV[</%2%1IW9>.W@8#;MTU%L
M,M]WO,L&P:&J@9 +?2&IX $B3W@^HZA"8=NN!:XQ -ID!PCN(/>%DKZ$W0ZW
M[8'?Y@$YWU;C2"2.MYW((QZM3X\>.JE8]BNQWVBJ2NH0CZL.\*-78=V[459P
M^WJUSBE1T[C2V7,7'N1.7NMVS%%V\:=1#\!E^7;WN--EDZ]$;<VEAZ4-VABJ
M5&DVS65ZC6,:+P # $:"..07BO[.["K57.J[&V77JU'%[JE? T*U1[G3,ES!
M>9),DGUJ*&Z_LA9#AJ4R8M[6)_W?SG-$;7.BB9,!2=WU7E^&8I7%U+1$ZK2@
MP8^=Q!,LI,G%9?/8N'?-QJ>]<%[!NVHIPPQJY\_;8,1M/&@&"(Q%7K_2ZD=8
MU5+>S79W(["V*!<']EX4G,BXW1&@M$@*6KWL6MJ##+3353-XK+++):-]XE>0
MR +W:/U9&PM>Y)'UIN1;4';^V '..T<= :3?$U,A>_I SW1;6Q4?HSV>-CL+
M8HDC_->%L28L-WG'1?4ESL@=M"=#M14KUMWL0,*I.8=\8I WM5^AW$<X:=EY
M#/0^@IT#N(=EAZ6W+QEMICNO&FF+AJY^3$[0QF.\V<3B:]<4CO-\[4<\C>:#
MNC>)(%P[//B#;[L!LW9VS36.!V?@<&:S=RJ,+A:6'#VAUM\4@-X@@P73:R[1
M]":H>&;#<#O[OW2+'?3N-[A-L=YGX;V+-_[VUB,<:^0 M$ EQ'$D9<Q<=W="
M] F3) ,F2")!Z@V,Z@YK$<P]AKL@5(Z-F*:IOW31ZFHQ0B%->7MVM9HF,CHR
M*>L.F7L:H1\TM/7T0_?-NG++;Y\V]>O6W;MDEHL@Y'A>UW:? T*&#P6WMJX3
M#4&>;P]"ACJS6,9)=NAL@  DP!$6B!(7BU^SVP,56JXC%[#V/B:U9_G*M6ML
M^@YSGZO)(G>.KB2?:HF[S>PUHA*] 9B5ML+O=!,%9'<XTA@T5,=[DZHJKQY+
M2E5Z14ZI$0()5F=B :$#36+FR-:?O6@W",0YBH<-13J'9-YW;7M>9WNTFW'Y
M3&U,2TF(R#3&EP-))L"%;'9GLV#;L_L-@_A V7AX;-HF-;3)G.,U)Y[V$>P=
MP70B%S<K#F)?L0T.7VZJKCOW1$O62TZ<. W,S/I7SP,-EVZ9NVWW6BR&NZ;#
MVX[9"!^E&W).0^<*LF)F 3F "3RX!5#LSV:,G]&]A'=O/S91, P)/*2 "=8O
M==WE/L4-I<B/XJ+DBH>\:3XE0<NW$=$2OO"KHA/HQRY;+QTYBFTR:W#40Y8>
M--/&';UIIEALEID!HDZ\S:.WMM;9;1;M;:F.VDV@XOH-QV(?7;2>1NE[ XG=
M=&HOS7U879&RL ][]G[+V?L]U5NY5?@L+3P[JC =X->6"7 $"Q,1I-UWD]DU
M0XC.X#?W>V;;Z=QO=)\.[\-K=V_2W&.,:\L6 UB+FY,<>/->D27$EP$N))#1
M OP&BC_/W8+]GG,*FISW4I9W$+"RH/85M<G"=]U-5HY0C7C#N&3H)I275F9"
M^?-L.G4) PQB8EHAAB'A7-F67;.O1H[9VKA:-+#T-IXW#T*3?-TJ5+%5:3&A
MQG=#6O NXDP +G(E>=6V1LS%5'UJ^S-GXBM4=YRK4KX.C7>X@ $DO;-@)+B9
M &<643-YGS/OM6EW:Y628-KLGU[F&OR?*3<12Y)<5[J JO%"8PH0#+#IU +$
MPL)463!-Q;8=1;0<M 7OWN[J\.T&W(CYWVK:Q'R_%-@B0?1#C<96$Y@1 5D;
M"V*X@_-&QP(B?FS"D1G;T28X::P=9%N_F>KLV(>&A'JBF5O@WC\PT."_W&U/
M<LO(V(9 =P[H-S%9M^^?$.G+E@EMX\LP[9::U:;VBVYO-_;&TH>XL81CZY#W
M .<0 ' V#"8MEW$=A;$$GYGV.=T3]6X8>CH[Z,7)X=X63Z?]A1LEI:HQBU3&
M9-U5/E>/@O>N/5I(W75HE>/C4XOG,4U 148C3/"Q$1"^Z7#A_P"YGKTN/3.G
M;WN=]AEL6\7M+:&.93I8W&XO%,IO-5HQ%>I6+7[I:(\X3 C/=C6,[?1A-GX'
M!.JOP>!P.%?6I^;>[#86E0WV$@D$TV@DR/XITR663V3=#R,[@=_9:MG]G3N-
ML3X6^&UB.EB,CGI;X&RV"3+A>\D$B^0T-K#N7W"!E8#)1SJ)\S^]G+4*9GTY
M52=U^GJ<EQJ%@8F:)\W,50F*8UAY 07H("$>K"ZOQ*E'-PB=!EU"0[40]+B"
MA"PZ=LN7)#/W8?;&U<#1IX;"[2QM"C3;4<*5#$UJ3&@2]Q:QC@ !Z3C$ "7&
MZHW67<6-DN#;CZ3C#0+P"XD@""23 !T40=T7S.]L*AMK=>)KVN4ZJA-];DVE
ML]1-'85*K?-:^Y4JD)Z1'B6X%U#1RV$=0>^_;EW#/(.,B&89IZPVXB"[LV!>
M/:+;X /SMM,M+2X.^<,3$2(_CD@@D@@$6-]5.[3)<(9Z!(=Z,P18@Q,$1.M[
M999SD_YFZ[-"(DZ5HN::=U8AYD>RXAOIB<MURGUV7*X]3(1M6=-,.E0N'9=1
M[<0R67)]$SW;,?26.JAVBV\0"-K[2@B9&/Q,#7^F#WD<D+:?^C9I:.-O5XY+
M+=+>P,[/>F*O\-J.1>XRGB]')+U-=S737=#5B5E2,1%!N'BGT&%N7)AA(J(3
M(MY#0K]N'$0U"OVX=P]:9::=NVF;&)VKM3%L-/%[0Q>*I$#]5B,35K4YLX.B
MH7#> (BUIG@4#62'!C0X P8%KN;8W@@@W!T'!9]^A-4.Y.X'?X3U_9U;CK7M
MG]V_M^2VO@ @ 2;>V\^.152FQ0.A,M;=I$-/94FJJ4XI/ORH+@6*P5-G"K4X
M&)4V89A_"M39.ZFJK92W A79@DWW7[C@RV_:<.F&GSPMRBS9HB:(O%L$L- &
MQ(-B>AZ'V?F1SH<C"*A*8.RXW,I%8ZLU=I1N(3)5<U26=R,WQLF-3#-R,[@)
MQJU5.0UA$CY4G%$17LS4\;F^C4FBF%0E&5'HB);572;.\I0JNNLQ,0U\N'#J
M>$90K%I<(83!$E^.?B:C1E#7-%,  6(, 22KKZC7%[B)<=TL+;- I412I2)$
MD3+B9WC<D@ +OE:.S_W%52HEM;E&:8JA%=)YHZI5R,YIVX689\G*3GJ55F6)
MTE>3G4!-"A)LQSC/:I2)+F-$@$Z8IIA)>F*:V9:85(M80U91;B89B6&IB!7W
MPS?P%;!N>W=;YNK5?3<<0S/=NP AIS$B-*6O-,@M;O@8ZEB0QQ,%C!]!PD;X
M/!\SK*CPJ]C[7DS)4YN'G*BTU(DX4D1)&4UN<(V=_A?5)60$ZAD-"14T*3N6
MU6<::QT9%4EBXQ<696J;.,B+L9%($6JT/BV(1<A5JZTL<^OO, ;6Q%:NTM)!
M#JF.;B#)_HELAPB'N])GH6%IQJ 4',< :-)M)Y(!WFF@6N M'[WT@<P/1!!N
M+A-CM#9\VX[:Y%I#4A7E%9FB6(R;GCU_(Z8FI<NPB6N3BO+Z$DN&4>5)#3%*
M.1T94@4Q7F"#DF4G,Q*L+&+3,O)7N[W([^JM4%1S70)W&!\  %X$.,"PGE90
MQH:ZI$[KJCBP$DD,,;H).9%_C>5E/</3M4J]02M-*D.,3T]9J32R?)%2H]5:
MB&4N"49JEA31(.*46H5S$13,##Q$:[>Q1AX=^_#AELNG3QONL'X\2QU3#UJ;
M"&O?3<UI<2 '$6)(N+ZC)?11J>:JTZG]![79 Y&<C8JA*9^Q[W!S @R_$(CK
M:=3M=@YL]]X*2Y3,UQ%,Z;OH60Z3R4U.Z(B3!3-4D^H"W.$93N.F2H<MJ]+)
M+BU*.C$-F6*D2LJ)RZOS+6XAM<U*1.Z*U=U,O](TZ3WL= !,&2#Z5G$$";E4
MC<;AQ0(,-9APTBSI93>'RX02-]P(F>^%+BA79X5EIQ5[>/,ZC/=/)-E+<?*%
M5Y>156G#I14)]AYHJ1.TVS0G3^]4YAEB FF3G\M0<TOB^D[YYE2)=BIE;>K$
MJO9"2F(>7F*GAIP+\*P02:;*;Q8LI@ '><""\N,N!=)YR5;#CY^A5?ND40=Y
M@  J";  "Q S,2=9F\=)7['ZK$R1<FH-5(_;M(M,I<JG16<8V2Z%2;+ :CX*
MD]"ZSTN5)D:C9LHLY<+2U.LPS]*ZU\&ZAP$_Q4L0:;,#3BI*M$QB9#P?TTJK
M&5:M5S&O:Y^(=3HG*D:U-C6WF(;N-   L.L_.^D_]33IU):S#T:3ZK@2ZKN.
M&^2209-R7&Y)TLIT;,.SDEK;%5RKE>528'RI46H,ZUP92TU A)52)-1:;5*K
M#'5(0("(91I%EF:I@F:#3G:!!1CV<ICFY-EI\X4TN1649!BVH=[\-"D:=.'?
M2>UX>),0ZO5J-@$F##P)SM$P!'VXBH*]5SMT!K74RR+&6X:E1)/_ .KB!E>8
MDF+.6@2PTR+7[I OQ>V+ZO&X(F)&?#FK:JL1]EM9I3WDUXW&H$31A50JKIJN
MCN6)A?38YFQ?19T2:%(*D@S\[3D-J%446E\#228HJG*?#KC]PHMU#6(%Z)0
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M31$^AH5 _?/^TK_A?I7_ %*:(GT-"H'[Y_VE?\+]*_ZE=$3Z&?4#]] [2O\
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M2Y- E^>49T\A6YDE1%84$YJ+^@TWM +XSAP%RVPL;V,7UF_!4.&Z0TD$N9O
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M+;U0;M1PF(?5;Z+G"^Z3>YFZVLYC7[MGU"T/J"SW,94J5&L<1$M!>TQ_4$9
M*2&V?:9)6V%U,+J4YFG&9F5='DZ44SX6F5F3+4A4\<K+B1Y-3!*LL2P[4(27
MW4Q+# 7IC=K<X*S,2Z96YA468.##F\'$B"!-I<&[H( AMLK-@=T9!6W$O=O.
@,GTHY;SMXQU<2>_URJT4)HB:(FB)HB:(FB)HB:(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g491933g95a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g95a09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2"04&AO=&]S:&]P(#,N,  X0DE-! 0
M    ('2^@P@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!JUVR
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             #7    RP    & &< .0 U
M &$ ,  Y     0                         !              ,L   #
M7                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M7     !29VAT;&]N9P   RP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   UP     4F=H=&QO;F<
M  ,L     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   #.$))300,     !8:     0   )<   "@   !R  !'0   !7^ !@  ?_8
M_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" "@ )<# 2(  A$!
M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MMJIH:]Q!&UWKUES'?NO:UGO6E0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( 8$!:P,!$0 "$0$#$0'_Q  >   " 00# 0
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M]1B2]3Y-U;49J()N4QL3$1FLC(:C^IE,N2WJ3*N2G$D)>D/ON!#07\M'B_\
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M+8(T]D<0R!@Y<9MM2'?DPW&VV7XS:T?BX#DF XK\-(<0>F,AJ-;)9ZEJ"?\
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M^F?*Q\Z0Q*BQ5L*0^AYYM"%L.(?22RH+Z?[^_P!<'$<N[--O[F!WC'7C=V=
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M&T"FD,&3%@P<"+8\^[BM2EGXU55>\JU%$E:ZI<$E1ZDJ>;C%[=F=NS_:G_\
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M,E2.TO9QF-/T[3O%NN5J:*]31M/7GZU-2TTZ@RN4I5*^8-)2W2%!%-3$L"0
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M*L"/^4RP(XG:HABF2XY!QD3XR5^GXJ^_Z$D)2.Y.H0E( -#YR:.]U_Q!%60
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MEZ1)><3\-_:M5R'WWBEL#.#Y:"\XLH;3?TMVE  /H2FE=;7HJB,C4+GXM0S
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M<?<##@CGH!Z.P\Q \B#&<<2.#+FXEQPT\N[\8!D\P-AGM0B__P!?YKD [_\
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MJ"&XY(^E0V*2I)2;"@3?D]<TSU(A63;G-40U@Q6+#EWG'HKQ'02VDE24J_\
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M_4HM"P3P&? '^1YKH0.@Z=(OQW;RG%N\_.?1_IT?M.$=.8:@1B,95[_U*)1
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MNP^5"LMBTDV%Y&&A2"$D>A4AM*TJ20;"@2"DV*YOKMS/T2G)9M33^'JFQ/\
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M#1RM17N*:1+)93 <@L'@=1<V@XW_ -N>4S*/:UXZ34I+25:W4J(2I*AN0:5
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M3OPV=S7X<ZG6S1WT@:%>C74G+#^G>JCL@!DJY8/9^$_982V/B/7HV;W*A/\
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MZR_E?5Z@K@<[6?/VJJX!)VY]VPN8]?OIY87@^5W^1'&%\GZ;L[_ZU?*K.YL
M$^39V-MBOMNGKS@S21:+\'Y1#QZ'J_E>ZJ/') ]QL#=\C@;U9&X%V'[Y_?KP
MWSP91L'M]>]HYE_H"?*L *5]ZV') Y(_D/N">=NIL5V^<S?[[&;83]^4\O\
M3]#A!H#R;KCFKNR/:MQY!\C;IL59OE'[Q^N!!$M<R;%^]Y\V=OEQNL@-.J4?
M4 @T*-$_Q7="P-Z^XW-;="D@.>([G OU9^8\FO#]Q(QFYO\ LV_\"?\ W1UC
MAC%69)&8R V%KC _3O\ 3$9'D@@$C_BF[XZS2DP01?KY']8\VN,1G/\ MK!R
MS.X#V#7ZXZ'F[X%6:OBK %5M[FK'6K]_?W\L9V#7=C^W/[!^MB,/?C]?T/\
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M;?-KVZ[A',Q@"%'<5M]JL F^!]M]KY-;UTQ=K<-VB"&ZN7=X=C8G$1NRZ?\
MPHOC.!('^U>PFX! V[3,&CSX'Z_Q;7?07/F#/D/I'Z],%))# .SGBWTXEAT
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MIO#",,5AL?",5:%QUM,@.-+0G)(0L/*"EE01F,JVA962AJ?+;20VZM"HP?\
M:/+I'/J3BL6((-I,&&?B78])Y9XN'T'@ ; @UR#MO]@?4"!^EV1U;??W_C&)
M27!+N[@D!BT]0_:T< 6B/VB1_P"%E\8: ;].,^' ;FAOHO5WGCV^W@GCJ"Y]
M/TN/T]/ED7( AY>!_2P%W@O=B;$C$MRA1(\$[@<^*.] @\;?\11(N(00+$W!
M)(Y,7+3:>EH;#"#7]T<':R#L0#0&_P!N:'WJF,0'//()8=9Z\&]YZ87RS]5
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MO1^N#Y9!W-4-R3R1?V_X6=J!'3#:2X(:Y B XM\0]8Z]</Y9J]]JW/O0^U;
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M15=0 (@XO+Y8L"_ .]"MQN!?)!.YNR+-78T>][LQN_R[-YGSQ]^\N\.]R >
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M6$WFXDO 9VAO2)/82/1\)37E*O %D7["C9/)(.P-7T)Y8]I$DQP?UQ14+NH
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MTI (2FW"D>HH"3ZCYRIU342E2P4+&])0/ZT@CXR#T8!X/Q&UL?IM[L[/>/\
MF5^4QM#0Q/\ [.3+.V/12$*2"E06#2@;M)0:I25"PHG:B"037N.M7=V8$CN;
M"[$DDPW:9QIM_C[[!_DSA\!10WNAN3O=!)JP#5 GF_OQ=BIIAN'-[>9+'T+W
MZA,=3@] ')-CTC8"[4$FM]]KWV\6/IW-?I(=CV);M;YN3P'.#?-N>@#W]!QC
M#^C.U!T=W3[V=S%YU.03W>E]OI(PPQOX7]WCH;1Z-+%+F1,^2G*#*J0)J%&%
MCC#)$:I14'.L78DWXCJ&N'L>LM:[C&3@@#D.>S2?/&76U,O)]3+S3S:5K:*F
ME)<0'&'"TZ@J0H@J;=2MEU!/K;<;6AQ"%"NJ%0[\R0T/Q)+W+-9I$$8A'Z/_
M &X\OU=B#BI7RT)6MQ8;;;05NK6I*$MMIW4XM1/I2A(LDJ('TDWL0!4WJ0>P
M'I)@2T/SQ@ 3YS'E]^?I.*$%IYH.M.I=;6E*VW4*]:'$FBE2%)L+2H40M)]*
M@0I*B*/5279@+B'^?2SASY]B<@ %)"C\+B89G^4\3RYY&-1?[2'7^I(&J-"=
MO?Q$B'H^1IMS53\9M1:B:BS@S$B @3@*3+&G&(,20S&65-MOYEJ8ZTIZ/CGH
M_:_LSTS*5EY[-5$IJ9BBH(HD@*53IJ#J*02P!+C<7Z6OXT_BI\9ZYI&9\/:/
MEZE7(Z;G<I7S>:724JD,SF:>9J44T*C?F30IIIK*' /OG.YDMK3_ 'D()_IB
M?603:@!=!(_O&B4CTT -DU8Z[A5E0IG*X@" "[PR2 TCT,#G'B[_ *A(<[T$
MDRY8N!M<DDO ;R%\4JU&A2/E.*0XVXGTJ0KTK0I!]*2%-GZ2E0-*3L%5O=5U
MA3R%)>8"%J*4&A5<+8L?A(8DEF$=6.-1/B52*1/O-I%1-1/NS>JA]I#!*AN+
MNS2P#D-C=G^SYU[J?779G(Q\_-EY*+I+5DG3> R4QY;SZL.UBL3D48U4E\NN
M2DXAZ>[#C.N.*6W $2)_YNGU>>_'.0RVGZO5IY7:$KIIJJ*1>HI=0*+CDA*8
M#DDRQQ^D'\.WB?5/%/@:AF-454JG)UZV0H5*Q*U+R]"AEETE;B'(2:I2E146
M1M%L3T#8V-[ _P#1%$W1L#D'[6=P-Z'7#@;%C/#-/-Y':!-[OCO7K+MS'5N(
M^3V\\'HYW/.P !OVK<5X&_W-UU7NW]_/GCYX??3RG[\^EG:BU_H3266Q."U1
MJ_3V S&<%XG'9;*1(,K()_$-1 N.W(<;M)EOL0PH^D*E/-,H]:W!>)4 .]Q8
M^9B.O(?%"2?+KW9_/M8]L7@44*) H \?51!-$ GT@U0) !Y22#9HEO*)@D7Z
MP+=.@@'$C]?O[^9X?ILG>R#SO1YYL\D\ ;UO1!!!WAY-B!T>&-FZ$_)\6'_9
M_P!Q_;L06QA7&Z%T]VV[A=X^]&5U-\F/W-B]MHV5BSHR(\+!#0V-R.GX*F)2
M7W7IJLL[FT!;9CMEI\-,M_,^82,822H\V ZGOWZ\S$-BN2R;-<GH.L0(_OPV
M8)4J'!;;=FR8\1MZ3&B-N2'FF6W)4UY$:)&0XM:6UR),AQN/&92HN2'W&V6$
MN+6D&DD"0))#"\N1#<P_/;$ ?GS_ ':;DV'UQ1CI^/RS#DG&S&)T=J;/Q[CD
M=Q+R!-Q<Q_'Y&-ZTDI#T*=%?B24))+;[+B#Z2@]7<_D[/^X,@LQ,M#8$-ZAQ
M]_28[M..[Z*K?<;G:P>!Y ')^V^W'-!/?GBWE\GD2XLX&)@"+-$[;$["R0!M
M?V-5]@=K ZC]!UY;U@&_=N<5N_G_ (Z_?=FEOC??:^*V&^W H>0#9L^-TD_J
MYOT(]0>C^L2/OU^_G?"+>UD[C>O!V 3N>!QX&]5[]"8Z=&[. Y$ 'CY@O:\A
M_7[G#]'D&O-$'CS6P-\^GC<#?>@!+ EN#R3-V[WCIV$N6O\ 3['W&%Z-Q9LV
M/&Q KBS0J]_MP*H]5SP.MXMY _5L3 4#DV=O-@U6PL"]S5#8^P/4GS9WX<L&
MYZ'O:!;%^Q]?WZ0.<(I VO8GR+-"OYF^-P4^=[ Z._ZB\]VL>.>GY3B8 GP#
MO[?<;>:)-G;S5D7U29$ \=P]^.DW_;%_?[ZS;YX91M142=B?-UM=[#:]]]N:
MVVGDT="3P&EGXL/,O8O+T?\ VPO^\8?RQ1'.VU;_ 'WOVW!KBAQ9M+]6\^_0
M&>OH1< &A_O]O0>?3""38W(/V&U^=QXW-;60*VZH+R/F>EH^5HZ]L.W^/)_O
MUP@BSR30!^U"A9\>]"AM5\=0&?/OYV'UX<2+-A]O;J6[]^A8.TFA]/\ 0/41
M_9.6-ZL))XV&XXX %<W8A,>8+-/5Q8?/M-I"X\WZ?7T[^6,C(_@1_A3_ *#K
M2QK"PX@1TQ9\U(,^<5))_IT4=Z_YLQ_*_P#*O<^,TF"+NY;R$?-F(L7'<'35
M*H\OV-W]'M#0QQPE"+!]!OF[WJN!0V'_ /WCQ7)B8O8F".3>S] X#F!C$'[X
ML0(ZA\((;'"-@. ?L+/!K]?< UXZ/T8.7$2_=I(,R+F"UL(MSYAF\_/"#;7^
MX=_N?\Z%6?\ \..H]^Y5 +&>K]&N+<X>G1G'V)\CY]:BVC<E*@#O>]<[>W%
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M&Q&21)9T?$R[>E&4PYDM&3DQ(K643@EY2+.>G)/4V@&?0=IZMB$I!X<"))[
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M!=%?,J72*1*@I)H_$IGV"V]GNXT:/B TEI-.H$DP%4T;*@46 4"*K@)+$&"
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M&S$NQ> 9!=A%S#-SSBF\%VY\K7=_WL(;%.WJO>@3]1O<6!=[4=^+X%^XZ!V
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MAU@-_@CM)X<7D 3CC?/]"]Q_9K!/)KTG@@C^($G[$;=."2_('(MQ%K#CER9
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MD3'4,0(\@!W=BYX!ZXI)L^./]VOJY (WN[/%D[GQM;W:9)8P;<FP!!F.G&!
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M4**=JAM+@1T+!Y/)> ;]F$TU!*J2BNF0"%V2>I3<E)%N8)D6KLV+/G[[6>:
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M$SU@/ZEV,?CD^4<%Q:&!+AFL$X*(]/Z_4?UWX]M@/8?;@I8OM[6Z!Q=WL8[
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M E2$U%ON4@ DIQL@[,]KL)V<T'@] X%QZ1#PR'5NY!]M"9$_)9%UV9DY[X;
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M+3#3U AK#B3@XH'>O 5M5[FQN30W(JAX&_4@DN;^0)%QQSW9X,X$1'J>AY'
M;I>8Y&#^\!Q2:31HD5O? L[[[':N#75#_,N\'R-F CKQ'<2/\= ]@?\ '))<
MC ![CU;&JX))KR+-UO?C^5QH?@=0'(-KCT<N+M D>!RT]F!<7+"\ #@-A; G
M?9)VL<;W5B@"2" *&Y%;$]5@)'<&#!^9'D#<$ NY(.2P<SP78O9['H;F[AK8
M+X'L#Z17BR;%43L#R+).YH]!!(=32S#]^L\0Y!?!H!@6DGHPM,.Y\AB('9,_
M^%5\;=;?[7^'NJ-V3V?C\#?G:QL.#[5'N9$!F $L/-NK/^F+PD'NX]>9'#_+
MSQ, G@>02*L5ON #M0YJA[@;<B]IL2&/=W=Y')AXXDX@)ZB8EI '/IZGA\&X
M(/\ P]B35T:/\QN3[ ]3ES:22UX=F,.WV0V'#0_( ))F X,B?1@, %@\&Q?G
MGV.^U"KV]O:^L@28NUB&  (ZL&CJ"_ L<.?.X$SQ!,E_['D8=63= 6>%&AP:
MHUR#1(_6N>HT/#AP3)$-)?F>A?C 7B>W)^3D6<=/U5[$#?[[D[DCS8(X H5R
M5 \&]6;L'$AGD0;$N7Y8N'P8WZENDQT>QX(M:; -@>;5OS>X-[[FA9!WWWOS
MT+?$Y!].P+CB>69SR'&)-^P/UA[<LUX:[86X%"P-J-'@7>^Y3X/'U$W[@3EB
MY!:"_)%Y9_-I(AL7Y.">C-TF_67X:2V&-A9VW-CD7S2=Z'-G[^U=.6L"S@D'
MU8]ID?5L+N9)D0#W9V<3VCYD@"?[QXL;;DT=B:%WL!YJR;Z /V>T02\W<L.E
MH>,"XF>'[#N6@F99P_))PMK H_H?%F_>C8XY\$;]6P/4.W0!Y%R'XYN+B<7D
M3$6O O;L?)C8Q@KG^$ ) K<'8[T=S5\[;U[\0!+V!)(^;,>"(,\" Q+,(Y>_
M'!ZFT%YY%Y)9YPQ2KH#8']-]@:_38V/;[=4-YDE@T"6+M!'F P9^ [@BUW=K
MBX!^3 =9ZX7/WO8@$BN;Y-$^^_L=[OK$&#UX$\7?K!-WY%HQ6#\_WZ %@TV;
MCD,1AD>UT+W'I%;#Q0 XNQ7)/G>@,2"8:XMRSQ+RW)<,<2S=N#!X<P>L=FLX
M.$*L T+ ]R+H@D@>]T#OSSSU>DC@'H!:'ABQAK]2S.O-V/)_R[%NC]9>V]78
M/DU_$3L18)WXLCT[UL=Y,R;CFS/U)!MR1PSC% 'T,W^O$$6!@N0#8V&P.QX-
MW1 '_:*WVV'(OJL!=G $[F+\0.@EV/F;XQ9^M^CP?\OP'+S@  /FO?85?.WB
M[(\;C:O[L '<NP=[$6%GNPD< CMD38_J+SR.\EQU8]2$6>2:))\62 -N.>-]
M^#Y!Z2Y(D/W=B[&6<L2 2\^F![W =F$^DV-[<P"^ 6?5^E[C8_\ 2'V!WYKZ
M3MN!U!S9[3%P;=")' CE\(@@<D^B6@L]V<]R_FSSM>]50Y))JMA=?8T?/F\B
M+?(DER&<@D.SMU)C@6QB_I'$1]0Q/9G/R?V(WWYXO]+.P_Z0_D#72[, X8W/
M$L(] 9$W<XO4F'@MY<^?3SLPQ2+&P')VH7Z=^3Y%^HGGR >GU')>;38D\EPU
MS);%\F!=P+<W#L#8-PSP^'1 )-WR;VHC:P*L>>1OY!!Z$.+,"Y'87[W!L'L6
M$N('!$RXCU9K]/1BSCE>?).YI/BQ9/D"C8(YW_3J$&"+F!M[/_HEV 9HP!X+
M,[]'MRT0#W/<QA7L=O!' WW NN1N>*^XW'2Y-NA !,>8DGG]3QA'2>I+'GJX
M9F_27PQ[W='[[7?!WLF_U.UT:H"78,]X/8FY!ZM\P8G%CD$-%H]69@XLYFW+
M@WNA[ *%'QM9.X(W.]?]M)':2Y=GYB\,&'9RTP(-P#V MT_S/GWC'$]?RG *
M--N?R(2O;FKKSO=@D\=.IN?(%@S,[%^DN]V;XL'ZE@&8#K>P(@R>U@>,7<C^
M!/\ A3_H.M/&MBV) _KDWBOGHOD;_(8H71J[L^#0H@@WFF0W'-X[F?+AH-I)
MTE$@OZ")]'!C^[V@($*(_0>W(-T=]MK.VY!(&_3N&+ FQ#6D P]B?]/&;](
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MT[5N.J"?S!^ICN?(&#+#BX,@0+/8Q)$,";NSFQL7>PPP;NZ&Q!)^_ JMJXV
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M;$\S,<F2Q,=,1[MSTZ=VMTL 7\L(;@"@"/Y["R;NO8<5P;'("+/%@[\])EG
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MR--025%)8\![NS@ /#VGDO@!'I^H[T?L-K'._P!QS7-V>4AASTD1/P@GCO\
M)RV*4%PE/Q.'!0R^F[<SR&):Y!B,5>H*.QW)KQM0\4/ON2.+H7MUD4LQCZ%A
M$%S(@09$-9L8%*D_F24W$@AS(#=;V$=8.#V%\';VV-FN?%C_ */'-$P!W*@6
M$/S#N"PF"Q,6Q+6/[">CGB+L8!D6+WKP/\Q1%6-@!N.11KSL>I!,"#Q,2Q+
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M))-;'8C52%+0%I25 V#B78]4@#F3!X!QBEBI8*B@TZ8J*!"W8@,!\)=0!F
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MTBBC4"!3!132P2 0;;7)-CP' ))+7,W%CM*"FHS#92TEE*D,MI4EAH*#;25
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M<XM[.RV(+:4Z1U4IK%2I.K$Z&:9U%(&'+6 +NJG&\,R<LJ&A^2M*V5K9)>Z
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MN0UW/2,8=P#>+/%VN]KR!-[X1HD^?>AQYH;>"G@[&]K\TL\DR"[,TOW-W!'
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MK!P\P6)"?P\@L.6GKJKQ%[7?"_A[-')?B*^NYZ0K):'ECFZM!:2I*A54%!+
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M5<W[&M71IF9IYK/>"M2RE>KDU+K*76RFH.5+R]-2E%2*:U*II"4E( 6"D%0
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M0!L356@A:J%13(*7V@B0Q(QM.I:!D]473K[EIJ4DK53336I"BR'V(8 AV!#
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MFWH"_P!7$8DF(#N>C7@P[.W:&O94*X-\?Y^Q51(J]O'V !$ :1!;GY6#D_(
M-+XI-QQ?J)F\,_UX:V*'B?DO [?0K?Z2?X=A?(H6>:%WX!-!O!L?I=P7GN3R
M(Q&9IY[@3\F@?V):+M1_ G_"G_0=:>-46X]+8MA__GLZO_7IW- _\V8/V!V
M.YX%<GK(6(ZQT;S/=SZ ]<8*)W L[<3U(<1Y>O5L4UZ;/^="MO8I)&VW^?(!
MVZLQ/#NQ,0029806B&[OB1TCH\$]B!)#S+F+M(?)^^U[C< <$@F]]R:H'F[Z
M@![V[D2!T'+]^.DFCN.!! !:#-FO?N6(P*!2:X-[^..!L1P*L\59JR*H=H9^
MQF!VGAG?DL)!Q('<7@!@[O>#V</PX;%)HV/!)HGG8^!?IY^^_/\ N]# )/F
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ME24J!4?J7Z;)()[>*D)4RE(21\!"5  +@A#P'(-G>UBV.;E5, [5N@@%"JA
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M=0<:>4KYJ&O0?A;Q1HOB_3:VJZ-F$5\O3J$*1[Q*JV66NH2FAF4)431KI2H
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MOL41T+<2R7A_.Z8C)^**^:S!JIK&I713"EY@T5D$YA:0 OW]1U"L"/@IL?A
M.)?=JNZ>D>XV?[ #3TX+GZ:_V;J+$RB&IV(EJDY!Z.9"?F*2N)+;!5#G,*=C
M3$)5\DAQF6W&] >$_%NB^+=/.:TC,JJIHU%C-4*Y"<UD*J2ZJ.:H_GH[72$A
M:4N##FW8N4UK3]835JY2H!4W'WE)1VU$*)2-VTLKW:PVU8<%1(!<*2-G22"
M;!!')/LI5_Y'CW Y!XY.7,E3[9.V06=F(ZAILY+'C&X *Y+J8.;_  E*2D%X
M;:0W9H&*CMLJKHT2!YNJN@1^IO8\BNCV/!$6>>0W8  E@6Z' -P#)@<$CJ[Q
M))'#W-P5N;X)_0';_,_Q"R+!.QH;]7JP-Y #N']4Q:',&TX.[3:!VXX;S>P
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MFR2 MZ5,=??6NRIP@$'L'2M$R.BZ?2T[3<I1RV5RH6*5.@D(-4K!!J5RPW5
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M[$F_-#<??:[/%B[L=9#HX(+AP>0"[B'O<= Y?$+]"PZM8F!:/KVC#V].P/\
MV ?4+V !/-^0#MT#-P6%[D"(L_66@&#AU<D'GO)?D"T=RX&%5;\FN:VO[[>"
M#OL;%;]1Q#L7$ONZP2"SP;'H"^#*X?Y\D#D=I[#UP<FP19^U\;^:WXYK_0]7
M@]"7ZV(>2]CZ%^["\R+$.7:[M8_I8!H DJ]DU2=^17-\>^UDWY))%T,1;R(]
M!U8 B>27@<XA=QR6\YFW1C#19V>,&W*;HF_ &W/OQ>UUX]@.JP#>5BSABW+@
M E^3=VC%<F>7)YY 8/!=AZENN "]@0 =J W)WH7Y/O1(/G;<HN2]PQL000;
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MEP\<P.O+V9*1=V#N!)L(\N\02'+@D!-"JKC>P1=U?-BR0/\ *^>HY/D ; .
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M4;%FSMSYWV)V%GH7(D%QY\DL&/7]@!)Q069F8M>;-R!QY/+RX.&10L$<F[Y
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M2.W:TP&E@S"88QF#UD22+<@B]Q]6+U%EW?\ H'QOR&7K(WJZ0"?!][L$ GI
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g491933g96a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g96a09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1JV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &IJ^:! X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!JP]]
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             "+   !.P    & &< .0 V
M &$ ,  Y     0                         !              3L   "
M+                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M+     !29VAT;&]N9P  !.P    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   BP     4F=H=&QO;F<
M  3L     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M264;.IM%@MSL1I#"YC@W:0=[=7^I;9^CV?H_^,L1,)_5#D,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M='6&LF9H>(>2F+2W1F>"E::HL[C%T=?_Q  = 0$  @(# 0$
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MPZ#P7(+=56?L+ZC?BD.0H1$<QD=GW;WQL_R'U0\A6O%G3Q:;1<?8[ON?NHA
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M]_AY]X=^1\ZLK[EB7>MNEAB()\0#A\AM'&:KKD)-TV"**A-GAV9D88=RG4'
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M8X.^?DXE(<04X*.G&B$L],&IG7#9V'M7UB'*H0IR& Q#E*<IBB @8I@Y*("
MB @(=P$!$!]PZ*5Y:(FB*D+K2_WK;??(\6^\AQQP \U^)'CD>W<?>'V\\\#K
M5/.^WX-V+ 'TU9R^A%AO"K N2!4>ZBP3G"?T!@?IDFM69ICO1QV,SAV7IZ*@
M_P!BNX[S_?W1PX\B']ARWY(<?#W"/?CMP Z[N:8?XKD4]L6WK/D9#DUH[]6Z
MJ[>07L& AR1,F9Z"$%L14X8GJ#"\/6T%FR:(G]!U!^_)AJBC1G^M!+N<3+#8
M[U"@;+5;B5B4[(E\HR;Z,F/EBD@QF4:998)*<:K&8-@22F$WR30A5R,R( \=
M^VXF(AODQQ EG@#L&)<N1T8<G?'J48.7#;::=^8 ;/>I*E, \@ ^.WD1'CW"
M//?O^?7)P21F&<;#AX'L4^'OS[%Y:E$T1-$4;@KD:&YDDKZ78/38G6D3"$E)
M?)32!;,C$E=?-OROYN%?YK$S$JPM05!M^3R/J*8O7TXNEZAZ/0Z72KZSMT>B
MSN07?8*9J" !6)B3@]6#%W<-2A&-36A4D==BE-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%C#]8+!6SW%V7J/:!VEX>R+
MF3<"AD;+&2,AYIS%END5X*AA]WBR!M$=4X*I7*'3M.3YUOD&'5KM>CSQ,8SC
M8"9EI?VC<H:*.OCCKQZK2NE(KBU#:W,U_$V-*ABRL43/N>\<NHK'UVGLA8\L
M4S0LBRM4=7FD6^S/I&5DX"UM8MA()D6>+IL) 7\<DJJ5K[51KOIM&JG[]VKY
M=>BK[WJ99I"F^>T7';UN'Z;%KRE$[>(G"F8\9;V+Y\V5>B1;?(5Y=,)*D6Z&
M.]C"VGYZ-9(7+.*UE49P6,16EY5./%TR.#@]GW*#O(W-7N*LYZ8$/0J[L/VV
M06,LD,\N4N+H)FL7D2*@9.LP-C=I6*=">5K$!,HH2<-4H^P&DX>I1;M/VC*M
MQL8@4RB1$U#...-R#$T; _?M#:E3YT4K:N?[FK\?DZ_V?X/CG@?/?GOSV[?$
M)AQ'ZT/B>KWT"ZYGJQ?LYGAQ@H/=,;^#ZVA<\<_451O';_N6G_J\?9QSWYU:
MW[[7MXTGQ#NA5;<7LBP?L133Y46P*5.7/W*<G?Q>W3_1N2U4JV5='0X_@E=B
M/\1T9^D9R<$?/'OT16LZ(FB)HB@=O"_=FZ=_N'\<*3](B'(<_BK[E.P_#L'
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MU1#%%>I[ZENJ56H5!YD&*6*M+9'+,1;5-TF$VFLY1^8"B86GZR9Q+RA2))H
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M,;PP6"<X?L&@/TR1A4T$P"F8!K@:[Z^KHI=JKN/^/T\I ^/_ )(+?:/(!X[
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M3C_1CPP&!QR.>+^GHI#S5-QP\_\ Z=T<![!Y"G+<_#GOY$0#GWB/<==W-/\
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M%, @( (:YH"^"]VB*)^][*=WPIMDR9D[';YI&VVM-JV6)?OF#23;-%)JYUN
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M'S55>_P_L^JG?\WN[#]P^-4'*JO)GE#_  6]/[E.IEQIBJR^O9%YT?YA:_\
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M[C>?/T_IO(_;]# \#QSV >X]NXCP(^_CS1_5NT#_ &K;,L/Q%@VMC[J!<N0
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MVQ?_ .37%]^P8/4X/6(1'ZRL!>X?KVP /@ [?6]2>.!_/[@[<>?</EVYQ_\
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MP'D.W <AV >PCV[>:?ZK ']+VQGHS2)#9ZC@+MY ^P8"_P#EICZ8BM:Z9ZT
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MX8@16;! =?E0Q5##*M:Z$BC8>^(@ N2\ @(\C]>N !Y[=A^MVD>[\KCGGGP
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MW#V'@>> [AYXYWJWU=>OHH9G_2;1A3#"K @DUJQTYSF#YU8@,?(1EV_UCGU
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M8^1#R/[/^40[\\CWYY[&'P'/NXPGE(&OV]</I9&[Y,.&]L=*!7UTGI7?88L
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M(V:B)%$CAA*Q#YK)1KY XB!%V;]FJLU=(F$! JJ"IR&$! !'C12OH@("'("
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MGGT\]OT?G[!XU,+N#1NE#O=S2M&*ZYOJ1_LYG@%!_ICCST^]H7O_ &"J*'/
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M06+0OJX[LEG5Y5N"ZSC2Q$OA^8...>0W44I_P4OCZ$[U.PA_9+@CGGCW1.5
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MF(/(F8!E=-H_Y,=>LN[,,PKR9[7.RWR215V\K!H,JU+EM5^B#O #C,O3P,'
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MIUG1'%SD_>>O$8E7*=:3^#;SWQ_PDVZ__P!T&&.?A^;6OUD*I5Z#@@.]"_\
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MGGGD>!'GQWUJCG><\F[$*C\LR'_X*\&PUTT-'6"<X0_((8/\\DT&AAF/WT?
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M.>].A9&I[F2=UFX5_,-%;3,,YF8:1KTHJR6/B!1,AWT++2,:X]21P,V>+$
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M*T5LUVQ=&*UG(,A6%/IC764O2H:Q3T93P^M-=V\I$S:-"^^O2#4JK85@@(#
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MKAH"IV".GT9,/HAG799+)>$%GM5HM,ZU6:&1##.LL,D0]&T29O2AB\M.^41
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M9<AG4B^.JZ<',HH81*<WW=S_ !7,M$31%Z5T$G*2B"Q .DH0Q#E'N!BG*)#
M(#R @8IA*8I@$I@$2F 0$0$BK)K&P&V4?(3:H4W.$_ ;&65A/D1GM19Q+515
MC<1>*'5QK&9 >/%WC+:O(*+GL[[!I8OV9+"F6NQ]B98O<.J$8HX>FF/;PRLP
M81[*+9M8Z.:MV+!DW0:,F31%)LT9M&R946[5JW0(FD@W02(1)%%,A4TTRE(0
MI2E  *5O-$7@=0J8>HXB >HI>>##P)A  Y](#P'(]S#P4H=S"  (Z(J6-_\
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M2E*4KG>B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBT, B @
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0B)HB:(FB)HB:(FB)HB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g491933g96b09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g96b09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1BL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &)"^8H@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!L6(M
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             "J   !9P    & &< .0 V
M &( ,  Y     0                         !              6<   "
MJ                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MJ     !29VAT;&]N9P  !9P    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   J@     4F=H=&QO;F<
M  6<     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U5))))2DDDDE*22224I))
M))2DDDDE*7!_6SZV=4^K]72;*#]J_:++7W^H0W9Z8I/Z/TF-:QGZ?W^KO7>+
MRK_&=/V/ZNN #@*,G<#KIMQ3,#X?U$NA4-P@K_QI]?<(]'&+O)[P.6M_.'M_
MK/\ T?\ -_U%#_QU^O;-QIH'N(;K89 ,3M]KF[?Y?TUQI+2[;N]-WM!<=0#,
M_HG-=]#Z'_J-1<T.;:]QV.;J6Q(DNV^UY=[]_O\ >A:XCPZ/:_\ CJ?6#?L%
M..X\@M<^#)TAV[_SA:7U:^O_ %OK76\/IF17755EN>UUM)<2 RJVYNTV!]>Y
MSZ?S_P#!?YZ\Y<"UH TVCT["T%ND[O>?I>]=!_B_&WZ[=,9$:V[P8!#A1=]&
M4;*J'9]G^PV_]S+_ /P/_P!(I?8;?^YE_P#X'_Z15M)&UM-3[#;_ -S+_P#P
M/_TBA9=-^/0ZYF7<YS"T@.].#[@/=^B6@JO4_P"@V?V?^J:D#JA__]#T&_H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 2 "8 ,!$0 "$0$#$0'_Q  ?  $   8# 0$
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M?O\ K%SC[]+3R>O]4='^&?\ USX==1V+W[%W7;XM<_1RS3SJVV\X8GN[5O\
MXJ&_K%&<WI:?3O\ ZHJ1TQ\?Y,Z?GU/8/?L7?[-?X4\ZMM?XPQIO\:WI_P#S
M4^_^Q,X%ZVF3@G N*CGH._:9H6'ANR[_ &:_^'ZZ>=6W_2&/[9O_ (J&_P"Q
M!C_5I:?7J/\ 5%2.OK_ZY\.NH[%[]DZ/6VL?:FGG-M_TAC^U;_XJ??\ 6*<X
MO.U#R]\7#2#C]$S3L7OV3G]FOK[*D7%N=GV3ZG4';?95<B_;&(S]^=J8^NX:
M0/AUZRQTZCKVT[%[7XIW3?XM?X>^O=3SAC27FA(!$N($@['4T^_ZQ?[M+3[X
M_JBI'?\ _C-.Q>V[%WO_ #:_MY8.]1YS;?\ 2&/[5O\ XJX^_P#L3^[6T^G_
M -8Z/_'[9C4]@]^Q=[OS:_PIYS;?](8_M6_^*GW_ %B_W:6GZ_\ SCH_IT/_
M *9IV+Q_Y%[^R6/M33SJVU_C#&FIAU!T[]%4^_\ L3^[6TA]MQT<?QS-.P?_
M &+O]FO\*>=6W_2&/[5O_BK@7_8ASB]+4/+T)%PTD@=O7VO'J/7UU'8O'_DG
M>[\VO\/"@NK8@D/LD#<AQ! ]9!(KG[_K%_NTM/X=+BI!ZYQCI,^/3[=3V+W[
M%W^S7^%/.;8[7#!_^:W_ ,5#?UB#.;UM(8[YN.CC'VGVSUST^.H#+QV:</J0
MK\*><VW5]D>MU ZQU5W^^HKC[_[$_NTM,_9<5(.._?$PX['OJ>P>_8N_V:_P
MIYU:Z_QAC3>'6SUCHKOTKZ3?MC*&1>=J'_[0TC^(S,ZCL7OV3G^PK\*"YMS)
M#[.F_P 8C\:??[8W]V=J?](J1^;_ -,]?33L7OV3G^PK\*GSFW/_ "[/]JC_
M (JY^_RQO[L[4_Z14?\ [Y]1_1IV+W[)S_85^%/.;?\ ;L_VB/\ BKC[_;&_
MNSM/_I%1_P#OFG8N_LG/]A7X4\YM_P!NS_:(_P"*N?O\L;^[.U.^/ZHJ/W^'
MZ\[_ %:GL7OV+O?^;7MW[4\YM_V[/]JC_BKC[_;&_NTM/MG^J*C]L9S^O.V.
MOV==1V+W[)S_ &%?A3SFW_;L_P!HC\:Y%^6,>UYVI_TBI'K\/Y,Z_FT[%[]D
MY_L*_"GG%O\ MV?[5'_%7'W^V+_=I:?_ $CH_P#WS4]B]^R=_LU?A4><V_[=
MG^U1_P 6_AO3[_;&_NSM/X?U14?_ +YJ.Q>_9.=_YM6W?M3SFWU^/9T_ZQ'X
MZ^RGW^V,.]YVF/\ [14?_OFG8O?LG/\ 85^%3YS;_MV?[5'_ !4^_P!L;^[2
MT_\ I'1_^^:=B\-VG/[-7X4\YM_V[/\ :H_XJ??[8W]V=J'[+BI!_BF:=B]^
MR<_LU?A3SFW_ &[/]HC_ (J??[8W?[\[3Q\?OBH__?-.Q=_9.?["OPIYS;[]
MNS_:(^R9H;]L8=[SM/\ Z14?X9_]<^!!_/IV+W[)S^S5^%/.+?\ ;L_VJ/\
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M._O+2Q%G:L&\NF+5+S[KK3+9N'4M)==6%\R64*7S.* )#840# !J;O+XP7A
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MK3^4KK3_ *Q7U:Z3UI^2V _JUGIU7T,_T]IZ5S^#>X%N_P!&':K_ /D/Y_\
M=^_U]]/RAS7]8W/]HK\>_P!^M/R6P']6L]VI</VKKC\&[P*]/YF':KI\:"#_
M !O'_-UU'Y09K^LKH;R XK4'V^ U^SI/Y+8'KC6?I7ZNBO\ #I7/X-[@6!R.
M&':L#X?(1Q_C\]/3KT'33\H,U_65U/>7"3Z_7'LZP:?DO@=O@YF/6ON(U]/Q
MWWVUTKC\&[P+?WL6U?Q_I%W)[G/GYZ_H^&#J?R@S7]976W[0^^NQ^ZH_); [
M_!K.\[N;C7^GWT_!N\"V,?1AVK]?]@?CW(_']"?JP/JU'Y09K^LKK:-7"?<[
M?0)J?R7P.G\FL:;:K_X^X1ZM*?@W>!;TX8=JAW[4$#U^I[T[#ZB?7KI^4&;_
M *SNH[NT5H.Z)(^KQ.L$1^2V T_DUG3Q<_X_?Z:?@W>!;^]AVK].AH6>QSZO
MDC\Q&GY09K?X2NIUGXPB9WFAX6P!WQK'3JO2-!'IZ13\&[P+9S]&':L_;0B>
MWKU?^S] QJ?RAS1WR-S_ &B@?IG\*?DM@?ZM8^E>F^H]*9U^BOK\'!P+CMPO
M[4'H!UH)]!CMYQ _-J!Q#FQME+P09 #RH'=60X8P0_T<S]+G_'5MEJ;![.;!
M>);L_1-F]O+:VYIEQ<)N]-5KU/MB&846J3X.XVUT6')EH+B_.>C,ON-L+4,H
M;6M*<9(U8NY&]O\ AZ]7?7+UTXC*626E.*D(;+%R5"#)!/*F --*K&L99X[B
M3'HL;=JV;<Q]XXZE',>=8<;2#*B28D:ZD=0!K66W7+5V--*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*5T2OUM(SG'D/=N_\ 0U=OKUDCY2?G
M#[16#GYMSYBO[IJPGPO3G@;V5/\ PFY6/L^=J^^_0?Q#[-7/$0 R]T!_1M_]
MV:_Q_'>J'A8\V$M#_P"]<]9_YR]^ZL<WW4,<>$%O&>^-S=BCC_G,HG?ZO\N-
M4E=#6L7H]90B9(#E,C3'9L941GSW%)3%6OL\Q@<P4@_UI5R]LX'77DXV5!'*
MXIL(6%GE /.!,I4""(,ZD"=)[YWK&Z1;J?+MI;WG;6SK"!<%46ZUC2X;*2/C
M&B"4!0*9)GPJ SMI>5R[>5O<9MCVBV[<JD*DU*2[-97)COOMD1THC.N>>N.0
MXV@*;2I"<H  PL(K'<SCK7+6V$4HMWMXPY<L(2T>S6E!(5+B1RA9(48/<28Y
MDSUMIP%Q5F."\MY066$7/#N!O;3%W]R[=H-TRZ^VDLANW<7VIMTI<:02@1*D
MP"$KY?NW-N;=FV)=%W3+\H](K= EPD4NSIB%_+5PJ=(#RX/EK*/*CA1+BDI<
M(Y2EQ4?"5F+K)W=ME<?CV\5=7+%V'3<9!DCS>R+8D!V1NOI*DG3T0HG3/#<(
M87)<&<1\2WO&.'Q>5PK]LSC^%;I#BLIG Z1VBK,)6F$- RI24. $'G+21S5U
MT:S*A5+FM6AUN2NT(]S/0U,UJX69,"FLTR1[J*EYDEM(?@<R58>05H44E*5D
M 8]KK),V]E?7=HDY!=D'>:VLU(<>4\C=F$%02[KJDP0-QWZ>'X0OLAQ!P[A\
MTZ.%K?B!RV5;Y3.V]Q96+>/N"H(R 6\A':V:N4A#K:BTI1Y0N!I4:\ML:36+
M_%B[,*K^X$RF4Q;=46V(<A$^KTAMTUF70O94MA^C!MOSX3CG,ZI*N0E:@A6J
MC'YVY8P_POQ3YKBFG7AYLF%H4U;OE'FK=T""4ORL(<@0")/+J*[GBKR=XK(\
M<?D7Y(3FN,[S'8UQ.3=!M'TWV4Q;;IRUSA5,]D'<6 WVUJ25N*"NS07CRS3*
MO4^S8NWOFKEUEG<1JX!$ET:3&"*8U0$LH/M2'74^>F8F>"PMCF P3E/NJ*;9
M#M^O)J"6[56(5:)<;NFWB7UW*U2&PV-.S#1YN>3K$$S-<1=6'";'!S;B[S+M
M<>,YYRTNL._;<F/:PR+=4W"G5-I6FZ1=I[$M%9)YB2@!/,:<T&&_->>98C/R
M5E&?+89>=<*0'"I24L!:LX23S%"D\H62G'46*UH;',XM"$R!S+4$C?J5$#70
M1O)CQ'(L6[]RX&K=IY]PA1#3#3CKB@ 23R-H6J$B22!H))T!BO\ ;-:VKMZT
MJ%5)M"J-6W&HUZ0YSM/JKK1M*JVO&_'/4V7'"0^5OO-K9=/*2IM7(,I(2.?O
MK;/7E_<VS=VQ;81_&/,H>9!%^Q?.2D/M+,"$)@I$Q,[* GZGP_E_)OA.&<5D
MKK"W^6\H.*XOLKMZROU)5PSD>'686[87C'*5\[JTE#JBE2@DID%,BJ2W9=T6
MO7G5*]%MRFT.),J[LR-0:>7/DZ"PY*<=1"CI4GG$8)4$)0.7"1A(2DI2FUL[
M1=I8,6:[IZ[6RPEI5V\1V[RDH">U602.<D!1.HG>=ZXCB+-VN;XER.=ML-8X
M>TO<B]>M82Q"O@^S:<>+@LV.8)6&$I);2(2>4F ! %?+PMRH;NT^Z-S['V[H
M5FVE:D:WJ+7J-0IT=(3.D-HCMS(E-<+<R2[-=6EU:&(ZU-H&7%.N!;BN?L+Q
MCAYVTP.6R]WD<EDEW-U9W%TT>4,)25EM;R.9" @ \O.L$S$ <H/U/B;!9'RH
M66>\I'!O ^%X6X9X:9P>+S&)PERTD^>O)2PB[M\<0BY?5=+4DN!AA7* "M2U
MA:ZHA]^M6H5N5*UVH\-46?/BR)2GX;7MJ%Q"L^6V\M'FL J2GG9&,E)YTX40
MJ_58V[MZSD.9SM6F7&D<KA[%2'%)5S% ]$J!'HD=)[A'R]GB3)6/#^5X3#5N
M+'(WK%Q=%VU2+UMRU)/9MW"TAYE)6$\X$241I*I\UFU^LTRNP:_05N1JM2IK
M<Z"6(ZICC<B*A*V5):3'>"DCWBL+:4E0"R0H A'I>6UM=6;]I=\JK9]LMO)4
MLM!:%^C'.""#Z6X(,QWUJ\/Y/+X?-8_+8-:V\MCKA%Y8K;MS=+0ZP"H*+ 0X
M'$@ E7.@IY>8'0F)F@P+QW:O:/%2A,NXKTJP; YH%/2]-<0A!0E*C'A1T IQ
MA80E.2HA)R=:CKF.P&*4M7,U88ZWG9UU:&TZZ?+<623N))D=(%75E;<1^4_C
M9NT26[SB3B?(!/+-I8L/7#R2G1)+-JR$H:(_FI]$R2HDF4ZW:M3M:XJK;]3Y
M14J34IL"4VT\T\4RH3RF'V4NM%;*PI20D.-+*%$DI42 D[MK=LWEJQ=LR6+A
MM#S:E)4A7(M*5I)20%)T(W (/3>J+.8.^X>S.3P.1;0W?XB^NL?=H;<0^@7-
MJX6G$(6TI;;B>?0*22D]# J;:0NTZ;0;F:N*FUD76404VN[&6B'!@O%Q G*G
M-NI2M27&0DH;;YE8<YP4#"]:]P+]VZLG+)VV./ESSU*VRXIW0!"6E3"86"5&
M"01ZXN\4YPQ98?B-C/X[,)XG6FT1PZ[;.&UM;-T*Y[E=ZTJ%K2IKE"4P2KF/
M+RZ+JNW [#:E\:7!K/\ :V6WFN+#8#$%!4M9;5NW9Y\Y;G+R%92 E>"%>8%%
M0 (&MWFA?*$&($K$1/= UZSUD=3M7+EIM5H;E5PR+CM>S\VA0<* D'MBKE*"
MDF0(452%$@==R*#D9QCO_'W_ //!^K7I6I7.E*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4K'C>I_GH>Q"0.W!YOGGMV^<_:D_QGO\ :.PU>,_J[>_ZSLC_
M /8NA]/W&N;N"/RHQPC_ $9>Z^/:,_02/'6*R':HZZ2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*Z)7ZVD?O#O^+5K)'RD_.'VBL'/S;GS
M%?W35A/A>$'@;V5(((\W<K!'P^=J^Q^;\VKGB+7+W7S;?_=FO?<^NJ#A6?@2
MTDCY5S&D'_.7MQT[O9N:QU_=/WE'PB-XP\DK1\Y>QF$I(&5_.51N4*.0<<P'
M0$$$=]49]_5UVZUT0B3.T:>OZ1/L/=XDZT^Q['M.X&+E?N"ZX=H2*'0)=6I#
M4IB9(-PU..E!9I4-:5(2TM[FYD/+/(,I)24 J%5DKZ[M%V*;2P=OTW5VABX4
MVL)39LJ^5<+E)*DITD2(G4S KN.#^&L!GF>(G,YQ5:\,NXC!OY'%L7ENX\O-
MWS0^+QS"DE(0X]H4J(684"$$!1$KKK55@4J11XM3FFER)"794&-(?;B2GVRK
MV=3L8.%EQ2>4+0XI"E-@IY>4]=;Q896\BX4PWYPA)2AY2$%U""?22EP@J (.
MH!'CTGF$93*,8]_&-9&\1B[M33UUCT7+R;)UY$\CC]LEP,..)"$\JUI4I.G*
M0*A;0FICB4ZAQ*2I10LM%;9*@I!3G.>H]T8("B1E*AC7N% &)$CH2#O&I!W]
M]SI6IR.!(<4EQ*53RNA)*=H()TB0"!&L>$5,%9N^Z+N<H3%RUV74$42E1*)2
M%37%NBFTQ@GR(,8*5EMID+4ZV,D) )]W"L:=M86F/%P;.U;8\Y><NGPTGE[5
M]STENJ&@*EG>-YGPJ\R_$N?XC&';SV8O,@WA["WP^,-V\IT8_&,$ABT9GY++
M86HI29(G<P*G^XHDK:*XZ%(L+<=NH39EOTZK.UNV'Y$5R ]68S@G4%Y]+GG^
MTL(6I$D!26EH=2%MMJ#C:*VT<;XALKAK+8=3#*+QZW%K>H#@>1;N)[.Z2"D
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MZ!&D(D-*4I"W>51:/*CWP4D*(\,GC[/)VCEM?ZVW,AQ1#JV5!;:PI!#C:D*
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MITZ,M2&)\"2]$?962L*4B4D@LJ*>57.EP'H,JP,CQ?89N65,W#2'V5@A;;J
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M-T\_,A:X[I:\QI7* MIPIRRZD!#J"E:58.K"UN&[NW9N62"V^VAQ!D2 M(4
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M4>,M7N!^8Z@!"5 E13RH!4I(U59S)76,M[9VTL7+Y;U[;6S@;!/8,NK"7'E
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M/VBL'?S;GS%_W35A'A>$?0;V6P,?C=RO3O\ JM7W^;ZNGPU<\0_I>Z\$V_\
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M!2HC;BVV'@X5)2QS *5DE1MO/&%6=FWE0S:O9)M+"[-Y:5!3SC7.Y;!6@<(
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MP2+WBC \&XOAO@_(\/\ %;F=SN7LGW^)<2;%5LW@+E*FNQM4OJ,W"E<SJ5$
M@]D' 0E837LVT^;U%$O%R])-R,U-JANJM!NB(C&.]7G2$L&JO/IYF(+2N4.%
MD)<<"E86"&TKSRAS >QHQ;=FI@W8&35=E?,+2 2+=*(!<^4?2D3$B"8\^#CP
M&FPXJ7QA<YUK))PKAX39P[;*FW\U)#7PBZ\%%JU0>0J+8"E)4X KF"0JD,WI
M-?R<CSE=3D=<Y)&23@GWL*][!ZXZC5OML(\#]ACZ/LKA#,F=YDR2HR3K)ZGQ
MG4U5& Y9[]H5VGSZ76)%W//T]RW9\>;&9I,.""M52:J4=2$NO//)'+$4TH\I
M',M)'*DZ%PC("^MG&7[=&-#3@NV7&UJN%ND#LE,N2$(0G=04E1(B#J3746%Q
MPFWPUFK?(8[)N\4OW5D[@[^WNVF\;;6B5*\_;OK50+KKC@T8+9'*=5 00JFZ
M%B$\Z&E)7D!!R5\G)D*45 <JE+21GH2GH<!8 2=X3IW[[?5!FN8F"8V\>NLZ
MZ]X!/U55NC7!!N:WZ-8=310:#3(M4EU*3<Z::ZNK)<?02EB3(3(*7HON)1';
M0RV$%2/,6I*$D4]S:+M;F[S#'GEW<+MVF$V(?2FVA*Q"FVRD<B]RI14J95R@
M%1)[W%9FVS6*PW!.3&$P>+8R5SD'^)?@]US*A;S2_BKI]-QRO6\A"&T)9;*2
M4%:UA JE=1?3!G2(D8QY4:.\H,/J;4"\D'+;Y 6 ,I5E/P3@$9&3;(YE)2I:
M2A12"I$SRDB2)&A(F)\-(KB+A"&7WFF'4OM-O+#3P20EU"5$(<"5>D M,*Y3
MJ)@]9J=<>Y:Z_8M*MA^W+:B2:?+=D_+L"FQX57EI7%+8C27VU<SC"0CS$@(2
M5*2,+&.553:X=-IDKC()O;YQ+[?9^://J<MFSS<W.V@ZI4-0-2 "1M$=QF^/
M7<WPIB^&GL!PY:.8Z\5=?#5AC+>TRURGLNR\WN'&0E*FH*5$A )4E*I!F:4(
MJ:TP7( 98+;KJ'5+*5>9A/, D*"QA.",>HQ@'5N4@J"I,@$1I!DC?3?2!KU-
M<*EY265LA+92M2%%13+@*.80%3$'FU'+,@:BKJN >=(:XV^#V(E02U*XJ>'I
M#N%.9*#NU:64I_&) 22<X6%>]GH,:F "%0"4[$@$CU3/U:U@'%I0M"5K2AP<
MKB4J4D+ (,* (Y@" 1,P=1KK6YJ0@(2$@D@= 5')_@ U-8]_O'JKZTI32E-*
M4TI32E?(6DDI"AD'!'J#@GJ/L&=*5]:4II2FE*$X!)[#J=*5\I6E8YDG([9^
ML=QUTI,U]:4II2FE*QY7H ?%"V*[].#W?+\Q^<[:GT^&/\N?3%XS^KU[M^D[
M(=-NPNM>_<1[*YRX_6?']XQEY&ND%UJ?;W>-9#=4=='32E-*4R.V>OPTI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E=$K];2/WAWZO];5Z^FLD?*3\
MX?:*P=_-N?,7_=-6$^%Y^T;V5'P=W*'_ %M7WV^K_P 1Z:N>(OTO=>JW_P!V
M9]_N%4'"OZ#M/G7/K_SEW?>#X3]&PQU_=/[KL?PAMY78ZE-N*W+V*0I39Y5*
M0=S*("E1'=."<@@CKVU1GH#KW#?7?2=*Z1"E-E10HI*T\BBDD$I.Z3'0]1UK
M75P]F;2D[)0=RV]S:!$N*HU>?!?L24EM$UAN*F2I00\AYQ_SE,!$O\;#;84U
M(;0EX.<B5<<KB6_1Q0]@E8*[<LV[9IY.4;)+96ODA2D%M*.0*)1HXH@I/HD3
M'WRW\D7#5UY(['R@-^4;"6F=O,C=V[G"5XE";EH60?/9H=1<+N"\IEI-R>TM
M4LK0^V H*%6[,7+<UN,U)BCUB?3HE4C&F5-$&2[';J4,N^9[+,2P4%Z*M;8<
M4TZ5)!3^3V ZEZTM;DLKN&&GE,+#S!=0E99= (#C?,#R+ )',(/JG7XSC\[F
M<,WD&,5E+VQ9RMLJQR+=G<.V[=_9A87YO<I0I/;6Q4 H-.%2"0"14O4VX:[1
MY*Y='J]3I4ER/(BK?IDR1">,62T69#"GH[J'%,2&E*:D-%10XR5(4%!1!]7&
MFGD\CS;;J.9*N5Q"5IYD$*0KE4".9*@"DQ((!&M43S+-PE+=PTT^@+2M*'6T
M.)"T'F0H)6% *20"% 2")$5Y&</O!<IQY66U%2O+\PA8Z)2,A?,"0DJ5@8 /
M?!.O3W^^O8<L^D2!K)W^VIBI*(+3\IV2XY'?CI;530VD$N/I=04H*3S <S7,
MHJY20OD!2G/+KS4"82!S)4"%3_1,R0>IUVVC;P)6XVXVMDP4K"@KJGE,A0F-
M4F%'0Z=QVB5V7C6[IJ;E9N"6[/J+;,6.I]_)>6U#0Q$9;YP"DA#+83RX)]WF
M)R<Z\+*RML>P+>S:2PR%+6$-@!(4XHK4H ?TB==Y[^M7>?XCR_%&2.6SEXYD
M,@IBVMU/N*!)9M6D,L)D;A+: D&)F3,U)E0F>W.!3;(:2G.&VPK ).23@J_2
MKJ1UR <#:&FY)GO[S^/=5,M049"0D=PV'? [IFJG6'M[=UR6S==X4-A"J/9<
M=M^XGE3XD9V/$GJ\MH)COGS)"'"RH%*$.8Y4D<B^4JJK[,8^QO<?C[M:DW&2
M6M%FD-K4E3C<$\RPDI2!S)B2-3W D=A@. >(N)>'^)N)L7;,/8?A%BWN<X\Y
M>V]NXRS<*4&BVTXM+CTE"I" >@ )(!I7-!3-D *'NOKP0$C.%$ X22D 'H?K
M!['5J-0/57&$02#I!.@/-U[^OW[:U%*#.#%7IZYJ7IE/3+:>GPTN*09<9I0<
M?8*P%E/FM(4@KP<9"BDXQK!Y*UM.I;5R.*;6EM9$\BU)(2N#ORJ(5'6(K:L7
MK=B\M';QCSFS:NF';JV"N0W%NAU"WF0Y!*"\VDHYH/*53K%3WNS5K-N"XI-8
ML:VW+5H4A45$6DN.AYQE;44IE*"C@AMV0DN!*0I* 4CF"B>:OP]MD+2P9M\G
M=B]NV^8.7 !!6%**D@SJ2@$))(!(CNKJN/LMPOF^)+O(\(8-?#N$>1;AC%N/
M!U3+K;*$W"@!*4(<="EA*24B>\D"F#2Y824,^>$A2E'R@KHHI .>4$]1@X/^
MUSTSDV<QX=-3H=?7[Z=T5Q8!)T!.AD 3H._P&OAO4^6K8E>N]@.0(!=9]O8A
MO5!X>3%C.OI=#29<QQ7(P5^6LISR@A R"HH2YI7F1M+$<UPZ$J*%+2VD\SCB
M41/(V-51(DQH.L3'3\/\(9[B8SBK%;MNBZ9M'[YPAJQM77TN*;\ZN5E*6@4M
MDZ[:#4K2%25,;DQ)$F&7%*#+KK!4E06A7*2A7(K^N203CE!R""!@ZW$J"DI4
M)A24J ((,*$ZCH=1(Z:S7.OMJMWW;=2D*6RXXTI2%!25%!4A10K^<DD>BK0$
M&177!0%O$+0%I#:CA2.8=.4%7;W2 ON <920-9>S8$_1[^KOKR'M\-)Z=VNF
M\D@Q]%7\\$-3M(\5/!/0XMJ,1;JC<7.P<R9=*9BW79T%6ZUG):AB&I'EQPPO
MF5SIPHA22/4:KD6M\C)/W2[X.6+C"$,V(;"0RZDGG<YQ!45R#J)W&P$];=Y;
MAYSA''X:WX;3;\16^1?NKWB07CCB[VS6CE;M#;$<K*6E=$GE)2%;J5&X;C*4
MIL\RBLA:D\ZD\I5@]^7MCT!3T.,]R0+(P=1$$ B#.X[ZY!$Q!))!()(Y9U.H
M'=W'J*]&HK*FE*:4II2O'4)#L2#+E,1URWX\9]]B(V0ER6ZTTM;<9LGH%OK
M;05>Z%*!. "0J"-M2/5'=X_O^\?F=X1ZA)W8X?N'KQ'M_?$4XA-I]WMW.(9-
M%J]DT^^I=2V"-8G;LW%9U#X6J?P_&'*HT,5"F4J%1W9ZF'[FI\ER9<<F<EA"
M9++[O?6FNT:1O[ZSM]>O?=3:_B>[WUFL69NW+VHVP9X3+]XVZCP.4)EJ[KE5
MQ#PKGC7W7MLJ?NI6*2[2T64:#.N^@2/;MOHJTW)1[>>:KAKE1*7X; :]WOX[
M1M]<T/MF"9&WJ VD>_C2W9_Q1^+W<^-PSU"J;8</U MKBZK?&+M5MI4Z97-P
MY5Q6GN1PV6UN?7*'=MWTB:VNG2+-K\G;]RES[>I-3E5ED.(K#5<0F6*)">_O
M]6FG6D;ZGW^CZ=3W1O4C\#W'IQ\W];O 1M+6I.Q=_P!X<36R6\N_5R;K7RW?
M[-5I5E;;;CV[2GF)](MR7&AU6[:@S5Z_2X-/H[-%M^(TJV7VWFXM(J5,JD3]
MDP=/?QJ?N[NOV>._^%8;7\43?*][7V.W?K^UFV] X:.,C<S=S8?9=5L7E=,S
M?VPJ_:D3<>#;%W[@PGZ7'M&?#N6H;=U5=3I5L/PJCM_'ET^7+J=?4W.1'$P#
MTTW[J@]Q[M>X^'4>RKUO".NZZ[]\-G@^O*^;FN"\KNN':*G5&OW1=58J%P7%
M6Z@Y5:LAR;5ZU59$NHU&6I#:$*D2Y+SQ0A"2LA( FIK(QI2FE*:4K'C>G[J'
ML5\/H>;Y=3G_ 'S]J.GYLY^T]1CKJ\9_5Z]_UG9?^1=_;&L]P]G.7'ZSX_6/
MY-O.F_QC6D]/5UUC:1D.U1UT=6!\0_B-[(\.5]5/;:MV'Q.[F7E0F*9*K]-V
M,X6=\]W*;0F*Q3VJI3S4+OM6RY%DJD/07X\ARGP;DFU2*B0W[7 85D:5&O=U
M[^G?L8]]:J/PP<<7#1Q?QZ^C9'<,56YK07';O7;>[+=N;;G=>R7). R;LVRO
MZDV[>U&B/NDLPZK)HHHU0=0L4ZHRP"=*">OO]OVGV3%6'>+9Q4;S<-E4V/3M
MU=-9V^L:L6?Q%;A;BWK;<[;6G7+(G[-6=;%R6M85NN;LVI>%J5^MW+3ZC=U:
MI.W42#2+EW&J5IQ;:IUV6O2GZ[5HXS&FT_A/U?=2 3J 3W'[?'?U35VE!XSK
ME^DMMGPX7OPU;L;?P]XJ%N#7-IMX+AN#9Z9:5^T_;&AV_7KCD_>O:NY-P;AV
M@^NFW'3'6(%X6G19:9#[D1QEMR,[A4^_OWU?EI2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4KHE'$:0?@PZ>G?\ H:NVLD?*3\X?:*P<_-N?,5_=-6$^%[D\
M#FRQ/^Z[E?\ :U?0_P GU_;G.KGB+]+W([DVX_\ QVJH>%B#A+4]ZKD__E/0
M/9[DZFL<WW4%EWPA]XVF??=^<[8O"0,G*=RZ(2,D<N1WP3V!] =4GXQ[=ZZ$
M:F!J==!KMO\ 1UK5W<RAG)( Z*ZYR< $'![8'4D9..G7J%/?W^GZZ[68[SW/
MY394$IYU'*1A.>I]XCMS#..N#D] 3I^_;7;?;U4CKKIW3UTUCQ/7:IDI%'<?
MIU1G./QXZ(RFB&7W4H?D%1(*6TI_&8 P7!C)3A13T'-Y*=Y5H;Y%*YP25A,I
M3RQN9D3.@C4P)WK>9L%/6=U==LPVFV+0#:W E]U3A*89;.JN425'0 =:K]0;
M6V3JEE6N[.W"J-%O6=6)K%=A/P2]3*?26HTAV'-;6EDO<TF4(S"\/*5E]?XM
M+;:BKF;S(<3VV1O4,XFWN\6W:LKM'$NA%P^^I: ZVKF60.1)6H2E/,E ](DZ
M_7\'POY(,GPIP^_D.-\CA>+[W*WEOF[5^R+^.L<>TS<.6MTE2&0I0>=3;,@]
MJX0MU<H"$>C;Y5(\ANI2/*6)3#"W&(TII"6T/,LN*0T_R\P2A2TH2OW@%.%6
M5 Y4-=2V5*;0M22DJ2%%)U*2H24D[2DF/97QFZ:;:N;EEEX7#3+[K;=PE)2E
MYM*U!#J0K4)=2 M(.H"@-Z\KGM\F.XVY&#JRXE1=3S*="<I4E&$*+02/=*3R
M)4H*[K '+)$;R(\=.F_?,B#W]>_PY3!5T&^F@ZR3TCQ,=PWCY@I?A+6IU(9Y
MU )<44+1D!:5!82HX&%D9"1Z)_))TT(]<$'J/5W;UD >:)@A0(D IYDP1,C5
M($F1W]VU<JC-VXB[4TIZBU6Y$;B2*O)9N: _TMR12FE+-/4SY:D)4^R0RL%9
M4LN+>Y@G""NB:&87GKCSEFR7ADVZ%6;R8-XFX,!P&9/*4R"3H!RP=2*^FWKG
M #'DUQ?P3?\ $+?'UQDGD<2V#O,<#<8]MUQRT4T$E*.T86&76R0M86MWF A)
M%+*E8=XM4&)>\B@U!JUZU/D1*=7%LE$"7-8)4]'9>/0N)P0$D^_RJY,E*PFQ
M;R-BY>/8Y%TRN^MVD//6P6.V;:7'*XI)V!D'<D2)W$\C<\*<26N LN*[G#WS
M?#N3NG[.QS*V5"QN;I@J[9E#VP6DI5 6$\W*KEYBE42. H=<X/493VZD_P )
M&?7'U$:W:YZHA36RMQ:>8)*FQRD#(YDK2H)P,J]Y0 "0DG'8=>L$Q[="/#?N
M/=[=JD3(CIK^'=N8\>X&KMMI+/JT6T:_N?9,J@5ZO6HU56[AM&KQ$2%4RVY$
M#V95P<DIYEN2$%QQEMAA2W4N)YPV<$:XOB+(VJLC:8')HO;.SR#C"K/)6JRD
MNWB')%H2A*U(20 5*4 -8)3(57Z$\E_"^5M.%\UY1^$+G!YS/<-M9-G-\+Y6
MU2\+# 7-J63FB'W&$/*^,6AIEM2U2E2BDPI!MZ^^%UHR*<]5'8M,ES6I4Z%$
MRE#C@3CS4I2A"?,2%$(("0 H =.8GKEVS7.AT--./M-%MIU0E208] JCF(,
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MUJKW@VW5!NC9'<9- XIJIQ#6Q;6X;EJQ[.O?A>LOA1W<V!N:FQY$FY]OMU+
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MHZ)($5*$YR;3W&VY!6KVAXI6VIYQ:O.0OE*W0"D!U)!!ZGKD8Y5'5DCLU %
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MB5)2$ICH ),:=Y.O6M;.7.+N[U+F(L7+&T3;L(+#KI>7VR$PZXI92D0M4J2
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M 0 /?O[YJO7$WQ1;-<(>UDO>#?&Y%VY9[%P6S:D,1(;E3K-<N:[JO&HU#H=
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MRTVRT@<J&VD)0A(.IA"0$B223 @UQUY?WF1N7+V_NKF^O'E!;]U>/.7-P\H
M)2777BIQ92A*4CG42 D;5-5:W)JUQTZW:94F(J&;7IB:93EQ6&V7G(_."1*<
M2C+KA)*PZHYY@1G!.M.SQK%D_>W#)<*[]_SA\.+*VPYUY$& @$;@'7K5[G.+
MLIQ!CN'\9D$V@M^&\>K&X]5O;I9>5;*Y3%PX"2\L<H/,0#,F-:J4Q6]LZOL]
M4:)68*J)>]OR%S+?J%+AMN*N;Y1DI]I8N"0\H>4Q2X[:S$#*&^<*SE*BKS*M
MRWS3'$#5U;O)N<5=M]E>,/+Y18AI*BARU0DCG6\X4I<Y@J 3)@".SM,OY/\
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MYB<_/7L,2$Y)Z@[D8Z = 3CK@GMK*M;F3U(CK!$^RHHG[FY\81$4>7PJPO:
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MO;CP:9)N6TZ7>]GW%;=]VNU'H]PT"YK;JK4B,XB+%DQ9,68PZTMH1Y+ZGO\
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M:&V76UNK8*T(2I*U8YNM:[Y=\(R'U.\-\)MIM2$W!7=I3V*EDI2'9;A"B4J
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M@G&1KU'E@94!_D5@% @$$*7!&X(/8QK([YWZS6HOR7/-K4VKB?+H6E2@M"D
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MP]_LII2FE*:4II2NB3^MI&._D.X_^[5K)'RD_.'VBL'/S;GS%?W35A/A>X/
MYLK@Y_&;E?'_ 'VK[^/7MC]'IJYXB_2]UW\MO/K\V9FJ'A8@X2T(_I7'A_SE
MT?=O]]6 ?=,%!JMU^%'N?;5$8#U7K6[&PU/IS2G6F4.R7]S*(EI"G75H;:2I
M1"2M:DA.<GTSSEW=L6-J_>7*RW;VS2W75A*EE*$)*C"4@J48&@ )KM<'ALAQ
M%F,=@L2R+C)96[9LK)E3B&DNOOJ"4!3CA2AM,G52R  -]16L NJRZW9=8JE
MN!MN)6*.^8T^&EQ,CRG0 I0#[*EM.!.4D$*Y5!0()P=865[;9&U8O;1?:VUP
M@.-.%*D$I)(^2M*5 R""" 1'C7KQ!P_E.%\QD<#FF1;93%W'F]Y;I=:>#;D
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M?QGQ('KK1[58;[,%7*#S1SF)]1YDCPA,COJ$QV3(>0RE7*7"0%'F4,\JE=
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MQ 6$?"3+'8JNNU40A"$J3JV5% 4$%0YHGED37T)ORA<=-\"M^3-N^>1PE>9
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MQ^:8Q.0<?OVAE'KVZ#(2\W:?G7&OXPVE2_1,*4I*5I;<4FE(9,I):_&-!!2
MEMU2^@;4YDA.4H"5#WA^0D*'+R''-= I)$_3IOI'^T-C/378BOG@3S?)!Y=
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ME"_XK:P%I2H#TWY(!!UU'O%?*O*JZMK&XTH4I(\[65%*E P U$\I!C[=15O
MMRWRH'Y!HV#@=:9 (QW.1Y'4>G?U)&<Z^_\ F]N>7XAGUAI'J.D".FO3PZ_#
M'+JYA9%P]H%:]HX8,* $DP3$G72?"LE_@C1XL&I^(,Q&8CQ([7$YMR4LQFD,
M,MA?"EL:XHI;;"&T<ZBI:R![RRI1R3G7Y0\HR4(XORP2 E(-L8 "8/FEN3
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M!$QUG?VU<IP:?MQ.$@=<?2CX=\?GWBLOL/C_ !ZK\C_F;WST_P#[)Z:Z#\2
M:V+35]&A!Y51W0)T.NG4 @1O$ZUN+_\ 3X:Y:KBFE*:4II2FE*Z)7ZVD?O#W
M^+5]1_B/V:R1\M/SD_:/5]M8._FW/F+_ +IJPGPO<?0;V5 .<.[E#_K:OOI^
M;ZNGPU<\1?I>Z^;;QZO-F0/JZ50<*_H.TUGT[G7_ .I>]_>:Q]_=,$=B=X4N
MZ$&=*;I<27NWL'$DU-\E$:'&D[GT)E4Q]PE*0AA*RMW*L)0E61RY!YVX=4TR
M^XAI;RV6%.MM(!*G7$I40TC?TU%(  U)4*['$VC%[E,?:7=ZWC;>[OK:VN+Y
MPPU:6[S[;3MR\20$ML-J4ZLD@!*#/?6M*K<^9M?<]T6_9EZHJL"0S)H<BL45
MX-PZ]2)*4*=:2GG4'8SJB4K"2E&4\P60<:KK9#>:L;&ZR6--N^E2+I%K<CXZ
MT?03R*V!2L#42!H2"-Z[#+7-YY/N(N),-PCQ8C)8YYIW#O9G$.I1:9O&OH0I
MUM02MQ+C"U>@HH6H%224JC>GK<MQOS%KAMR%N-NM<S[:7 A3H*#(:2%(YG&@
M 65@A25I0H#/+BWC;6 ( &FN_M/W?9P*@#!D@H7*E '=1D[3(/61MI Z74\'
M%5X:5;YVXOC2^_29LBQ JL6H)M3VMRI,35Q5-TAYUB'(8JJJ1'DJ4N2BE>;.
M!#:FV'VDO(<XCR@,<;_DMD3Y-_@IKBQ2FG+$Y?T+-<.)[;F4&UI[13<A!6DI
M,D2"4D>K[MU>NV#-S?7(M&GVV[ESG4X\S8A"SR6J70M()=[(%"1Z+/:% "BD
MFW;>-_;_ .=K<![:-=;>VM3>%?.W:[E2RFOKLM%2D(MM=;;846D54THQ#-;0
M2&I"EH.,$:Z7"G*G#XLYP6PS1Q]F<L+0DVHR)MVS>"W*I/8^<=IR23Z,:Q7B
M 4>B5EWE)0EPI *TI)"%J T"B@ G7?;NJ-7UNG4+RIEG0I$"W:4;-MYJWXSE
M#C-PI,IEH\R9-14VM1DS.<!3CGXO*_,5R<SBB?'%X9C%.Y)UJXNK@Y2[-T\F
MY<[1#2CS2VTDI!0WJ8$F1RI)( CO>+^/LAQA9\*V=UCL-CD\)85&%M'<39^9
MOWC2%)4FXOE\Q[>X/(E2EI"07%.+ "EJ)I6[+DU1XJDR7I#CG*DEQTJ45?DA
M65$J(2D#N""?7W=6Z4)2 E"4I .B4@ "9V $#4^&]<,Z\\^LK>=<><5$K<6I
M:C&@',HDF (WT&G=4YHMF U;"ZXW7*<Y5'*BB"BW4*DKJWLH8D*>J3OX@1T1
M6BAII0,KS'ERF?(;6&I9C8=HKMRWV2^4()[79!)TY0=95U(!@#0[IK6[10N.
MS[)P( DND#DYB8")G4QJ1IIH=Q7LI-[W)1+0K-E1Y(9HUP38DNK0WH<(OREP
M5A<<)E/LF2VE#BU$!IX-X*UE!YE$ZCN-LW[^UR+K95>6*'$6ZPMP)0'A"O0"
M@A4C^D"08(V!KKL?Q?G<;PWE^$[*Z;;PN=N+6XREL;:U6X^NR4%VY1<K:5<M
MA"@)2TZE,=#*IFO;#:^Z=W*M4*):WL"YM+HTRLR14JBU ;1 AI:"@VIY0"WC
MYK:&ADD<Q)+*4J(U,WG<?P\PU<Y#MPW<7"+9OS=E3J^U="E#F"=0GT5%1,C8
M09(JZ\GGDVXE\I^4O\1PV;$W>-Q;V9NU9&^;LV396BFD%+9<!"E\SC82F( ,
MDI )J/1(>\=/V3O*I4>=*C;6/5^+2+GAQ:E#+,FKI+#C;C\%*_/4RTM,8*D)
M*FU+Y I:D@ZTKA[AQ[B7'M/M-JSZ;-;]BX67 46Y"PI*7-$<Q3VA"3) G8Q7
M0XVS\JECY)N)[S&WK]OY-GL];XSB"Q9O;0M/Y-M;);4NV23<*90\FV"GFR&R
MOL@>8210&@U-VD5-%4BO(CR(CC,F*XI: IF1'DM.-N#G'*HI4@K*0E96!T3Z
MCI7&T/-.-.)"VW6U(6E1B4+$* ((U@P(/C/6ODMC>7..N[6_M'.RN[)]FZMG
M0 KL[AAQ#C3G*1"N5:0>4@@@:B)JK]S;DL;DKMZ+<J+>H2:0U43(J]&IK<6;
M5WYCTB<J15E(4%2)"Y+J6V_<2EML!'*A(P*.QPZ<*F\59+N;KSE;11;W#Y4A
MA*$H:#;)('*@(3S&223UG2OHO$7'2_* ]@K;B.WPN&3BV,BFXR^'Q?8W>2?N
MG';POY%*%2^ZMY8924A*$)5MH:I ZW(3+5*B.*<:40&W&5)0I?*GF"TA15[Y
MY"I7^U6/7E)U?&#((&J1S"9&PD'P\#XU\T,H)4VHP#"51RD]Q@3!($GQF)K)
M!>._7")6. .R-GZ)L?/A<7]-ON55[RWKGLTE<>IV^B7491>;N 5=^X)ZI4!^
MG4-%N3*1%I-/]FD5%F09+;2Y7R'&<)^4FU\K.7XEO.+K9[R;7&(1:XKA1M*T
MNVU^&V$K4XQV*66PEU#UP+Q#Q<>[9+*D<J93MWYL;AK'OV_GB<DV%C(NNOJ6
MS< <X"4(+I$E1;7JCF3V9$PHS;RGB$95L$=C4VA;CB&:@:DU=.4_*;9]M$LA
M,8))7)*D".N5[0#[(H-%I0 6>M3PG'%IXH&1NI4P6C8C5@0WV8///R(D\G+\
MHR3,1]K5Y;I\BG\#ZN$L*H)O!=(XCD(OF_XXF[*@WR N714.R-R'@"R>S[,A
M-1O@,HE3J7'%P<KIT:54!!XH-@:C,+#2G#%@HW:LT.2I 1GRT(4M(4H] " >
MH!/7.NM,I"GG$-I4KE27%! )U( *C!) )$'6)BO@;CB&BV''$)[5?(V%*"2M
M9D@ '4J4$D@;P--ZW*8(/8@_9UUZ;UE32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI32E-*5CRO3/X4+8H ]^#W?+.>O;<_:G&,'([]<C\^,ZO&?U>O?]9V7?J.
MPN]^F_=]U<W<?K1C^X8R\/M[1H?9H=-9'45D-U1UTE?FMXH^*?AWV0XZ..G:
M*L<(#O$)=>^%A<'=$O:SK]W-VO8H^_6YUU/2MOME+-L?;'<NFM4RB6!2K:JU
MPG<7=ZKUJ=;=*NBETJVU46'7:W2':R]]_NZ??41OK]0T_'Z/;KI=_P"#ZWPY
MT>W>).Q-F.'C<OA"W"V\W2M^W-^N&"^]SZCNE;^V5V2[4;N2V9^VE73=5U6F
MQ9]W6W7&ZBP+->I%.>?B%#U#A&)'<D*0>^?<>^D ZZ35X7&_PK(XI]M;1H-%
M@6*S?]D;R;';C6O=UYP%//6U2=OMZ]M]Q+ZBV_4XM)J]3I55NBUK)E4%GV%J
M,S4)+\.'59<>FJD/M#K4^/O]>GVU9_N9LA$V\\5S@BW!B[B[RW5)W0H/&Y4I
MMJ7]NG<]W[?6<J+9.V4H1=M;*JTEVC6%"<34ELOQ*&TTP_'BQ([B/*C-::3[
M/?NZ_1]L0?#>1TTF?I^WKUK,'5*@S2:=/J;[4N0S3X<F8Y'I\1^?/D(BLK?6
MQ!@14.2ITQU+91&AQFW)$EXH99;6XM*2^NIK&:SXM/#L_>B=N4[0<<:;]-O,
M7<JSW.!;B?;N1NTY%570FKI>HJMM_E%JW55EIVE_+2XR:?[>R[$$@OMJ0(!G
MH?J_'IU_QIZS%9.H[[<EE#[86$.)2H!QM;3@"@% +:<"7&U@$<R%I2I)R% $
M$:FE29N3=5;LFRKBNFW+'N7<RN4.ERZC3-OK/D6Q#N>[I4=O+5&HLN\Z_:UK
M1I\E:DI9>KEQT:G)5@R)S:.BE03$>_0G7W'VU8#LEXBEZ;S;WW5L>YP&<5>W
MM4VUN2U;9W>NJ[[BX6Y5L[62;VM"!?5LS+A3:7$-<E=K$&H6U5J345JLNCW/
M(B)J#;,F,W*:D1VGO[_74^_O[^VLFR5!20H9 (R,XS_ 2/X=*5^%F\_VR'&S
MG(_FV^)GXC(.XM2[].QP.HSG] #W^_[Z>Y^OWZU\L#\<R2!T<;!!QU]\ YZY
MSCMVSC Z#2E?I3\'RMT^VO"?X4[CJSBV*50-G[AK=3>;:<?<9I]*NJ\)TUQM
MEH*=>6W&8<4EIM*G'% (0"H@:?73;>L='$!]TC;"P:71*WPG1XFX\5VB5:IU
MBG[P[6\5%@2JD][+ F6LQ950M'8>_*-4DUUMR:R[(K]0MV!$4JFR43WXDF4]
M"B=O&>[I[?LI!]GJ]^L?2-^G7P__ '23L14:35JYQ9PXFUK#=$HU6IE,VAVO
MXI]PIE+?7$ES+I@WO4+NV%L2A4T4)"8C#4VW*G<5.EN(J+_MZ(;$5^6GWT\/
MQ]])B#[CIIKZXGN'A5_WC.7%2[N\'GC$NJAO./T:Y-A(%>I+[S+L9UZFU>MV
MK48+KD=Y*76''(DEI:FG$I<;4HH6 I) FIK6B+'OKS_MU9__ 'CT)^W.>O7K
M]>L !$3W1KT&HZ"">NFP[]:SUWCOD@::Z&>^/HDGH-;RO#A'\\2X#^G]MQL7
MD$?_ %YI?7[0/].F#( DQI&@UZ#??Z]/&=9J"3 ZSJ3XGZNGU1 (,[63658T
MTI32E8MN/GBCXD-H-X>&[9#AVI6Q<B?OC9V_MT7/5]\:'?E?I5/@;1+VGCQ:
M?2H=B7;:DD.596X\LS5S7I2"B#&0R(^7B]98G&KRMWYHAP-J4VM:2I)4D<@$
M@@$2#.Q]E5^1OT8^U7=+0M:&U)2H((2KTM/1)V(,:^WUX<G.$[>I[?!&]KG#
MUX1:GOFMD[8KVZ5PE7DO;B2N5>#%W+OI^@.7@IYR_$%@T-%<5-4GY"??AEGG
M67!TOY#79F;VW!DD_$KB9(V"M)TU]D5SWY969('FES!VEQ"C*=1 [A!Z]-))
MBLN/!%Q0<45]<16X/#EQ TCAUC0+,V(L+=>TJCL+:VX%K1F8E?OJ[+%7;]2A
M7M>-T-EB!'M1MV"*8S!;92\&N9QM"4)Y[+X=W#NMLNNMNJ=0I8+:2E( ($:J
M5)VUT]57N,R2,HRI]IM32$KY.59!48$DZ   ["->LZ16.3Q#_P!U!O\ ]<\&
M'#< /^=KB?[? Y.<_#((QG7U/R, ?".:,_\ -+72-OC7M9\#^)KYWY6OT38:
M2/.E]>LL^(Z3U]<"9H0.A'09'UXSD]SD8SCKT'J,'OC]" #8\I,SOKIW[=YW
MGKIW?!W#\L@=%$@Q&G-H-(VTT$DP8&D9%O!3 ^6/$''3"N)[;4$=<$'A/V,*
MAZ8'*".GYL]#K\D^4<\W%^7!U!-LF#IIYHQ/4S&I&NXK]3<&C_)K$@D"&G00
M-0?CW9[ND]-C-8 -\4)7Q=\<Y6ALJ^F5OH,EI&0E->C) Y@.V$=!VZ=\X(_0
MWD80E7!+"E(;43D<B)4VDDI#R0 21J4QH3N(.L&?E/E#*AQ(_P BG$?Q2T "
M'%)!A*SJ 8@J\($D1J#4D)CLDY\IH'W3R^4@9 /7^M)SE70_$^AU]6[)O4]F
MU!&OH)CT3&LS!U]L= #7$=JI*2E1>,%0"EK)5+B%G34'E 21! C;K-?K/\%<
M<OAB<*B>W+;^X"<=!T3O#N&!T&  <=,#'PU^ ,WIFLP.[*Y$; ;7CPV&@]E?
MJG&?H['_ /<;,[R9-NW,[]>I)/?K-:MNM?T\KGI_+ZNX/4Y(JLO&!UQ]8QU)
MP/3/T3!$_!6/C_HX'=I]7KZZZ]9'-9 1=WNDR\>G?W2?6)T^O67ZJ0*55/C\
MGRN7ZAY*\8R!_P".>OKK;RA_DR]) /\ %W-"/#H>F_4>KP\;23=V_0=JW(G4
MZQK&Y,?S?DB>@UVEW$YG\"#OMV_<O-P/7& >%FIY.>O7&3^?MC7QOJGUZP>Z
M?L/V37<&8TWZ;]_OX=^E:IQ/8?8-=PW^:;\$)'0ZQTWGI,:=^X-4"CZ:M(W.
MFV^OX^TU<EP:9^F)PD8]>*/AW'V_JQ67T[COK1R?^:/0=>T3W:B4^'<#]U>]
MI^>;.H]!7W@ >&GC,^ETK<7CL/L^W7+5<TTI32E-*4TI71*Z1I!_X!W_ !:O
MM_B.LD?+3\Y/VBL'/S;GS%?W35A/A>X^@YLJ1ZN[E=?^=J^_XOT:N>(?TO=;
M_)M]]_\ -F:H>%OT):[?*N=IW\Y>GOCU=\UCG^ZAB4^$%O&1W^<W8K'3/]DR
MB>GK\,:I/NKH:U?[4AQ^9'"E$J4OD6HE2?R^4*YUYYLCEP".B1\ 2 Z3OZNO
MJJ0"I0DR28E6VL 22=N_4;?1<U2Z1:FSU\[-WIN%3:'NE8SM6MZY[HV_I]4<
M@BO6]"J4615+6J-2BMAVGN5B"V] <D-ME; <7C)0HCE7;R]S^-XAQ^)>NL#D
MDV]W8V.5N+8/"VO'&7&[>];86H)>2R[RN%/-"@!N#!^@<7<#IX1MN%[N^S..
MR[.?L$Y!UG"OA+]HS\62PZX >5V%%(6!HM"QHI)BK.\M*X6-R:%OEO1858<V
M8NF;NA1D;2<*T.C3[EBP]NZU!9F3:Q\XC!;I,%-)4B2GY%=C-/-/NQH3?F-%
M ;J.'3QSB'.&>'<PRGB:W9P:U<1\<EUBQ4O+,$I2TC$A//%P5)*'$+4GD"BO
ME4DA7#/)M5O/*L4NM6@4A-LS<O*?NE @A96YR@$!0'+*E*/-$DB561S+=E0B
MIRHQY41+K >B*D1WF"\VI)"'#SH2,*Y?RTGRP4]2H\V>]0\R[S]BZVZ$*Y%%
MM25\JA_-5RS"AU!BO6XQ]Y9!'GMK<VI=;2ZSV[+K7:-J$A:.T2GG0I.J5))!
MT,Q-2JL86H A7*2"H'(..Q!Z9!/4=>QZ]^GI6E7OI13[:USJ(00L$@!1P4*!
MZ8(QCJ,]CZ@XT]_W>W;O[JD;[3H3 ,3H3OT/CT.M9+XSNQ'!K>?"YO[;->L#
MBN<F4V;==[;.7-%\BDT&L"F(:I\*NL1'YQ3Y,ZI.3X+=3C..,U2AMO2H4N.X
M$(^0N/\ $_E$QO'G"=W8YOR?%FX1C,3Q/9K2JXO;13BE/W%D5AJ"I+0;4IM8
M'9/@H<2H5<7.)3BSBW\H]C<O;9.R;R+EECKE?/;]HIQ(LKYQ:%I#R A"W0&@
M%%2FU)TFK,-^]Y9&_>\-][NU:WZ%:<J^:^_6%VS:<#Y/MJWXRTH9B4RC0?,6
MM,:%#988YWG%ORG6U2Y#CC[SA5W_  O@&N%^'L1P^S>7V21B;)NT%_DGU7%]
M>*1S*7<7+RB2IUU:E*('HI!"4Z)%4Y1;I6H6S*+:W+BU-L-@!#2%**NS3 &B
M2>[PB-*@MHT^MU^N4BW;'35*C7KCG4^WZ13:876:I4YM8?CPHU+90PXE3CLZ
M9);BLH4ORW'5I2I/7 M;UVS9LGKK(FW;L[%MV\NGK@!35LQ;H4XY<+*@0E+:
M0I15K &FTUN,WC]@M:["\NV%*:#2G+9QRV=<:< #["RTOF4VK5/*5$.#0C6*
MFO>3:O>'8:L5#;+=>@5^Q:V(L&L2;8JCZ?+D1)[)>IM108;[U/FM2&.934EE
M;N%>8VM:74N#57@LWP_Q39LYW WMCE[-1=MFLA:\JP%,K+;S(64A;:D+3RN-
MF""/2%:]OF+ERSN+!F\OV[,W(\[QSJKJV;3=H *57-B\EKXT \R5N-!12H*2
M2DI*K?L]".F.H[#MD@8/3KZ?'Z^V;ZO*N,C/KGT[]>A]">_UXP?CD]%*K'M>
MG;Y55B*W*37%6TB)4 \JW_),]$WR'33@E3H2D-&24^>%'W$#*59/*JKS R_F
M1.$-J+WM6@GSSF#/9\Z>TU3)YN68TCIOK79<"?D3\/(_+Y.8/#PM+XN'!EI-
M[YZ6#YCJZ""UV\=J="$Z@F"*[+[J.UGR91F+"@W'$J8ITAJYY%;DQY+$VH*=
M<\ERFML#FBL);/O@K"25\F.A6KSQB<VER].7=L76U.I\Q3:MK2IMF 5AU2]%
M**IC<R)D2 -KB]_R?.6F";X)LL];7C=DXGB)[-7##[5U?%U1:<L$,IEA"6HY
MP2$J*@ D$*)I32RGVH>9@IY3D*Z=>9./ZTD=0#D=< Y.,ZN1$ZB?7]7U]^E<
M(-9_">HV]]IK,CPJ4W8^QM_^!*M[0[BU=W<ZN<2W#I3;TA,2IT9?R?6=P[48
MN*D3&"H-1XS;C[L!*&5E,Z*XZEX%MQ24?.L-=\6Y#B#(VW$.';8PS#KQL'5!
M"P2T[%LZTX 2YVC8"U<Q!03T$S^B?*-PEY"[/R7\)9C@_B5S)\?..6#F9Q;K
MKKQ94JV4;LK86VE%HNW?/Q?(2%)TDQS5M@(H 92 % 9)'-^5@G(S^8_7]OIK
MZ& $B!IX3,>KP[J_.@ $I!D))$CK^->C4U--*4TI32E<$X_S^GV?Z=/KT[_#
MK[_?0Z?NH%!78C](_P GI]?;43WZ=TQ^-0"#L9Z>_P".U<Y'Q&A,?CT'KJ:X
MR/B.OUC\_P"CUTD>N=CT/@#M-*^><? ]^7/3!/U=>O7I]NA)$>BK7U:#O.NQ
MZ1),C2HD?<#T/JISC/+ZXSZ?$#MG/0GKTU.V^W?T]5)^D].OX?77UGKC!_@_
MSY_@U$Z@0=>O3VU-<ZFE-*4TI6/.]<?A0=B>O]I[OG@9Q_9/VI_S?QX[G%XR
M?\GKX?\ :EE[?B+J)]6OW=:YNX_6C'ZQ_)MX?_N-#ZYC[IB,AFJ.NDK\_P#X
MB'"-=G&[N7N=2;:VU\/KC"JFR]R;;4Z+M!OZK=;:C>'9RVZUMW)NBOT)G>;:
M"K.71SW]7JE:MW6>NJ1*3:;=/7<E+?$N; <E(?1 ^GOU^FGOO]W3[ZN5\)RU
MZ?M796\NR+?!9M?P55_;^\Z%4[IM/;/B)H7$<U?=4NZESE,7E7;H#B]PJ9+7
M"H;$*G0=R<515*;BII013HJF65/?W]GN*RUZ4K&_Q&C^>.^&H?46?QS_ &8.
MWNT?^88^PZ4JV7C1VAL;?SQ(]FMMMU8]UUZPJ?P.[S7Y&MFA[E[F[>0!=]-W
M]V-MV!7I*]MKQM&7/FQ*/<%9@,(GR)$9#,YTAH.I:=:A1@3W1]OOW^JH)@$]
MWV^Y%0X>%YP-?*YN ;/W7\O*IJ:*JM_2,XH15U4=,IR<FDFI?/3[:JFIF..3
M$P"][*F4M;P9\U7.?/G.OU3&GT >_P!>/./Z)_P\?7'3N/A4X^'CME:.RG&G
MQT;6[<MW/2[ INTO!S<],MNO[A;A[@QJ;7+EE\2$>O3Z=-W&NJ[*K#75FJ'2
M1,:C3FHKGL,<^2E2,G-)) )]]:R!D3[[FK=.)29NYN)QY\4UFQ>)[B<VPLW;
M.W.'<6I9^S^Z[UC6W#=O2PJS6+CEO4U%&J2'Y=0J$-F0Y(+B#S%S*59 $]_=
MI'N>_2(/US4[Q,?1]'^._P!E49H7#76;9N>^KUM_BUXW*-=>YM0H55OVOP>(
M*0Q4[LJ-LV]"M.@3*U)3:W-,?I5MTV!1X;C@4MJ#%9922E&-32/?]WM\/JK)
M;X2-V[AW-M=Q+TC<3=+<;=N1MIQB;G;;6M<NZ5R.7;=L>SZ/8.TE7IM'EUMV
M-$5(8A5"NU:0PE,=E"%3GL(ZYU \??Z:=9_PK\VUYG^:0XV>W3C:XFL'X?JB
MU$GL<^GUCWCCJ.CO]?O[FGOZMZX9ZO-=,DNM8^K*P>G3KT'7[3]>9I7Z'O#%
M_<6MD?\ DU[E=\'_ -.O_P"/3]/Y]*5^!3;G]CK;[MD6)9Y/3))-NT[)Z@=2
MHY^/,<')[O?U^JLY$"-"8Z;P=.D]XV.N^FIXW'_8ZW Z#/WBWAW _N=J7P]!
MRG!ZXQT]<0?K/V2 8(^KQH?I!&X G8[CI$;C8#0ZF?W@^*" GP(]]< ?M0=N
MB<#H<QK"R>G?/J>^IKS[](UT^H_:36N'7T6LG'Y:^O0=>8G/3'09Z>@Z>G36
M&QT)!(T&IU[SXP((@F===Z]!MKJ 1K(\- >[VCV5>3X<./PB7 ?_ ,KC8OX'
MI]_%,.,X]._<$'K\ 0WVC3H9_H@:'7I!,#3KUH=B9F3.VVYB=1UVG3NWK:R:
MSK"FE*:4K"]X@W7COX!P.F=EN.(?7DS.%OM_Y=LC!/?J.$/TRC_N[Y^I/U_5
M7.\3F,2]MJXCU?*]FIG7QF=-O<!U'3/?..Y '3H2,? @D' /?KGZT->;4]^D
MG736/4.L#J:^4ZRF!UWZC0ZZ"=_;&@J$<'H \27>#N<\#NT77I_O\;N],@?'
M[>V?K/S/C8_QVU\&#'@.<^)]^IC3Z;P@(QKGB^H_4/MW^JK*?$/'\]"O['?Z
M&'#=\,C&[/%!C&0?7MWZG'7(&NS\C&N1S0V)M;763^T>]GW[CK7(^5K]%8^?
M^E.= =NQ.FQ&P!U&^FQJA"0?='J2.AZCH#^5Z$>G8@Y^W7Z%&LC< @@[]Q$:
MR>NL_2-!\(<&BB#$A8GO G0QIW$\VP) )TG(OX*1S6?$$/3)XGMM<_FX3=C?
MACZQW[]3K\C>47]<,M\^V_W-GW]<5^J.#OU;Q>TE#W?I\>]_A].G6L .^&?I
M=\='ICC+WV(.,C^J!CXY.!ZXSUZZ_17D6_4=CQR>2 V_;_23U_?)/R?RB'_*
M1X&1_%;3O(T;)GN&@T/?,ZQ,EIQU5ZE)Z'T]Y/* 2<GMGKW(]1KZUK&D 0>D
MZRD:Z_4.[I.O *4.8#KSI.A(.K+I[N[8Z1.H(TK]9G@M #PQ^%<="10=PAT_
MPQ;B#Z_KZ9Z:_GUG#.;S)_[6R/=_TQ[NT]]SO7ZQQGZ-QW_<;/\ W=L==:U;
M-:_IY7>@_I]7/K)S59@[=_3 QTSZ_#Z+@=,5C^_S<'<2/'7:(.WA$1(YK)?Y
MY=[CX\#J =M#$:Z@3!TZS ,OU0?RJJ>#C^0)>"1C.&5C(Z^F>O;MZ:VLJ/Y-
MOB-Q;+!!@SZ(D'0:]3$^PZ5X68)NV)T^.08UZJG<$]W4[G2>6MI?Q.C^<@[[
M#J?YUYN!_P#XLU/MU_\ /OUSU^-ZRF.AZ^HZF1]O70FNY/=ML9\9_</IK5-=
MP!U'0?9V^ON/_(^NNX:_-M_,0>HT@ F1M$#68CI-4"@25 ]2HS /JD'?Q.\U
M<GP:'^;#X2/^5'P\#_KBLS6EDY%H\.G:(Z3_ $?'21![M_$'WLX+S?@E7KB"
M1OK ,]8VTK<7CL,ZY6K@;#U>_?32III2FE*:4KID]8T@?\ []?\ K:O3UUDC
MY2?G#[16#GYMSYBO[IJPCPO<G@<V5SG^B[E=_P#"U??UG^/5SQ%'PO=1_1M_
M]V9_P_?5#PM^A+3KZ5S_ +R[[=-M==*QR_=0_P"Y [R?X3=BA_UET3_3^#5)
M70UJ[FU<BDJQG"BHIR03^< $ _$_9USI3W]^_P!51E+JZFORVV0/):\Q2%/J
M*"EM0"E *2I7,>;! .,9.>Q3 $3UGK$?9O\ OK,<SA@#1*08$Q T)ZG4P3$1
MZHKAFJKC<R2R%+Y@0HK(*%)P"1[O7.#W.,D'OWGH0=01!'>/?KOTVD&$J*!
MB4D*08$I4""#)F1(U!T(TJK^XN^-T[K4NU8-Q0Z8A-ET1-(@O4^&Q$D2F6U<
MK;TQ;;)#KC;:6T$E(3A/Y)YG%GG\)PY8X%[(/6*GR<C<&X=2\Z76VU$:I;2K
MY*22H[D])C2OIO'_ )5>(O*/8\,66>8QR$<*8Q.-M'K&T1;/W*$@)2]>*0/C
M%I0A"0 .603!YM*%.JYEK4$\O.M1">Y3DD@'HD>N,X2!]0UT%?,-YZSK/O\
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MW#F2/_;IM9@9[$C[ZSZ_$]>WIU;[1'K\/J]^_1[^_OW=U5G\*GC&X1+'L[C
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M^. H@="H]P#CU'KG!QT-?+CIL9[B>O=]-=D60Y%?;?:QSM*"@" I) .<*02
MH=!S)/N]1GH=00""#L1'<?8>A\:R0M3:TK3',E04) 4)!!$I(((D:@@@]:G"
M^K^N#<*HQ*G<+T5YZ!3H=)A^R0(=/;;@P6DM,->3":99*FP.7G*0M0P5$G&-
M#'8RTQ;+C%FE:6W7W;A?:.N.J4Z\J5DK=4I4$C03'4;UTW%G&&;XTR%OD\Z[
M;O7-KC[3&,>:VEO9--V=F@H8;#-LVVV5)!/,X4E:R943H*GW;7;W;ZZ[(O\
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M$6)>&]5F;4;;TZ]+A%;%;NEMR9:C=5I%"N:CT296:^(#53>#W]]*=3]<^/\
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M8%O-<*&Q.W<*S*RVE3U9<@URS[>B2[HBR5NHAQW*G3J<E+,1,IN%&=D.LHF
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MJT<[;5=O=OVA5)45^;D#G)(&J@L$ZDZ:G6K_ /555Q32E-*5CRO3]U#V)/\
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M+;A#:.4+22H)Y;4ZBQ)=DK?*"4N@+"N8$X"4IYEYY5)(Q_7)02#S8 R1VD0
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M:W8MIW32(<6EW%9B(Z[6J,)!;D49X!(%<K+Y%;8MUOI7:"R18]@I )[%+Q>
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M*%!1"UH62Z\I+BDO/. MD<QP[975HYDS<Y]>:#MVM;;:B@BP!*H8@*64J"2
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<WMJX&;(VH9986B5+4%*6%**H)($[:=2"#7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g491933g97a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g491933g97a09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1IJ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &DZ^9S0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!LP(M
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )3,S  !  $ E,S,
M  $  3A"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$1       $     (   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             "DP  !)0    & &< .0 W
M &$ ,  Y     0                         !              24   "
MDP                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
MDP    !29VAT;&]N9P  !)0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   I,     4F=H=&QO;F<
M  24     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M%TWJC>I]2QKMFQS<?*:[83948NQ6;J,O8RK(;[/S/YM;J2D&=AUYN*_&
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@!$P'I P$1  (1 0,1 ?_$ !\  0 ! P4! 0
M   )!P@* 0(%!@L#!/_$ '(0   % P,!!0,%"0<*# \1  $" P0%!@<1  @A
M,0D2$T%1%&%Q%18B@9$*%Q@D,J&QP? E)C0U-C<X&2,G.59V=[/1\2@I,T)#
M1$=469:VX45(5V1F<G-T=7F&M+6XV!I&4U588V5G:'B"B)BFI[?3_\0 ' $!
M 0$!  ,! 0            $" P0'" 8%_\0 41$  0,# 08#!08# PD$" <
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M?==,VC2=ZRZ927:Z0=43U!UBKMMNM![1+LWW/MPMEN[?SU!+TE4EQU*E?T1
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M#_=$NZ@@9E=6^XU])^11=-41!(9&[O 7WL1 YVF<GFBWDM(4E33Z=CPB9MY
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M$$JN:'1O>]!D%UR#<VX9T6XL:Q*Y4> S9^U*$(D=R#5$'!TB&[Y4CKB453$
MV#%(8XE*8,E* XQ-T"S?=R3:9)R4B3)@FUXO:PDZPH\NTP* 6NVV@&"E+V@6
MP\       W*4& % .  .@  =/3&M'T^G?-52-Z(FB)HB:(FB)HBXB<@(.IHU
MQ#5'#1,_$._"]KBIJ.:2L:[\!4BZ(.6+Y%=JN"2Z:2R0*I&\-5,BA,'*4P2
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MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(N!JE04J:J!3Q"I=R$ECBJ9PT:
MF!&#@PG]J?IJL6W=QGVAZDJT1QXKE-1$AR"1:4J<%*;@3@IXP&A8HWB^,U<@
MIWF*!O$!RP0;L7'B9[_C,D4FJH"!T$4DS%(!0:\C'P&.7>%S^BJMZJO^DU9O
M_!;>CX?QU:D<_'CCWZ*3/K'IGCKTMSS<+HJFB)HB:(FB)HB:(NJURKX-&U4L
M*X-@2IV94]H%Y'QX(]R.<F\47LL@YBVA4\ 8SF1;.&:!0,JX1.D0Q1*'OX<K
MVF.>ATYB&/XD3&G[X' S%H('!1!8#![.EDP+-BE;+9'(^*W(1 _Y2)"IB4-%
M5R6B)HB:(FB)HB:(FB)HB:(FB)HB:(FB*F%[;@+VGLW=BZ+6,2FG-M[:US7C
M>'7='8H2JU(4S)SZ<:J\31<':)O3QY6QW)&ZYD"J&4*DH)0(8G#X^A6#U_[L
MLND3(#L/H$V!'Z0WYJ$!ZC@ #[V/EY9'(@'(YYT4Z7G6W#O0W.%>WV<OW3K<
M#?=O0L?M0EMHM'VVC[N3%1QCFM(V[TU4CV$+!454M6$51A75!1"#T7*D"1D8
MJD@W!$K@7&5!2!%0E^X[@^O,+(TWY;I'>S+;%<7<6RHHMQW5"J4:U:T2>HOF
MF2;=UC7-.T4V(>H!B)TL<1LK4!7AU!BG?B%;"B)4P4\9/E4?N/V=IQ6VBE1X
M1O;Y/D8O;3TZTV!YJDN@4MGK53:9#&DCS$6\[*W*D=^M\Z0W"V?L+NZVNP=A
MT+]Q%QW5K[DT5?Z!O!2J\Y:JETJXJJ K-HI1=!2]*)A2)7LJQG1;R<4JLS49
MN%FYA,JEMI:7OHEQ#Z5,O=T:)SD2()F\8R%Q&\:=*H!+:KZ3 2(]ZHUIB..\
M2!IK< E5*E^TGVK5);^\M1V"OK8F\E9VAMO45QY"CT+RTG2\;\D09#)?*L[5
MKU1\PIZCQDB!'/JV,RDH*+6,(N5>4P4TV7-#P#NN+0.CC8QPB_P73<=[1E,B
M'.%4ZV-(.+@<'0Q8\8X5MAMX6V:7O$TVX-;YVP<[@UV[I9:SK.LX=Y7S4\=3
M+*L9)-:GDG(RB8-*8?M)[O+-DC+Q"Y9!$AVQ%U$KND[P;)W").N0!/&=>MU@
M^ZT%UI!ZV$F/*8Z*U2J]Y>[*;W+;@["[<-H]!7<B]O*]L&535G6NY9&U"D@_
MN=0$;7L>A'TZ>T]8G,FP:O5&3AP,J8JJB15"D2%04R<J<O;5=)]VMN".3;BV
M,3?KR72H&L%*#[U2E[6#U(@?7H;\:^5#O;L99-G;:G=V5U+.[>[RU]3\9,.+
M8SMTH60-&O7SM"*<(1TT^;4\I*0+>=7^1VM4NX:%BWCP/!#P5A\$.A+34--I
MF #)D9TQKIW&"'"F*CFP)B!DDR>,<B9^%U2W>OVFNV?9O;^YLC.7.ME/7DHF
MV4E<:F[$NKC0E-UC6Y&\<YDH:*9 JG)KL%JE1:+C!'5C'2LJ5(YXQH^ HEUS
MWH>6@ESA493<V9@O#7#$ 6(UF\*M:7?B!:#2?5:X$7#-X0+S,M(Q&;P+R!T[
M*_+M/P4WX/L_RQ#1DKX J>**'R@R0=^"*H%("GA^-W/$ A>_W>]W2YP'5P+7
M.:<M)!Z@P5AI#FM<#(<T$'B")E<SJ+2M^W+5WMRMC:^0N%NGF+<4_:&DY:G9
M64GKIM8MY2<+-!.,FM+R:Q)=F]:MY)M4+F.+#/B)%<M))1NJW527*F8(2!$D
M"3 DQ)X#B@#G$[H)@$NC  BY[Q)%\PE]IKVS6S$^Q*_K3:#OIM6?<.2GZ;):
MUO;.LFXUF$F:N:72?DIU$K8P>.%/GEBJ%*7 ,O:,8 -9=O[U'=Q[>E[3B:0>
M"^/(?O@[I;@+W/L&TJY:3 A_LGAG*SB .)QD*=VSU)TW 4DQG86GH*$EZ[C*
M>JFLWT/"QL0ZJ:IUH".:.9^>58-6RDM+KMF[5JI(OQ7>&;-6R J^$BD0O:IN
MBI4;2&[1%2H:;8(C>J/<77R' M(Y!>)LV\ZC1?4)-1U"@'R;C=I@1@1!+I&)
MF(N%46:FH>G(B3GZ@E8Z#@X5BZE)B9EWK:.BHJ-8H'=/9"1D'BJ#1DR9MDU'
M#IVY62;MT$SK+*$3(8P<G/:P2YP:+"YC-AZFPYKR0"XPT2>'+7T"MOL?O:VB
M[E)V<I>P>Y"S=W:EIMI\I3<#0->T_44NQBO:?8OE<T>P>JNEH?VS#49=LFO&
ME<'21,Z!59(AM&PDV%KG%SNB_,VZV69@M:8WG3 U) DP.5R> 'I]+:;U=I-Y
M+C5!:&U.Y&RUQ+G4L63/.T+1UPZ:G:E8)0KLK":5-%L)!9RX2B'QR,Y15F1P
MG'.3%1>G04,!=![P#A<.!((P0)DCE8_-0NC\7NW#2#H[A/I^^-T3O3VD3MYW
MNW:&W)66D[Y1[AXR=VL97$IEQ6B4E'($<R,1\B)R(NE)J.;'!Q(0J1%)1B@!
ME735$A#B6-(> 6>\'"06W!!O:,V6JG\HQ5!ID&(>-TR>O4>H5O\ VF)BFM?M
MN[I@'':";#\X'/7<I0>.G3@>OU==";2+C,@C%[C(.(3Z94CNJB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HBX.IE"HT].*F6*W!.(DCBN=TW8E1$K)<05%Z
M[1<-6?AB ']I=-UVZ'=\19%5,IB&*'NT]_'HMM+J@O3T&L"X.?%AXM05@=MW
M_C"=DB<5O;F:+9H]\7(']K:MT&[G/C(HI)G*0I!WI]2N>T55O=5_TF;-_P""
MV]/_ *9M3_FT4^-]>OTT\NJN$T531$T1-$31$T1-$76*U5!"DJE<&<@S!&!E
ME/:A?LXH&_=8KF\89.0;/6# $\=\7CUHY;-L"LLW6(44Q*>NO?$]ZPN7B#B>
M+CCB?Q1,Q:&\3QDW(*903'O@X1211< ?\KQDDDTU,]XA"E$  @[Y<N_@++D-
M%4T1-$31$T1-$31$T1-$31$T1-$31%;CO"07=;3-SK9LDJNX<;>[S(((($.J
MLNNM;JHDT44DTP,=150Y@(F0H"8QA "@(B :AZQ@^BAR#\>$_GCCZE>-$:U%
MT<_S;5_QZ4=4(Y\O_BX0ZAR&< .<].*GU\H^7IZVQ,=]S^V^KZ%[7K9G)S-#
MU?$1K:JZ]%P_DZ:FF#)N![/W"2(*[MTR102 RBA$R>(H4#*&*0,F,!1(;"W
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MNV\%-8!5%-WWWJJYCA:USH#F9OS/K,E52_JJMD_[@+J=?]Y4C\!_]]OKI:W
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M""/B 0I +Q-B;6B!8"RQJP* "(AT'H'I^?/[?#$)TB9SP\SC2X77=W)=D8$
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M*X1[N/,Y!\Q4(7O]MIK>PI5GP(HL>\Z2&DB)/$";C36)7&@P5JU!KC/M'TV
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M<AR.>@].GN_Y_3ST,_IF?6((Z_IEAWI#KXR!:==/C9,\X]<#G/Q]PAR "/D
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MHXSXJ>/7O!CC&><^\/M#3>%A(N)%\@:]+JDQ)-HS*T!R@(B +)B(!D0 Y1$
M'H(AG(!J;[;>\!(D28D3NSTFT\9X%)N0;$1(.1(D3U%PHZ.TP,4UK]N %,4W
M=[0+8=D $!Z[E*"$.GJ Y /,.FD@R 9+3! (D$C6XT,Y"*1W6D31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$7!U,?PZ=G3^(9(2Q$D8%"KO6QB89+CWBN(U
M)>11, !DJK!%1ZF( =J0RY4RB4)@7[[YVYJTW=T?Q-F5QC]\5/$HVDC"J99Z
MX.KWYZFA[YG$DFC(K]X! ?%?HHOE,B=TF1P8Y0'U\I_547C23CKTE8U90'/V
MYX] X ,CC "(XQU'IQJ3D\!IP.NG#GBV;]&R#><09 C@ -,X(\@%J/(8#'7.
M0ZASGX#D.?K#ID= /TTM>/GP!'/*TXDQNF8S!])Y:<--0@#P =. XZ_# \^\
M??\ $.6N>=N49L;=",QK<TP(=8@VFT#F#YQC7@I\NRR_F$K#_"O,_P#).C?\
MWU>F-!C]9^.JYONXJ2_564T1-$31$T1=7K=3PJ/JA7Q#)>'3\N<%2.9-D=(2
ML5Q\0CV%1<2[0Q/RBN(QNN^0, *M4CJD*42FHMU]#D:CES7+Q YBXX<F-^(L
M_I&576,?+=(1,*KHI72HFSD5')".%!R=<I53'#1!^_7X_6V++D=%4T1-$31$
MT1-$31$T1-$31$T1-$31%T&ZP@%K[C9$ #YBU;R/_@%_Z .=$%B#P(6(Z(\
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M%CV@-4FJ9#)>#IKMQNTM:(&U%A>8@Q2<T@6,7+0>8D&0NCO?% FWL2]S1/\
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M<Q:5N]#=HALTC)2DS4)<F/*UDJ0W+48A4+8U0RE(,J76".59N">,A.+-W?<
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M&!Y!?0Y"'#!R]X.\ B&.HEY 1\^,?'R\^<S''A;GQX6.NBI -BMX     &
M   ]  . U55KHBL#[3&KK;T1L\NO4UV-L4_O$I",;TVJ?;U3=*%K.2KR95JJ
M)0IU)2$,UD,Q\1.'834K(HQLFXB(UBZDF\:]7:IMEN%8!S:=I?O#=,Q!Q8B^
ML$&9N++=(;SWM+B&BFYQ@22UN=1>]B)B =%@XV9MGMNO??).^>^GL_=SEG*
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M=@&/>+K&UVB3'$+OL_B_ANUU31V?;=GK508+&/)<#<C0"X$V)X*X(!R #Z@
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MNTT @*<J8\H3NCD.Y(J'?$QW7AQ7!0=/T[_/CS03,B9!$>5_CCC98U =X>N
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M?N$Q$B[PQ<"Z6((IJK^(<@B40'6CEW4_-8I_V;)SNMZXM*['J+:VB<@9 3%
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MC6YQU$/T>N/U_GUD#\[@YXYUG YB=%W!;F6])&G&X\N)$+:(YZ8X]_3J \]
M' \9]_'&KZYXYUBW#Z<,X<1 @B9XCA'EG)CEA:<YX 1SP'O$1ZY ,AP(_6.
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M ]WW@&&2< :6C.HXCT2X1*/0B(Q&)% 8I&.8I1?LJH+-@CDVR9&0-U0,?Q$
M; D"1^\;OD[IN\;.1P?Q&;&TC@=<WOPT1D 0+@0&GBT"W?%?AJ^H"4G2M1U0
MK&S$RE3D')SJD13S!26GY5.*9K/CQL'%HX6DIAZ5 6L8P2$%'CU5!N00,H A
MA[BULM )F "8^*V "8)W0=1)(MP'.RAZVN]I)>"YC[M(*QW#6+?V"H[9U"T1
M6=(VQG3L5[L)T%,VCJ*Z2CVX[AA,3$*QJZHXF+82"%,M4FRE("_^0)A5[)M'
M;@N:CWLV45VAKG&O5I!LD /I[A>)M;WVP>L86-T?Q)8-XM-$.!( D2Z#QONG
M)F!T73;2;V=\=./]C5UMSK3;\:PF_><94Q$TC;JG*M@:_P!OM3UW;J>NO9R,
MFZNFJRGHBYK2=IRFWL#5[EM3-)*1E0*H.XP'+#\6/U #*HV=P]ZGL5>N2)(>
M[9V%[FSI %B!<V,&ZRZ:C-YONSM5*E,C^S<\"^@SY3/(= H_M']ZCBU%D]^E
M5P=BD=EM]-R=/6C:VF9T]5+:]5!V@N)=)Q9^W%Y)&Y*U8.:9GIUU4WR3-5'1
M2%",6C:G)I C*8]M:NCI9'NG96N)+MI /_"ZJT5*3;"(+29.A$'*Z%S/\\?(
M;3V;>@_XA1)96)F#[KA(B=\21;-^_:6K$5M?MN*4PB8.T!V(B81+W>]W=RE!
M=\"@(9[W(#W0#.!XZESHVSB)^<_)3,_2X\C@J2+15-$31$T1-$31%Q$^_6BX
M27DVY2*+1T8_?)IJ9\-0[1HLN0A\"!NX8Z90-W1 V!' AHB\_1[]V'[PFSQT
MV)M2VUF*W<KH%,:2NAWC%25,0HC^^LH=X0* C@,=< &B*@%__NIG='N&I^@J
M<J3;=8& :V_O99R^$:YA']Q5%WT[9JO(>O86&> ^J-PF6)EW\.DRDU$2D=E9
MJJBT62< 0X.^^_T*NX_=BN\,!$ VI;:1#/&9.Z.1#G&<54 9$ YP !UP&B*;
MWL-.W*OGVJM\KR6MNG9RU%LXFV=JF=P(Z0M^ZJYP_DW[FK8BG#,GWSCF91N5
MD5O)J.0%LDDOXZ*0"KX8G(8G963;HB:)T75WSJL$W*Q8^(@G+,I@%!9U-O&K
M@Y>Z F!5!.&<IIB!LE "K*9* &[P"(@#]=?33K*G,Q^7'KZ!<'%3U;2S91VW
M@J>!(KU^R[JL^^(<%8U\XCW @ 0)P$AEFQS)&'!C$, G(0?HA)GX_"WY]XNG
M/OGWQ7?&HN3-D#/$TDG9DB"X205,L@FL)0%0B2QTD3JIE-D"J&12,< [PD((
M]T*BXZHR"I3\X0$@7$\1)E!$6JKT%1,R7#PQ9(.&J[P%,]P6J+ILJN!O"371
M.8JA2AQ^_EA6F;O4RH[,KCI F5'PJ-I0@H@T6C_"$L]30=P&3A=TNS N *5H
MLX<*MQ**2BZQRBH)!^F9X\O*=8O<+&G !$<A@,\^HAGJ/3W" @. \@'G&G??
M<K8$QI\YS:.0M/..6O='D?,0'(?HZ8#/O]_30]85#'<M;$]CI=:E^CU'(_7S
M^L<X_,&-9-[1QCX=;&;SY@K;88"#$G6_"W+0Z2<7%E/GV60YL)6 ^MUYG_DI
M1ON#GS'XZH^5O3\L+FXR2>\*2_564T1-$31$T1=:K)$7%)5*@5$'!E8&63!
M6#F4\8#L%RBC\F,W;!Y(>* ^'[$T>M'#H3 BBNDH<I@*&+3H9Z<_V\[2HO\
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MF:F?,8T&C>KU$:;:5-B-;)SJS1%I)(KKLUE)2'MFBLUI !86N(GW7OW:;B,
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M8,X"SS*'8-8RBZ2CF*4D@S8TS M&B$SCY71;-HIHB@E*  F )%-),A'H 8P
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M(U.?-3Y=EE_,)6'&/[*TQQ_Y)T;[@ZZT.[1\UAP <0,#\O/YJ2Q01!,XE_*
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MN9NLIK:3G\&JRN<?R!A>G_<C?JQYZ#\^\#UURN?8Z=]56&M_Y&U5_>]+_;[
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MF4PLWBG93C]$6TDN@Q7_ "'2R:0F.7Y*^"^H>]>G?#*C#[40 +9NS@8 @%K
MWT0201 O[U'0 3PFQU&R7=X+X;90Z"8!X:)S)E*(O..^:TS.@B9OIYQR4(?
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M-3554%5'9/'RGL:D?"'J&2D5(*GT4XY)1E3T4=K#L7"SUPV9I+/G1E<F;0<
MGTC3/$6X\X,X\K>L'\ET'&<8YR ?$0#X?JR'OU+$R>AC!GI-\ Q$8)(5ZK3
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M=,G %A?,P!,PK._/ >G.<"/4 X#'G^H>=?LY)[MRN//C'2)_,@ XN1$XDV,
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MC2WFLBW;18:EZAVY6V<NZKNVT-4M 397Q(2\=S())F%=P5.0DI\AIQ-4,RP
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MQTZ@1/ :] 09(-L&>$CIBT8_-D ''.<9P #G ^?UY_8-!U&3\=+<XS?U@0O
MR;\P?@;SKTSG&4OM)_HTV5Q_<%#>[_8S>7E\/+WZTO'-R3Q[PJOUQ_(ZJ/=
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M#)&=,%C-U5F_A+*(.+:<0<9D',Z<-450T=RE_B+)'/V:N_$"E4(8P_-FPF0
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MY1 PB(Y@G\1DSG4@8!F_SZII& + <.@PJ/06SC:S2=76]KRCMOEGZ-K"U(5
MG;RHJ/H"G:4DZ4;U4P>1U1,XQ>GV$< ,9=N^<"]8.2N&2CDQ'X-RR"*#M+1)
M))U, ]!\+9QR4=+C+B)!D0(QBWSB/JKE]%4T1-$31$T1-$31$T1-$31$T1-$
M31$T1;%" H0Z9OR3E$H]!X$,#P(" \>H:A <"T@$$$$'!!$$%+BX)!%P1D$:
MA16TOV16WNE+C4U4C2XM_7]H:%O+(;AK>[5)6OXYYMSH2\T@^=S'SQI^DQIE
M.HBH1E12,K5$#2[^K7U*0=22KZ4CH5!14"E4A[(4P"7>R %-S[N: "T06[N
M8'#18J-]J*C9+!5>Y]0L@;^\6ES3,^ZXC'(WO>5)-,$R]T!$0   ,XXP&.
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8$T1-$31$T1-$31$T1-$31$T1-$31%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593273857776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Surrozen, Inc./DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1556622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">171 Oyster Point Blvd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">489-9000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Post-Effective Amendment No.&#160;2 to the Registration Statement on Form S-1 (File No.&#160;333-259496), or the Registration Statement, of Surrozen, Inc., as originally filed with the Securities and Exchange Commission, or the SEC, on September&#160;13, 2021, as amended on November&#160;8, 2021 by Amendment No.1 and declared effective by the SEC on November&#160;9, 2021, as further amended on March&#160;29, 2022 by Post-Effective Amendment No.1 and declared effective on March&#160;29, 2022, is being filed pursuant to the undertakings in Item 17 of the Registration Statement to (i)&#160;include information contained in the Registrant&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 that was filed with the SEC on March&#160;31, 2023 and (ii)&#160;update certain other information in the Registration Statement. The information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No.&#160;2. All applicable registration fees were paid at the time of the original filing of the Registration Statement.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">171 Oyster Point Blvd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">489-9000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Craig Parker<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271541712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,690<span></span>
</td>
<td class="nump">$ 33,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,978<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">51,148<span></span>
</td>
<td class="nump">68,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">3,338<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">81,305<span></span>
</td>
<td class="nump">105,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="nump">4,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,268<span></span>
</td>
<td class="nump">4,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Long-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">89,435<span></span>
</td>
<td class="nump">137,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">2,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">8,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">2,226<span></span>
</td>
<td class="nump">2,193<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,732<span></span>
</td>
<td class="nump">13,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, noncurrent portion</a></td>
<td class="nump">3,376<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">8,301<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,434<span></span>
</td>
<td class="nump">27,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6 and Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2022 and 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 500,000 shares authorized as of December 31, 2022 and 2021; 30,088 and 35,034 shares issued and outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">254,892<span></span>
</td>
<td class="nump">252,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(241)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(178,653)<span></span>
</td>
<td class="num">(142,649)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">76,001<span></span>
</td>
<td class="nump">109,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 89,435<span></span>
</td>
<td class="nump">$ 137,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271446432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="nump">30,088,000<span></span>
</td>
<td class="nump">35,034,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding</a></td>
<td class="nump">30,088,000<span></span>
</td>
<td class="nump">35,034,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271459696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">37,013<span></span>
</td>
<td class="nump">40,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">19,826<span></span>
</td>
<td class="nump">14,214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">56,839<span></span>
</td>
<td class="nump">54,391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(44,339)<span></span>
</td>
<td class="num">(54,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">7,554<span></span>
</td>
<td class="num">(329)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,004)<span></span>
</td>
<td class="num">(54,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(122)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (36,126)<span></span>
</td>
<td class="num">$ (54,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (1.04)<span></span>
</td>
<td class="num">$ (2.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common Stockholders, diluted</a></td>
<td class="num">$ (1.04)<span></span>
</td>
<td class="num">$ (2.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic</a></td>
<td class="nump">34,722<span></span>
</td>
<td class="nump">24,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted</a></td>
<td class="nump">34,722<span></span>
</td>
<td class="nump">24,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271812512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 47,293<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 135,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (88,001)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs and warrant liabilities</a></td>
<td class="nump">114,465<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">114,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock upon Business Combination and PIPE Financing, net of issuance costs and warrant liabilities, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions', window );">Reclassification to liability for early exercised stock options</a></td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue', window );">Vesting of early exercised stock options</a></td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_RepurchaseOfEarlyExercisedStockOptionsShares', window );">Repurchase of early exercised stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase and cancelation of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock granted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock forfeited, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(54,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,648)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2021</a></td>
<td class="nump">109,700<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">252,464<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(142,649)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions', window );">Reclassification to liability for early exercised stock options</a></td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_RepurchaseOfEarlyExercisedStockOptionsShares', window );">Repurchase of early exercised stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement', window );">Issuance of common stock under Equity Purchase Agreement(Value)</a></td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement', window );">Issuance of common stock under Equity Purchase Agreement (Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase and cancelation of common stock</a></td>
<td class="num">(2,607)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_RepurchaseAndCancellationOfCommonStock', window );">Repurchase and cancellation of common stock (Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,382,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">4,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(36,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,004)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2022</a></td>
<td class="nump">$ 76,001<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 254,892<span></span>
</td>
<td class="num">$ (241)<span></span>
</td>
<td class="num">$ (178,653)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,088,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital early exercise of stock options value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital reclassification of early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock under Equity Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock value under equity purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_RepurchaseAndCancellationOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase and cancellation of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_RepurchaseAndCancellationOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_RepurchaseOfEarlyExercisedStockOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase of early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_RepurchaseOfEarlyExercisedStockOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271760240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (36,004)<span></span>
</td>
<td class="num">$ (54,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">1,955<span></span>
</td>
<td class="nump">2,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,517<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,314<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of premium on marketable securities, net</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(7,890)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement', window );">Other expense related to the commitment shares issued to Lincoln Park</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Transaction costs allocated to warrants in connection with Business Combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,978)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(2,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other assets</a></td>
<td class="num">(379)<span></span>
</td>
<td class="num">(510)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,038)<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(1,782)<span></span>
</td>
<td class="nump">3,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,191)<span></span>
</td>
<td class="num">(2,061)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(44,145)<span></span>
</td>
<td class="num">(48,813)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(728)<span></span>
</td>
<td class="num">(1,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(29,600)<span></span>
</td>
<td class="num">(91,739)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ProceedsFromSaleOfMarketableSecurities', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">68,637<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">38,309<span></span>
</td>
<td class="num">(77,708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">124,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases', window );">Proceeds from issuance of common stock upon employee stock plan purchases</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase and cancelation of common stock</a></td>
<td class="num">(2,607)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Repurchase of warrants</a></td>
<td class="num">(85)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_RepurchaseOfEarlyExcercisedStockOptions', window );">Repurchase of early exercised stock options</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(2,565)<span></span>
</td>
<td class="nump">124,630<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(8,401)<span></span>
</td>
<td class="num">(1,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">33,496<span></span>
</td>
<td class="nump">35,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">25,095<span></span>
</td>
<td class="nump">33,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock into common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">133,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination', window );">Assumption of warrant liabilities in Business Combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Transaction costs in Business Combination included in accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_VestingOfEarlyExercisesOfStockOptions', window );">Vesting of early exercises of stock options</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions', window );">Reclassification to liability for early exercised stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension', window );">Increase in right-of-use assets and lease liabilities due to lease extension</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract', window );"><strong>Reconciliation Of Cash Cash Equivalents And Restricted Cash To Consolidated Balance Sheets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">24,690<span></span>
</td>
<td class="nump">33,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">405<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 25,095<span></span>
</td>
<td class="nump">$ 33,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumption of warrant liabilities in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in right-of-use assets and lease liabilities due to lease extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock as a commitment fee under Equity Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock upon employee stock plan purchases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock upon exercise of stock options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification to liability for early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of cash,cash equivalents and restricted cash to consolidated balance sheets abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_RepurchaseOfEarlyExcercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repurchase of early excercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_RepurchaseOfEarlyExcercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_VestingOfEarlyExercisesOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting of early exercises of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_VestingOfEarlyExercisesOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593277602528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Business</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 1. Organization and Business </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Surrozen, Inc., or the Company, formerly known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Consonance-HFW</div> Acquisition Corp., or Consonance, is a clinical stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The Company, a Delaware corporation, is located in South San Francisco, California, and it operates and manages its business as one operating segment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consonance was a blank check company incorporated as a Cayman Islands exempted company on August&#160;21, 2020. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On August&#160;11, 2021, Consonance consummated a business combination, or the Business Combination, among Consonance, Perseverance Merger Sub Inc., a subsidiary of Consonance, and Surrozen, Inc., or Legacy Surrozen, a Delaware company incorporated on August&#160;12, 2015. Upon closing of the Business Combination, Consonance became a Delaware corporation and was renamed to Surrozen, Inc., Legacy Surrozen, was renamed to Surrozen Operating, Inc., and Legacy Surrozen continued as a wholly-owned subsidiary of the Company. See Note 3, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recapitalization&#8221;</div></div> for additional details. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Surrozen Netherlands, B.V. was incorporated in May 2022 and is located in Rotterdam, Netherlands as a wholly-owned subsidiary of Surrozen Operating, Inc. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred net operating losses each period since inception. During the years ended December&#160;31, 2022 and 2021, the Company incurred a net loss of $36.0&#160;million and $54.6&#160;million, respectively. During the years ended December&#160;31, 2022 and 2021, the Company used $44.1&#160;million and $48.8&#160;million of cash in operations. As of December&#160;31, 2022, the Company had cash, cash equivalents and marketable securities of $75.8&#160;million and an accumulated deficit of approximately $178.7&#160;million. The Company expects operating expenses to continue to increase in connection with its ongoing clinical studies and anticipates the need to raise additional capital to continue to execute its long-range business plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management believes that the existing cash, cash equivalents and marketable securities are sufficient for the Company to continue operating activities for at least the next 12 months from the date of issuance of its consolidated financial statements. However, if the Company&#8217;s anticipated cash burn is greater than anticipated, the Company could use its capital resources sooner than expected which may result in the need to reduce future planned expenditures and/or raise additional capital to continue to fund the operations. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275350336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 2. Summary of Significant Accounting Policies </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, as determined by the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, and pursuant to the regulations of the U.S. Securities and Exchange Commission, or SEC. The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany transactions and balances have been eliminated. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination discussed in Note 1 was accounted for as a reverse recapitalization with Legacy Surrozen as the accounting acquirer and Consonance as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the consolidated financial statements represents the accounts of Legacy Surrozen at their historical cost as if Legacy Surrozen is the predecessor to the Company. The consolidated financial statements following the closing of the Business Combination reflect the results of the combined entity&#8217;s operations. All issued and outstanding common stock and stock awards of Legacy Surrozen and per share amounts contained in the consolidated financial statements for the periods presented prior to the closing of the Business Combination on August&#160;11, 2021 have been retroactively restated to reflect the exchange ratio established in the Business Combination. See Note 3, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recapitalization&#8221;</div></div> for additional details. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, revenue recognition, certain accruals for research and development activities, the fair value of common stock prior to the Business Combination, initial fair value of the PIPE Warrants and stock-based compensation expense. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could materially differ from those estimates. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist of cash, cash equivalents and marketable securities. The Company&#8217;s cash is held by one financial institution that may at times exceed federally insured limits. However, the Company&#8217;s exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company believes it is not exposed to significant credit risk on cash. The Company&#8217;s policy is to invest cash in institutional money market funds and marketable securities with high credit quality to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and marketable securities in a variety of securities, including money market funds, U.S. government bonds, U.S. government agency debt securities, foreign bonds, commercial paper and corporate debt securities. The Company has not experienced any losses on its cash equivalents and marketable securities. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash equivalents relate to securities having an original maturity of three months or less at the time of purchase. As of December&#160;31, 2022 and 2021, cash and cash equivalents consisted of bank deposits, money market funds and U.S. government agency debt securities. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of each of December&#160;31, 2022 and 2021, the Company had $0.4&#160;million of restricted cash in the form of a letter of credit for the Company&#8217;s facility lease. The restricted cash is classified as a noncurrent asset as the Company is required to maintain the letter of credit for the benefit of the landlord until the end of the lease term in April 2025. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company invests its excess cash in marketable U.S. government bonds, foreign bonds, commercial paper and corporate debt securities. All marketable securities have been classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company does not buy or hold securities principally for the purpose of selling them in the near future. The Company&#8217;s policy is focused on the preservation of capital, liquidity, and return. From time to time, the Company may sell certain securities, but the objectives are generally not to generate profits on short-term differences in price. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Short-term marketable securities have maturities less than or equal to one year as of the balance sheet date. Long-term marketable securities have maturities greater than one year as of the balance sheet date. These marketable securities are carried at estimated fair value with unrealized holding gains and losses included in accumulated other comprehensive loss in stockholders&#8217; equity until realized. Gains and losses on marketable security transactions are reported on the specific-identification method. Interest income is recognized in the consolidated statements of operations and comprehensive loss when earned. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company periodically evaluates its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities for impairment. When the fair value of a marketable security is below its amortized cost basis, the amortized cost is reduced to its fair value if it is more likely than not that the Company is required to sell the impaired security before recovery of its amortized cost, or the Company has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost basis over the fair value of the security. An allowance for credit losses for the excess of amortized cost basis over the expected cash flows, if any, is recorded in other income (expense), net on the consolidated statements of operations. Impairment losses that are not credit-related are included in accumulated other comprehensive loss in stockholders&#8217; equity. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, including leasehold improvements, are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"/>
<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Estimated useful life</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Shorter of useful life of asset or lease term</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture, fixtures and equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">3 years</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the period realized. Maintenance and repairs are expensed as incurred. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Material leases with a term longer than one year are recognized as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use,</div></div> or ROU, assets and lease liabilities in the Company&#8217;s consolidated balance sheets. The Company determines the lease classification and measurement of its ROU assets and lease liabilities at the lease commencement date and thereafter if modified. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses its incremental borrowing rate, based on the information available at the commencement date, to determine the present value of lease payments if the rate implicit in the lease is not readily available. The ROU asset is based on the measurement of the lease liability and is adjusted for lease incentives provided by the landlord. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. The Company has not identified any such impairment losses to date. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Public Warrants, Private Placement Warrants and PIPE Warrants were classified as liabilities (see Note 11). At the end of each reporting period, any changes in fair value during the period are recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. No Private Placement Warrants were outstanding as of December&#160;31, 2022 as a result of the repurchase of 1.3&#160;million warrants in December 2022 (see Note 9). The Company will continue to adjust the warrant liabilities pertaining to the outstanding warrants for changes in the fair value until the earlier of a) the exercise or expiration of the warrants or b) the redemption of the warrants, at which time such warrants will be reclassified to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue in accordance with ASC 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers (Topic 606)</div></div>,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for these goods or services. To determine revenue recognition for the arrangement that is within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract with the customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At contract inception, the Company assesses the goods or services promised within the contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligations when or as the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the variable consideration constraint) that a significant reversal of recognized revenue is not probable. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses accounts receivable for impairment and, to date, no impairment losses have been recorded. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a collaboration and license agreement with BI to which the Company licensed certain rights to its intellectual property (see Note 7) that is determined within the scope of ASC 606. The terms of the CLA include payment to the Company of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment, development, regulatory and commercial milestone payments and royalties on net sales of licensed products. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licenses of Intellectual Property: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone Payments:</div></div> At contract inception, the Company using the most likely amount method evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received or the underlying activity has been completed. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenue in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties:</div></div> The Company recognizes sales-based royalties as revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalties that have been allocated have been satisfied (or partially satisfied). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The incremental costs of obtaining a customer contract are expensed as and when incurred if the amortization period of the asset that would have been recognized is one year or less. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs consist of external and internal expenses directly attributable to the conduct of research and development programs. The external expenses include the costs of services provided by outside contractors, clinical research organizations and contract manufacturing organizations. The internal expenses include the costs of salaries, bonus, payroll taxes, stock-based compensation, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, and the allocated facility-related costs, such as rent, utilities, insurance, repairs and maintenance, and general support services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into and may continue to enter into licensing or subscription arrangements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company&#8217;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records accruals for estimated costs of research, preclinical, clinical, and manufacturing development, which are significant components of research and development expenses, within accrued and other liabilities in the accompanying consolidated balance sheets. A substantial portion of the Company&#8217;s ongoing research and development activities is conducted by third-party service providers. The Company accrues the costs under agreements with these third parties as incurred. The Company estimates the amounts incurred in each period based on the information available and its knowledge of the nature of the contractual activities generating such costs. Clinical trial contract expenses are accrued based on units of activity. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. For the years ended December&#160;31, 2022 and 2021, the Company has not experienced any material differences between accrued costs and actual costs incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts accrued expenses or prepaid expenses accordingly, which impacts research and development expenses. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes stock-based compensation expense for all stock-based awards. For stock option awards, stock-based compensation cost is estimated at the grant date based on the fair value of the equity for financial reporting purposes and is recognized as expense on a straight-line basis over the requisite service period. Under the Company&#8217;s employee stock purchase plan, stock-based compensation cost is measured at the beginning of the offering period and recognized on a straight-line basis over the offering period. Forfeitures are accounted for as they occur. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has elected to calculate the fair value of awards using the Black-Scholes option pricing model, or the Black-Scholes Model. The Black-Scholes Model requires the use of various assumptions including common stock valuation, expected option life and expected stock price volatility. The Company estimates the expected term for stock options using the simplified method as the midpoint between the vesting date and the contractual expiration date of the award as the Company has limited historical exercise information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. Due to the limited trading history of the Company&#8217;s stock, the Company estimates the volatility using volatilities of a group of public companies in a comparable industry, stage of life cycle, and size. The interest rate is derived from the U.S. Treasury instruments with maturities similar to the expected term of the options. The Company has not declared nor expects to declare dividends. Therefore, there is no dividend impact on the valuation of options. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, the fair value of common stock was determined considering numerous objective and subjective factors and requires judgment. These objective and subjective factors include, but are not limited to: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">relevant precedent transactions involving the Company&#8217;s capital stock; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">contemporaneous valuations performed by third-party specialists; </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">rights, preferences, and privileges of the Company&#8217;s redeemable convertible preferred stock relative to those of the Company&#8217;s common stock; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">actual operating and financial performance; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">current business conditions and financial projections; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company&#8217;s business; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the lack of marketability of the Company&#8217;s common stock, and the illiquidity of stock-based awards involving securities in a private company; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">market multiples of comparable publicly traded companies; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">stage of development; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">industry information such as market size and growth; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">U.S. and global capital and macroeconomic conditions. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of the Business Combination, the fair value of our common stock has been determined based on the quoted market price of our common stock.</div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s comprehensive loss consists of unrealized losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing the net loss attributable to common stock by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities. Since the Company was in a loss position for the periods presented, basic net loss per share is the same as diluted net loss per share as the effects of the potentially dilutive securities are antidilutive. The following table presents the potential common stock outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested common stock subject to repurchase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,930</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div/><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is more likely than not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&#160;the factors underlying the sustainability assertion have changed and (ii)&#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits require significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275206512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recapitalization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_RecapitalizationNoteAbstract', window );"><strong>Recapitalization Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_RecapitalizationNoteDisclosureTextBlock', window );">Recapitalization</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 3. Recapitalization </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;11, 2021, Consonance consummated the Business Combination (see Note 1). Immediately after the consummation of the Business Combination, certain investors subscribed for and purchased an aggregate of 12.0&#160;million units, each consisting of one share of the Company&#8217;s common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of one redeemable warrant, for a purchase price of $10.00 per unit through a private investment in public entity financing, or PIPE Financing. In connection with the Business Combination and PIPE Financing, Legacy Surrozen received the aggregate cash consideration of $128.8&#160;million, after deducting the transaction fees incurred by Consonance. The cash consideration was comprised of $8.6&#160;million in proceeds from issuance of common stock upon the closing of the Business Combination and $120.2&#160;million in proceeds from the PIPE Financing. The Company incurred transaction costs of $6.3&#160;million, consisting of legal, accounting and other professional services directly related to the Business Combination, $0.4&#160;million of which were allocated to the warrant liabilities assumed and recognized as other expenses when incurred. The remaining $5.9&#160;million were recorded as a reduction of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital in the consolidated balance sheet. Legacy Surrozen was deemed the accounting acquirer in the Business Combination and the Business Combination was accounted for as a reverse recapitalization based on the following predominant factors: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Legacy Surrozen&#8217;s stockholders have the greatest voting interest in the Company; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">The Company&#8217;s board and senior management are primarily composed of individuals associated with Legacy Surrozen; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Legacy Surrozen is the larger entity based on historical operating activity and has the larger employee base at the time of the Business Combination. </div></td></tr></table><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, for accounting purposes, the reverse recapitalization was treated as the equivalent of Legacy Surrozen issuing stock for the net assets of Consonance, accompanied by a recapitalization. The net assets of Consonance are stated at historical cost, with no goodwill or other intangible assets recorded. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the business combination agreement, upon the closing of the Business Combination, (i)&#160;each share of redeemable convertible preferred stock of Legacy Surrozen (on an as converted to common stock basis) and each share of common stock of Legacy Surrozen, whether vested or unvested, was converted into 0.175648535 shares of the Company&#8217;s common stock and (ii)&#160;each outstanding option to purchase common stock of Legacy Surrozen was converted into an option to purchase shares of the Company&#8217;s common stock based on an exchange ratio of 0.175648535, or the Exchange Ratio, with corresponding adjustments to the exercise price. All issued and outstanding common stock, preferred stock and stock awards of Legacy Surrozen and corresponding capital amounts contained in the consolidated financial statements for the periods presented prior to the closing of the Business Combination have been retroactively restated to reflect the conversion. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_RecapitalizationNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_RecapitalizationNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_RecapitalizationNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_RecapitalizationNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593276117152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 4. Fair Value Measurement </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records its financial assets and liabilities at fair value. The carrying amount of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable, restricted cash, accounts payable, and accrued and other liabilities, approximate their fair value due to their short-term maturities. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value as follows: </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 2&#8212;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government agency debt securities<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,982</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,982</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(2)</div>:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:61%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122,725</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(2)</div>:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">They are included in cash and cash equivalents on the consolidated balance sheets as of December&#160;31, 2022 and 2021. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">See the definition and discussion of Public Warrants, Private Placement Warrants and PIPE Warrants in Note 11. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Corporate bonds, commercial paper, foreign bonds, government bonds and government agency debt securities are classified as Level&#160;2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrants are classified as Level&#160;1 due to the use of an observable market quote in an active market. The Private Placement Warrants are classified as Level&#160;2 due to the use of observable market data for identical or similar liabilities. The fair value of each Private Placement Warrant was determined to be consistent with that of a Public Warrant because the Private Warrants are also subject to the make-whole redemption feature, which allows the Company to redeem both types of warrants on similar terms when the stock price is in the range of $10 to $18 per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PIPE Warrants were initially recorded in 2021 at fair value using a binomial lattice model. The PIPE Warrants were classified as Level&#160;3 at issuance because the fair value was measured based on significant inputs that are unobservable in the market. The significant unobservable input used in the fair value measurement of the PIPE Warrants is the expected volatility. The expected volatility was implied from the market price of the Company&#8217;s Public Warrants. The expected term was based on the remaining contractual term of the PIPE Warrants, and the risk-free interest rate was based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the expected term. The dividend rate is based on the historical rate, which the Company anticipated remaining at zero. The key inputs into the binomial lattice model for the PIPE Warrants at the initial measurement were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">August&#160;11,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.81</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the adequate history of the market data of the Public Warrants as of December&#160;31, 2022 and 2021, the PIPE Warrants were remeasured at December&#160;31, 2022 and 2021 based on the observable market quote of the Public Warrants and are classified as Level&#160;2. The valuation technique was changed since the fair value of the Public Warrant is equally or more representative of the fair value of the PIPE Warrants. The fair value of each PIPE Warrant was determined to be consistent with that of a Public Warrant because the PIPE Warrants are also subject to the make-whole redemption feature, which allows the Company to redeem both types of warrants on similar terms. There were no changes to the valuation methods utilized, and there were no transfers of financial instruments for the year ended December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s warrant liabilities for the years ended December&#160;31, 2022 and 2021 (in thousands):</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Public<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/> Placement<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Warrant<br/> Liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance, December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumption in Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,647</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value upon remeasurement<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance, December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value upon remeasurement<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(157</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,379</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,890</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repurchase (Note 9)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance, December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The change in fair value of the warrant liabilities was recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables provide the Company&#8217;s marketable securities by security type (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,817</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(221</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,389</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(242</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,920</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,725</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,588</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,753</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(98</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div/><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table indicates the length of the time that individual securities have been in a continuous unrealized loss position (dollars in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:47%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Investments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Investments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and 2021, all short-term marketable securities had maturities of one year or less. All long-term marketable securities as of December&#160;31, 2021 had maturities of greater than one year but less than two years. There have been no significant realized gains or losses on the marketable securities during the years ended December&#160;31, 2022 and 2021. The Company periodically reviews the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investments for credit losses. All investments with unrealized losses have been in a loss position for less than 12 months. The Company determined that the unrealized loss was primarily attributed to changes in current market interest rates and not to credit quality. The Company does not intend to sell the marketable securities that are in an unrealized loss position, nor is it more likely than not that the Company will be required to sell the marketable securities before the recovery of the amortized cost basis, which may be at maturity. As a result, the Company did not recognize any allowance for credit losses as of December&#160;31, 2022. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275226928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 5. Balance Sheet Components </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,515</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,881</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,985</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,355</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,541</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expenses for the years ended December&#160;31, 2022 and 2021 was $2.0&#160;million and $2.1&#160;million, respectively. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued and Other Liabilities </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other liabilities consist of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued payroll and related expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,887</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">638</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liability for early exercised stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,662</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275168768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 6. Leases </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2016, the Company entered into a lease agreement for office and lab space, which consists of approximately 32,813 square feet of rental space in South San Francisco, California. The office space lease is classified as an operating lease. The initial lease term commenced in May 2017 and ends in April 2025, with rent payments escalating each year. The Company has options to extend the lease for additional years, but the exercise of the option was not reasonably certain. In connection with the lease, the Company maintains a letter of credit for the benefit of the landlord in the amount of $0.4&#160;million, which is recorded as restricted cash in the consolidated balance sheets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2020, the Company entered into a lease agreement for a term of 18 months commencing June 2020 for approximately 6,478 square feet of office space. This office space lease, which was classified as an operating lease, was amended in September 2021 and expired in June 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The operating lease expense for the years ended December&#160;31, 2022 and 2021 was $1.9&#160;million and $2.0&#160;million. </div>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aggregate future minimum rental payments under the operating leases as of December&#160;31, 2022, were as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(555</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,602</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>   <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents supplemental information related to the Company&#8217;s operating facility leases: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.48</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI https://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275112368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_CollaborationAndLicenseAgreementsTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Note 7. Collaboration and License Agreements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration and License Agreement with Boehringer Ingelheim International GmbH </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2022, the Company executed the CLA with BI to research, develop and commercialize Fzd4 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-specific</div> antibodies designed using the Company&#8217;s SWAP<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#8482;</div> technology, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SZN-413.</div> The Company and BI are conducting partnership research focused on SZN-413 during a one-year period, which BI has the right to extend by up to six months. The Company granted BI an exclusive, royalty-bearing, worldwide, sublicensable license, under the applicable patents and know-how, to develop, manufacture and commercialize, for all uses, one lead and two back-up Fzd4 bi-specific antibodies selected by BI and their derivatives. After an initial period of joint research, BI shall be responsible for all further research, preclinical and clinical development, manufacturing, regulatory approvals, and commercialization of licensed products at its expense. Unless terminated earlier, or expiring on account of BI not selecting at least one Fzd4 bi-specific antibody within sixty days after the end of the partnership research, the CLA will remain effective, on a country-by-country and product-by-product basis, until the expiration of BI&#8217;s royalty obligations. BI has the right to terminate the CLA for any reason after a specified notice period. Each party has the right to terminate the CLA on account of the other party&#8217;s bankruptcy or material, uncured breach. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the CLA, BI agreed to pay a non-refundable upfront payment of&#160;</div>$12.5&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million less any applicable withholding tax, success-based milestone payments up to a total of</div> $587.0&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million and mid-single digit to low-double digit royalties on net sales of the licensed products should any reach commercialization. The royalty payments will be subject to reduction due to patent expiration, generic competition and payments made under certain licenses for third-party intellectual property. The Company received</div> $10.5&#160;million of the upfront payment from BI in November 2022. The associated withholding tax of $2.0&#160;million is expected to be refunded to the Company in 2023. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the CLA is within the scope of ASC 606. The Company evaluated the promised goods and services and determined that the license to the Company&#8217;s intellectual property granted to BI represented one performance obligation for the purposes of conducting the partnership research and further development on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SZN-413.</div> The transaction price was determined to be $12.5&#160;million, which is the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment. Variable consideration related to future milestones was fully constrained because the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based royalties, the Company determined that the license is the predominant item to which the royalties relate to. Accordingly, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all the royalty has been allocated has been satisfied (or partially satisfied). The Company will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. During the year ended December&#160;31, 2022, the Company recognized the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment of $12.5&#160;million as collaboration and license revenue at a point in time upon delivery of the license. The associated withholding tax of $2.0&#160;million to be refunded was recognized as accounts receivable as of December&#160;31, 2022. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_CollaborationAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_CollaborationAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275200656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_LicenseAgreementsAbstract', window );"><strong>License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_LicenseAgreementsDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Note 8. License Agreements </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stanford License Agreements </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the Company entered into a license agreement with Stanford University, or the 2016 Stanford Agreement, which was amended in July 2016, October 2016 and January 2021, pursuant to which the Company obtained from Stanford a worldwide, exclusive, sublicensable license under certain patents, rights, or licensed patents and technology related to its engineered Wnt surrogate molecules to make, use, import, offer to sell and sell products that are claimed by the licensed patents or that use or incorporate such technology, or </div>   <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;;text-indent: 0px;">licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases. The Company agreed to pay Stanford (i)&#160;nominal annual license maintenance fees which are creditable against earned royalties owed to Stanford for the same year, (ii)&#160;an aggregate of up to $0.9&#160;million for the achievement of specified development and regulatory milestones, and (iii)&#160;an aggregate of up to $5.0&#160;<div style="display:inline;">million for achievement of specified sales milestones. Stanford is also entitled to receive royalties from the Company equal to a very low single digit percentage of the Company&#8217;s and its sublicensees&#8217; net sales of licensed products that are covered by a valid claim of a licensed patent. Additionally, the Company agreed to pay Stanford a sub-teen double digit percentage of certain consideration the Company receives as a result of granting sublicenses to the licensed patents. However, the Company and Stanford may be able to negotiate a lower non-royalty sublicense percentage based on then-current value of the licensed patents for each sublicense product. If the Company is acquired, it agreed to pay a one-time change of control fee in the low six figures. Stanford retains the right under the 2016 Stanford Agreement, on behalf of itself, Stanford Hospital and Clinics, the University of Washington and all other non-profit research institutions, to practice the licensed patents and technology for any non-profit purpose. The licensed patents and technology are additionally subject to a non-exclusive, irrevocable, worldwide license held by the Howard Hughes Medical Institute to practice the licensed patents and technology for its research purposes, but with no right to assign or sublicense.&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2018, the Company entered into another license agreement with Stanford, or the 2018 Stanford Agreement, pursuant to which the Company obtained from Stanford a worldwide, exclusive, sublicensable license under certain patent rights related to its surrogate </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">R-spondin</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> proteins, or the licensed patents, to make, use, import, offer to sell and sell products that are claimed by the licensed patents, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases, or the exclusive field. Additionally, Stanford granted the Company a worldwide, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> sublicensable license under the licensed patents to make and use licensed products for research and development purposes in furtherance of the exclusive field and a worldwide, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> license to make, use and import, but not to offer to sell or sell licensed products in any other field of use. The Company agreed to pay Stanford an aggregate of up to $</div>0.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the achievement of specified development and regulatory milestones. Stanford is also entitled to receive royalties from the Company equal to a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-single</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> digit percentage of the Company&#8217;s and its sublicensees&#8217; net sales of licensed products. Additionally, Stanford is entitled to receive a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> payment in the low six figures for each sublicense of the licensed patents that the Company grants to a third party and, if the Company is acquired, a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> nominal change of control fee.</div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, the Company incurred research and development expenses of approximately $0.2&#160;million under the Stanford Agreements, pertaining to the sublicense fee in connection with the upfront payment received from BI. For the year ended December&#160;31, 2021, the Company incurred research and development expenses of approximately $0.1&#160;million under the Stanford Agreements. No milestones have been achieved as of December&#160;31, 2022. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UCSF License and Option Agreements </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September and October 2016, the Company entered into two separate license and option agreements with The Regents of the University of California, or the UCSF Agreements, pursuant to which the Company obtained exclusive licenses from UCSF for internal research and antibody discovery purposes and an option to negotiate with UCSF to obtain an exclusive license under UCSF&#8217;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from the Company&#8217;s use of such library, or licensed products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In January 2020, the Company amended and restated the UCSF Agreements to provide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> licenses to make and use a certain human Fab na&#239;ve phage display library and to make and use a certain phage display llama VHH single domain antibody library for internal research and antibody discovery purposes and an </div></div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">option to negotiate with UCSF to obtain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> commercial license under UCSF&#8217;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from the Company&#8217;s use of such library, or licensed products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In March 2022, the Company exercised the option under the UCSF Agreements and entered into a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> commercial license agreement to make and use licensed products derived from the phage display llama VHH single domain antibody library. Under the commercial license agreement, the Company paid UCSF a nominal license issue fee and agreed to pay a nominal annual license maintenance fee, five- to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-digit</div> payments per licensed product upon achievement of a regulatory milestone, nominal minimum annual royalties and earned royalties equal to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-single</div> digit percentage of the Company&#8217;s and the Company&#8217;s sublicensees&#8217; net sales of licensed products. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2022, the Company incurred research and development expenses of $0.1&#160;million under the UCSF Agreements as a result of the CLA. For the year ended December&#160;31, 2021, the Company incurred research and development expenses of $50,000 under the UCSF Agreements. No milestones have been achieved as of December&#160;31, 2022. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distributed Bio Subscription Agreement </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2016, the Company entered into, and in January 2019 the Company amended, an antibody library subscription agreement with Charles River Laboratories International, Inc., formerly known as Distributed Bio, or the Distributed Bio Agreement, in which the Company obtained from Distributed Bio a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license to use Distributed Bio&#8217;s antibody library to identify antibodies directed to an unlimited number of the Company&#8217;s proprietary targets and to make, use, sell, offer for sale, import and exploit products incorporating the antibodies that the Company identifies, or licensed products. In consideration for the rights granted to the Company under the Distributed Bio Agreement, the Company paid Distributed Bio a nominal upfront fee and an additional nominal fee upon entering into the amendment. The Company agreed to pay Distributed Bio an annual fee in the low six figures after the first three years. Additionally, the Company agreed to pay Distributed Bio an aggregate of $5.9&#160;million for each licensed product that achieves specified development, regulatory and commercial milestones and royalties equal to a very low single digit percentage of the Company&#8217;s and its sublicensees&#8217; net sales of licensed products. The Company&#8217;s obligation to pay royalties will end for each licensed product ten years after its first commercial sale. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2022 and 2021, the Company incurred research and development expenses of $0.2&#160;million and $0.3&#160;million under the Distributed Bio Agreement, including the milestone payment of $0.1&#160;million and $50,000, respectively, as the Company achieved milestones with regard to the Phase 1 clinical trial for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SZN-1326.</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_LicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreements Abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_LicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_LicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreements disclosure [Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_LicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275204080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 9. Related Party Transactions </div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Repurchase of Common Stock and Common Stock Warrants </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2022, the Company entered into a securities purchase agreement with entities affiliated with Consonance Capital Management LP, collectively the Consonance Entities. Pursuant to the agreement, the Company repurchased 5.4&#160;million shares of common stock and warrants to purchase 1.3&#160;million shares of common stock from the Consonance Entities for an aggregate purchase price of approximately $2.7&#160;million, or the Repurchase. Following the Repurchase, the Consonance Entities no longer hold any shares of common stock or warrants. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock repurchased were constructively retired and the common stock warrants repurchased were subsequently canceled. The total purchase price was allocated to the repurchase of common stock warrants based on the fair value of the warrants remeasured on the repurchase date, resulting in the</div>   <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;">derecognition of warrant liabilities of $0.1&#160;million. The remaining $2.6&#160;million allocated to the repurchase of common stock was recorded as a reduction of equity on the consolidated balance sheets. <br/><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593276117152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;">Note 10. Stockholders&#8217; Equity</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2022, the Company entered into the Equity Purchase Agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, pursuant to which Lincoln Park is obligated to purchase up to $50.0&#160;million of the Company&#8217;s common stock with a maximum of 7.0&#160;million shares from time to time at the Company&#8217;s sole discretion over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> period commencing on April&#160;27, 2022. The Company also entered into a registration rights agreement with Lincoln Park pursuant to which the Company filed with the SEC the registration statement to register for resale under the Securities Act of 1933, as amended, the shares of common stock that have been or may be issued to Lincoln Park under the Equity Purchase Agreement. The registration statement was effective on April&#160;5, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the Equity Purchase Agreement, the Company issued 0.1&#160;million shares of common stock to Lincoln Park with the fair value of $0.3&#160;million as consideration for Lincoln Park&#8217;s commitment to purchase the Company&#8217;s common stock, which was included in other income (expense), net on the consolidated statements of operations and comprehensive loss. In the event that the Company sells its common stock under the Equity Purchase Agreement for an aggregate price equal to or greater than $30.0&#160;million, the Company shall pay an additional commitment fee of $0.1&#160;million in cash to Lincoln Park. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As contemplated by the Equity Purchase Agreement, and so long as the closing price of the Company&#8217;s common stock exceeds $1.00 per share, the Company may direct Lincoln Park, at its sole discretion, to purchase up to 30,000 shares of its common stock, or the Regular Purchase Share Limit, on any business day at a purchase price per share equal to the lower of: (i)&#160;the lowest price of the Company&#8217;s common stock on the applicable purchase date and (ii)&#160;the average of the three lowest closing prices of the Company&#8217;s common stock during the ten consecutive business days preceding such purchase date. The Regular Purchase Share Limit may be increased to up to 35,000 shares and 40,000 shares if the closing price of the Company&#8217;s common stock is not below $10.00 per share and $12.00 per share, respectively. Any single purchase of the Company&#8217;s common stock shall not exceed $3.5 million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may also direct Lincoln Park to purchase additional shares no less than the Regular Purchase Share Limit and no greater than 0.5&#160;million shares at a purchase price per share equal to 96% of the lower of (i) the closing price of the Company&#8217;s common stock on the purchase date and (ii) the volume weighted average price of the Company&#8217;s common stock on the purchase date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company has not sold any shares of common stock under the Equity Purchase Agreement. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-the-Market</div></div> Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> filed in December 2022, the Company entered into a sales agreement with Guggenheim Securities, LLC to issue and sell the Company&#8217;s common stock up to $23.0&#160;million, or the 2022 ATM. The compensation payable to Guggenheim is equal to 3.0% of the gross sales price of any shares sold through it pursuant to the sales agreement. As of December&#160;31, 2022, the Company has not sold any shares of common stock under the 2022 ATM. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275297296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_CommonStockWarrantsDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 11. Common Stock Warrants </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, Legacy Surrozen, as the accounting acquirer, was deemed to assume 3.1&#160;million warrants held by Consonance&#8217;s stockholders, or the Public Warrants, and 0.1&#160;million warrants </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">held by Consonance&#8217;s sponsor, or the Private Placement Warrants. In addition, immediately after the consummation of the Business Combination, certain investors subscribed for and purchased an aggregate of 12.0&#160;million units in the PIPE Financing, consisting of 12.0&#160;million shares of the Company&#8217;s common stock and 4.0&#160;million warrants, or the PIPE Warrants. In conjunction with the Repurchase (see Note 9), the Company repurchased 0.3&#160;million Public Warrants, 0.1&#160;million Private Placement Warrants and 0.8&#160;million PIPE Warrants. As of December&#160;31, 2022, the following common stock warrants were outstanding (in thousands, except per share amounts): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:49%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Type</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price&#160;per<br/> Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">August 12, 2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">August 12, 2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Public Warrants </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole Public Warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $11.50 per share, at any time commencing on November&#160;23, 2021 and terminating at the earlier of August 12, 2026 or upon redemption or liquidation. The exercise price and number of shares issuable upon exercise of the Public Warrants may be adjusted in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. The Company would not be obligated to deliver any shares of common stock pursuant to the exercise of a Public Warrant and would have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act with respect to the common stock underlying the Public Warrants is then effective. The registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> to register for resale under the Securities Act of 1933, as amended, was effective in November 2021. The Company will use its commercially reasonable efforts to maintain the effectiveness of the registration statement until the expiration or redemption of the Public Warrants. If the Company fails to have maintained an effective registration statement, the Public Warrant holders have the right to exercise the Public Warrants on a cashless basis until such time as there is an effective registration statement. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the outstanding Public Warrants at a price of $0.01 per warrant if the closing price of common stock equals or exceeds $18.00 per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share capitalizations, reorganizations, recapitalizations and similar transaction). Additionally, the Company may redeem the outstanding Public Warrants at a price of $0.10 per warrant if the closing price of common stock equals or exceeds $10.00 per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share capitalizations, reorganizations, recapitalizations and similar transaction). Notice of redemption shall be mailed to the Public Warrant holders no less than 30 days prior to the redemption date, or the Redemption Period. If the closing price of common stock equals or exceeds $10.00 per share and is less than $18.00 per share, during the Redemption Period, the Public Warrant holders may elect to exercise their Public Warrants on a cashless basis based on a make-whole table. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no event will the Company be required to net cash settle the Public Warrants. The Public Warrant holders do not have the rights or privileges of common stockholders and any voting rights until they exercise their Public Warrants and receive common stock. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Placement Warrants </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants (including the common stock issuable upon exercise of the Private Placement Warrants) will not be redeemable so long as they are held by Consonance Life Sciences, a Cayman </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Islands limited liability company, or the Sponsor, or its permitted transferees. The Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. There were no Private Placement Warrants outstanding as of December&#160;31, 2022. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PIPE Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole PIPE Warrant entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $11.50 per share, at any time commencing on November&#160;23, 2021 and terminating on August 12, 2026. The PIPE Warrants are the same in all respects as the Public Warrants except that the PIPE Warrants were not redeemable before August&#160;12, 2022. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Classification </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrants, Private Placement Warrants and PIPE Warrants are not considered indexed to the Company&#8217;s common stock as certain provisions of the warrant agreements could change the settlement amount of these warrants. As a result, they are classified as liabilities and recorded at fair value with subsequent change in their respective fair value recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. See Note 4 for the discussion of warrant valuations. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_CommonStockWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_CommonStockWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593276088752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plan</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 12. Stock-Based Compensation Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains the 2021 Equity Incentive Plan, or the 2021 Plan, which provides for the granting of stock awards to employees, directors and consultants. Options granted under the 2021 Plan may be either incentive stock options or nonqualified stock options to purchase common stock. Options granted under the 2021 Plan expire no later than 10 years from the date of grant. Options under the 2021 Plan generally vest over four years. As of December&#160;31, 2022, there were 3.7&#160;million shares of common stock available for issuance under the 2021 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Legacy Surrozen maintained the 2015 Stock Plan, or the 2015 Plan, which provided for the granting of options to purchase shares of common stock to officers, employees, directors, consultants and key persons who provide services to the Company. Options under the 2015 Plan have a term of 10 years and generally vested over a four-year period with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> cliff vesting. In conjunction with the Business Combination, options and the corresponding exercise price under the 2015 Plan were converted into the awards under the 2021 Equity Incentive Plan based on the Exchange Ratio. Each converted option is subject to the same terms and conditions as were applicable to the corresponding options under the 2015 Plan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted the 2021 Employee Stock Purchase Plan, or the ESPP, in August 2021. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to plan limitations. An offering period under the ESPP consists of four <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> purchase periods, unless otherwise determined by the Company. The eligible employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the purchase day. As of December&#160;31, 2022, there were 0.6&#160;million shares of common stock available for issuance under the ESPP. During the year ended December&#160;31, 2022, 0.3&#160;million shares were issued under the ESPP. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Option Exchange </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2022, the Company&#8217;s Compensation Committee authorized and approved a stock option exchange whereby certain outstanding stock options held by 59 employees were exchanged for stock options on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis with an exercise price at the current market price on the date of the exchange. As a result of this exchange, 1.3&#160;million outstanding stock options, with a weighted average exercise price of $8.81 per share, were exchanged for 1.3&#160;million new stock options under the 2021 Plan with an exercise price of $2.16 per share. The vesting terms and expiration dates of the new stock options remain unchanged from the original stock options. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The option exchange was treated as an option modification for accounting purposes and resulted in the incremental expense of $0.7&#160;million. $0.3&#160;million of the total incremental expense associated with the vested options was recognized on the modification date. The remaining $0.4&#160;million associated with the unvested options as of the modification date will be recognized over the remainder of the original requisite service period. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of option activity is set forth below (shares in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:47%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> Remaining<br/> Contractual&#160;Life<br/> (In years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value<br/> (In&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding &#8211; December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding &#8211; December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable &#8211; December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,430</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest is the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock at December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intrinsic value of options exercised during the year ended December&#160;31, 2021 was $1.2&#160;million. No options were exercised during the year ended December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&#160;31, 2022 and 2021, the Company granted options with a weighted-average grant-date fair value of $2.28 per share and $6.36 per share, respectively. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Awards </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s RSA activity (shares in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSAs, unvested at December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(56</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSAs, unvested at December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div/><div><div style="background-color:white;display: inline;"/></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of RSAs vested during the years ended December&#160;31, 2022 and 2021 was $0.2&#160;million and $0.6&#160;million, respectively. </div> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Options </div></div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of options is estimated at the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:81%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81.07</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71.23</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.89</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>  <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded in the consolidated statements of operations and comprehensive loss related to options and RSAs was as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">1,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, there was approximately $9.9&#160;million of stock-based compensation expense to be recognized over a weighted-average period of approximately 2.5 years. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275198224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 13. Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No provision for income taxes was recorded for the years ended December&#160;31, 2022 and 2021. The Company has incurred net operating losses for all the periods presented. The Company accounts for income taxes in accordance with the asset and liability method, which requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is not likely to be realized and, accordingly, has provided a full valuation allowance. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>  <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>  <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#8217;s net deferred tax assets consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,985</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Section&#160;174 capitalized expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,775</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,521</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrual and reserves</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">590</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee retention credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized intangible costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45,343</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(35,665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(962</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(101</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(95</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(139</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(781</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,202</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total net deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net valuation allowance increased by $9.7&#160;million for the years ended December&#160;31, 2022 and 2021. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had net operating loss, or NOL, carryforwards of approximately $139.4&#160;million and $53.0&#160;million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. NOL carryforwards generated after 2018 for federal tax reporting purposes of $127.0&#160;million have an indefinite carryforward period. The remaining federal and state net operating loss carryforwards begin expiring in 2036. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had research and development credit carryforwards of approximately $2.2&#160;million and $3.8&#160;million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. The federal credit carryforwards begin expiring in 2036 and the state credits carry forward indefinitely. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning January&#160;1, 2022, the Tax Cuts and Jobs Act, or the Tax Act, eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code, or the IRC, Section&#160;174. The capitalized expenses are amortized over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-year</div> period for domestic expenses and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-year</div> period for foreign expenses. As a result of this provision of the Tax Act, deferred tax assets related to capitalized research expenses increased by $6.7&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section&#160;382 of the Internal </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue Code. As a result of such ownership changes, the Company&#8217;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be limited and may expire unutilized. Such impairment of tax losses and tax credits would reduce the deferred tax asset and corresponding valuation allowance, as a result of the limitation. The Company completed an assessment of the available NOLs under Section&#160;382 and determined that the Company underwent an ownership change in September 2020. As a result of the annual limitations caused by the ownership change, it was estimated the approximately $1.3&#160;million of federal tax credit and $27.4&#160;million of California NOL will expire unrealized for income tax purposes, and such amounts are excluded from the carryforward balances as of December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The unrecognized tax benefits, if recognized, would not have an impact on the Company&#8217;s effective tax rate assuming the Company continues to maintain a full valuation allowance position. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the Company&#8217;s unrecognized tax benefits is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at beginning of the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">974</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions based on tax positions related to current year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">654</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reductions based on tax positions of prior year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(427</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at end of the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">974</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S. federal and California tax jurisdictions. As of the date these financial statements were issued, the Company is not under examination by any income tax authority. The federal and state income tax returns from December&#160;31, 2016 to December&#160;31, 2021 remain subject to examination. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the statutory U.S. federal tax rate to the Company&#8217;s effective tax rate is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26.88</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16.92</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">NOL and tax credits limited under 382</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain on warrant liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.57</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;21, 2020, the Consolidated Appropriations Act, 2021, or the Appropriations Act, was signed into law which expanded and extended some of CARES Act provisions, including the expansion of the employee retention credits. The Company claimed employee retention credits of $1.0&#160;million and $0.3&#160;million for the 2021 and 2020 tax years. The Company will recognize the benefit of those credits as the refunds are received. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inflation Reduction Act of 2022, or the IRA, which was signed into law in August 2022, includes several provisions that are specifically applicable to corporations. Among other changes, it created a new corporate alternative minimum tax based on adjusted financial statement income and imposes a 1% excise tax on corporate stock repurchases. The effective date of these provisions is January&#160;1, 2023. The Company is evaluating how the enactment of the IRA will have an impact on its consolidated financial statements but does not expect that the provisions of the IRA will have a material impact for the year ended December&#160;31, 2022. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275141904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 14. Commitments and Contingencies </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i)&#160;the Company&#8217;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship with the Company, (ii)&#160;contracts under which the Company must indemnify directors and certain officers for liabilities arising out of their relationship with the Company, (iii)&#160;contracts under which the Company may be required to indemnify customers or partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights and (iv)&#160;procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts the Company may have to modify the accused infringing intellectual property and/or refund amounts received. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains director and officer insurance, which may cover certain liabilities arising from the Company&#8217;s obligation to indemnify its directors and certain officers. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the date of the consolidated financial statements were issued, the Company has not incurred any material costs or accrued any liabilities related to indemnification obligations. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result, the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Management is not aware of any pending or threatened litigation. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275194496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(K) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(K) Plan</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 15. 401(k) Plan </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted a 401(k) retirement savings plan, or the 401(k) Plan for all eligible employees. Each participant may contribute <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> or post- tax compensation, up to annual statutory limits. The 401(k) Plan also </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">permits the Company to make discretionary and matching contributions, subject to established limits and a vesting schedule. Each year, the Company may, at its sole discretion, make contributions to the plan. For the years ended December&#160;31, 2022 and 2021, the Company&#8217;s contributions were $0.2&#160;million and nominal, respectively. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275194496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Note 16. Subsequent Events </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2023, the Company implemented a restructuring plan approved by the board of directors to reduce its overall workforce by approximately 25%. The Company expects to substantially complete the workforce reduction by the end of the first quarter of 2023 and estimates to incur <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> restructuring charges of approximately $1.2&#160;million, including employee severance, benefits and related costs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2023, the Company cancelled certain studies with its contract manufacturing organization and incurred a cancellation fee equal to 50% of the contract price of the studies plus any raw materials and handling fees that have been incurred. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;10, 2023, Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or FDIC, as a receiver. On March&#160;12, 2023, the U.S. Department of the Treasury, Federal Reserve, and FDIC jointly announced that the FDIC would complete its resolution of SVB in a manner that fully protects all depositors. The Company has access to its full deposits with SVB and does not anticipate any disruption to its ongoing operations. The Company is working on replacing the letter of credit issued by SVB as required by the landlord and transferring substantially all of its cash deposits at SVB to a different financial institution. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;31, 2023, we entered into an amended and restated warrant agreement with Continental Stock Transfer&#160;&amp; Trust Company as warrant agent, or the PIPE Warrant Agreement. PIPE Warrants may be converted into Public Warrants on transfer pursuant to the terms of the PIPE Warrant Agreement. To the date of the consolidated financial statements were issued, no PIPE Warrants were converted into Public Warrants </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271401744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, as determined by the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, and pursuant to the regulations of the U.S. Securities and Exchange Commission, or SEC. The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany transactions and balances have been eliminated. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination discussed in Note 1 was accounted for as a reverse recapitalization with Legacy Surrozen as the accounting acquirer and Consonance as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the consolidated financial statements represents the accounts of Legacy Surrozen at their historical cost as if Legacy Surrozen is the predecessor to the Company. The consolidated financial statements following the closing of the Business Combination reflect the results of the combined entity&#8217;s operations. All issued and outstanding common stock and stock awards of Legacy Surrozen and per share amounts contained in the consolidated financial statements for the periods presented prior to the closing of the Business Combination on August&#160;11, 2021 have been retroactively restated to reflect the exchange ratio established in the Business Combination. See Note 3, &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recapitalization&#8221;</div></div> for additional details. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, revenue recognition, certain accruals for research and development activities, the fair value of common stock prior to the Business Combination, initial fair value of the PIPE Warrants and stock-based compensation expense. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could materially differ from those estimates. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist of cash, cash equivalents and marketable securities. The Company&#8217;s cash is held by one financial institution that may at times exceed federally insured limits. However, the Company&#8217;s exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company believes it is not exposed to significant credit risk on cash. The Company&#8217;s policy is to invest cash in institutional money market funds and marketable securities with high credit quality to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and marketable securities in a variety of securities, including money market funds, U.S. government bonds, U.S. government agency debt securities, foreign bonds, commercial paper and corporate debt securities. The Company has not experienced any losses on its cash equivalents and marketable securities. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash equivalents relate to securities having an original maturity of three months or less at the time of purchase. As of December&#160;31, 2022 and 2021, cash and cash equivalents consisted of bank deposits, money market funds and U.S. government agency debt securities. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Cash </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of each of December&#160;31, 2022 and 2021, the Company had $0.4&#160;million of restricted cash in the form of a letter of credit for the Company&#8217;s facility lease. The restricted cash is classified as a noncurrent asset as the Company is required to maintain the letter of credit for the benefit of the landlord until the end of the lease term in April 2025. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company invests its excess cash in marketable U.S. government bonds, foreign bonds, commercial paper and corporate debt securities. All marketable securities have been classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company does not buy or hold securities principally for the purpose of selling them in the near future. The Company&#8217;s policy is focused on the preservation of capital, liquidity, and return. From time to time, the Company may sell certain securities, but the objectives are generally not to generate profits on short-term differences in price. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Short-term marketable securities have maturities less than or equal to one year as of the balance sheet date. Long-term marketable securities have maturities greater than one year as of the balance sheet date. These marketable securities are carried at estimated fair value with unrealized holding gains and losses included in accumulated other comprehensive loss in stockholders&#8217; equity until realized. Gains and losses on marketable security transactions are reported on the specific-identification method. Interest income is recognized in the consolidated statements of operations and comprehensive loss when earned. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company periodically evaluates its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> marketable securities for impairment. When the fair value of a marketable security is below its amortized cost basis, the amortized cost is reduced to its fair value if it is more likely than not that the Company is required to sell the impaired security before recovery of its amortized cost, or the Company has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost basis over the fair value of the security. An allowance for credit losses for the excess of amortized cost basis over the expected cash flows, if any, is recorded in other income (expense), net on the consolidated statements of operations. Impairment losses that are not credit-related are included in accumulated other comprehensive loss in stockholders&#8217; equity. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, including leasehold improvements, are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"/>
<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Estimated useful life</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Shorter of useful life of asset or lease term</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture, fixtures and equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">3 years</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the period realized. Maintenance and repairs are expensed as incurred. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Material leases with a term longer than one year are recognized as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use,</div></div> or ROU, assets and lease liabilities in the Company&#8217;s consolidated balance sheets. The Company determines the lease classification and measurement of its ROU assets and lease liabilities at the lease commencement date and thereafter if modified. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company uses its incremental borrowing rate, based on the information available at the commencement date, to determine the present value of lease payments if the rate implicit in the lease is not readily available. The ROU asset is based on the measurement of the lease liability and is adjusted for lease incentives provided by the landlord. Lease expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. The Company has not identified any such impairment losses to date. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_WarrantLiabilityPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Public Warrants, Private Placement Warrants and PIPE Warrants were classified as liabilities (see Note 11). At the end of each reporting period, any changes in fair value during the period are recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. No Private Placement Warrants were outstanding as of December&#160;31, 2022 as a result of the repurchase of 1.3&#160;million warrants in December 2022 (see Note 9). The Company will continue to adjust the warrant liabilities pertaining to the outstanding warrants for changes in the fair value until the earlier of a) the exercise or expiration of the warrants or b) the redemption of the warrants, at which time such warrants will be reclassified to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_RevenueRecognitionsPolicyTextBlock', window );">Revenue Recognitions</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue in accordance with ASC 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers (Topic 606)</div></div>,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for these goods or services. To determine revenue recognition for the arrangement that is within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract with the customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At contract inception, the Company assesses the goods or services promised within the contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligations when or as the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the variable consideration constraint) that a significant reversal of recognized revenue is not probable. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses accounts receivable for impairment and, to date, no impairment losses have been recorded. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a collaboration and license agreement with BI to which the Company licensed certain rights to its intellectual property (see Note 7) that is determined within the scope of ASC 606. The terms of the CLA include payment to the Company of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment, development, regulatory and commercial milestone payments and royalties on net sales of licensed products. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licenses of Intellectual Property: If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone Payments:</div></div> At contract inception, the Company using the most likely amount method evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received or the underlying activity has been completed. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis, which would affect revenue in the period of adjustment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties:</div></div> The Company recognizes sales-based royalties as revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalties that have been allocated have been satisfied (or partially satisfied). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The incremental costs of obtaining a customer contract are expensed as and when incurred if the amortization period of the asset that would have been recognized is one year or less. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs consist of external and internal expenses directly attributable to the conduct of research and development programs. The external expenses include the costs of services provided by outside contractors, clinical research organizations and contract manufacturing organizations. The internal expenses include the costs of salaries, bonus, payroll taxes, stock-based compensation, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, and the allocated facility-related costs, such as rent, utilities, insurance, repairs and maintenance, and general support services. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into and may continue to enter into licensing or subscription arrangements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company&#8217;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records accruals for estimated costs of research, preclinical, clinical, and manufacturing development, which are significant components of research and development expenses, within accrued and other liabilities in the accompanying consolidated balance sheets. A substantial portion of the Company&#8217;s ongoing research and development activities is conducted by third-party service providers. The Company accrues the costs under agreements with these third parties as incurred. The Company estimates the amounts incurred in each period based on the information available and its knowledge of the nature of the contractual activities generating such costs. Clinical trial contract expenses are accrued based on units of activity. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. For the years ended December&#160;31, 2022 and 2021, the Company has not experienced any material differences between accrued costs and actual costs incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts accrued expenses or prepaid expenses accordingly, which impacts research and development expenses. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes stock-based compensation expense for all stock-based awards. For stock option awards, stock-based compensation cost is estimated at the grant date based on the fair value of the equity for financial reporting purposes and is recognized as expense on a straight-line basis over the requisite service period. Under the Company&#8217;s employee stock purchase plan, stock-based compensation cost is measured at the beginning of the offering period and recognized on a straight-line basis over the offering period. Forfeitures are accounted for as they occur. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has elected to calculate the fair value of awards using the Black-Scholes option pricing model, or the Black-Scholes Model. The Black-Scholes Model requires the use of various assumptions including common stock valuation, expected option life and expected stock price volatility. The Company estimates the expected term for stock options using the simplified method as the midpoint between the vesting date and the contractual expiration date of the award as the Company has limited historical exercise information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. Due to the limited trading history of the Company&#8217;s stock, the Company estimates the volatility using volatilities of a group of public companies in a comparable industry, stage of life cycle, and size. The interest rate is derived from the U.S. Treasury instruments with maturities similar to the expected term of the options. The Company has not declared nor expects to declare dividends. Therefore, there is no dividend impact on the valuation of options. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, the fair value of common stock was determined considering numerous objective and subjective factors and requires judgment. These objective and subjective factors include, but are not limited to: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">relevant precedent transactions involving the Company&#8217;s capital stock; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">contemporaneous valuations performed by third-party specialists; </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">rights, preferences, and privileges of the Company&#8217;s redeemable convertible preferred stock relative to those of the Company&#8217;s common stock; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">actual operating and financial performance; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">current business conditions and financial projections; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company&#8217;s business; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">the lack of marketability of the Company&#8217;s common stock, and the illiquidity of stock-based awards involving securities in a private company; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">market multiples of comparable publicly traded companies; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">stage of development; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">industry information such as market size and growth; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">U.S. and global capital and macroeconomic conditions. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of the Business Combination, the fair value of our common stock has been determined based on the quoted market price of our common stock.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s comprehensive loss consists of unrealized losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing the net loss attributable to common stock by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities. Since the Company was in a loss position for the periods presented, basic net loss per share is the same as diluted net loss per share as the effects of the potentially dilutive securities are antidilutive. The following table presents the potential common stock outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested common stock subject to repurchase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,930</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div/><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is more likely than not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&#160;the factors underlying the sustainability assertion have changed and (ii)&#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits require significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company Status </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the accounting policy on Emerging Growth Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_RevenueRecognitionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_RevenueRecognitionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>warrant liability[Policy text block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593276151888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Summary of Property and Equipment Useful Lives</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, including leasehold improvements, are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:51%"/>
<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Asset</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Estimated useful life</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Leasehold improvements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Shorter of useful life of asset or lease term</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Computer equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">3 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Furniture, fixtures and equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8</div> years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Lab equipment</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">3 years</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">. The following table presents the potential common stock outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive (in thousands): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested common stock subject to repurchase</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,930</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271540864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government agency debt securities<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,982</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,982</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(2)</div>:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:61%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial assets measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,310</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122,725</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td>
<td colspan="4" style="height:6pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(2)</div>:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total financial liabilities measured at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,774</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">They are included in cash and cash equivalents on the consolidated balance sheets as of December&#160;31, 2022 and 2021. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">See the definition and discussion of Public Warrants, Private Placement Warrants and PIPE Warrants in Note 11. </div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text">The key inputs into the binomial lattice model for the PIPE Warrants at the initial measurement were as follows: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:84%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">August&#160;11,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.81</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Warrant Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s warrant liabilities for the years ended December&#160;31, 2022 and 2021 (in thousands):</div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Public<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/> Placement<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Warrant<br/> Liabilities</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance, December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumption in Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,647</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,372</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value upon remeasurement<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(71</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance, December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,527</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,608</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value upon remeasurement<div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px">(1)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(157</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,379</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,890</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repurchase (Note 9)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(85</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance, December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The change in fair value of the warrant liabilities was recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. </div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Marketable Securities by Security Type</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables provide the Company&#8217;s marketable securities by security type (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,817</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(221</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,389</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(242</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">51,148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Gains</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commercial paper</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,920</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,725</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total short-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(83</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,588</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total long-term marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,753</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(98</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock', window );">Schedule Of Unrealized Loss On Investments</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table indicates the length of the time that individual securities have been in a continuous unrealized loss position (dollars in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:47%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Less Than 12 Months</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Investments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Investments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Losses</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Corporate bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,719</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Government bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,082</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign bonds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275137072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:74%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,515</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,881</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,985</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,355</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,541</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Liabilities</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued and other liabilities consist of the following (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued payroll and related expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,964</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,887</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional service fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">638</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Liability for early exercised stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued and other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,848</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,662</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593273685056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aggregate future minimum rental payments under the operating leases as of December&#160;31, 2022, were as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year ending December&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">891</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(555</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,602</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock', window );">Schedule of Supplemental Information Related to Operating Leases</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents supplemental information related to the Company&#8217;s operating facility leases: </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,743</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.33</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.48</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.43</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593275350336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Common Stock Warrants Outstanding</a></td>
<td class="text">As of December&#160;31, 2022, the following common stock warrants were outstanding (in thousands, except per share amounts): <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:49%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Type</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Expiration Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price&#160;per<br/> Share</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">August 12, 2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">August 12, 2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271486416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of option activity is set forth below (shares in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:47%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> Remaining<br/> Contractual&#160;Life<br/> (In years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value<br/> (In&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding &#8211; December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding &#8211; December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable &#8211; December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,430</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSA Activity</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#8217;s RSA activity (shares in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant&#160;Date<br/> Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSAs, unvested at December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(56</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSAs, unvested at December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of options is estimated at the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:81%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81.07</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71.23</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.03</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.89</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded in the consolidated statements of operations and comprehensive loss related to options and RSAs was as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">1,612</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,580</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593276227776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Net Deferred Tax Assets</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#8217;s net deferred tax assets consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:72%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,985</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Section&#160;174 capitalized expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,775</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,521</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrual and reserves</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">590</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Employee retention credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized intangible costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">176</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45,343</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(35,665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(686</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(962</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(101</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(95</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(139</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(781</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,202</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total net deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the Company&#8217;s unrecognized tax benefits is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:78%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at beginning of the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">974</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">921</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions based on tax positions related to current year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">654</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reductions based on tax positions of prior year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(427</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at end of the year</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">974</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate TO Effective Income Tax Rate</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the statutory U.S. federal tax rate to the Company&#8217;s effective tax rate is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State tax</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.78</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.26</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(26.88</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16.92</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">NOL and tax credits limited under 382</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain on warrant liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.57</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593274175728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (36,004)<span></span>
</td>
<td class="num">$ (54,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in Operation</a></td>
<td class="nump">44,145<span></span>
</td>
<td class="nump">48,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(178,653)<span></span>
</td>
<td class="num">$ (142,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 75,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271490656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 25,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">5,907,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantsRepurchased', window );">Class of warrants repurchased</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantsRepurchased', window );">Class of warrants repurchased</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ClassOfWarrantsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ClassOfWarrantsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=srzn_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593269225168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Property and Equipment Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">Shorter of useful life of asset or lease term<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srzn_FurnitureFixturesAndEquipmentMember', window );">Furniture Fixtures And Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srzn_FurnitureFixturesAndEquipmentMember', window );">Furniture Fixtures And Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srzn_FurnitureFixturesAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srzn_FurnitureFixturesAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593359783664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">9,930,000<span></span>
</td>
<td class="nump">9,248,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">3,896,000<span></span>
</td>
<td class="nump">1,794,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srzn_RestrictedStockAwardRSAMember', window );">RSA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember', window );">Unvested common stock subject to repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srzn_WarrantToPurchaseCommonStockMember', window );">Warrants To Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">5,907,000<span></span>
</td>
<td class="nump">7,218,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srzn_RestrictedStockAwardRSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srzn_RestrictedStockAwardRSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srzn_WarrantToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=srzn_WarrantToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593274350608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recapitalization - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 11, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 124,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital', window );">Reduction Of Additional Paid In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.175648535<span></span>
</td>
<td class="nump">0.175648535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=srzn_SurrozenIncMember', window );">Surrozen Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=srzn_PrivateInvestmentInPublicEntityOfferingMember', window );">Private Investment In Public Entity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued, shares | shares</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering', window );">Proceeds from cash acquired through acquisition and PIPE offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of units upon PIPE Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Remaining Cost Of Acquired Entity Recorded as a Reduction of Additional Paid-in Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from cash acquired through acquisition and private investment in public entity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=srzn_SurrozenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=srzn_SurrozenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=srzn_PrivateInvestmentInPublicEntityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=srzn_PrivateInvestmentInPublicEntityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593267693296">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 64,324<span></span>
</td>
<td class="nump">$ 122,725<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">326<span></span>
</td>
<td class="nump">8,301<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,194<span></span>
</td>
<td class="nump">32,310<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,549<span></span>
</td>
<td class="nump">49,136<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bond</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,797<span></span>
</td>
<td class="nump">19,480<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Government Bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,802<span></span>
</td>
<td class="nump">18,082<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Government agency debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Foreign Bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,717<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Public Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">151<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Private Placement Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">P I P E Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">175<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,194<span></span>
</td>
<td class="nump">32,310<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">151<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,194<span></span>
</td>
<td class="nump">32,310<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial Paper</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate Bond</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Government Bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Government agency debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Foreign Bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Public Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">151<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Private Placement Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | P I P E Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,130<span></span>
</td>
<td class="nump">90,415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">175<span></span>
</td>
<td class="nump">4,774<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial Paper</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,549<span></span>
</td>
<td class="nump">49,136<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate Bond</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,797<span></span>
</td>
<td class="nump">19,480<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Government Bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,802<span></span>
</td>
<td class="nump">18,082<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Government agency debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Foreign Bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,717<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Public Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Private Placement Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | P I P E Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">175<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial Paper</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate Bond</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Government Bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Government agency debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Foreign Bonds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Public Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Private Placement Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | P I P E Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities(2):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See the definition and discussion of Public Warrants, Private Placement Warrants and PIPE Warrants in Note 11.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">They are included in cash and cash equivalents on the consolidated balance sheets as of December 31, 2022 and 2021.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_CorporateBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_CorporateBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_GovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_GovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_ForeignBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_ForeignBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271416016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Transfers of financial instruments | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=srzn_PIPEWarrantsMember', window );">P I P E Warrants | Measurement Input, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Alternative Investment, Measurement Input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | P I P E Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_StockPriceToRedeemsWarrants', window );">Stock price to redeem warrants | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | P I P E Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_StockPriceToRedeemsWarrants', window );">Stock price to redeem warrants | $ / shares</a></td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_StockPriceToRedeemsWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Price to Redeems Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_StockPriceToRedeemsWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271844992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Measurement of PIPE Warrants with Binomial Lattice Model (Details)<br></strong></div></th>
<th class="th">
<div>Aug. 11, 2021 </div>
<div>yr</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, Measurement Input</a></td>
<td class="nump">0.0081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, Measurement Input</a></td>
<td class="nump">5.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, Measurement Input</a></td>
<td class="nump">0.189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, Measurement Input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271756128">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Changes in Fair Value of Warrant Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,301<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination', window );">Assumption in Business Combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value upon remeasurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7,890)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ProceedsFromRepurchaseOfWarrants', window );">Repurchase (Note 9)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">326<span></span>
</td>
<td class="nump">8,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=srzn_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,527<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination', window );">Assumption in Business Combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value upon remeasurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,354)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ProceedsFromRepurchaseOfWarrants', window );">Repurchase (Note 9)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">151<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=srzn_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">166<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination', window );">Assumption in Business Combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value upon remeasurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ProceedsFromRepurchaseOfWarrants', window );">Repurchase (Note 9)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=srzn_PIPEWarrantsMember', window );">P I P E Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance, beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,608<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination', window );">Assumption in Business Combination</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value upon remeasurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,379)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ProceedsFromRepurchaseOfWarrants', window );">Repurchase (Note 9)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Balance, end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 4,608<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The change in fair value of the warrant liabilities was recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis assumption in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ProceedsFromRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from repurchase of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ProceedsFromRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271754704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Marketable Securities by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost Current</a></td>
<td class="nump">$ 51,389<span></span>
</td>
<td class="nump">$ 68,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains, Current</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses, Current</a></td>
<td class="num">(242)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent', window );">Gross Unrealized Gains, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-sale, Current, Total</a></td>
<td class="nump">51,148<span></span>
</td>
<td class="nump">68,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Value, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost Current</a></td>
<td class="nump">22,549<span></span>
</td>
<td class="nump">49,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains, Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses, Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-sale, Current, Total</a></td>
<td class="nump">22,549<span></span>
</td>
<td class="nump">49,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=srzn_CorporateBondMember', window );">Corporate Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost Current</a></td>
<td class="nump">10,817<span></span>
</td>
<td class="nump">15,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains, Current</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses, Current</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent', window );">Gross Unrealized Gains, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-sale, Current, Total</a></td>
<td class="nump">10,797<span></span>
</td>
<td class="nump">15,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Value, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=srzn_ForeignBondsMember', window );">Foreign Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-sale, Current, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=srzn_GovernmentBondsMember', window );">Government Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost Current</a></td>
<td class="nump">18,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains, Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses, Current</a></td>
<td class="num">(221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent', window );">Gross Unrealized Gains, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-sale, Current, Total</a></td>
<td class="nump">$ 17,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Value, Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_CorporateBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_CorporateBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_ForeignBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_ForeignBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_GovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_GovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271433232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Individual Securities Unrealized Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Investments</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Investments</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number Of Positions | Investments</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less then 12 Months, Fair Value</a></td>
<td class="nump">$ 27,520<span></span>
</td>
<td class="nump">$ 34,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less then 12 Months, Unrealized Losses</a></td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=srzn_CorporateBondMember', window );">Corporate Bond</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number Of Positions | Investments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less then 12 Months, Fair Value</a></td>
<td class="nump">$ 9,719<span></span>
</td>
<td class="nump">$ 12,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less then 12 Months, Unrealized Losses</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=srzn_GovernmentBondsMember', window );">Government Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number Of Positions | Investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less then 12 Months, Fair Value</a></td>
<td class="nump">$ 17,801<span></span>
</td>
<td class="nump">$ 18,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less then 12 Months, Unrealized Losses</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=srzn_ForeignBondsMember', window );">Foreign Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number Of Positions | Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less then 12 Months, Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less then 12 Months, Unrealized Losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_CorporateBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_CorporateBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_GovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_GovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=srzn_ForeignBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=srzn_ForeignBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271492208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 14,985<span></span>
</td>
<td class="nump">$ 14,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(11,355)<span></span>
</td>
<td class="num">(9,541)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,630<span></span>
</td>
<td class="nump">4,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">7,052<span></span>
</td>
<td class="nump">7,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srzn_LabEquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">7,515<span></span>
</td>
<td class="nump">6,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srzn_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srzn_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271371648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">$ 1,955<span></span>
</td>
<td class="nump">$ 2,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593276494800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">$ 3,964<span></span>
</td>
<td class="nump">$ 2,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="nump">3,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued professional service fees</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Liability for early exercised stock options</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">$ 6,848<span></span>
</td>
<td class="nump">$ 8,662<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred for employer-related costs classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271690592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> m&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>m&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">$ 405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">CALIFORNIA | Eight Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_OperatingLeaseMonthOfExpiryOfLease', window );">Operating lease month of expiry of lease</a></td>
<td class="text">2025-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_OperatingLeaseMonthOfExpiryOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease month Of expiry of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_OperatingLeaseMonthOfExpiryOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=srzn_EightYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=srzn_EightYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271984544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary Of Lessee, Operating Lease, Liability, Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ending December 31, 2023</a></td>
<td class="nump">$ 2,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2024</a></td>
<td class="nump">2,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2025</a></td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">6,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 5,602<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593272200704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Information Related to Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities (in thousands)</a></td>
<td class="nump">$ 2,743<span></span>
</td>
<td class="nump">$ 2,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">2 years 3 months 29 days<span></span>
</td>
<td class="text">3 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.48%<span></span>
</td>
<td class="nump">8.43%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271842192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreement (Additional Information) (Details) - Collaboration and License Agreement with BI [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_NonRefundableUpfrontPaymentReceived', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_SuccessBasedMilestonePayments', window );">Success-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AssociatedWithholdingTax', window );">Associated withholding tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_TransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_CollaborationAndLicenseAgreementWithBiMember', window );">Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AssociatedWithholdingTax', window );">Associated withholding tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AssociatedWithholdingTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Associated withholding tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AssociatedWithholdingTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_NonRefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payment received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_NonRefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_SuccessBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success-based milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_SuccessBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_TransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_TransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_CollaborationAndLicenseAgreementWithBiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_CollaborationAndLicenseAgreementWithBiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271837136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,013<span></span>
</td>
<td class="nump">$ 40,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_StanfordLicenseAgreementsMember', window );">Stanford License Agreements [Member] | Stanford [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones', window );">Payments for milestone agreement or earned royalties on achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones', window );">Payments for achievement of specified development and regulatory milestones</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones', window );">Payments for milestone agreement on achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_UCSFLicenseAndOptionAgreementsMember', window );">U C S F License And Option Agreements [Member] | Stanford [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones', window );">Payments for milestone agreement on achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_DistributedBioSubscriptionAgreementMember', window );">Distributed Bio Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones', window );">Payments for achievement of specified development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_DistributedBioSubscriptionAgreementMember', window );">Distributed Bio Subscription Agreement [Member] | Stanford [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones', window );">Payments for milestone agreement on achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Stanford License Agreements [Member] | Stanford [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones', window );">Payments for milestone agreement or earned royalties on achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for achievement of specified development and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for milestone agreement on achievement of milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for milestone agreement or earned royalties on achievement of milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_StanfordLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_StanfordLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=srzn_StanfordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=srzn_StanfordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_UCSFLicenseAndOptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_UCSFLicenseAndOptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_DistributedBioSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=srzn_DistributedBioSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593274543168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Share repurchased, shares</a></td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantsRepurchased', window );">Class of warrants repurchased</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Repurchase of warrants or repurchase price</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_CommonStockTotalPurchasePrice', window );">Common stock purchase price</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
<td class="nump">$ 8,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ClassOfWarrantsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ClassOfWarrantsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_CommonStockTotalPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock total purchase price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_CommonStockTotalPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593272102432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 27, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,088,000<span></span>
</td>
<td class="nump">35,034,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=srzn_ClosingSalePriceNotBelow1200PerShareMember', window );">Closing Sale Price Not Below 1200 Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=srzn_LincolnParkMember', window );">Lincoln Park [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherValueOutstanding', window );">Common stock with the fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock purchase commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sole discretion purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Description of common stock closing sale transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Regular Purchase Share Limit may be increased to up to 35,000 shares and 40,000 shares if the closing price of the Company&#8217;s common stock is not below $10.00 per share and $12.00 per share, respectively. Any single purchase of the Company&#8217;s common stock shall not exceed $3.5 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PurchasePricePerShareOfAdditionalShares', window );">Purchase price of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">purchase price per share equal to 96% of the lower of (i) the closing price of the Company&#8217;s common stock on the purchase date and (ii) the volume weighted average price of the Company&#8217;s common stock on the purchase date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=srzn_LincolnParkMember', window );">Lincoln Park [Member] | Closing Sale Price Not Below 10.00 per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=srzn_GuggenheimSecuritiesLlcMember', window );">Guggenheim Securities, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_CompensationPayable', window );">Compensation payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Closing Sale Price Not Below 10.00 per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Closing Sale Price Not Below 1200 Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Lincoln Park [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_CommonStockPurchaseCommitmentPeriod', window );">Stock Issuance period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PurchaseOfAdditionalShares', window );">Purchase of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Lincoln Park [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_CommonStockPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock purchase commitment period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_CommonStockPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_CompensationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_CompensationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_PurchaseOfAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of additional shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_PurchaseOfAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_PurchasePricePerShareOfAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share of additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_PurchasePricePerShareOfAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=srzn_ClosingSalePriceNotBelow1200PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=srzn_ClosingSalePriceNotBelow1200PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=srzn_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=srzn_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=srzn_ClosingSalePriceNotBelow1000PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=srzn_ClosingSalePriceNotBelow1000PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=srzn_GuggenheimSecuritiesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=srzn_GuggenheimSecuritiesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593267917824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 12, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common Stock Warrants Outstanding</a></td>
<td class="nump">5,907,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Common Stock Warrants Expiration Date</a></td>
<td class="text">Aug. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantsRepurchased', window );">Class of warrants repurchased</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo', window );">Warrant Redemption Condition Minimum Share Price Scenario Two</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series C redeemable convertible preferred stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common Stock Warrants Outstanding</a></td>
<td class="nump">2,733,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_BusinessCombinationInitialWarrantsIssued', window );">Common stock warrants issued as part of business combination</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Common Stock Warrants Expiration Date</a></td>
<td class="text">Aug. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_WarrantNoticePeriodPriorToRedemptionDate', window );">Warrant Redemption Period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantsRepurchased', window );">Class of warrants repurchased</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne', window );">Warrant Redemption Condition Minimum Share Price Scenario One</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PublicWarrantsMember', window );">Public Warrants | Common Stock, Closing Price equals or Exceeds $18 Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption Price Per Public Warrant</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance of common stock Per Share</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PublicWarrantsMember', window );">Public Warrants | Common Stock, Closing Price equals or Exceeds $10 Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption Price Per Public Warrant</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Issuance of common stock Per Share</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common Stock Warrants Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_AssumedWarrants', window );">Common stock warrants assumed as part of business combination</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantsRepurchased', window );">Class of warrants repurchased</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PIPEWarrantsMember', window );">P I P E Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common Stock Warrants Outstanding</a></td>
<td class="nump">3,174,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantOrRightIssued', window );">Common stock warrants issued as part of business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Common Stock Warrants Expiration Date</a></td>
<td class="text">Aug. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantsRepurchased', window );">Class of warrants repurchased</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_AssumedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_AssumedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_BusinessCombinationInitialWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Initial Warrants Issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_BusinessCombinationInitialWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Redemption Price Of Warrants Or Rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ClassOfWarrantsRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ClassOfWarrantsRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_WarrantNoticePeriodPriorToRedemptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_WarrantNoticePeriodPriorToRedemptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Redemption Condition Minimum Share Price Scenario One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>WarrantRedemptionConditionMinimumSharePriceScenarioTwo</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=srzn_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=srzn_CommonStock1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=srzn_CommonStock1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=srzn_CommonStock2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=srzn_CommonStock2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=srzn_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=srzn_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593267501968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants - (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Common Stock Warrants Expiration Date</a></td>
<td class="text">Aug. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants exercise price per share</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common Stock Warrants Outstanding</a></td>
<td class="nump">5,907,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common Stock Warrants Fair Value</a></td>
<td class="nump">$ 326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantOrRightClassification', window );">Common Stock Warrant Classification</a></td>
<td class="text">Liability<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Common Stock Warrants Expiration Date</a></td>
<td class="text">Aug. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants exercise price per share</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common Stock Warrants Outstanding</a></td>
<td class="nump">2,733,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common Stock Warrants Fair Value</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PIPEWarrantsMember', window );">P I P E Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ClassOfWarrantOrRightClassification', window );">Common Stock Warrant Classification</a></td>
<td class="text">Liability<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Common Stock Warrants Expiration Date</a></td>
<td class="text">Aug. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants exercise price per share</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common Stock Warrants Outstanding</a></td>
<td class="nump">3,174,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common Stock Warrants Fair Value</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ClassOfWarrantOrRightClassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Classification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ClassOfWarrantOrRightClassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=srzn_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=srzn_PIPEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=srzn_PIPEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271882304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation Plan - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>Employees </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_CliffVestingPeriod', window );">Cliff vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value/shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="nump">$ 6.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,088,000<span></span>
</td>
<td class="nump">35,034,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding | shares</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">3,896<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees held stock options | Employees</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price | $ / shares</a></td>
<td class="num">$ (8.81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Incremental expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=srzn_VestedMember', window );">vested member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Incremental expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=srzn_UnvestedMember', window );">unvested member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Incremental expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=srzn_RestrictedStockAwardRSAMember', window );">RSA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSAs vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=srzn_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PercentageOfDiscountPayrollDeductions', window );">Percentage of discount payroll deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_CommonStockTradingDiscription', window );">Common stock trading description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The eligible employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the purchase day.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=srzn_TwoThousandFifteenStockPlan1Member', window );">2015 stock plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=srzn_TwoThousandTwentyOneStockPlanMember', window );">2021 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding | shares</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=srzn_TwoThousandTwentyOneStockPlanMember', window );">2021 Stock Plan [Member] | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Description of modification of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Options under the 2021 Plan generally vest over four years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=srzn_TwoThousandTwentyOneStockPlanMember', window );">2021 Stock Plan [Member] | Employee Stock | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_CliffVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cliff vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_CliffVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_CommonStockTradingDiscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Trading Discription</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_CommonStockTradingDiscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_PercentageOfDiscountPayrollDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount payroll deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_PercentageOfDiscountPayrollDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=srzn_VestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=srzn_VestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=srzn_UnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=srzn_UnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=srzn_RestrictedStockAwardRSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=srzn_RestrictedStockAwardRSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=srzn_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=srzn_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=srzn_TwoThousandFifteenStockPlan1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=srzn_TwoThousandFifteenStockPlan1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=srzn_TwoThousandTwentyOneStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=srzn_TwoThousandTwentyOneStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593267500288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation Plan - Summary of Stock Option Activity for Company's Stock Option Plans (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding Beginning Balance</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="nump">2,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options Forfeited</a></td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options Cancelled</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding Ending Balance</a></td>
<td class="nump">3,896<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options outstanding and exercisable</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 6.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Cancelled</a></td>
<td class="nump">6.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending Balance</a></td>
<td class="nump">2.43<span></span>
</td>
<td class="nump">$ 6.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Options outstanding and exercisable</a></td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (In Years)</a></td>
<td class="text">8 years 5 months 8 days<span></span>
</td>
<td class="text">8 years 5 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, exercisable (In Years)</a></td>
<td class="text">7 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271488016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation Plan - Summary of RSA Activity (Details) - RSA [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance | shares</a></td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares RSAs, Vested | shares</a></td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares RSAs, unvested, Ending Balance | shares</a></td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value RSAs, Unvested Beginning Balance | $ / shares</a></td>
<td class="nump">$ 9.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value RSAs, Vested | $ / shares</a></td>
<td class="nump">8.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value RSAs, Unvested Ending Balance | $ / shares</a></td>
<td class="nump">$ 9.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=srzn_RestrictedStockAwardRSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=srzn_RestrictedStockAwardRSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271406176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation Plan- Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Options (Details) - Stock Option<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.07%<span></span>
</td>
<td class="nump">71.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">2.03%<span></span>
</td>
<td class="nump">0.89%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593273816576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation Plan - Schedule of Stock-Based Compensation Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 19,826<span></span>
</td>
<td class="nump">$ 14,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,517<span></span>
</td>
<td class="nump">2,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Research and development</a></td>
<td class="nump">1,612<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,905<span></span>
</td>
<td class="nump">$ 1,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593267019696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_TaxCreditCarryForwardsExpirationStartYear', window );">Tax credit carry forwards expiration start year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 3,775,000<span></span>
</td>
<td class="nump">$ 2,392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease', window );">Deferred tax assets, deferred expense, capitalized research and development costs increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Uncertain income tax position, Description</a></td>
<td class="text">An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_ReinsuranceRetentionsPolicyAmountRetained', window );">Reinsurance Retention Policy Amount Retained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net valuation allowance increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Capitalized expenses, amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 139,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_TaxCreditCarryForwardsExpirationStartYear', window );">Tax credit carry forwards expiration start year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Indefinite Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">127,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward</a></td>
<td class="nump">27,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Capitalized expenses, amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 53,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_StateTaxCreditCarryForwardsExpiration', window );">Tax credit carry forwards expiration start year</a></td>
<td class="text">indefinitely<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets deferred expense capitalized research and development costs increase decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_ReinsuranceRetentionsPolicyAmountRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reinsurance Retentions Policy Amount Retained</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_ReinsuranceRetentionsPolicyAmountRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_StateTaxCreditCarryForwardsExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>State tax credit carry forwards expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_StateTaxCreditCarryForwardsExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_TaxCreditCarryForwardsExpirationStartYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forwards expiration start year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_TaxCreditCarryForwardsExpirationStartYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131251-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=srzn_IndefiniteTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=srzn_IndefiniteTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593271926560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 32,985<span></span>
</td>
<td class="nump">$ 31,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_DeferredTaxAssetsCapitalizedExpenses', window );">Section 174 capitalized expense</a></td>
<td class="nump">6,812<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">3,775<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">1,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrual and reserves</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_DeferredTaxAssetsEmployeeRetentionCredits', window );">Employee retention credits</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_DeferredTaxAssetsCapitalizedIntangibleAssets', window );">Capitalized intangible costs</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">46,124<span></span>
</td>
<td class="nump">36,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(45,343)<span></span>
</td>
<td class="num">(35,665)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">1,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(686)<span></span>
</td>
<td class="num">(962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(781)<span></span>
</td>
<td class="num">(1,202)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_DeferredTaxAssetsCapitalizedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_DeferredTaxAssetsCapitalizedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_DeferredTaxAssetsCapitalizedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_DeferredTaxAssetsCapitalizedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_DeferredTaxAssetsEmployeeRetentionCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Employee retention credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_DeferredTaxAssetsEmployeeRetentionCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593268001360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">$ 921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">654<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions based on tax positions of prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 1,628<span></span>
</td>
<td class="nump">$ 974<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593273816864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate TO Effective Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax</a></td>
<td class="nump">2.12%<span></span>
</td>
<td class="num">(2.78%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">1.72%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="num">(2.26%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(26.88%)<span></span>
</td>
<td class="num">(16.92%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">NOL and tax credits limited under 382</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities', window );">Gain on warrant liabilities</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.57%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent, Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation gain on warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593276131856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(K) Plan Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Company's Contributions</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593276671184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Additional Information) (Details) - Subsequent Events - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srzn_PercentOfContractPrice', window );">Percent of Contract Price</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srzn_PercentOfContractPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percent of contract price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srzn_PercentOfContractPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srzn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>d491933dposam_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:srzn="http://Consonance.com/20221231"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="srzn-20221231.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn08_11_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="P12_12_2022To12_12_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <startDate>2022-12-12</startDate>
            <endDate>2022-12-12</endDate>
        </period>
    </context>
    <context id="PAsOn12_12_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <instant>2022-12-12</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="P08_01_2021To08_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn10_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="P10_01_2022To10_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:CorporateBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:GovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ForeignBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:ForeignBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LetterOfCreditMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srzn:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LincolnParkMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">srzn:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:GovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:CorporateBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:GovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:GovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:GovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:CorporateBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:CorporateBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:CorporateBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">srzn:EightYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srzn:TwoThousandTwentyOneStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srzn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteTaxYearMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">srzn:IndefiniteTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStock1MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">srzn:CommonStock1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStock2MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">srzn:CommonStock2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_GuggenheimSecuritiesLlcMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">srzn:GuggenheimSecuritiesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:CorporateBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:ForeignBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:GovernmentBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LetterOfCreditMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srzn:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:ForeignBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:ForeignBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:ForeignBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:ForeignBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:GovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:GovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:GovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:GovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:CorporateBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:CorporateBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:CorporateBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:CorporateBondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_WarrantToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">srzn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_UnvestedCommonStockSharesSubjectToRepurchaseMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">srzn:UnvestedCommonStockSharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockAwardRSAMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srzn:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:StanfordLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_StanfordMemberusgaapRelatedPartyTransactionAxis_UCSFLicenseAndOptionAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srzn:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:UCSFLicenseAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srzn:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:DistributedBioSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FurnitureFixturesAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srzn:FurnitureFixturesAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FurnitureFixturesAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srzn:FurnitureFixturesAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_WarrantToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">srzn:WarrantToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_UnvestedCommonStockSharesSubjectToRepurchaseMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">srzn:UnvestedCommonStockSharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:CollaborationAndLicenseAgreementWithBiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srzn:TwoThousandTwentyOneStockPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandFifteenStockPlan1MemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srzn:TwoThousandFifteenStockPlan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">srzn:EightYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srzn:TwoThousandTwentyOneStockPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapBalanceSheetLocationAxis_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:CollaborationAndLicenseAgreementWithBiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srzn:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:StanfordLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_StanfordMemberusgaapRelatedPartyTransactionAxis_UCSFLicenseAndOptionAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srzn:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:UCSFLicenseAndOptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srzn:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:DistributedBioSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStock1MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">srzn:CommonStock1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStock2MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">srzn:CommonStock2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LincolnParkMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">srzn:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srzn:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_VestedMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">srzn:VestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_UnvestedMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">srzn:UnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P08_01_2021To08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srzn:PrivateInvestmentInPublicEntityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="P08_11_2021To08_11_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srzn:PrivateInvestmentInPublicEntityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-11</startDate>
            <endDate>2021-08-11</endDate>
        </period>
    </context>
    <context id="PAsOn08_11_2021_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_11_2021_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_11_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_11_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srzn:PrivateInvestmentInPublicEntityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">srzn:PrivateInvestmentInPublicEntityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2021_SurrozenIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">srzn:SurrozenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2016_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">srzn:EightYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-31</instant>
        </period>
    </context>
    <context id="P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:CollaborationAndLicenseAgreementWithBiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="P10_01_2022To10_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srzn:TwoThousandTwentyOneStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="P11_01_2022To11_30_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:CollaborationAndLicenseAgreementWithBiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P03_01_2016To03_31_2016_MaximumMembersrtRangeAxis_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srzn:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:StanfordLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2016To03_31_2016_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srzn:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:StanfordLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="P06_01_2018To06_30_2018_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">srzn:StanfordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:StanfordLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="P09_01_2016To09_30_2016_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">srzn:DistributedBioSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">srzn:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">srzn:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2022To02_28_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">srzn:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">srzn:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">srzn:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_ClosingSalePriceNotBelow1000PerShareMemberusgaapMeasurementInputTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">srzn:ClosingSalePriceNotBelow1000PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_ClosingSalePriceNotBelow1200PerShareMemberusgaapMeasurementInputTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">srzn:ClosingSalePriceNotBelow1200PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_ClosingSalePriceNotBelow1000PerShareMemberusgaapMeasurementInputTypeAxis_LincolnParkMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">srzn:ClosingSalePriceNotBelow1000PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">srzn:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_ClosingSalePriceNotBelow1200PerShareMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">srzn:ClosingSalePriceNotBelow1200PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="P04_27_2022To04_27_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">srzn:LincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-27</startDate>
            <endDate>2022-04-27</endDate>
        </period>
    </context>
    <context id="PAsOn10_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">srzn:TwoThousandTwentyOneStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="P01_31_2023To01_31_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="P02_28_2023To02_28_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">srzn:RestrictedStockAwardRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PIPEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">srzn:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824893</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_sqm">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Investments">
        <measure>srzn:Investments</measure>
    </unit>
    <unit id="Unit_Employees">
        <measure>srzn:Employees</measure>
    </unit>
    <unit id="Unit_Y">
        <measure>utr:Y</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2022To12_31_2022">true</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2022To12_31_2022">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2022To12_31_2022">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName contextRef="P01_01_2022To12_31_2022" id="hidden73306884">Surrozen, Inc./DE</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To12_31_2022">0001824893</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2022To12_31_2022" id="hidden73306899">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden73306900">CA</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="P01_01_2022To12_31_2022">S-1</dei:DocumentType>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2022To12_31_2022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2022To12_31_2022">2834</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2022To12_31_2022">98-1556622</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To12_31_2022">171 Oyster Point Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2022To12_31_2022">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To12_31_2022">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To12_31_2022">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2022To12_31_2022">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2022To12_31_2022">489-9000</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Craig Parker</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">171 Oyster Point Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">489-9000</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2022To12_31_2022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2022To12_31_2022">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To12_31_2022">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2022To12_31_2022">false</dei:EntityExTransitionPeriod>
    <dei:AmendmentDescription contextRef="P01_01_2022To12_31_2022">This Post-Effective Amendment No.&#160;2 to the Registration Statement on Form S-1 (File No.&#160;333-259496), or the Registration Statement, of Surrozen, Inc., as originally filed with the Securities and Exchange Commission, or the SEC, on September&#160;13, 2021, as amended on November&#160;8, 2021 by Amendment No.1 and declared effective by the SEC on November&#160;9, 2021, as further amended on March&#160;29, 2022 by Post-Effective Amendment No.1 and declared effective on March&#160;29, 2022, is being filed pursuant to the undertakings in Item 17 of the Registration Statement to (i)&#160;include information contained in the Registrant&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022 that was filed with the SEC on March&#160;31, 2023 and (ii)&#160;update certain other information in the Registration Statement. The information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No.&#160;2. All applicable registration fees were paid at the time of the original filing of the Registration Statement.</dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">24690000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">33091000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1978000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">51148000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">68760000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3489000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3338000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">81305000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">105189000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3630000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4794000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3268000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4582000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21655000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">405000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">405000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">827000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">549000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">89435000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">137174000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">658000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2718000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6848000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8662000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2226000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2193000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9732000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13573000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3376000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <srzn:WarrantLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">326000</srzn:WarrantLiability>
    <srzn:WarrantLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8301000</srzn:WarrantLiability>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">13434000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">27474000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_shares">30088000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_shares">30088000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">35034000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">35034000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">254892000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">252464000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-241000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-178653000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-142649000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">76001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">109700000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">89435000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">137174000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">37013000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">40177000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">19826000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14214000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">56839000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54391000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-44339000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-54391000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">781000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">72000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7554000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-329000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-36004000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-54648000</us-gaap:NetIncomeLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-122000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-119000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-36126000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-54767000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">34722</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">34722</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">24689</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">24689</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">18257000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">135292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-88001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">47293000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">16441000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">114463000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">114465000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">161000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">411000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">411000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-225000</srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions>
    <srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-225000</srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions>
    <srzn:AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">207000</srzn:AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue>
    <srzn:AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">207000</srzn:AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue>
    <srzn:RepurchaseOfEarlyExercisedStockOptionsShares
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">1000</srzn:RepurchaseOfEarlyExercisedStockOptionsShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">193000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">-16000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2316000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2316000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-119000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-119000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-54648000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-54648000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">35034000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">252464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-142649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">109700000</us-gaap:StockholdersEquity>
    <srzn:IssuanceOfCommonStockUnderEquityPurchaseAgreement
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">100000</srzn:IssuanceOfCommonStockUnderEquityPurchaseAgreement>
    <srzn:Issuanceofcommonstockvalueunderequitypurchaseagreement
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">273000</srzn:Issuanceofcommonstockvalueunderequitypurchaseagreement>
    <srzn:Issuanceofcommonstockvalueunderequitypurchaseagreement
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">273000</srzn:Issuanceofcommonstockvalueunderequitypurchaseagreement>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">347000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">143000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">143000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <srzn:RepurchaseOfEarlyExercisedStockOptionsShares
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">11000</srzn:RepurchaseOfEarlyExercisedStockOptionsShares>
    <srzn:RepurchaseAndCancellationOfCommonStock
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">-5382000</srzn:RepurchaseAndCancellationOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2606000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2607000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">101000</srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions>
    <srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">101000</srzn:AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4517000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4517000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-122000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-122000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-36004000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-36004000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">30088000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">254892000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-178653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">76001000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-36004000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-54648000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1955000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2066000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4517000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2316000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1314000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1231000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">108000</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">105000</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-7890000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-71000</us-gaap:FairValueAdjustmentOfWarrants>
    <srzn:IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">273000</srzn:IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement>
    <srzn:IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1978000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2296000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">379000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">510000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2038000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">857000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1782000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3789000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2191000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-2061000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-44145000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-48813000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">728000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1269000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">29600000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">91739000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <srzn:ProceedsFromSaleOfMarketableSecurities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:ProceedsFromSaleOfMarketableSecurities>
    <srzn:ProceedsFromSaleOfMarketableSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1100000</srzn:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">68637000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14200000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">38309000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-77708000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">124220000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <srzn:ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions>
    <srzn:ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">411000</srzn:ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions>
    <srzn:ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">143000</srzn:ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases>
    <srzn:ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2607000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">85000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <srzn:RepurchaseOfEarlyExcercisedStockOptions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">16000</srzn:RepurchaseOfEarlyExcercisedStockOptions>
    <srzn:RepurchaseOfEarlyExcercisedStockOptions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000</srzn:RepurchaseOfEarlyExcercisedStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-2565000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">124630000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-8401000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">33496000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">35387000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25095000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">33496000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">133097000</us-gaap:ConversionOfStockAmountConverted1>
    <srzn:AssumptionOfWarrantLiabilitiesInBusinessCombination
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:AssumptionOfWarrantLiabilitiesInBusinessCombination>
    <srzn:AssumptionOfWarrantLiabilitiesInBusinessCombination
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8372000</srzn:AssumptionOfWarrantLiabilitiesInBusinessCombination>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1792000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">85000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">22000</us-gaap:PaymentsToAcquireProductiveAssets>
    <srzn:VestingOfEarlyExercisesOfStockOptions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">101000</srzn:VestingOfEarlyExercisesOfStockOptions>
    <srzn:VestingOfEarlyExercisesOfStockOptions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">207000</srzn:VestingOfEarlyExercisesOfStockOptions>
    <srzn:ReclassificationToLiabilityForEarlyExercisedStockOptions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:ReclassificationToLiabilityForEarlyExercisedStockOptions>
    <srzn:ReclassificationToLiabilityForEarlyExercisedStockOptions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">225000</srzn:ReclassificationToLiabilityForEarlyExercisedStockOptions>
    <srzn:IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension>
    <srzn:IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">257000</srzn:IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">24690000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">33091000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">405000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">405000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25095000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">33496000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NatureOfOperations contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 1. Organization and Business &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Surrozen, Inc., or the Company, formerly known as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consonance-HFW&lt;/div&gt; Acquisition Corp., or Consonance, is a clinical stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The Company, a Delaware corporation, is located in South San Francisco, California, and it operates and manages its business as one operating segment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Consonance was a blank check company incorporated as a Cayman Islands exempted company on August&#160;21, 2020. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On August&#160;11, 2021, Consonance consummated a business combination, or the Business Combination, among Consonance, Perseverance Merger Sub Inc., a subsidiary of Consonance, and Surrozen, Inc., or Legacy Surrozen, a Delaware company incorporated on August&#160;12, 2015. Upon closing of the Business Combination, Consonance became a Delaware corporation and was renamed to Surrozen, Inc., Legacy Surrozen, was renamed to Surrozen Operating, Inc., and Legacy Surrozen continued as a wholly-owned subsidiary of the Company. See Note 3, &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recapitalization&#x201d;&lt;/div&gt;&lt;/div&gt; for additional details. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Surrozen Netherlands, B.V. was incorporated in May 2022 and is located in Rotterdam, Netherlands as a wholly-owned subsidiary of Surrozen Operating, Inc. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has incurred net operating losses each period since inception. During the years ended December&#160;31, 2022 and 2021, the Company incurred a net loss of $36.0&#160;million and $54.6&#160;million, respectively. During the years ended December&#160;31, 2022 and 2021, the Company used $44.1&#160;million and $48.8&#160;million of cash in operations. As of December&#160;31, 2022, the Company had cash, cash equivalents and marketable securities of $75.8&#160;million and an accumulated deficit of approximately $178.7&#160;million. The Company expects operating expenses to continue to increase in connection with its ongoing clinical studies and anticipates the need to raise additional capital to continue to execute its long-range business plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Management believes that the existing cash, cash equivalents and marketable securities are sufficient for the Company to continue operating activities for at least the next 12 months from the date of issuance of its consolidated financial statements. However, if the Company&#x2019;s anticipated cash burn is greater than anticipated, the Company could use its capital resources sooner than expected which may result in the need to reduce future planned expenditures and/or raise additional capital to continue to fund the operations. &lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-36000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-54600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-44100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-48800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">75800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-178700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s consolidated financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, as determined by the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, and pursuant to the regulations of the U.S. Securities and Exchange Commission, or SEC. The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany transactions and balances have been eliminated. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Business Combination discussed in Note 1 was accounted for as a reverse recapitalization with Legacy Surrozen as the accounting acquirer and Consonance as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the consolidated financial statements represents the accounts of Legacy Surrozen at their historical cost as if Legacy Surrozen is the predecessor to the Company. The consolidated financial statements following the closing of the Business Combination reflect the results of the combined entity&#x2019;s operations. All issued and outstanding common stock and stock awards of Legacy Surrozen and per share amounts contained in the consolidated financial statements for the periods presented prior to the closing of the Business Combination on August&#160;11, 2021 have been retroactively restated to reflect the exchange ratio established in the Business Combination. See Note 3, &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recapitalization&#x201d;&lt;/div&gt;&lt;/div&gt; for additional details. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, revenue recognition, certain accruals for research and development activities, the fair value of common stock prior to the Business Combination, initial fair value of the PIPE Warrants and stock-based compensation expense. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could materially differ from those estimates. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist of cash, cash equivalents and marketable securities. The Company&#x2019;s cash is held by one financial institution that may at times exceed federally insured limits. However, the Company&#x2019;s exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company believes it is not exposed to significant credit risk on cash. The Company&#x2019;s policy is to invest cash in institutional money market funds and marketable securities with high credit quality to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and marketable securities in a variety of securities, including money market funds, U.S. government bonds, U.S. government agency debt securities, foreign bonds, commercial paper and corporate debt securities. The Company has not experienced any losses on its cash equivalents and marketable securities. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Cash equivalents relate to securities having an original maturity of three months or less at the time of purchase. As of December&#160;31, 2022 and 2021, cash and cash equivalents consisted of bank deposits, money market funds and U.S. government agency debt securities. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of each of December&#160;31, 2022 and 2021, the Company had $0.4&#160;million of restricted cash in the form of a letter of credit for the Company&#x2019;s facility lease. The restricted cash is classified as a noncurrent asset as the Company is required to maintain the letter of credit for the benefit of the landlord until the end of the lease term in April 2025. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company invests its excess cash in marketable U.S. government bonds, foreign bonds, commercial paper and corporate debt securities. All marketable securities have been classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company does not buy or hold securities principally for the purpose of selling them in the near future. The Company&#x2019;s policy is focused on the preservation of capital, liquidity, and return. From time to time, the Company may sell certain securities, but the objectives are generally not to generate profits on short-term differences in price. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Short-term marketable securities have maturities less than or equal to one year as of the balance sheet date. Long-term marketable securities have maturities greater than one year as of the balance sheet date. These marketable securities are carried at estimated fair value with unrealized holding gains and losses included in accumulated other comprehensive loss in stockholders&#x2019; equity until realized. Gains and losses on marketable security transactions are reported on the specific-identification method. Interest income is recognized in the consolidated statements of operations and comprehensive loss when earned. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company periodically evaluates its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities for impairment. When the fair value of a marketable security is below its amortized cost basis, the amortized cost is reduced to its fair value if it is more likely than not that the Company is required to sell the impaired security before recovery of its amortized cost, or the Company has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost basis over the fair value of the security. An allowance for credit losses for the excess of amortized cost basis over the expected cash flows, if any, is recorded in other income (expense), net on the consolidated statements of operations. Impairment losses that are not credit-related are included in accumulated other comprehensive loss in stockholders&#x2019; equity. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, including leasehold improvements, are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td style="width:47%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated useful life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Shorter of useful life of asset or lease term&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Furniture, fixtures and equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the period realized. Maintenance and repairs are expensed as incurred. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Material leases with a term longer than one year are recognized as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use,&lt;/div&gt;&lt;/div&gt; or ROU, assets and lease liabilities in the Company&#x2019;s consolidated balance sheets. The Company determines the lease classification and measurement of its ROU assets and lease liabilities at the lease commencement date and thereafter if modified. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company uses its incremental borrowing rate, based on the information available at the commencement date, to determine the present value of lease payments if the rate implicit in the lease is not readily available. The ROU asset is based on the measurement of the lease liability and is adjusted for lease incentives provided by the landlord. Lease expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. The Company has not identified any such impairment losses to date. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s Public Warrants, Private Placement Warrants and PIPE Warrants were classified as liabilities (see Note 11). At the end of each reporting period, any changes in fair value during the period are recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. No Private Placement Warrants were outstanding as of December&#160;31, 2022 as a result of the repurchase of 1.3&#160;million warrants in December 2022 (see Note 9). The Company will continue to adjust the warrant liabilities pertaining to the outstanding warrants for changes in the fair value until the earlier of a) the exercise or expiration of the warrants or b) the redemption of the warrants, at which time such warrants will be reclassified to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue in accordance with ASC 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/div&gt;&lt;/div&gt;,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for these goods or services. To determine revenue recognition for the arrangement that is within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract with the customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At contract inception, the Company assesses the goods or services promised within the contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligations when or as the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the variable consideration constraint) that a significant reversal of recognized revenue is not probable. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses accounts receivable for impairment and, to date, no impairment losses have been recorded. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has a collaboration and license agreement with BI to which the Company licensed certain rights to its intellectual property (see Note 7) that is determined within the scope of ASC 606. The terms of the CLA include payment to the Company of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment, development, regulatory and commercial milestone payments and royalties on net sales of licensed products. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Licenses of Intellectual Property: If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Milestone Payments:&lt;/div&gt;&lt;/div&gt; At contract inception, the Company using the most likely amount method evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received or the underlying activity has been completed. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect revenue in the period of adjustment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties:&lt;/div&gt;&lt;/div&gt; The Company recognizes sales-based royalties as revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalties that have been allocated have been satisfied (or partially satisfied). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The incremental costs of obtaining a customer contract are expensed as and when incurred if the amortization period of the asset that would have been recognized is one year or less. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Research and development costs are expensed as incurred. Research and development costs consist of external and internal expenses directly attributable to the conduct of research and development programs. The external expenses include the costs of services provided by outside contractors, clinical research organizations and contract manufacturing organizations. The internal expenses include the costs of salaries, bonus, payroll taxes, stock-based compensation, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, and the allocated facility-related costs, such as rent, utilities, insurance, repairs and maintenance, and general support services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has entered into and may continue to enter into licensing or subscription arrangements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company&#x2019;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records accruals for estimated costs of research, preclinical, clinical, and manufacturing development, which are significant components of research and development expenses, within accrued and other liabilities in the accompanying consolidated balance sheets. A substantial portion of the Company&#x2019;s ongoing research and development activities is conducted by third-party service providers. The Company accrues the costs under agreements with these third parties as incurred. The Company estimates the amounts incurred in each period based on the information available and its knowledge of the nature of the contractual activities generating such costs. Clinical trial contract expenses are accrued based on units of activity. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. For the years ended December&#160;31, 2022 and 2021, the Company has not experienced any material differences between accrued costs and actual costs incurred. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts accrued expenses or prepaid expenses accordingly, which impacts research and development expenses. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes stock-based compensation expense for all stock-based awards. For stock option awards, stock-based compensation cost is estimated at the grant date based on the fair value of the equity for financial reporting purposes and is recognized as expense on a straight-line basis over the requisite service period. Under the Company&#x2019;s employee stock purchase plan, stock-based compensation cost is measured at the beginning of the offering period and recognized on a straight-line basis over the offering period. Forfeitures are accounted for as they occur. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected to calculate the fair value of awards using the Black-Scholes option pricing model, or the Black-Scholes Model. The Black-Scholes Model requires the use of various assumptions including common stock valuation, expected option life and expected stock price volatility. The Company estimates the expected term for stock options using the simplified method as the midpoint between the vesting date and the contractual expiration date of the award as the Company has limited historical exercise information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. Due to the limited trading history of the Company&#x2019;s stock, the Company estimates the volatility using volatilities of a group of public companies in a comparable industry, stage of life cycle, and size. The interest rate is derived from the U.S. Treasury instruments with maturities similar to the expected term of the options. The Company has not declared nor expects to declare dividends. Therefore, there is no dividend impact on the valuation of options. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Prior to the Business Combination, the fair value of common stock was determined considering numerous objective and subjective factors and requires judgment. These objective and subjective factors include, but are not limited to: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;relevant precedent transactions involving the Company&#x2019;s capital stock; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;contemporaneous valuations performed by third-party specialists; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;rights, preferences, and privileges of the Company&#x2019;s redeemable convertible preferred stock relative to those of the Company&#x2019;s common stock; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;actual operating and financial performance; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;current business conditions and financial projections; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company&#x2019;s business; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;the lack of marketability of the Company&#x2019;s common stock, and the illiquidity of stock-based awards involving securities in a private company; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;market multiples of comparable publicly traded companies; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;stage of development; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;industry information such as market size and growth; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;U.S. and global capital and macroeconomic conditions. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Following the closing of the Business Combination, the fair value of our common stock has been determined based on the quoted market price of our common stock.&lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s comprehensive loss consists of unrealized losses on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stock by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities. Since the Company was in a loss position for the periods presented, basic net loss per share is the same as diluted net loss per share as the effects of the potentially dilutive securities are antidilutive. The following table presents the potential common stock outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,896&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested common stock subject to repurchase&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,218&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,930&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is more likely than not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&#160;the factors underlying the sustainability assertion have changed and (ii)&#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits require significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company Status &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s consolidated financial statements and accompanying notes have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, as determined by the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, and pursuant to the regulations of the U.S. Securities and Exchange Commission, or SEC. The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany transactions and balances have been eliminated. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Business Combination discussed in Note 1 was accounted for as a reverse recapitalization with Legacy Surrozen as the accounting acquirer and Consonance as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the consolidated financial statements represents the accounts of Legacy Surrozen at their historical cost as if Legacy Surrozen is the predecessor to the Company. The consolidated financial statements following the closing of the Business Combination reflect the results of the combined entity&#x2019;s operations. All issued and outstanding common stock and stock awards of Legacy Surrozen and per share amounts contained in the consolidated financial statements for the periods presented prior to the closing of the Business Combination on August&#160;11, 2021 have been retroactively restated to reflect the exchange ratio established in the Business Combination. See Note 3, &#x201c;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recapitalization&#x201d;&lt;/div&gt;&lt;/div&gt; for additional details. &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to, revenue recognition, certain accruals for research and development activities, the fair value of common stock prior to the Business Combination, initial fair value of the PIPE Warrants and stock-based compensation expense. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could materially differ from those estimates. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist of cash, cash equivalents and marketable securities. The Company&#x2019;s cash is held by one financial institution that may at times exceed federally insured limits. However, the Company&#x2019;s exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company believes it is not exposed to significant credit risk on cash. The Company&#x2019;s policy is to invest cash in institutional money market funds and marketable securities with high credit quality to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and marketable securities in a variety of securities, including money market funds, U.S. government bonds, U.S. government agency debt securities, foreign bonds, commercial paper and corporate debt securities. The Company has not experienced any losses on its cash equivalents and marketable securities. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Cash equivalents relate to securities having an original maturity of three months or less at the time of purchase. As of December&#160;31, 2022 and 2021, cash and cash equivalents consisted of bank deposits, money market funds and U.S. government agency debt securities. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of each of December&#160;31, 2022 and 2021, the Company had $0.4&#160;million of restricted cash in the form of a letter of credit for the Company&#x2019;s facility lease. The restricted cash is classified as a noncurrent asset as the Company is required to maintain the letter of credit for the benefit of the landlord until the end of the lease term in April 2025. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021_LetterOfCreditMemberusgaapShortTermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022_LetterOfCreditMemberusgaapShortTermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company invests its excess cash in marketable U.S. government bonds, foreign bonds, commercial paper and corporate debt securities. All marketable securities have been classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company does not buy or hold securities principally for the purpose of selling them in the near future. The Company&#x2019;s policy is focused on the preservation of capital, liquidity, and return. From time to time, the Company may sell certain securities, but the objectives are generally not to generate profits on short-term differences in price. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Short-term marketable securities have maturities less than or equal to one year as of the balance sheet date. Long-term marketable securities have maturities greater than one year as of the balance sheet date. These marketable securities are carried at estimated fair value with unrealized holding gains and losses included in accumulated other comprehensive loss in stockholders&#x2019; equity until realized. Gains and losses on marketable security transactions are reported on the specific-identification method. Interest income is recognized in the consolidated statements of operations and comprehensive loss when earned. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company periodically evaluates its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; marketable securities for impairment. When the fair value of a marketable security is below its amortized cost basis, the amortized cost is reduced to its fair value if it is more likely than not that the Company is required to sell the impaired security before recovery of its amortized cost, or the Company has the intention to sell the security. If neither of these conditions are met, the Company determines whether the impairment is due to credit losses by comparing the present value of the expected cash flows of the security with its amortized cost basis. The amount of impairment recognized is limited to the excess of the amortized cost basis over the fair value of the security. An allowance for credit losses for the excess of amortized cost basis over the expected cash flows, if any, is recorded in other income (expense), net on the consolidated statements of operations. Impairment losses that are not credit-related are included in accumulated other comprehensive loss in stockholders&#x2019; equity. &lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, including leasehold improvements, are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td style="width:47%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated useful life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Shorter of useful life of asset or lease term&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Furniture, fixtures and equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is recognized in the period realized. Maintenance and repairs are expensed as incurred. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <srzn:PropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, including leasehold improvements, are recorded at cost net of accumulated depreciation. Property and equipment are depreciated using the straight-line method over the estimated useful lives of the assets as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:51%"/&gt;
&lt;td style="vertical-align:bottom;width:2%"/&gt;
&lt;td style="width:47%"/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated useful life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Leasehold improvements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Shorter of useful life of asset or lease term&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Computer equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Furniture, fixtures and equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;Lab equipment&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;3 years&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srzn:PropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Shorter of useful life of asset or lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">3 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2022To12_31_2022_FurnitureFixturesAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">3</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2022To12_31_2022_FurnitureFixturesAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">8 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2022To12_31_2022_OtherMachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">3 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Material leases with a term longer than one year are recognized as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use,&lt;/div&gt;&lt;/div&gt; or ROU, assets and lease liabilities in the Company&#x2019;s consolidated balance sheets. The Company determines the lease classification and measurement of its ROU assets and lease liabilities at the lease commencement date and thereafter if modified. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company uses its incremental borrowing rate, based on the information available at the commencement date, to determine the present value of lease payments if the rate implicit in the lease is not readily available. The ROU asset is based on the measurement of the lease liability and is adjusted for lease incentives provided by the landlord. Lease expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. The Company has not identified any such impairment losses to date. &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <srzn:WarrantLiabilityPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s Public Warrants, Private Placement Warrants and PIPE Warrants were classified as liabilities (see Note 11). At the end of each reporting period, any changes in fair value during the period are recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. No Private Placement Warrants were outstanding as of December&#160;31, 2022 as a result of the repurchase of 1.3&#160;million warrants in December 2022 (see Note 9). The Company will continue to adjust the warrant liabilities pertaining to the outstanding warrants for changes in the fair value until the earlier of a) the exercise or expiration of the warrants or b) the redemption of the warrants, at which time such warrants will be reclassified to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital. &lt;/div&gt;</srzn:WarrantLiabilityPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <srzn:ClassOfWarrantsRepurchased
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_shares">1300000</srzn:ClassOfWarrantsRepurchased>
    <srzn:RevenueRecognitionsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue in accordance with ASC 606, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/div&gt;&lt;/div&gt;,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for these goods or services. To determine revenue recognition for the arrangement that is within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract with the customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services transferred to the customer. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At contract inception, the Company assesses the goods or services promised within the contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligations when or as the performance obligations are satisfied. The Company constrains its estimate of the transaction price up to the amount (the variable consideration constraint) that a significant reversal of recognized revenue is not probable. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records accounts receivable for amounts billed to the customer for which the Company has an unconditional right to consideration. The Company assesses accounts receivable for impairment and, to date, no impairment losses have been recorded. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has a collaboration and license agreement with BI to which the Company licensed certain rights to its intellectual property (see Note 7) that is determined within the scope of ASC 606. The terms of the CLA include payment to the Company of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment, development, regulatory and commercial milestone payments and royalties on net sales of licensed products. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Licenses of Intellectual Property: If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promised goods or services, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Milestone Payments:&lt;/div&gt;&lt;/div&gt; At contract inception, the Company using the most likely amount method evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. If it is probable that a significant reversal of cumulative revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received or the underlying activity has been completed. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis, which would affect revenue in the period of adjustment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties:&lt;/div&gt;&lt;/div&gt; The Company recognizes sales-based royalties as revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalties that have been allocated have been satisfied (or partially satisfied). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The incremental costs of obtaining a customer contract are expensed as and when incurred if the amortization period of the asset that would have been recognized is one year or less. &lt;/div&gt;</srzn:RevenueRecognitionsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Research and development costs are expensed as incurred. Research and development costs consist of external and internal expenses directly attributable to the conduct of research and development programs. The external expenses include the costs of services provided by outside contractors, clinical research organizations and contract manufacturing organizations. The internal expenses include the costs of salaries, bonus, payroll taxes, stock-based compensation, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, and the allocated facility-related costs, such as rent, utilities, insurance, repairs and maintenance, and general support services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has entered into and may continue to enter into licensing or subscription arrangements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company&#x2019;s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expense when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <srzn:AccruedResearchAndDevelopmentExpensesPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records accruals for estimated costs of research, preclinical, clinical, and manufacturing development, which are significant components of research and development expenses, within accrued and other liabilities in the accompanying consolidated balance sheets. A substantial portion of the Company&#x2019;s ongoing research and development activities is conducted by third-party service providers. The Company accrues the costs under agreements with these third parties as incurred. The Company estimates the amounts incurred in each period based on the information available and its knowledge of the nature of the contractual activities generating such costs. Clinical trial contract expenses are accrued based on units of activity. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. For the years ended December&#160;31, 2022 and 2021, the Company has not experienced any material differences between accrued costs and actual costs incurred. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If the actual timing of the performance of services or the level of effort varies from the estimate, the Company adjusts accrued expenses or prepaid expenses accordingly, which impacts research and development expenses. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. &lt;/div&gt;</srzn:AccruedResearchAndDevelopmentExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes stock-based compensation expense for all stock-based awards. For stock option awards, stock-based compensation cost is estimated at the grant date based on the fair value of the equity for financial reporting purposes and is recognized as expense on a straight-line basis over the requisite service period. Under the Company&#x2019;s employee stock purchase plan, stock-based compensation cost is measured at the beginning of the offering period and recognized on a straight-line basis over the offering period. Forfeitures are accounted for as they occur. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected to calculate the fair value of awards using the Black-Scholes option pricing model, or the Black-Scholes Model. The Black-Scholes Model requires the use of various assumptions including common stock valuation, expected option life and expected stock price volatility. The Company estimates the expected term for stock options using the simplified method as the midpoint between the vesting date and the contractual expiration date of the award as the Company has limited historical exercise information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. Due to the limited trading history of the Company&#x2019;s stock, the Company estimates the volatility using volatilities of a group of public companies in a comparable industry, stage of life cycle, and size. The interest rate is derived from the U.S. Treasury instruments with maturities similar to the expected term of the options. The Company has not declared nor expects to declare dividends. Therefore, there is no dividend impact on the valuation of options. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Prior to the Business Combination, the fair value of common stock was determined considering numerous objective and subjective factors and requires judgment. These objective and subjective factors include, but are not limited to: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;relevant precedent transactions involving the Company&#x2019;s capital stock; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;contemporaneous valuations performed by third-party specialists; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;rights, preferences, and privileges of the Company&#x2019;s redeemable convertible preferred stock relative to those of the Company&#x2019;s common stock; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;actual operating and financial performance; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;current business conditions and financial projections; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company&#x2019;s business; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;the lack of marketability of the Company&#x2019;s common stock, and the illiquidity of stock-based awards involving securities in a private company; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;market multiples of comparable publicly traded companies; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;stage of development; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;industry information such as market size and growth; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;U.S. and global capital and macroeconomic conditions. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Following the closing of the Business Combination, the fair value of our common stock has been determined based on the quoted market price of our common stock.&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s comprehensive loss consists of unrealized losses on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities. &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stock by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities. Since the Company was in a loss position for the periods presented, basic net loss per share is the same as diluted net loss per share as the effects of the potentially dilutive securities are antidilutive. The following table presents the potential common stock outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,896&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested common stock subject to repurchase&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,218&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,930&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2022To12_31_2022">. The following table presents the potential common stock outstanding that were excluded from the computation of diluted net loss per share of common stock as of the periods presented because including them would have been antidilutive (in thousands): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,896&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested common stock subject to repurchase&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,218&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,930&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">3896000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">1794000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">105000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_RestrictedStockAwardRSAMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">161000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_UnvestedCommonStockSharesSubjectToRepurchaseMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">22000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_UnvestedCommonStockSharesSubjectToRepurchaseMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">75000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_WarrantToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">5907000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_WarrantToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">7218000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">9930000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">9248000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates expected to be in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is more likely than not of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i)&#160;the factors underlying the sustainability assertion have changed and (ii)&#160;the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits require significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to unrecognized tax benefits. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <srzn:EmergingGrowthCompanyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company Status &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&#160;no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. &lt;/div&gt;</srzn:EmergingGrowthCompanyPolicyTextBlock>
    <srzn:RecapitalizationNoteDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 3. Recapitalization &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;11, 2021, Consonance consummated the Business Combination (see Note 1). Immediately after the consummation of the Business Combination, certain investors subscribed for and purchased an aggregate of 12.0&#160;million units, each consisting of one share of the Company&#x2019;s common stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; of one redeemable warrant, for a purchase price of $10.00 per unit through a private investment in public entity financing, or PIPE Financing. In connection with the Business Combination and PIPE Financing, Legacy Surrozen received the aggregate cash consideration of $128.8&#160;million, after deducting the transaction fees incurred by Consonance. The cash consideration was comprised of $8.6&#160;million in proceeds from issuance of common stock upon the closing of the Business Combination and $120.2&#160;million in proceeds from the PIPE Financing. The Company incurred transaction costs of $6.3&#160;million, consisting of legal, accounting and other professional services directly related to the Business Combination, $0.4&#160;million of which were allocated to the warrant liabilities assumed and recognized as other expenses when incurred. The remaining $5.9&#160;million were recorded as a reduction of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital in the consolidated balance sheet. Legacy Surrozen was deemed the accounting acquirer in the Business Combination and the Business Combination was accounted for as a reverse recapitalization based on the following predominant factors: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Legacy Surrozen&#x2019;s stockholders have the greatest voting interest in the Company; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;The Company&#x2019;s board and senior management are primarily composed of individuals associated with Legacy Surrozen; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Legacy Surrozen is the larger entity based on historical operating activity and has the larger employee base at the time of the Business Combination. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accordingly, for accounting purposes, the reverse recapitalization was treated as the equivalent of Legacy Surrozen issuing stock for the net assets of Consonance, accompanied by a recapitalization. The net assets of Consonance are stated at historical cost, with no goodwill or other intangible assets recorded. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the business combination agreement, upon the closing of the Business Combination, (i)&#160;each share of redeemable convertible preferred stock of Legacy Surrozen (on an as converted to common stock basis) and each share of common stock of Legacy Surrozen, whether vested or unvested, was converted into 0.175648535 shares of the Company&#x2019;s common stock and (ii)&#160;each outstanding option to purchase common stock of Legacy Surrozen was converted into an option to purchase shares of the Company&#x2019;s common stock based on an exchange ratio of 0.175648535, or the Exchange Ratio, with corresponding adjustments to the exercise price. All issued and outstanding common stock, preferred stock and stock awards of Legacy Surrozen and corresponding capital amounts contained in the consolidated financial statements for the periods presented prior to the closing of the Business Combination have been retroactively restated to reflect the conversion. &lt;/div&gt;</srzn:RecapitalizationNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_11_2021To08_11_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">12000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn08_11_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharesIssuedPricePerShare>
    <srzn:ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering
      contextRef="P08_01_2021To08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">128800000</srzn:ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P08_01_2021To08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">8600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P08_01_2021To08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">120200000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="PAsOn08_31_2021_PrivateInvestmentInPublicEntityOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">6300000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="PAsOn08_31_2021"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <srzn:BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital
      contextRef="PAsOn08_31_2021"
      decimals="-5"
      unitRef="Unit_USD">5900000</srzn:BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital>
    <us-gaap:Goodwill
      contextRef="PAsOn08_31_2021_SurrozenIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:Goodwill>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P08_01_2021To08_31_2021"
      decimals="9"
      unitRef="Unit_pure">0.175648535</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="P01_01_2022To12_31_2022"
      decimals="9"
      unitRef="Unit_pure">0.175648535</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 4. Fair Value Measurement &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records its financial assets and liabilities at fair value. The carrying amount of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable, restricted cash, accounts payable, and accrued and other liabilities, approximate their fair value due to their short-term maturities. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value as follows: &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level&#160;1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarize the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government agency debt securities&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,982&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,982&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,130&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,324&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:61%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,310&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,310&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,310&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122,725&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,608&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,608&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,774&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;They are included in cash and cash equivalents on the consolidated balance sheets as of December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;See the definition and discussion of Public Warrants, Private Placement Warrants and PIPE Warrants in Note 11. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Corporate bonds, commercial paper, foreign bonds, government bonds and government agency debt securities are classified as Level&#160;2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Public Warrants are classified as Level&#160;1 due to the use of an observable market quote in an active market. The Private Placement Warrants are classified as Level&#160;2 due to the use of observable market data for identical or similar liabilities. The fair value of each Private Placement Warrant was determined to be consistent with that of a Public Warrant because the Private Warrants are also subject to the make-whole redemption feature, which allows the Company to redeem both types of warrants on similar terms when the stock price is in the range of $10 to $18 per share. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The PIPE Warrants were initially recorded in 2021 at fair value using a binomial lattice model. The PIPE Warrants were classified as Level&#160;3 at issuance because the fair value was measured based on significant inputs that are unobservable in the market. The significant unobservable input used in the fair value measurement of the PIPE Warrants is the expected volatility. The expected volatility was implied from the market price of the Company&#x2019;s Public Warrants. The expected term was based on the remaining contractual term of the PIPE Warrants, and the risk-free interest rate was based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the expected term. The dividend rate is based on the historical rate, which the Company anticipated remaining at zero. The key inputs into the binomial lattice model for the PIPE Warrants at the initial measurement were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;August&#160;11,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Given the adequate history of the market data of the Public Warrants as of December&#160;31, 2022 and 2021, the PIPE Warrants were remeasured at December&#160;31, 2022 and 2021 based on the observable market quote of the Public Warrants and are classified as Level&#160;2. The valuation technique was changed since the fair value of the Public Warrant is equally or more representative of the fair value of the PIPE Warrants. The fair value of each PIPE Warrant was determined to be consistent with that of a Public Warrant because the PIPE Warrants are also subject to the make-whole redemption feature, which allows the Company to redeem both types of warrants on similar terms. There were no changes to the valuation methods utilized, and there were no transfers of financial instruments for the year ended December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s warrant liabilities for the years ended December&#160;31, 2022 and 2021 (in thousands):&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt; Placement&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PIPE&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; Warrant&lt;br/&gt; Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance, December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assumption in Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,557&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;168&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,647&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,372&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value upon remeasurement&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance, December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,608&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value upon remeasurement&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,379&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,890&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repurchase (Note 9)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance, December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The change in fair value of the warrant liabilities was recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables provide the Company&#x2019;s marketable securities by security type (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,817&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,389&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(242&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,148&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,920&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,725&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,588&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,573&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total long-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,753&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div/&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table indicates the length of the time that individual securities have been in a continuous unrealized loss position (dollars in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:47%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,719&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,801&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;242&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,371&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022 and 2021, all short-term marketable securities had maturities of one year or less. All long-term marketable securities as of December&#160;31, 2021 had maturities of greater than one year but less than two years. There have been no significant realized gains or losses on the marketable securities during the years ended December&#160;31, 2022 and 2021. The Company periodically reviews the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; investments for credit losses. All investments with unrealized losses have been in a loss position for less than 12 months. The Company determined that the unrealized loss was primarily attributed to changes in current market interest rates and not to credit quality. The Company does not intend to sell the marketable securities that are in an unrealized loss position, nor is it more likely than not that the Company will be required to sell the marketable securities before the recovery of the amortized cost basis, which may be at maturity. As a result, the Company did not recognize any allowance for credit losses as of December&#160;31, 2022. &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarize the Company&#x2019;s financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government agency debt securities&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,982&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,982&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,130&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,324&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:61%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,310&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,310&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial assets measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,310&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90,415&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122,725&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(2)&lt;/div&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,608&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,608&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total financial liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,774&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;They are included in cash and cash equivalents on the consolidated balance sheets as of December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;See the definition and discussion of Public Warrants, Private Placement Warrants and PIPE Warrants in Note 11. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">9194000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">9194000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">22549000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">22549000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">10797000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">10797000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">17802000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">17802000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_USGovernmentCorporationsAndAgenciesSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">9194000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">55130000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">64324000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">151000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">151000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">151000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">326000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307294"
      unitRef="Unit_USD">32310000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307293"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307292"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307291"
      unitRef="Unit_USD">32310000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">49136000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">49136000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">19480000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">19480000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">18082000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">18082000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3717000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3717000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">32310000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">90415000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">122725000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307331"
      unitRef="Unit_USD">3527000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307330"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307329"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307328"
      unitRef="Unit_USD">3527000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307327"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307326"
      unitRef="Unit_USD">166000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307325"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307324"
      unitRef="Unit_USD">166000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307323"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307322"
      unitRef="Unit_USD">4608000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307321"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307320"
      unitRef="Unit_USD">4608000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="Fact_73307319"
      unitRef="Unit_USD">3527000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="Fact_73307318"
      unitRef="Unit_USD">4774000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="Fact_73307317"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="Fact_73307316"
      unitRef="Unit_USD">8301000</us-gaap:LiabilitiesFairValueDisclosure>
    <srzn:StockPriceToRedeemsWarrants
      contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">10</srzn:StockPriceToRedeemsWarrants>
    <srzn:StockPriceToRedeemsWarrants
      contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">18</srzn:StockPriceToRedeemsWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2022To12_31_2022">The key inputs into the binomial lattice model for the PIPE Warrants at the initial measurement were as follows: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:84%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;August&#160;11,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn08_11_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_Y">5.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn08_11_2021_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.189</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn08_11_2021"
      decimals="4"
      unitRef="Unit_pure">0.0081</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn08_11_2021_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn12_31_2022_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s warrant liabilities for the years ended December&#160;31, 2022 and 2021 (in thousands):&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt; Placement&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PIPE&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt; Warrant&lt;br/&gt; Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance, December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assumption in Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,557&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;168&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,647&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,372&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value upon remeasurement&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance, December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,527&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,608&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value upon remeasurement&lt;div style="font-size:75%; vertical-align:top;display:inline;;font-size:8.3px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,379&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,890&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repurchase (Note 9)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance, December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The change in fair value of the warrant liabilities was recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2020_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2020_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2020_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination
      contextRef="P01_01_2021To12_31_2021_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3557000</srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination>
    <srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination
      contextRef="P01_01_2021To12_31_2021_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">168000</srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination>
    <srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination
      contextRef="P01_01_2021To12_31_2021_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4647000</srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination>
    <srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8372000</srzn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2021To12_31_2021_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307381"
      unitRef="Unit_USD">-30000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2021To12_31_2021_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307380"
      unitRef="Unit_USD">-2000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2021To12_31_2021_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307379"
      unitRef="Unit_USD">-39000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="Fact_73307378"
      unitRef="Unit_USD">-71000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2021_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3527000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2021_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">166000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2021_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4608000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8301000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307377"
      unitRef="Unit_USD">-3354000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307376"
      unitRef="Unit_USD">-157000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2022To12_31_2022_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="Fact_73307375"
      unitRef="Unit_USD">-4379000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="Fact_73307374"
      unitRef="Unit_USD">-7890000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <srzn:ProceedsFromRepurchaseOfWarrants
      contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">22000</srzn:ProceedsFromRepurchaseOfWarrants>
    <srzn:ProceedsFromRepurchaseOfWarrants
      contextRef="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">9000</srzn:ProceedsFromRepurchaseOfWarrants>
    <srzn:ProceedsFromRepurchaseOfWarrants
      contextRef="P01_01_2022To12_31_2022_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">54000</srzn:ProceedsFromRepurchaseOfWarrants>
    <srzn:ProceedsFromRepurchaseOfWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">85000</srzn:ProceedsFromRepurchaseOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">151000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">326000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables provide the Company&#x2019;s marketable securities by security type (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,817&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,389&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(242&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;51,148&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt; Cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Gains&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt; Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,136&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,920&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,725&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total short-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,588&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,573&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total long-term marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,753&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">22549000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">22549000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">10817000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-21000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">10797000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">18023000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-221000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">17802000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">51389000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-242000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">51148000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">49136000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">49136000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">15920000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-17000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">15907000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3725000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-8000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3717000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">68781000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-25000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">68760000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">18165000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent
      contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-83000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">18082000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3588000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-15000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3573000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21753000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-98000</srzn:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21655000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table indicates the length of the time that individual securities have been in a continuous unrealized loss position (dollars in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:47%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Less Than 12 Months&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Investments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt; Losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Corporate bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,719&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Government bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,801&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,082&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign bonds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,717&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;242&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,371&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="0"
      unitRef="Unit_Investments">4</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">9719000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="0"
      unitRef="Unit_Investments">5</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">12572000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2021_CorporateBondMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="0"
      unitRef="Unit_Investments">3</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">17801000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">221000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="0"
      unitRef="Unit_Investments">3</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">18082000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2021_GovernmentBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">83000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn12_31_2022_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="0"
      unitRef="Unit_Investments">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="0"
      unitRef="Unit_Investments">2</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3717000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2021_ForeignBondsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_Investments">7</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">27520000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">242000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_Investments">10</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">34371000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">123000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 5. Balance Sheet Components &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,515&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,881&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total property and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,985&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,335&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11,355&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,541&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depreciation expenses for the years ended December&#160;31, 2022 and 2021 was $2.0&#160;million and $2.1&#160;million, respectively. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued and Other Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued and other liabilities consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:78%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued payroll and related expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,964&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,887&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued research and development expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional service fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;638&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liability for early exercised stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;205&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued and other liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,662&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:74%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,515&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,881&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;309&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total property and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,985&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,335&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11,355&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,541&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">7052000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">7052000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">7515000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">6881000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">299000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">309000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">93000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14985000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14335000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11355000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9541000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3630000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4794000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">2000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">2100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued and other liabilities consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:78%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued payroll and related expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,964&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,887&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued research and development expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional service fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;638&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Liability for early exercised stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;205&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;492&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued and other liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,848&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,662&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3964000</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2887000</us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent>
    <srzn:AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1665000</srzn:AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent>
    <srzn:AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3666000</srzn:AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">638000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1520000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">89000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">205000</us-gaap:OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">492000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">384000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6848000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8662000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 6. Leases &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2016, the Company entered into a lease agreement for office and lab space, which consists of approximately 32,813 square feet of rental space in South San Francisco, California. The office space lease is classified as an operating lease. The initial lease term commenced in May 2017 and ends in April 2025, with rent payments escalating each year. The Company has options to extend the lease for additional years, but the exercise of the option was not reasonably certain. In connection with the lease, the Company maintains a letter of credit for the benefit of the landlord in the amount of $0.4&#160;million, which is recorded as restricted cash in the consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In January 2020, the Company entered into a lease agreement for a term of 18 months commencing June 2020 for approximately 6,478 square feet of office space. This office space lease, which was classified as an operating lease, was amended in September 2021 and expired in June 2022. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The operating lease expense for the years ended December&#160;31, 2022 and 2021 was $1.9&#160;million and $2.0&#160;million. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Aggregate future minimum rental payments under the operating leases as of December&#160;31, 2022, were as follows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,596&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(555&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,602&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following represents supplemental information related to the Company&#x2019;s operating facility leases: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities (in thousands)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,743&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,856&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average remaining lease term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="PAsOn08_31_2016_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis"
      decimals="INF"
      unitRef="Unit_sqft">32813</us-gaap:AreaOfRealEstateProperty>
    <srzn:OperatingLeaseMonthOfExpiryOfLease contextRef="P01_01_2022To12_31_2022_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis">2025-04</srzn:OperatingLeaseMonthOfExpiryOfLease>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn12_31_2022_CAsrtStatementGeographicalAxis_EightYearsMemberusgaapLeaseContractualTermAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="PAsOn01_31_2020">P18M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="PAsOn01_31_2020"
      decimals="-3"
      unitRef="Unit_sqm">6478000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">1900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">2000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Aggregate future minimum rental payments under the operating leases as of December&#160;31, 2022, were as follows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,596&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year ending December&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;891&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(555&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,602&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2596000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2670000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">891000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6157000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">555000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5602000</us-gaap:OperatingLeaseLiability>
    <srzn:ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following represents supplemental information related to the Company&#x2019;s operating facility leases: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities (in thousands)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,743&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,856&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average remaining lease term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.33&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </srzn:ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2743000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2856000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022">P2Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P3Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.0848</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0843</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <srzn:CollaborationAndLicenseAgreementsTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;;text-indent: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 7. Collaboration and License Agreements &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Collaboration and License Agreement with Boehringer Ingelheim International GmbH &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2022, the Company executed the CLA with BI to research, develop and commercialize Fzd4 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;bi-specific&lt;/div&gt; antibodies designed using the Company&#x2019;s SWAP&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;&#x2122;&lt;/div&gt; technology, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SZN-413.&lt;/div&gt; The Company and BI are conducting partnership research focused on SZN-413 during a one-year period, which BI has the right to extend by up to six months. The Company granted BI an exclusive, royalty-bearing, worldwide, sublicensable license, under the applicable patents and know-how, to develop, manufacture and commercialize, for all uses, one lead and two back-up Fzd4 bi-specific antibodies selected by BI and their derivatives. After an initial period of joint research, BI shall be responsible for all further research, preclinical and clinical development, manufacturing, regulatory approvals, and commercialization of licensed products at its expense. Unless terminated earlier, or expiring on account of BI not selecting at least one Fzd4 bi-specific antibody within sixty days after the end of the partnership research, the CLA will remain effective, on a country-by-country and product-by-product basis, until the expiration of BI&#x2019;s royalty obligations. BI has the right to terminate the CLA for any reason after a specified notice period. Each party has the right to terminate the CLA on account of the other party&#x2019;s bankruptcy or material, uncured breach. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of the CLA, BI agreed to pay a non-refundable upfront payment of&#160;&lt;/div&gt;$12.5&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million less any applicable withholding tax, success-based milestone payments up to a total of&lt;/div&gt; $587.0&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million and mid-single digit to low-double digit royalties on net sales of the licensed products should any reach commercialization. The royalty payments will be subject to reduction due to patent expiration, generic competition and payments made under certain licenses for third-party intellectual property. The Company received&lt;/div&gt; $10.5&#160;million of the upfront payment from BI in November 2022. The associated withholding tax of $2.0&#160;million is expected to be refunded to the Company in 2023. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined that the CLA is within the scope of ASC 606. The Company evaluated the promised goods and services and determined that the license to the Company&#x2019;s intellectual property granted to BI represented one performance obligation for the purposes of conducting the partnership research and further development on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SZN-413.&lt;/div&gt; The transaction price was determined to be $12.5&#160;million, which is the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment. Variable consideration related to future milestones was fully constrained because the Company cannot conclude that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, given the inherent uncertainty of success with these future milestones. For sales-based royalties, the Company determined that the license is the predominant item to which the royalties relate to. Accordingly, the Company will recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all the royalty has been allocated has been satisfied (or partially satisfied). The Company will &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate&lt;/div&gt; the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. During the year ended December&#160;31, 2022, the Company recognized the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment of $12.5&#160;million as collaboration and license revenue at a point in time upon delivery of the license. The associated withholding tax of $2.0&#160;million to be refunded was recognized as accounts receivable as of December&#160;31, 2022. &lt;/div&gt; </srzn:CollaborationAndLicenseAgreementsTextBlock>
    <srzn:NonRefundableUpfrontPaymentReceived
      contextRef="P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">12500000</srzn:NonRefundableUpfrontPaymentReceived>
    <srzn:SuccessBasedMilestonePayments
      contextRef="P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">587000000</srzn:SuccessBasedMilestonePayments>
    <srzn:UpfrontPayment
      contextRef="P11_01_2022To11_30_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">10500000</srzn:UpfrontPayment>
    <srzn:AssociatedWithholdingTax
      contextRef="P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2000000</srzn:AssociatedWithholdingTax>
    <srzn:TransactionPrice
      contextRef="P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">12500000</srzn:TransactionPrice>
    <srzn:NonRefundableUpfrontPaymentReceived
      contextRef="P01_01_2022To12_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">12500000</srzn:NonRefundableUpfrontPaymentReceived>
    <srzn:AssociatedWithholdingTax
      contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapBalanceSheetLocationAxis_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2000000</srzn:AssociatedWithholdingTax>
    <srzn:LicenseAgreementsDisclosureTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 8. License Agreements &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stanford License Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In March 2016, the Company entered into a license agreement with Stanford University, or the 2016 Stanford Agreement, which was amended in July 2016, October 2016 and January 2021, pursuant to which the Company obtained from Stanford a worldwide, exclusive, sublicensable license under certain patents, rights, or licensed patents and technology related to its engineered Wnt surrogate molecules to make, use, import, offer to sell and sell products that are claimed by the licensed patents or that use or incorporate such technology, or &lt;/div&gt;   &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin-left: 0in;;text-indent: 0px;"&gt;licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases. The Company agreed to pay Stanford (i)&#160;nominal annual license maintenance fees which are creditable against earned royalties owed to Stanford for the same year, (ii)&#160;an aggregate of up to $0.9&#160;million for the achievement of specified development and regulatory milestones, and (iii)&#160;an aggregate of up to $5.0&#160;&lt;div style="display:inline;"&gt;million for achievement of specified sales milestones. Stanford is also entitled to receive royalties from the Company equal to a very low single digit percentage of the Company&#x2019;s and its sublicensees&#x2019; net sales of licensed products that are covered by a valid claim of a licensed patent. Additionally, the Company agreed to pay Stanford a sub-teen double digit percentage of certain consideration the Company receives as a result of granting sublicenses to the licensed patents. However, the Company and Stanford may be able to negotiate a lower non-royalty sublicense percentage based on then-current value of the licensed patents for each sublicense product. If the Company is acquired, it agreed to pay a one-time change of control fee in the low six figures. Stanford retains the right under the 2016 Stanford Agreement, on behalf of itself, Stanford Hospital and Clinics, the University of Washington and all other non-profit research institutions, to practice the licensed patents and technology for any non-profit purpose. The licensed patents and technology are additionally subject to a non-exclusive, irrevocable, worldwide license held by the Howard Hughes Medical Institute to practice the licensed patents and technology for its research purposes, but with no right to assign or sublicense.&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2018, the Company entered into another license agreement with Stanford, or the 2018 Stanford Agreement, pursuant to which the Company obtained from Stanford a worldwide, exclusive, sublicensable license under certain patent rights related to its surrogate &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R-spondin&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; proteins, or the licensed patents, to make, use, import, offer to sell and sell products that are claimed by the licensed patents, or licensed products, for the treatment, diagnosis and prevention of human and veterinary diseases, or the exclusive field. Additionally, Stanford granted the Company a worldwide, &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive,&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; sublicensable license under the licensed patents to make and use licensed products for research and development purposes in furtherance of the exclusive field and a worldwide, &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; license to make, use and import, but not to offer to sell or sell licensed products in any other field of use. The Company agreed to pay Stanford an aggregate of up to $&lt;/div&gt;0.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the achievement of specified development and regulatory milestones. Stanford is also entitled to receive royalties from the Company equal to a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-single&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; digit percentage of the Company&#x2019;s and its sublicensees&#x2019; net sales of licensed products. Additionally, Stanford is entitled to receive a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; payment in the low six figures for each sublicense of the licensed patents that the Company grants to a third party and, if the Company is acquired, a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; nominal change of control fee.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2022, the Company incurred research and development expenses of approximately $0.2&#160;million under the Stanford Agreements, pertaining to the sublicense fee in connection with the upfront payment received from BI. For the year ended December&#160;31, 2021, the Company incurred research and development expenses of approximately $0.1&#160;million under the Stanford Agreements. No milestones have been achieved as of December&#160;31, 2022. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;UCSF License and Option Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September and October 2016, the Company entered into two separate license and option agreements with The Regents of the University of California, or the UCSF Agreements, pursuant to which the Company obtained exclusive licenses from UCSF for internal research and antibody discovery purposes and an option to negotiate with UCSF to obtain an exclusive license under UCSF&#x2019;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from the Company&#x2019;s use of such library, or licensed products. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January 2020, the Company amended and restated the UCSF Agreements to provide &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; licenses to make and use a certain human Fab na&#xef;ve phage display library and to make and use a certain phage display llama VHH single domain antibody library for internal research and antibody discovery purposes and an &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;option to negotiate with UCSF to obtain a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; commercial license under UCSF&#x2019;s rights in the applicable library to make, use, sell, offer for sale and import products incorporating antibodies identified or resulting from the Company&#x2019;s use of such library, or licensed products. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2022, the Company exercised the option under the UCSF Agreements and entered into a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; commercial license agreement to make and use licensed products derived from the phage display llama VHH single domain antibody library. Under the commercial license agreement, the Company paid UCSF a nominal license issue fee and agreed to pay a nominal annual license maintenance fee, five- to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;six-digit&lt;/div&gt; payments per licensed product upon achievement of a regulatory milestone, nominal minimum annual royalties and earned royalties equal to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-single&lt;/div&gt; digit percentage of the Company&#x2019;s and the Company&#x2019;s sublicensees&#x2019; net sales of licensed products. &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2022, the Company incurred research and development expenses of $0.1&#160;million under the UCSF Agreements as a result of the CLA. For the year ended December&#160;31, 2021, the Company incurred research and development expenses of $50,000 under the UCSF Agreements. No milestones have been achieved as of December&#160;31, 2022. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distributed Bio Subscription Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September 2016, the Company entered into, and in January 2019 the Company amended, an antibody library subscription agreement with Charles River Laboratories International, Inc., formerly known as Distributed Bio, or the Distributed Bio Agreement, in which the Company obtained from Distributed Bio a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-exclusive&lt;/div&gt; license to use Distributed Bio&#x2019;s antibody library to identify antibodies directed to an unlimited number of the Company&#x2019;s proprietary targets and to make, use, sell, offer for sale, import and exploit products incorporating the antibodies that the Company identifies, or licensed products. In consideration for the rights granted to the Company under the Distributed Bio Agreement, the Company paid Distributed Bio a nominal upfront fee and an additional nominal fee upon entering into the amendment. The Company agreed to pay Distributed Bio an annual fee in the low six figures after the first three years. Additionally, the Company agreed to pay Distributed Bio an aggregate of $5.9&#160;million for each licensed product that achieves specified development, regulatory and commercial milestones and royalties equal to a very low single digit percentage of the Company&#x2019;s and its sublicensees&#x2019; net sales of licensed products. The Company&#x2019;s obligation to pay royalties will end for each licensed product ten years after its first commercial sale. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the years ended December&#160;31, 2022 and 2021, the Company incurred research and development expenses of $0.2&#160;million and $0.3&#160;million under the Distributed Bio Agreement, including the milestone payment of $0.1&#160;million and $50,000, respectively, as the Company achieved milestones with regard to the Phase 1 clinical trial for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SZN-1326.&lt;/div&gt;&lt;/div&gt; </srzn:LicenseAgreementsDisclosureTextBlock>
    <srzn:PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones
      contextRef="P03_01_2016To03_31_2016_MaximumMembersrtRangeAxis_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</srzn:PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones>
    <srzn:PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones
      contextRef="P03_01_2016To03_31_2016_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</srzn:PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones>
    <srzn:PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones
      contextRef="P06_01_2018To06_30_2018_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</srzn:PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones
      contextRef="P01_01_2022To12_31_2022_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022_StanfordMemberusgaapRelatedPartyTransactionAxis_UCSFLicenseAndOptionAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021_StanfordMemberusgaapRelatedPartyTransactionAxis_UCSFLicenseAndOptionAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">50000000</us-gaap:ResearchAndDevelopmentExpense>
    <srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones
      contextRef="P01_01_2022To12_31_2022_StanfordMemberusgaapRelatedPartyTransactionAxis_UCSFLicenseAndOptionAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones>
    <srzn:PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones
      contextRef="P09_01_2016To09_30_2016_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">5900000</srzn:PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:ResearchAndDevelopmentExpense>
    <srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones
      contextRef="P01_01_2022To12_31_2022_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones>
    <srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones
      contextRef="P01_01_2021To12_31_2021_DistributedBioSubscriptionAgreementMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis"
      decimals="-3"
      unitRef="Unit_USD">50000000</srzn:PaymentsForMilestoneAgreementOnAchievementOfMilestones>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 9. Related Party Transactions &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Repurchase of Common Stock and Common Stock Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;12, 2022, the Company entered into a securities purchase agreement with entities affiliated with Consonance Capital Management LP, collectively the Consonance Entities. Pursuant to the agreement, the Company repurchased 5.4&#160;million shares of common stock and warrants to purchase 1.3&#160;million shares of common stock from the Consonance Entities for an aggregate purchase price of approximately $2.7&#160;million, or the Repurchase. Following the Repurchase, the Consonance Entities no longer hold any shares of common stock or warrants. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The shares of common stock repurchased were constructively retired and the common stock warrants repurchased were subsequently canceled. The total purchase price was allocated to the repurchase of common stock warrants based on the fair value of the warrants remeasured on the repurchase date, resulting in the&lt;/div&gt;   &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin-left: 0in;"&gt;derecognition of warrant liabilities of $0.1&#160;million. The remaining $2.6&#160;million allocated to the repurchase of common stock was recorded as a reduction of equity on the consolidated balance sheets. &lt;br/&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="P12_12_2022To12_12_2022"
      decimals="INF"
      unitRef="Unit_shares">5400000</us-gaap:StockRepurchasedDuringPeriodShares>
    <srzn:ClassOfWarrantsRepurchased
      contextRef="PAsOn12_12_2022"
      decimals="INF"
      unitRef="Unit_shares">1300000</srzn:ClassOfWarrantsRepurchased>
    <srzn:CommonStockTotalPurchasePrice
      contextRef="P12_12_2022To12_12_2022"
      decimals="-5"
      unitRef="Unit_USD">2700000</srzn:CommonStockTotalPurchasePrice>
    <srzn:WarrantLiability
      contextRef="PAsOn12_12_2022"
      decimals="-5"
      unitRef="Unit_USD">100000</srzn:WarrantLiability>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P12_12_2022To12_12_2022"
      decimals="-5"
      unitRef="Unit_USD">2600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;Note 10. Stockholders&#x2019; Equity&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2022, the Company entered into the Equity Purchase Agreement with Lincoln Park Capital Fund, LLC, or Lincoln Park, pursuant to which Lincoln Park is obligated to purchase up to $50.0&#160;million of the Company&#x2019;s common stock with a maximum of 7.0&#160;million shares from time to time at the Company&#x2019;s sole discretion over a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36-month&lt;/div&gt; period commencing on April&#160;27, 2022. The Company also entered into a registration rights agreement with Lincoln Park pursuant to which the Company filed with the SEC the registration statement to register for resale under the Securities Act of 1933, as amended, the shares of common stock that have been or may be issued to Lincoln Park under the Equity Purchase Agreement. The registration statement was effective on April&#160;5, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon execution of the Equity Purchase Agreement, the Company issued 0.1&#160;million shares of common stock to Lincoln Park with the fair value of $0.3&#160;million as consideration for Lincoln Park&#x2019;s commitment to purchase the Company&#x2019;s common stock, which was included in other income (expense), net on the consolidated statements of operations and comprehensive loss. In the event that the Company sells its common stock under the Equity Purchase Agreement for an aggregate price equal to or greater than $30.0&#160;million, the Company shall pay an additional commitment fee of $0.1&#160;million in cash to Lincoln Park. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As contemplated by the Equity Purchase Agreement, and so long as the closing price of the Company&#x2019;s common stock exceeds $1.00 per share, the Company may direct Lincoln Park, at its sole discretion, to purchase up to 30,000 shares of its common stock, or the Regular Purchase Share Limit, on any business day at a purchase price per share equal to the lower of: (i)&#160;the lowest price of the Company&#x2019;s common stock on the applicable purchase date and (ii)&#160;the average of the three lowest closing prices of the Company&#x2019;s common stock during the ten consecutive business days preceding such purchase date. The Regular Purchase Share Limit may be increased to up to 35,000 shares and 40,000 shares if the closing price of the Company&#x2019;s common stock is not below $10.00 per share and $12.00 per share, respectively. Any single purchase of the Company&#x2019;s common stock shall not exceed $3.5 million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may also direct Lincoln Park to purchase additional shares no less than the Regular Purchase Share Limit and no greater than 0.5&#160;million shares at a purchase price per share equal to 96% of the lower of (i) the closing price of the Company&#x2019;s common stock on the purchase date and (ii) the volume weighted average price of the Company&#x2019;s common stock on the purchase date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the Company has not sold any shares of common stock under the Equity Purchase Agreement. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At-the-Market&lt;/div&gt;&lt;/div&gt; Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with its shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3&lt;/div&gt; filed in December 2022, the Company entered into a sales agreement with Guggenheim Securities, LLC to issue and sell the Company&#x2019;s common stock up to $23.0&#160;million, or the 2022 ATM. The compensation payable to Guggenheim is equal to 3.0% of the gross sales price of any shares sold through it pursuant to the sales agreement. As of December&#160;31, 2022, the Company has not sold any shares of common stock under the 2022 ATM. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_shares">7000000</us-gaap:CommonStockSharesIssued>
    <srzn:CommonStockPurchaseCommitmentPeriod contextRef="P04_27_2022To04_27_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis">P36M</srzn:CommonStockPurchaseCommitmentPeriod>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockOtherValueOutstanding
      contextRef="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:CommonStockOtherValueOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MinimumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">30000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SharePrice
      contextRef="PAsOn02_28_2022_LincolnParkMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1</us-gaap:SharePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">30000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="P01_01_2022To12_31_2022_LincolnParkMemberdeiLegalEntityAxis">The Regular Purchase Share Limit may be increased to up to 35,000 shares and 40,000 shares if the closing price of the Company&#x2019;s common stock is not below $10.00 per share and $12.00 per share, respectively. Any single purchase of the Company&#x2019;s common stock shall not exceed $3.5 million.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn02_28_2022_ClosingSalePriceNotBelow1000PerShareMemberusgaapMeasurementInputTypeAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">35000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn02_28_2022_ClosingSalePriceNotBelow1200PerShareMemberusgaapMeasurementInputTypeAxis_MaximumMembersrtRangeAxis"
      decimals="-3"
      unitRef="Unit_shares">40000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="PAsOn02_28_2022_ClosingSalePriceNotBelow1000PerShareMemberusgaapMeasurementInputTypeAxis_LincolnParkMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn02_28_2022_ClosingSalePriceNotBelow1200PerShareMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12</us-gaap:SharePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P02_01_2022To02_28_2022_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">3500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <srzn:PurchaseOfAdditionalShares
      contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_shares">500000</srzn:PurchaseOfAdditionalShares>
    <srzn:PurchasePricePerShareOfAdditionalShares contextRef="P02_01_2022To02_28_2022_LincolnParkMemberdeiLegalEntityAxis">purchase price per share equal to 96% of the lower of (i) the closing price of the Company&#x2019;s common stock on the purchase date and (ii) the volume weighted average price of the Company&#x2019;s common stock on the purchase date.</srzn:PurchasePricePerShareOfAdditionalShares>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_LincolnParkMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022_GuggenheimSecuritiesLlcMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">23000000</us-gaap:CommonStockValue>
    <srzn:CompensationPayable
      contextRef="PAsOn12_31_2022_GuggenheimSecuritiesLlcMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.03</srzn:CompensationPayable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_LincolnParkMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <srzn:CommonStockWarrantsDisclosureTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 11. Common Stock Warrants &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, Legacy Surrozen, as the accounting acquirer, was deemed to assume 3.1&#160;million warrants held by Consonance&#x2019;s stockholders, or the Public Warrants, and 0.1&#160;million warrants &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;held by Consonance&#x2019;s sponsor, or the Private Placement Warrants. In addition, immediately after the consummation of the Business Combination, certain investors subscribed for and purchased an aggregate of 12.0&#160;million units in the PIPE Financing, consisting of 12.0&#160;million shares of the Company&#x2019;s common stock and 4.0&#160;million warrants, or the PIPE Warrants. In conjunction with the Repurchase (see Note 9), the Company repurchased 0.3&#160;million Public Warrants, 0.1&#160;million Private Placement Warrants and 0.8&#160;million PIPE Warrants. As of December&#160;31, 2022, the following common stock warrants were outstanding (in thousands, except per share amounts): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:49%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Type&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiration Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&#160;per&lt;br/&gt; Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;August 12, 2026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,733&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;August 12, 2026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,174&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Public Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Each whole Public Warrant entitles the holder to purchase one share of the Company&#x2019;s common stock at a price of $11.50 per share, at any time commencing on November&#160;23, 2021 and terminating at the earlier of August 12, 2026 or upon redemption or liquidation. The exercise price and number of shares issuable upon exercise of the Public Warrants may be adjusted in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. The Company would not be obligated to deliver any shares of common stock pursuant to the exercise of a Public Warrant and would have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act with respect to the common stock underlying the Public Warrants is then effective. The registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-1&lt;/div&gt; to register for resale under the Securities Act of 1933, as amended, was effective in November 2021. The Company will use its commercially reasonable efforts to maintain the effectiveness of the registration statement until the expiration or redemption of the Public Warrants. If the Company fails to have maintained an effective registration statement, the Public Warrant holders have the right to exercise the Public Warrants on a cashless basis until such time as there is an effective registration statement. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may redeem the outstanding Public Warrants at a price of $0.01 per warrant if the closing price of common stock equals or exceeds $18.00 per share (as adjusted for share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-divisions,&lt;/div&gt; share capitalizations, reorganizations, recapitalizations and similar transaction). Additionally, the Company may redeem the outstanding Public Warrants at a price of $0.10 per warrant if the closing price of common stock equals or exceeds $10.00 per share (as adjusted for share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-divisions,&lt;/div&gt; share capitalizations, reorganizations, recapitalizations and similar transaction). Notice of redemption shall be mailed to the Public Warrant holders no less than 30 days prior to the redemption date, or the Redemption Period. If the closing price of common stock equals or exceeds $10.00 per share and is less than $18.00 per share, during the Redemption Period, the Public Warrant holders may elect to exercise their Public Warrants on a cashless basis based on a make-whole table. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In no event will the Company be required to net cash settle the Public Warrants. The Public Warrant holders do not have the rights or privileges of common stockholders and any voting rights until they exercise their Public Warrants and receive common stock. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Private Placement Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Private Placement Warrants (including the common stock issuable upon exercise of the Private Placement Warrants) will not be redeemable so long as they are held by Consonance Life Sciences, a Cayman &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Islands limited liability company, or the Sponsor, or its permitted transferees. The Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios and exercisable by the holders on the same basis as the Public Warrants. There were no Private Placement Warrants outstanding as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;PIPE Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Each whole PIPE Warrant entitles the holder to purchase one share of the Company&#x2019;s common stock at a price of $11.50 per share, at any time commencing on November&#160;23, 2021 and terminating on August 12, 2026. The PIPE Warrants are the same in all respects as the Public Warrants except that the PIPE Warrants were not redeemable before August&#160;12, 2022. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Classification &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Public Warrants, Private Placement Warrants and PIPE Warrants are not considered indexed to the Company&#x2019;s common stock as certain provisions of the warrant agreements could change the settlement amount of these warrants. As a result, they are classified as liabilities and recorded at fair value with subsequent change in their respective fair value recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. See Note 4 for the discussion of warrant valuations. &lt;/div&gt;</srzn:CommonStockWarrantsDisclosureTextBlock>
    <srzn:BusinessCombinationInitialWarrantsIssued
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      unitRef="Unit_shares">3100000</srzn:BusinessCombinationInitialWarrantsIssued>
    <srzn:AssumedWarrants
      contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      unitRef="Unit_shares">100000</srzn:AssumedWarrants>
    <srzn:ClassOfWarrantOrRightIssued
      contextRef="PAsOn12_31_2021_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">12000000</srzn:ClassOfWarrantOrRightIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">12000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2021_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">4000000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <srzn:ClassOfWarrantsRepurchased
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">300000</srzn:ClassOfWarrantsRepurchased>
    <srzn:ClassOfWarrantsRepurchased
      contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">100000</srzn:ClassOfWarrantsRepurchased>
    <srzn:ClassOfWarrantsRepurchased
      contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">800000</srzn:ClassOfWarrantsRepurchased>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P01_01_2022To12_31_2022">As of December&#160;31, 2022, the following common stock warrants were outstanding (in thousands, except per share amounts): &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:49%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Type&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expiration Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&#160;per&lt;br/&gt; Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;August 12, 2026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,733&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;151&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;August 12, 2026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,174&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <srzn:ClassOfWarrantOrRightClassification contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">Liability</srzn:ClassOfWarrantOrRightClassification>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">2026-08-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">2733000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-3"
      unitRef="Unit_USD">151000</us-gaap:WarrantsAndRightsOutstanding>
    <srzn:ClassOfWarrantOrRightClassification contextRef="P01_01_2022To12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis">Liability</srzn:ClassOfWarrantOrRightClassification>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis">2026-08-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">3174000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">5907000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">326000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="PAsOn12_31_2022">2026-08-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <srzn:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="P01_01_2022To12_31_2022_CommonStock1MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.01</srzn:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2022_CommonStock1MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</us-gaap:SharePrice>
    <srzn:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="P01_01_2022To12_31_2022_CommonStock2MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.1</srzn:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2022_CommonStock2MemberusgaapStatementEquityComponentsAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <srzn:WarrantNoticePeriodPriorToRedemptionDate contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">P30D</srzn:WarrantNoticePeriodPriorToRedemptionDate>
    <srzn:WarrantRedemptionConditionMinimumSharePriceScenarioOne
      contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</srzn:WarrantRedemptionConditionMinimumSharePriceScenarioOne>
    <srzn:WarrantRedemptionConditionMinimumSharePriceScenarioTwo
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</srzn:WarrantRedemptionConditionMinimumSharePriceScenarioTwo>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="PAsOn12_31_2022_PIPEWarrantsMemberusgaapClassOfWarrantOrRightAxis">2026-08-12</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 12. Stock-Based Compensation Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company maintains the 2021 Equity Incentive Plan, or the 2021 Plan, which provides for the granting of stock awards to employees, directors and consultants. Options granted under the 2021 Plan may be either incentive stock options or nonqualified stock options to purchase common stock. Options granted under the 2021 Plan expire no later than 10 years from the date of grant. Options under the 2021 Plan generally vest over four years. As of December&#160;31, 2022, there were 3.7&#160;million shares of common stock available for issuance under the 2021 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Prior to the Business Combination, Legacy Surrozen maintained the 2015 Stock Plan, or the 2015 Plan, which provided for the granting of options to purchase shares of common stock to officers, employees, directors, consultants and key persons who provide services to the Company. Options under the 2015 Plan have a term of 10 years and generally vested over a four-year period with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; cliff vesting. In conjunction with the Business Combination, options and the corresponding exercise price under the 2015 Plan were converted into the awards under the 2021 Equity Incentive Plan based on the Exchange Ratio. Each converted option is subject to the same terms and conditions as were applicable to the corresponding options under the 2015 Plan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company adopted the 2021 Employee Stock Purchase Plan, or the ESPP, in August 2021. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to plan limitations. An offering period under the ESPP consists of four &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;six-month&lt;/div&gt; purchase periods, unless otherwise determined by the Company. The eligible employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the purchase day. As of December&#160;31, 2022, there were 0.6&#160;million shares of common stock available for issuance under the ESPP. During the year ended December&#160;31, 2022, 0.3&#160;million shares were issued under the ESPP. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Option Exchange &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2022, the Company&#x2019;s Compensation Committee authorized and approved a stock option exchange whereby certain outstanding stock options held by 59 employees were exchanged for stock options on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis with an exercise price at the current market price on the date of the exchange. As a result of this exchange, 1.3&#160;million outstanding stock options, with a weighted average exercise price of $8.81 per share, were exchanged for 1.3&#160;million new stock options under the 2021 Plan with an exercise price of $2.16 per share. The vesting terms and expiration dates of the new stock options remain unchanged from the original stock options. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The option exchange was treated as an option modification for accounting purposes and resulted in the incremental expense of $0.7&#160;million. $0.3&#160;million of the total incremental expense associated with the vested options was recognized on the modification date. The remaining $0.4&#160;million associated with the unvested options as of the modification date will be recognized over the remainder of the original requisite service period. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A summary of option activity is set forth below (shares in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:47%"/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Life&lt;br/&gt; (In years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (In&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding &#x2013; December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding &#x2013; December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,896&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable &#x2013; December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,430&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest is the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock at December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The intrinsic value of options exercised during the year ended December&#160;31, 2021 was $1.2&#160;million. No options were exercised during the year ended December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During the years ended December&#160;31, 2022 and 2021, the Company granted options with a weighted-average grant-date fair value of $2.28 per share and $6.36 per share, respectively. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the Company&#x2019;s RSA activity (shares in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:71%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSAs, unvested at December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSAs, unvested at December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div/&gt;&lt;div&gt;&lt;div style="background-color:white;display: inline;"/&gt;&lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of RSAs vested during the years ended December&#160;31, 2022 and 2021 was $0.2&#160;million and $0.6&#160;million, respectively. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of options is estimated at the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:81%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71.23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation recorded in the consolidated statements of operations and comprehensive loss related to options and RSAs was as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,517&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, there was approximately $9.9&#160;million of stock-based compensation expense to be recognized over a weighted-average period of approximately 2.5 years. &lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_MaximumMembersrtRangeAxis_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms contextRef="P01_01_2022To12_31_2022_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis">Options under the 2021 Plan generally vest over four years.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">3700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P01_01_2022To12_31_2022_TwoThousandFifteenStockPlan1MemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2022To12_31_2022">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <srzn:CliffVestingPeriod contextRef="P01_01_2022To12_31_2022">P1Y</srzn:CliffVestingPeriod>
    <srzn:PercentageOfDiscountPayrollDeductions
      contextRef="P01_01_2022To12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</srzn:PercentageOfDiscountPayrollDeductions>
    <srzn:CommonStockTradingDiscription contextRef="P01_01_2022To12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis">The eligible employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the purchase day.</srzn:CommonStockTradingDiscription>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_EmployeeStockPurchasePlanMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">300000</us-gaap:CommonStockSharesIssued>
    <dei:EntityNumberOfEmployees
      contextRef="PAsOn10_31_2022"
      decimals="0"
      unitRef="Unit_Employees">59</dei:EntityNumberOfEmployees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn10_31_2022"
      decimals="INF"
      unitRef="Unit_shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="P10_01_2022To10_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-8.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn10_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
      contextRef="P10_01_2022To10_31_2022_TwoThousandTwentyOneStockPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:StockOptionPlanExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="P01_01_2022To12_31_2022_VestedMemberusgaapVestingAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="P01_01_2022To12_31_2022_UnvestedMemberusgaapVestingAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:StockOptionPlanExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A summary of option activity is set forth below (shares in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:47%"/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Life&lt;br/&gt; (In years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (In&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding &#x2013; December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding &#x2013; December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,896&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable &#x2013; December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,430&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">1794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2021To12_31_2021">P8Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">2198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">3896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022">P8Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_shares">1430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022">P7Y5M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.28</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the Company&#x2019;s RSA activity (shares in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:71%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSAs, unvested at December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSAs, unvested at December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2022To12_31_2022_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="P01_01_2021To12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of options is estimated at the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:81%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71.23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.8107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.7123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="4"
      unitRef="Unit_pure">0.0089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_StockOptionMemberusgaapDerivativeInstrumentRiskAxis"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock-based compensation recorded in the consolidated statements of operations and comprehensive loss related to options and RSAs was as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:77%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1,612&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,517&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1612000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">736000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">2905000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1580000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4517000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2316000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">9900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2022To12_31_2022">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 13. Income Taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;No provision for income taxes was recorded for the years ended December&#160;31, 2022 and 2021. The Company has incurred net operating losses for all the periods presented. The Company accounts for income taxes in accordance with the asset and liability method, which requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#x2019;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is not likely to be realized and, accordingly, has provided a full valuation allowance. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;  &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant components of the Company&#x2019;s net deferred tax assets consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,985&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,826&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Section&#160;174 capitalized expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,775&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,392&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,096&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,521&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrual and reserves&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;590&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Employee retention credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized intangible costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;46,124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,867&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45,343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(35,665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net of valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,202&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(139&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,202&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total net deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The net valuation allowance increased by $9.7&#160;million for the years ended December&#160;31, 2022 and 2021. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the Company had net operating loss, or NOL, carryforwards of approximately $139.4&#160;million and $53.0&#160;million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. NOL carryforwards generated after 2018 for federal tax reporting purposes of $127.0&#160;million have an indefinite carryforward period. The remaining federal and state net operating loss carryforwards begin expiring in 2036. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the Company had research and development credit carryforwards of approximately $2.2&#160;million and $3.8&#160;million available to reduce future taxable income, if any, for federal and California state income tax purposes, respectively. The federal credit carryforwards begin expiring in 2036 and the state credits carry forward indefinitely. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Beginning January&#160;1, 2022, the Tax Cuts and Jobs Act, or the Tax Act, eliminated the option to deduct research and development expenditures in the current year and requires taxpayers to capitalize such expenses pursuant to Internal Revenue Code, or the IRC, Section&#160;174. The capitalized expenses are amortized over a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-year&lt;/div&gt; period for domestic expenses and a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15-year&lt;/div&gt; period for foreign expenses. As a result of this provision of the Tax Act, deferred tax assets related to capitalized research expenses increased by $6.7&#160;million. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section&#160;382 of the Internal &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue Code. As a result of such ownership changes, the Company&#x2019;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be limited and may expire unutilized. Such impairment of tax losses and tax credits would reduce the deferred tax asset and corresponding valuation allowance, as a result of the limitation. The Company completed an assessment of the available NOLs under Section&#160;382 and determined that the Company underwent an ownership change in September 2020. As a result of the annual limitations caused by the ownership change, it was estimated the approximately $1.3&#160;million of federal tax credit and $27.4&#160;million of California NOL will expire unrealized for income tax purposes, and such amounts are excluded from the carryforward balances as of December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The unrecognized tax benefits, if recognized, would not have an impact on the Company&#x2019;s effective tax rate assuming the Company continues to maintain a full valuation allowance position. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefits is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:78%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at beginning of the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions based on tax positions related to current year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;654&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reductions based on tax positions of prior year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at end of the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company files income tax returns in the U.S. federal and California tax jurisdictions. As of the date these financial statements were issued, the Company is not under examination by any income tax authority. The federal and state income tax returns from December&#160;31, 2016 to December&#160;31, 2021 remain subject to examination. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the statutory U.S. federal tax rate to the Company&#x2019;s effective tax rate is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Statutory rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State tax&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;NOL and tax credits limited under 382&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gain on warrant liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;21, 2020, the Consolidated Appropriations Act, 2021, or the Appropriations Act, was signed into law which expanded and extended some of CARES Act provisions, including the expansion of the employee retention credits. The Company claimed employee retention credits of $1.0&#160;million and $0.3&#160;million for the 2021 and 2020 tax years. The Company will recognize the benefit of those credits as the refunds are received. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inflation Reduction Act of 2022, or the IRA, which was signed into law in August 2022, includes several provisions that are specifically applicable to corporations. Among other changes, it created a new corporate alternative minimum tax based on adjusted financial statement income and imposes a 1% excise tax on corporate stock repurchases. The effective date of these provisions is January&#160;1, 2023. The Company is evaluating how the enactment of the IRA will have an impact on its consolidated financial statements but does not expect that the provisions of the IRA will have a material impact for the year ended December&#160;31, 2022. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant components of the Company&#x2019;s net deferred tax assets consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:72%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,985&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,826&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Section&#160;174 capitalized expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,775&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,392&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,096&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,521&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrual and reserves&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;590&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Employee retention credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;129&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized intangible costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;176&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;66&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;46,124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,867&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45,343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(35,665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net of valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,202&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(139&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,202&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total net deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">32985000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">31826000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <srzn:DeferredTaxAssetsCapitalizedExpenses
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6812000</srzn:DeferredTaxAssetsCapitalizedExpenses>
    <srzn:DeferredTaxAssetsCapitalizedExpenses
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</srzn:DeferredTaxAssetsCapitalizedExpenses>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3775000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2392000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <srzn:DeferredTaxAssetsLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1096000</srzn:DeferredTaxAssetsLeaseLiabilities>
    <srzn:DeferredTaxAssetsLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1521000</srzn:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">739000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">590000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <srzn:DeferredTaxAssetsEmployeeRetentionCredits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-271000</srzn:DeferredTaxAssetsEmployeeRetentionCredits>
    <srzn:DeferredTaxAssetsEmployeeRetentionCredits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-284000</srzn:DeferredTaxAssetsEmployeeRetentionCredits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">201000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">129000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <srzn:DeferredTaxAssetsCapitalizedIntangibleAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">176000</srzn:DeferredTaxAssetsCapitalizedIntangibleAssets>
    <srzn:DeferredTaxAssetsCapitalizedIntangibleAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">122000</srzn:DeferredTaxAssetsCapitalizedIntangibleAssets>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">66000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">46124000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">36867000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">45343000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35665000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">781000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1202000</us-gaap:DeferredTaxAssetsNet>
    <srzn:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">686000</srzn:DeferredTaxLiabilitiesRightOfUseAssets>
    <srzn:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">962000</srzn:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">101000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">95000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">139000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">781000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1202000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">9700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">139400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">53000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteTaxYearMemberusgaapTaxPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">127000000</us-gaap:OperatingLossCarryforwards>
    <srzn:TaxCreditCarryForwardsExpirationStartYear contextRef="P01_01_2022To12_31_2022">2036</srzn:TaxCreditCarryForwardsExpirationStartYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">2200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">3800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <srzn:TaxCreditCarryForwardsExpirationStartYear contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">2036</srzn:TaxCreditCarryForwardsExpirationStartYear>
    <srzn:StateTaxCreditCarryForwardsExpiration contextRef="P01_01_2022To12_31_2022_ResearchMemberusgaapTaxCreditCarryforwardAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">indefinitely</srzn:StateTaxCreditCarryForwardsExpiration>
    <us-gaap:CapitalizedContractCostAmortizationPeriod contextRef="PAsOn01_01_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">P5Y</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <us-gaap:CapitalizedContractCostAmortizationPeriod contextRef="PAsOn01_01_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">P15Y</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <srzn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease
      contextRef="PAsOn01_01_2022"
      decimals="-5"
      unitRef="Unit_USD">6700000</srzn:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">27400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxExaminationDescription contextRef="P01_01_2022To12_31_2022">An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefits is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:78%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at beginning of the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;921&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions based on tax positions related to current year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;654&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Reductions based on tax positions of prior year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at end of the year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">974000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">921000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">654000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">480000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">427000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1628000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">974000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the statutory U.S. federal tax rate to the Company&#x2019;s effective tax rate is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Statutory rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State tax&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.78&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.72&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.70&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(26.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;NOL and tax credits limited under 382&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gain on warrant liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.60&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.0212</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0278</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.0172</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0226</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.2688</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.1692</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <srzn:EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.046</srzn:EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities>
    <srzn:EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_pure">0</srzn:EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0057</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <srzn:ReinsuranceRetentionsPolicyAmountRetained
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1000000</srzn:ReinsuranceRetentionsPolicyAmountRetained>
    <srzn:ReinsuranceRetentionsPolicyAmountRetained
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">300000</srzn:ReinsuranceRetentionsPolicyAmountRetained>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 14. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Indemnification &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i)&#160;the Company&#x2019;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship with the Company, (ii)&#160;contracts under which the Company must indemnify directors and certain officers for liabilities arising out of their relationship with the Company, (iii)&#160;contracts under which the Company may be required to indemnify customers or partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights and (iv)&#160;procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts the Company may have to modify the accused infringing intellectual property and/or refund amounts received. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the Company&#x2019;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company maintains director and officer insurance, which may cover certain liabilities arising from the Company&#x2019;s obligation to indemnify its directors and certain officers. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;To the date of the consolidated financial statements were issued, the Company has not incurred any material costs or accrued any liabilities related to indemnification obligations. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result, the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Management is not aware of any pending or threatened litigation. &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 15. 401(k) Plan &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company adopted a 401(k) retirement savings plan, or the 401(k) Plan for all eligible employees. Each participant may contribute &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-&lt;/div&gt; or post- tax compensation, up to annual statutory limits. The 401(k) Plan also &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;permits the Company to make discretionary and matching contributions, subject to established limits and a vesting schedule. Each year, the Company may, at its sole discretion, make contributions to the plan. For the years ended December&#160;31, 2022 and 2021, the Company&#x2019;s contributions were $0.2&#160;million and nominal, respectively. &lt;/div&gt; </us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Note 16. Subsequent Events &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In January 2023, the Company implemented a restructuring plan approved by the board of directors to reduce its overall workforce by approximately 25%. The Company expects to substantially complete the workforce reduction by the end of the first quarter of 2023 and estimates to incur &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; restructuring charges of approximately $1.2&#160;million, including employee severance, benefits and related costs. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2023, the Company cancelled certain studies with its contract manufacturing organization and incurred a cancellation fee equal to 50% of the contract price of the studies plus any raw materials and handling fees that have been incurred. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;10, 2023, Silicon Valley Bank, or SVB, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or FDIC, as a receiver. On March&#160;12, 2023, the U.S. Department of the Treasury, Federal Reserve, and FDIC jointly announced that the FDIC would complete its resolution of SVB in a manner that fully protects all depositors. The Company has access to its full deposits with SVB and does not anticipate any disruption to its ongoing operations. The Company is working on replacing the letter of credit issued by SVB as required by the landlord and transferring substantially all of its cash deposits at SVB to a different financial institution. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On March&#160;31, 2023, we entered into an amended and restated warrant agreement with Continental Stock Transfer&#160;&amp;amp; Trust Company as warrant agent, or the PIPE Warrant Agreement. PIPE Warrants may be converted into Public Warrants on transfer pursuant to the terms of the PIPE Warrant Agreement. To the date of the consolidated financial statements were issued, no PIPE Warrants were converted into Public Warrants &lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P01_31_2023To01_31_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges
      contextRef="P01_31_2023To01_31_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1200000</us-gaap:RestructuringCharges>
    <srzn:PercentOfContractPrice
      contextRef="P02_28_2023To02_28_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</srzn:PercentOfContractPrice>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_73307291"
          xlink:label="Fact_73307291"
          xlink:type="locator"/>
        <link:footnote id="FN_253467" xlink:label="FN_253467" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">They are included in cash and cash equivalents on the consolidated balance sheets as of December 31, 2022 and 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307291"
          xlink:to="FN_253467"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307292"
          xlink:label="Fact_73307292"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307292"
          xlink:to="FN_253467"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307293"
          xlink:label="Fact_73307293"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307293"
          xlink:to="FN_253467"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307294"
          xlink:label="Fact_73307294"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307294"
          xlink:to="FN_253467"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307316"
          xlink:label="Fact_73307316"
          xlink:type="locator"/>
        <link:footnote id="FN_253468" xlink:label="FN_253468" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See the definition and discussion of Public Warrants, Private Placement Warrants and PIPE Warrants in Note 11. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307316"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307317"
          xlink:label="Fact_73307317"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307317"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307318"
          xlink:label="Fact_73307318"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307318"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307319"
          xlink:label="Fact_73307319"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307319"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307320"
          xlink:label="Fact_73307320"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307320"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307321"
          xlink:label="Fact_73307321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307321"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307322"
          xlink:label="Fact_73307322"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307322"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307323"
          xlink:label="Fact_73307323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307323"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307324"
          xlink:label="Fact_73307324"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307324"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307325"
          xlink:label="Fact_73307325"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307325"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307326"
          xlink:label="Fact_73307326"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307326"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307327"
          xlink:label="Fact_73307327"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307327"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307328"
          xlink:label="Fact_73307328"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307328"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307329"
          xlink:label="Fact_73307329"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307329"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307330"
          xlink:label="Fact_73307330"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307330"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307331"
          xlink:label="Fact_73307331"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307331"
          xlink:to="FN_253468"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307374"
          xlink:label="Fact_73307374"
          xlink:type="locator"/>
        <link:footnote id="FN_253469" xlink:label="FN_253469" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The change in fair value of the warrant liabilities was recognized in other income (expense), net within the consolidated statements of operations and comprehensive loss. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307374"
          xlink:to="FN_253469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307375"
          xlink:label="Fact_73307375"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307375"
          xlink:to="FN_253469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307376"
          xlink:label="Fact_73307376"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307376"
          xlink:to="FN_253469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307377"
          xlink:label="Fact_73307377"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307377"
          xlink:to="FN_253469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307378"
          xlink:label="Fact_73307378"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307378"
          xlink:to="FN_253469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307379"
          xlink:label="Fact_73307379"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307379"
          xlink:to="FN_253469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307380"
          xlink:label="Fact_73307380"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307380"
          xlink:to="FN_253469"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_73307381"
          xlink:label="Fact_73307381"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_73307381"
          xlink:to="FN_253469"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>97
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "M)?U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  K27]6$P(UT.T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)VU ,'1S6?&D(+B@> O)[&ZP:4,RTN[;F\;=+J(/X#$S?[[Y
M!J8S09HQXG,< T9RF&YFWP])FK!A1Z(@ 9(YHM>ISHDA-_=C])KR,QX@:/.A
M#P@MY[?@D;35I&$!5F$E,M59(TU$36,\XZU9\>$S]@5F#6"/'@=*T-0-,+5,
M#*>Y[^ *6&"$T:?O MJ56*I_8DL'V#DY)[>FIFFJ)U%R>8<&WIX>7\JZE1L2
MZ<%@_I6<I%/ #;M,?A7;^]T#4RUO1<5%)9I=(R2_D[Q]7UQ_^%V%_6C=WOUC
MXXN@ZN#77:@O4$L#!!0    ( "M)?U:97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M$?:W:#(-*<RR 5B4$18@T+MFJUA"=SZSV\.[-5M=:6@+D76-BNT%Y:[W@6@
MJO(5^O[%N$GKT8T=ZR?/;G!=HN+)_W_<A*TUZL]RKJM6?%C5VJ<'Z( \M ?
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MY8 ^ZFHOJ6S>/U=;*G1)&7[Z+MRQA0B'Z>((MD,(X]2-.NE0)U[4G[DBQ0D
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MDPZ 430)IA<P+5)A,*5VF-,6YG00ICFHUX(7!ZAXGML@3CN+7X5AT,%H$1L
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MAAA/^Y1 R@]S4+2X00N=(TB@?'8I:44/[%8]?F'R, 6FYC ,@RB8]$D %3I
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MXM&H\H_!..V(WDOD54OB%9^DGZLB[)$6SD1L<)WUVL_IN%T%W]5;.%!@S=J
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M&U4/<A:9HH\T;)]@SX!BF H-\V@6?/[JX]6'XC?EP)7)2="D)Q@4L!< CK-
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M_B9HRDS64I=#5Q)2"'PF]QV.<.@&K\<$;"3)18Q<8YXUT!^S0+VUW.5%#:F
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M1!HW&QF=XY)IR(1==*H&E?%I(@Z5*2X-4%;NG((XFEJO4B/7E#0L$NHFE%?
M%?4&/_-,+MK2,;BR_F!&)3_A1* 8N]29@L0E@) AY8P[THX;\BQ%K)OXZ7!.
M . O:7AMONO:K"WGB"&D,YH;M.$7$)<*S06U@:0LG&KCO2&Q$]$E4W*)NO\.
M[#M0F0@@4Z?0$BYCPR1;J7NP+B41L80=Z$7DNH/T,MF;-OEW4FB7)$"B33K
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MGZ!9YH]NW*(T.7_H@I*W-"E?;A7:K((VX/G:H&RH%X1@_^73S;\!4$L#!!0
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M&6N&>+=T1O)2 ^O:M<-IH,,8.5HW2FM*C:86I!AXVVHEHCJQKZV6F!86^,,
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M>"!L=>.I7KPIPBUC83SN+.%OBDLB69Z \:7!.;1^80?MM7/^+U!+ P04
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M>) &;',1;!F_7BUL"+:(/]<D459\ ,^7%A[5%VR@_9QY\2]02P,$%     @
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M<SCL7+O&BJ5PZI:FTV]2&;%A;S:?L BZ2"$I=WNC=Q I="R-:WHOGP][H^&
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M307'"$4;\'REE*U_D(+F4O3R_U!+ P04    "  K27]6?0^1S:H+  !@'P
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MX</P%."CY7^45KNT:O8UKN4&01&'"V #=& (1LV/<4/.IPU;A036B$@*[G9
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MY07X7AG(6WY@ \/M_NH?4$L#!!0    ( "M)?U;]5X59] (  (8&   9
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MK0_@_87A=NPF/D'_Z9G]!5!+ P04    "  K27]62>B 40T%  !3"P  &0
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M]I"&*!3QX &4DT,)RJPU&T,\K3K\=<\VO 4T77$T"RQ8B;:?G312,]@&O$D
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M0ZPDVH,W@2UCL>.'RU ,*6[=J B.(_ZUK4];C=D3(ND'7CD-\SY=IH_MO$;
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MWM>C8QE7 V]5O"$RN-PER:H4+U&)"UF9]&X6;].'-NA:E;@O89!&85FQ1#Y
M6+M3OP<6((Z<)@4;*XW5\99#W72//%4ZI#I &_W<!T,1+KFTBLZ9M[(_!GYI
MN)'K/3B[>,)R3.$+PX%;!:NP?<-5^)1%9I0>KG1PF0)1R !T!BG=HT90C"V)
MO_)]7DKDPH$\)^$>+-GDPB#'WFE:5$8EQ[^WI#OVZ<TJ1M))C2WPE4';%:[^
MI SI54R3Q)K&@*O %"(JJ)J3ENA8,AO0]P -$//7!7=OR0E?#+Q:WT) B]?R
M0?0XZRQ+N+[[PN.AMAF(]&[X$H,/6M [$4"DEJXGTETS1!E$^3[\N>8 GFA9
M42W^RJ"O/KZS]QV72%\_H!O0SW^(ER'1%=4%R4!:\&MJ8+I;KR,.+ZC1K6K>
M]P]A4-0#(%06!M*XV4#H%">-73BL(E8EB(R+ W' @?QD#ZWEX0E@1U/J32P3
M'2\-$]>Z\BDU,$6=P<\\4AMTZ1#L67<T+I6><%R@*+M89(:+BP A0>X)=>1B
MA(]692%7YL;=.8R"O\3NI?FB2[.UG!< %]-HOL,#OP"[%*@NJ$HJQC)5'>[H
MBIX()IE"=%2I?V3??I5Q :3J%&K"=2@89RUU#]+%4"R65?CU(I(^0'H)[XVO
MJC52_"%!B;@VN214834KO:'"LNF5(.^^I*+V0A=17<81@G9,?)GXJ]>B Y/D
MR2R3HQKE2#! \F[[ WX. Y#>I!]+NT(_4"2(G86\M0"L:EN1*O=<@8#I&]^G
MF-)1MF^'>@H5+(55TV=C4AC\9V\[[:_'">R8&.ALSAV)5ZR6\W>LK@9U/A^L
MFX[F?>L@1U[X.;A#()D?XICD=D:\&_%M%P;B3:+E_!V@?P%E:9W7@)9O\ F/
MR6U_ZR 9/G>44]45;2\^$()Q-(^;20N3=?2\%3J,TUH#SI'PS([> =/%J<)*
M21 ;,&\KKC>BN=R!:4S+F8;/C7 \$H';L ("6X5;VK#6LB=UG5Y4NL&BF &.
MVBE1%+QW*TF"HP^<4-GU47(1.E85O:]#"T L<MA20*VF%S&"74IOF$^LGOT?
M:.!_8PR4/$BCQ&S%%W0B.8[2EI/$FO"OW")*[@/@Y88 ?&9V-#Z]>#'J\(F8
ME<Y5SZ7;XN9 N^H@49UN-7M(T65 "+!J]^CU@S04]X!"<1B&>_";^"KI!I\L
M7KYZGBT7+UX]??"9+LE1Y"9<3.0%+\^?9<OGR]ABL)UPX=^F97\PZXMG#T(Q
M(?P8?AKT?K9X=?XB>[&X6+Y\\+M%'?YJ\>K).?S_XNG+N4??XEVBB_F[1.^Y
MB/)WS)U.*87Y[D>JLY,QQS%R#DF1M\.M*&N;O'LA&;7D28I]N.7EXQ,44<"O
M,%<K4 O&.?JJ"]T9FC8_,: Z<#TG7DT9URE+F ZFY2=$CK^GP8Z5KA7[)-"C
M)?\KK<%>44$?RW70(51? 5_'HJ T_CLNXY87O\ZR?P>? U/1.Q5;)^\;40*O
MIB>M,)!(_8L^UY,4'123 ?$Q!4D8$74T(#]$_N$M$[FR,SCX4'E%]STEF.UU
M)HROOE"92L;W43UCX-VEOJW32V84L$LR4GWM$\]AM 4-Q 4!$H4/(5#P?7&
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M(B1%2QXSW1I0ON8\C@IB79+1&WKYDP^^),F GE/WCA\7*C@.6XNZE]0%79R
M[JRD2/E[K7B?_9+:)IZ/Z4B&!8AF"P(.Y*]PD,4'J@9[F+Z>0?@AW%EC)8?J
MM;;^VNEQYL%EDP95Z[4AU4+O*I)1 K!P:W.Z6 CGB@@Z)+2.4RE4!GE.#%QU
M&2_,+"39?_>#=LD-NR04PRZET(1VS0<33?+Q$X$%UK:7JZ_^9<!!!'P_/I=I
MM?(X>4P:B4M/9M,;:77'[TJ';\.SW)?\&'5LSF]Z?U0M(8I2KZ'K^=F+9R<<
MOO1_=+:AIZE7MNML11^W6H&48@/X?6W!K9,_<(+P6/F;_P502P,$%     @
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M%S7!NXJ@WT/0\\D7*<Q:DP\B9>DQ@3%PU[#H[UF\\P<IOF>+"Q)X+O$GOC]
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M0QRG2%:I&;X7Y= .HS0JP$R6C-J'Y#(,O3A-R16Y++PT"<F5<^[N+DCL97&
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M&URB^54L%%E^S9+P#'/-90X*UR-O$@ZF'>OO'!XX;O71'FPF*RF?K'&3C+S
M"D*!L;$,C)87G*$0EHAD/.\YO3JD!1[O#^S7+G?*9<4TSJ1XY(E)1]ZE!PFN
M62G,G=Q^PWT^7<L72Z'=%[:5;Z?G05QJ([,]F!1D/*]6MMO7X0AP&;P#B/:
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M:6@ZN&U*XQB5=:#[M93F8-@ ]8 ?_P502P,$%     @ *TE_5DZ]H[C !
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M :[=!KPOE+*[!^>@^X,Q_P]02P,$%     @ *TE_5MW]BK?\ @  ]P<  !D
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M43D#^SV7TFPF+D#;VH[^ E!+ P04    "  K27]6K4,W3,\#  #1$0  &0
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M0FN8)^*1[OY 58<&BA?2A!?_P:XJZU@@S+F@:14L6Y!B4O["ETJ(HX">=R+
MJP*\5P'>J8!>%= [-Z!?!?3/#1A4 477[;+OA7 ^%' Z9G0'F"HM:>J@4+^(
MEGIAHAZ4I6#R+I9Q8OJ(0IAA 1/\#1;._0;NHPBK0YB !U(^BNK&6Q\)B!/^
M#KP!-N Q9(@#3, 3P8)?R8OR^'-,<PY)Q,>VD(U35=AAU9!YV1#O1$-<\(D2
M$7,0D A%'?'^#^(]#<"6JM32>'MI9IZ6>)]OKH'K7@'/\=SC3I<_75T\ ]C;
M Y^6/GC[YEU73_48'X4UQM-@@O,Q)UK3D*U7/U&]@ML[P5WF*XXC+$<=L(0)
M G^NP5+0\!G\\U&6! \"I?S?CN;.2FR_&ZL&S#N>P1!-+#DB<L2VR)K^^HL[
M='[O<L(DS#<)"PS!&M[T:V_Z.OITP6B(4,3!FM$48,YS2$($Z!J$-$WE2\X+
MI_),'LYR+J,Y!W.:KC I!P'Y;H/%PR( [^45$F*RN0)$3F>2(!@D');#?TBY
MZ'I!9MKF7>JQ29A?P@8%3,VNVZDSMK?'QK5+N%[?\P[%&I8,:DL&6DL^GR.;
M%G&I;(-6/_K.J[[Z)BL,#,$:\@YK>8=:>1]1E)?BRG'H:&9;0!S)Z0W,R]FO
M2W0M^%+1ARW1![<MU4W6&!B"-52_J56_T:H>O(0Q)!L$F!HVNL35QE\J;@F[
M/7YWK]V;P; _&O0&KS2^H&Q@J)$-"4>UA".MA,N<,?H-$?F0AET":J,O%= D
MS#<)"PS!&A;<UA;<_IPOF5N3WIB$^29A@2%8PQO7.20NCO8%^4!IM,-)Y]"M
M#[W4@8JF^3;PC588F*(UE3U*"=T??"7B+13R 2=;Q$6*B% SY2)?)3B4V97
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MHNF;R_/4H$2H ;,.:9:FNT3HNDOHBWO+$=S.NVAP@Y@%6@,WO=6J2U2_2]?
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M]OW;LKW<AU^Z#S@^NO3B_U!+ P04    "  K27]6:<S'WYT#  "5#   &0
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6S-5VUOVS80_BL'+1@ZP(Y>'#MI
M9@NPZQ0S$*]&W+0?BGZ@I;-%1"(UDK(S8#]^1TF1O<96AVP%\L4F*=[QN><>
MZD[#G50/.D$T\)BE0H^<Q)C\VG5UE&#&]+G,4="3M509,S15&U?G"EE<&F6I
M&WC>P,T8%TXX+-<6*AS*PJ1<X$*!+K*,J3\GF,K=R/&=IX4[ODF,77##8<XV
MN$1SGR\4S=S&2\PS%)I+ 0K7(V?L7T_\"VM0[OC$<:</QF!#64GY8">S>.1X
M%A&F&!GK@M'?%M]AFEI/A../VJG3G&D-#\=/WM^7P5,P*Z;QG4P_\]@D(^?*
M@1C7K$C-G=S]AG5 ?>LODJDN?V%7[_4<B IM9%8;$X*,B^J?/=9$'!CT>B<,
M@MH@*'%7!Y4HI\RP<*CD#I3=3=[LH RUM"9P7-BL+(VBIYSL3/B><06?6%H@
MS)'I0B%1;J +XSCFEC>6PDQ4V;<LOIFB83S5O\ 9N* 3IE #%W ON-$=6J3Q
MQT06FHE8#UU#$.U!;E3#F51P@A-P_ #F4IA$PXV(,?ZG Y=B:P(,G@*<!*T>
MIQB=0\_O0. % =POI_#F[!!\RQ&]AL->>43O^QR.M4:C82QBN.5LQ5/BD BJ
MJ8WA@X [C JEN-B4NWZ70C4+$Z:YAB^WY!]F!C/]]1B#%9B+XV#L+;[6.8MP
MY- UU:BVZ(0__^0/O%];0KUH0KUH\QY^5$SH-2H-<@UK+IB(."F$"VU4896C
MX2\X.X:Z\MLO_=I7Q3;TAN[V")1^ Z7?"N6#25!U3<)$EZC*I:*7"LRRG))1
M2OA6:A+D%%<&EI;A,A,=&&])OFR58I=$W=4LQ5.(^_\6\:!!/&A%O( 9+. &
M/C-%-)94'=ZYF<@+TX&;QYS>6*25*=_R&$DC=\S@,8"MI[U0")=-+)>O2?.7
M/R#4JR;4J]:TC5.#2C!;/2A'6]3&IJOS/'?'@%>N!]\7T=L&S=M6-',N>%9D
M\&6.V0K55Q+1M[HZAJ/5Z0L)]+U]D?%>DUIJ-/]SM <EU6]-T=+(Z %RQ2,$
M(ZEWB1$SV.UO_:GJ4Z/WG[UX_!.B\8,]IJ!=-NSQ);)I]_I2)O>%U7]5E=7_
M$:75W]=6O[VX_E?=/"^Q_M4WNG$/.L4,U:;LAS5$LA"F:AJ;U:;G'E>=YGY[
MU;#/F=I0W8<4UV3JG5_2P:KJ@:N)D7G9=ZZDH2ZV'";TW8#*;J#G:RG-T\0>
MT'R)A'\#4$L#!!0    ( "M)?U9N&[+0Z@(  -(*   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,X+GAM;,U6:T_;,!3]*U8F34QB31SH Y9&:GEHE<I6P09"
MTSZXR6UKX=B9[;3P[V<G:4BGD&T()+ZT?MWC<ZZ/XQMLA+Q3*P"-[A/&U=!9
M:9T>NZZ*5I 0U1$I<#.S$#(AVG3ETE6I!!+G00ES?<_KN0FAW F#?&PFPT!D
MFE$.,XE4EB1$/HR!B<W0P<YVX)(N5]H.N&&0DB5<@?Z>SJ3IN15*3!/@B@J.
M)"R&S@@?C[%O _(5UQ0VJM9&5LI<B#O;F<1#Q[.,@$&D+00Q?VLX <8LDN'Q
MJP1UJCUM8+V]13_/Q1LQ<Z+@1+ ;&NO5T!DX*(8%R9B^%)O/4 KJ6KQ(,)7_
MHDVYUG-0E"DMDC+8,$@H+_[)?9F(6@#N/Q'@EP%Y(MQBHYSE*=$D#*38(&E7
M&S3;R*7FT88<Y?94KK0TL]3$Z?"<4(FN"<L 70!1F023<HT^HBMS_G'& (G%
MSHSISB:S,W1#I"1<*\-7K]"8<I%0PM"4:$TC R9B8&CO%#2A3'T(7&W(VBW=
MJ"0V+HCY3Q ;9<L.PG@?^9Z/T8/<17"-S$JK7VGU<\B#OVL=*06&^XC':$K)
MG#*J*:BMT!A]Y>@2HDQ*RI?YJB^"RVI@3!15Z,?4X*.)AD3];-)7D#EL)F-O
MV[%*201#QUPG!7(-3OC^'>YYGUJD'E12#]K0P^WI[.^<W82GF6ZB6H!A+T>S
M%WD=>AW/&^# 73>P.*Q8'+:R.+M/S>4SZ?P&,D%[MT!DLQ5:89Z9JFY%LON6
M7-%]!:F]2FKO)5U1@&%<<T6WXSWAB7[%H?]OGK@6C&B;XH>FO5M!GIFF045Q
M\)8<,7@%J4>5U*.7=$0!AOV=[P0>'#5; GN/CY#72N.4KFD,)GVW%%C<^%BT
M CPS2[CV2N*W9(F2S0NK?7PG<>O;]+^N*-%Z=5?\X0BW5J'8:N^"R"7E"C%8
MF!BOTS>?15D44$5'BS0O6N9"FQ(H;ZY,T0G2+C#S"R'TMF/KH*J,#7\#4$L#
M!!0    ( "M)?U;>GW$$H 4  .8<   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;,U9VV[;.!#]%<);+!J@B47*UVQB(+%;;("F:R2]/!3[0$NT3502
MO21E=_?K=W2)9$D48Z<NT!=;HF8.YT+.'(E7.R&_J35C&GT/@TA==]9:;RZ[
M7>6M64C5A=BP")XLA0RIAENYZJJ-9-1/E<*@2QQGT TICSJ3JW1L+B=7(M8!
MC]A<(A6'(97_WK) [*X[N/,T\,!7:YT,="=7&[IBCTQ_VLPEW'4+%)^'+%)<
M1$BRY77G!E_.W%0AE?C,V4[M7:/$E840WY*;._^ZXR06L8!Y.H&@\+=E4Q8$
M"1+8\4\.VBGF3!3WKY_0WZ7.@S,+JMA4!%^XK]?7G5$'^6Q)XT _B-V?+'>H
MG^!Y(E#I+]KELDX'>;'2(LR5P8*01]D__9X'8D\!NRT*)%<@=85!BX*;*[AU
MA5Z+0B]7Z*61R5Q)XS"CFDZNI-@AF4@#6G*1!C/5!O=YE.3]44MXRD%/3]Y1
M+M%G&L0,W3.J8LD@J1J=H\=L(2"Q1-,UC59,(1ZA/7%X\(5*24'Z/:<+'G#-
M0>CUC&G* W4&&)\>9^CUJS/T*E']N!:QHI&OKKH:#$^F[WJYD=/,2-)B)";H
M7D1ZK=#;R&=^%: +'A=NDR>WI\2*.&/>!7+Q&T0<0@P&S0Y7QQ9SW"(+;HKG
M/I^%&Z685N@F\BMAS9/CH[\B],"\6$H>K5*I#R*2Q< M55RAK^\!']UI%JJ_
M3='.C.F9C4DJS:7:4(]==Z"4*":WK#/Y_3<\</XP1>I$8)6X]8JX]6SHDUL:
MT,AC;]""K7@4)1& 9;EAD@O?Y'B&UD_1DHJXG8Q<!Q*XW7>H*>04$A4K^X65
M?:N5D-(XW*1E#O;!;:S@N5)H*L(%CV@R;K+5BGELDC*P0<7Q(3&[-2C<&EC=
MRLI"XM(R6;[;=/G&F[0?A&4M,9AS:P?^BHVK=M#PX7PX&CNU[)FDL-G18>'H
MT&K/ ]O$TEM#=T&O/PC-T/C,9-^P.?.H7[/..M$+-\NH<&-TV&9A4#6LVV34
M\,0E@YHG39G*5JI8."XL'%LMG,>+@'M/;<78**P Q^Z*$X%5?,5.V7F=7ZGH
MY]:<*'2G0JO&;H^UX),6_ARNLJ3[9%A;TP:IEM*/26DI^0G%WPYZ=+*(P?O^
ML,6UDK1@:V__D0;P#')+!\BU*B76=?N]>AI-8FV)+*D&MG.- [M CE*9G)"Z
MA=:I7KI[2CZ"[83D\$Z F\0!]^N$R2!4V5Q5*TMZ@>TT8"[YED*<YP%$(GTK
ML34&.]C1.^9$:%772\*!A[]4:S@1+<EC]S-(#BY9#CZ0YAS:&II,!@_J;,<@
MU%902K*#[6SGA9WAI PH1ZLZ/S)[1DIF0ZS=_T<:PS/(+8TAUZH47=ROMW>3
M5,L[$"F9"+$SD0/; FE2B_-QW3[K3"_<.*1D*L3.5 [O"J3))^JO80:1_5U5
M-;%D',3."^;H#LW16VLCL$,<NT%.A59UN"0=I/<K-0)R(EZ2Q^YGL!Q2LAQR
M(,LYL!&0)HWI#9Q1?6$WI5HZ 2F9#K$SG9=U COHT<EJ?CCI#7HM)(Z43(;8
MOYW\2"NP([>U L-GF)X[;-1:@Y@[;O&VY![$SCT.;09--G'>>(NQ3_72W5.R
M$V)G)T=T@W'C@RD>UC]\&80JFZOZV3QA&M61LA^[]GX,R^+CFB'/M.[ #0W/
M=OFQ1;!71G=4P8KTQ"KB_T$Q!3T!HA(N/!%"-MGW#8L4.WN#(J;1CNLUB"1@
MGHB4"+@/;RH^4AK^DO6LDKD$Q"S=O0I1""( 0:;6R9G9EJ% *'5ARE1W[S G
M9'*5'HHIT(XCG7T9+T:+@[?;]+BI-C[%ES-L&+]QG<LIA-CT!,.3[,BMG#H[
M ;RG$JJH0@%;@AG.Q1!2*;-#M>Q&BTUZS+006HLPO5PSZC.9",#SI8 -D=\D
M$Q1'FY/_ 5!+ P04    "  K27]6:?&IK.,%  ":)@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6S-FEUOVS84AO\*X15#"\2U2$JVW#D&$@?M"J1;
MT+3=Q; +VF9BH9+HD732[->/DAW1,J63T%"!W"26??CJ?% \#R5-[H7\KE:<
M:_0C2W-UVEMIO7XW&*C%BF=,O15KGIM?;H3,F#:'\G:@UI*S93DH2P<D"(:#
MC"5Y;SHIO[N2TXG8Z#3)^95$:I-E3#Z<\U3<G_9P[_&+S\GM2A=?#*:3-;OE
MUUQ_75])<S2H5)9)QG.5B!Q)?G/:.\/O9B$I!I06WQ)^K_8^HR*4N1#?BX./
MR]->4'C$4[[0A00S_^[XC*=IH63\^'<GVJO.60S<__RH_KX,W@0S9XK/1/I7
MLM2KTU[<0TM^PS:I_BSN?^>[@*)";R%25?Y%]SO;H(<6&Z5%MAML/,B2?/N?
M_=@E8F\ #EL&D-T \MP!=#> EH%N/2O#NF":32=2W"-96!NUXD.9FW*TB2;)
MBS)>:VE^3<PX/7W/$HF^L73#T2?.U$9R4R.-^NC:3)CE)N5(W*!/3'[GFLW-
MT35?;&2B$Z[0_.'QZ %]>5AS]/K"&"6I>F.&?[V^0*]?O4&O4)*C+RNQ42Q?
MJLE &Y^+,P\6.__.M_Z1%O\N^.(MHO@$D8"0AN&SYP_']>$#DZDJ7:1*%RGU
MZ-/I.E.*:X7.\B6Z3-@\2;=9V65QB?[,T><B/3+);TNK/T0NJR_.F4H4^OO2
MZ*./FF?JGZ;<;)T)FYTIKO!W:LT6_+1G+F'%Y1WO37_]!0^#WYHRU9%8+6^T
MRAN%U*=GF9 Z^<^D92:41C.3!3/-FD+>ZD2E3K$&W4TC3./Q9'"W'XMK-8Q'
M,:ZL:DZ&E9.AAY,G1<'ZBW9/03'?XFS%AGL!$3R*:'- 4150! ;T00JET%<S
M[5A:QO7!K.OJ!$I_Y/B!#U+O6H3-7@XK+X='>?E$^D%1W_0/G:""YJ!&55 C
MOZ NS3&'<S]RG.B3D!RDO\DH:O8UKGR-?T8!0%'? L1N6..X.:QQ%=88#.N"
MS_5>OSI!9W>F.Q5=K&_PIZ]8RJMRG* O0K.T*<RQXUF$<1@?E,6U,@O2L&42
MX<!VYP",P?:;)\L!*_G68Z=67Y"&4<M,PWNX@<& 9B++N%PD+$57;,UE8R2@
MA'<D':G5 [; @%\4,>!.D:$KM7KN+#3@KJAA)U2;KB0*#[&AP2P<8SILF=46
M'#!,#D<T6NQV_.#06\BD[JDE NR)!,_H2]AM^8ZKD$G=58L%&.:"CM9O[/;V
MQJGAFD%3PW( AD%@)N1:2*8Y.A?YLM%!4,#[DNU(K1ZN10D<OZCEKE,(Z4JM
MGCO+*Q@&%H_ESL4-',1X=#BG&\RB,6FY,HFE$@)3B>=&"5;SWL:Z9$*CN(45
MB043 H/)$4OX3A':+#68M.R6R-XM"+#K'HOKL*IW%<AS%WQBVSV!V_TQO8FX
M';U/G"HT&.U=+'5W;=,GQS7]I^K0Z7T#XC)"'[=0.K&40&!*Z*CUDH:["<%H
M?+A,-9E%XZ"M0!8@" P0'ILG6,F[*"Y+T&C4<C.'6)0@,$J\%Y(GMWD)$HVW
M4N'QWE'\#)(@EB3(BR()TBE)=*56SYTE"=(52<!"WF&[P$%';;>GJ.4-"O/&
M$;T95O2-B[K,T=+MJ 4.Z@D<S^AVL*1W5"Z<]%LXBEHZH3"==-0ZX+-X1^K2
M"AVU$0#=>ZCQ!+"(.R[S\H%9ZYH,2W@'TI%:/6"+/#1\26LR[125NE*KY\XR
M%869RN,16 ,/Q0&A!]@$G^_8>"Q=49BN/#>!L)IW+5W"PC$>MG4:BUC4\['-
M,SJ-^T3F\.X8?-)C*V5)BOZ4YSNPJG?%W"<\;2W48@Z%,>>H%NHB2I\X.T;X
MQ$=6++3 $QX'/$\]D>X4>D(7>OIQRR8FM-@3PMC3$1_LSK+_!@ >F47RH(ZP
M,\?6T<)0",.0QPX45O*N'7'3$P<Q.:C>8._%H>*MK4],WIJ)AE)^8\8%;T=&
M0&Y?A-H>:+$NWR6:"ZU%5GY<<;;DLC PO]\(H1\/BM>3JM?1IO\#4$L#!!0
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M'ZALOCFK;P:2I?EQ=\ZD.CSGETL@(7 =H)XO&)-/ WV"+O\Q\?\!4$L#!!0
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M:4G"C0T7*%[;SMMPI?O8+DL]:4&8!'V^Y5P= O.!?G9G?P!02P,$%     @
M*TE_5G+(!VT% P  E0@  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL
MK991;YLP$,>_BL6JJ96V0H 0VB5(;:)IDS:M:M;M8=J# T>Q:C"S3=)\^YV!
ML#30* ][23#<_\_OSO:9Z4;()Y4!:/*<\T+-K$SK\MJV59Q!3M6E**' )ZF0
M.=4XE(^V*B70I!;EW'8=)[!SR@HKFM;W[F0T%97FK( [2525YU1N;X&+S<P:
M6;L;]^PQT^:&'4U+^@A+T _EG<21W;DD+(=",5$0">G,NAE=ST,37P?\8+!1
M>]?$9+(2XLD,/B<SRS% P"'6QH'BWQKFP+DQ0HP_K:?5O=((]Z]W[A_KW#&7
M%54P%_PG2W0VLT*+))#2BNM[L?D$;3YCXQ<+KNI?LFEC'8O$E=(B;\5(D+.B
M^:?/;1WV!"/_%8';"MQ3!5XK\.I$&[(ZK075-)I*L2'21*.;N:AK4ZLQ&U:8
M65QJB4\9ZG1T2SDM8B#+>LG,15Z* @JMR'NRQ!635!R(2,E-',L*$O*%T17C
M3#-0Y'P!FC)^@:$/RP4Y/[L@9X05Y'LF*D6+1$UMC83F/7;<TMPV-.XK- N(
M+XDW>D=<QW4'Y//3Y:.7<AOKTA7'[8KCUG[>2<6Y!TXUUF#!5,R%JB36X-?-
M2FF):_'W4+*-NS_L;O;GM2II##,+-Z "N08K>OMF%#@?AE+_3V8O"N%UA?".
MN4>[Z2_I5@K."<XN;N&F'/",'47!X&PWKN/:U?23=>1=!?[47N\GU@]RPW#2
M!;T ]CM@_R1@4PHJXZPF3F"-7:O$'J2/4C?6P1[0* C&!]3]("\(@F'J<4<]
M/JW,4J2@3*.DG)BY9+@(4QBF'?=  B\\@.W'C,:N,PP;=+#!4=A=*]@2/$L(
M5IEOL:H@8Z8P!6Q<\1,1I>G5@]A!#RF\.J#NA[C.>!AZTD%/CD)_TQG((9Q)
M[UW^E7O TX_Q0G^8)^QXPI-FW"Q/8=@(_]=AASC#WF8)0O]PNOM!81"X!Z3V
MWJ%A#NRO5#ZR0A$.*<J<RPGJ97,(-@,MROH<60F-IU)]F>%W T@3@,]3(?1N
M8(ZF[DLD^@M02P,$%     @ *TE_5LUE6)_Q P  Q!,  !D   !X;"]W;W)K
M<VAE971S+W-H965T-#4N>&ULM9C;;MLX$(9?A= 610NDT<'R(:EMP+94K!=)
M&R3M+HIB+QAI; N51)6DXP38AU^2DA7+E8D(96]LD>)\Y/PSXFF\(_0[VP!P
M])BE.9M8&\Z+2]MFT08RS,Y) ;EXLR(TPUP4Z=IF!04<*Z,LM3W'&=@93G)K
M.E9U-W0Z)EN>)CG<4,2V68;ITQQ2LIM8KK6ON$W6&RXK[.FXP&NX _ZEN*&B
M9->4.,D@9PG)$875Q)JYEZ'K20/5XN\$=NS@&4E7[@GY+@O+>&(Y<D200L0E
M HN_!UA FDJ2&,>/"FK5?4K#P^<]_8-R7CASCQDL2/I/$O/-Q!I9*(85WJ;\
MENS^A,JAON1%)&7J%^W*MD/?0M&6<9)5QF($69*7__BQ$N+ P/-.&'B5@?=2
M@UYET#LR<(<G#/S*P#\V&)TPZ%<&RG6[]%T)%V".IV-*=HC*UH(F'Y3ZREKH
ME>0R4>XX%6\38<>G5R!49N@=FL5Q(D.'4[3,RP24@7P3 ,=)RMZB[/4?[G#T
M'B4Y^KPA6X;SF)VA5XWRV.9B3))L1U7_\[)_[T3_KH>N2<XW#(5Y#'$38 MG
M:H^\O4=S3TL,(#I'/?<,>8[GH2]W 7KSZFW+P!8OQ[@:3*#'_(7S&N/L-6S!
MA'K,;+O>8]P!6O$V3D.M7AW_G@+W3L:?,0"DT@ %P"*:%"KPWZY$2[3DD+%_
MV\):8OUVK)S>+EF!(YA88OYB0!_ FHI!#YPVYQ<F88%)6&@(UHB-7\?&U]&G
M,S'S([(2\['X*(%QS $55*P1E#^A_S3)--=RNP;')"PH80,%DXO8PW3@#T=C
M^^%0=$,]-D3OUZ+WM:+?"J%I$G&(4839IDW=$M _\,%W^DT7%B]H$V@'TC51
M#<$:F@UJS09:S3Z)E!3+1;Y&J9I'.-"L33@MI6M:FH0%>O_<$<K4(M4FO*%Q
M-(0?UL(/7RB\FL#/4/@H=I ,VL0?_I21[H7C'*7MSXW$CO.H4: =4]>\-01K
MR#>JY1MIY5O,KI8?/MU^7,[$=!K*+27Z"I@R].T:LGN@K0N?%MDUB4W" I.P
MT!"L$9>+.BX7OV=3<F$R-B9A@4E8: C6B(WK/)\8G%_9EK1O3JNS@);<-4!&
M:8%16EC1#C<Z/6_D]NJIM"G^P7'-[;34JG5)1@,>BX0^R2?UHE5]/5J<4/KO
M'+]5::UE9Z5-TD)3M&9 O.> >+^Z7ZP(S<W@\<JK[Z:SQ"9IH2E:*;%]<%N1
M 5VK:R*&(K+->7G,KVOKJZB9NH YJI^[EXOR0ND94]YO76.Z3G(F/H650#KG
M0Z$]+:^,R@(GA;H3N2><DTP];@#'0&4#\7Y%"-\79 ?UQ=WT?U!+ P04
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M3XJ/&THB*O(.^OL5YVI_D3NH#\[,_@502P,$%     @ *TE_5FB4E'CC @
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MI1,""I'4#EA==C #2K612N-W[6DT0VIAN_WF_J6L7=6RP@)FC#Z16"93X]I
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M$9_9P\^TZM!,X84LR?5?]%"5=28H+'+!TJJRM""-L_(_>:R(:%3P\4 %7%7
M1Q4&6_"J"MYQ"T,5_*J"KYDINZ)Y"(@@JS/.'A!7I26:NM!DZMJR^W&F?O=;
MP>7;6-83JUO!PJ_H4C(7H2N6RN&4$_V#W"0D0^_0113%ZIXDZ#HKAYEZ^T-
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M2P\I7I^8H^Q(HX.(WYFE3KOQXR628M=DQ:X]!U4)L1Q.*57NV$L):$(,BA9
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M=94_GT9<_Z)]UK9M(7_+!8TS8ZD@#I/TG[QDB2@8.-TS!DYFX)0-.F<,W,S
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MR(2EZ6W2<*%HD0?;W!2YWJ(4"N:&V&W3</,R :GW(YK1HV$A-C5Z0U+D+=_
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ *TE_5AAN:KP!!0  ARH
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  K27]6$P(UT.T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  K27]6
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( "M)?U:WAB,OO08  &P;   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  K27]6
M%L9!+?D%  #@&   &               @('_#@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ *TE_5IL_? K= @  Z0D  !@
M     ("!+A4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M "M)?U;@T+,G;P0  # 0   8              " @4$8  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    "  K27]60**VW]$'  "P-P  &
M            @('F'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ *TE_5N&*_/WP"   7"D  !@              ("![20  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "M)?U857#1!R04  "@.
M   8              " @1,N  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    "  K27]6L&.2488;  "O4@  &               @($2-
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ *TE_5M4W] T8
M!0  <@P  !@              ("!SD\  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( "M)?U;6,%'?"0P   4E   9              "
M@1Q5  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ *TE_
M5B=KMQ>Q P  1P@  !D              ("!7&$  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    "  K27]6U(#@Z0H%  !C"P  &0
M        @(%$90  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( "M)?U9>M??3, 0  %D)   9              " @85J  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ *TE_5N+P#L4-"0  U!P
M !D              ("![&X  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    "  K27]64(X>([T#   S"0  &0              @($P>
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "M)?U9)BU#@
M5P4  ((.   9              " @21\  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ *TE_5A46MTZP!P  VA0  !D
M ("!LH$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  K
M27]69#=Z^%8(   @%0  &0              @(&9B0  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "M)?U9]#Y'-J@L  & ?   9
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M970R,RYX;6Q02P$"% ,4    "  K27]6O9C')0($   $"0  &0
M    @('OR0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M "M)?U::#>$PY0<  !(7   9              " @2C.  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ *TE_5OA_EAR6 P  00@  !D
M             ("!1-8  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    "  K27]6=BB)+'H#   ="   &0              @($1V@  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "M)?U9V5C?KQ (
M .P%   9              " @<+=  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ *TE_5DZ]H[C !   C@L  !D              ("!
MO>   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  K27]6
M5%&?32L%  !L#   &0              @(&TY0  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( "M)?U;=_8JW_ (  /<'   9
M      " @1;K  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ *TE_5L30N]P/ P  G0P  !D              ("!2>X  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  K27]6-KCE_/H"  #F"@
M&0              @(&/\0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( "M)?U:M0S=,SP,  -$1   9              " @<#T  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ *TE_5K8>0P$'
M!0  O1T  !D              ("!QO@  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    "  K27]65RWL07X,  #&=   &0
M@($$_@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "M)
M?U9IS,??G0,  )4,   9              " @;D* 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ *TE_5FX;LM#J @  T@H  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( "M)?U:WHK=J: (  ,<%   9
M  " @8@E 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M*TE_5G+(!VT% P  E0@  !D              ("!)R@! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    "  K27]6S658G_$#  #$$P  &0
M            @(%C*P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( "M)?U;G7BOQG0(  ,H&   9              " @8LO 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ *TE_5FD$EF7X @
MO@<  !D              ("!7S(! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    "  K27]6K%J_&5X#  #9#   &0              @(&.
M-0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( "M)?U98
M]Z,6YP0  $0C   9              " @2,Y 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ *TE_5FB4E'CC @  : H  !D
M     ("!03X! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "M)?U8@OX-S. 0   42   9              "
M@>); 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ *TE_
M5CLSY[DO P  [ @  !D              ("!46 ! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    "  K27]6X4:=[O\"   V"   &0
M        @(&W8P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( "M)?U93A-UO3@,  &\,   9              " @>UF 0!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ *TE_5IPOF-"V!@  >C(
M !D              ("!<FH! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    "  K27]6ZE.?16,$   +$0  &0              @(%?<0$
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( "M)?U92\QR=
MW@(  .0'   9              " @?EU 0!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ *TE_5F,?(S^4 P  K@L  !D
M ("!#GD! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    "  K
M27]6H6?TF#T"  "Y!   &0              @('9? $ >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( "M)?U8"08(*? (  .@&   9
M          " @4U_ 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#
M%     @ *TE_5IG=K@!I P  @1<   T              ( ! ((! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  K27]6EXJ[',     3 @  "P
M    @ &4A0$ 7W)E;',O+G)E;'-02P$"% ,4    "  K27]6&&YJO $%  "'
M*@  #P              @ %]A@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ *TE_5M))O&T1 @  %R8  !H              ( !JXL! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ *TE_5L"(;73I 0  ?B4
M !,              ( !](T! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ $@ 2 "O$P  #I !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>231</ContextCount>
  <ElementCount>347</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document -  Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement -  Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement -  Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement -  Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure -  Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/OrganizationAndBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure -  Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure -  Recapitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/Recapitalization</Role>
      <ShortName>Recapitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure -  Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure -  Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure -  Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure -  Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/CollaborationAndLicenseAgreement</Role>
      <ShortName>Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure -  License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/LicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure -  Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure -  Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure -  Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/CommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure -  Stock Based Compensation Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockBasedCompensationPlan</Role>
      <ShortName>Stock Based Compensation Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure -  Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure -  Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure -  401(K) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/KPlan</Role>
      <ShortName>401(K) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure -  Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure -  Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://Consonance.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure -  Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Consonance.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure -  Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Consonance.com/role/FairValueMeasurement</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure -  Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Consonance.com/role/BalanceSheetComponents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure -  Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Consonance.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure -  Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/CommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Consonance.com/role/CommonStockWarrants</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure -  Stock Based Compensation Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockBasedCompensationPlanTables</Role>
      <ShortName>Stock Based Compensation Plan (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Consonance.com/role/StockBasedCompensationPlan</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure -  Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://Consonance.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure -  Organization and Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure -  Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure -  Summary of Significant Accounting Policies - Summary of Property and Equipment Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Property and Equipment Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure -  Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure -  Recapitalization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/RecapitalizationAdditionalInformationDetails</Role>
      <ShortName>Recapitalization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details))</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details))</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure -  Fair Value Measurement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure -  Fair Value Measurement - Schedule of Measurement of PIPE Warrants with Binomial Lattice Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails</Role>
      <ShortName>Fair Value Measurement - Schedule of Measurement of PIPE Warrants with Binomial Lattice Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Fair Value Measurement - Summary of Changes in Fair Value of Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurement - Summary of Changes in Fair Value of Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure -  Fair Value Measurement - Schedule of Marketable Securities by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails</Role>
      <ShortName>Fair Value Measurement - Schedule of Marketable Securities by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure -  Fair Value Measurement - Schedule of Individual Securities Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails</Role>
      <ShortName>Fair Value Measurement - Schedule of Individual Securities Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure -  Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure -  Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/BalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure -  Balance Sheet Components - Schedule of Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure -  Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure -  Leases - Summary Of Lessee, Operating Lease, Liability, Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails</Role>
      <ShortName>Leases - Summary Of Lessee, Operating Lease, Liability, Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure -  Leases - Schedule of Supplemental Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure -  Collaboration and License Agreement (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreement (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/CollaborationAndLicenseAgreement</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure -  License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure -  Related Party Transactions (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/RelatedPartyTransactions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure -  Stockholders' Equity (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/StockholdersEquity</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure -  Common Stock Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails</Role>
      <ShortName>Common Stock Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure -  Common Stock Warrants - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/CommonStockWarrantsDetails</Role>
      <ShortName>Common Stock Warrants - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/CommonStockWarrantsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure -  Stock Based Compensation Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails</Role>
      <ShortName>Stock Based Compensation Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure -  Stock Based Compensation Plan - Summary of Stock Option Activity for Company's Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails</Role>
      <ShortName>Stock Based Compensation Plan - Summary of Stock Option Activity for Company's Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure -  Stock Based Compensation Plan - Summary of RSA Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails</Role>
      <ShortName>Stock Based Compensation Plan - Summary of RSA Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure -  Stock Based Compensation Plan- Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails</Role>
      <ShortName>Stock Based Compensation Plan- Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure -  Stock Based Compensation Plan - Schedule of Stock-Based Compensation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails</Role>
      <ShortName>Stock Based Compensation Plan - Schedule of Stock-Based Compensation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure -  Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure -  Income Taxes - Summary of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure -  Income Taxes - Summary of Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/IncomeTaxesSummaryOfTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Summary of Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure -  Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate TO Effective Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate TO Effective Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure -  401(K) Plan Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/KPlanAdditionalInformationDetails</Role>
      <ShortName>401(K) Plan Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d491933dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure -  Subsequent Events (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://Consonance.com/role/SubsequentEvents</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 5 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d491933dposam.htm 12554, 12558, 12562, 12566</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-1" original="d491933dposam.htm">d491933dposam.htm</File>
    <File>d491933dex231.htm</File>
    <File>srzn-20221231.xsd</File>
    <File>srzn-20221231_cal.xml</File>
    <File>srzn-20221231_def.xml</File>
    <File>srzn-20221231_lab.xml</File>
    <File>srzn-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g491933g04a04.jpg</File>
    <File>g491933g11a02.jpg</File>
    <File>g491933g66a66.jpg</File>
    <File>g491933g66b66.jpg</File>
    <File>g491933g81a81.jpg</File>
    <File>g491933g82a82.jpg</File>
    <File>g491933g82b82.jpg</File>
    <File>g491933g83a83.jpg</File>
    <File>g491933g86a86.jpg</File>
    <File>g491933g87a87.jpg</File>
    <File>g491933g87b87.jpg</File>
    <File>g491933g88a88.jpg</File>
    <File>g491933g88b88.jpg</File>
    <File>g491933g90a90.jpg</File>
    <File>g491933g91a09.jpg</File>
    <File>g491933g92a09.jpg</File>
    <File>g491933g92b09.jpg</File>
    <File>g491933g93a09.jpg</File>
    <File>g491933g93b09.jpg</File>
    <File>g491933g94a09.jpg</File>
    <File>g491933g95a09.jpg</File>
    <File>g491933g96a09.jpg</File>
    <File>g491933g96b09.jpg</File>
    <File>g491933g97a09.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="638">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>103
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d491933dposam.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 638,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 231,
   "dts": {
    "calculationLink": {
     "local": [
      "srzn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "srzn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d491933dposam.htm"
     ]
    },
    "labelLink": {
     "local": [
      "srzn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "srzn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "srzn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 541,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 7,
    "total": 7
   },
   "keyCustom": 72,
   "keyStandard": 275,
   "memberCustom": 31,
   "memberStandard": 33,
   "nsprefix": "srzn",
   "nsuri": "http://Consonance.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document -  Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://Consonance.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure -  Fair Value Measurement",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://Consonance.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure -  Balance Sheet Components",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://Consonance.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure -  Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://Consonance.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:CollaborationAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure -  Collaboration and License Agreement",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://Consonance.com/role/CollaborationAndLicenseAgreement",
     "shortName": "Collaboration and License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:CollaborationAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:LicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure -  License Agreement",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://Consonance.com/role/LicenseAgreement",
     "shortName": "License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:LicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure -  Related Party Transactions",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://Consonance.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure -  Stockholders' Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://Consonance.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:CommonStockWarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure -  Common Stock Warrants",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://Consonance.com/role/CommonStockWarrants",
     "shortName": "Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:CommonStockWarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure -  Stock Based Compensation Plan",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://Consonance.com/role/StockBasedCompensationPlan",
     "shortName": "Stock Based Compensation Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure -  Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://Consonance.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement -  Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://Consonance.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure -  Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://Consonance.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure -  401(K) Plan",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://Consonance.com/role/KPlan",
     "shortName": "401(K) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure -  Subsequent Events",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://Consonance.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure -  Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure -  Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure -  Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://Consonance.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure -  Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://Consonance.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure -  Leases (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://Consonance.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure -  Common Stock Warrants (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://Consonance.com/role/CommonStockWarrantsTables",
     "shortName": "Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure -  Stock Based Compensation Plan (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://Consonance.com/role/StockBasedCompensationPlanTables",
     "shortName": "Stock Based Compensation Plan (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement -  Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure -  Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://Consonance.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure -  Organization and Business - Additional Information (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails",
     "shortName": "Organization and Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure -  Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022_LetterOfCreditMemberusgaapShortTermDebtTypeAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srzn:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure -  Summary of Significant Accounting Policies - Summary of Property and Equipment Useful Lives (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Property and Equipment Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srzn:PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure -  Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure -  Recapitalization - Additional Information (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails",
     "shortName": "Recapitalization - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "srzn:RecapitalizationNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn08_31_2021",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details))",
     "menuCat": "Details",
     "order": "36",
     "role": "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details))",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure -  Fair Value Measurement - Additional Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
     "shortName": "Fair Value Measurement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn08_11_2021",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure -  Fair Value Measurement - Schedule of Measurement of PIPE Warrants with Binomial Lattice Model (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails",
     "shortName": "Fair Value Measurement - Schedule of Measurement of PIPE Warrants with Binomial Lattice Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn08_11_2021",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Fair Value Measurement - Summary of Changes in Fair Value of Warrant Liabilities (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails",
     "shortName": "Fair Value Measurement - Summary of Changes in Fair Value of Warrant Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement -  Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure -  Fair Value Measurement - Schedule of Marketable Securities by Security Type (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails",
     "shortName": "Fair Value Measurement - Schedule of Marketable Securities by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Investments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure -  Fair Value Measurement - Schedule of Individual Securities Unrealized Loss Position (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails",
     "shortName": "Fair Value Measurement - Schedule of Individual Securities Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Investments",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure -  Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure -  Balance Sheet Components - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://Consonance.com/role/BalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure -  Balance Sheet Components - Schedule of Accrued Liabilities (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn01_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_sqm",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure -  Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://Consonance.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn01_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_sqm",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure -  Leases - Summary Of Lessee, Operating Lease, Liability, Maturity (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails",
     "shortName": "Leases - Summary Of Lessee, Operating Lease, Liability, Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srzn:ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure -  Leases - Schedule of Supplemental Information Related to Operating Leases (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://Consonance.com/role/LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails",
     "shortName": "Leases - Schedule of Supplemental Information Related to Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srzn:ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "srzn:CollaborationAndLicenseAgreementsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "srzn:NonRefundableUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure -  Collaboration and License Agreement (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreement (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "srzn:CollaborationAndLicenseAgreementsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P10_01_2022To10_31_2022_CollaborationAndLicenseAgreementWithBiMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "srzn:NonRefundableUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure -  License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails",
     "shortName": "License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P03_01_2016To03_31_2016_StanfordLicenseAgreementsMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StanfordMemberusgaapRelatedPartyTransactionAxis",
      "decimals": "-5",
      "lang": null,
      "name": "srzn:PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P12_12_2022To12_12_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure -  Related Party Transactions (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P12_12_2022To12_12_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchasedDuringPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure -  Stockholders' Equity (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SaleOfStockDescriptionOfTransaction",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn02_28_2022_ClosingSalePriceNotBelow1200PerShareMemberusgaapMeasurementInputTypeAxis",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure -  Common Stock Warrants - Additional Information (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
     "shortName": "Common Stock Warrants - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "2",
      "lang": null,
      "name": "srzn:WarrantRedemptionConditionMinimumSharePriceScenarioTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure -  Common Stock Warrants - (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://Consonance.com/role/CommonStockWarrantsDetails",
     "shortName": "Common Stock Warrants - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure -  Stock Based Compensation Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
     "shortName": "Stock Based Compensation Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure -  Stock Based Compensation Plan - Summary of Stock Option Activity for Company's Stock Option Plans (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails",
     "shortName": "Stock Based Compensation Plan - Summary of Stock Option Activity for Company's Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure -  Stock Based Compensation Plan - Summary of RSA Activity (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails",
     "shortName": "Stock Based Compensation Plan - Summary of RSA Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2021_RestrictedStockAwardRSAMemberusgaapAwardTypeAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure -  Stock Based Compensation Plan- Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Options (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails",
     "shortName": "Stock Based Compensation Plan- Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_StockOptionMemberusgaapDerivativeInstrumentRiskAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure -  Stock Based Compensation Plan - Schedule of Stock-Based Compensation Expenses (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails",
     "shortName": "Stock Based Compensation Plan - Schedule of Stock-Based Compensation Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:TaxCreditCarryForwardsExpirationStartYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure -  Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:TaxCreditCarryForwardsExpirationStartYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure -  Income Taxes - Summary of Net Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Summary of Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure -  Income Taxes - Summary of Tax Benefits (Detail)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://Consonance.com/role/IncomeTaxesSummaryOfTaxBenefitsDetail",
     "shortName": "Income Taxes - Summary of Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure -  Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate TO Effective Income Tax Rate (Detail)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail",
     "shortName": "Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate TO Effective Income Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure -  401(K) Plan Additional Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://Consonance.com/role/KPlanAdditionalInformationDetails",
     "shortName": "401(K) Plan Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_31_2023To01_31_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure -  Subsequent Events (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_31_2023To01_31_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure -  Organization and Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://Consonance.com/role/OrganizationAndBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure -  Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://Consonance.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:RecapitalizationNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure -  Recapitalization",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://Consonance.com/role/Recapitalization",
     "shortName": "Recapitalization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d491933dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srzn:RecapitalizationNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Number of employees held stock options"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r293",
      "r421",
      "r434",
      "r460",
      "r461",
      "r472",
      "r479",
      "r487",
      "r520",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r293",
      "r421",
      "r434",
      "r460",
      "r461",
      "r472",
      "r479",
      "r487",
      "r520",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r276",
      "r293",
      "r323",
      "r324",
      "r325",
      "r420",
      "r421",
      "r434",
      "r460",
      "r461",
      "r472",
      "r479",
      "r487",
      "r515",
      "r520",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r276",
      "r293",
      "r323",
      "r324",
      "r325",
      "r420",
      "r421",
      "r434",
      "r460",
      "r461",
      "r472",
      "r479",
      "r487",
      "r515",
      "r520",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r134",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r196",
      "r232",
      "r233",
      "r355",
      "r375",
      "r376",
      "r377",
      "r378",
      "r396",
      "r406",
      "r407",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r134",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r196",
      "r232",
      "r233",
      "r355",
      "r375",
      "r376",
      "r377",
      "r378",
      "r396",
      "r406",
      "r407",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r221",
      "r222",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r473",
      "r486",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r221",
      "r222",
      "r445",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r473",
      "r486",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srzn_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srzn_AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses Current And Noncurrent",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrentAndNoncurrent",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_AccruedResearchAndDevelopmentExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses Policy [Text Block]",
        "terseLabel": "Accrued Research and Development Expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyTextBlock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srzn_AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital early exercise of stock options value.",
        "label": "Adjustment to additional paid in capital early exercise of stock options value",
        "terseLabel": "Vesting of early exercised stock options"
       }
      }
     },
     "localname": "AdjustmentToAdditionalPaidInCapitalEarlyExerciseOfStockOptionsValue",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital reclassification of early exercised stock options.",
        "label": "Adjustment to additional paid in capital reclassification of early exercised stock options",
        "terseLabel": "Reclassification to liability for early exercised stock options"
       }
      }
     },
     "localname": "AdjustmentToAdditionalPaidInCapitalReclassificationOfEarlyExercisedStockOptions",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_AssociatedWithholdingTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Associated withholding tax.",
        "label": "Associated Withholding Tax",
        "terseLabel": "Associated withholding tax"
       }
      }
     },
     "localname": "AssociatedWithholdingTax",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_AssumedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed warrants.",
        "label": "Assumed Warrants",
        "terseLabel": "Common stock warrants assumed as part of business combination"
       }
      }
     },
     "localname": "AssumedWarrants",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srzn_AssumptionOfWarrantLiabilitiesInBusinessCombination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumption of warrant liabilities in business combination.",
        "label": "Assumption Of Warrant Liabilities In Business Combination",
        "terseLabel": "Assumption of warrant liabilities in Business Combination"
       }
      }
     },
     "localname": "AssumptionOfWarrantLiabilitiesInBusinessCombination",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax, Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax, Current",
        "terseLabel": "Gross Unrealized Gains, Current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax, Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax, Current",
        "terseLabel": "Gross Unrealized Losses, Current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current",
        "terseLabel": "Gross Unrealized Gains, Non-current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Remaining Cost Of Acquired Entity Recorded as a Reduction of Additional Paid-in Capital",
        "label": "Business Acquisition Remaining Cost Of Acquired Entity Recorded as a Reduction of Additional Paid-in Capital",
        "terseLabel": "Reduction Of Additional Paid In Capital"
       }
      }
     },
     "localname": "BusinessAcquisitionRemainingCostOfAcquiredEntityRecordedAsAReductionOfAdditionalPaidInCapital",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_BusinessCombinationInitialWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Initial Warrants Issued.",
        "label": "Business Combination Initial Warrants Issued",
        "terseLabel": "Common stock warrants issued as part of business combination"
       }
      }
     },
     "localname": "BusinessCombinationInitialWarrantsIssued",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srzn_ClassOfWarrantOrRightClassification": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right Classification.",
        "label": "Class Of Warrant Or Right Classification",
        "terseLabel": "Common Stock Warrant Classification"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightClassification",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srzn_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right issued.",
        "label": "Class Of Warrant Or Right Issued",
        "terseLabel": "Common stock warrants issued as part of business combination"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srzn_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Redemption Price Of Warrants Or Rights.",
        "label": "Class Of Warrant Or Right Redemption Price Of Warrants Or Rights",
        "terseLabel": "Redemption Price Per Public Warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srzn_ClassOfWarrantsRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants repurchased.",
        "label": "Class of Warrants Repurchased",
        "terseLabel": "Class of warrants repurchased"
       }
      }
     },
     "localname": "ClassOfWarrantsRepurchased",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srzn_CliffVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cliff vesting period.",
        "label": "Cliff vesting period",
        "terseLabel": "Cliff vesting period"
       }
      }
     },
     "localname": "CliffVestingPeriod",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srzn_ClosingSalePriceNotBelow1000PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing sale price not below 10.00 per share .",
        "label": "Closing Sale Price Not Below 10.00 per Share [Member]"
       }
      }
     },
     "localname": "ClosingSalePriceNotBelow1000PerShareMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_ClosingSalePriceNotBelow1200PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing sale price not below 1200 Per share.",
        "label": "Closing Sale Price Not Below 1200 Per Share [Member]"
       }
      }
     },
     "localname": "ClosingSalePriceNotBelow1200PerShareMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_CollaborationAndLicenseAgreementWithBiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreement with BI [Member]",
        "label": "Collaboration and License Agreement with BI [Member]",
        "terseLabel": "Collaboration and License Agreement with BI [Member]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementWithBiMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_CollaborationAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaboration and license agreements.",
        "label": "Collaboration and License Agreements [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsTextBlock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srzn_CommonStock1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, 1.",
        "label": "Common Stock1 [Member]",
        "terseLabel": "Common Stock, Closing Price equals or Exceeds $18 Per Share [Member]"
       }
      }
     },
     "localname": "CommonStock1Member",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_CommonStock2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, 2.",
        "label": "Common Stock2 [Member]",
        "terseLabel": "Common Stock, Closing Price equals or Exceeds $10 Per Share [Member]"
       }
      }
     },
     "localname": "CommonStock2Member",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_CommonStockPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase commitment period.",
        "label": "Common Stock Purchase Commitment Period",
        "verboseLabel": "Stock Issuance period"
       }
      }
     },
     "localname": "CommonStockPurchaseCommitmentPeriod",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srzn_CommonStockTotalPurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock total purchase price",
        "label": "Common Stock total purchase price",
        "terseLabel": "Common stock purchase price"
       }
      }
     },
     "localname": "CommonStockTotalPurchasePrice",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_CommonStockTradingDiscription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Trading Discription",
        "label": "Common Stock Trading Discription",
        "terseLabel": "Common stock trading description"
       }
      }
     },
     "localname": "CommonStockTradingDiscription",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srzn_CommonStockWarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for common stock warrants.",
        "label": "Common Stock Warrants Disclosure [Text Block]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsDisclosureTextBlock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srzn_CompensationPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation payable",
        "label": "Compensation payable",
        "terseLabel": "Compensation payable"
       }
      }
     },
     "localname": "CompensationPayable",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srzn_CorporateBondMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate bonds.",
        "label": "Corporate Bond [Member]",
        "terseLabel": "Corporate Bond"
       }
      }
     },
     "localname": "CorporateBondMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_DeferredTaxAssetsCapitalizedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized expenses.",
        "label": "Deferred Tax Assets Capitalized Expenses",
        "terseLabel": "Section 174 capitalized expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedExpenses",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_DeferredTaxAssetsCapitalizedIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized intangible assets.",
        "label": "Deferred Tax Assets Capitalized Intangible Assets",
        "terseLabel": "Capitalized intangible costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedIntangibleAssets",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets deferred expense capitalized research and development costs increase decrease.",
        "label": "Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs Increase Decrease",
        "terseLabel": "Deferred tax assets, deferred expense, capitalized research and development costs increase"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCostsIncreaseDecrease",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_DeferredTaxAssetsEmployeeRetentionCredits": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Employee retention credits",
        "label": "Deferred Tax Assets, Employee retention credits",
        "negatedLabel": "Employee retention credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsEmployeeRetentionCredits",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_DistributedBioSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributed Bio Subscription Agreement Member.",
        "label": "Distributed Bio Subscription Agreement [Member]",
        "terseLabel": "Distributed Bio Subscription Agreement [Member]"
       }
      }
     },
     "localname": "DistributedBioSubscriptionAgreementMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_DocumentDocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Document Document And Entity Information [Abstract]",
        "label": "Document Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentDocumentAndEntityInformationAbstract",
     "nsuri": "http://Consonance.com/20221231",
     "xbrltype": "stringItemType"
    },
    "srzn_EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation gain on warrant liabilities.",
        "label": "Effective Income Tax Rate Reconciliation Gain on warrant liabilities",
        "terseLabel": "Gain on warrant liabilities"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGainOnWarrantLiabilities",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "srzn_EightYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eight years.",
        "label": "Eight Years [Member]",
        "terseLabel": "Eight Years [Member]"
       }
      }
     },
     "localname": "EightYearsMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_EmergingGrowthCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the accounting policy on Emerging Growth Company.",
        "label": "Emerging Growth Company Policy [Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srzn_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis assumption in business combination.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Assumption In Business Combination",
        "terseLabel": "Assumption in Business Combination"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssumptionInBusinessCombination",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_ForeignBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign bonds [Member]",
        "label": "Foreign bonds [Member]",
        "terseLabel": "Foreign Bonds"
       }
      }
     },
     "localname": "ForeignBondsMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_FurnitureFixturesAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture Fixtures and Equipment.",
        "label": "Furniture Fixtures And Equipment [Member]",
        "terseLabel": "Furniture Fixtures And Equipment [Member]"
       }
      }
     },
     "localname": "FurnitureFixturesAndEquipmentMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_GovernmentBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government bonds [Member]",
        "label": "Government bonds [Member]",
        "terseLabel": "Government Bonds"
       }
      }
     },
     "localname": "GovernmentBondsMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_GuggenheimSecuritiesLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Guggenheim Securities, LLC [Member]",
        "label": "Guggenheim Securities, LLC [Member]"
       }
      }
     },
     "localname": "GuggenheimSecuritiesLlcMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in right-of-use assets and lease liabilities due to lease extension",
        "label": "Increase in right-of-use assets and lease liabilities due to lease extension",
        "terseLabel": "Increase in right-of-use assets and lease liabilities due to lease extension"
       }
      }
     },
     "localname": "IncreaseInRightOfUseAssetsAndLeaseLiabilitiesDueToLeaseExtension",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_IndefiniteTaxYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite Tax Year.",
        "label": "Indefinite Tax Year [Member]",
        "terseLabel": "Indefinite Tax Year [Member]"
       }
      }
     },
     "localname": "IndefiniteTaxYearMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock as a commitment fee under Equity Purchase Agreement",
        "label": "Issuance of common stock as a commitment fee under Equity Purchase Agreement",
        "terseLabel": "Other expense related to the commitment shares issued to Lincoln Park"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAsACommitmentFeeUnderEquityPurchaseAgreement",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_IssuanceOfCommonStockUnderEquityPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock under Equity Purchase Agreement",
        "label": "Issuance of common stock under Equity Purchase Agreement",
        "terseLabel": "Issuance of common stock under Equity Purchase Agreement (Share)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockUnderEquityPurchaseAgreement",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "srzn_Issuanceofcommonstockvalueunderequitypurchaseagreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock value under equity purchase agreement.",
        "label": "IssuanceOfCommonStockValueUnderEquityPurchaseAgreement",
        "terseLabel": "Issuance of common stock under Equity Purchase Agreement(Value)"
       }
      }
     },
     "localname": "Issuanceofcommonstockvalueunderequitypurchaseagreement",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment..",
        "label": "Lab equipment [Member]"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_LicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreements Abstract.",
        "label": "License Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementsAbstract",
     "nsuri": "http://Consonance.com/20221231",
     "xbrltype": "stringItemType"
    },
    "srzn_LicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements disclosure [Text Block].",
        "label": "License Agreements Disclosure [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srzn_LincolnParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park [Member]",
        "label": "Lincoln Park [Member]"
       }
      }
     },
     "localname": "LincolnParkMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_NonRefundableUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable upfront payment received",
        "label": "Non-refundable upfront payment received",
        "terseLabel": "Non-refundable upfront payment received"
       }
      }
     },
     "localname": "NonRefundableUpfrontPaymentReceived",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_OperatingLeaseMonthOfExpiryOfLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease month Of expiry of lease.",
        "label": "Operating Lease Month Of Expiry Of Lease",
        "terseLabel": "Operating lease month of expiry of lease"
       }
      }
     },
     "localname": "OperatingLeaseMonthOfExpiryOfLease",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "srzn_PIPEWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PIPE warrants.",
        "label": "P I P E Warrants [Member]",
        "terseLabel": "P I P E Warrants"
       }
      }
     },
     "localname": "PIPEWarrantsMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/CommonStockWarrantsDetails",
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for achievement of specified development and regulatory milestones.",
        "label": "Payments For Achievement Of Specified Development And Regulatory Milestones",
        "terseLabel": "Payments for achievement of specified development and regulatory milestones"
       }
      }
     },
     "localname": "PaymentsForAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_PaymentsForMilestoneAgreementOnAchievementOfMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for milestone agreement on achievement of milestones.",
        "label": "Payments For Milestone Agreement On Achievement Of Milestones",
        "terseLabel": "Payments for milestone agreement on achievement of milestones"
       }
      }
     },
     "localname": "PaymentsForMilestoneAgreementOnAchievementOfMilestones",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for milestone agreement or earned royalties on achievement of milestones.",
        "label": "Payments For Milestone Agreement Or Earned Royalties On Achievement Of Milestones",
        "terseLabel": "Payments for milestone agreement or earned royalties on achievement of milestones"
       }
      }
     },
     "localname": "PaymentsForMilestoneAgreementOrEarnedRoyaltiesOnAchievementOfMilestones",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_PercentOfContractPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of contract price.",
        "label": "Percent Of Contract Price",
        "terseLabel": "Percent of Contract Price"
       }
      }
     },
     "localname": "PercentOfContractPrice",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srzn_PercentageOfDiscountPayrollDeductions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of discount payroll deductions",
        "label": "Percentage of discount payroll deductions"
       }
      }
     },
     "localname": "PercentageOfDiscountPayrollDeductions",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srzn_PrivateInvestmentInPublicEntityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private investment in public entity offering member.",
        "label": "Private Investment In Public Entity Offering [Member]",
        "terseLabel": "Private Investment In Public Entity Offering"
       }
      }
     },
     "localname": "PrivateInvestmentInPublicEntityOfferingMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_PrivatePlacementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private placement warrants.",
        "label": "Private Placement Warrants [Member]",
        "terseLabel": "Private Placement Warrants"
       }
      }
     },
     "localname": "PrivatePlacementWarrantsMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from cash acquired through acquisition and private investment in public entity offering.",
        "label": "Proceeds From Cash Acquired Through Acquisition And Private Investment In Public Entity Offering",
        "terseLabel": "Proceeds from cash acquired through acquisition and PIPE offering"
       }
      }
     },
     "localname": "ProceedsFromCashAcquiredThroughAcquisitionAndPrivateInvestmentInPublicEntityOffering",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock upon employee stock plan purchases",
        "label": "Proceeds from issuance of common stock upon employee stock plan purchases"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUponEmployeeStockPlanPurchases",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock upon exercise of stock options",
        "label": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptions",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_ProceedsFromRepurchaseOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from repurchase of warrants.",
        "label": "Proceeds From Repurchase Of Warrants",
        "negatedTerseLabel": "Repurchase (Note 9)"
       }
      }
     },
     "localname": "ProceedsFromRepurchaseOfWarrants",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_ProceedsFromSaleOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Marketable Securities",
        "label": "Proceeds From Sale Of Marketable Securities",
        "terseLabel": "Proceeds from sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_PropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment useful lives.",
        "label": "Property Plant And Equipment Useful Lives Table [Text Block]",
        "terseLabel": "Summary of Property and Equipment Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srzn_PublicWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public warrants.",
        "label": "Public Warrants [Member]",
        "terseLabel": "Public Warrants"
       }
      }
     },
     "localname": "PublicWarrantsMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/CommonStockWarrantsDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_PurchaseOfAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of additional shares",
        "label": "Purchase of additional shares"
       }
      }
     },
     "localname": "PurchaseOfAdditionalShares",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srzn_PurchasePricePerShareOfAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price per share of additional shares.",
        "label": "Purchase Price Per Share of Additional Shares",
        "terseLabel": "Purchase price of additional shares"
       }
      }
     },
     "localname": "PurchasePricePerShareOfAdditionalShares",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srzn_RecapitalizationNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization",
        "label": "Recapitalization Note [Abstract]"
       }
      }
     },
     "localname": "RecapitalizationNoteAbstract",
     "nsuri": "http://Consonance.com/20221231",
     "xbrltype": "stringItemType"
    },
    "srzn_RecapitalizationNoteDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for recapitalization.",
        "label": "Recapitalization Note Disclosure [Text Block]",
        "terseLabel": "Recapitalization"
       }
      }
     },
     "localname": "RecapitalizationNoteDisclosureTextBlock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/Recapitalization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srzn_ReclassificationToLiabilityForEarlyExercisedStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification to liability for early exercised stock options.",
        "label": "Reclassification To Liability For Early Exercised Stock Options",
        "terseLabel": "Reclassification to liability for early exercised stock options"
       }
      }
     },
     "localname": "ReclassificationToLiabilityForEarlyExercisedStockOptions",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of cash,cash equivalents and restricted cash to consolidated balance sheets abstract.",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash To Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Reconciliation Of Cash Cash Equivalents And Restricted Cash To Consolidated Balance Sheets Abstract"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashToConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "srzn_ReinsuranceRetentionsPolicyAmountRetained": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reinsurance Retentions Policy Amount Retained",
        "label": "Reinsurance Retentions Policy Amount Retained",
        "terseLabel": "Reinsurance Retention Policy Amount Retained"
       }
      }
     },
     "localname": "ReinsuranceRetentionsPolicyAmountRetained",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_RepurchaseAndCancellationOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase and cancellation of common stock",
        "label": "Repurchase and cancellation of common stock",
        "terseLabel": "Repurchase and cancellation of common stock (Share)"
       }
      }
     },
     "localname": "RepurchaseAndCancellationOfCommonStock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "srzn_RepurchaseOfEarlyExcercisedStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase of early excercised stock options.",
        "label": "Repurchase Of Early Excercised Stock Options",
        "negatedLabel": "Repurchase of early exercised stock options"
       }
      }
     },
     "localname": "RepurchaseOfEarlyExcercisedStockOptions",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_RepurchaseOfEarlyExercisedStockOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase of early exercised stock options.",
        "label": "Repurchase Of Early Exercised Stock Options Shares",
        "negatedLabel": "Repurchase of early exercised stock options, shares"
       }
      }
     },
     "localname": "RepurchaseOfEarlyExercisedStockOptionsShares",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "srzn_RestrictedStockAwardRSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Award R S A.",
        "label": "Restricted Stock Award R S A [Member]",
        "terseLabel": "RSA [Member]"
       }
      }
     },
     "localname": "RestrictedStockAwardRSAMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_RevenueRecognitionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue recognitions.",
        "label": "Revenue Recognitions [Policy Text Block]",
        "terseLabel": "Revenue Recognitions"
       }
      }
     },
     "localname": "RevenueRecognitionsPolicyTextBlock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srzn_ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental information related to operating leases.",
        "label": "Schedule Of Supplemental Information Related To Operating Leases Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Information Related to Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srzn_StanfordLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stanford License Agreements member.",
        "label": "Stanford License Agreements [Member]",
        "terseLabel": "Stanford License Agreements [Member]"
       }
      }
     },
     "localname": "StanfordLicenseAgreementsMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_StanfordMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stanford Member.",
        "label": "Stanford [Member]",
        "terseLabel": "Stanford [Member]"
       }
      }
     },
     "localname": "StanfordMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_StateTaxCreditCarryForwardsExpiration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State tax credit carry forwards expiration.",
        "label": "State Tax Credit Carry Forwards Expiration",
        "terseLabel": "Tax credit carry forwards expiration start year"
       }
      }
     },
     "localname": "StateTaxCreditCarryForwardsExpiration",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srzn_StockPriceToRedeemsWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Price to Redeems Warrants.",
        "label": "Stock Price to Redeems Warrants",
        "terseLabel": "Stock price to redeem warrants"
       }
      }
     },
     "localname": "StockPriceToRedeemsWarrants",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srzn_SuccessBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success-based milestone payments",
        "label": "Success-based milestone payments",
        "terseLabel": "Success-based milestone payments"
       }
      }
     },
     "localname": "SuccessBasedMilestonePayments",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_SurrozenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surrozen Inc Member.",
        "label": "Surrozen Inc [Member]",
        "terseLabel": "Surrozen Inc"
       }
      }
     },
     "localname": "SurrozenIncMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_TaxCreditCarryForwardsExpirationStartYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carry forwards expiration start year.",
        "label": "Tax Credit Carry Forwards Expiration Start Year",
        "terseLabel": "Tax credit carry forwards expiration start year"
       }
      }
     },
     "localname": "TaxCreditCarryForwardsExpirationStartYear",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "srzn_TransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price",
        "label": "Transaction price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "TransactionPrice",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_TwoThousandFifteenStockPlan1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen stock plan 1 [Member]",
        "label": "Two thousand fifteen stock plan 1 [Member]",
        "terseLabel": "2015 stock plan [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenStockPlan1Member",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_TwoThousandTwentyOneStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty One Equity Incentive Plan [Member]",
        "label": "Two Thousand Twenty One Equity Incentive Stock Plan [Member]",
        "terseLabel": "2021 Stock Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyOneStockPlanMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_UCSFLicenseAndOptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCSF License And Option Agreements Member.",
        "label": "U C S F License And Option Agreements [Member]",
        "terseLabel": "U C S F License And Option Agreements [Member]"
       }
      }
     },
     "localname": "UCSFLicenseAndOptionAgreementsMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_UnvestedCommonStockSharesSubjectToRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Common Stock Shares Subject To Repurchase.",
        "label": "Unvested Common Stock Shares Subject To Repurchase [Member]",
        "terseLabel": "Unvested common stock subject to repurchase [Member]"
       }
      }
     },
     "localname": "UnvestedCommonStockSharesSubjectToRepurchaseMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_UnvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "unvested member",
        "label": "unvested member"
       }
      }
     },
     "localname": "UnvestedMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront Payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_VestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "vested member",
        "label": "vested member"
       }
      }
     },
     "localname": "VestedMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srzn_VestingOfEarlyExercisesOfStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of early exercises of stock options.",
        "label": "Vesting Of Early Exercises Of Stock Options",
        "terseLabel": "Vesting of early exercises of stock options"
       }
      }
     },
     "localname": "VestingOfEarlyExercisesOfStockOptions",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_WarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability.",
        "label": "Warrant Liability",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantLiability",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets",
      "http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srzn_WarrantLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "warrant liability[Policy text block].",
        "label": "Warrant Liability Policy [Text Block]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "localname": "WarrantLiabilityPolicyTextBlock",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srzn_WarrantNoticePeriodPriorToRedemptionDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption Period.",
        "label": "Warrant Notice Period Prior To Redemption Date",
        "terseLabel": "Warrant Redemption Period"
       }
      }
     },
     "localname": "WarrantNoticePeriodPriorToRedemptionDate",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srzn_WarrantRedemptionConditionMinimumSharePriceScenarioOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Redemption Condition Minimum Share Price Scenario One",
        "label": "Warrant Redemption Condition Minimum Share Price Scenario One",
        "terseLabel": "Warrant Redemption Condition Minimum Share Price Scenario One"
       }
      }
     },
     "localname": "WarrantRedemptionConditionMinimumSharePriceScenarioOne",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srzn_WarrantRedemptionConditionMinimumSharePriceScenarioTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WarrantRedemptionConditionMinimumSharePriceScenarioTwo",
        "label": "Warrant Redemption Condition Minimum Share Price Scenario Two",
        "terseLabel": "Warrant Redemption Condition Minimum Share Price Scenario Two"
       }
      }
     },
     "localname": "WarrantRedemptionConditionMinimumSharePriceScenarioTwo",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srzn_WarrantToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant To Purchase Common Stock.",
        "label": "Warrant To Purchase Common Stock [Member]",
        "terseLabel": "Warrants To Purchase Common Stock [Member]"
       }
      }
     },
     "localname": "WarrantToPurchaseCommonStockMember",
     "nsuri": "http://Consonance.com/20221231",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "CALIFORNIA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r7",
      "r485"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent": {
     "auth_ref": [
      "r118",
      "r128"
     ],
     "calculation": {
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them.",
        "label": "Accrued Employee Benefits",
        "terseLabel": "Accrued payroll and related expenses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r118",
      "r128"
     ],
     "calculation": {
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "totalLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "auth_ref": [
      "r118",
      "r128"
     ],
     "calculation": {
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.",
        "label": "Accrued Professional Fees",
        "terseLabel": "Accrued professional service fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r57",
      "r141"
     ],
     "calculation": {
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r150",
      "r157",
      "r373",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r148",
      "r429",
      "r440",
      "r444"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r2",
      "r485"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r505",
      "r506",
      "r507",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Alternative Investment, Measurement Input"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of real estate property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r116",
      "r123",
      "r144",
      "r168",
      "r211",
      "r214",
      "r218",
      "r230",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r367",
      "r371",
      "r387",
      "r485",
      "r518",
      "r519",
      "r568"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r136",
      "r149",
      "r168",
      "r230",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r367",
      "r371",
      "r387",
      "r485",
      "r518",
      "r519",
      "r568"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains, Non-current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r50",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "verboseLabel": "Debt Securities, Available-for-sale, Current, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r50",
      "r139",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Fair Value, Non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r101",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r364",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r93",
      "r94",
      "r364",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Transaction costs allocated to warrants in connection with Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Transaction costs in Business Combination included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationPeriod": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Contract Cost, Amortization Period",
        "terseLabel": "Capitalized expenses, amortization period"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r138",
      "r463"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets",
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r37",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r495"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r31",
      "r36",
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r31",
      "r112"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r168",
      "r189",
      "r190",
      "r192",
      "r194",
      "r198",
      "r199",
      "r230",
      "r248",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r258",
      "r259",
      "r261",
      "r265",
      "r271",
      "r387",
      "r462",
      "r492",
      "r503",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/CommonStockWarrantsDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/CommonStockWarrantsDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Common stock warrants exercise price per share",
        "verboseLabel": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Common Stock Warrants Outstanding",
        "verboseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/CommonStockWarrantsDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r12",
      "r119",
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6 and Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r60",
      "r242",
      "r243",
      "r448",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r505",
      "r506",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockOtherValueOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Value, Outstanding",
        "terseLabel": "Common stock with the fair value"
       }
      }
     },
     "localname": "CommonStockOtherValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common shares, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r1",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r1",
      "r485"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 500,000 shares authorized as of December 31, 2022 and 2021; 30,088 and 35,034 shares issued and outstanding as of December 31, 2022 and 2021, respectively",
        "verboseLabel": "Common stock issued"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r18",
      "r153",
      "r155",
      "r161",
      "r425",
      "r431"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]",
        "verboseLabel": "Computer equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r122",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r234",
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "terseLabel": "Amortized Cost Current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r234",
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "terseLabel": "Amortized Cost, Non-current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r228",
      "r236",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less then 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r228",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Less then 12 Months, Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities by Security Type"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r227",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number Of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "negatedTotalLabel": "Total net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r91",
      "r552"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r91",
      "r552"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r89",
      "r91",
      "r552"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r91",
      "r552"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r91",
      "r552"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accrual and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r81",
      "r551"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r91",
      "r552"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 17.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r91",
      "r552"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails": {
       "order": 16.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Company's Contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/KPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r34",
      "r55"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsAdditionalInformationDetail",
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r102",
      "r103",
      "r105",
      "r106",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r297",
      "r328",
      "r329",
      "r331",
      "r336",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Plan"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r162",
      "r176",
      "r177",
      "r179",
      "r180",
      "r181",
      "r187",
      "r189",
      "r192",
      "r193",
      "r194",
      "r196",
      "r377",
      "r378",
      "r426",
      "r432",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r162",
      "r176",
      "r177",
      "r179",
      "r180",
      "r181",
      "r189",
      "r192",
      "r193",
      "r194",
      "r196",
      "r377",
      "r378",
      "r426",
      "r432",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common Stockholders, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r341"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r169",
      "r341",
      "r358"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r550",
      "r553"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r549",
      "r550"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r550",
      "r553"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r550",
      "r553"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r550",
      "r553"
     ],
     "calculation": {
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "terseLabel": "NOL and tax credits limited under 382"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options Outstanding [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r63",
      "r133",
      "r157",
      "r158",
      "r159",
      "r171",
      "r172",
      "r173",
      "r175",
      "r182",
      "r185",
      "r197",
      "r231",
      "r273",
      "r332",
      "r333",
      "r334",
      "r354",
      "r355",
      "r376",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r407",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r34",
      "r62"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails",
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r379",
      "r380",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails",
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails",
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r107",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMarketableSecuritiesBySecurityTypeDetails",
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r257",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r380",
      "r417",
      "r418",
      "r419",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r379",
      "r380",
      "r382",
      "r383",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r257",
      "r278",
      "r283",
      "r380",
      "r417",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r257",
      "r278",
      "r283",
      "r380",
      "r418",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r257",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r380",
      "r419",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r109",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Fair Value of Warrant Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in fair value upon remeasurement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "terseLabel": "Transfers of financial instruments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r257",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r417",
      "r418",
      "r419",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r384",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "auth_ref": [
      "r107",
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementSummaryOfChangesInFairValueOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and office equipment [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r142",
      "r237",
      "r423",
      "r469",
      "r485",
      "r513",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r169",
      "r342",
      "r346",
      "r352",
      "r356",
      "r359",
      "r361",
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income Tax Examination, Description",
        "terseLabel": "Uncertain income tax position, Description"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r170",
      "r184",
      "r185",
      "r210",
      "r340",
      "r357",
      "r360",
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r156",
      "r338",
      "r339",
      "r346",
      "r347",
      "r351",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r500",
      "r565"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Investment Income, Amortization of Premium",
        "terseLabel": "Amortization of premium on marketable securities, net"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r23",
      "r209"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Year ending December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Year ending December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Year ending December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r168",
      "r230",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r368",
      "r371",
      "r372",
      "r387",
      "r466",
      "r518",
      "r568",
      "r569"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r6",
      "r117",
      "r125",
      "r485",
      "r504",
      "r511",
      "r561"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r137",
      "r168",
      "r230",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r368",
      "r371",
      "r372",
      "r387",
      "r485",
      "r518",
      "r568",
      "r569"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities(2):"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend Yield",
        "verboseLabel": "Measurement Input, Expected Dividend Rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected Term (Years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r200",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/OrganizationAndBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r31",
      "r32",
      "r35"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in Operation",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows",
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r20",
      "r35",
      "r120",
      "r129",
      "r135",
      "r151",
      "r154",
      "r159",
      "r168",
      "r174",
      "r176",
      "r177",
      "r179",
      "r180",
      "r184",
      "r185",
      "r191",
      "r211",
      "r213",
      "r217",
      "r219",
      "r230",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r378",
      "r387",
      "r467",
      "r518"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r211",
      "r213",
      "r217",
      "r219",
      "r467"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesSummaryOfLesseeOperatingLeaseLiabilityMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, noncurrent portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r399",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities (in thousands)"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r501"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r404",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r403",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/LeasesScheduleOfSupplementalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r118",
      "r128"
     ],
     "calculation": {
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r63",
      "r152",
      "r155",
      "r160",
      "r388",
      "r393",
      "r394",
      "r424",
      "r430",
      "r497",
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r118",
      "r128"
     ],
     "calculation": {
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred for employer-related costs classified as other.",
        "label": "Other Employee-related Liabilities",
        "terseLabel": "Liability for early exercised stock options"
       }
      }
     },
     "localname": "OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]",
        "terseLabel": "Lab Equipment [Member]"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale",
        "terseLabel": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase and cancelation of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows",
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "negatedTerseLabel": "Repurchase of warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Common stock purchase commitment"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r163",
      "r554",
      "r555",
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r277",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "401(K) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r0",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r0",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r0",
      "r485"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 10,000 shares authorized; no shares issued and outstanding as of December 31, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows",
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of units upon PIPE Financing"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r135",
      "r151",
      "r154",
      "r164",
      "r168",
      "r174",
      "r184",
      "r185",
      "r211",
      "r213",
      "r217",
      "r219",
      "r230",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r366",
      "r369",
      "r370",
      "r378",
      "r387",
      "r427",
      "r467",
      "r482",
      "r483",
      "r499",
      "r518"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows",
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r56",
      "r140"
     ],
     "calculation": {
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r58",
      "r126",
      "r428",
      "r485"
     ],
     "calculation": {
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r131",
      "r410",
      "r411",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r408",
      "r409",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r78",
      "r130",
      "r576"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r493",
      "r502",
      "r577",
      "r579"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r41",
      "r138"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r446",
      "r494",
      "r502"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets",
      "http://Consonance.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Workforce reduction"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r34",
      "r240",
      "r241",
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r3",
      "r64",
      "r124",
      "r439",
      "r444",
      "r485"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets",
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r133",
      "r171",
      "r172",
      "r173",
      "r175",
      "r182",
      "r185",
      "r231",
      "r332",
      "r333",
      "r334",
      "r354",
      "r355",
      "r376",
      "r435",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r207",
      "r208",
      "r212",
      "r215",
      "r216",
      "r220",
      "r221",
      "r223",
      "r274",
      "r275",
      "r422"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Collaboration and license revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock, consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "auth_ref": [
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.",
        "label": "Sale of Stock, Description of Transaction",
        "terseLabel": "Description of common stock closing sale transaction"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails",
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails",
      "http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sole discretion purchase common stock"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfIndividualSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate TO Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSA Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r69",
      "r70",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r66",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Unrealized Loss on Investments [Table Text Block]",
        "terseLabel": "Schedule Of Unrealized Loss On Investments"
       }
      }
     },
     "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares RSAs, unvested, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value RSAs, Unvested Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value RSAs, Unvested Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares RSAs, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of RSAs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value RSAs, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfStockBasedCompensationExpensesDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of Options outstanding and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Options outstanding and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Options Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options Outstanding Ending Balance",
        "periodStartLabel": "Number of Options Outstanding Beginning Balance",
        "terseLabel": "Stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the weighted average exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Plan Modification, Description and Terms",
        "terseLabel": "Description of modification of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfRsaActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r301",
      "r320",
      "r321",
      "r322",
      "r323",
      "r326",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Issuance of common stock Per Share",
        "verboseLabel": "Common stock per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life (In Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value/shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, exercisable (In Years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanSummaryOfStockOptionActivityForCompanysStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r42",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r168",
      "r189",
      "r190",
      "r192",
      "r194",
      "r198",
      "r199",
      "r230",
      "r248",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r258",
      "r259",
      "r261",
      "r265",
      "r271",
      "r387",
      "r462",
      "r492",
      "r503",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://Consonance.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r63",
      "r133",
      "r157",
      "r158",
      "r159",
      "r171",
      "r172",
      "r173",
      "r175",
      "r182",
      "r185",
      "r197",
      "r231",
      "r273",
      "r332",
      "r333",
      "r334",
      "r354",
      "r355",
      "r376",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r407",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r197",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CollaborationAndLicenseAgreementAdditionalInformationDetails",
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://Consonance.com/role/LicenseAgreementsAdditionalInformationDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r0",
      "r1",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock upon Business Combination and PIPE Financing, net of issuance costs and warrant liabilities, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r0",
      "r1",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (Share)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r0",
      "r1",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of Series C redeemable convertible preferred stock, net of issuance costs, shares",
        "verboseLabel": "Share issued, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails",
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r0",
      "r1",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Restricted stock forfeited, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Restricted stock granted, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r0",
      "r1",
      "r63",
      "r64",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercises of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r14",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs and warrant liabilities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r0",
      "r1",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r0",
      "r1",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Repurchase of warrants or repurchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r0",
      "r1",
      "r64",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercises of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanScheduleOfWeightedAverageAssumptionsUsedToEstimateFairValueOfOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock or Unit Option Plan Expense",
        "terseLabel": "Incremental expense"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r0",
      "r1",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Share repurchased, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r1",
      "r4",
      "r5",
      "r48",
      "r485",
      "r504",
      "r511",
      "r561"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets",
      "http://Consonance.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r167",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r273",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r395",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r395",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r395",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails",
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r395",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails",
      "http://Consonance.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails",
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails",
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails",
      "http://Consonance.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/OrganizationAndBusinessAdditionalInformationDetails",
      "http://Consonance.com/role/RecapitalizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r83",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carry forward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government agency debt securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r337",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of the year",
        "periodStartLabel": "Balance at beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions based on tax positions of prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesSummaryOfTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r201",
      "r202",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net valuation allowance increased"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/StockBasedCompensationPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Common Stock Warrants Fair Value"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Common Stock Warrants Expiration Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/CommonStockWarrantsAdditionalInformationDetails",
      "http://Consonance.com/role/CommonStockWarrantsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants, Measurement Input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/FairValueMeasurementScheduleOfMeasurementOfPipeWarrantsWithBinomialLatticeModelDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r188",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r187",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://Consonance.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "https://asc.fasb.org/topic&trid=2208923",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r489": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r491": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131251-203054",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>104
<FILENAME>0001193125-23-086961-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-086961-xbrl.zip
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M,,4E8P8#IKCI'+$<8(I+QA9:1FLNVFPL:I>)U)X3?4_"1I/V17&+-I1 FX9
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M&>F;\S39/Z%!?ZB!TET[_+!7->;S",P"/-2^#^"[TT<1MMV(CKC?X2P O9W
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MM7I]O[;__L,S^3CK9Y23SZ]/)ZCI2NT>Q^)%!BSC=[??%XX+WWEHG[E!J"0
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M1!<!!E5M@5I690 W\IL(N[!JMTG+>A,54)%;P@L>9ERILY"+T8%E]!U1#^^
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M_UR5\H6T!R/5"_GRWL7B<!0SA%75:GB;1M4W04AUD5N)E#7U &\6L)05.V*
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MGSPU6]K4C1O]M,YXAC+P8D>)3RTICU(;/;M-FY[(A$V:XX1API+PR9-)2H5
ME4L/Y'B['/.SV'RCD@;<T*$D>XQY[=L_54IS]9O?3A:Y*YU>T#3I!6N67E!5
MNOW%3R I/,HR<I1PP 2 :!YYD34KS3[*17A:A!0EX2@X:^WEC^(Q"Y'-0"W)
M-'/E["L63$>#T/5DUNQ[E37;XK B7H@LS:JF)\QB@T*BUJLMC<QC'26+MDQP
MG9S=]6J#IN3;_,C+4YFS(T094GH*;]"FX^L54OXKL_%X,G-+D'TC<]WM*?H,
MQ3:FZ#JJMV(>)64YJG&ZA S@2]4E3;H_R3*, \Q!?/5UM<ZOK_)KFU]S2AK@
M:%ZP91)0<=LI,%LMETD.T[P";:LE0DED=2*R^JM-\N3K\<4H]WX5/B5T'6N9
MW!?V0V7&]NL-7R>5$BG$>3YI_(6VI2!I0<$A,$B]CT(K2IJVL_1Y/;4]I=<
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M"7IGTSX+MEK^%:^WK*Q'5Z_E;JV^CR33T$B&,_ =A4/4A\44+!,+,TM\5 5
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MACX-?<[5)F\T]FOU@V9E%2B@N2FE:4FA(96FAW'I(AQQ;,%#Q<IJ^3)8DRK
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M''UA6O>=W/#M8""8@S!DM2+7R9"N(=TY"WWAAX'GR3KR'-^<1A=@5+LA0$.
M"R# GMN=(CK&"8/!=I#$*>* *DPV0JN&, UASH4P,X"9%-X_M.!O<B>675*1
M7ASXC"@8IG&86NDDZ@>/_$SYS0($9&$:<]P;HEZ@IMH3?0RR&([&E3LJIY<L
MJ^-OQS6KW;,]Q)X0HTEGHT]',"_\G SP<L\+N@C#7GHW#?8:AV3#GD:$,RC9
MJH:7@RJT>30.1>8VX+4DWQZW[!BO@*TDDIEWAFL,URR :[H8'RS";<3_W\[*
M-Q;#+?E&W5"=H;KY.+,#5=JV/901>(QCIX/?ETA8&<9MA*$ART609>)W8 G9
M_3O)O847'Q1]E$5/W[OPJE+?;%A0*B(P PW5&JJ=IY_+SB)251C<1-_#\=4_
MSD^V&X?*]P#_(FQYDLF<1U/4CK%?U<R0L"'AN9"P"IX%NN4" U,F)G-)$'9E
M>,,TYXE2KR1*DA:-2&+Z@B%)K2/0?"D(Q!"Q(>)Y$W&Q9*>"9L6;7PJ@4N'_
MV54P>N$DOEBJ:^0@9G,5;/M"Q!(\3/6-6$%!RY-)!1&C/LET#X83XWMEBOXW
M1&^(?J[*!_K8>C;YTP@EN92&:V#S>8@&P ]T$]@!JH3S"2G34*2AR#E0Y+2Q
M"52J;Q!*V ],/,8,[]0#JVIBNK'E!%.51UEX H>>X*<*0T^-#**A",HLV2RH
M?!QN2P7VV2E8!Y@QP:F<LXV$0Z6BLOAV"2ZD!B:S-.@FB5.A:JJX*L4=:I%;
M _A(">C!($523W-W"'$DLEIA8",  H,#</H_9TUC1$J8%7U5L!0P9N%Q^(JM
MP5;K@&N8>8\=Z*FO8(7!'^UT;)Q_:CW8(6;3,D3DS*LV"GL_"*)X.X.N45F*
M.:U!KUA9LMY+F-V]N&2AV1[0,)08PV%8F50DR2.B+>#[&LX331.NGIB17,M#
M2K0$);[*S:/$&;VR.HBL>Q>_?D7P3IRPEGBK2CSP"BT7_)EZ1L(V#@B\+$H3
MIB7NIIX@B,* $ . "'K"&R!45Z<0YYQW92ODCWB(2>%8S<'&Q.L:0DCU")=K
M83/$=<Q /'INBW#!*74QM+LR&(I2-]!2\&''M 3[&+&*JXFW+_3ER<A=H=72
MV9J6HJ ?TYM3?,T0V*1/#R:^!*;T,0R\4$$Z[.,*8]I9#:5VU L>?!5^N,JI
M>DV3JK?LJ7HY"![TZ3\A0V(4)2#3P0@MA(\*#;70EGH8K;0Z9M+\<"TS?IJ:
M4P0HM(2G:2''?W+*KD7 >GP ZD("$[Q1N(Z<@HG/YR"#26#WV*\[8#0$#5+.
M<^,8FR$J@@^G+<%A%S&T6164X!MDXS**3M!.9.$?F;%/WDA.<QG*NC_J_!N.
MP)6QJ$S+(%2"]:PEH%T^%5T#OI3)2@KW"6&T(J&*PRB;YW<_UH_<"$&G8G+\
M(HD@D#9FP*KM+@5=>"T-Z<CZ"0<KB P=;(&/UNZ0-,C99YSJ6!J)X0(HN'!\
MS>^,QST2L82*#?QM=>PVQB:I$SX4 ]NE#M]1QJ0$LI:Y)X[=AR,'2SEB]C)G
M9++U%1'0):-Q,F DL%3H"@XK)! YH0PX1'E02I#$6R_'$=>(@93M/%BY@MFH
M9+1I,;9>WJ1@]T0F $NA.#5A7[*!.A=)29CI4#F*D3CB)0@0*<GX0YT5RY@&
ML7Q3T@-J%?>!=Z^BY%37H(G@+F+ &\* Q%*<I@CWDW@3.T9EW"5+1G,T,/R*
M+BO2/A&(?GRO[%D8M]BIFN\B;R/&7TY&21S8CIX)G*.S4,-[)ZBC40!!/=6Q
M<%_;$A080"HN; H1>>)K'<7!(R5%9HXM.(Q0R09VBVB+I9."W"(9(M50PMUY
M[D\\6O@436'3>,X,X\->H<RAD$%](2M/ZU<+LC(5RJG$D_#;L)U73]&K1N,?
M9^+JF4TGG;%QFWP_2"BW%@9R"5*&JKTTZ\UF32H),*( \Z-0:!:@&>1Y-"K/
M,SXJPR34P>0R-,&@##,RJSQ0!H8])12SCLVKR8:4HM4S"@Y8BEW6V990PTB/
ME@<=YQ.VP"-D.XDAGIGM 0&$);[+4$%H$DM  (7T-$9@4(UC%M(Y%/)4Y\>K
M08*-5Y*%]5.P!1[*^JV4,82/I94;8C#LE Q&7J.#&DP\9E(<:J;IEBB6Z1+.
MJZE-:C=M'?BR $*O] 2B8];.)1 :@I+Z(S&M4<'IJF&LR,J;+CM42W9HNN-;
MT89 NX*J<B VRV0-4"DSM1P3IV\JX$N*/':%%.PM,0P*=P3E(>N$$$QJ&J+H
M:OF>!.?LYU6X7$8_4E\!2!<$$4A"0@6XST#SJ(P+G&L(#*!I:G+#:I(MN026
M6DVY)/@>!>">9I04U#N-BZ+IA+RK2M/".U.@?%75F?'7)0OAH+!_]_^S]ZY-
M<AM)MN#W-=O_D'9MQJS;#%57E-2OT=X/;$KJYG1K*!-;5[;[#96)K$03">0
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M$0E/;I#2U\=_S:^98 ^'J<BMS)*4/X3E6PE(YQ(5P:GK<3G$(8OQ_I2R:UU
M$.NNI3F-R$86*R.L?BGG+WF4G!;<G%'X?M-QQ\L+PVAJ#D;G!]-]GR^RJ#]8
M\-9+F?<7H05F TQR:A11;/KR5ARS#QZ]?Z("546U3/>72X=L,<]',4^9@\%,
M$_@T-QRPK9&?I%8H(@STMQ2L^W^E!%90+Y5<0P_1Q5074WV<AED<ZTR$WL1^
M0TC>B6#+<>?IU-6=6KO7VS1_U&O$AW\D((VCO74?1TLC)- AM!%IB*K;+A:^
M6/@C.V.G-KBEZ),&)/\9DA]#R))=PN)K3;+6]4V-4LZZI_$N2N*J\/\IVE@,
M=#'0#QW,JEX32I!*X1_,T@#;D"41.6(N!E/]#NOUV5=73;E^M[KJ?L:?7WRE
M"'#F3&"I[5@D7>QYL>>/9<^)E$.B^RJH 2W(<M,9<K2+QUTL](/F9VN0R 3/
M^%VE/G'U%U)U7W7CD0J_TEL!L$OX9;*>TC873UY2ML5Z/X#UNNZN]&!W5;-!
M3U%4O8C[5ZO&BQ$N1OAA0."1O4W4O!N67&)]@/JF6L#=B\T]FLUQ2^DP\DPK
MS(X5.M\3/?UD,K'<_2>EY$3X*P;#V['=,+!Z<P/>HPP2,T<1MKU;5-5HL=:D
M_'?,D0O*^P;,!JUFO4:/FN]$X/1-)I&7"FWFVDGOWRU]*@3O/Z;R6U=U=Z"S
MLUQC'>=IV>I!B0$O, A  A ?6*#:05\>TGY6^U$&/8][N1/L<OL^5NIHC]TR
M%J[I7:1UX"(C0F(2,##6$MZ#H;D"($+HXN_ ?E9-[QZ[__ OPPGGS:OJZ6IJ
MWNM;ZO8X5(BII;GN'RT^"?71][\2=6D/:3_W:W"6?@4(Q$//KC"^<]K'GH_N
M@?9X^4E#M'^W0+0_.D3[UYT'.8CQT-=[QCTS9JUB9^? +.I@(Z7D=D6;G6I8
M53@%Q:G]&/9<(Q#(\*LKAN(2GM#@;>[PG2=*G(<>@^.P@K[F+7!5L</!S(GS
M]WL8KQJB;Z5+UC?T^W+7G4B>#S3)<754L!Z!"Z-T#!]^*R,FCAO;S21?]\S-
M',^K8)8AFNCT7AQ/,,9$V]I3GD;-3%927JM(<+OZMKKJ0QAS$MEB>NZ66^3A
M..X([Q;N:T?0XO*ZKRJ;D"ZUF,@!)$LVN<_@AOX>'J9KVM7WX:1:O9(G_38X
MZV+U][^_ BNZ_TC!/,CDT<-/,ZI*S8>K1>%'&$1*X1?]51>6GBG<"TA25@VX
MAM.KTOTFMP+&3WQ14GI]QO% ?_R7WWUV^1E[NF#<C>/(H.BL(Z?>K=_);!69
M( 'VZ'_IA865N=?S?_'[BW"9XTY=/Z/U"M]54]!RIKOJ>&B,&3>39E:XG,-Q
M*YH-QR1N.UF.*Z'0EH^YWRB23G:AAZ]T200+%[ZVJ;8EP=Z24_Q&"*$3CAPD
MNU.30@#-I1C\?(Y<Y1M,[MJ_M_S=(()D 5UZ4S1B'<+3OCMP6 :D^LS2P7R&
M$+/R)%;R<TS?3RM*8U80&!Z\HR&B77#\A7B/^O.TIVS#8ZM]'?[>*81/MQJ[
MIVP/_66\#GXMG#O[U5OS@G'_Q'\N6)2@;:MUQ(.'B^ZJ9IMN5NMT$1;A6Y(:
MOS]6N; X95LW_"JSYZ'1M6$8%3Y+:Y7O&-E>GW^1;Z\1VH9D&_?>R;T?*(\7
MX4+2!TEG7\TC&\@^P=@/72/X>C8!L$7XV[>[S-[4Y>HO-1$,TS_==(1'AMV*
MN:N+YSL:"L_M>\51K782=0N7I 4FIXA^78\;G'P?:YE^$HDT($DH4BHXG<'\
M0X^BO!PQ2L.]A9OA G_)!2UVX"#09"APS^N]+6^Z7I]Y' IN49' 1@IT=V?N
M-=99EV3-4[5U>\^$\0>!./]DG8^Q35_<)+]CPG;L=M[KW%]6\\$'RKXG])K\
MN?6+0ROG)$28A-\YQS._*G<7X<0\<L+8YQA)W';A7]&1N6ZZJ_ 755C6;A^"
MA>SLD=E^&DWE^*?CHS6Q>-:/6(?76!^S"06Q?]T6/[; X;\].L;QKF\V(="M
MPO[<\7%*/I?O.T*U]=Q)I],-FI(@[AE"'6G82H6H;%<_7KZ]Y%L,=AV^Y *N
M 3<0?PH1CWPSQWGSI !)8-< &.XJ.L/"WMWH_)FNAB-4H(B0$C0FC"4[#EDI
M><MV2PCV=95^P%X)4^0C2B0!;?[7L:WVAZ8[P:7W<3G'5J((NH^K+H1-=IUP
M!/"-X*0$5)^]C;M??5^;BN#I%&H2#_I1!E7><801#SN$N#1WQ1>RLX\GDC<U
MG920P,"?B;Y!\.[R[\UX1.WGHX\J0!L="NKG][%Z''K?\<R7,*#@R6L* 1M:
MFG $0[>=FI;P>FXP43R=' 'L&;O,9C&D':+!-25!5^7Z'39_V'JQO#&MMB6"
M6?6!,"UQ+N)L(4$':HFZ -X>H9'UQ'Q/=ZBJ=R[M(,7B7*/"?A?[)5C''54U
MZ"2%>VIJ)"@E@+OAKZ(6YJW>11SD\(MJ1PD:)<Y=TE7VE"JX:UU5K@"+8R;<
M9WBV81>%"Z!+,K:9X^7I"TYO1$SA%SQNW=IVNN6YV6KRI%A@CFHIC$K>;[^:
M$IUW1$?5W#S%%-<;4P"QG>%3 SLN9 QIB\$E2><DKZY^KGD@V*E*TL$($90\
MU::]<D-.)MTH2&5NI?;.U^7#$=E5^ #F=>E'&EK,@:]Q50H,MPT/A(REO>[D
M3N8W24QKUEU_Z%@)@]@5I"2A&D3(GJKVFG+QK50GY.2X$7FP;#+:J="?_?7Y
M9D7(86GTN3E%-U],'1D-7=-XD9Y]HT4'>3T5>(OLF2/7>;6YGW??+<@_(HD_
MK@,_J5Y*WFOX-WIE%&*,O<YSBJ0$YN0:FM!:IIJ6_N:O4Y$0(J(0;/,LGJ^7
M)W7R;,\]0\(95UZYOW&UX%.6O?2A]]*9./1L)W&QR<4F'Y4XLQ*39 K-X=B/
M:T952%"(<7Z)A:0\BZ 1]"Z.Y)41_ !@:8^=ILG!K69_,:&]H';K::;9:A/=
M' E34-LLH.O%^A_3^L/?5;Y1AMW *;G:6T(N,%C-:+5A@$3=;IDZ@Y*B [ET
MQ.%H,U&.K[2"KLJZ6/!BP8]FP<*" @^Y#DGAG<&Y:77>5M":W52Q5'+6*C]1
ML,OO%[#+8X!=%G?R?XP[F?#AUH <)/A9*?(RIF&^TI9H?7/U+!@0%8FI5)A"
M;I:C<+'=QQS_.)M3J]PUV,+ZJ I_NZ/B-_>14DBY:S0G-JN*V6>*W-:.7DQ[
M,>U',VWFZ:_;&V)8!&Z(\W"!L+.CQA^J-ACZ6LM,FVHKO9M#>;2F$E<_:5*@
M:2IN9X2]<Z@HA^<FW6*\B_$^FO%&Y,FN*IO@=*M#6-H]E30S],EB=HO9/:K/
MY!C4A-!GR"\7N9_%[AXWA=)0$V#%'<\\* B#RMVGX5A)=K3+N4>J?B#L<9.,
M)NE?>FC'';BE;.1K"#\\;$\,&C"@_\#$/#)UP=,.IV<B^G,&2.8@8PJ7 8\O
M06FK37&_R(Y&[C,4L$K 3Y.6="T_*Z=0W10UL^\VM:ZJ>[N'IG1#!<"!*3R-
MX8Q O0Q#=11X(=#.93,"S*13!\H@SQ^D<$^_+!SIFWH8NH8I/2+W0G*#37<+
MG'79QM\@&N!MPU!.2>SC.D7JIF<H-/2325>@$K%))A<C%H:H@L,O!2-8X[/5
MP5X\#6VNZP/#>-R@,:YH0X@;O832 E*M;Z@JYK% 9OA4P\'OMP1'@>:#QQS4
MG8?P#S4]AB+G"7(;Q[U RKVMCS#>30=L>9S>"H<$9JF323#U.#(1UJ_Z[L1<
M=/SO4BS:&"WT':N*L3&&9BONME%^]A'#:KX,A7[E0\:.^SA62I(;5?"]M+T5
MCK6=Q01RNU$Q94"C4@^'E)U^\B-M?E"6S<CY\LD;.?_L.GUW;NYV9CY=\,9
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ML'5<;E/NPT^&5T_%7A;WVO8TA#NN&2&C;R/A$DE+T(^U^3KAJS8DIKZV:I,
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M,=J.DA53C\N0G3)F3Y178Z$@Y5*^JMQTH<YI191ED1F<&Y0&4< #C$[K4YJ
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M;1\3B& Z K+I@.HUI1U%0;#A)H2E3]E,C2H-"=)J_ID<P4JJ[J#+2HC.MX(
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M163T2FK/ /0X,&(/DP?H85:W(#8.27(1<AK$7'.;\5>^,CW#=85.SE*9 5(
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M;8YOK%T4QVX7#\ R%G;C? [E#[<-B1,J7_+:#G5O[2?5^;81E.N>C$K4>G%
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MOL()Y&G8/NC6ML=;_/IX/?A7N^XVU>HW>L#>U/VHM)@A==E3:<<".WN9(>'
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MPRD ?H5DR-&J-UG]]>QQ$M?FS%BDDL):'35-1Z3%A:K-(0Y"&J&4KC/&C=9
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M"X]FD.8;H:)I#)>2(%9([Z4B1_IKNE"3]QXE5/@3KF2Z'TVM9MI_L9I/A)U
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M%AO78AYIU"W%TJ:)I2WYS73YP%2)-HTB7NX;](P-:KN+V5[,]FQF>UH>EO)
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MLCL$C U-QYEH!%_"K7?F+4SNQ.HG*@D7 [BAJ53!$(H,/+TYNM#K5N$(],V
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M=YNWLXC-9E[)@O)$@APKA:G$BQECH!T2W8,4/*;QZZ->B*%3.>V5/$< ^B>
M?&<S1<7<?&) .%]O#A->3";SCX#$'T1FU7;)V$L2UP%:$'D;0M/\*8'F)?))
M=TR5E!M #C@JM(=W_CSQ:[F&R4+(0K!H(8- 9L2+F&>'^Z3% RIW7HE-Z],T
MXT\\"W"[P#6^8O<])[MAY=\Z)5)P\[W<DR#N6L24$AN:#Q9 B40S4\2,EP^^
M\/UK\$.MH/L-&5/NZU&1E$["#Y #0B[&5Y&4Q2Q ,7W2 E7G<!=XNW ^ FI
MGK ]E#5TH+6_7 0;Q0]7#=,-%[E,=S+U)W[ >H^VP4%FJ >79!)KR'Y@O&[M
M>G_R[BWIY7V+6,"<(AU#7%,<J@&NA:TRGT/<X_6^Y],-*\-??Z?OYA_\NR_U
M=Z]Y@^*%7WPW!7^'.HD%?W.'Z51 ]M.!K*_UF2W/2PJYGE"&Y #7C\%;FT"
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MH8!-&:0DD D0.K^6=R0?04*?YDRIAFQ"W4\WJ;9(HS12>)+OW*GH _G]1&.
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MWFI7_E43=.E!%ZEFANR)R:7\X/2>N"\8KD> 4'N%OAK&<,A!O1#0G*XW>_
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MR]Z0,<Q369(M@W"]>ZH)PQ]HOPTL<A"TAO.QE)V&>P!)J2&8Y;^Q"3706]3
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M3O0I!T@F*$.9^)JV_Z0Y;J@$,Y1Z6=P;38'==.T==#MB,4.>^,*Q7FY<9>9
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M" PUL(9,]U,BV8HC\3L:SHJ9PFF].TV9+I#52XWD$362L4$%'WS;FZHAIGO
M*]EHE#1R$)M-C(-[XAL%<8,U<%)&6YMV%U?\R;>L00L!#BZ(D!D\?MJ$W,?X
M/ZTI7NJ)E[URIGKBWWYX&7A=9[)EFL[%Y)K'D%%P?"BQ%H#<L7 <3GGD*+9'
MH>)J8 (A.DR)L+5,-MFE(W6Q[//TG+4PE"D?*74%#$1?3/!B@I_$!%$ZDACX
M6:T1XFBK=H^, B1/RUQBD'R_^OE-KHX$#''"54[?]/Z3Z<N(,,$P5H0*9.-N
M6G&XDN[< D.*25AA4&_7HEH/9K/^3H_>Q&6+7+;(F;TT2%14P\BA!2BB^:LL
MV[);8^+[^N?OJ1CN4_X52OA!/.&(_>;'5T5P[3ZN1T'9C-U>S/9BMF?R[*MN
MK 8"B53TUK6&@LDDW&"UY][,)<*XV.$GL4.I@(OI:9<RM3C4'R(9 J3>:?OA
M:H 9?(Q*[B_]XGSYU;B_U!\N!GQ. \X%EU!0YFH[B<?@/P'Y0;MJT9+77;MG
MD32F8KZXU8M5GL\J:>E]YG0WD_TP@=+%U"ZF]I&F%O,A0C/9QXUP)O\3^']9
M^WDS)_6V8>FPJIFVM"\&>C'0,QCHWZ@S#D)HB(:##OF*.8]!EJK!2E&J)BO\
M[-^_GJTA$9%_/[)D'PTC$Y3.WV-]4#"=L#PFK6[_2:0/JUU\6R0.4#7 V2MU
M-Y% 87!7U6D!81U-]%B0*A(R(6_WIAZQ4"QR*!7HAM$$M>MP8L?_ZW- 5O_B
M&#7M;Q>FD5RG( 8$JR'Z 1.&[:'W?@; EN&C8P.$LRA%BU46@+K P&,/2FOM
MBF D6*PDU$"4>4P]$$)I'H9%0@BA&QE:IW>K.F6:L7#_ED >1OXN!QH2$,WU
M@DVYF&9'*CK0XU _3DT2-R,^]/+@O2S+?5LSIUKLZY^_5TY04\7J@W@'#Y*0
MV8).NB,A5+1OIM5<_ #=M'?T #^U#4S*P:>^AQ(8#73I55APY-3F'0.-K*XA
M'#GX  %^(3!@HGS%5T,D2]%*981-S*]&K3^F"-$+2 2/OTK%;A%MG/R,D7-M
M.^,U'O+8D68)OAS5N$PZC]NV]B]AA.D[UP-Q"=L1FS]@5WCL +62"+/<%W;)
M+*BW]"^X<1N1C2?6P])G+>,-DT#[I!K19(MEA600JX+9K-%H(E)ZRTJ.-^*-
MLA)2-V8^[TG-A7!D2MPN:@C,X5LUH\LLM9 C!N23 3[AQQGNA*M6V)TA?X43
MRLG[4\3KPR&)A?RL#"L&G15_/=P%4P2T@*@ J@<[2O@6#9&Q</_JMSN8.AF=
M&;&<PZH')%-"Q0T/&99K#AEFP5E^PP'VR;$WZ5$\&O0C;8B7 O:UN"V#%O"7
MO[IV[WT#$.]/*)NYM2G7 Y [BWC*(O##6Y%FN*D5O:L5(T,M/27<1T)1>3:1
MYFA1=Z71C29'9? Z:(),] "N')??&"L^N4@<1<:;!: BU3OXB1V1+ J%!&%1
M&S;F7 _Y4<;]1<M/_O'K"P3\.4/ 'R]&'NGCLM0LTJ$3?Z._8I/= QB$EU8T
M)[I2+ ]R,C+N=$$8AL4][ O?OOC&$'"<N&F?8H[L&2Z8:C2>$,Z7W0PD83;
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M,Y/PXJ&_FXL#GTB0' ][?#(J?+ [I/4-&JIX+-!A:P(+2,=GPMU@_/"//XX
M;O!KZC_%Z0DMPHQIOX[H$36(@3* 7=>YU0RL16S3O?/^ J*P*4=2+^'1OB;-
MWN#_X!]@4"AYR=8'?MG=C&\NW8S/WLWX.%ZUS^'\;L82)("=FWC I#^"X>U\
ME(I0"0A2)QN4E*U*S=;:+C0QC_O5W(T'\L? JQ<"M)F:I,8"XD$ 'F,+#HYS
M(0.V^/&GEZ2.W.>XUA!1D2%00S8=(F.8P6G,'?'DPC!"HU\A^$)2XM=;*>)J
M_&S]C#PVT-1JZ'.]>!FMRWH$)6T<DJ0@*;XOJ8]5S2W I>*HD.+DJ"3#A1&J
ML/1FQI(#D;9WV6,D*H.&L?L<N5&;P<?UD[]2Q-&L(8F2)<ZH1M+KF;>6+^AP
MMR!>LG8<$#J3><:,U=";7TH.S?PQ4;0K?8=*U<*CSPKY-6YA>RMX@\C9L2I[
MP9I ?.V4SC^<\SZY\ODZ7C ^=J<*\2>%C)\DE0E.\4CL;XYY(U-_7X8C"2<*
M!$ <88H&5-LL0C6XDA27*IS<Z:"_T-*JK:FRCCLM*N_8-+J1;H[9JJ^U0(.B
M?]T LO#^;^[:[@,_EO>K@=*0PYK$$<8-I89J@81I"O3H4E+K">ZJ%2:@B@:'
ME@FG""5(=1Z)W>3\\(G&N)H!)_FX 4M3B'D9:[D%4UZ9/\YB[-,S3%JD@Q3\
M3R+UE>.#G'E8\23LWB-G<KWX>WOG-">,&SUB[/#B_9MR=(ZQR"KZ.]. ,(C-
M(N X5UBR0P8Z0WE5E\T$)A:7; R*"MY1(N#Z-*G/])VD7&A2O'C$R\F\F2BZ
MN)O\^-LMK.V+)^"1>XD2N=XMX@5@A?[3[T7_WSXJJ$&@ZV:KUH3MGM16YD_9
M8Z<>L4!@)T(ZWWC)I*VE_H_K:=PK"0*1_K;P3,/CC*4GPKUI'S -#CHYYUB>
MVW54LX%++DOHS6W:+A?GY0,562!58K(1FR77YY"4?@* R'R#>,ME#4')V-00
MF?Z^^@,EAA0@T0>ZR/]R%0F1"J%DCN\1_VX'?22,F*#$M'+?^8N&JSJ-GNY<
MIXU(6EE=+Y 1[(?JA@7'-Z(3_E]N+3K?#5P8?M-?W%Y=[QCP"=X,H,Y$FCPB
M_ :?0G8^I,=K[K?>MKD"%'2P7H511[CHPD;N\NLRE-'8KU&%7/ORX45"B,-+
MC/<L9,7X4$*S^7&WK/CM('CGL/0$\;B&NW6X*1BT>?'G[]*X-CK+;<QLIJEZ
M1,ENL@T6+*U #[ G?L^]/T,XM^ P=.<&<F!B,-J3,7N] 53LP+,MQTXI[O(/
M4?C8+%[_QP]A^?F1^APVWG\\2&Q&(7V*S/^W5V\Y)E,')H'U[+O5=E[ZJV=Y
MY]XN 4'@W([-T?R;6B&O-?RS+/@]RT5-23A?-8U7#2"B7V5\!E-<VL?3L81
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M%((0+ZVR7*8S.CZVBHC"8?!%K&1//*1?[XNE\+1Z3^+W!BNMF5>*34:6DYO
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M1&G<5'8/Z-[H9E^ .A3RX-)(9SVQGV)M;FGYB*_@&&#VY I%H!L!_4M[\-Y
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MI>FQ$,$/IJF4L*_W\L[>OMHA+E:/B4G0=P>A'81VVU<^LIFFBCKAL5D)N;L
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M;X<8P]?*Z*UW)9]@LAYC!\9R+19-#2?0J"-7*$7@95RF.#Y$C$2$[KG!RO
M.9:?9.MKJ<N87"UI#EO?AMMC;-P_LN\O'OSP20@_?,_8OK^L!T:VD+O<*0J/
M(:U[B\!%\F9*N]OWH% (5C]21#&< _SEHH&)^(@2 7WGI"@7!:%^!V0TF9G%
MU'7MD" <'Y@/0Q,NR13,7*'?VV3AB-M$(6ODE3&L#0P (=]]1D/"JL1%8V3*
M-+]$9/Y22'LQS%&9\C*=\"\%\T:7G#(=#*JSE$.#[?ST[*N4"!5=X?I:$ AE
MX:&SUSIP5 R4TKOM 2R1\\\/$')4AI78^>M3^M7;N$KB?SX(%(P-L, WQ\%
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M[3]_/BP&+<:3PVC_V=%7C>GIM[,:.R^^:CP_? .VU?:4ZNIRB6]%K>[_&+U
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MNM"(PZK0%5HQUJQIF3-T.*V^<^\C-[F@'[+%@**@OR:5&(PH""CHG0GJD02
MI!6.18:3*\8UAOL\IR->P!<NQ;4@,[,$FR:#A1NA%;'2W6$/!1XIX_P$EP?<
M!X:33>E4U @I@@*T54ES[40?] A(,KE.<21>:$'"5/!)D>]PCOZQ@.&P@@F5
M2W\H8W?$ 2A\F@U"L0&V?^SD %Y:X(9XP\,3CW.2\,T4GBVJ4#0$5WF*XL
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MJ=OE^8]X L#L3?J\$S2*49A9^/N\1' ZZ#9&=](K/*:7NRID. !L@U*T))V
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M.*IS[-Q_\K%8I!-\XE.9=[3NP;I A%+ 3?[\-&$$J=B:*C*)$,Y3U"*S IN
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M3K')7')3<;[<$5"F21M&0$,]7@0$0Q,.,4UTG1?QYJJF;N1$]*'W O^76"6
MI%P+&B!,!&/$/+H I&%!<0;4TQ3'81U-GRNE;4J_0M&."58AYX%&3DO[?%QP
M+!<28GN.<8#JG2PG&9<J@@Q;S*HXT\!8_QPH9H/!(1Q#4]L@'Q5$Q 0AEQ65
MC9Q4MIVM,AFOEAV\%&B/JHL8/1XO^.I865KE@-[]T[F?.670]7][8S32SLL5
M[U12PY&7V)<;UX'GK86?MRO-+*;<"E_-P4Y3&O-*D40YM^[%X08[^/^S]Z[+
M;5O9MO"KL'IW[W).46I+MA,[.?M4R;?8O9W893OM;Y\_7X$D)"(F 39 2&:>
M_LPQ+VO-!8 2I3B6W%%55T>62&!=YWV.<2LT/XO0?%LT'_>>UV2FO>3JLF8]
M>DL71 7G>R[*H$\<XQ,U&XTA: "++C'C&(#H?<WFVF;T6UZCSY"1[P"1J[%J
MJ2370)%T01UKP(C3Y@ZLV420)N;Z)C6C0#H$U]O[<'L?/I<1\;1 R0>I]_\I
M\L6LXR$R?IZ<::1L9_K90#[A;8HT[TUG>97Y;RAP5 (<'8*6YN1$-RS@9M52
M:RB%H2$ RWK41K[!R#6WCMNXPR7Y$L'/GCJ%FQWZ,R$C(ES/EMS;.!4&3:P,
MAP"KN:9 "UQG 7+VPC"XF0>\S!Q1-IRBXE3CR5\^6OS<X6TWYT.EQ[S6A5.%
M"?;7^_L/^KPG?SWL@.N/'2+ 8K,C..-?'^T_ZF%QKRNT?[2EB_1O'2AG%\:Q
MMRP!U=&\!E^3K'3'7U(W^6S/@B;1_CO<?R!K*(57X7'^((H:\A=-4<UZ=F'(
MO7$-HU:UFYI:!U0>+GL9[W;ZTCJ!B$TF65K<&6T$-5:6&Y@-VQ+"O:8DF,LD
M3YI<*Z<R=8]"BE:SR6I/)'*8?) JF!]#4/3:U]?'P,(7%)NQ),N*#NBZ%;?O
M"30<QQ U':SPEYPZ?8/8%W)3/[8DPL=Q";FT0DHUZ 2\@%PW'*)GDD)[%SDX
M7JIF:I*,Y-AJQ<)+C@JMGYI4=*;Q"FFE 2JA98MG'HLP"&EM6;%2_+*EJ59:
M+>423 'BL!JEZ$X3B&GO#'=28%?8".F"H0T=CR;MFE6N^?KKZC:G=6L,7L$8
MK/,%V2)<;T[J;L9B/;;D>M1'/K%2I"!']H=;A^3V#'Z.,PC[) >\95;F$+&G
M4:O&(M1NW;J$XL@):6[/X>TY_#RRD'MSN!F$*[,98$> Z\G?7.0G>6#F0.%8
MOC2$+AXY?I9OUF;U=PJOJV90]=^>W]OS^UG.K_$,1#K,T@, N_Z*VR-W>^0^
MC^I&BPK9C(%G)$#Q-=W3)_V,^,OMZ;L]?9_E]&VC\LG(+_Y76\P0-& JHHB<
MP/S4A7142G"B0AN6<@-EPJBI2MH.]>UYO3VOG^6\"LB25%\LE:,U28=[LS#B
MB""\;,<950A#H5KSTAU/;2'A?6E^T@J/VZ-\>Y0_RU'6D/(2;/,K)99S]3=6
MG[.G?5:AI.7V -X>P,]R *5<"P']V)9]>[AN#]=G.5Q%.6N;=;U):MG,A%31
MAZ\+BE9=G:WGPK%Q>_YNS]]G.']<9L9G:U%- $BB>1<!8)C654Y^=K4D[R7Z
MV_]NW0'?W78'?'&TK-\-@NH3[Q'DOPD=FA''1]J+&FO,!<PK_!=>!G):&@/!
MQFE'7&G!D/:2?L\9^046I\]']G/PL6HF3;XGB?=L+1 8(>O$G4.,$#A4\I"6
M%IPE^.-<+A-HIW2&MXGY6Q5P!15P41W2:RE0?J,]TC_Q8>,"F-=O?MJW<J1(
M+$^_'5LC 3HH^#)P6A6E5I(N2&X68&:T3(P/?P!7T+:%#B8$ A2*3QS39U9%
M UA\[H8U=GN^<=H9SU=;N^P&+FS =HG)-06%<7>8B1?UKQ,4I6:+S6^1U3N4
M4+]'0X/R"X"LPQ%.:)5FA+QF0C%P,Y#\X>R>%JQ5[5I:%4!Y43&.$\",I/"5
M!E!,M30N@C\),O,D#QWJJWRJX.42YID535,M6F-U]LNIK#W%$F+-T,=O;<Q;
M ?,'"Y@WD21@[X,6G8Y"[?C;G.Y"Z<7.FP_/WOZD8D=N,_^&K]FH(?L&)H"%
M+7$_FZ+IWA/1T"O4H\X3XN%UREJP9U6PN' -$E!!MX>J:;VM18F&8 7PQ9@!
M5ZTJFPT.2"*3,';3PQ6/]@J+AQ[)<K## \)UM3",S\#BP%-1*7?]Y>FHMAZN
ML,GI/=QXK+!3X]V*$G<SDQ@JB6SES:0FTY %KUMYTDXAW"W'QNS#G8VZ7D4E
MLCT&5:>OT;IB::[VN2/N/IA*-E.*: TT&A3,='!R220Y#&YP&L'"+[CE;3"E
M-$;C)( U8PUN)S^*HKN54IZDT$],;#GX5-.574O9X9BU7NT+"%JRJ&=\C/4*
M!?Q#:R#MU\I:(V*7Q:-#)-)?Q6S+.BIZ%3<%=NQN;LCB7>/K*3:"S- Z)9-M
M5ORR4IM"M%(L1\7N1-"AU.KI&OX>1&^ <3V.BX]@S7 R3C;IP4.292>6*4OX
M1)8I;;=X"97/^]4]ZA<<<'YW?&Q@-5%>SFPE3;L9KWW #QQ.0(4N!)FI0R]@
M=+DF%A]C3[OMPJZQLV8(SLS!/?2;V] 2AQY3D]&=;*WV*7>Z\I)G2=\/]D9Z
M\=1JM7:Z66NT?U^<V16+/O6X8T9_!"(JR]2E\$5!_XW3\G,/7A0ZG]6"%%JD
M3YUR]"B=I-HLMM]R:W9'-2K]RSB@F8X!AS\?'0,C:1Q/32UCZZ9\QJYK6:<[
MV(%M<KTC+'00(E;W1T\BXAM*_A."F"9W-D)G94+-O]3:T6_FQ:IQB"#,/^4_
M+^"NO").#V918:<2*:">"M]D@' -SRD[XJ(C9T2B^;UT?%<R.3>,.C>+!N.C
M(Y4)1'#@ZDKZ"@)>K9PJ^N]<(&7;4N7NVN] EA[.^/1P[KCWR;0F4]=9@T/E
MSD\PCY1UF7EKY#@[D,H$X];/WX%Q-SMV#DW-@1H"T+V.CC4+\K ZTGY^51S#
M=M(.\CQ00&Q#)/U76S%/7 =GL_N@&]@U]5+08-^#F>5FP.@J/BUSQ3A[20DU
MZ$ ;).5&K:;]D0530@@!G"I&#9I]DN\VR9<+C;9LVU$[PQQ0<2!&L6XN(..2
M;*[KC8=:YFM-[\43!8=\> ""/T$.F&A?^H:TCT:%K"R(UKI^[!HR\6O%P>R,
MUWB/[!'"?D@67&SI0F#W+(N?;F"H% T8&3G.$KCBY/NS=IH/+FG"D$RK7['1
MP*V"I!A+#I#(),@<X)98D"_AIP0!5%4.KYDR_PB;[2KG0V6=RK;QZ)<4P/C<
MHU[0]Q5WEX^0QS3&%M'JH2HG@"\^SJ=9&TN_8?+30QS@:RS8%6[AL9?,$_)2
M\E/#/G$\H#:IP2-(MA.>%Z!YLTEUFN_A@?3-: %T5T):RF1=D^44)M,$*7V>
M.6(HF'*DKD_[.[__55.V/+Q-0GU=22A'\TWG,=AJJTKID>C(?V2"/;8RHQ+0
MX-#8^SF BTTPM\V7#4^3\(=0CFG[>C#4R<+! \0VCYS, L3-",>+10[K:<)T
MFM*%1\_A5[>D7J2,#Q89OB?U_&X0>*4-1&(WD94CA Y,[R1BT+X5;,JF;?!(
M$WO<\-N,/$"T5"[6)S ^(^B/<5OSG(LM<KER7+PB2Q@O!5X$AQ)(8*T7>3 ^
MS0B?9 N.*)&R$"!L '.79)C"T)UM60<: I"E17#QLH$_0<U3;C#ODUL'LDNQ
MT,3:34WTW@+1<X6-A7T"L8(E+1$),:/"BOP=H?W="5Y.(_!9<=D("X-$:<]>
M2 ?+W4OO@(OKCVPTZ_^A/W&%/BU=:5.[X!U9,M0E[G6P^DE?Y&=)B<P B--K
M)J\8GGK#'D;\V]A1)(NW53HOBUU8-E"XHTK-&/$LF @A3Y .F/LNXR+8;;HI
MG!L&3.BS=VP=-Z,JR"JD#D^ -2E)B(T.#NE*E.OY=6!JY#.F]N/X $Q(NKYG
MC-D/?]@3"P%/A#R)  G"@0D&%@E"@P&J$R,EV)Y3)+S6B>$C+OG/KU^)>.30
MSZD=IQ*07V0FDI-N*\C6)BZQ$KISD)VIXP0GXIW$%Q2&X^&A7:>71A/Y5FEL
MGU2SG'<R<$8;*Y^)766?"4%]#%*-_]Y;A/(EF.T&=L&?/I,037\N/-S5FG%#
M$$._J^$*YU/S.X=X/"]&C*_SO?#&@!NOEY&)_:*N2;8X*TM!&UV2/\:;NF7.
MYZ_L43^@WGLR$% YU*]1V.X*C4&CCI"M!_3)E$CP$_^&KM%?#SH(+1PPTB/M
MCIV@N7RW?[_WX2>D:^A@E46&!1?9SY0 V,$$-\?9 .X$<E@-H33SM=C943+V
M8%8G]KYJK'.P8[Z\&(#T757D@F^8)]U#RP0L(>YP)>]0&)B-9$H/)1\4I8#$
MQ!*WF<]UX#5+_QQ"-\R;QV+3D6$RNI.C*BZK.!YF[K#AT*FI3T0.6("/4W';
M)/,UQ#Z>+7,\\63T(Q>"!M22=T*O= UACIHU9V[CD@)5B]JS='[VXY.NF,5N
M_Z-=KDAJU&M6VR&0]0Z_:E?-Z$AHA@_O'AR&N.L_7C]^AS^(R6+_@O>[+-:-
M1^*$<4HO'BGO%$X8&>-"?&;5W!@WT(5FPC!2JGVK($<,9K0$,B4_#.8'4^>>
M,HR+AG>X#0:)'=%%,SHVP9#+9I6G^VCRP2]%DI&-L<,+'&;5Z:=A^SQPURY"
M*$10M8OF@KGD@CDC:W')B8TB57J,LD;S:,81'F;!D>RA];$G@Q]F4PF9,/Q@
MISF8R<)RN:A(F#,T%78T88+/CH\+-@@!IB7.1$TSJ:8TV0U*<1 _#NP8VQ<H
M!!?L<(:#EL2H)?KIN*0&8F<-!_!AW4T2F%A==@<NZW=![+B+=T)2![K.>LNZ
M6W$-5'MEH*/AG" S06N@;A%P> 7]*_^4+QTDF$3B9HX53+T+64M/!YYNS+MH
M@9A[YA+>B*R"NF_>W5&X 6/MSF3)-#A<UL=QI,+S5PM2H8X/GQ]#9R,:SS-#
M:.ZD^3X>7QT\6X;DYY.W%]Q@,LH0H53@6F;$5K>CV31TD$3!J6FDQ1Y*OQ+/
MG&-2:^NF9:>^2BVM^W?OWYE\8S?@759/,A*S>Z\_+4C>T'+\X"Y3&&Y(AJ4)
M$B3IR" 7\/ALS>=\DL?UH._LE)TV96%FI>J,Y% G#):CI]5LMO><;NW'T0>,
M[MVZAJ?^%H&M)1^C)[1+@,T:O:FKM28);7HV/W_?<&W<04LFQ((['CD%%C/A
M=!2OY6NN-82;^AAE##^H5WZJ[]/UBJ3@=*"F+=]3OZY[9@;1:BT;EU7%Q^I@
MB5C(?O@A:EE%5DLCLT-XEKTMV= G\R(_'CT+SWB-2',>SV7R3&8+F!6LWY5]
MP/_]6KA^V+H6W@+3"/&<!(N@JVL:5@))^&61-8CUA&*28]HMNE.<A[B3Z0?9
M #E\,![=41:O-$UAD.0"Q:@.R@D7D6O"F^V,]6B1XVWD:AS>4Y#(B<%!0I]-
MW;AZ;Y"<3KX,R9-,PF-,/[_@C $4$?WT0ZH<8Y5)=[P*MLHQ- Z>_?4@&17>
MO]-5=H T=IMG^63M6X,]C:.4>,WI\N[Q-!/.J*\T;/_H-FQ_DYG6!YRHMY(5
M<X*<E$99(<PK1L?EW:A+23%0-_U< 14<)_;02N$N-BPE7V!6JL#E,Y9L*^8W
MW^>$RGH"\U>S@,Z>7"7SE8*!A""YJ*/[8BS8,;@U[H&SYAOG8(./>AP?Y$H7
MD_AJG&*PV]0BA+$]2,X:*H:^:I'QZ.ZMR/BJ1,; )HZ*&4VRFMY_=/#HWKW_
M_^#@+__G\2_O7O[\[-V[JUA%OT^@P0X]+>@#7SC^@\#-DFP);1V!4(!GS48Y
MBQ1T^U@T#_T^:,LCJQAPR["ND2O9('BWJ(J 3_X! *'9>DY'F.,=;/Z@//!4
MBN@=/3K^.2E XTOV^:QN3TA"D"29&0FZU@MR;&!9S2)%I'L'ZD>G,%5@_+&U
MNZXD,L%&TH@9W&M)OHXF=97-8K=.59]D!B'/GR91"CD\;VEY;*(DJQZWQ8+3
MO)R-E$I&)$H7H[.J_FC%&L>5$*]+0)C+/[C@-9N=D@E?@Z&S"BNA'8"8",I&
M^#L?<_@T)Y@F5]$=]^=J!B!$](AE!EEC3"D?EMBB$V>YU8.(S8T_<L!UA0 %
M=M)'X@OD)^M2D\>2^36Q3P/!(&2GA,^F2=_>I.$I,B^+F<9SCA?YIP+!G%F.
M])<N]-X:%K!"]-/'<_)FICKPL--X*;Y#%[<\Z:44L.1NTL'%7Z%J)0\V:SA#
MX$Q%2$LC>LG#QSHZ.Y]Y2?=,'^+6GRX+D]!IT)^#D=Q1IY.*[_K -5AVEJ\G
MED\^"P?&9NW4#X87B0MS0TTVID,^0#7;:%WEP*84Z%SA)'"E$"XEJ$FXNE+J
M^&VQZ )=Z'N\I7_#: B4QBNX_449,.ZE2^]4$OC<-Q(V3S9HGJGY,WA/4HQ^
M03Y/=ASR#BE_Z\DP<<&9X+P,+CC=1ZGJ8G]:3CML,KP1"Q:O9'IG.&"-(TYG
M]@Q!&70UYPK*A.*W/,@77T?B.B#X;YKP.CY>2*>@Q+I 6D@6VH*F56.N],\,
MG4IT?^F_BQ8'^F,Q*_,-?CN=+_#KYF-!WBHM-K>UB#V6@UYP,:()GD(@2.B*
MNPQ<JU/#]RJ3&V8BA0U*:\R9:[@CF;XF&U,]@F#JK#A9AK)!TR9:FVYI2.#Z
MB[%)6UI(B;/4$5_/70*7\CH_L<R8JCPM%%PL^L(R'C32D]K<SID%FS"[!0T?
M5'28">XKOJGBCV,+J<R,XL7?3R^+<G_/Z:30+M 86#4ZZ!L^[B9_:56TS%NS
M+F@:&+4E"3HZ%RB.E*J,XE]M;$Z0:!6-4DR%?#HO68O36_DN+&)2T$3TQ@\S
MW-NS:IN8NI;@E)1"<3' Z,T<VW005W!=FZA@M0*G9_2O-JO7D@EASI'C783?
MN__[\][!O<-OQR;\!"Y=9XXW^,T2QW FE:5L%+'T(#=QD2V7&1>&3JJS?&%'
MBT-2+Q\_'<M^MHLIRR\..*+*5VHN?I&DGCAR=8,2\0H);7\B]J\PEVST_+?9
M@WB^+GS").JA\ S51F-<MSA"ORIQN>2.!.J\=Z2)JM_R6+#V[L/1F__=M ,=
MS]\]H",RW)7[\/[#0W(LZ6O_)Q[OC5:R8&;-;F48'_A=*@J"KE-K0H^2270Z
M7/F*=HPD;"M"&#C[=OJRLEC"P@6_N11P3UMM.)F26BHY\J[;N_.NV8A"-T$S
M!\N>.0(0O##C1/?F70U:>@D^\YH)]1IBPPU,CA,?4:N.K9@[G.@82) B;U,1
M4VE^Y*7YF62*%<X(STY62D@DEM^0]0 FD1H\BBNI-,E+,E\600CB(J-$&95A
MI Q9!<\JO4+OCN@*<8)&+$8<Q"U"P5$T77KM87GGV6(]W^B R>XDZ9>VC>1)
MRY TDIA@!X<D6]IMS6DL?VK@GXQ#0>-DAQ-;YWLJ!=V)Y32*3#T;$(C]\4/K
M[43-3-MWS_4XQFX'\J_H#"U9%DR+E; DJZ_(]D%,FBX@%T9W?CIZ_.S5-Z)F
MPI=&37:<&].FT4P+P3->+1YJ_'2<>M0 DX$9]X6J&2J-=D3?%SM5"@1)MN(
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M[KBU 49:((I<IJL#D05,JR1"EL;\M9,E]063**2[ IUH680M52ZR906N\ D
M=E!4LUGE$7\5>_KEK?LKY-N$3%3(PJ<*V"E(+!UJ(73&% S$)_T\#;EKQJC
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M0MIOW U]\BED>)UV/6?$K1V<^VFUIQ^WXU %9J"[_NFBG6P@%TKN:VZG?ZZ
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M&!R8,F-_]<0B8K.-K4/#)GXY4IS@!X+S+!87)BOJT2;,M8X9E]P?U\5OORU
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M9N4B<T(./PR[NP/P =YZ_^">>Z>%4G@V-)%?<S^184A*:9E;C )QFNNIBQT
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MRLUS4YYKF(W&^'+)R!Y\9JXIQX\,4K%$:60&L)%+-!5<8*(S<D.8G977]VD
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M1,,CAFO9&'03QWT$[_ $8>.JGG'ELM6&<?]4(*J"]4#_S<;@^2WS3.&>LRE
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M1^]D=TIQ*8!A*6R%2S'7')NO-*7(29\ IAH*S(GEO_ 1.GH(4S?RY:@:81Q
M3^/1*F.>9/[&AAO?+? CL%0+,#TQT.GH0YYOY#-0&E)?S*DV4A[X_<QX]22;
M1/?$D;V"+UU6J=91BQ0-8]!DC'ROVA_RCX$\57E42:C-%<]B:^"Q$.B19;<O
MPJ,U&.>4!?_&*\N0,S$!?2 ):V18)$1Z)BGNMLQ.Q: 6] _==6WCM?XXVL<=
M;LVP)/JXM55*P'>#7/)B>').S3W8AP; EHA'-4M5^)@I&[>%9'^19PCO#:2R
M;7T.REF0<)HWQL<F9M7ZH>E#(T:/*81QCV_E8BHB0,Y!XM+#--:3E FV%7@[
M_D-K&UD'1='$7#' % "];G4F_&X&2_ R@T)2DKI,\U](#Q=)1'W;5%(/[A_2
M*]]6$_F^87$E,LZW\;R=V"$>O*E2G_CE8%G@@"Z%S>CZ>\;3YHB:G\N)'3VO
MJMEX]+1N->/SI&I0;3PZF2HP\XVD1;6MZKN\/F7*4_R9:2M_?G?B,SJ?K@E2
M#164LS80952OR'.,Y.[!C4SRZ-P-KNO"<.L<2JE6IU(]'2'$?^^:+U$ZOH^Z
M9*]J250)G0-IGZV/>OSKVZ?/WAX]^?75JY,W[Y[]W7XX7V]TY7,"-L>_WTL.
M*KL!&[:RR\5__^6>_)L=<?VWC"6<?:<G"A!]_ST[K8J9?FR6'LWO_AHGM9T-
M?N3A7W^"[4#;K<>7%N@O(_SXWW_AX_L7,5*_W_^,^X//&'BS?ZH]8NB;;@]'
MZ;:-]NOR2^Y!1U%QYVO$I-0W"99?XCP&;.!.+1K0:]K=/H!"=Y>L.RL^:&Y?
M5D-!A+[[&#U"@?WX!1W[V%I@-WJC;8EQIE^\>C-.S!EQ*[ !]#\U_P^/Z'!$
M#D?D:D>$;J5UT32:W#*]#B3BZ.4O3\=J_J+*0Y/QL6)"U;\$Q])PM2E^&NQ!
M5@^R>BVR&APLCB>6'DH&WP.U4A,FRH3.?/GV\5A _P$_/LK)!9TB5[%FMGO0
MX4L7Y#37TI!Q8M(]]'<U:N!TDD:?'43\(.+7(N*;O$8@UM#L!LN1THO5ZDAC
M2QQ4'5:[YULLI-)3JP5FQQ-[AAD=HSLOGKRYFP90'+M^\LI0\>5C")S1"  X
M1"T4O;1I:ZOB KQU&LNW>@")T'.$LR!5 SMJ%AC)#B?N<.*NX\0AD1^9]O8;
M1,'-;6*)AJ>")&E]_(I=;S0B27V/C%&0Z4D]2/!!@J]'@J4]JI4/M0V"/IJ_
MDHIRF$:J9TE&#Z)W$+WKL<A#)90H4!<:['1GTC)RSJD7&^W12Y(($.X4$"_'
M"A+ZVXGD'L3U(*[7$^P@R6H$KK_K7M EI/9D=LJ->7;<A%E=1)%!0^BJ(7T0
MR8-(?FF1!$>6EI&R;%Z",20/>("(;004QTA36,DF546,G-&2D-I^1G\Q(/?Y
MXV;UCK5BV*@'E9XL9N_%@9/L?<:ET$TO06VU/],7K]^DWJ5\!P7.2\.#A-&,
M S6:46&0"ZPU)N8AHP8Z)]OG-!UV"+ ++03[H,V6!K'8+B-B ^XH/-/#P3X<
M["]_U^Q<;2_8D=I9$3$J \%(X]94D.3,",4RP:YO#,BC!KX[3MTC^.+)&^-:
MV>:+VO'GA-?R<W\*1;*'LW X"Y]Y%IP3BAQK $HE KMA1R+I&AR1:YT8H= G
M!K*H&!9LE(UEN$/H\<4"_>7AF1=VAG7)Z7>:2;Z=I@"/)0&B8$<A]>F!6SS6
M@]8<06DCGNR7O'$:$9"71<6D'%7=0?79RXY';Q* MV7CI0K,Y>QSDJ,V0/;#
M&Y?YFK&2.\.Y&*Y_['GZ:+BG!9D20XG_:,-@)K$)"G#30G^2G^:1N$IZPTX%
M%NRCW]FH5OZ%W!#% 5Y/@BH@&\,48@X#$V\\?$@1/4G 7: [T:#R>(07K]XD
MG^512#S^O[;5QV(J1 _Z+@;=(TW /0\:4$C0GB$JNC5(;+N*EU5W\\!6M1!R
M'EPXJ;F9\*%DM"B[;;ASQA"Q6.N=7$B"JMSR]0<N1[;85IG.IKM@>P"],9Z;
M-4I+9(GN,.U"JHK_TS(Y('9;X,M:;1\(!/DIJ"!>TZL;(3;W-6I"N&$]TBL]
M&$+,]AG)]./1._X:@VJ/0- X<'BTLE2[ETLXFH>LTY.]!)VLSCEM5RXC:]S0
M'B8MMBV&$X,]3/N!3NLZ!S'A&1\:2"VSHA%$S#2O2V!FL<(*.(W= YS/$[(^
MW<70O9\J2DS+X]RB+4G1HHI6(,PXE>.P!";8!JCE\6%+:I1ZYE+9WFX9Z3I3
MFCL9=9A>ST83WE'LSTDL2Q_[;$(0M4"@IK7K>E-!+(TRLSME87U'LODVNM>D
M%YA>1I^'N0PYQ_<RPQ1:><'#;^E"?.\W7JJ.:%=]26T"7S3=$+E.C>QOGXX
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M]0;4A#O9#OA@K/#D:C196N2SE&^P;\+]O7M8#@W>#PW>+V[PGDAD#XQ<=8F
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M#)<O*[YTP+L5>%6UE];@NO#(\]/<*!@^[_4"Y$,]JR%TA0*1D63&-4*+" *
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M+W6\J)Q=->,0+<=90,U&L02TH9?>;^L@V@+$,P3$UFP=S>7$H:HM32XXH?@
MM!2M@I76(KL?,MP_G,C0P+L_Y 3'^0H+I(J61,"&0S1R<,1#$#^THS_ =/CF
M@LI'"4YZG/GB=R^<1.HPKCQ$TPRA\A8L:@?K+I?<C_%82QGP:?:/YJY'Y6TB
M2D[AP^-)["GDJWHVN20.O61BY2#N#TCXYJ\'#76+#*U,;]7+0Y=5U7Z.0\)Q
MNP%)N9+#%DA][<F?#K(XT7V2C.M%A57#A"P$.9<CW3<IU.?'"DZB@AFI9!CJ
MTK6J3T%4JAJ-(B:C\<HT%76MEU ]Y9R9O2#U$N4=PF[7+L7>O\>Y*5>D%.F
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M2C&%%4P2FY?%GMLP'Z-4?8YK"L*K6A\OB27MW\)RD0Y^F"':,-NU;A30\X"
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M YZLCS8C"F'<N??#/_QI-A4Q77[Q\\N-7HPZ.?]4E[78C,D NNTKNAL.TVL
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M7?EO,6$?IZRG"Y\?IW(J6O46ON&;@IWXOK5(\6S_7P8B+DM*5:<JUCP=^_1
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M?*L!M!E.\O,D.I$<R'-8/DSE, #PKN-8,LS[PDLO#GP\G(2W1T,@*[X((Z(
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MAH#%9(P5)]J"7OK?_P4$>37R+]ZJ_\)RZ/_!IU73<1'"S4T'/[( ZT".HQ@
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MB:#V>!C!VHF.*TZSWG#:?4XY;;7YR)#\<N8'!1/YR!#3XU@HF X,NW8,=NU
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M/:61GPP#SY]:P^/@,.^)/\.IP^NJ#$C^!@?$92AG.2. /D%.4:;'CX%[E-"
M"S3,0A^+3_L(>H"E\(E8^J&BVR!+P$\&NV/LCZ*;HV?J;$ YW/->IPY&"68?
MGJ<$EF,I4T<T8W@XB"*@ "J_/Z+X)_SUAP"[X+;8-+W=:SY]TW3D@5X KGA_
M!MKV/YD_$N\!-G_[_4!\_OJEI K>GQDU .QS]/G@5'SVP!N+B67%23HJ=#-]
M73S].0J!>22HZRCP4R_V(_V;0L7FWU3\"GPU*0Z"V<039[^?BF.85?'#XLOB
MEV<?3L39Z>_T9#%_^+1D[-Z!LHU^FI$_'QR*S\>?2VI?/6 K/X4B26#SZ5D
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MRNP"O.9HE26UX!A&QJN#)-(4V*D^GBZN*YX5.6<'0Y0^4 N^=MY+T\YSQDG
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M%+/S2C_ +2A.I6(JACH7AR71H:T2F)9*>:K$\G+J9],EZBDG(QD38D\Z&HB
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M$R\@6N&4JWF^KN>@2#='BTV7M'G7N0ON-7E<\]_/^;1JY?J=#?,C]9/5?_/
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MT0V.FJF@D@61T62&0<Q!F#H H!J']NM0W2YL3N26DP&Y*RA^0PE1TJ;H)ZG
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MFQ]_<NGS8:6[E(@T%@*J2&3\XB:=$'6/$/C6;9&K@&VFG$.P8_CUJ-2#FXC
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M!C<K14H?>Z6@KW9B6"-.XAWV]ZM(1DB./(JU@+#K=,BNO8M 4RGB*/PA5'C
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MTQ$AY4>Y>\VX16H3MB8N6/>CVR$<.9.Z&P5;,,\@*/E )89910VVZU4[.@,
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MDH2LIVJ]4-AK%/T52E<$6KH7[GN,O)5P&1FUP%R!6'@XAT]6*!+IX?>E5VL
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M'D,R/RQ^[Q7 /K-[Z@3-+>%3(O6QOZ2:]L#J*"]A(T_%!=QD!.MF\CA$F#M
ML[F K994Y_VRGG8["H@MGKL" .!EY!MQ<99R(J;GNVGP&&]O>/?)0^>J7[JK
M_D5<JH9R53^\V.[X3Z%?-.#8'\&-!LG8,E65-<C/39>T@2>-4B[V3$47.S>I
MA,]:&ZO)I6M& JDI%7*XKJTW,-^$>X8M^B8O3F?UI23C#&=&!03@ RQ+,1;-
M98'B=S'QA_C*S)T8X$N9$-4QQ:V:D6J970,_W;:R/.:=-3HS:<%::@7">J).
M-#%-X5MMR8)+I)]%QZ#Y?.5<>>.Y;_8;;O/@CQ]BAHS/T:NR%?S1=.N1P0ZH
MU*@Y=K.EMTO_Y<SI[=O^2_/S@Q(3*>5.6B.^R<SEYJ_PJAC^HJ:C4!C^>= U
M+J<D1J\1VUW4MXMFWZ@A"E:/P%)5.P]HDDQ8LSX<FB=9#9U41[/N4G*_:<>S
MG>;J4>PJE2',_=;?M*Y($'DN^N"T!SOU*"@E'U$-M,45<;>RA"^VJ_BJ,;^A
MG1"=R=RY4<T/T8K?SB)%)WF5]K!59 6Y*"C*0#K@%Q =DX_\^\[)+^??3,NW
MR;^8<LF=<U^S'5X<!:L&QS9-ZK*SXFHB"/)67QP5>"Z+?W: P*^=WD2N,+Q_
M;?]K/870.] :C*?<X\_G>2I"8Q"P)+KOJ'V:Q8.KECKSRES.O..T3D0]V3.-
MS3K:MO9K:<-._P"K8BFVFT=#R5A3J5O);FU&(6(-KN0LH/"VXHGL&]-(4?5I
M]\(TR]F3AK-8T;9I*LUY*:-K#K2-<2,1AZZT?JP6;.F4W\7LTA^M&=)L=::J
M(5\ZQ:8O')I$H=,6%KV0DO\A\S;GD45O^R0JOC)9D%1JJ1=26:$]>I9G0/&D
MFQ^"?1&W-!X3F 99]';?W7(G&&IA:;KF2JJVJD/45K8R(>;F/IPK]!<#]6VC
M3FC]H<T=6:LZ*%^!SK*?L8IP7>K-GBL?= O&,5KA2[2FEZJ%Y$,+>^QKTQH3
M%6*R1AOD?),*.4WK X 6WB*VJZ%V\7TUU#K$Q&GL5.]A;:6,.TA!^<QC;E<#
MU#(X5&V&4]$0J\KZ<V^1I@*$:HRFSE@K*9&R>V(G2C*PT<N.W2TK/U?.Z):F
M_6PZY/G9Q;;>VP778_E5.V0TJ#ZY99#OQ8(K4%0]M:I?0W&6FYB$U4P.=0P]
M'I'K X+&,(BN&7B!=5#I(6;54HXG,GE,\D9C#^LR1#3KO\5.R??:R 2HZ,EF
M%7N'B$9F,3QB*(:&.9LJ.S,M<#C).ME>P\#*.E4!3)_3^6(.6I\..5*\FF+R
M8V*"+U/MKKER %'$IA1_">I=37RR]LXKDI]"I3B?([^GJ'19S:[+9N40,>?_
MC106<CB];OS#2_B$B?HKED79!W+"=<FX#>-) )VU('\]-3>=G+'18:4C%U9:
MYPJ09Q==SP_=5U9Q_5Q>55.&-EE;PTRSBA^47 V<D:\*EJT:42L)_,6UW?@#
MVQ%%42>3)IY:.>3JY]6$ M?(VC5'>T9S- I*T#3@;%*$98(I_#)+=(PE3;Y'
M&CI<,H2,70VVAS0+L:0F6Q?;VC4O=C0Z-QI]B7U?UZL>Q[]SKFT-R6&4KGVR
MCP66F>XS*I]4$HW;"O1&>F,H3P?+/^09(:OTLA_2N&;)CC <8<Q"&#( 0?F$
M#X+S_5X:<I@N82$G?SQ5+,E:8.XYD*2Y&:_8 U&Z0W0BZS=%S+.GRE7.E5(G
MJ\Q8QEV?3_T4G1VK;+)PM6+9CS09<UPHD+RPV,4WQ:@/Z@%=&;C7<A4=PZ;?
M*>="^R\["4XK?:0QF=T04U&C(7M*34P;1S'6S;$K[]ZZ.4OEF'1S TP+U]-_
M*C<VG0^\WD<QJ::^^2+4=%;. Y0^4APKIX-OLN^C]/R4IBV/&WXZ6D,P&B@=
M18!4MON8'3'D6<-,T=>,;6D7$J[Z!WOK2S-DA0S3WQ91!-L>)"'ZYZC0H;F5
M7NV<[<8) ^SNUWG<SU:F\8*EVJL&T7"& K<ZFOY@+W$!>Z:#9,UXN<; 02DY
M=KH@ @8/.).(BE(?RQW(I9F #VSO>O4W"UB)SN>FJRTU@BE%.7H1[ #?WW"G
MN\]/T9RV&X%)B-49.]6<*^Y*G:MA@E5_^DJ&D,G(%5!^6@MX%2Y]4:"8@N$&
M%:SVH2JO,'@(P@B_]$=</*K(6TU-MOOYC?IZ9O#Q^.5T,G^N_*.2NA$ ;(>F
M#WFC)D#)-/9Q]93AFJ1&VH#UXE(H3V8L3-UG8-?[W7#0:@+)C&J<XIRU15AX
M_BFT0U6<I;NE4GD75Q7*?(O#ECZBU9^G\:6/21IU'['XIN%-WB J.(N#<4G6
M,1:RNE677A=<J5CC?ZDVIYZN_SL OINH-+-0(+L3*I$$42Z5CE&Z&_K]S#?B
MJZ8["*(&O4,-]F9.ME26::496@EC2J]:PS"RJP1_O97@:U3^_8)J!5<J_F9*
MQ9\?I*NK(F^25Z7<[T57F;\PV6#:BG15VP<HHKC,^"+UYP)Z)07MFYH-<>RR
M(5Y9-L07Z7DX[73(%&'ZQ[Q3TCQ/.ZM*P;M"G2A3<W6X2 &K\T$&U4Y+(TO6
M&@4'C.^N"+MT"A!:_2*Z(QE+6C9SEPZ1-/6=ZHDT90&,;YH,%*K2_W+Z_>S4
M4B'"/IH-979<S>$,&UI/(HLQJ:7-]9/RB>U*]D5EA!;+*M3V5:\Q\B&RK%;O
M5TZG7AC#%D*2*;(:IU+#:0T"P8IF+&F4I7>!:JQE_=2TTB/ZP3R\/%$]+*V,
M9I\D^UTJ>%27#J13CX-$=JOPI8L4^'VA>J&7NUI46T,:HS&,?97MSY7CI>"U
M&G5J]JT3>LF3CE!3H"H-$<0EK>]F%CQ4+ZX'G>'['@%=V&&/(\I"KO53>QAY
MM^UH2 PZJ287A)JZ$2&(1^VAT(6+!*([G*<8XT\ KN8:5#_$T; G@;*49&#<
ME@#>=.C+.\L42IA+PGO)L55>1S:CU@,82^5&VFLTLH#&#@*'^C4YYDX7=B R
MH"AF,%16KY5?OTO\@<SD2&*3&BTM*8U/5J%-395TXH#-$PJ;2.^$UH]4EV$"
M1J5/@KK47>\F! :*,04[-WTL=U \@3 !*3NQ?=%3X;/F&0JIGT<%0WYO-Q'<
M^4&-N)'\>72HT5AO\SC&6RX6EB^7+8XUOY*E%>Q4+3(5;AQ79BE55&M1?1@*
MNB*#E*JW/46T,OH;)R%J=YI-OKJ"6,&BW,_']M+PZ[5U-^5+??56BPI1T<:I
M$+?":EUAI9U_%LBF5)*YDL:[I<Y'?(,L(1]!K&:=>]$M(EGXJKKSZ,8\F$!(
MM=_EZM.)Q8O:LT;7 '_#LFENWK'#TZ>-84N3,"2!^*;5M1(Y*=CVI*N378Q_
M2.UAK+ ^I5DAYD?6L/<P-3_ J_&EZ2:P86(L![F#=0MJHF:%-OOFB36ELP-C
MT<GNQ'7T"^HU'^FIIYWYN@>179*#?"P57$$.2X)- Q@1\2^:%PVSK$ .<R7=
M.JB!*(8Q<R<2$WP)^]J=2!?/2)(H:):FCE58UQKZ&V?I![:[LF8=-M- VC:=
M<7IA9&<Q(B6@;LKYC5KRVH1J]9ZP>\1HHJW.39D4^+&3J5_B,D$DYV%G"2N:
M0U,X9PKFK'XV\)R.O-M=M2CL5>&6K( 11J:JP0^F)S4T6",=L:8I44E]0(=P
MX^;LN%(G"L+^A,X44KE3T=Q*DC?/F>.$S?(K2Q6#<.<@(W'JC#Y?0WNE  M5
MHZBV 5MS&Z?O(VVE:Y:62"11[F7QS6GZ/]7U%%Y,]R>9KO2L%E ;[3<Z<7ZC
MC?(;U=RB%W;AD$GGX$/[P_[^'^T/[WZ^^GKZS;O\XGV^N/E^??'+;]\O+K\M
M/4WB=Z%2[L(,]JFT#=1=R%D#=DY!8@NX#-#3L0\$[G\X/FB(2OBDT,!2E(G8
M\[;";:]]<. ?'1V-C6,H?8E0IG9LDUKE*@T?D']?1<"_B,/I@-!6"&\[\%NM
M(__H\/B%[S/K7%U<G9=2&O%%\*9]OW6$3[1?^":SSE4!PK1C27-Y.Y3'5+TB
M>"/J";*,( -I0FWE6-D;ZJ!,JK1L-(YS<N'!XAG.;Q#*3,!T1626LD4^7!JS
M.K[S_;9_U-[S]P].F@YJ^;KX)]-=@HROLIY</U.D!'M?KCX-0DVS=B,F;=,M
MJZ.T#]O^_M[^"@?N:"(U.LV TMO !A'2$R.>!B*F_O-QAS+RE/ACO$GM_ /;
MF\&-51(:Z,$S8#(TK09%BAQ KE(*3K,>TH1P4F7 P0O4M:W?ASO0+F:,@9,S
M4=;<#/V1>AI&5]:!>],:+XL"NSUI#N-<I'0EO1JUW=C:(R >3Z(F/TF]HZ&%
ME,E#D*$\BJU;'A3#HU([:T&-N:NXA4SQA%0L[^[0XLRM]TL,FG#5#(PB[=P'
MU8"R!03M[]8HH%S:&D%NDS0VLT\:P;5L-/A>2I0NL1I.?.Q47,[C8-9!+ZMZ
MK)SS(5G6""F.\NA)"*529;07J_Y!T[Z<!M!D7C>)!5:Y#<"FO:,_V;)"6Z1P
M/6CG)"GW]E(.HLI;0F%-U@YZN5!CU7)1E_&B;-_:K;+A<1?V<K4YGWS]Z(*[
M#P>5] 1='BLW/P7#"CKH+ND*X*%=3DY#E8?.UP]^4,Z+Z,AX6MTDRQR]57>^
M#JSCW>$@%I6JA)Q!MK['/YJ,>LJSXY$EJA1*>?$)XI+47]YY$/%N!Y;:(>(3
M::4!H0S *]@] N>@'C)$SDRJ,J> 4K#@F9@R@H*0@)JDUL.IX-90"C;XK&H?
M)=\CN02=+Q9W21X&6C4).A97:KHUA!]^I\1%B=O:T$QZONP;GO1O372 '9=F
MOE]?Y/=)U]4YNU*QYY2**>F7<6>8VS3Y =36%4#JQ+MD.UL,K,5=2W,G05=^
M&J4UQOI FJC(ZSAES)4!.Q2>"PKK@=F,C@#?$C=F9[7] 7!NDS++/T)]!;2A
M/-/J8.H0U"'H?!#T-B+C'BL3:I%/,= L\41\%]P)E2*0YS0?!/--I<*@U'G4
M*BD*C=UP4:,HU9IC#3O^WI-IOLJHX8V4N#JLW0-,B'#$FYQ29TC%48"C@+E0
M0#!%MM1+[8"2)16R"I)R&J .<G)-,%##MR#K!O]Q^.WP>TZ=2#CO"WD\U9M&
MP$,]BI]P#GC"ZG6#C\#6DJ\!12<32[MU>[C35JAOYN'HKF:GG=SRXL>XHXZH
M3I3%B:/HLZ$M-VOJ,E^N5&EI?9L5\#&[H3'%EGX?E&N;N'@_[$@7 HNCLO$K
MPPO<>!T3?((TZ M*(RT5)9/A48*SHV)'Q7.A8FIVP2CJ<,KAU%QPJMR:'A3\
M_B!*AN2A[@NLDX,_T(1ES#^4?F'JG8)>>JL^;8S7W.&JP]7Y:C& :X\HEMD]
MGHD\E_(=L_AD0K:.5=R+[AU%]HW=Z.L,=JM,5/UPI$$$>NP=#CL<GH^O92C#
M;.PU 48)C+4K;F70EE'6)&4[YND0;TZ"7D3!D' M"F$SV",D139'^;4.RQR6
MS4=$)W9!)]G]**FETEAR)S<CW:8F$W]PR<3S2"9V[.+-L(LP5HE4TO/'22RZ
MX% Z_U23K!Y52,./R EYT#ZT/(NF)P^7P<."5OH+Y\_8>3=6BDW%ZZB*A&K3
M;LB]9_W6SKK)[-&6*AFI*ZS&I]@!C!-E@LAV+MHVA_5#;9VHU^!08IV#A=U2
M99O.D9YV&=?>&@CJM7AY"LXYL>_H>&YT/."<;YQ%5Y]UYI#-(=N\D$WY:LKX
MY1K4.Q2;5S[ 4 I2SEZU:GSL.*05;XR"QW5H?UWN((L]<*QZ%(QZJD86/3U5
MNQK;;1\<Z,F-F"3/*I;^*@V,]C&VE&7I;8G+S7,;0MFZG4BLVF)0K6PD,\Y1
MP<*\I#3!@TY1W@LG^ $[KDWR*!79J$XS.JK2&$TI0[529I1A'I3R=:M$K7(T
MG)JEX.H8TY?N'N[;:#U$*2<!!:CE+ .K.R!ETT_>*/>3H+Y5MT-=8]-+A5!]
MY)E=&AA4CU89C*RTW?H3[WK?*Q,6]<\%UJ-Q=\A>#Q1SU5*\/))1>_--O1?L
M&RB7QS<#(I"!0-U\!XQ'V(2@##@KF\"NN6<&43Z44/U:A*IJ4HM0%RF3,V?U
MX.GH"NP1 *V@/J<$/@4TOZF^)NACC4>71RLH*(FZ,AOXKTJ:0%+E ;&=!FR\
M&.WZT"UUS1TMB2H76XRK&I*5\M1;'795$RR2M%+V71E+J[Y)6>VN56J(7MF?
M<56Y6TS!I%03DP]0 P,U' 30F2LS]=FXYTFH^L>((75TEH,UQM<^C0,CU=+6
M(37ODQ,_)3^JJ97$2=&PST*6W/&/]#ZG?+UUE<F@IF;I!5?*HD,2@>R+)5WI
MRB]03I<=OUY%.JC:M-'J-=6'S ;HS"_C/CMT.>,2J;:"K$RZZ :15$T\JT>"
MLHK(VU/>CHQ\E>^]6M0Q_B0^3[ZALN, 74)!$>7^[!#QF9:XR5F)A'B3W6:Q
M-2^0K4!!DI,"E7NJCO^P9T@G>D\HNJ2KY4 2J90,\<JJ5%2-&GTX ,&\Z_W2
M]%+&4E8CK/)5WZILY=E!6"1)-&D*A!LVB(FV??XIUV-;WHFPWQ?=D)T6@S0T
M^@+7%*[@?G2V8X4]-M>VCI=N*C&R<B$X2TX\P;.YD+BOQQ:-N>=;Y'B Y5T)
M2>FYM8,\NF>;F=#4%T$L6U:,NFGK.CIENI23)]^HQMYZ%L4$E%2]G[#3DH@S
M79T_ H?:0^G3<#?VAH+JU2"'TC7M'E+56O#@D1B9*D4GY5FV!+#&EE1^U2^R
M7-M[*H?UW_!MU@VEP*1VM$I#5PTSF-O!JM@?H2NA2S0J,:TRTL3J,:LV5MT)
M7(F:^\O&)U6WDY)B9L65W\\F;2CK\<FHE;AGV>?T/CVB5\WDU>RCW,I!KSG:
MBHJL*S5YAM BS%3W6.Y6MI)N"MS2$?O;<2?A1NK0O9ZP]>(._#P<R-9ZIOC
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M0+K01P;U*3_ZELIYOA5@\6SC2[>&MLBM_I!UTTG+ AQ0YQ*!=),^<%<JGA(
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M3Q-")JH*AZ8,Q9BCF2OBU.&Y1W&;A9Q!,FG<\./CXR[@U.Y=\B"I<F73W*S
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M6;7RAP?^R0=7"[?X2YMGHM;AGG]PM&G,]Q7QV$ZGZ!<1FN2R4U$GZ0]2<2\
M. _"BY+L->63;DUL?J.@00,9SFQ87,0 &O$5 /)-Y)>][\'3_!A;!IN$SR81
MR\%\:Q>V7P5[6]Z=SL;WIKO3=GN^PS>VG>HY9[;8%;VP$[ZF$> 3*.9:Y %
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M<I@IUW:6RWG3R+.WZ<AC'[#IW^A/FN:YA:'8?-=Y<Y?77NGE.:?X\TN?HR@
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M_Q;=.W'^U(F*+@LQTD_A5_ !RKHDQ;V?YGD:WA8TH?![\BV)<5]I$@%+O+O
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M=$[-0#OS4@$8T@DCX<62K^&G^.<.NFT*;),9QE[BI/8:/[ZQ4OMP:6C_60P
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MU'+9OLN]RP5QP0]M_WA_\]C@:^)V:0(,O)MYO33I>QG<VIO@>V.:*2B(? &
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M;H@0&RP>-*U/%%1";PWR3/C?O$&+GG?<H(I>ZC[.O@B-A11>\!Y%)5*6P8Y
M@67Y!PEN+ASPXB\K1MOMF&P$'MYBE%7M!1P7VZG+S_8TXSH)%QC^3AXO*BG"
MZ>WH]<;C8C #BW&U>'C.ST_1\:;U!0O3EGA9K@YJP7?<4WNZZ45C\ZX/>?;3
M -[L PQ=(FVDU0?NEL?()W="BY"XK&A0M9(\THEAY(@-<>0DG(F*RST1O<85
M610+PB:''UB\W*R4KVU:?Q3?%P85IRJFZT=:2H&X'C+,?.PAB:BZ!6O$DB'F
M#GQ&I0/#(AX5@W-CF8+X?TW)P]+R K#5CLH0$TR[=/"G(98,V%&@E0MLDLAU
MSL4S)C!,#Y>5(<HI@(]7=.<E1#71(__U1M@JB?<;^A.Q4<ZOL"NI"XBAS_SP
MB0!DCS#MY"]*DH@3GD/0D($N_2]$0EA'2.X6_*KV+F\@PGO4<L?W?F(J'=UP
MXIVR-'2*[X8X,_Z='XFYV5ZYR4[$"]K&1!9JYO=6[,1%H29:CVQ#BK]J;Y&+
MPS49@(CRZ&[K33!YWAN_>7"C\J)$R6&Z _3=;.ND#7EJ5K/P/HG+WA==ME3.
MCTAKS&>RJ*I.TKL&@"?%&A545/EQ%?:XI,W"E-K.=!Y0$?,E=4^\JVIE"W%0
M069YH/8"3. -GXB+(Z'FH2!5A^QULU]5 0\JOJ6.7YX6F,8V 80.P?->B42?
MUPW>C&0)I@>4D0%-[#N7#\./=,S#35R%6ZWH>%8PYR;"(R23&Q_K:0,77=64
MAF7BF[.M,@DX7K<GH59EEE6!GR983X7]]Y@-4O\+JI7DM%H+%M9B%^:@PN1Y
M](0#\I"3G0!,)H(K*W)W;,&RZ5[:";_7= D'A184<"D<3Z1*5[^/%E,/HMT3
M2_X9@YZ$/I1C1*/0?33&H33!E%  _.Z19?Q-9+W)E/LY(W&?X3'9^$Q<0NDZ
M1N*>M5\X$C>_W.F%_.-&9I(^>^QD14O_>9,HYWD6VP7/8O?%CL4IO=&7\S;V
M\#*L8\;EM/;V:QL%NJ,(^%CF50-60L@:KDN[M="TO"^5C'X]LP[@A=5H?I;J
MHR"KR>&%).\/=>;/VI'UN/W4=[Z?J"@^=\9P^T)#K<J[Y@E',LY<KD+?*M;1
MY$EQ\TH8[S?&Y7G54DMC^X2WKZL9'C^E44!]?AK6P/NE&OYL#:TK]\ELF$X4
M/#\):.K++DDS/[YZ@3=*1_QK<93<8I6AH*8B'1TO$(NK_7GM7]/.NW+"Z HG
M6ATOY1>[?RA\]1I=(%]M9PA8B28O()X%&*R:]K-8<M9ZG-/DCI46)MG"";DU
ML=4]PN()NZPAM5(91#AH"-<4UI?SNC%;-$RJ-)7%FJ,0J\=44[OI%1E:92*6
M9LG(!^D>Y(FJB@Z(-KU9\.*K3>Y46Y; \5;]_(#"U49!6=F#]UDNK"_8J9V1
MZK6*K/SYW<BZI_OMVN*@W'*&P5=1!,A575%I8_/42FQL60X'1DPGR9T(]5.:
MUG$X. 8]OY&+X< ]N[W^WLA56I+.K]=;BFLWLTW;K#HK+2Z1):_*= DG:\T_
M@C^ #!^)^BZ,(L#F9N]-A&_$FIC6 ;N@%:A"6K 78!4#M!:\ :8=4)+&G-#@
MCJ7&7DY-C2UV$GM!JFS&EQ9-V^N>+M9+K)SKMT1BX.5N)>%>+M4OK56W+-QV
M:ZG]S^A'5>,\W!UK*]9>JD]=N[/T.[)[;-)O3?KMIL1>/I4FE7TPJ/$YG@Y.
MV@^CB#>EPO2WAL@_% %UO2>7RF61&D-)5VC06#&IJE1G07 U8VQ/1)L2'K"C
MS#MO-/:I:;TJ]*'>['&^287<!5>0E'9#B2_ZU@NJ4+:@U'TF<E:-[?XWC67G
M-/%2ZC1 (<6Q&+,@J^QE65'3(NU;6D=3*Z2T.2E</\X;9 C80JRSD".1>9#Y
MD7.52T2),95:1RQ@3X#0<)SE=G%4B$1+O4=)*6%']">94#L3D;K#?F&&;\R>
MV1HJ2[.XCCZ0/6S[UP-,*43W@DMQ*5.=/<?$TW)5L"D;YF,2]"P.OAIEET?L
MT6-/8IB!3WL4=D<^H8VR"['Y!6]D01G-O/T:;S6E=\6!#S#UCT8-VH4>-UD2
ME"W\,90)3$G.*JF,<XI;^0N_]YC*QKF#6\[;*JXOY(3HKX]Y#FE HQ-YMT4M
MD8LW-='S#R(MPTG+,:;<M#C%CDK9@U0Z[K)(]0R2^7*-8@J:;"FDIWOIY]$:
M6<!OV:XJ(*=MEK<LD:T.P__R76LGU2"@'1H 1RD;RE-%RU4WAY#YK*(W!$'
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ML=(8M_+"G;R?5"_0^^7%1]3;B#;W'7[XP6V](ZSK]8 $XG\>??[V"9@+@!-
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MFM&DHJ\>\EP^T9W8**7W:;IOA7\PIBGPJ)CTF=YXE3?$$="A\W,493K5=-S
M!H,0-1+^ MZ+)#<&=E+$T-063DNPZELFFLIY?]&C: -\\&)LV):NO2',V>7T
M.$<53W^ID?0<@\@Z:5I%("UBY*V%#5\'5B]] /V17XYVNV%AH+;!K;6 E%TD
MWG3$1[%/:[9GO8H9L^AX[==-Z_-HQ%S4%/&*#1+!;M5"FMI?W;E/<AZ/\K!1
MY45&ZD1>7XX=1_XA<NI0M;7LAX>(/8A!TK/CW91]]YGX\X<4^]3?T(WF"=X
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M; </'G)G 23I4MM*UN9-&F%,1&5QR<'U: -E7B\P]NG6-98*SS2R="8*Q:O
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M#KQ?S#W^BT4AKX!H=]Y.*=Y<W]P60XJ5I'AB2-&0XA9)<0=):+/RU-C[SU7
ML5L-)@1BAV=[S*+#F1WWO#N9P>L&P;70):JG@FVD@R''&FG;JY,TG4[C[+3<
M^,20X0Z0X=8U;<,5#YX<#XF;&0?U7/TX&H<XQ<[JA^B=-NKQG)LGP/4>H&64
M8R,&]H 8]T@U;K<:%Y<71C7>/2(TBK$AQNT2XR%Q,N-/?JZ^_$<(FP^HNL\H
MS#N;>Y%A$1F%B38>-#EN7?_=+#F61<U%H]LJ-^,W9'AH21B&*QXZ.>X>&6V8
MFQE_\N+Z,0 &2 *PV$^L&(F)RM?W+/]Y]^YXK13Q[W<9P4CC'8Z,+2-Z2#Y
M,'>*=(Q .F1BW;Z:7B-B+8F]D\9EU^CPVZ;1[>OP-:)1PU!K2*S[1F2;981E
M]5_3XU$=K4L%Z-+6@BBSYUTSQ[]$A7WTT'_5:ECX?Z^G:?QR9TNIWUO?G\%"
M'?9GL%"'_1DLU&%_>QV?/=F4_XGZKI1[*%:W2C0U\[OE+MJ1:CU#2SO@S5D=
M+9V=-=HG+4-,!^QV,3Z2/2&J>G&6\]/&26>#1>7[Z,PX =7<#5-L$EU/VV$E
M&S1XJ,<&#1[JL4&#AWIL<'%Y4\R!$2\XUUO^JV.K/K%9C_,=>=XD$*VT0:LV
M5V35B44=D5ADNK_6;$OF!-O?TGYZJ3?&Y&Y K'J.]:<=13;-.=]_/[3&J??#
M&?V#(U'B<--ISF=MXW'<,@ENW8>]41(TKLIZ4^/6G>"&&@^=&G>.BC8I5HWE
M/T\I_GSS<=LJ\>83>O=0+P8\&B%@"+(^6O+&"+*B&O5L'\RTW:?"&FC'ABT>
M/$'N&"%MDIT=1C;*H26R&RP8+!@L&"S4!PM[%[3<6FF-GVE$!UQ?LW?^FYUP
MIAIRVA7ORTX8'X:<=L6-8IPB^T19]6(P)YUSX]W8>LIX[3=H\%"/#1H\U&.#
M!@_UV&!)WL _-BPY;6NXB_S&X!-+=QQT]>(5>MGTE:S24B47R4Q_BJ: ."#B
M6<05$/;+\5.7O?MTW.;:O_S DL?G OM;.F*1YU3\KA5OP)]0+?&"E/J569[[
MSZ-[>.\=\QF)^Q\7)R>MB_;E!==?X$'F]I+"0[WQF 6N>O1'^VCQE<];"Z]\
MWI(KRR-/@3YY>PK0QX\TOU:?@>+#WMC^DSV)C]YIH%-K_UXXP@)G*F]WB;-U
M"F<;*LU(N,\NZ;^W@OCAAKQ]\MQD"*34^NWH]]7OOK/,[D^F8T;SNS6[Z)S+
M4&6]L=K-\XOL,XZN[&.]X,FBBB=XCVT-(]1N_Y:$SM&[>[S25CBPKE#!IDPI
M>T&$EC_1MEUU_[0_<]AWFV=>[JJB"_)MSAUIITDH/XGX0?"C1>Y(&<A+8.1T
MZ3=D5W?.!9O.PU_@8]6 :'& +UW\=O?]]O;Z/Q^_-:S/WZZ:5H[5[=9)OH4)
MK)R$5C)D2-CD\+<3YEJ?E+OY+H$/R%+,G_3WN?>PW<DDW53!EQ=T*%#IHCG,
M]\>VZX)=^L\C9-[P.]I^\G?QLO?7MQ\^WAY?77_YTKNY^_A&_K!<#(%?LLO.
M;V^Y<O"F)?;YIB4NT103$G#XZVW!B.2+G;=_.UI4B1'O/\U]8^Z/A[CD&H)(
MW7FIO);8JR7(,;N_S;-Q\G9A]\""ZTRO<6YG1<Y"AQ4KM)LMU"!YM.YO+?IO
MOKNIDF7X+($/C\5-X_1M"0[VZVV9@2S';GHQ"M /S"%/$S_I2;MA=5J=]E+5
MOLO@Y*!IIK/K)$/N;'Z^]9&(0<&"*.@8%&P;!2<&!5M! 65A[)*0.I"2_F4U
M$.Q39UJ+U&Q+Y@3;WY(IEER$W7P- S;!=_]DB35(<1+Q?@U6JW_;T'8]\_=^
M$&E\)<KXE&Y\ ",Y73\!E+F7M7-YBHD5C9.VZ9"\1:K<>AK@AJE2R_8J$>2)
M20"K&75N/:NP1M39,=19!^K<0:J:*XG;ZY;$QGOP7'7^*AR-6$1QSK$]9M'!
MM#]YYCW-X'6#X%KH8M5373<)[88<:Z2GKRZ;_O2RT3Y96T*](<-UDN'6%7+#
M%0^>' ^)FQEW]US]F$^99E8_1%^W48_GW#P!KO< +:,<&S&P!\2X1ZIQ^[)Q
MVMV+>,BA$:%1C TQ;I<8#XF3&7_R<_7E/T+8?("(-PKS[F9R9%A$1F&ZQAXT
M.6Y=_]TL.99%3;?1ZG:,TGSPN1J&*QXZ.>X>&6V8FQE_\AS]^%,8P4>!48YW
M5SD6*#0RX.!I<?N:\>9HL=RTL''1OC!:\<%KQ88='C0M[A@-;9:-E=7A?>R^
M>FB3' P6#!8,%@P6ZH.%O8M7;FVVC$WJT &/E=DG5\TJ._2;0O(#][6LCI@N
M6XW3MADI<\A>$^,#V1.BJA=G:7<ZC8N.&96[_9D(M=^@P4,]-FCP4(\-&CS4
M8X.+RYMB5HAXP;G>4E\=6_5AS7J([\CS)J5FI0U0M?&!JVY<V!&-"TUWU9IM
MR9Q@^UO:3S_UQIC<#8A5S['^M*/(IME+^^^)?OZ@UYJZHW]P)$H<;K4IV\D)
M-F5KG'7V(H5KI^ERZY[MC=+E]!:4\/_&IUE' MVZM[PN!-JY- 1:&P+=.<*:
M)Y$[W35+9.-)F*=D1]XCMGJZ\0&N5,.^97U[\^G >ZAT<Z0JG&Y?BESLK139
M?7JM@3*^%7J=*YS.C]ZUSTU7U5H0:0T4\MHQU3/#5.M%KSM,9W.9X>E:F:'Q
MDC];@?]\\]'H['N@LP,>MR]2]G=>T^[3: WT](W1Z%QQU#EZ=]HX;W6-=EX'
MTJR!=EX+]MDV[+->-+ICM#67[;76S/8.(]W]T&IE#18,%@P6#!;J@X5=C<MN
MK4C?S[2A Z[4WSNWS]HTQ?:ER76L!XUMW6VS/AKKHC5R<7%J:.S0_2_K\*:T
M]S=I9/>(K=Z,Z/SH7;=QTFH;M\C6BUEKOT&#AWILT."A'ALT>*C'!DOR!OZQ
M8<ERL3<7.QW8A;;35O:KV&=+KZK'=^%K<$7+8;X_MET71/@_CUI']#M*1/F[
M>-G[Z]L/'V^/KZZ_?.G=W'U\(W]8,@6' /6F]?;)<Y,A?-;Z[6@AUT]!JO*O
MG_Y6%-=8J*[I1.BG 1B_:K^>B_OJ;RY-"2_P_6AOM^CUT[Q!0S:Q[(A97N#X
MJ<M<^,%R['AHV8'+?P ]RWL$Y0GT,PM4P&3(4+$CGYV=P!?ZMF\'#K/B(<-N
MCS8\-; ^,(=4.$XE)^V&!5I?AQ9%]:]I:42:H\F#(J7./I'2'6-$'"X;>*"$
MH[F Z';!($CC&'\%NBB47C>LZ64B].U<$AK2YK<0'F[/("#2U-'R\(+4YJIZ
M-;"(SUDESI;WP@(JB[0RB[!*,\X;<%=&(Q:1JW5LCUG40 ,D&UO3L!X*4Q[I
MW-J'0'A@Y@!8^XD5HX'$?;5X:1V,"WL##SVVL446.+]P'?P]P;O]Q. Y<N/B
M38WAWW0,J$#<PL]P^I\LL<:1Y\"2L#$K]N!<=@2@CI,H):L,P8Y6SR,3S\.F
MQ?>U+WH(+R1<:_HJXNNP,SNA P1A(I9NT+%'H<O\8[Y/W#0A$!#B# ,/S#W^
M)C"T'.!/O@^O>0C@^ X0!RR/3@M:->S'+'HD+N)QAB7."5^&9ZT^<K H"ON$
M*(#+1/^*>!:8F\TADO;C!-X &/0GM-H@A7<G+!HA1>,'O-&MHLE-TALP\.*E
MFDT:;<M-X:*&M/$T9G@&@$D9 (1BPGT!_4V+7CKCXLXFS?+[9T"_DJRTF 7?
M3!:LP.68#?0Q=7_6$VS(98@_X&,N;J7/19H7)_C<DY<,.8DB: K0A6<=&[>=
M:##(G=SVXQ")YK_,2>0Y1_9/=OPT#%&/8RX;C8FN!\Q.T@A(7U%T^$37UKH*
M1V,[F.#7\7DV M: FYJ,&8G7)_E"6$4"!0\4PU*,DWR<A,Y/?D$M+Y87 ;[U
M0##Z>[5K)X[^"M[<X5=O\)OWX2V]/I8G+#AU6NT?+7+H=.Y#Y=SI_/@* F"4
MCK@7)XZ26WSKRC)>?@ 7_7$WM-'%E#EY6LK'TYK7V+'<>Q@!O5Z(V+_J#)%R
MVH\%2X)*!TMNCZWE9#\),E(LB ]'S$&=C?15U"CS(4M@+* GPN7M>T$XHC"G
MG21X%4C"" Y67G\JUSK!];TX3DG5U7F ]E)D+"J$RH48W<^2D%+R+PVFR2J^
M1?V[A6=A(62?KOR:MH]1YB:5$JJ@1W$NPWZ-@4>AJ T!/,A0)_RU%7^@PWFC
ML8^P&43A2)>KG,N(5PG>10[VB[=Q43H5WD!B%-=6\"(VQ48VX!I0B)<+:3*U
M\R(W=R"N/- 7O?CG\2!B""%XG,6)1<I8Z0WR*!./^8#L1QMX* (6_OR]>0>;
MC B($^LN4[E(,-APZ 0_F6B6D>3SN6/QD\*M01GF\GUXA6T,0>:$$<DW_+L4
M!;H,0-7#\<:DJ61P 0+"V 9<3GYQOX&6!>L4//2*B?#6O+W U7SVPION7@?*
M[PX/? N#2/[ZW@:9^&^IA]TK->P>074/]_N]#WQQ(0YX9#%@1F/8&RB$(C8
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MUS/5X7WLY']HX\0,%@P6#!8,%NJ#A5T-R]4DRZJ]1]Z/.H6WMQ][VX^)A =
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MV,:).G;@L/)%F<47.]GTIJJY8M,G$:7CL4]#D6S_O>WCB^^&C"4?O-B!MZ:
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M"E>H*'0;Y^<;[&"^CZK"=LNZ-K5!@X=Z;'!J>9U5+@4JUEI8,S.J:;1"?#W
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MY@"=("GS0\I?M/D].B@(Y!%[2'T[":,);W7P"/9)HP0CSC\QR,(102,PD,8
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M&R <V @!S,D@43H5ZFH<_O#7IM5SL.TFJGF3_.N$#T"<7L%#OM@6;5!?>:)
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M\U7W@KK^9,?Z?<8>M0)TPFXEB3FKW66FVA<38Z:&P4MA[Q7-*K#$L 3F]@!
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M)*";,1 _YN'KR\30WN1MGJR?MWE8?MKFH,G:7"5)\&C7DP3_!^MB+E!/XDF
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M;DC"U[-#8/6C[,^O +^F?) E<;#LL/HU#_\BGGI),VEQXC4*%?AOL@\=2:F
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M"Z<2*RD-/W+O:8FQC_BK22H;YSR'S$&U..*:P0R6 (1#=L?!^,Y^$ >&;T?
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MOS+TN,E$@]C^N/%!J1@I;+MR7>]!.,1XE S8IF>3!,<5Q?P07 ZE)/Q>!-4
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M$)E>:RG:LP8?UK22K-I2M-)3VIMBM*88;3FV-L5H:?PJ&Z>:8K2F&*TI1EO
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M\P"8AW'CV2!WKZZN4(+NNL77[31B[W6)O;P^D;M].B'WJ'Q-R+J31N@U0J\
MV6LF]'J'G=.CK)_SW',<<R@DF##E%L8#R^@VUNME9.$7CTU\V[T'P7<%?SJ
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MXL)WY:#6_S"GLT_&_WB1>P\FRDVUPD-U6MSJ+YL]O\H]_[P?PP4&S7"!9KA
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M3>O6_CVS6IWO$'F?94R8SQ[M<-(V5(7:SZE"_-=R9?^G]E<F:_ "DDR,"Z/
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MBL4QNV5XR)*YL9'_*%ICSIPD@BM>V^]\0>U*>S3>*Y.[M7%!@ *V#A-/<OR
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M"T\6%!;^_&'H67,LV NGSN?_'U!+ P04    "  K27]64"6SXI]?   HB
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MQ:'U K9,%*4J?8FK1622*CO*1N-58A2354J@&ABND2GK5?1>WS44*J6JWVI
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MW!-+*KSVDL,11\J,.Y0RT@Y*;I9!I-V5PDH!5@;'"-3(A>&@S6O'DGZ5EV+
M+",$(E*7TI<C<XD\#*1@+I</.ITVD5_888N+83UE7W8@6<)M5NF1O"*":0U<
M.&_DBG:O*Y BK+)4&D4#)5=2EM1*E(:XVR_XO93-$DU*<%KOB;M- :2DR'-0
MUI7V(HFR8?OSK!9)^1URE\&*FI1%VE](6]RFJ!O!J6+:Z*<9"YF-^$"U'=:X
M;6R AS%$%41CTF!6&N-LR81+F2<<Z90\3YKJ >5T"%0;C2CI3<;LN8C"H+ Y
M/4Y[),D ,="LQ[,FV(CP+&IE@J#"R07%L681OS7GXV06AY<T.4(4GW2HE+EP
MH%#>%,HE<+ &X8 H;D=+$"'5>=4F!4>8U19Y$/$3%$I8Z; \&D3]NK#'9;1H
M$X#'Y711)L$ B(.Q,$$HG4*=<DY:#QB42V3^,,I8# $F:XTK[5I'42JZG2&5
M3"44O$4MAUT,AF1X09] E$0@E8<)*\I%4FZ4UN<+XH8%*#].I8QR1%=>0SP'
M&3,%P&3-)W,Y9RB9Q!Q(40I)K?EBX!]^E'VY&$ (D(;@+ 7)D"(&F.T^%'63
M$A++2D5O5H5!>PGA,]FT4D*XXC&7 R(8.JI0TA(7X#.ETK92%C;EY+*DO%S9
MB:E#I, )V%2,P@8F%6%!GM,:LG+(13HB3)0WN4HZ6FXG=<:T 2SHG!YI/A2,
MBQYMA()J/>C'&#COI2-)/90GZ@$M+D1-V4K&D,*J3EET"!ZD_8+=I\\%0)?.
M$S9 J(!(%2@9D&""3F>RIQ1@1"]3&VE.\"9)%R6/T*C.IB#4B#Q?GK+27= E
MY,52*@:68"CDXZ(21J15)03*NSW28([D'99\, MF5( &,6@)(:53A91!4Z!@
M-I<\<))6IA0FL]7I#)GK 1&:-<%Z!4MZ4 U!^%2AD(1#$5;@,&]1KTQK2J%$
MU*3*D*C:#$;D@!,5 D4#XH:].)V%C7D](N=]43%D$ 1)E]<0MB01 ?"PC->A
MQGV2>)#'+* TH3=$,N*:13).&BD8(\Y4"=&#9LZ9*2)^4O0KL*"6@P1JP76@
MW2GA0N&$4*ZE4\8B'>($C# PA(M1VY"T$S,%PX#5H!)BBI#%KU#*(%F:PC,I
M69H6XJ+G,0H,2.$DGU%:I19Y$6%R2%+"%I+)LAT:9)C4'V:*"0GH!$NXBTG3
M"LR%*>BP5\$Z3!B*V0BI'M'[D12K\6N=!84AG0W5,1HIF<9A&Y+U6NFT%:%S
M97YH)NQ1(1B0(S;.1Q6]J-,@ESJ<!<S@EXCNB#J,2 F-YK.HRV)SA$M^NQ_A
M^&BP5%*KC$D@YRD:(+!$,?: UR24\S* \2E926 D00HM0$H-$=)%;1Y/).1C
MG9";,P>#]H1/GE8#QKPU(P@N(,Q3HGPVZF30$@=C4GV)$7P)(1\,VNH!TZ@U
M5]22>:G%876X(2!I"#J*)*)V>FC8Y]+GE(JL2X<YBQY;VEO*@UY;,LH8@Q8.
M"43@#,&C#E::+J)T1B7FKG)PT$.D+V\.PE:OSAU3%=Q$Q@E8<Q%$!M(:V()D
M0B5I**T-*G*P1>W3F3$G;/?S1MHF@=VT!G"9HWF+E$TP(:D,+)-V74H'!/R<
M8,!\:$Y%69P&U,"6H'Q8'PD:W#+&9=1K0=BGUQE"F:@_YY=XO45G+N5/Q.6P
MWAP)!N)^O1[3Z\-,^4D%F18$&/8BV:#"AX*,/T I.-(==UG@K)54*A-NAUDF
MT1F"UI +%#O7P.H<[R7]*9$1L:@?\>>5K(]-.\V@&=&6J8A*70S0QA@0YK1(
M 272&86-="OB$2>J136Q@D['L'5_\CH^P9I 9PC.$V[>DF?<: 2.0QK6J\R;
MXU$S4Q#*>3GFL2O-1DO" TI3F#(7\$KKHG!)#5I1 Q'-YTK%K)>W*'5^@\$:
M"S 860R'F9*M!,,@PA(1W)!W1"1&F()TOO(CT8!@L%D,F$@!2]:,N Y8D5&F
MDTFEE38$;:Q(77V 7Y[/LEZ1B"I1.!9)43$JAQ6<K$=DP256*U@#<IKR8V&V
M/$(<J,MH$&BF:9,_HG(A>30&J:)!28@5R+Q%'M!&8W0P8E8H4V$F'4840!!$
M@B[8AR(!!Q[48%G,4PC 12ZD+*< DSP8UJ"4A_>1Q6+ B03"OBB8!F$GQ]M3
M),6$0PJ%S$[*')3*G0?]J6#<Y= HR*+%XR7<THQ.'F8 'Z?CC)!,*#/8+.(H
M\H@Z&_)G_&D;B?!ZN2Z@ (6(Q%XL%%PID]>3MOA,Z9#,1;N<2L)+(K 5"$:X
M ))R*T2&'TI+4!**J)U\F7UYDW$SF<%B))7&,A'(F5>)%9I1'I+9+:"%#7)V
M! )$9BYR6;L-"5IY1X8JX%)_@J7\+  9H9 ?AV!=QE["??6 VJ#37?( MJ3<
M4BR)&9ZW\?9@4D'#&*102-* )L';K+YDR> 1"7S*#>BT26M4:G29+<4<'@K"
M=D_<FI00 DC)X#*=(P5#5"I+&S5>TFE,N($X2^5B@"W@L%G4=H9Q<;Z",:G&
M2U:24^N":-)0(&A C?#F/"0!L*0,3)A<@DZ6T]O+];)'XI0+02<A*3$E*J@6
MW<WH5\9BJF2"E4<)@TJ+P/:<Q^K*!C,I<Q'0,QA!AM.\ES8YDVPBKBPHM(#)
MHLR263):CC91N5*%*$&UR^FE5$P^1A"@A4YGE7:9-(FB$.DA^*Q1[@VE2RF)
M.4#[DD4+2*ER_K@B HM6!%(@@ :IH#(8E97+VY A'@U"@)0N29)YEI!SD4 Z
MB27Y .&5V&Q^?< 0]=N-(%Q215R(1N'.!G-Q**!E(84ZB$ >GQ@^\D6O*4O#
M@7I -Y $@B05L(JIPA?A@Y2+*UA5K@P<SA!1D%:H2<$,6D5^9PKZP(+&$T@F
M4G9*Q!?S.6BQ$V$Q=F8$4)',V,N 6C^94HE%*B'F8J<SD,04\A2&>B&.L87B
ME-K*)&1XP0NHK 9K0*,,,_XL"!=-$CJ(^4HDP\%XD3=D(1#/ '2\'E 1<RG0
MJ"6BURCUB$B'Y8#42ME<0+1(U\63D%@\8+Y01 O)S%J/.DUS8D(SAD3C=J%D
M)D?#?K$DA4Q&FQ2Z\CPVGK7YU5$O;V?R"2P@B\.II%1<<DW*!(>+:!(.@1:9
M-PV!*5O2YW"E\EC:P=%>"Q$M>5)X(A4RD)EB ,9%:L^5LYX#EB,*(LP+6J2H
M#A&9H+)84$194*VQJ2.$SR0IX)3*Z@AX7&D"L'J!N,,KD?E4OER$U?DQPJG,
ML7%O2L5;,[BQG)=5"5TBCH@>#MMD""O.-6Y"6&E.X#+Y;"@:2$EL^I1+1VB"
M7-"50'Q>QAD".+D\2_K%0DOPBFS/4(1C*KV+H<J>HC%@1KR0M7H\AI(AZ; R
M1KM(#Y3R#.DB81A .3]HUPE"&*1(.(Q!9C,6T_DC%.-'Y?X F?: ^;Q(X#'0
MRI:_&= 9;#)EB80#$K[$PE@.UTB*3@<7\<2=N-5AAF5$ $2R4DM8[,%)IUP!
M3BTQ@;2%%$)1E"6D !U,EA0)?=Z6+YM-. ,&*#I0<D;CVA@M9S!Q,NY@0E&$
M]9 0RBI!CPTH0;: J!O4PGF;,V(I<7DE @6D29M-Q>%YP&H2!( P4>5X*-A$
M.B=F:IP(2C&5#35E QR3$"D&1=NCMG@0U2<9A='C*RI2N)7&#&8B2Z:2  XE
M844N(-:,4J\4D4A+@73<4/[FQ@M[/+Q#ZS(!N%/FQW"#UH 4W'EQ=S(NFQ[.
M%DAW)!4J,LF0QP7JBPFVJ"O!6-+K<N:IDB^F5I",7^>%I&I5.8WB7H@$-$(6
M23EM1E01AY,FNZ<4,V5M*IO2):1-6<@)<QD;(Z,X-N&(8 1N3*83X4 @%8T&
M_<F"V:DW<I"9M%R)AS'"X_ @,0#3IW(6BUGI+Y%!W,0'7$6U&7)G,8"P2S0(
MGI0)&8<C942-H(M!0"8:*?ART7S2YG(9*!T0X6&B"-0#8JQ1;X,S$HW+"Q$R
M'VO39F![P,3Q9AHHA:(2P1#3Q4I1#9 .602OA[&3HL7IBD*)AAE(5Q+@6(Y#
M<SH Y"SE %M,6LQ!CRZ'8'XP@N.Y$I+3."V:**;W:0-Q%:\PL88D&TQ*"39H
M0Y1>52*(&O(JDP$UBAL9-R5I5RD13B>4.6/Y$4'8D_=X 0ONLT"L@.."!4"<
M631N5D@4G$*L]A6$R^9,)YQ&4UXGI)+%B(NL6UU42(<RDC1D<=E":://3UJ!
MK+L\0EDA$8]3/&N-H*P"+X3$D?$DI86TCH(GP<)91 52<E>) 1VV$LV$Q-A,
M&5@&DAHXI:<42B6M)4_6H?5!A+/\4#>BT.9!C.43E**.V<.1H%XE ,$ []+3
M%LSFEUNR4I!*HE;4R(.:DDA^=0Y7*0Q9=7Y7*8?D!'<IX?<$]8X<7+9#5YR0
MAB1!OP2DK/ZBNR!&.GF1(6%QE%@VP! XC(9R%.@R.DHYJVC#O#G!QU%>);4&
M/:*L22P]4FF7W05ZZ"N$T^&1&*UQV )'0:NX%G8:=+JX+..,*[*,&_+Z0W8!
MM=NR(.,HF3$FX/(9>%7,&? R=%X68G.,R@&:=0ADLPFA\O-#/"&Q(@&;3S!D
M<MZ"3YI1)_4Y>UAK<QC3D%5D7AF@1*KUX4S85+<DE)A#?&92Q9O 7*#HU9L
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MQ)^001J>S>GPA"7A%3F.A#9'(#(B=?N*.MXH%'DT;RYG/:2H%'-@4LX39$E
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M5N6Y*%(*)1"+*@QI8D@F":H=JJ)5;4B&PKB+DDC+:31@(-,.6!,2BIF,Q*N
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MO]^K_P%:=^5TZQ5H_!]"_T;]#]!.-A%+T"CU&YE\7L07"98$44GE*IG&H--
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M58ILR M'7Y).A'A$'/CBW*15+LC*:?Y$[4F#ZU;SFEW3NK\_R<M$))9"LC(
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MQVRF0WA8H=9AP+OVU3)U@C3A_>1R]*>WZ\+P*V];16IW@DZ4%69Q"'PD,LB
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MD#V0/9 ]D#V0/9 ]D#V0/9 ]D#V0/9 ]D#V0/9#_,@CUGR]Q@, LI=E<V&1
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M78'&*W&0W*E#M;J,Y:,U3H] 4N$.+OXZ+Y9''V5C)BX7Z!<6AJ*%($F/G\[
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M[&8^?DKMEE];KO=1P/=TPU"*Q\0>1"?WS$PH8??V;>*[JI2F5]76YH4A[XQ
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MKC2GCTQPS=).U%(:P]\_933V)07O[KCQMF9>#B,R%RP>6U,)%E=PD\/2R;/
M/(6ML%L/Y(MHR:7Q$%.ZB@LZD\W0::<;O@MKP@%N#GC2"L0XA%<G_N;,VR9
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M\FPI(\'_, HLMKB67I[!@J):PYC=6FMCM]8^%3</79BBFQM&!J1I!"S22?*
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M[$%KPP0>Y=!("M;THAA.LG;^_-#!"2F>NR=P0&00J];E.",ED9^!@JL,F4F
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MF (GO;NJ5(11^;.!52->J]H7L8P"_7-'I?K>%I2-:UO0<@NH$]43_O!BU!)
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M^C\ <K?Q2A*L86B;EH]<[M*>@]+SIAWL&L<8 :!6.E7W:/?5LI I+"MDB)S
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M)G,-SJ_U-P3; 7%,E")K]'O398'5MGBURTL T$[(1(PLZ,_UC0]# M],T9N
M=FEE:2%WB9OYF&.N"O!\8,CUS_J+/04SRO,XG[[P$8%S7H/<P[-%[G#*\LQ>
M+:H#F2P_W*$GY$\4#]\"7A$6^1+?-'0BEU$!T'.TP"A7VJ^3&_H&8U=<%Q^(
MC2\BD;1!A$21 80<*D!?WK-8IDY:\ALDZ^OK+4"QO@<0C4)036!VVM+N2\=(
MG(3&>!YC"SW:!X"Q[8L/Y(MZ3[XU=,Z^#I'70XDB@]K:!%J1J$[H3P3$%UZP
M3BFL*>UN4?)F+_\.5G2=__PG?$_<K.B7WV.$(MX6TN'D5*AK4[-5/! Q%1]4
MU((L_GS-&VGV!F2(W'F,6XV0B)YJ1Q2J=\ /9A/+ES1@>_LEOE .8J-NM0VY
MY(4'P#]^AHT3*-P-OH[XQD4P$O?12VLL)#M8?@;"/6L"YR^@M:2Q=')>&'78
M$3DE[" J] YJG5O87RIM]&!KG1:[LR&4K2[SG;E.:C8HHYG9+6OM,*)C63?@
M-IA]FM-77SGW1VH\I7'Z:&J2N+[[0!KP#-&&W+H9IM="Q?+^.@C4#DTP0LN"
M9UWAM]#L&VN[;'RK_B_YL_>57#<9<?4:3W"]A#:'U%6(C52#U'Q8'\F4 51N
M*1W^[+LVOX;BC&@6-"R ^$:E-?!MW$QY:=4OI*8SFK^;7C449&[H^R1>,,[;
MA\A!:,'A&QB)H&PT)3>-+O ^C5__0GTW=2%-9+2?;IX'.R:N/(/=.N37_/E]
M::Q9@"X.=<UD\QL;UG_MEN,&EFY-79D;^J'*F!BTX>+QZNBQ6.8% $<%]Y&J
M)&M JC4AL%?&0V$^_5!^/E((?^>20V@X_RR.V8&3[#^:H*7SQU^CW==L[#_(
M6_<#E"IQQ4J&E3\Z+#?ZFR*W<FIR??M'@QG#C5>M]/XR5T00<#.:\>/;_BG-
MUR: E59'H<)N8E#GG#1(F;$SH_4J6^ABL,T_^7ZJP>S0Z/[L("KF5]X@K)+M
M%^X+#8"!G63">:-I?[7&H2^H+UJKSEOXR=-.LEN!R<,_=\I&'.XI+<X,A?!^
MA[TN)Q;: _D-67DUBJ7$]@*O8<DE&=>7;3L-3SH351[)W*9^P>T%DOOC%1.N
MC2.-UU=IS5$))L@]>>'V46#=B_53LS9XSJH=/&FL?PF \.8EK6)P$"82G"D:
MRL6XHPDN/IW(HC\KOE4'/0:=XK]7E/KB0HMFX4N!7NCP=22-UDH?O9+C!+U"
MWM4W$6<"O<#.351>-*>Y.Z!+2A601BSPT8_WW'IA!&GR$4.LTB;_$0R^<\32
M<($*0PK;>G_NJCU"R"% MD<@$QW ^M'/^D^A=:AS?K2>&,2G_"5(G2M2(_-3
M]/>2)V;I>7D\*3).WM BA*6'I_.P9(X0TEKDU8DA<4*],L>""!]"V9$Q.UIS
MT&?#OM/ZFO,0PG\4H@0+,'YN.VL&V\C@1)O-S42"J26ZZ@W:;VJW@/C""3_3
M*]M3E19 ZL9 YY[GV'F?,+(#)Y0?%*T]7@CBRX^!+AR3_*-JY0CJ(?/!(&H7
M_67SI2#S5H<,4,]ES#K3/;1H]TQ[P"E<V8[K Z!<*P/]_8)24H@Q8Q2TI=K^
M.)KQ:PQVA9.,KE@F!33C7>A68R._=\2B'SCR+"E:.&_KENZ26?[3/WF /QN>
M_.BF'/MC[6\3A3J72V%A*]WU;RS^=^U?%:V]XF,%+B1[!N.CPQ/_?Z",RUOG
M<_<'0"Z:X^*8XEK(I&&3L7*R1"@O;V+.KSYDF<&:]]!/X\U-AJ&:P6K'"P6!
M*1ZH\F8'+Y$)&^ MN3JC_9YO<4G='O;# R"GUF7<[B/LM*B#Z8#,M-27B?;=
M9X^PT4GDZI*NL W#%=%/IV1Z/^?>#+  -9&O%LK]E1'RHW(H,G7QBZ^C>Y>C
MKB>(E4.'53&R-;>X8Y])=.7SI/.B=2@_0K<,UY-N=JH;5A(0+=A_.' G7A4B
M73<]X]HQ/;DO2I]2(!68#2L6'UBU=[YMLY?H$FUDM>YD_&3X8V=SO]*SP*FA
M\MD1*HE/FM!0>S$^GUT;3/UAJZ*VZV>]8]E3CF;?N["8.Z5!I942BY-^S8WM
M0_2H^_V[93&@V<59B$T9$AV$3,Y&-79D;%'\H_+S8-CPRVE[46VPNU"N4;M7
M-(C2?FS6R"=8\1=N5$./,-C<B(_[(-'[Y,T;V;M!_C<SWPR>ZX7]]+1R16B&
MX,[>I/S'N$_6VT*#UC0C2AXY40DN[XZ98E<UB7MN<0XTW=M(I1\7,"_;&YU;
M**W3=.__O2'4R[]GLJVV97@S%?GU^7.>-X8M$(\!YP7K\CG^I[1WG/4Y!E(;
M#)7<7DUMK;^>\W.;N)[)ZT_#CP;FNGKNC1T1YLOX;75A6 S\SY+P."_'2LM>
MCOES"*M9?M<D%*Z _E0@0@N&7BF^)8P3PK_96K@')=OJ+M2_0CDM]I_ 9N*#
MK/G<SCO<:D*R5TB7:PMJ7J_1?-"]9&Y6>IN-PX#1;?IS1P#^[7/WIDNG=L:R
M9KQP>07LX-M,51!JF@'8LLN_##%N_,_$6%8&0G K$1J:XRL#-Q%VD7H&LH@8
MTK[?LKJP<>N^S@YM_6\_4C)>26PJ#%U^3&1)XTK&;R4S;9O"$FSKG.\5BU_$
M#1P5;;E\#I3=J:P$[XRXM@Z8Z#+NGB?E_^T>_X+'+%O-)N\HU%O2A*^&EWN)
M3U;@)[D86_)JXBQ#\A@O4.RXU>LF#5>:=8/U N;&I]?\?Y<),'CVGN4;W;V'
M[FUKE0G+[GW(<0FUK:41.=,[]G9.A1,0T;LU2MM'7%M*:G@UHO96N*3=5]<Z
M,E_PB#>:\G2%A5UM\W#I5I<;N4N63$=6*A:8(G^  ^F'$,6;&09PZ71F'>YH
M"-\AT)-@2K+)1ZPT#\Q:1:ZDIO@ B.D2O< BKY-RBO+-H TD%U]>]2OB4M?>
M@FO GZ=-U,;JJ]$EOV"$5Q<7!+F\@T0\/,!C9LHG!FS6U"SM:JA(O*>^R[Y3
MKS."=:;(07_=A>]@@W*3+? Y%(Q(&.)FXRA\;W"26M="&*YVDB+S5*-32Z5_
M@C&8#/'KBGY7<E-Z4^"NMY\OA"W17"U;Z%&<IY $U&+>F^IMNFV9YPFGBMIH
M;PGNX/5Q=;'%'T^JS--$:UCXYIAQIK3*BO[37:I-7P7V_%A*)?63X!.'C&'<
MOV3 P5T%2'VVU:K(A<S PBK5FRP1:%/,]D@K6 ['CHQ\!Q956E3I$!P(WT.Y
M\#];K6G9[D3$Z&T].R#BN'6+_#.[RO'^PU/-.6+H&%/%V_*7@1'JCZ5.9;UK
M'P#3=UR-^_SMTW\GH6W>XA:LX&VD4%QLXIL0BZ(*+//GJ3TP=![B7>UGS4L#
M'V=-G\S[Z.8@/;^W&ZO_K#DS^D7FIQ?<2@JZ;2] Z@! *KD$".#=F_62.M1A
MRE> ?WZNK<78V%COIE[!2@GUS=[63DAFWC3!=6JZ>2%!=3''2SQIUS\6!7AC
MGX_?YUJ9$ACCE>@IK*5%=OGEA""CUGSW3T_W \!))JAS:EKD+\'O&/G&$J'P
MQD[#NO\C5Z/1(;+_.@B P2$;)(A4>?J>OI@UX"VN45O*X=\>5,X?(]Z4_'?:
M]PM%W;V;1R9JKTHU"GSY.?@Y^MN7IO1 ?\T,6+6&(D$LF?]TV5Q[_@46\07<
MQK;G(I#TWL,4$LLRIM)G E/M/\_1^!Q6X3+=.R$'#0=%;^##AJ:*8,_/91 .
MB#>>H9'^]'EY?&5JJO(X K<%3L!)DH;ONR0%#9%URRB?$6CCGVJC$CF5#FYZ
MZM4;FR/:']A%W(H<;]%L/@#[-B9*A(^<O@?T,DW+.7<DNVV:C''XPJ,X![(4
MP=K>&GO[!U#=UND+#9H_3+503?WDBD_-TT1_B2$\4: [;>GZ]*CCZYQR'XO/
MSY>6<IYG,T6Y,,W1HJN=Z+U6/;T'QQ*-4;\#<\![YY#*:;##?SL9,F?IPG&8
M;8*6YP688@=.\]N,L+^-NS3U.HM?:%WSUKAAVM'#D2S=/:IC@$Z#%P<)?["+
M;D7\K=\U?>S+JONT]J,@#X#_0"::L[!G@Q^J>WKT )A:($#$,6KFCF!=KE?!
MM4OW3/#EKF$[A,KG4_.P988TO(Q#A1Y,4B=[95MI"^M75K,_DQI,VMOE\F\_
MS<J*-'1O&_;^A@0\JY>J6'""R]I].QFJ-LOLT9Q&\O''@-_!]^#8=H_HK_C]
MT>[\6CO?[A$U\P>D8C=ZA]+$("K6KG'3''\<CJ1?L]U?,/#:;*;X:;";T=+%
MP/KF! TW;]5^T4MMY&T.Y)7P2>%9A">W7KST(^['"E4N8O68N@V+'38OW9%^
M!:IDJX%M*1>(I/M[4,XC'V**;Z-:5#N=S_8J/BN3?;'28&TR\C=(S:S/]U5Z
M)(-C5$XAWY[N+]3@?0S)S\8B_2"N8%A2-LKK54O@DI61F\C@4Y>R8*YJ*)JY
M'KYBGG^-@+CAP5\1EZ\?1JT@TH<"''%8 ;KXBIRL]Z&WWRDEHNK#4(ZME.S6
M[./4$8NG8/S1PT+_F,*C_M,=NMI6_U-YJMLVC9'_ *WD+_6;J-Y<><;!4Y:A
MTPV?FN5#A&38XL@K-8RVC6N2_+K\DN)Y7=0A)R$K(8AJBX)2:R(-_X+EE9**
MANK5"DNP?X:KD;1YGO!_9)#J""MSU4C0LR3LNRNUU*NW_H[4YP&0\'$81W+,
M>YZ1>^.91J:1&AM-J2&GKN,#X&-JH#NX\'GI4=+IN/=W[YSBL..0EMDSEI=#
MO2>1952ICR/%3<*MD5O7'E8HOQ+?C#:)\\/UN:1>U-:2> );CY7?4LTO7AVE
M'8:FSJ2\Q2K>U4]5Y35*\BDFT&2XF<_+]M_1$M*I,+)XW\!Z>8U]_CW11OB=
M-IA47,>0_UM;^X!$CHR7<<$>S=[JOJS QD\DS!$-/?Q!":;?1K63;E 32F>V
MWTDA-89@J_RH9>IOGK?3(>(.E47[2WP3SO]^80J,IXWU;YJ4XP^+27XTT.:[
ML,\C&8UZ"^=6N&LI+(W-[V!2V8P0M3T3/\50;FR05'>*Q>'3+_]DQ<M[E*NG
M7+M1@6B7UT=,FMW@\O39%X<?XO(7GT:5=E;.3;=-N\W-P0^4F%'NG20)0CDO
MM]JL<9;<]_C:C*S2? Z\EP,Y5\80XA7!C4PK)#$NC;"[V8'CX P;J<^CS=!6
MQ$9.8>A\.^FJ<&*.:_6K3)/<@9<"\]+-3>N>/YBZIL5M9DKH C\DQY@Y[J_(
MTKXK.QO<@*&\JZTA/JA'*)*,)?/^L>#5:[$H='EH>7WY'$R<*KQ+(:X#,ZKH
M$T4RKP+Q_!LJ.9U];(_2C-E>?.I@/UC07^O4<&5/F@EM>-N'.#!,OGKGT+.>
M5_^%>;B>ED%YGDKI#W*AGFQ.;-K0&?&.[\)Q[V)5$\ND:WC6Q?S%J$_WG6ZV
ML3"=36;JJ+J\J+_Q&3(0\N8:Q@IVW5($:6K:D*"IA =8#3 B-V(&K6U,%FYV
MX%^N,U,^6/\[;KUP$XB17\1TUQZ.G3,AJP3@+:'\-F6]2]@QY0WF+#E_(PC:
M/2(0;/Y)<V!2L%N\T6]=6K]N_NU5C$WDC->]DU;&CCXUYH91,[1 ,:Q#'8.;
MQA6!&S7$LY7VJV># #TP?"BTG4?R@VPN3,OH&'81 K_S/N<ZNTA,_O[B*UDN
MWBEP]%10YN&_25DI\6LP]R65#)TA9FT%83+=_3K'^)A;;^?_XSE EF8[0!'8
M"U!(!>*HR40]2<_;'<UE=H5&99; O<^*[I?GI!$A<#8_K<M5K,>E1X596?I7
M_;]9P#CVS1V2,OJ,S2V5R-=6W>.A05Q8$O>;B=</ *QEZ_GJICSOX**$V# D
ML(NHK@,6J<<O6JVNL-LR8_<2X/$>J,!^S_)(YJ#M;$[<R<1,#.&S9.69P]3S
M\B2$(S<@?B.POJ+A4X=4DKDTQ;(&Q5/U0D]F >V>@3TOEQN#'%KS-\V%PEC]
M5_(@74.#'&>&,J=XI9.I]#:I&S>9KYI5E9759RC]XECCWH/NRNHIQQC=_Q:#
MCWC$I'DOJQT83;YD1'J,#12O7)SUI96ZD/\@SE<_AUKAY&LUI=P:^*>;CV08
M%#*3"IKNH'X<@BQ&IT]OGF75S76^1?Y,B$<WO"NM+/=( SDZR97N3=U\N,[.
MSIY?*BO!.3+":JN.CVF*NKJ"1Z">P#QO<4@:I2+71&WE7G%1^26FHK@B^W,U
M%"YNZ;)*>_N;*L$U8+1\P+8QX?6/*M?,I^9\.J4-)=BDT 87Q<"%&),*:+[
ME-28J%DFC]&?D*5X6YGY()+ZCW,Q(Y:698$#C>]F\ID4?6NAWY=5RA'F:#1<
M4YE!(RGXOGP/YOCG7BP14L$>+((2!+N[T+(()V9()!W@VG\J%.'#(;C+[[DL
MEK_C_$H?%S7,390"5$]5G42[AEI]H#$U>+J@F*7^STUT_3_RZ:,R,;9)DVP
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M#A4_RBS%Q^;_] )7OYCZWN=->CZG6>+[[NXM\<->,D;.."WPYT!)-79.+/X
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M,[%INBYY'GNO"&>HE^,B#/&NW"X;(6[IB'\TQIO)1H0:/16=[4;S%QCKW21
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MEG!9?RQKEP&Z7/[@;"S&%:Q-E@CV51[@54N@YK#R&A26BNW9I1VF)91<0M\
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MDNG/\14A2D'8RSGU\K22J47?FN@.UL[7N_OM/N'FYL'L4;A$[UCG;2TT3^U
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M,JD6CWN'C[V<<F[(B7'P'#>*11L9YRK,,_>I>F1,E6*=[X"+(A'B)RJW$@.
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M'WU69<#R;SJ6()]C1,.T:&[]P^DZI-K[&K9G^G<KPC73S!OM8(!N5F$B[]*
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M>#VL\V?0">SN0#M,L E[H'',8-)KCX[]MG\V7S1#H0 *[E%@ZL :4P2$"3+
M]2I%27K#K+GUWRD\<,U>B:A_'!#2FH0$<;^W96#%C#IQBI:OJT#5:.?3?3VL
M - 8@-K=6A-82W:F_5/Y5M\&'S,S^TS*YJQA08G+XZ?C*/:M-,>'-'$*1W\0
M/3E!C4V?46:/8&-:%N;ZTX]C=!D4@WCMOE%_GG$&G[_QD'5,#M@T\;6<WC9>
MP);:.9UL/,!6YV1):X*!DA?:YD?L'Y=>_ZUJ0K?J7N89KI$+H7H;#'6B\NKC
M!&%W,F+YU<FU_U$DI2C:=G/*C'V!T%'F!S8EO8=C71M0N"@QEFZ(9]RE37N4
M6VOSBS@R5JN3Y0^B-M7[723XLLI0#C3^H]/_$^.L+QW_R'!\'12NV?-1'J"<
MQ+B*Q//*$JW=-PWI.+=/Q<:?G\C':7UO\<\%J,I*]%-/NQ 1X&2)#DW_?82T
M0X(,2%+!]+EJOPVH?5.1C(+W]T4G-C1.L#&N,E)*V^C59=S+V;5B!?EBZ#WF
MY][' 19FWD=PK]WOSSASYV-8E7,P4DMB_&?9\*CIS#GW>30I&?U#>NF]KR),
M-2//MF7&""9C-6\>_NJH8$2SH7^F6Z3^N['0G_M$ +6,:@U9>/8P&4)CIP0E
MS ZA@DTK4??GG@_KOGV<4O-;[G[ 373EA46BGW=&=W",N06LZ18@/HU!Q=7S
M#@\;"1W7J'=.O$R^5_U;45PXQ7/>_#M$[JG2CW<44 B #$Q!1Q%*)E-^"]"E
M(!LE;"[>*UGFY:8>HD$\%59-MQYV',I?5HG>&"X2&B*A/^)FAG\.__I'%1.[
MF2SL+]:%C\W7SO=^;;&*0Q[F92$O-'B/?5&DG*V#/C2ZJIR)_I[8=O+\D&%>
M4*B#G;\.J=TY* N\!XI$H.E%P(<%- X(Z=HWW!O40D2#<&Z7#&+/9CK3A:2(
MS8'E8 4.-\15 @7O>V*_]+T@L3"?^/I66NYG2:'!QJHC+RAZ_K..W/ZQ6,I)
M?Z[_((_HU%U[$"_"&^B7BE%-+;L%K 3R?V"E\K6V4<+K*CR$;PH.AL^-+/>F
M1T=A= 8))$GR>#E *)!A($$MJ<:5#NA90<D+9MW-[=+TRU*;XQ9[XUXT"&%)
M9B:P5"%C-%I+E-T9@8S@<#HRY\BRR$.9WEA"$I'(X-H^"#E@244?WT=* >=>
M:/3 X(VQKWXW-86_70BV^6?R5-C"\[Q*6"G8)MA.B$:A0!"]0)$LAH64D,MJ
M1BR03W4RTC>--6':/T4MT.EC2=BE%85;'OG$PO*4*Q7*WWUR^92R,CX;"V]A
MG%^+<&LA&>G\NUMYD^MAT/I7CVWX^VKZSATH;X3H&XSSSU!=Q?&,9Z^?-2J#
M*WD!1*J6S\R<R@LKS7QR;]A&K6V>O#,WY6>)?+TX]B->!!4H7L*^B-=X@XSZ
ME%<B]="'KOW/LX9TNE0>4%J63-%)EFYDY$GR_!<*MFX$[?SSQ;F6%4J916/H
M :4U](-?3?X&F!(;F:\FPOL0P'QQ'Q%H0 MD)DF6^9:U-DP!+->!@CTH5FI-
MEQ=)*5"</8BP#.B*F4-%SE?6?42&(K/6XOWZ]4(Z"+75KI$7R?*E'4,^0.R,
MY(9_\M0Z]L.;5%971XH^R^R_/<#!N-5@_XM7RHXH)?OLQX-@Y93TRC(ZJW2U
M V7@ 7"/2 P<!K %NK&0M1T4(7&9#DYM]_+RF41A6<(%CEDVGS]#+Q. ',-9
M8J)DW)%AI#;B K8X4EV>Q*J)F.$2VX_W1)A$??X!X:M8WLM"W9/+4&+I&!&2
M\' _J+"L6I(=(!CC1!=+MQP8C1 58N)[.L+IH=R=P1G5+U-[0%<Y2G->'LET
MZC,8N4]!T.?A(H>$9"C&,=*#0L5-V$H<=*4!S,$.@C^^[#HU/:UW@<55<@@O
M\/S<\TDA8!+^80Q]YW.EMJ.^7!MWZSXH1L-=B]22Z*Y=^6499N\+-Q1XPF6E
MU'^_U/[141-<ZJ92&&#B_BC3=,'GY*UE_5VT&:7=9L#B#?V1IUIG]4S=XB7<
M@L7XO+7*U3)=4;"YQ;C E[$)Q:)C3Q&J8 (E23NDR;?K@K)])DX%1980*_Q6
MJIL4@N_RKB,/D90U(FN]J$-OW-]2-[>?ID$>5#Y]%+.5B9IC,  U#=!S=52,
MU)% !E#;-# )*?C>/_&\-M'U%E!S>NF8Z5;ZQN3_%!O^_TH@U:.8&E3&ZW?J
MQ\I(72 '\) /6\,XJV[%QO*=C^[(<C/V=K*>KSZCLF4:96F,K7-1,V7E:> 7
MT+89:^"Q?L<C,V#I2P-@PW45W0*R8C?ZO;-; HH'3-'FD2K3$59(3]\Z>XO#
M5"AJ=<];^]PTTAS3W8'%(4\Q(DQ[+,>?+P(FO:([$N'52_-*9F3MOI_2Y_MP
M]/<8_(1<MU4F.'MQ1V/\6S#OH> OA]$27T);W78JC_[JNO+ ?6X!$<'<,F;_
MC4HVN<1FJ35O9M^#=C)'81_*<9_[,(L(;S2/UEQ8GLE^GQY'!00Y$(8B47,H
MEM8/+/+R<$'Z5I&/6Y9IS']XH>=D^\LTP ,',C!UGEM MI%3IP@]060P K :
MXM%XZ29D1K:!8E@1,D/XC$J;]_-SZT9T)0('P0D@$GH(\?MP*5GP_C<*6:Q&
M <3Z/XNQXFRF%X6T$A1K&'F]&LRKEJ:>%33 JWRSHJB9"@CJIR-+3 9O:_:1
MSTMA+I_0Q[#*+Y<Y.#![MD6B\/E=/17GR8HZ94_ZD^D"H<D<8H.\P1.C[._C
MJ12TOR#DH-QBD#Z;=T@&(6NV$^M7=O1]AF)1Y(E.8:P'$*@LR$],CE<Y@FPD
ME57-*L0\-*<-J;!ARID!Y]N M<"#UYZ2D _XJX49@1*O[-36Y;,@Y.HV%.QV
MB$>Q?QZ )61+9T;^893:D;).1-'-6;$*'E8\N:;U&$:2^2_2H7<@F@QE6:S#
MZ<RR"N#8?7!$RE+OI]8Y/ZXUQZQYFQ=0MHWOBY9,W0D[)4MI:U%7WUXSTZG%
ME"6 0HG>L(;1=R6*%LM#-%-D <!MLR-\L)[A\.9>*Q'BTZ=4WD!$C'^E963O
M(JY,.#$(E9%1'>Q!B^$=%WNHC^L=;4C;HZ!0UKQ#]'B_BU# :T<'GL=I\;W
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M74V-7^VHGR0MA3+/DTW+XO577;R%66NZC0DA%U.Q21)SL-$2G)^0J54*S\@
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MO_KCG?:2TXFPQ@%6YN B%^.@'UA=^UGA75\P_^+F%M!N,M.JA@ #&**B5 $
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M;[ROC_M?)HS?)7M5^(E_Z#L?B7/W^%G \%VP6[<?[+V10['YK0X4-[\H[$Y
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MZ&N(\<$04$0,>K_VH7[?EW[Z;\I[G#T)W-L=]/]"^RD""?B_'B _!?]7CDF
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M_70 <@!R '( <@!R '( <@!R '( <@!R '( <@!R '( <@!R '( <@!R '(
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M2#SP;F4K!2N'+UEV2_J18K8AH%LP[:4ERI*2*)")&2+8H('R19E7TQNH8F*
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MK)M^?HQHU?<O[:J CXJ">BBU-//UF2+5M?A*>(O:*'6_A "I5]4W@)1 K;N
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M-Y*\%4=6HQWC5W9659O5_O#.:JZ>YNYDQ]9NI[-T-9N.3-P=-JM/B%*O4K(
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MJHBLNA9,>ZZ>B9XNCO>5+/:Q3U";)ZX]$UEK(2B%AWJPF4"'_IL*R<F>&SV
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M%EB?\Q"%E&&H&03X%O]Y]%GJ'8"UZGU9D:$H)I5[W1\[:>:KO1J+FDM0*!#
M?>P,%T -21L6&M7_13I[&[\S>QCY4U9GD/#\"-JGM"A!KT$*4Y1D\LK,U4PQ
MSZBHJ/BN;612:<(CSMP^<6)>K+,6O)/%HC-+&]B-P@7H,;)-GK/!)J2)V+-1
M><UI7TZHUPH+M*"3P0/3==YCJ II=\?+J$->QSG<77_:._6*.CKNA%L72[\/
MLA;:FE=-NG.F%)5KP%O)KY6IO4:5;X8!$54=X6@QU>5]8 %_2%GYU-R$<L9M
MA1%(TDN"5T!EK7=;HZB"N;- 2=* I&'(^Z+:#GJNX*&Y6L"*^Q-4ZY;H&9WU
MZ]7#TY+JVWYRTE-5)O+F#Y>8-E#<B+\20R41MIQ<\O2"N I"%,!L@7R.QYTA
MC%5,V-E5['>N_7"#;)MH+[-S?VD1CR;")B *2)G 71]CL.I1OGB\>41<-)_S
MV#J$RJWNM'/H_N-:25=51DF:W +6B:H:/ONM<.]GS=%I3XG\6*6Z63D#QYCD
M<6*0:.75ZS=)!105   -J;H"C0X X3X#)0S<ERVE[LZ)F"&G\Y^G<D/028:K
MINB;?2-_J'?+8]O>$G'L,[:Z 4D%5>@9MW84\D"681*5-\NY+I5H3 >4>+YI
M!_:0(GY??B)MZ@"^"8-J[DKLP<O_4'U^Q/]F^HW_'].G#!>9GCXG>3TV16SY
M#PK/=_AMLZ$(-_"^=%C(ZT6R;T7IU)E[K2%<UF3AOZ: LJ:_X?Y-^F#ZEY4>
M_%<7HXLU]GSD3<^J:AJZDO-;M,-)*=/5J+NV*AY9G#&CJTWGR;58T.+.N7E5
MKVGU0*<*\;;XL%@?RPN9L:ZJF^T)E JALZL[E^<G$_N-C3;>!DVV_%O6.PHQ
M7>SDW/$5&BS\(VD*J*/GMR:0,=[CZLG*<ZTO(;^ZC<.9<6-C9$+=U)<85SM_
MO#><9_J?.T.;_L_R7OZ$O'SY;'<=->15ZHB\B[I0"'?D!]<!/BS2J;,S."!$
M#4^;"C4-;D96CN>]<_E%$\D^0Y;"Y?ZUC<\69E(KC:*)(F0A\.MH(B1&NQH.
MG#LL].VZN@H4$-^B5'!20A%E"DNS\,@P*)TUS\\W)JLDI.=(Y]E>LKNTTIVN
M*[B2'N!_)68?_+$UN=Z#8Q6SVH]#NUS)TXESI':U-:@;99O <^5PV0HOJTXP
M-_)@O;A82O/9,&7S4%_EQSO1"^J8[@+AV1)<W6"U)]OE:!#/YRC2:BALM\BD
M9O%892]:4[64J3",/&O0L!UKJJ!/ENS+-!VCDAB\"4[7&._=ZFTL&[*:[-W8
M&)2(5LJ,I[#8I5S4I76T6 R5&<Y;'K-C8"B/"9CE1-EBVJQE9=3M(OG<9,(?
MG6"<%FN/2&^)S D&D/!9#MT#F?ITC6)7)E[&+^O(FX58;_YJ: P(#DZGXWBJ
M,N'-'6EKP]_1CDW,4H*5:^B'AO<F3E5?=!JCY84:1:4U2\%E'-#Y4$+MI/9?
MV$<5P$$DM*  BQ_O ('-@U3J+IT?2\R'L7^J+^W'Z%U5F65)E70PP+BM:O,A
M[E>!2!L;Q\QC=$^'XM3T5_?PV@_M*Z5&I>4DLMK*#A6L)R=;Q_?/G=_OX"<F
MEF&13!F8,V?^(+,:Q#?AD.@RV?W(!2&6=)=M([?65##$0<+._-[5OY^#4&VO
M(G9.U,[[KL& OYRTO:R:#N2F/'Y(X)VV7M,\+8! URM?L#]4+S(FV\-O:>@H
M,CP^8[OO^R9BX;"VL2(WOQ/)L%.B*U$=J\P.2'/;0W,@A@,?74.K^RQUFALX
MFT^Y]_,UF]?%3$*KN17_2-9[E=L+4&%1I[$K#8ZM14YG(_%AMF15<4Y!@A3E
M:#0S+MVQP,.?, OEDJVZN+C SA[_^X)\K_^Y'^STQFT;SH@T.0Y5.U4X/;N\
M>HH5V<PLD\*HKC\;1U-$0M;%DL-G4RQ#Q8"9*US9;>..&#-B4[^@#,ED[V-W
M#E-R]E-7=J"9NO4-)HHLA'U14A3&VV<J_[ZJ0E];%RQ4WOLB\TUS<=0:6+=H
M5#9,OEO5B@Y#S2 -PT )1RG*I N[SSS6\VPP4 !M&]"MMM6T]>M[>P9ZFM;<
M[RSY]NPL:V;L3VS?;UP\V%NE<XZH2W6S:"RUF\WF' JI%(O:SQ@]^G!%?L@N
M3FQ\&FZYV5N"&=1Q;W'ZJ4.-%'0\[8*A2DYUROB4!APH+_'@L U=Q5E><"<6
M7)+1?^%ESFLGCF'\U"D.XCQG^XSM"6"JLMH"(J8FP?%],(CVSVJ5YF_M7,>H
M]*E\#CHZ#$D<=I6BM6%*YGOAM9V4O9'6OF $*78'"XJBO]Z=B[B6<))0- [8
M)SC'_B]M9VHY[2^;3WMZS.+&FV1P" X J2_DVI!D2)J5\<,VQW-,7WU[7!8\
M>,TWLUR-%LH3%TKL.,K7J<$QJ32':0]G5$UER92QW?W%9'>##_S79?DV%FGC
M9NHYI> 1%E'VSZ/641(+VL,DO2FIGKCTR)R3II*CTC(R @JTF>(U'*5ZT8@N
M-T;R#\1EO;Z*K<T(]BRZ'7KJL\F11+ZSU/0Z,F)8I6'ASG)4)DBJBH^?9VK=
MWUPU,O1:%\FEYY(K"&PF?ZW77]U]/29"U-'K<+:!IY<25D. K,L\1<?<_S%9
MWI!\G<6%RYYY_[U-NX@ 7:&HPE4!_Q8Y$=C)EL)4DUZ;!0*1('^=L3E+ON#;
MDK2M3)*SCSD3&,]Q%TFEN=NOS7*YK/P<W<V5?"AM5DA#M"6#A1@EA<'F7%<0
MJJMQP5?AJ'%AF>VKTM7V>W;:3:=C/I.IJ\@GLGL6?;B5<@9Q6WDT69Z"$_I[
MN9P%4YN^1;G)G+Q5N3K#G;ARXW(Y6 V[5A"NO^EX4IY/=(CHH&?EBRCUFIER
MW'=\J7U&BMB2.(Z-^^BU%U];WVX+G BL[8[$L)8RYZP!47,JHA3:F-O@O1@A
M6(]5W^>\J93J8TY4@Z/%=,YA_I/MB94.O6^1<5O@\&<Z51LZ8C &9)%%&Z%E
M;GSJV&XSI '(Z5,9B/V,;HW9I8Z,8('\^UVIJI:&E)BF-H_71HA8@ED0K]J4
MALO=-/-0N)R#%%Q>)9CF<JT,V5-^[4NZ4O)V'A5\LD8APIHIZX\O,/Y<YMW<
M?T/RI$]JYL&&-DO1/3_=NXTM'8ADC7L)?<5XKYEGA+=55)I'MAAII.OB@3F&
MNO^L0BD=6;'/\EX>1N7YZ3^PAS/JEC69TI]'BEDZLJ5'C0$]NC8DV!1L4*1_
MNO5)-= :Q84F:5#=N'X2[:OCQQA<IK8L*5:.=IKYO7$Z7%E8*_D9M9I'0FP?
M99;SET+[2@%3U"9$21.O7QB4;(D[&N![M#6+[HXE,K5Z>EP#4$P\=R*G)TD!
M";_)+-8PH%.=:NK/B):Z)95B0N+#='TQWNE<JKI6QM4L*A:_WRUR=>$;EZE>
M*%6I>#4*)_.K4YE!9(C(4/GEPG6,)97PM0S\*+];=TKNB+PB/HD 9:[_"D6#
M[1-'JNS"?"%7AK5)5,X/X ;-3I1,LUMM9! 39%SFA(2F<;')0K14U)*ZWP1E
MDOX!<R>XMM& X1/EIKR<W$T"<6E>C^39:KW*2GK8H-QU:T6*.G7.1$=^0Y&>
M"GT-06[.;-L1C!%E[B]^H^\8-$S?+[1Z'.ZRZVG+<1FHE,<E1#3!8,% 39DS
MYV9[^:VHE!/B65$!W.J)UOA EI59.NV\'[:$U!:X-I*W)5G6$G%I\BLDHSRQ
M%,EL"OB27YW^?"\N16\DF=)^@?9EWPJXL.Q*J?*V5@&M$, D:U';.T\2_V#\
MQ$JX6J!70ED:;+6P43C"XJ$@8C& =<XS.[G98?$&&AF1BZ:' E^NUIIP.E0M
MY7,%0IATBO++UWBU.^Q0ZW"Y4T/'4C,@2TDR9G.(Z[8YA2/"#.2/$(>!/*'(
MD$I7V_VJ 34&?39D;CKB>_ !O?%D\$$YK]1L05%15V?S?I1;E: XR9M*P2&.
MLG? 'Q+H+;F. GQZ5J+8VQ';RYTOJC@Z:G#5XA?$X"T&V&("&R))^75N]YT[
MBX(1.WNO$(ASPA5CP\)$-@#ZBR6KX9Y#2VN<J:;,2UMZG,(3.2HVM5-.)$!9
M&OK9R)G*SJN1+^H/Q)PR\KHG2O<C[,^O.SMS$7SDRB21?VOS39W;Y9L+"&Z@
MHGDNF(N1!J=Q63$Q4)RW>-B_ ^"M.[[.>81 53HNR:_:GAT!:U"P%;PXT8^(
M1R@I+!?BJCVCAWD<DOHNP[85GV"YIFA-O.=$UB'&T$_ ]2%$[G.>D5&^>#\9
M1V\!N3Y*/'&CET)FIFB\<%>+NR/CVCSLZ A0)-X31J'R+^T1;QS@/]L0P';Y
M=0[P4O2G50P%LRM25)1&S"4!\0M)KKJH <$LZ$P^'S[[CFAT6I_Z-\^(G]PH
MO8+UFU!7)I<U<#-WE5E0;WDE*YH]<HD56E1F)#<F$OW#(4@#A%/+:',!V9'(
MDEXHH87PD8EP"O7K4EHTHA).7C\]HVZ&[7BW@ZVH(.\ZH3&,!XW.)6!%N'<I
M?T^,?ROOLH%TZ(,]>_-]];%=^>D9I+$3(<G"DI77=K>@DLC&@D]+!OHN198[
MC) 91(6_*\(#@(<SC(RT<C@&-X0:$/[84ML)!<X*"/V^+UB#[HK*OPNJ#'X:
MG8*51-6B0N,2A(:&2U"R/K5=6:0LO#_:.@,4O>:&/@<$VDEN*'6D(5S8CT(K
M'F#W4D7)* I[\F5A6._\X7>;:_8X)VS=)"'F,O[T#B#+!,< _8/YG]^TX'2!
M!UHI'2P3HR/PTUA9JYQK-@!4B&T2DKJU!R=DR?@_Q&]=QH@%,V.4#'S I&3^
M?9_8^1TQ\Q-72(@+'GL,:( 3?!"2 G2P/A<<,@> ^.7Q ER?RVU=:$->F: .
MX96/I.#5)=T?5U$_XR."BZ9*?(-.83S7"V0EQ!NE[Z?D@_Y*[.>?#P'8*8SX
M2UGAD(V"UI@@0160=)5LID#)BG?]%85"!&5M N*5G) ( 0%PC6'!A<XJO,EK
M0QAJ0$99GIVAA ))1L$;=;E53\58@'3J_UEY#U3N[^XU6T1\@F:!X"R<"(T4
M%NMU,UV?C:H4\=-M*3+4ZV2>[W:=\,6)7!_S'5#I%9@RY?W\I/I3\6;Q!OV5
M(9(":5R$:D0!T<4LBT.?3R!.,CY/YVJIV2GJ:@[>8"9X'N;L@+*>36(3,MA*
M",B*GC"5+">!0HL>!>V>C5*TC8ZV\V>G 6(IX _Z7&"DGI[@]^%2QNUI/-K?
MSQ3L<<T@5P&&$*P=Y/"6PIO:M6=$!GKB9V+&8 QI102YT=L>.NZW 7/ 2>J3
M!04!:B9!1-%**13*#,1]/^N3PCO@Y?[&\2+C?NU1W-?OZ<+P.,-R 5AX6!.U
M/5N+)'=AL\2->8I]V+';8%*7_R9Q\=ST#O 1Q$8!CCYJXGT8BA^H9O^0;"SR
MXYKDJ>8GP]S_/=M1C1U5G#:PPO@=@"J9<#2$&%I0L"YPH\K]G\NZT1>BI-;
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M;@F39X*@J#T2>6>8MZOC#N42A2^,3[82B0R"J#3$Q3E?UY42;UJ_2<9<,@&
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M:VR8^Z>[;[2S6L]R#H)+; +,<T?6D*:02Z:>?K#Z;<MTTG"4*\\XD Q[YO!
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M5$B1X3 VFEDCTR"Y]/,9S:ZX[-6L#567'\O,[C.KK$U?JB3N"WTHVF*X3<G
M9]=J4';.YZ5WH;1S5H\@4 ^=CQDKC>X3D!LCK-7+RR_29U+->1R_/9["P\>@
MF2=XT1@[4S=G91VC79U6/.Q34=2YJI^+D9:R)\%IP[FEK _C5KS8^H.$UXPD
M.<4R%=-:6^V# [9[K<R0J+@:Y70:'^M,$RJV:* (-2IL6:"<"$W(5_Y A:\#
M7V?F0CL(M#/$II97?RK;H?$1,C4504&5<W5GF3*DE4P\(DIV$M:F$\NM*=AZ
M:?K3#6J"?/K6PF]7W]52F=!_;R^WB/EV%" U=##1 /V6B V>8U)OA,VU;Y7;
M?L/6_)ZOPRSE5])XE&OI&QJBA\['RL?2"HK>W+4KEUB+L86-36I/<Z(2*Q\<
MG?%M.QUV!A0ST\ZB<^\077Z>AZ[V1:843T3L'Y>BB5S?+<O>#\^.:&X=S>)(
MG'."<M_3^5N0DBZ845BC7@ZPMT)H!JMC+R](4$;25/*I OS"[YE3?SHXEGJ9
MLQ^>5($5>@I=B@L;G*W1!\B&/&)&G F#J'CE5&EA54%?20W1Y^#AX3E1Z8*X
M!Y5OH.H+7$@8CWQ1]UY5N6^"[UZ'H[3?WQ^JOX1'"B#LAW8L]L_EN1LI 5P8
MBASH^AW]5U!=R.!#B45_J+977M#E]EL/DL7QYH![EI)JOVXS)5MT\C>H8P9*
M4-W%\H%BXI:S(EA_@$=>\EE0A=N>$LLYY>W@R@L1 $+\^ 3H:8ZCOJYF#7#@
M>B@&P=+X[0C=J_YGI@K;:COHY6):=W.FORJ*FAC[5#8_N5-J]/8X-D@ELUO'
M6<ZX+14K5=]%%//#$#4:*0)M[#HJO=OUY-J0G[JMAI>]5*(SO(4<Q6VA9,?H
M3&,H0ZOY-G0&TQY&R.V,YM6 S/0\6;!CX+KF4=55:-Y@$7$4K#I> 2@IF7S&
M,DO5="/!:Q@WHI:<BDR[\#=8V3D#$&.FHOV"B(Y*_\YB[8?+0MMW[M'O^;!.
M,7L8PX&=K-+]2.XA, D@;Q&PQJ9<WENO$)CO@8B^L+1!*UVV&73!@EX#CX^_
MOLP3=IL06KK+J"WU$0XJG3*I1#J\<0,IX2B+UTH4VKID*]&7L"9BL(ZH1IQ]
MA'U-;[)XL[$?4;KYL^XS!1B?5AO%(DO>M3@ZRQ;F%4M2D=<.G4Q:*= MW[-,
M7TN$4J1ND$^(ZG>C@B# OK^OBKY3L)@![XM<CAZ-XI)58>S-QOL9I.2FM&4[
MAB&!]KG+<QO6.=KN%SG?NN;:&D2ER]+0SROJWJ]YR[%(8$K4^QSWZMR^BZ3'
M"!R<DQGHN)1O\A;/.;KB?5;@;5F@*F(9<M^WB=<3,")>V@_'-'H>-M%JZ>L"
M8!EP8F$9-1+IT!C1!-0*& L4?4%)&'T>6Y  33DWGU[)_4X_:Y1:^X;>&L,J
MM8J2\)UF/?*<+X,'6C+;_H6O5_3/"IUTU:Q-ZP\C\P WQRHHGMX*ZRXTKN?8
M]L#N?8/]WO2<3AY7Z(IVN!Z= J!]WW<*"L1$A0,4^6X6[Q&7[L.SO.QTR11H
M2XN:;S HAT-.,)+8=Y1(V! -J^5=#A]ORST#C@+D6>=O+0^[S^\"+BF> '[B
M+].W @>+7/8*HN.#O+F;7B9+BNEP-8K%K4=/P-A\LUL Q8'QHS:_P\-C-E3V
ML5'UQ&>ICK36A60?\0DHSF6#,\Q;&VGSX<UH#G_<>?1K\=?V^6>IR2W_P80P
MJ\OZ?>'A^F_/#P<E8Q^^T\SJ/@'+UMTQ&'T/#>YKMU#^NU3Y[MCK':V2G]?U
M5NAXK><WWW9)AN.^E)^3NB.O=>U\%VZR7B.9\KYQ]V1Y?N1'0/AL1Q?5[!,0
MM9&K;NR/=L\F]XG9 FIX^P10K/GMY?[E[A-@]>51"O=L&A*P<W&\9W!9NQ<]
M1X+HEX$8P>HBO$_R!$1"L$UG6U_5!)4/81MP!;X[&OD(MY-6 Y/(SA6%W.VU
MEO^E5%_CYU3>&VM8\H>&JS]-C:O.'-R+]K&A./%:*L#LGT"-6T4\ECJ\V[O@
MCR=XX;[*']!EO2*XL]%[-ON/WG*2X37S^MO,*JV;/KO-#[/L?X?W"6B8[Z8(
MWRIH>@(F=]?F.KK/.QA8GZ-; Z"N#-Y]FXR\X/Y7P-82_B-3^++S=H$DJ6IL
M[!J7_;'&+U?<VG>(*,B/<Q):7'GP!, M13[O<)=H@ +[H]F-@.!V'0EB=H9,
M?'_?86;P)#0R.^3X@V(Z3(UF<5M PWS;30#<H=$_*?'V;O[UMQWSV /=7/[(
M;>&A+1('[7^$ES#=OKU]SH6_-ECJL5'TQ&,IX4%R\C(XSIA^.,Z9P/!R6FW?
MJX'NXYDH;'B.=C^,9/LB$CDIX:0V7=).][[5R"M A%682;#Y,4#AL=#+Q/X>
M,K0@_KSOAA@K*V<D:_#$N</!,R;)]LAE&ME#,1^TVVVW-)I*-NW;;/"35L8]
MF0C/S;=<F%%6=)CI2!3 @8F[A&!RP/ETH.01[][^GIG]M)VKO2_Y.GHII"T2
M@ZFT)2\%IJY%AN XH_*!Y,JIT8FL/%XZ[C@2'B_A@DOI6\PWSDL$8.Y+!X>Z
M_XL52E,.0ATDR]+MV/3\^6A3$V,.X^DV"1YL#ITFZ4AJI145=( ;03A-8#^N
M8^.8MN5\5&7522*EI9&VM$SB")RLF,YY9<<11B N'XL#$5,*.0.KD,+LE<5Q
ML AU/!,)Y"QM48=N.PSQ#TB'^&NB_ /U30]5H'*/3TADEK]AS1DE=*H H@>(
MY_F[%1+)'SQJO/">FCCL)V;&8\5IT70?IUOP\B]K)?*1XN'A7^B)B'@@O4:E
MY2+6A]+O_P_F^$M-IMO)(V[ULR9XW&I6GQO_+KM;.;J_>.S9H/Z'$ON#OX='
M&W>WS5LLS]#W]>X9^NX=1M;!$2;"2)@NYAP=EJ!]UNVQMSJ!A"C?2+DIO<81
M16%@9O7@$?W7 ;7]XUG(Y5QW!AZ)OO'CCV<%]+/_8K62_\X_:_HS$EV0LQ:5
M\G]QF_H_>.LP8@3^F)43(J ZDVC,,0 : 5YXKTCINPGE*4EYO+\T)ND@,0*M
MN-V_ M]^_O!,O8?;:RG]_YA\_H?)7O^9[TD^%WVQ/V8 &>\(&'%W>!Z*P_TY
M[&8(_7_;A>>P@4I;TW^+#]*KR [@#:CGP8 O6T-$B+FQ[%]PWLX$IOD \%(B
MKQQS ^HA2@=^3\";!(XMSP&Z\;?8$^BH8KG=VLXCJF<26W#(?2+%F.AR2E.H
ME+2Q'?$]U=W=W2ENB?IUZ=\D-M<CG,\S"*N6DM?>H;-U"R#"S*N"2E0#IM%4
MTI;3 ,="37#<GBQ:N4"@SN_B][SS:;1 [9#I1"E,GZO2;E8?ZQ/@:HP')B<E
MQU,+]'L@O7]W?B-%,:RNX,2[28;J1,-E@C]*@:>ZF18DCAQ-3HF)'&$<<281
MQBK!@3$O#1=/?"*,<L!1:?AL- 6*"6X&+-Z$5D0R!A8^.FWD)2 ]P)H$0+]%
MF^"*LJS+$?N8()X,+5?>7WV^$%YT)*F<H"<5. =P]IS!RGSDL(337\N2><VF
MOL+3VGP6E]3UN7GD<#W+N4_'K2H_ENS*_Y!=3KPYM$=66F@6\BLM(CF?7)0V
M(KDM(@(!FV*-P/5L2\^F&NRLBC'26 +/E_]S2]=$@VX1T\7XY\\26M26>%[8
MTL!2*H V302 D7[^Z+)(#=4K8-"T=_D2$D).3ZLVE!_):YH^1TZU2:F:50)'
M6(8E1HV  8LKEBIVU%.!EK/CW?*?_:;[SWYG/N^WFL^298F]48(-^?!( 6/"
M!TK"_+H@HNT+>)'(K($ISCDI>8 G-DU-H./NKM.KS^\RR1EY5_9(?#A4NX2*
MY1?\:\-.7<=2)'YTWU+2-)M2=(Z-4ESW#LZ>2J"0^ 7IY1&P#@DW>/4@L*L
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M*[;HF=O^=?L-KU?:DBR,KF!0G 5B"EY]G^2::0$Y5HGD0N:[7DX;=%=*[<+
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M+DA+CV(:-_H]A5IWOWF*-3TQ6SL5=WH5H1I^'FK_"L[^H.L 3D/3LAJ/B"A
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MSRY;<A<[TCT RS.,@N342-LC'O%+$!$]27M%[!-D5X3JW>KOV X>K(V;<_*
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M+LN'RSA,!+F^S^0ZPT+DJ"@3B^!3')O YN:>+5,@)$!4B8)FR/E:HVD=?+B
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M! 'U,T] 5/.2*ON(P/E!7%<V[?F^O\&:49=F3_IOP>ZZ\IDX0</4ZR&[M>.
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M(()(44"*NM4OXM;M?K?ON<[YSOG/]?W7Q6">/&NM6?<]LV;-/#,)^'7FZPL
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MK?MW' ,#.75OB-^WD=115_H^[Z'>$#CTK^&3DY5V!L.D7*! <2A8!@@#2X&
M8"E9<:"SE+,+5$;<108*=CXA^CO8/XATD&B,,_+;85$)JQ"!8TED(9(N8+"X
M"Q L*PD%NH"E7($NTC )( P$@H*EQ&1<H!(_H7]Q_P?T]Z.DL^<O]'Y^6'P-
M<0EI#4EI<:":M)@T4$I-7 RHJBDA#I015Y4!RX) 8!59T _\WV#\@T<;CL;F
M19#2W]+]9"$R@_G^7?O#X D_69A\G%'HDT.L(M>/"<?U#X=O/B=+@)PSY-N2
MIH1V]H=!%43_IOOW3O!_!EA20E)*3%+&!0B2DI &0IRE)(&R4F QH M4$@8"
M0YV=Q<"@'_CPWP7X7SD"W&'(?^:;&.A'OOU2Z]^#?)MM <XHF(H;-LY*WQ\J
M?WW\+"$A(LXI8 5'0KT#T.=_0/[=Y]]C0]R=D6XPJ)+H#\<?BG^,CNCWX?E_
M<=ADH""(LXR8%-!9VE4*")60$@>"(9*R0!>);WI):3!$!O(_,&Q_+1.GPX8=
M(H@W\MLG*O^%H</R.&/W2# 46LD5Y>W%Z>SCXPF'.'_S$O5'0O]\W/U<2CDQ
MWIQP+V<WF"C,!^WZ@^47D/_%SD)A*/A_)4M_:>7/.''^_ZW3_^V)^9][8)U.
MS'_1_OWI^..)^\^GZ8\MR??<U/R67?^YP58XV>[^=Y;2?W'_'3KT_VIW\0_?
MWT%[_[<V,/\6XY\Q_R6TOUJA$#G(]TWO?VUOHW3R!?!_9>A_R_2-'[L7]W+&
M*/VZ5/RE_?5T\'-CJN;MZ8W";I%A2E(*HK]3D_[:D%^.BM_/H:)_'D2Q9V#1
MGX?@W\V$__ER2G)*<DIR2G)*<DIR2G)*<DIR2G)*<DIR2G)*<DIR2G)*<DIR
M2G)*<DIR2G)*<DIR2G)*<DIR2G)*<DIR2G)*<DIR2G)*<DIR2G)*<DIR2G)*
M<DIR2G)*<DIR2O(_3$+ZUY^5PY!01:X K@M*7^<!:@"<_V;Y!O+?Q<#YV@6@
M)@88XCKAX5 #<*EQ\*AQOCX"< !P #CX>#B__']*./@$A$2X>,0DI%B[*14
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MIFFS-CH5*VC+DISL<D1BWHA;4N!G0Y*7_&S3FB/1?"1W/.5\E'C_Y3R"D"<
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M!&LJ#\RX#7=6>;8D7501!$#WBGI&:$9"XAQ^GXVRN";7%1IE'4!M9H "S33
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MU^'*P+OCV7[(&UB0K +>;UJ7,'NTB*A):=CEF<2$:KZW5*^W"M-HM)D&QKJ
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M9)RE>0<_8JHTG$X=FIZ#%3?/^T -$3PAMOY"O?,&'_R'M#R<--HG&H![&9&
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MC#7@R*N+R.EY?Q.UT6]=(L?:^K.,<R9@!S/JO[2E&#A4XZ;;^&Y5&U>;\T$
M,Y]R5/:B%OZ.^H6 E3R'GJS<*\<IYOW-Q&7_ERW]-[2_#\$](,A)+%V8R@D"
M *3SS.R'XX5>U6I'<K+&=2G:Q2T&'FRN4@=P0ZO!%E*L3QZ)M!7A\D29 NE,
MU#*O::O2.XO'<'>1&E-3OR'GZG2F%]P96/379BH2ORMKTN;BT'0NR?W5B_1/
MM\Y(:<^\HG0GWA]VZ/%Z1%Q6\V_&_F"6F9.LQ(PMKUWS$RTR /RR@84J$)M
MQ?9%,NP?[LD#XKIXK!U+[;*?->PMHEQ&VX]29MQHO&;;)0H\E]75KY)40-7+
MDL.>L#^Z3KC<Y1-]9L(@L'0CNRG!)$?%;W&QX%[>,X>81FN&&%]8#MSFAL-D
MZ/:U[,IY(LDSU"INNV*F%,R%BY8.3CMD"1)W^L<W7U^:4F0<.L]<-Y82-<ZN
M@AHW90CN9'Z=D9I!:Y%^Z%7@8)_&E;I234VH/>U^7Z>AS(O?OJB,^!R-&P*7
M0+!F0,FRHN#.-/&\H7?3S7K>?(T<P_M#Q<R4C66?C31?$E"%P><'SS8(CA;+
M=J+:XO)7#$E2AA,+C<N6]8_OTC[N7]YG^Y)MX7E7*$-7HZ0!PLR3E;W7MJ-)
M+U-'3]L:D2'L$+MI'<WK55EHI\OS-F-\#3$D'AE ['>#TTN@3M,"2EJ1<=&R
MLOCF& -HS6+52RY!.R0H)34+(7'XP/%&M=4+7OXI.!%Y+9];0=H52(P;+>F2
M1D:$9\!MNL#2])3\;F&."RE"EOJ>]6C2Z:UWM=0LE]V;_9J%SU\#R4!MMY:\
M&$H]O.+P31GTS)\DBI6#F0LL#59<=6;-Y$KTO\P:E0UF[%46@B5,N:W;I NS
MF<:%+J&FB&N\%AYO(+P<G08U29X*0>6*2EIQ'*#.=.Y+^C@)66<4RFZ87;BO
M]!7 FP(WK!CQ4&S:93QGE%+4IVS5L(-D3KG*92"]RYHA?=/M4EL-.BDA;T1S
M5)]TEG)K<5-+(P&YR^%+*Y9RL#E]T/GN)*/H,P+^X/9^"OH*F$_X"O#6NFAY
M9O[H<VB0GT9Q(\),>$*(%Y1'W*,R5H3S5%MT2D">9XL'F@!=8=:T<BRU]YF4
MRRVRNW]IN;&JKV9ZO@6:23\@!#9""7/0IDJG/;7)LIJ3J$G)DY82ZN054VX)
MYVRIK];1U=7J<'/04:FW77PQX%KRI+]OH%-X%9JDJ=N/'Q;!8WG%_S EYAI3
MN&)+ESM!!:D@L7( QJ[4(KE#C6H73XDV+WG;$MR1;R/U\@SE\+[Q%NQL7?#R
M$)"XC@!L:V9CNS'1.E38C?L0J=KPGKO@C)G)>S:O):\_Z$'OLT+(U/IWHB4Z
M4$\YSN'..0<O!-UZ\TC[V7IRN/W;C-%+)4\]DI,$@I-3:+4G"C)Z.%;WABOK
M?)NLUTPEQJC&H#XK;([J,H$P)E7P+9P[%BT2[\KI'?C*H [%KRS,7),[PGN5
M=DDNNLK%3Y$^Y)P##%>9V5Z47L.]C-LQF_6I5)14Z=+H4ZW$%#<FG>2,=GGT
M-;MT]>*[U1=ADT[3>NHB!8N<J@0]98L,M>S04'IZY39KSR0"7[/$N@Z7I>=L
MNRP$EPW.02UC(&Y6!*N3 (VR"(M-\>ZR>>2KW())F>SM!;=B*L;;IKJJW%V\
MKA^E^5B*)4&BE'#PS*MBVEC>)^PWP[BH@V2_Z"<"N2'LT02Q<9=OO[];-W0@
M:27RS"Q55I? H#-FTL.":U*L+<:UZ.P]O>W%5T'U3: !%5U3KT;75MOFV5=Y
MW#$2>RM+(A(")@Y:1-TA]4\W=ZWO@+5:'3J@4)R5 \)IA;%[MO,>GK@CW.O0
M-78/VL@&,V#5!JE[0G3$^&S.5P!$X0MX@BV?]TZ+I<G*ZFWEZ'M@R)CV'J5P
M2KMY?O'D*E\AH[ON!"KA)J\$:H// C$FG1.?78!@62UG3-2WU>ENSN;R44_'
MO"]+#[>ZZ%<IWAEQVRJ]=(&SR)NB;$Q :Z#<E)G8/7IB/EW0,SD9H:=6O#,H
M]JKL24[3-6^QG68V-87:?*8[ZF+1A6GGFYMD_<</.L5:9&)4:QZ;74ST$M"B
MJ9>S;?"ZX5?H(6ZQ29>9ELI/4[/E EGF506CPWNLUK7MZ/M]N(9?V[[06XQ+
MG:U0\T\942ZPVTHY@MZYEAD<DTW33W!&NG=^KF/B/>EV3GU#K[P3Q5WZ32)R
M7INAO*1\OL5:AJ^ 'VMY_="5J+ _MB[4\]1$][;%<R%&,K-;MGE05V_=^D+,
METZ'YTO][:^7*.\!*%I\<,/Z<X(^GBVN"A(B?G'N]>ZEQ;#W+Z>K+PZ5L%VZ
M'-NE>.[C%65/!7F?R"Z9L^/A77N&U5KW\+;?O]ON=O+KOR#UH6EYW^<+NRJ;
M7.WF='644U P.VU]>7GYD5?35X#,[=&PU4M!7/Y^?A'=K >A;2U$'$SJRU.L
M5S:K#W:[G8(X 8%A5[0VSBR&FTWN!U^(H-9<(+KJY_N%W?Z*UFBX(>MVLUMT
M;_/NV<R-;LZO@*?1R.=&5I;/#8FJWQ)G!LN>N?B)R&HD_-O'& ]>?P7$\!$E
MQG$ >VZ]FPG8_!SR%?"6U"D(_T.7[%< 17BHXK7)&^97O<*-1K\"JIN.-5B)
M1B>;G?PIYXD* CZ?%:=]_5$I;NGI(K:'1U_NPVL"'QB-SB@ZJ/007P6P7WM
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MN4$1C7$Z+"\[=  [Q.NW#]KZL5_[7JD1IOLR&CG;)E7/[,QA_^F52QVIME8
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M2,);LTOH07@X7O>^_ K$[R:Q"D \>&1JV0@^$:=#4, ."3 _2HYS[JW<;;D
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M'A";EE_5UC>YHGS2UB,P+KV@^G'_^]6] &IJBK>T.SXQT-,I[K@@+,M)2_'
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M5P%4ND*?>46H]7RAMYEQSN9:%TC7.F<?5Q]3R-@"0$>/;9#>P$%\)='I>&)
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M=OSU\AP^P!LOV8'+V?A\C+OW]$S)=>-3MTADA'[I)A@<SU],2%C@N\@S+LB
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MVQ>+2A4M:AU52#AUK7:<796>L:AP7RK@0!9$QZV!_["VWJ;H&FQA#^"MT6)
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M7Y14+"Q<4<GN1TZHY[D)AIX6>*C6.9R7]PZ0M7#WX6VI>Z?O]5(JV[Z&$V/
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ML365,9E/B2>;@'K?4AQ1,DD:Q'$U?/K/%BW+JHVU!HA.Q8VSBVT!MW,F4#Y
MQ3QBD""U;\4^](&$E<1'1S/LC#XM4?A-]W:_J<Y^<HHK)<=Z$0RISI>O5I3@
MH5[T3R O=8S\ ]0G$&-(4^3Q^-X']-7!TDO<3*0HFEE/UG2N&WLO&:??(%P1
M\T*F(-A1$K?/S>P&2H[TN513'<YFH@]'K:=>._Z.!LQ - ?"M]^IJL/Z W9]
MEZVPBK^ O$JHM\HW%A4^(B-BG5LR: ^>DC]5/ADZ]T?)H=0]5<-6/9LO9/!A
MS"..<2U[%3G-OMQFB&K^C*4&DZYQ1JF[FL3A/D+=+OVP>^U1)WU+*QO$=UP
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MXH'F!X>@?"6(_G#PY0*YN[OUZDT&]C$83G[D<BS\J]Y"Y7@[ A%(C3'@4!J
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M;5P;EGM_HZ#Q?<#QGGKVR$J$/Y1EH*DO3Y?(B))R"B;>/3L!DI1(-,@3  F
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MV.V]9NWCAEN9KKI/?91GZ,F35"1  XBS/)]7G6-Q%QU:].J[-//D,#)WS"G
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M4/<:]_\'5T"HOVJ5;SL(-WXAX9U.BLB\BZ+X()4.0VV PWQ*)?> S-EQ6L/
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M*E 2?B-=F?@@U?O_ !#XUTZ;EQ&CM<'T%]%E:UJ3_$W=5?2M?*264JW;0DD
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M!AS I4P YDL"00\@":X>1J+R+UJ[;OA*;2T"[_B7E!)6IV^- Y5*91/*DI4
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M$H4+B%)U"#I[86ER;9N-RH=DJ4"P <VJ?:TW.YJZK=$J558\XRGH1:KHVUW
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M1.^QKM#\#8'^TOCEO_S+PLB4R?XG5">5YZY9H+/6 _JSSZJ_4G)XZT;TC_\
MN6I'M&0/$?7.LT\-?^!\-ZBQ'R3^]?N)X&#^'5;,O0G8?_>M0Y=O.<UC^0??
M]PQX]QX_=D:OOZ]OHW^M926(V^8>,-+'$NY.VU>L;[+;/H8Z!'_]E[W]A/\
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MO(E@:]6'V3W_ )CO2@'QN#K'$_\ WS;\_+Z>,^=:'\6M_M#KC))N(^MFV>Y
M ,#[/+_C?_S%K?\ Z/W%61ZQ^L2II2M"P",^RL9S@>P/Z^?/C5)_,GOS?M2O
M-_\ ;9'_ &\N@'_W6[]/C_\ 2O:_ /\ 7](.#K9OL^_^/\[?Z'[SY;UN?V3
MD\48#",NQ^$%B9_2J;8DXYQ&/'@_0P/IS@3$[-^_U_MV$P:W*X$&1A^C/M.\
M2!C>:N]^Q.QN+U/'WLW1DS[S7=5XY CG$#G(UJCVB?\ 'T?_ .*NQ#GXD=OM
MY>M)^UMO?Z+?X$,1C_AA_O,5GW]J?_YF&^2"$E&X>GBY/L=XVM!&)S"B3F)&
M3$ZQ7P^W\PM03\"V?J6.S?/Y9-<2?B8'_P!QSQ5/+RV;9!B".<=NO4>=>4-3
MSO8XF4I'<XJ85D!2 02# *O^48[8(!D1MQ+?Q6FA_@2#V@B&DL[-G-?C.2HV
M>4L Q4"'<@*8N8 5W5\(2!,1:W=75'['W:SA$*_U0=5YX!OUZS\RC$<D$GC/
M.,21'C'5=K=WU^$AH9GZ@!NE=Q6B_P"":T6 ?Q#JB&V!\57R#\1+D=U.78F6
M%4JW5A6#)*5\\X9<R()$@IS&.9,Q&7)QC=GF<1B 8S\FBN&@X.7(!( "0[),
M@NK!&(R'))BUCJ6M0^R;Z&K C_;LO! ]I?WX1^H,^\&?(C6%6)\4:QY=://\
MR>XZ=<.*[J\5*;\&/@X@#_QO3EAL3K>);=<QE^[&JI4.*2^ "0"XY!&8E(/"
MI)!("08@0.>-9GK9T*@0Y][I7!+"!>V!&,LX)@!JX:LGDO6RDL2E0*@1 5S%
MQS DNW*2S)8;M5I?7M2C]E[Z0UP2?[*M^DB(R.J>08/D8/GG\\;TBBCQ1Q8A
MP^E=I)'^)I T%^NW3T[<]JL_A3]D#IYB-9PU.6__ (5Q>78AG:8!."Q -6!=
M4")^8P<G!)@'P??RF.TSD@$G)/?G +8:'\FR69H/GO7#Q2Q_I)Y2#+9;IWAT
MD!)ARSU;3ZNED?9S_9]J,$J"R2KD3M>XY'<9/O !/TY.L5X,'XUXC.#_  P+
M@N7Y5,Q#^6V&KN_VX*;\-_L<)DL@NH#(L.Y"I^0<'I533KROAUY/\IEXF"H$
M**D^\Y[O8)DB.<ZRRV"%\"8N$H+8D!#;0Q$M,>=</(657]:H@ W+:@6=)25*
M2H#=R% C^DD]\6M>NQ2AZ0?L\4YQTB8)4"HQ&R=ESDD$05P"?H09R<1X KEX
MKQX__P!;?#__ .=?5]NS,)KM+\0H;V ^P)LC@OA\ L__ /*XA\P69\^=5-5+
MBTMU![X'PW21)*?V%3B!(((([3&!C)(RPWB0T&&#@@L6'E,#R)VKB&V#[ZV5
M$@&XER&*0Q!)/4L28)#,&DU:E]H HCHKZ#E \=&*?P3(%BVBO'@9 G@8!R<:
MQCPJQXEQ;RN N9_*ET[=6$>35W-^+ '_ &#]CI<_!PR\IP,E/#N''T!(<NP$
M9+"JLG7UAHDF22[!/F>P$B52(R,CG '!UD[?X&H &0ERSYYX[R78$;DD!ZX@
MLJ)U.G)+D7[9!)8EUH<ERX,&2[;3->Y+HN2>D_3:>/X!;.C$?_-ZW^_^D1K2
MFK_]\U?_ /<7/_VC]_+K7[[>'V_D/!&__-'#N_\ \)9\O]:[.UX5=Z:4KK^[
M]2=OV:Z5EHJ6+N]5T"F4U)I+>7F4JJ*=JJ;2'2Z@*)9=02 )!D'C1_O[SZ4^
M^GZUL%3U3V^ZXDMT-_('[4VP3^RH#!J9Y(, 'B8QFH$!*BX^$SY$$?.<=W ,
MU1!&KA_=6$7%CHDZC3VP?_TEI\@YKRR_:8W>GO?K#ZFW*E14M4]1:-AE"*MH
MTSZ?A[-M""'6B5 $J'<D=TE,*$B =G^' 1P;229O7B<;K<;[@L8WC>OR,_%\
M0?;-Q3$<*X.-P0^@M*\CD,V[@[5T?Z4JQJB]3OI[K7$NK:INIVU7%H92EUU2
M4UY(#2"I/<XH.)[1(DD^1)^GB/\ X9Q/MI;I.< $^>(;MWK7/L-/_P!UGV?$
MB$^(^%.5-_\ A:2&&26(8[$L<5V5]H-<V+KZQ^M5QITU#5/4WK;RT)J6RR\!
M_ G;20%M@J[25 C*CP0/?7R<%!3PZVDY3:0"QCUW\F[/TK,_Q5J?VT^(U2 +
M&@3C!382G&[J26)+$3#BN)>B:N;H?5UT K'4ONM4N\T.+;ID*<>(%FNR3\-H
ME/<HDJ)2%3'<9"OE'KQPMP"ZH_\ X47.Y!-QH^1PS#$19OPX*;VS>!B75R<0
MUD)<D/P?B .1',7CF R\D"OW];EP9N7JVZ_5;*'F6ZK?BWFVZA!8>2A5ELXA
M;8*^W *H,D @S',\'#<-T;B?='JWYE?68ZMEJK_$L4J]MOC@@L/XOA9909GX
M)PT$#;9RX<?^HL=_^S[N;-L]8O0^OJ&WW6&+Y?75MT[?QWBA.RK^(0WWCN5W
M*/R$G)D'(UY\?25\,NI #NE(),.0KI$F,3DG8WG\**B/;7X:$GWEG7@,Q#&P
M$I=E. %'!$,6@BNM?5-5M5?J3ZYU39<0V[U-W@I(>04/)#ET4KM6C/:H?R@"
M?(()Y]^%..%$=5VRP.WQ[@P<&9\LC _;8I*_:KXYN#"O$&N =)!G4+<2(8CE
M4)<G=F/??V:5WIK-ZQ>E]QJ4U+S%-8=\!:*1HU#Y^)LZZ-H"6NY)40I0) 5*
M03P1&O@XS'".-\V?YIDNY_[TSN<[!XQC-;5_"8M*?;'P5Y'\FXH@@3R_[O4P
M(=QRD*)2YY22-HQ:ZVU2*GK1U?J6I:2]U3ZANA#H['$)<W?>%CXB"3VJ*" H
M R,IRH$B\:183I=*F"VGL,6>3:06&^3T?RK27M0N)5[1/&:DP#XAXIS/VU*L
MAP)2?U$EU5FE]E7=Z>S>K.BK:I%2\PGIWO)*D4C)?<DU-@(7V!8D!*5=Y(!$
MB1QJT>(GO</Y4@!043D)=P[8EF'G&];\_!HH)]JUP2 O@^I3C*RI*07![GF<
M E^TX&[U=;=WYO9P$E+^[]W+0A4!10[?*M20M$E(4$D?*51P"#,Z^O3$CAED
M@J2RK<@GI#$ L^%%BP*JY^\>*0OQWXL49]YX@XH4I4$_E5J+K@I@$R&2M026
MERQ%A_V2=\I+'ZC-Y556BJ>;=Z.[@IDHI&OO#@6[>]JI"U(^( EI.$J63( $
MIP=?!XJ25?PB!CX5 ;!EH42(;F(>0[DD/+5TA^"Y7)[1/$I+L/!O$A\.[<2X
M>06YBD, R00"P :#58]6N7ZA7@U5:3D _P!VU@(4 8X,$9R2)(F;[8_X-K,V
M[9G)^!/^AKE3Q02/$7B D$_[ZXLY27@:_5 O(V)SY#X7JVO['O<5!8.M_5&K
MJF:ZH87TM88":*F-4M"CN:WF5H[T=J(!E4_,08$1K&O%8/\  V22(O%V#F4@
M/C]0V>D]G_@<N(_VE\;\J5_^#\+Y7<GE&HU9[?"[C,F(# 8#>JR\BI]4GJ+J
M&FW6VWNLF\W4HJ$?#?0%UC92'6RI10L@D=LF1^0.L_\ #-O_ ')P]):+ $,7
MA(<'!Q!;TV'[D^";93P-:5&4*T0+2'"-3VQ!<YSMGH9-S^821^T)F.)SB,?O
M^D8C5_\ =;/\Q+OZ2[>LUE2@X('0G8.?,Y!Z9^K^JO[,_J#9+'Z(NA%%6T=Y
M6^S:=XA3E+;P]3J[^IF]E#L=^,GN,<F$P<'D#6@O$MI0X[Q!@"]P$,986D00
M(!B!)_6N6O&##Q)Q$?\ /<2H-AO=(!<M$I\C&:SO'5K;7\SW!QYM8^G_ -8R
M<C]^L>26 !SC!W)_MG%8X"^*?V6MM<?<MP9X_P!B_P#VC57W\Z4_LM[:_F6X
M/_PO_P!HU#C[_3S[4I_9:VU_,MP?_A?Y_P#UCZ'4OGM2JH/M?=YVO<GINVTS
M04MT:4QU9V\I:ZRC33M8L&Z#V]_QG.XJ"Q">T=Q';B-95X2!/$@01"2#N05<
MK$?(A_E!>N2_QDK ]D5Y,A1X]P=70-[W4@OU$N4_U!QVKSC.D%:N0/CD\DS\
MSW;@$1$#VQDP<C/4D@73S'\JP [;IZF07P'/1M_R?'YE$)+?$IY+LH%/Y&9F
M+$MC(<5:!UUOM+4_9>>EFQ--5B:RDZK75]QQQ@HI5I4_U3A++_?#BR7 KM[1
M" KP-8SP8-QW7DG\V@402<_X]@.=^@.X)R]=M^U%8/X4?9&CXG_FG#P<N?\
M='&7 D @JR%;.XW%82B ^1DB!\HYP.V$ >\Q!CYN.)UD@)Y =^9WZ_%VG)&)
MC$UQ&HP0<.D /S$&!&&&7!GF<@,YJT;U67VFK?L^/0G:&6:Q-1;37H?<>IBB
MG<*MNUAFG=[X>"1V@J*49\$@:QCAB%)XYK5X"BB06)9P>[3/3JPKN?VX*?\
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ML.^74=CA>3W)[%HE03A04,D'6A/%EI2>/ZH'^M:5"8^&U:=_U9R[N[XYB\;
M_P"T>I#@\X3RLS?#EWD9<=1Z58>>K6VA_P "W![?[E_^T:QX$'[/WZ]8S6)-
M_?(^_3-1_9;VS_,[_P#_ (7_ .T:./\ 0$_I2AZM[:C^XMP9!S^%XX/_ -8_
MJ_/4$<R%*$@ .6."?\I^M-P.K_1O[_MO7GD^V5W907[K-T*JK>S7--T_2_?+
M2S74OW916[NO;2D=@[W H$-KD^,>2-;2]GMI0LZM1CF7;^7(P<.W[^6VZ_9,
MGX.+8FVEF9PY =W8;X?9VJG\W+/<2/SQR?'$?IS]-;,]UASN3$_5^A]/2MNM
M#3VVAR?UW>/TNK^QEWA;K'N+U*KKF:]X5-FZ-I2*"D%04]E5U55+O\8CL20I
M(2<DJ,9UJGVAV5>^T:QA-JX"W=2,#>0Q;U$5I7VKN+NF4<(3;<9@I"8$.^^'
M%9T?:=;]L]^](>^:"AIKPT\N^]/5!=70%AJ&=Y6E2P7/C+"5=J@4B!)D^VL7
M\.H/\?:+,$VU%M_B@=-TDGT+%ZX>_$ZL(]C_ (I!<&YIK/+ODWF<B!^4^I'6
MO+@T3#_>9[0\ $RO,M),@& 8&)('S03K96I)&LTG*2/B0#+%N5?4X<!_(GO7
MXXVI"^9G%GX0D<PA24DJ 41S$ G8?$VXJT*X7RF5]DKMNR!NM^]HZ]U-47BP
M12%'X[=E_)4!9'>GN@I+?((./F..G_S=?S_PE_H/U?UKN&RL?_8PMH^)U<?U
M_* G\O\ [2:@B&."#@0<8JK4%89E2A)#@Y))":=WM!5GF)"1R3P=9&K\WPGH
M1],'9L=G#UPR>9)()R%)+.5'X2T[.7Y0()4YA@+2>H5[IGOLMNA=G#56'Z?K
M57/.+<:(I%H=K=])0$/]T+6?AK!2$D@$ B"0,2L(5_/M=<?.^X(3S'N  0S,
M'+=Z[H\4D'\&W@WX2PX^BVSP2G5ZA3DX8"Z'G^E0:"]7;9EAR%$*4XD R!RA
MP<Q('RG)(,9.!G+"OGNE)D"VHL79W'*6)R ^V^TUPT0>5;%E I<N-P1'PNP+
MN"H&"2&S9QUPO5*_]F1Z2K0&ZM%51]4+^ZXZ^S\.F4%#JB0&7@H!QP!0(3VB
M ,QQK%^&I5_.-==5/,5 %R20'?<]!L'(CK7;/M2+_A4]DR)<7]"H\P(;ET/$
M@2&(=3E@#OD562%H  "@28$G, R3!3DY D*, 20)3VG)SS;.0Y)>>A+.=Q&-
MO6N)"4@"25P )(;LPR7D*+ /#P+2_5K?:6N^SY]!]K9:K&W[6W%2X\S\.F<)
MVQ<9%,^5$/X4 8'U,@:QW@Q?C?B( @$:42'QR$#/0B8^I>NZ/;C=2?PY^QY,
MADEP8#(M*2H.#DSR[$2=@:ME.$KJ/F X!DCM6F%0.)[8 D9!)!DF!K(=/&GM
M!R2G0V@EW*DEU.QAB9!(SBN&5W";ZUP";@!8_"MU)9F#L !'-DDY) M$]:]\
MI;GZ3O0!1LMUB'+9TH::?<>9+3+BCLO9Z.ZG<*C\9LE*CW)$8YC.L8X*".(\
M0),+YE!]VN6P2=WDR=SF&KMS\0R@?83[!@.9APSAH)!@<OAXI(=W8"$LY9F9
MJJUJB$MU$P 6G3*U"0>T\DPJ!,$!2NT<3 UE*7=)>7#D8(>8_P NT;<2(BY;
MAGN)8*@I92<D!VP4G(5;TV\7A[^#T35&*S%D=(@@72.4;:2C1$"0#BDID1X@
M8, 8+0VC&VE$NA$503H%E ZEZ_V]_\&YGN<\GW/?UW-=IZ<1@RA3.UKSL5[^
M_E7=^TN]X8]$#BZ"W2_]3J=&9A&SAUK"0B:]S^V96-?YR/LNY4,6 BUBJ--;
ME[\I9F1UNY8UW@!,,I!VH@M.9)8.28=:F,,M&F HLQ/(JJ6R+]WI#8&N&RC5
M*^60O$0S7>89C'".(2BQ_L2F)%VZF<^-!+7;[6P&)%EBGIFCK.A+QZ(0=X[P
M(_Z(DQA8<?'A/[@LC@+,7.62"=_TP4857"D6O(H]-^[KGW$51#;X<3]H)?D$
M34KYL9"@(AC&TU?/61=6-M[\92USOP"JV.9A-;G7&)7(U/&2F[8_?+\7:7/@
M6)[&\1CK6]E]/1Q@3W&1>0W L[OV@4&5>790PK9D5=KE^7].XEXI=& 1Y595
MU/SMD7E),'=A54%1>=%IM(#7TGA=RH>]AP$F4S5S:4J%&K\,#)/N=<7ARNT7
MA)^[6XPSKH!_SL90"E#R[ N;LG7E0!%?W<AC&$HH4%YWW]5M]S?1W(Z)80HZ
MJE0Z>,RQJ&"-4;T6IX^[$E!$<7UB[T4A!#])4V@WKV>9MVMN?YU4]IW*-_\[
M^E;:L#>-=.WM?A_35U>>U$^R;*_^/CA^UT16IIM7(9QU\; 7G$,HT#SE<AH*
M4(T$J'UC5T@E1P>7J'@BG7"F^+((F72%IO Z247<Q!G]:?,CDP8Q;H]D3),#
M-<F'H)])TF/?D/H/JG?$UN2<-ZJTDC@6"LYI&7,PKY+JD]%81&\@@$'NA$9D
MX.E&D#"*\],W_8>?X<2C'_Y(L+?HKOW>G%^HWZL.^[KCTG'9VW' 0F58:/$D
MD<(*3\Z[+H$458K9^OXMSD3)DIS;24:T10V/#N.Q=SVTY47MV[#!4D?H?W=1
MTD8H=$%7U^9DRO10P?6IU\+J 8X' K-S?U*#;9A'$3R$,'Y[V5^<[[-=E4M?
M,:I=H.9W>#$:0"O-O"U0JQ;(>%DSH\U&)/@+3;4D@ZV6$H)]PJ:7(5[.*RVF
M$>S+LZ.@9 WNQ"\2#@X4<A$)[#,T3\AA)?W=GC_VX[ECN*.VMJ0VCDPGQ?&&
MTPOY@B8>@*DH_]P _ZP$?,5GJYLQT>,+.5@G]"G_+Y,40DA22(Q^[DYCORH,
M)W4.CA+K9.>)(K")!3,.T$AT!YU\\_JC7-$B$1U!57_T +U$__&N1P"!(E+[
MW3H0+W_X2WC]FPB6;P6 >?/F#[SZ"*@3!USR"Z?/FKP&P.#9GRQ$(.D*',4]
M4&KH]")'P&;8:AR&PU7/NQ_C]RRBK,F7ZBV^F @6AE6+"(4/W,KBK(V%_DJ*
M''Z.#'I'^AS_]"GUZW*&64>UH.+3B434?T8HU4,HSHXZ?;LVU61%I/=P;5!R
M7L5!:\-K(EM7[>O@*>W14!AQW8YP-$KX#,%#CU>%OBB>3+F-IJ-ML\T.-RW5
MF6T5$)FS&*,G2V1ZQW)JI4 DK;?,[:P\U?0D[M_^9_&><&YY)MZ[Q+##!E44
M'XKI?9!S$$]YICGVF87>XH]9I?Q6WZ=,/' <X\L,XIAW01^T8HP_=/)&-R2J
M0D1#(\X/"7*#RO9UDW5+\3M4?5;,-\ ,)SP[*^\7;;6G2$\\-:GU54H<PV9:
M:+TO_P6'VUZ:13&?\_%93 (I14</ U2VT;,>5(A$>12(L,TFLS4J?/:D-]O:
M=_[/C:M!E.YK)LAU0$^>PC<:_(Y:%3]UK\TY,?.H316CK#/;8@4@=B[="#9U
M],0C%*PQQ"I!"8/=Y2 0NE'N[I##'V(_!2FO&R"N^^5BKX90R PMS+9Z[>0$
M#+D!R,6H59_? $:A5\E,((Z@>6=(["[>C9C2D.+A\BP%@I)2&POEOQ,4G5 5
MWN-,99PVG&5(=P.@!._^58Z3M! \%4&;[!#W. L*FES<[L%\I?:Y94;0D)%G
MF",G*L/6$F[-=,"/?T[Z]I$Z;V; *08ZB1-BX-J;&\XKD>G:'52.K'[LN1)V
MPZH>'",/7A1%CU_?^;7V^ZR?^=$S]L5^9V8]G!C;8%24EV.([1%&Y2._ ;3V
M-M?4SU1X>417>X2A]3/-AF!]!;2'YLE,?Z!Q^TD0[M ]V2V"CZV&3Q5^3-2J
MLB\M]\E@9;R&\^*UHWZ.Z=FCX"7V(M@-$/WY61A8(JN::N*!OU[)WB-(->$&
ML*>9@Y(]!X1N_:H#IX4/P-.N?%,BM\,[ZQZBF#NZN^%9M=M<&U(7F4LK(?'3
M^@ '6K_UM=F';_HHUCMW(>HI,1XNN9%=RE9-,&2V!U^@K94>Y_>^6@;'UGNN
MOYX[M \K&R4,6ZWE5&?^I57RG=X:#YE>N-#\[J[:FJ'I7[W;5;D649SD<S>@
M^.L(7F4U7%9YU24K$*/33K^%Q[&6LVWL0G9X&*(.-T8X[R&5X3]7 ]7D.1&Z
M7WX0.AA,BSFLR0XJ5AU..Y=4^==/UGW>%X LZ0<WOG]U3+E@>K,"Q!8U__7Z
MY..,WQ(/>>_F1;;RSB9NYA?0?W9_%1CN1O+&*$@&O6J0QIF'C2NX'V\KVRI1
MO0OIDU%6><?>&1/Y\FKJ%M6SX5:;5;^1_^3X]!7K<[M/EYF?CXMZ[!U6&B6S
M?Y$U,LPK!W\(J(EQ-^<LB/C]Z3CAM^_USM7Y"JCTQX7!-;1-SE1_-D9EIZI1
MEQU,X.MM84CE@\'9PD=B'];J40G,K@BOX<AG0@3#HGV)_5,^K,;U6;G;R3!0
MRWXED6#5V5KZO"U)S)T6;I)MUX3-HPYU)F?8F]NS?JC-@--."F[^Z>>V?&>K
M@7G["B%^.N<=9SD$8"RM<FSD</#,;O5DOW>F>N8<%!?22A*,33%ZF+(!* 7Q
MRI$BB492A*U& DY2CO4&H!)D=S'62'(TIJKA.BAG?O%"+_!,=J?=Z5/^?M$V
M+M(FQI'JJ\A^ECB(;L1*(@RV9%VFMT>B!Q?4D(62AQ-I]# FT27?T5XEX?K@
M<(<*A>PX#>_*\Y@-6K*)?C,/8_'.D%<5,8=H2A-'*Q"GE-T_DM,/^W/WNW83
MF5,I60,E7G>AG%N(IQG!&6SMU9G![H<PN/R%@0U$<=AN_PH1^+ ;XAK)LS^[
M'5J,4WD[#II,7[%"!+][Q3ZL9/_?\[!^IN5#$:H;D!Y(#R,@!G H+)S&UORR
M$4'=-S1'WV11R^K*P.,VT>T;'6LSA!11A;&(J"H.4H_BU>,3:(]MMD1[;H 2
MDV\ISM_RY"W5\B $?!*/W0XX%TZ418XZ^QT_9]57SB[+K:CU1H#HM^GS$2C:
M, GQ@IU=D;/"HODTC&:;9\K%M>.4*%P^(XYVUEYQD$9DG8K,:KU,:B+RF$0@
M23"BJ1TLMW]-#T&!??F)P<5$* 8V:"+N[9+5XPF"-N[YG#&"E9\GYVA%V3K/
M'$OX"W]]62&JV-&(!(=>.7\)\FMZ]%WO05B>0A3::5;I#334][AG&18*"Z>,
MW?>'/ZRQI$U,;TD144ON7"&2@0W0K/_.___'6?,-,!5B/<)_)CH)JXVZFD7!
MB+B"HCGSRNA/0MYXP E)WS])2F"",40&Q&?Z<'HY^<&NKI1 ?#!T7X-%4HSV
M!OC73?YJ^8MXP#%Q^)?B.B++OW#S5#VA%KH[:X-W';(=/PY<WAW+>],I\,>5
MS<0)*8B9G=6(=D5)PI<UEFPY:>*Z<^]<UV0D^/Y3O[:K/M/E"]RJ:V=YB_F7
M-81-3UZ,N*_:P1NW?\MM19W,NH<XP^A9R7B$HOY'%:9I21[&2 ,. BN0G=[*
M<)B:\,KBAUO7;K\4X6Y23R!:(,V+)!0L[?+^I;C:RR(*H.G:+M>?+^1M0]XF
M[?:0D@2Y;)G<A7YRPD1P+&.YP U@=1'BY][-TVR6[Y' "[,'LX'A&M$K_<N[
M6KX^3SS([M3S8U8'FX@>VBR?:M@M^%;V7]H\;)T>R[@!UA34JVX ^F*;[VF#
M< B7%;)TLJ')P,@5"C):3TV"4"0:_=!\?ID'M<,D:2S%O+=D-KCD+'/?QTB'
M^F>0TVV)27B91W:07WMUFJGT.S$^)1,?-UMS@H H%8@"Z@-X[=:)J2%_7ZJI
M)$_%X6CYZZB!>^\T(%+%/JK",L2:!T*W0_XR@E[,<MVS_/S*_>JK[AE%W:L;
M #DZN\W[Q5_Z*/=)XJO.(X'$8HA\$HH477,)FA:'!CN!:36N8+\L2)8N1#ON
M*U;V4O*'7)_6G(.R%1_XJ&!5]FEDKN.5PY64T_TS7&1(* 3U*2/9^@ 4O:SD
M7H+R^>#5]VB/Y3EQZ^#+XXQUT*"?)-#L9U#COZWIP%JEJV)?H8[^9S=66Y\K
M9/2KU%+0@[_QJL&O21Q?PND/1BEJTX8<N%_;CL,^D@CSN/LXM%?.ZGCQOV__
MR]N73!E;R-&MD*VXZO-58DN2MR_J!OC"*<NSOJ\=HJ>XDC=UY6%6O2>Z!CDK
M5\]GOP&RK@W^[:EM<1V\7R%/,2";/0N>.HB]3XZR.5#F69_O$ _X1%%D<1FU
M?5V17&PP$G,MU0Q!G,9TQI7> .9QLADTC'(B\Y@7@PEW>=/^3@X0SX36?K_C
M_SF=,[)C<92S6&8GM-25P^"/P?N*VI":]1/*'7T8W?(#')%5Y[OLU&PY?C.'
MZ=:Y'\Z##%]M:/N7%!"S=X+=S1JG9?DF&1>7&WXURIB0V=.OM1JZKQ!?;,3E
MKJ:-$"?$BNME.#A>Y-_+N)3C$KF>%W8+U,.2;?:954N$:)9E7G (I;\XV92M
M&"\0K/<.),J+U=$S**3,U4!E3<=ZD U7Z.RPOQ#6@XJ*+MT ?T7_*;>K\=4U
MUNL/U=D&,B_>!D=G?+I*'M6KLSAN'T]O)W:3KKVKP&13CQ(F4>@;@4,J][D?
M 3T=?^6[+I4;)D@RWCZ[\QBR>8>W0(-%H0DG_%J%T7SQ6&7%BC@LOUI=(?LM
MYBE5U'/)< D:_TK7T3%$AT$LK),S) F&4!%X)]!#KG)_^VV!4+.K;98MKQ!*
M@EV6I%:=#6@,SH[E57U+>FHPTD?74P2OIGC_MO7U0GE>25_2L<G.?CW1QY\M
M2;Z1#G4+NSU0$#H"(-+N@-E3_+Q?%J/,W18T\TL4[)I(Z)AY&N)0N8@2O.2H
M &0;>ZL6'E)P7O2D4,X5Q4_+,)T])@4G,ST1DX6.PXN!*.U#?';$H0:KKF9@
MPH!)=/3 @V_&GBG6?M2OXMEFOVR]'J]E)@JS3CB ,V,0W&'87VEB&,JPJ1AF
MA_9,Y(7$*Q%TF,IT?+"=E5![L2TG.A2>T=%!GVGCNPL^"/*<JT!$;;G2FA6[
M-;$Y5&X<F'%U9H=;#/S'VM_,FV#II4[4CQE$R +KC9TMN),#4-A#A:_#\$#^
M#E@8L5 &5)?."7AO&YXD,QQB5-#,3ZT_0KW'GX^H9)N[%[))THU3Q=OXX 'X
M60V3'8>3)_'VTK]J!9RA?)PO!A]@6!Y;A U)5!6'1?-CK58ZNX="4IW?IE V
M(8.:/QUWLFZ\V?GJ#(_K^EIKB\^R#,H+=KT!=@,?<GRDF_1X8-S>\T@<Q].$
MX">ZHSVJM-0Q$ N:N $6^!PVN8+B'EX?]<B)=/^U1LRNP!UH>X9?OY:R7R@Q
MCCBG_(?$8>IYEB/!:8_?5YC'WT%!Z5Y44ZS&!9!1".JQ3I:J_C03:*$21QMB
MY-0#^4R':_K==HY_/:?K;JS9-1B5(Q>Q3'TA@,=+/QNQ3?7O*#^231+M/8'J
MQ<*ZPH!2[2P0_"\[J&RM+%+Y?,P,/Q'F>@].PHPS6R4E]JYDXD]#FI4,=8JQ
M11N(KZ=8CYK_#GY2VVYZE_#J\3]!2I3)L42A6JLA'J&@[E@<E]B1IB_.1PI'
M_53H'+BU\Z06[2;;YY:_=3OZR'DGN^=.^I1)-:[S!DAQ!,1VYVCF(+:2UR:;
M[(!0K66@;'<I!;==01J,]9'J$H,X'H^$$0;A>G(RLIO*C[G/&ZRY"EUB*N;6
MFY\3(+F>8&_*]<N")!+>!=8!$?.)C/-=[R)"UMODR$CA"VAU$F@&\:AF!V('
MPU)S!7][27:K]U3H?19/CQPK58RE'.\Q1#)EI'MUTB-8B.HEW;1:IFXFS1+;
M?S!]]ULX]E[#TCL&HW=%2?OPRUY4H(!M3P0$<54-3O)B&(GFYVLBI)O@S%\0
M0#4BC(=?%(Y)U:4\=:.97.H&N:,.;GD\1:*:L%2VI&+49%-$- &4&ZWCOXI:
M&477\2%AZ8_CTO[#^";F13LB:VMDGS^I3VG]']3$(@^W,]SA/!9,$TYO^?DI
M>RQ)IZ8N59?*#:#6?38IX7GN_KI:B V>B\(2TB"V:K%6T(>*K-&3?00XD5TG
MP\>.Q6+80YO\M_-VS(.2'QM*3F9_^A-W7BIG:6Z4DI+A"GS6]^IFG=TGW%7<
M\_P/)X0,__XK5ZPOH [%%31U31X2J2'$ V+!#N," #'7H=<;E:J4HO.=J].J
M)>.L/\QEMO_=5^C883RLJV3@'7%'](ID07W4IXY&@>CX(85&G IA0GKY5G?X
MG@AR%\)+>!CXJ6RX<<;VPQ,5DWEDT;.(ZB&1"X::4M]9U_@#Z: 24S6BVY0]
M:(,8Q0'YKZ="V:\WL%I :V2,Z\"N64XW>6^PQK7H&%G]SK.MKJ;_K#SI2UXP
M3)V)O17*-OK VX^ _V)2RJ57(?KYV'S3?@*-^^.*PM ,8I)X,=A['&64V0 %
MV6)T9(C8"@RWWOL=-)?N,!!;2:R!7:[_79W]=J8=RT@<<1H>F09CC'013:'P
M6&4F3LWHZ6H5WB%W?7/75,FZP(YP?\;-S >I):BN0^!(:1R, !+AB00B*-20
MUI-^N2N1X'$DD$KQD"(0Z /^]$AW]-JWOUFENW \ %<;O;\3+N$P[\69.Q)C
M;?$@^H6L0UZBE-'F8LY[^0C9F9,6HG1/08PQ?>-=24$,XW]8 \DE)7/4.W2(
M$361E1I&>>@<"7SB;=N<;)0&5,9&P4?][;2*1;-Z8>V"7%]VX>)B:MXM$0+7
MC^Z O$+)B1#G06Z\I7K&\R^=&G"S3@O1IZ[W$W/K\O<5)()O0140)%:IR"QQ
M^-<B6B%%%>W0Q[-UD#QM)A4%+#^E-1*,LV':.?VPSCE[^1(#<(W<1Y -7!OE
MHNA3##L45$GB>"^4];_HE3]]5[>E\^E'BMF2F1NW&"]*0>T$UE"-(6HB01F#
MV9;\/7T2'1G7!EMPE*\2BQ6Z953'[9]>G.J27<]<RH BVY[I<_W8SPT7AT%9
MH3PA&\052B;)TT<*D\F8T(C&\;:?,]!07&+^WIH3 @3CAHDAT1BY'HK)B7P#
MC\47SQXX&@=#.TZ"':=D++:(CI>2CTM^><@AKH,JK,?DW.<5"8?%!1*,6B=6
M4/*]NQ]5EHQ>]6U\D9AR7?]AO1A1M^7:%"EX6_J/P>'=%5Y5.#QV?1Q!I* -
M.O3$%OPI1X%<*.U\%.=CUQ]_[/#UJFFG$,EVF9& )FO2K@RH>\MCX KJ'P=M
M1+;OA5?1U>M,TM9*O+Y0MS#<A$(3"6#IB-W96@P.1 (C@JH93$FH*7VN@!I=
M\F9'!V/\2 WS)+)J0TPK5'90%1</#G* XCC(@13[BX(C2O%GNO[-6O(&_$GS
M'[6V"0\XW$O/[2V?T=5E9;B3,"^X%N242*7[*'U;\H0=,ZD**F(5;#,#%9WZ
M4IDX;0[$:4.* I\=']TSV]JW9;@!G)>(V!3YSKBC:<5@SV+Z%%Z<E!-O@M2#
M-!9S!7;0,LF;VV@8WX/#VO\Z%WFF&HKE:=RT7GJ[;*Z@'1%)(K8"P&D-:W6U
M5D@?ZB5Y3=89'I[N]99 -*-EPY!@"*H]"$5SP+!/P$$04;!FHK[@P<+IBB.*
MUNGB9T48>:7F;- Q_K=S?'-#O%K"_ *N[@1(F)6@9G=>[!^K\=+V#^-:"H/'
M6@/WAO\N?IS4OJ;H5%8Z8'T,SB8[X"73#MOS-B]:(1-\Q&K=&\-@%.]90MYL
M(@.&F?R,!Q&O74Q@$#@&.5A$*)0\D4#BO&=[ X0YK:8[_N.&<9R31R5/ER5<
MZF*SZ3W'B7 J&0>\BJ1D1B\[K5'P:E#JZ*YHR'9884&3S\=2P9)"Z]R&%J>'
M*V:ESXKPC'ZB$@'X*.@FT;N8QZ@[=P#BQXMO\ 5.SW$YB)815,)^PO?:VX';
MG*WJ^_>1!R9O5,%<:RW:'W4)T0L(/%44<%3Z[>CUN:#2DU=)!7:BM3^4;.<W
MT)#LUQ%$%Y)3/QRU'$^4\H_8,B>6X<3+UYS-BC_U[;7AMH-_7^Z>7GW9#[DF
MR9%U<2C28(8NQ_1YO/HI=SOL^I3KBQ!Q&E9;\ZCS? M^8I%T<GP16";D-3XP
ME^'>&M0S647WT7G>O>R?TL;1[XHZJ;M5[FY)\G_KO"ME5WWX X!ZV8;$>C#!
MEY DJ!*?Z27S5N7O77I:+7.TYD-F5U=^E46^YI ^^I4@JQCCW1'1L*CI+(]#
M/[:^,MXR_GTSQS"N.6]]6(*LPV5"]H@+YV]0)YF'E8_2%E/@"6^,7]JAPNBL
MM1054_$-<)8WE34]F$<8E+M'37\'Z-$^P'K_UE,_O@$:J\:-)+=:@SA5W::&
MMQ_&=;I*&)SJ5'?"PAZ@\#QQ*^0'YR$&&=XJ>GM&OC? 4]PKWRVEIR'@!MKG
M/Q>6-!D-]:TU!FWUZH@Y?^MZ1ULK6_(59XU\Z[)'!;)=Q)15U;?$+KK_^VI;
MDI^37VC6]G@VS,4^[?4<M['..-J. .O<@1'*8.\@/B'[M6.5<$R/>E1W5,*]
MK"B.,KP*6VR[;6,R6Q3;4O<*%&@N>P20BT&)$;QA;%6RZ.(!\5K"YX)PCC)!
M%4A\TK)ZTSHMT^$@;$L*X;/(C: U O@5NT6D5?)W'P3K)9;7D/3SU) (6^'8
MY0"HT9BJ%85S/6>; 29_N_5?E<F)[R/]/4,Q 9]_]V<L/05*-[O4.%X29%>"
M4;R]OD.:0[H/5;I^>"K:&*+QFOLNU+^O R@[D*%4,N8F[@&Z:*93PV-M'"*8
MNWN0C+THXL!OW<,T<_CUNX[2&B8A"Q1'/'\="1&O$%8;/D VJ%V6D7#K,PDD
M1E^D:*1UA^&; BE/<R4WD%C^ @XII!L!H09M"?2MAUAS9H6)DO.JPH*""Z4@
MZO%Z+=VHTO"AH'\2,YP!-T"XC\7:)"1"L%=014!,I!"^@I*] 6B$3)C'JX 7
M)9GO\"#J6[?IB72[6ZZ:BE+V)[;?:%Z?!$4[F)R&,#0CV4?7EE *1L8LQHV0
M*9[6%7XJ(DQ>5 !R1W(&_I#,4Q\'1?Q$L(P:>7"]GD^"M_X-MGW62=*]^OIL
MDG)6=1VH(<X<J]17%6X H: C3Q#!MDW6$\Z<#25.?Z[XKK)'[V1&R#T::V#W
MUZY+9CXS[IL>W/4?CSUA-,[ZJS1'??'8FT3=K,+R_M,),_T7:Z&T259R]B)_
M#U3?[*KT0)''#-OBAX2PSI=0),[\U'<(TZ,(+UG*BH-//);#Y-W&.'PR\$HL
M@/M!:A5>!QZ6_(7A)6Z7G?H V==')<^);X#6B@:G>PM>1$T^0&(2%MT\A.K0
M(ENW^08=V=4:>"&JMT-29)V0JQREI5TWM"F/TBXR?]8P<Y?)M2UVR6"^!.7C
M) 0C*N8H27AOHPB4R/@(PV5Z"OT39V"?@+''S D*D[[!HOJBIRQ3I51D2Y-X
M)%9OOX4?!:'*LN%#\1(F,*U& AHGH:4^A"4^.XXARK-6-3L^8!<'NQYWX=>3
M>UHO!F/("&4<&5P<S-DQE\SU<:GS[:0PG=@8HPR'"U2(,?ZGX/HO7YAF)$D]
MZ9]QU=-1=_Z7_+C@67;<MR&A_]?\S2RLK59A7DNG\< H!O.F0".22[YZGRG=
MQ(=*B&MEX1.N3Y5]U)ZUYI2PO&3B$'P7<<O=CD"N%^E=8KQ!NH#O\GC-"ZMY
M#2-W<BYE@I,4PWU+^J&H'13X!^,J?S-8F$>".B=UM$IFK&ZC:I87GA[8@47"
MYGFKJ=8!./+-K\]T[#9A.WNRR:\79=8$30X< 1S[O7L<F,=?GJ3,]/U@OJ[P
MUF%,W!&/DJ=R,BLN++*+BVZ4,5XB<>,F-*0PP?U$+>\! ^+Q99I$#:TNXUZ"
M]T;*DT-_.Y#$?76J[+RT%17Z>:&,5J74B_R6L!]#]N@EL]A<3AVD\ZVU\_78
MN8E7G5V7D3\!3/M=:<*[6.@JB9;."1U&N8M]R+<3A/Y(^!S)F. [ \52P(BT
MA=-B*<2(0Z>=5F-)0RL5.I$JE[JXDFAP=F"4> HIE"KMT13$8*?B+5,.YD>"
M<UW\B:]'*:6$WH$5^P<;H1@)7;VZA J;EQ!C*MGQ*N)EN+E! RT"%DH.\;1L
M:R!V$@&>N.Y^'V*E?LUQVSWE_0U@L2>#VC(;/Y(4<$U.W725A\PZ:;G":=Y_
MC*%I4,!$#,H"'DABB]M+$5ZG?AIFY/H#(:-Y>Y]D=H5+ VEO@('[4W_90F5F
M8?ZQE:<%)WLI<A!;J+*5*H1"-HW=0W-=*ODB'T>.FW_'E6)I2L86D-9''BK^
M(WKWU];3C]?#+D8D[KF?XXS&]6>S/;>BC(8RB_,*/2<8??P""LV?S'BB]6&=
M0K%3?+"MM$M+;_Z>\QRUKZ<1"DL!K2*C5@S)K&<F$B]G;P")*L<FWH%D?CDV
MB:\?JMT[*AZI1,X@5V^ FG$L12@\: Y)SPGS_ZFP1Q92N-SRD[LYA9]6M\O!
MK0I_57)*4Z:R;51\I=.2P$<*8ES7XTF TPWK>BZN*E^OYS3CSSA.!L-F9>=D
M4R^)QL&WC?*Q(7.;RG?T[M\ JC'1X #'J@/7"HJAYL=EM!<?,Y1!Q==UP*Y%
M]C?_'O\86HO+S:N&YP9/SHLVKN[7_:O+'<W<^_:GJ,@YHWFVN>%OM! UZ5@P
M:Q WO*CK]&_#53)98U4C/M+T==2:V#R(ECWFW'CO6/?))-/64-A? ]KL5:3#
MJP*]=G^\_<L;X"-<\]S_UASGUG5VU=E)YN='C>S'9W15EFWK5>[;:O;)&]Y'
MBLX;3L[!3'<?8L(-NWTX2IZ<9]5".-7#P"4UXN!5JX,"I>*R^:=C,6LG,A0<
M**,:69(87UA# (WPCL50>5:T.BAT34S=EDM1MHSH0FLG^?PNT@)1;(V-C)K]
MM*W;^P/SH_8/Y8*O/H'LEEU]:'MRL$W/<?Q[*W.FB6)T..S%_4ZP''=XMWOS
ME GUM<#; -B!'&@V:DJ$/>%@\V'G'##*>CQ\YN7T#QX)J28N?1+!APY(1Y&@
M,+;$>(=F6#1/'<=SL[>* T"4 #(J'-ZMW+O4JKMSNB!:(I*_WV+;Y$&^9DW
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M9KQ;7Q0VO(G*+KE_?X+*2$&L37^KBKM.I-"PGLWFV^4[WXL;P*1GN[^LCV=
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M?PK)N2R*\*C&VPFM?9M&8Y%1JB1"@^@,%JFOS'C(*I:;BCUD@(^?%'2HV@%
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MV5%-Q7,L.) 4H2&& ! '+E>EA*4)3V!, )/L !  )$D>QD& #,Y'D4I4GD4
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M\SB>L$D?W%+?WV?SCN\0PZT^&J,)$Q('RD9 G]TXSCSC $$AI(#.G!QU8=,
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MG98$8KZM_U@PBQ&%CL*=F)"-HI)1-FA//I9X#MH9"4@STOPZJOD%8*O ^-4
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M*: J/? Z!AU%]>\Z!D:-,<T\@FWF'!O- M-5B-)=8W(*70/_YAW>'43M<I@
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M%Y>U34S2F_*4P.$0W"3L#QIRQ>53MVT3(ZQ[',!D1JR&YQLU]0%&>'M:9V@
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M'7AQJ73 NN\'8&!:\?S&CJ<[3\Q&O9M_8_:QVG>R\[Y/PC\+IGJ)?S9:8V*
M U]Z;DL=3.:CQBF3!M/'_L.ZN#B.&!U$<P@27!(.H./O=REZ=WD*07]7])SY
M[=* KIX7UEJ=UBZ3J82D/A ?IJ/!UACI@WBCYG.=W9-J )F"EX_-"^][_ #<
MTJ5&;EGQ.BIPTMV>N7J*09:O [XW6AY2R9XYFCQ9=VKKB/PE[3+[OZO4*.!^
M<ZFNY5V:<%4(UA7*:.LJW05,8]K'0E5.LZB_WF!WOYUK&UT#27=&I J;"DI]
MD#)=LA ;,QH)B0-HO\1+&NG*-$YG!DN/*7/ZPZ,B++DE>4$]PV;KX$6? V+:
M*@*CIVDTV(%WH:<AM_;/DS&7XO+MQMX^ \58T6O!I.<5Z=7\S4_/C[H3TM1(
M8V+C*] VB!>,916W07>:@J/6/UWO1/3:4,S:*.<6+$N$\Z YU3P7'3'&#XIO
MUB;/(\'D:/1+SRG-O]-6,VK"IH *X!M:/D7$]B(;>S^\(N$1S_8\H[NA5904
M6 \SMJZEKQZ59KSK+WEU@C2U68X@D]1HNLT$'$+)\+G*T5[G5!AE> Z;3WB'
M/J3E1)N5&"^P-H>>*A#*TZ[)07(6,R*O@Z)&QGO=Y^PT;XX9[T![G>UUM(2@
M/$;D7@FYMQY=P$0.$Y2(9LKW[QJ-]'0G!Z\WU.!V&$+-FQ;H&)U/,KS^O+)2
M_,=YE3>H.TM!AVNNPXD.F(5='[E:>E1\L,=R,$UQ-<?^SOSJ5KN+/LUI(K0N
M942/?YA%C^!0MG%J<'0%9 I7(Z4@WMW):(C&G9N#0]:<'#E.NG,J) 3 >BCG
MS**$8%>HKX:^%BCA+6 KEFEC*"F4YX01CU,7V8;21)MWVFSH>PTUK+]M8*89
MFM&<C*[YK)^%L0),6"^(^1;4%')WC;_7[$Z/I6D*/RB09FHOUHO_ L3&:6F[
MA?DX:4E7MT2UUOVRE1B9]PT"6XX8O\E191(UYEF)#G/Q"0)P66,'F=>TZPT>
M%"*P#GUQO:F]AC'$*)FCK?,2KHUTC](C]:?';%+HI^,PBLTITI#B1?DFL22D
M7^D9UQ;R/=WS^_TD!]-UB;&)CITL-0/KX*B54>PB2PZ]TU,UY[_#BMQ0.WAR
M/C<Y6KLCZ^W_KHU8_L_:R'+;H___:[QL^>2]_YU/=*,%[\SE8F'^0Y>X)-W[
MC0;PLWTZJH0?@%7W\*Y1)ET"L'K%T79J'WOPH6V.[RB:@S IJB0N:A[*HW7R
MIB3V&DS]EHW9#C6G3K>!:SGX&>GJ@H/?6]HW@'MF*8^QK!:7CZ+K1Z$U^W\
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M;;,0D2T1D+NEHLBZ_!M=IIX!=H;7R6= 9>*TI]K7N,VIIIH\,L93"<JXDHF
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MMY)PBV#+N"@2E/(]+8*KC"B=D-^]E( 9K-9E=]S"\H6!"\8T;YYK<E$!BD?
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MWG/=O"V2-#(A@U#F=1H?-+GXC=T>0+[R':*'/,K;6H5K\ELNW(!EC;19$Y+
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M9O])9S^BWIW\#;__/0S^IUC1:0%\\.N-_\V4[9?7[7XNE;_KNVTY0=:<D?/
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MK!X.<-<BPT"P[\7R1VT/[MD8P/;)I75Z04_8L+1NY=>JS+EDEX]E<%65' #
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M;033*4&S&2;C2?IR30R0CVIZV*9K)?<_Z2^.7P/SEC!XL_LV&?'1=@H.!M#
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MIF>22LU"HE7T'%1!6"FZ0&CJ^ZTI>['F&U?Z]G(+ KA>YZT08V@R2\D <7H
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MRVD%0?!:[C09J5OOO47D14;'+P 3;1&NH$%J6H@RGU52."T[/\(5I1=$;X[
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M6T#[<$D#%EU!I,\093#W:#76JY(643\=,3G@MN 4A-T]"9GMQ"DO-$XG1M7
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MOG?<][OON-__C\'<[++F7',^<\U5]EI[A[TSN?,<P 0Q!!L"2$A(2<))P@&
MG36.'$OO0$P@VCLPB%]!6A:@J@LV(R<'[!+'F5MVMG\F <P\I # [A\/J26
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M .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0
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MDT'_T8[T;W<\0G@/F49R\OS%9T7!U<HR=[\&A$5]1FF9'WWU=N$VRW6_:RI
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MA5U3V 0OYZW+@Y<2$S<GL'!)2ZQGSAR*6+]%-;\XT#5T?P[A9YI;A\N%4+P
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MU3>0O*<8@1I7!O6\#/*X!"3RJN?>35&9RX[-C;,-80"//1&(/I%-Y)R1*21
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MCE@DX_58\K$SZ\AR<?1]=T(Y<TIW/VW6%0$?IR8W HA_\!#J)01*Y,)B8\2
M^D=49C\'7*:/;Q$;H[F)]W>>[@FQ!K5*(<O#H'E7'JV*.X>RVD387#8NO57)
M+]WV1*UWPV]3E)@]#ZZI/6+>1\_!_<YU3>4S%!Y!63TVZJP2G:ULR'<R4]V_
MO88Z"U=EPD9(L"W4QW-L-<VP\E5^33L/'\S_ECJPO0/H<JKV#+^%CN-\HQX!
M-"T4]Q0_:<^2&:]_5V9U!>2T",CMSY4D .67;]2%A;T5__K,.:EUPH-&4PN]
MIAK@6\@B<V?DA<@1'T=B]FQVD0G+\$3.>\M[G>97.R^+:R!*Q=!4ZRH?4CNW
M\G/=W]%-660FT^3*,*K6 %G[]7)/7J]N )D<DPNB D2<ZCI.(WM3)@J?YX'.
M5J"0 >>"4.]KC<^"+'W9\ #VZ@X(UD")\^,U X&F=^FDJ',GM5\6YR<GORR@
MC[CJP"Q%K7^[+9OZ'$_Q \7I3!O+_.TI%5(L.H8L=4LHS?P\GY(3SY'#"?_^
MS^BN+E$(7^Q76$F]PT*B01=U[.W#*]R ?O)K"K9C2J(-@170*I!4<*MDE\)I
MNQ>/X@-9^=C>3+8VF[^;IA&OA[!/ $/4FAQ\YU5L2L>>4+&RL]=@A42<U3%1
M[3F([N/,'Y_Y];UCZ4^+/'/N:X%Z\?%E@Q CO5G9MKLIG'A/E.<0-D:K'=+)
M1ET<)B;!_)&"UC<("A_78M_JQ)V43SCA"I7LYQ20XO3IU[:4)W)I9\"JA4TH
M;1BP.N2XI(Q9H4Z*:1]GYE.'42=I3+=/HX2FLS;2Y,3]PUFY@]N5\NHR7,)C
M>?0M-[78%-L():J?W[03*Z<"%;[FWZ"\_U[R$9'7+.-D0WB'M9R]3XV\IT6&
M?)!83D4-0P4V1MHEG76]MHDY-:QS[I8K$2KB<8(TL8&S7&9-X1X-JRP$E(>C
MY(!U 1&V% *2D(3D?  +@#?NF_H'I_!>@)@@)B&)I#TKX%H0DB)VTR6%IN3S
M TU>O_1>.T?3MFS+Z0HIX/@PVS9VZEUT6U,!'\']S)! 45S+,R&[3Z<HRB\<
M%^^<\ZHZ+ =2 %8(UB\; [6/6++8J[$KDC:><T!40K.FC'4MT]-Q##AR@I@Q
MM?$G;0@45\'XR((LA1K][=CZD_D\7'1DQDG.X$]-@;Z"U3]^Q!H3JN%U\0X_
MW]/<^>/G)][J,]^:G7Q2W/)V0^C8.]]G=CU)#D\H@_Q:OB9X/,L>>AQZYZ)W
M'^J*DUDSM-I%A8=*DM#O[R#%9YKSX7UL(333TAGT.. ZAT:S(E[4K;PV]:@$
M!$@F?Z8&NBA\I5!,%P=;R&,)%:_+T..+S9@W=,W&K-ZH$[\W:*[NPF$:8^[4
M<%'>&YM@[8D_8T LJ8GF!1HF"KY]#V\]=M9WC9"AT^ _)1G!WNAO/57^:"EC
M8Y@H5O-NI!62('T;Z!PX$#+2>C1]/K6#<-G R+4^XBVKG99[8J64?HWAPDVJ
MV9@VNG'FDK>3,RZ(A,+D[B'8C/XBOL:C(^=H].E# %5?VXQ9QB/?CH0JSY:-
M!#K<GYS"(A-C!D24#)N&CJ_VW]3)]';:B  .5=PDV<9V-KUZ0_X@?%$Q2ST/
M9'*6LC!Z<,-4N>GD6U86Q<C[;@#@Z$>=4/<'@\<N\E8RUJKG2^(23AAJAH4*
M*%#F6>+!-2"9C[<TQ<OMJZ/ <FM2K8]O7ILZ?;:6;WKRPY-<R.F!<S!U=A%)
MQJ2S @!-M?'<@$]7"-3O.J^Q;?0943OHLBC=+4[H<1?YE-E(DW/EA825U0X@
MG0' :'GO^?C;B1?A12HJKOFY#W*3\NS]<B[[^WF)HG5!GAR!H*WGZV"OK;I6
M^(//.K:A<U.R7K5/;N0FY@Z!HYIRH=Y*DUI^#$2?U(Z8VTS7!!6G8&-?G YW
MV(@K%DV(#7DAT#>ZOG@[8-DEAYG6JEDVV4NYS5+T$9J')\*SP7#%7N@#!O=T
M3T@0"XUQ2-SAX=><RWZ)XK*.HO=$MD^<8SN%7$XR*9\0Z+G5LCU7_:#)ZV'-
MF.CC+(+(.G(V:E,3-GE-BQ2OOM0B'4X5(-U2K@,C7-T@3CY%CK^J)_0?'K>G
M;B\;E7;-5(1(G(P>S&F'9#EWV[-%4?#&/:VO^=J*GAGM2J/7?YJAO[25W-#W
M^9PSB'9##K78GY>P 2P%)! FK\5YB2QS:\@X)%V[=/\4I*.B,?@U!I0>0/7Z
M#!9TQ(-8?/'23"^)CBGDEJ=AIG;5#3SA?+YLO0K7*QNK.,.A9?_[KC:;ZD%;
MHOE9B'G3.<;UB7A&>=C5!W.NG8I1-+I?"'*"&LRS,N9'&=5U7<X60#[SH8M,
MG!YS@N-!A1?NU1CJ?J.0T^^KY?;N&5# 6MQ/+[@<IC^]G;7PM.\Z0O%$JV2-
MU6(<),UT()=Z*Q'#T!C;5PFT6L9V@H2U!%I*F)9 8]^$/%6=;C/<2&,DZ/ID
MR$:2B>K?*2MQ1*7PLX":X>>WC-+AU^C\OY5U4PBPB@PY-8NUV756VK<!$YO;
MC_9W\5IE$U5B[S&:1T 9#AD!/+S(JKU4A1D8A1PL&T7'5K8_[0",WS?0I4O?
MS5UZM88$'>DPL&J9Y>P1O0UXOHX-V^PC Z2Y6M7"L)4!\:(OM$)\ YE">78
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M_GU1B0S6<2!L$97A.-;5X1YYY2]G=P+N=KVKM"$073:@,P[0?]Z(6R[<HI;
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MDS8M-F1@>4> E9,9HEP3"6#%SJ2R*%41OVD:?>7G-'SZ<\9AXOUXK].D_P]
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MK7.X!^1"@J<VOX@,*?KQ-.U^$202*C]EK1PSV0\1F4^8Q4RMBVLA_Y H/:^
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MG,>+ARJQZ#XW(=!HYL8VA#CF4?C2"\F",.!OO$5?Y5<1-)ZC6;Q$IO-JNKK
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MM3_WY(-* T/H]&,<_=^HMM[L[G)*2A2-P[T0IM20AQ*OSCJ:BEQOY5HQDG!
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MX_%RQ/(H+>P:(U5(-&J"_P!2S#CYVBY7PJ!G)60DD( P!TH5T(R$I2 2$@D
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MB9<"?$/O@,I"D[J7:,'^EBK3!@CG'3WS@D'T/)U5@IJ4866LA6E*5F@!+,*
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MX[98C> C\G:X2I)73:LCW^8672<'N.#@G.!D'!'!QV/0B'ZBQ8(<C#$JI_S
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M*ZFP^V%+?0GY K^3=6IM*NK"DI"L$JR:5D&@(+&X]_[;_E&_<CPB\!E>%DS
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MC[-[^UVD7%N-2JM/J=#ICE&@NTVO5.CL-TYR6_/>0M-.?0EYWXEQ:DJ<:4Z
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M52RG$H*1ND8=9*@"2HA2 1L"#[Q\]WVNH@DK  "AD')Y2??/?VP?8'.OE,G
MGS0 "Y+L;THP;L6)I0N0T?5@X)(+BY9Q4.VWUJ6WM81GA\$-SUZB>#R-6[8L
M^7?M>BW5>9@VM3ZY;U!G5=U=V_"N,,U"Y)T&D12RR\N4?BWVU/-LN(90XI2,
M_5+]GE!D>$_3R99)F)DYL"E(+A\ZS(A04V[BY !:C4CY6_M&HRR9XT]28+%Y
MO+R_2K(4S5KDI4F25=.Y2I*5'RE*)*52U?"798 ((:.\NOQ&^+BGW-8-.M_P
M-W=4J?6ZY)A7+,J.ZNVB6;?I#<7S4U9FHT&K5.%%=1("$+CUMMAJ='4\F)+:
M?8(<VY)FY@TD&6?+,R8#5-OA8%3%JU9B]0&>,#PO1W1&(P>:XK%>(4E>+PV'
MPZL'(D2IR=<Q2INM*I8E2U+!"4@*20$%6I3AW][L-NOIBNNQA%4M"%%@J;4J
M,Z4_.UU)RAPM'Y%.-'I<Z?,2HA7/=*JE!7]ZX HSG@M=P'W?9JZW7]I'VA"9
M,C%2$4&,7I,]" 6"DG4"'XTO6T=D&% X)P<^@(YP/3O^)XX&,:I"A6[ L^SO
M2VW?T>\<-J.X]'K^NU^UX@L$X^9. ?VGT &<=R<\9)[YU+_GOQ?V%K=V:(;\
M'W_7Y1!CJXRI) XY&.V0G.#@CMVP3GD:./Q]:=KU<-ZCF#.6_7Z&\6]O%)I5
M:MRNN-N.4V(^N/)6T@J6VX\XIL I. ?-;DDLCJ!?4V68Z7'W&65V26TEG'][
M'M=R>#VBZ*@AZL*?_: _Z[>];PWX-7CNO17XDYAQ:VY'E.><VHK"EAB2VXG+
M:TLK2EQMUM*T$E#C25)(U4D@@V+EBS<]@>6YX[4D%)=R&%"U[^U:G=]ZTBBU
M6%,AOO\ V'<,FG192RMV,I,EQ25%)3U(?;FLN+4@'I;>=#DSRTI;5-Z$-):@
MHLRMC=MN;GFMJ5B=5R4\5KZ^G<>S7)CG-6Z;7HE9D4I(J%93 F2&7YB'UB5,
M8C/.Q6UM0TN2DL+?_P JS%2]*D+<4OK>DE*B$S2Z'J*#;Y[>PIM'(DRCB,3A
M78)0!J/ UDTWH_SVI' M^([?]@6I4[DA?9=8K%N46KSHS,.ITU^D5:HTIEZ=
M%$&M);J<0Q'I#\=^E5B.W*&'&*G%:E8,</X@%BQ-J=QVN.VVQ>*\<0C%3$"R
M0 ]Q]Y0V !# !Q;9R[PJQJB^VU%J-R2I=-C%*DQDID-..I21_(N*<F2H^,CI
M:7\,M2#TJ0@*2G%)UI!4FI%6#7U,Q]G;]$<=*D@@J1K36C/J&DF@9S8.-N8K
M-F-!ID5B(RIAAJ.REEE"'6D(#:,@8#Q2C"B2".D +"@<GD79<N?-8JEE0_XA
MR";NS_UW<,8MK.%*F^W(P?\ Q4L)MM\@.Y+4J(IJLVG$GOMUR#4U4B>RR''9
M;2TK8<2VVMOK?Z78ZHZ@VLI<E?$*:6@=#[+J3UIK5\)#@@T!IZ]^6V:K"M[D
MJ6,8@^7C HI! !4"H@65R02*7]S2(H5I(^):K=3JJJ[)6VT[$=)4N*VA82XS
M(:69,IN40A?F1EH+<5I:O.8:#X;E)H(<W>E27#5-=JC:C4+[/:TS)0*9DP3%
M:B=0(+C8$AC0WL6+U>*T+&,%*<$'&?N!^\D<]^V>0.3JJ@+V=A^N+?013?ZG
MVB PYV/'.3QV4>"<]N_? [#UYR<;?T_%MV'J8-^#_K^\"PLX)[\^G!'KCUYY
M]3SV^AP&[FGN[?K\(7^7^?Z^D:@RL^GM[\<8P,@?=_=QQHX.^Y^GTM7Z[0@I
MA:CDD\'OC!]!C/(SWSVR,'.CCG^VWXTA&DLN9'!( Z>>Q^\Y^OJ".^/71P-Q
MO_?WY_N(1(96<$_><9Y[C&,Y]<GC&!G.C@7[_3Z_KT@WY?6/#WCM\)4OQ8[5
M0;8HE7CT.]K0J[MP6?-J8=52GIDF"8,^E3O*2IUF--90V6Y333SL5V.RORRV
M'<=KT]FZ\GQ&N<EPI)ES$N'* ITE() .ER"'WHZ@ =D^''7R.BNH%YC+PO\
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MF-U-Y;++SZJM*6P#\-&"NGQ/4Z9F>R\4$J\B2G29*VU3)"V,P*%0DJ2*.2U
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M\:6Y.H=3I=?I3RG8<A<&5'FMI4XPGXB-*::4X8SWPTA+3T26EF4UYRDO1D$
MFI]3ABP<_2GJ7>CCWBABDBU][._X,S^O,6//A]JM%DU$[?[CUBT*+52I4BAJ
MBRZBW$!2E'^*28U;I2G AMIMEMR0VJJ>2EN.JL&*PW'U00Q9P;5]8JU\BK?7
MN*1<?;G;"B[<P)34!<JI5:INAZLUZH**YU1<2IQ;22E*BU%C,K>?68[04J7)
M??G3Y,R8\Z\:@D/4@[L [C]<7'8Q"B_I3<=^Y^=&L=HY]][>T;<.BN46MM.#
MID?%T^?'+:9E-FI9<C"5&\YMYAQ*HSCD>1$?:<BRV"XVXA+KJ7V*A\*@IV8E
M@U6[ 6W((M?T@D%)2U2 '<>S]A2AV<.(L\?#Y<51;A4FZ-TJU6+8I[S+K-*;
MA3&GWTQL".B3)F7#44*6VC 0Z\Q+<B]*5T]4"2U$DP[OF N0:F] W9J/Z5Y
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MC$A&&*L(,Y^33H?2YWDV%ZBR;-<FQ7\25F>H)F% 49!4"0H2]0UZ5:2!J0X
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M@K<B@X:6=R>:GY<!NPJ')!I6)SV'?UR,GN,D8]^59[D'D^^C!@-Z^@/+@]P
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MDC!['^X]^>XXQQWQ+._=CM=N]"2"Y ^88/#^K@7[4L=MQO?O33@^A)PE1/N
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M6YM8@ 1) :U]W<4(%"[MZ[MQ%5I[#[A_=JB+L4W*(^*D_P#Q$\X [M-G!)]
M1[9[8^MP/IHYNX]:-R;O1O5Q6R6U%Z![W[_7Z QL@C R."1WS]22!GD<YR58
M!'[8< @F[EVMLS=F]]^(FI!W!#AZUO?<M3G9@Q:2"2<$X'TX],'D#U _'.<@
MYT!)<5<@O;\0/8#:P-:11P: 4I[U!J?=V]+P)^\CV)]\\#'!P>XP?]TCN*T-
M'<@;ABSFSTN6<EH%BU17F@!I2UAM5AZ"H'!)'..5<#L!QW.!V^\^@P1IN:-<
M)NSF[4V8U8=WO M3?<T'.Y#GCGYTC3DXXYXP#@]SC)R>,9!_L].PBA8;O5A2
MVQ:E;L15J@F V!+"OZWH7VH?K&E0(&1E63C'  R2"5$G';(./I@9QF@OJ#!D
M4K6[GW! VIN:TBZA*%A07-TITGX*C40E_P"4::V!59F+"_D/>[PDVWO]NYM)
MN+?=TWFFW]FWI-8MW;NE2J?$M.KW9*F,/_;]V,.M2W;A;B,18D>!274Q84=U
MIRH?-+6V4<6=ETF;.3-4M@ : D.H[K<'4S!@P8@&C5R[(NMIN191F6687*)!
MGYB\I>.6F4J8C#E!EF7*(6A4LG7,65ZE*+@,6<>M/(*>K)()#OS)5D#JZ"KL
M 1A62 <D8("CG&N7*E2Y( 2IR"200W:HK2O-7!8QB*9JU2UX=0)3-F)5YAJW
M9ZJH*6+5V ;''*W#@'\J!;MBIO(L*'@VNAN19Z:^ZB+^<AW<H\Z!->MY,D1C
M6%6_&E/LSUQ?C%4UN6EMTQ4.XZ9>(DR<V5*.$Q.B;ADJ5/$R7Y9F%0"PE)GZ
MDW.DZ 0G@7VY(R>8KP:S;/$Y?A/M/_B9@\'A\R5+DIG?N\9+U!+GA"])GF2C
M'(PDM0#I5-4XU>6M2<@CT=^;&,9YMU;#S;S+Z5-12B0AQ"T+ZPIW*FE@X+2T
M@+'R.H2GJQW'DRY<ORD!24 DH*E*4L!:S,+J4I1)<EG*J, & $:FE&;+G2YW
MVW^+A%!<WRS,"L7/E +2F60E("4J")"BLRQJE+*=22E2O./AB\*5O^%NH;K1
M;%NR\:E9&YMVMWW'LRZ9L&IP;)N)^"S2ZK'M&3&B0WX%MS(5/I34:A2$244T
MP$IAR$Q7&XS%J3A9>'*E(4^MC\3E08.#84))%[BI+QE'4_6$WJV1ETS'Y=)P
M^:X*7-D3\PD>7+&+PGPG#R9B$ E4R0KSEJF**E+\YMH]8@=SZX[G/![') &/
M3OCU(/OR+@@;O=]P6%?0N>=R T8@Q)8AS8,VW:@-"*<!B!<<1VH1&.7GTLI0
MH(6XM+B$)*CQESI*0D>JNH(2,]1!SB?+F$T25$V =1(["I[U.X:H@DI4)GQ)
M3Y04I96I$N6-+NRYBD(7>R"HEJ @-%%N[K[;1):Z=*O6W&)K3I86T[4F0EI\
M+4GR)#V2PP_E) CO.MN$@I2G)SJEE>:))!$VGPD-0!P0[ D $U-H2VG2C-E+
MES$ E)")J)DQW'_LI4J:4FAU"6SU!:*U:E-/Y6RL.-I(2%)"NG] O%040 I!
M;4E84E100H8)R :)R=24H(JI6DLSEK  5LU&':L7Y4HIG--4-)EZQ+"TK!45
M$'4VI*54 (44J N&(,8,?$9^4OJ7^$ZI[96A1ID7;NC73^;MQ7/2ZTN'==?1
M!D,Q:ZJ@^4TAF%%@/.31&CR):%UB3":;E*13'7&9&8X;IB0K 3)DT+3.1+$U
M2=D2B&UJ J:D  %1O\(M'CCJ?]J^1D/7G_3^!RR7B\HP68KR_,<40@3#B)<U
M,J8B3+4 E:)9) H2ITJ2L@$)]-;@[H[2^'2IV15;=WE<I]8KL2B5&=M[=]<;
M??N*W*LE$QN=)B0H+,.GN2&'&(ZI<\1/A7BEZFNQ$1G(E4Q["9/CIBIQD8=4
MZ6@K&L*2 " P(UJH'[5MZ^B\X\1^D,KS3+_WGGF R?%9E+DB7@EB;K4K$R!.
MEI,K#RYWE>8ER#-T"M2'#Y)W*_1HM-55'ZA&8I:(BZBJ=)>Q%8A-LE]V2]*)
M\E#+<=+;OF+6$IRLY!) X92I,U4I25"8C[R=)HU6!JDL&(J0/D1F"9LI>&F8
MM,Z4<-+0E:YOF(2G0M@%_$0HI<@$A+5+D5,6N:WGV>N.9(MI%V4>6].4[!?B
M3XLB+#F"8A,<Q$R9T:/$DJF=19;8+ZG)1RVA"DI3F%(U)2I:?@J4'<G40>#4
M@MJK1["O8C[1@U)F!83,2)?ESYB]$O":PF9+")BF0HE*TS6D*6Q4S:@4BY=O
M4:CVY1X%OV_3(-$HM#I\&G4RF4V+'I].IM/ALIB0X,*)&2B/'B0XS3++33*$
MMLM)PA*6@D:! 2VE-&8"] +5+@,0038L!Q%N?/Q6*GK5BIDS%8E14J9B5)F*
M5.<W"YB I>D@BKOJH&K'G^HN-7_XCZ93T.!VC;56^N<^2E2F7+BJ!CO^3A8+
M>&OM"CO,N!.1+I,WRU^8R>B""% $,]0*$,_(H>+AS>L<<*^\D)F@I'Q:I<U
M%@X4I&@UX)X>X'IX)/!QV^I'&3@# (X],$D8SQC50>PK3DDV-N/R</P(+.[F
M_ [;;^[ ]XH#<BUYMX[?7C;%*J+U"JE?MNL4>FUF.&/,ITZ=#7%C/+4ZAYGX
M=#ZF$2FW$*!CE2"E*R@II"R+(#MV/<@N:@?1GK%U2,//.N:CRE"FFP5W^%P=
M0_W 5%32.KV6M&OV%M+MY9EU51RLW';EJ42EUJH++90Y/BPD-.QH7DMM(^S*
M:7#2J< VE28;$=MWK=6I;E:2G3\2=*NS-MPY>K@AK]HHF'SEZ4_PD)  2D#2
M2*%1"2U0:\[;1=$$#D#'[>G QCL 2#V_\=1I2/B34DZ6+VJ338A@;&[U,0*#
M0"-(KL'-KNUC7<U%HUCWQQ@X]NXQSSV(Y(SV[C)U L'<5<FG#WY)-*T>M;Q8
MTKLS-4T/PE_1J=@P,1G@D9 )&."<$G [<' &.^#[:D]J$!JT2'[,X?NW>A +
M:O<TN2WKL[V)%>\/OP#@%) P!Z'(^G;)QQR0?0XH'X8$&Q_%MJ4HQ+5$&M':
MY[O<?*OO:() /J>^<YQ@GZCC/H#@8[GL=*DT'%=Q?=P?JQN]:K"KL;,U;FOH
M2.>-J2.>1U8(SCM[GW]3CU''/N-0]@" 22] !;L[BN[OVB2U=QLQM8FXH6!)
M84>O81SSG]B>2,X!!'/UR2.V!@<378.GL[D VW]NUF<B(Y=B?5[BMMW'UJ]X
M@@<=7/)_I'!Y]./E _'GN="]C8D%R79Q]:.'?@TO 7H+ T XYKONUQ3> ![\
M8R3[<'U'!Y/OSQC![Z/L Q:E&/>KTHY .]>'BQN]CR.P- _Y!Z;1(^3O@9SG
M R!CL,$#!SCMG(SGL=1V[/N'#=F)86%*NYVB34$]V]'-Z4J7YV;F!(.1@$_A
M] ><\$=O?L,>H"@/W:7<ER&V%MV!9B_%V]* M9VH?:E+OWH: 0.24\@ \GCZ
M# /W' /OD:$_"KU8!NXW84'#4< [0 ((:OHQ;G\^V[Q2M[S:A3[8J<NE"8B<
M/@V&GJ?"=J4V*F74(T29/BP&8LYV:[ B/OS&6!#EI<6PE+D=ULN-J6'_ "[,
M2&Y-P=J4;9XJ!=0%Q[M[V?Y"IW KYNKF^.X=EQ9K%4LZ?(^&G1:;1ZO6J5(A
MR:LFH*D3*=4YK$1<6DA":6S(%5@PY,:JT^33GG$4^6N5$@&DD[\=ZOO?T/%H
MJT@AOP8#AJ5:II>]8J^H[E;I0*K3X2[)\V-(A.S)U5BT"YIL"C1TU\TZ&XZS
M$<>EU4&!T51ZEQF69TB.Y(9+L -L=9R>:U/TV%/?TO  #=VHY(X._#;>[;QU
M5O[B;O5!J-$J-I28ST:FTI^H3GK=K<9Z7.JELUV5+I\=2F$PX#L"O1J7TR5P
MY33<$J8?2N;-+*(U'FPH'.WMZ<\;"&D/W/Z/SX+O6EXK.VKRW#K=8@QY=J?!
MT=<UIF=(=I]PPIC2)C#CICM*FH8:*Z3(BRXM1G.M(AS#\.8$>"B1'>7+UV_+
MY?E;LU($7J79Q8FEMGIS?O%P+NLVV+YH\RW;QMNC730*@VE,RDURG0:I3Y!Z
M$J#CL::AUOS&W4H\IU*0\RM"%M.)6A+@Z[,LLPF=8:?@LRPDK$X;X#+ES):%
MI4Z0H_"IP64X#MR#9NPRG-,QR;&2LSRO-,3EV+PQU25X:=.DS=0=PF9*JDD%
MCL0X(*3%NMLO#GLIM'*?J.W6UMI6E59C;K;]7IU+975BTZO*HJ:G)7*G-1#T
M-K$5B2W&!"#Y:5).NKR#H[IK(YJ<5@,EP6"Q3LN;*P\I*U!)U(&M *B/YA4
M$N.^0=3>(/6G5^'$K/\ J7,\?*0R96'Q6-G3D2V&DS BDO4H.G4 2P[O%[6T
M>6$H0D]*2E.#@#I')40,$]) SCZ)2 .#DNI4W$35S$D2P@B6:$%1=F +BO\
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M4=CRG8,)4\,RY"XT=;[JXK"6ULEOJ-*@]0:.Q!-7V!)X?V 9[F*@KLQ8EV'
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MQ]<GC(!'IJ3M2A#!F+M9N Y+&I+^C2 *UL1<L _+;]J5%XU$'OC\>#GT^8<
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M&>3A/&0KOCD>A&#P=0]ZU-F ^8-A4FKN0[L8-6Q858U;N1W KM45 B%8\MT
M#_)Y[9_I 8YQ@<8/;T' &-30'T)=ZBSLU-Q\/+7+4DFW#4-K*9]W._9R?6JD
M]A]P_NU;B[%.2<_%RB"<^8!D=QEA R,GTSQVY&1JXD.!^G8DU!IWY8'F+)N?
M?T#TVW9A7>\>;I/ARI$N\*Q7GKTNK\T*]?=/W0K&VGE4/\WI]^4Q%),>J.5<
MTAVZE0DR:)2JJNWVZH*6NHP6)"F0@.,KH9[5I8/Q[7['TVBIVI785I2HI>@I
MR3N[/%(-^$>A.4&;;=6O^]:U0DT/<.D6]3),>@-?FW(W2=G?GM6(C\"DM3*E
M4:A$JM4ID)=4?EL4V%4IK<)0<4AQ)O3]?KU[1)4 ;58?B*6[FUZ>V_5/#9(9
MW$LVX+=O&I(LNF[K+W2N6R9ZH35/CUM5BU2V?CJ14(U'%:?F2:@_19HIM4K
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M?0^2OVF_"#K#Q.7D$[I<8>>,M&./V&;.F2BJ9.&& *D^1-EZ5!%?XA42AB"
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M_4&4J3T3+VJM-%SWQ52A);"WYM>K316\$I>>3!#CG4I(S>PDT2UA0*2I0,Q
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M8C=B7)*@"?9X[3]DKHY74/B@<RQ,D+R_(I)Q,])21HQ>)F*.!4A)'E@H5(F
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M$L;@O4<;-&K[\G.<\8P02"#S[?>?V<15E"KL/SH-VJ-FO8$&)=+@LP?\AQ^
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MEU"FP02HI*D93UKP0%K!X[6+7#?UYJ_ [!S&1:E:0A1=2 $E0+A3,DF[-Z$
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M%6.F6KYG80OEG/S,9KW.8QQ/-'U66]H/OQ'</]UOLJ@MXKA@VV"ID9ET*+N
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MP-\O .WYIPG]=\U!"#_)&;[+X=Z>7C\KZ+XKB+']$!_T'+*7WV(@N_6'(G$
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M&(Y%68:;62'"?1&J2.!)35KU4+50?XP_"N\F&.KOA\:IA6H #YVK$>\/Q+)
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MA RRVT+%3UC?++][0]0.)%>MC^E%9#[6UQY(>>;T.(.1T"4*LY,0Q-:ESC!
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M,GSL;ONSS<=PLX9QAK'[]_5QXK;661!);@%Y3E9(*.<'5R@3(K!  ,\/;":
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M':X66-(J7SH+])KC,5J1D+MF<<TJU]Z X,$<BURR3 LT#3"WG4CGGB[Q*C,
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M0[HW6G5R%5XQA?D=;WV[NE&RV5Z>VCA9J:5RPC"-<3PY@Q&.C:$WUR)E::[
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M(HG,D?WXCI$'3RN(! #@7@8U?#*A2D_[19U.N9?@GB K29W._AA!/E@1EJ^
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MW?88AS2@% XS -T>T<ZS#V=1&P-I*["5 @[#4XC <"'+CZ-F8\!\HS/O#?
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M<S#2091LFLXG^U4J=(EM9@\[M+U+6N20]>\W8F&*&+'3?O;4%.(=B\7@_9J
MKHS#+YU2\,0U^SDO2=5>L?SNLRVU_I'BV*H91.D'V-&RD]-9G9QB[,Z:BNTW
M@7^.3[*TM^>8OJMI2O5]7U7VZ&\C'^7:08B1QD06K2HO96GPY=_D?SV*;MCQ
MF2J$5&__<ZR1;R(@&ORJ+GQNJJ[X:])[VB8].RE5DU]GGS='<?W (!AI4>^/
M6%VZ9@]-Q-]V&U=[+'.Z65FR^SSF1"O4!;HCLMUYK3:+K9$:*56E 6M76[X_
M%1M:0Z3FU2L1>!1]*)B#G)2 "['U* 0$B^+KC]JK$RB?4:U9\S&E"R,#!(44
MCU=#<>U7BZ((EX;<>Q#4/F%979T>JTUT$[.H<;&F?JW48&LUDM5>-6/[O/!E
MZ9WZJ1HR+8^8F(K78,,0;,23!N[B,#4R_L,A?BO+:%$[_RQ_DCF=T[%[51,R
MB "YO/;S]M4?>Q:)OXHTY,017L3 @60'MQ4A/?O O;V_IQ5CGFQJ+L"65'FJ
MVG/U_0B$,"862=+-RUF:(2P:4E8:.C19TZBME@CWSMPQE)!6_FW9Q!0\]HQ.
MWI]_,=RYM,;OKSBB1I['PEO5R:FPFZ6D<5;GXE&T*2>FL2L9@(?B#C%H&1$$
MV%2+UZVU-<X$Q@LVC+;6WR UQ#>0J\QA8DJC>^X .-F^5G>[&H#.E9'9:E:S
MR^UG:IF8U<6=2;>4!4;.\.9DH\2H48DO\KA8#FZ980FN91XD 2P-*CL$8<B)
M56/M0T:ZIG6UM:ELTNU=.O4[ZRD.[S4AKO0XQL4QU62$SBP/6O"C'K*?X&+&
M,YV+/(JU ,Q692<=AU%+FB;I%E:0C<N1 X[/2@.$(TY4,32J8M$AW*>X2C'2
M]L /(ZA^+7^KY"T^M]#;LVBNB6/UV6)7E:!]T%0,)*U5QHV+3.PO@N\C%'?\
MTFK2V+U3UW:'Z2R&A(J&==#J%D-.2_>Z^]$HH9.]84@;Q)E@<TJV;0#B0(M0
MI+)SQ:*-FY37:%N M4M5$BIJSIG^[%A1DC=$1^:V2%PUU-]J-T1M[P? /:D9
M,#]UIO"HAU<J;4IP9!G\,W;C%Z=\=1/ '$ OI7'..@2G^3"5CMDI#B:TQ5"3
MSO0?KJA^;$AUQ.%\2$%A,)<>.; Q'VK2%6U<=.8-NRA;'F*.+Q?Z_A5BK(4]
MX0\<N4/KRF]?7ATKW@"FP^_^G+*9&_H:21:4U]1@2JB@41GW1_U" K%(LH9F
M^L;/M@;^I:PG![05)QO/^V/&V3_J3IM.>!U;L6(;5_R/'QK+ANZWOMP<VWH"
M>MI/Y3:?9GO.S[*M'1UITO^ P4>.]*<(GA\HB.R-LT\@BQ_H54H<YFAI&H\C
M%;%^",B*%HHFRQCXE<A$SD9*>8Z-, Q6,#31?S1UDSX?<GZOX3'<_6Z&)H*F
M4/ZCG_^J&NH4PM^7ZQ0[4>H_ 3NC![4M1,H-6K)X.-HZE?X4/-R5%^\&;#[^
MS4(O?,8]/[H*SO*O J,DAT=GJ$1-#,XP/N(S2_R8X_)<J#?8I$)6"-9PE1)1
MSB<:K\33B=7HKR3#74%K["V?E+]J7RR^:"YD/X,5(S*(%FXA+":+$JNF?P-H
MBJF@0%9_WQIT(<269K/TTXO94U3RQ@QS&J)3V+,,=O:_DV7QG$2D6XUR."Z5
MIE7XX-'Z!D@MC^]P?7&DNFU\\M17Z'%Q?P.XMG0W)@]A?CHR G>K#IXS,/U]
M9.>%TX:Q=& ?,@IN: R-M%IX9@GI4*7, _&0JZG>O>?XB[=JBX[QMU2T@4/A
M[N%JU;/"<HGBCU00 <?7:LP9*IUBEAV^*,<AQG?Z30QK]:D+NQ)'[)D[490H
MGI+ ZB*\!A?P6J'9DL0O)N>##-M<]%)VO:F(E5*,FB^HJ<-9\0I >I%^ZY*?
MX;': 94#&J,89;S^)@_7HX?C);\GUAMB8S]2JD&,".OMT@(*?2[&XL_N<M5L
M^5=O#+-O\=9R>K161<DT?\T7&>Z^+S#1_,'<V\F&W,]MHF%VW[(CAY5VH1).
M\6FZ%TSUV0JY0:&R6(4?F@OX;FJ#I[) 5J.]8'"Z:OF8V'YZ_D]>6V&O(,/V
M$,.AI4)M8>8P"6,*!5.XP^$>]O6&YC/"^%SY@O]1V5N'Q=DDZ\.#! C!+1#<
MW=TAN+N[NSL)#L'=W1T&=PON$((SN#O!'7[DW>R[>\Z>\UWG^W.>Z:JNJNZZ
M[WJNZ:FVN@ZIN!R=;,WOY?/2?0NEC<VIZB(YWI+3IUQB"])#KIQ*#7&06E@_
MNSOU K%.>VS5"-Y[C.I3?.$/IL AUXK4BO3WKA)MPH=HP(_*<S:_RYTM^L=9
M$P K,IHL &Q2048 OGWK=',V%/QT[:NAN<0D =?L\AY$7;LJRBN T.$5L"X5
MK2$473ROYTN,.(FOT^DAL.S]Y='IK=R<EVFX"+':QO$1O-_"S4$^/;U<TV-B
M'&4WAQ,\68B?K-Z:/P'9\A+@LOX0DQ%P 0/L[>'RY.],&_0I;S2./'SG/#D^
MW5GLL@6PZD@202V(C8"# [ /"7/VN0$'C4]/ZP-W)SOR@I@D.)?DY/RJ"YAK
M#E?3\@B&8-N[V([PP6VR!HT!G6C="Y&3!KC!T!QG'-A;?7:"*,'N-CGF$,79
M^DA@/UCAO[;"0'M'>%T-B!]C&V%"/GIIG<HB0#G)".EJ^L)854U$9\NXXC;@
M?6V:EZ82(("/YKDQL]4)CMW+<-I9/OBH/Y]-&]S.Z<&3[:, SZJL?U9#O!B[
MN.FZ['@.PE8J !#A/EZL#4_:?K$H7NE;/]D:Y59&$J>M.</>=OO"X_8 KU:X
M!DR[!%R>-4/ECOI8(2M]FV!LQG:WZW3R%7T.W.,^$42YQ*>X]:A?DR.72G9K
MQ53"XC:^0=!)'73G1K0!>&#KZ@J")JM:BGJX$7D]J& ,W; SGS6&<.[=C!9E
MDQYA/-CAH75__?B:'6.+J1PC@ TQEG6F3G!S4L.;-5(28M=LC7T+U6K3[.&Z
MEH+0>@H1A"#*&#NTGGDYI(^$: #I!6E86NJ"\)EO(9K@T:B*[_D:ER%7D1/A
M](O3\:Y8O6L&"C<NP7RSD!W=)N]WL.9GH/=IF$$C!X'K'N=.Y\N%*_%7V$TG
M:.&E$"A?NW8^KT!V4,H!L!M(XH17<SV#0!B?>7L=C<*Y?H,"MI-Y=,O:G>/S
MJ[QW_A4@7K)1'"_.EG*G5A2!7=A!W U]M_D*B)V\NSG9:UQ]/MJWC88S3],5
MA%YG^QZP@7)[=E:9.I@"'/_=\N9?AV]AU6#^/L]!J?;OC:!R4SS+>9^X$>_^
M>[\<(?7?_7(^ZTT6WE:7\+L%9_.4Z?^C;8Z,VK^?>1 ^*PU_!<!._MI=4*S'
MCCBZ199?3(UK\8GY8(K4WJ3H5-9/-$I/S.0RG:Q4?VDR;>E1B7@9JTR,.8W\
MQ>PKZO \!FWB"%7,6$#>\BY1XDK/+9+&I?F8F89&%E)"OVX;F0M'9*W27+SX
MF/&%X[E$L3JAGEA;A&W?%-V:]H1EW<U9)K\N%^;1<-AHQX.&'-^7<MA=-=R6
MPMX5Q]V.ZXY/MZ;A$V,K 5'&X5A+3F8)FG F7!;MZ"9,<1KIJ3]9ZM']'9D;
MT5;%6X3/4KJ'D$Z)M_!^@\]516AVAL%NDLIN0UZY>&&W%O&"28*M02*V=.]"
M$ES^QCYGIG<U:Y0B0NOS8VIJPD%%+C;ZY4Y*@_W)QWX9)G:= O_$P\OR<)R%
M(AVKV?;6T3+I&>,.)S*2E2'M"E6*)AOCNK)^JTJ1@@!S<2R6CV8:FJT1$8,R
M/=0=MOOCFG=EOFH$A5;<>C!TENI;5")&^%+Y?"UZ%^('#\QI\J0D&\PHY_'V
M<[!TRJ)Q]8O8U@V65"M<I]\K4L,)L=!)X4FH"[< Y>^H#=RK-RT5HWDE2V:=
MWDW(K9H 9<L;J*Y?H-+?Z8TWC6NK(1Q:WSRVI[!8)<RJ,DDE+1R"D:G>IU*:
MBUNFYZ0J0*' JN9-.C2E*E0KY?/W"<-+=G-$,(>DV FU..&\%&>B3&-5?>+A
MJN*TPVA(Z^.U"&)#F/5([8(89='1Y/,6KK4>-@9FYB6V:+S/6@RPW#2=3IIN
MB54>*]MLL;\9.($U5D(COC@]TJH5$1B:RV EHM2TBG6,($5.K!Q9Q1M[,"U
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MULE&J.UL0]ZAZ1OC">A@1_%??/S_L7/_DQV3YY*7_Z_)(Y604\$6!'BH#B8
M/$N?C0?Q/&M<+JH'A!XAF,_68C,7,RD3!+-BJJQ1BM%&]GU1KYM(+Y>H>2?A
M)FTH>]>O(!!B0W9>!QVW2C*[66A;FW)R90M/MZ?[<WUNR?@G2:M@"6^K^$5E
M\THZ,K4X,>98Y:?Z\(_8!"/S'PKF/V4"@TKE\EWX/XE9GYB24R"-Q@!PK6A$
M/[]'I@DDEE30,@J[SX[CO$UWJJ@;",IHE]F%4AQ6<1Q 9$R*'6]/+E-@#J=#
MB4ZC8AN%U%BH2QP9;=3N//3'"ALBN[!)'P3_G+"KTCKP3*^[?Y/^P?SC$KVH
MM8LZ\%JC?N<N7:MYAL5+JU*(MK(B0W&P=.%0(1>1'BD*(\0! 06V:C>-K*M,
M!J/*I,(YZ5&JN7'::$;GFI>(FE?Q>S^)A0.)0H6<D5OQ4'^>GMS&NY%?!)#,
M!C7C+SP;'(;ID[M879:)2BQ.Y>2E.*QJS"C9@L$U'24:="&]<9Z'JQCP\1AX
M*985 :X17.\TZ< ,>:@+=)J)AF_RIWR@IYV!:_G)GY3M(\F%9L\>E+X4ZZY.
MVB;/W3A)VU@+)Z,P ]/ 8@ODGYV'D()53' D&H 92\Z:MK$BY=K+P,**@SD=
MO,;V^KIO!\= \@W4%:K/L:%TRS3B[9;EJ,EP'(E1?<;9@9I5MA.//%GFIL9X
M*B9.--]&G<2GJ^0,"3_'9@/IV4=V]96S1KADV _':E1K\UE2Z7[M4W6G,<&#
M8G#>3^Z^O;UT]T]D3SVB%JEK6[8&/MSD5:]I7%]^Y<X_/[A1TW29<4 <]B-:
M#B!)9TBN%+WW[\ +OA-MZIBGQU>:(9AF6:B7(F8MW(BB]SOZ=K'YX=$U)HK(
MZ%#+[X-^CQ&I2IV:_).3>IU0%$]7[DY';350L!-H]LZ5,9=TX[,82QU13 ^A
MHGA!:T]%( ^X$_VD5B7@@Y)<:V1F'!4B\=#0%CLN>+#D/D)^Z:%JD\5/S"H6
M#S-:N*=/JJD^-"%3">^(X_9%L++._1QL:T$#%;7Q"HARA;.>=L7J!\E)53G#
M=J4@$-4RJ-SR(;*R2SWJ/2*-/4NA8?VF>>M%K52P -@-)V,:CZ9IS'F5;,V*
MXR6MDV2H=Y'JQ=6NX1<58NJ4A=+KQ7[U5!?L/IYF28*?@@;,!P!B=E<1X1-0
M,?IL;3^MG<1^5B*BH%TES36OF.Q,!3W=-:L'QH<5D4K@3L"4^N)6?4@M'A@R
M'0%6;$3Z[#.VRH%NB:>9F9-'\4%K9N1U96.&O2U-_56S/R>'%(O!J<D&)Z]A
M[?6$9S6JY<A7*-,),U,5([9U9L-A2OUZ$UO;,<6EK'FMJ")32?2LT9 4?S7&
MLA]])"36?6F(R5\PW;/2W>RIQ)J5Q8\G8'3EY)PKZ>7:IVSKO^CY+UDNT7R<
M2&IBTK40W9?A02W*=N%D9RK0IB!'R7@_VQ,%:)C=)ZLLLU1]&.^L=""YY=*M
MHLTP/5RA944,P,Q+(NMH#'%A3&4:0"FHB=Y#\:):BW#7O*W__?,A2G1Y=,M#
M*O:)EP/IK<].$+4T<7-N]<!8IYNEH/]L2@.SZ6>;]$\NW["N=-3HK5%^P9%N
M6CM.6_5JXW''F:%CO'!1IE'EM#?S*X^E-+*K%WIV;X94[>1IB,[BUT9K&+*D
MQ'[-)R^R(/MHB6Y>H5[T4P3JPGJUIC5O/UYZ!1B 'F(\:[G3RTXC(K0W,<N)
MW3?CW(IL43,*BJMS^C'E&D)UGUR)?)RHJHH@ZL'9A<6S+L9\F"[<86N^)QL?
MPUS'0D $T\PT5+HWF?5\E(8C-X?#XD"3:=@G^5"Y/:F7Y;K;VA\4.2-E'ARE
MT0@=+T[_R<"**:R4GB&=1)E9;!])NM4FWK5D,MB6WR=KS:**"$=A=&)8H%@F
MIS4F*BX!*$J[I<AH'*/Y^?.\=^F8"!-8G& JW.(X\V"J%'!]+,FXK,=8Q$$$
ME7)OL@V4=D;_<19-1&0N.-,YO5YKI";2=CC @XPA9([:*1ZVA2F>.I_N.3\<
MU;1R0326W4Z-,9W9=CODPVQJ<70=3IL;O]O41!V>CAD:G=&D%O7Y.=,4(E4X
M4CF*65]:F_NLV$\X9$_Q'&<+U<B,3SP3:33G:3(K-<Y3ID<EI1D$BTH:7V"5
MX8--;09U($G4S7D?[KK%LG*+Z3R#:23]!@HB'B3Y'WP?K3[>QUDC$#LRKR+%
M>.#8@?0F:[5T%Y+Q#)9J]8EX@L6.HGW2NW2^?WU\!4C3!O]R!T#?8[:X71LM
MR775#71EJ\%) \?6YJUKR)_)2-P<,7%JJD^A>L>KCW:VL6\/P?&_+,]C'TD
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M+V(NQQ]#3F?E5Y^,CH[: \#@V7^XPKOL<IDS[PVN;2., &3M)3!!)%G:-YP
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M141$JG9S@I.NX8.@R JW8\M]__JWBY&GO#QM4"II!#U*J&_2JF%)C@%)XH?
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M#HRJ@..0-X^X&LT#:FM[+P@Q..L5L*+V7/0$ %!?&.5 'YP3O@):#"2++;K
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M4N3YLU\! 0%B 5)BWA@W<4DH%"HN 1('@8!'-8#8(#3..1"(QO)^!_F!HX[
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M1G>(>A[Y<"\+7$%^[Q91H>:!@<VVA@)&=TH;#\5')\'4\. QRG[4]I1"S5?
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M6V-S8V;%'G[*(A^B3A/&EHXA1CRCK"=4=3+=TE[/#@M@,E[SA_.36[P^Z"7
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M^NGHR@B"A*_CDG5WXQB?"PM37B C?UA2*JCC0[VU'"7[98JTI@OC,5*?SS;
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M?LZF8H@O>!54.1+9C%#<U7XRNX7 -F@A'@6]-V@Q1JB\+[R1TM##$)Q.O6A
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M?=@J9<GT2..DUB0QB1XN6N'AM ^"NIBLB0LKY4:B<>WSE'Y2\+/XX/MWV]'
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M@/_X8P P.BY_/P>>NO'=E#X2@; WA*$]W?5LG:'';*)C)20 <;S9'U<U!,
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M#WQ/D/TY:\C$K^O&!G+N@-[[2\MUKIH1)):+94;4]<"AQB?/=NQXYF,"4G
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MO/&Q%)M?D2ZGL%+I.O.#N6TR%0KL*G?1CR7.:X'!+T*67R7L/[(=>:4;W&O
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MZ!?5_77:[_-@(K/1O)F9QZT[ELPIW9>=0%2YXS'X3!08#4,@H:F&_!$6C)L
M^K8>SI5=*;E]\"-531J6W#=7%0Q7Q-F_N+D%C6--7[G8?',@&[G1OO]HGXQ9
MYFOQI8] EABO\\K#D=Y3)J5:VW<7XFC#!U(O(NI,HI5F&>T?C"Z-UZ42"6AK
MU-6JINHEZQ8_D**X<G^L:,<ZV$#;DY:M.<S8*S6>)YDZ9\:=1"KMS3=V$3,M
MYC>.=&8I-A^+-"588I1#";!RD\C,"DT-NAO52.F?9>#XTSTU;6GO='L4''D[
M!JS!.O2YCARC9<+3Y<&A[5O4X,(N5\'#:$3S9&:X;HF$;JK%9&)1$61EW#FZ
M:35V+J\/:0F<]4UQ:Z*IG.)_^*G7CBO-(_]P*7C[&VF7[."6B(]COR#^U<^D
MU%#27"KF!Z!F=5-3#1O"VV9)61<&W 6XX[O!P.J] APM.J?.#DVK1!RLP:SF
M>PF,A4 'Y]KK.;M8G3)9F,Z3T >[)O6UUZ/>.QNE#0VO^7LS3GDLN"[G&Z6
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MH6J1W^E %,K9FZF=,R1]LXN'(G]\(S7&?C@M;=K@,MO3#Z.(2%B5B(\F\XI
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M[Y>>6U&F(;_VO,C@Q0I!]O!S6$'#ED7,[S!IRWS")0)[! R8$N*5+E90:W2
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MN+L/ GJI^%GLMS$QY!GVU=CVFV\;R8<_>7(O:S>D8DAVM[YA'5#'5E"WIIG
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M!<Z8A*P!VFO"9%ZB"F)4$."O_2D2P[S6Q4WN]!3#G?^XN86G2SQWK+L<VI"
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M\:M=?Q?ZZEFQ4>+WE'IVUNG>8M.](<%DWC6/E66B0@TL@MUN(0((P+E;R?\
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MV!/333],+8@PO6@BXYDWTU&M;97DI87BPY O;TC:N$4Y&1V)"5N_HEN!H2^
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MBAT[Y6Q53!<0HXGK.CD6_382<"NQDEMO2O+[5TK=B@/.#UKU-]S]M6Z/VA9
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M[!>!;1^Z>]M*8+T3&J%%GN_;7Z;CS*M&G*VQ?&_W"=Q[3,I<;=>S<T3\ZF/
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M,&@/<5X\FE#,OJ:.'D_U\<@*F/K*V; SOR8MY:JH;'?]B(RER&KJ041TA@A
M\%Y7LS#*O!/N/#SLOO+B7]B06S9J_C+]A7JI\.SFO-G'>IXFH7'%>H7$^_U3
M_+T=BG*I8JH )YK3T/4LVVDJ#>[ E[V!Q/&W4*O2'SK8)VNG^<O*AM;%.ZT)
MJG>>"H[%]9IE]3(E4Y7CH7#-IC&K@C!(F%*15$%/& F426NBF6@=V+4WIQK<
MM.+%R8 K3 D;R,3*?Q'C/CZY/S,IA!O^[\HM"/!%M&ZOJH#092.^6N1TY3+'
MK/<GGD1?RS2WNS'AM<H(\/LCNUPD6@U&95ZP)_F0#*V"\EMXG<[5+T_PNW\
M!%T8NZI@R3-C@I&[&_2N$@_-;VCO?5F'G8=72?@!1K"=)@,;]F>U9U2@VJ,U
MNMWVD''!R;*M$K25^?KS?V'J3_\ 3[/_ -P.R_Y>LRVE0H]GM;]NCV[#?F!+
MZJ!XPJ6/WV_^0!;5/RNIKM+/8P,X2*%_\_E:)>3S%"#RT.'I_?;X5UQ59HG]
M8DY4HTA0,_3OU'=/SBPWF_F[0:F]),;O J). SZ5C>Q #I966>U%E-,$HGR*
M13 /PXASUW[\QY]N77["$UEMLUHS,8%-;(:8[F@K'^7L2P-_<4P94,3RD7O6
M Q4D:3$SW#SX]39INW",^OL7AT^;SBL\\>W_.'6=.Z5ZHI2\4 4X\>H7GKW$
M"7J>'<-:209TRE3YH:+AM912!8SN!#LE3C-["UHT)X4+?"T&"7R^\@.[AQ%[
M;T.BTK>]#2:H[SY;XDCXQB6$0POB8=2R.<2!<(#N*0>$'NEVOZ,8'W<G\\.4
MQS;W&VR!6!U,>GICD6"91+1^D^T3>)OOC-_C@E/Q3!N^XLI:&M[O"CW;;&BG
MF@FIFUX=6_V)=)S>!G_ZQ[K22X$-/"R6^>4JAEW%2H70<*^_JR%SB..DQ,.6
M<YDW83LV%_48FE"=\^E4UM(=$#"9:+N+40!9B5+WIROMIZT':GRR=T$Y?4!]
M[^_D2E"_/QUL>M(B/EG:DE^0UKWOKB4+%-;F?53Q?JPYS!U-FVLQ\ 4K.N$*
MO.4I>"^!'##3,&Y+OF6<O6M*60#GM >.71(WTJCKOOS^!XBSEP<OQ,3$1"-T
MN<"7F N+2LSWS.G7/BME8H++GG8=;2_JMAHEBW:$QB'B<"X4[K%LW&4N+>H8
MSF&BZ@:>,O>I7LX/I$&$=N: E:MC8_:]3\6^HO=&HM\F\Z"'YYE<DL_\3E:Z
M1?.VEXC$ 7V-?(AG]W=:9CV:TK'H$<,!6_[H_@I0K59:6)G@E46]?[?&1A#<
M<,=HS;;_%Y6ZNR-6F<;^.P]-=BK_@M7H8..21= 58M9(#V9VR0NRI3<Z7;[J
MA]9<NM1"#?3UHP90G9)W&-7.R5>[,H1B>H?ZAJ2L+2R!YA$!$8MJJ\C#D$NR
M5A'V^3/XO+ 8<K5#UID60D5G:/R3<T$Z$'8.E]!414??#F*T5^D1%76I?)AC
M.M?+E</[@/GY/PKE5P*PN',.-.SM)8&K9O^6#@<H9&TOO5:-0"DMRB,1YI!2
M::]!7Z@7=OJTE=%!AL^?D-W'E.=IGLJTB:X^D)Q<G+B%5P",,_X4_0\08GI\
MR:EV=/</L/JBM.JK5:7](]M!-65QK'@O3#==[L3QHX-CR_M&9SV[]Z5_="@V
M.)I)M._AXX&/U7-9Q<*<8_8W,W<36FF=!3;>Z*0?P\LQ]=<YA3N^'2@)^;VA
MPZ8B :/@6LAAWDL0:*&5!O_&L%GP%^Z_<'_\.R6@O;V]S?XN)A+@<JSY(&E>
M3$\P.X&$&EX.NGBW)5,BCMGF<K"2US%U\LLWB@-R0J:Y)ZU-F7946N\VH:BQ
M^'=04V"0E[E9*:]>0-D!H3X%NRF#K=3]&/R:G>F=\/Z0).MG*9 A)2PHW @7
M RD40&/C$]L284Z59@0*2Y/$<*NC@ @PK'^+<_PA E"EC4SD$7%<S$-[QA#E
M7GH9JIV/3R1" ?0H 2-.NZ^JR\YSS?8K/\%&"$Y<UD,THR>6G0/3=T8=N6JN
MH#4-\,4T+-+$(K@4&-48Q<%NB=>BQ+'=1[=7PM+A!*Y)TI:V5J165D $&OT.
M9G+NLCVK4BX-;10BIHY.MX&X\&QIF?')E%\]IA5H6UQ_N:W^Y>BP@:C/2*&R
M.SN1_V5CN>QF"-+0C[B##\9')ND 5?+!WP8CUS09_PZR*43.\1I@6!2O02K=
M3/XG[[R4J?!$;<A;<]5UO20A,D'-74!NGH0FL2+!SQ)->CH-_&V-OZ,UZV<Z
MV\8GZ=I/I^U QQ^I(]F*JP[U=\5F)=HT:S^5"X1!+KOGJJ/M%KP"C7(1!IY1
MY:M&7^R;)OT1%"GB^7S4%EQB9!GW5D4DHPJ:QVA28/>+%.0)CZ[4M_,HY=P9
M\N2L.#O$S$4[R/\ ^$,G"DJHI<K]AL6-LYM='F-OVZN=_E3VFQ(@%TW%J*P_
M3U5K.(DJ:B73?/K\)RO^(.^\.^WM5\)H1.J79:SWSF)RJDTMB<G^_,3!6\3Q
MA<NUMF<BF^Q9LDWTFF"Z=C6R :6YTN3$W-RT1JL J;8ID<+F?4$M&QR3R>:L
MXJR>P-WB;*UBG8RO)W@'1?G3)5DEBVLQPMBAI_&=*HBY$PWLJ^4$2H^6.E@Y
MG%V*:T)=B6A"1BKNSVH+6R706I]\6>D_%WQT$(FKB#;5([  RR<7KD;-NU#>
M]2MYC7##3]D!?56K9*H&]@C%;(.YP;*M=6O(A)MRU7FO5\.44,I+D5XMSPZH
MTY95]3:W3W)U1'8[F,_\82/I<FL<=7NA(R4Z.M)>GB1\9(1Q"RV"5HKU=C<B
MGJXC5_'3^6=>F54+3 K\H#F*2#O"8^KYX,1]Q31S[-)@)*_/=)6KEL3AY-XM
M0F50J2.E 1R,>1AJ2(M_'L?MPZ*(ULZ;X@N\PS7?0Q<GUH+FN]::8Z,2'UTP
MQ[ 2EME*4]5#Z;D/^AE(&FK%LU6DDV.MSIAP6-HRKN9BJSX0&I%<("L7(MQM
M2Z*A75-TDQ0]%9K0YK15VL.XZV+/*/)V<7O^2;2V++8GH>485\OD1PL^^_G3
M)%?5W%C!N9WL%U@K(>(V3#9K;$MD+P+A2?XNKTQVB,(RG_VHB/6!E)1B'7E@
M/-!AB]<QIC,WTK#_>0+G&SVI2W0:K+F#ACE0.B8_+3<!JL)3]9ST?LA132@&
MB <":US#4('B <)Z,,"'SJM<7DQFJX24P)^H+<B'NDW;46M=W?(,WYEO_:83
M8M.]7&GXR#NK&<JZ[\ET?'(7-];8'3S*'-H$EB&ZUU#$W%)SD7I!IEK?1P\G
MSM4! Q*_;N7RK@'8F0_7BHQO<C4MN,QI(N[-6856*X+> D?6TB)YB[@45O\D
MNM',Z_-HOF-A:5DIE%&(A('U9M-BU[<_,@-*%!B?3"VH:60/2#$L-V$^_0=0
MW6YO_4QUU=UB'!X"_F:G=K*I(Q*B:B+!ZW+7]5+F5-G<3BL=R*7@1QP=,Q$6
M;3>P1!E'GX@5" V6XE"J>3%:'.H:O9>TI-9YKB%29$!SIL?+8XZ:II/G3Z)!
M/95N*U%(Q2N>)W_."I\@^]0.:%G@:U=!")2 C++B^\<]'Z;MY!"N>UI[(K^S
M3* X1\I>RAA1 A:?V;2(DBDV@)-WD;=+A[VS  =C#CD*)#2O[%0&IK*>XG.U
MX/83HUX,SE<B$]LU?!'I"B(DD!)]J8FDL8NCOWR7G0895*;=DS2 [N?%&LQ.
MLL%>%-?Q/W^6VHO9YMP,*N&&-EFN=Y99_J>0L%:@H*)F\W;+M7F<&PVS$+=@
MFC@F0+[M2T'?M$\\Y1"F52&AE 0I/5Y##0L 1'^"74.2MJ%QG#9SRM*W;B+T
MZZ;E]CN\W;8::@\K&4>H1$XE:K1<%;936E',F,BX@Q;(B9C42]1M/BQ#*5)H
M2M[>C._N6M=J)@07AL6%YQ4A@&.*/*:T_1=<[']2)W;W+B^NA;_)A,6$FH")
MAE6;?(J_WU_\N=B=KKRN99UA/(^[^]N@;8_#6GH[\AR-RV+"[?E[Y((,*PDY
M6Z%@1%L 7)<=P]>H5C9OJ&DGF6/=E#XEDS!)[2X:V,%O"2<7/\JWIO 8(TY.
M%0D-SI_?DTF$)G&GN-*Z'ZCQII,+M0[@$ >&^8;B$&@ T,!L;TIA?3GMD^/9
MP]$$<U&V6+9LU\3Y-47,)6-A=$R?T0_'N%TMK((=+5QCB@+5AXBU3=IR3K;L
M#*J]N?6C)-[>AA&I:R4_];CLK=R&&/UH7?COLHS*@D[C$L<Q.4BK3CHMB4 *
MEJI\/I=R+F=&C45=*]]>1SM16N&PXW".3B2&%$L_PWHB^EX@RZPBD7V4X=O[
M10(6Y;0K /![@Z!7V<L7_]OZZN?X$FQ+,<W5=BAAO+5LE'Z ?9:*TN?'"YU6
M03DP\^3\W7'I@)>8%)6179:##X<2X8QIZ5L68D0.+#$9R5!I'GD/=R3DICII
M0$R.39>6B>_[&P) 2BN4")/H.*WI9Z'KS ?)&['J#7:C33^;,(J&T0K%+ZY.
M)H=J811X^2QRO@Y_OL#G+376( MW3T-SZXEE/!KB&[RY[6M9UW1\BAH/B; 3
MW6*NG=Z88;^MI?58_J*@A+"(2-9"<LLB-EQH X,D@8>6<*,-OI)(+A7"UZ*M
M@($E73<(M"J_4Y2IF'[O:2/*J>C:<J41/C#RMJ";$J&4>:6O7::][-1.R9PJ
M@27(J(&!9*%N0_ %T.JUV))O8GN*9(+6QRNB*#V?#*T1R92!2RGYIW'2/.X;
MN<CD0P]TP5/U>+GJ<0(>QUP<X852P;.Y2< %$ C#,8V@V43S+X:T-J0"B7<6
M [56K&3NAC__%-"&E>J2(Q%/L3?0_)%7'Y,)0?/Y]& O7749RNK(6=6WV]#R
M6WMS39I8:91+"^CT?44M[)U;B=N\)>J\Y9EJ::1BD4+BG%%P0=U?T!/;"(8I
M9??D)2]E&JZ$4B2OL8NK"Z_+RV$G)B3B/+&"0S.R41^HQ(9$&:Q=7"\:O=!R
M]RLR/E+6]PMO)UBG#(<Y?VR@65!@_Q>/A< RTZ&NUX][+T\I8GFB1JY\W57/
M!W[%R:+)3.I>&YE8-P#1H)+B1S 'G>0_0.5-62,#)AC:)K,!D_G^A"1(9(AZ
MSL[5)K8@]**YQHZH8B)N&V0Q+'V.3UYO5)83KQCP8N;4A*=1J+19'=59SB/<
MI0D0!, &4[L/:7L*=KRHP5 #.+!7Y(C)_E06\4I0!)+*+2PM0K$Y@2@WY9J\
ML5X U]H2[,]_DJ#EP" H4L]FD>D&E<Y8-C3O=9V,,.#4C=NY#F:C%I%0(54!
M5?(P)7'_RB7DV?NW+S$JD^+))S#W!IU>6^QT V_?5KSXKC=B?5'7T5U=,PCE
M.[;D5--=?@:*2)N\7VDO\>R+8G>572>)1)!@&"G;":*K<HDF=;V45O)1P'XN
MB!]+.49"4FS4^TK=N2T8D7@L6Y*+BDBV=O*54;=)D*:+@1)$06)\&%Z\WM5#
MW<T?9&Z<),ZKQ*\K=&UY5O 6?U E>/PI3;2L(RHQK73DO$#4T1;PP2IUL,)G
MJOK6.=ZG,!"^3JR74$7=NY#6D1 DS;]W^U/X6JV@C\2*Z=TR_,"WQ<GA-*ZI
MG!$XMUIW7?A=.V8!M\&.:] FW:QXTH3)53,[#5A,H]DR4PP_@HH;R9LPPI&-
M(:E<YH[ D>3$^5!>X2C7S)TFR!BT@1.O5S)1'9[;W^F>+-+&2Y!R+P^6)EWU
M9 9)TO[<'&H7K[@R*!F#1M+:T$I#XB(R55KW:=.9]<TZ6X1G>C[1"YOO%QWS
M$T^RPK>7L\^G'.YN(RIX+O1KV(QR3 !EF7.-V&6;5J\'OY"46D> X)&6%J;&
MVU$3YTL/A4?M^TT44<EL.E/,8_6^'&U+]H=@D67\;<N&DM),KZ8Z>R$N?/1_
M@#\!Y_2G<7[LVU\/.K8;$9AF$[3JO$BR@9A7&Y*;BZA%_ED[$&IF6'L/,_)+
M2/M4]CPGGNP(/C?G@ZW+707^1<357*M(>#JV+>::*"8]]\6*W4:G)CW+7] 7
M4NH*.FGNVP$@^6?(O @U[*_L6%S&N;Y,9UP1)MLQ%EC20./$,%^/(1)G$N>/
MO9E$T)M@_#F1;=W_QFHU;P<0MG[&QU #+;4W%'D,P/H#;(V3H5$EI5&PH;0V
M!R8]T"]9\LF"2*,K-21<ZLU]6-1'2VJOKA+#[[9'&- QS47BQ%0BXCP+YG<
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M741;!M<XERMTI7Q86"L^O$( +*6ZG69+EB? )=H%;L?:\Q%_V5[,"2_^P%O
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M5-_QI4I'AZZ8FPNKKO10K%PH?O;]5,*%C<<V2?PD\@\:S#D5*5<<Q 0X.2Q
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M+DDZP!H)F& KTR_!H_\ O6]S6.!UJWA<6M8G:^Q;8O<7L>1VP<6'BO.__?\
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M^6=P!_1M#MM]B@_[^<T.4SRIF&.I_P 7@1V))<#3<F!6%5U_\<ULAP ??53
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M=[U1M$:-8[WD/_JXI\JM_P#S9JV,?\ZV\+8__/N,7/-P..=3JEP!O-_QL-/
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MM]>@^S>>8BE[Y-_K)O%FW,5Z%[-1_O*H,"3DALX=VCR2''KV\PR9IQ=0 _\
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M^==Z<4D"$_\ +Y<@WD) 8[ZW[BM2N9\,?WBXXO;C7$B1-CCXRF+&[3]TD L
M-;0_A,%:O$'U$2026NAVY46L>!NK91!/IBY(!P,#@#72\<43PT$!C^T(4-6<
MI)![,6TEMZVM^QV&YDYL:QY;43+_ /K$@7 ;<R ]A JL"HK*)\SRN$@S)2K7
M]9#E['S=B+JS?\\Z[5.*5(PRP#8>&!)OTIW_ !F?$ZH<QA^8>-$.W]IYPM)
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MET2]_2=-+6W_ (A?\"38GE(Y[@"Q]K<>^L'Z$[?4_G6 MYMN?Z$ZWWI=1!_
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MC8>5-CC)*0+6(MZYL.!WMKN<3&0E2DLQ!9AJWB7?0ZF7#UIYQK#/]K\3*3U
M9_.,Y*0/W^(#-@&,=4VEVJVSX0P+G6OJHE5[GH_5B<<I5N*@E6>]P +@C%CR
M+:Z/B^(I>1P.HB%($,(<?J="2S%ZW"^QX@(YBYM("AU\J94D*<NZENQ,6+.(
MUTJJ*HDFH5 Y'EJ$SRV)! +[A%['G&;W)OV&NY5C]&( 6*3E<!W\.'A]P/)%
MRPU$X^E:^.\44LN<7B&?6L !!ZU9S$22 "WW  00Y5)#!ZM%^$@HK\0W44\7
MZ&[DO?@D[GV4%&YL$CS$GGA0&; 'K>+XB5Y%*0"/WZ.K?I<,'!+,1,L[]WVN
M^QXD_P!XN;"""E/+^*E( 8)Z<WADS&KF7(!9V855M.6I4V=W(G30/H)+M@1?
ML.,X!)OVUV7O!ALDB.G#"0X##W8)+_Q!R22+DD /?5+F) _M_C0$?[2SQEUN
MV9Q$A, D'8$$,\B*M<^$"2>O/48'^5^\U62<<C]TFW@K(OZCWL3QKK.++&+E
ML,72C-X72T,_2]A8MZ6=C&VGV-,-N9^;B1?EU8)9O_.PSN\E3AYFSP:H'5*2
M[(2+6+[M^/Z:@>;=C:X)]N-=HK,)"U071#O?I_,I)8L8E@9U+YBP@./\5 =U
M<4S^MNK-XT'600EW(+[I!%IOPB,^)#>2!P.C&YB<XL=S[,2NY!/">.#VY!UT
M7&UJ7PP*)G^T<,V:Q)L6U?\ 3"MJ_L:IZ>>^9OA (Y1QPX-O\1EPSN6EI+%P
M7AC58FX5$U^MJ\MU??-4Q[&=(L1SP; C@94+$:[D8_3B+22Z?=8&G3\02():
M\QH0SF:U:YG0_,/'3TLW%N(!G=1?&6IV8DI!<%[3(*0!99\(WYA\5%=";^8=
M%=ZVOQC<>QLF_P"$!/)4<#DDYM_#Q3%3B9(](E.8P3=S*P+/ N6T>PL=I/L:
M).'S_P 84Y?^Z^=#M ?&PGDW=F)<VO$5GUTDURN'DFLU7_\ 6$D<G]21R,=K
M:[(Y@@CKE@ABZ1'0E@ 6$%Q)%Q+6U<YK0D\R<;)(!/%,Z3\))<9K%8N'9P!(
MN T@ 5:-\'PE7B?W/>_F_>:W0?;R_NKV-^78X'&1Z:Z;C"@OA^)'P_M6 PT?
MIPQ<.=/$W>:VJ^QH".=N/D QP!$M_P#6J=Q9B1$:&[!_3($*MV /H;"XOFV>
MP!_FVQQSK%E)2YC4ZG?S7ZA*()4;EW.CN3OI)@'MV.[[>2I-;@F_X;2 ,@Y^
MR23;_'@>FN*DI"26F&D[TAS$[_3Y01IOM6];I053&#<'^+'!Y_TJN!GTN,6O
MZ:( :VOY5Q49MX,^')!# $SMW>.+J1BUTB_'')[_ )VYL<7];#Z)1UEHCXIT
MZ9?Z5QZF2IUJ2M22C#*>H'WJ@R ^A<D&SZ[FJ7XH7A(KO738M%ZI;)E1CNOI
M#2MQRJG19CZ8K6X-F.LMU:J-PY*TJ0S5Z2[33+@(>6U&E,2)K#SJ%IA_+[/(
MYS R@7@8A4E&(2I!20D>\,DM9R():7?>M:/M+>Q[.>TK@N0XKP482>8> 9?$
MP$9(IC-811U'#2D @+.*CK2 &Q%+4#)0:J$\/WP\^OW6C><6D[CVE-V%L6FU
M=F%O+==>D0HRHD-H,2IM-HD6*_-D5.N3*?(0()+*:<TI]+\B:$-^1?:GB&3R
MZ#BXF(58O23@IZG#F%$ APPN01\JT^]GWV8^?N+<SY;#YAX4KEKA.5Q\+%SN
M<X@.K"QQA+1B# P,%?4E2UI)*5>[]VQ= $1 N[]EVJW_ .(CX)-P]>]C[$K/
M2A$9W>?2:'/HE-VK+G)@-[DVG+CP"Y IDB2XMABLP)%.AJIR)S\>')9>ELOR
M6%JC.#JN%\1&67FD8R1[G,+*P5,743]XZN'@@78O#G;3[0_L1S7M$Y>X+B<K
M@8/'.6\NG R&2S1*AQ/)##2C&3ERL*2A2%88&"?A 06=V>FCP[> WK;UMZBT
MW:E;VX]L;;$1Z'4=W5NO28L:2UMYNHO0ZDB@P8[LB34JFXN',@-%#/V6GS51
MOO5Z*A]E+W:8V?RV "M6(I84DJ *B7=)"27(&H)9R27,.3J9[._LR<\\8YCX
M?_;W!\UP#@F!F?\ %9S-+'OL1&$L@X> X4I2E=)"'("'!+!*7N9^(IX(]S=?
M-B=/JSTD9BR-Y=)J=4*/$VY.G(A*W/MB8S30N''J,IQ$=NKTMVDL2*=]N<8A
MS&7IS#\AE]3#J>MX9GTX.)BA:D(P\=74^( K#PUDRLI+I< [/-I(K;C[1/L4
MS7M$Y9X"OEM6%EN,<M#'RV3R>;$\0R.+AX*%+62#^]*<##"5$@$ I4H@I:F?
MP_\ @,ZV=;.I5/V96]MR]D;:C+DS=U[DJST1*8U!HU4:IE:;H[,!^4*K5793
MBH-,4+4Q^0ER3]L?B1)!':+XG@X:,12,SE\51"DA&&D=?4KJ^,%OA8@_=D2T
MWU"]G_V8.>^-<Q97"XYP[%Y?X-E,[A_VEF\\05G+8&(!B*R)""?C"62J$GJ<
M_" *N7^(;X(]R==NG_3NJ](41E;PZ1PY-&I^V)<L,-;CVG+C4UI4"',DJ^0U
M5J:]3(KL-4MQF/*CN3&WGFWOD.)ZO(<0P\$8N!C**?>*ZTJ2HPIY( .[7> =
MP:V^^T)[$\QS_P M\,QN6PI7$>74JRF1P,173@\4RV)AX22E*B#\8_9P4DD
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M604H4Q 41@((4J"?O$'I:D_H9X$^NG67J33-BU?;4K8M%CR*@YNG<U:7$^3
MHE#K+%(W$Y2VH;TH5BI(D/JB4E)6W"DR@5IE_969#S7<?M^1RP7BC'Q,3$4C
MX4J6HE*V(!2KJ^$;A+$AW<UI[R7]F;G_ (SQ[ RW%>%+X-PC"SR,3B69Q4I]
M_D\M@8J5%67*<,JZL=74,$]?0Z RTH0 /33U^\,FQ_$%X>]P^';<JY,#;54V
M_2Z71JK" =J.VJKMM4.5M;<,+YWD#\NB5.GP9OR7_*S4&VG8<M/V>2Z-=+PW
MBN8X5Q/+<3R@ Q,-:ED$? H*Z@K#6!_"M*E)($@%P':OULY?SF-RMFN&8F42
M ,IEL'+% LK#PD(2D$!G"D)"B[2HFYKR/=;OAC>,7HENQ.W']D4[J%2IHJ<J
MB;SV5N&AHHU5I5+?AMR*C-IVX*G2*S076DU*G_;(,N(^TP^\\Q J-59C":][
MSD/:1R[F,J<7-8Z^&XN& K$PLRZBLA+J3AJZCU%3$)#N"1\()%>]Y/VC\$S6
M5Z\PL<.Q0X*<R 58ACJ1ADDD=<C#58=6U7?_  P?AE[G\,=>G]<>NDNC/=5I
MM(DT+:6TJ),%6@[$I-20@5F74JPT$0ZCN>ILH13OETU,BET> )K<>HU)ZJON
M0O,^=>=,+F)>%EN'=:<AA'J6I1Z58N)<** 2P21J02= $A\"YTYWP^8$8>3R
M" ,O@-[S&9E?>'27_P"I02DN9#AC5RFZ=S4/9>W:QNS<]38H] H,!^I5:I25
M%+,6(PGS..8NIQ:_PM-,M)<>D/.-,,-N/.H;5@'CS'C7T^CUYN#<.)),FY>'
M%[F]PS=SC/M+:&XO$#7Z5U3ZITB;0>G=$EM53I-TDK#9:DOOMF\3J+U&@CSH
M=K4ANS^VMLON/QMO17T2I2'*FZI>H)_5_'Z_E5);NW]6EP-"3!_"LN0P00KS
M)!)Y%^_I:]K&][6!N;DDG5W[3V\RV\>:A+Z&8D6-]C!@ZF+6J?D*(%UD^JA>
MU_0][^EQ<G36=Y_1_G1V?9G >6FUPU[&W9A6DQO,E0+BP"D@V4I)R,64""#Q
M8@W%P0;ZAB09G3MI_*Q\4A9"%)Q&4>DC#4V))8^[4 2%])^ BQ(@BJ,OBJ>#
MW?>_*[2O$+TZAJW 8-#I.S=[;79?;;K+8;J[C&VZO26G7 W4?M,FMN4J;!;6
MB6A9I[\=J4VN08_=\*SN&,NK+JQ,/""%.E6(D%"%.5'I27 );I=(>;N*TF^T
M_P"Q;CO.N>RO.'+.61CYS+Y0\.XCP<I/OL++X2^K+8^ Z8/O,3]_92D)20[J
MK"KP6^ SK3U.ZI;+WAO':=6V+TOVGN6G[@JU9W)&5 FUV1MJKLR?W.T&F/J$
MV0](J$),.=/4TS#@,)E*#ZY[;$-[^O,9W"P<'$]WCY?&7B)*$C!2E*D*Z2ZB
MH %C*>EY=Z\4]AWV=><L]S7P/CG,N5_L/A'#.(86=7F,5\->8Q,IC#$PLO@I
M;J2HXF&RULD!#AW+5G5\4GP8=0NIE<I77SI92).Z)5"VBK;V]-J1'&OO<4^B
M29]2I%=HS+ZVF9Z&45&9%JM/:=^W*99I[L&+)<5,*.OX?G<!&$<NLA*BL%)@
M.DD]0226<DQOMK7NOVH/8AQOGC$R/-W*N0.9S^4P$\/XOP_[N(C)X2BO SF4
M"K$)/3B =)*6*0LN!7[X+_!#U:ZN=6]L5K=5 F;,Z?[#W#MW<>Z:A76$4R=/
M$.3'KE.H-(IA*9TIW<"V6VFZJMIBFQJ>9+R)CLJ.B"[V&/G\GE<+&(6I6-B(
M*0%+Z@$D"0EV2E26)&I=3?Q5X/['_L[\Y9_F[A'%>/\ !LUP'E_@V;P\SB9S
M/IZ3Q#&P,4XN!E\H>@J6<3[F+B )2 R>HI"4BP3XG?@IZC=6:[1.N/22D+W3
M5J5MIO;>\]J0W$+K*J72Y+\NCUVCQG5I:J(C";4HU5@H<;FK;1#?ALR3]H;;
M_FX1GLKAY965S0*4E7O<(A@4J42?AL4J>Y)M![>Z?:B]AW,G.F9R'-_+.51G
MN)9'))R'%> 8+#.JR&%TG!S& M18**%*4M 4E2@RAU%Q5=_@T\$W5+K'U@VK
M*W'MVJ;/V%L^I;9WGNFJUR.NG2)U($YR;2:=18;G\8DN5]^F/Q$S"VF'&AB5
M-2^IUF,S(_JS&>R^71BCJ'44*&&!*NL@])ZBQ=F$$;N:\$]C?V=^<N)\W<,S
MW,/",;@O!>%8V6XAF<;. ^^S*<MC)QO=(21U$XO0Q5U,A+J^\4)78O\ %(\%
MW4?JK6=N=<NE-)>W14:'M/\ <QO+;$5T-U)RC4>7/JU,K-&:>4EJ>]%%5JS-
M2AH=1+=9^Q.0VY1:?0U_'PW.8:,'$R^)B8>%U+]XC$Q@E2$3U$)Z@0DJ;I<=
MB0;CW_[4/L0X]SQC<&YJY9RJ,UQ+)\-&1SW#$'W?^$P5K7@XV&C[I45XJUXP
MZTKQ$J21U=)JN[P:>!OJSUFZK[;J&YMN5/9?3W9]<V[N7=U5W A-/GS:>R^B
MKP*31:4XK[=*>W$(AC1JDXRS3HL<3)3<E^5&1">_JS.=P\#!649C QW2P3@I
M 4F]R " H00()#2(.O\ [%OL[\X\6YRX/Q'FC()X#P3A6>P\YF<QB@HQ,TO+
MK]Y@Y;!1*OWF(CHQ5.EDJ-UL!8W\4/P7=1.K=5V[UKZ2TI>Z*O0]L_N3W9LY
MAUENKR:9 G3ZG2JWM]$AQMJ<_'<J<^-4*8VXW)=95"7!0^\A]IS^'(9[ 1A>
MX60E1Q/>I8@ I4&4E6X)2;6),%S6PGVF_8?QSG<\,YJY8RF)F>)<*RR<GG>%
MJ^%>8RN%BXF+A8V6ZNE(^+&7\"E)"B"TAZK/\(G@DZM]:NK6UQ6]M5+:FP-L
MR:!NW=E:KL15,=F4-$Y<B!!HT=5G)<BONTV1%8G?AB1XC,R8J0M;$=B5VF-G
M<GE<MC-B*5F,1!2 5$A"3HGXG8N3H+EG-:\^R'[.W.W%N;.%YWCO LUP7AO#
M.(8'$L;&S29Q</ Q1B#!PP4?Q*0D*>$()<D!*568_%$\&/4+J],V[UIZ3TM6
MZ:YMS;"=I;HVDP\$5EV@4^JU"L4RL4-ATI:F/PG*I5&9T$*;DN1WXZH:7EL%
MI77<*S^$E(RN82$)4>M(3 +@,%$?_P!P$P(>^Q/VF_8KQ;G;^R^8N6DISN;X
M-EUY+,\(4 G-Y[**6<1&-EU$#JPRI2L1&$I71T*'0':JSO"5X&.KO7'J7MY=
M<VU4-I=/MO5#;^X-XU:O)^[9<FCN/"H0H%"IJ[3IKM>;AOLQ:DEINFM1VYDE
M$MY^.F,Y_?C9[+Y?K0%'WA20AB>KJ(5K$,2#(@S#5KC[(OLZ\Z\8YHR.;Y@X
M3B<%X1PSB>5S&*K- C'QTX6*A2,/#00_4HI2Y(*4L9=TU9Q\4#P9=0NLDW:W
M6'I+2E;EK>U=NKVMNC:<=UIJK3Z+$G3*G2ZC1/M#C,>5+A/SJG'E0%N(D2V7
M8AA*6[&>:<Z_A6<PDX.+EL4D/B*Q4*D@ CXDC8&?Q+M&RGVF?8EQOGG"X=QW
MEK"P<?.\(&9X;C8>( ,3'P,%U890H@@JP5E@DLP6"G^*JQ?")X).J_6_JWMV
M-7MM57:.Q=N3:!NG=U8K\9V!]JVZFIK=8@T1A:3)FS]QN4R5 ITGRM0V643)
MI?6J,W'?_O7G<' 0HX9E:5 D*/4'^'H2IQ\!"CU ?>9)+M6MWL<^SOSGQCFS
MAN8YBX)F.%<%X7F</.YC.XR0E.;Q<OC!6!E\ %"G*UX:^O[J0E0)*@ !ZU&8
MOD;2@'R!( "4D^5/E0D )3V'E -K6OFY)N<8)ZEDBP7\)NP,QYD]Z_4_# 3A
MX:5I 6A"0O" Z4X*D'W?NT 0@,E"RQ@XBB-:HG^*3\,C?7B"W@UX@_#VW3JE
MU$7185&Z@=/ZA-CTE>](U%CF-1-Q[>JTY3=-9W)3J>&*)/IE5ETVGU:DPJ:]
M'J,2?33&J_HO)'.V6X"5\.XJ%_L>,L+P,1/Q*PEDNH=#OTJ))=(*NJ6(+CT[
MDGG/+\*2O(9U:_=]7PASTA1+N'-YNX()$,QJD?HQ\.CQ>]:MZ*V=3>F4S93,
M1U/W[NO?<NG4O;] AIJ$BG/RW1%ESJG6'&I427'8A4*#/<F260S\]AE?VI'I
MW$/:%RYE<I[S*Y["XGC*2I*,+*#[JNDD)Q"2 ""R5%TSH-/1L][0.7\IEAB9
M;%7C8Q=D+7UNMGZ948*HT %FU]C/AD\/6V/#%T2V-T6VE*=GP=J0'U5&M2&_
MD2MQ;CJ\V15]Q[@DLA3WV=55J\V7)9@AYYNF1%1Z9'=7&AL'6O?%>(YCB_$\
MWQ'-1BXQ<)39"7 0A+STH2$I$RW49->!\:XUC<:XGF\YF'!Q'"$_Y4@ADI<E
M@P8)!$!):]=]F.;_ ,M7) M?/Y<V'?GTN<W_ (/7]3^AYKJ^K8!S_P!6_HP=
MK._:M:6/+<%:C?C///-^V?IQ;-AI^MOSU_JU<27GI.FI+:N!&@>"/K,EI.1Y
ME#C)&#?DV[CL#CZB]](;Y_T^M^S-WI)NWF2XL2'AHT&KN[5C3XMO#3MWQ7=#
M-X=&J]/51G:VB+4-N;C1'1-=VSNND/B91*TB&I;1EL-2$JB5.&V_%=G4>748
M;4N,Y(2^CLN#\4S/!.*9?B.5'4K#!"T$D!2"X4DD& I)B_26478UW/ >+YC@
MO%LMGL %7PA.(DOTJ27=) ;X2#J=1Z>/#JG\/'QA]*=^CIY4.D\_==1D/4UN
MC5G8]3I=9V_7F:S5546CR8DV7*ILRG-U"IH^QML[A@4B6R\;R&DM^5Y6P>3]
MH?+69ROO\;/X>1Q0)R^92?>8A <X>& X*E@=*"%'XBPKWG*<_<O9K*C$S&.O
M Q0"X0HI 4!V5(!DZ,P-VJ^;X6/PU-Z>&BNU3KSUW738W4^K4.;M?:.QZ5-C
MU>-L:A51<"16:E6JM'2J!,W=554]FFB/1I,RG4:E(ELIJL^35Y;$#RGG?G/!
MX_BX&2X>,09#"5U%19/O,0!1"NA/4R0[ J8J48#)!/FG.W.>#QCW>0R"U*RJ
M3U*5U,"I)Z@0RB')2SQ!.CU=M,@,S([\60/.P^VXR^A7E/G:=0I#B2#@I4DY
M%TDY'F&3K $D)4E3 LH*8V*DEQI<7>?Y5YJK"P\=*LOB,G!Q\/%PL4:$8F&I
M *@2Q9:F<Z@$6%>0_P 2G@CZQ=#^J5<VS2]JUC>.TIC\FK[/KFWXAJ")&VY5
M47$A"J,LJ^939U/6ZQ J)=0F$7BS)CO?9Y3"1DYSF#F$!:BV( !U!3%DA@%$
M%SH).I%HK\G_ &F?9QY^X%S/Q)'!>7<WQCA&>XCC9G)9_*H/1E\+-8ZEIP<P
M@,A&(RB2>GI*4A2"7<VX_#(\&&^NAL;=_4_JY =H&ZM]4:-MRC;05)9?E4C;
M0D"9.E5S[.Z[$1/JLA,%^/#:>><I\:&C[4MJ3-?BQ^OXGG<-:<OE\(O[K%&(
MM3!U%W 47<A,W#@ " S;8?9I]BW&_9]P[C'&N8\' P^)\:5E^'97A*0#B_LB
M\'$5BKQ_A *U+*%)'44H8. I12:E/%!X'NK_ $%ZD5VE4O:U2W7L:HOUFN;(
MK.WFOO1]6U8DEMSY5:IK!,ZF2J.Q.I\.I27V!3G77&Y$:2M+Z6T=GA9S+9AD
MA?Q@#WCD]16 .I3EBY)+.Y-S>=4O:=]G/G7@7,^:/ ^"YCC?!N(9S-9G+8N7
M!5FL# Q<92T8.88=?O,-*@A2B"%$!22?O"V?X8?@UW[T6A;NZH=5J;^Y[<^_
M:%"V[0-IOR6WZE1]O&3]NJ4RN-Q2ZQ'GU.2F 8]/0X\_$B0D_:?E29CD>)UG
M%N(X:TC RZ$J3A'J*I!*00PZB9.C,SN-JVH^S+[%N-\B9'BW&N9<)&7XWQ_#
MP\MPWAZDI*,/A* L8AQ4])0"@?'T.KH" _2IP*G/%#X)>L/0_JCN&B4G:M7W
M?L^KRJE6]H5Z@P%54JVV[4O*PW5FT)+U.J=,5*AP*G)*1%=6]'E-/_9I24-?
MW8.>RN:P<$G$6G&PD!*QUJ'O$B.E:7^)(T27"7^$:G5KVG?9VY[X%S/G\3@O
M+^:XYP7.Y_&S?#\_EL-*R4YC,JQ5Y;$4$!2#ERQ/24$ASUJPUD5:_P###\&&
M_P#HLWNSJQU=I7W!N/>E"A[9V_LYUUERJT;;OVMN;5*A7RPMZ,S.JC[,!,:G
M)<4]"8@7F*3+ENQX7\&?SV O#&%A'K*<0XF(YV8 1=F@-+LP>MG_ +-?L6XQ
MR+E.(\:YAR9P>+<;RXRV'PY(ZOV+)8BEJ7B9CI2P65%*@.HC#*"225 "JSQ7
M>!KJWT(ZEUV/1=LU/=^P*].W!N#9U=V^$SWD;>:E"2[&KE-:7]MILS;[<Z)"
MJ4K[-]UO%4=]F6E<I49C^[!SV'F,-"\3,9?!*4!/3C)25*9AU=1!40S  ^!%
MM8O:]]G3G?@/-/%,?ESAR>-<%XCQ'%Q\CF\ND8BD(S&)B8BL#%'2%)7A*(#E
MTE+-<FK4/AA>"_J)T43N_JUU:IKFVMP[RH#.V-O[+<=9<JE.V^Y*;J-0J5?+
M+KC4.;49$>"B%34+,B+'BR%SRT^^B/&_CXEGD+1A8&'BX>*,)7O%8N".A"R2
M%I#:J2Y2Y$,U;.?9D]BW&_9]E^-\>YERZ,'BW&<JC(Y7@P'5BX.27\6)F,0)
MCWJUA*T!))PT)#D$LFJGQ6^![JOT)ZJ5VE;?VU5=W;$J\NL;@V96*%&547(^
MV$U!*$0ZXPVA#T6H403(4*I25,&"X'(LUMY EEAO^S!SV6S*4@K/64#WKDD^
M\ '61KU/)ASY K6GVL_9UYRX'S=Q1?+G!LQQK@V=S.8SV2Q<N%*S&6PLQF<3
M$P\OC+)ZQBX2%I02".L_&2RB4VD_#$\%O43HS)W;U@ZMTY>V=P[HV\-H[<VA
M)=:-3I]!F3(E1J]5K)8<6S%J,R5!IC4* AQQ^&U'DJE?+=D-L(_EXSG<MC9?
M"R^3 4$+"UNQZE),*(:20226?0S-;(_9?]A_'^1L/BG,?,F2Q<EQWBV25DLO
MPG'6<1:.%*4E:\4EB/?%2,,AU*6E&&"Z>H@5@^+;P/\ 5OHCU.KZ:!MZH;SV
M!7YU<W%M.OT-I%2DM41$E,R9&K<)M9F4Y_;YF,PYT]QK[HD)^S26YR')"XK'
M]V!G\OF488Q $XR</]X7Z7Z0WQ,_4P/PDO!@5K;[5/LY\\\*YMXGF>7.!YSF
M+@7%,^K'X;G\D@J1@XF.2O&R><0P)Q4+( 6H$+2!)!4E-GGPO_!;U Z/S]R]
M:>J])D;:K^Y-N-;6VIM24M@U>!0I\J/4:U5*ZVV76H4F>_ I;," F2M^-'CR
MESVFWY"&(_7\1SV"M",M@JD+*ED, 2E23ANP'5TL6<.#%[[(_9B]B?'.01Q'
MFKF?(C XMQ#+#A^!P[[Z<IE,0XIS6)C@$I"S_AR@'JZ.A1)3U$&MSQ9^ /K=
MT?ZC[EJ6U-F5S?73"O[BDSMJ[BVQ$-2>@,U^IJ-.H%=IT=2I<"HQ9,Q%,:?#
M*X=0#;3S#HD/.Q&?[\'/X6-A8?7F,#"*4C#4G$2D8BU#X@M2R[PI@"1*?GKE
M[8/LX<[<)YIXIQ+EKAR>-\#XAGEYC*9G"2%C!3F%KQ/V?%PPD'WF&L@%8!24
MJ27?X18I\*;PB;SZ:JW!U]Z@L&D3]U[??VCM';!?:=J+%(-:;>K]3K;;:E(C
M27JA1(,6#"0ZIZ.W'G*FAMU]AMKK^*9U!P</+IQ,-8*@2O" &$H@N"H0"I'W
M2MG9,6>MBOLN>QOC?(V)G^:>9LLG#XAQ#*C(8'!$#]X,DK$6K%S.-T@@XGO$
MA>792BA*I A[KTL(  N<"P/. !?\1)42+G)))Y))R>H9P-SW])AK]ZW(4P*@
ME*PE)CWBB5,_P]>ZF "HOLU;G16@BLP%#^E(OFYO]CDX_+.N*['T_$=A^%<D
MEQ\]+MKKO/>MYW$GS2F?Q #[.,$V)_A7/;ZC\SKB@L-;W^7KWK@K[VG9[1/U
M+B3]&KCORS_21CT5;\/<9!';@XO>YU]'WFY]?U>D-!;R-B2#%M1#W K@/5F!
M*J72KJ?3H#2I4ZH=/-YP(D9D%;KTF7MRI,,-(0@%14M:PE("5*4I02D$D PD
M#8?KN?Z=JX%RTDEW87TUU!UUCY]6^&VKP:I0]YL17VU.IW7#JX25%*W*;6]I
M;:>I\YM) ^9%?=B3XK;J;H5)I\Q"5'Y2CH""Q!<?1]OP>VU<A\+]40VCF]B?
MGM'BLD CMYD<CE5B+GUN,F]_R]+:K_@1ILVWSWI$,KX;[AR-!J(:;5BEU$Z%
M;A:W*K>_2V<W!J3\^95Y-+%0;H]0IM9J22*Q5MK59R'-II-:/E?J^U]QQ'=N
M5>>55"1(BON2T2) ,;O(ON_G]/7$O-M6:!<[]FT^=<2F4GQ/[MC.[>JB*[!I
MKR%19CTJ?T\VG$J#"P6G&ZM6=GU'<NY$H6D%:E;8IU-^=YO(I^.TM31>:)@C
M2?D/6!V^G;('I/TG@]-*8\%2HU2W#5&H+=6J;,1N!#9BTUIUJET.AP$..*I]
M!HZ)$EN%'=??>=<DRILEU4F6[8/7\/Y?KZU]%%-G_G^,6)^DAA7;:F[\E!/I
MYAD9N+C(!S8W'J".=6W>_P!0S_J]<0UG ?6=)MOX._:L3^HW0BOHW(=\=,*B
M(%4<G/U6736IR:1-@UF>0W5*SM>I*B3:?YJP ERM[6KT!_;54EI%26N#)+YD
MQO6[/&G\_4W[5Q5)![3>[EK&X@VB&:N*3*7XH=V1%[?J:*Y!B/MKC2Y$F;T[
MVK$FM.)4VM%7K^TIVY]PM-NILIUW:E'I[RRI0^:AM:F]'+-\]/U+:[.["HWZ
M_7D_,UW]TDZ40>F5+DE4F-4=Q59F&Q5JE'B_=\%B#3T.M4R@42GA;WV"A4I#
M\@1&77I,E^0_)GRGUR)"?EOG^M1]?I)KZO\ " 6^Z8</VT:/GY(KMPM**2;H
ML#R5?GY<@E7F MS<@@6R!HX#/'U>>_G]/4)_ZG=RP!9K^A<>1=ZQ1ZD="=P(
MW*[OGIC4!!J[DUZIRZ3]N%(F0ZO);6W4JSM>IKB3J>E^K(2@UK:]=@/[<K<P
MJFR50G')OW@U?]>OTVM>BRX @R'UTV_,N_BN(S*=XH]TQET"HHW!!A/-KBRY
M,F=TWVNS+96DH=;JM>VK4=R;A90XD%2GMHTFG/+! 2XSYE(T_1KA\^WGO.Q.
M]=_=).DD#IG2I!5*C5'<55:@LU:H1HRH%.C0Z:A]NDT&A4]3SQA42D-RGTQD
M+<>DRI4B7-E.!<@,,-7KFD@ @V?N[QMH+WG2NWOEC'XT8']( X!R+^YO?M8F
M^#JO?8^K2/$Q1P[DR[_A>[ 2PON!KAIXJD6G;3L3C:'4?BV )FQ#[WO;V]>V
MJ8F&UE]R7/Z8-.M?,26FXN-#$;R.UZS++5O,;@?B41<@&Y)[8_(XR.>VN(/@
MCTW]?U%J^I(L3^)=VU=VW#]A,U^;L9E]I;4A#+S+B5-N-/);>;<0M)0H+0M*
MD*!2?YR5HL,I5<C5?^H%G_G^@ !7$,+$>?B!9WTMZ5^GE0>%D#''8Y]R2>02
M;W]21B.XW[OIMLU"6LQ$EC;SV[""+-J9\J;X43<FY)&"![ =K\6..<6T_7Z_
MK1WV  TNSO!+R\M3R"]PH$_46N+7 ]P+>:YX(QG)_$?J>_F=K4T8N!M\Y\/8
M"-R+D$I-_P 7-_SX]3>V>UK'VY6H]@= ?3PP(<^OD&W3O7UOR]*]PR$FZ(-0
MVC5)*[W#$"D[UV[5*C*<S8,PX$63+=)\H2VRI1(%SH]NWZT^I^M0D,=HN-1K
MV9MSV$Q\GAY=9?Z8P&$K'VBG;AWK"G-)4"Y%D_NRKLQMMU-@4%^%)B3H_F2"
M["E19"04O B@A@]SIW8Z]KQ>7L*X@L2T-8ZD1K,W>>TO7=A0VH$$C-_,%!"@
M?6Z5!0(SE*@0H'RG& ?3LWZ_7>\US?IV.H(G2VE_F&M:L,]P]&-_]/=Q.[EZ
M/27WJ:4+;CTVG2J8S6Z3!<>7).W'*=N%QG;FZMK,/./*IC$J=2*[MMA:H5&D
MNMR%N(E<3)+@=MK"U_&NOBMHJ4?Q)=48J]NUBD.T:B2D*C5%M5-IVQ:)/CND
M(<C[BE#=6]MW5")\KS!V#MIJGQ*HE!@U1T0)3P6]=?P\_K:IYG:_\O UDPUA
M63G3+IO3^G-"=@(E)J=:JDI%4W!6_D(B&HU!,=N*TTQ";6XU3Z338;+-/I%.
M;6[]DBM%;STJ=(FSIK\?U_6OH5#28U=P_<N[Z]A!W['+:#8*R/Q7 ) *2"@I
M-B"+I-KI5<<BPSI4!D6LTZ1O?4Q;0/#89[EZ*[[V%N1>Z.CTF2["(?$>ET]R
MCQ*Q1HCKYEG;B8%=+.VMS[/1+<<?IL&7*I59VPE;K5!E+4['$)ZT67Z2/4."
MP;:/]>P:MJJR/$IU(C+V[5*,_2J3);5%J:$4^E["HDZ,X/*\UN&I#=F]]V3(
MCB00_$VI$B,SDE<24I,"0ZUI7"Q=OE<_2('KZ"LE^F'3:!TXH;L/[4:E6ZK(
M34-PUCY(BHF3&X[<6-%@P@X\BGT6EQ&685*IR'W_ )++1D2I,RH2)DV2KZ _
M ) ()[DR9:6@CZQOV4$)-OQFWK?%[G)QP"+^IOS>PT?\OHU"1V<_0Z?%KM#
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M&;,8%6+0Y=WL+B_:^KOV%84[HZ+]0^GNYW=U='%ORJ>H2!&I4%ZE)JU'A2)
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MBH;GVW.+0>>C4Q6Z552)&:2Q!3NW:42;3=P*W#38H9IL3=.U)$IRK1&&'*]
M2B+#BMQ1B)F?$@DMI^6XCDD F=M]>V_RK,;9M0J=<VIMNLUVFNT:LU6A4FHU
M2E.Q9$9=,J$V!'DS:>J/,2F6RJ')=<CJ;D@/I+?E=2EP* @4H@F(83W-SX]/
M5J*"00Q=]!/U_P!:Y+\M%_YW']"_Z\9O^HY[:KJ@QM)+:,7?ZS+R7 J1^H/\
M]/D;:N^6BW>__H&W_7^@T=6C&6;N\P-O)B:0\O\ ,&&MI^H9Z%M&+7^A1?\
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M%MJ(W4K;U+5O=J@M;J,5!K;6UW:B_M]$W/G%+<JK+-1,:UBD2T_-2HJ3YEI
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M,?,M2N'[_JM:V[LS<=<VW27:W7:72WYE+I#,29/=J4QLH^7%1"@)7.EJ=\Q
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MCMH]FF;6M(D/?QL4E_5#$PK;AD>#-/K2)0P\QT-*C X! 0%1+"2DE!K;"-V
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MSA\WFGJR:8-5#D'-SXWZS('D":1HY0()F%V ;;1DO<8A*-S @N)U2_ W1>&
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M%',UE!],)-8;C4*MZ^TN<L5 A_3>\^*4QYFVMQ9?.6$/KJ';"O5XJ1+#W_\
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M3=2/%_8.57DJJJ:*UZEP;L@&Q2'-^X/UXS^&D 7X(M](M^='A&*']ND5F4Y
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M"0XP^@CH,AE=OT73BD.]A@X]Q@AO WNZ_(@]AWIIPHQ&CI;H$W=2:@@AQ14
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M49DUS3$70%T_LS#\^PIPN\;\[3Z3)(/'8CR<R *"%2-#@?@WJ%Y5$R/$^U;
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ME<D6*]R<:3TJA>ZC8:H1KU[]HS&<&L&S:G$;V_Y/6?EM2;;6$6JI@([>YE2
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M:+R("%<0;-N(EL@'AQ_MFC9&2ISWBUBB6.:=S'Z)2>8JJV-SRWLLQ<ZN<9,
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MN[/X9\"?<IRK2X0?LQ 2_A5WV:"(5_QE>0 .UA\)2[LXU"XN/P( \1?'[5W
M'0#"^?CY%@#S@3G$#&PB"03<.-\&8%]Q //'EW;G4P!_ "8:&AHZ&B8Z.B;.
M38R;. 2W,#%O$=S!PR/ P[N#@WE%?WS\,R%@W;R)A8UU&QO[-CXV-C;^Y0D;
M_X<)SG_BX/P-  ?M(O@T1 1JP T<!$0<A/.9BXIBG+<BB%]$B8QP17^D$1&
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M%CF[.FS#K> 8EMR8#]X"CX3/ <0XTV=9T_S:-1"S:HTENRV:(N*C3)/ZV1O
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MJK;9,[P2T +@H':*.Y'W<U4P?H;CWN$7OY96]56RGH+6+4))C+/ZXWR2?(=
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MGT?3855;8TMW&LY@?B-M&U>^\!U_VS@%[FC8%MIQ >5(=T_N8"U36:[ 7)K
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M;*2M+9&U-*I>.\;)KLGF<"YO+OR43(JAN2V*4M4C:K'O$8P^]9\N_Q_7 0
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M[<\26?6<(VK?Y[L4]B29UZ=Q5]Y 0N#,;W[%BI%>5,@Q[..C\S17@WFK+8O
MK)IPE!"%("UI_:S(4,G+=5.W^DL!0QKM#.W0EZ"\1RIY[3@''[(58ND&LX:
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MS:Q2-8!T*EN\AUZ,M/M-DOCMLSA$BT]@&"_'YRSF%U,#/#VY7)"/MA/G@[7
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M;+E2,QD(1%FB"DFKP4!1S$S6"IQ5?_C/U4+TH#7--SOEANTZCIOEF#@C-.G
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MV-V?+754/]]OVVKY->&G4,DEK[B:HPW7A "9LN. VG>G"T4CC7G<AZC6 &R
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MYBB?P*U7H6<ZM8HGFX.XU>!-TZVT-SFP2%XY2X<;UU">3:UE.>/EW3WW5,0
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M 5NO@_;L3$M:#I(-W'B#I7]" >5>1%#V=W;J]]W4:LH]Y ;R/%DE#/8SV2X
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M6VHP-(!M=<:0Y]BK)&3?*@/R6 ;7IO9,6HS99]X/X#5JXS=5UJ91SGT!YM#
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MK4M=F%=J7ZUS?=U^JGTGOVBYV!)HZ:95Q<4XLOU]'W-":@:;V9<9@;KE4DR
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MCL[(+(UF+'+O.^<'+U^.?2=%VE^>70R'KGSN/S9@C')5B$\^,\SZ.)^&%>(
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ML[]<R\B8ZR2[G$NLL,H*18IP$F?'<^TTM6 4[B^>PAJ!VBYWKTH#GR@X_ >
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MWT_M6 MA;AJYD^T^OHHPM.XFWCA\50-<UE6=WG\DEJ)T'G0XP4I$%%$I/A8
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M./H]SY$]HP)[=?P(9\+IN\>T#%G"Z>ENVAQ]_.%:$=YX$_2)\AB["-;8NUK
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MBM.&VSE(4XX\RSP2O9S0\ICP!J8V0)D1\K>0ZZU/V3@1E[.M'/"/X?>?,_9
M#JLZ%:;!1FH-'<G3&EDMFE2\Y8@I1%_Q./Q<)%5*7XY!8+S%<94;7AL/T3ME
MB1\'M=;_1)Q*T2R2_,.;[/1R_DO-,#7#VE+'YQ>@L45C?H./IZ=\B1U'5LXL
MAZ.*CA,5W>&HUKU7KC=!8H#%,?Y:65'41('[]QAW-&E;+?H#3QX3=TEA._-
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M[;&"4K0;J#L=U>>0M1+4"?[OP/YO#/6F7^'025ND0I]85X GI$\0C]$KS/T
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M&F7P L;;6Y@O  =Y/.JAO^<5IM;>\0]M;+__#J+\]QE17^O_ U!+ P04
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M:)1#[&%H)CHV*F7>Y?BM37N?SG;XS2)",(%=R8@+\G5) #T ^<(Y0.@H](V
MI+BHHOR[K]5$]M*SJ12L:'K=2G)U6F_PG0/>FIDSQ]%:4+[F$*A]P2ON(41B
MMV&[Z1J,(=39O)<A_CV_^"W]E(UFK%*UKMN=K7N2$N04J14:1:-F9=+(E%:.
MDXA*A.YJ="%VG!]1/K^D"U0?$@W26N11S?Y EV&]%,3=2DHU)[$GC(I'505[
M?S.E[G!SO_P[64E:7L##5IX=?ZJ,A,(,;PS%@Z&P+ \$#&]N+J6M_AH>?FT
MNL?K-P;#''P/%>DRUG)R4D$S1RH$LDN!-$>4-3UC*-KF2*?/A;Y:(G^H)OFN
M"U! (&5M[*;&[GWW[-'BC8R[)L7II6FM+7)Q9J[47Y \,/T"1)J\W[" G\YW
MO^NE"5QX&RE+6M"Z[O5%QZ,%2UI);Y2WZ#5F#QQ@T"1>YD'QJOKQ8VMM6.;#
M=<$7'<'4F'&NQQOM&L>^A!QF_:4*\UUQ#$3/2:<14S1C5/*RQ1^\4>UA' AK
M)CQERK=\P6ZO;$;!W3'R38*G,E=?9Y50/-H@J5R%M!#'O:R8??AS_S<*L([3
M,+&,KNEP:%AP2+K4RQ")VX3&EC@^:AQTTNH[BEO6IXT<6M/%6Q1-O)_:,:<+
M:WH^G-W[\+R2>;C8K7[BKF<H>K'UB;.P9N^[]U9M>/6^"M#\\3TVCS)VC3&G
M91_Q_"W=YV@'K=F=Y;35<$QMNB\[L_Z=%? 5XX#8HU/W,8]4GY&4<\"K>4;]
M*N+&J%-"+K.WU!$-))(\ 3N;4SJV193 ([[O'Y/\DLU&022AS/B$U"UH[40,
M[0:ZXP.T>Y\WJLN[3CV>D.SVG_B(6KD[+6H:6[".%IT#/N +,5E;0QO*Y74J
MLK-+=:O\=C2'B_*Y N)AF5WXN9,\C]JX9EFQ_'1YXT-E</P3!6S0O5/G/([S
MN1?#XA*;]:S<D>\Q<Y)(CU:3<6M]*Z%[2/8>JIXC)[GU*?*;7*NNXX9-G%*J
M1H5/N'^9A$QHQ' _P3Y7L:3VGJU<9$N"Y-E7R[RFD:;\",L9E1$WZYZZY<5P
MSF))E;E#ZO[R(5?S]E$BF64-B&)E\JQM7\S2]OY$K^,>7XTM5]!4=+TB"&UA
M:28I+Z\<FIFY9#2S,L/[C&:CL?G#Y]K9@UJHU8"50$K(@JU2E-9D7PQ*"7DO
M^='CV/KG4WSW%S')U#-A-?(IRZ%MZ1-^;@'^X;4Q.&E5U@-;!7&4U/HRK7KF
M9)LHM>Y"6SF;ZF_6[#]]^@0C/M6^G?A8(70D6=4[MV_N&.D#)NAF9Y/0=NA^
M40F_.GPOX]&,XQ;[HV%3YL,/]_6]USPK)^86)D3?3Q%96>1 P8QK(MW2;,4R
MLLJ\HO.\^WT6G-5Y*YZ3B35*J%WKUN">-??^9+,:^WW=2>9^YO@Q8 6Z68RV
M\]C$@+6]%L,WS(?P8HWLU=W^]Z&!>10\WVLQCO:V<<0TW^%2]B=]>0^855-Z
M*1['U-2D9TNFH_:__<"CJO^%I)*K9Z).WFEJ@P)85K.Y=T:6:R-*1]\]+)W$
ME[SNYZ13B-\@QJ<!62\QD'IF1B!,P6S<P\I@_@@=)(KWI;IW7H6@)%3I]H ;
M-VB%$QP675,L/3X2[T%7%D&QW\#8&!H<WT7ESX5M'J0%*JR2^1*F^W',)"VA
M6S[SNX*Q@*&LI7HC547EF>-9T3%3JK)KQ1RU;\1TF7M&R,E)?C7Y(^IU0OM:
M?:'8D'*US:?5&S?)&B0FQVD[#YE,>^\+A.I5#5!C]P7=5 W/[GA&$%U,7;.K
M^@:HF%95C6^1;)<C:0F<^QJIKQ:]U;TYSX0UD7*3;"@\.24FHHSBI*+<;-LJ
ME8*E;]BEPS/CAAD./>.66+##:M/=7=G%,R,FJG?LNTTO!9S%.O7+.)XDIN %
MS@!:J.LCYRQ5:V-GTJ54@V+)/_HFI VK->\C(-J'M.CKSZY],SX%IB0LP-JK
M9H<(',1FO_;(Q ^=/M'<2_3.GG8;,U&39UFKWR!T/7;5U3G^!+0M2<S\OC A
MI;J@58L3J_2X#$<V?8M<_^.L_VQD<_ZR,UH: J96H43[FU&&_A#0HS1R/=(6
M)G)RUC*;Q0R*^$I%ZNXQ%K,@H&XE--*B^N+(% OW ]"I0.9=6T:MCY,>JHKD
MN\&7(GUVT:B^L,NUETI@;@,0QFZ+KY\"V )3IKF%2?ODC?CKH\X!>$G>F!5<
M(Z=%N8B.-7@K3DAKA[.)T5C2>V$RNWKQ$X?U.QCK=F'$2"C.[RWVC*R\5)[M
M*N.C(F.,B*FI=EJXQQE*A0II!@',U9CT*FCS$I@(WK#. (N@Q#Z@G<)D,9J\
MB!=^%4,1>)7/8C29GC@3R1)PODJ);X_$"]4TN&OC6*X<X[]5_AS+C7S.U@&.
M<I][Q8;3L(2XECV+EU>.NG4@CLOYPQW73-- 23Q6M?!(V3L%#'B\2-0^O#*Z
M=R?S@U^)+FH$K17X&E7P^UNGURX^?ZU@[+N+!_JZ]7 JA]&F,-:\Y0,]J;T=
MSD GI5U,2*=$K/U7OQ?:B"-Y5H]*0"]3SN:<4T/?A^0 GU)Z"S+=:FM;F4_B
M0[ZE\HJ*^]U!& 0!<(<EJ;@>>V>LV?C5F8@TJXH<-=2Y,;)-A#&2*[9M:QLI
M)-*,0NFIZUX-Z5-4ZR2/2<[*RI)#0ZJ9H99 Q2K#957G!:84O>2*CO2W'+&/
M"QUO@!.TWYL%=55*FDM9]:M (XOUL].;O(E-@T"\GL,TL\U>DCI"/GNT4'&Z
M@EFM&L.>.C]TFQ9Q/0:/ -!&BC)F07C^6$&:^=.RSLYW.X08^SJ!SRMU:3LT
M&'JG$J1[GI=KB'3BDP=_VQ6H^RY?T]\D7=%[.A[3Z*:;"^5K,+NX0XT=./>-
MN4\OJVO#L>IE5>/'5CC.$F2YK;LJK(D.48^HRB6'9L88T.]WZ4*XT8+CGD=]
M^;+W:;U8;ZUI;<BV/:.BL-PM[CY4Y G=S4R!4+/^]PQ@JXET/$+2CX):LO6Q
M$".Z =3WI]&/P[KK<;/G]#(!57=+;G8H&:C73!T%Z#E(3'Q[ K$9'(_.6#<D
M4Z2:!"F^&TALJZ_5P^@XJ(0W8FOGYW#?B'[?X]UQ9^QA;TLK"]Y I"T^O:+G
MMR\;.36+YP"RRB]4G*;4XZ/HG9X!' U3>A'W=0(J@VWA@YH);CJU:EO#@6I9
M%$95ZK:E93$>E/)E@0GR[;SDUDQ3JG9Y@M^&OAVC<X^\5$R$4L47%;FJ]GK8
M\LD=FXT6'@U!RX8R"C4C<HQ7G(K27;:HOM2QGP,*[CB['PPHO_1\MO]F@+=E
MM3W_B1@-[:B\]>+!\>%HAVR>(3E9?Z\:+8EW;OQS]^=I)[=% L [ZT='V%@^
M3>\%/_L^:ZX_7%NI2]=C**8QI0^E23/06UC(R%YBD)5EUW(6(@%U1]$&NGQ>
M*V;#-%DF$5?@>.%5A\KQ>)U:L1XRI.E3EJYN/_IN-/T%QVE"95+59EU5W;PP
M[]&DH&85K,ZH_?$HP:1J1Y_AM%/CLU:K@6C&S)FC$@7^,'/*IR<&==XFM7TL
M1'IWSK)OXE%/(CWR?/&R8&RB(<)2[^6*1^ZT1C5&M,2MGLPUAMY=O]$7F0<D
MM5.3F'+[5L6E=9L<E!*;-F&418</+/%4/T<Z!74/)U*3CX.\(U6=<^]^^U(B
M)"?2VD(*D\E5X:Y^?80T%B9",K\M^,WI\/9[I ;:FLICO>_!RHE0DJ81!2%\
M3SF4> "*"IWBN*_[JB U7?W#-QZGR.DQ#W":=!RM<<=LL?D*HO!(A(8@60M%
M1!79:VZRO;P2]ZLI&Q3SW?AEY#BK="PU96^5Z.M4W>0+,\V4]G5,>INJQND3
MD$D[FOMY>;GH8[_'5OD2?661"QF'D_B+TZ0EO_>)L2EU2P:[O0DEP,.OB<"3
M=W:%FD:",55;070A"TIR87SII!U);?EL%-JHM=S=[KC430^;BZLV2E=KM)O)
M&6D9UFB1#:17)./,8'I&W6,J[GI9)4[!9QD*>>O!0*$B\Z@Q^S+^1.K&.\CA
M34-#H4KW.T#L_E&8P\;+2L@2F:/O/IVZG39IMH<DEZ;!@Q /CLJ1W5X9.#GU
M>WJ45VJ-%1(DE1U.5X3;'9G9'[G>6*(:2RGL@7N1>"'"$:V@S9SW3X.DY9GF
MRX^VT#R_G0/H)V>.F4Q7]JLL3G;\IN:FR;*=G8)5]8LG<O37+=T)JJW*L%]D
M@].6-O5[BU@V0PD5I'*=#$59A+]>/+QNIC]0=O]V=J81]>J82EVB$R&),9\N
MU[D+050#"WYDJG6W.UTD7QJ).DTFKQ.9K)&:502#TF#J?^\1_SYS ^KB84ZD
M.@F(3E-PK?+K.8 "=\4CG(L*2A!DKX-.E$3-8K]YKZCQ\;1S%P'VVM+@XV5$
M)F7]FK9;W";A*.:O,9R)$!M&-1Y%/Q;%SV$)(I)!?C.*QQ&HT\'4HAO3\XA\
MQ*,6<*]14GB&W &CV._+5Y(N9(#SP'N=->O@)*=:CH(/YX!@(Q7M@@KY&!K;
MO8>)B@7;9KHZUM4=@0S#+=$CYIM]ENR* ?RUR)'8<"S=>RD1%12:IE%LJLP*
MPZXC)5,L.V?)S@7O<+6U5;3GON+=ZF GCR4(>F H+ZNC8S!(K"B:XT]=^VRY
MGW=G>P(CU"'1H&_+F.!M?@\#,:9$)=2ZTG^$\=8G=G%&V"L\ROKVR$]?EW;M
M.P+7-7MGW::)@N9=QZD6^OUR-X[ST&RS.]O(REORA#V?,60S98A232>D./FV
M8"YW#AD+J-8Q&K&RIV+U>VC./]_EHQ<01IS_SN[$3X6KI=U";[GV\C2G-C.U
M-I)[9C2F)ZK>#8A)6=JJZ?,H!B/;9<8J)\?A S"('.$0Z[;MARE$K./GU%T4
M4. :ZG=A:^.E[QUU7,['X7)0-1UF#RM=RP++ODB-'"E*8R;(70Y3.VK*1^'Y
M.2WD ;0/Q--Z$<+ '%^/Z+C(Y'U5'H4WT:9_>T&,M#9G$[%RVQ6<.#+]!0\(
MS31($2%4P'9AY6*GC*RM[CY&H=RRUD'("CU8<UKGI08Q$U=W/!5))[ V]PA[
M[3&0_:[D$<NW,Z17)._=-UC1AZ7#0D(1RBV3E>:W>^.6=RBYLO2D PED%XF1
M'0(793E#"-U"Q=5<"/&,W93Z' T3T^AS42FLJ4MM\36QI@)#LX;V4T,VEY65
M4H FG+O'\+XDN%:/XFR=>+B1R-?@RJ_3925)R""Y.&O5+^> !\P62.]=G?+C
MUU%A(X083;5?Y9_XF$T2-RJ-3*P8MNS1%Y1.3MBH]&7'^;*[W9(4BCT'T*2F
M%M=;-1Z=3C_FZGOLNVM>1E:5'3F<# I(_(1+.[G^);'[5IXE)W?)=S7=*'T#
MWWP["M*]KPN6P55IY SWWS#'!YDZ1O21(<<TAPVF'S6\WYMM[7$I/G3X+KC3
MQ#QSQ$Q:Q+7EEL?EEV.O1F!!0+9N0VZT&?R]O3F-^\CAN2!\!OYZS=,3E5+?
M:>\MLV&1&.60D4"2'QD@E7D(>^\L1F-^21C5NLX\%$BO/ZF^1_]APVP;7:ET
MYOGD.CN.AT>4-L]6*&Q)LS,QZV);$7=_;8B14 WJ7'G+$DEK_1W3L%CN )EV
M&U5/&,4'W+VUYH0U+[F9!A4+S/A]D3ZN?:Q'>VQ,\82SL9'"<W.]#"_H+1VJ
M++L$MQZLDTE_=#W==T)"-7\.!'E13K9&R$$V?,>$S;&D^E:COO9]/_/R<"]P
M'1I,UI*/.$(E/GXTP?0X,6N) 2S6HD%[Y'%G._,0[5O0.[P\PK),H3BYNSR/
MC-CRM"MFE_H>R86M-T_N!S4(==*37GY$'EY[>O;X8+!WO3+L;FVIT1YZF7-H
M5%R<6Q!!G7:HHN'XU*K@W39F*ZFAJN+3Y*2!8)Y0;TFK#FM5]@^,VX. 8$(&
M_V_W.&_);)-E/!^*^[1Y6FN=QH?E7NSS+!'70I]9(&?L<T/SDE)509L;[7)F
MU#2>4M"B3Z.FB12RJY ];0ODL%UDLBI/9ZI/>MD&";,L;9:\OW/1V -Q5;]6
M)OUDD]GVMNI'0]N\W3--UCWF#[8,CTNCC :Y;K7E[XN_2 X8#>.\C;4<9=5"
M$?UEM]YZ4E'N$V?N!(Y"4IPJ_0=T3J1RA2-!05WV6]]'R5=J30LSZ>X^VSB!
M'<.RJQJKM#.Z%)\ICOHG.V395"8V3LQV*-'U\Z; <[O:_'8,K"8=XE=C'4:I
MOK/G./I1K>7X%HGKD7 ]VFO6+BNP"O DJ7#@S38]G%1&]'S\V&7@6[[M*RZ%
MML7IAI.A?OX3,2OB%#Y"[5THN9K]XKAH\2@]N^5FRBC6H<MVRLSB@LO+ELB!
M'6<]*=8IAJRYC4$VM2K*%&4=&<<SI<2O*54GQDJQ0,RNDZJ4W>,,UW'MI1<Q
M"RX,KE^R,AR/IA:,/B].O?P\SL]V*/^J.H=.-,.*&J_SQEDL@\DX/OK)UGH"
M86D!UU<&?6U:3H,"/L3PC8]>CS9 @XK-\ *NU\/?!CWWK8"GQ2=3IX(3DKO:
M;]=24E'3UQ/E!-8-:+AH*(AT\MDUSV9S7-CU%M$>[ZF%@DU(!_S</VS4F!SO
M+R562I8BK(VV?SQ$SB&KH6^ 2^M">;?=/WM%%=7204>T.S^B\;I/P!P:1R>R
MOUG650>-"]"%1'USKN35-1>WIK *9[>^D=$Y;8))#4M(:!!XK*$>HQN=? PG
MJ8LZ9O ?3=;O,[ ,2(Q;XNIAFAKG;X^8^&36N]4ST\A4364_&U%(7V'(BJGL
M7]2FD1^N9-VS_IK%?3T+B2BCE3A",E9/3_=;#@.N[0E\S';[Z#52;'7%BP<6
MAC$>4P)SS9JU3SZ$2NL&[W'7W77*7L4V@#L5VSPQ:=N@"?.:<GE=@?G-E/*^
M\\OG">DM-B@P/Y(@*]$;[(,AWKY"YP#CSD_]^B.+"0M)7AK[B/))]Q5C)V.<
MSH[S(N;.E(TF&/N3VI1ELT2&7CA-&$@4Y'!T(EI.YS@#J^)M*5JK#<O;;\:$
M3 18:TC6>2MZ?F]N-XR5S272D FXPX(2G4[Z1+GPAISJ'>%7$DVO=S*>2<@A
M(R%(B""A>0)W9ANUMO^T![B7 '\2V^VZ;#]<\27$XDUQG]_8/B;-D=1'<<VA
MA<#BZ'3*Y6?9,;D&6"=0T]'L3R$O%(,DCBT2N-%J:*DU>I6?&'L=;)D<,U,*
M//7OX\KG<TKP  IYS>I%B"W?%MK38RJ4*U/'M1;A,)V>,E0\[8F9]BI@/!M0
M9]M9'PR6U7H4C^\3X$=4(2S8X+Q6%=!CV':W).KH)C;M =DVQ3=ADGH$K#>"
M9V\\3CQ<QK"EH(E+M^FY]@5S.'P:P8@MN(^V@X#$A3//QOI5'KVLG1U15,6G
MYK];?Z2+F<*D-VUKZ;3.$NWIS.6A[CU*,+Z.\680-=J#X-N*;=8Q0]'"S&@9
MU%:8V+[VM36N/<QZ;&B#0_WBX60V(NK5)B$GHQ"TEH+9Q,D@XG$G:F9AZ&.;
MD>S/)<8E!)W#9B;C%9O/Y&H>_WEG)3+J)QZ=9-S]-1<>U\QT&H-XTGUS)]OI
MQ5-!,>*#AP'S+]QW8/J6Q[;'= B]C<^XJMZD<%0>#!HVWDW=5E*V,+S'CHQ7
M4^7GY4,!LEJ1NE<XZ*?J0$'4:II4KYM'6&5G!QU^YQNAL8XJOWN?3@:$2\A2
MDRWL/3<]R,KWE:Z^+;Q?A8@PK?:UQ8TQ3+A7(M2 ;+R:>'>NY!Q@\7F&.8R
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MS?[15-[W"G*HE>HR<5=L4/<B/=GG'SN]XSCE#9KPBZSRKW#9M)Y.*)4S.'H
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MHWY&P=2RP2Y3ZU4L%6CS?EW^^T9& ]8Y CH$G>+6T9D6R=&@-9W5=OJZ$)^
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M^6:BV>XBN*B-Z/'NXK4L,.1<YF0T3>+*F#JL\W\$9X_N$@3;6A_P 8@ ,,<
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MNC!XIPF:V7K<X+([S-6J3\9:S*G(],"29X-Q+LE0 L6HDV%5DZJ3RLED58,
M[@7Q8/%(5DBV;D@ @!#W,W\56G,I@PXN4IL5$KY]$?;R-XZ)*F;^APC$8*-A
MHOX_0)^S\>,>J)U-9 P]<5&\^.KA[]]_@+.+NY38X::UCU-FX1T, ND:UNA!
M645%@\,M$<GV^)XY[5S*^2DF!Z-0]>TML\JMDEB^S%8Z(6?J)<I<(14S=/EP
MJN2"I@V5L=+T>.**Q9ZIZJPK)T?]2 E:1"7P<JW9:J-<\G#CJG40J(=V^"L9
M";KX, [:Q+7()-;[:_J,IUAU6^?XSIZ^_73#NRKJ'"XWUDMKU![]3])5KSL:
M&IVP5'EZ(![ZR><K6AV1@$8IU:\>C1ZZ?->HM)W]P9K/J-)5ANLR4Z-:IZ2E
M%?3'##@+-&=Y7(ZT_-8I@:P6>2"7S1XEL<PFE>% 2FY -_*EQN>$$@E];R8"
MO0N]N_:1-+&URJ6$6EM >?4HDV/T)H+$^O.:,#J7[BI$V;ZHGKHI >)6\_6?
M1A718_F+5#S:#2#Y06Z:AGSE,'VTD%3E-N&&_A8#J^MM#0=0FWZ>NF1SNEZO
MF<ON)M7Z3=*PZ #8W7%=.&@15DM!_DW=F%\D#<@-ES7Q?;V=6<,L4DTK?J(%
M$V]&(P[B1Q[UG]@4+KWEE6SX7Z%55Z.&"O9T5:9($0 ,4GP50&Z$_/WC;T/O
MA[_T.?&W.3H.M&#G/70*YT#'Q<(4D^^5+=<H@:'RLE3H*#U?XVLYA=$U4F:#
M406&K]': EF65FY:.!W\H7Z0H/P-%EV<)AUI$>/09J24W3>4LG(0J0JA C&/
MN*ZA;J0XJ[\D7'AJ$P+@'2_KQ&,>L)70O/0SP7X /Y1DA(U1&GOX@IZ R@*%
MB=/=&>GH<U3H2"F*$OL?8.UG4VXL_<X_P(\1#HC"@D+25H9C1;%$*3:10#)4
ME)VW!#@(EY@L0X\Q ?W^JJ:V!;9P5Z_F8O6ZLL=#@AN^":0" =$8\A0+R/D6
M1LTGVNZHR'%,W9A"/#?8"NY>M(C(V[VOI[;^KU/L[_.9;TW;].97>PJ.4$6]
MDU(5=U/MJ*5%X1S^ZNV)#?EM&U#*HCZ?M8>H_SRHZVG%-SG0]26X?[3B;K?\
M_&<2&-*&B9J;$_$_ -KK"TK Q[G46_]8@A\H+5<[9(3L+.?641?U#,E# ,J'
M<%F$;Z?B=AKLHHJY24BD,SY3C<*E<8C:_)KC3U)\C*-(=T:**?XN)DF?^IBT
M@RI*%-6U"& O"M,'[.7V$-]G:M).O1V]+V[+-+2O"7MP!#/1XY-$H$8N%*G,
MSU1,=)Y1Y FBT'!/+#.K_ZSJ-B<U,8=?P/8J<[83A\6-2^POXVUZ)^S/Q5PM
M4+."@A9B7O8P,U9NE->:/K 74Z?X0EY#/<0$68IFZ$LC1HTM+0O)KWF$@IXF
M^4G##G5\)ND&GP,&_/=O#MX@%^Y_  SW NH4_AA>.MS3J?VU47.T[D:F"(%L
MA+H ;/W9;O?&\K0C<3#1:,B(YZ3Q9U11-N! ,)F0< ALHDRT#[OQHILX)O\U
MI/149C/REX*S;80,GB7WSZ M./?&BROWUK93L!> 4)VK'2-[!%=]9VE@:L\Q
M[3/F.CVU<CE?V$\H5%2VL!_OLL*GYT)_[_P_89\@4B0B#VUE3!US%?,Y=U0"
MS8:2XSW$_A!ZX*QO?^@%Z UO&DA2_S9EOJBAHH,\NM<@U\?8%9)B#X&B\_V2
M/A<"G)#V74*V(/P#F$GD.]HBZ"5Q VSL^*I9;!VSESK%[>[ CQ&N?%'YT^T^
M&?($)5;I:7?,7)3D5\M462PCDC>QQFCBP#9Q58,LWE>G?X(3)V-JY<$'1%%<
MLF*Z.!UHU0.A"R(TVZ[/?@EXGV(3P5*BG0WP^QDB55"UKDM-_ .,!?5]F%M?
M(K\\@=8K,PS8-@/(^549_%S8'DS('K;%$WU!V[M[N/ JG];/'L@]*2;.D+.]
MT6')\A/REX31N(@\^S=URM#9)R-6VH'QS^YVX!.I.A,X.*%..F 4"BSN)EZI
M*#2,2+4USI2<DHJ?Z(!5]*7B_I=.AIL FC?+1]5K '[B^.VLS=90/U,%S_K6
M.GY4%*8\%=2OC=)] \N9"^(XBZD2!!_IEJP].*F. R]!Z7\ ABAK ZF;DLH"
MB^L '*$Y(]LA MOR#NIA9(:8:29D) IF81PY#N@>&]T9<5LB\0:N+0>_PHS>
M]\"'])5P0J]X%W+'8"CMK<^6,^SD&')5/@,'J415IWNR<T0W L8EL2A<>'!H
M:F7J@ZXRINCTKNCSUXX<(1'RO2UV=.[59YJ4R 2J3,5/Q"*',KZ;%.]@2*M3
M+>E#1@<='5C(E.@_NLF=$:?,?QXX)B^>=A.K[K?%$+3OMUG1?TAQ&+FJU\UH
MK<JUPH&)YI-7B)<0CJ/2M>C'+ZY<B <MCWK,*1\IBR["&(C;#6VX3VXH>JAS
M0-;GCSUGG4ATXC"66U4:X^  6 N#X@&4F[H&LN+/8V@)[:5KY\G++]XO7$ /
MUGJ+!K6&NO5J"2T><KC^)BWB((&L=+TRB+XD%Q*\Y6%S#0S"85=CBZ0YAE,G
M*[^(6T0K4\??2T6ZB&S<L-D8'.:)4IE=_>OWSAOV@GTR] FN^)\4=;Q'S8W-
M('+U E!JW0 !>6V;39@ Q*[MC?FO'H\OJ%2I:/&&+_U>]PO16F.-H54@QEO8
MHT'-$H\2@SM7I,U%S'CZ*1(N4Z?U=HS3?5*NH1J!9EO=V+44TIU+!\X"EL?'
MJUGO"/6KMNJY,CJZ&G6+ &.;F1VX2@9!&IG40*G<]FZ_]X=URT3C+)>PKZ$W
M<'#+/HR=U7=%P69JSY[^]S"37JE$M&JV=2.GE@\PT=2\=&#3:Q21(;GN$:8&
M$+H<]2=@Q\JFLGSX\B#^84C^G8#-5 8M^P><>T3P1*. O6_C,LO?'UZQT"5C
MO(.0-2D%N>CU"2D^TG(4VE2ZY'<<8Z@>#8R07>V5H$Y3>T9]271)CIJ6, 5V
M3'ES3#XU,A'A$E-<$0#$U684C.A=(2]7HV_..F?WZ"97/3/-)/* M/M'+F?S
M"%Z&-1ZF K)K6?*<Z7](3FJ>TC#L?GH[CC;JWX1P;O^*L..$51=I).M<R]25
M!TPP7L)Z.S0N^O2 6B:K!(PG#6V@$K<_KB;="P(3H%G$GZYR8_L+2EI-=%B+
MBTE7CL:> R'K;O2GB)-UI]S)67VCO^;C]TOBQ)]YRIO*1#9"RN8G^8D:HY@*
M<D3W4^X(_O*P .H4I#RI(L,Q YZ,QIQ2M;?<J8FZ?*#M//4CA[(#TD N9YI;
MGU13P/A*_34..IM#3@)Q1M;#(X;@"66,.>Q4::9!F;)-3V@7,\7"WKO]P<#7
M:K6HDH16\>$9&:7V],BL5'-Z;%J"/D]RBTH+4[+'V)?OZ:''@G:O70\S?K=#
M\9)32)@&!6X$V' A%P:/]^;WQ2F.V-C5!MT,UP$-?F?>^$UA'!NA],_M;M9^
M> C]*^M**!(Q;JK?UA@\(>,DJ[5>P3*'/Z,8E;1%R;?WE=W.CN[LVU>9(XZ
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M'S[H+\J?)0!2<,-)$4@12*&?PJ'A#%>+2LHDR\1%8  >T7WQ6[+]&Y+ _7
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MO#)X6ID".V8YG2S88A  1C2[B@)-'-/DQ<S.H?=\41![B #2>8+ /CV9+0@
MU1)KQWE1'AZD?^M3L_)?[") ;;=W=0?"YQUT$I&_MLB@S4T\>>9(3I\.R[G'
MD8 '5QU_XBHKQ&5&N=L:%V]'@HKM2D5YTPJ-%%7;V8#JD!*##7VF_]RI*+U8
M:"ZRZ0TE*$B]OVJ[D<P"UV=8JR_3::_'L?J566'/U#%5-LRZ#/ILR-M,L=C
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M(*Z5ALW2$91E%D)GE$33=FGW1Z4BCKM:R]OH2XQ^&^;A'%$+_[,F<&RV1/Q
M=X_?]'.<:^Y-S]A5EY0TV<=7@-6ID]IL)$Y *GK)4X.7!ER-'S2#MX!DP!,[
M_G-\_%OGKELMZ"7W-,86S.BP7*0<O/QFWRC+]X7B5O4%XAGUX_-,SE9<I.D8
MIK>AA\]P36(AX[O8,?YH+#!A>^\_TJ;O&]YT'_BQKB*J0E&AC,T#K?K(2UMA
MIB&H@UI5;I"NI\>MD..1ID=[P J>K!BZI8%!/7XRX0R\BW#J(.+F 9UEM/&7
M  +.4+EYDE=P?XVW'GIZ',YT026.F;<SD$=E* C.A=SP4#70""=T 5@%4RM'
MND_+?!6O^.?SUM6)])6M<NEO!RLV:EC/,6ZSM$6E.HP0Z@R5/_+X^<%/EBNN
M+WLTS)%-B<1A+W@3R%1B#[LR&-0?WN_AJVO*F"D+'C0S@8P>B&\4ME+QME(A
M'[_&",AB:+/8HS9QH>J- )W9W/U?GAH\3.G6_U&%Q9$EB8!\P#%1SV-G1C$F
MZR.ON-4[VWUY94Y:(X&RGD. M.X.(6*)//ZZS>3P(N6:B+],])PS#"V'FQ%$
M48TLN%!5L8C[Y=W5$:Z\ EX+AO*W6RLL$S>_U>E%Q3%4W:'BW7T><7X.KOP:
M]4O3-,":Y_R*)PDRM"9;*AQ -RKP.7$M@(9V+D#KN9DHO@D;$%AXD O;T7'I
M>#9G%T\2]<!,Z?9T<2R(PT*E_M_\[$B1G_6?X=;I: ?K86M<:,'83%<&ZM-;
M&3G\^JD?@G.C;C?%^<;>IFL4-^S7!D)B8OYY].S(DI^O,%K$PCX74](K^R<K
MA89$;OOQPMA6PJ*[?)*UG.8>]3T-EPI,#+:.-"9>O_C^+]+>,3K3IML:O>.D
MT[%MV[9MV[9MVT['MIUT[(YSYXYM=HSN[WGW/N-\YWS[^7'&./^O&N.J4;-F
MU:HUUUQ^K#,\+5VU:T<6!6LUCE29!JZ3C?IQ"3R@;@_\W>/#?&[;9H9UIXP>
MM_5'LBFC8    +, 4?3U,X+F__I5"4Q#<P_HZQU^[,[%KOO:K1N%IE]V+M-_
M 8;K#'4<T\7U"NV17^MZT)[,:WAFKV?<;;]@])-Y&PP;@F0EF+FLWR;+YES#
MROM]?-RP.G:NBO$TVQ^"%!\@)@>"0'W0S%WVUV>1%5'EO9DG6430:J+#"T]U
MBMWM"9KN=ZQB5"1-\(C3AKH&^02.&FF88_49HV$4!5VNBI[K\R#"?HZ'98UL
M7$N(Y"AJ=[7D"L"96!$S(-B=&)QPY!$9#&D4$-!4'K"/UO0Y EOPGW(0V(*H
M$R+#P<&'KU?Q*R'FE_? +5)/@B>@UUN@T,@_$X4H1 ^J#V(G.O4Z:OR@,(.M
M3/KW!R:5D&,BKQ]Z-J9VKYV(R4T.8QCA4" "4=KQ5D*:>G-G2JINV7L,T,@C
M@==S<M[@V2A;]G-!PB#",!04M_4/C#Y'MX1Z2(H&'\<>2R8[_?VOLH0K+:+K
M'[%""]XZ*\R\EIJ'2>SVF<@'-N< Z 95,6E$?W.UB>RD1..371KH5._XPOK!
MU5[$BHWJG$W2!AJ%7W55T;64PRIYEG=*WUR0M,G3O-N!_@ 4!;(6OA  6YHE
M7TML-$'4 7K(C]5$[QJYB %FG8QNA09I-T-Z,,QNZ*,Z*6,-]*6[=@_J2.UF
M['LI#0T99D_?R/ZBG\1NP6Z;VUR]@"S.^ZU .IHT]6'):6R(9EH89D"208P:
M"@#EY7*+]W:W<;/ 4?7F0O37Q'9?RU_ P[3KS@ZGP9XC^T"I2/>=<K<D9+?+
ML>^;EW;<P*H^0C%T9S7V&&NS8N?:N/BEWE$>]C&?%R/=T\J.UE$J3:KKL"XE
MU 45:LSWP&;-UU>M5GK.1"JD)T:N>HQ5J(;>S1"3TK\ ]+- ZM,:9NF).!A.
M&=RKH3Q34B+O,<KDC?LEB90L+.-,I8AG/!B.3CRB40\("?8C^;+_=#\&7#91
MPP0$WA8%BNS>O^ ?\\+H@O)Z_I@;G7@(*/;4M7Q,I_RSOGIT?P$+U8]_ 53W
MA&$71-& IX_[CC^? <AYX/Z(_T0'3(*R^*^SJC=&]/Z[FQ?46G?^?JN@K+C'
M"5(H'7"A3 6'B"")FOXJ.)ZD'TK'!B'R*3T^Y[R6*#R_]4J@2_$;\E&V%YF7
M6I7WY!/M8B#UP5F1[44 P-W,5F$H*>2#5@MR%365I?'?M6ZRZP/RB<W0QU&"
MJK"<2 YS*Y/!@   Q L YKW57(]U_7^@DS@:IBM)Y"T1Q?]3U"_@P>]E?0<I
M<*#?[^,?C*\OP[:#@=T6@UU>+@0_?=S%J2 #KL0!$!=D5V!?KQ)WM)3**!BP
M #!@='81@"@[.JG)#^ENF+@JVVMCDL!KUY+:8P$V*?#/-@ V*4@8C&C(.4Z9
M!S* V#0ZVC<8,$1V_OQR.?#^@A14V15H$O[_\,W:U-X33^>)AP)/EZ<D*@+X
M12==?7Z<";$ ANF-N_X"CI?='09)_99591_LHIUSA>2N&Q37%@[]KH/:S+H%
MO(O/I.']7&=7&F4YC=1E)^F,0_!0%R,**$)\_>7[DG^2 M74OPEP[>P.1,T\
M&JHIO)6=)+#FF6WYMZSK@HWW;O=!;V\]':1CUJH>S/_4B5]EI=<5ORAH>G8X
M+"//!QY>>>106.U%*V6R)JK12.^[,2?ZO?QZ^!;PQBC3U_4&N?#(\+N&ATKN
MT"(N*_&\3[#_/N.DV\$M:>6"8@Y^XZD-P\^J/3U;U=S@$@]5CMN_#>]7F. B
ME,H_Z(F$F^ZB7MH\8Q<<7SM=_NF[VE?R!F.F'#2:Y8QOI34YS?\6N2_G-ZWR
M$OYZ(OOXITCPR:(+*PPK%I2N3%._(UD-&7JD@[5+?W<?A"Y)(O4?IV89X,?[
M^6]#%B)&0W$O#2*I\QVA)>\9HQ,\Z@:[7ZZ:<L;LO0(K<"3#\+6R_'6>'69X
MS/D7CIYUM>,'&S)9L60 2G0)]\V:NG _(]\_4^L/+[<S.3D*+$>=\9F$5"Y&
MJ7W1V[Y\\;:N;AIBN[4+?&[V:NV;4DM38Z*-GM$UO/WR/ZM-'30R<BU7#V;_
MF&C6EYEB^MW]6;*UB*X3^DDP4-W$L&/4R"['#K64X?30^Q][EVWU[*0F3?O5
M\^S<O-<8T.>57)1+&O)#O);$D7NZ7^7WG78=*H1,%0I8%]))K'^CV;BC"1J(
M5B3#82$1(N/+06,PHE&A1+3=P=QX(F)(/6M==R;<DB49#<_C(0O[)$$BQX.S
M=/=?;,9L:NF"?![;L3(X*"@*'/*S4]%5I'!$N?>'BE1J(7LHP431ORADLGK,
M"A $\-SFP9SG(>O(C\'G60![(LW'!.5@">IW$]#B)VA)ID@U#:UD[BDFVB*Q
M)15O]61ZJK_QL"5 \HH+6V$D&+QU]/#DJ5%1B=$.#]8=TF0Y'4DLR=(1"L0J
MG%7DA"7H_<'9$ZA^(9#";@'EI145X5(*"E#LEIS!%]ZE$<?%1>Q]D@L0]0Y0
M5Y*]-BLF%97EQK&YL";&9A#R+LU)# @X(M.L0'@+!,X+)H^#-X3NVAX8J6N%
M$3/E4JR&JDP\GKS\X9RR0BG)AC)]T6\Y;,D$LU.?^7K_Q,C0KD_(S.ZD$#^&
MF*=<MHP0AFD:S!MKRRL0F\'B"X77IV6((KE'CIRQ&.S@.M9K?/BBS0O&9Q,:
M*$8\,]M2C!EE*->:=G-;;M%\4]T,7501O_S0>$!]&2T;/'C-Y.KB*AJCA;,&
M--1E\BFS)0F3H!YI)STCHQ&)AU^*L3(8:NF< \LNNK9_Z#P)A"&]K1 66\%&
MM(?X!@Z1IM"?9SSS5RDF^,3\AL;S\/!T3)(%:5W?]%)U=G>[#-]E(?(:Z>#A
M'7FJ!>;@S-7^ P'&W#'Z>6AP6U>):7N@V-A NO^U"K),+2="NOOQ= GA7BYL
MF8<BR0T4=;3?,2H?N9,/)X)9ON(:@@WYNXX*V28>$5DT@AG^@\(5A*X2@X^/
MQ](%^2>="&_06*_B>[Z,<H=KI?]-PBGOL6NV8HOJ"U7[F2MQR8\EG%@6CZ/O
M$S<ER<2#UF60/(K^2(@M*Y9>^$NK<^Q)7JH3F=?U[;/V2B.N7(MVGRQX!5&X
MZW$R!BK\C<"M&'B9_JGVGYQ4HOJ(G6W#)\,=[/_SRI?\ #5ZJ8#20Z"QGFEG
MZ5#3 1%[F(W6H^C2]\"AHT&R%JF2]'I/H9I"9S:1D_6Z89!!XO#%C 9WNSM(
M@<NY;=7"T8FI!6\YOK'ZE6%M'Y]!Z=G>^5;?1 :^$-F9SJY'=]07<7+>;%?#
M1'Z@L/SMV%:U7[W#4+ER1'X4N/V9CU<2YPY >'YIV'E.+U"@X>*J.T/#].[.
MYF.OIZRD,@UKSDFI0UYVVB/;EAU3Q.7HE5Z6EYJD/2[+*<WM,+8ZZV*3/"LB
MER\C?.QL7K[0P#EFZ+75,&W_Z?%R*1X0Z&1.@M;&D*[@0=+NN'+!8X.EXYG:
MA%X%U!.K/*0(BBO3.":B4F_^2D,P3O&VE)?]<0E)@]1[)FC+<D+T(+A<2[^N
M4*ZPC=;;X25YP5,@@(4@MHMQ5G.\\CB%T1%@RTJE0/S540FJ=O PE&QO-YI-
MUXL-7L+TX!/0,Q-4ERDZ[08=&AKZZOVJ7V]I.JM_8:GS>6I=L0U:F_*-HB%]
ML@AHYW*$/G3AH*I<B:W*S; W:1_'5(2;G:FLIUUL%Y -CXN*$C<^'7L7=ZW3
MNPSP>',7IA=BROQ1,DC(>%8[7IP\**][>FF9U%VNH8@:):WY7L]88GNA%IZ2
MFT009MLR^37HRC["W(3+ <O=[* ;3LWF^=A(;B"+Q/?9_KOIV(YNX'\K5T &
M+!H8:$R5*Z[1,+6?A7\!3LW]@UW.<?@]2!$">[_2DEDWI9)UA_='O@SZ?6 F
M'704$]85<5Q)99<GK?'\V?NY3!TP4B%W5FQM]7=YC*^I6.>OH(RG2L\F.ZS'
MN<*)7VY?X:=L&J'\]F6_!G5<\]+1!:)JK?-I-S_1#V)]?QO)".O8ZAXZ3'%Z
M#PQMF%#?'ATY>HPGKYZ-([LPF9,6<AI+Z,N7G7-D)9/NVNR+9>3QZ=WJ(5'Z
M*-5>^;<45-W;QDT$Y#52LRZV.;B@C=1Z[[:GKT[WD^=I7*6MR_&D&]ZD>?ZP
M&LWP^B8!V>NA&N>H\L0Y,/ GMU'N+V#O:^:%]_SF/&@J@3.('/ZW)U6>]%6Z
M-=O(Q%YNV)KE,@NH6'<Q6D[JPL::MO$RAXPE^T/XV)$AT7R&*;QSD+!G]_=@
MS<.EM\;Q>,<ZB')_PE'=5O<O@''/K-L&?C(@Q&_=#57WT&S"31 T?]Z<427:
M0C?U[>."?$0\08&M@CC\8K+D1CG90;Z/M5SPZ^-\4?9/QWWEZ*0CZWUI@E^C
MU'F#[*A+G.ZXW07_S?DJ>^_#-3ILEZ1G-= S\ZSZZ#*14:G([,@R=XPZU0Z>
M>GR&8-@E?C8'/=";M'+EZ:ESYAHS2B>X0K7ZCY8/C%[UBFWS=V(ZC=Q'=@6%
M<'%T2'Q=!#-34E)@41CWZPE"LO5<#0WQ-OH2B2SDY0T(*IGS7Y\X#(B;2F"_
M'I 178AC1H7%?2'<52[_ M(K4:[$SB!VA7E.R>)<]?) <$=XU2Z"F# J56H5
M/QYF 3!6"'(1SP.AZ\L>6/XN!@K7,P4ODUQ[O>_C'=0V]:8]$<B6Y*9N71W\
MUE5PJ>J7_%S%'(M/V'.$L;1(7=_\EZ.. [E&NTX$GWNDF?>N^!#-&B!T\?=I
M(-AR#8P-_@+*$ACQ,":[5 9O&/D/ NE\4%7VKOX"'(U_K2X:<G$?.,7M-_D4
M; /]E$9_FBJ$J!9%&4$)2?N*+1# #)I\P Q._/X:5+(_K^_0W+0OV=%<?C!P
MFQ-32C^/Z/S^@O+*9V!P?^1#UV_W.P\G#(V  T;"#D-&*%#E,CRZ.IN\-,),
MOUE#-4:?#ORIJZA9EISPQT:^U+>PF-<U2<DSY^^(%?P42T)TB7PQ:0C8*Y@]
MG**&2POZ5TF+X=I\>-&]_1_ML) ]]=<IIQ\ZD#!LH"\WJT %UM!-/"SVY IP
M0@)JS3JS#>+%?#=H&U;;N1+C6 1E1Z/(;>C)%/8EF1[J$%4%4O0(Z7"2;X2I
MT*X+$S'ZO\G*D%!Y;C/&EGFE9L]%&-NC_Y3^Y!I(V%G'H6,G " @V.F5)P9#
M!"B)S>Z\\%YOG];\=_!8?=SJW+/BC[ S(TJ]Q_"!^TU(81'$SHSR&9%G.\=:
MG@'[%] 'S=?1S)JZ5$9K;!;K<@&+? "V1D10A6RR#- GSWMG.0;DC\:O=^-B
M1L''74Z9N+QM0^.H)(-D@D.9.2A^^8F<.P5W&>GA60O37G'_K")KHR)RGR^(
M(W.VJW\:4RVS2*;..B64$&-UHB$M<@<P4I!/WL@L]A+I9<G^&)A@HC9&7VD2
MA>KMRCN]!YQZVUX6"&9J/3('@%(+X<&V1W^67[LNZ'N 3DY&) P?[@TJ_@=X
M#26_?"LN:0U*3>SIOFLH)LE%!)BU;5@14$Y3HF+2H/'ZD3Y-ET I4)Y34@&8
MJC60SF10J9N72<I@N"/;L'A& =!'&7+YN/#Y]FMQJ9Z$7[^UIZ]VE[R7%[.H
M5'*C8OGX[.TRG;Z'.+5VQMZT>M!NE:Z#--[=(SQGB \$IL369EM3-4X;5)3E
M6SDCS\I!55UTT;7G R]0$*,2Q;-,//()O-O!$)4%20+MNM=:&'ON;M&4]3;)
M6#"1X'O#B,7CP\^GF<_MC7YA;%N(#V03\T'*%@P@F\<MC\B&^W#'T;6U9X>2
M6W0:&W3Y6O;CP\U>S]4C]6CR(U-Z%42#$=G/O-$4 Z[9'RUV]:NJJRI* ASJ
MJ&(<_"54XW<0"9-0U^N:8-6\! @A.CVZ-;Y=)E45&:EC_ &'YHY#(?X-35T^
MO #W_HYNK9,]U%=3VLI[^ VQY05LJ68 8K X+^ ]J0L 8TD8UOP+RNUV-^M5
MQ:C)Y[:U@<_UJ:R+:#S"1\9\E56RSN&KU *XV),F?!D7$U3A(L&Q_<F0*OGA
M'2TMB)#:+Q?CC-&^U2YJ*=XH6PKYC>'MO#/J;>>CHOL!K/5<3S>CS&=W/..U
M4ZCC!%YOV4^RM=F,\T_(QCJ'W*8MUN4RMN_O"XP'$U)\VM4\=SXVW>\;BV1$
M!!O(]GMAZ^MOZ[MZU>KR0Z;H8]3IWPG>Y0G@_%"N( 7>S_S>_0(-@:H#=_]_
MA#UZ5$R<2[A:XH9. 6G7DLXWV9IJ: #:_@I]."S(6"C4O!4A[KM:>@J:^3QW
M3?68'PL"=OHZL=_)H&IKF6Z.4'IH33G\+HYQB!/JF[M(EGCF_RS,15.".G$/
MZ_?G<<9<[$+8T6]BHVUR5I^$%LOL=)WR7Y*ZK;&F\7T8*R-Z,A2$)@@"%%/$
M)X%SA&U/0_.P,,[]F=--\T)T$8IF.1[8&1<LP<VS9M1YI+X]J#%BO\*:2B.,
MV5GX,5<4UU<U+8G03JM=?"!O6)E;!,,YC^O)0_:'O/&Z@B*8XVD]=6NX!>\-
M%6XI/.P2+,2V#%P/=Y2<8B?V.S1!P^<#U"7*$#& (A.JN@/UX F6@7-9< &_
MX$< !##:S^LV#],_=-U,%U%^B8]BMPMA86?OAB<4P-\)YO8:O1N@6,AW6;%#
M(D:$ GN85BCB8S13:8&E7D#9:TAT]OM=0A)<=K-C64_3H3C:6/BRMZE*;6*R
M(K@;VPXP7M-%GAU;8!9+\&=CSQ!M7WIK7,M,Y[44.QZ/KS?G5]3WD".NNPE9
M.'J77JO89YZ?V#V>+0T#'<5EV>?YDS1S$=&XTWON&[NP -TYC\2].4'7X_3_
M]E5$.8,4NP/#)XBE-C@52=G5_[K?&#T$=S*F\ZS-8N ,@P3\0ASGTAKIL:C7
ME^EX#)6(S^CN2HZ"RA0:P5!7829)?S7G;(_N4C_P=H (TP?NV%)P43[;D)27
M*KBFN'J1B36OL:B]S.I]&XF(PS70X]F9,PZ4S'QTL:MSYVE)A86$*Y!@"E?-
M6J%\C#)X6@_\>KE^^V,D_"F8T_)9/PEFY_?BT?JNE]'7]K+J]"^)47HW(9G
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M ZLZSP-/H\-#]-:B2UG^6#*:M6K6&M@%RKF8;[PR,G5Z_R/$HLPY-> CRB"
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M[>'X$&3U$11'U(Z*Y2:*&J<$+7^'Y2M]8ZRQOZ[KRBLUI!8(.==-'W/SRDQ
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MNL8Z5UEDL("G(#O+J;0/?SFZW'[T#+:-?$Q:YKUT=>'+XJZ%%+]^)+MR( 2
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MNT!4:8#!QY8-'_TR+4.*=,0C"JD_*]IF27HH!36,X1 !P!WL$<EIA(>$/-7
M?S35J;J;=W?5DBE/3YL@2IB=*&O*];\:ERS\<YHO0 S\!2#]!6R1QB.1X4^G
M+:Q.)E"5@2I=CF_^8-3@\AFU<U-?ARXES(^M31=2E]1*3\])2WB5/&B(X_"Y
M3ZFOH"19L=YP0<6;0L-&,- @U=7PX)AXB>'TZI_:W6W%=3(W#]AMU((E')Q$
M)(2F>W5%B$6PL^_IOZB!%59,*)VCBGF 7W<3P]#V_W2D6N^RFW@_J;,AE:D-
M#R[<;G?<*=?P\MEXAE1V<VCF<?[G)D]-GYLD\\ 2_#B\3^T9CZHOOQ=7Y>3/
MAV2!P.3R@SV1YRCWD,6GF1AOE\XAW5ZZFTK#*UQ9+&+IF^7D!CGC+_(;*KZC
MIO[WAW55+][41OMY5%+1[D1 -@ V^L\BX#W(VU*GJ L(KI1"I)'F\GWUE!HO
MK8C0SNE4+V#W7&"6(!@6%LDH:KVQP:='&WB5Z*=[V.2"0'7JX,\EF7]PO>*Q
MN:YG,W\!Y&&8K<<:/:*UNY&9RD[=UL@6'9"VG1U+T8()DPA]$&U10<C/J491
ME*DLFP=CK?,0Q!5U2Y?+EO>*:4K$BZ2Y]XU2D^(O6&%$$52\W[,D*0X9GX.T
MI/S9B47B/C_72WZ8N&;G\@T1?L2T\0=\A86!59 & K[+"-DV'NL4CYWAPPGO
MK WCJV+<E,NO220\'CG7]*(+/H)(Q3DT(\.EZ[(YWL"N).#<[L0XXSZ5ZARR
MA(3T@T*JZ18B/'9-;#A)=&H%5234V"L2JAP[MX1)56HA"WG1"+U(/>.,L[F=
M6)U7^YI>6^*PG]1526@8VB$_96%D&DH5>UMCZ$!A\TU.,Z\IX23^(9XK\\8\
MZ<VRLX;=;G[$2I_EFAJ?EYM>CIKUG7&*_F2/S$BEDR$WQ&>^.+L>>[ZTW.P@
MRW=)EY3K?#Y]63<,9E)9_+P( @))$F60KO3L,C^0I<SIP).PW(47=&$O6+#*
MX>JEW+'N ED@,82 F[8_6)*((';"I>!8X\?'V+F(7P7,A&FD9TA07@-ICCCJ
MLE!W;U"_-J=WYB<_DF_-C'*8\+=J<EJ-1I.GE!(R>ET9(+,]]='HB7"Y:!B(
MR2_@2@6P8>]G&TD&R]Q!C_Z 1VE8N-<@<)?4M<7=V(%;H\Y_/COL[8"PV[+Q
MVRJH@7G5=EO[XR*EY7V2'9*D+8RG_7+SL?8(3DD 4VZ5P=OB9<=J01V#SFL<
MHHX*MTR=(4SE.7C.S8XPHY$X:0BA*(OK1I8XB(SJSP#A(+V"UC&]=^#=KU8O
M%R8YGI?\OM$"#?PD;_*W,J!'?#Z2W<65RJP/A<2IGQEEY&\6$M4$W>KN>%'$
M5"L*8%>F#RBN$>,3L")5A4J33].B2P?I(%PR%7O!B:YEG[/X3N65[FIHX9%X
M=$_@V\\O.008M8=T'/ ETN1I:9FLV)/M6W"P;9/YX[\9GO2,R 5S8'6257G_
M!6Q[B>9S528WJ!LL*\-^&[-].N,/#-$?_'/QC:M$(W\NHWD@)@7O&SPYP>/>
M,(_2^S8Y D/1$'/7U"?K6DPMN0GX4,>-'6M(E8UC8O>FA)HS[Y1'X[AMC0CT
M_?#:,NLNB'$S[T*$;,1B8^0U=6_3*^&$ 12K9*^=\A2;]I%F<150\K44A8*A
MZ9S0LTR&Z=;@F*Y>GDAJJ2R^^QV&/PK-;,,>=+(<M!8)6[WO]"<EDX]AK%4_
M?[ZW>\-O8B1;SB&W4(>?HCKG9?W'A!,QH*EI 9YN<GW+=_&]')6BGOU/^_J>
M^A_DP"K5VHS?[S!%W-1UZGX:&!@"Q!:(;MD71+=5E$(#IC5T=!<S$1KFR\VC
M7?$G7%@$BO:9B-TK0'8CY<6:P3#$X@J>HK)8*GB G-A<9/#6KIZ]DTL0/&U?
M'CL*BP1YM&+48 ]!($$@.-@KU@7$XXQ^EK,+DPON]B_&=9%F 9BL.4/HR$UJ
M.^$C7)C)AX&LIL'88PO;LF'BJ,"1QV%&EIP.GN!3Z4IF[''J*L)!X>R=8E3?
MWL=_:##M_'(9&..+@D_3?2'5L/.9[O;&-VBK8#:!NL&TR=E9P\ QL]/?=1%'
MGE%"V>P@NJ[6\U-ZEJK14);TRZ-.53U,ERXQMSDF"VL![>%>R8R<K*R@5;_T
MO*:%H%' >SW/*)I]1]65-Y*WU_D6ENJF]EE0=EC/]#JY#130:*%1R-,@=[^L
MRI99WPMLG_/!C[M=:]<MM+0$*Y*2SGE%CL E(JID.5XAFE/J,9=1U\L&0!;E
M?,\J&SD'L$ L42 C@R%)1XD*?/A%HE4.!LHY5U,:N:;#WT!<D3T!P*,.UYN%
MOQ$EPXBLH>[\!4P,=.K]FXDN'U*0\S/BQ#/,B5 K,"@2!2 <&+9[,TR-?U?Z
M9?=6]!? -T@1M$&'K:3WL:%$^-]C+_%ER;>5I<>0E/.E":I4HZ-]_9BQBE&8
M=@"WE[N=E8W^#ZS!^OA+LPW-K-]#9ILHI?\"4/PDKNRAB^*N?<!?7K,!>-UK
MO8W&V]'=]X)Q>Q2I:*3*-.+3V1%GF,0A 9*HC^  8K.HIG>(4G>A8+\CN%QI
M '?'.AN"B0WEG$GRYJ$+Z=S,+/RN!/0APPRN/IR=_BE[%YA;YE5K/T*2099#
MX637O'Z8L;SX0!%/>.G+T$ R./:!4_^5 %A@0=3M)W24$(DQ?<K&=A8;3D[=
M0OY27GS\TL;<N.FB@V/>E=XL,!4.PK^(8VS^; %J;.Y1'UR^R(49@ XQ$$M:
M+8RP*"XU, TP[#G[N1%/\,6L+\+ PY; &@/6.U]<SPFY9><LY"'M!N\&T\JH
M>A=(+ P]P><:)!\VM1GL,/T5"^]O'F(D([<; ,"7-PSVO4(Z9S(FN0&'.@L"
M0WZ9CED6=BH'N1/_A@E(TC/R(-Z"\,R[@#?(*2,0@1[)?+=V-R1]::'5W>FF
MLNN='5^G:Z:F[WW3D:INMXV5R3]/!TPPU5MD,B-'=PK'UK34I)#'NF$7]N*+
MH92-T)C7-!32>@,1PE,Y&H*$9W:.=H4999K CW5,L3,P,>0X/$E4$"@PV+YG
M8*A)KXF@0>?V_8@5M=^Y+NKEF:E6,5.-:G&[M!*]UEL1C["+\[U0OFF_YC1N
M0'%IJ]1[E\W(-*D4_@&$K3*Z%Z4!R5$2D::L2"_#)7'&%AIRCQ(WCI)4A46>
MS>OSIF]I:*FCXNUZ.<"P6VX8O@C1X7WQX?]R\^' $ BRZ1K%WB%1I.EB@DGY
MA]<#)#V#&C2B_#F6EP7JW<X.W)2<E]:MJ%C(^:/D\'U2S(DU?]ZC@F,0*W"(
MXQ6?R?<CARN0D8N&""O<D)Q1+0@0P#Z1XF'D W_4X@[A+JRQ%/F##>$U(=V0
M-"!@D7XPSLXE[ Q!Y9K-_04LG8VKH)DUT<<C,.TQ(H:/O#!U_PC:P4/[A.JB
M?DS5R_2^-?&2O$A47D*_$5!?A<*;;_"))*:I]7_S; 2Q.0+W#FCN1>+4<&==
M.^,N\EF&5[PYT/6=)I!YL^ KK0/1PKEW6HEJ?.P.([GQ%PQ$#R8++=U@O!>;
MHKL&\;1X"DY"4_:7TKY\(U'/;("P#*V;94G>E+-0Y=V.UXB%+?L=W&/[<?&^
MET:IE+8;I%_+*WO[Q5.8!:=6FZ,)!?HWGG!45K9S)0PK[@M+2-OT)2[T^J):
MI'BTJ2HN;PXB42Y4]ODJ1KHC,O F]DR%NE'\/\.6^/IB"S.Q0<,'>V1N.&@
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MUEH=G3E"0P +2XIR2]5%ZRBE.^T^IJ_N'*6_[HMZF(NYNF$<?GH](@^*OZ"
M>60PM3R2@?LD.#4>0I']&@5SR@2>42\8D7V# 07\&<</*!*"JU247W4N_>??
MH0;9$,GUPLR_+F!G1IJK8L:G=: PFKJ'\<4T!I\L03'#/YGMM8LN=]JZ,O*C
M!W5I=B4;=0#0/@ ,FC"&GL)&83< 5-0_F3F#K;]L7;9>#?2S0ZDY'?TFQT4V
M^A*X\8V5<CX 6^<C%\G^^8_";*^D*G,="0)X.LC?C:/U#8?KFY2<O<7V/"YB
M",B+C$B<WX5JF5?0,._'OAM72I3AW"7BCG9Q]M[Z_.5B2.VM^AK24"U$MD$=
MF*%60<O0=:\?)3Y(^"WP\EXX<'YJ^RYI],DBLX9Z@*%\QV]:Y#0S@6)I2M]?
MO^0<NV\W&^RW 53(#J%JKW^U2PO!%3*>/,?E.5$80LK-_ @#$<9>*!]-0H.L
MPE#&=6H6-(Y.:J IC/CUIMO1VWP5-\596JLS6KSVRE[3'=W"5&O%Y.,RS3X,
MFBL9%0WU_'1.D4?L-V5< 5J@#'SR$9'$Q'V8O1<*@LJ]?ZQ9"JX_%H(+HN#=
M;=*LNCAA56(Z\D'.CVK[-9H &7$PRM:ZI57C#%_>';DVWMR2*+S^,MK+Z #Z
M=@<@YD#YR[$"<:J+L1 #A2[1-J9$6'!O+P )W\:5,_9&L/44M.P-CP)USWAD
M/JV]/<:16/='M,FE( \)BJ3<*+^5+ZO$+5E#E*+%X"@04+&&R(!SXY_M'Z?-
MKF6Z1A7Y1Y^TBQ7M#Z-B3S_B'U3V4])@_)D9,(!@OY6QY-9ZUCU=;+/R[6:3
M-=3P\%CZ\ONVGNV&O@OAS"PJTU?;NG%"Z =Z=I8 J8,SG.FN&P1-PS.7*[7
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M[+'82GP\T.[34F7M[.&==F;!1=OI5@+]7+P_J#AU8@S5C^G)[<U2*ZRE*48
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M%U1N.>DX<@X[XNZ0>BLKB]R/ BT;L^1GRDT&UA%U[9]^@R]O&N_[6W%L-:9
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MB:3C7\;7K#J=!AZ#&M%6[L):FDQX)YYG902?CR>KW7P- GUQ+*0T?0I5VD1
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M?0"@LTE,XM&N?5/[X\M@-#N;%S+HG2 53PQ.$O&2(( Q],)X(B+#MRZTR?T
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M?V36RC7:VVF<+?O'SF[#3<?E+CSL[H#[7K\%]&@^DW[-OQE1XKUZ5Y(<"VM
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MN^,#?B9TO+VT?R9($?[3-,SEE/L?@?CN( "I!],BG2CVKEWY^5U]",['?18
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M1.K@]\+K_V#O1M<5[>9$V!O#Z +0./QOLEO^8/\U.X.SNY:/EP_NE^"R?%>
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MAEC[SC6<%C'GAP$!1<G/$D4H4>EL207Z_!&P"8YO\WJ,GT2[X+G"+JNY8.0
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MKP6?\ Y@Z^+694P6O@=V*;M[>%#E/'MLFC_W-)PH(#)GA%^B9Z,[A$P&Q[<
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M2)FVU%=69^X11%79K^)0SPV[B4)NB)@#S]4'>J<,;WM]FE95G8?AA[+%;3/
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MX;KB3/.NY[G"4=;C"0X939'FZ/;L5=/4J:<UVJV]HJ;9F5P+NF@4<CDUZQ]
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M5;A>6^?M,B5%JE(F#8F$/*:,E9SO,A@0&B5VI:%KA/ R?+!>"WOLYIWBEJ2
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M<K,AAMOFB-"EN<[0I$:U',4*^W/XC-I_V5NJB/LYTP,'L50 ,=-AJICT9XX
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M8CB%W787'#%8::"H'R9B1/L@*P:P*TUYD"QG=B/=NXB_3G2]D5,&8H 6G 8
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M=]<R%O>R_-*1F+]'*(2L-]Z&P&3ZYLRZJKDR1L.?&O$9"OB,EI?1[U!A\L,
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M"2</GY#[EE]=5,GT/1B,,XZ=2KM"C0(.BIO^,A%;)<7_MC&Z7?R0EL"1/%3
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MX]C3Q)GD+[7JBNQ.]0K#5N=BQ.8,1QE^,$3:!3>!&-E;7U'<\:J\+"Y41<5
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M*Y ZHA_XIGUICG<AAJ0TNJFXBZ3#3_ZE&B6S=:/:@:XK]TV\[0/%ZZ+MJ\6
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M?'$CM[8M"5O[I?E?M%/C_*C\,?O<." VW\3/I<2V=UQ',B8^C0NS,A9G@%5
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MI<Y:YJ9F-F*4%EBOV94"\FHT$'909Z#T+*_%1XMRT(1_Q'@\0A*$IE*3ET@
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M3P@;\;_7WY^?8]P3I!P+DW(K?N!1VL:=MH>@O;*#@;'^//&^<_0Y'(P^_O\
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MHQ;-A697;J1X;_%[+>HS45U,2L>'+J7:4"69$V+%$==Q5:W7:73GWA)**?\
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M4K*K)*PY]X&-P>"G0<SKWKC*\"9,P91@9G]5S><:258'!)4%8:8MB1^:6M*
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MC9>/R..P'/.2<?J-#0U#<6LP<=GXV<DN+F<4KLPW)<_!@"YX;:G%;2@62?.
M)</]K&/^=L#??N>.>WOJ#7U?X[D5:K,^];FX?J%/GS_&]+@^E7H_83_X4_P&
MJ8YHIJ0/\]F'N'&_U+2/SQ[G]0=5 M\:_+>P!+5N/01Q*9P'-O(&_P!@6(+!
MA' XP/G@=AM]#V^6_.".=5;,U7I2[TW<T-S384>(W?N7WK4W&QY'<VA@<[9W
MXR3QO[[#./8[$#)P( LP86=^>"P?BQ%-JF!-]^  &N_I]>3 8';?&<XW/OG
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MECX=J.A :C+BI<I\F*&I-->D0'8S[NWL*N5B<+AURT"7)F2):Y:  C2A2$Z
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M*I)W:FY["KAP% 01:E'KW^Z5B"/??.>Y &W^![G?MG2IV)J]038FCUH.QW8
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MZJAQ;$>G6G:-/E5>YDR5MIP(-0I<=ZB.%U)0O[S2TZH!Q6L[SA:%Y1/P\PJ
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M>E-H/6@(["_QJ>-N;;OEMON.XXP1GD[?3;;(!U(+]R2[^@L]'%*5:M@8%^X
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M>P:'/MC&Q![\\XSOL?G@$YSC4BCBSUJK2VVP:_[/5HII?O8APU>YV%O@:/$
M!/X@ ,XSC&YWY5W(WY.#]3J& KYEN&-Z4]+"U2&,U--P_-=[7J:VXL!$Y(P
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M*("#-58A0/NBK>[JK1])^#'1F"EG%^)W5J_R72/1ZC/TSEE,W.<YD-.P>78
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M  J;N]#& ^"/2HZJ\0\GP^)$I6!P"SF^<*4L^Q&6Y4A>)GJ62D@&8H)E@E2
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MC)UCG_0_3/1'AGEF:8K#'*NG\#F>=KPV+F29YQ^.$R>G!39LN:E:Y,D3DE
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MCR!;B&DM6];^G=W=Q8ASW>*X[[GZ8]\_QQC/R)QMG1WVH&M6I;F]K4>M34F
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M/02Q+5<>=Q4^?VT2 2*$7--J-0W>P(>_>,([8KMZV)#I]W4Z[*%:=S].?!W
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MJ@I21[&44H4C0&0=9<.4NY+,U-J>..)'2P X0,>_9!X<>&&#  Z?Z?3F^>(
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MW8CAG-V-[WI>H ),4-Y?&SVW]"]M[Q!P21W/??VQDG;W.W&1C.^\;W(N'?\
MTCNPJ;@L]+;SMR-P6>KFF]M^*[4G\0SMG&YQGY^_?.!SW&PT+B_<4%'-=]S6
MH%*>4*4;RJ>X%6V;R-ZFCAMSL!L,\'Y@]N^1OV^>7/&U-S5Z,P*7=S07-HDV
MI?FI?;N[%@#9S1JQ'MD['?<';;.Q.1C&<[GV &^EW[!T@D'COP+;#O>*BC<I
M>M=C07N*M<;Q(WQR=OISG?WW^6V,X/&A\AIH[%SR1<LY#/1V%8$&YJ; $&NV
M[/SOW%X#N,]S^7<^_&>_?OO@  &?>@!- U2_=VI2OR,[4-@_?8-Y_8+$F,8
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MC;_&>=L?+G!/:*UX#DEF+D6I\^-PPA:SU9NX%N+EV-SP'JSL%?7/?;?;^&_
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M[DDMQW@1S>QI;8>E.'W8TB#@\\Y&3\\G.V^V2??)YV&=4L"UJTMO\!4 [.'
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M'L(@WW:^]OG6K>;Q'L![D'<9'?Y_OWP#MJ2P\A<CR+5W)!#FWQ@]R:DV??\
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M#E(P D'8# V&VIW9MP&Y8UJPXY%7, :7:[&I <,!=W%=B=ZBL/(DX!0G .>
M?Q'RDDC &< ?BSOCWP-&%+&_:U2Y?>P]"#S#D$_3O4>[O3T.VSQ)P,XVSR<9
M'! [;GYG?&1G!(,L'?GD@BQ'%[&M2]68L!_>U#SR*,"*=G%!#&-L;'!]QVSW
M.^_]V-MXYW9WX+G=JAV#5^3DKL7J*4H;4[,*N=A<Q/S[>^,8P,[YW[Y W.^<
M[C1ZTN3:O(H:NX-7>O(9H6N:T[BMZ6(:E&LP!O#&VWS.<YW/ ^8WY^7&3G0/
MR=WJ01YN6J>&+><"03ML!1J-78V]6V=JQ^>%'!(WX&-O<#)/;WQD;ZCL01V
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M&AGOD<]SV[?0D?KC@$G$TK7YBH8@ O4%B0:"@YK$D&S$49F.S$\N'L>]:-$
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M>P=V+FG>S,'9N[-45DX)_7'&Y&<\^W;MO[#4[U%+<ER3L#0.X'=C4@1'R?Y
M@<<B]'IW@1WV V/&_.3G?Y9S]=CMJ#5J]B^S5J_K0D\ Q(WI<$#Z<7ML#N6!
M,."<XQC8G/<8W.P_+@^V=":EZ5=@[UJY#VW.[L' 9E !<O>WE0&KN6?S(!B,
M;C//OQWX!!SQG X.Y/?4DW?]-*>CW<-2PL39[P'S]*<."&O<["E(D\;9&<_E
MM[[@#Y?/(P1I6E YV(K0G>@N:4%Q$7N;-ZV%!Y;]JQ&#N"=]@1GN!OC;;L<X
M)&X^D"KU#$,U7< 4 (8[;O05-7J)H&%!N>"=R^]00:'Z<MO8=AW.^<?/?^\G
MCG2HVL;FK68/:E'KVI .=R'!XJ]26W%_@&+L(X\9.V,\G<@@@8W\QWP-QVT)
M&X/;G>A<DU>IVHVQ@.US<;$-<,PY#'>\3L><[$A.V>-N3O\ /ON"<X&FX#,Q
M+,3N'H[%V;@/>\18'>S]JGBE_5C1JF'&QX[#.<]SCN<<8QN,?/4\7>K5V<U'
M-!5@7#6L5WM?CLP?8/YT+GR;'/R[$8^8S@C;?@_N(.8NY=^7J!>M*$7%@0[B
MMUF[BX=S6HM?^]P0 /&_;?;Y;XW]^?EQG&C=W%/+BIKOP38V9P)[5J-W+^35
MV+WXA^USG ['\MB/KOO\SQJ0&)VK\G8,2'->S&CD6B/+@4?=JF[/M] \0,[<
M]CMD #/MO@XVP-N3DXVA[@ 68[,3OY#?YDT,32M>3W_8>KOP 21#R@'/<^^/
MX$@YXWSG/)W.9+FC;^@W:C,Y8.]7K4,)#<V%N=KUI1V(H!8AS$_+.!D#."<9
M_7/.<D$;\'C2S&H  V=OBFYW-*D7:L7-GNX?CBMAL!L.\6)=\/UJN-E::Q7F
MIZ>NG\_;51;<IWQC=R&04&BH4810+>71 JVG6E)3/52%?\^$I7K-TM84=S:O
M#CS&P>M1>\@VV(2!4M4FA[@;\\-%JJGX4W[9I%\O]++SJ<6O5B#?PLJDW FC
M4^W[7J7427.FU^3]^6Q;4.])KT5RIU--N2ZU5ZRFWG):'(D&866]0SVK]_3O
M\0'B=3WL#WK]=ZMVI:M&]-?"#4:3;5]6!7YB;6Z>W%%LV5;]!H56MVYZ[2+T
MM.N"OB\'[A<Z:6C!F!Z33Z*VW2*W1KA9F-0Y2J@__G:8B#&K]^]F)M^]+Q(4
M"US4;7#L#4\MN2XM>+]VOX>:!;M7LBNNW-<=<JUD5VZ[C1+G,V[ CU>L77;I
MM9UUZDV_0J/2:;%H])4^U1(%'@P(T=V5(D3!+??=?>EJ^G:Y#U>U[]J5M25%
MC3BQ[U\P32EN8H17@ZLI MI4&\+SILFCVJ_9E9F1V;/ES+IH<BYJK=KAE3:Q
M:]1?H55<K-=K"S6K4<HE1$><XTT\RMN,]&DI;T>O-"13Y7-*E@S@JI9A^UA4
MM04!XVNS5G6O#9:=<M?J7:RZY<,!CJ;?U"ZA5*9'^Y)#E-J5M,V;'H=*BP:A
M1YM-FV]%8L:E1WJ36(E0:FQGZ@U++GQ#:FJ6/K]^FQWJ: 4,3J:Q=AN.^QI5
MF)H;;QUD+POT*GQ*:8U]WLFMT[K$GK4;C<;M)R?,N<6DW9+T&93U6P: *0Y;
M[9C1&H-(B.TU1:53)$0QV6RX>E>^^_HWWLU78#X\5>E]WOW:KJMX8*-+E0ZQ
M0^H-]VA<\2Y>JE>%S4$6P]4'H?6"M,5B[J$N/6K=JE-;AM? TF+0Y@B)JM,1
M2HKPFO/)67ITG8'[>G]WI8M#5WLVYV(W:K[L-BUX'PH]/FK?O.U(-2N*#1KU
MLWII8,IE,F!(>@VSTRFSYT")#E2H;SJWZZ[5:FJX),\RERG)SS[88?"5@4^>
MP(:H-/)_[CEX:NPH7<, 34!P>?-]XR<0 $A().!@DD\@ <<#..QP!@)PG&*K
MT%*\@O4EC<&X<DEBP )-:*T?LWD!MQVY-;B)QSW)QG&W?;OG/.^>WT!@B[N:
M^7;AW-@PT^8#"7H-N.YW=Z-5R.[;DQ W[[<G'[0VQ[[;YP..<G07XH=BQ'U(
M]!S4W&WR#D'<68"MN2S4:HD9QOM[8]OSS@@YSWV]M+L[OML*\GO6PK8- TL7
MI7T:M-F N^[UB,;<\=_8XVR",?3CGN<'4AS0VJU-^"-K.U*UO$GR:SUN"YH7
M<O8D/3BT2<8VQS^_Y\?+?OVSD:AA1C1Z!V+V':]7I0Q%7 -*;\5_9PP;XO#?
M;<  $>VW\1L#WP<9TWH39_*@;GD)I7TI#9VW#78\]K[=X'A1SL0.V^#_ '#?
M8@$\#.I+AQ0DNX&U'IOR>+L(#8\?#[_2'L*/M 9&^!G;WX^FQQSD#!&VQYU#
M/R#4\U]W:^^^S5($"U /44'-S4<-M>SPVXV/U&_?'.Y.-OH"<Z5';FKT8L2Q
M?>XW+L*.-1;Y;^88>E_-RSG8=N^V,\8(V['?V[9.E0P ?@WVH17@4!X!%;!R
M;/5GJ*&Y?=N[FI AG<@9W!W[9)&^PS@9&_8#C;2Y%B!6UA6]N;.!3=PYGJ0Q
M<!JO;S-^XJ3>\0=NVW!QL0?UX(QM],;XT9A4-9W.]0["I# L*7-Q8_!J*C?=
M[EJBI)LV\3OM^@[ G<DD8^1QR.^- Q!%2Y)V-A79W-JCN*TA4'R%6X<4O4"F
M[[/$[YSCL?Q8WS@Y&-SP?[N3J2] 0+FCU[$U%;O9SP6B.:\??=BWU%!#G;Y#
M)(YS\O?G8CZZAT[]GHX%&(J7^MA0M$VKZ7K1B[ANWG<<CYK(RU_\5#^?,IG;
MGG^ QV&AW-7I4$,; N*$,[?47>1=(^H +.[NUO7D15:/V$_^%/\  :HCE%A]
M_2GPBFG_ /GLP[_MH./?_)(_U\'N >VJA:^]O,,..3N.=HXE>34#]J]OJ.6-
MQ' ['@[^W/OSGY<#_4-5,/=!8 _/N[.+\V?]-HC:EPU*$<>1<L;.[7J8;8R/
M?MG( V&QP=P,'YC?;5))-:[>3!_OB](-M:A>S5[U<!P:GRJT!CWVY/8<;;<@
M<D9/SWSJ0^PI05JY(9JT >]J,.! @>K?N;D7.U'J[LSP[XW!SG._'SR,<DX[
M#ZC!D[\L"#2CD7#]Z.:-1H;#BHJ[>8;:E6 +FI+P(VYW&<;D$^^_';(^GMC(
MGG4S,S#]V]*"C;O$#R%QR?Y/F'WL]HP><9&-]L$X[';.XQV.<<8.J: VI2^]
M'^/E2SWK4"&8ECM5P+A[D?3<@V9SW]AV!SS@G!X[8QOMSOJ:/2W+>1-@U+&X
M +-=X(;CEG+;@$5!K?X%V+1._P"F,]R><C^&..=2SF[?R!L+&KN ]21W*G%[
M!Q1VN7I1V<=^8;#CMG8@^V^#CV'OO^\0S5;9_NX(((%"6!J[/!W87>E3R[/Y
M$\/O0$1(/'SXXP!VXV^7N3[ZDL&N1Z6XJ*C@"]31H&KT;U)<@5YK6KVW(WC'
M.Q S[Y/._8X/<$=\'W&H W>CVHY( ( 9P'/%1;<P>HKP.P#UW#V#['F@C'"%
M0KHMGQ&U.LL6]+JMK]0J$E<RNQ@T(] ET6CT:"&)KKA*FPXNA1$"(A3;]6>K
ML:3%2\U;]02W)4] XK5P[#N*[M%9(9J>1/P:Q8@WXOO%->-WIU ZH>'J[;6J
M=-8JM-,BEU&<U(4XU\+'A2T^6KB2RMAZ$BC2G(U6DRVU(+$*')4YAGU1KDE3
M52EHFBN@EQ<&]R7=_4?2,;ZHZ6RKK/)<;TYG4OVN69@@(Q(TA2TA)U)5+J"E
M:5@$*2I)%QQ%)^%+P<= ^@,!=\]):+736;XMVFN)N.[ZA(J%QQ*%4$,U)FE1
MVGXT9BE,^?TOCF68K+\MZ'&7.=D_#, =G%YA.QP*9H"$)9DHNH)>JCLP)(Y-
M!&(>'_@]T1X98C&XCI;+4X3%YA)&&Q.8S5*Q&*&'2H*$N5K]U );7H(*J:RK
M2G3FVR@M-);5M@G!V5MDX.P&5<<X)/<G71>@!+L!4\M^P8,S%B 'OM$Z 0$)
MT!("6>ITL"M1HRIA=:F?2Y%1;Z>4!7FW!*0@DDY SL ,;8)X& -O;&GE0L#N
M2>3;R-'8APU3$/Y'U84]:AJ FX<5VX/(+C:T#?S#<**D@@D$@J204C QMN,[
MC4%(4*E@;D5-WK;UWHXI6)!2#4*+7"5>S)V8*"5*#W/K&)\CIEU8Z;7)7*MT
MB?MRI6W<\QV;.M>XD//)IDN0APN?!)-1HZ5LI)$>*ZFKPD1J4B)2Y%,G_=T*
M<US3%%:)?O*4M!&DD60*T<D@]K.=C>@EJR@9:$J"ORZY@F29AJDJ60A)"F40
M_O.Y( 8-CM9WV;O2NL=4:CUMZM65;$FZJE6OY2IM"A5"L(LP7 [+$V16:A0T
M2_NMY:Y+8?%(S4X;LIV;,JE3K#TIIN!VOZAB A*$'_(N74!ZA(!+5)I<F@--
MWU+/\#/#+%=5+ZPG],896:*6<44E:CAE8U4R7,_,*D,F62#+)8H4E:E$K0I1
M>-?WC^\!G5:^O%>[=/3V?;T^+UH1193,>O5!5'%"J])HD&V9D42#&DIG4UMB
MBT^4E4=+<IN55HM.:CNN/Q5/]O!XY$O#243%3!,EAE:0%(8$N02H7?8<7 >/
M.?CE^&SJ/K;KW&=2]-XG#3,+G7Y 8B3BILV4<",+)1(4E!ERIKR]$H3$)=("
MU*24J$6&^T Z(W)X;NFGA:Z)K2J=:M MZ\*W6KJAM.MTJO=3KAJS,^XDJ"D#
MRJ@T\,)H0EJ$MRCN.MH2OX>1Y+K@YPQ*9L^6HHFR\0$G62"<*4ATBJG.JI#,
M: %VC67XD^C<TZ%Z*\..DLOE8F?E&6(QT_,L7)E*,F?F,Y("ID\("A[1(4TH
MK"2)94 5>\!E=]BOT9D)=ZE]>JQ37TLK9A]/[)ER65,M38ZY+-5NR?3W70GX
MF.B8U18 ?9\[1D09\=#I<2\EOJYSBRM(PXF)T$A3!3#2 6!3L2 +&[/8D[+_
M  :=!3\LPV?];8S 396(QNG+,L,Q"AKP?N3,9.EA83JEA>@:TO67-!W ]!/)
M!/Y;;_O_ #//&V,X.L;9SYOY_ NQ9B+-9ZB/==@0Y^-&-'<7 L0QK:CB)QD?
M\>QSMQ^HU%RS  L[.>]0#2UKCF\0/YH6%VW-Z=O*&#OGYC?.>P YX^6W P.#
MH*5%:6(%!O8EA5V:MMZOI_NUA=N7:O=H.">=\#!W&Q]_??@'^_9<[. Q!?R-
MO@VY?S*H\GV8U9_,4W:G#TAWWV/!R0"0?H-SMMC&/XG<MRQV!8CEZECN2_
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M?;/8]]_R'^,<#0.*OV&SAZLU0;;4%GV#[INU'H.-Z.Y+B !R23GCY>_^OO\
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M\SFA<4H\0":$V^K/P+!_39VH\O P.-^!O@C?G_<=P3J+7WL*5=@;%DB[-ZV
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MB'>RK)5FL^\R25\ZYO-#@MIC^UF"M^L:_8Y M7.6K<>$6BFHL<YO^AZV)2<
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M=@(ZK[(*!1-^]^)M>K#,W!>)K="1X:W9?'@ H=4&RF<ZI1LI8TS1R<_T]@B
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MUF/!/C;O&:;\5UH$Z(,/\/G>+GV?&[-2Q-YN.K3*I_X.GD3(_1TZ;7$:RQ,
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M@P'NS/OB*@AW:2>BF<1R; N8:ZB7P_X4.2GQ!ST>K\2U)=<.3^^U_')SGM;
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M<C8D& X+I^I?KN4L<F13(->-UC,Y3G14.&R3O9_D(I)@K@Y_$5?\'.@E5Q[
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M/<F1DAEND"]I4DLQRR22N9U]_.C 4<>Y_O9CTH7:\NLN'HE2[7;JGN#8L)6
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M]P8:QT/M$,6,-<SFQ&SY 7-E"PT]"!L$%"3KPQE#)&?0$9CBSJ6%QWO]TPD
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MDC/#X&N1/6DWW:A !W)3TSR <]69/;36%,"UZ30;L":FRZ-)>R' C%I3UU=
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MV+VA1L,XOF$[<VEN@\@L!'/\7C(].8P6@;4$E_NH_Q,/N<8KH#_!_MWEVN]
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MK\&:*-M1X%\:^JLQPG=V3@[ITJ:.?I-+K*? 0OMKX;5F?V60:?_J32==&YG
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M!S0"P[D!),Y>$(XXT8_'_?5@&'3*?QDBL@(1AL'X+V"),V<()08Q4QG' >]
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M*)/K-;9!/3XL78]=DN6OEBD/[0S#7TUW!_5?-$)S<+:%C<)+AAAZV8K&B$=
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MW&6VG1YZV37L:TD@N)Q)AH>]X^7F?C:H]U62<<\JZ# !X;W,=ZE<K)258'W
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M5V:%^K:WW'Y[.+XEN[U$"U\U*CNMP)U[R> U6;H>\Y/#/= MJB RJCK\L:A
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MSI3#>F8B;GKZ$ZVPL']$RX%91]YEF"$NMF9Z<*]6<-F8/N,30@4QPZ^;H[4
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M'ZU#YP][)IJ8Z4Y'M"[IV1S#LK$)_;BX>6:A ]2($,UQFH#(N'![WBO8[2O
MDH0:<?*L>-N(+SX)),:D^1E0#!G!L"^T]OH4_KMCQJM@&K@ TMGSC<5RP(8V
M3Q!K@CEW#+B&FU>0"$4UR@L\(ZPIN>Q7]]$#2=^=D\T'EK!YUH4CM<GL&R\>
M7]<&.MCS+NZ%RRVUOAF@('V+[!LP+A_FCG0Q.'-AQLDEBT_P5Y?Z2[XE04 O
M0W=Z*MY"LGG'CD_I&1S+I#D$/^)L35-\U^,)3T'N*P <(1+ (VL^LKA@*6!;
M2Y3T3]DD.1;<@&)@*9E43"&@BJ0?JT1:,J)?"F?63F(]G/%SO- 1WH\W?\2B
MX1]/-I#[IPZ!CE3>GEJB2S(0^+^W C[@[:D-/3V_'-?,;!QE@ @L,,055:RS
MGZ.7K%J#4N[YYSN7\=BOKP]\2,#  5[(_8NWQ]TK(!K\"J XW^;O.1*CV=$O
M%B<4$.FF*JM+_N\@8: %86>1]K[3$K&$QHB?#X!?/"90S[I*NUMADAH-FF6@
MS$(+E:DVL?&UO5[#?WQ!@S*]+%85T!&FSAP12B-;3<>USYC;N&?:K$R?GV*>
MRFMI(4W)B,2.D8BG-D#[I#[ZB]L_)SKVY-&< ;C2'(J>J30V?TNZ;6!)7=!=
MPFV3K%7WIG>[I_K>@N/[V.\ 78N -,OD9=EM[ZZ9.CV]>>F-N]7]C6(E9AK;
M7&%<0\.HCN3RM,%6H"DOURP++]'2L62+G@8G-T,/L^#O[-^X\!&9I%$2G8<:
M=5R%9-H)GR-8R!D6'4SQO1AM &F>Y?83+V_M[H@<:]H L+\@9PDP><"!7#@2
M]VAT$S4@@GU4%%[<+.VYGQHY:SK>ERJ';G2?LKSX]EMB=Z5?H)(+:Z!L6Q@'
M _J'&.GM8Y(C7C\7TQ,!:'MA88U)PG5.Z6%4:[LINGR&-6$H:$@_*J?>@F>K
MY42":[HZ'R:N)QSJDS;&>N9FNBKT4,15=U8CALHJK15O;]V%0[4Q+^M4/;><
M7N5OV-\Y2[((GAB_F\XBW47&D#<>J$/Z/AW24,EXCF:I$LI7/: 0F7%&2L^V
M:6N8<8USXEV:E3K'=V>G;M_VS04O5^_P[?OWAY8V]KGV;'RT;!.A=!^&WA=)
M]84R!IG>#]L84(]L^"?[W,$%/]8YH!3UW243]NT^&1'VQBMMJX[?I%FM$8#'
M]SEQ[<:]2.!?!H1,L-SYNW?XJO*L?/+ 4!R3)]K@I#0[?2IO@NCB@F^Q7\-'
MU!Y*;3P_K-&ZT ;(Y6#%;54Q &OYCZW/QI$*W+\V/.NMD+VH*ITXUORHW&(#
M3;"U):5NEH,S:'',BS7-'YM3!$B(6.KO(RE.=P_^K.)'Q%VL/#1GB1&2&)$?
M+2S[O=M.V< TG3)U30&7_NS,'*!;^+.DH*^R(*2S@7YAL"A#$]<X.LE_;: 4
MXO7UAK\_Q1T;G'#Y0E>:E-9J0]8:SDIVQV(>7-.9.CW,$"T!785,(,5@6]74
M/'NC_TJ--1L^3]B6Q.P(8@<JA/66]$PGPH#CX(3_6"K^!!.<$#.V<E%8?+3X
M%N/8YH5#\:EA:+>SK?(%&DXVI/?.%@8*<9PK^_QQT='74%,RL?2_[J?74&"/
MQ13JM%FPYA+HT*M$S["[A^&34#%\, 5GIBF6R%UDV/#1PK:XKEKB\X56N&'U
ML$KV#\HN/1]LKY67_E%ML"M].3F*]HJ_48E,AX20>.R-S<Z-'"I-SG-4%81F
M!D]'K>8:^BN8S^YNW!2/]FLH"T52>ASE_.1I9S8A^<9N86AEVA7]=F%7,*NB
M\&Z=6V?VP?CRX@\S_/S&8!.<I09!;M;3I=5?P$. Z;3*XGN\RYGS.U(7@UZE
M GEKP7^G)[5E[0<C=[IQGYQM@:V\0]WXVM;!PCCSCWTZ]A?7JR@A6XM=^*:+
M;BRH!<41^:-3(M^7-BA%:B7Q+1-COIGII@T0BU82N4O8(XMJ7"<<DY(9Y@G+
M&%M'19JA@].HP*S2#W.4AEE(*F8Q"G]V9CA&8J6]CH='"]K5@?;LK1?!%<P>
M7F'*MWB]S1849K7)&-##&C8!LC"0_7<=%T5%4 DD/HYSV\Q>,L@_)^1]3=?L
M6;B;C*B7 _VF+V5>+Q=9ZZ@Q^F:Y,4YOJ67E'Z:D,DHO%E@EUXQ>'EI1AKHD
M(Q=67!TJ Y9U+%^HKAUIC+[P*,DIXTG;7T]T<!.Y?9S/];0E0W,!$W./;@0)
MP^T.*W"<*ZA^NK8<#H5F@>10L&MB7+A%S&0:HIU,>JS]O991[4R:B,'68(26
MVG2CFQWO,D$%1*] 0V@&8^R*>-@);7BJWV[JA0EN2"0Y?NIO@)Q3PWREZ\AL
MU^S-0FNV1F73\FTF\H^(<D(&*?;,'T*\S@4YW;^6EQTU=F,\K'3DSUH<&M"
MB,RD^HM@64<@8;431$<&4W,*IM-OZ$LS'&IV%=43&(6>6LQA6_!3:C.];_-^
MCQ#Y@JM:MZCTG G@%*1ZKD3OM]P.5 IL0_PGI,]QMSUKY+B3-+\L: T^"<4U
MN')^3^;\R1.1W4,%>Y)P:)+TM-O0,ESC<C5"43.<23,S8.3VC*ELHU0*;F$?
M:RUG- VV!R)0@/0!20N/>#,'<Q\=;:V!SZ+@,GD]QNWNF!"#GHU1</F.W[.H
MF'Z<%T5*WH:)'<<\GJL @O/$C2_@ECO[*;2W)A3XL^V,0LFM2=CEES?1,E<\
M:LO[EY-@&1D3F1_)LTT<12@+XUV.5(W6R^_(@A >0-)VOT*OM2A);54E\(^0
M;>+>:"N-UYO>GH-BOWO&JVDTR 'I'(SC4C]:E=R1Z8E8IX0P]F6GS@ADWFEH
MZ'CSG<W5#VZ0R+(8LII[D<$% ]5ET>D9B%N.30\I1/V=O'7\L/JQF(\FJ M*
M?Y%3J$> =!*52<--IV;J.,BX1H7*5>:%^V*E,H\#JL3#+K?ZYD5[?%GURSJ"
M=,R'.CASWMPR=OV0=_,PN\B^\9WC9,>8NTR8USPKKT^HD-/RZ:*X/(E'Z<<I
M,O<R@HN(-GR_.N<N)V:G8B"<8[ VP0[9/)WY_9&B^TGXZ(7T(&C5ASZ%X04B
MZ(XYIZG;<N17IJXO2?Z)NLAK_S?YW]OBH5> 1N!#@I"K=$FPC(97; E/]B2Y
M\]+W)9[M8FLWBG">MWPVZNP+7$W31[>J[W^<B\;=:6A"]:/S['M!6 [ 3QXA
M'^4"2:GOLGM&\&WH@93QZG>%/-2813*+J7;2TK]2?V21%MVX*%&Q.+6;H8W3
MA43(;%Z !["1F#!]&91PVGO2\4J2]'ZAQLY(T?@(9Y:7NVG:7]LJN ? 2Z[W
MQX>LKT_?2O[B^"[O9^+%X9PEHE@8.6K /$^I\5%6QR21)>0E?K/RW+2%1>2[
MS \*L*":69.# _7F<-K!0\OY.KT]I1:]J!(1N6JPJJ9Z-X$#FW]O3Q\-MIL,
M>7,Z^:^X(CLC/EB1J4=&BCO2E%,C]H>\W*>-<$'37[X<;00^PL&FN:69E[Q8
M1>/P$)D@]4EH?,]7O$]4##QSU<*+5%GVP[<ZWQ7E0*Q]LXQASTEU^.!47!3Q
M.^3@D)@%-W%*1BR!>3I(7S/[J)XZKEJ*0N?5<4FQ(,WL=&,>95^ZPET8R<U(
M@-IG1-763PM=_6XLEY0IV[SF'E; 0 Z.YO9++=V+AMQ"9X,+.'"Z4T98N]6%
M7K)@]-C@5K!=\#3^6$AI\J7OH=)NP,W9K3,D3^ROX]32FY?-L;9*#X6@*3/5
M^L!O M5=+)O3O.\L+)EGPU1$2NFMG$)0R\Y\+R'5U.8I^M4+6Q12QJJ4"DSX
M%&RFBTMOZ,E!/(.V7'LSR8;=%2\UKAFP6.10:ZZA<^LO/859@C\3QTWC19(1
MLUT+HARB=MX);WQD[*K*O,;)WN6^AGYE+3FK DW?G/QM8&Z'"P[P-,=][U#"
M9B:!9L 088^UB>8L+QLWW@RCFQ9OZ/L$"_-;H@$?T7I-K=RRR^OPRP2$L:<=
MO5#(V=N0C$RS_V#"DT5OA"U<6YUWD(YMI8?Y9,KV3_:%S3^VZ!7^+8''7DU_
MCP2 R%9)ODV1!A4>_OAQ9&3:TJ+ICP5B7]3U8T^/8[B4=:8B!64=-V_46C43
M"9%4&_>#R@,9P//38F@M-N2:*:TVS<N#BU-$W95MJ8E!<+#S/)JWYF*J2Z%U
M+EE<H25%>U0&TM@K0.&&7$=G2-8AQK;WO8GN;<.,I9OS /.-!2;H^Z*)TL(6
M_&.&R&SULD,^54DQ; 1R^VCUCW</9_RLLM'ASMBR-183T=4GP"[H_ON7ZUVD
ML\*]'79TR9B7P0SY.>E>5L541U"C;&YFK&"\(>6Q?8E_\MR$$QG X-WZK<";
MO:<'*^];:3Z2<SU)[F4'8:6M#Y)V C-*!>^D<8(8Z^G?2>!#0#TX"2"2NW,8
M<,![7NTRM?]/<K+02N<M8Q7'J((<&(S)WE:IO$,^5N=F=:]OU*IO=%M[34LB
MTS;@DNW<L2&H+.(-HN(^EO<5$WFZG\B PZ$0L\9(8S6IYRF+GW\ I/J)OW>;
M.6XC,]UQTS_8ZCU?KV:WL)8LC@EG['I<PE<@3TQBWGYM$#CSN"_O94RVX,2*
MX,ZN@\G%I,'DI_>WQ.M]./EXF,L*R@M$':TV6)G71KIOMA7-!Z@&*$UWFE=&
M*YHG>"Z5<Y1:1RK:>RLJ&@KDY6L2'NL@NT#M)A9E1:NH,1>.Z>GMMP:;O*)+
MD5>NEV^]"Q\,]AM*5@6%QFT'S\GVJL-);4FR3P[Q0P\<@JYK"^O4JJKO[I70
MJ,+-Z,41O[1C4][%J3"\D./18+J?9?U56?\B&"5,)3XCL1Q)V@!B-FU_#X]D
MS[>.VP,J&-Q=XD %WYX*"O2?,"3C71P*9C22L?JBO\WS((I_WQ([9)'<2Q[S
M\B$<40:'R KTB?03\HZA@:PR3@:CN)U/)W=,I_?+XH#8_0M0HAFIWJ#Y?_Q;
MJS&<\;!A=_W^V[9LO+]DSI%<^5LSV46E79_@>_M+FA;45$7$H,MB-[65>%D[
M!CAJ#U66-"*RQLZ0'=>6S'%G=N=&SW2'2/XK8+ILG>T>"KGFS-49\'Z^?-AH
M%B=YZ1*\@V6/S&1;;A;(\<P=222>QSB(/#UW00,^S<:B\"C]O&;ZE/Q6O7KV
MP4>+H<,QD[\\0A*E1J"Q)8^,%A>1)J)IM6RN!U^FA7$Q+!./-$!E1S:BA:V#
ME+-^)6I/DJ,AV-R^0K!#*73[NGJ(GXI47YN YTY=8V9FA%%$@'0H<=0VT*&'
M#15%Q4U;%WW##/V3VU(88E; "37HK'48(S:2%K.YM]@5JX#57JF"52%,S6=?
MCR!CET7BUW-^&>DX80PI= "<91*1L@IOR >.@JWM+S+&GB77 =8M+2L34I(I
M>\W\/0N=7>=$!VX[%>CSXPL/@]0']N'@BJG#E*0^0HJ&5 I$Y?=#M[YD5++X
MB43O&66'B4-(1KHT-\S.E@D3X .:;)J:,SQ9T4D_2M9E[31&SW<$6IAZPUIV
M^-[ <3#3..PXI 9_QYM]\30T=>8$70H /(_WVIC)J>)J):3K#A\U?8]U4XX*
MZ199"DPH,&GOOK80Z6/@D[,H?LR,9"X"#4I0#B_Y--1OJ]7#*0ISA2*$4JUM
MMI/04BJRDGYX,N]:.34S#8R,&#8@>IO)YH=OQ9A:-UP2OYE@Q>VXOB"B.:@L
M^48O$?W4\O4C$9]%AJ]B.(N"'5>OK'ITZV6$GLJ,?0Y0/YI=1P(GD5EW@!M.
MI!@]L^;B^F;,,0*._]M6G]2E#D\J6HVOH5*BH*;E!,,$VRLJ;3Y33OSMQ5Y-
M!?&/_8YL :MCQ_KKXP>GOT-I$HP"6\9U<OZH4-] M;UJB@0H2 :\<6/E,YM3
MT))MIIGH[2+6&(K;NX*1V.QC3^$28)94F63CL5.-PDK)"QK?QC*9WUA#3 >4
M?N?A+A@' )Y"5>P>\1.6-\G1%Q-UV^V>_2KZ11R>/8M4^WBFU[]7= Y0M0(+
M]0><FPR2C+X+X 4QL@XG)HLV][@DLI(,> 91R7*\V<K=68QS^%DG.M29YBVD
MYQ;%@-O\-JMPOGE&6;LUPC[[4'0!*!Q0-'=218'0+HQ:,\2O7SJ>2;/F^$4;
M,FZO_#G9<=D.A6%)@-J66L-*#V<%2#_--7BSB]I7!86.NU&'^VH=60B1[O3J
M'%45XRJ2DB)/<(JA6@'2=6(_VU8B1WZ8G%WESXD&Q_0/4_!^:SAM(?Z+/6OC
M;EO9 ;;5)FFPMT\$)S8]4M:"HD&FQZDP?7S"6-CL9:[K>$/Y]I?%AT?-^377
MW?#R3\ETGCS8\K4K(XML.^\)C.J5H7A_LRE&:0M:*-XNG:R&PME7?R4@![ Y
MU%0XZ^F 7.R]=W#D.B*5*GYO^!K9"FXT<93-A9%UQ-4P$R"2C":$:TY/$M7&
MRX>&N'#B\!A]%U%\XF"0&<V0>4@%8?/_"R&8RL6ZI(Q5(55&@5]A\6W6(LB[
MO[P&&!.P]([,;Q A1YAU:D:)Z[U *!_.ZI](RX_L%ODVGQ@02MO\=25UI;H%
MWD'H:<-[(9]T3=52LK@24"$?W[,MXH.$=CS!WZH/'65B>^9GQ@2#&PL8=<;!
MF32V&Y315JNZ]'(8+E1KBWM=K($A4 7/]4T]%VKRK"$RD!>6-O]\BZB^F8,0
M]8JF=.N1GF]K%4F3D9WI@:;-$_6H$G7UZ#<=?Z?G?5L>R[CX WHIRX,*S&<9
M38C7; 9H7".;OSNKT&K?)&IZ;O0H=H8+GB2SO,E?$_K+:[]@"$6)T$E]3)W5
MS+_@5/Q\^--*1LBH?;FC,[MMYCN=^<BE-?+:'OPZE<;Q]J:%P(FG^I*TW=^J
MJB"F;5YU7IQP(L9M/IE+W)MOSQ\U0_%&PMR9APDA>\?F5(PAHXM@%K1AX+<8
M$54E.542)\2 5P!)=<.?.%ODCQQ]\75K_ML]G\FM+.,&^G.SF&UY;<T !:!>
MY3QW/,[BYMH!M_%=F[[.9TO#SJ\>:ZMJRY&ZTU.XSA(&7X-SF-B5!L/E2VN"
MG_GD?IG78LB3*8SSK2SUD!ME5>%$_9RIUE!0Y]^R9;;>8(Z60[#B3#P-$0C)
MGH4G(?]*NIW[(4]MN?@T22%#&!T9RM5,27"A 9N;4AG21*>8OE%5%<V&E*7^
M\8J301VS)8X,,./\/>]Q([:9F\K179FUE&"K]0I@]C:KJW6<1R??-J:G<2YM
MQ-TS]8WE%/AE0U>LC%<E%TXD8G4D$TAXD^K\+:+$@VD9&2E8#22X3LSF86CH
M:2<8&GG2&E%1J&<WV=S>\ HHYTL&1MNBA+#Q4B5#G^R/;G%[6,^,"/LL4VLG
M-ZLA0H6A&#_5M"9[,4@2I5AS@K1Z"=5SST<LBE-/DBP'X?PQWU3'-),K^1ZU
M[N<I0]-)NQ;TUNL<"JL/*QCW&-_4T:]GU,$%G6EIZ_!N-^48OS8O7J+\-N\J
M5,#B53]K9>86Y []LJ"M/C.D1#!N:V@A^]FE?"^68;I[K+K&J694?N?.D@RD
MX_@.]$2(:5#^YWQY6>B@5.6>[)0J^$^?WMT.R+FCPC%B@?L>8L<^ O*A/C97
M!^UW=F.O/_"DIB/WK/#]7:[N_J:URK.(J[F?(B!J5\@P.-A=AEBP!WS#R+6C
M&5F)'+"L2B>TP)3WR+\YCMYW#C$FVRY7G!3*"HX%V##O=^$2.'IR<OBP17L]
M;Z4S+W!9Q5P%]OO4>QG=5 0YB:.?H2!-CD5LY9&7]*._+ZCH"V;7.(I*I8\F
M&R0E?X=UUOY)DF(_R\CAT/;YLFMM9E[HSR^&[\W;Q"W:RYVU".:";,VFDN5)
M27OF(>AHIJ/0#S!E*>N0]3 = XS!;&QLK_AV1A^ZHB5XW5(-&2I7)>/W%-->
M6[!\V(JJ$EM/0  WZQ,S?1BR2#6PPJXZG@**PM_B7"G9\S+M4ZPY,V=Z=XO=
MC_SA22T9O:"$3S,ACJ>T5J8F3D.*;UI IHF5FGXS15J?7H$7!2FE%6G-M]O!
M?N;'U&.UJ,KP&S6Z([)Q:'ZP$$!C"_]]3#@9*G>16$+SB?*3'03;($5B]R.-
MW(=INJYCR;]G3\:]JRR"ZHC;E?A]I5$<S+KL; G-0;%R*KWDJZB.@12ZLA@?
MFYT^8B$&O#M<%/4CVO+6CW!R)Y8*;</MW0]6V.O-2ZUN*&*V\HS7?1N8=IXX
M-G**CNNSR^9;6ARU"'<K)U'^TJQ[D'- 1#K&'%-H(O7#DPY0Q]X^</O"IA\B
MSS,:LBIM%,F+(2\Y%/KVK!-A3ETL@(U'QC(OI+*P(4ZPV9]?GVRHRA*@LU>3
M+[" 1>K?\O%&\7=1=*>!7-2(MBB[*/E.'>>6NNAIY L#O&V5XG"QL6?Y#;U"
M;8?GD:17^7Y6RP2K 7%#WF?^&LRH6E_)\/F((^2W:-WNL'Z-XLG<!;,_%(PY
MUO8MV/S BV$W@\01]_(S*M$_]20&V2<'Q@.SIB<8O3E)XGW2BPQ31Q% AJB?
MR0 XL6!(TU5]^@8\VZ:=_9B7</L=;)-LWRF-0CZ;WT>*4#4'7!F6$5T:5Z-$
M"X$F5MC96;N$C]%+1VH([+\"U'\,="[,XNX>2\+T;RCCJ[4VC/"&CN,_4'K8
M*/#-NDPM^2R>LU7T\XPY>TWEQJ?240C68ORQRU+9._!\3N#I(ALHJ8;I'%#P
MB$C'8 #0A%I;WF99K2@KH'K<@FP5"[G@&YRMA-Z84L?1I138P35'6E78,?C]
MKP"F;,(2+K)2LA_N/$(0Y=*&.&!NM 4\/K&_HH3T;3;#S]CCC*NY5K=]MV-X
MN?O32%1I@4R<GEN<6R?$C3W3Y>NGH1+^$K6U:"@<[]\#1[N]H>I"B:;K_+M)
M3%$FCTX\&K;@E.A&V','Q^S%(E2'2*D<?44*:^K+32+BBAQPN:,9_&:A_3:#
M2X320<CQG1KX/6;,.0H6K %.G-O[_OMWP9&1G>B"7&L=J(SHLB5>WX"(H/$'
M-T/@J#&P]*_U_VO@PW<LF\HTS6NB&JK\0BW66W7M^G" AF!1(,8!3NO0*:F)
M'>)&5@16?4H4P,=0L*$8C,\PA>)2*6#M8OV.$-VY'?]F>:)H'^6-FA;LG,4F
MAY@KF7?VLE0U?8O@TZ"E,1,]@L]%YM Z+EU8Q#,CGC):SZ,$WXFS^?1W/W:?
MY$8.H_8S/175$JV;#%_ .YK%J[?%Y+BY=:(BA%R=684D12'2P'@I5D1(7#12
M095MY32Z'"(NR$>&489XM=1SRK6"VV3Z>QTB.A"KLY^+/7A72R)UO->A1@OG
M<Z[&U4"0$,4WB00M.W>&7QC.%/Y+E:;YTBGM2=I:_5JV>67%YJ8M3PKF+N9(
M?T)QSD<#' \GRTF=[%B\!4WQ3:_B3:.L0%;&B!:I-?4!\_\4[*[UF[&&8/_U
MX86E;P WK#16"_D9PJZ%AX_5K?+9)5\P:7G^.'D<!XR7>, 0-^G&2I&')=7L
M!W1PT92JN72!:(*Y:Y'<J>\&[+%$(TVOFBL(^..'D/GQ<_KT@>>*8RY+[TV4
M(AFP3$A73LTY'/K*^"G$@S0T-Z\+HS_8.*'P*++(NX5ERH,\O"1YHO06^'3S
M*=KX?LKJ'-C[E?XI$[587A E]H?;:.?&T?\D(3M6G+^FOWGCC"B@YY'Z]F1R
MQ(Z;_9"6^^A'89M9TVB>D9;"M=V-7G3;MQ"D&.VS>=*(+4$12&[N@(5=0WFX
M?Y5+6L_TXNK*N^6;],&W<N#;NC=RPARLN7[4H.\&G_MF-,SN.JG1Z8I*2Q,&
MOW#'@Z)V(EL@#-\00^J1ZS&BAC^B-1V@X>2G%=_\K=&*)-@ZAL9S7'VH%^FE
MLP@@C=@,U26 PO4=T!HQWH2Z>LE%L8EZ )UM!2Z'21%#4E-=23/D.#X*Q<NU
M+'Q->G;3S0Y-_(G1B&F%D).O@V *'^XMN523SGC\!7GRAI'>/7I?%-C[_)?.
M-"*<HZQT4/4ROH/5_OOL"NX&*P$;B7)5D)GM9I*W00KN"!W:6O028DS\(<\:
MQ4[*V(1U0:]!"-Z-X6<"T1O):<CZ\.0R2)_D6/6A<C1TI= ],S_8X=!ANK7V
MS/FX:]31MEQ(JX[" DX;>2<8_2NX2':,S^G8<RJ5GVUZHV^)/<'8&>D(N^+!
M?FDW=\54+.OA[+%@$67=3V5[8F%8".?PK?!$;9$0S@QW[I@'4&M[U%4R@A_+
MF]GA4W)( 1W?8%5).3]M07G "L*@\[WGA6;Y@_7<W%DG[$=42TPVLTNKOE(?
MG/2Y-E$TPY+*V_+X%CJ182DX,FO@@@+:^1$E7TS,AU')[H3H$57M$T-G[Y@+
M7;SR.+RP5/P0M;_V)3Z;<:CN'5.=V\; 4,I%;=-N%RO7Q>.%,5@>#,\"0XFV
M$]K+5LOA24\D=GL>2KC I2":KAY;?T2B.M&.::0Z"R( >>D*ZU*Y UML?<-T
M=;/L7M*NBV&EV@+ZGH,^>2:;K+8(IP*F%;<8BEMZ%^PL&PC=?/2JW@:1/L^]
M]&+"'B\S+*G]5H"70-*QBB;NN(#;#:UZ03Q@P+N=SUK19@L?!6(0!9&_<+RK
M6>:VYT/$D:$C:@O>I_Q15N_VE%ET8+SR[J&] 6HX63_F*7K4[E^WP*%;!$T'
M%^H7QF5BQC<>DDI(?IW[\\575^NG8E1"GP0C7Y&MFPQ@>B!VQ1RQ/21NQ\#1
MAS.=_^I"\[_5=59A44!?NT=$) 2ENT&DNT- 0$) >H AAJ%AZ$[I[I 4Z>Y&
M:1B0&'J& :1AZ Y)C]_WG(OS_9_O/,_>=_OBO7C77N^Z^:WN#PS<SK;M9O2"
M@F_Z"EA:W3IS.A!W7'G#I0$?12\2UN_B4'32?-]V(73_]%)X':%0M.\W1_!L
MZ".:C8H,9V<]OZR?,FT53N?1$#N^='9;>/B&'ZD);@=>[!5HC[KFWKR> TO[
M@T=_Y#>3Y(+>.X!QO-C.$MON>\CO7?D_EEH);4D(K0 /C@HH&I/+5&]_*[F@
M+Y(FSLRZPO'-A*_I+V#43N98],23I>':HF<)&[[Q+-+:N2Q2TXL =:G\XS_J
M)C!I27_KD\0ER<KI2#+^=PN;I5:"(6)45"G<>(F:A?'"7/;A?:-KJFJM/V31
M$KF:<7&OJ69C;(ZX&DS@QO?'.S^0/(B2/@3"N&#Y,?L*L\>3N10*?VM0U%X6
M1"RF6"(7U_ZI>2LZ07I9::+B)D?=QA^29!G4/7DGH??(&2#4NFB3P'63&$F3
M9RX#EL%P4(33'[@J43[PB$?*>7AD78#0O5:[/3E8A'7,$,$MW5>K(Z/5WUR9
M7%UYM\BU:=(([<=K"+._*)<W-M% .BZ=<V^WS3!C^6K,D#6O0*^H!]R$X"\_
M3'Z6%@S9F%I:QO<!X/YJR=V 1Q).?Y\3T2X0;CGZBZ:89PT3^+9UE\@QG$^N
M[W[];Y(5/4-1W+7#!#9ADINBDS 7%-3?]?5/0Z#LZ-KZ<4-G:("K4-M+\]E2
M* (M)C1J8?&.!K.HX*6J#^0[L&FORF!RJ4.ZJ/S^H:C33UGL+']);&#%+2[@
M#"4&$\CO6>H5JD%^IVK/(3-:<7&A<$I#4\\R?)TEI]K&^B.(C@NO__:?I!K[
MR5PO@;G(OVAYD(K\ISK47S34S=IRR#.NKI9G87MCJ_;AB5)".L&.7K>!O5R6
M;'M/AEV+XKNQK!4\3L_WJFK+&1F_5JAX>5G@+WO&3S'._6+T1*/(84C/K< K
MY'ECC4NY5<&'4U/( [42G_DI"Z;&-8&*U8ZJJE(*D*X@./&$X7<$=5/ 39";
M$\-(+.Y)G5&BD1NR[D[(/JC-34I)^R_:GQLC.]:_:$4+%T^255E;8H+/K!*^
M+/%=N;A<:.5?VB'>W\"NF/Z)!MO]1;M_8(F4__=6J^TO6K=7!=U?- DJ_;]H
MJ^LDE,-[122+M_"J/,05:3C(74PX^!/+;Z[*/[L1P+!S3)5O4&HWGH%$$4X)
MMFKA'2 (5_'-3Q3V+TYQ2%L*DCN->;>VP79?;=53WP^[6:B+D[MKR<BPP\$8
M)E1GK4M?+[PC9]O!H<FJ\M.X;86^+^PC]P!L6Z"H^23M-,_OY*&F\G_ 040L
M[\ST T_^69+!(4I(_(A*L'T)IX:[B'[/R";>J<LC'[17H\,YCOP@\)$Y9Z?V
MC?BPN+.1@^L5(S.] NV[(MY/O.KW=)O[S?/2.6D%4CF'*X^-7F5-5[X,HX$%
M-6G&]NU?LVNZTT%U9$A2\^!K@LOWM.1W$N!6!8/?UH \,:XOB8*'$0#;U$^B
M=\M/=,/+3P]IIG[QK4LFOOYUVZ=&HCUJ=G C$Y?E52T2\##2&+X8JQZ(A!+G
M=JT#;B\VWY].L@7M>A6\+Q->?,J_]773XBK]XKMG?]6Z8B_S0W=73\//%-WP
M(*!ST94AOE*^[M<DJ,S0[X4S9!<:G:K5MS1AU*>,0\>ET0_ 7-;/LDC<^&6N
M/Y]9JCWO_7HQ\9X);Y#W(H1:!C$O7:TRFC'3DB*.J4B^^XD0Y73YJ]59J0E[
M!D5;&?)*SL[G;;9W$+Y:#G:3"=Y$_#+6 FYPR^5<>-=&%S];,KUL0C?\9KN,
M/&$6QXX.(DRL9#OVZ9XXLX&WC(A2) W%.:PR%T%P!&&?;(/YVVZ,_MIR/P<!
MJ!V_V1;S_L I$;8?.*]/PHPG=?O(R+/5:#*E&FK*X,1*EK(FB+:\:AS1UHUR
M;8GMH$W5/8"G"O.^=_SQ M,L:YK38>P0=M%ZV/5I; "0%<'KK1GM7(AS-Y,?
M!^6L&$?TUF_.9)*(#:U'!K#BW,NG1K@ ^%ZN>>O*?SH#)S?K?-;4C8 -4+A[
M<-G'&M$Z'%L9*<$SR(1O(YB;:[Y],]06''=H%<O<H,8USGSV]5V#.-5R[#)^
MEY3\Y0A\COU3'@]KY_U^X$C!6)JJV;SXR4(.9F.-CN52Z8BPM.2$W9L.,2'$
M]G" @2RA@TS@4$8N1Z9+K@]4TRDZH%AU,/.W'@/I\U!9=0-JOD#A;/;%#@PU
M/.X4.7(:YV<BMJ-8-LQVCD.?Z,LLN,K+DQL,OG>MK:SE!)LK%B4W("J18SRE
M+*+UC$5$BRNWTNM81.;\2$>$ WK(W$-4G?#D#A-IZV<5NOG1]T3/'%D(%V]X
M6U@X1F=+K<EU9L;P5)T#:=R^IZ>T\HQ6; B0PUS>N"F)>$0_MX]-<JA5G/E%
M09]AE4$]P'&HUF=+AL>,*YH32Q5<QU0@Y7B)2U(3C[0XHH4=-@:/Z].'Q[[\
MH-%\]5#X+5:$G];@@J$&]5N:"ZH3)LAP367.6?S$UH'/<\]V\Z!Q]*TNRM:&
MH;AWSQGYW:TL#9[)QZ^Z>3K&Z) V'27#JH^.$D5;6KSI+>U?+SJ+\R#AS]J&
MG3%=8@Y?(F'C"B/,2X' BT-36?QD_,;2 ]()9!DWET0T)[+L!"P/:V%IOM=D
M*"P.'\V>BSA[+-UBN.Q<3$EG\49%?$UHF'S5D RBST'VI,]BMB<]PQ^%?T47
MQEB\%F;F+.V%Y]'04Q\>^4<)SZQNC"E?6Q?5RW35^#D0'8?YMM:4*Y4['/@O
M7<UE2[S002<$TLN5*2T6QT,_CUANAW /^8&2G0WM+R*',$7%PC]D7)IZ*1SE
MI?U\^T25$\D4R,#">3GNQQA[WM;J?$-A57@Z9FR^GBTYJ+)A8C)PG+TJJWZW
M>T8WI-MJQ2O"9.5BRV6#AJXVPJI=T!*1.UXC>XE$*'SO9WC91G.3CVEA]58N
M"[==XMF?E$)5""'3KUB&<*XL@BW!8LF!(RZ(^,S4IHH6<2XJ=VA(5[;#./ST
MUGF^=^T20=&"=CYE>ZJU0R8%XU?:4-_N/2K=HC5&VIY  @B65F**GA*.3 XF
M]_P!9!*/YISPVL'6C=A6H?*%JF;S,>,) VCZ"SOF+8>QAWF.F,AZ*(-PR;T)
MP74##ZZJX9ZW'WYE0N5; &@\\E6F-,\;H5K."">2A#-A+@JAAJ:8X:HB2TO6
M]3Q-;7R#)0ECHOC::7O1E[R$3D4M7&1;#FY/=9<91?,MVXK%ULV_9PTHCYQY
MY<B+/+7--&T[,@7= 2D"1J7R.>)<9G)YEJI?"*)3%FEHU*".JGM.^-;C\+,)
M*R93HZA [6"%/Z-?80O, [9E :(!N8S^K8X^F"<N-MQNT4Q&G$7FY,^W/0%9
M%.Z)/BXC_"L[PY^?M1P*M0X9Y81.MP$<*(6^U;]OS.LW^,"D3TMTCULO LG2
MME,'0N;$'5,<W64SR)7'I$G0=2*(3@Q-!C*UE8?Y3TUM6OX(\WTPO=7#E?PL
M?3X[$#D[\R_<MEM9:AO>R._LW  I-P/0&NJC/TV69&>E3E"[-DQP@4<HX]4S
M7)C?8,&>405/JOEF[8+A.0KT SFI?D2+-Z?7'>8.[0>U$_YXA-\<'#P9U:HT
M'#G<Z!@=V3^/=\2*B[)YVV5$:> -<'[TF9@DO <.-NR/V#'V\8X*:XMNQ;1F
MYQ!E?"@RXBA+$48FOOP=A]MLM/)2UNUY#50T,'EN04\D=OV):>66YJ.1E)BG
M'SJ^OJ6$W0=9<5--CS:W+LP[@"+=]JQC0'GR,_;^G! 4B+,R#*8=!R(W?PL*
MI$AC@O*G"<]HHQX/.>BHYX+.-0A:13[B\L8X3-I?S*X3NW25E%[;OJ)']V!N
M;D]1MT_1)4FL&"P1V-#]$\'$AR9MN/^KTN1T*6+'O=:S!D.H&/ %?E#87MX=
M_0B 8U+5VQLG+P:XF9M3]RTTVS^>.^;9N6)<U5^.:&E\H4)+BVJB21AKS#):
M^?5:,)*F?R[7FOB,KKF;92..V:R].,VIU"%IPIM-7IN"@;D>!5OCI#:4,7L6
M%A$\9JH:H3D]R2)/D,P9[P=$B?[XV,;&>!<B1+_ZH0L:RQ<T76;P^./KODQN
MX"\-C]9"E[@@<BC=68(WQZJ1Y3E"U1:V;;U-2@;O1PAW3.%^D\_!S>$$!)5E
MT/YP<FQR='X\7JV_W%:Y<J;Z:6M<<J0&7P(@>6L[%R<UX.F=6U2J-0B3^GZD
M%=H">90*T*O4PIR"/(MHFJ9:"S #!.)F[VR[88MA,0ZK7MR:IN!&D@DN+$3D
MX+;>D$$6E>@=9'ORA3@$[+^,#5@Q,)QA*T!V4ZGD1PZ5Y8H'/ C-54:-(39C
MATJ0#DZ)L'6(=)CX3%(QJVBF;!D>,<S_6;P_A$!JHEG+=#!62R/L5,F-QUQP
M(?W#>@*PFX.*S1Y)SV.O? 9NL/CQ>E\P;L*Y):]\@3OYBG*AD&CL-;XT@US<
M4()\[)M- 6$';V477F0Z2VG2Q=&0:NUZ6'L+J*=\1_N\Q5K RQL2*? 3DWIZ
M-M4;[#,_"<8; &Y612T'3S%$"$BVJ(.-=04,?]D!GV4=VC0!4 N$\'A*_-"4
M#KZS./"?=:"QJB7N!0HFD.M] Q:%!CGEM[J@-C?%AG.MQ<Y&52E5E2EB/;N_
MWR78"35]8;9:CG_"6!DK< ;78??7UQVB_@VQY# W%,5%[I_;BUP?F#1?OMB?
MVZU%&#XE:4XL *\&O"7VXNUV27$*]7.@HZ.,"%IR35U7S:FI-G;8NBB4)-%1
M-PUU+S;JVD-[DEN&@O%M]C?DDY]M#L=Y%S0(E=3>Y%Z+?Q0Z%G'F3S'AYN1T
M^HYF@X[VC-2FGG3,R7.Y>55#]V![\/_F2B"-;5N.MGH9+L3[M)B#UKG:!^IO
M33><ZQP[\0>K6R!.,)<%T*^3&] 4Y]<M\/# (7I[<79]"W-+B2LJ^YH_Z?[Y
M3XS^#\XRG+/-WXG=+L>C/ZU/4+0ZU7\F<\$K/;12H^=:W8&FKVGY(OY5H[()
M7^)[G(_W6</Y;6WD4*+-3?)^E\U^E[7"5;\;^%-0?W%6.?Q0<R'*71#];/-]
M%B>_HH3KU%S<[?F%;0!'/_5D[GU:+IC](M\K7^SB14'_(-#D+QJ)JQ@=;FR1
MF#(:44$[Y1>GP)BYR%*AS]=,T%#9JB$K1@I'=G("/(J$",E'XL:?0B>0=Q?Y
MY'(-<9MB_0VY;":VK\R0K?\&&O:#RGUJ+'ZBH+=_T:@[3W8:C2 %Q2Q8PRU8
MZH1IFX=I99OD4.D%*-_9/P- ^1Y<OZ-U=5Q+ S/$1)CS8"5N_[F1QSE6SDM#
MJ_;>VLSV,<+PWJ"!=C8OT02!&$S06L?)JVE9IY3*KK5+-@&4?!I*J^YG#E%S
M7J\;W8;180)?E@Y!)BT:$XU[)H^<CBNZOSU^6*21JG;<AXXM7DUT7X__9A;N
MO0?$9,54-&KCS^R!''9JX\B:%T\?"\<L:E,D%9BB.H7*4**7(A2)7 6,V'5!
M;6696@3_A0(/;T3[?=CB8R[T>$2Y GT(AO'9&P-UAT^3P4EQM^3>&)8[]$H/
MXWZN'Y\8$+SM!JG1GT#JS?D8G_^BM4D)7ALH44D7U=C1F'/(+$GU</4XU#NI
M+\@:*AP,9 ]KZ$-(#"&EF*U=$U5 8:&-+]ZE XVO/C!'PU6LL.XQF*PLLM!/
MN@_SSA][ G26%""?ABU+0&S:D-:X=;IC,)N<2RZ3-%%N&074.7=;%.829RTZ
MC/,R:%+JYF#>Z[1$5*$@H&]?=[9I;LE23W>C]O.'C$<V3[BN*D1=$-1Y/%U]
MC4;%=R^A%\R6Z]ZGW0LB(V>(+OJ+AD_H #6..V ;W6K41%2L+)H^^!!=3 .Z
MN/9($-7W8PU4XI,6)21X343T"FJ5U7(NU9@1$RM^2]Y=-LACC6A: 81HHN/J
ME,M[SA1#@?0[=^P#^M&18IG&H,!'O)[&E./_WBX1]7MZ2NVHQ2\9H0Y-7];Y
M(62O]AN5YTE@.+KO27^%><S+!6)S5D0,?R6J#WI&RQG\(7'AU6Q4"!/+F$!^
MN5[Q<XLB(Y]'B8/["M?_AM)QVK:PM^6D6S*\D\ 5GRLJH9>0/+?;J(G->-'"
M\Z*O#:WI#!FV!SBXPR,#30[%FQ ^N%<$4;^32NAZZ*RAN>S;4^_=A6>UV!T\
M=E<YN<?_-#!SW=_]Y^AF@)K?IT*+Z,)2*"X7YT2V@MH!=<'KM:B[4 N#RN?<
M2J*9&FMEW?>[Q6W_+[G5PN'S5PX:R5Y#O"7*?818^PB9FZZ#9<\SG>6%216W
MRSVOHD2F/^40I="CI'T^NC/3&"<QCXBSE-"+\Y.CBZERC\/\$KW1)1WI\>DK
MQWF$[Z#CV6IZWG']EFUDPK,.&MS2\LMA1/UGZD<[Y_-WR*N.'XH8Y=R+:T].
M^/5;?2G\0J7@CT%.)Q?JX)JH)[_5_=(97/ZE4)H00JI4(8)%1V#Y.#L5OP5+
M,<OM*P6=:/NHI>-UQT+Q$F4C4=/9\<C&_,H",@Q@;"R0BNZS#_T2R/&;20;I
MI4E::]KF<+HU"L9?8FDP?&/]?I*-H!F->T-Q",;2>Y?Z>Y*QQ+7?)1%U@CIY
M%$BD^WV1GXA"G?S"0TNM8*U@W0[HQFKV:W_4;?5,-#K*"V#<-L@#MLQ$R"/F
M_""*K%O-OPNI,UCQD5I<22ZB#T@"H\E&M!9<7]&L<06>EVST8SQ"GU?-%#L)
M7,K;+LX4[*Y.JHU$3#U/ZB5VKO2F-BIOOG14[B-]:T$N&9DM0_GA("%6<SU$
M[<$ GDE=9([GF/N/L4Z#[>WI^=%=P!NSOK=*+;14 D+K\?@V]&^F\'+1F"!=
MTTC-NO?J'S8[GGPK<+6<ZVB#]E&_$^E:7>(V)V^M);\*U;9:15HR3+1WY7(_
MH\&+)KM@_Z[4U1'K3X0-%4#1^=]>Y)],YO]%0^&!#96?:W<LW_D\&W$@9E>(
MH7!%&^M%-R6YT%94CWIW;/:1XY:-@B#/CL!T=(>-#^O)E$5M=)R"796P'C'E
MH0RQFV2OWXUA;"LKO88N>.6%-LD:>BC?UT!C9R47F'\?I/9'+^7P5/[^T@!I
M5$$R')R^DB?2Z-0KT=\_-<0+S4\:C;A8J!L/IV@MTWJ&N3[9 QR6]5NP+QNX
MQN&JN4*-)Y]?2@EJ,<P'B'ZL"W"=$9=L@',.MJC7E4SM?(NEV4WZ-5H=$L5U
M^X91R0.U@7>7/!?<8.+A.!R20>%BH.T#L]-JVM&.>WRX?7+)I[OXB_9^-LD0
M&R/^H^>EPAF6BM3*LO>-]7+UT^UD'!CF=O\ IHYHJ9E(_V[% JMOM:;YM>].
M61;$ CK,?ER9,/#6Z_E99 P 9@OM',+T7AC-+)//&OHG'8;S/GC;]P&4?5]N
MG._0AE[U$(\"78J+^ UGG65$2,5=D4+M"W<WEW?E]Y<SNRO0/:7'$_R_:/;%
MAF3-K6^6WH5K&_*%*= R?Q@@8M38V0POER"JWU0)58X)=6&'-#'@ 1T.\K\6
MPG(P6[X'S1?T2#P+,KY+^<HZMO8>#&KMM"MY_=\E3/A4)(6S$C 1@L.B[0&'
M8E4M:P56?&C3)^;O,':NK5CH')P/ =T]?%#@(2Q0^RG7H5B"#"UM ,61IZ.-
MMW_G8K:JU[R_.3^IT.K#^\HT&$N#ZGES09!IB:13XPKPHK1]YW)2G(CEM%\A
M9CJK*%5^XZ=]%N=<XOL_X6'^,'^PV&0^.=3MOY9:)^;'@5%B3YGWI[%OOJYF
M1^$-Z3"1@:8X:\;,'#+H$CZB?\_,8/L(^L)F^4E(+]R ]86ZJDPM(<^;P[-*
M1W^^DT&/LHS/:CW!G8U$2T\_V[G%;!"_M!>RS<SXIL)GG+83,G(=V);(]>7@
M4-V2!35L;LP&<U[V7F:+7HR/&*SL%"+(B+LDC<@@->EN5<$Y'@_<(W?+QN^^
MV(NW45S)M(J,&6D2)/.=<.(+GH(LWI4/ATKQC,QP\%@LMV14"L!.];5@R+=O
M07WO&Z\)6_5?O$HRMXW"2XA%-Q"Q?*OJ6'1^=E@KOZ<&JFYO6XP:L/=XJ/_*
M'[8YVI HNJ[P=+VW/=G]52<FX5>QR4%TZWSU9QQ]$F&;!S*H<?3KLZ+2:O^1
M6U<WS:;P!B&<Q-QMZ?F.1+P*;YA BN_5[&0/$@C+)!YSE#PCAP@BYFYJD)RM
M:8^<!=Q@=L/9.,L6T47].!2%7*Z<[KH*E%_U+UK"]9\JN9SF72-TR=MT#F+^
MLY< !R']K=:OF_5G^\4H3,#Z:U<COAG=!F:#P%=9 P*\01N;HPG+)3](Y2B]
MKM_W^-)+N9\+'X!6\](74\W)(AJ1[]1!-]2V<86J*JK'3>$5.UEZ9+F2!VQR
MYP>0;4>1L"H.=;ZXTQ(W Q<UR798<MA<Q*+V >@79\$6?UP9C@^$S=N%BW4E
M;GNY# M*G+L-^!>^DC]KK.[INJ@*^TZ],2M=P:/1+DY*R.!]C*KF_6)XPV)W
MRVWBSW<JL+GT]E/$$L0 YK:6_R_OQ>N7>HPVBP-VM4;K(T<)O#^]+_UJ(5C(
M!]7@?]!?35BJ[C<"*ZHEIT\ /9LR4OJ!XU\W&_<4KB_NO+:#A$SCV06AVHQ,
M1\J@<1_(-;5J=4?<)D5_C@N%%FGNINB_!,PV>?2-N/;I/_AW_OK]NIO2 O_.
M@W_ DTMNT#>!QV7&Z,J>BF)O$D!Q73,V\U:CR9@ZHWJM>3<?DJRO.4=]E@0O
MQB=DDH!*P3?6=)#1[TVR10(59'1CE'Q*<%0((R]<A6TE .D@50_2?&%?F6!K
M5S G8,BI5>?.;+ZO[^I(20+5I5W0-MN/42L9#YF#_5"JRN-139*S9>/')3 K
MQMP[SS>]J,O("W^I42']S?])!<FTC]<V&/\\@D^U7L/;@28;A+*QYG#MF<;_
MWN0HDU>E+A/8*/%'PEC,M[\:GX&@M#J=SS.^Q.03Q?6I.OX[F7R^U>&ZV<*.
M*S(G"=9&IW#DV][D=%*P+D1VZC50C^6U8TE 14<#>Q+7R\.<M1>-#$.ZRE]B
MQ1;A;0WRXT.2]Z(#B6(XV!)_5GL.*^;QIZ[[?\_Y&*U[VDVH+__6T#0JZFNQ
M%5]JV7BU@J0.Y>V7+[N6AAO_^21M)W!:EN_Y4S:CL" <.^.P@OV+1G[0Z_,F
MT>-A1S.IKS3EQWIV##&.CM^O.O'A;$RF?7ZO?LN2'KRE2=XUBDH?-C2V7#!.
MDW=V-6P>PEMDQ*@1&:(0C:1/LA\_V"O+6'T^SF.YVC.]#S^@4=*KR@=ED9[1
M&<X^_#X(909 1E8,K>4R=</,-\;9E&KEFH[WUT$OBX?XB]9>4*8M+#A)F9CM
M80Y,>;F4_3*0RCZ*>)I?VK!D3V#$M VNDG+*$G9A?U?D ="CF6_RU.4-I2("
MC2^Y1S=3;A3,TBN\-"=3;FW!:(Y<8<'WM(Q[S5S6?=P@U=9E_*5.K05W?-^H
M& =9.(AX5W.@A%@@.F _(FV:N<#6C9[SLO7Q$D#?SWD11EEI4G7G.#-Q!:6D
M9 2,8$8F>CV\FSLJ6[VY/=@.@&KB+:Q,:[#9E ./Q%/E)TOLFR2 QC]<#Y3[
M!9KLJIH->R,>C!F%-VT-CZ5,I#2)ZHX#JQHS'%_T9ZLRL4^J.3-'!ESKF-I[
M4!$X20#M3W<].<Q\;1>,H(]U1T1^6#;[<VN(NSCV">-D5P7J6KUC8Y<IHQ*/
M,54WU@GGO(1R-TAZ+0'O..^ABH4_B3@I1G7WXJC3JA3/V+K+O-U.\,FWU<6<
MUW6&<[OLDMIZ5%U3W#?>-J%Q_)P$CZKUK7_13)9+=C3;3@</+-6+MV(_=?Q%
MRQZV27<_77BSOF&AOYZT:D2T)7A[?I?._<#VO[)8_ZNS5775KVJ+HV2>-R2_
MOG@S?2+'8%30*&41(_79@27I*!B-Z:T%QKOS@I#KZ+&36O$2CMV?,_4[_"&A
M 9!9#=V:X[NXV#A+#_VK%(0EKE5M2&<IYDC99&U,*(2M5"&4Z5,32P3(06P/
M=E:IS(_YRD4KK-@CY/V&57?,,>?8TZH.HF%U[N0<$)'UVZ2?5#&.T1M>[R ]
M4.JQ;QEA)O[)]3"ZXZ1(RUR1R(XD;_ ]2 MDF4K"E\8(NGKJ1[/S>_%KZ;7>
MFH2PE%G>8X"4GXA>AI1\V[KG!3F6"I&V0R%#:+%JEI'@)6FK8EAYY +->)0'
M5F-]23RQ8 4[!!W#JVB<S*:,QOWG+)Y$U.FOLSL/<?RKI4WWKJ5O,TW:TQ=\
M7XG='%:,<,4%.MWT!4W>Z;E?#8"D&!M9:I$C=6,)MR FL(3XF#.&BB2F12$]
M]N2O#^-2VC.(I[N'[@-!8R]6RPH4EJKB^-PO=($J8:ZU I$\Q^PJR&((_SMY
MEXS8^H Z,+9)C:1[S*^L'$RQ",Q^RQ%-M;%$BOZ3-Z;7>T'23XN5\,:CENK
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MCPK4/6>;Z9-\<#)<6N:,T"S[':(,T?W4M918W'JTW7*CO+=M1WPW7^U/8.9
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MU[J]Z957MI%,^K+1+R@.A[2G!U_'B'W5Q7)G>'-^H$EIB6]%GUP$51R=S6U
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M(/4LX'#[LQ(JCD@8S-'5X>?]Z57.'G'*$Y_9ZMEZG):0M46>VOSI$X;0-'>
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MQC*5X'GKK\L^>B<W%3Q_X?!1O'XH+:RV)"J9.VD!8TUET)L23,XZ)>+\56>
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M_6OHA=KO"QJR27@.0;(+UU\GZK#?8>]^A)?'<[/BL31X05=3%[,R%L]^+*%
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M_LE(8\'7%UZ!,<I CS\CZK3?8<_&;<P>461\UEA&]R<TD61<F12*,8 7$4Q
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MM]R\>G(&__.<X;]@B[634&6KI<]]]1-,K@)0\K.,DE2],&SK" <?4.'T&HE
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M13KB_Y,HD=Q*<QR,ZF6^K@!T?3LE.=6M<PF9C#(R5OOM[9;K+,55%D/)TA2
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MJJ?4Y@-URA9SZ7*+-Z3V+@H6<M%@.YL12EU%MIHO+=/:NY]BAF,Q*I]&LOS
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M=0HZN>@C&-:/KD9D\09\"0OC@L?Y&_8UA>\FO2[:E881 (> ,P[Y^MR^;S!
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MVK11,Y&@B3?N76?18YU%.#:20+5-JCS=#OX/HTWN<YZVKAD)ROZNZX<*DGU
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M^S\*P:@E*7;FR/F?MZ=3OO]MYG^T PZG(!@XA1=]6.7MIL7U:*@Q<[L[XZ+
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MOR^\JUKN/7_],.#F?E>VN*#.1JCBDJ3S[AYJR:,C+I&LE R8Z)#P.O937+5
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MZP/K*'*-=_$S\J0KBU_@W]^O0R^?8M)/ZMYO?#&^TMYT@)BH4(2RZ60)M73
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M#FRRE!IV=_$-S[9:(0-+\Q&M\7@\@Y!;7L22AL[X PPL91@7'LX  >*S$,"
MV >Q"8-.<-WZ@@SWL1(D@,-Z^#\ A*O[>+>H_V%Y*(Q=%\C_BXI'XIERGLD,
MZ2"1]VRLF%$ACB?B=/WP0E2!\=RW,X876ON/5=HH:FH2,UP,:X^"=Q=+[_$W
M:X=-@M$L_=)01J7Z3GBTA]F[$Z @6OR@XY>P^I.;UEUV@_@71YK-,JKB/&/7
MA$"H/&&=D]@2J+6%\0>M*!8TO^WD?L?W2[ER%06KU%IYY6;V,X'T)^VV<W)C
MP@73L/])V3NN=L=?67[/U^:>3YT0S?_K T':;=I/M*_5>?F2=13OW7EM-X&C
M"1(7B?];@:VD_4M"WES5%*.M$U:O1;NJI2J)R#V*ZA9IM8.4MGDA<0I1G)\W
MT42K9*'!1(W9*OMA;0KO"MU:496(E@3_$@[NXL[AMFG!6[PS\TY/_CY/+IOM
M5VP(](,29MFFLMD5[+O*X(8+YBP)8@$CPMM!"JK++F\TV.S<X?-^K[CLWW7)
MU[4K7_P&JI]WD5]W8WM-6ZKZ&7_S(_%IT7$&#V8AQ8P.\+E>-N7*4C,]>FZ;
MTS?1C3'(I$G_=&H$51X (Y17-3;:=>'7TI;7)JQ=_GZ/-WG('_1.Z7Q\^MWR
M%.E['>Y5_-,3B"@A0: _I@+S')8<O.1A_M"%_%,F@HO$B0D^7D)" KD>OV==
M^%3XX0SFT)"1*__<??G'+Z;)-790I@BU"*$5G\9SV!OA'31'G[?.6&?T->SA
M%=^96!+YP' H?_GV 1-%[1\@_<>*W%RVO+@W$8)\SWKN!]Q#:8SMWPZ6$B..
M*L;PM O&U(8#!QL'\X5!OBAD:?9/,!Q33WM8 VRKV1*EKCS@TY<,E!]?_\)>
M;I[>><2K%,ETO9%I9ZJ!*^P"1(Q]E^QP;1RM?W]="YWUJO2(_P,X3HBSI)0+
MTL09Y;,]$F$_K:<B0,]1[5&7!G(YQH(LF.:P/U=Z,M9H%^A.ZHVIUEJ/$L[S
MU$F&NGHPI+(455(RN=99HGR9!)X25D:B/=MX#0'QJ$7"T'C*DX_&52&*1+IT
MZ_KK&Y6Q^OWG4$D32BB[).LBY>?\U<'ZZGC:0&S3+T2.M/*;. XP7#5?UV_
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M/P/_R/@-Y=YK?<AC],7E?P+)HUM6[EBK>Y=*;_^L)Q?._M5_E6+P^C_?^NT
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M>[U035M&]VRM2=:])AV1/)51.K>E/)="@\[5RE)89N#; YWA'Z?A9<KQ+1L
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M9TH$I]T$C%_;SM::32O;U=N6'Q&LL%JB@(6UYYH[2FH9[KD/TM#_!S 5DE7
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M035A(4[R>IEYS9"\G+TY(4ZF7Q^$=*&@,!)4'L"AZ-=PML[ 8/PL$UN-FH&
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MV!K(1\==QO6<-#(! 8,GP+-8HZK+TD4.*KG8$-1P.)8U\=HX\+2$?U1PCWB
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M .!>8M/@'/QZ>,I([8Z "9K-F6H *'(__.KB<NEG,H)!H6;>#[!2FI,.4G^
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M[*<D3[?8\(EL05F^ ]J)KB8 RL#> -<I[O4YAQ%KE%&H+%< \>E%$O%<YPG
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M0NEJ([3"M"7AZ77X6+X9);GLM#W&-#&//VB^A9D&";^YXLD>'7!F_%CHR&B
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M>S;VL^]N/A^E(]H8]PGKIURH_%J*.>HY>4YE5YN=M&P<YEUW12'*F]9.1G&
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M(19=Z:B1F%BCL?#'Z5@/B*5'Q^DWNTQSW1)EMX!JQ"N? -,KJ\P)2AKZ>#4
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MJ<7Y9)4BV.=O(2:*+]>R,? R\L6(3"AA8O0/JK(&SY8>FY7EY!U1OTY*;5*
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ME+5KZ#!EY_@:P/?Q*^5?9,,Q-$P<I=H*Y?;2<K?HS?3LMK>$5H-VAS5K?$-
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M?4]N>9O@>)JRDV9<P7'O0QX 8G"$_7SKGJ#[NMU1A9%+:Y#+@GNK5"C]RNE
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MQH.J*&[+2+,Y5(C[SM20CEF<E)AH\S/%&0G@+V=+F8P/!_"^Z2T;7!C8B@R
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M)70\.+=JAFM8V,WI8V:U@3<KT-=;9L#7S?VBK8<U/VORE&.B+^+VE#_;=<D
M!;J> 2]7=(^5HUC2TTA09G!PEQ./F&X)NV8ITPVVW0CYL5M6:7 38#U-[ZP0
MG8WG$8TU3#JIVBK-AH6XG>JIEI5V]+S)7E/M#?"0J/S,F*H81P2._R>06]O'
M%@ZIC^9>NM=(I6Z2P<JX!\V=4M,*"/:(PI$#-(TO2;<@395@T9SY%=9I+VU
M#-L.))Z504ZN<M6X5#T[)<V:9#X%E= W>11HXV;4F[ J?EO.5YO 7[YV>89N
M58F5G'*J*"@65BK;6$P^%DA$AL6TWYBF(XQ3X2\CBCD!?P8X2L_PPC3,ASC8
M+Z!&C=!]E:(R_M*Q]'TC#2L!,1D\-0P?2USZ7KT_(FXO6")9R$A/?IS8C,M)
M[,-(90T97WDG8>.P#K 'X1Z XCS+A ('W@D@('\<(,:V_(IH E@'G.6-9?7V
M@^2%C2.2G)%$UN(J8LR83L.]2;#:.6W!GIK1ZS*LP$6ZW NN2F,8;''KKGHO
MVE(/]IEC;+ZZ.CP(66(#_75EB37]"900.$GK&JR>)4&(C-/$3Q/XJKN'FC4J
M)ZF17T+."R"A'D2>4=WVSK]7U: YTW<E<CEJF#H/J0Q%DIJAJUXGJ)1"HLHQ
MU.4R"QD9+;&5&9E0:0R4:TCX!+E5SLMTYL,FT[[GPV2A45KZ.E9;8%%0M)15
M#]9'E7KV&I6/8!\=_I0T=+ -G$&+]DU)5A$XVLYD])X7+"B&2^L.ERR.M=2R
M+HC,DF\"N$8,B04!%0&:4ICY^B2\V52^<SPI\21C^S789+.3BDS/@ DL>MZT
MN'PB'81JS!-KP*K_UK:L_%>]OA2X?,0"!*XI]]UTKBE?6U<?R@02(FC0(./7
M=DKA3R 20\K:X"D - IQ:(_!!6$:V1&D25#GXZ9M3PZXWB]D%TDA=384"SZ>
M\D,&G$:BEG)P"T[%*"U1(->=T@%@V%=R <;0)X.9.1$M22Q%KFQ3H[@$FL0[
M<$S4(0$.V#T*BN)V$/'M1K$8V3K-SV+>O5*42?BO+U0JV&FJL)"L$$M=%M8!
M7DR9 1"'BH10._9==MQ UIP*!SN' )DI75X&7TEX44--.]YV7^WZD+(H8KNM
MR6W;ECO-R+:4+XX;J:T09Y5O(0Q+#E.Q.*8[/AVC%AO/;D<VO+!C-;:U34\Q
MV#BP SMGMK(QJQ2:/D2_E2,6MP0VLQ=!HIP&P>EX*+]B$Q+.&#!NXMNFX9?3
MR2KD:(S6.,CW"F.1Z4;*W+U$3(K 3DQ(Y3:/QAM\CUSXMGSF@H6H!GU*2+8J
M%O_BBZ P (:9,,WF).0N>J_B$":V7LZAT [Z=)C\\NCSV[8>7LK'S!\ AH:O
M1#R:P@]8C8?D%?^9+*CP9?->RN/IQK[LKUJ3_?\QX?N_[,'G<S.I\+;7)<(;
M!BW[LPN\ZKD++M5*I!Q)$:2L*[^R6#(GAX+CW 6E>L;TV6$?*.-&C@1-P5&N
M+],/WW@G6'$=##?33VS.Q=&5X826\7O44(HE*ER<3;J[;*M,NX,1DORLJFQ8
M348*ZY*DY3/ 5,/XY%K3BL92)MUB.^-)W2#C/PY/)3W4@Z2L3+!F6*8</ -\
MXF)]Q25VWZE<\RYCYC8Q2YG%78HYFJ+&*IOJ6SM"T,DG,4.]41?I?<#Q8B2D
MBET.-:92CD*,+^0K1R8K!P>GZ:HB&(23Z:\J31;)-:P_[> =AVTX1"=N:3->
M(6L<"S 5VR]]- 9SK)&\.$UR>-C1OIYXSU^T?Y:1,$^C:PJN7Z28LM &:F5[
M,[&_ TGRQU.QSZ#O&O,A;)9,1E0GZ#YJR:Y$ RFO_\:W7#XD=#RY^Q7'J+ J
M:*D*PE5*F.S!<J79UB!?%3FB?VPB5 L560) 1?("4/1DBX[^9=#S(V3DYX'2
MTX,@2LU;V6)4D5 ")HK1Z!W[]2IB,07<I#2]*F+V/;Z?J$]8D5?!LNL2)Y*.
MO,QA=]$*TOZDI.D\0EGRTOK.&]'>\Y^TEYX!=E\^1)]U-*RH6PPMTP[BU8XF
M&_%\7NU79>'90O40:L@;V&*G7%9V^X'>@[%#.>F#9XUI3DNH51<E"%=+,_5O
ME_CX*'3",(UC'?3Q!;[YJL.$A_-1H.)N5,4:Z[%93T<@$6'=ZZ^\-&?!53V1
M%/.0ITC9:=^>46>L>9$PCSF3X_-AM<[ N*YMW*LJ_ '==WD<!2_+$L>2@@#)
MRG$\+6.TF.57:2$L1Y])NY09E&^8ZNZ4P)'>59CFFN&@R;) :__=R\:G:3\]
MM9WO@*H%(5JI*%7AOY"TJ#33$%DPNQ/6;^('O-IMAD]:_W_9P!(#]*^"'O6F
M-/.7"!>>7$T"_[FROTMB 1%Y47)2IQYU5%5_30S=A'S4C[>P[U$!V1E'/+A[
M**7-JOL+NVM])LCJ+V)C1<JCE1\H5N3&N&Q6ZD)UR;V/Y$O;[J11E4E^5]I?
MHI,SFD%>* HFZ9=\@R+?=Y.'QA+Y.O!HY'SJ+-N%A)9_Z/SF;?F*RO+4Z'=+
MO#E3 $N\+XJ,>I6(V ""R2*J.0@S4Z$'@![18U6*8)(NI"H;A$=B)*/E)5BX
MT?@ XD.=N!',@&K,AAP'):VEM;[^TE.C>UF_:&PA3-^UU_,=8!?$%V>(+B[K
MK%A=RBNDV$0E_83+="7E$?*(EH*I=[O2C9U,AO U&X5ZAD@$IT(6.])E'P)O
M!'#=1VI-]+\G47"1I'U#EHKX0% S\77HBU3XWR*BNYX+34O[$!:M$OX<K5]-
MKZVL<5A8.PQK@86,-)1/6"CN.1\_V[8Y,\)G,64(0G8VI0+-W[@T:@61N>:[
M"?DTHMYVW:!T&5G\3+P:GBO3VJS]\"&Q)D5QF2"XQATQ(>;@9Y(Z-??!16@)
MB9DGD:/L^NWLZO[F<8AA:6J$</Q/FQO]:P.+>5^&5X;OGP&WH1=XF(\?]E<3
MQ @-'MYLW$26;?Z^G>C_F9>7D(^6L-%]0(4CNB<$#/":/U[\([_\#!!_W,GB
M=6&C[PK>=.E#FQ<XN7$6BPQ[82FG]F$"T?'V [&%\V#PNZ2!H#+423B=#.M6
ML)UTG6MNY1-UX%X[Y8"LT-O]/O>33H0!3\RH\EO?$"+J5C>.3"RG-"L46H:Q
M\LIHRM',LY[>@HM;:]&?=.:15#VHK(L60A[%*H4F+$+%S(+]%XKF*APR1MC\
M;.@U[&HA^4J;O8\E6Z8,9OP9E+I'NFECL(HTCK2<.>),4, (H2#$5H$=NP&J
M5<(I@,J<OP;[S;JK)U=D)Y6(@FA_\5K/^T(UY#O'1$7/5)RR(_@33A8LF#8)
MJH.@TG!QN)?3-,^M<L]]\Z>;\%N_#I/UJ$"IKOYXL31)U=A'?NU)7&&M"+@3
M%D+9K^(LM#&0.DV3SU\N>R4-#KLG.:HP$(&\;Y"SXV\8UR:L^*ON7%0G5)!R
MMCI9^'[V._.!D^S)#_TSLW;MX0:TJ5AK:S,A!VTS$@FFJN)Y(%2>7)GC$E59
MI]TM\M3$.%C99"!'3UAN3R-5MQ*\W=<,R6)1LFZ"5%"F2;"),HLB\V^P0;NI
M.\^ 9@TJ ^'"C\!>2.DW8S8=)L^_RE]26#25O?C-D]SVX[:Y1G]B=XC&I[N]
MW:J^\VA*XR5S!WF0Y7N$F%L\*+**HB$(MM"):2F8@WL1E'55X)G2"-U_;$IZ
MMBK\**6XN!PYCB(6(PM&[8<;)N'$=KKC5-9%Y4HW6,CARV5(AK.CY*H*H*)&
M$1S_"B%MUU*=Y6^K5?C.>!>XK2!&@'& #@6#[F-#MGC92!)VZ+?C/RT89W%G
M-AYC\? HQ<\=R'SG"A?5!J0+.X;C53"&EHQ%;<KOT]GL9S-NU2"-4*L9DV*4
M3,-UNWAS2(E5Y/.0.UEC\E$ RD%>C"W1"O;,JC#VX@YV3& 0-EK-3O@4,AQ8
M\1;GUQ=HA$5F$H&98;+ETA'M[I[)*,NNL#BT))6,3-&21U8K@J1<1MR7/8LY
M*%EF$NI&$@4(?Y$&,M+% D4#B5QH#>^O8THF8/.LEF1I+.9)<%,C!]D.X0IQ
M$N%YRI]7 "P,OX@/[D</#I&TSP"!2V)3KU3O[$KV9#QY.DEK0)\$3:ERQ@;Q
M*<T>$(A1EL'Z?5/#+#!918LE%_P,&*N>V)SO[_-%*^\D\]2=)PO+9]OC#Z('
MR8/9"79S^YE0 0"T8]&"SY!7X:#1K\U'(U*?P$0:!B@VEX7G=4QHA#ITEF,B
M)/NR3$HH !(JW0$9]W4HD]:F\X!TP0B0$0;7*N+X,/ 7!(*VY'=IEUN5GGGS
MR7[D@'#H#C F#I UO?._K)![, TMJ:,;R+C@9]+B\ C)Q&/"6,9T=2MH\=G<
MH<)!R[K<A,3HGF-IS0M04%!<-^E]7#A/2=F6B032B*2O[QYL7]D6:KE]P0J>
M5)CCKTSC%:_$"K'/R)3:S9&1*7G)%TF#KINDKZ("&2,K$5KA )1_B@:2CO:?
M$+5'I9-FR8HAD7$#8'+VI"1L$0CC9Y13Y[</PFZQ3:2(D JNF,%#=5U=R"B[
M+#& WR%U0TR9AK*0A;X/U-;/+4T5Q7^ *C?M L\W##4/-*</8>&4FZ7@MC<F
M0X%.RZ44YV(Q)LE>)7YE*O__!#XO_%]0@F>VL$K[KR,ZB&A%T2T^F!:?AG9F
MP@$[TIL6"93N_#GM\>LS ;.*6GKF!*YAB-^/OK.BJT012L!VL[TXE=\YC\C2
M_F,"VP;,F(TL),PA&D\U]IV,2K),C_1F7$]04 1?,%[0PZ'4 ^W*G!Z/'W04
M6G&PG"(SSJWO^CJ#0=HU<B0%<L0/#LF*Y',K+-2-> 84$\@O"EPP]@)DO(GP
M,,2]_GA\>I36&\<\J&M/:!"DEY-NYOO7_7E:\HR@8U0&9Q#US9^R\U2KGL5N
M2$$DKJ*Q^WX/AN_FF\58)K_$;2[3R/QSYL6F[]/Z+&[>@DX*8]19!J_N4PXP
M-]8$?EMU^CP#5BP_[G0$GA[H?%82$2Y/0G&-Z',L$Q!]!HS;^1"<63'$.2$B
MA&DQ%!0P;^F"A$=<J.B;+]Z;@:X1_=['E+QS:J$,7V%PJFOW>ZEF-.7&AR11
M<TRGZYZ@"#3_/0 PL&O#[QJG8LUN[=#N81 LX1OZ+?O/WZ^>B=,OUZG]-8L[
M591QVK1FJ%U.R_=\U#%;JSPXXX(1;(8EQ/LCYE)G%V_DO9GYBJW(3N\I(+8^
M?XUZ&IVF)KK5F:\8GJ:_:#U^7$+=B_,+"^$!AL^JDPJ(??FSR/Z9RI3D])6*
MT/>BJ__:.N;_T9_T72C>CXA*UZ '0K=#<]K(QL6U@"];RO-H=,<5;T[4%C:O
MZ'-^'\URO-F6?+@?JO=<X("OOO"H*]8_81F+#D@P:)&/7IIAE_3_2$;0V0<)
MMDIV>]3580[OK(3R,,J5!RKBO&Z$5KQ"A^*ED?Z:-9-[JZ)-TF@$QN3:BV1T
M,)X9O<!=TN.S+<]6S^UT@B('@\%\%,LTQH%<]%64)2A?\^7=B46-RP!\ N>1
MC-!+I)M$%*6, MIBU90*CW5Y<NL[L]L#L_L.ST[S]F< A\K1H[3=5&F24E'C
ME\S7+=VST4.DUGJ=]4;$2.U"V(J,K0>EWH'GJ2G9:/!H$%E0OHM3#J_QTMUP
MQQN\Q1C/2MD+\2N?H#NGS3",_0G*M3O1JMOB*M0]X5#Y@-#--YF.7;3N@1ST
M\S,-E.Z?(&UV?.XYV$D+'WU'*-R7\;?,E:\4Y-MVH[7%495WN&@_2B?X/Z4G
M?-7Q:4<(7=HZYC&9N.C'-:.'!D0R_UK[[!](XT5+V,.)5[LG\";KD2DIDN#I
M&?"M^5Y^B&>[S84.\/XW[2Z=LM07PL5);\)CZ6[SVU<J9+_O(S[;B9]*+S;I
M#//\H1'].>UWBP<@U,@K*E?51M.LN-H_?C QM*&!_&V]%&D^.R2_".VVN(OP
MF'MZW4ZP)43U8.C%L]HAW#^7S,OAZ('ZQV5+^@;_)#^H]G6/R]<>GZ//5A_>
M:/40\).+G6,#@LR"E[A7^U8),^L[=7-&X/KA-G##$#BNL]L6R93S[=N2AIL=
M9:VBB*6XA#3_MU[^8_!$9*)#JKN;BPZQM99G_2)?^],U=R\_$L>5$K@>O-PA
MJ>]$WZ)[5$FB9^SPE\,KE)<L6FZWCXRDH4J"[#..^S?1?0]\6!IY/B&QR9@J
MT&9,S78!:=C.,SBNI$@BKY?*&SG#J:7,!/J8=8[I'(D13?J/,@7,D.PI@^;1
M$(+7.J@*#Q7[*MKL61#5%!E+_G)6RT^3N,L18E:ROO"U-A 'QT6A.:E'!LNL
MJJH,QBEJ-=50/859U09NB6?YSD;#.'\8YZ'K<D-7,6V;@]YN>$C#4*M_BO/(
M]<4QZW(*IE-*+!@A3-Y317GX15LC6HVD3,-P3,YC_$NFJ&JFJA;@.,.NPWBI
M6#W;=EQ-#2K1HZ$++&=_,7&^V^=J^4"O=-K@=))^O\VLS%@3P=%M^#"RLE>I
MF60TX<"K[N(8KTI!BD\C:=W8-J^Z?9]^) F:/V /CF/I^=&FKB?%RARM7@YB
M%]13D6=A4;+(8E&%-7R&AR>E\8^I83:2THB\F+843:<+T;'8JK3[V2GL]-O6
M&)YM!#^L1)0"R2K>LD'(XK;>]7[ I<G]5C50$J35LL6S-A0XWP02/*:L8P;5
M'*8TG.V]@=+??@P%;XU\U8<29[M_*]PU\#_5MMV6Y0#3%:^'(K-S,#Y/Y/+'
MF&:="$1I9U?G-[QO(HNVIU+%@<_[S.1TQ[T5G2+0*BH=+)LJ286$* R7IN6J
M"I%F&$EQF@Y^^LV_P$VR_R4$%7V$F<N_.;2NE?:2 G\4A4< P?>@3G_L,=J/
M>W DM^XW45DWKQ!2[<$QDME>9;->7@_[9J+RBMAQAQ6'"39C$C*:QFH,#V>%
MC9X _O'HI6JI:2R98>C1<66($/2BOO*^N\H&WT\5.B63V6ZC#CEIZ!SL:<*=
MM>:R5"1-C',5,K88EA&N_1_BL] ']?-DC?7C&^+63?%XL@8A^#K!(8B7+J.X
M?K;0[80TMU#=A%7[\+']4%N-!3>%3S&6C2GC/$</"P*5HH@"#[MOZ2\J4M.1
MXSCLY_L%YFJ&TER]B%X<%3G#'W!#!9V9F^!PU>3(N6_:R6H1<]\4?@-A>GKJ
MBN)E4\E\*,SMNC'162QUXM'8T/0TDI9V5[*[#J.WCJIA\<?;5!+$8QY+S+8W
MU>\X):3L-D@XB=O7E$2,\1\[$&7XP)%M)JNL[@R$M2Z*!Y.C[JO3(>/1.:)H
MQ_1VAS*D!Q=,I5*A 2<F,G8[YE!4E2J+B_D5V3/ 5<<D<OOZJFRBN+Q,>5B_
M@"0Z3=@+W>EW,2A!A[523Q+YZ;J\U-T-2S6\RMF=F/:UH7+K&@4%7FZI[UKZ
M:YX%^![848K]2\(V)@XW996-CI5?2WB\ZGA$PAL/"1"LH8*]LA?14A;)ROWJ
M?):,I;90B]UX-HVM6ZYX ASBR@*=2)+!P>0)4HR#Q,;N8W^=/][[5JD(W)^H
MS'C9J="K+*J!3-> 9WDDA1U(,V4%5<SC)+K*-'_0KZ/SP970=O%E7^)+GRY]
MFE -(UZKD%Y=:OJDAG8I]+9ZGE=)53J71.P]Z/1(<4FV^,/+)%3Q. ^\WJ-?
M]AX_;$H\(.19.@+L68C%]F .:"R3!?O(/B-9!ANO(3-S.-]WUMJ=BK9 ;AUQ
M=2E@89I.,92_LJP4%LZM0YK1E9;FD(D:/<I+MO\7!V.YZYK^R</M.*W5VOY'
M0\)7+Q9,];*D;*GJA>8,JK*6_F< ?G$51L-+ZN2;@E;.)-D7BLS#>&"5[K"4
M4OZ,<G=385@GMT<&=_FOO;&LEU]@WR_]*BNQ..60060<B]%.JAS8T"!0T/!@
MVP<:TW/&Y/!ILJ>K(7)M;OO*7%B,G[:B"ATI2?2QMAZLL!2JE2:LDZ8(%3@-
M&VJG[I]1#,CP[(%>Q7)KR&W:H7&Z";^GPNGPME7G:"@?^-60.DJL7#O'EH"G
M[\+(E634'^:UK]9'KA,]:=R;GL;J#,&"PYLF,J'34/GB<5D\&18%"D:E%?X/
MQ#@$],@P]61^+=,<-4;82DP61 OZ J\'0S4U&!Z?!31%>^<[8$=RFS84(M)(
M1:%UD=W[=EPP%FSM![-B8GJI^H&;DX)GG2;+&^3D*T(X8V:$R7BD856Y8%DY
M^S5N74P-8E[47MY?N4]5A2B>J"PNU=#*14D6UQUD@>'$S:;(J W5VM_M$E>G
M7<R1V2?'6<20798 PZ 943M,UC.B%+K-\$H9=A8CJ%PT8ECH'2(XH_F:6;7F
MZ !W\)O\\F<\\&Y.9H19ZM!I*M/9 @GE &FI&TDB1QA:/KYCY@8L>^(-<669
MBD)V3$5C2;XI2( \4PT]-$Q:QE#:P/Q4Y(FHI*)PVQ\GO1XG0X\9OS1#*[R\
MPCZ;"*</Z:)AJ?H^7CBZM+-\Y;]A<O\70&GL[QSWTB4VL_$7- !"H_*MGS>1
MXP%5TWW!HN'L>(^[Z\T]W#]G)4^-NGWT)%I]6OEEXCA\?5OSX%!0APRLWH,X
M3"#)>Z,WSE8DA \G>4T!4>V70"MH].YZ/5/7?U2(-I@8]9)0KAQ9@2CED*E/
MZNQ^*+%SKZ^G-B295'UW<.<W4ELVEE*6V3EXC0TG4<KN2O"\[!J!TR8!Y"D!
M#P]_4=O-_TZM#QMJA(X$%)WHD/[KCDB@&RJH"Z#,P%@L.WVO5"=]$A>\["9;
M$0;K 7&['<VA0RU^R'9N?2=DQ  N"Y!$17;2MA.O"YC^:;JO3.MMBU&\*F'G
M46DX )[Y +JZ4P/X_C"HD':_E<8Q(EROH_BXO[$E=-35 9MXP+A*'/Z5J<!+
MIP#P7O>FSVM"\\?\<8_V??/@E:?9PS+*_LE/"T=%B2"[.:JA#6&B.T^ZQDUR
M8+!'OMT-4XJ)SF$[_5=:IT.3[R)IMSC%"9LF7I6T:/9T8N')O'M^BJ:Q(L,O
M_;.MVV@3V<GDJ6B7/IS*F>M.> F[Q5@*OXHJW=6P_N2G?,CP6.#Y#/C;O;*O
MPM8?;R4XT1N4I\KJEU:"O*Y0(9#G^OB9[?K^C:SR?O7_HP^"X'^>-I0:H']@
MJ.RFH=XF?%U_@OF#%NOW""""7\BTX*]]X(?,ZY;51R"\8=0@H^/LL*6^ZE$$
MO,U-P^&&+ZXR!+$WV98\,$TAD,0<$!!HE_URQ(>H\M4C@DN.@PMA;ZICSNX9
MV%^[-*O8X].QO:L,JHM(RX22C+UA?N>!*L/!9;QGO%V4N@/\:V.(SNASQ5/H
M$<BO5D]-QZ"6CG&1!!1NN-SZ<;0IZB0J^).U__R)N+$-X_V6PX$3FY>^:WYJ
MQ>(YPYH2*=T8K>.V03FU"-,WBT,BI9**=P'\+;C>):[!*$WY]8(H>1XX01.#
M1 B#=O8D.%JT/P@%#6 -!,IX/?&2O%K)GE.Q9:^XPEX1 <:5X'^+O8^/<UX'
M/0,66%#A+E0Y\4Y[&S7US=? ?TRU2\$WU[<AYGE1-J(5VUMX &T1#GCWLKC8
M1=)P!-9AV590U#7UMNXX(\NI\>EA$;[/U?ONUU]U;"!3OQ^YA&U=Y&;2UC<)
MV@%T5YLMRS\_;8CO.9(M9Z"<WOP8EE^X\1@-BC9?W%MSG<<D^&.(9AO)&ZGU
M,V'W\NR8\AE00[\=--W];?)O]7J.;-#,K4OBPA<O0F_O2-%=ETQ:K$>S#M=Y
M-[H!I:#<R"D=A.(M#U7KL@O^1//*#4KHD1O-?LVX?*9?XLC[A/Y?4R<C&&OS
M[<"OJQLHU &RS1$1WZQ0OQNW>_@$AJ\^ _B*#3XR@H+P?!Z9U]U__XQSA0?G
MRKAXD#X#FI+6'G?D6<:ZL;K?</JA%.$:?6*.EM+(FCM3":(TS*Q@V5P[GS><
M3: KS,+:^,G(FBG$&)794PLKF !H[[.S.AU\8<.VXG<[)2CQ(-&%#83S@AOT
M96P#5#$_=19Y;0<.VG= BRL''.NA.6)DU2REV:99[5?<'"PJV0*\**=*M;X*
MF1GD(I9V3R(6/>*L,C"N<[MO:;U0;=Y@@U"$^A>7BH#O[715"\\ )XX7\)PJ
MJ*[B)5>067BO+5OF^I$5?8W=Z4<EEE2U0=+]\GW @M882<\$"G#<B$<I#@LB
MXFRYW-;<]*;X4GLH]ULC^(_]11R)F;M#OVB*TS<:/PUULL07816P& >F&>M.
MW2+33(+]%S$=!PCIR[:0!#W>S+T2&7!.^(K,LOA(P$8T>AUR**ENI94D6=LP
M1IJQH,X,V"@ZHM"><E!I+ M'EG!ANR2]PEIZ_UU8M=?/XDE3V![3[2J#XUN.
M-9YCA!HCU3'*MSNS0%'J6;L:4MM:ZP;HB\+/>E8>;;?[XRI93#;@%60C36>I
M$;(0]Z[D3G.T>98_6:E$J_"U!3M65"([AA\ X/GT%D-D\OVA_UI@J-+F)9\3
MZE@[^*#=[@)5.@^)X$0@84P6O)2#O&0]E"_9S<7<4!+RZA;SZ^>Q1&Z.SI\!
MPL$?@^M3L;!H-9-0@Q+S"3:_G8*">[PJO*?Q:<;+;]]&L.1TL$.VW@IJLL[5
M%!WHV[#G*,KG9<GG 'K0QC!0 (Q^R'S0>,[UIG/E:E(:&='1F&F04Z%6L=G-
MA>T/929+G2R0O!A/81DC"6TL01 J#T')[@_]?1XW)BH ^RD=VBU#ZTDA$1&
MP @D\H/J[V29W2HXQ1<5-P3-/G])LTZ_R2LE)E%Q99-UIIT> D]3!BORU^:3
M\6J)!]$. 7J<F$ M/6@&<2LEJ$:9C5P44)QHJ']H:U>RM<X(;$$35LR*Z";K
M2<Z53^8ZW!2@FRO525! DW!A1!5%&<%<^ZK]<_.$HI8'E[2".N_]>^*!$5;S
M'J3T.Y1-2I1-ITC7!,QF.!P[H)6&SNOPL1#+;?'*Q>_/PS#C/Y\ *I'PD$P^
MVI]#YD3M"E<7D_UBJJ;65LP)FH3Z"<"_'6@ E&G44E;.__UG5A+O)Q<1LNBV
M<1WD%F+/&2R Q%G9++<@+MAQQS9SWX5Z%>=^-E><'!,; 1U\8DQ.0R4:H_C(
M&-D=>$;'.&\RW!7E((KQX;HVW8[&6@%->WCWX8@X,/'POG7_82"+\FS\ /^U
M1+P7T?88-E>QU0)5Y47R/"/EM]P*^J,34E&%/HY*;KHOKA/:9!FZA1C%*B=O
M?\[^G[+16EOEG+N&PN;2;39GVQ ?_B6!,A>\T<K+GCTJZN(U:T9DA)ZBKO!7
M5P\&TT(KM=R#_);<G]/,D,+3XY"5H; ZF/!TM[J*U=DK+(2-<OHWDL!5YJ5W
M[:X^I(8F)DM*&;M^8F\0SWK_K8!4>OWRHCC _E[1QG+)Z7:EH=3"*?]7!&.H
MAY@,;>'/'FVFF#!0#_[YY(YQ^^P2U]P<WN7$YWS6+Z@I<.AK*S0?&H>MKYU&
ME.C@K/+LK%1HDFZI&$#?$MM;!6SB^'KU#?L8;3[*42LL,&8)O:L;?O%ST/Y?
M!9)=K&?7O6<+,S\>1!WWI[$V. .3,Q\'6ZJB4IA3X[4YBDD?N.,*3#7,BV)X
MUUF03(@U1$M6E."XVCG12:=/=:61%%R;>ZDB[81-T=8A,+R85R\$REM;Q!6^
MMW?+\2ZYG7"[1VXQW!N_W?,0&F\*5 N0^!!IUM^UT=C5F_@FQ>IF@@X-$9 ]
M]=-9_FN\\@Y-T(/7NO /M+E7@+46U/P@66KI7;.F^P FK,"PY/&B^NNK5J3+
M^W,ZZ5]MQ?.L1@#.#=(L45*GS+.7:H(#PLI,3'*B!I9;4MO$IZ"U#D)M#98X
M*/ILI2\4''NGKS0TV7_BP9#W#+@)T4'_A8FA&_E$2*ZI^NH))NYGHKZR<MIO
M^*BS-.M^+_#?=Y6H^*\=)=9E(SQ?Z<E(+"]AN8B>T+<&/ /T]#@?[>V2[S$W
M#P("+-.,("[*=LM/[M5F@AJ>-^'Y]=SZFCJ<WM]VD;Z^U)0->Y97JTXZ'B2
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MQ+N3TA)'<.$&\-<CW#3LHP!_V0'$I("Q']5H:C"L#OW+K6D% H.)^>Q5%\5
M#GZ14A9?!EJPC)3[IT1^NNWYSF!BH?;0VN"SG_2-,@0/9[/R6VV/6PTJ>% I
M%?.NT/[,A$A8D5$56%']^UI7P%VHG-,?YT?4PS<5.H9L4RFW'5G8@H"ZO X^
MD =]L%DR$)AE'VJ_L !<4^>F)*/]8"(R)\A1:O[ 9VJZXECS/#W<<U*VWXH7
M6%-*\!7#;OL]B^=<=L9^)E<;!SN&/B,M#Q-0U)?#/^JK=-*>I"0<B7O\KLNQ
MWLWWYV:<",^Y@,[(,28UBFT!U=B0UP^J#IK0X7_VK)K'9C4<Z48NS%4ZC.F;
M$:7@U?B9_0#2T3(]6"G52#'U#IO_,NJ.+\>[+7&1XN]FMOVB!3"(M.ZHL_BW
M/H,&B='<_ICICET_EU#0?D,+!"-+YL"O#X</*3JQ;!(KXTT7J3@L!OQ5D(0R
M,*0*&Z2L@Q,=X<%"-A["H)F9^+K,GV[3D?G<[U:D'O\EVU):DEMO'>/0#=LL
MZF&USC^QLIB>,-1J2\R.$??;/'4JI W/:2X0%9<;<TPEGN/3&4S5FS4)H&3T
M\R'CL<&QP$2J&J6@FT]LOZYT*%.9=GXJ3*&$*J"QNA4OH]"+YMP$HX+ZI@78
M(PB>EQ,"DZ0('\$?>>ANJH#J<#U=Z[8QJZ.!]^=<JKJMS,A$16ZT.U:]ZU./
M?^:A71??[T4#V W2IY#SF=-41$NR\K49!^FH64\@OC" !,;P LH/Q&2<9NNO
MQD<D)\T"[M [YD(**?N-.T!@N^N2*X]-BOH%3:7# #Y;HHBO'ZF/ZM,V45\-
M[U<M#P0"[,*Q_LRWH6XHB8&J@UWFBC^%0QKB62K!=;LU;M *78\2LYI1\_5L
M:<8#OG[K1C3X([J:# Z!F@*4@I+XOHYK;B*7;IX7.V[:)NY@DG?7_@'H[,UL
M^D<0+,-.>=BCT&HH!.;:8$T&A=&@O=%U "-_)( TX_Y<.?D/DA=YU_8X;"CH
MNJ5V1>FAW<N8_(T%84C!?T$]P<?@(Y,0-5W:6_3] /6SG\X:SN0@^O75\,AS
M ]("^LB 4=[9'F?:5B3@)X[CYX]O?A3BL65YG.,B]_\ U#&&16'=I;7_ +^>
M+7:1>(021BL-<D!$;-^)52>)DQ9JK(QXC,F8.%!2J?%FC3_^\Y=]X%O:)[SN
MV>ONC3_ZXT>FWJT_G2M/@D*[WQ[N/\RTBPJC3C)\\[:E!GPX_>U.U^B[Q=7\
MILWWKS@5O"3+IKR$;68R<,U\BC-!%N>#G5;5/X01?FQ$$M.[OVD=MG?YD_X!
M&G+*Y6^_^:OR)O^=OT(UGDIW]E%2&;'6U^5]>6JI+Z<#0XC6(;+*?75[,K?P
M=:CI5+6KJ?\!5J4S&PNBVVXLU[4WY@YGEWB_4Q*;/JBL>M,DU;H_M_]L,*RA
MH(4^/H1]2D]"B>QUU'Q%!OJ[30UNBI1]JG*>'V>NF3)%M3=1P#R$EPT@UWZD
M]2WF[!7D+!NQ1(O_D(>(@#0"[RVA7O<-+342SJ^&C@^43+$C2P*HCCM0%_RZ
M7:!=<@=Q<I%C7QSXI\0EZ@1+![W(J6A[1 ;2H2NF,^FCS-HEICQGKE+G.N)X
M./UY+A/]B_>^9MM5\L 1&PE>&HE\QBD?*'@F2/P&:DD8>,"/=KC)]L"/%MZ3
M"K$8,;%M(-+8/KE*K<F69#_^<;7;60MW94C/P,*41OJWA6G%LC^EH*%5#W%+
M&3DZLD!3"W$(MJC?4!:N^-$$)Q0O$1M+\&WK:IV+7^71IE>[1QUO!6E<\[Q)
MO8"#%R>/JY*K),1$[%4-@! /'XFG#B   !B(?OE;WF^?_9G/R1,=/%CN<BJS
MC^=2<*".,J[,OI0,V!YSL1\4SW44E7S$E=3[Y8WSC/[ !?O3$SY!G@K?[ *=
M#8CNZYO?BRA/6QYY>',X7++#(C8O'1-.<[L9O+BQ2%%A_&R#B.:IQ22$W+<D
M6S99PU'P>H3&@,KAIX17U?PND+]Y8'!O$,K!D#1O(5YK-5:/$0O"=RLST#1R
MP)#@:7[):%'Z?-;DT%WBL3@>[DR4'TE"P"FT]HR3F& *:L<O4J49E/+:_F*M
M9@TB5Y;C6]@2&#'/(C"BA5D_8G"Y&]S4-%BW6X@[." #SS6U(R,!Z+H;K'%9
M ,>[$6_9U7^ 87!0O4NE2K40O+V*@;(J3A]@/71 4#0P9C#LV5TL&P(>T7I5
M)VTP!Q<'A3SZ5243='0_R:*-QW<VPL'%.X-'1^E)'5YP:#!$;H&'^ ZL;SP'
M5@D(:L+HX>\*WCCZ0LV\G1U9SQ[+6IJ(5!\08NQNH$S4M5F.T]*CI0VLG@+T
MO$^U%#2NIO>ZO ZVW9+0#K]W'7E$G1^B&4.H: D*]H/*EV@@B42DJ4Y/(5]V
M>PTYZ1:FWA\OH'@TX%4K^8@C5F!5\ZJR?6R0_:1D).%X[8ZYAG7:&KE\'G2R
M8 M;.O4KS&&6^1] WGLMWP7]9.%$BLHBZ&..ORRE_LOMM-R<[AJ;!G*Y_/C'
M&AW5S,HZ3K2ZEVTI-4%L%!/M>GCD.S?75$X*?)]W799_TZ5U4;OZC>"HH)1#
M]M>#82+R#!6C&N<667[[T7;8V.!%?9WE7:;  [EWQ3X/?W%LD/HC\2A_L7[:
M.&G>?'W'+B<FP\X[GW)3S=ZSJ2Y/&>'N^V;V+C&L JY/S'T%2-?/U.=P4%L?
M^NJ<!V,/NP[^RFFU+YE17O+B(970[SYR:2!;*9U<I3[!R:L3QI5.D+ TO:DH
M6,@&Y5./-U5<).'\?") [*+@,XVE=DJ3$]_ZM%2:N<SV"QT5;95508'O@_ZD
M,'XA5#?.FHA278(YKIP14L8I]VLG(Y"8X4F\(\[<ZCDHFE-2'\AOD%58#8I!
MP31SG@@^2M RF^]_Y4RQ\U+HO5>@#5GGSY_TLOHY%9T5GK4%"5E&YO@Y,32N
MH%<!PWS"_+_1;>Z\G)&Z]J.#.7'%:*;2D+#'T ]*?@PZL9],^3AX'$B:AVQK
MREL%[X_J^#F,UZY]%,;=!SW5VU(_603,'-?##W>"&]R-JC#;(#C_[+2DOD5(
M>,G9AUUU7DW>^L!QMUYCMH #7O%K7PY.5$6V5V53KKX0XN>'W+P(=3@P][>9
M>#_? WX9EZWU09T/8C-)4CZLS6S%:;Y[Y+@]ZWC;DJH7'W,T?H1$%;:)TKMM
M%=7XL<4EA%S5F%20\Q5$]SDJ5(N!M,2![X]-'U$U56-,8:UCB-]?P- ^ 0GH
MS-GO/L/*'T$5*8T4#3+F.?0I=U[8!:$J$;;+G"R3A.P:N!;%FW,R0OM--IL.
M^9*U1TW7RJ,UUMK2@2Y6WTIJX"S#V@%"4]-\67B#DM]G=.--QI4JW#_,*S4P
M (..F+L<&NJL]%TUDQW+?*V(F<0O'X[K#1^9&D)%$W4,\%P!5C%+U\^3L@E+
MC,:%)S-U_[?J?GCB3#C*3884#YNXIYC'Y/[<_ZR/5]3_ROYF,.1#BYI,?*"4
MB_P./0DS^Q^M ,[&+J+.[MK#)@W L>R#K]^NWQ:3Y[C02L( O$A:JLH,[+TG
M\)- T%RX:.6M^E&V^KLI8FHM8JVWCAN]21/:2@B)\$W_RS\DZUQ(#4(%.:YQ
MNR86FLU]C]4D.KQXG(Y4L0$S#:T$/:4R,I3VZ+5EB8V;F6=]"B%6O5=38WG(
MZ?=>.YS^;9R)6,!#G_^LJ(:"OC[E$O\IQ?]%XW-F_;U?H+U]?5\7T!U==O'S
M/=7+)W/V/9TMMG*,RUCKW"\N=Z+><S][N<JJ(7U3%9Y5"Z%6XYF0\B@! VNA
M+5-\9J-2AKTI'VG@G@@=Y:A;%]\Q:SP-8A+=]PZ>K:":4^]M8F/!W*_Y0I+W
MROV7S6AO4L(_@/N;%86.!"*F;X,/&9A3&,P%7MM4.:(57*-NA31AYE(V]=F(
M;)%&H;RN^+B*<6JV %LGVS#^TLU/3I\49E9_C57-7>A1;=WYQGT.\9:*OENP
MFIB_3)2!YYQ9Z8TJ*::UIRJ%:>(AC^GRWUFZ*ZAQZNN;)1OR[<"%:B[(@6^!
M;F *"W9QL7KIR;RL=(MOX;0+9O<F@6[*(PKG#$C#FGQ>5&-KBMBTVX?WC-G6
MW K-(!*@T4M]U$D-K,%ML2D[&P],("&ZW'>CMS!L(_S9(BY?N?N7)67*E@V6
MX\Z<B#%^^>@YJ"<4-E4DSJLIQ/A\:L[+1K6#KH:(KZ2>9^)Q2@NIK(X[4<!2
M(:P8!G=OT66)%]X#/469VTU"2XT58?A3-HQEUNW7$8RT"H_.B-8U+Q2CI-,L
M3!?WF-]ZE/;V^M/6#C/(Y403Z:?,O@LL?-:.J!0+X]60TFY -SB2@&SH[0[P
MUSMV0]KGE_SP6NXY9K.ZW4-Y_K2]4LS_)@Y6CJTD_!*Z/(IN<I;S9^;*SX]8
M8 #KV#?%R*RY6NA(*.E-..I7#=4%^E&6)'TTK*Y[55%;3Z<\*N4F%(1K:@:1
M?:/OT_ 4%I$E4B)=];Y0^_@T*?$?P*.8":4P]UCV14#T@Q%F656NG08552ND
MBBQ_'T,,B^@SW&^5HPP:9+MQZB"9:<R:<R !>>_<L/KVJR^ O>@M@N,-'\M%
M/KDG=T\.C-]^J]W[^-?/R2GV6-WX42G\\.GIDO9P5KIO8*6'\=NEYY*O3[U9
M]Y>\[S;25;1%L:+58ET$T,,]W/F$I92C0&B9"\U":C];=G66\[/^;(="'^UF
MF-X7UR(&&DC'^OT:]MO)3Q*T\^DB%;@3ES'8N8C[.?#APX75,VP?KZU4.!ZK
M)SWNE<1?_DB#32VKGH>H\LC GC34P&*WTSE3JVDZ]]2@BX;%TZ-U08OR9N=:
MPW!6157#-+N.G&+?@7BX:?-68[I[\YG\SMD)G^B6@M>ZV$G_N2$$V_.3X1E$
MOW BE-^:.9+6+=?L(X10H^(E?WQ3L;<N*KN5QT3VDZGW6:UH5&+V(X6X72K<
MSHN4AZ27^8-C%>U]LD%S"_4G6,8 )L,/'ORIP1O&K!.2&<AT>ZB</Q\OCQ]C
MTUJ/.9RKGN%0W5)6P#3FK>1?@O6_QD\LO&-*_6G,[WDC-NZLW6N'HU.]_%!<
MD7G AU8EW)7!*UO[DLV^RLE.:'?&];D^/^$N8DLI'QL[>16B^L"G8U$?ZZ&"
M[Y:*5O+I;A;+B4#O'Q0YR5[W)5M^$0@H#_C6JZ;YBR.J<DXVNSF<N'K54G7'
M:RLXUTA,C0C44H3MPBC2<9PMU_T#F*^\=K5PV95M'6$DO6QK\>-OY/KH0(_V
ML6:<H>SW1%11[RI[!1U-^VG9*^IT 2E;R?K]I\W]9)=5K?OI>ALJQ$;^A]IR
M;J#*D]W5;U]%'W740O0B_A/#..PV97Q':4%$$O,"\T&GQ>-O/=K4)WN]SG@K
MVMWP\,8EJ51J  ?<K4&DS&5<R5PT(PI*]S_2U0VMY=5>>M%X/)\.5,OLH SW
M/[/6GL5A^D1Q[.QN'R<&#'E^0!AT&/V.0$S?;1NT&&0H]J1,Y,XY1\PE"JWS
MX!H&77UA'#0:T0:X4D1&_QO9Q.F:;*4&3;//AO"55Z0!]?'U*#^7+&I- _VP
MT0L*$L^GC;K2*(^U:<$)2%UE0_N"6*FDUWZVX=1 V+&PT.1B O-479;@ED"R
MTH4YQ-0$Y9N:4]\A58<!2F$,WB8("%I4N4ZQ<[5QHR@/9$2FVX([D'ZP%^@V
MBZF 9G\_3;%QJNSNG6KQHM8A/=J+C"HF#377[&27'"\QCZ]70VHW.$T #VZ(
M).W/_*#,5"%/"N'[NCI#F>K&?P B42Q7.V)N)/%6K?CSA:\WT'.IBW%91YM&
M/<CF2T?O5_N$@K'F%N'WYH^W)3^A]W-UL/I3X^]?^56SSC*OT :]HH&D8^L*
MP6]^&/;E6,U]"NC;5-#^4L?"0%JH<CS D3N".$CTBUVBB:%RH "CKX/K&#.%
MR9MV/S\<%0Q\UA$YI5C_5X[13;@7N,E0!R,!F^AG5?/5V7QC#_D9]$7F/KC1
MDTM?<N_7&4T.26.DO=QY,=\:"^AAZA/A+UCSY/HB^N%Z&GF%)F=Z]="=V/F4
MT 9#*VPRF=<C\FHWF 7=#A'AFN)@<YEOV-'S)F?4N"NT_EW62V!3'<90QPK%
M>YUB\!/E:7>T?=R.:*W0!Q#MS4<V!QJZ;>K]X2R"@XM&>?-[":89LMDK6KL0
M^WY"SZJM^/>)I-_@:+]/5>;(*WEF.!E3UDUDFTKUPQL8J\*7VI>DR_EJ%?*R
MH!3NT_\ TO*"LR,#WN\% [T:\!*6T7!H$93GM92E5+IL@X:.JJ$3/LP-EJ_,
M-SEIJEA=K9XGZ=J:M[1&W/@!!JL[9C5MGWR#=)MM +G2<<75"S;!46741I>*
MLK$N:0/5E$<68Q"<0(96SVNI6N+:$B$L<$6(3U0Q7_8_)I3[!N7@\ZEM"U>F
MJYC>%5-J++6W-LN U0^=@&8U:FNJL**>V1(T;1"XU$115F<7*-GBRU& #4VK
MQ*\?EMK18X)'PCBJKR?=.A7G= 1/H4]3ZK ,.B&Y/WPS=(+<1H7>98W+<Y_Y
MQX$C=;*-=6R5Z2I'OD\&,R69P\5<.FML%LI "55/77+*C@BI(2?/4P.7.5W>
M CU=H44)NV8#F[J%$7C%^!AL,# UACZWGG"SB"33U;.28;J;G.;O1Y]-=@P0
MK2%;]"5@P!P23!!/KE(1S(_OTK<@A8I%&!S>O$A3ICLCB#]2$_(E#[23EQFM
M>$4-*56S:_5IP)0Q@-1I=Q_O;(Y_MF/8L'0O#H07BB@S,(<Z:;^]-K#7A-48
M4E;QH.@0>'R9-.JN947X\\*>,JJW#5*X!0JX8RC7?K[?N9LIL,EJHA>>W;_@
MA94G4IJ(HQ )JZ/)H#A$XW=SA9B*=S]RLPO/8!A*K1S?G\&\@ O"=N[Z,08W
M]:@0U$+]L@2FFI38P48+4/Q>BXVN^S=O_ =&\M]J=E5['<";65DI4$JD&] =
M 0)4>]N"/."#.M;Z.93^_+.=W"+Z;HR+/3:88H.'A%:=D#*V0\*A*#V*8@"1
MI9BY5&JOU;N9AF-VC:$"S8$^PJ;&.Y30L?[VJ^8]#(!%[B. TV$]Y)(V!#$R
M_']6O_[_N TP"<".Z $()9*1+EI$[!?;[(&?LY081<)X35<>*;X-)4C@$ P=
M0$U'_YG?$L/V.Y1U7BZG>@?H&=C,1'7N(W#O1, T.1W9F;!&T&/9 !UR)#\)
ML"ZE1M& >S12=T>->^QB4^HM86V^]$X5]R$=GZL-HX5T> I+;GML2)T;E% B
M\V/FFG[WX\FG!!TM_#LMJJ/5DT7I>UVP4KU'E*5F_"V)E9391JY&4N"#ZYP#
M,F\-6#(X!"UA:O)^[9SAS7'ZC#U,!/>B#J[16.Z?;P;9/5@T$?ULZY%<Z\]H
M4&<'QDB-\<6!Y4D7.KD7!?F_IM(5)ZYX*3AWWDXTTV'XO0+QQ/<2(X(:.HQ8
M30L1%8AZ;FXI="U<TXI&E+V2\BSRE\JPY;!9Z]%$KO(+8MZ_LT*^3+1S?];N
MQ[P.+3!D6U^*^SHL^MKS3;>%8)<-T#PXZ87^N^TM%4B/HJWG6!E_^HF;UM'R
M*M8O79'P_*$<OF*3@<Y;+JP?%^3,N=):SFW>9:+H:IYGY(<;$P76 #HHNNY4
MC9AD/W99@>3SU//40+37/-0UM2>=W'1PQD@#DZ@6]I(_LF$G]_S"U[#%Y,G9
MN+V?=OJ)35]NYNMJQTX$#$HM;;=G:J0S1PP*ZCLT'NO,P.@U!+6>BSPF5+CV
MC_S:T9BK)Q9Z5B+5=Y8SS'^\TYK0U0%(OTQ?%"N*$0](K39EFG/A,S)[AOEM
M;H2(!T *7$P#PMD,1UH9/DT+92?,HE$N'_(,"ET,OI'3X$\*!KTBVFQXAR1X
MB/J/(LQ<F[237A=YR3Z^T&26]MT _C*JRK&WJ6IYE\$*_OTHF-^@KA9H)C$-
M-'$3%JZ!PZO9G7_^FN46CW=0C']#!@,IIO$KICRA-')@V]^.^"!QKBBQ[WTD
MH>]J<I'65Z3'/<'.=IDYP7>J$8(3)%>JJ]8:J_"KIA$SW C[-"^)+,\^^JNJ
M]$5MOLJ2.=+I0HL[S/83?\NTC8E%/M7'#'$7^)*B]VAHB\Z&-3"SW&Y.V%VV
M>R;%%'C9]HI5A^OS;JA$"^O#M0;!6QE8LMKX(_\8_=2W_=&2(:J";SW%N</E
MGUV-EB";6]Z4/!'<%K3/"?LQ4,//'0FRC<K7,,?&N0W<).@SAEV2 0A"C:*#
M,"3[Z^RWT79S\_NM>ZF)MX(H\,JU3T6@:?>5Z$KE>+?]#IO>RN_EA;%)72/F
M5V5%]4J?E4YSW/&D)/:C)*52G\DC<^.7#>6R8@:B7MT^FE+]5/S8H_$A^.??
MCND1!\<6%MO'NU!VN;>,Q5VNY:P@;C[,LG^M7]IH]PN/ZP?;#$O3NKZ;LO8@
MUKK6.GC*PZ.P3UL;I06?O*5-;[[.3[/RWX63)ZS%P*PDNE^_DW[HN1[..P9*
M&RRTN>P^P?@A=I:1'M8>MMU2YN7VJCRI<KSS^"2Y 2Z?__PN?S/;=7UY>QZ2
M&::5;DB6@@4-2%S^=%:A%OV:'ZBW^$ SZ%@M[+0K:U"TT?/.U[=Z9F&_.#'P
MKR_2BDP0=R>V!UMB[PPJ](AZ$Z/ZZBJSJ93UM\+(J V=\2OSY.&?Z<&R'.6B
M15AS)\=5(XY/,<)A/3"V<Y%?M-= ?4W5T" !UEQ/XI:/BJV3:UE:P;XB?V)T
MY>\(V&ININ8+L/KMG_TN#W)[S[2\Z$#.-FL]#C+H7IDIV:6N11^MN33!]]#-
M!\[K)4?.O"^5(\)XJ"&;7QUTZ.NU:=YGO[7'6_7[!\CNO>M=%MSRWB$^6A8L
M>-;+?/]!MV6MYL*2@"3[4F3J>"5+HH;OZ5;]2]F#B3:T3];X5">]"^^R=5&\
MN10(-#K=YA_]MRTW,";5^6U9Y]^Y$IZZ;_]WGZ16TYVROS>HX2G8IQWC4EYJ
MFT\0] _ $8_AELB-SS#E7O(I3]$<\-ZE3ZW1I((T0.I*(#:X1IFN!IO$%,T4
MA$HRUZBP)C]E(\PBM\$BJZI4PL[3\<#9,@>U=>=?US!RHI4$F99*#IL:[E^!
M3&U0<=1AU[H+?>JJO^ ($3ZN4T[D$_VF3Q34%7IX(KL?I$X79HM5>!K9Q5KG
M!8N"'5[11M:WA/.50-.5F=[5\!A,HMM-H/ E<M?:=_6L> Y?D*,%OHPU7<=2
M9SSEG6=0<4^*:O/!0Y7.,J,!7Q_M&XKW6HT\3ER5GX)^U+'O<H4,#<7A#YG3
MC[7VSG7T#M=,U0S.:(<'T;,0"07OY@'M19B?0B+S7M]&<]N!CW'S(D2%LBP8
ML%AK59[+#%%<K%D.XR\RMG?CAGJ89QPOPH B'UV%YMQ4QJ"-K=%9[%;M^E(
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M\BL8EYM?T5I76]7U\SX_A6)=\-;(8)#<5:H'!%[M._Q>/L+CUQL;412*]9F
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M6] X:<#E>I55)[0Y+.E;>;!UP!<5V[+W8D^&@$_,@3E>##'#R?<"Q6A"GAH
M"[8ZO]C%KJE+(=K8!^<-V,3I'G?#S]WAU$P7P(QG_&E0/-G=\?WRHE'$;&9E
M =[J7"EU#98 #FY.52*.9CLP56G5G./Y42J ^<C<JS<>-CU\>[#P1//PZ_%C
M2'21CA.3OAI'@=HRV$*T"@Q=8S1&X6R!O.CT[,IL6_85*_5/O]0;#1^5BHW(
M[#GZF+;E%%^Y(<(]*6&KDMD6;-P>5HVT_$81KF)LT,IP#J>=,[-3G?L_W<VG
MJ/JS&F_^ TBBT;AMC"45-!'F"0#VCV-1HSH(N9(!J2X((H8(!G?B?X@C-RO
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M;ZIU70PN>6M(A2I"S'Q\=_FXLKQM(M"T\;*PBD^:E\S:A5D5,&I\,DPG"/@
M5Q1]$;C,Q;;$M#,SEW1BBWC>V8=-O>S6)78IN:*A_;F([N-I>ME'CMKOOZ=J
MH.#*\-<I><1Y'C@T-TE*R_*"H&X=U"GG1;'#3CLR8?FLDX0$AXA3K1L"Q''0
M_S96)C7=2-/6WCYIN A+QA.BCRC'G5IP+>(!ZTY:*IJ$,^$7 +$GD#G9;22$
MY9=T80\\W$KS.EYZ[4K<K]^*7,(B(QL0(]&C8AH6Y[O'Z[8FIIUS+*Y9_M)E
MIE4[VUW?OE4>,;)F)$<P.=\3S+X]!5/(4\LI'+4-+:+V$@U2-M\-[/,D,0ZM
M1"Q:']\2NOB5Q3'0';?)':3*)Z 334)<_O$S-<.YLIJXRB73&<XBZYL&3%*'
MU<CCQ4QX4:\0-:VT6G&X DV0$OCW5A0O</L__DTIHGW9Q!08B$GD55R$%95H
M2J*IXI%\4_/IA:MNEOR,,UV%"63J<#ZN'%=N69@8854@=&(@4:;VNTN^/E^=
MV<?"ME.;R./#,Y(V7H65/$J(DU!ETQ_GIL24=KBR-Y=L &R>KP.DS@<;.679
MTU>*OG".7B/<PCICGL'O6=#S7QA?>@D9,W5.J%:!#HZU7M?_#AI;Z;KF#']0
M9-))"5 JNW9C2-$"0-6"OKXL?#91^JC\0G3;-5<^M^L?JL#%&!'_TT<(@\JP
MB9-'(P*)KJZRZ"2)D6S*,?J>*97W$=9,9&^H^MVXH>V>@)[\VCW)@8V56^4O
MBZ^36?;/"/C/LRQXTS=8K=D-<IK24 "#J>;U4?X[W]57R>OQVOH9\Y'.^M^!
M>PE43F:=@4AGK7*O2&5NF3&(M'$*6!7HI78Q>8=QTF?NS:S@Y7MKP!CW>?*L
MCL2&[_2Y7X4CJ>6[2!WMQ7-4^,3I$E[QNON&Y7 >X*/31(M+K^1+=&^R$HJH
M)KR*T^:RO0\Y11"\+Y=$O#2RYN.G[>CEO/>]>FQ["HE*U1<GRDXH,%">V4T#
M(J:*:8 R?V7X[ W-S^XF* A(9(MS5%EDR,*D.PM@F ;@)<6*5)TK*R4=+'Y)
M,Y2<NK]Y:]W#]86X<%Q*$V--WWWZ=?$ZT' ,\FRK2U%/Y1^ K;>[Q'H*_+E/
M+,AV'N_60^56]Z')&% <)D60 Q'%4'<DW8 *9L)17F_?G]U"G5GE,=%Q5. D
MH2)_<IR\Y7)6#\1 1P@8$:S"S-[O37GD.<4">3V($_G0I-P5'AA1%PPT]Z@_
MVC.-DYNQ,9:+#BQ]]2F43>_#PL/L4A]'E==4X)G "U5Z,49<F#I2SNV-Y_ZR
MK_JDZ HOT[24 BQ*@[)N!*[^E2[1+79W@7C#;@VY@^$X:(6E:H%N2!2; 5\D
M\TX&< "ZGW;EMUC*SJ:?_A7O&*QQH'U.V8QBE!P:50B0%P>R!R;0'J(IMD,G
M+YR//D\NDD0XD_+:U;9ZAI#J%2LGC35Y#41@2_8"'7!"RKF-*8ONH%P.TMK8
M_K.T0W[R?1XX5HU:V?B!<]M&.!)*]!N/#SK*NI%Y-7%@U?;/V^+K8'!B20?F
MD]P;44VQ\Z*[[J5N ]JOLWQT&E''PU*"UG?4SR#^<(LV'7[SSF[^+"RAG\.=
MI.3R$N'GT)<H2ZGFRQ9B3A;Q!YYH7CU7<9BEZFAO;V^@!<44IJ(#T1X4+4Y5
M#33>Y!!,;(ID4WRK;;I@'1P3T_P^N$[,T<F0$*CD;"RGW',(@XW;4.MK.>DJ
MS**^JT%_E'8,8YL-;P4I,X7<NI\,O<W"[?IH"B-Z9Y1#EC[:+)'\:?S4&E#2
M2!J4F1;H!+/Q5;FE:GEXZL3IM32M\5;I>JD@F+!?!V+?CW[+*9FRL?K5'.@!
M=?VMW8+K].6,9<"T &.K I66#80YLGRS_\O_4"GYG]#85H6WNK):!.:D4FIQ
M%0 S/YTCU_):OBHSE6'Z<O[-^=%#=)H-Q,7F^\?]SMD7(G=BY&=FBGY1AV9*
M$&8?NL)V]#Y%4F?LV.7GPY1EF<6=V(=BAYM@]*L%='N$,6=(B)R6='<R$ @/
MOSC@7;5ZK+90; ":8>WMS-+JX1Z#</R_0>(.Q92G_V$AI+#C(;?^.XEOSY)7
M=&+TO;G NTMF>1<+C.K)T=-S=*AO8"=N'FX70"KIB.64Y;[WJ[S'[EVC$/Y@
M2R)*Q\XHHT$JI=X4*:.O<N[./HIMDTU4++$Y[<!/+J'C"6RA0(K0,H5*_GU.
M!QOFU>5A,0)HX+X<SS?. 'I;?@$M?"BQ2FI\I7]?5$RY:/8X1HW^/=T2"93
ML4%H;; 0!7:C,T2EOO&HOR[%G2JN^4=]M7IRS_FTBQ]&'NJ9^C>>#?<NF4X/
M$@A8A;R,>[7(8U*1XRS6AB28DWN0I"C)Q@<MB,5/Q=+'97KRCJ6N@GU#YYQ3
M9D>D<^V7O@_E0(G^.A<Y8'S6:6?9"-$_?99R'-/.\)8A'S4[8XZ<&IP5QK/Q
M4FJ<:C (&#XGL)*>3H3FWIJ2&<,4]7M*BL<'GW^X,J]%\3L59 T)[B:G$XMD
MVL-.R<^;)H)DVF'H=(MY:Z5_G0#!N0DS<!7^]B<#3D>OA9QTWW%B71H%;11+
M5*(I#$@4NW/12,&J!R_, S>U^+[;M"1I+-?>TQ0=[(C !;#2X2YD&!I'PDFT
M&@;&KXZFO-P4XEYHM4Y;UGS]WGSDS<R^>/12.3!"&(2J_VU6+<!^>1WDX*IH
M8;)20C<EV@&J)2;QF[K&Y-6_ROWZU%+[9RPZQ@?/C.2<#[FOHL+%AO3 NR0,
MK:2+^*Q6T5=ZS)/]/]]8,F3A-P%G1]@) C\L_@&HC5QTQ.$10I.\7'V78M:T
MXKNMG2>_[3=-3D[/ZO0Z1U9>E-.7WE9,9&^> -KLEN^8JH"FU0%""ES(X4Z
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M;#S?\4\\@"L=ES5Y87X9*89WAQ%S8J--[=?*$S<7*<-/"+5I16[;@TJL<C@
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M=3)O*42O(G0DN)L;Y76)J]U("[GUC>2ET&_A=H/=V0$[Z4,?XYOW947UC\D
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M;W)2,E-'*UJ<D#TRJ,LC:'E!Q%2M$U17*Y2P$9)3=S:TQFE:I]0_[7T3F56
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MQ#%F'OQF'C2@:!@S$@(0<: GY($_.URVC;Y[*0G&CZ.5 ]B:?#E."0  /-4
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MOSTN/3K7[2#-SZ ,E"["#P#+-&\P@!E/=_FX_@%L2EOULG.X/_IJG'%/^EF
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M=B/)L!BW^?T.V6FKG[=X:OBYWGR3?S=C^P+C;G.N++S^<\:#&UD+/8R#&N1
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MLO>:<SWSF6ONN5;VWLG8)V,G<P!B#15U%0 *"@K@'O(/<++&:'W% >8!0SC
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M#WVR^:;&]8*"/6!P)9 'Z&=57+&_@OA1%:?[W[>*9TF VGG\G7M#9$G_G=X
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M7>T0$WANG?&JU7,DF"*.1V^O3!MMK97FFXQ;I'2$H?0+H,?.Z%9ZK\..&$X
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MG0 ,'_'?V"T?<N%C)+7LDTOLKV:5D-&4HZRO+*4_?/Z42DQ^C'52Y]/,)&S
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MRFUA!-S;P_6*5L.:NM5P YR1LK%./SWPX -NX;IUF_W^\=1: (^OO^M'_1.
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M)@'3(J>;=FH.3#5**\#+HQ=O83N]'JV*&A&*''J=PS$@N-IK3?2(2JJ3<>W
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M^#I"8*P9WD\H5^T3'.-T"XH=[8/%)F^> 'QYTSU"T (T?D4OL9K 7[L?NE'
MU<6P5%-XI=A[J9TO;V+@Y>3D:S3PYC9Z[TC%,_?0JJJOP3W/^402%Y.PVK<>
M7E8?\_6IUT,)]LC=$2(I2+7@P(BQ5W9F$Y5IXQD3972B]:3#54BK6"^]$6'P
M6QE3X;YDE]M^9W(D/D"N-*/=5&:GY*Q?VGHKF)'D$L4B*(2B7"()?$FMF&R<
MA9.-J=7!DO!27;BL=(=$GTGST-;+\=Z<CZQH1'%:33$" G;80B\OU*G?KO98
M-PAMM;FVL,'\=604BQ!?G1A/B01=:U/W*2G! Q.=$'_V\1VU>ZH=*4W=S!!:
M\D<88)$N]BI]#295!,J4A-8V=<@;!A#FFU43]^MQQMJ7H0?KGEI=4LFWQ(3H
MU\7\A*]35E$[Y,';]\WI59,QQRL%G1D_,EWRX6/.0E]ZZQ8RHFQ([QPD;AK6
MT6Q0%56A$$5[EZFXC?,I-VUT O&@8=0E% J:Q2O5A2#"\NAEQS6VR>N5\_Z#
M3FC6(^4%;Y@:\9K6NDAN'!46:N+Y342L4.XBF%OSPZBZ$B05[G \0G7+U;^P
MKB 2Y52MREUC^<[)_)V1MHE^IE+-XYL!2F/N6\E51XE:X"G'P:?31O0V (+>
MJ&,;K4U(/I7<4"$)]JOWS[O>&=^V=A3MNXTI;1-"N.J1&"[[2B2SY;4(PF!W
M-SEJ12'<,N?N-80SJYCHW0O/6]L;9\36M?>D6CO-[F_/0-SZ\_1B1\JVX#-V
M*,0*E.@3[92-NTG^T+FAN#C+9<,(;:GT'>LGHMG.*7-Q?O59[N!VDK1YDAQC
MMX=<[F_@?L>BJ+=8[HL\%7^0*M.H+MVX?32*\ZIXF>"!K5DV2H[:A:Q':>$
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MF+U.2D9F2W^XDD.A>,5'P]=Z+ZLHR!.9#\<=6=FZ(_^6*MD)R;N#3TEZ'=C
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MA,9-0$+S,A(4&@93"S,"E2N<,18:?AYC:@V'Z<<D.FH!03$Q,456<AM J9(
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MG@[ ^>'2+-#+5_T0][I5,!-/FH1GZ3S9D;RY0J]OF ^Y]=FR*NFF(LYV:R/
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MK)[<]]T%F(E)I^?FT;OJP$=U\$6IPVF]:[6Z>F[LVMM]K2)S?Y1/HGT(6(E
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MD;;N&6"M1/WOD^$<W#WZ06BY1UG*,AWZ51[B;V#T1 MA_!,4S$I9O-;#62+
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M<5FD@O-MIM0L9,-IT?7U#*+(LAO=/])N?IYH)^ 5UZ.Y[JS2*"Y+=RZY=4L
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M<??'I^%%\O];G%'J:JT88K/G.2X>+"LN"F6<G!DUT<=-X%C'FV$>2[0\[0$
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MU;[H92!O2_:6XEB [Y;+@[A-RW(&G;AJC/QP*,V4]5VYN*=K>Z_"G$.LRS.
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ML@FR]1,;7B 7'!;%UP(2/C 1 :5N<\;&%<@55F*%/<%9"^DMPB(U1M*V\QU
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M-DBC7$XQJL7&Q_=:.C53FQ'[ZV\L\Z-6(AEQ^%P@N3V&[)P%O5UOE-1Y*(J
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MQ ,M1OH74&W1H\I"85M5]?)JB.9'7_Z/F#FYZ,.8WQ#F:JBE)M^IZ?O7CT3
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M.Z:>TFH"^SFF5WS4XC'23;9Q%\\20;:\VV@5;;#,3"1*JV@, [W+T:01N_8
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MBHTA@AY[TY@G5Z=[M/N^]VAMPEZ[G[UP>0[OFX*)8)J>V&$KP7L7(?84P6=
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MYJASUY4(Z_9N%V.K_9NG%U%IW 60IPW,P_=L\9@)38LOAC 7.R+[=CB%83>
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M8QH!%S5700,V:0AQN*Q)?8AYP67((%.#LDIJ1L OP*(S>JG//*>DBZR2F0A
M4&CL9:,$]:UXH%RG0D3;V8_E"*JHEV+NG%I.VHI6T>7=!FP&6W/&'7'&W?(6
MH998T3>?MN:,\IL7K*1!AN>K[M%_7S@T5Y 6 #UI(,15E=-HZ+KVJ7M<$'PS
M H _G0D*H6#K-U7-6B1J*L1*+[E1/#0-T(FO[H:AHA#)^6.OU+IW[^0S3WD>
MC2H'%QXUX1"3_0,FLI1IC/@A@\H3.<Z0#O(Z@AX0]I@MT"'@T2Q-RTW%R8;1
MW!7FT94Q'ER"O"KY[+7DN#@ 5)2%<8GCE;$$U-]F+B)V!CB"G#35+UBF.6>^
M4*MQT\6A=S*A8*!_LBA.N6H1K#4LY5]*([+G Y8UE$4+<V5%"1'VJ8A2X*SK
M=V,]Y@Y >N+>*2:A4&,/FS*3C'RA[_M]3PMOCFO33K/(2;'.DM7^*XXM?:6J
M9!!Q[&:PJ1;KF'TC6N%6ESR<C\HIW.QQ'U1\;IZDD<_KQ5GZ=TZP'+>"<F+;
MUMN]43 W5$#X&8"O&!)7XS?8697ZSU,MO +Z_MR0QZ(;2.V'*M"Z<2LS8BAA
MX%AG<C H+LZOV\JO,/K$4==]SE*/<[_@V]E-'1(QHBCW_.>2/K7#*^$](G4_
MX*=&5OD#"W.'O(9.ZNG6+$3:7-TZ;SOK9NQ)?[)KHVDBD=R4)LS"B]N6MYJ;
MU3S$N/:@=9P@,*40K-QEL5Q.,,I>LTU2 G(*A4;VPQPN]R:MA*J3A+2*/F-H
MV]C[KK2X546+<XH'=2_;-1V7,(D;3AO]-I\+8):.M\PHKOGY9:DSAE(W!.3?
MW[$X_6%!<S9"=L:^;U)(_<2JRO /III^T^8_Y(X$"8I8"(8&W<@.F5$%5LR]
M"LWC>(G?MX^:$>1 =:<21'07/!"H-&C&^ML>1:T14DP#Q,X"9.E3F>#U7""-
MSE95EUI[D0.SQ=6NAMIEO6@K6_6>GC."U&>*_)^5"0K8KZ/UY,,(6;-,&)5B
M"9@"\@()C]+TM(9F4DVNI^+*)# $1YC2B,=B)_*7#7M0,!3BD TH<C*C8LXT
M6@LV8M)A&+6J_AA"YS&^9E'JTYXN#5<DGCR0!R_/60W[CWC9Z!%+*/F#J*\&
M(N!5&<2CP?T_->6\1N3E"8"*9O8FV_-GWM2OW&$^7A&=E_,>KV+LTQ^WCRE1
MN"'\=#'VF$VG;/@,&5(QG!#G(70JO!?7X<VIA0W  -8Q&$_6K\GK*MBZ47&Y
M:;U[D\@G"7A1M!$T1PR9N_%QVYS&-M93(B,>\_)$*$2Q<.$94#MX99.:34=%
MT5#9W'A6/C14U85[.[,.#XBV*]<Y+J5D%(Q C#\M?L[[$>Z3!-P/TDL:V':+
MV&7@;K6WFK87'AF $)6$*=(@\9T8+OJ;JRI3)LH^EH?4,/T)[5EVPH1F.'A1
M%PHM^ 3ECN3+Y+49W.XH65_WDO>Z'92/9;&&JTM >R"KQ;M<EO48;MX;?&J8
M*V\\#O50ZX%-G073TG3ON ',@G)+3IQ5!B/-%>3[-MSP[VQ-+@0M9>+.9-FB
M<9RNHC!7=E$@M'CG3E;V5F<FL)][\?^JR,*^1T]8"6H75RM%'"P:TS4+ANB6
MB5S\5HV^7.],(-48(L+UDMWS)0MC$!71D9V0IN48;<\INC1 ^RN^_%CLFO'9
M*2AE/5=>LD6U42]^66F=4?N)]L4R*E_7;#ZGFB%IY)N8+QH]<JC 18.CJ9CV
M]A70)^?5M\+0\*>?G1_)"_]:"'_I[#[G73@:\S(O[0_^7+4@;\]%-3>K1(4N
MD?F=(VK&[AG0LRE,6F8O EE\*6HPB;;Z\E=,UJ[MDDN-JVC%K<ZGP]:B^[==
MSX"B_C59K7^M/;]E&CPMW1C($#.Q@3"$],>Q:_;2\*#V;/>)CEQC?K#P]L:\
M1H9OCX$NX.%DC0U[BSK>0H]D DS-Y>%]3$Y?0]L7VWGI(V..K,R3^B@BOHZ?
M;7%+'R5E<DIP-]#Q1\UA@%+9ILT)'YYRU*7O>US;!,2!]BTB:=97EJ^7R^)Q
MDM6*\K\*EBY]53)(^)NPF6J</X8^C#FF:W!'JLF\?Z@FR\0P6UN)2BQ]*$[1
MEM?65K^<<$(O)X35AF8GV#YUW,K@VCX7#'H:2&=/\?M7=BX[,2*/8$?<WJH#
MO9\B(G?O__XMZBOA2N!;_X.#5M4^0?QE^;O:+;.KH1 ^J1S_=_H>][3IT6@D
M<UKW^B='#<TR0[LKN9O\%PR_&/RP!<MT9=N[K.>C6.Z[TS%#FU5,9(('@0$]
MQV\^38P@== %ZC88_W9\=.R]$KAW_C4B4^JLD'8M*'@!&3$F:/.I-'9@S=#7
MM+N4AU_1"%96DP]V:VH&U"1'3G5)#K7:6W[6-#_@X2L]F*J-58>B0&O5W=!K
M"=Y%BLN+=<6^T&LDNJN%$MF&9_B05[4BL#W!/LN7%H[;\S-D!0J&M:B$?DWZ
MR=NP\^T'T36)BW[*RV< ><<AA L5A4CUPOQ7,NY/;2']G$T*C^@BTPFZ!^H
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M#6(;1_Q6"1;(89_$F<>-<F!8:7M=9":)FB4U+X1Y&>-]E?'XA5VY)&!)/C'
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M?QS1_Y4>NX#=_@>]A?\]V 2!5H) 7F%+3@@OKQ"G,(2/AQ,,!H$Y>:QX(,)
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M*\/ZX^*U0:B\Q:&@&COUQIEWDUOPT(+D# ?C[(VM@"98*<25)7TOJG]<6>C
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M&!$,WAKO863SB2GRP>K^Y&'88+W=KNP\=SCWUNF#8O+BAM":4 #.S!>A+\Y
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MV[NB^@QK$I3 D6ZMGG<+'3X, \EQ@\4M[Z!KE(\%NM0C&X>=7;6S'G=QC&F
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MC%D$OPV7(Y"]IOE1CFGN+@$O7#AVW".6[48X8K)\MPJSVV<EP8FIN^OZJI'
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MQ\'MSYWX:);U5OM0)TV.3(=[J0?BGAQ:3Q6%\<4XR^1<E.4E9,BT[:(ETKD
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MFCSUF,3)4&.E+\C?A3CMJ0MU)HTX8M5S+Q6LV HV*H=A6J^QZ=I+J<WJ1_\
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M7-1<1TNGYME>#!N46]\>!&VLCJ'4:U3FK] *M"2N5Z\B$FRRQ8/A)B+ @)@
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M-E:++JU@$?LDPUS4:/:N6$J1.R!<:S.N.M'E35^NQ7FXQ(1D]5AB"!U8&_\
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MR(.5;>Q0>*X(&^3IR6J-UM7Y[O9,6W/7=3X]>'LTL'5C&XIHB'ZH)"+[!<9
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MV+8>W.Z U;->9L5^Y<$FK/NE-AC%L<Z&.,-31@&DP>6N#22640;Z4J16&Y.
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M52!I-+(@BATK&>>Y"$Y$$U73DZG22%&$B#+J$?:T(R*::[\/:#@IHE>P7O\
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M",9R 8K;?Z</*N(Q?G3-%JRIC<+_ 'AHY"CIVZS)Q9.SB\ID=-L*5K+'TBH
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M9V__ $_]OK!U/UM[X[WL'?CF@K_BJ#+L?[]^.*Y&V0L%O\[S&W^DP,3,3O\
MG;X_KO&_XVV( Z<!O>^_E\[;YH^;P\,E@!87OV3!]P\/;?.'CNT5Y"NQ+)D#
MB.:&;1/4X1D(DAF8Y+,"-3AY1R4Q@[QRCTV1J.![M8WV-_-?.U<-"3% 2[ L
M2[<.^,TWXIRXXK-46TJENKABJB@K#7"&2KV4Y,&%DY1?5:47[K&V*XRA;EDD
MH]JL9FNFR@8T'4"<9ZA[91C%(X.JJC6]*JRSE\<724IL>OI,45O18F[N[/\
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M!5FJ31Y=Y>>H31)ZD]2X>XLC&/ZEDB1U.K!(JL-)Q] 2_P 0>E_XF]5]+_\
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MK+6_G%_>WXV[\?J8DI^Z8D9W^9C:(VC;_P 8W^?X^?Z[;>H=0;UO=/[;?/\
MMQ%$6ASEKS=_AJRR\?GCIL5AMUG5)G<'*,)^V"^)'[9C>)CD!<2B9B>)")?,
M^E=Y^_?L_;YN_OM6.'@,?)FSX<_U/^'M=4M:T:]?*8]69JU+2V,L';&:=@A+
M.8Y335;6PFS-9@2H#1U'%HBZ:ZRE<"+-3D]34^CK=$V,Z##$>GJ!Q5Y/A$SA
MXO'NAUYB"=7297:[JC,L]Z?VJ5JK1=ZKFFKL77NQ+[&6R51KAKPUXN>LI<@^
M2I15JM.RDDPAT5:/M3!S'DWJZWD.>B:,(PB.K"!&65D;?J%V+^-Z K,)DI18
MS(11Q*+C/_4MU+<3M8M4<!;M&!CK:V8A==MNS:315D!EC46U6#ACY,[$=BA3
MVM>),964^Q6$=IADQ.G'G=34C+ZL.@Z52WJ$*+'L_ HH7VXA91&"RC!"I.(R
M\=JDY<MI?BUR8*HI,P%8[ R8"US@"NN@HV)ACSL2Y:YZ5PH'N)$&I<]G$A+G
M(X6MJ3/]240C<M.,7$M3JDGLJKPT&-J/@@>V6W41E^EVPU7?<K%FYP2:=PU3
M-U#MV,I#O;A"CN6["DDX:M9C);"63O[FP%ARS[(,WR8H.2+:?0]3FG3F1TN7
MFRQTP(O3<@N4MY .VV^X8*Y*"7FEZ;CLO<[A5ACS\UP[ZNI,5HS0O7A9&"NV
M8B@^5C-I;2K"-TQYC(*KNK5E@P98MIK;]A :Q",>7*Z_-\_(U@DA_J4K&("@
M$<!M$:OW7;=A0"GM62G*#3^Z-<*E63P)U+=_-YL#=8IO[) G38JA( (\98LE
MH4B1(NUC3CNDDP$B)BR_J:?,1G#1T-&,(1E_ILL#,<]*M2$KSQ,E"7TU.G*3
M^U*.=L;OW\<<6GUEFL\ZLE#TXZJ! IRI4I(+D!@2'>>*7;0@QK+ 06$KZE\!
MC9N:F<KR<92E$UF1*<94R6G".?X<^7!OPP,V17M1!-AWQ^+.^>#F]XFRMFZZ
MO<MY1E<ZS(4-0)DC"S$$1A8 H)<&R?B @3F.<3P_ YQZY&&FNGIZ1)E&\MO3
M'IM%KM3@_H\'AH;KJG>S%H9Q\-=UKP=B[%^(\=B(:VX@)@#"2O7;$N'B,.Z8
M75+FR9/9;(DP!D$L89$;E(4.9]:YK7]NFD*K]*1'J#>J;*P(UVIO@A#1,+=G
M\5M5_M_"WY'[]&1S6A].+?\ I%>D>3%*UP )@*Y-$YAD@GM:Q,[K5#)?S!4C
M,Q"Y"1$)R_J/,D27U&'ZF^LBW[KQ9ESC%I2%<#G+3A:)9W-S(;8<#YSC:^(?
M2N=U!G-9X#]2<=7'AEL38KUP8DJ]N3*26-9BFDU_7$!)F*QJS.X$PFA !9U.
M4Y7E]!-.$M756M2;;+2G66G:.,6.5.W%>=HTU&E2[M*\YS9\8^_%GKO&<A8W
MCEN6_P#/SN,;?._X^/XC:8B/SOO%:P@>;P><MW\'QFTSCBI(J_&7SG'Q1XRN
M+[[^5#O.^V^_S^9C\?F-XG;?\3M&_P"=]IWGU!:O-M=NZ^ZOZX/Z</;BAJT=
MW;Q9=;]OC&.!C5VGAR]1%Q*YC*8AAW:#%K6;FB(<K6,Y,CD*,DN(K.$37,S*
MSDHX1Z6GJ]"VXG43P+?N?B&=QSEJS@D:&\%%6[UC;O?_ 'XJAJS&NM4\WDW)
MC*5[@%>QF/E]G%FW]FNI2&VJR&.!>)R"UPY8<%V%.LL,&/WZM_E]1C+2A"4>
MO3Z)LEC(I&YHG3[S]/9N)$,'!I5+3.G*R;!]U;_AV[-WBZ5J_F+]90V-/Y.U
M42("U*FED)F)"M:L%6B7LXTUVVJ:!DY=F'6%LJ2X4S/56ZSE(RU%U] U)^Z]
M18X-1B=2%%0KI#I")4@K=&E8EL_[#&\^%V+L\9 *T;Y'Q^E\/ES_ -F=I^I+
M_->$S[+<BG%4[R'8V[WX\VS2M)?5M6FHEB5DNV8O SXUX#2Y_P!+UN=U]&/^
M>A'E=*G5T2#!U&+9(F^Z^JMI%AVX#%Z7I[Y5O<<?)EK!5HYQP<:%QF-L&6J<
MWERT\[%U\J%9+,2SJU#%4T6JRZV3C)M77<37HKLI^P@X6Y5NQ;8]DD.=ZCJZ
M\;Y'E-#ZQK=)+4=2*<N 0NNCKZ0&0RFWD  XG9<9-%15?G<NON4;)5<6UT5J
MNEF(MV%)+$8^*5VQC4HL.(Z;&T2X;F\A;(-.!Y"4*:L"F>$2CE'*<YR3H]&F
MKKZLI]6HTL*O],:Q4<V]K+:>)]2EEGG&[BNW]:\<*:^J>-IEFV62[;RA3$3_
M (F2-O71L&4$+B0$^X.9$BXQ ,82ND0G;@QA'2C"/3$@*A42HVKN9Z1SWSER
M0)6I:-UGQVMQBO.[CN<.%/AE>>IXO)H!H4WX^L!R%@0K@VNKK<Y@M-K (V+;
M+#$AW9)D,@43)<\^M:FC+7@=,HNK-ZI5W(AOXJA,[QO?@YIZ<EN4NNL$:>W>
MN[NF.RU93%FSH?0..?6 Z%!5.NU2*+FW+ 9>;!JY5XY07<Q0H=82[K04-ZCW
M8 F0Y'3S7J.M9USE'W*BD:050]K36UV_M*OIF51:"%J7F]EK:WY/LK#(>8ZT
MR4:4QZ:QJ7/,H2RO:F.03V ]HR^1?!%( ILSO'&1&!*2OZ'H:S3G=2482/9]
M,ZIY"V@O=<)X4KA.LC4;Z78E1MV0P5]]P[9X$\[K?-ZGJ5%Y)9J8EDI;"+W4
MNTXC8RI2?=</VGS"1:9QPA!1)0<".]WE_3=#DM61I+J+%8.H'4,>[%#-IN5C
M \0=1F]/;N1;W3?P5F^^V,\?FEO'J<OJ4'XEE^Q-A@S=R-A:O:UZ9@'9C\<9
M5X:A<R(/??@NY9EQJ\1,1.'/<]+2TTUC2ZX/^GIB9R7*>3W&Z;#@,5Q*%]/D
M[V8$*"]]SLT? @V;TO3PVE<KC,7B@ _<7PJNLM&(>>VZ^(;;F 1)[S)[R9"!
M3,CM$\K/5UN8YB.KJV_ZCTN4#X[ W==L[-\1F-6#73N8#:S)MVWS6W?AI9W_
M -(QMRWZ%S\1\1L1?S_'\[_T_/\ /K1A^E^_^QQ75+[;5\O?_;_GQP@,S,3M
M/Q,1\;[[[_,1\S\?&W]9WG;X]1:JDQGQVQL[96]W>[WXAFW)=;K@OSVO;/Z=
MN]<1>9TUBL\L@O5^3) %B\(GF(K.6K&9VF)%;9E@#(_!S,C(S,SZ49R@W&?3
MA-^SO0G;=Q=#P3JE0&SN)_QM=>:+R>!B[@+U)Z''+<C56JRLI6DCDH:N&#%B
MO D4B!KX19(IE:> 3L4P8N:ITO[$L&!RWOD&WYN^"DL M.-K?&+.]8?/G?A:
MY_1F"U %N]9Q>3=9OWRL&P.E,)FK2M4 &PP;2>RNQ%VT2! R-9W#L L6UA)=
MO0YN>G.$XZP.CF(RBDKK 2L:Z38^[Q&4.I5C?;%_)V"V\O[/%7KWC3(:6S[\
M=DM+6\YBDTWW-,9# 5<MD46@LW+M>D.4OOJ#CZ=BM2BFF_71="%M$[0JA=Q9
M%V$?6CF-"$X<UIPU21I\U#6E"">VWZ84RCU%$J'/2[<5C22=="@62]U+>+^?
M@\?DXG8OH5:K&P*%K"V!K5\/DJDQ?S#+=>ID7M4-E:;%D$L8NBEU,BKG-5AU
MK)23.IH\Y",X RE#5.J6M%N.D'5%)H] RKJIMI';'!IZ9T&08Q99,V*_=[E8
MW*J^.3 5-%4KC6ZAR5>E"ZL7CI &2IQ8J0N+I /O$2+258MJJ1<6N:]P$%(V
M&#-?G8UN8Y^;"')P-5MCU/OGIVUU>VT,+7S:'>I$A/WZI[AJB[E%L,4?E[V.
M^.#K1&E=.ZTP&4?B]4XC#Z@J:D>&E*M[,HJ3;ID@K%RM&Q-LP@5I)E<A"17%
M:S,*$6$85^<YSF.2UM*.MR^IK:4N7C_FIQA)_P!:,DBV'21Z@7:XY;16<'3F
M/TY1C(6P5D]+24WD._QVVXA+.BL5C=19#%ZBU0D'5 -EMY*M0%B^ ,6Y6-@5
MK8ZNMW)=1_&%V)WLM!:'"<$EZEKZO+1U.6Y192.F$:ET_3W),FQE:]1:E /8
ME'3(R>N0CG.,._W"@<;5GRN<EA*E74=.QA\L5>E[VLNMV6%Q9;(H*7!6YD#N
MH'I%UH2AW:02,2+"@_6KI\QK2Y24-;2C/5(#/I%A';-E9)?)O5)C@702GTV5
MU4%N1**RXJN]X,AG@\JZ,Q]O':ZU%^IM.-$UJEA+:I GW?N&VK5NX%]2XOHF
MA-=5NPZ"DA0Z3(>PES.6\]KZ>IRO+L2'^;EJ_4'. Z(08RN+U8 3.*LX.1B'
M2)[5R!11Y<F;SAPE''/IC Y;5>JXPE/*4KE[,85[-09"_7G+5*M9Z'-J*RDV
M6@MAV'+.4RULN6TFW*L'-)Y$+FN<T.6Y1EJ<M*$M/6#1T&1I29-W.,97)B=)
MWZ,[%G$6%_I5LRVJ5>]WN^,H]ZXM9INCI+25"E1JY.E<KX;W"*3Z4+HIRC(J
M6;%M@*.":RIC46C)O[IK45;N)HL6Q0<ESFIKZFM+5GIR-/7I8UU2B7U19-4=
M:&3>UCQ>T(G33CVL5"[H+KS;=AQUX#!1I6V[)U[N4O\ Z_8JWAH7FI(L?:MC
M55D)DZS#2Q"J>,[:@J&%@+'(IA$E"_0M7F9<[IUT0TWEX&F]#C4A%6(W;UBJ
MF$O?OP*4"$F458O9SGNU7[45C:][ :S(NS'#$3QB+)'/QM Q*-YGXF8VY;[_
M (CYWVW]!T4&5M%5GAC%_;S62OWVVQ\-UQ$UYW@?GY^8_,?B-I_I\1/Q_/X]
M.L636?%(XP^<9 I[T>> R/<_C^F_R&<UC/$@!1&\Q$Q'XW_I_K.^_P#'Q\3O
M_7:-O48EY=UQYQ_/#=_8[;N>-P*3MGQMO[4[;N9<:[M.MD:MFE;7#:]I1*:!
M1$[@0SL4;[[&$SR64;\#$2B(D8]3C[7#7?&_]XX19XH7?%]L8VS][Q?%<M7X
M1^EI5*TJ!OZC7L^^"12;:0+BF%B87$$<UX: V4FHR!A*%12GK:>ERFI/5E,U
M),@B5>"\XQ5K]_N/!XD6/4>Y)4F;[=JJOG-Y#;"[MZ5Q>2C5E'464G"UBI!F
M=*5D"G8,JV@.-:['FP!MS8AI-$J+9L56*-C60"I+KNQU9Z<]*>B$Y,S3G$VE
M'>I:8U5E["4>6DLFO;0)O]W!_L?FL4(_3!8>67&Y2&EU,.3Q1F4FE:A$HIDU
ML+%58#)51]V%Q9X";EUR-8SZWN:-8A&&@!) EJ=(1"3?5!Z6\.-_OOPDS4K&
MMTNCY[K8&=]J*.!G$^1G5M69_(:?J?IU.D\C#*U9;6G$W(JPHL?3KN][^H-D
MWL%-A)P]D)JER.W%HCL:_(,N5Y9U)FK.:0=*QA**^[4U* .EINR,;K!5 NY/
M:L'Q]BV]]G+\;+BT=B=2:^BQD<;.4]OC&J/(G?>EX6:AQ+9(:_O"N ZRT&,.
M"%=CJ&0L*$B/UF\]J\MZ=46,(QE&1'Z<8U<<5=."XBKG>\CP72;%6FZMK/@^
M\NV'/#=UIJ"IIZAB--8ZY!ERFO:8N1!UB[8&$E7K#)",!7W*M]T21G+1GB4B
M,8W(Z#S6IJZ^IIX@DXU9$+NZ^0[^/N<'; C:RE+"95QVN[+?%';;A1OQ^GDS
M9Q#T)[(0QSEK0NTSWD!"R%DG-4TUG.Z4.:,$*E[<EFW>)LRYCFV4]6,XT-%I
M#ITZOJ@!3)\TV?AX/&&G62K<UE\=\[]P[9W*2.J].YNO>LXVMBK5,UTT19AH
MLF4GCY(WW5L-8$F8E36>V&.T%FQ+"L2(EZZ/T[F^7CH?6YC6MB]4*2Y%6DSQ
MV[;"9KBKJZ.I/6E#0C+IG+IBU9DCGO0*N+X8^A_&&KM1^VIV,Q;3%4H$E@[C
MR!#"E*^PP 2KFEIFJ1$CF#5/*1:XAR>;]:Y+3U-0T>5AJ"O5;+#VCAW\O<NJ
M,\-+0U-*;]35Z$B5LE5[CW$MD+H/-5NZ,=]/[!05;)9%SV*&$3V762QPP(&M
MT"N1ZFQU["WL9,??QA12<1F:GK6LD>C1TM.$?TV$T+P>_J7'9[9SA'(QCF+(
M<JN"[JQ*P^,69HQ1OI'PAA*QA8!E8O;?L.,9L.<,ERDE[7.<$8BPA4[_ "@$
MR8"+.1%2U_4N9USIE+IC1[8$8'G>$8N<7DSVX%.8.PJ7=J?;?&U;?-%\6Z4A
M='$T*R9F$U:]*NO\<NI*@6,;Q$1OP&/P.V_Q$1'K)B7+.6G+N_ER^=Q[WQ"2
MH);?@_V_E63?XX[@."@>,P4;3'*)^(CYB)WC\;_,QM_2?Z?$>)%H7O\ WYX%
ML_HO!ZG:A^1KLBQ66]26@UP1NT9CM)'+V]EB9^Y!6DO!<&V!$@:R"-I<QJZ-
M]$JOX^*QXO%_8XG&;&PKLHY_E_S^,\*_4/B^Q8QAHC$XW(S2L6CQR*ZEDJW6
M)B[0#E:-^5TBL,;70##1)CW##ZPUU[)5:TN;8S'KF,CIE)DG3U62D2+E1=]G
M;Y4YJ0E1(8MEI?W[5W#?A(Y[Q_CFEDM2V,"K E#[.;U0BCIP,CE<V=N@"<@O
M))6*L\ZPJH*ETK%5)7!6F$5^6/@&-T=#GYZ/^C#5EJ,?;IR=1-*!!.EBVQ>I
MP"O8RT)@@SA(E&C+)[2!K(7%S6'>M]N*V^1?IWTOK#466I8S2U/3>.RHT66;
M&)G(GC\KE<=-XT6<I[12VJNV R&.K7ES=I_K'.HVVK)*A5<MGEO4YPY<GS&K
M]=ZFXSE U#3FQ6,(X7:Z]W2"18YK;]'_ ,1^L>B<S#F.0UR.IRY>D]+J1TV5
M'5&'N@RZ;%D6BUYXI_Y&^D*:>9.C2PFC\WIA6DJF(Q6.R./ECJ&G\SA I9V_
M@<E9J*R%?45X#.G5L6ASP5\#V2J59>XZS0N0YCE^;AHZDIR/IZTY?34)2=H]
M?2Q*CLBQ.J\(4^C^B_\ U0U-'38<SJ\_H<[K:QS6MS6A.>EHO,Z$V?+FMHR;
MU.6(2G.4=(AUZX:<^J'L*4>1-.^?,*YVBL)I?/:.2C*_J"UZ:R-2XG4M>K0K
MT,EBM2U0NT*.(4>G\;.2M.MHR=%67EU2A0JTT9',)T9]6K].7+ZFGTZ4M*3.
M<HRZH1G)E""DFK8Q$263J5HX]/\ \,^H_P""->,O6?5>;CZGK\WH:W+:^GS/
M+QT]7D>8YB<Y<OK:!.M75G/F9QB]4I1CIR9)[3AI:0\Y>3O*6H-.%XGTY2TK
M9T_F,<W+Z[REZFRW?P6DKKU4[88I-.C:;C;F3HK ;.6R-2U:KDXRQDI6TF#Y
MKE+T90.F&E.4NOZ@LGKRD(C*KNAVI)#L.-J^B?X?_P -/J.O_B/G]3U;FN?Y
M34TN0]'T(:NEH\MK\PI_J<X$]/F&I?Z>GHQ):<:LP6Z=>?5H[ZA]0Z+TWAL!
M5M:PTWKK.Z RFKA,5W,B&&T?4S&,RWZ+2_6: $5 NK]JN9N_^KNPN6N6<=-8
MM+YJN=.L\D^SQ/3=+3Y;F^9Y>,Y_3A<9DJ"$I%E)3T;%(B]W-BE_@*?^%/\
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MN48\;6/B%MK543)L.H(0Y-<&2)&<+@EGQ7)Z@^H2GU"?4U$_BP,FP1RF=O\
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MJ:JA UTS8NMR!,6"P (*&GJZNI+FF$AA"I3$ZHLNH,2Q1U-Q V*X+%Z6,"Y
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MK#MRW(NC)NS[-,:?=DK&6B\][\-CK$LBQ56V&JMBK\6YK:]PO.:_FTO[R?\
MCANNQJ;2CKV*\/2R8D@= $/("@UF._\ E)9Q!K*(Y <"43!#$PJD9@ON#/4D
MODLHJG(X=N%XJS<*-OY8VQV?GA&V?'S;N3RS5U+M7C9M"FPQ'^_:J)ZGJ40D
ME]>RMAR1&,@UX;,"(F"]6SF9A")$2&UW[6[N-[6!;'S6?X;<-33J%F20RIH
MC1APY^__ #6C4?@C+8)YY?3F+UCDE7B"Q?IIIV3K-L6[":XA6HR$9>N%"K*T
M0%A]A<U$@1>WD+3;6YR7JW4&ES&KIZ48?IDQ1F7D98!5ZO)G*<6]?G-+7OZF
MB2G&,=+1G'4 AIC?3,ZCK1!),7IR6J\+C)>(O)%ZK7IN\?YR[2K6+),3&%X%
M9[8%B"$6"F5HKFR?<])2RVSM I):VLLZFCZIZ<.>9(65G4D^/U5>&LQVK#FJ
MIRU.DJ.I&?M"^E&-F:4NQS9M5VM/'XO0OEC%UJLEX^UBSLB4C1I8-CFP1 _W
M#[5I(I714M0]:@$H6V5H%2R=*@,NKZAZ9J=3+G=.+#OU2N0WB(#)JO.+K=X!
M9:TLVZFKC;]1=RQ@NR[\7P<L\6^4S/&SEM)V'WL?+_:Y"C3:\*'ZH4%( "!1
M%A5>O ):T1FPJ0,2<069AE,]1]-&4H:LCJ(QE&3-Z^A$F79%DA),-/2E[QM)
M-RM7+%0>_41*KX+-FPR+@PFDO(>CM$VUT,+D&Y3(5G*9475F\R4N^0@ES+&J
ML$9E,R74]<!)LG[]YQ];7Y3G?4(2U)?2Y>,05)=+4I.U);]K1N\\2L(XOJ''
MVK?>KO'?'[J>C0OE*]=6K*Z/U RD7!EZQ-.T'.0KMD5*KKJ,*P0DL(+<:RI<
MY8K9LMD#L'/>FZ?NT=?2A*J>F-R8M68,7=KVK;/$V;WF)=M";=LT4T5W;SP;
MX7QSKD,WC('%:@H5FUY=:LE3MIK57,<;15LU<#'$&"MPR)0D$S(')',11YCG
M^5^AJL",IQE[-,?=J0D#J(@U*4EI6[#\J,HO3[JPBN3JSOY\Y<8I*>'#I[Q%
M><[*-U5758"Q<*S7L *9L@R9$B(QF"B5#,,F9F"<3.#!&-ACU@<SS^K)A_EM
M+4T0C[\R234>EHV8H[&;KB<I0.Y.[[/D[V.>WV^>)5U6=)STX'0.6NA&X!95
MCK%MTBN)&"#@(K3&["ZHB9+:9WC>!X4NC7YAZM6?>PF[7\2\7M37XX=GI].X
M/@B_MM_OVQXX&:./U'<U9IR_.F]28]"<Y1LWG7,;9 %("R!LYME<#"X_SGL7
MW#O,Q._S8T]/Z?4282N/M1*&]CQ_(K;8.(3G%A0VNY3MX[7MX;O[\,SR=XUP
MOE+26L_'NJ\?D+ND=<X++:7U+3QN2R.$LY' 9VBW'9:@K*X>S1RE(+U&P^JY
M]"Y6LBIQPIP%,SZ=%#9R8ND/W-L5EKQXK]3>;HL,*;XK?M\??8X5NL/I3\7:
M_P \&I-6XO6&1RRM.Z3TTEZM>ZTQHIJ:(SS=5Z3O5PQ>>IQ4SV$U8Q&K$9^K
MT95VIL7@<W<MV,AIS NQL)1:P%HTB;[%^/.U+X.'OS?[/Y^^VY\?D@\>_3CH
M+QCJ"=2:0#7%*T6+C#?IF1\D:^S^G%T/<V;O6&G<]J3(X>&C?O9+(+?[26JN
MY3)VE$MUUYE#IEX_F=OSPE?Q\"HO?QV^>WGAX.QTV*[:S5'*["B2P8XQ,+.)
M$X&9+82VF9CY^)VF)].1E6Z9VNL7FJ?S3O>7<%LCO61K(V57?'QX_=*9W ZM
MI+;0Q^+FVNJSW1V?;-?%FM*H47LI2P)]X0 )'1=R&3EPA Q"VNL:?0%Z@K58
M78V_G;5;UO>+<=:"$I2>HO*+O3E3MDM?CA'>1/&NK[T=E72F1NH]\@290Q:[
M5^<6ZD0NH@#)98567;(K#5DHX."7]TPQX3M<CSVGHL^K5E&]-Z19$>IG#/BR
M(_SXC)@2FW&F5Q(HX.]&3S?EV+XKU<\.^7T7+)5]':DL4KER>JK-3*>W 9%$
M00"@894615^X1)Q*6?*6$@FP*^CT_5O3'2C&?,Z<-1$E*2K%M"RKH"*WAW+,
M<#DQETY C%P%=2JY0OXSVK\&&B?'WFW119-&G]*9?%8_)N>)$."V?0&V"4/;
M5?%4[%."4E7-] 1L\4A,0PX"%U>=YWT;GB#S6JZTX^TZ9R=.1']+TTQPKTW1
M%NJSQ #I=A<_[7B[=MS;XX95/#^3<AJF=3:IT-E;.2OT*E1K<=IJU6BE-,F5
MX7]KC)@O2I=BS964PZ+/M36==31]9NOS/*'*2Y;E>9Z=.,V48RU&<ILVVR@.
M@[2C?MNKP/$C%O'?;*XVN\WNN3P\</D32.O,QF*MG#Z+U0PV**M#?TVXN4D<
M=!$^T(JE(04FV&(>+)6)[S G]\_3N9Y/1Y:6GK\SI"RD],GM15%9V^SDQMPT
MLI(7L7U4XOL=J^V5I.(C"^&]9YC.4;#-,ZGQ-9H5_?JS++ )EVTPP8$P]NOX
M(ALN&S9-BUKXVG#)%Z-K>L:.GHS83CK:K+_2(Q2E$)24/:%W%3*6*1>%98WB
M^^;O\9^7\\7$QVG;&CTHPNG,6];/;J]WEPK]XB*5QM74N3GK!C!@H+9I@!Q&
MS37,QR&K+6U=26KJ29RFJR7/8H+]H!7G%F%.+)/38^[I/_C6++[!FM@_D\!F
MK[&LJZC'':,SF79?37:\E57O@F!#SEI2,E-0^PFA%,H!JQE8,& ,/4M#EM/5
MU#Z^M]'3A[C'42EO21MK!9MM=<-+5A11U&3%QH[59_3Y>^:P6?&&O<GF+62M
M:+U!!7+6Q,L8NZ\:9S)%#EHZV"Q,]:E',S'2IC6K[&"$>NF.=T(<OIZ.ES$=
M..GTJ DM1?U7*/Z8Q50?%> "RB34!+<2[W_,W*[C^W#$\=:0U7C]6:0?<T?J
M/'5J.14>6>W&.K49:1J)5@F#(@-:AUO[C,5P\W*87P,"&=S7,:4S534OJ,%J
M/_&6\_*_"9"9J\ABFMS;%G>\U?YN3GL6_(/: I<:'5)09H;*&Q#(8!]3UL4]
M+($YD&I8MBRV-9B8B49D4!O?[?CQ=[]PS]^ HKMC&^SWR6=Z[.WX44KZ7_$2
M\-H#3O\ LZI3@?%^G+6CM"X8KV6+&8'2.0;@V7M*Q3_5)KY'35H=-8&M8P>7
M"_C&4<33QQ5IQZO:R.0VU>Y3?8-S;?P_&>'+[[[NW^V=C^^T_HKZ=_%OCZ]7
MR>C]"4,'=J."TAB;F1>N+Z\(O3*<H=:YD+%:QF4:<2O 5\U94W*UL)SQ*+H8
M]K:YJO)YJV]]KR[]_M\\/>>_[/[/S]ZW.'&-*P$3^U,R6V_R,[?\(B=_X_.\
M[[_Q^/34FQ?W<;N#(XO?OG;99%*[N/CY:OXQW/C/&P:3MHW$AG>?^Z6T?_:C
M>9_^/Z^E2Y<-8KXSY\[9Q6?EZK\_RP'^W&T*[Q_(%,;3MO,?$S_.W+_2/C_G
M/J$HZDGW AY1;KN_R[_UI&+^^*LQWQ_8_GC<=07K)+T+:HXV-3@!JRC^8,#Y
M"43,;[%'_E,>H]$\8,75H@V)CP9/MM5X(2 []5-M+_;DSG;NE$(&CL E!5ZV
M(K5%&R72-.3JS##F9*0E3!D(WF?M'8(_$#$;QZ=C.=_4M<9)9:O=;NNUW5M&
M>&)R'$I'Y<^;_?B&N^-L'D3!EZ;EJ4OAU:&G3(JNP$'6EWM(>*I@C*8EQ&4L
M/D<Q,1!=.>MI#].27ACU>V6WZ@:=K.XEE.>%*75N%I5UG_C-9_WXY;_C>L]0
MIIW&40&)_P!RH!DY*9F0:0,7V0>Y=DL6<FPNTMRB)AW5U\*1D^7Q_P!.5*[]
MN$(&16][JC\5_M_Q$!XG5^H*R;K2K-M= L;#'P\P*H3U/A;*8-3488RD%B\Q
ME\)&%2THB)]3>:YOH=.+ A+4^JB#*,Z8XEEH':ZV\<$-33%?I[^:?R;_ &_?
MB8GQQ4E)5N&-"N2X"0#'B.T1QB D2><-5$"/V-(XB(&('81B!L^8E(DS;W_4
MXEM8778O.;_'#FI ;-,'\5^U5_SMCCHP/C^MAU0FXY&636>;L>F<7CZ%:CV<
MY9"D50DFL.3+M:YDRWF7,"DB(EKSGS$^J<9#02749$G%-6UTU@3NUC>+JO8#
M[7W^U;>?Y\;-6:/KY\,2YB@%F O'D<>N*-.U$MFA:HPI4O&&U^:;1A$57((]
M@64RN.,0@:D1@+"&HGU&+_#=[&Z%5A; .!DT5[TEN=QS;>WS^=SA 3I'76H<
MK7LW=(OQBJ8#^W>;1MH(&&EUVLLHLS!K;9K5)XN 8=T0X30:8YW-/Z?+W'3U
M'5@R3!*$H1Z0ZR32,G#3?M\5PG4: -P)9&T5IO#CSW.UWQ8_5>+R&1.D5%,M
MZ0L0S8U#$2R52'PTPWF>)?,;[?,3^=ICI2C%>K9,6+_L\02]]D-E&[_I6_?Q
MFN$AF/IYT?J5^OK&HM%U<HSRCIW#Z2U_%G(725J?3. _4HQ&#O5UY,:ZL?1C
M,YG@BFNL+?U;)>X[HO6H;-^A;2E_#7[5?W/-?B/3(V[75]K=^^Y_OBZO3B/I
M<\4X;.V]34_&N!+/9*OEZ^4RUZ7Y3(9/]?K8FCF[62LY.]</(Y/,4,!@*&3R
MU_W&5O4,!@:-NZZKA<8JK'_2MS^::V_*-]Z_KPDEVOYN0_W_ +\-K3VBJ^E<
M%A=,:<PM/"Z?T[BL?@L'B,>*:]'%X;$U%4<;CJ:%G )K4Z==-="H^T% (Q^)
MW75 V?Q3Y\_UP.V/$[<6>+V/OM_;GXN6_2,C.W['QO._[B]YB?B=_P!V?C\_
MZQ_$;>EUQ\_R>&JRG&#&.WXKM_/;A>:C\8OMLOW,93A;\J7+)H6Y2?<.@5+#
M(((FP(7EJ2H&_P"Z5:6E4,V8!FTQK0)062]%;BE&:S;5]MOZ\'-1JG!X,'VH
M[/SWOSPOJOBG5559,L8-F4953;4:BR&/JGFD]=A*D/8J]76$-K-,:9]E;]/M
M,4[D(H@HLSYO3G-G&?TY8Z9$%"BKH/@LK.]7CAR<*235E&&C'P8SMBW^15;5
MWTM>5;>L)/2.#O8_2(O@Z^/NYK$G A$*8:K%Z,M9NV$=E:)29*,R;9E9*&O'
M<KK>2_Q-R.ERFE#F?=S$2III2I!>E*@F1MK9"\\59P9.%8TXOO\ -M9^[5M5
M7$?5^F3S+&0*[>T85D1*N*5C?TO"TIJ $"( O+*&3:4%R88&P@@&F[L@4#/4
M_P 1^FRT^F.M,DDK33UQN5TJ0R1\+V *+X:,022#MVKL=]N_RO:F^)3/?3EY
MMS]FE7+2KL?CJPUU&U.2P!6';FHGNDXU!+$"'&62FN,1)+4I<R!,9$.6_P 0
M>F\K%DZ\M?4;<Z.M$[U%O3RO=6L[XXE)DR>BH"N$5[9+Q6U&W%B-%>&=9^,J
M)KQ.-G4%U*R&M<@L/4:2FNA[EF-BZ.]R!-J$DUS5J7U!WPI00//<]ZGH>I:W
M5JR=&*W+VSG Q5$0NL#@/P[D*A'I@XMPC6SE'"[9Q9\<1&>T-YOU38,W:<;C
MA;O*3=F,,\T%U=)%R1=. 6V&V3B [) 2A!+GB3B)I:_H^A",G5EKZD$8A#5@
M11LLE&G%>;O.,<,RNPK3[2DG4-.*!2.U9I/NHJ"[]-?EX:^18C'9.U9OPY#5
M1E\4F0!BS!K:Q%E8 U.-A!%=L5Y-,[MF"2I<ZT/7O3>H",-$C53=&6H*73TD
M)-Q[+'-XJWB(1R:BZH_P-CWP2=JNVEV[\3NG/I*U->MG<SU*_AD#$=5:IE:C
M[<FI?7SBR=ZTH>X",8 )$%D"CB%D3=QZ_P#B32TQCHRCKLBOJ2T6,0:LZ91,
MXVK%-K?"8Z;&,8Q82%5ZG!;6U+VMMSML\/ZGHC7.G,,.*P6G+\PAI_ONRF*8
MRYOOL^1+(<1F2B&?<83O)#(>N=GK:',ZLM37UR"G;2DW5X*BT/[F*/,L&!MK
MNY;_ )UV>WXQQ8ZE7OGIO#(M5Y3D0H8T;M>26<ILA57%E<L I4?6WD/8LR M
MN0$43&^5,+ET..IZ7;%X^W91S5GCA6?SK9W/-9#%7_0R+'->!_'^I<SY S^<
MP62LY7REX_Q_BW7%E6J]5T0S&@L26IFX[ *JX[/5:F(]F_6>JW5LKA$8W-)9
MJ'*RO)1%MF\#J<(5DN[[;U]_Y>.%\WGM7]_^>_ XGZ1O!=?(U,U3TWG\=FJ1
M);6R^.\B^2J.359K8M^"KWHOUM7KMSDDX"Q&G5Y4G3E TU4Q>G!N1@\/BZ%-
MP_&79\_@V[8Q7#VW?^Q_Q_Y[WQ8# X+&::Q-#!86FC'XG%5*]#'4*J@36I4J
MB5UZU9"PB(!2E+$1CYG;\E,[S,N&WXEIB)C:?_*?^7_Q^/\ CZ7"_O\ O^7'
MX,;?G;_C_P#G_P"S^FWI<+CPQ0,^# 3&8F" Q$AF)_,3$C.^_P#,3\%&\3_$
M>D*9&GR<1D/;;P>?PC6<Y^>!3)Z*P.4:-AE,T6!6Q8NI6'U3D&!($+%K;%=O
MV_Y(>IG7/R$C/J<=74@)%PY1I+-FGO\ D^7B<5CLY\[/[_\ %? 4<)3/>$S7
M2RBJ@3F%9*M>K/KS8]C#@N,-DK?66)UY)ID#FVZPB^+BO<DAY.,8NPY_4BZ>
M(Q84DZ.JXFUTON<5M7X.+FGS&G<>LE%#]66F@P%)?VQW\BIS/A'4.3O5 PFE
MD8?'8#'YS%S4R4)FMJ*IDRN/&JV*E]\,JU;%Q=K&V+<WK8FJQ6M0I=MB&:/+
M^I:>G'4CK:\]0UY$YU%)Z4\$F,F..L*ETF!PB' YZ_4T2D1,P!0B]I@ #E>S
M98<5ESOT&:=R&L\?KJEH#5F&R@TLT-G'8W(X>SCU9W.W*V3O6$&V\%INGZ62
M#W=+"W6@A8U5JK/BI9/&,OQ]=DZ3I:G-:2QJ$-;Z<H:KH&",I=.99+E4GM10
MO;^D_P"/O5/3N2_]-&&ORFKS7*<QKZ6M*;"/^7D5+2!2$VNKJA$>JV[X^9/D
MS^S,\XW\]3?A/$NH+9XW1N+T=D,MBK&FL<'D>YB<C^OWLOJ3'KU%3QV*7EJ&
M6O:26FY3S#*];',H8NUBZA8ZP#'->E2UM;7GSO1JZ^G]*<X?4C!T4ITW3C%)
M+72S8DB,JL+X^@_\._\ UE]$Y7TZ$N;]0Y0YK7Y]YB7+<QI\SK'I_*L8Z9HP
MG+3U;>N'^9'2I"738LHK;\6^%OJV\2:,71T/]/'F+3N=F?85,EA-5852,/C[
MFH+MR]@L;2MYMF6Q.(IU,K6N2^?[P4,IE\3=@:0PI5YII<UZ)*,-*7,Z,]$H
MZ/HR4E0$Q8F;O QZ1J.W'._X@]?_ ,'?XD]:YGU'GO\ %/I.KH:D>OHYGDN;
M.;U72TZTI:[H\M_EW49I"!II,TE^IB)5Q)^G[S\&C+3)TKD\MJ3/VZ^7R#,J
MG&18%MNEC:]M6;$\HP\H^FU3VA405%)55)I1^VH(B6AZGZ9IZDSZ\=/2(L81
M8ZD[>JAC[4@('Q?;CQ;U3U?TOF_5.4U(=1R_+ZC%G&<R$=.,I$6$;OIZ:Z0M
M"O+=F/!GAW6RO%VL]"ZTQF4QTYO*V[C9M2)\GWL?BI1:QP0T&K5194&+M=MD
MV-R*;$RR0;S'&Y_G>7GSL=?0F3C$CB(Q BR]MT.<W6UYK9I^M^I\G/G/3>:Y
M)C)Y/3-,--J4HW)MD@=;U6KFQ4"^'_X.T#D/&?BW*:.R5I-QV.MZJ<JS5QMK
M%575K[6W$L"K;=9-9G#BETKM/KL=VG7.%;+7E\[S!S/,2U@Z2408,NN10!G=
M  L-_GC#]4YC2YOG-3F=&,HPU8Z:QDP6,R(3+B%Y_BI%R.>.?6/U3>-]#ZAR
MFFLW5U+&0Q-KVEHJ^.QYUY.5J:+%$[+UWDE@."4L.NN&[QPW@ADKO)^A>I<]
MHPYCE_\ +RT]0N(ZM2PTJ5Y\U17SQE3U8P:E=U>*V_?^6_ ROZT?$C;2*BZ.
MLC:\7&''#XTHZZX$;&?;G)(HCCP %"QK&2(@LI*/5F?^%_5].#J3CRY E&+_
M *WN&55BL%IEXC_F-&R/5E0JO.W]_;YHH_\ E3>,8J,ML#4*A""(%'0HRQPA
M,09KE>4-7 =XG<VAR&8(.0[3Z#_Z!ZAU$ T;;_\ S';\?\;/!.N/S_+_ )_[
M<>9^J7QU%55V,?JTJCTRY3XQ5&%G$S$  D>6'FUDSL*PY3$R,,X2Q?-2] Y^
M*G_V_48?]:ZS6:BI?9V_'#DQ0+S]O^>)O$?4+H[-2/LL1JV0*%\7,Q=(5GV1
MO$+XY4S9,?B>L"B)F-YVF)]5-;TSF=#_ -W4Y8V0-55+JRXGAK]VC>:)V?MW
M_O\ EP<W_).G,=35<L^]CL4#YJ]2(NJ60P4]B&60V)<D(,$2*8(OC<(DHJ_0
MU))$819(#*5%NV:3M^-^%3G&W<SOVLO^_G@*P7U!:*U"XE4L?J94 9+-]O'4
MD) X*0@9/]3/<CF"@!"#DY$H&)GXFQK^FZ_+P):FKRP5:&K%>FA_Z=JK.S^Q
MPR5OQTO\Z:1KM-+<=J.&1:.H$%CZ0$YJS:!RCLR(=@!U1)3$24"Y,\8Y% -_
MZ;KB1=7E[8$\:D6HN1_2^,XW#QEZ>^/[V^^WX1VX):?D_3MQ4L%&55 +@V0V
MM7F5_,1Q+IN.'E,R,;04Q]T;S$;[5OIR,+%3"C8IBQ"D=Q.W$B$GQDOOXOQX
MSQSEY7TPOF;U9.M6$9GW-BM76EACQDUKGW<FQ@<PDX$)@(F"*8'Y]2ARVIJ%
MP"7;H"Y76^U;8WX9@F]?S_W/W\&_$)E//&B,6YB#7F;9@L#@J=.HT&28R<*
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M!! R8R*%,EA#!KW%<$4=@;Q]P[N:&LND]-1U_P#VE_C[4.UWY['[3_']^?\
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MB&E# !A&IH@.6CJPKJ@E@ET&?E_O)Y.'8H6F"K<5DL?L_'_/$S.6H1&_=/\
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MTK'V,L=R:<7E@W%/2#ZTA)=B6,. 9$E'5$1.\N(%QN11O+6]-YWE]-U=6$&
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MU(2C*/ZHM?#_ $<4]OW)7_/$=J7S/X_TH LRUC)JF4A9(:V.:]@ 7^670);
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MK#LWPP=2[ NW[_AV=RLX.+;X_,U*NG\9;RMQ%>#J+ F,)L0TEQ*HD(.3<4E
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M6,!FV(>+Y,1LV&BI,5MADALLZYE4JV80QQ[@,97Q.1Y3E>J\C#Z4>9Y2'T9
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M;7>Y=B+L*-1V%!,0I*7]UD%U8&)(K,$WGMPE>F\HRK6FKRXSZ82_BC=4TER
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M'COR!DZN%Q;\I6L-Q&7HT\E33E:5RAD4XBTA#JQ6*.32FY7E(L(757#7OT"
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M._QM.?SZZ/.\OJ?PPC'ID#<E96K8.^]^'Y)Z02T9Q2@ZHE5V.H__ %LOQC@
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M5V3B'5".4"_(]LEWB_-83!WH=SODO.ZGLV89FQ3B@4%5?N%$>5NA;B#7* 4
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MSG$Z2F;306;5NAO\?\8(<?Y&N!H[*ZIR3C"V(E4H(("$)L3+6.L+5$ #R77
M35);+8V!1,@3)VISY3IY[_*0FSB0A+KB#747(E344+JW+6_$R0PR55%/EH!4
M##YVI^.*V:AR>>M9%%O+HL261KOZ\8V2ME,VE?X7M"M:!AM)0>Y=#ULWF0"
M3 '*^OY71T(:+'1Z-.>E1+4D5&35I=8[8M I[\5TDS5>WZ2PJU&[LIWH>SG@
MAT1XYU!;A+\=%K%5IM%D77[QK>X;;:K*K#3VS%7%K8B[9$H[19Q9O)-B B:O
M.^I<O";IRU/J2( FFUIK8Y3,LT=*4K=WC@L8L3I2G'OS[OBBS;MWH.W#RP_C
MNGX^3=R]:1R&?) "_(DP7LHJC:!-QL*.ZS";+FJD2$4BQC!$I)!3B<SZEJ\U
MT:<B,.7A(K3@$(CW4K+:J6EM;O#Q D=-BHHYZZ# ?PX*LM^^03F7T5JWR7E_
M;6LE9QF*6P)!<*63+5F;?N1;;.PMJR!(UHFR=D'+DX*)[8&8G6T/4^4]/Y3V
MZ)K:DHN^*WIQ=7U/QBTOB+'KD]7LI4[W>7?P5O\ ?)P59BE@O&\11K2%S5B:
M (_772!6 051! -6R<02E^W8$NR$B,@MCP22X5:L'5T8:WJMSU;TN2ZNHTC#
M*2VU=6=6>V#._$_TP\L6(;"%A6/A._P\5WU/GLUE;44TVDG;JV*-YM[_  K*
M]E$L&RVI22P#& 77A56S=(&640!@OI VVAZGEM#3TBS.D180TH42B@TWNBOW
MO'AXJZB2240C*BW]1TY]M4'Y[/&:'\<9G4=NZBA>8!V\A;;&1R#TME3[@K.Q
M3KND4 JI$@M9(X,@V+KGUV2E9DN?]3T>6=+K&1IZ)#Z>D6R214YYPX2S=3!B
MAPAU"G7MXQFK^W:\-'SL6Y+QMH_2]=M[6TCFK0,!2\57MM3[>26:I;:=6Y.>
M+'$EJ::F+8*!(FE$MB/57E_5.=YO5Z>1#EM/I5UM6!*I=HG45G&4L//!71(1
M&9+!OYNW$:^'S?>NZDU-4Q1D5?2C)QJ273L+DY-I5FPVJ9B<[+8PC7 KB0Z&
MDC;@,#!#.ER4]:KY[W:XR-26 U(J@!FRL=Z[%<!2FH6%YQ?AO:O+C+@X5>4N
MCF*.1OY1]C(<@LVSN2NVLE,JDIDO;QE;1M]9$0'&TE[G:M]G8)[6C&.G./T8
MQTS8L*!$H=\F&_\ I*=N!Y=U^R;6YOP'Q_/L3Z;UC;L4\'CZS[ X9N4Q]U1F
MHE5J\3:8-2T++%=#TQ-6XA.0IJL$>T/[PDMS@6KR>C>OJH=<-.>22W<5>KSF
M+*^FBP.XR%-L'\G/SVR8? XXOQ]6-,+%[1Q$P*VU//!-L@Y2C><9,,&?B)8N
M((E"4[$6_P 'M*RX#T%E'_,=(2+TAC==14\+5[UM\;7?!]2))!:H7:_^-L_N
M_+P@/'>I48#-.2@U7@4:U6.:B5(MA2VE$@80P&.6];I)_:R$L6^),26R=;U'
MDY<[HP!82TQE&@23:AELV,E^3/"A>GU1=I2&RV\48JO%T=OCB?\ )%\)RN5R
MM$X7.S6JMWUKLD->!WF70(B+9A/W"$3!+B.,'L$E#>E1F<IIQU!LU)1HDE@Y
MNB[:3[[][EJR8SDB7T*66"&)6O8<55N?C@/T*Q6/R56ME,U9)58#19RS4%:L
M$::QNKG96CVZC:\^%0I4H%@;?VEP(E'J_P ]'JT9PT].+U5&,!3#(+O<Z1ZO
M#28[@Y>Y29WF42VL20M>]77YLK>^&U&L-+V;"7VZ=&YD52MK$/,S"25P$'/K
MP0" 3,+GD41N; @=F3$%B:?IW.:<91AJ2CISWJK%S(HE2 ^;K+Q8^J%"9NKM
MQL';?OG;;:CA0^2]69*]GJ^3?CFT4WU+- V:8JJ%22@E59KH[ B:PA58'N.0
MJGK@8-K(F#VO1^5AI:>IH]9-ZV4Y"]4)T'11U;7C/>ZVX#JR9U(_2"7=[UC.
MWS6UOP<0.E6@O+5E9*S<3CK2(8I%$*UNW7BPA;!731+ZPM HF7@EEB!,H.(_
M86M7J[S6FO+:DM$'4CUQ(RVL6K4W^$V*WXA"S4&@TW#+N3[5C;;?XOX\:^2_
M2C<;FK_8=1AU,?8"DROD$K+)6%KIS;94<P4B1NZ2EYS,60ZWP! ?&'(ZL>9C
MJ:,"#*$)3N5DO8/6$4MB)?A"RQS'7BPE&1)+4*[C65OXK:M_''7;KXE^,J6+
M-%N0I6U-6A$5%.>IC)B&*4N$C+K+0"5D)P9/F&RB!@E2():VII3C'J2$K92Z
MJJA8Y,;IF[MR^3:<(RBDJO<?B_@_ ^$^>-.-T!;QWL+^F\2W&4?:'>J64A[.
MZZXF0J5Z)>]4]]4F2[O./;6$;)8NP("4M!:OJ4)QU8ZFL:C"B=&(Q&XJ#2W9
ML;'P<#Z'/28NMLY^][JWM=8>_#JPWB7!'5R60U"_@]E*:U&)%QW*K&0#K600
MM)4\7%F;C)#J'$E7%"OW%'!!(XNOZOS.EJFGIR'2BVP3$MRI2IE1N%[GWX+I
M\N3B$I.,[#6:^S1?<MS]CO$Z0P6&3C:.'Q=^,9C5.M-RF722U(.1(BM%D2ZQ
MM6K+T@V5508T?@B1 <"]9^IS6MJL]6>J3GJRKI),NG%>Z+B(44#]TLXF:1I"
M&:NW;%?!AM[53^;)Z2)S#[EVM0M:FFPV1K,!7Z?B*T],(ECS]T9W7;3O#V^S
MX&,C" XQ$4]248EQ.EM^H$F4I50!&@ S@<WC-\/1;EM^VQL U^^<E\%E/1=W
MI37M "5 VK]D0I50@C97Q8S#"(F#,#+WK.!WB)AIQ!L/E$=D<1GT.6M:=,:4
M:)26C?(Y&GY3/R\29T? I\_->?#]FFL,^G$X[$C 4*:41)P9-$")[2^9-C7G
M).81S&Q$1?\ :XQ$0,1Z8G*2*[]MSS7^U_G;@=K*K0QXWLQO6/LNWAXSR[C;
M.3T3IT:1$#J6?P-\.OX*8KU+@R \9@N)0S[^,[]<%OO&_H<-2&GJ:C.),D:D
M.EP+*P_;<^>#1!<X"W?Y\_V=MN*<>7ZC<=K%2,848UV6)F.;?N,A2%)A5/(]
M/(848!8$I2!$V0V8J)7 "1>M[T=-?E]=G%313Z<8*. K8RWDV_XA/]=D16/2
M%UE#L/\ S7WX[L#%'6VBK^!ML:RWI\''!P<-8=-L!*WI=/PV4-E5B1B8EJCL
M%)%N)2/FH2].Y^'-Z-?1UJ M"*864<Y'W!1L?%D U(,=IP>JJS9O;X03%UOC
MA.U+%NI;L.J"JD>F+==+&38A=N[)S8FS8*H*5P"=N*V(25A;^9@;@$8&>AU"
M.IH\O'5):ASMEPB,=/POS=.:2Z+12F%RG,&! M)%25N^DW8VYEX,68XMA2LX
MKR=XW2%J]-(L2#9N7&U'Y%@49&.V#KI*7N,9E+!$-HYU62PH@QF.4U(3],Y\
MC'IU&"]!=".0E5TWA#_F[45G DW3VNP0LWW[_P#?9JEA,GA=*9R*5&Y,7\??
MNLKM*L=:S?Q-=R>=]Z^32AW:R <,\C@3K!P(HB9ZW4TM;FM"$]73ZM+5TKE1
M?TM7#TQ\E7[JNS>ZJN3C%)BO3.B)CJW!6MJS@WJW-\3&N\/C<V=W-8NZD:LS
M5MM.G*H<C@\"%(A:!H'7E@13^VLY;*^\B<$;5P/TW5UM'1T^6YB":A*1$E=,
M&4@; JB@SVPBG$=2,6<IP8[]728D6"X;X"=,ZCJNMPK(WKB]*WLECCR=&*CJ
M5B]&#N-;."<9+6L 6QCGUE5+ +O(G<+<-1<%>IS7*L],(:9/GH1ETRDV0C($
MU !5*"YC2=Q+J=9"3=4[VTXOOBJ'^EY'B!M:>G(2[,T+S(MS9A#$JW8JK763
M2[&56\E540<RF#'O8!2<!$NE<LEH\ZZ)#E9B2DT2<+.7QY7SY<UEE+2^IIRE
M&49-69WC=^:H*M+^2[.+'Z$\3X75FE;NH+NH;-:D.*58QJ**69=%5&%IC6R#
MV0R5A(V675S2 ))K16VR!BHNH.6YWU;5Y?G7EH0BR-34)?46)>,&'8QO67%A
M5C3T3H_5:1&D[Y[E7YQ5]^Z9I;3AXFWJ#!*K0W)9;)X^H>5:/NQ7IY:)?E5U
M5'/NJF0R;X;CK5^6<2&LVP#65F YXN<YO4F:.O'VFD6Q%HU$1C>\@"R[Q7CA
MXP)=4<T@77A6ZVVHNLY?%M#1_CO*W4T<9@'NTWHR@ZT%H)'L?D>-RP9RCL*>
M/<<+WE75'1,R^2,R3.1K\Q&1-F]6IJ;W14DQYN@*/GBW^A#>JH/-;W@\;U^>
M+(X[&4L0B*])(K7ONPBC=K3VV(WG]LM.>,;[1 B/VK$1B(BE:Y:HWJ\YHOX[
MY[=G/ YR9)M?X[Y*<[YV=^]5>R0A<D4[$1S\!,1$1,;R4Q_,_$S,SO,\8^/F
M=Y6RKB_ 7\^:P[W?=OB)L!GSO3G&&KSAQ^>."R(Q$E,DPXB?C;X$9C:8#??:
M"F-YC?>?G>)^(]2CB0K;OX,(?[8?&X<2CE:V<G=>_P!\;-W3WWX*<;,SI+(3
M,3$S4RDS$S,[1*6[1O\ SZCK5UM>.U;_ //]O$^[_?\ +^>_?P'$9DYXY:Y/
MQ \RC<MHF2)8Q$1/S\?,[[1^(^/G?=Y2(Z<17>S?&'&*_!>U\12S;*]J,7W_
M !3B\UCQZ&8F(G:-HB=]I_\ #YC:-]]M_G^?^'S6G*Y+=B;75?R,XKY^3'"B
M4!X;[;Y/]_Z<=J1G;?YF=HCX_$[Q\1/YG^LQ_3Y_.T3Z:J J[NK^3^6V+QO>
MQ+B7&^8':=XC:8GEO$;3'S\3\3^8^-ICY_UCT]T6[5D\.2(%8I,N:W[7PW\_
M%?\ /SV[=ESPLLMI(L2=_.X>R05C-MN_B23S0E!*D[C<=*P-\''&735XM2P3
M8L5Q(B!V-/F(SZ-/4'JVNT<*TIBV[<M#VX)&=%2O+]^V;/WVOOPIKX4\N5^C
M%<IK6ZM1=<*D5X6ZD),8MZ(-@0%>:[GH: P;5#8'K"3!BQL1GJZ?1)U'$A:M
M"*;X[6?TS@X-*D*W<KTAV<56*NTVWVS=>O(&"C2Z<5D48^RF\EMGW>3.2NUJ
M%8C)$IO,6A >TLHL4@58)-5ZK2C"?=5UCRZ3D>>CKRU8RU]!TR TL8ZD@C[@
MBYMEU ;[7>W Y")VZOTYI[%N-OGOV</ CELWEM2Y>J[-"69N'%6JUK%D/:JN
MH*=;W%A9B+$#$+KBY;)EA<>41,F0ZNAI:/+:,GEY0A!6?58U*3>^4V:^-[Q=
M6<;8Q1:V]V]UG>BZRID!NN/9X@M"9RHZTFRC%92G3J4Q-\KKNPP%+UV$K<)5
MF'B;KK-:M;)LFL8L5]FK:O@6,]/GM!^C.,M31E[IP+21*,:ZCM,,G<RX%XCB
M,@V^+O%;6&]8OSD>&!CO*6,Q5;'8V\A[:I7E=Z*SB62:._6:I?87,FX94, ?
M*(%:S8)1OR''UO2M?F)ZVIU!)+2J!%LH[8M3N\%)% $O=),1:ZL-XN\/:_&^
M."AGD.E7PF,O/]S8N7RM#8Q*#2LZ\S#XIDAS.P;"GRHVV'C68(KWK]ART#]4
M]+TZ6IK:L(2AT:25J120QL&TKWY&O%[\%E+$;?U=S:MLUB\E[7PN[F6G+Y7'
M^^"RO(5T5K*ZR34^JJNVN]UF+T])=3@6I+%(CC>E-A+UE]JV%H:?+_0TY?3D
M=$A'4E762JBCO':ZPAGOP-D=\M-#67-8K;M\[VKP>^/\'C:D6=0YM-6AB*QV
M(ITNH*O07(H!9!)[PXP"!&SM,+1 0L>)K$,OU/F-6<CEN5N>I*(:FI%ZL8Z8
MB7T&9=1&B3A[<'C&,8]4\;=)YK?'9*#R^&FYG4?EKIS&.#']U>DM:UI%;6(&
MO2^"98"9F.[<X[6F\>37;S$2!Q$AT/0F6E.>O,)HRK%^:7'FJM;7B+J@[ 71
M1OEZ?MXOP!7#5QF$KZHSNA=3HJC3RN*U)1LY4R6Q$N2RJ92R%[!Q1<"0+KE?
M"+K5'Q6K<IRM/4GRIS7+JL-:)$SB,1:P_I5O)3^_$9"^[+C>[;=PMNO-OF\'
M"8UWIW#Y_7?DRTG4*\;;5E\ECK=%TWJ]NPU5*+9S1.M6;,BTY4CB#1FP2T\A
MZUK,=_E.8ERG*\F_Y<U)>[4AJ&H 1%@W$&FW B.=S'$#W"12+&3E+WWH[[X1
MN[H7  4[E<,-4PQV"!U?(V[@):0]K%,1 EQ3,"!L58"L)$T@2*7@YYF5<9C6
MDRGJ&M#=TZN7M;1:WL+4;K>_O.,=A+ J6-[O8OL)CX\[PU[4"C95(;:VV]V[
M-J\9!?0'%"R81R$N63!6?.3D&@0\13"Y%].'TR0!TH_"LKN^]72.5+JZX+*1
M+4TR,7^'I0< YOL715W>>/ CAGHK6K]H:U<9EE6&Y, [IBM[0G.L@\5&FPQ@
MDA#'N,A8D(ZR$!5/3^J1Z2)*58!SC=NJ:B7^-^'YNFI1@],4)5%,V10BF:</
M=N_'!SD+3TX]=!*6PRQ6]RDH5,":',K5+,!6:8/L@-4O?1,"36B#(JLY$5=5
M+_\ N8ZA(D0N&H$E!W1,_I)&';OFN+&@<O/1FZDV.I%73*:947U;8_&;:,+P
M%WM.9#3N#K9NQCR;6?;1CKN1RE@0"I1:H7'9*N>[)ZJE4H8Y8[FM-@GM4 ]Q
M6WF-/5U):,=1A+2&?2'LET_PJ- KA[5CL<5]'5(,23'Z8J:9'W=5-)/+*A2F
M]U&C#.TAI?'Y(*^7P]RKG*;*N*S52V2)LW9IG3Y6<?973$:JZMM(58J!1&VZ
M)0SB3Q(.S)YKU";%-;3=*-:D8TRZ5NK-UINT:EU-@F'I93('TOJ(2C**LA*-
M\1:K)>]XVX>2M,DRK-BP1X]3JKW>\JK4W)U18DHKN"R2V+&Q62YQ3 QQCVZN
M0B45PG#GS9$:6;*1'IE)#I>KJQ:(&W:\F<\%^F73$>E@B-'5%:'?#_*@;X_:
ME&BE,Y^_D6-1CJ=/&NL+:"F//%0V]3)JD%,2]C7E8A8K&8L6M]RB0"%)_3HZ
M6ET+J+%E=,&T8WO&4>YV>)2U)=2>TC-]Q0='49!J\6UDVQQM1?QV8JBRHRQ0
MR9M.4UW!68WG*YE0V(JMXVI:!#/$K"G=>R^<%]T#GIZFE+W'56Z%G9:[I7V/
MVX'.;8,F48@#=K$=UW[MBM&;VKCIJSV0RT5\5@'UJZI@K%LF;5;;/Q#&M(99
M'MCAIK:NU7AIP2H"0CDNQJ.D:2SU5DM!'.<K=-A4?W0=LC^H0Z@R,UC9G:MZ
M_'['<>"_&:(RNU[W5?$5ALW5/2;DKM625,"UARBFNI50U+HA=<2;<.14#6NW
M.5!6GK#T!)Q!&KRY;#%M4WWVW:XA+4%:'M?VO&][_8QXHX,%Z9H@L!LG9L%!
M"<L)W3)L'>8DQJPF.J)GX2<D$CL#>S[ID'4.+E:?-^&T[7BL?-<"E*2B9/G+
MGYO.^/ >>.Y=1%:9&NA:@$BGBL &)CYB2*1&.1_'Y.9F=OF9_'I$NI#-G;./
M =CL=TK\<-)]J9'&;\8,!_>Q1QTTI&<I1GXY2X)G\Q,[\O\ PVCY_,S_ $G>
M8CT;!"45M3;+=/>UJJ_?;.&,7#=U=';M>'#G%;=J^%[Y9/ U,J=[,3 BFC5(
MH@XAC Y.$8&#GK"9+8.PH^)*!'D9"!USZDM0T]/48RE7MC:AYD#57NOQG@\#
M$I/31O9;VQ59/C/_ #7_ "&L@U6[])P+1PV)QJ5)R<1<KJLV[UPX"I-+N8EJ
M8M5IBPX[(KXHK.!1+F%Q.UH\A+E-,U^8BZVOJ3/I$8]1$VZ\%+%IISN--A"6
MN2J!8'>DZK:I3\U][[YA,#IPLOD$1BSFL&TKRQK=9N8E:%B++8UI/@L+<$FW
M;?:6!,&&#,N,2E,SYSG#E]"49:D9"Q=-H^KU^[VSC^HCDRO37;-\*,+?:4%J
MK;;G?':+M_X*,OI#-:RR"L<E(8;16&$%5[CG J7G#E&XFFN#'W+104B59L6Z
MKC P$I >-7E?4-/E--UNF.MSG,*(%FFYL_J15^>)R):CT2.F$<P?^I;N_(5B
M\#WQ7!-1G1>BU&0E^NY,5-K]UV0?#C:DU;&C[K;I)<% $4UOW9GCL4A$#E+G
M^>7K/\MIRENOTXR^78M\UFJ^>(O3#VK;:^7*T"?.$S6?C@*S6K]<9%JI&NS%
MXZ%VYIU9]JN6](+E"C6PUU,85@Q97*Q;7/LRAGN6"10LM'EN0Y+3@FH?7U!(
MRF-8\]O@6L^#AI3E,J,C3,+"5(B5^MOJ7]KIWQQ.:#U/J>Q;_3TXQEV'J65X
M66UPO@WK:2XLH98H%;I]@)8:SFN:P!J;)(D):#G>2Y:,9:L9?3))'3@R]S)#
M)>:4_5M>+N^)1F@7EM%_-X\H.>QD ['FL=65*-:<+I4*K+DHX9-ZI&"=O,%8
M<]D !357RB6<3!MF!Z^ I<3#I\KR<]6<-37ZCER51BA>K(;+\0P6K5HO8XC*
M;%C(,S6*/:+5NU6)A+[[T\5??9RMFKD#KK]^]S"3CFW:MP'3-9PA;54 +#*K
M4P^6-%LE6)6W3*G[D2>JBZ'+]$9RT]*$8BQ*2,9%4%EN=_R\!G"3&HVC*C*N
M'-EN,5?A+WL,- ^&L]E63GLFM5BQ">*DFKIQU:N*90-9<L:(2U<0 ?,V('C,
M')M;VQ0Y_P!;TV+R_)Q8Z;[74MZF)M(D9%S8;675Y-'1TSIEJQD2#!=%64UY
M\_)FQP\DJQ6CL=?970FSD0JB%&P'5*BOD!P]Z%2([+0\REK&KB5M@JT2*X@R
MPW5UN9U8DL2E(B9;1PEOS>.S^_$IX*NC"FWY=KVV#[\4QUGGLI<L/?22B;#\
ME^GU!S NNF"5U;3;=RM5!Z:EJV=AF/047[2ZE>;928-8%5)=QRVE#3AI:*L0
MT?JR#$NL?TK7>KP6XKN<4]1DS=3W2(2(@YCTH,I5:7O04T7? 4MEZ_5+-T)P
M]T"L6\?[BJJ4'%@;;E(]A8][:KFI8MD"*!$K)PJQ6,X+V86YD"<8:TYP8NFC
M<OTS+RX2L7C%U\\1ZF02B%-Y\IO^/&Q>U#Q/Z2\79O.8EY^W>0W+96%#83*H
MLK<PK%A=4&' V0%@3U2H>("WJ."5Q%8>>]9T=#62#'4CHQ(7IG4>WVW),DC>
MEWW\\2T]%"U1:?.^4N[K8/\ C''ENDAKY_&Z7KUP&U4R6/.P *8BN )<MRTI
M6@(KK!A@UA-.RN>COGCLHV2N7]1-30UM:2AJ0G CU"OLRIN.0**H!5*X=TI"
M9'PT1\XQL[!GO88'B^/U(SB?;X,;Y#%GHR)5()<,&9EE,"(HB>R>)&L9%8D4
MBR?Q\3'$>G?5-?JT^JBNLBI>2K#>CS]N])I$4RUX^_?;.W\ZXI#395;>;364
M!D'J]ZMM=<K P02ZO,6;%+&,[%+;'(#(0$8X[A(]FLG1=8+"CIDHWO@NS)N8
M:4JE07&,O-2*W[_/[X6QLK%<=69R[:QKQ]NI98#J[>W(RX!BFX9!1UV+9$,:
M0;L>4L$%[+6N?GCQ6CH=4/\ 2ET1T_>P?_R7;+W91CL%V]59SPKJ4ER)(,75
MA=_WM?$;I@49*WD4KN"'M&I=9%P"1WE[I8,I '"QC)B&FFO&TM(S!;)">7J?
M-,H:,)U_[ED?MV%,V=_'SDXAI-6EB7L[=6-AKO\ C'X@]58Q5?5IYGI>[8D1
M3%'N*_"E+6)[!398W8"%BN:RLSUS .26XFLK?*SD\O\ 3ZXVTEQO:KN566""
M#;]^&8MVGS_^J;*YW!\MCE>"K4)%E\1"\OFV(JXRN=.A?MN4J,/4K1[F1KE9
M!2*Z:HLDG<FR J:T]^OL,0Z,H<KJREI:<2>K-U-0QNWN9L>V,-7;@E*'7IJ;
M2H#;9\655/Y^*X"YJ9NL_&7L16QHIB_3G)7GY7'5JJJ#E66V;<+WLVEN-2JZ
M1654YCA.Z%@N2*U+FN6CHR^O/H9QDG3%7ZE)&+2'3NM+5MN> SE(2$-HL>K.
M,4WWR^=ROCBRVE],/SW+'YNC4C$E8<DVVBA5<GH?)T]E&!-MK41*:%J5IKSS
M$X=9(^M/+:_-QT)SU.75E(P@1$=RS;JNTSER4'!X]>H=,HA$<_\ 4/Q]G_O?
M8IQ'BW2FBL=C<=3LU58K#&[*])%6K5&MMR<.*T8 #K$@XRLQVD*VVIADKF("
M(S=3U'F.:5U(RGJS(Z9T7$@1]H$2CM[FA NVN+.GH]!1LUE_#AR^#&.W!5E;
M,)Q=*Y:6C]';;L#7Z )S#K;S G31(JV!A?#=H%13,G#8(QF0:493UI:4<3(G
M7;TQZ@5%<-4/?&S9P3VQLD"KL%NW[]O[[26,PX6EH3B<;;8Y>UP6#+"$&GQ,
M(N6!8"86X3!DIED@7'[9/C #"<I1FNIJ02ZE@5[H/8,9_;A2E&JC'IR.]_;^
MO^WFV1AM*7I&;6J+Z\M;:$1[%:(1C:43O^PI<,)CQ6'VL)Q<&'&XJ"!&)K:N
MM"Y1T8?3 .J0JS[W>XY0S?[<#M3\M^&K&_S?F\;6\%8(KU5Q70A*%*C]M"@!
M:0B)@H@ "! -BG>=HB?F9_,S,5HR:M7&+56ZSODOX?Q86R9*#R_/9^'=W_'<
MXUF7")WVV^9VG^F^\;1^8WWF)_,_&\?CT8RW\Y=@:Q6;^*[WMC@3XQC?S??X
M[?S[YX@[K3.)@!&/C_C^=Y^/G\[%$\MXF/Q_6/4M.2RR[/GY^#)Y=OL*\/@D
M?-;#N;CWW%#]CB&\UZC/3'CS!Y5:3;QS6$2SKCE*@;0N\GD$[\UKD8DP^)*)
M^V8+:?1N5Y7_ #G-.AUD+^K*VJ>@E+ISW:QW:K@C-@7\IO\ ^=^Q7QXXJ7Y@
M:O-8G&:OKJ8ZHZ:36V*M:7 MU-!ILH[9"064+!=I0,D(8!P4!^T43I^A2GI\
M[J\IJ/3JZGZ8KTC54H.%-Q.^<WPM68PT]0=KZD,W;C&YG-;]L[+/PAJOJU6M
M5RS+\7=?8QMQXG,&%"RMR&F22DY'8UV0 3V&/@5AM %ZW/\ $G)O^3P5*/OC
MT;]0]ZR1V5[H+\5^6D0U>J3(&XMYME27328K]]N//E^CC<3K3*Y#'N;0QCE=
M,3E3Y0LDR,W7N8,[!6)B&7%M9)0 A+V28Q"Q7H6OJ:WIVC'6AUZD-1IB]+ B
M@#$?%'4>7A^:.G7ZE",H%(FZ&*QA["F*-WB6\4:NM82^>'RLO#$WQR6) )$H
M33IY S!_4L9EC@1+%F+HETQ*EC B._:WK/(Z6MI2YF 1UM(BZL;J21_BK=NL
MU54.QB6EK1'3TY-DUI#9*N+V P&UN^4X5&OK=G ZERB[*([A9=4RH,#'?8K.
MFL*8>?5"1EL!',9F>V5-DG+ALCO^F:4>>Y'2D,H,*C"0O1<2^I/XUP4FU[-/
M%+5G]/7U,%25#X[*4!F[J_BE5VY++ECEB&*!]*K9P"*.6H-8-[W+5W <;ZP'
M$=2'V_8*B6=4@<;B4J?P*<-",]5CKIJST]0GI:@=,@K&.]6^TO<K<>&)YLO,
M,XP+BL_8>^*[UPILO[NI=I)0VR5%URU8>-5@.JS>A16$"4,-J%[+AI,, 74(
MEK$X9LL6:\&)&4G3ZI?3KK,3Z<%+OVV4^=N*TF[!NM^JLVW=K:)W['YX=6(T
MQ.H-"*RV.U U#F92QINYA+:;02_,5:U?(37IWZ?M^\;96:@U1*JI 628MI'"
MCLOY?F^:-'G6.ORY(T]..MHZD4*.W5'%RBE9O93P6M,JI0#JF!,;*  #XE63
MRN[Q9G%YG*(TSA-+/R@Z$IB2*"L%C@6V[DL;6H6$C6&TF%VJ5:'O2^PQUER[
M$0-;;VS!)G)<Q&&IS&IKNE_F),OJ,YSZ"/5FNE<U7ZBE+'-<7XQU)11D0V<!
M0]L5^V+QXL&9H'QXO(A3SYU0JUII)H3;1;*+.9I)GI!IV55U2\WI#NL6Q@1*
M2%5)DP17 SM?F;ZX$V1+49R$8A-PAD$*Z:/^W!AC$#,IYN?D;Q7;?>JQ\4O]
M-:GCZZ:E)05ZM14(4I(<5J4H8$06(Q.PCM/^6)F?F?F9^<Y>J1*6]X1NZ_\
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M1]EH\KR_*ZI*,H:EQ]FKJ7T#8W$C%;_^78*6W@4OJ3T^HB RM.H&@[^?/?\
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M#Z?7^F**VC=W=8_\AEJ/54+(F+LSY:W+.W].,1XUR"3D:U6I54F5*I0V\UW
M).9?9LS"S)ACR-RJ^YK;9D3:80,2,'7F%]!.2@C7Z?NT[U_6PQPNL\7W.P-[
MT7V^>"'#^-E4GM9D+JKB3>]GM*M%-)3UN& X7V$RS8N3QCD<$U:S/_U<!  N
M$]24HA'3Z$,)J2*7O0]-C\-]_/ UMMW>#RIB:U!<)H5*U-,?$+K*6D-OF8^P
M!B-XG^9WF?F9G>?0$UI-S>JKK.VWS^]_C=.%QO*NW?<8&?G?Y.8G?_3X^/Z?
MZQ^8W],PD]A^Z?\ ?A<:IIN_,<)_I'.?B/\ QC_E\>F(3L4+JFG!F_W_ &V_
M:$HV_C^\5_N<:IQ[MMH@"VG\R<Q$_P!?B1F?^<3^(^(]2Z)N\BOF[M<^*\W7
MC??B6:[8V/GQ_MVQQJG&V/G:%1'Q\2<S/^NT\/XC_G_'\>DZ5]S]L9-]\M]\
M?FJX6?E^<4_BS[&,<:&8FR127$"B1B)B&0,;_=O,_;$_,%M^9C[1F(C:8)OI
MRC734L.ZQ_EDR_WY5?/CQV[;?WVXY686[,3 BHHD?Q+-I@H^(G>(^=X_.T1.
M\?$S/SZ(1Q'80/+2>,A_+YX;SARAX^+V.U;+^#/'FK@[BKM>PP%\0:!'Q=^!
MB9WVCCO.T3\1\;SON4?'HD7ICTG>]_DK?R8#X\]E[K^.YW^YXLJZI\9W"=>:
M%R69S;<WBL93O6YH(J#-VRE*Y%4F4JX-%@\6<H@C,#$)&)A9_.P=2&IJ'1UI
MIV+$^/V,VO?;\<3&G]O^:_<SW/ZHJ/IRR^H\YC;>L,'@48K!3-G"T,5^GRBA
M<AO<!5*XH4%4IL$-QEE K8=BJDM@80N1;_S#H:#I<OI0694IZA<X83J@UB1O
M!OVM 5PZDJ$:$K+@NZ*H<^?LV511GO$^IKS\;4KZ3QGZ34M.XQ7RM"F=2O:2
MQ%EJ BL7)[8ZPL&)(*W7*P@N*3!<1Y3HY>,IRG)UI8<6=+?47>^SCQ\\,RL"
MD,XOSG<VV*_'?CSB? -YN6LZAU*FK;NM4A"ZU>W$P*:;#;15)RA2?\&;6RAL
M*EBAB(/W4R$C:YCU#6>7TN5T",=.$I2%-F?ZG=RBEU?[\*,DFSD6@=-45Y'S
MCYKPG8IR6BO()0&/P./PN&Q[(9-FQ%P2.9+<OE*@EMEA&3)Y-(0W84]8G/+U
M4T8<N>_F75YC5,PBIT1V[/;MC?=SO-U/%F/B[N]B_CN]WQPI+W@KRK>NU+SK
M>-6U!N$Q7D0>MW9$1!F5BM#( )$65UAPE#=R+M@%CZVX>I\EIZ,M'_+M2*&H
MW=- XIV;;,57 )192N2)\7_6C?\ #6#;AWCX]U!@-)4L%I^EC+MPWC?RKGM1
M4%UY4H(#6)*)1=LH7+6$$R,\R7 S(B&%J7KZWU-74FYZ16TTKKI6U?;B_L?/
M!20=6,UC'?Y\_)OMX.%UDO'_ )LRI2IOZ-56=2TCW"\NU[JY'( F:JW*E"3A
M4G,L%<B)"("$"1S-S2ER&E3]&>HX4D1(6>2U<['[^>!K*5)TGV$N_-^$Q_9P
M/7O"?EA@J->7*XU)$@0=DAKJE;(I38MS$,;!RV:S(!74HU$4<(%,;E>T_4.3
M&I<G CG,0N.Z ?D,-5?QPY89E/;M)_E_=]N)?#^,O,&!;C^A>,R%1+)]\FU?
MI-]ZI@N%BV*)"0))28'*RY'!1M#)#B"ZW,ZOI^O#4Z=&<-1#Z<C:"9;K*.WQ
M7@'A7J@D=1K?.6\.^/L-M5ML\3>J/ 5C4N1JY0D4Z[-E-:F+/1TMV*65]T+-
M1I6SB2F+4LNL%A(_MQ,-RWJ?-<MI?1&,R+4)2/>0_P"E<W>+^W"D$@&Z&\-+
M5^?N_'?YX(<7X-HX8)L"A=FU"NL4UF+""'E!S!VK(0PYWF>)% 1$;1(EM!>@
M:W/<SK=77JRZ7^$V"LT?S_!WX>-0?:-I2N;K:^Y1CO\ ?-< NN/'GF7,4;&$
MTOA-*X7%W0)=II9,(N-3L6X/>FL;WFW9<0.Z$+G8SAL*!16.1UN0T)NMS)K:
MLH@PTXQ&+*L,F\T[4;7=FZG4_/Y_[48O[8\\<&/\):^TCHX\#INM1N92XAS;
MV3?DE!VWW5U*4#1<J&.ITH4*4R42;EDTFJ@F%/J<^=Y?F^;.8YF,XZ,)?Z>C
MIQ_ANGJC89%QN+GB+U50YH!^V]X:L-\Y?.ZYQ'TW^5(L5K&7JXASV7:5K)6/
MU>6 ;D%:-CZBBKRR5@%N5BIT 4N6TZ_MEF$GJS]:Y"ZTHZYID6,(NF%'3T@U
M*L=Z$KY+X%'22U2[=AV[7?R?[WE.'9]1OBC6WD?)Z9L:6K4+-;%4,FFY%S(Q
M0+MN6\4P 7$@R&"5>I9@YXP0D2X$AY$0Y/IG.Z7)&K]4G+ZC!&-8Z(R,KY7?
M^7#ZL)3V[?C_ )O\>?AXK2?T/G9H,PN1\<>+<G@[5ZUJ3(UV8C  >0U?>4VM
M9U3966%F+.JBI/?2+4U@FY=Z&&#+4K-H/O/JW+=75'3D_P"I'5!"G5C1&7_3
M5%)_XZ5:?333C1[_W4**\D1"JDF7O#S4HM >6[<T:<,3>:?%'A9Y&_(2LZXG
MFI=9XL%D)"^KC/(0\K9+LTG8DY&W:K&'78PU*F-O=\\_]X][SGTYY_[Y/9_S
M?3O?\_V<[^><[UTC&;3XRJBO_8A.F!R/IH,Z-/YNJ5MS,Z3YM*U>OK4Q\S(Y
M^+5/WR=L&4DWHMFT7T/O9(O(! ,NT/N]V<G!Q#5 -RB:\]LY/TC!4N!$X^)2
MG,#6UO506/'MO/=BZJYJO[9C>_,)QJ]+*FJY<Q+4U^8V/83&PU-J#WIA6IE!
MN[[C:[:+?O8G3U^:5-F6Z.;RN<^WS)6O/>=Y$5DSI_%N3UU/8V-C15T-Y:PC
MLWJ,J)^K )!!M!:M-K6'4A"7*Q-Q2?W)RZ:W SSAM[G:M'>H^(D03MG3N2R#
MEN7>UT5:YCR@^;YYZ<=++O*>VBK3$P&+/\.3WG^4B)^RM?*>+#R6SD9WH7"=
MHM61PO'-?>_A\,QMR"8851)98+6LNB81%$D1#N3OOMP;&3T7APJ_E<G4SOLR
M;S]H;JJL@]I"ZWZ"7-GL6RJ).Z( &%%ILC91>?*+Y:Z_T';ISS5X##_)(KQ9
M8_3:OC$JKD.H#XF!OS'6_,K)B(N?TA/8/V:/GE,Q3B7<]JYS?'4%8_5I.(;A
MF]/B.?U,2)I9#89\'G];<<I;YP!A\&G]ZM[=6:.7QKIPB4.:-P6U?PT \[2C
MFH8,?J#6J?]>;?E@?&SA9D_MZQ6/$HH$UP/N SKRW'5)W'FA\HXS^#A5?NW:
MV41N5*X(Q' ZRWP+8LX@G5GK+=[!Q[>_I,?,T$EMVCQ/\Y9'4(!:(MLD5LN@
M,!I<1)<J@,/DT6*+NXD23[I7Z)I=QL8L=BA9HF-BK*$D:]!+*9ZE7'-2-E<&
MHSZ"[Y2B]EBSV64B^NY*H23Q] H:U[X@,QXK<!EPYY&X(A!H**I+RERGBUJ<
MTG$(*K\?'3%CF#[>.34;]JT_+48!0+A1S71098U_*>'(E14;2*]T!2S.)H#X
M,226''0XTVSI<9X_MTW@Q1?V]<ZL=PM ,+KLP[$[K;'G^[&J-C ^*9LLE4,Q
M^$J^>!HC3E[TLH@JC\G32]T=U1U3H3>SJ3SRQ?)RYV;7JPX*P-B>->34%D-1
M #1-]@ C!D1<P!_.NT9+']LO#R().^W*; JWWEEW*H 9EM9]6_ -XH%N.\F)
M^8["">N3^W*?UN9H']6U;<]K*XH$0_+<UEM'71VC7 ^=]W%9+)WD8N(QK;".
MV65@YOF$'(GUBD6Y3$6B?R5U$(\4&"[I=C240M0'OZID; =KO2KPO61'N'BB
MU,67M@]MF4&!WAB'#<'!6W%9EIX>S+C5@4MU4GEDXXY#UN23)A8!1Y^GX>B"
MS[;LFJ"KG @_HD@PM\*I]Q./L(9/$0VKHA]Q?!.V/OU8O7IF*0OPO*&:L\TH
M.W?K:F=5[3:MXQ#U_E\TS#)<XCLR]@L?V(<OGKQ/0/6]0*-Z(KD1$+5CBS!V
MT9IW?57%Z7+[L5KO5H\>--C9,N4*TT2]\[RD(?RFER\ETL-\<(I@"JZ:X!H=
MP(@+1]5W#L:'-:C4P#7]3^P(XD7RF=(K"0Z_N+AI0IS#[AKTVT.'^>T7[F^Y
MKH7.]M?LN%AGX1E2/A^AV5>HA=9/R[@=+M;3?.->Z'?--.QLMHUEQE=U?/:F
MF<ZAW>':D4'V CN?B6!4*[;<87!))Z_[H2^G['IJ(@V7>UC3#&>38K,COS[
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MY67]-;"@[PE;SWE9Q^%( @";#W/X4:^Y+@"DF(FL5L '$7.*O/V\9BM A34
M&%D>V? =7O8EQ7R]]@"@^L*%"[<O5-^^_4[X]:/"33;DZNH9VU@U-5LUM5CA
MZF5Z]_WE7TBX]?7KUH$VP, @UX&!@<&#G OGNF+R;M-_PT'+$H!+^,*ZZO4
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MZKT\AD\W.^-/%71ZO $/N[@(S!=E6"+)/%G6N8ED00%*]%U/")E7.2>A?4\
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MS"U=/[)W#MD=8\<:7"[&2D;RK;0.KJQ"5\1D(&NT!YI9DOCE9>#@A*>S\3W
M!1>I(Y^#Z=M*8UJ<4A8"*^$[6F*^SO=N=BLM.W8S(W^^NY2*(0MQ6]]2-YL2
M@L[$RLQSET<5+L!>\?GCTGA2I=H,3@Q/&(=/TZW)0E]\6CKZGT^:)6;OK3E]
M+&:S@E=?OC(W#0-IG6?'^)X=RWP<\:@?%1.>MNNI47*O[V0IC*WVDF5](N+X
MRV2&;ST]?V&G\J.NOF14S"T/XW;+P(C"Q.C@FL *2J[L,.LU.WU@.,SJ6>(Q
MWT#Y8\,G" [CLLS=]2CZBZPB>@[S?0.[M(_9E.?MTO)4J-2-?G,W+NDZZ41.
M%(JJ@ZA1[#)RYC<X"A)9<S!WV.^=. -AP%AW159)]7;G&Z)6).2W9*4D=DR)
M3T1_-DKU<+8_:RB*OISMH&]4&_["6G@,X00_]*"$S90Z.(%VR5 1-M3IJ"*@
M[]JK*:?JEN/) "@K>CBT(FFA#VY7U7;/4_?BL=.=R=F>UCEV"/7G3"#^-.(4
MDLRK__@I6^=*#:+$1QM#%HSS=3KI&/H^)"\JH+D4]'R@6CNE:WQA)_L$-1IJ
MO]17JNAT5M=_@5FI+:,KO9;V#"EZ[KFWO5:9B+UE8% /X8I>"X"!L "34.WA
M>#CED=?8J0QG%[_>08M6P8Y\SW)2,% >\]5A"G+T.4JK:^3T,=>QTL97OB#G
M?7T>,=I5J!BI=G;V@J)#A;&U^8Z-'A,!VOHM;5UC])NO[L_WH3N!WN-"9.Y*
M(Z =<^>=ZJ^FW][<@6J?::Y*"]3P*^KT?]E7D%ND $T(N!Q;0$6UXTB]M3D7
M?#$YY6CKW5^@O/EU\()B-YX'Z2TMS[*.<G:'HW7>5L4Z.^O?[BQ&.\G4^Q>T
M$Z&9R4K&+1'C1OTM9 #B$RO-^];EA]^ >REMEB>S@HK:!" H/$9J>EL G#2&
MR4"0UVOV[]K3=D_L<*K-N44UOR#QZ:\@H63!4 G;)"29.Q_Z, :33CU9F]].
M)]F^VSTMUWW_%O&,.&5QJB*&3>9R9'2N*[A-83Z8)BK'N@5VFA#,4= 6,D]?
MI?<XALR[\];2=3E<IM.9TS@>89)(Y9+$0Q1,,NF"/N*+I_K0-E59H.B70@VU
MN7.!Y@;O)Q'P@<2G6)TY5WR?W<^%ZLC;3L_(,-A5'B:Z?AV_##K';_)^;P\3
M\]0#\: PXIZN+OJ3^H98GDB10H=TW6-\Q\_SV)8UC2I6TNK.LV62KYY3#@8(
M'#$$Q(>^%Z^7Y&GI+:Y(M"V_BRN]>+HS8V/&A\0VE$?,9PAYO0-KZ)S(ZPU1
M_3D^$S2/_?'%$M7:KX^=VNB#'R^AI& G^RIC,&1^T26%.=BVFTV%&B_RGA-Z
M@DX%@!X_S@=FSS="10T0XSNFO'HFN^F?$)_5,>X%]:"'28=AS(.W*8[GN(JV
MMY=W$!-;I^@P)S9YXR:/A8VX_1,[1$0#MXQS51P(@*4Y$F*,\ND0AVPQ:0'=
M\.=1WP ]:;;@<JK=51=PS=QV;,]V;"=%B'!_7V_/#$7#RTHEM^@EYL@2]7E"
M0+R.HD1=>^@5Q0GMPM?B)EEV&2"2756+70?J2^$44R5G IZPX;E+4D+&J1S$
MN!]LXNQ%5\MP/E3?$M([;_Y+#;S^:Z= 9^7FCWL(O022 ,R#_O&0UJP4F;_!
M.:;E?4VM\<3^TCIZ %WN0_&YPA+&J_E>=EO>FS'FE;$!J-<I:.#\93USDTF_
MF.88(;$>2BO5GYW'-KVQ@."#>-OPI/O+[\PUA)0EAN*<V29%^6S.L9C]/+M3
M8T<,RL/;X=WU^K+2WDCM#N GH_YBMM-".*O8M2>?!2)SVS^_L[',MVX,]0::
MG_N-CK!#;9%#Z^3JIG99=),,C8]0REAS&8Q^MMT\J!S\4 3NO7!QKI+T.5 A
M.S!<.]P@O*CT33EELP[#)[RN"]M9:9ST,-!!3"R)J2#98L[>/";TE#2YCQ;<
MBFGT'\X1IF.82O J'-!G0;Y9HGKRU9O"3$7YAY  ^">!S#J1"Y)G2SXSY?%V
M-."1,*#3Q#R]_I5S>6K'O#6_1X;E3;:.-[.LL*A0C9PEF=O0#WB<&'@9*9GG
M<M:';NG'/EH;NC5^K217$?2F$)G7;\I!F:L">8JX,;^G<]:**H$P.< Z(19.
MCVM5YYF&M/3C$?7=K.0EF8>? Z;GI^J@%]M+;N&(E-0 W#2D(L< Y^%\.@A?
M+&3Y/O15BN$'S2PRX%XT9GP[VZ\4<8F];GS*NKA_2;A%;KHARN]T78>S>5W)
MYY3/A*Y%N@K>IY^A,\5R6Y_7EWC#0S&\>O+4IL=7M+L-UO6P([ZP;YAU.VB%
M8R+RP4]UQ;2X'A%+*%9X>_P 6V-)1AEH+3)?CX,FY'XNS!&IKSQ;:I(&&9=L
ML6L/'(/AR>ME]W,-NAV>R-G2+MO;"W/B3COEU]B[D?Y))AR&*2SD>N/:VNYR
M\TT*(]OF@'$6HMDO/$9.<8=YM<N=P_3-G:DBL8PZ?'$?.*![7AOQA 5=]_D5
M$29%\@><,3+FJV.D>;!?M9!Y\S<MO5*D!79[:7QS$WE],N#.3BT#^"TJHLX
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MXY>9V%[D?7$HSU]%VB<2ZWW0;Z/7%L$B5-B;A(LO/X%T[E<[1>,1HQ/P3#:
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M*ER_T5YY\\NU1_9'*:U51#71'<NI3.J #CH SEAB.6(D;BDR=D?=$/],3)=
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MF _?/>F:+A&9..1J,KXDRJFK:-,ITKKWV87OWHO>18Q[-V3U*U<N/P-+W*8
M31@+ \,?_-"I^)P*!5<,)[\Y]I/8\7;D"%J?$>XJ:&P+-,[#(IOFZ,C&+3E#
MF2RF;4PJ9_MW)$QA9+^AH_?!I?(8)R=>7,,^4?D4G>,1=Y/Q$FEF'8B1^Y;7
M8<<RI4[.4:DT<?'S\Q-9%\^C^Z:N9W*Z:$O[ JM#5_<C(PSTM6J\?91$@\&0
M5EG&F,3F@6$)>R-TDC$H:W()?FSNV[5V7$Y[X;OJA4;#2;X-=X(CD69.E@'9
M?O)=I[>=:]O8DIA3Z>6ML.?0/@-L=![29E*D_/3CSIM#O?GN)<Q$3J-GZNH2
MO\'>N[\8[E2+/3=E];'VK7>RA.EPO(]?O5:62-M7;A]U3;-,@/VSQRHA@D\6
M,_'JD;WZHDP@?$G<ORB]UAI&O>/G8_+H>OJ9=\)8*8WXLB.0.>YSG54.=PH%
MHUXT=O!<SV_?W[;?55LSOD)$7-Q,AIK0=GY[ F^^MT3LMOJMX^768BF!S>6E
MI%?Y+1F/'X-KCXT_$GX1 .!)LW[P:/1HSDU3HW5.2U]U==N3^IV/RUNK/%$.
MW+^I(B!,#WG-*;4BYU&V=Y^!Y5[!<OEAXW7(7:2U-KPQ9\<NTHXZT(BAM@8*
MH[-X; P& 0P47 =7[=I153U6*K(-R*L]I7<UL[QHD^;^68$]NA\%W3_PY"I.
MN>](T2+)ZBH$F0F.[[90O.<8%T^:LAZEP?;-TY>P2%3+^(+9%&<CSP'5YV!
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M)KYYT6=]ZQES/?J\6DOUKL?H+<ILK8MO9O0W<8?@[!1V#'M#4\,T4EM8\C\
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M[TRG8]G&PFYX,])GU[5<;F^IJ&6+'>R#&;?<=)AANJN8DJL;86T\&[M=D4H
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MQGWW/FFX3Y^LR41F+-H6@J:R[TI4&R/2@\\J/Z@BJ79GC<$E6= T7L&3*_3
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M'W6/)^'_15(RXF".:K<:K[08P75/K6B:.#/"_.,@*I-/-/!SJ4F*,6]IPF3
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M::&OM"-1\9)L@7YVY\J=8%Q@;+B2@_-,D1$*1O+<&>A/[3F/" R-/8X@_-M
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M6GHE\LL,HS@M@MGTFM8(51/L_(RF]]&Y]'>""M+2HG&X&.T_&2'3Q+& >2@
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M?D@6^SHZ'8<<],&?:B)MKH224V4=TL64L6J_(J+P>4 3@9C)X+CN04(!'"&
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MD:EFM5)(<^AVW96'!S5%/E^\KG>&,SWG++?X_>A.+Q>4Y@H\J47=:3(+3)9
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MTJ "*!%V2.Q/K$P/=VX4%RE08_BR_P!-8S0:&"NM#MFE81<RS5P4<!<+GV8
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ML237F4B]A0%T0/05MP-]9W4>-.9:JY/XXO3LR[D/%[C,8*JHLV93UEW2$!O
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M19$B2R1IK50IL,%(]"H+$:B "#VLC<<1R;9Z# ZB*?)&_$;(.KNJFYJ0D@L
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MA8E0;-"@"3L;'L#9XI;$GCS-&VTD5635 \1A9C@G.:+$,".5!Y<KAX!)FFS
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MI2?MHW )*_:;_&0">241I%-!#%U6QT6#'DZ<8,N1$-9 CD33'?WC+%)9I5+
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MZB==7DE(C'38I("4TNBV\F7B\O@DBQ(Y6D\J2ROI9-1V$0M;"H#I ^\U;B[
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MA0Y9I(B)R9'OA8D4JO(8Z1KAI?)2)B>!\<TDT2#),U8G/6&1*_'5:TZ->S
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MER9BZ11L(HNFR!I9UU2!CK#$ '2UT+ -$-0;5^%.6MEF7,G+K!"1#$4(U2S
MAV:R#1TGV[G;<[@;I,O3U5=< *0 #1EG$5DQ,0MC<FB3'LK]16 E)XEE&1U^
M+(@Z3="WAF63AR9"HS9VZZ')=GBD*LSA.H 2D2,$+0.Z%=FJ-@35C6B6%4HO
M&[A>3(9(XPYR5T2K'(5"O'&720DL"&)A/F7[II; L'@/N\5RIQCFLSEN(+C
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M"II'D2<I1*R9#(DG7'4TM$O%QAQCEV,<F35+*RLEO0(1G5Z0>86H !;O= L
M:(7[&*O,*.CVVEI--3%$69D]KGH:^'3A6=A%$2V,.HOV8S0$K)*K73R,J3((
MD*]/$Z1Z.DCV^%U8EC.'!+CS(D:=.<NV+)$C%#JD@^+@6AV!E0T@;R@T:7)F
MBGUA]3*\P*@Z@54A:(L@ #TK=B#1)NBZ[D?%]]=\R9F\R>JUSLSD2X]/M6&T
M< ^IA$.%M:6JKJ J*&[J39K2U)',)E6T'44.%8[D H,2Q<F0\8<SA3EF3!FX
MF()\I&Q<(K.6Q)90T<LAGC/3E4(@*!>BX9F+1LI*CAWF0BY=RN;3(9&R1HZ;
MV7\U=AV*A2;L>IJB5(+GO8<+<$<J;W2'8S7 X"U<RQFN;9O)+L+%9S4,=Q67
M)5=BIJ+1W6QE'LY;D8RPJ8(J^Q%)](,6;%(\MN=\-<UYGR[!@^*QVS([58H_
M[N^.,8FZ31J^8)H(L8%1$RK*Q=2-95*TF!@9G-!##$\+9$8=4CA+,@B 8$=1
MK4$;6!78#8]^ :I+C@,<C4F4D_*O.=O180@*.OTTU-P_F8J-L->/./F:R+,:
MRXGBJP@ELQ*PXJN"B"A]:L$9;%;'J\F#G&G#29,#D\,^:K]7&,W-,@S NZ-D
M2'(QH]4DC=-I%1V+'0#I[Z+%FR)6RG$F(DB.P:*7'$KD%=+ ,^A;[VZVQ["_
M1H:;7\4X_3!Y CB?C"UXQ*,SVI0@T_ES27MEF# U&(+BTL&MI0J2S@C++JK&
M.D]#7S&UQU?80E^2/'VE8V'S7+QI,M.8<Q3F6F?%(0<L@A2>.0N$,#8TLDB-
MI65.KK<)(C(0&8\,SR1$QHV8\<:J#HBC$8!(-G2NQ!8$ ,2:HFMB(HT'*6 E
MBF;0=WSBNN!NJXE+(JLFY?MI7(418DR%AM?R2\3..=%# :QRC^I$&FF+&?,"
M0UQ%I#RGF!TM/SOF3RPR+TQ(.61@4$ 1JP0V11)4TVEG4(P# A6%S,6%G032
MO 1;HP_S#Z$TFX!W.X) )('&PMSP;BLL7AP9G"7;*B;3!'#KY.:WU$17!U(4
MH=U:+8:=-26]?2D4Y^EL +.U'L!99*8BL-@*\0XSQR1]1LG.A$RX[QM1R,&9
M7>:16B31CG&4*&$L>-&\<;(P$HD4K(EY@D:LB&.-G7RR+9$@<!02  =5FA;6
M*KS;$2)PY)#19W1YE?4Q#!#O.8>?+L0!+"?2R9<!E63D+T\NI&M*QM-I1WZ.
ML24LY\3J^<Q\#&--J_$;]5L?)#J6EJ,11KBR.H@$\AE7,@1)&B820,()%")J
M615!^[-\)8&1+SA#H71$\CRN5T1@TNCRV=R2/XB*!L#>]L97E212S$1#,DC>
M0Y8I'.<Z&%K']&OB:,]9/&2<0ADZ.F%&>1-*V='HD3Z!2JD!&<J= !'J36X(
M8$;(FA:5V"@:2-^.QKEF8LL@@+$N>^GS!M3#>@0J^8&Q[#L=-U'V4O=Q+Q61
MTO/&@$F$L^3VH%C@GM5J"888ELJV,42SS-:S2G#C%0)*B3LKP1)/&Z(MC8L+
MXWYL,F;'Y7"P=,&WR7H@OED%3'95=X5U(Q%J6=MC5GY[_M)\0#F',!RN!E,&
M#(6GTV?MPH7I@L.RVQ)&Q8T"=)JUOC[^(V1_O>JOKU_TG%\OR_#\/EVPO',?
M?ZGTKU/M_/U[\/#L<'#5W3$DQ.OC=U5K\Q>M7IUZ]%JRNO3IU5/;Z]/;Y]E!
MIE;U4@C\. $J00+((('O1OOZ<-K/<<U]0]GJGRF*#&/%7/=$+"P4<9!IHX(V
MPC1R>!#XRCO+?++#ZDPF5K(D?#"/[DG>2UHC4;9B;!)NCOZ@ #L-Z/#TDS/Z
M['O^O?WVH_Z\!OS\Z(\JFT>GHKR:CI!]1 ?4N2>/X7;'$4+J700@QB-K;2LI
M6C1V4I3S;!X9UM,'/+"T4H:&_P"3Z@L\4,RK+,\#(YTJ>D(IE>!6\SJ\WW5L
M -H.QV/%_P F>2(F'&9.IE9<-%C:K#(],6(W 94E VO8$BMN*T-$9I=EZ:]I
M*/5V( >5%I-A;T[6@2AU%7(1ZNYL:JO(-<370CB1-<V-/.L38[YE2'#7 I9L
MV\20XBZ))<:(O/)-B0NI8+(=)$*,X"A[;N*$<?2+MU'Z?'2<8XF)+/RW(?'6
M09*/CDN%7($BC3I8CRM&">GKT#458V#7%8/>6L-+7ZL!2'V(VKS95K8L/28J
M:XSE<"7'D<3'-=# 'MHQJ.ZB.K'P-<&0499(>PI8ARS1^E>&(L>7#D($?P^0
M(XBA55AGD9#E9H6)I$ZS2PLD@8VJI$4T^9%,/G,\:92*HDDCTK.@L,UD$1Y!
M.ZT6MKL[DBJ&\T<0=XS2T&?Q])<:7,E\'<(W+S2P>5L70;<[DW>VDTFBV%/3
M2:-WQ@/0/G-LTR-7G[,:LK:\&NL-%8SW.H?7#U'-.009&1E218\R\XYM$5AD
MY?E38R\NP$7X?%EE&.JQ/CI4:Y+SAGE=Y$A5(X#(U=TCIS9S//').@@:>&5H
MGI &MMQI(NUI' K[NP"G?#]L-A].%81;GAK0Y>DH**5HX&:W%8=8VI%@R<!$
MZ#9ZH6N?*!#80.%'*9*-(]Z(/$Z/U(F2?^R[-QY81B\SQ\J::>RV3ARK'%I*
ML7-Y,@(4L"#ITL2#9) >F3P\AC>9,_6!YI&R(]4@6Q6C2YMR=AY=K-"@>*Y;
M'[4'O.2[*UGXUO:GCW-;(P^3-X>HS6*E;74L4\J,#DT$^0N+XF[F+?%/(0<-
M.47(.64>P**0=5WD7]G/A_X=#FQR9F5BJGQ6;)/E(7F*V2L*9$,7050:4.JK
MJ41ZR".)387+8&3XC#6<II;6$9RR[+U,EE8:6)(  !"C<[@DV0=VL3[0&NY?
MQ_)O)N?Y6"Q!F<W,NQ*V?+5#HL]H12LVJX^8/">HKY\6;'?#PS(X&AG@A@<0
M<2\2&,AA//O$0\&2<IS.7<ORL"7,:?#^".+RV;%R<62.<KD5G,)%R4$6H"Y5
M)84J.6X9YS/R?)QIL:#%Q,>=(UB1<?[A<.' :0J(VDHVWVA(4*OSX/'D;4:3
MB[A+8=X+-@H7K9<CH9HXWEV-D:_7V)<6?SXD+K$LEY-+2$3V%H77/@""*?!%
M8/%0U]E:$9'!QL;,YI#R>=BN+\7 "7V_Y6)2\C.%HZIAI17%E;(]AQ1\HQ8\
M_F&-RYMX=1FE%';0A8@WI UD:=]_4<4W<=<&1]X*INN1.5>4K6ZV6NHO4 WM
MU;3#CE%I%*(C+%MJ(\2.!8A28Y0PV!V8M *8X)]R.V8(+I67S8\CEAP^7\LC
MAP\?(*M'!&I9%L,!'TCK=B67S.>D92MK&U.>A<SY@N#\/B8L,<>+ FB4+6E:
M84(X5H(0?,"69B15T2.&-B>>N5NYW;C5&.4LS0T%W1C6*J;&3QUR)E[JHK?@
MGER%V0,]C96<L90%=9U%>1$^",(E#1W#V91<[)Y%@>)T>?(=8X)X,AX@BD9N
M!-'))U=E1Q"B*5:19'4ZBZZ&)C5?6?D<NYOBQ8TL$;PRH%,TRZ,KX@L0'A;2
MRA50DTS"VV(9=(6UC?\ VA7&3>+*SO %YBWTDGW=+QA^:H-(M)<4&U=,,3'4
M@>I%&<\#8F%5X+=(9."&-65ZL/@8@MJ/%@<'P9S!LR;E*2Q0R),N2DT^.)HY
MX A7JNP)7J8T:R-TEUL9'&@MJ0\8F?P]DXV>,*,Q?#R-\5!E)_GR8NE1TR&9
M0LJ,K%EU4 RFZ((IBW'V@O>HY*+M[?+<J8GB+ YF^=0@4=1--260($$N>&66
MRL#GOO+*E*;HP2[)DD-478_";5D4'F5/H"NIXO@OPWR]<>+,Y?G\SSLO%.2\
M\J]2,L3*S:--112J865+,BJ)(S>ERZV,.-BPF;3CXKICRM&[REWED"@[L=)0
MN0"6 L>:A\Q_A[P'&6BHI+O7\;W5I2;DBRT6ERM)L2,Z'FM(##Y$5YQU//3G
MD#E&#$/>T(^96% D/RT\%LE> 5-H)N2\TBR$QL7/@6?EZQP09T^*L\N5C2;]
M'/03(& 91;(/(Z?%!HM;JK_+X</&QWSHY9X(<I_LN7@:80ZE2Q9[45&#]G6D
MD,5!!/# *=GDK+-M;J;4.E,,MX&YP@B?4&!I*K/05YD4Y><K2Q22GU3Q82 @
M+BH-'@LB*DR.,.>2PB^($L/5Q(FF2*,G( CQUDH6\BE1/(K*HE5BKO%(C&-9
M$)=>&95A,<_3R=0DF#1_9L]%C1MWJZNAL-ZLFMI@N+31<>8CBW2!5PHNMT4E
MXZC-*Q&<:-'G BA(PJ P*VSAE7!:V%LXV_-<((V0ZILHV!'O;$Y#*7'2+/R^
M98C32?"PF,SJN;D%C,Z-KG5XITD:*.)5A34Y"2HVJ,6-%GDIBQ@9<V)%DR+C
MQ0J3'I5R6:4,2"3=2"OND5VL</#@CAWGGO"<NA;^'B44FGI@A;0^^QV,I</0
M:ZI;:YPXNDMIF%XS.&P:.OGMY0&/M9WOLZN9ML$)66#RJB-SKFG)/#W*GP1S
M-GFF+*(LW+ERI\201Y"12P^3)E7X=PFLE4TI,.D792)*N6=<B99IXX\&&*DB
M:$M<FD#S2J=3 F]O10-@; XLWW_<&[O03+R_Y'B'R Y<E<4EK6P&.N*V<TV.
M(D8$];+54BTCFA4$/6MI*:!L+XB+LXN2QF1G.\'QOS[[+&P&;(*+(I24KTG4
M(Q#,NB"3J^:8^>64Z]0B5=(XF=/&SI!-\.N0\K @ =RH5E%>5D!TV0#6QI0!
M?%?MOQ;E=_R?1\3\!@>EK]'LLI0UED>]4-.6<B"OFTMVV?SED]+# M@2+ -%
M'/4A?O,$$@+9.VM@YGEPX<G,.=2$MCXN2[QH/(H"-(L$-56HMTU))997[D,P
MXU,PAY#RZ29XXRY7KR=/8H];(:[40 3= U>Q('JKXEQ-+QG'QOQ[G8FPT>,Q
M<V>KHVP1P*Z&K J19"7LA5L*RE2L6>;RV-5)G2*GB21?#P;F61+F--F3D];+
MR99Y+;5YG-@ DDTJ@*+]!5;<<-R\J7.YAE9DIMIY"X!_]V"32'?N!7R\P]@"
M2G:HX\\,,1C9-?M8WHUS'T^5:]JHGA<QSK]',=]%1R+T=U7Y.7KT]E[>6) 9
M@38%BN]BR/SVX0$@@KLRM8;U!L&P>_TK:Q^?E1YOXY)X3YMY'X@F%(B;6Z6S
MT6)1(_+@+S.B0FUK) XVR1Q2#UH4T$$KW(K!+#Q@(UD#Y9)^X8&6.;<JP>;
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MUT.D8#*CO%J94+6\H",\@0Z2:/GZ/RG"7EF(^1)')%)DZ90[@'2!6R+_  V
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M@'VH\7<<V57&%KCON_M5I3@J7,6$+\YIY\U7 K5655*,;3#AL)K:Y\4'I8K
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M-XX8T0B+*),4WRR"GE$7F&^51QY<V4F13J5BL:F.%RVH@".U5RVIF)V8+I(
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M2&A3&:NJ=,@[S*\I V139/*\98&)Y,"/(S"J$)(3\)"KZ_+N1\1)2FM8&.X
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M$@#3LV+V2\Z$3= 5UQ[B4+"BAJFP\R(P:H[=4@F5)]-P">C90N5:1>;J9>)
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M+P'4'R\!!R]CT#8<=&M:I&^!C<ZD!PY3I,'N2P ^_AR]8>%PUD(P+S(JZKZ
MC6_3@>%Z1S-,<Z60$QS)2)7$O'PE8C)DJB\!#R![1UCT6 !V+O3* &>EY?7%
ML&D3=%#'-Z7NX1V_[A-?CX9SA@0"I*B]G,5X[N"TV8L(18%1#3;_9X0'=5X(
MB ]:)]EBL6WQ6!WE*X81>@FHP"DMDDC?#E+V%OIZL?M? L0:0#NN:887,:Y7
M8@(TA,9,7P+"GGZ&85]&SZ-U%<_/I1<O>KB1[Y1GXSXJG\OSSL8@UW#'1!E
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M:Q4S-J,XHGAV-5JS$7'=L(^^>YM'UQM.+@$Z%8MX2@H$BZ32+VD4M"4 W$:
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M9A$\[[ ]=/0$5+[*P5T#-5$]CQ UBE@#(JDIVPT MG9%OSV7R^":)Y,=G,+
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MQQQJ@2/7IU, HIWH=FP\3DO@_$>.0?$\R>%#LJB6GDJSNQ"]0/Y ^H  L?>
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M'&"Z"UU*D>HA&#1ZJR#43$M%2NT&8#1J+%25I1ZD;"P1MW]"UUM1H6U"HG%
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M%@6AA)$4V1M8#]3:- +(>NH_E5$\VM=KR/PG-ELD_,5:#'8U'":668U=@D[
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M[X_#0V3QT.#S]+<U>AK4LI:7E<*QUU?G*8@XB$7/VH$,]C)/8Q#"GH,<.MI
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M%A7;A\$D43*8X,(D8VZBA>Z5@H,J#SV _FJ^%KHIHO%,D#G.^<N>\E')N=_
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M1^&/IT3UMU<O$MR*V8Z[LH9S+#RZUPK:W!YIR/F>6>0\E<Y,;RM)S3+C$?\
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M'IDP5E@F3-A(C-B)6U/I/HJH#K94)8  %0#=41P\;;3TG& (%# -QWR#OLW
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M"GX+_/\ ^QVCZ![G]/Z</:A^RO\ ]W%!GVOUJ6-L.,:T\8AV8L<Q<#^N\<2
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MCG&+/JCCC9ECD4* JK(I5B0-B= MP0O0.30P9!RLA@L<..VC&342,B,:;E-
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M/2]_P[=CMM>W%I?;(<9GAL[7^)NM_O8OO]ZB^QP<.;L< _K_ #X@CG?F?/\
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M%-/ENRM@@DT3M7;HT=9I=UIAXL_13%J81'4@5F?*>DMF03  DB$25=6I-F]
MHD->\D2$4>%(V'QM7SP7+D2XW+\5NO.H8 RO),HJ)59ZTB22H_.= T.S$FTV
MT.'H8Y<J0/IT8R*0RDT)!5DDG;<WLVFA7<[<7:<,QXWN!]WJI[P6M%+V>]Y)
M2/)Y3$T\[[2LMK?,!:&^AB88KY&UE+GE!/)N+1(CY;0ZGKCJIL<4\"F\9YQ\
M=XSY^_)<.:/$P,"23)SLB9 D\,>0V-'':BM4L_471'Y1&LIC9B0X7SD,.=Y4
M?+H&B@Q<"*-LJ:,CJ3-6D0Q=O->J]P"+9NU&M[:\_7_>%VNEY)VM]':;>S9"
M-3T[!BA*^E!K7T\]73T\<B5T#$A6R(=91C^IM8!U)D+49)3E7?XGA^'D6+C8
M&-%TL*(EI9+0F5Y.L))9=)D--TP(RU1,: UTO%OCY44&,V-@0*G15@0#3L1J
MU%R:MMP:!.];';AO\<]X:=F,U/$MY23Z3CK3NK17Y8DLF"_IHICP)2CL=;@N
M8(!:-\^%[Q;-"(3Z\!C+**&2D?#VD\Q\/UE0<S@G7'S8=;MDA5?&F*HX1,N)
MSJ>,TP#QBXY'N/4LM\>,?+3)F@E-C*QF91I&B1D==PNKOW-J=Z]?O'B+]=D4
MQ!<UG1'NM*^>HK[^CN)K*:F?&TT4ORS!!P"TMX+%UI2DYBR4D4@>M/A8DA*-
MM(38K+ SCG*L>2G3D65\>6)8TEO2ZVKF1>D8^G*N1'I8-(AV7[-D/KF&$N.6
MDQD(L-(PT^I]*W74P]0:]#['NWURS0OJ":D<12# K<F>&R#EA#!?I+)1HPJ2
M>TM+7XO1U;XYH*Z]<\,V"W)E.?,28D$C4QX1C]9)B^A)(T4Q,"[C'CU%YA''
M'TIY 07ATLC1#1I521Q'DD=PDL*C5TQ(22#IK8Z5"@"*C= $@A0+4#@H</:5
M_(W"E7Q1;A4-?H],'J)N.-@80:1HH=K6:-MS1X@265(J8BKT;6F!!PF"]'F:
M()&S1#3,BDR>8DG+^?2\QC,LF/CMCIGXZ*BP'$EQ^C-EN+,@EQFTL[(?NPM=
MLI(O3%U>5B:*:<2BY'A<*RN!(6+1@#4#I()!8>4?=)[!K<TKFF+70U6TE&8R
MTCI3[&A>^ZE/HZZKB.I+4-TI]>+'E%DMBB(Z0)Y=</.C'3Q-&F)%VF//:=1I
M,))"8S/''.!%TYI)3'/&Z]-V.4!#&IFD"NRD@>8*U%D8]N!&LDL6S8[:1Y !
MYHP'#,*;4QM58ZK!(JW8;D1!>.LSR-#KZ70&W.PLJ:',&AH"]@=7GJZROE2T
MLPI(JR02QU'@>ZP,JJ*8AC[."*8@D-LL5<MWYCE<O.)- D6+'*V0C=0%Y9W2
M'[.%@9=<>+L4668*>E857IP11)C+(S!P'8DDZ %IEH:R#Y;MMM@0;(%<:#8U
MB8J.,LDX)T=]*RU8S,645OJ:ZINGV,B#T=Z;">=&&#5-%J);4APJ:%[G+6ON
MH&E3,DX$S9KN@C93 IBO)C,6+)+%T[,T"%(V>24O,(AKZ HR"$Z;8SX(88()
M [REY/,J ECM:LS$ADH'3=CV!K;@D> @1"!@PZ]592$V,VBDZ'S7EK6$_#@B
M["K>4RNJQ76_DTK)+!@@3(&&VU=71*4^*7QY+Q,S'(4R49UC$'^6(8Y$#NJ2
M!>I(W2+25&6<MHB>0T" -9X:D,/+LR5-72U@*&9CI?5I#E38!760.Y UGUXF
MS47 -IHS+)Y8%<$#'*1XX$>RLDT1$DTQ 4L#(E 'FED:^&%LJM<ROKZL>5TD
M$[& YV.&1(DC"NSL0"&\S]$4 0;UL/5B+4NTA #*=>@QBL,6HQM(74K 35I0
M $@! :XT T[ %G<T--M/'=YX[^!-!WAYU=Z,U?"$P*PKJVT&RM:8CC;!''#V
M4<<]S*3-$.XV$(4UK)C9"6UD@PI4+F>89S)C*DH< @JZ2.AG=:"@+H+"'0K$
M+U"ITJ$9]17)>)9D>./"C\S1RM+-.5)43,!1H*#: *&JZJO,;(ML[K@SF;8\
MF&"02CESUJW+C&AF#V\-=#:4L1D)RE!!R-@80V!@C"H8#W)"]Y8XQ#B1F8'G
MC*Z1,PU9.K[>45I8D$@*18O>V )4&@"0%8\MYJJKTE6R5--\MC5WZ[T3W)V
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MU<.CO/Y!O)W>IYDJ<L?7TU:#L8SAF6V@$#SM,)0UR5,:F:5;&(:A!D6/-TP
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M)!D32XFA'>$N$Q8U0KTHA%@+$VJ,+.#*=R3I>[SZC?#96C59=;,I[KL 6"J
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M3Q)3R8+DFL$"T_+7'MF6#KB 3E.35&Z;C^V+8H1PP3G,BT>3K1*V<:A'*-(
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M<%IX@)IL65Y8IHB%&J:>*9(8I0"H$4R2O&06!T,X;+5L=YEG,*W!,=*2/&+
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M;&W1%QFMZ_+[LWJ_)J_*K*7Y/ZM5?P\7MU[*O<?4?SX5>X^H_GQ7Y:6^7+Y
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M"\RHLI8/3OL,M1SAU84T<#G*L([;YFE0=7>%9HU]0B*V9KG<C\>Y*SY\.+$
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MJY@D(#(MJP^6Q.S>@]?*.], !I%"IP>4+(H(U D5O\C0[+=;W\]SMO/@&0J
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MAB=(8Y)L*26PC2RLQ>:-ZDM0ZLK '4S&^A>+%^""QLJ*[-)&[(X8+"6D?4E
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MY4J!).UD;V\G/S.:F3'TQQ1SS]5T@14CU%40:J4$ =($.S/1L:JLBZQ^486
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M7,SV[U\\R>F1 @)9?6HOF97QUS>/"Y=R]<?,D7G#9<68CZD63H1137,L =S
M*G$795E\ST5('#'/,W)P( $>(2AR8P"24TQ-K+J0"4?7H!%EC0 HDB%/M ^,
M^[MP1KR<3Q%O%9#G+>H'V?"E86D4<5E<A>,HHJ1]$2PNQ I":,R,RPMT+>*3
M;BPV=78I%"3<^!L[GG-X1E<QQ PGQII,;G$JZJCA:E5?MD94>83+H6,H&6-N
MF\>IE97(DS>7X^;DPO%++-%#"D0-9".VS[:J4$/= 4-.QWTC:)9Y2[R>LVN6
MXSJ(+N*V@J A6:*TFHJ>M5I(!%>\(J8YVDCLGPU<'CM#YFI9I&QDE@*L\(M^
M\>5#F8N#E\SE..8>NSC'C$\LMB19 ZA.@4U2&HT7R62L;$%I"Z7QFRH8DZZ3
M/"ROOIT&B1I';8FR!M6RT"9"[LFSJ9[K=<;;C Y'D>@THFSY-J<^>Q,/8Q\C
M\>51]O41U!]0775N?#>%#9!%!!C,C.' \)*3%1QN?7>(L658<7/Q,W*P)L=L
M/ELLR$YB'E^>ZQR%TD1Y9W#,CJ[L2CR K2W4E=++"Z,%U.\O6TK]X2H&+*"_
M=BI2AY0&)]C&5Q39+<W3]B+6SY:RM8!8ERM785^]JKC7VXRF&6<<S]E6:RJ(
ML_$U2IR,W:U,!(YE@?%9M])&/9P396#B#$=QE11EM.7(LF%+#B0N$2)A\*^-
M)HHZ0LZ2E66.,QVVIB81Y&>M2%2A)=-NF\C+0E0K9\MZ:(4D&P+ XVN(Y&S_
M  !RR[:9F2\ M,CE8S\DPNNI F6&_NYAX[6TD!D<&-\)"<016U8<@,X5A4ME
MA&FK2B/20LYG+\GQ!RM<280RIE993*:.2=S%@0J3%$LBZV$CT))7619$E*LP
M=5U%XMCXXR8<D.D!@*%"P"R/(SB3YDA0K1FR0Y.JA1X^=;R/QUS'$!N-UFG6
M/,[+$(&TSO'P%+D<_O5<NCLQKN\K"H"=?&50'%RL]D*1XD6*.XMO<7=W+Z[%
M'8IM\<7=W;VX+12*;W$M%"M:*.ZNB]Z^=^:;^7[?\R]SDLQDGB0G3WZ<$/<#
M16HP(6G&7\1,\>)4>80R>IT^/$/B55CV9::_"/. <56)C4K7 ?UH+NI3UH2&
MD+U*?7F9"B3!NI!<:BQ"H:MB0)ZH/-9"/ZFP*?D,^#M<R\BM+$0AX%,=@LI;
M4WYO(K-R9K7?)9P59O2_G?3Z^N**!N9_+TNK&]"G#DJ1$E4*;<C>=XP:$KS[
M(>NI,6Y.._XFEP=50#)"/VWXW<YHC9*5C2+0QD#&_*A22H:L_ V49SNLN&A[
MFL>[R48IYH\M># ,Q81%@E3MQWM9A*>P%$FD=X#-O9<IM5/L2^LS^L[*%#)A
M!72<V!\?+CLD[?>2LFKYV"DN<,B1UGM!YA\Y)ZY(5-%06Q5)P'.AV=X-N:[/
M@[$"G -'#'Y,)=8(2I:&*08TU%T1^V-2OP[P%L^(/8HF.#@/K+Q9N11&IV%V
M#F=:SUL!T1HLB82JW _[3#D[LAYG1W]."^FO7O+Q+VYUX,]ZYR?)/XE"N='K
M:-1^+ &_/*Q?G?*+;++,O</? 9R9U+7>B/;R/D6Z4_7_(]&O@.E70&:K1[2_
M'<(+OYTX3IC-[.U#/-$U_/H)AD;.V/I\!H/T'SQU!_P132 *7_R[9?;66M[*
M/K&IP!R-6$"NQI^6YS,#Q8Y 2E&! *G3C#YPJ\E[E%:?1L)<TR)\)N4@A.\6
MGO *@!V=]3X^OYQ=;YG_\[%Q[!2]X4Y;T<'"0OO(JE-S)?O _D3%-B(A3-&+
M],[OG=_BL;<X5</4-H147+.?WWS8N_M9Y)I,9(<O(RN"#EC77HLX(*/[_<<2
M&4+HY-#8W'YM,FFB0PFKSGO\TJPK]6C:\=AD/IXH_X8W65%F#R(M#@&NL/K?
MF'E.$UV"A"K&T9^LJ!M4QV)1[DI 5#K'$#%6\<R>\57!^";H!A92F_2D;]+Q
M:7C"+VL3X?33=%0VW5$_K243GF9&K=I(2I<H:HT?-43.@41Q%?$E:O9O;&CU
M\;>>$Z3JT.>J9;0H@I8L0.P?\7<I,-(@]N1#R *K0_0CT0O2XYAVS0)(TYX]
MN3GO?0D:5W/7@Q*=5SVZ3=7P&2()V,H4#.'$;>._RF.LST=/ .%J]*NNOGA6
M^R.27 KE^O*XQWZB,AUO121'W%6^)-W_/,F(U,**S$[CD<%B@?DCHMDB4=!Y
MC'=!1H%2#&,)?&GVS RLLD:A[?0SM28WR/%3S]1:ZV[F#AK98KH3]H>Q$41Y
M)'ISMUXQ4S0]>(O VTU)<B0U+IFEH11F V[,%*89O$W'3K-/'H(7H=:7$WD^
M!(UR^N7QO;HTF?K1T=98'4F26D&Y6O)$*>R1\"?EIHFZ72R\VF#C-SJS<YZG
MDI:-U=1KTS\SR2^ >[-0>6>?RWY3E3IL3@L?]X4?&W):9 +ADOC%/%64/=*E
M-\7WLGRH36V>"3-B/I,9@G8W[T@(#FT^=9MQO].9*Z1]""VN2PNE<VA([!>I
MY.KD^<:/_CNC* =)8 X!D.($Z)]U&WB.WYS46_^@@TKE=MHZ4\LR JS,Z&@"
M+X0SOTOC&6D%(^KM(4531Z#I)'+HR.;0D_N@&FR=%(Y-# SC;>_96-:F* V9
M WO @,ANIA-A(P= N'-Z7:CFYHR:QXB@Q#2;,7$LDI#>)[09)Q^"4;K\$6 5
MT#6PZ[V(QZV]1T'MH5^![*]?%\\R.S$F/2[\\@'E#<$EH\"D?GJG,BT53CD>
MMU7RUL$! 16/4DM;WX0T>"#'#O&F/@=T;SQ=)YW!%1J6,E?;.Z=8ISM9)@M:
MP9>@Y.B:>E0<C./Q_MJT*_%#";<T"$L"4)QM!418!2@*0U%^=EW(>ZE1;2;5
MY)ODHES)D+\==G#]T<"U9%P]G]Q2JZEA"'BOB2?4H0! BY?Q*TD*][^TX!9<
MX/C7X7F2!O:>HOZD,X'9>ZK(_FR#!FZI-<BG<KP3<SST ENE!S'RH1LV"C6-
M(% VU;_KH9&.XEXJ E!X]6]:WNZ/I9JXN)7Q<J6&<_OQ#K3_'<9I7&$=5ZL4
MU=PUV-<7L'<), <F:79W)WPG?#&^N"%@DH M9K)04N//=!H3[Y%:3=LPWB K
MJWUTI5:U<'$<X'VY8/0.9R+PQQ.$L]_PUQF>&"/O*-"ASMWS_$;&(W5"KB:S
MUF%>?4;6;.;V8+;"_O/P)XZU1[,VB@8HG>]+%X_Q(8SMAZ_+%_&/<(0OQE(/
MH2:_U:*Z2>?5J_U*O,Q<70K%"LTRS7)NN_OC9?TG%XX#L->V9N'. _8&M;EO
M9E?<CHQ"5Y]!_E.D+G3IUML&_B9"S=QN)POK)8N_&,?/CXYC3V[4\G']R,^1
M!T,2?8+67P'!L'2]B4(UT2V^OPA0H^, '-C4RK_69K#"/K!&1F8E;\E;":.?
M6/=Z$I]LZH%D;L'].XF,'EWAGTO;'BY*4^/M8FA]IA@F[J.SFY,PKP9^%=PO
M$;C=TT2\S<<)8<I'[T"C\]]*TA_H<1LO$*3D;@< :DQB0G!V%5]R<5S(N3FI
MO ANZ249.C6;Y'\'K3KW'VM^0G\[1,K7CP2R<I,9*C4@=X-"H?$R,C*.^D,M
ME='3N+CX2_C-8M_[I5WOMJ#_6J^1K1;RC[ W%B*RZ-JFBN]^DKO+@Y0W#X=;
MY=K?BROZ^GG)'LU6Z!Q7*W%XT>N#S:$K>_U)XR"\LE^=\BS_"G*:P*7'XC'1
ME"6T"^+I;E]7Z]EE.I;,@EJ9-G/E,0B2223X"'(G4PH1$Z!_)R]$XH3BS\R#
M:27CDUKE#C1\T9D2JFZ#YYM",V4\%EFVG,OF,!Q<QGXD*0(J9]AK[RV'-3AC
M,Z^^@+-B#7Y<-E*$Q0T$S3&]8X4H >+!Y%X!V5O.6&)7(@MZ"&3@8&0;)S"H
MR5XWS:!S&B.DQP#W;P)K3>VO@[&&QIM*5OFKX:#[;"]L!S%C/(L)7<=](AWF
M8DU@ 9_<)Y'C(87K<,]?A@<QJ7[)J<$3\&T\B8/D1!$\"V[:))FX<FU7#A8#
M \18)'2++S1MM2Z:?8FJ<N6*#:T5%3'*X[8Z64RX"!_L6MSU-/?L/U2#0KRR
M^]Y]GI\ORI80^,8K^6V FKK(G60:+L_A5.59#])2ZR.6+A4TITDV=8HN2:>@
MDWO[DZZL]G)DQ[.9H_K%<CSQPTABY5=H*>GXRO,*L(8,I3IAPBE5ZCBR3MP'
MJ]/OV]RVBGF(F[YQ-$3WTV*'0T=4_]NG->\.P]RQQ2'22%N]XN;'(=DG\'27
M[1LK$>8/-.#W[W0;7Z@&7@&XRAPLJY,JQ/3SF: F$DKF2SP#FK2,7$(%NGNO
M(/E=[%H'*P.2(YO$]QVK0P1Q-]0)P"+]H3?BJIJ*O.U\_@/K59C>GW;J+N_R
MNA5S?MHXK;(EZ:W_3M>V4&/@NC@.*F6O^KNP("3H/H.%U)';%7=F28EYC(A8
M3T-1RS?,)E+9+B>G M=D'G2-3%(H\*^4M$X@P0;E)&C8$%]8Q<_/0?7'#9M"
M@!G$'2 K=W)[0X163%5$ F8AV;4[<U<+["/N88%G",GL6?L:S6%&0FD:W])Q
M-V'Y2P6?9"ONK $_'AAOU-'>:JYI(*P9D2Q7R,#J<U-,6)^HAMN>V^XN258V
MG%@D_R%";R?+PVHJ,1$XEGRCXV$Y(65#7$<\S3*4$D2,AY9\G\&E8Y4UF.B*
MV#'05,VM !#EMYDE<S[408Z];' #YT_!U=L'R'V\4DZWJE&,[\AC;#I5F!%7
ML3[Q#Y(QH^[7EGTG4%2UJA8)[;$S+ T+'2)W"DZ6)'5?Q_O'DO'S]B_AI]S^
MNN:)1+@A V/E''3[0].<2[6"F 0MF:M01HQ)#L%.ZZV?>01BYIQ2M &:&/PS
M+!A<OUI7<RE;_+7W!+^$G7J,B417;V/S;=:9-  O/ZC>VE%XYK+4YONZ_C)O
MIB6V\3W(B"L2ZRN=YJJ0!6D$>?9H<\L\"I338H>/"_+'"(*QQ7 X=HE__34?
MC>?>8B-O9^,(_789EL.O]LUN()NSGX2VW%F. 6-H(>73E8@=5-O64J'-B9XC
MBB1:%2B/V)8N"=KH:Y1C0BE1N$RB//&8)Z$Y:-A/+*H-\+?PEZ9I(DIUXI5)
M?N-_>![C0VN-S%?P<VO!!&7Y+W9,6GE5;Y9,L=K/.3I:IPT^D8MMKLXVE2[=
MG>FM:OSB)0FGC 3]7F\CHZHT'Q-MCDUA.Q7REAS&!&D>NP?F,OGTK.YX0J.
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M7F$1KH/^"B@+TE[XQVV>VHQ<?2G'>*H>*JEQ+ZF?:ER$",G=4EHI-@TCK6U
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M;J;XC^F.W[PQ2L%[]_9)CW2]ZIITXY[#FI4)N($!U=X4G\1MCJW'<JO-'
M0$D)].=E<P%+XT1-C.9P%/NZJ[,N(OT^'@SPLQ..A4F<.IMV]F]XK5E6J!50
M=;0Z1!6:X9SW5L;>L_ *L<,Z;H.F!86)T]FM.&H.*)=/> ,\V0/7NN1IA>EU
M!A](0.#U3T6NIX!UWZW\8B>RRYY)=IW#'E!+]>.US,-QS[^DD(&S3S5?RP+
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MVF_T"V]/9T_W'SO\I#_*"N#N[>KZS56 U,[#V]T>_J=5#4$(_G!Y;RG\DH;
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M*VV,XG!B"K6"7-2.A@2KEW67[-#XZ>[(@"ZBOHB1;20%+VC8K"\&7=X%7@R
M5H='-KM2*^<S@K5*^QS]/R0F  =T0 =T0 =T0 =T0 =T0 =T0 ?T?Y!VQQ36
MG! (3RE^?G<XG^W>1TA\$ \W?E];3WY!/@%^0$;.U],6X@)%L-E!'9W=9=D7
M7J+8V9SM9=E-1;4%M#V5H$[.:OXPJ*&_CA'$WP4B:<\N!R:7\97R=?-T@R)L
MV7S=7-WA4KZR[/O&I?#G>VQ^=K;]+@@76?;]#Z[8S+3UV)0\8% V23X!7HB
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M>>)"+&$I.5?/XH.[9SC3 C^DV)T+F?:V$I!OY'_" SR5+/8W%<N]$<-)HRE
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M9V\)^@QJ$EBF##IN;U+YHLL,^U;>@4YJO=,\*RCXB$WFJ?5[=7*2,W;J=G3
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M2_NGGL[0\&P7?Q5P)I/6A)A1SZ6WASR7IP6E*1WNJ):^CC%P\]*Z3DO?:(=
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MS#H8PC4VPDZ> !EK4X$+_/ GP(%B[A.@=^+AOS>!G_X@'Q_^'V&&2/7F[T\
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M*U7"9 (<PD&1K&]_1D_$RYHF[]36;%$ZY1=C?,G\&17<E8MSH@:ONP7.,>*
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MS233RIL/#ZT)[M^Q=83TQH3>QR94(.#"Q8_0!P2<J?N_^/V_BQ5#TT?#MGU
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M8IJY')"$.%LFO1PAAN2%BY+_&!A$9Z8O.>MBBL-ETYVN=K-R0? &\_!8N"L
M86-DTI6I$\0$G:LZG.+JS4^ 5__VJHG][IN7PYBF.RME[SKP7+!BBR('=E]+
M9G\=F8NP6V5Z]3GTC^<%G-DD1N-W";VL.4/U8"VS5OYK?EQ^4M<SC/*6N$'M
M1<+8P.AVD4N ?GLJB'67 U?U;[1VBP7W8&4-^Y5P;93UM>6T\X7S)4TLY55_
M:B.C@IQ-[LX/:=EP%/V:ML4\,G2T4;_#VXEW# >-FJ30FK1_PJ.77Y=;31R;
M5_DLLE:VW31D8306BG\%QN#^-]\?(O:W?8""TJY59%LV^(WB\W 2=BAVLM00
MN<"?)J?6N!?F%)#%XDA5/QD$_TUV8&5O2A(D,N'WEE'?U*[9=JW?*B]Z2;B9
M,N*;DE>DR"FQ2!-:/75A;,_?2-A+ ?"OZX;"X=WP*J<O$L2BWWY=^$WT)SFM
M?I<K%P-16#!OL8B!:!C\U*@^/1AFL]AE<O7V?(Y6G]X;D58I\XFR>, S'32Q
MB78RO,L_H5.?GM7Z7,6K,+DJAKHC7KZ8I69V@D=(T$3XE2UHXS>V/((G=\ZV
M'7+'"^+S,FE7F=U():M?S=3]7":%7\A:]B*[\8N^7)[D&>Y^5[/@*O8*]V]P
MI&>"/JA0M/A?/'"RGTOM.\EG$8Q$%J52="5A!5:]*ST]NFBL5;.1L8\4"FV_
M_PX.L;;73SH?3]>/:.'GVQ! U?^&JF[XB6^ P/S)%>D;-7OF\4.[[G:&+2G#
M)GI#ZB%_Y]Y&*2N K-8K""5.FNIH^/V7<-0R^.7^X1MO\EF"(LI(I[;"::#0
MU!-W#BE2R(@9JG:X[=M$$4SFN$,=?[LZ,_-/&0DDN!.;:;2IY7%IY,0O2UOK
M\I.L!4;7I[X:5U]_<HKAAWII:'32;O\2)E;:')_8*N&H<&X VE -LLYPU*GH
MEW]G+),<(B,@&^Q^G9]>:6&?$>I8?R)C;99*ZJ*O'N^1]I-3EB&0F3ZNR =5
MGC(/OE#0NFMASJ.9084>2Z"U"'I'",+_@I]D:?A%G#>90=KD7Q\978ESYX?-
M*<UTE@4!;S&*:"7F!D+Q>'$Y8_RW*%I?3IA?&$EU84U+ZE-K@51 3D4>QKMK
MB2,[.JEU2K4\]^6OP>Q2*EH-?I3YGGE9)!"1J/?&9#-J_CJ-$^+J2H!B7""5
MT>KO'8[$"U_+3W8K<I5DOA7M;B/FOU4%O=5&%V MQ9L1DH^Z<=(JM?,JXBJ)
MSJZ\ARX;"-#:.R6HU?2663FVP)N^#_1)B!HA+BZ4/7$09(MN9MZ9+V+7'+N6
M[H*:=)%):X[YGUQIEO.+<#5E!9QCD(JRT^?<0'3B_>PT/Q673_K3JY72=WR_
M,MC&V-\V_Z:*$1W?..<N5H27J"ZUTH9JE\Y4L>T4OF!X1S%*WEZ.5[:$UDNB
MQ:>17,:UL;DNES"T<THX0F&GXMOFH-MQ0)1.%RP+U?\0OF['7)_]6O&3W3BH
MR/)3148288*0N\*W4D!Y1D1_<][W[1=)FC'>.7"AW)UR8P7"F1+C.O0ZUMJA
M^E/(7V;0.\6<LGDIET]! 0!X=F^A2 L:@QHG9^5X[SPS>I(0Y%@*<-NV5Z;R
MD>?%WE=L?%,&?K*WTFA_8)8P]U-%BFO6J^R2AKMWV*.FN=1C7Q590G6T6AM6
MU>MBT_9>UF%9K?+>TJF@5CD9LY-I8LR4J4]E\RJ!9'[Y"KA)IELL-<QHS ,4
M3K<1*.(+J%&V?5G4?+/NN+79=#CH:8SN@/)?C@6LK-[VE67!&BP7!VZ=K/W8
MB(&7N"Y_,5YL%__6F>+^95Q#NYBT2W5(1\ZV\I+FEG_F8:RQ:"9ETY HEO#3
METG78T$*B7RI C/Y2(18 L%5,SJ&DI:N;U!?'#,@F+=[WCN_1](4[A3T ;6:
M1<(1<^)P0]$%RKO,9>LGYMR_D^8;2G7SK?)=G"[BGP_Y2S!$0%>\D39<?49#
MA#\HEW7Q]>#\M:%P&$<,H11+[E"X3._'I.N+B5/&0)H&\K=>9U/'6013Y'BO
M*7Y9668KAOWM'TQ(PT"K<\$S-FV^6W?RR_ #[GH33_.U_V68_L0=GQ(^':A#
M2M\WZHY(F"DA'XD&4U/O'HGO#T@$L?,OLTIWL3F5(U0C-U\)&D7*I)!8<E5N
MT0</2Z_\7"8XT9^N\/N*,T2ITL$=IC_!56^5.\,$8M#&#D-C$? [GJP.XGJM
M6@ $GGB%TY:P?H]#!C-((8S1A>6:<4.)O^SR^-R5F"5<\K:@-Q3+&O==5WV;
MTF07/:OK8;@Y'B0BLJ"S1K=WA0O#Z>\N@<<UV\5B% 1>\>@O7E8#<8A1YC%U
M!0)D77OI"0O,$:8IC.)I"T[,39CR0MQ)-F8)%$"[XV[%\Z1D;EWT*D%O.P2P
M-?*=UA, $Z_T>#M5\7Q6I1+OL"K*69Q1(\)>5#'_VI U)8[#BVCYT2(>1/:!
MQ221UJ&1R]Y343H%[57-1J(Y[B]H K$?;5XZT*H&UJ\$X/QN,,W,1=WGS=3M
M_?Y\-EB(>=A/C/J,U$OK8_/B^F -"),_V>4HB@U=A?VWNHKTT=Y.[/Z(IK78
MY]F*S5EEFRL-9V+]HU5H@5%X23O*4&::N)-ZW$.MSZ!ZZ*_[6DX$TV;["P[.
M@DEZSSI:S6"KE6YN]\;7FUTHNLT"RDR%7ZEHLEY5.J6++!&KD\K251-5N8F7
MH#N"\L7FI1:HTLS[-,],;><'U0;J'5<RW]\4E(\1EXAR%\0M6-&%_HH'&4F=
M]/"KF!+$<]#QN+ZQ3I"*+I9T<F90.2 /W:9LQT2M\ "(YF&?:,INS!JY4+BL
M"E3F_G#F##X&Y*NMYA[<=@#1E"M^Z0W6O578_'F/!<VT<T^&TUN%8%FNHTI5
M,.T>OUG;6T-**1(T<XN3WQ#)XV!.NXAMG_M<3J)VTSG(@*B%)*'6E]7^0F#%
M->@-].@*"7NXU^QX;.3[;(:%H17D+]GN"U^@ :_L@86IKO>(Q1Y])H2SP2/7
M=6);8_\>7;F1[;;=0EC_KCNI8A?V][)/'IX V0?+!]N>E]L K"= )O)*V.7<
M'0#;_^_>% G6W;L=TWD"@*>\:;*I_!5O)^C_.VKHPI,R6.N\I[XXF^B<=M@R
M ,O[;Q^)HX(-A3OSJX3 ;&MCT+?89VLY#B=DU%5'G=&/O;<33P!]W^S@_*/%
M1W 3!;BS23)@[58(*T#T@H?W"4#IA?07]+J/7;./'?&@B'D"%(G +ZMB(??'
MV=&4CQG(V\[I>V'P,];(?63VR=4=$F';F4U.)2SO</L$,*2F[H1FB^S=+NW[
M__$ZQXA1O-J[I$Z9:H+JO/*$Y6_I"N^[<E><68+7NI&"/G-%:]DE2-:UI25$
MO\>1OI7MXP:RLS.:^E1Q$.N6JAWYD)WML :MWJ]9B\'S9[T\M47 ]\^Q8=O9
M<%_?[$S?-YT!KCQ85=Y"&"\?>SKW\O]U<,/V?)X SYBKST%KL<)%"57@O=L'
MI-?^Q%HFI7^180M2>!R/S@#L*$!)_<R=X=PSG0:Q\<+?(1=@463LV'TL<HG?
M_ZQ*&)P]=W5;E;72.N4OX$GC23YW4O'8X2\0"W<PVZ_LNKS.A2TUV3\!=BSN
MIX_]GP"PN2%Z7X#'Y;H=7JR4Z'\5VB/@3IU7B,<EZISQ.S[X/#6R2I@FDWCI
M8/1A#7'I9_N0_3S@6E6L,+F0;P!W_M;$Q!6%.OCHWBW!H+T<UBSY@E1A\)P(
MDL==ZU:Y*0E]MA$IJ;TSZ-GMU=G<!/6=B%K5!-OT. T>XM"22>1H3/K^^W_%
MV&U&GC#8T1CX^K^B] <R+(>U.60LU4JQVR<P$7=BY$'&02VI.7=NPUS[+ZX1
M/"OI_\KCZ=P7T-U#CU\*(""=<S.%-XK,9 .%;SJ3*%()"B91)3X,J?8["V.!
M*ZC+W/,:(3SC??Q)NH\V1'['J&#1I:,M+K+F7(59+L"X]A/@8P'*;\(/R29H
M'M48L0$X#M>7G4M%3JI80X,]DS^\<"=.#3D"6PQ#.P8"*&(OT9>=33^6+Y#'
MV>>I.35X45")=CJ-QO&[#C:EI<0XL_#6:J4G!O6:"(]*$K551[U(Q <H23.9
M(9?0IFW\)*Z^:U+3<;W&U8PVUQ\N]6CLR5_K!#O:Q&*V+G")W.T*<V<R4"0T
M:ZP4):/5;,^-C>,P[,'M1E/I(>C$[Q.EOWT@E%V$2OD .  >S'1CT0$"$FYL
M]0O.+C53M%JY?:$B()U+<MO)ZBJ3O,&V&PJG*4 \A3LC39$+-8>'O?.K^_!J
MS*7J!B,_/M=MF">50_3M\4(\';'+FM4!%6\4YF3-8_2;1BQ==#2D@65"=YYG
MK_Q7O+AN<J+PO83,;C4RE6D1@7C694W_I'YN.LD:8(U,][< ]43R%4OK/*SW
M@;NQ%&Y*K;&A940],U+Q7BH>I9<^.@ET^G3 N6WL0M,WP>0C:M@:6@MI:5I9
MRC J*L;,2K/U SBF[_<(_!9<Y11'-XT[ICCL=2W:NX,Y4*H$UU88YB=MG#AQ
M.6:27AQT\ESUX7@LP6^7LRC?@F2"?!_S_5TE.^4SCWS._?W8 :S6Q_QHJ^43
MZY"QJ:/+Z?BO:%DKX432N^'4@LWK-[<G<Z3YY$'ED8O^ZFJ8L]WSL!Q?AW^(
M;*'&%SCG1.1WN\<^FDUC39TR:%7^CRMAQ*87CV%7%-=CKWG:.5E_3 ".S*CY
MSD4>H?\01X]D5[\%/E;BY&/DB6#%N]_[#9X9+ -\7-^AD[4)TVA>/0%D#H0&
M/FWQRQ)U@=Z_7_HW;(?,%PDL% )W9M.?S89U#],W:_ /U:+0W&X] =37CJ"Y
MXX[R?GC><$3;$Z!*9[;, @_OA9LZVHXL)=Z?T.L_V?QS0W=K%6)4KKB^=5T"
MF:L]T5DLT;X^CE\I3:9GZHNW%X0-%\JVEBIJ'@X3@*5GJUT]FF C]),7U%18
MR7!^_G/> YXAE&/%)J:]&*]U?[^CF&KS'6EB3?\;EF:ZK0?#<=<$81>NTML2
MPX\-3%+B>%0*@ZO=\ 7AG.NM-X< ?)'=?B?8XA/@TYS9HX\(Z[?RRZ5%9.R>
M_NA-KA]3Z*]7J(N7?^Q\&V]A6U>K _\>A>T^EG9\.D2._7D\NCX2/KDZ&!,E
MJ(ENHOU*W@*6-&P1N1 AQ^5]>+-WS:>/3^UA!&+1(K@2>,P66UI&! <B1#RJ
M[9'0/8,9<-K-D5;9&'739Y[,G=@G@-3\2E3D/2MG$H,T'/T)H'Q9LS?I#B7W
M-.=9#OJ*5E,S?SEVOZ;5."D#Z4<9)>BGFO'U,:2FO$^H1L3D=QM0;+O3U2D-
MF_[]9M9")T6!_U*=O@PXR$\3SRAM!GJWJ.WZEU;\9QN[__5O<VA*[&$)'2O5
MXDNET(\P\;D:WM$U9<2HD"I31GA]&(V 1<J<NQ[[#4WDUGQ&!U\:AY__<"_/
MZX*XZB(B6PPX&<N$[.GM$)&SY$A"60_$AU#F7S@7EUQX#IV#9KNAK<ZCD!#0
MEHB]'+=F.J[D\HT5ZCXJJ!ID:T36#YLDO0K'51U"H''PGXCWX3.?;(HV5$(+
M,.CUE7=U2:FP1W1"$"'I)WZX(72GW'^+,44_A'28&*&0SPNV7N8?@B.+/1WZ
M8!N'I/$B7/_.^#Z;S]=B? )1(C&[CA6Q.BGI BU86)A/P(1?EP>[E&4%("+L
M] 1J/AYB.RL2_3"S1VVH[72UB$5JD956T$TTLDC7]/TY)G2(3 AR%]F_Z!&6
M9_>=\XN^F,/W-H][3W1"G_@^:D2GV&2B2)M<\(SE>(5,X_= @'H6:R3W6NF*
M T["[EK6D,J//S7&>UDO>@E-XXYK][FH)LFAR"6^ZY%59AC]5^W:[9&_9(J,
MVRC-AB( <N[F\=HO'<NO$Z'%N )!9H7:(1_HE8S[78;NS[_N[16"YO!Z[_I]
M_1* B#PO<Z_B&T ]3<(2QQ"7W1M6#"-:XTV>&+&][DBC74OS/:_4=8HO$?5V
M$F=NM@U5MD2@=0*#%2LKS@;<VS1I.6$@"C/OGX#?+P4#Z)T=IO&:* 7OQ1+D
M8FFT#-@L.G=^@8#XF'&#!CQJD!EW_-+&5 0^"IRJU:7+ZPFP25H#C'#:$-?:
M_D#^.:1+S!<5%9\$$2S6).CP@?X#;734-T>K2(%(()A6$:TZU^^$I,I@/!G7
M-7S9KLL<DN$"GLEHJV9>^]=-7>1"":>JI$/_R@KD\RE[.Q188$UUP4J1T/#M
M%O/X==?M04O:A/I.KHP?;9!J.KTA#4PJM@@049$IL4$QZ3O-S=!BXRMQ=*J>
MKTW/K;SM);B0K^]>RNI+B2J"A):.]5-1S^K2F(Y][B7TR@P7&=DA2:Y;IGG4
M0/>ARH1=.&U#-31T7A*53N1]>0M.1>LWI-R_-)2O3.N'*W:+!8U;W(X:]CP!
M8KO,^:G@)5=5"H3;7G3+9J?(SR_XURH-QV)/[Y/=6=S#V%@^TU\JR1AW3@=X
M4J#Z/4ASR&^)]/3WM;_N@1I#;6[N,SHZ]%<P1EU)J_7F8MP,8W9W1G?R2YA>
M;Z>6W1A_T8W[W+-BZ[F=_.5$HP6G![UHQ7NW]H;)EH-#WUG0R9F]MOY7ZBR)
M;-2(M:ENDC2&/CUO0USPP3J^3Q!;<5&$$T)IRLCLSH>-]'U@]ME=BV,^<I-G
M8><XKH3C^'WY!Q51BJR>3V/GBZH6G)$#2W00:'D9!MCU2\/JQ$&^TW)_VZ\O
MD@Z)@!#5K:D\<P@N7O)A;;WQ-GU$!Z\R^GDCQ@*1!.+J(3"-=>O]: R%== ;
M&JE'?+0Z5'\)0A2!=.*E@@BM3\:1O^9C/K#*RA/WJ9;E]Q78\+Q<G$I"@W:K
MSY-=N \) 8>),[4-)TFM0JNJA"&(.VH6?U@XYXFFE,:??OGB2NR:TU<77^J0
M^MQ\V2DE_0Z.:;"[;@U=;(OCJ1EMAR%ZN1-]FR$D^Z>%1E,<.M9JAR9H!9I,
M?P*[):F%IM9-#D61S?9KA;.@)3]DJT.*5*C>70-1O#+0:D*2^&>D[0EP)!A&
M+0UXT*1P>V<.<R]55&6@MZ7@_3L?]&+P(Y'?CAJ'<@Y.Z(20;^99]U4+O08P
M G0QJ.)765GNM)1P,F:?F0^1_M"ZR$F<"K.HBKSWN-D-T=1LVE^K]*0**])P
MED4I&:M=?NG]2QC"U<]@)S'$X##::TEM15+%W4>,3#+8^9G/TYZM!";=3SC*
MWN#@N&2GG2:X@'UK/$"]SS>'R*3V?,$=/5,?':\4&O?ER-RT'#>-$7$=^2[K
M7AA!;CJ&PZP/:RTC1N7-^@JL(L14;9%2QX(,V>L5#SIC%L_^'P!&0+F_,I=G
MN6$JE(B!821G+D*1#J1NX J %\* !OU,<;8D2QP;_+B01J7&[A0![FFXL7WN
MZZG^*$2 18Q8)"BQKOL\I0H?/']??J0,9E^.5Y.$XOC^/A&;K6(9.0W9IEM5
M<C*^4>2I" Q*0K#298)F4CO)[B3V[+MKV3HV7H>E0X6!-AZCA8>='JV47/\
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M$:L09GE^"/%.3IYQM0U;+R)960+'&JQXXCW#>V0P >1@K':K; 2!PQ'$TS?
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M^XE#^Q)WY\[_ '\GUGS[<_!OVK]?V?S'2C@7\$F[_6_R']OZ]8#TIU/@; )
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M^7L.@GSY\[UK7[_._/C]M>3Y_P"/HZ/W[_L]K'TKM?6GD;!_[O@^!_Q\; !
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M[%,##U'5];CS7*1'1A*GJ"D2#(0*38.X*'+;>.W)'8LVMS3018[PJ&8SA6!
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M%BD>*@;UIDJ!ZU2@\@5D5E-$,3TQ:YX>QM;6?5&1,C$A:%\?#QE,;XX27S2
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MYYY[5?P0>>3OA00R1NJ*3&>X=X.F*D-I]!?MWXT1X!/DGT T0WN*-'MP;_\
M?/06X*D'U<<?!X-$]_H:(]JJCTHYK*_S1XW:M7K)'%[:I6C*#N"CRQ+$LQ)\
ML=#N_IUY];'?>;*A>_X00+_4GZ7[]:\>$0AJ9WLDVY#GDGBZ' KBK(':S73;
M\ C]?GR?TT-^/]#OX'R?!T /6O\ ?SUOKZ>_'MQ[=O;@?I[=&M^"?!'@'_Q_
MO\ _._)WK?HZ/?Z^_P"7-?Z_OL$D;.]C_3X_7?\ <?\ P\_)]'[_ '^_]>@7
M[_OCZ?7\_P ^CSY_7P3H:UO]-;'SX\_/DCQZ/W\?Y_OXOH[?(_?Z\<\_[ =:
M'?C?G1'QY^-[/G6_! )_0^?T]'7O[_R_?[YU_??]]^!K6SKX_P!=^?'S_?T=
M>=_\^?\ 7]FN_6@&@=['CS_\/D^!K]?^&_1^_C]_T_KU[^_W_E^^37G9\']_
MV) 'S^NO.AO_ )_/HZ\[]O;MV L'_C^G;H^?TV1_IYU\_J-$'?D>/GYV/1T?
M(N_D?G_I7T_K?6NQY\[/Z:\_I^F_ _7]_P!B?1T?I7Z>Y^:_O_GT#SY^?(T=
M?(W^WZ:^-_\ 'UY7;Z?V]NC]^_\ K^?'/T';K(K0B9V5BWV@'2$ [/CY(/SO
MP/'_ +_7O['1\5\_/O\ G?SP>_P!TY*..5M*-E0Q/=L=WD:\$ #X_M\D^3ZQ
M8@?^R#P?;_COQW';%FJP:Y _V/8G_/\ 7Y<,&/CC\*&/=X;R"=:^-]OZ#]_^
M'SZU,_-\<<@'^Q-<_P"G6DR#Y'T X%U[?T_SZ^@S_",Q+#]%OU*HN]#ZHYCL
MZ_\ W2].AH?'_AY\GUE$Q8&Z[^W^W^HX/YWUE Q92:%;C_?G]_';GJ8/XFN$
M6/IK^G33@+'USRG>3ICV#@.>#C1WX \_TCMV3ZN;[%D$FM:OL*!4TM=Y-$A1
ME1%EH\BAR1WH@T0.FO6I/+C@-$EG<+S7.T41[<'G].XKKQ:"4Y>Q%C<7+&8A
M(ON%8^]9@#IEC_W=#0[O!&SY(/KH59/\1ECP,&5/+W@NWEV'7LP%#\( MC6V
MSR;XZ8-Z8\9FELFO2 0"+ //R3V')/' /8231P28.W#4MPP5X+E>1HC#&A D
M5=>X_8/M!8@;)U]IWM=^IEA8<6!(8HHX]DZ  )$%!DCK>6(7@N&% FO2:[D=
M,F1(,B,N69"C4P9KH," 3?LK#CBP:]N>F7E,=9CMRVXIVDKL@]^N&\S53]TB
M+\,'[ 0H(UW$]P[=GU6WC[P<=:@RIE999(T:: -M+@*K.4 K>@)%-M %63VZ
M1Y\$>7BJZHHR8@[1;E!7S5Y6B30)<@[OK9^>F=RSHYEI>,Y+G/#E7+<<JB*Q
M<LPL&EQJV/F*U&P8:C8%!*.T,QT#L$GF?3?$46F>;IF;ITT<YEFC@RI 65XM
MS(3&S)_$C# J&1F051(ZCFG>,,1,^'1M540YSLR1%CM24*/48B3;=^ IXJ]O
M3:X?'8FXWE*Y8)[4<FI0^I&9XF)<_<-D'PN]=Q\^#ZO'P.)\CP[E*=J!4E=2
MK!6]1<_-@UV'-V*X!'5B8J[)0NX,N\!&!!.U@">UG@D60?S%]5_J?DUJYO$Y
M!#(MU7AAL!?<CJR*[/\ G&A[7D:2)%;1B8,AD+JKL54\Z>+H)(=2FR8W#"*5
MTW,WK<$^H$DV;:^+(%<]NLG\PY,,T=!H3P"P5I.3Q9[[NQ)X[<BN(PRN)DQ-
M^2E)(LGM@2)(- 21R*&C=D#%HV*LI>-_\R-CV. RZ#;@9?GQK(H*T38(XM;!
MW6*(L&C9!'Z'J0QYA9/P&VXH6""&I@#7)[D$<>X[]8)VOC6O W\'?SY_4:._
M_ '7QZD<6:0FS8H-<FE%?7Z$_H.>W2F-[/+$WQ7N.*(/;M78WR>N$-Y*D:(!
M;]/C?[^/CX^?]=>M"S,20VT;?4#VL=J^I[\?LK+!JJ^./GWOD_/6WW 24&@=
M?O\ '@Z_T/\ ;_Q]:3D*P9/2"UG<2!5\UN/;XJ^#[=>$A>6X%#DW\GV(JOK_
M *=<+E5(#CP3H;&_._V_;]=^D;,@:B5/R11K]C_;WZS656% W\4?8^UCX'Q[
M=8O;62W$.P1R$'M9%[58'^I6(&A\#6];W^OZ8 Q&455WQ7X3\[CR.3S\? H6
M<@Q8$ BZXYY^?8?'Q^?OPS<LDB7K *GL+[4?[AV!Y4_T_!^[Y\_KLGTBG!65
M^*%\5V(^1UF/;F_]?^17S?STFA7\GM(\#9U\?.R3K7D[_?7CQY/K5^^>.O?G
MW]N/U_H>_P"QUETI%BD>7;+(B@Q=NO+AU&CLC>R2/&V!TVO&_7JDJ0P[@@G]
M_/;].O*[$?[BNW'Z=J_WMR(ZV&2Q#+OO4/*"P9HV&P058^  !\C7^A]*B=WK
M4]Q9%\CYO\N+_KVZ\8&N.*'^_:N;[5V'Y].RK6BFQXL%7-A9-AV/^680"?'C
MR>[Y()&OMT-^D<F3(DJ\V!5<V1SP!7M0';Z@>XZ;69O/K=Z0M%>;W'^@(HUV
ML'Z&^LW$923#9*"V8O>C]N2&S&K#4]>='BE7;[0MVN3&2"RL%9!L#668!J$(
M4 )(@!5NSED8.MW1)]OD\@=831?>(F0'81;+N (5A1 KGT\45[<DGB^I]3DN
M/Y#0Q7"N$8^["M_(U[N>N2G3S)#_ .BKN8B8S7KN\D\I(6/W3'H  [A[XT\#
MS9^IR(QBC>/'0&R">"1N%AB H463RUD<=1I,*;"ER-3U&:)S%&XQ(XTV)&6!
M)= ;8/( JC;ZJLW8'4H9_.T^+TI\9CE-F_=B>CWV4DL6((F*LZU2@5*[3,&B
M/L@N828QI&8-GX;\/9.M9<,A4[582>7&A8N0;%J 6(X#=^YMNHRJSZC,'E)2
M ,)%6*PLC@$7+7+5P07(!///LJ=,L'E+M:OB<7AK>3Y3F+#K0I0TG-V2:8[B
M390/V> 7D=DC V3I3X[&TK5--\&>&8Y-29(9UB*Q>=%Y+^8R%HXAN 86>!V!
MXXIB>G35-8PM$T_[WG9"0PQ)(\H=@A 4%C=E3P *-77(OJ=*..SO3+)4Z/,,
M=$F4]R>.5)+"R3PRLJL#+ >YXE"NP0N-:0@G[U+6)X*\2-EZ3@Y.;B/CKJ4D
M@BR)&N4TXV7&VV3R67<?-H*OMR0#'].U['\1Q&?";=&BDJH0I'-W 97*V31Y
MJQ= 5Q3>YIR.GQ:AELK/:B(RC%I8&[9"_=_F)'W:T57R-'05P1X) ,F\09V)
MHF)DY3R([YM+LD"L2-A0[3R1&%L 'T DD431?\"%LIXUD!C6#\1#';^('U @
M#<6/.WGNIX)N.N']2N.Y?$?FK]V*I(]N117E9?=ACC&NW?AC&PTP( 1=ZWZC
M&@^*M'GP7?-F5&;(8*  3'&B@;0QHA+%U5"Z'<=.67B2"16QW3:%VG>Q6V)X
M)6^X X/'%>P-?2'Z878H_P &3@V4A2.>&/\ #3X_D84F#=LT:_3)4MQHS(RL
M4E155F1@2&)5MZWQAX@*96MZT\1/D3ZAJ!C;N2CYDK*03\K1!OX-=3+&3=A1
M(2P+0@6#R 1P>]W^M'M9[]?-F^G_ .G;B?U(8*AEN2<UAX%>@R,>.CDGQMF_
M^9H2Q]L30&K*KQK!,/;?\QVPK&WNEQ&A/J!3OKN+E9<.B:3-K*10'(ECQY(E
M>-Z+ %977>\M$(D89F84!P1U4_C?Q_F>#,P86+IJZ@LL(E>3S2B8[@@LTJI'
M)(Y=6#?P@[6NT ]COZA_3YTFZ.<MR_%\US1^=6&DB3CMKC3&>O[#D)+)-# A
M]V[5[NYXFE:/N3M8.IV;I^S1/#?B+POGY7B'1]2Q_%BH\>'HTA,#!T0K"9!$
MJJN^0#>LGJV@EA9XUZ#XTU7Q'I[Y./@?=)06!5O,,<KAA7E,Z(1%)W3>@.WD
M;2*ZI-U"X7A..2W%HY"3(V_YKDT3=1847&QL4K2687 LQ7YW9_\ JI#+$JJ0
MY<@")9F#G8V5/'DXWW7RA4L)_%!/9WPD4/2K!D1^ X6QQU9>C:EDYJ*F1"L1
MCAB+&P2TVRY%'N4!X[UV]NF-A.'Y7(UZ^1-5TH3W11KV'1=36E['DCA5^TS=
MB/&9) K1PB10QVR@^8.')G3>2AVD(TA)5F 5:L':#\V+H<'FNEV3J&-C,R,^
MZ98VD**=Q10+!<"ZW<;00"PW%0:/5J:/&\;BJU?$<2QL.(EO8ROC\_=RLT=Z
M]>O3#VKK)-)2J+C:365*UJU;O<JG9/9L;8^ICX:\"3Y]Y.H9 +-*%Q(PA6)8
MR14KAZ#,2 $<WQNK@]0\?>]5EDGR,HR0I)NQX(HW1(T4@D,!S)( -Q+=@0!0
ML&8*'TVVL54O97*2K/5DQS21::,,5G5"0%+%_=;86)0.\D^/)]=!X_V818T$
M[9303+]V]**"7<J@!6MH!8A0% )!:@#SUX-2Q6=8PDSL&7UDA I'N#N_#\DB
M@+XOJ?>@..Y+Q[,\4Y98R%'$3<:Y%A:N(K5L0T$3Q06HT2ME+=:.&B'B"K/:
MLS3)-*I[R793OF+[0?L\Q\K_ !;2<"+-U76<S'G0Z'BK>=I\,D+ .[/;3PR-
M:4Q(4GTDL IJ'QSE8:',T[!6?(R),;(RY!).99(#&AG!QXV+.[*45H=B ,VW
M;9(/7:U]5'5S%8S%<#S.-Y-QZG8_F-6KRK(X^:ED,[C>+6,E0CY(,;3E263+
M8ZQ#VQ7J592;")$["1%T.2M!^R3QOX:?4H=?\*ZW@0SNTFE#4L>6#%R<F%#]
MW)D'"2QL05F9JC#[@1QNK;3ZU_*QTEQ,UW?394&+]VS<&"74VCD^[QS9,@@$
M8!D9H&+! PD1V D/73S]3+<?M=39>>=*,98P_'$X[",! _NM9K1V(9(),^U<
M-V8V7)M+)/7I*>VA!)71%A;MBBM[[/M(RLK3)<?7LF"3)BF)RBNT*S;_ /L(
M&YE6%2J&7^<@NUL>K?\ "D\D6D/I.?.[S')(E:9T+N8_+18#(E+.4V;GD0N#
M([('<1B0U$XAP/*\CY,M>X;@D+F1I )#-(VBX3N?M8%=^"#W+VCP3_3T_P""
MO#.)GYT&'C.FU4:2*.(H-JG_ .H%4C:5%$2<;3S8(ZLE,G%C4Q%EVQQL2-PW
M$BE!7W+$F^Q)/][F\KX<^*Q7';MS//;DHU6DQ-9XWBDQZ0*J25O;;32 $E&8
M*%![M#Y)O[4- &&F+D/J!:;3H3!A%HDB:.) C"*-HW+R*"%LD#;0/%@%ET^T
MRG$4%">-HW9: 52; ;@4 38Y()!(6R&Z:/)>"YCK-C<52BG]B?&*FVD50# #
M)V) 9&WH(JDGP=DQ@:!8LN7H^L^,H-F?)B0XN&T:0/Y;AY W+,:!!?T#D #G
MD@V.L=/>72\S,AR*>&5O,0H5+ @D "SZ1;'@\F[_ #5.$=/,=P$9JCF8Q9MR
MUPE59:Z2),5@"$,&5PY)V=@D#7SL#<D\.^&L?1/O:YBX^0TR((;17$D*QGS5
M1&!)<G@BK%7V-]+LO,?)6,XX:(648K2,C"E0L00=H_$"+LW7?IC<KXD,)F^,
MYKC,\E)IBKW8Z04*J]Y+K8A;4<F@K;$VP =@;'IBUK2ETK.TS/THR0>:%=A$
M%!# @L60@*1M8C;)QW!]-D.F)F)-#EQY4:OL#1(#_.I)4"C[]C8YHBB2>G-B
M\%CH^H*9G/XBQ@,9D*3KC,K(*]:MD;TB#4D10._N3[<A$ 0A=_U,#Z58&G11
M^(Y]0SX)<3'R@7P)9C!!"^0RH-JF(CRV=/,D5; +4 Q) +?&9HL&2-,@YDID
MW2H2)&QH%##9&#;;5.U2Q4V >S7TAYCB>9X3?_-8\JN0S]B20Y%K$XN+BYI!
M)^3]M7["LQ@ <R*'924(*>#"_$G@5X]?P<Z:09"1SR30Q. Z.QEWJ)5>U=O0
MC40PL+R=HI$L,&NY:_> ?NV)'$[0R+N3S06)H-P 37)&[;5CWZGSIU#EK8R7
M.^9Y2>O>Q:?D*U*\S".UB9X5AEI%.Y9$COQEH^Z((Y#DKH[)>_%'@EO'?AW4
M8]=ER,/,,4T>FNNR./%DC3=#,8W&T>=/2LRE6')!)X$=\8:?!J$#8.G/&DD<
M0D54J5GFW,5=0389"J[6.X<'<*4GK-^H;D*<HPT6+XWQ.; XS(M3/\IQ+O'0
MN9B>*589!(X+UED03,&(=I DBED$0[N8]#^R#Q!X9\018^J1C/R=0D9,'S#M
M:1!9<B1RVX1@[F56)]C[=0#P#I69A:ANU/,^\Y2.^W[SN$H@VWN ;T[% #&^
M.Y6^.NL7J!T:Y#B<O&W)[>.QL]N)K +33V$KH)1'[<X2%YBZ]RM_EJ[,K>X6
M)V/4E\4?9_J>DY+?>UCA>1(Y(EC;SE='+ BU8D%& %=C8 ^O1.!KD$49BBQY
M9ECD*DJ-@8MM-H'JZ%WP".#P.FWQ[-<CQ7Y+"8RP%_D]Z[EL:*ZJO=9D@A6W
M)$=+*X,%1) A&V^\JO<P'IBT*4^'M5.47CQLJ,+LG+@1J0  05(*.!5D$,3P
M1\J\R/#DD74MMED7'=77=M5R5&\6>"S!;-  "S0'5E>#]1+G(<)EZ'+JN%R4
MO8\=.6]+-'<0V8VC9ZM8(U<RZ8!)'[#W:UHCST'HWB<ZSI^5!J7W+.\MF\EI
MYI/.C=UVDQ1[&42<AE+;>0IY%=(),""26*3'WQ>7+&SI%Z0YC970R"P2HY Y
M*D$_D8TYK3AM7\1C8,E \%HH!&H29X',@C\LNQV*C, "1X\[(V/3!JD"S208
MWGIY<A'IVJY4[QW))%5:UP:H@BNG8J9*1B0!NX*EB2""#WX(%_2^>EC/=+K7
M#VIV\5''G[&6A%6H+%6"Q3@ELP2):,U9W)9A$VZDOQ%*?<T)(X_3=XN^SO-0
M8)PLI73-".'C!],A6V VMN HJO8 G=7O3.2^=*RQL\,,,A\T%VCEW*6HA@NT
MQ\ D=QQP ;Z1$Z?3X7*XN(5+RY*U!':<WZ%;\E1D9V$TL$;36A-5J!61;=H1
M]DW;VJ9 KB-XW@?4UD73M;QBJS%VAE@+Q&3'_ LV0I%D<'<[VH(/))-GG9>4
M6@D91C!V3S8)M\C(@O;(5HJ[[@0O#'W%=_=_^#WCK.._ ]^L.K<MID+,U;ZL
MYY+,=>O51VL]$\8VTBJI'"NF\AE5>XG?Z;,7\;>%L7POKFG:1@L6CFP<*84;
M&^3+GB+@C@M2K9[M0%&NG31$C@PI4CW-'%(__=)>2B@('JLT.P[U\WUXO^%=
M(+O$^$8GF>$RRVLOE/9BDIB$ (U@*610&+-(BJ^U["X[-D,/CI+0O"DNB:-A
MZAI646S6@B;RTC&UC-2/3!MS2 67X]F]QRUY&HQ2Y,V%/"#&EDR.Q(+4#R.*
M4\*I+56WL3U/'"K4W'\#D>69=I)[D$LD"P1J5/9^6!#]AV0GN $Z!".I_P!_
M>Y[IDDV/I^1F:D7:4LSR':Y8)$JA551R 3NN^ 23VZ9\U$R,J'%@I$H"[ 3>
MQMCNY!(%$5R1S?/%#^KG.,KR_-^Y>F/MQ(RPPR@ED#]VF4MID8@@'MT-;V/&
M_5#^--;RM6G(EDC2,QR1QXYLE$8$ 1@GTDWRY'))LT!;^($Q$2&,*5K=(=ML
MS;0+:@:.VZ %@ <4*ZABA5FL7X8:GN/9FE6.!(@2QE9NQ536P2>X]I\^3L:/
MGU3\&B_?LW[L%,K2L8XU! IF(/I('8<VH-\]CTJDD)B"E1R0*/&X?6_@_/''
MY'J>>"=%.>Y"](ZT+=.2!HY/>D26.5&[N\NA\?< .Y6#KHZUO?JS=$^RG49U
MFAEQGA5D"NTP,7I8VRJ9 A)*D=KL&ZHCIMS)\8HHDF@5"-H2,B4M^*@RKP+-
MW?Q0OI[<DBYGP.S_ "B_&.0X8RK:./R\9M5I^Y669)?<_P Z.-TL68V:*5&*
MV6*E72-A&_%WV.8NG93KC0M 3$K12X[>66(KUAUVV 20Q)Y8$'L.FC_#X,A3
MDXC-$W&Z2/TR(RU08"FKTJ0.U 'D=HOY%TZ@Y):I2<=P=C 6+]:)!1G$K8NQ
M<KU6#I0LLLDTDN0L)"849! DEA@95C3O$#U+PKJ_AS ?+U,A\-96,.0R,&DC
MX'+L*('M1Y':^EV-JN1IL<K:G/&\$3"I57^)M+ 6Q' 50UFSVZA'FO!\[P[*
M6L)R'&2XW*U&"3UW",(R45E4/&7C+$$-]K$@$!E!&O4;Q<K&S8A/BN)(GX6S
M1)!H\'FO;D4>_/<R73M3Q-4@3)PIA/ P)5U%,*[[A0/!!'(_SZ87Y1EU]I[B
M=#[?.QX\ G>MGXV3OP-'YWGO7Q]*(KO8]B/KS7TZ<K^A^G)[GMVKN?BOIV-X
MDM:4=WVD,P+:9>W8W^VB3O?Z:&]:UH:*%#D<B_R^.WS_ .^LPU\$=O@=OKV%
M ?7D?Y89C[3Y79_;1U^FM#X_4?/ZG>QKUX?W^_\ UUG\]<+J1_2I U\=ODZ\
M>1L_'_?K7^I^_P"G[_S/7E#M]21W'O?SP>?GYKCKCU^A_3QK1!!&O!W\;U^H
M'[ZW\'[_ '_;H]_KVY[?/YFK/;ZW[=:Z_P!?T/\ Q_8?/QK>O/Z?I\G7OST=
MOP?/QXV-?!\#9&_['7Z?/]SKRO\ /_CY]Q_ZZT([=;'C>]:.];_<G^P/_#]@
M?1_;M^_;].O>M3O]/'QLC7S_ 'WY_P"']_[:/G]_V/\ WUYW_P!B#^_CVX_7
MK0^!L;V"?U^?U^3HG0 _0C]//Z>_O]\='[_TO]]O?H \_P#  C8\>1KXV?@#
M7GP?U))(/CC_ (Z+X]NUWW'^E]:A2?A2QT2.U=Z&_P!.WS^H^3XWX/SZ/WW_
M #_?_KH/^Q^G]?Z^WY]9E6G++.B.CA"=LQ1M :.OU'GQ\EON!_7QZ.@G@\U7
M>O\ +V[^W;OTZ*&+5)"2O<I \E1H^ ='Q^@'=H[._(UH^M;. .*^.XH?OV[?
MZ=:RVT'G]2?I1OL;^/R%\@].R"BB(.U0FSO2IKP1^W[ZT-#_ +O/K07-GOP"
M!?//^W21Y6)H6W'S?%^_?G]^YZ6:]3N"_:-J "Q4>#K6SO1W^Y_3_AOUH9P.
M>Y//Z?G5?Y=:B;NB>;X)_P!;H>]#W^>PZ]_7\)3$8/HT^I)#^OU/3'X^2>D_
M3L_H=?"Z_7]/ /GTIQGW!^_%>Y[^H'_(?VZ68WX2/KV[CZG]?]..W3[_ (H@
MVD^EGZ=H:2ZMVNO=R%-=Q918X%R$2,.P_=H ^!L @%M ^;#^S>?,@U>:'%!$
MN? (9%6R:9T8U7QM(-^PKMV8_$K,L.&58K_U)!('<;"?K^?^1'MX^..XZQQW
M#--,U=IJRKV)I!.Y?99M#[BQ78_31.]DC8[-T7!FT72V;)$32+&75 JB3Y*O
M)W+$T-O//-?$1DE7*FB1':@=I8@@<#V!K<%]VH+1XNNE7!6Y<GDZL\SR.B,R
M]DI9^Q23VH5)/@-OP#]N]_&_2_ R7S9FR/4J1HXV$T%+U7!')I3?Q]>LLF-(
M8DA W%F7U<G=M%WR> ?86./S-/7#\2BY)RZGQFI6EER5^S/$BJZA>YC[S-$0
MO:B>SN0&3<4499Y![:,?6&H9.D8^3B#.8139,QQ\>5V*H)Y1:HQ+ 6P!">W<
M'D]1/7=<30<5L[+D=<7'*[PH4LY"L5CB7CUM050>[E5NN2^^MW2/DWT^<6EP
M39_"9&ES? T[J_R&S;>*:E>GLB"M(LL<$4Y3\NQ-C\L@#M)[6@H)K74]&T7Q
M#HNK-G>'3BY.E:QD:;I\^5 D>?)#$\3B>.5 2(,DRDQTU2*-WQU&/#&I:?\
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MS#(9IWWA7A<)(?(C0<1Q$L/2#P0MT>TJT73H,3$7RL=8X@-D,:(J#:2J^;L
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M-''T:P00G>R>_P#,,I_XK^FO7*/BG.R-4\7:!Y\>UU&DXH4D6R'492.W'\Y
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M@BE4'110$&R3]S#M 9_]Y@3H;UZY7\=YS9FIY;Q97G1MD/5,:-'@L;%D+0/
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MN=]Q/<CQL3'TY,^:$*'GEGRY'8;$WT652![*."QHEC[WTK),QB0 (BA(]B@
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M3&,AA=C^GUKX(J^Z1.BLC#L[7/\ O?J?&M:)(_;1\:\'Y\!%*RM8[,3=F_\
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M"EU! ]*G8.1V/!(]K/\ :NGIQS@_#+.3GR3WEAQ-:UVRUYK$;7BH_H*PJ"9
M?!('<!Y4EB"3<W@CPU@Y$6+J.J9D @W5/#?_ %FX'_Z4>X!D^NTMW-_#:<[-
M?&59Y$B# _A 5W/P/2P&ZQS].!?(^HYT=2&;\'/IE5B<?E['X;'%DA<-]H@;
MZ:,>E=@S:([8I8V[B=[&_P!!Z@LB09'BTXT$B_=LG6Y8T<FE,#:BL$=M^( (
M];[!]R219DJ;4TRO5M7%8BB0:V'FP0;(KW][!X%_,%YKTZRW$+UNU/<,N,OP
M%8[L79:3<B=XKVX X9X96$:"02=\$G;, SQ]K6_XW^SW,TH,^/Y)@;RC$\7&
MX62V\T'9B".6.X@66/'4222&:(20IO$+C?"XVR*231!((L7R1N)Y#5[-O%\?
MZ=0XY/YI-EN4\BV6QF*0G'XJA)(P+O.P6>Q=[3LO"LD2*2I+."X]5 /"?B+(
MU*.-&QH,65R)9"WF93*..$=2%%$[6JR#=CVTSZAK4KB'$BAP<9@%DF_[N1*;
MHA%O;!P*#L"#[50/2[Q_C#7^58RAF*1QF-G6Q-7I0JT=3M*K($+;VW>8H@\C
M.LG^4G:%6.-$N#PIX1@P-3PL;+$I:6&2\A["D%K"6#M7V&\!30))OLJB0XVY
MI ^0^QB9';>Y;D66'%@.UD "R#Q=B<,)P[A.!Q\>6JP69L^MZ1F]EI!''%',
M5#(HD[69/'@H5.B3W;&K;P=-T/!PDRXQ++GKD$@1%QM$<Q (0>E]HVD$L;9N
M0:YV29.5+(\,8CCQC#RQ5#O)4"B3R1W!!4"B"3SU)_+N5+&:2UJ%ZY8FI0>]
M-9K&-(]( .UD54"E02"P\[^=@'U+-:US[LD<,.%),TL6\O-"ZJBOV() 4L22
M3M 4$#VJFC#P@V^22:MC!2D<B[684.0!8 JASN(V@W9O%J9/&XWEN$S#R02V
M%AC,)/8B1LH!FB90"6=QVJ"2"NO /=Z3-D8?^.X&6\\),N&(V*[5$,CQ,LBL
M.Y;D=SP/<\=;!#DRX4T2@HD4KMY9;>9!N#1L'!X4T;'-]R 1S)L_)N%4YLOR
M6FH7D&9B>K^72-&%1E4EI6?17P@,GC^HDH1HD>G:;-TS$,V6DD3SR*L<C1G=
M/)Y*L45U!(0"O4S4&"KR?3:'RLQXU@(;9""P4BHU,A L-M]1NZ O;9L"R!G\
M+R%O'T>0\EANQM1J1 RPRN-2V!&L@*[\@CO8[\C; :  /I3#/&8LG(DF:6'<
M9;( $:I DDU6. QY )VCVKW1,KQ[8I%"NH-@GD[C2V0!P!=D DV1R!?4(=3D
MN=7^1P5:4GY/\K5-9"SE(TBFC$CH71H@QD<.=[8KHJ#KQZA6L8O_ ,EU"+$P
MW5%QX'N60LH(E59'-KN/)"H*LVG>C?4CTUXM-QFGF!<R'A5K=1H"K X/# FN
M_P!>9(Z;?S/&\'RO L=EX)>55K,T,-=7CVU=R8FLQ;8C91.\'NT-+_IZ?]&C
MDQM/DTP9..=0Q/O*79/E@RGRI"M%BALLM@TS %11'2+4&CERTS6B?[O*L3%0
M:)(4VOXMMBJ/JK;=$BJ8&6P?)>)03YNX9# )UCE673!YHG+2M]Q8LO@D*-)H
M?:3L^FG*Q=4T5)=2?)\Q?,0RH'+[F+WO96[JQ!-=UK\()ZWIE8674&PH6#J/
M20H7;6U:'!''(/([7TW;?/[U_)Q7E,\O^6J+"JE.XGM4LB(J!!&0H+* =E1^
M^HQJ/C],;4(\IY5CBBB*"(L54!AN9PMV-M>IKW &KKIOE?"Q)&C=HP@1ED=V
MHEJ5EH_A-*A%%:[^YZD=NDG4&/'TL[DH(<1E.0A<EB<1E8Q%+>Q+3K5_F<\9
M[9EJ]Y4"4]A<+WC:B0^H#X7^T4^-?%LVDZ(L>3()99)LD OB1) ENF:0"ZL0
MI\L)ZW6N22>HIC>/<#,U5-/Q?5BQRKC/D1[]IG<';C*Y #%J9MZ[=K@I9  "
MK:;)8[$YCBUOCZY[(8<?S&W?P]:S/^60QAC)8%:-S! B@Z[S'&1\@L#ZNC5_
M$VF:'",#6\C&;*:,-$JD11RERTBV@VF(J=II>&&VN+Z?<O4M,Q)X9)\X8(GE
MVHDI+2LP78!&2"'WT0;H@V>3TZNEW7?$\3HS6LSQS&V;M+%/+QZ[EJ[W<;C<
MQ#*LRS9+'Z8V&DKHU6LQCD-2<Q3F!Y(E9(#]H>?K7BWP5)IVA93Z;)GHB9N7
M#* \F(8V5H86"VA=MC$JP8@$6 2IC'C;PWJ>OX>GQ:3FSC#;4(FU"#$H9&7B
M/N39'8]:QRLLC(:#*AY(%]19U2Y[U#ZHY7E60H9LXWA/)9J63O\ %Z#E<6EJ
MI$D]>" 21K))%'WO)!.S>XAE:-B&!4UMX$^RM8<+'U"?%:7+TG<!J.1)(9VE
MKS'9 9#0=318 %ZVN6H#K=X+\*:7I:8#94"MJ6"^3]VS'5QD49Y(V#J79(F4
M;8WC4$;%1N3;=1?AL7B5P5K(Y.E'(Q=D1W[O)C)5-J6"[#D>3H?</C9/JY=.
MQL%=+R,G+@M@PCC?=W8<=A0[F^PO@=NK1;(F66**)]E#UB@?<@^JK"D<@>WS
M0XR>)+D*=B]>P>/-FG%7E$Z=@:.$$-H %0H!!_J&P 1IC\^MF@R9F/-DY>G8
MHR(HD=95(M5!!(46;NP2:O@$GB^M.8T&0@BGF"DRKM8$ABP"V%X^*[T+'%'L
M]N"<OEFRU;$BW)B9\E:3\]HA(Q&DK,JR#7QM?\LJ0?G?@GT^:!KGGY46&RB&
M6>5Y' "4:#D1A3N WD!5841P!R1TDSX$,;2*-XC10EEK56H$D@@D_P QL\T*
M/3IZ@=39\?S/$87(0)D\'2N*\]B !8?<TIW)(NF)7O[&TY388G]=N&J>(!IV
MJXV*82<:U;(E#>I6=/00""/X;,"0"+/?GK'"TP9&#-,KA9G5T52!^ -3#W(+
M@;=P[>W!-L;F/3_ \HOYGE(R<<5.)D&)JK)*KRRE!(L:=S!F <A-ZWW :;1W
MZ:]<\.86IOF:O)F)Y.Q1"J_@DE6-206+ 6\E *JGF_85U[!F>5#CX<N.&9+W
ML3>R-F:MP^ @]1;@"@;)ZV<(Q?!\;Q^;B>4BA_FF>L]E[+SMW14Z[-LNNB%$
MB>-(Q0=I8ZV"2ET"+P]#@-IF0J#)S?-$\I556S?EU-^%"*%* I9^6) Z\FGG
M:5<G#4""  1JJ;3(2P$E*JJ&)YLJ; &U>_2#Q#@?!.)\SY),,O4NK35FQ]Z4
MEQ,'U(-(6$*+W@#O"L0!K>V._-!T;0M*UO49GR,:7R5C:*29ULAU6RQY1C#R
MI"@VWJJ[Z79>1GY&#"(H987F.R0("64 \+SZPKGDEB#MNSR#UP=2IKF>CJ-Q
MB2[B:\P2 /%/*:DTI.K#UW[BRPR,-A"P'Z #UJ\2SRYS0/IS94&,X:)6!98)
M'W'<8MMJ5((%4%-7M!XZ4:7$(#(N08WE!#$TID04-I>^68<T221=7P.O9E^!
MSA<CQW\$SZI<=>F_-VX<E]4<RESVJ\;]'./>U&YT3VL4[') ?RS=P8@^N>O%
M6#DX'COPY%)_$E,VBRHKD$,#J3JB,0#2LW#,/4 2>2#3Y'+%-AYOED\)*K/S
MNLPV2 :YJJX(/'OUXF.L/6/+U[UWC4<6/,<J*]Z.D$_+QS-'&B1QR!?<$B(I
M#AF':2-#;-NYO''C;-PS "M U+\^F/\ =_+*7*L+*T>Y:;:)BH=F4V' H7M!
MXYZ8,+3X88X\E%=I64L'E9U*AC0_A[J!(%\@5\\FF+TXZ6VN8TLGR.\CP83'
MTK=N>Q'M3+)%&[A% 4MX;VP65>WN=>[P=>N3_$_C(0YL<4*I)-*X9XX]H4;Z
MH^H<LWXF]SZK]SU'M9UV/3\B##C(.1/.L8%7M#$?H!S[V>U>U1?Q]:>4Y-0Q
M\T:1U)LE!7[W8E1&]E(P\G;V@[# N !O]_VLCP0L6?EPK.H!=X59G)(3?(BD
MD70 W&ZJJ^.>I3%"417/J.UF<5W*@DJ!QQQQ9]Q=4:[3X..X;#82.J:%04,1
M'C[-N.L");<_9VQQH!L;(;O[#M9/N!"DAE[+CP\3&PX\=8$\F%%98TCK<T2B
MG*+1D8D73<$][/44?(GFR!(92))"ZVS?@#$@HI/"K1 X(H<_7KFSF0RE#!9'
M+T[$>*QL$1MTZ5A8PZ(45W]Y&!"CO[B$&U UI5^?669.8<')R 5C>+':5&D6
M@NQ-VUUO@\%0+/)YZ\QXUDRHHF&X-((WVD>NV/*GV5:#'Y_*[ZY.H'6#DG)[
M,M1;/LTP\\3)"(BLJS:6;1"#:N NM'[=#M[?/KG+Q9XYS\TB"27;'M=?X858
MPCTKT0+:]M@L6VG\-<CJ71XN+C1NL";2;#N3N)]B.20!1()X/OQ?7)TNX?:S
M65L\BL\CBX_C..TSE;]E;4D%^SVQ2/#0H^VRLUF[)'^63X6,RJ[:4>.>_'&J
M2B.")8#F??V6*.P"A!9?Q@>P'J ()^G;I@U;4(\>.+$7"DS)LN7R(KC63&0L
M0IEF#;E980?.*L"K[-K AB&>LF,M<?K0X*"1LA8S\>-SN?$4TTHE:PS3X^C-
M&VP)*%:=YIN^-I&M22DN8HT/J1_9_I[ZAD09WW4^7@R?=UCC15 8?]QF4 6V
MT KNMAR.*Z1P3#4LDSB.\;#D:#&50%#A-L4\O!5:=T(%@!0 @I0!U;PY:G2X
MUAL;C2U>Q/!&DZ*H5]RH(W314 ;4:!&BH&QHD;[@&3#C:;@Q1$(^1#CQ01J!
MN&]55FJN">:;O9[\<8NI::=GHHA=B6)KB]J\WN%$"NU"KKJ5,C^5P?3X6+TR
MB5<:C0)*$*&::42PQE2.V0AW !?N(UL>EF1.N'#+-(XVP1%B7/!<#:H)ODM)
MM7GN2+)YZ1Q[IG4*O#,+H ]VO@43Z;LT:%<?2LG#4B?/3<MO6/R=^6XW\HL.
MHABJU*T<R9?,QA43[\= (:V+0*#9RMV*1#)^2EC;A_[4-3R=?U:?%A6#(^]R
M&.::,A=NRPL>U-J"B2=RJ&)7DD$VP>),AYE; @C\Y52W"]YI R-C8I[[0RAG
M<JP)2,@DAZ,P\1Q_&N59/.<BL4ZJ5ZLL"TU6)*ZUL=4@6M4C$<3=H18($#EF
M)=@7<EF+'HK['O#&%I'A;#F?%B?4'<DS,NYT&Q0J L30 )[ 6>>XOI9HV-D8
M6!"LKL995:65F<LPD=V+@NWJ 5@?0I"T38YKI[<D3$9.OCORL NI7@O&,U@X
M**L*MH?=V]K-X/<I[F"@^"?5PJFZVD56(Y7<H8VP*M5_^2VI'8@\GCAS!==U
M,R@\E@:H#D$]N0P7:/GMQ=]=_5._:R_))A8$:G'GV*D4;'LBC!5NU$7<<9VQ
M)"(OQV_ !]<R_:9D9.I963O6,?<TDB1=V[RH@M;(T.Y19_$0 3SVY/4A01Q1
MK$EK4;,TA))D:12Y8@DCN%HUSQR!2]+.7BX<M.+!Y3&(F0AQE",7_8M>U[HH
MPBY4869D[8X,DUJQ(R*_N75EKJ6C=D;DJ/3]6=Y<K&9ONZSRDJ OXE(LGC=>
MT>75T +4=NF?%R=0,JSQ2-) 7<%/1:[7L/:K8)CVQUQ0HU8'41<IZ-**3Y?!
M]QBCBALSU'D]Z6*.T[O6C]WPIF:(Q1^V.V:25)V2,*%7ULQ=<_C_ ';)6CO*
M))5 E0 00.PL,UGA5*@FR>I1@^(%=_(R.)&)5#57M M@.Y!.XWR I4'D$F%I
M,4\#F.2$QLC%'1NY64KL,I!\@C1!^&WL?H/3\) P!4V#='Y'!L4!\@]R/S'4
MB7)! KXOCW[CX_X[7[#K(BJ*2%5=>//CXU_<G9 'Z>?G8'K L19('P/GW XJ
MO;CX';MU@TECO\'L/[_U[7WX/'2A7J$ C7<-CSY'_@/^/[GUK9QP> :^G]NW
M/U^?U)P+78L@?U_.^?J0*X/%GCI5CA" ?Z?MLZWXWO>O/_SY]:"W/%_UX_M5
M_P!2/CKS@<59][/8_2J_]]OKG1PAB 1K>_()^/&_V\_J=?/^OK6S$#CGM_L/
M]AUYQ[?)_P"/G^G/;I;JUM!  /('S_P_??G[?&QK_0'TD=MQ))]_Z_'T^GR>
M_/'6-FS]?D_7]22>_P#0=[Z<-6$G2@:)/Q^@'R3O]=C?[;^!Z2R,*X/%?U^!
MVO\ K_3K%SQW[_W'O_F.G-CXE\[\]OZZ(.@-'6Q_;?Z?\-:"&5CP:J_;ZGM=
M<<>Y_P!^4<A(NO?Y_P!_TX^":^>O==_"MQJGTB?440/+?4G*Q_0C_P"E?P%?
M(WH'0 T!K7Z>I#HG,4YYO>HYYX"WP3]237]_AUTUB8VLD\^_T)]_U[?[],+^
M+2RB8SZ3_I@D$8F!^HC))V[(!;_9MR9CW'X( 70 V 2"?&_4[\+9?W/.R'7:
MQ\@)M:PI8NK!3QS=';Q^*O;OAJ\)FQXU!K^,#_13W''%D7_QSXNNFI7+W\7>
M: "@L"268@2C_;K99-'95@&!_4 !MJ%WT5X.?[_EXDV1"@AC*M-&MV$4VQ84
M"0IICR6(%?-Q9I9%CG0%5=!L0H!RQ'R?37S?N;/<D=C/2WI3=YIF1/7Q@N8'
M#T?\1O#9EA_+VXXHI'AKF.1U:97EB+RPH'8Q1:D'8QW<VJOCA<"*4'[M)EQ!
MB*6'<8)C"LAL%$9Q&%X"EF7L#?5*^-_$<6D_<H\K)FPH=2S$P&RT!N))R5=R
MX!5=B[C9-K^+U=*75O+YCE'):_%\QQVMQZ&@<8T1J4ACA-CHX99%_+TE556&
M5I&1)4'F'M9]EBQTZ3I\&)B38..<K[KCS,5DED+F1)7^\-"DA \R*,/]W/)!
MC 6[4$J? .-IVGZ9DXVFZD^J1-GY3C+>7SI&=PN[<Y%DJ5-,M^H77)/5(OJ"
MY7GZTR18BS(N*I0BKW:*ABND/81YV@!VQ'GX!\'U%?'.?GP-'#C%X\8)<I (
M5Y6))%]_0M=S5[JOJXM#Q83')*P#RDVH(NE X(_6S??M\=19T?S=W.YAJ60E
ML-5>"1N]CW#?< S'SO:J= :'@G7G0]1[P=*^?J:X\S2F*2*7=S^(@7[]O?O=
M;B?>^EVH[8\9YT0(ZE3ZA0(L GBR:[UQ?4^5NF/ \2\F8F:2Y8MVG]N)4,C-
M+'LLHWX7MC )&U !_J+>/4]B\)Z#B3><\<L[22DJ'+.&>BVU%1+( Y/(%CN#
MTR_XGF."D:1Q,5!9PH!Y HL785=BNW?BSQUE4N#\:MX/-Y.Z]XY(WHZ>)AK/
M(B0&3VV1WA5#')#(YD#[(T =$$+Z:I/"^'-CYN3>29WE:'%*LZQQJ'1441 >
MH,Q)<MZ0!P0POILU!LIIXVAG*OY2K(C!2C+98V6!VD(NY:HEZX(-=(-G'9_A
M>9@J72ZSS1H\+JT97\O(- ;5V(TNR58=P.QOP?36B:IH&?CQ/*7:2A%(H#(R
M,2A5K_E7FP0.0"+]\XV7*B1&)**2'1AZU>N"=HK;1L$,1['WZ6.HM6C/PNU*
ME'\QEG4&K>E#+[3H$>4^YVGM5MLHUM@>[6MC<G\;X4.7H603#%+EM&L>/D-$
MK&(G\3L_XE1D#@#L2P '-]9Z>AEE, ;8H:2P]#:2*] %D<%5W<FQR;H=4VK0
M3<HMV8.3":RLD!HT[<TIDL8]XV18I8))6)$<0'8T?]!A[8E55"%.*O%&EK@,
M[X48@$<C'R[K<J-ZE7D6#7%>YJZ!Z<7=< /]TI=CEI$L;9 "1L(7@EAP";Y'
M'L>HES&$GQ&2MXZ::O<2I,\7YZG*L\$B(2!()(RQ8,!Y'AE\@@'P8_BYJ3QK
MN!0L0?4*(YHCX/QVYNP>#T]8^1YN/',BO$)0&,4@(<$5Q1([?B)'XN/D])$D
M!@8JP.OE2-L&&@=@_&B#LCY']CL>GV)XXF57*U0L'D<@$>Q!!L_(H^W2_P \
ML!3;6-6. 1^O-<CV/]NL62*-PRD:5_';X((^3O6M?&P/TT/U\G%_)>P3MW$_
MD0":H#X'%GO[=*8I7'%AB.>#]>_U/]/]>N*2M$R!"NQVJ FOM[?@ CQHZ^?^
M9^1I"V(#S%1!YVDBS?P:H79[U^?MUYO?>S(P- TO<V*/UOVJ_P"_MCK7,([D
ME3L5@JQ+Y< ?J6WOLU_?>QY'@ :(Y&63:58 &K]KOZ?\#BS[]*5G8C:ZE2>[
M$<=Z_J?R'T%\#,4^YW J/'C8\^#YW_8>?/Z?\/3U#>0&11?IL_EWX'?V/:K'
M8<]9%@HHM0/]+_?[XZP;6+@LK]Z]K'9!70^X_J?U\_IXT0#ZT2Z<617W+R-U
M7R.+_EOV]C_;K,3 D@"_[?G_ '_+]>D%L%+5*S02$O'HCP2  ?('C?D;&P?C
MQ^@]-K8LD?J%\<V:/]O_ %[_ )]; P)%'^W?^HZ789/=C2=1_FJI5@3HG7AE
M\CY)_P"1W^WK;8D2Q6X7?R>WU':C8]_>KZPD02*R&Z8<&C8/;CCCZGWL=ZXU
M2Y!.=,_LLF@2X[>TC]B.X$CQO7C?[GT@<FR*Y!_J>:L\B_W[=(_*EC_$?- [
MB_8@"@#1H4/?VYH'K.-FW4"S06'[$^X21RLC1JI+*X(TP[6\[\$;/[^LGQRR
M;F0,I7<WX?PE>>/ROBK[<>_6M51V*/&5?V#"PU57/8W8%?[=;TR>2EF,TL_O
M2R@_YI),DBN0W^8''<WD;))\D;/K2V(J@* $3NJT!7Z'\^U7\5Q696.-3Z2H
M4'CV%=O;^X H$UT]8^4Y*"%(K=6I(3&W8LE92 O844G[P5(()4@^&TWGSZP3
M3&)M"P![TQ/>ODFA^GY?1E;&CE=G02$;C=-WY!/M]/KP>N+$<CPE!9/SM6RD
MD\\9ED@F!W$.[W0@8CM9B5[/.O'D>E@GU'$ 6&5E 'ILD=NWS[W=5S\]^B;3
M\J;:49:4<!@01V(' '?N;'<<#KZJ'1TUK7X+/3&Q5:6.E9_#*XA+59U L1TI
M_I=Q[URYC+ S1PM&2R[!D3QKQK/3]TFH8!F(WR9V)YC@5M+9$99EX[@VR\<M
MMOYZD$:R)@JDOKECQMI(/=@E$#MW(H\#@W8YZ^=UPS 8G'<0O0<BL#*8EZ):
MGEL@YFN&:PLH]J=#L]@[E$) ^U5?>@ ?7=^D8$&/H\@SY(\K!EA5H\K)IIPL
M@:-T;<#L"'9Y1#6"QL<=0C.GDES(UQPZ3QG9)&O"L5VLK>D@-N!(:Q7'>NJZ
M9K%<3P].O=P8C&7IW&D21922ZAV!C/\ V@X*KH_(5_V8^JPU&'1L'&2?$(.3
M#+PPKE0QXX L$$ 6:%']7:600*7GB0)2[4"T^X\'D&Z')_IS9KK#3D.8YE<I
M5\72L29]B*6-KU(FDFNW)F4)%7AC#-WL@?L"J';[B"H4CU#O$OC5,;&CSG=8
M!CAOO&0VU%CC4$G:"RCS&"^CBCV- ]->?FX^) N29!CXT0D>>:5HRL2!;8-N
M8 BK.UB+( 6^KLR]*\ET"X#7SW.ZU"UR_*RR8O*X Y_#7<]B[V0KDX\_R.O8
MGO0QRJ8UDDDC5H9).V0!I%;TM^RS[8?">LMEZ=A8NL96HR;YHL]L(G#R%K:L
M<4[>E2\PVA0"SD$A2JD=5YHGC%/$>OY6DXZRC#CN?%S&PFAA<(567S6O<"=P
M**ZKNI_42K%678ZKX.A@L?B\CB%J9J&K52>/)0$SSVY598DA'M[U&&"MM@ ?
MM4'P?5Y'Q3B8V,B9D4T>>D,"MC31>66F9:H7>Y;%EBJV30XLB>?X3)+(9(Y$
M?':1F$L;%AM!)-@=S8V]R!W)]NE#@>#XY+CN0WN3UWO9T))8J8@([>U%*#)$
MU94 (#;3O8#2_=W; &C1M.@*9,N;"LV9([S2XTB!S!"X$D8AC(/_ ' >&!W!
MAL!6C?F;/+$T:8LI2"U7S@U*S%BI#-WH,.0; )9C5WTLP8;A6-->YE</DH*^
M=Q>*R&'GLRQ%):]6R]3)2,(YF, >=& CF5)I%'>$"LK>L=.RO#>;DY,6/MD>
M%8DG:=)?)1X^#&LC>D2(Q7[P+-FP+6^FN+67SI<S&P\@9$FG9!QLJ.)>8YG5
M6 8E5$H"@E2A=5(HM9 "]R1>"RX.S6XY):6^0ME:T1E]CV^T'3]W^7H#XWMP
MVP2?CT^SI!D8>1C0&$_P&D"8]#U*+!I0%*L!1]B/TH1IUF228OY;R"-O,NJ8
M\J=W;FB*['CYZ2.GW&,=GJZO)::IE**CO4,IBDQP :R6[ &>1V#Q,1KM!7P0
M3I+I$<1QL?)\O;-%&T :-^2I*N0X['=9#$\THJJLJ<^9Q(\:?]M]I)925KE?
M0;%4 #5U??@UTZN;]);/%,!PCK+2M083%]1;F?IX*"E;!NXZO@;BT[-FU B]
MT*W9$G[9!*PV\*'L.@8XF5B9/B3*7#DGQON\2P9&5' HQH<A783I,&78//5:
M6QRWK[]1+1_&8U;7M8\+QP32+HT44CRR[2L[MM/DQDL74P%E"^8 KA&\LL >
MHMX3B6YI4Y=3S\F0RF0L--5XI[N3./-#*,YDAR<D,BRC(5GBCG1XVV"TW>#_
M +OIIFT;Q#XA4F'7F@BQ<]C)CY<;E9X:)5AM5RHH^BEK\7:@"\^)(]4Q)='F
MTJ5$@CE$FI8X1 \\)!W0HY*@. 5L$CA1[D=+&,JY/I_R&W^5LXZMA4CIXG)7
MK6-BO1BY&J_F9:=>PCPJTHB$3F2*5F39 4L#ZCN3]DL.H9(D\1YMX$,[2N^,
M[1"=91_#6RNX $A2=H LW1LAF;0AXAPX_P#$FG3+7(R)$AA:F\G<=D;NIK=$
MH:@"21[D&C,5[J]SCE&4O<JOWJAXN,9CN(0P05XZMBQ4I1+'W2MY[*4]EGLS
M54*Q-+VNL>D4+(/LZ^S'PUX!SM7SO#RM%A:D10G)EG:42+YDWFL%*J7,D2#\
M10**J@S?I?V>Z-HOE*5GS,N&8Y41G;<(&&\Q !?27BC*(C;3M')+-ZA'\G5N
MKTEQN>MR+FY<=S/.SQWTKHT<%BMBJ<8I4Y)Q()+5:2W:E_,UY L9 A<N-[+1
MXAQ-"C\;YN;XET_'U;3/\/C@P59/,DP<U77SU*,T2@R72MN.T,".PO5/X;Q/
M$>NQ)DMC21:7IRC%3SF5XI<QRQ<[01OC"@J3N]P>2:K3-R&SEN,6IAQR&!,U
M<N2XZ_+&Z5U032#V(Y1]JR1A^WVNXE0/M;L4GUF<T8OAQH4TB&+$E>7[GFN-
MJ11*^T1B1A^).5Y8 J&-$<BR%QQID<2I/YD6+"%(+A0 3M#R*2.69AR!WVT1
MV.-QRUE)UK\6Q5BM+9R,OM*Q;[4<HD;(A.U !\JK'QM@?C7K#0]4SLF-=&PM
MH^]MR78!2=O)1A8V  $'WY[T.MJYL3;99L<KY2%BX((9C1+"K)L;1WY(KZ]9
MV8X7U&Q-ZQQ23&ID((HEM00U(FL3,9>YC),8PR ?:[QIW#?R!L$C;GX6MX\X
MT)8X\NXFS(4@(9Y$+;6E"G:P&Y6 W*HNA0OK!]3PW*A&2'(/XC*X5R1R5103
M9"D&P3:T1VKK(XIDI,%7B@L9&6HMJ2S2SF/:%ELP(A4D0!B0S2IWIV_U*5';
MY(W'L7Q)K6D+J>G0PF/)>-XTAD'J$I! 5E4DH],U65/)[=-&;FYGF3X\>*)I
MA&KX<UKMW-R6L$A@>" 1R0.XZEZK@N 2T'DIMD(<[D>Z>LTU?V761MQ@2,YW
MV?<I##X8D#PVO4W\,8N,T>6FJ8N5A:IEY,N3CS>7*-\;I B.K*'55$K$ /7\
MQ4T#U'L34?$.+D3#4(I6ACD#R&$(\+*2+\SFP=H"KLX!L$#@G)S_ $9M08-<
M<F2%C+O ^1R3%"YJUU)F,O[EC(1$H!&];"E03ZDV3X9,VG''@R-^2S@OD9%A
M9#N)<*%!8&]NVSV!NN09<VOLD@9(@05 2 ,/2E*MN.*  );_ .X;>Q/69QG@
M5YNEO((I:TD_*%CGFP*31R&*E595DA-(, )9I![K(2&82.H\ CT8NFY2:%+I
M\WEOE^7.^/$RJWW4R[UA6)W'H8E&8M88,U,*H'7/J.%/K4<!(5$B@?)5"VUX
MF;:22I]0+ K1'(2ZLFZS8/IGRZ?CG)>29K.-5EI3RK:Q\X ("R-[([M=Z2A4
M9F"L"J]H.^W0@^)X6SGP<[4LK+,$D+3@X[H0Q2(HY!-#::/IJR6XX'4BDR,(
M9N,D<+.6VB-T;:@C8D !?YAZ;-T.]7?##Z;X3(W\SF\5F7EL0YNA(,?(KF7_
M #HY?<C*,-^P B;*MVA@5_4 ^FWPU@S96;F8F2YD7.AD^Z$#<8W0[T YI0 A
M!)(!OVXZ>LJ9<>%9T 7RI$:0DU<9W*1^BD?-?4]6$Q'&[M'B^-Q=^_/-6AN]
M]N41[_+H6+"/OT"H'CP/.AL;\GU8^/I.1#HN)BY62_E#*,DZA+:!-Q&W=8<*
M#1:@>38(XIAESH9,_(G@A E$ 6%BW$S42:'X2:% FCP.U=>SG\'Z2I7_  9_
MJT]BS"U:I8^I]EL*Y>,(G1C"3EW8;/V(06\;UH?W'//VHM!!]HVA?=YHWBAA
MT9O-5PP0'4I7MF!-E5-M[FO;@=/6E&1M,R6FC*.1*61E*D$14:!)(!HT?_$_
MJ?G\Y;BN:Y'G^2Y9):C8_'O-=N96Q.(*7LA7:&&*0@+)9M")XZM9-R3.A0?!
MU#OM"U=L;5)(Y)C+)DRW!Y%-:@^MC6W:+=220._%\@))]0AA9<?=(TLKI'&D
M0#$ CDOR-H4$!C0(L&O?JSW2?J]4J\1ZL4ILK6Q&%Q_32+C_ !WB[",KELG/
M/6KO8(C4>[<*"U>L3,/,\JE1HA10FIZ)--J.E&..6>?(U-IIL@V6CBMBH'/"
M %5I1>U3?5?^(?#@DSM">. 9,KZZV=EYIW!H(5@(16LCT!V5$ W4$!-DWU$7
M2OIM8Y3>R')_?CQE'&,]MF(\FQ$PF*P,WV_=K["3I7&B1O8[/^SWP;-+C399
M:/$AQ@LC/RS%XQN 4V 20I8FZ4#U<GJ=MEC#2)'4R2/4,:5S7 +M9/!)  /J
M:S\&[_<?SN'R/'9:UJ.6&ICL;1CM3JVYI[$*,&D^UB2I':22009%'Q\]#X&7
M%-B1RQN2L$:I*S@#:8XE,G())('J)XN^V[@1>>%QD,J[6,CLRA2U^MVI0" !
M1!'O[@F@.JX]5^>4,I2O8ZOE;,420/#!5D!'N(%*@.=D_</M;R6&P-ZT?4#\
M5Z_CY<$N+C9,BJ%*O&$VK*X+6S-^+:;  (%T"0IZDFF:?)"#)+&I<]FO=L4U
MM7FP"*)-7WH$\$TJ;#6)E>S'3F$*CN]Q(I"B G0)8C0&AL;\?L1ZHO/TJ;+W
M.B$"[-(30YJSV[<\&S?UOI06EW'T$CD\@T "0;%<#WH?K9Z7,/RK/\?FEJ85
M88I)3"[RRTX9I U<F5/;]Y'[/G4B %92$[U=HX^V(97A+_$9EAFB9E@-KO#!
M& YH$5VJP!W[<@])9<"/,5&D$G\,, J$K8(INP]P?SXKN:ZN9T<X1ELIE:W,
M>0%I/?$-ZP9" TKM[C,9 0JJ6(;[ H"J2 %^WNZ0^SWP:FF18^>T*0Q>6'BC
M4?\ >>G4.X)!]!.X;J)) H <-,Z8^! ^'C@[V(#D?AC0\JH]R6'XNW-[CVN>
M,S5Q?+>7TH\56DCKXVE))D984[5=8K"%T70TS!2/(T6[D&R OJQ,B"+*U+&A
M=F#8L#S/M-"C)"(H6;LI)MV7_P 38-D]-4N2<?',88&7+<>6!RQC6]\@4<@!
M188USQ^<6]7NHD.0RM'BM1S2QU&Q#$S31^?;5Q$S!.Y  %16*LZ]BAV)[M@0
M'[1/$,N-@YFGX5>?!$\\KFQYCI&[)&G)!"FMS<6WL  2K\EH,*7)07*T+B.-
MC7&PD GN Q 4COMY)!-#9RF7\[9CX]6:M9CR;U,+A&FKUX,GB>(\<GNT,1[D
M-:5XJ=OD4LEC.WU96:Y(]>^'/>9)N;OLZ\,R:]XF:=TDA\_*,LPD%H90U&07
M:@6Q- V;!KCJ(:+A/E3_ 'B1I (_.S,H DQ/F9927,968 N(CL@072FU50O3
MJEQ=OCM.MQ2E(WN2/&TG;X$SV"H'N-X9E7P""P'D$CUV>F&FFX&+IF 2&-('
M9>2I9C)(Q7M[D]SM% =3!&5W,DB@1QKM55]CM H \$\AK_\ (V1P"K[R'',K
MB>,"MB!,^79EFN30G2M78DO5B=B.W:D;T "=[)V 5LJS)BLN,P$B*H0L 2Y5
MPSA=P(4LNX)? ( XY(UQ21//NF%QDFP"U*-NU2:VV 0"U=^31]J8YCC.6.<K
M6XHI!>%E7K2N@ 2:LZNS.#M=K(-]@)[O[]VO5)ZQX=GSI9(9X&=LH21'>M65
MXDLT:*GX)]5;23QU(I(<?+QW)9;,5$AOPJPM6!]QM!HT/84;OJ:.5=(8[W&9
M>6<HS:09QZ,D]>I#4J4(5>6>>V5,%6O K[EG9SW(7("QEPBH$6X_V2>'M*T:
M8&3(CGBQ9)682#R$EV,VW:5MK)V'_P"X^D'J/XBPXS#'QU9D+D,]T2>+8=P!
M[@4>/YJLB$.*9:>OQ]\%;:2249>*2K<6*N(<=$52O+,[F+W+%AHV)02RHE=4
M[HR'<,O%WC/0?N.KRS#;Y++*JQK^*1E+MV% $\&^+!'/MTGRXR,M9T*J%A9G
M3<2TP!)" #M1')5398BS5=1?U6X]_+>561''$JV:M2V)5>.1;8L5H93<[H@8
ME_/%C<* GL]Y8R 5T&G1L@OB*'+-L=X^;].UB%46;.P +9/-62?>4Z%FC*T^
M!KVL&D!1@0R%2W\,[O4?+KRN>^TGJ.XJ8\#M7R-_H/C0_P"(UY'@?/QKX<V<
MCGGO0^E_T_Y[7T^;_D\>W'O?(_SYXKDD#VS4J+_O=H^01_P/DG1!W_W?L?6H
MN;XXK^]_(^1_3GCYZ-_?W^#VOZG]_P!/;G%16\#7D_\ =Y\[^-CS^A^?C]\#
M(1[FOG@]Z^>_^GY'KT,Q':S\<@^]WQ0_RNZYXZR8J"KI@-D?!^1^Q\'7G^_C
MQ^FM>L&E)[_!OV_RKX!_V[]>FR.2*[\#V[GY%=^.W]3TKP0$=O@[^/T\?I_I
MKR-GX_\ #TF9_CVOL/H1P;OWXX_7K$N #S^O'>N_]:]@.]=+$<?:WP=>#\']
M3X^?@^!_S])F:QQWO\ZXKV[@V??V]KZU6">#V^/]^WZ?[=.2JI # ?U !B!_
M<?I_H/D_\_CTB>B/RNN?S_K^@[_2^DTQY/;BS[W[\6?KW_+CKW3?PLJZ^DOZ
MC/D?^<DX _0#_9;T_P#^'D_\R/CU)= __59/?^+R?K7/[L@>W'3MI5>0W_Y#
MM?Q]?I7[OJ/OXL^:&M])7TSV6JP6C%]0V098[ /M$_[.>2LS%02#]OV ;'^I
MT )KH$IAU&.81QRK$RM(C\JXX%=B;4L"!7M_3'5A<4"VPN< T>X",>38^.>_
MOW]_&5T9Y.W)[[8NOAHJ9@@:5&KKI62..,2[TBH(U71UWDZ&]#SOJKP+J U#
M,$28:P )(RL%VVBHJN6X V$$;1W8B@.1U&=2C$>-+.!M%D!;LL:LF@/GVY[<
MT!UVE="+?-)<.<'B\-;2UGA+4P68L=].E!0>..K/)-)(JQFF/<L,]AF"*J,J
ML6T/3UXNGUV3!3(PXXI=+\R&&?%API,G/R F1&%>()NV(P#$DA*\NP2&ZY:^
MTW(AG&//DZ@DNDX4I:?"55=WRHY&NBHWJ^V10%8A0;L\'IL]>!GL'RRO+GK[
M7LRZ"K8L!ED,%:H%C;\L>XQD$((B%;M"#2K\;L7& C@BCBAVQ*40(UH8XA&2
MHVU8*;4390KFB2*ZLGP;)I4NBZ8=&@&)B_<TDB4Q[9!YH1BTB$4)I6<L^XV"
M3;\L>JI<OPN&Y$)(389H[)99$T0T9< NW<RZ().] D_(_MZ;=9TO%U95BEFV
M-RH IJ [,!S1%BS[GL/<69@Y,V&&9(V85N%BK[V &"W9'I/8"K-40V\5PO <
M0K^]CG/=[<AFF8$_:#M>UM E7!;?@=N@""=>FS&\/:?H,39,4S!DB=GG?FK]
MD"C@<D$[K/!]NMS:G-FEHW3:FZJ(K;7)9MQ%UP>*KO9KJ3L+B[6*BQN0F,T^
M4:Q/(N(M1>WO%V:ONQS!''<)'C=9(V"]K(Z'?DCTX:,R9>+'F0Y8RX_,R%4^
M8"@0/M9 !8$J.H))/\U$@%6Z9&U3#RO-.&\<JJ_DEXK),L1]8W<E@"&7Z%2!
M>T@R)C[].ECXLEE:J8W$-,&54$;I+,H+K(ZJ%<KW Z':?"J0?T]/$CJB%F94
MVBR9&50H)K\7*B[ '-WP>3UIA=YBU(0&-+M4GS"?>JW$\7R*)%@E>T*9^[1Y
M1RR6Y7DL3Q+I6[XP(X==JI$NSHD(%<E?T)'@[/J+R)BZOK*+&TLL6-$JNZJ5
M16!W,JLU<,2&)6R22!QTZQK+CXTID1([?='5EV!&T%J!^2 MBMO/8UQ=3^40
MX+BL]=1![%2 $&QVDO(P*(H(\DE1Y&ALE01L'>[Q?J4>F:1DL1&-\86I#:[3
M[ &CNW 4:)'?@D]>X$(:3S"6(C+?AX)<CTVP! !+60"+_(<TMXUR+*6,G>R2
M2XRC6A6>S9AN5Q*CQ(5]M:/?#,6G;O:14(0#VD[R0RAN+_%N-D:K*]Q21I)(
MSJ\##9$2Q*@V58[=W("B@!Q=6JSX(Y55"LC/8*F(@;23R&!(-  #Y_$>X/6-
MQW-6LKR:T*N PZXNY9E1<>*,<D21R)+"\:SR(;),D#S>Y(9.^*1UGB,;11+Z
M:L'P9EYJX^+#---,P&YB0J&11N!8V"%!&X@<UVYZV9&.4Q4B&1/). I%'N5H
MU6Z@%["J](*D^_6O.>!R<?KP9O%JF2X_?:PEK'P^Y)=XU925E-6RY!9HG0=]
M28LWO1CLD(D7919:3Z7F2:9J($4V,WEEB0RON)(*GN>%!]0%@\<6.M>FZG]Y
M=L/(#0Y4# *\A4+DWQ:\\LI #BA9-BR3U"TM8,9'A/? #L$ EEV=]C@>00#K
M>@#KQY/K)G%@D@H*(?G:;(/ [\=N?>[KOU)!(\14,-L@'()L$$<'C@@@@BC?
M'/-]8;IV_9LZ(((WKY\^?UV?]/@D@ ?.W<K%=A)5N"17 [=_S_N.WMTJ28%E
M('.X62.W85W]@?8<UR>DF:>>"55BK&5"-MK7=X(VQWXUK8/G8)'CSZU,[1/Z
M4W#BP:/;XN_ZV?CWX=5 9;X]NPH_OO[5V['CK*CLQNNSN)MZ96(&C^WSY^3\
MD?V\: 4K.-HVEHGL@^PKZ$<_Z=OKUX8P;L;N".*Y_,DG\N!_KUO$I!VK*X)/
MZ@Z&CLZ ) !_7]M?KZ!/(A8HVX$G@FS]".YKGM^8Y'6&Q>W*D$4?8U=7Q5WS
M?/']]&LB,,T@"*/DD['[?WW^O[?O^GKW[S0LCCM351L5V_(WSV->_7JHUT3?
MZ5_>J[_Y']6_=RE.,@Q1F9_/;VL B[/W;'=_O;.AK1"^/!WZ;I)HP?0I)LD=
MMHOG\^_Z_D.>MP]KHFOW^_\ UU@'.I^E&!@->3Y/_'QX.AY/D^-:^/6'GCC^
M$GU[_'MQ_KQW[]%<W[\<\?T''Z7_ 'XX6L9E8[#&!X.TA2P[/*>=LJZ.R!K]
M=:W^IUY5X>1$K,)8%<$':!P=U&C??\P*OCGK1-$6 :,A6')-7Q[UWYKM_0=+
M,67K(>Y(55HR5+2^26!\,@';]NAKM(8_)#G>@GFVS.6?T4_I"GVY 6OH.+[&
MND)PY&W[IK,E< 6*_4^YKWXYL?/,'>U*K3RD1R=Q[OU5B=CY&AL[WXUKXUZ,
MGSHHTD130X!';]>;!Y'?BCR39K)84@ ""F4"V((!_,<W1OCV-#\^.3'RV/=6
M%9'2,DEM;  WKX[M;\:;X\CR?UT292F-=]>8U<\4+JQ\W^A']^MBSB@&(#$U
MZ>W?Z]CVL7V/'(Z^KUT)D-7\$7H^\BF45_PN^!&10?)$'TJ8HR+Y_P"T$8 >
M1L@'UOT^58L_ E<6B9N&[C_^V,B(O_\ X7TJ8%X9%%VR2 '\U8V:Y[_F;_/K
MYEE'*97E6:3!5\R\7',E;HM7 >1!%6DC8O&=A=,C,5D #*/.CO7KJ2#(R-2R
M8\!<QUP,F>#REWL$1'X]0) ].XV *%D]R!TTR111HV0T2M+&C-:A;?BZW'V-
M C^_<W(W4KH&V$HY3*8.\\M*"A'9CF#LT<DCQCWRG]1905=8V^"[$@CNT7CQ
M-X#6/"S,C"F(ABAW[)'_ (@< [W ' H;6'Q==@26"+4H\W9%-%6068IMW;"%
M]2KW-,W8]@:NQVZ8/3GG:=,<_P :S'3_ #%FQS.YCGKY++6Z7L'C&1O"2DT6
M(#K*UCV8)Q(]P&*0S$K"5$:N>:<KP?D^*I6TC6&D@Q?O44L;I9$BI( %D5B-
MRLI'IYNZ-=Q']0T23Q!%D86J8PAPQE!HXDE(^^1H]JV2%92H"J"BH>5H-1)I
M;S74G!9#)S6\E+R"_P KJ\AQMX\BDN?F5GE6^TV7LY..P)9)7D@+&!0W:C@E
MM@=WJT<;3]/\/9/AW&\/Q+AX.CS[<@(H!DC4QM$X14*;TJ9BSMQYBU?/2Z/P
M[)I4F''I[PC"V2QR0NFS[LC!?N\4*QJ05_[OF.Y5AN!4D;E#QRO/^)\PYWE<
M[:Q4W(:-+C\(JU7 HM// Q6U8#P]X2U&9(#33M/<Q=R5$>RZ^.M;GUK5,<:.
MYQXY(XL>.=D)E\U':0@!0P(8<*2=P ([<!#JN/JD>+B8.#GMA2RY52314;:0
MC9'7'! .X]P2/<@EX]-LA?3%<OL9+ 9\9^2YC9L/DZ-EISCL038:UC[L,K)
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MX!\#UZZQN5"QH65BR,RABK,0S%;[$L 0;L$ CD#K>9W.X;F (IMOI!5!Z=P
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MQ//Y7"T</4@@-400B:-#IMQ(%"E@54DC?>0JACY4#M7M0ZIAOGX;8L,D:!V
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MG<L(RS* &^YU*A58 @*-[M?U_ \.Z;+J&?.(^3'"'(W/,5] 5>Q-D4HLL2
M3VK[QEX@BT/#"22KCB=& =)-K@"D)2BOJ)X! H=RPKGM I?1ITZAZ--0YEQ^
M7)<W.!S_ " 917G1L=F;..>S7%*.*2O'.:?9#$HL(ZM(LA3L)!'"'BG[?_%N
MH^-M(T' 6?3--.KY[DSZ=% ,R*&5?*=YUD%)3MLE5:>V!8D\54F?JXQ<W6QJ
MN2A"IE8N#!*J0QQ@*]3(JAI9LA8U.5NE)&XHI4*">E?.<<L8];?8ID[;!IPI
M&.V0RH[J6<@:V0O:P5C]_P"@WKUWSA&;(TF"9_+DR)\*&4_=SM5GD122LEB[
M)Y(-5R >KX\/:G)F8&%E9!3;,\IW$[@%NHQQQM %)R?<<604+$\:@2VC789J
MDIBD9$<&,R. 22&?M9@ 0Q^? [B/.CYB:5CX[ID[=N15%=X(#&]Y%>IQS1O\
M^>I'+F%]R!J3:6+ &Z 4$-?I%$D@\V.Q%652+I[R?.5Y<RV+RB\0IW*U')95
M(IUQM=[-D5H5DL(/:#RNPC7L[B'&R!VMVL.MRX^9J4&CY6HMBIFAUAQ8Y1OR
M5C8\I&I(!:J#,"%XOL0(SE>)-&$JZ0NH0IJV3'O18RDLBDBSYE63M(8[>-R!
MJ- 'IW]0>(=/(&X?C>(XJ'!Y;"T;*<CN26+%LYB%O9GJY&Y8LRF(6VG:Q#''
M6KPJD"H2Q) #7B^"(,36DS<;,E.(T:R3XV4QGDB:*0^6T#L0L:2$ $TI&UR"
M:%M>CX?B'#U;43J.I)J.#.D,N$ AA;'DYWQ)'ZP%%*VX,;#;2MV13_K3DFL7
MZ>&Q\32PQ=LLMR60&LJG["2W<=:.VT0?! &]$"#_ &Q:[%$D>"J^:%1 K%]\
M+,X#-7)'H&U22.]<BCU8&(HCQO78=BSC>@0-R0 R[5 /%V18'SWZA/F-3%9'
M$U3C+F2MIA:SS3U&667'B9Y$$LD:/(T4.V(9I%5>Y5"_ V..7FR5U"=\A8(S
ME2,L4B$!RBV  1R5VK8 NK[=NE^CO-'+*LT<"#(<!&&U7.Q6'X@/5^$@ WS1
M'!'27Q#MS\CTA 5B;W8K!CJ1/*8)BBPI$X0 /%(ID^\K'V=SCM[ KZ<G?CE6
MC(:0E?+#. I?N0;->H<6.;H<CLX:E_TL32L06 W(&D()<&V])YHJ?8$V !^(
M].VGC^+>_-0J9?)8*421P-?+":FX[PGYJQ5A1K"=H8.88@?N/<&0+ZW-%J3J
M)&Q8\A402M&C ,!P-P'.[\0' )L\7STQ-D9:H'DA7*!MRAY=19L*6//X@ *O
MGINYJ+\AWX[/8^"R]@K^3S 1A2O0>T>R5)]:,G<\1D0$31EBDO:?'I5%Z@CI
MYL3[?7CNY+JUV1MLD4" %JKL@=^E>._FD28S&*E#28^^Y(VL_BC%T"+ -$>D
MT1WZC"SBJWO,%C=.Z2156!_=C4+VGN[&VY WV@D[\;T#K3DDC(A\Q6'%E7L
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M:\8@LU>&-#NMW A(];91$0&8M\?HGTP:='A>(,F'"QYH4E9,-LED/HH_]HL
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M&\W(Q=(\1S9>%C1F&(*Z("52]@60+[BRS%-MD<=SQUL6*2?"43RD&05(:]0
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M$ O\ T23V/LYL/@9.0RXWD\5&W0CQMU)GO4K+0ZEV4,@KGM=9OE0%4/K>R0
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MS*^.RL;C=QOK;:@4%^#S?'Y"^Q[)\1E\/-.]>%XC;$$(J5V8+IF*]H4!0 R
MEB1HH%V2->.AF(W%-ZE@-S*#Z@.?45N]I]C1!O\ K&"C; VUMA!_EX( Y%\"
MQ?-51!'R [\TU!FK7\U-(\\$B.D<7<_=/*=$MVJ6E+-KM)4C?DGSZP3>+6,
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M;W@?P?%J.8L,2)#&B[]SJS D>D @<D <V 3WX]PY2:=#@!(X5"Q+;$T"P/%
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M;W!/UL&@CV>.\AR"R--))$8FC->/W%?M:/R)"-]@?SM-N&7SX&_1%FX4) 4
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MU11(12*H\+0-^W]/D?'5AN/]/+6,P6"YO$[SXRV_YBU)%W((@NXW[E#,&,9
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MXY!!%WQM[5QTCQY/#S9 X3&8V.*95CB_FRQ??'*8T5]+V!5",6'AS\:^-^M
MR<)Y?N6+B1HUJHS=OK!VA6H 4 INO5]+ XZ=0DRIY\DIV@,?*%!"+)47R&)
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MGKU8:TOW$)-WLT[E59%BC[5:0E@X1@>TJ3VVQ]FS9ZZO$<7%3)12=I,?H1
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M;_\ ;A"FUJ?A@-O-]UN^W!)%4 >>_/5E*O4WG;U*CQ8^.K5Q=4UG5-%Y3)$
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M&2R4(E:1) -P%\@$@!FN^;(ZCVD>5'/M=9HS'.] 2V!"4+)O<DFVH^D'^4
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M"C<%4\-='A0"2*O@?GU>?HWT=CXM"_)\@\T5Q83)CJJ$CW05$H9AW%B"5&D
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M=>M)]3 ]^;^OO\=^/J/[#K690Q[DGW^G?X_=_4CKW,_PJ^__ "1_J.)))_\
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M'HC0UPU>P_#PI!L?RDU=FS?4"Y/A6?S.4JTFM6X;DLGYBU(T<_:\*D,&5?Z
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M_9,%V+(WLB\9$Q*E5AHPOI4$1'<6!T71@Q)\;?M,U^.98$8,L;AY,N>04-[
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M$DE6"*5HT<2.H7R8!&TT@$>-%)E3 4B1(78GCD@<U1Y]Q[GGBQ\WQ'I^C1I
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MEAA\O&*F<PS,L>2\8WJQFCB=GC92-K)RQMNK4]8?K$SO\RZGTNFN:CQ_$<Q
MO$ZF)EQL"1C'5@ +>/Q3]PPWM0%8*S1(LK",S2Q+/(!$E\,:7EX^%CZKXC@B
M?Q+CX[QY63%.V5L(0+2E20Q8,6*@,NQE('-=5AX4^R''DB3,U^/*AR9]4;.7
M%278[1B=9H5S#3^8Z&-"&$C5+N4NUL3U*<[ZC?R.%K$T"W:_<XECW[4K/)VA
M^U'[=Z)&S($W\#?G37K_ (J?&5K1)L>GWHP,9Y'K--M/  .YU7W(L=NF]/TJ
M."(&-610B@"R3M6PO!XYH6-W- @V.:TW^I.3KF*S@S[-:Q/+*(9%9Q _?W!
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M=9> O#L7AG%?)S"B9>1C.Z,392(E7+/80L2=@VQV=JD<6#TRYN7+EM'!06I
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M7TSJY")&>PH?/=N:+RP"@ #8UH'K'$R8,F,9&/(S(Y)LTM-=$&F8=K/?GV/
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ME9LR77B-*9))6BQU(7H@/_1^N?L+!FGQ%0R2-JN?DID8,$J_Q(,))$\D2=Y
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M^E<,WG3:(V-[]<<_;5EQ97C9UBB"G$P8<2:4[0TLL99S)2E@PIQ%N)#;8T%
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M07+>66]2D N M FQR#9%N+KGTHX?TZ7 W>-<C;*C+K(TF,F[?S%2.*- LK:
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M !O-U[5XFPC''*K^:JXCEHW=6(#L=QW.*IF%=B#S9.\1X^)!]U:4S#R&WR.
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MO(ZCM*1R, '(![%)?1"]KTY]K7B_&TC0LW 3&EFR1,GF@G8@2,DE@RL&-F@
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M@XYS/,TXR9&1D7)0DM2.!6ZR-HNQ1-$_U8,'3M-P9<J7",K/GS>>Y+M(#8(
M5[- 5^'=0'T /4P\(XW0Z8<=J<FY!&\>:OWX)(B9 R1U8XR7KLJ @PDOWS*X
M9&TH8'LWZZZT/2,7PAH^)JN?%(F=/EPR1E9#0AC0F1"%Y".3R*&Z@3UMR)$R
M9'QHF58TC'WA@FYO,<^A5X]5 -8'?@F^D'GG6:MDL+^5X[<RD.4M3EK]AGEK
M H$);V620'V=Z$2>%$8 *G>O37XH^T'$_P -0XF1E1Y<Y9IY&E=3):G8%4,&
M2(=HP0%VE0."2,L?&$)+,D13;MAC* ^79'JDW 7(Q(;=18GD'CJ-<3TSY;RZ
M!N0W!9K4+52U<%^S#8E:Y^4.I1"6';(Y4;'^9X/Z#X',&O\ CL-ERH)&GE=E
MCDM]Q]1]+.S$D!:K\_S-Z9M9P\60PEU?)$L<.TNH92XH6+L+9KD5R/ITP7JQ
MXW-?E\5)/=D23VHG>(Q,TS:C*JJMO>V*^""3K_3T[>'X\O4GC#XV]I60HNZE
M(-BW!H&^-IHV?8].S2/EP;)=JWP A%L3V'>C_8"SSU<'@^%DXOA,=DDPZGF&
M4>6$UK(+258&MA&M]S!B)(H6$B,")%#,B:4>NJO#FFG0M-PIHL(-K>6SQ)CR
M(2((Q*JG*&X EP" C?!*@5TTF-W#P/(JXL #2R1NH$IICY9*^DA5X('!('P.
MK 9;&4,!PR67)2+_ #BW'(UZ64]PA#?>S1[W]VU51H^ =$[]6%D0K@Z+E'*=
M3*T!;)R";+SR46 8V2%-[0#S5\DDEK28S9R>6"J1L!&@) 5([ (5:'J!Y[U>
MT5R.NO3EEI;UR:""_'(27$&G6.0!VVH;MUM776R3OXV-^N8?$6='/O:')1A"
M\@&T[9-W*@<T#P>!SR.U4.G\Y!F99#'<:<7M_%1YY[GMQS7?@'NU</0W>2ID
M745YF$+=K(S=S,%V 0Q!\^=#N?\ IV"01%](A;.S$CF(,;D[FM=_<>D7S5"O
MS8T!9KV60/0@4JY*T?4.XOD#FA7 ^/?CJY'3?A,/'Z=S,F&."G32*2)Y &>P
M[HNECWMP7)"^WO>]DG8V>B_!_A^#3()=091#CXH$D3.H+SOMW[5+7ML[4"V3
M;  6*#;F2I2XJ R9$K$.QI6135\T" !;#VI22>G'R7+7N"V\/SW*]\,,Y7^6
MXP$,]>-S_F3.@8GW64COV!\$ GR?3GJ^;D:/F8OB+-VK%*?*CT\L;ACD3:VX
MT%$A1C='TDT1W'6N*..>*7$20B--JRS[0?,D#4A6B;3<*Y%E0"IJND'-=8HN
MJV2H<<QO'9!2R$GYG)91X@#6K44:>R\3:9C(T:M]K.!LH54D:]5?]HWVO:6-
M&RM.Q\>1&E0(F1(ZDQS-04PA#=J2;:B:( -V>D.7$FG8V1)]X"Y 4I O'\26
M0_PQMY8J2*).VB+-BAU7_G/4NGGZTO!ZE&3'\?IY&:2O-&S>]+:63V5MVH]]
MLQ*J1]WE0$52$&O7->)@2Y.9_B<DC394Z* 9/4$7:%!ODBP 6(]V-\GG9I&A
MY&+(-7R)AD9L\*[PQ_ A7<8T)HJM'MV))YYZY^G/2_(6\I%9$Z2U@4*RPE@C
MH77?<[J!W]H;2K\, 2?CU</@OP7D:WDQE%62*.9/,9TM=NZW&YA0X! K@$US
M7*[4-07(39M"!.79B3MXY  ]S[#X]_?KL+X'P#$8.EE>1UL%1RE/ X>S::*Y
M)^32:Q&%V>Y8W:U/%&TCQ12,D;L4#NJ ^NG)-%T[PYC)F8>,TAT^)I#CQ(AG
MFVC;<3$*JR"R5!#61ML WU76O:CDSC%B@F,4"9^*DH ;<Q)):, $M3J#O84"
M.*8FNICQOU/8+%<'BX1Q7@-:/E&9CL_G>363(UFBEXA)*5**(&JLZUHPJ7.T
M68DL% P(WZ;L'7VS];GAD5Y\:2+$.'B>2%>":-6>4Y4KAP)0\ELJ6BQ^4U[P
MQ,1R/!F=JWB[)UO5\N&;2L2-(L32?*+(R1;)(FE#@ LD[3,16XEF4L5" 0AG
M,A8REULER#'O6I4HA7B\]R(J@@'O<=KMW?+'1(!!\#U*RBR&:;4L:*+'Q59H
MS-(LRNSD;I2HX%>D)Z00#8YZLQ%9F2,,RAR%(0;1M4,0+(H<CM_;WZCCD->^
M(*M? O"#EY1! D@C7M64Z]PM(1'! GEY9FT%C#OH_P!)C7BJ;,T[3/-T2,SI
MDH[KB8T"S3L@C#DXZ-M 78"Y (I1Q9 IP^\^1#--*CLV(K,6%L6() ("_B;@
M"N0>P [=0QB8LEA<VMBX59*61:M8RB,#2/MRM"S0VE"I/&=$K)Y#+VMX[O5.
M>',G4CJ>'K63%E8V-$Z+--FX\>/Y=LVY;C8ED4U8D(VV-O<];X93F)%DOO5)
M8U920JD^8I!21:!M:'Y'N!7,A=6,Y@[W'X_Y9F4L69^TSU:B;=V30['[#X!.
MV[MZ(77GX]6+]HOB+1WT%ON^KXWF.S$10R!VD(% FB"I4]@1R.:Z,5'B:2-@
MH9@FTD<7:E@J@D418X/%]_?JJ7(:2IP^W<FC%6Y2R5*2E:=6-B;?YA)*L+%^
M\1R+,+,K]O8#41&T64^N,\W.9]6WX\S2*Q!>0.=P-DFC=FN17SW/8%QPVO4T
MB!+++ XD -*& &UV -%EK:-POU<"^C@-N3F&4J8R7#P9.U''[SRV;C0+V0!%
M7^H2!B2P^SL^XD?'ZV+X7PL;Q5GI%F8B9+QP.7,F2V-N\LQ[2TJE7<$$@1L=
MANZM1ULS,089DE,XAB(-@\ \V2#M/J XL GV)/4[K5X]Q;OS&>X&F5R,Y6IC
MJ\&5$RPRJ>U M1T[0YD4?>D9 '[$GU;VEZ9H&@+]^RO"\$T\Q\C"2+/:6-2C
M$486)"2,Q-R(K$KQ= #IMCWY4?\ !R(TC:R9 K-NKG_N, !P"UD"NW!L=97*
M.:\KQE&E9[<-TWJ6*H_)F.06;[S.&+NJ11H$F5>T22^6[B0Q/@E\U?7=7PL6
M!TAP?#6-- QQDC*.[,Y_':HK77 (53W!/OULQ<;'+R  YTJ4OJ-1JPH"R&H@
MBS5D7R .OI*])I/<_!5Z?3O8-QY_PQ^,6'N,--=>7Z6Z4K6F4[^ZR6,K;VW<
M[ DGR>2)R9M:FD+&26;4UD:0FVDD><#S&:R69_<GN/IP+ QEVX4"[ H7' V@
M7M !M>?C^A YZ^9A4Y+U&X_@,36QU&&*AC\;"/SE<E36AN+W67(5@BRRQ1"&
M5^QB8Y&78)WZZ:\S5\>+3I\6,X_^'1A_/QCY1V9$9659F2O,5@JBG)!(4_R\
MQO*T?3<K*CRFC0SK)O=30\W8I]+"@2L; ,HNAN)HV.GIB>$\?ZD\N1\O)V8^
M"@:=:U)_DR7;4&)L-9L3=Y^9\C[DJ@$(0L78H\ *?#&G'Q0V/E:XH$LB3%3&
M-K$.LNVV866 IG- ,R[:%\(X)\O"TOS9&$V0^2TJ ^I$@DD54C % *$_"OL2
M#9;O5SEW#;?&\S:I5UGM5H'"16XU+KHL5 +J.U78 _9L'S\?&Z^U_0Y=)R9F
MQF=H\1ANFW-:Q1D&0J]_SQ@EA=DD_)'3P9?X8D6U5D$CV*915D-[\'D&A[\4
M*Z4*O$>4XW)8^K)CWM6+M>I?_*CN:2.N9T>$RDC09C&3V!B1H]PWX]-7A34L
MS6<S(QX8),A(Y+&^V:XY$("DCD=C0NR 1V-HL/5,;4&D,1!6)BI+4%)1O4P)
M/\M=OD@GMPX^ID^*DLU;M)):4WNQPY?',Q417D3NE=8O  E[2)&UY8;)WY%@
M^(9,173(C63'-I'E0DD!<@7O*J*I6(]6ZJ[-57TZQQRJEEM]M:LO\T=%ASS1
MV]Z[USSVL;@^IN-Y'P-\)2P[LXBKT'ME>SOB4::C&-E4G=U[TF&O#[[O U.<
M7Q3!J6B-@PXK,%BCQ-P $;BEM5L!A-(-Q#<KZ@PMNF,Z8!J;YWF#TR,?4*>Z
MNK8@^6"P!KXH^D=9L/5+&5>)Y?!7\2]F"T[4VR)B!CH'^@'O&V7:Z3M\$,X)
MWY!VKXIA72Y\*;&E=2'Q_-7_ +**X(4.I!-J?PA388WP.>A]*<YL>3%(J@,L
MA'\Y*F^.1PW -J>WUZHQ0S=CC>;NW<4Z&13=@KS.H+H)BZ+-&QV5E"GPZZ.R
M1^OF@<;56T?6\]\3UDF9$:P'$K6X8'O9LJ6!]K^@DI!DAMEL [2""05# ;C5
M6.">31'!/5AL/S7-<IZ98_C]>ND!XO+9LR68/\N:TTLS2NK,I+$LI#,?.R"/
M][S:&#K63JWAC%Q$B6'[ENGE="=SON<LI'8496)(-L2";JPW'$BBRY<HN2\R
M+$%)](*A>1VL,$6P; ';XZ0L9G\OGWE7(9:W5@P4 EA1)WU3"AHYFAA9P"Q&
MRR*I# !3X.O33#J>=JHGBDR9XAI:'R8FE;RXY"@-HEUM) L 6:X[<-[1F99G
M2-(WV60H \^0*WEF0CE@& (//>N]VMY,9LXJ2IBI_=Q-.M=S$3/]DD\, +K/
MH  F93W/H:9V8#9\%<K:DV#'"K!X88I<QE%A3L'JE4$F]QLDCOV[@];<.1UC
M@EF6,S,1%(0#8N]H/)Y%V;-=C8ZF;A/)5S/2"3#W+^/DNY*K)7I)+7B-H2R>
MZ'0%@61D=04!\,BL1XT?4[T7.7,\)OBY&5CM/-#+!B1-_P!TE]Q"M&UDD$GR
MV[BASQPW3P2KJL<PC+)N5Y60$($J@0?D@!6'(_K8@;ICDLGQ#E"1S0P)[6;_
M "MGW(T[(T>-"KLX!_RRP';&=@'N/C8/JM_#^3-HGB+'<Q^4IG:"1V(V>7L4
M,I45LLECV!W"^23UEJ6/&\J(78!T8J220] LH Y%[@M[K'L >2;T]0+EWBF&
MQV1XSF>VKE9/8E:.4^VMFP@D<EHF7M#.H&_D%0"-$>KM\0ZAEX6#'/@_=U:3
M*$+.R*RA90]2*:(NU:R.Y;N.;C>)"TDYC(,AK=L9V %,-Y(!YX(X8DT./@U^
MI2Y%\5GKF:DM0+#$%[(Y&CKWA+(C-,8N_P"\.VB=@[(/Z^H3#'/-INL39TLT
M06,6J2LD>0\LJL[,@(#V:)-<T#\#J29,,#""")(RSL^Z13S#M0FPP' X(/?W
MOV!;%^?,/@Z57C5RSD<-[\TF40.RPT;)9DL5PJD=D:1A/M(U]X)\#TW9'WPZ
M3!!I61D9.#6[, W^7CS6RM&2. JIM>SQ;D=^M_D1N@+>3%D%$AAF8@R20;4*
MN#W+DCGW]-\#CIF9NG7QV-AQW'\?%D+V;O20^]$GNVZ=B#325D;;,8IO>BGA
M(TJ@L.W:@>JU5UEU;5M%CPYIYESM/DQ9E]97?CF218Z]6QG7?(JW9/('(Z9<
M=3)J.3!DR-&L1A,3%@JL@!)<D\"Q3/R+ ))I>I;Z?\QR(P^+I-7DJS)'8I6T
M *23&!?\UE0;.X2I[G;1#'6P0 ;A\.>*)!'C:8D>U\421Y2JA#FPQW#@ F.F
M&X$\\GL.E^5#BY&5,$+-+&$))!"1E2%VJQH%6)%@<=JOW7NEW):-+E&5DY#+
M9:C;NR2TY;$I]GNKLZ!I/=;3I'[@"#1':&[?@@KO#6JK'J&I#*R)%7+E=H)9
MY#Y9\MFOS"S 7M951N0*85?/6W5\,R8^,8HU)QQ15%!<6J\)0+<'U$"B:'?M
MUIB>'/U$YGG;&-EK5\!4DLW+UEQW13-#OMFCCT02@4:;1([?!T1O5'I::]K.
M?D0.B8"Y!+2*H)GE)(38IXOT_B^ 3[B_),N/3<''68;\E@-H-6@6@Q8@78L
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MV4W[?NT\#1B*TZ&F#310@A+ML-Y[Y$7N$97:IVLVI&.I]!!D,IS<CS,?1,-
M,?$&X-D+&NV/*GNMQ=0&;BZ/ W725W17,*2QME2697L$*68$HC D@+9!)-;K
M]@ :T<YY])R[.IA[TQ7'I:_)4ALNB0LQC$SF0Z5  3VGM[0!H#6_7/?V@>.,
MW/GG3S1)CP.T4$,2EA0(.XE16[L2#98\-SUL3'>"&5X#O"VY5*];H"4!YMB&
MYOMSP/F;QQW X#I]B;?%.:4%M05;T5^A$P>Q9M68S'_7%WND<:]P*MI7\ ,
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MUF[-&STP.'6(^?<>OT/R%=#^9>"K:"@R1,TD[*F_M/W!D;N4Z^1OQY:M"/\
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MEXDQ+W [BJQL (Y93;4FT*R\4/D]NI"TD,8(4J4(8 #:"S$$%0HJR219]P+
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M9QU6P(*EJ*56DE"A6)!#%-^&*@E06#> #]I(]=/Z5!H^C&#&F6*#4$)N0@*
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MA5]SW!NC[MSTFIPS(QT<E8RD-C'SUHIY:7NIJ"X*TG996*3N"[B;M78[@Q<
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MO.R&#Q2R[SA1J5(*D'=LD'&U$!_\BPHGK(Z7IVB3+)CJ(?O!K)97+Y$H6V4
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M4*RQDAB@7W<*>.P')Z7QHB3&#*\IRDK38L2.5D()].[D DDV>X)[@D\>S_\
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MDT3?<;;/?B^E#F>9_P +8J3'(QM9'+I/+.[,$DAF=2Y,2*DA9?+A4+;T/ZV
M(..LZI'IN&^0S(K$-' '<)1V-4A)'JV$*=M $FK7CI*FU;=W1(X]K$L:4DMP
MM^V[U#WVU?/54:69MTJ%J_Q7!6L5RN>Y+C[/(+4KV+<F/DB8V!C(7513]T((
MI)@DDJI(T8F/<2>;LS1\GQ%JQ^\G[SB1D2+"F]6D<DLK, 6+\#\3=[]NM4VG
M/K.J+C:IGQYNF)$)CC0U'"2""-S@D':6'HVU1LM8ZM7T01+O'5>[7KMGDNR*
MTMGN:[-&P'^9+)LNVU+@$:\:W^QZ \+0)C:-CQI F.$\Q'$:!&8HQV&4 66
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M)QVR=IAI;CI9[BTTZ6W,CK*VN\Z8L2"Y!\; UZ5ZCXUGS]&PM,(=7Q'G*RL
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MRR2 ]PD@[(O$D<B.6CF# J!V=JL"6]1O_ ]7\03:DL><JZ ^6QQH_,D^]Y
M%T#HO]$ 9!/$R[$578;5X:@K5U8$BR')*Y@..%55CV !SO&WU$=D)2P?>P>.
M>N3AU/F\O)J>.Q#PXNA6:.2]C[,3&G(7;V(;'M+&S3RPB1)$"H[+,@WH^1I\
M*Z=XDT)\G#A7(?$Q<AI/NDY),D.0R(6BW$'<BDS; Z@A#5V%.F5X-(TS-R\N
M*7*VR@P&&F9EWT6%%BJ<@D$'@D \D]6^X?@,14:L/Y?#F,IDS^9FMY.JK23+
M*>TSSB52T2!2JPJ>PJJ@L-G9M=XO*+D4I/,C+0D<T H9P%)(4!0":"THXZ:Y
M<],S'D=9I(XH691O5@08Z9O+60D-'ZN9%L$AB#P:KSUYZ5S<;ZU4),3D:<LE
M_!I>S%.DGY48>Y-8*&@Q]TQRRJ24,BD*&_J(T=5GEB7-\6Y;X^W'Q],PX7S<
MD2 ,K*#YKFBM,%VCDV6[_P W67@SQ<NJ:7J[Y,/EX&!ERXV)/(2_WV-6;9.@
MH^B14:4* /3V ''34YIT\Y5G:4'-,9=6C%A:3U;LDUR6Q8O1$F!DK1>P\2@E
M?8$D<@4=R][$:]0[Q?X_TC*U?%P-$RLF353&<-6V/Y<C2 V0S+L Y);;6\L0
M1V/7D?CW2\:8Z/&LLN1E2EHG, 6&/;M/)/J+  %%8=P "2#48V).28_C4N2I
M6JF-HX>=V;'--"762P'+O$LI[))I2";<S1R2$A$4CN .>F:-K.FZ5EZK%D0#
M++_]7)+*8YG9BP"Q$?AH,;  - %1W(?\;32TCL8Q)D9T3;GE:57" 7PZ,I&_
MC^8 &K;MUR5\T\O'H,]2DO3T99'?D$"T:L=<_>\4D<, M=[R*WMR&3L6-QL
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MLR'L#Z;- ;;[$]N: ZL,V'X9QKCN;3%!Z]!HI(7QL;_YM^V JKD;#$%DC4*
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M0H5A/DN/*V(S$LE7'V[KF%5G5NV*17 =XY*Y(E((*N3V]Q7>M.+@Y$,/F9&
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M<6(LGO0K]47IIF>)<>HTS9R]Z&KD%L-D\?7F,'M2]J0PS&)A[;R[B57/>O\
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M>P"VCF%+2PE$TS/R3297"L25(,K0NW<_TQ W>5:FG5:Q^T.,@N6]_2:??,H
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M!L:OM2!74$/E\A"^+YZ*[G8 B_-U83NTDA<%.(8*C\3VR_3FL+*A4UW_K@+
MHTUL/"%)+VP^04',D+/UA$^TB@D1A)Q'QI\Q_;?#W69)857;&7[:FD8/ !C_
M]8L2][*$_&1<.Y#M8<"SQI(FB5B\18[0X"-DC,:Q5('+V#3L5[9DNK&0KDT8
MKRSK/0K0:D\BU3!<%]"AEX;1A> QAN8[ISP 8?A2&M%F_C/2WYK);6_T:T#.
M@>CM"*P/05%,Y@\DW>66]>5)8A")H>0+U;)=.H=,=,E8J[18]"CAJ6%%=&5,
MXWW9F8;Y _)M70K'E)'#P_DL,,#_NVKN [?FU5ZVTXQ 8'7Y.^0IF6 SB3&,
M+$3UK14DO:_R&?+3WOS-N4,</7M4:]XY018_B=9Y25;38)9@48;#ROY*<C<5
M596K-7"I_ NX1W>9\S2O_L$9%N-^%ELOT$@Y/78H0"@Y:1*TO4UQ]QX^ZX?6
MJS-PHK_]7!;!D%_(VJQURF6_.KC8:+^7/K1X(PT["5KTM.(F*RJ67_60)![=
M7TPF[E47[HVY//L.U?\6!2[+]3!HY/SFN% C[?J2)U+D1",HVMZ'!LOF Z%3
MGT21%?&/+1HT[C$;?>9X/5E)65%.([K[FWW>92UL^9J,K9J:HJAUTZPG@-$2
M]EV;0M-W&!Y._%=M;KXD1,3LH>F7[V??E-IBR<E["%%Q4H.,?'!*TN'LYX $
M4ZJ$<*'M^V_&9B&I1R4/95N\LIU-D*73^;"_V8I2S>A?-HY%E4'56U=UG1R%
M173X#.4)EAIY05)?*?<+[T&-?XYXJ0ZG+4?.UXE6V6Z)9+A?TYU>FIQ80C82
MY5I7^X?'[6?Q_CM&0+N"S2>2GPI4K. 58H_\I9Z0-.[O?+,&^&1^@ =6" XH
M$ 8-P[/\,R$]K;^  JK4O5AXL%O3]@D_'6.BK3R-_/:[HP5U+F(^]U&()B:Q
ME;5Q[W@_,ESL/]8D^0KX8\T*BF-U77Y=59=NNU&GUI13EF0,*&A0;MY7GII=
M[4%1 /["5)8@$[EEA645%H%G;0EM-P,)?U=-VU]!Z'3%GN-QI6*NUXW?4'R4
MLK^?\1/'V- LTRP)8<B?K\S$FS7/=OU;2<S#-6E[W%=^< S<*BFD?3/D),/R
M(_Q<ZFI/QEN+3T&Y39_54/C[]"HLIF U_?%-B*;=H5D:=:4=_U63(U.<R6B_
M<;EFVF:RSE$3_:Z7\,?.&/]*0X;ELN9H+_ _X=4O!56\F<,!FQC^9:_8#8%(
M,=!*DH=R4\[5SQVYQE%VR4P17DF%^&V CH+P1Z7.6XD&G)\LR;^.4 #!S=3#
MM,:9[^6!6I[W7YO?4L\GI_W?6 CNP;'=ODD^V7WZD-V8<*S'C$GBS]!:ZS[7
MK#EM;313,I.C1UWQP[908MG0_74--F-$'R.&_Y&IM5)5V0<['HX\>CDQRBI1
M4NOC$[FY=PSEFKF%OW]=)7C3)D%Z9V_F/@N?BU$\DM>G[6/R/_N!9?.U6\*0
M0(*+&^]19"LT1%3S.G.3J['Q7%TV;7/R)E:JU9:+OQF??1@S050S]Z8;!7C%
MC 6JM*?)->LT?1^GQ31(=ZHNFSO]RX?DAAD[&\F4AM;R&OLYI)MX/3+Y^?F=
M^%FO<2_QKFO!,#8 [&YAV]L!_=$<ASR%B1^-K*]7QQ5S$@18&RG"A!;*\4G-
M: ! .IQ2KM?2Z=B<ZWUO%.F_!?1KUL%']1"C>6>1Y9;EX2O?S$WW_,I]903Q
M5*_\4T&6=<"-Z>] !I!GB2#$.KV$Q:O@1L&RX;:.IQZ;C''-I.$-HX=1(X.%
MYL/2G1C,^58O-/E$+P'D<.!_L&SJH3(]B&'7\6:)KJ8_H0@%V$D8LKJD780X
M<"P3=?(2).Y21.'9J85403LYUV0+^,([0/:>-FRYS8+'#@ VHSGZ0 'O G-'
MH'5OU/T^"WE$<[AE17WE:,.$]2MXK_N/C.U]W'YLB39EC1>&>$;'Z=3,Z4)%
M(^1MZFW\R[VQ BU++5M)Y1--KA<7',G*PU"@;B>NJZ_3C!/+Q$3V90N7=9 "
M4H&86WU7#3^,D\7F6[6G11G]>'\':RM^7_?#2Q2@TFX@]ZCRJ#<5<$\H^*=W
M6NV4E GN%3%];?G35<WO/L@:/8DO8_(ZOTZSI4R&0K)L.@5_K!0_MX7>;>X&
M,  "0!W+PL,8;C+?/YZ@U7R,I!FDYT]@2<X2@ ^07Y4DJI.\0; @%):X,DEX
M![8EM!]^5T5Q,=;MS[#&4K^][@W6$FD X%&+<.=UEB&3',\S2SX#?"%;D^6
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M&J-WWU[XF]W./_LZ_TTTZ+2SH:G#@>7!CSG%;+:P71#+]9>)QPNQ#_N>*P*
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M"QDP&?[3VWP/2:H^1D!'*O?V4@/IU\CO+A'@1J1O><.WJ97 Q9.I!6A$D50
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M-F@>"P,L*[FLI+89(1]#9\51P#'#5VA8O>?\%GK6R8G'6G?140##?FW8VN$
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M95[]WS%=_[_P?R LH);^!U!+ P04    "  K27]6KT$_>#K_  !W5 $ $0
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MTLB-XL3EC\:#R,2( -N400EON\\OC$Y%'AY^2+SUP:VG8RD?3MO?I!'MQ]]
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M?8_ ?9(QA>&RA45^KRWEW:F(BV9\%\X-T,T!2_4-HR84(I>X&+.M+C4FVLU
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MOJN]9,6B( (V1O%Y;L1S?$6LSS4,^RO D>?F( "W4),BJ\P;.K\M?*W#_RM
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M-;LV@N-4M0"R6$L')7G?MN!U($/97=]3X/Y8'N-\_"PO_&CJD*'G*^!.TU?
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MG4<%?CH*W>JQO1SH6IK!_C$']%XREIE0NY)D5.9Q% Y593&W@4@"=4=I5!I
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MP>'*C6[W4*?FZ:!7&;EU6A7>S7+Q<IVW\9?G@AB3/H)P\:5]&)@9^XQQ3$N
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MW"]1ATH$O7X)68DE_"'Q35TU;+'IK=QCZEJE7U2XNT&&!?U#"J+;C&:(=+9
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MZOMDJ1<_QDF(GP?%MT1>B.52;F_%,X&(88>7,Z1OI&$4S':.,7$D S>4 '!
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M;:^](%-Q)2ZG61BF8 >GUD0=-?"M#OCUDQXX_JR;?11R$12!^"$L1+&)0->
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M>_&J!295G5'"TO47L_TF1'/7%(MMW7:NA@C[O+@*JT6TD8?!-S^(1W^T;>
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MB*+X6?DWR;4_@'.G,FZD(U&'8TPU)*#A7'='RVEKV\NA&\9:S+:>>$L:O"&
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M*JE6/5/JE5/.7#US=T-OZYRZID;)$6E#&]CMVP^+J2>@(@KU)DC9=EVW;'5
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M']*B5N'4L":.:ED&:"8B"6!,!A=50[*$_6N+3I<6D&I5.$FZQ:6XL<@E0OY
M?"#T=&U^#[>\S^#"=)N]?QXCQM ZQSV+LFJ.#4J\0M^%D3N1[*N43FN_ZB^E
MS/G6#G_+P6=7=Q;DJQ'[,EVC0SQ8>@SIL@Z.08XSJ,4/]WJ7'O? #FF[U3^
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M_A\!(_16N8?T^)?KG*^F_0-?:X*[/>%TEOUL[$ENH[[#],&MVK_4;_89%;F
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M!4C1 ($,2.+$3);FF0AE<6!LD>H/3T2HHR*#;@?#T2:03=2K0E3_FU@X$/E
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M-C1<_>PV7Y9[\!V_V^I("J@4+P&/[."*/0%08_$B]GNHXL_-KROTGV)''V4
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MC6KX[G(=/EI7>>_QN&20ZK"JXS[ZOI%W2HSFM] K$MO?M]0/0,G?\_^%_A^
MV@_ @]Z-,!Y/D>3S3V;@M"CURP TQ0< 44S\@I)B. 8@[  @)W:LT3-$@ CS
M]G35/EL\%S^Y7[<99+]HKGTEPZ0C^RU(2-HZ3GJZ:BY\R;H*S)Q0Y1-[?(G[
MEVK/J3:!M9XW4%/" +_[^Y/L./1GENBIQW7<0O!-2$SEJU#'5C[96E>2[;$=
M-$]+O<9?\:ZJP\PYT>6IS0K,MY9C0[3LGB_KH3Z;/9:G?G?XKP_-X'<-A2F$
M(15AI(GL5-\,R+^(M8I;$)1.>.@^USUKS'/#[G:Z%+<M]+ MJI_7>SOEJ^1!
MXFFJ-=Q*.!CZ6[%SL(K"L ZB(Q!';I$*S#9&21 N/K52-I?] /R8%$+K,ON9
MY87@LU$B^1AX,&7OY;(4(\*"?G=J@_ES_FREV??/LG)N^*P'V]=G+K&C$+BM
M1=??4@,O]E1BK,=4\?-L;AVYZQ4B8Q?VI7,.:6U%>L7V8PN0I*$VU9M-V$JD
M[W*/=SM$ Q3\F9[?CFL9M.(%: _,-<W@BJ0P ;0-,N9>(K6G$"^3I;)Z7F_M
MR][MS.<F]D8]U8+)3VF.H,R^K^MF _%Z?']KERR;+U9*FB%%C%YJQ*.*0\:K
MJPH#&C9 ';USU T;/U1H(DP,<J:ZLZ/UH;T+HJTU,_.5G ;%_!:.V-7:Y)KE
M^JA-:RRYV('1LHMX3%50M):0+2-M>D!@R*'RT&>"K[OT"(Y9[<M"1(@KWA5A
M_6>5J$AWQVHN@O.U\V7S)ED:N<E=43;5U!+"FK=U&38VNT)R]:6:J_RCRYY)
M;F1*Q;157T3R,\*L3-9U %$PH%%7-TC!9;+ORG4+0>6!/MCQA\AZMG+EWIYF
ML2WK*?.TG0BR99)PF>F/@?'*_ ET73F8E9<\V5)AP6+=;#G98JBS'HLI2TC>
MRN;R*_.WJO#[@-0*Z+3"+<U/NM/'6W!R<=1;RO+?2ZVXW %R%+D*NB/3@1Q4
MP56.WKHR]Q*N)KHA2\^KS#26*"BIBS*>0@G<%$5#ZO447!?=#Q?DXK(HO11C
M9%<]+F3TI;CD-RY)\ 7XQ (%ST8= \.^1YVTD&, 7B!DUS3']Z19!F=W^ZL$
M0$J.,,M[VU;NDT&[YJS^F-V=LI=$\Q9=9J76!1MA=]0(Y-<O^3L1_X.D_"J;
MJR8K==,AB3LIQD&-Z>5$\7/_O 393Q@'>A+JO0H_5KV#7S)7MPJ(PEQ9"E"5
M,4\GQ-0\@WNY'+!SJ0D#  *'705JBUR><QS 6P&SJ=[*.!L_ _7_GY)7:1QV
MMLO+;O3+O=\?@!EEP%'D4["7#SC&%NU1,OL?*E/W]MVO#CP==CD]7EIJO<_V
M12-QOU'3X]P;N+IZ_ S&6U>@:OV-.ASV ="TU04.W[YU2J 3(]RCISJ>D 8(
M:W@^NCF^WADL5_P_Z@>(K/*D*U(!5U138FXD_$\ SS#G(\-M^!CQ>8&8E*UA
M[YG>33'B;K*0A/PQF7JWG.*V(/<]2(W6_6%GY[\0='MZ"A9$>WIE]B7P'PM[
M4@0[)1(-D[+QY)XN-BWY?0 R25V/E\XOEP6=22S8I"4?^:Q\I]0NJ+]A5CN*
M;#*-^62;W"T.QHG]:6J*.86Y<WX,\P2!P$I[8!\OY\.XEP[XK5Z'3Z,#7M4?
M .?L^M^W>^.5J'Q6?FRCG)@FY%"\)!"8RL'=G$W/&/"K7.2+[Z61F/+M90VS
M:PPDP];JE27B \!^</$.]AET]7T%PDX]%PBDW8J<*J1Q8,3%'D^3"3\]5Y>0
MYGT OHN)ON_GO>:@6;PIBI(MV^WE &_TU0J5]A2WN=&)KJA:':9XN+LR?9.5
M2"^$JQS9T4G]/S<F"KR\>8)>C4F(9G/.6%>)B0+_FII<-=]PE<X%02[ZR.[
M1J<OAQA;PG TLW9CW;>,YCZE6@*KI$S'TWRX>D^W+QO[U>O.=_>+</_#(CX
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M)[]X9Z^C,275=M>=%3A&QR<93G2H]J\U_]X_4(%=$'C=;=^@HL0(D$SIH^8
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MB *WLH8&WJMUI]5823R>=>7"E41:;8*CB6$NMIDW] K4UI4T]:,>3-:^JPD
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M  !27C%0)\(N2POX'RO_%U!+ P04    "  K27]6NM+ER<&6  #XZ@  $0
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M]@\W-^T0T.\1X9D[0^P0$.B92V0;YTQ;6E5?^=MHB)SJH[+_UF.27WJL[H"
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M&7'I?Z'O';-W^ GTQQ'\%R-5U?_:S-[^CY9PA*P+XK^VA)]^L\"I"8;#G)U
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M3FW.ZI2P&>BTA(J#8-#3+T_!R!G^C?_OAD@<,^1I NP$%[=T@MG3FSDXV$%
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M*<WOS=7#ZR&ED,_%#9=UCV;.Z8]M#(0Z.F,6/]2D)X]:7*NS5<_8M8[,+=G
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MHZ9UJ51OF<1F*/JRFTW@VFN;0'3S]$CNZ!P,T4@>V1+@AE[HJB"NNG:<UVM
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M0S]D2[WRB[_F(T:LVBJ39_Y<7X6OI+&,@-9IB17'_QZU1T@[1ZZ)385@N$U
M K^DI O#"):BY]U'<!'[;FXU?YV<^!I*2%>UR(UVK:7#%K&!Z+ DJDW\F\KK
MBX/W'RB2?7P_(<S[@F Z_A5YZ"L<5FFI9\TMA5YRS^]NX^["%_IS% >[ *IV
M4OE&C"> 7 +&N'!)BDJV@<3Y_A?RK@A=9X&UL/2FF_<SQY_ 1!7Y#*./:%*5
M:!<^/W?4Z46\0@PHZ3VY-1YW;;6+U1WHE&*4WSK0#-FTJ@Y(6;J9Z"_(S4X*
M?"V2^,1&6,;@0O,;\R66_AMMB^9FC R),2DB!)\4K4%)#\<OE@4E:80O#=K8
M=:FA]UE@,SYILK56=!\&5->-:&Q".:U21DM?EE*]F\S2_?1.19FNG81F6H6[
M7P77A8(91-E9E/9"=YM%=_SAA!(C%5@Q>7G(*:]=F^VV(V;\\<LA)3C;V\5;
M5VZKY2ILYE-KRD3+#UAA8P7EAD[V% W(C(UU:(UZ;5%7/$TM +-A1E-(92B3
M?Q9YCZY5$%K(-D*"]W1-;3%\"KVCH#1I7E^G"^)L4')M1CY=UN"2L*.,5 2'
M@VVR&+T3*L581!EA)03UF?U&UY$ _1#+<R.7%('>4CHMA\SIP'NW1X]0LXNI
M+[R2,C''9"_M*,XBN\Y$@9,OBU5D2XIG.-6%SJ1*F:J3WS:<:Z"8_1G*>5$A
M8&UD5/NE67Y7Y-+6X8%%=X%U M_[>3-I2?1;31H-TP;+HB7V!E_;!OM=*8V[
M "H^ L718;M:[^J-!%@JO9IN6X_=ES3J=#90+(A,?(&=RMPFU:66J&TCRZ[X
M13EGNN-&R2JY.50R&?Q(W[]_/WYI:5"%^@WKHA3)-0)R3([@:UZX&*&H&2#]
MZ =A0U3:&_;-I0]\"3;N*_BQWWC27U4=ABBI?5;JT[9._/ BG3[CP4BVXF4E
MS,<6NNR)T/<6L66C(F\A0;;%-WI5^7,TRWHU-"U'H:ER;R .T7PM;,1+)<E&
M3PV5/,80+_>3Q9PY&%6)7W+99\E(2<F^?&,VV^9Z'7,DK^2SH;(U#Z%B#Y$-
MYMN<VR_2<-CWG8U0Z(D ]%UYO%)I7324.7[9^R5!H5"XWKB/PDO3" H"H)EN
MS=J[+(EV.)ST\>NM%WI7HP7&.[K)'T1]C./K4)NQ"KQDS]V-CPA!P9O#(# V
M3F*8EVDC#:Y)Y5<OTIBA8\.@(ZYTC,)2O3Z@66MCU[PJS#:2=2O6O!7F7B/I
MC/: CV\R?0Q @<9<^3'A4;5:@M$A#WNE6MYU[0\.U+V/5[('B"8[?"O?7WY-
M)2!)W3QJTE@6(='N26ZI.M'OA.BMB/^\X5$(1=D:1XVL^%3UBH^;X(BR^2Y/
M9&;DP))'8M@5)LFR^(U#T8MW\Y?$&,HY:9M*EK@'#[?)S18#2O-3;S\3V"JZ
M]'#(R_YS%TS'$9T(7( YHU/#5,Y65BII5@JYA8BH<:BP#-#LX#"@#PI3F%-D
M VJ];Z=JOZI#6U#8K!,/W4GJ7U2W5%^:\8P2*MCZ6*"QH\^AS:PO.I ]/,MP
MB^'C8C^C)WO7%3,?EQ<H!.$KV5CJR?+UB/FE)IU-V==YACK5/87,.'Q+=G.F
M.-P95XI>6/-S4!!'EW/%JUULG5WB&V3C5YNU#GGF6( 7MY6H-MO]&8 %?#$Y
M+C9BQV/KJH_Z/A76^Y'&YLT;JZ>5NWEO,1X @,&U]63S.=\?C<GT4;3?J_/'
MRT_V(REY0E!1@'_Y4E3PD1QQ?W$BXZT'8,UK8D*S<R FLR<&8?<MQ0YY8@J?
MC04_(,:OYB:0=J"A48"@E\ $+S2$CW*'Q_#>T47)OFFJV&'NOOYUJVJ_G(YI
M=C!M_J\G<=A8X80O9)0)\64(T 8#D3%0Y'QEZ1R6 L38 ^RH $\5+BLYP.UL
M:'!L?>A)L-$# 2V!5#X(Z0\3IJ%>G0IL)P"9Y2-S.7.+Z)PA:/:KNTT*Y0^O
MJY#BI98'5E6W,4!S5C=L/G@15T;SNT6F+I2\B8W!#(YC'Q1<+V;9XZ?$^<A(
MJ>R,RV>%,7^LZL_)4FK\JDQ]^<*NT?X*@<M5\9).8\UG^,V=Y0G,VA$\V]J\
M 5^W*"M+'$/@!E1&8^@:%X,@;SC0*?82H(V><>CY1;=WFL:L6 8-<K0AI0)Y
MCBHKX(D756-D5S+EN^ \'3EZN\HW;@7*U?7+L]F]/&I>G8MI:G>6-1&*%5!M
M+:L4+$Y;HFRK-BXEUHJWK'Y#_;J.$T6V@"[(07#IW6?I#41CY(0J[I#UW>02
M:+^M:WE&FG7Z#I6;F6;"Q%*)P]?X51=ZW^M3HW)^$+'T3GPYK;R*)KI :U3L
M!&!N2:A9CG$DG*/O:N=2S[%GJI*V/!2^V6Y\549E,ZJ1134J<6CDT9KV=*;\
M$[P<HJCBXNRT9\8B]N4:W.NYH4G235>E:O>O0W7:3)?X>@3E9Q<'X,K2DDV:
MCF9Y&L34Z5S:! [LS'Z.*>T*5;'-#^_/AY!J1SBPC6PU41=N"TTZ4*#*YJ=^
MS 'NU"NRZU8*[4.G^R%1(8*,BM#4=#8FEC:52!T*Z0ETWK3(RI)W#"IOP3@Y
MD-7Q5",V6>7VGJ7J&,>6I4V\5$ZN.2WS=YZY9=%*TP>]S5@S"JR]M/M\BJ34
M+;ZOK-%B :0\<*=G*$/Q[SS' _+'F*72C06]^K_"%7/U;%<C]ZY@+A=<5G/*
M]<K5XI-*[_?5SJE]5*7W0C7MDXW/I/)S)Z!Z4Z4!(FLHIRGNL:-T)F+:7E@N
M6S'HY=:HD/&XLSVQ"SDC/Q7?)U$9.%7AHC#-:QMS*&,F^3.0U-.R CSJY)&B
MJ29C@_*T,="BMDBX"H9'PJ+6):TJY1SSA<J#AA0AI4*^D@DV5.J:#EY%]P@5
M8(+RH^SQQ$\50R9]PA*EQUW:7I6IJ_AC6]4W(5]T7,.9<0AHU4 ZB6\M<%7B
M4-C5!@P&_;6:0VBQR+MF\2EP!)1R2.*CI)4(YX1FC$-OJC_4JK_3?3AK0%TK
M63D=FOYES%[<J\Y^O"! .Y-Z*YYF8*Z\G!/WW<5C]3MNU3T4HB]]E>]O.I=+
MF\80UU$O!$(-/V+K[4-RDW*#5?BJ^Z76(&SL0V9!:BFDZ4M8"E<H,9/MAQ[/
M IX^Y+6G@H0JVYCF\.D?$;HU(SR,E/ADG09MM5#C@W&!$R1LH ,\6UIY7#JC
M7;ZN/:W#T<QIHV#)W"X1!<)+BIMFT0H(KA(*FNXV7'O!AURE0QC$7VY']K_>
M_.+]06"!*K7^*C,:=>,S22)QN+)Q<5!)<I8Z%UQN]NU(SA#VT\$<F<A494@_
MHN\VG2K?4DY'T1/T_?AK7S:<C5B,JQJ4M-(M0JY6N)BR7BW1>Y.C*22UK-FE
M$Q_L'1>?+EQ@I(:9S!*UIEIBTP\J(D@%-)BQ@X),^6:>(4@^V=?!>FKS"2_*
MXBF_W&:[M]E3&M5]91BC26#O+7.DW-S",1G3#@475$H7P<N^XA2:PK@$+!LL
MQ[6ISGE_YU&4I76N*_NJN(GOV.M)N1BQC]$T(LGF&E%+O,R,-49Q5_(XI,BB
M+P5"R,K[ C52#&6!G\VLT6G$<0H9!:A-$I:+NNUZ,Y=8PCR]'[?>>"ON9+3D
M9B4H*,=)?JUHH(YKGE"FM)DFUG:O>\"R:R+NRM&HA:ML0ZW_NE"CP,[\2"Y6
MCHED$V "^(:_M(F>&D11?EF)^Z,H9AH62A.[(&L3A_+3.'"J)?+C.?H,NSXD
MS)@>QP=]OC>70R3_!-!M-4-'OK[>EJ<9+@A?FZDI^5GZ3W<ZI0Z?/\4N6ZX1
M[[*25<87L'060D0[%6? 0B@*B@.([(#\'4,=IV[N[*L]23D=GVRLI'?WG8,\
M"<G3*VBRGL?6NT]/WI36>HAYOY#5O31[KQ#CF4[JK0(AW]:]YYBN@8QV*K)W
MA@>>O08(>KS(?HTUP&D;/S\H%!,.Y>B+K;CP:<<[M9MW%IZ4.L@A7C0\5LVB
MB3,/#?_"M#^K2<YFU^I/**;!2SD#\O<W-D!EF& V_U+]-<!LLAJQ\M!.R$5:
M]H-73M"3%D$]5$&'Z:SJ:?+J',V_/VV93G60_.C+TRH7@.B-YPP.XTA5_J28
M+H,H"7AZ,8U<I\,"_09A71"QG9 K>7Z:69(P=T>$VO0$-TDJV:+Y#*738LR+
M!()W)0!)-+F0X?O6E E@N.=5>@JAUE5'C.8E21_=L<$<DQBN588FE4K$REO[
M69@AP2@>9G(-<XW;6_)J^Q)EU9)[<9F!D#3%NI0+Z+/-<\[;+^P#''O%NXGA
M9I_7%\/82;#0Z2_W;K;%4#'J6?4FD8AZ>BW"NN8W#WN>[3HE7Z,3.Z[5;85S
M,@@:AL31/&<1BKUH:DHR.T++^KI:+U1%R9.:*#:)*K,IE9H,-8$H/>T8%?]@
M-WP=%L5DTE3M\N7:@3H]P2)#S^1+9CW25JP602<B(7S)*4) 74_N;XGP\\LR
M?4^5@RGCO)2P YF=>RV* D<G@-4^LO@_/,3ZSW:/7_''[394ZXK.'Z5YLRCR
M6C_NVOHC\G^PD]5/0 8GEI>RB&:=Y+VC_<1;8G?A5W\47^3K @-\@Q[Y^=G+
ML3?SS+]]2_!!Z*$[U=%X68(S[BHC2[G#*O4C.R!R8L?-.HO?0F957N)@8&TN
M;BR\C%PQ2,IH@\!TKM:\7O%W;HYSP:Y*^&C5DL&7G6E&;UQ&J4_;IEIGC16F
MWE]MM1C*JR5._W7C3>$>>]<KWV(_C;R2125M7Z(UNN(,2FYEML*$>TW04?.+
MTDS9LK*8[XO'[1\6"!/H@3NERN^731;W4=S];W?;&]GM.HE]-L7DWJ FF=M6
M/\:9X8U0>?*C''[/%?[<_OP-8:5U)YI 4AQVU0'F6MQCEHP/"(D 68-0%8=C
MIKYLKN4!,6?<IK:ZD "]-5YE>E1 F'?HD_3]#*9\\-2&7IGU"F<N7#E=_I83
M<Q!!!W.//Z\@!Y7QD? U5"XYZ0K/Q8M4KQ[V7L*KO0'X@#BZKA*1^C4$U"9C
MG+B3I[-\9]Y=O>($D,+E-BZ1*\TDZNZ>Q-DY]'5KW9X[I7ITUN1S/B&X.C%^
M]T:@&)OJ586KZF"P1=2"O(*<:!'1RDV,0\.1"$RA@\T/X"R[EPTN^@#7ZH9(
M=J;-4.%L+=O_;*P<'5M:]DKWW990MI<$&?.[,[W6.89ZVX[2#(]TF#_TMG4,
MUZ2]^JGMX";^/,V3/-TY>.R%3O#L?(*$*6(_[W;[=NE'V7K<L?MQNTE655/@
MI+2+B?Y?QQ_.%=4^]*_:%MRDK%?^2+,!M6H+W5H+_OJU?LZ/HHS'E$M!U&A_
M\XN/Y*!AE<CSR=DTQ?HRF0GG#:?"\6+7%;DBQYT^]F.91ZG)*1392_?$11&W
M5FY_2./$' ??=WEAM\[9)CBOH6*M+G6UUDZFVLXU;HT<^K:2]D-!8Q/X"11N
MJV=$0O"D==(J!7#7584TG7)*;G'[$G</D^\.YJH]K&=D_? HWD>QOTU#:I=Y
M>YMX[4*OSK7_>K"T>Z:B7>O>;V:DA[RXILI5O)_$$I=JB364K+([8*-PG>"=
M\JWH*WI\$-6HG%0U"R_*"UR=04ZS/#*B@UWFN;C--%@-Z9_X9UBQJ8_)V?"G
M($);G8&$!%EW"!JKF)5=;;3C*.-J4'/RJ$L2+U=K)C.4!-$WY0RF/G),#DM_
MK:(0W#*?ZP*]J>LF]F'G6<6$30N[4:[=(&T^V3:5: @O_9O>R?*R2DBZ0U2"
M0&X!>X5]!X.Z0YJY]F7@GNJ$X5>'5<KE&(Y4[4+Y']TQHL.O(7A4RI#OGK=M
M>N=8B[4?*_#K[7P)[O;9)/ER=<HO*0;.4^(T >Z?=O.=/2\8D@O5"[RLO\/!
MV3ZPOM$4?*P02V_5.M)+_P5%:+,ML)+*@O/SX5UG+1B1QSW6T=85$5;9#*JV
M>9Y.JR#O^S-5WFK.5^_>H[MB"2UHDKVP-Y-J)"?D3DC4:-\Y3&56AF9?]![\
M4I^I9B73T.+==*8!.%--"DMSA#Q\+I9Q*H2,[%IQ'JW:L_>@1@(2&;^D1G1G
M=#+?^7COZTQ,0G?C<*BQMRL##/PAY;:V%K%NVUOOK,N],Z^6.APUS?>,+:&Y
MH(-,CMO'W#Y(S(E^XE'0:*[A>W=7)'3S:GR(2&_:_"7G&0\+<LJR'<S.)C/*
MV_Y47=F'4-0GCUIG86IU'"'":02,8E>$NCMDQM:+G41#V.E;B]-BL$CFV!_"
M:('C0[)Z96B$^JME8GA&H%WF")\^U_=6!_U\\^;\R3QD*OT%MT(S%1QM';YZ
M6!J ZZ*%5=W0?!".%QA??_9*\<N_/KU0&VTPPBLXTJQ--(T.'<R=BZ,*5WA;
M./GBOL?_Z621QP-)N7NA%+YQ K!.:==4/=S_I;;+-D[MA]$<\,KFX)MWW\EC
MRNKE]ZHCU"\R;'9/,&S^.-8J<DCH*L:>RN:FCN+F<^6PO7R:_@[MAV1WFDTH
M +!Y;X$.E,R9)5$UPE,8OR4]F_7HP=0\!?E+.@',68%N_Y4GT$3_V=D&\-3!
M0-1X'>_7-H]JM?8!=[DBP\.LIT?>$X_JY*5MC>XFXF@4%,V*S5%;759IIYQI
MUELBD&<"@6*\.:[F1C[7L7D:(]&]CO/$8Q /C[DAB_ "[LP-KL5FD>RLX&JS
M '87?7" I 6-#\\]YS[CQ,^9#<UV[#&&9,7KI=>U7VME+R4\$&I-#S>RQ&%H
MB""G)U .];PSGCQL)J)<ME[!7A[6I/&\9$-[L0\L>;4LP40 C9JZ 9OIIFQ7
M9!6SCDX.+L&H4ZI@H>S+9AE1T VQQ^!,&1GJX<M-HA2 W8E:EZ96#KM.NPE4
M.^=5@G87QP#(YT0F>_152OIW[;6%]L04I</<6N5>+YHU+R[;KSS7P,W/1\LM
MPU"R(">BIR0 M+\)?E1\'*&_U*N_XLU_ @B91RL8W6!]P?C1I$T[N<T%I!H1
MT.]UB7^#=8K,^_#FRDO <<0*J>/A,KQC6!1(4TH>(Z*;F+E8>?BQZVTY35DS
M:<F5J;'0>W2Q+BD'*XOZKJ;8X%F.B9))_T#PN^.M$!OO:R*7+3_G)K#.'9+=
MX+$)ECL!Q%-7]V2@5Y0;#R?U44;:W=[YPCU&6UY^[YX(R'J&N^=U(MK+N6J_
M('RM0(BM"C9ZL<4GM+3XKD]/8=W^QYRBR_K!#QPN>' X7_TO,Y#S6P8>T=N3
M[K$IIB0C9"U_:DRM>\EO+J>Q*^21LQWIS:_&25B]WC2HCZ%)$4$5[,*_Z]1;
MG3WBFV+U8F1EQV"99IL6OO1Q[FNK_3VX.7L(L%=Y(\C3N;:*-;3\8R*U@YW@
M>F\8:\.[N88G0VL;G7K3?3Q38HE>7O>N[-J.BNP\USL!4+'4E9<OR>C.)Z20
M(.@D"%;)-0HJ7Q38#MY3Q;\OBB*K$BU;/*20U-CP5:X %([EP;UV*Y$4AC<?
M <WYW!3X^;C-)<MRJKOT2","?;TVC("H0J1L1L1XC'#-R,@A15 REKC91,S5
MF!1S1!P-=:15BO%]7CAL>/^-Z%VOXXP@/9JI!AJQV]SY.+V5V!45E47UJ$?V
M>UP>)O.7^IA$]JL2MV89^4)0$\;Y;6MV/!NQ^CK3O]+D^PC1 DI]JF]\I5F$
M7=<2N8CG,T9<<#AY;1GST.-CE< ;9N(QX!6%48O>PZ^OZ<%$B&'M7= RY2'Y
M/:D"<2!I T>(B<P[TNDD)<X[F<[WUM+-=V^,UW"^MW"-MQS9G\)F2984HKH:
M,?MA(%[D[J<%C($1& KX:6&378E(0>@FUJ)BD\JG%.*($/IUS=K_^FK4\_8)
MX/).X&$T\R2Q?O)?XD'?(E2;([V7)X"H]OW=)7'RZZ"]O6U#*K>JQ#3!>Y0F
M?#M$J&W,0837WP5Y''H860G5AFQFUT\W#7GA@84N;LS&S#@;S7R]TFUTIV"O
MOODN%$6 <0PQF[^X.AM3IWV/7Q=R-K7K\D,RY3T2C<1W#<D7YWLRR,H%M@ON
MX>P1I([2/9QX'+OD<^3$>C=<I347H_M-B=;X+&5II8 XFO&M4=BK@\M,!SP8
M60>II 6A15!F<.-11;UMM310P@:$#K>W,C(4^9!/I"LW=VPB@![D4>5&AU6N
MCX76*NQYD&X)DGT\;\W?L;>8M!47(; FE5ROG!!$&!R<?$/A8]BAKF./9UOV
M;F*FF)3"<A;UIY10RQTM3\OTF%>3&ZY.&Z7=+_L;:C?? #9MJ2_@0V#7[RB#
MZ RE?8ZA$<S-<-39N.*%7OH PS%&>R9PLD1;\-<[TO<>]+K<*TUIO'RE%/ &
M<>&Y;L34"4! HO<+K=+5C@.;J+[]W,C.H6OSDX]M!HJKU[OF2E9I!V6V8DFB
M)J6;'OFL= E[^HY_E#>][)GVGO<H(($A0#^(F)PIP PGV;AIG.Z#^>I@1T![
M5)*4HI)>8-P="2V9&(W++ZNYK^8W5?D\->W"=0R 4VW/$C":5!:%W&M8DZDQ
M>YK_&;53AX(T;J-M3>4H#VC#[/@OUT=DEO; $X ,5BFL:?H8>=V6&VE_ I#H
M^B5='OJET82U<6SGX(,.7@PY0FTLCEH"FP<+6CDX@V9GL6[-CMV]9Z,>1G<"
M( YU6W)O2Q:GQRFJDVKY*NP1[,GAL;6]H?& =$E,8;;WDNC[KP*LSX0]D BW
M=3M55F^FW$XL"94(S5WQ9(6MRQ7=27GPY8/_":"2V)U_8_M853VL5KYFKJ"T
MOL!V7?V-,\&;+?&/&[-M.5JT&@?IO92-L4/NHMZ6HKTAARW',<&VN9[L.]X@
MP\-1WQJK_8@74O<L"@E7&B0R:E.93P!)CD\$CMU'**8C*IAJ$;9?X3-02<RO
MW;U)>YBM(^UOF%0%W0:>YI$/!#Q)(1+',O9XQL]:T\<2WD?1W7ZI7*W&I,'T
M@Q\M.OBSP-<V_;F<0<6WC65%PS,?^E/NOA\M..+=.P%4QQ0*4;#?2+2XGT*
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M)09\1)A;QY9P9UNIF=B(*&?,FW?6A8CBOKVPEO^\/>0/<FHCNA>EY&6Y'KM
MS27V<T5TA!+DVV+_\_C$FS5/E[A8*WI$F9^[^W6 C.Z#(UUHZD(;ZIF0],=H
M_]F:<M;4[ ;?H]_8:O)V';PCHT/3F:)O.X4U[L@G-(\2BN-^HG \^$5'B9(
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M2#EESUI.T9)I2_S/KGS2!H(@_H?:^<2]'_MRI?D,$[(6&U1XCH$@T@V)=M[
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MG!PF*#Z^U!V/9C0A8BYDU7XA\*V%X(*%PG"7F[ACFEYA-?L9C.L.\&!>_F@
M),0=%E]?E8]:_RK>;;.)LUV[4? @5&=MU A13Y05!VM21)<Y,U)&F?=]-4_"
M;J^A4JU6JWAW/=EG:>?2T6>^NHT)-U^T+/*6M!HOS<)!/I8IX%^F[#'?#.\
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MF]L[7>?8RL"0I24VT&2?>>7J]1T@UCR+&IPY:\-UONA?Y1 @J+:K. ,;O@-
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MM-6\YG_$ XU7I&H9K;"0P^+TS=0EU'AR"7G(^A_Y$!FG_*VZ)^@A4K0T=0=
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M89=H[\67_+D$CS ;;$XE_8I5:7B30]NB*JMOV\3LO$KK'^T>CNN0$/H3%Y,
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M$YY+C(SEEWA(XH[Q;%]"5@/;O ,Y>N">FY^B6F)Q;A#ASM;'53NDRILW&(6
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MU=]BTA>.]RR*DJ"FNHR67#D'3/DL2K;2N$O+]X]K&("[A9HNAH8>:EDYB_?
MI(R+ON)4@0?I>-&+='&]I/""%_=P^L'*N.'O8NL'=B1R:1IQTC]7M^U[TQ+8
M^4F/,(B_1D%2BIZ6L[UX_B903;>0&I?$T-$&YQN>CLUZ]P2\T4F*N$/F8S2Y
MFFRTW8(?"&+A"*G*]+C0!FF_T(KI%N]*P]/B:?G@ZNM8:35;>44>>:XT[>_O
M.L,C4=63A9'@S3FEWF%M]>:DE^*CL+%$D%-8NA65R9VIOIAXH9LE3=[??VF$
MQB-/<\NH!YV9\$?5Y[?/PJ:)V7\P>^JJ;-S[9>. (Q-& JPE>+F#=HB##S>^
M]P,K2NH+DY$ OX>13 CYS*\I=)+_Z$Y8R5W]&-W@K/!(N:^&>IBFZ: XE_8/
M2M!4B%7F(TC4Q7U,)95-?+2+M=$YW]@U-0,G5[=A(*^F>F(:1+<+*H3-Z'Q=
MN21'V;";5^6H;T+P8N>]WPD-!!N;)_VJH(2<AO1-7\F/F]:].><7 ,H5";,N
M3::2N..3TE)_G_=+F990B1E<DCJ#.,QNSH&]X13[[2Y^X)$YVSB7/CH\8VAF
M"HO_D472HXXT'$'NQ&'<:\*/BNCYB)L<KWM?LLY>I?I15?SZ>OH V=/F-Z]C
M"'L9[]]>:_>'YU.:H<.SBR-761\2/#(;&Y.'40^7S:93S2O+U6'3,[4FXA7'
MDCE2E,]2@N:?OD:\<1;YUN6G8G(@N*(-$/1\%#!>K=[?^3KXW968XPK?:[^L
MXE=-%/%^M6$XW(V55MRU&0!'.GVQ +C8/M+9S^5SLM7,#MQBG>D:_D2*^D6R
MF='OL"+L,]M[5&05FV.X'6UMK]\*ZW16LZI5L501["_L;1WL$L[%7"R^F^D(
M:KX_Q:E\K!+?94B;3HWS]ZQM:B./U%&XG"&N;4F,L\,\TLXEK':FS1E;.U/1
M4>\#<S-,EQ84A8>6FN= >IY]W5-12GX4?Z1$WM;LPZDV^U))0)@^X=W4+^/Y
MIU WL-1IUTAT+>*][7;B&6"#"N N2<8CD.;!^@&!#\\XE9FG/7%C")25^]/9
ML[Q IU=P\X'YT8\B$>CK+KOY-PI&"1%G9?(FFO,^3I\Q& /HAHB.DIHZE_8!
M@IJJ:=-]^0Y0E],H*"]6 (9DGS*ZFG;N"GR#V<L:S[D)W>\%2YB(/-@R% C9
M=$J0UB9&^TK$[1Y;2X80X6^5MRZY2QM-%*PO[$C2?28_I2'!'W7B[KY],OHH
M5<]NGI)++GQQ^MWT3;9</$*![AQD(VL<!PLT77*M)A%=AO3@0U?%)2OV+-W#
M/X?U:,C&'BDV9B'O.03+O.'UN0S,2F/Z$![[A7>@_PW)1UOC !R"/QP/V4H$
MRSL*-:2(LPG-GZD@J8YK(][SR_KVI7&+G5F?=HVW#!=$M>WR@^Z)S^JW?2;3
M>:?M1'-&AX !<#:E.P"/NK;B)\P[XY.79A.^8\AQ#TAC.8BY4P"L]Y7GZ?OW
M79\RN_BLN,RLR1;1!KOI_*@<TV']\+STR.3J\]/$G"2V1[7T+X?[K%F5]YO=
MS-N!D7$Q#HP%)9(K'/655A;RN;-+>$?5HP("@A07[;34G(HP38YD8GSCQ3=R
M53WN48'XT8%B^,:1M/BJVQ#[5*^46X?MRF><NI]SU[_X&3Y<U_BUPKP9V^?3
M&^QK5B:O_1[T=E1;]K4@:YK^;H?H6\]@6OE9D>-4V9^^4# 5\<S5<^(,AFMM
M\M!\R@"6Q&KXI:2S$P9L!'LA,++0,H@.M"D_F(&I[8GF"&EP-^KX28R:#XW'
MOGTE0JU<ZU\P9.UFEF[-F4O+N:#RK-F-157BWDVM'Z6)?7YVO7,F0W8Q4L15
M' M1H?_X7>G&D(O6$"E3&9G[S7T!$(/,][]/;A=-*"Z-1TA0MCZU0,PQQTI$
M  ]Y/TZQND<4^O[D)ML4AMR%SS?7K%8W 3AP>!9FT3"UU_F=>-]$)^:_J^C9
M:Q45ZCY1N/XI2/"QU<#Q'E*:X;.D=7KHO;%IN<*BTD\UN ^F(W3.+&N7^L S
M[IM1<*! +_]T+D],@RE^Q1!A1Z1-(%OT]$728#07\<_G5CNU<[UJML42OI_<
M'HJ^\7J=ZL<EU=43KRWF*59+TE7Z1H;<FD;A=98^M47_&+:N*5XK-_WU(T;]
M/S&IX^8\@X>?GO[>%A$A#ZIUW_)7?UEB8O;P?2N-)2R$)T_]Y:2X 0#'A@R'
MN[C\YR1];:S'/+] I=(/U5<_.%631%<<_>>2 :1-AC#T3>>;IX^0=>K.'[\]
M& G(*WK3/>@\^R'=L:=7-_"SH7WLB%%*MI+./1I7E#3ZW:=805O5,-WT_'2M
M0)LOTZGIKZ'&*H;Z;CR,L=:%,0_.VJ4.'E2X0?Q,U[?&@Z585,3FZP$/"T0X
MQ7^4BW<+N)TS;!DGHF@)XMB5V]3/@>QB)3\/BJ>N++1[##*CLWY6C<5*OU+5
M8M1Q<X_/OJ4??V2'O\5(3O) _(E<ZK@CDPLKXP,M&PP]G?V[3.EN*"))D_I=
ME8) C%KWF^)2?J_M?6'"B0[#LI$198I"F!M'SVVL:S1Q=/V(XS=KYZZO]UE0
M *<1$&\RSH+S5Y,E ?;&X_!^2E4J-T%:VRK)H%G8S*J)RJL':P\R<HWC,G/D
M0[GR>7[T5<2ZI'P\O*1Y$:6_ID4N\ER&E?$5@8B%562R/:\830G__]?8?04U
MH7!Y  ]50(AT*=*+$.E-BB(E1%((& )(APA(0E&J% N]"$@)"4UZ#46I$IJ"
M 00$I 0!$:0C08K2KBB7]>[.SN[.[+>S[^><I]_,.4_GCYE4^V'3T36P2ZNS
M0 <XTC\0$ , G!BUN^L+K"WZX]K+D%O5VO7<4';5=E:=]"<I:^[7*9,ML"[#
M*V8@XV1S<UN21N/#=%3IE%V"NQ(K!$?D'1=?SK2+#>#B'6:_!O9J;8"(BOS:
M6R*^KS07WJE_? TN8GG!+H_%ZXO9"-9/_!P7QI3\NE3FX!9IO7J2='JN998A
M_7G*TV+YPH;=^P'T[&\X$[:PU.U@H/?Q AL\<WB:"['9\=46B!\T0WY-P#.I
MH_$T^L]+@LB5"EB\8LW$H)(B3%>5(P=3!AM*?%^SK^@KT3(" ^\\G9I'O)G0
MV+S^+1" $!0_L?9C9&U#I_0O]=&S:V;?GU#8=+\:_SZ&^^IGEIS=6"4YF[NQ
M[I5\X2'[NLG'YM*S<+\?L399Z5982CD?ZY&H)XFG>4[CLODN>ET00X_%%[ZW
M"( OGR!_KJ,3@T'N/K3>ZB,C&$;4"5,9]_S\7BTGM&+H'K]"!>!<:'?4CQ4E
MIHG006M*:F&QU:^R6^="(P @UGK >4YUU<NV>>^@S@TGM8AT?QP'.G6N.0E1
M/E1I<E=@5BD6VMB-TV?#C[5_@!-D(:4>0PIK;R>H6RH?)MJG>]KCZ6[TP3FQ
M30Q($*P9@7&[)C8)JQ&TKK-1?>E5F!"D>QD$:='2;,V.V]$  .JW;NAMWCC4
MV*02FRY \#0R-ZWCF?!JAB'>W\$7.C$4Z$UIRK";XW.H(:RA7!Z2;N'8MQP$
MX68&,024--7.!U7#'F1J$)'@+F1"]"!%>40C@R.9!([\L]=79['[L1IM?)EN
M J^*%WYKR L%+GV!;H>$X#EIAS@M.EGV:ZRCXRJ,C\A/H[IL] *96ZCO)?OM
MX\K!^#, ;9G9)CL#,VK'6#\I.;V3IMRWG43[3I;$0![JU.!JN([L;<NOKTZG
M]!>!QV/1H!>Y+YZM)<8>S*Q[.YOD<WNBV#+8?V_K<%19\=HY_SD*Y:K]"X'D
MT[=)01P8IJ^9@)14JP88GK3T'8WC0F/$.9;TZD^7&)/.[Z2I^R0.72%9H!\+
MQ+$]N1SJ%_ DF7\G#>RDX$)C';FS><5%."KSJ*C!:(QVK>'FM*S/NQ$^7Q!]
M[.@4O:D!?E4^1<;@>J7:\R5%R<&F&V3&T2-!#U%107ZG^ AXR"87.?;RYN-3
MT-2M,M>JL>).,>,+CE&EH]\U4T ;P)5.Y-':S5O G 4.\9F<COC:(>WJ0UI#
MB[!UQ275O*)F2SY/MK<: 9MLW7I:6?3L$1"^!PTOQLAL23?+>\BA.6'PK$5]
M;K/)Y5=+7CQ?!9@*'P6O\6A*F<#,'XW-6S[2OBH_G:!ABPJ-#)* _>@#J[+Z
M;:HF[OE/HO9PEGT:>H'Y/:;IX@T4WD^U.NM?\)02>_XV/RVZST':#/=U*HIT
MT]8Y#=5,*+4<Z\OBYYF_;<Z9>'P*.H=)LP[+H[/.3"]-%R2LDV7D$_<Y4<WL
MJ2 )"G24\Z-$,6J-&JIH* -Q)N:_OS]V?ZOQ0-)M1*5;^SEA_>JXC=TBMJ$$
MZN(%3V!X$IRO%=\]T/%@@NM./RP^S$IT3^*%+-,9H.+8*VMBK5!&O]F$]SBE
M-: M]R:#.,6$'&EK0LHL*"D"OZM#),J-9F+7P,3U=W57WKYO )Z>!J(F>6\C
MH;:Q*,@5GXJ;;V(><#%P"+-BZD-(,>$W\OI0FHP,&E#)JFB2[TW5[$%V(MIS
M9%A<%+/2*Y?:R9&]\ZS3ZBOI!W$'Y5ON3Z[$-E9?JU&V.FD1[S8>!KHI4@S>
MO824#+QTS9#$E((N+1EDP?)V@^1?I2+Y%LU+_;]/X*;LIX0W -PX?9*@[6O?
M[ IF _XW#_%J)LF]YZ.*?JK+I3%$N :9,N(W#*O8%PY:<]6CN9B,$^.;OC2#
M&IO0I;S'_,70DB\VK,]PE3C<(:8$K7TD;@%2^"4L;9;0.&Q<1<(]4QM.([$J
M2AI9N@LPA0SZNUTYKPBW#*R(!7[=TF.U8%&H.B%4#>J[==[)!><H+?B$85C%
M?>N3(GDGJ_>&37B87OLT;WY4%'O)L.HF   +F4MWRYHF?7'1D65R5;,@\E0P
MNPHX1&:-%TW-1%A;.T6Y(OET17K#59*21N>5%(S5>2D?':IK.URM#&<\% V)
MF((NH793:>*IR#D@9'_'>H;%<T%M.^1!R)'1MA H4^?+(_J<!^JMK&]380D:
M_2XVN<+Q<0\XK)SE>R0,=,)HLES+-*-&=)OVC9NY8\F6;(TGT9NVOB+959;
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MOOZWE!/KG(,/\ZK!%!G&OW8OO1,3O%2;4+T4)"CASY>5;%1;80"BJ!PP.S4
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M2ZS\I1V_B\Z#QD)]R%GEJ\(6WG\3'S]]]@A64IMVE_>'\#US[FG-#YTBBY?
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M?/O.1_C[ESYR1)CT_?&-T]_5Q/\\G8"<@)R G("<@)R G("<@)R G("<@)R
MG("<@)R G("<@)R G("<@)R G("<@)R G("<@)R G("<@)R G("<@)R G("<
M@)R G("<@)R G("<@)R G("<@)R G(#\AT&(_GB' ]S#09;=CUU>[O ]0 F
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M5DY]!>:6C",R7"*8K.L/"PP&IE!,0.^VMN8^E%;)KK^9OY+N9S3)U1&3!Z)
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MC6G/;V60)PLLC'R"K\K/U#'X%7S]#:%W004M5K7EUW=+1C5(FKS1J*M7)G5
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MJ..\3O%Z>[4K^5["@DW?(XC&CEM .(^7Q(?%-0!3D%/H4J&.@DWR/1HM"8
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ME#[5"GHE!@ZP-Q2\!ME4H^B@D_3.<%?WFVKVKGX7!'95F_@HR8T3L0<)IPB
ML14,OG J="$\!'06%1J;LG5J,#R6!+0KZJ6UW]\(9! N1-!^N7<EG?NF"A7
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M"T(%CI5L+"A9XB?/Y[RG2E6K U[TE/^DX5B8/+>YV@NVKH5'22;'9ZK35NA
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M%<>\>-4I&>5-+YPW?(#S5./)8QY*RH.*,1PX^LZD)3B<3J+2BC]QM&=+DJM
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M5D \4>L;Z\*\+7-%$]Q,2+OVW]8\"^]&!+/ZL0!601!S,4-;>_[4R-2%J+6
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MK?<"$_S /MZ'0U1N-U7DX8H@A&82"GK=N>3<7]G/Q8 ^C-G5I<@F$\'HKV^
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MX"V!"O?5KSX<2 7@/1@G]SD,,A'%C]QTC$?(#/L[;O5QPL*'K?L-L"W=66]
M!TA6"9FI$9L.Q%#@W$2EBT=S%Y2=C5?')#.A#-E?_3=;[1?E@:U7\IJ9)W!.
M!:)'=JWJI772*,O64W^&"*RQJ,5)J708JLK$5*%C.PKO-*T&,=-9)]"O2*N(
M-EY'PF>.8_[82 #19J[]<G8ZEEL&UD98Z>']3#;@4:WVEQZDW7WK7X.:@]X
M(Y_](&1V)4PW/C=;(DQ2H50%!;]OX-&4\!,9$>9WTW4[X;+OHW?,W^'JDX^
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M)I98ZYS'A Y3R^RS*?J_8Y6@@D];AL=%0*S_8'[#1"-ECA4?9WJ,CTJ&S6P
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MJ)=NR9]DMA4"5KX,-?!R3<V+$@M!AQ6#$W\KC EDV^]-5@"+B)TH0M2,E7#
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M&I<E]B"V2XM98Q[<6.IU2G5-%Q166Q72?3^_[\>6 !A[SW(9^L^9/?%+6C\
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MN'; MYB"SO9A,AX,DPS/:8D=HDJ/Q8?&#R3^5_#CQ_""=&:NX/G[FJY!.^\
MDGL&Z#JTS8/@39[%^&>//O:\B.<2W]*^/2!=#<'VOVHUR*!\UU1\@(L6[#B_
M%Q?SQ88?$6<]'9[DDO$!@7GC $+LD@@[W[?8&Q0&Q^_/FQU/3Y][]?E;$<3V
M:S"T=?3C@2#@"2#L#OL"-J.YV]O-43P//-Q2W)LQ;]E<2?(?+!Z5$C8C>_YB
MQ5D#VWWOQ5=.O4=8PCDO'4\L.IO_ &\\%*H@"JK^7-C;?V&^VQH;GIT^_OU;
M M'DW5VL>O=Q-B;8/2HU])-['G<$'QZ;_2OOS9/0]A]3Z\6Z7^CXC@7-AV>#
M#3>'+B3>S8/2OV//!/\ (?W;_E^A._2_S^_OY\C"+ BQX!;F9:YZ7=F%@H5Z
MOX4^]W8%T0=AX-[\D#G@D?N6^O\ ;%@ R8[ ?+]N#PUL'I5S6Q(W.P'%6:/-
M?>_MY?9P#?\ L7 D,#S>Y<@>1<6((PO2YP$UM?'Z5>WML!L#6VVW03VZ??'W
MS&'PWW0X'! CSDO_ '-H?UFZ"@/J&Q(X'L!O?@$&N>#TXZQ%^.'[OS_?!DB7
MDM=C+N/1NAX82QPZ5=A.X]MO:CP? (]_8GRGCO'>]_UCOA#27>SL'$N+B79^
M&AA@HF]C0/!.U <; &M@E0KR..GWS_;K>_7!O0F.'=[F2>2S=.6;!2Z%;W^H
MH _8#:ZWL[G>]STY[=KG]AB?";1W#$N?5W^MV>,*ED["_?G<4"-ZH@50(%\4
M>>GZ_?:<"U["[=#8V4"+N0[!SY#C>02TZ% C^C<!%6>+!KT@U8'/%>]UBNQ^
M^'Z?=WXQ781)+,";]6))\F'UA\Q-_P!FW_@3_P"Z.M'&6,<95/\ M;([U;[(
M'-G^J1T[<#< 'GDWYZUD?E'WS]V[XP(/TZ_/BSMPS$@L&;I>@BZ(XO>S5U15
M0H7?TW1":YWZRPVF.IY#1<LX9KS>>[ GH(\I)%FR2?%;4+!!/DV0JQ=GI@0;
M_$S C@F7>]V[-$,PPBA0)X(-V/=-79/V.P'.P%"CTCSZ^K_[/8BSX@#L #V]
M"+,>7#Q=[FU0018V":!!.Y]-7M200>*X)N[VZ??W]]KXNPDO((FP:/ZB7:6L
M!<_-%)W]5':_>ZK87OL!=#;W%UTPVDW#/#GH7EASQW<WP_03LJO(&^U7?->-
MM['.X%IZ=_3[\_\ 6)M4!\(Y$P]K#U>.>'G"+9VJB0?N3>U72;HV +.Y%[[C
MI@Q+_+@,..8CA@2Y'. H5=*(^GR +LC>_3QP=[)W!(N^F#= 9N# ',$N[E@(
M8E^,'H-DV.>39JCL ?[PL<?ZDFF#$?(<@3R;EBT%GY.$AH(^:4)0A3R@MQ:$
M +<6&PT%J4!]2DM)#072CZ A'J*0FGW^GZ_M.*Q )8AP!)BSM<#ZV=@T%_+(
MYI0)-&S?)*A0 *39*AMR+ ]5],1E-8"">#+W,DM+>9F#@4DDDV  10 -CV/G
M<#<FMMR=K!8!*@\$1R0QM'%QYLX/#X/2H'E)WO>CQL:L7?G;>P15"RCG[Y^C
M8;2P '!M\VO;KN$<S& (4=Q6WVJP";X'VWVODUO73%VMPW:((;JY=WAV-B<1
M&[+I_P#"B^,X$@?[5[";@$#;M,P://@?K_%M=]!<^8,^0^D?KTP4DD, [.>+
M?3B6'0!CB710J@018NB/TOVV)NSL-S]^K'W;G_'UQ DQ!+B1^@9^.)/D#.%\
MM1%FQMN+-$;;50)/G;WH\5U';_/3[Y<8K%B+STYL\EFX9H@@=7\LV>#N;YW&
M]7L=R*(38K?8]#VZ?5AV?C];WQ #W@]AW(!?KSS$AGQ3Z;/(H#GR3SX%C@UQ
M9'VKIYOVN;MUL&9O(<" !:WT!L&/0'N"8?J3AEHD#@^H[D>HG<_3M5>WDD"S
MN :8,TCT=K@,1!=[O$D7QQ2(S,EAV-(:;D1Y+;C+S#J4N-OLNI4VZRZA8*%M
MNH44+2H4I)*3M8Z'S[OB %,BY'8M;H28[A[!G.+/8[:Z)C2&)3>FL6J3'BO0
MFY#L</O_ "9(F!]3SKP<6^\X,A/09+ZG)"43IC3;J&9+S3A@]G+7A_OR[VQE
M)_\ ^7-X\P7-W,CCDXZ4;M+V]C2'I3>E<677LJK-6ZTI]MO(*:PS8=99>46F
MF6CI_"/L1$#\*Q+QD&6PRA^'&6U-H[\<]"XN]L699KV,<>?,&6-W;BX?W0TV
M5.DX3&*#WXDN(<CMJ;],QF1%EH0RI)0VW)8ERVY#;:4-NB5)6XDNOO+4;OV\
M_2W^_E X$<F_<M<[NX'/J\^?%[=Z.@O.OQ-/8V.X]*DS'E-L))=DREXEV0ZY
MZPKU^HX'"):0HJ;CMXC%LQTM(@QTMU@>;.T!^G=CUGK?#XAPX;L&FUQ9KM([
M''H8S2.F\,(PQ6&Q\(Q5H7'6TR XTM"<DA"P\H*65!&8RK:%E9*&I\MM)#;J
MT*C!_P!H\ND<^I.*Q8@@VDP89^)=CTGEGBX?0> !L"#7(.V_V!]0('Z79'5M
M]_?^,8E)<$N[N"0&+3U#]K1P!:(_:)'_ (67QAH!OTXSX<!N:&^B]7>>/;[>
M">.H+GT_2X_3T^61<@"'EX']+ 7>"]V)L2,2W*%$CP3N!SXH[T"#QM_Q%$BX
MA! L3<$DCDQ<M-IZ6AL,(-?W1P=K(.Q - ;_ &YH?>J8Q <\\@EAUGKP;WGI
MA?+/U4!6X\FE"[%5^G-60*'3U_3Z=?K;%DPQXEKCH[F&>7)+D>=1;- &@*VW
M_N^>/OX&WN;V+ @W,OV!=B0#>8<Q'5YP*036Z>3O]5BB39!&][B[/!H\@, D
M@P_'#$NUK-=P][,6P@@U5#8V2:%C;:O3L:-$[ G;[]/O[^OUP*2_4M82;&;N
M0" 7/:8P!!(Y3L15; DFT[[B@-MB:NB ;Z'Y?+U\ONV!28+'NY$V[L9F>3(-
ML'RSM6_&PVH60.!93N-JY%?<L-I+>1N#]9,GT[2(/0?39/@$$635<U]0.]D$
M_IN:Z8;2[#F3 FUA!9CP2):'.#T*JCO1HG?U; #R":! V%<>:W8 $OM!L 1#
M/8LS,[*]'ZX/ED'<U0W)/)%_;_A9VH$=,-I+@AKD"(#BWQ#UCKUP_EFKWVK<
M^]#[5L!0-CSYW+S^_M_KBD*CO^7@0?-QU9BS#HV*?02.!5 [WS0)'WL[)VXH
M&P#T^_OZ8C2.#(>_4"T.PN(+DN(P_2H$"]P*H _K9K8BJ.W  KSTMB[7=PH@
M2X8\$M,D7XF7L^#T':Q1-^X-@FP/M5&C>YVL=/7_ #]/[8C%@H,!,1Q:+ER6
M!%X-\<;S1++I/_JE^=S220-AY(WJ]B=Q8'6*C\)\NUHG_/UYQ6(9X +N;/P+
M]^\M>2<L-_V:/\"?]!UHXSQ8.3;"LI/-U3S1'OZOP['ZUX()&UGFA6J@QQ'S
MY[6M]3C342#'Z#]?3Y <@XZ8:)%%5FAX-T/?<U578 .WMQE;[_W_ ).,=Z@P
M![ 1ZGH6ZEV%C;!\H;?431V)WOCW)\W[>* \HO\ ;?9_OAN5:W9AP._Z?3##
M8KFZLGZ;LW]CM]_<["C75?[^?]N/.V&]77IT]/OC"**NS8KZ35#:ASL1Y%\5
M]]^F+O5UL7L(GCI,\!V9HP?+%<FQQ6PW-US?\K -WXZ@/]Q]_?;EIO5_[/U@
M1T^G7KTPRT3RN]O %;FZJAMOQN=JX) / N'^8^GV)XP"B'9N\#TCMP>'N[8/
ME>G^%5[[4!M7D[[G8610Y(W'27/WU^[^@Y;R ;3<,&9F$6A^CP)-L8;[B=]^
MU/:IU,36NKXL+*.(2XC PF)68SRF7?[.2K#8AB9D(\-PVE$V2PS$404I>64D
M)W+3]&U75P^FY.I72[$U4FF@%V<*BQ!-^+\GB_B3QWX4\+4T_P#-ZME\I6()
M3E::_?YQ@S$Y9(J5 E3EE)D@E0 8XPY#^.'L0[(6S)GZJ@L)4$_C'])YE]DH
M*?5\SY..CS9R4I_]M$;((2D))!ZWQ?@3Q6$J4,E0+ J(]ZY+<#XKF#R>G?@E
M'V^>SJM6%(ZE4I[E;0I>2SJ4)W0"5&D P8ON(2.3#B2NBM=Z-[BXI.;T5J7%
MZDQ@<^4Z_CI*'7(C_I]9B9",KTR8$M"5!2XDMIB0W?\ 2-IJNN+YK*YS)UO<
MYS+5,K62_P#+*24U1;<%J$,2\=.1CM32=<T?7\D,]HNHY?/T $A2J=1"UI4K
M;&U!=-I%5U  B#B\OEBP+\ [T*W&X%\D$[F[(LU=C1[WNS&[_+LWF?/'W[R[
MP[W(!X Y?@=/+I@#0\F]@+%@^?\ I#CV% 56^W3[D=/T\_\ &&Y77Z#YVNT=
M19V<8 T-S8L[D^][V+.WFSP-]R*/0=&;_<?3[,LW$W(/9AQUBW9^O646^-]_
M?G:AR!=435[[G:_X3<-YBUSQYGI_;@NX&(B]EVPKXH_C/H[)RO8($@<7VE9O
M8[>#Q8)K?<]8C\RO2/K]^9OC(K4$IEW=WF.G;NWD><2\#7Z ?WA5#V)O<#@^
M*OQSU7 ZR_SZ!X?H+>F)O5$B/+GZNT$W:"<+Y=G^*Z)Y!OWNK-^3M='[]'Z^
M5^K^3?Y83>;B2\!G:&](D]A(]'PE->4J\ 61?L*-D\D@[ U?0GECVD23'!_7
M%%0NZ@".C- M;H9 YGS'GY&9!Q4*3DLG.B8['PF7I4Z;.DLQ(<6*P@K=D2)$
MA3;++#;84MUU:TA"0%*4D&S$E2E)2E%1:EJ"4BFG<7)B(+.XZAWQCFJU+*4C
M6S&:I4::$FHM:]@2E 'Q%2E$!(@.8-V)Q%G.?&IV"Q$E^)$U'EM2+CDI6[IO
M3V4G8YQ0)03$RDEB)BIZ"H#TO0IK\>J"'2I*JY/E_!GB7-4Q4HY)(00% U5^
M[47/(-KN(FUB#CJO4_;E[-]-K+H5-857K))2H97+5\UEDD$I)35II!4LE)!!
M64@6 ).+@TA\6?8K6>0CXB'K5.$R<I:&8T35>,R&FFY;ZU!+,:+DLG$9P\F8
M^X0AF*QD7I#[GTM-+])*?FU+POX@TNG[W,Y%TD**4T%IJ%02Q.Z2H$ \!C:#
M)W/0?:WX!\0UZ>7R&N91.:40E.6SU.ODC6"]Q'N*E4A)JC8R4E0!W.0Q#R32
MW:2H*V*K&P^G?T@6FP/JM)Y^ZB>MA25$#<G:2'*3_2_$R6AS#@X[%4M(5_+-
M8I(!(KI0E;DN0-@VE+,RI-W,8K+8NR4[&CM6W)VVW\_YV1?5^WCAG'JUKP>F
M,"M7)L&Z=2_UO@4T+)]0J]@0:VNS["[LWM=^XZH^6&Y4EY/+!_LQ\L!;"N5
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MRFA9Y.W! .QXY5UBJQX8'B\'J/)F/[8NY1(!8N1P(EP89^A%[6;&3F_[-O\
MP)_]T=:.-7%D9!/^TIQ.P+[=&KW$5C;P;/'/ VW%=:B('J?T#">3?HT7D:2P
M'/H_27<]N/-_GU/EC>E ^PH6!7ZC?BC7!(XZS=N7/3FS\<M/?LX;%CY=VM<3
MZ_O>V&4<$$\61[#R..=ZKBR?Y3EV\W)# R7?R_:&P;T\F(-HCF[\\W.&4I]_
M4:VVY-[FS1VO;W'FK/2\=#P+ ..8+V[>F#0_W/W]#S@]&W/'V!\V:NKW.];@
M6?(ZK@7(Y;Y]8[1^N)@+>P-U7*C1_7@C<W?G]-MH_7AR_3@?,?,VQ6>W:#<]
M6^5X_;!Z+%>JCXXW'W2=]B;!VW\[43O'ZCK+6/%_G@!])N(_3FPOC&'>74F8
MT5VG[EZOT^TN1F]+Z&U7J#$,>CYR7LCBL#/FP0MI/U/-B4PVIQI*25HM 3:@
MM/TZ?13F-1R66JJ*45LR$FQ"DE7Y39W>S@A[\XV/Q5J.8TCPUK.IY&E[[/93
M1M3KY>EM=Z]"C4716 SE04D6!C'S7R=83<E+F93)Y*5E,GDY#LW(Y.>^I^=/
MF/DK>E2WR0MYY94$@FDM-MLQV4-,LLM)]2933J65H4Z5"F**0A"2FFD)=D@/
M#7'<=R9./R0U/QEGM5SU;/:EF:V;S=2HM:ZV84I2]Q45%-R3M*B ""S- ;'!
M^\A!L/4!O?KL#T^GR5"B#9!!%$6#0ZUU9)+*FH[-=0+EX@D 0." _);&WCQ"
M 94A()=W9@&L27"F)((*9AP <2 ^%KN7G]+]^NW2-/S9 _>G4^(TOGL:T\X8
M^9PN5?,20W-80HI>.)0^YEH,A;:G(#D1Q33K,9^:E[B7C72\OF='S%?,)2E6
M7H[J5=26734%)VI"K_S"R&'5^7QW1["O'.KZ=X]T#3M-74JY75-41E\_D@2J
ME6H5@M%6I428/X>F#6!#L:<, 0?H3F9+&XP-JR61AP$.N?)95/EQXP>=/J*&
M6B^ZR'72D A*;<*1ZB@)/J/G*G5-1*5+!0L;TE _K2"/C(/1@'@_$;6Q^FWN
MSL]X_P"97Y3&T-#$_P#LY,L[8]%(0I(*5!8-*!NTE!JE)4+"B=J()!->XZU=
MW9@2.YL+L223#=IG&FW^/OL'^3.'P%%#>Z&Y.]T$FK -4">;^_%V*FF&X<WM
MYDL?0O?J$QU.#T <DV/2-@+M02:WWVO?;Q8^G<U^DAV/8ENUOFY/ <X-\VYZ
M /?T'&,/Z,[4'1W=/O9W,7G4Y!/=Z7V^DC##&_A?W>.AM'HTL4N9$SY*<H,J
MI FH486.,,D1JE%0<ZQ=B3?B.H:X>QZRUKN,9." .0Y[-)\\9=;4R\GU,O-/
M-I6MHJ:4EQ <8<+3J"I"B"IMU*V74$^MMQM:'$(4*ZH5#OS)#0_$DO<LUFD0
M1B$?H_\ ;CR_5V(.*E?+0E:W%AMMM!6ZM:DH2VVG=3BU$^E*$BR2H@?23>Q
M%3>I![ >DF!+0_/& !/G,>7WY^DXH06GF@ZTZEUM:4K;=0KUH<2:*5(4FPM*
MA1"TGTJ!"DJ(H]5)=F N(?Y]+.'/GV)R  4D*/PN)AF?Y3Q/+GD8U%_M(=?Z
MD@:HT)V]_$2(>CY&FW-5/QFU%J)J+.#,2("!. I,L:<8@Q)#,994VV_F6ICK
M2GH^.>C]K^S/3,I67GLU42FIF**@BB2 I5.FH.HI!+ $N-Q?I:_C3^*GQGKF
MD9GP]H^7J5<CIN=RE?-YI=)2J0S.9IYFI130J-^9-"FFFLH< ^^<[F2VM/\
M>0@G^F)]9!-J %T$C^\:)2/30 V35CKN%65"F<KB ( +O#)(#2/0P.<>+O\
MJ$ASO023+EBX&UR22\!O(7Q2K4:%(^4XI#C;B?2I"O2M"D'TI(4V?I*5 TI.
MP56]U76%/(4EY@(6HI0:%5PMBQ^$AB2681U8XU$^)5(I$^\VD5$U$^[-ZJ'V
MD,$J&XN[-+ .0V-V?[/G7NI]==F<C'S\V7DHNDM62=-X#)3'EO/JP[6*Q.11
MC527RZY*3B'I[L.,ZXXI;< 1(G_FZ?5Y[\<Y#+:?J]6GE=H2NFFJHI%ZBEU
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MPB"#Q]0JJYWHB_T_W;_47MT$.\, ]^2+@Q8GCJ0#@;"+D]+  EF')YX X#X
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MO66 F&D=>><'I/JXWWWN[H';VNB>-^+/MB8+ QP7;S,"]P\OWP]&'([EVOQ
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M):DP:O2 2MO,X69CC2%FE'U/)"0I(^M*:]("KY!X@R7_ "&BZCD?B S.1S5
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M,@R9+,>3D<G(;;5,,>.PW#BH9]1Z8\5^+,SXAK(0DJ3E*:RI"%JW*4-RBY(
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M0+TZ%9=112 & 2" Q )=(W7?"5\*F.^&O SW)N6_>;7>K6(2]5YU#"HD!EN
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M4*R0(@$(K54BBJHETCW::JEJW#:%%\2E;<#J XDI4E0M*D?4*/I-BZ!2;%*
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MMS9GMUMA[#<;[B[3R1?' !O8>3^NQC$\$"!,MW+D,P[?*&OD9FQZF)^(F[D
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M2H8R=E,CCL1!D9/+3XF,QT1"5R)LZ2U$ALI<6&D+>?>6VR@*6I* 5JKUK0@
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M9X!YZR%KVGHTAWX:T3+1=],N3(B0(\V(GU+L&],<9-5OM6QY !WH"AM>V_\
M+;B]'<1!'S<M8M/)8/$'&)EY#O(/6TF.]H=HE@'BMA_G5^:V\;[B_97CH;L
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MD ./*QF2" 5>AHK2E?6GJ'M=RM?*5LOI&ED5*@*5U\P5)*"S )2%%*@0#N<
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M$BP?SAPQACWQ!TGH&LUR+$M+V)MCB=_LGCN1\I=; ;E) ]-\?;_CN-[+$0
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M>@H>ZI5"^XA--*4 J*G(),SC*H0B_2$@;5N!M9WW3Q9 )!]A9XZY*4IW!:@
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M-[#P:\$G<'GCP+%58X&YZ,.#/3@@$6O<B";E@TXL\B!Q(9QR+P'+W[G!M>Y
MO:R:/\/D;&N./\@18I>[M,W$0;.\"2Q=R>)Q+7GIS:(/2#!@#K8H@ W=522
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M$&"+F!M[/_HEV 9HP!X+,[]'MRT0#W/<QA7L=O!' WW NN1N>*^XW'2Y-NA
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MDL8Y,W+MP>8X<,7PQ5W_ (B1=<$U=FKO>P3Z?.W3OTBXL[GES+.S.\-ROST
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MYQ2>=BD4*-'C<F]K%<#DCD"]@6TM(<DDFP(_;CH7[$.<F+D $B."(#=9+/U
M83SBOE(4DF]_5L03OON:H5?(X\T3U"0'X(>29 Z!H#@O\S$'$8N'Y9@;$MR
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M5UDSN8\B&CS-C#%H$MC%V OR;RYY//<6>W#E  VJSM1!L$FP?[M#^?%>![2
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MRF-><"3 FLI=#R&'IB'^(^+]$RM?0,[F:U&A3S%$E5"LEQ42 Y:H5$_T@!@
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M;/T+.TF6X&,?+SY^$%OGT,'#JC>XOR0*!H[FC5_Q&_'M5="_/)/,!H<FT$F
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MHYK+U$5*!2HAD)*2HA0$J!+@\ OCDU',9?.TJ=7)UDU:*F*%I/Q@\I,LP,3
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M%.5<JW*"-X*$J9*5!/YA&Y(+APXZ_;O2DCXF-0Z_[N=WID^?.B:*[@Y_!8)
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M:FF^+<UFLSJ'XO\ %5_&PI4U5*PS>9IK5EZV6"4J55R]*K413KU$[D4P%J)
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MV<HY&C5SF9JTZ65R^6JU:ZZJDI9#.% J(<$.]X9GN/HKYG+92FO,9BJJFE!
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MB!W%^'Q16CT)[:Z=]2K 0$_E'=!(-^I0394E*@5'ZE^FR2">WBI"5,I2$D?
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M&KEQ]']_,YCL.\H)BPLGA)4J9#'XV+D"ZS/@:FQ;#,M4B%%=>F8K'8I^2\R
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M=G]KV/R>E9/Y?;:XH^.Z><9 N,6+[\]E)PCMJ2F!MAD916WZB9?N?SFWM O
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M4_)[UWD2C*CKRR!'6OL>7G#^F_%'4/3-[O*UO];JOJV-T.#[%ES,=7BD:!5
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M@X##(?I@I*O3->N;(!0;'Z #0 #@J#\(@!&@#P #D !7@-.IRGFGGZ-_F%&
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M_HW_SXHH'"#J, %&N,A"$'!'1J"3$]0>!#S1.EGGC$CX;RPWF,WWE?4S$WY
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MYK\[>)\MS#]Q__[$XJ_G#]]/++[]] 0(_>7,RM45%7UQ(6LAD)"8$(^U$$2
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MK\U@T64M337&02QM-8Y\]_ 96^-\YVKZU;S'[P0(&=A\)$LZ$KP-;TVL T9
M3S6S0[(K'!;U1W-D6R0HLCQ>#&F&.HXOJH1UB'+LB6DV9$?=6FMPO9RYYR_M
M#XV!1,-]#%1>::5@?62[%D$]%_]$F1J4V-QL.*$M&>5*[7"N0AK.7)E695RE
M^_RR8PX<RR@'[BY2XDV)^;9DT(OQM9G@Y\<*']]/6.C#>;=S9V\N7-53X.F\
MIRKNPST[??D9K:^4@$P6Q#\K9'BP-9$2,N#R8,57V[6R.[&1#-;O+@+4E#?H
MK+[FZC%LAZ3V<IC(4D<?19^TB+H#K+Q>RIWW2+?-J=,8:A00HWEII4?+F-L
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M/X?,?.1_/XMKQ!&!_JZ-),)A-35G<DO ;5G+7;:C7X]3Q,EF+.W3G%D@W:&
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M))OU,NB5\KN#^^:KHO.L[O.1+=9A\7;]XC=)>")\$.?(I-D@+TS7!*Y*+^O
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M=G9SR[>#1M; *)#-N7QS;_O-DO=(_ZA$C4?;%#>KM%X';>J/MF$W5><"5CA
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M4#PH*)UQCP'/ULJF,\/J\8%"=&%3A=1ID:;<U/.0SS6AT-KI<U7EIQ0>D'I
M1E@9O2E,>M$RA%:76)X"KYJ%*_/D$V1\-^X;HZPCWD(?EZ=\C_!WH(S-M,W/
ML>NO3QB3^[-CTK]$VJMC:K\DE]-%DVG4" U#S%B6F^7(4*%7INU1&0T$9JHX
MN9J_/%Y,#M#YKMC,>1.N.-*#=-X-QZ1&^D=K=-Y]RG!_IE85WJ98_O+T+"/\
MW& IS18E;+Y0)S0<%"^?QG-/]22LKJQJ_J-^#?5[U]ZBHW*J.)WER4M&[W/#
M*RRA!S5RCF!B#K1/P#W*'A+SKI?#O09!IKCH3$5'R7/]^YA% 'AGON8LT)26
MD?XHM]E[2KI-@[IIF1XY-BFM27MON;\?B %2C]*&:J>!R6R6EHS-YC"=(5%9
M[?38^U0]4G%"F5[--/O0O:75XXC!\VMNI](.94D\P.0Q4'G*3U5\7 E$>,R:
MFFHM;W40>,[Q'/7*GU-I/H0IO7H6\TF\JHK^E+Y9^F9D5#.=DK9JYM4G6#S!
M:1*DIB;\^S.J6(PQ-K256F.HS?RG0P=( @HW<JA=9A_[IWOG[8)D:YY_.5,X
M70I^[1WN '_P3QI0  K1V5\R(?3Q.!=$;N-NZQ2(]C7UQ:73/6L1<MC,>6XH
M[7I/=3;G>^9$=^*;_2,*%2UQ[UOAE@_,XWI$YPV ?80!Y_!O00($SGVLDKSF
M_']@A;"K_WFN.YH)B9F:&CI?HOC_H0D&R5WQ%FVG'[CNC:G+N<__VH]J<YF;
M<,,3>6Y3]:977WZYS+?98E4@V,-X89H6G%B%E46[AOC6(,%+$MN_^0.W5E)<
M0*2R[4(15E#A" J<XU%*BQ_V>$G(C>S7V5[Z7.-RV]V<>?^5!7$@&LN"^"T8
MRE^';8=65[VZ)CJ<]O*N"=/FOSN9H"4X::X[&[ '(V\]<VQ4-)^@GZ'1R^A4
MP31I&Q_'3^:E%H_^+C&_( >F,F9)\5L!5BID'#)DJ>L3H6=96U^SNFU:Q7OH
MQ!ODG/?$2:FA6;=_4>>'#2$IB2-0!OQ)+2-&@5/3:([Q;9F&QO3(#^*R@(M5
M( -$H,(C70Z@$G^%*T1#M!PRX;/O'SDV.-IBL:/<E>U[GT@6 '@@>>S5Q1+Y
M^ZV_G'#S=;3)4=1T:I+[JYE5_E[&J5T%DK*HZ@=U0_D)3+Z_S^*52=O<.$HZ
MG#8V@Q@%6W?.J@UUM<S-A[J7" SEM(0R;30D7#&3<XICM@S)_\!. G[O<]-X
MW,71M11S52WWK+=[LJ AJG%0F\MEH@N2>PH9^?01SUP3SY]4\HSGH<K^T@R[
M#0]BC,<@3AVZ9.MOR5JM..1J]'AD+6?\1;3*GCUSM"R<0U2B>BWW/L&HG$S#
MZ1[E,LO/WV/*91W#VVS*AR56QMJY5F(%*FZ>84I' FH/*XU4ZGH\S]'/!1T$
M9[L1(=3WMV1G=>!9M)[H9'US &HZ4YW-D6U9"?ADEVPV+ORE$_TSG>!V/6:$
MXY2LE![XL2<%R@'-:==EODRY47)[\OD).B33PIT\VL%H8%Z6^:N Z<E2@25G
ML*@0$)&#XU6VME$9M']6\>*Z*K1.@W$:EX/H'&Z[.%D@+#&+MX::$URV?+(H
MH;22,)=B[$@I[*O:J)6Q47$U9W-X62&E1I9J;Z4@W(B!+V.EW60?@\-=B-:0
MQ]A4?JKBP?Q$9M*.^II#FE2RW97\(]'[IWG%5UFF0,<%,(Q=!.V*4E0G\]AD
M!8?;-Y5VF>*(9/WVB*)LT?@8P53SJ'T!8**CNA"H=6?EW*=52;CO3Q:2W=,W
MCFL(@O,2A8EZ0HE2??<OUBW;[5%D<B-AQB5J-M[\WW[M%EG/JH9]0=0WQPSQ
M@=NR<FSCZ=5_QL$(#S>5_Z7(G;E*J$.VK:2-R5+^Y?!QAR9P=.U>%9<Q/6UU
M[P)3=$E7R6T+1*/R0R=Y3:\[!B4D9[A>H9CFZ5<@OTKM1GIEW!FSR\-W'1DY
M@6?-Y(2^G]T>>/(59I^<%RD0$5DO9K.3^.Q4'O#K@0%N/$=KOO5Z*[\UCMC'
M_>376'I,7:H_#^KZ=^*GRY018:NW&*D%E"/*(+7&5\H(P;=^5[-Z:[J5L_DD
MIM9P3:/0*4FH204N(HMZ0+PU>@!D@X+WB>@'[LZ5=GI_<IYD7KT;U*#B7_=(
M2PQXE>S2_1*?CKN?(#)4$$A6B(W.5W*H/,V_H=<;JTQ+5+\]WI_-5 OQUPA/
M"XD80ZNJLJ6MNR[ES_5?^>FC=FXKTYATU.;%4YNAJS"^6Z:#6%^<<<#Y@S\K
MG>;/,A%CBERPL/0/%:63I91Q,D&<B!ER57,ZLF9J]L<BNN;'Y+4XQZ5VH9CR
M=#R6N:*Z3GP(J]&;%5*]Y.T!_O:%>S>0JP?X&UNTN](MS^BL,FN2&U=XMAFH
M28>E\>V'JBZO+3\MA06KU  41ZZ%_W+:O?%!>_D%CG')^?B9=V*[[7TV9R<]
MG4(?3MXFS0_N:,N6LA-;+U;^/-(DE4%"L>Z4F$B]&P?6R*6,J66T7U^3R^0%
M4- P[J\RW.XNWYK5Y!>0F4>46UF4JO;/EL]KS;TM.#"?1:.9O/6+EP^P1CM#
MGI48-^P2W1O5ZEMDXFS8GS-INZ(MB-J-T @<V78'?A9!>-P?5IP O8\N!P;+
M?"SOYA69R:K7<]O4M"4&;#U+;IH8>D&MR 0T!&FE5_,Z+^D6Q$H5WP5TIP@2
M".V&5$5GLXTG36HQ2?M-:^(QP_NGI'LCI2.A5^,3'?H<?&"QC=.SW(PW!-B'
MB\L9;Y5;:D+OFKW#'%8<D5YA!7)CKQ\??+=K%'<$M9']!_3'&-MSJOP;T[=8
MP.J3RABPMHO=,RY1*^RX&9H6SLF4WOKCX8M5J;P2?#4&9/4_"PBG6232NI2-
M2VTQ5.F5$#=:+'BQ8*BK?.I-LJB'U'<UYG[XO1A?3A^@VHP19)]Z+>@-"I)K
MBOK'03:[19 T2E1CN];TUY^2,54WRWGK]US8N[K(YA"!C&\S$Q&^Q/^8H'9/
M#\/^ 3R1GN8:Q:XY<&CBEH:56D T\:;ZPF!<*\;L3T,X[#B^-ZVRN.;@W)\I
MZ]6C S\H(+?Q^DVW,W^F6X^BA=+^NB[$(90((CL;#.QC4ZXV^5?B#*HU!'_?
M+WO3_-(,]@.P9^$DP@=+L@;@!B!YGD)5>M>_+C[9SPRXS]G$O&G:JBXE>NY-
M??'E,&D7/$R\_9T_B1/(4SZ_&6NJOX9<E'7_ 9A@ZN+[RZ2'8-4/P'C&XY/(
MBZRH/B=N4/76'?&;TG8N-I-?L=/_+P4GI?>CMUNOYR7XR/5@C0_YGA_UH.XE
MP,?]"ASC6N&Y\=QN5/MT/+7P/F"_RCQ<P.34SSU@Y! A.+6+T+MDXT>2BZ]1
M6E#Z4-YVB238VR%T+7"%Z[4^*!IP3?!XM@OP(^B:\]40'#I+\G^!Y\9GJ]94
M-??F_B1(+"J$G)P9B !_V./Y8-.O3]@2,3DGIE^<(@_I+2Y'P<3G!,,-S('V
M1O_)$EH'=X_4ATL*PE3@VX5*!CN2Q#\)X:UB!8K&B!NB$A[!\L\CCR)#\AWF
M#[>WZD>N:D0C^9M+PN-\E[&X1=^BA*0U(I5$0=H21U!!_T4TRI74IT0D=:G<
M^K=?BOQC(3]B2+(H5\+REBYC B$V!B'G+RSD<4<T*YHYJR\Y*XJ,CR[VF2AF
M,^@V)!(-'PXI 0W'#(7ITZE9/ Q"A3@G82(!L;B]I7)8. R%T-IG"\AX8.?
M#J_Z-L:,TW>K=67ZM/"(SY2&+-!#J#0!"/A)8B40- '0OI00U)>&*)#)9__]
MJ.*6V%@:'#H7Q&.LX!@_\";L,'):3+/O D0V3P<:5?DDEUJ]HIPA2[DOZ<:?
MN\I4L;C1'1_:_X>^<KD'LA"1?G4\@JZ,TZ$HKY0*[T[/.S?3_)I_+BOPQ)S[
M=+;=XU21E@C?RA%XJCXW!S%X4EW]6F(,Z^YZ?VS&5Y"MQW"U<F#3&992RM)0
M3:15ORIK]BLPJQJX;*)53(.HZC=I%&JY*[.JH)9P5J3+OAPKH^$(NY6O3K+&
MW\FTXU>DS)WIR\SK,8J"%SR9-IN-1]S"'N#=N*I/WC2R9/G5<F!ESNJZS_K,
MCS^Z1Z'?F/:LZE NSFH:.]+M T!)F83\O26)^P)HR,$TU\BZN_[;)M-6JY"E
M0;I&>L2C ]?KSW:7PP![MI-9-JN)W0\D>$X%AN(-BL(OP9:W> 4+&6CA>1,_
MK51%Q?">6U4\*S*\:'0T=%_8/1Y:=06F5T/?'6#)[M^-'JR3N*+>5=F6_HD^
M1>3N[MOUF9R_S!,=11'S"[0$ _E\Q6:\8WN?%W/]N FAGN&<*V6O4[NW:&[#
MLNO<D#<J[8A,-5FJ F.XLA2\;\UH60_.51)[(T&ESYP4%<EVE;GYP$L9&]G'
MV.@/@,#4!T"!?^/_&B,SKF26>ER!/5ASQYNCQQQ!?0_(A)([!.VMG7 WU@<J
M;G4?@.@&M"T,]GW")>>Y+RYFHX>MDPR$Y58)9VE0(D,*3;!)$8(H3+F"S4RY
M8;'Q1&$OK\=I7G."ELX^^=L-_3H#QP//=8\P_ZU.W;4$?%BSZ;L&NB!XGRZ\
M(N9OO]B"#0#WP=ULL6OPUCYR&[^SD[TD]W[KVF(F1\"$G\+#"X *;Y&V@CPH
M9$V>;R&D[R9 !V:4@%_O>Y1%3XE.^8UV86_>WKI.6C/\*X!4W6=%B(*HQ"PX
MAIV>,*<XAKSPC:(9"]N5BE;SQG3A&N'5>8VF,UCH7?-I!C_N970K9A$+&5!F
MF9V0C W:(E+L9N4+)A:=,:C_##GC42Y7O'@\G UBFI^QZ9(3NXP7!.NS#70G
MB3!]SX)+Q%0*2R3!9$]!<6V=3\NE6EN42WLZ:<[N4 '5DE<.G5N]B+3@O;0R
M,NS9B 2:!9ITJ(U^Q__1[J;.MIK"-<2YV$Y8M[.S/P'"7:SG7M.TNZ>#PFK6
M+H]39@>-I&-9U6G_*=CSV!>9HO&YHF[*[,W*YI7&OM7L(7B^'*-3>)\HOU3V
M%J<I8$P86\9,3*.\*@Z:]T8EKV>?H=L3,Z*_8488]J7<&7]^G:*9,[5AL6)1
MFQ//+Y8Y9E'F4>IK@1W]YC*?U]D&.$:R#5V]-9M-COZY=1R\BO=H7WJ@0[!9
MVTX+P\V7[)AH4UU)621FIT")UYG(HZ)T >&9;$)BD'2YL'=@&FM@A*D83>Y(
MEVL^LW!IC.5CN$8A!SJ#:>'*1[@Z.3/;WP]KS@$RV60ZO/>3-A4E7%A8Z/(F
MNIGIU>3/D9ZCRU>(2%3+1(HI"I,FK^'^3\*[$7'/;28$TV;<7;S( 7;I[Z5*
MOX Z03EUA2T3J6A15*7?8#P1+,R&[OA^\A2V-)2KV[&-\'4K5U+_D> N$<^L
MS'"0^C+LE7<Z%$G!G#_9<96/4XXS:]6;=/(B3:MEF^)AP4Z3UB@V:7"5T\;@
M-%WCF F:CW<L:)<?W2U:'5B-*\E'Z=_%-XXF4R0C-\63;,2A0)N_&J:^ !KH
MWPUQ-BL>P4N.8NB6]JRFS) XV>:/4:O3/V4T*VG/F<&19^1?IXJY]+O/73G0
MM)E&7*M4;PR)O$C=:CC-1S231& O='G8?H-,&M5:5Y9I_J99*Z>2*RH]OT="
MNKE(7EF#PQ<05]MI&G%Y04(PG'9U;JQ;I]0Q<U+/G4'[YXAZ[7=\& ^-;K"8
MC@;)F-4K1,?K6Q[%Q6;@@W?;P_U-C>),PY-BJ]=)YC'PA3M[RW'U/YUDY"L,
M\0\ .]7#!X#K[;FIU]I[ R;S %5%!C&X7WU-?Z1.[0. 0O<!B*"@=?HODF/S
MGY(C.?+>/Y/C\P'H3,P@;:[^YQU'1]I N4I_=K]'>OF=> ,D:*EO_SY%-A)J
M>"H .P( K2<W&K Y'_Z1&&Y9WB3$65'9^'[@SLM"Z(L7_'T_)4I0YQ-;J7*V
M[<!=P5N>@?N[D;?5OZ3&![(Y\)E9\):D<%O$PT;+NWG4^?\A,SX/7VU 7)\J
MVH1B8!JF/P<NR47B5#H72"+)Q(<@F*)\"Y&JR'^"+VN SY(Q"Q\5IK^E:+K<
MS-EK9;M54N;9>HLKR$3.5E75:Z7],10.\STKQE&P"#O\LTEPCY\"!<D@^E9A
M*2X)_6U_>;;#RK*WQB+)6/YG)VP$T:12F@AB8N,T;NJ @# X.'<("!0BA\/B
M?PY;T8J<R+Z=V#Z,7-EWA>([0$WZD7OL>KL3>?AVW?2=J-[T; :[T4/<+F3U
MA&C:?ZYCE,(@/*9'RZ*Z_01[E&"M;IYV(4D0-4606EJ0]P$P[HSY*W<S [&D
M1,M.FPGX/OR_^1_/^I ZVTN(=MK1[X=:JYYPD.0M+Q8Z*EOC]/L#0LGETG."
M4'1057Y1E3%W\=O"9%*&Y?YQA;T8_556*.%?#=V9)5>W?*&89].L$ZZ9=!KN
M4TCYS&JR%R'%DBZ1;A8DXU@Q;+C\5<:(<Y2-1(.,E1B9X,6.DA1O%XA"D0,X
MQ4YEE)3 S[XZ5@I.16S)<-\'V#R4TZH K@$"O)ZHA/R_^1XNGNY&^\G-<88'
M0@-/5;8OINL]K93^>53L/N]:VIDF]*0:WBYG_T"#DY;V29J%:23[JF' \5J[
MOVVP7__M:Q6#L*+M$U]L60F3@0)C:ID7/U*J3$]CJV3!U"Z6;U!Z&3&$9EIB
M\$(PECNB#&JTO*5J_))QTO]H3T-SX"ZH7X=_:,4KUI*@>/LT,IT3\I?$. X9
MR7[64,H1QE:9T8-'PZ<9 I6@<MW\N:;=I\6G3P3:9UY\5RQ18$-*L^*W0J=?
M$3R/X%K"2IDCJ1H&46MG]E?Y:%KLAGJQZ?8+_(X(X-*/TY^Q]"IL])%TJJZ>
M13JGTT5FIEL,ML;+4I3B.8R9\!#^^ D5R;7-2C7/MKCE+P]63ZZ'E1=>Z>9Q
M)4]G6 3==D0E0[4T8F<[5)_-^<RZ(P\FD[W(=7Q^>KK\EHFW^\6[_'O5SXL]
M 8M^ISE9PD%S4#TU68%/CY6+BS_7*;@K>E)_I^J@!)K_<V?=6XNP"7W<-*/R
MSB&E-58\:9[I"3,'YP_-4A%/[4'H,6KI =7"TT^)H>7BG=]76:N'AXE5J./1
M%*>XP$X(\GA0#V>(Y2H'XG16!R\9O42)M??^P> <V&D_[QM0ZR EON2)Z(Y7
M]^V7&HM*K--]#\>@X'66WN 32]VKZ7DU/*#]2TKN<Y=OEO-FMO9FSU)K--4@
M;[Y:*U8#/5$]^MR>>!V-2JJ@4U;VJ_ZZX$P[@VJEF1X!DF"0AK'@H(O%$<YH
M/Q&?]ZWX?UJ1!%U,ZYFE_FW^^#2"4F%.^.^T+TFG@DC]?<B#?5# GIW39X:[
M5S9_WP9:Z_&C5&ZWIU.C*:C]EB!>MSF_SZZM$- 14-/$,$AOP/HOT_[^?IY$
M,>6]R:PU?$7RT5"?U>K4+W_](O!B[E5^L-(@__=/#[KEF+?B +?=+9A*S_"
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MVL0MGZF8#N"W)Y+]@HMB%&:.@LNSP'BH[#EJ,DM:L4-5<__2H6I,;_EB\9E
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MZ[3=]-"SM-*62FMS6&RKY^^LR>MNTROH7@I^S7] YME#(HV]WEZRXS,)^@]
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MOE>,<*;QQ6N-5FYJBFC0E<:Q(+G9!>HT!9QSMHCD[9]X'QKW IOSSXE# M*
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M5<%<$;&43ST V73;I)?KA=V45N?YJ+ YWF<Y_?%QF\:0$'%5,ZI(66S&R?Q
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M#A1'>;W>WXY+1=DP4Y(Z-=DJLSO8JH ,6&G9X,29HYAXA$&S.GC&*/SHL5X
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MC9=!=Q:2_VF,:+)JS#;+5HY4C26V-FYKUB/@4ICUE5K$#H.*M*98TS-FY.*
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M Y,X('Z W>GZN\MR&=>8O(+Q9+'H2$LPS^-G@2(\!@>9R)I,(\@\R@R'LE@
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M\[.NE3!K<U[:[U%R(#(QL4^#<RZ+RE6S@S%C(/T+7<HXRC:'FQXB@-PF_L<
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M8AHZ2^VD++XZSK'@2Z$O2BB,O-]5^T3$$M-;> -/S<47HC_-837@$[SA[!6
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MW')H5+SCP2\'?&JCMY($1=NGY])Y(A9LD5K]8"Y^V&I FHAM;QS'@GX;9$Q
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M/,-US/V$4O_8=";X*[49_F8OX7RE3S5+WO,%NF)83$KL_%BWP=-L2U:"'6U
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M=LL1M$^DDMY)*R>1)8YC!PX07Q"MZ\ YD7;*6L5 S!DZ^LN%?_> \P\7]@<
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M0(Y CD".0(Y CD".0(Y CD".0(Y CD".0(Y CD".0(Y CD".0(Y CD".0(Y
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M(I OMP]\T5GHZ<0-L4=*?FG;1E36%Q>LRA7[@UG[W5'<E&7.[0/M4O*92OO
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M$&ZYB%U73VI+>ZN8:)A*.I08HGZ"Z-Z8Z>>YLE@H3]OC3;/AJSR80$8[X>Y
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M-%MF_?,)@@=+I",,/$YGONA0%KN^9B)\EC\P>+J7']0]:WI5A_7&G<=QM(7
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M*!_S"8/H&WGB\7(H$NY WY%KZOI;RSKY[+"^S@J>9!RA,+>1B#9.^J);=SB
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M;W6!?O\6-FU8W1*/\O KJCT/V11^1^W0J?PDA<%@H5THU$+0AB8-N*B!:D"
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MH$\4*'A1D7?$.5+#!-;E=5Q>N.;I(,@9*08^U7B]W\#S$L'Q$VC=JI9AL3/
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MUU0N 6&;7(Q35X!,3JTI.1C];YR]=5!<3[<V.EBP! N0!!B<8($$@KO####
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MUJA)?DG@>[># 98@0CIF,1$ 7I,.KR69W=S[>T@ZV ?RK-?G++.@JF[S@"1
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MH<&VQ6%59J$&H%FK /8^1$FUP0;-G']_+R?W7_RA=9K7;UNPH<IVN7'CZT1
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MLSJX8P0<"P&=]W);[3Y3:>*:UU^N&BC_.OM"+S8>2W+.B5+15ZUG7$HFD\3
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M6WCP7I$9VF28!-$(5N<$#*$\,]>7&=BYH*)M57&@5*C_%<DX='RF)V\3KIN
M48)$L6F]IJC#PD>=2YB+=5:3@V9]C3ZR6G.5GG)8X&*1)R;S<BP1<%*SLCKM
M9J$O@&Y_E9"T9/J$Y(L_+:3CHZ&AMIH'6C11P",0PQWEBS6?:C4=KP;=+.1
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MBB[8FL*4 I-KM$]H[_1V.%8Y-F_&#4WCV;K"(?0DS#@ .^K0PU@I$-D8'X(
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M%062U;+?/VP6&GU)5Q01C>!X-/1^ZE'D-"]@II?#$]"<GO)>M8M?4*WU8"X
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M.,'5DHF@61I?%,'IC<&,^]3JOK3A72E=;@_94QE%JHXV>O"D]EKGZ?MSQ&E
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MR:M2QO9#" L'!EB)T:*_:H.,1X8JW<8@+0%QP:%UZ3"RZ&<E)WS(J)]J_JN
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MO,3@.], 48_EXD#N_*>RU*AR2D!%X(F.>BW$MV8QJB--V,]O0+PF_>?<G$8
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MJH8Z HI><TQ#IA45LEY \$9ARM8$-G_I7[_BCG#!./9G3MT;S;+7 E<<-6_
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M>KHO5K^:/3[N\PN)LH;*4_U94,W+Z/:<HDAYO7;M.PAK$8T$I\;'&VI]!W!
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M4@/F0M+S@6*\UW/48;L4B"]NF25J=E^NCHK \S)$K&HBPN:I:_6A[T:=9DN
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MI+NDFZ%K9NANI7N&D)(&Z<;]N3_/_7SWWC_L?5S_P+6.ZWVL=9[K6NOU&H?
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M'ZF/O*/-#S0V(B4@=.4@@=@["5-2QL3. NY#?0!2Q?%;AW=L1<6\[I61 =0
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M8[+0!I[S_@MX[G[NFS:<.#1/=:D3S7J!6[KI_>2]AW&6FG[MKF+*\TP6'V+
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MI&,- *!+%"C4D@/+O+B,=@SKZ_UPU>*.K8]C=AJ"6XG<+:5ROT^+)PAF*18
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M Q"H^HR#ZRVCE0.BB3,75;\3W0C^"TCP&3>Q\V#GM>JG07)/S=BUEOWG7)
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M[';>+'L0U\K0M-QKW,/^;N)#T7V$/W'F4('T']84 N"OMNB8W*!MC4K,9PD
M7PJQ;=<;R@<4T<[DZ=EG^/CX53,PGZ^9"RHK?F$7-5KY,FP67*]K4&RA.Q5]
M\@:L+2+;(B,D0R&*V)1KNS>CEBJ)0J_2JUU5Y6PU)\.6U/BU=4B-Z=4J@4+
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M+@AH3^=-,'R$@<+CDO*!P( '8$V?*/5-"&E^0TE<7 )$7B KAKV'9G.JT6W
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M;J5A-BO%D/HDD36=E%OR4K8-=L! *C>63#MW:V:;?,P>=[)ZCL"N"K-=!VB
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M^;TN6:J=I!POA-;6&#9?;N !?.B='UA-+/C&\\VV7/$XMB:1$PRM^ "S2Z^
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M)GW(5EJP6%;&/9B)1!3DDN]6[L++6X8"+77QI18S51^'=R<3)1<M1T_$[UM
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M6'8P_?QGN?>Q7EX8D$!*E9B&U.[TQ]R\(OQ0.^H$(T4J0U\+@4^-1EF(ZW^
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M2QVIS?;)\.>*F 9Y!R) GOVM3"HBD#5'U*<%L6=J%#*6/(R EB&'*@14%1)
M+I'^32:42 D9G@0@#@ZV)A 3B*# 33_@D?:'>JGS>DD1D"@ +(F5\-[AZCL9
M@NP5QSQ7[JUTD^R1'GVX?I56W3&CV96]1>IAK^2B@_*P2K@%1 2\SXA D@$<
MX (H@ZAS NR<6S>O\>@4(_&[Q!@6AGT(LA,<9!2$\.C4-5V*BYO[AOCJUP,(
MA@2\F]'-U@ XE%TI!2'"O@'[\)/"$*I1)&45')0$A>4]:2&4$F_#_Y*)Y>+)
M]5O8R^,/=1+>H"() <N5$4F&9?M3U"X?_;XF)\"RZKNL?&4$$)HPD<H=*67Z
MJ?=E/:L9!GLWN)8Z+/Y%YX8)JC!0F>:[??IT5%EXE3F89#M:OPD$WGPJBC[@
M9O3(!)$< !]N\Y<T?>;5A.]38PTDW!^/XB6VX6EC !%[%/+E9,G)?9"^LW(L
MGU;GN4;,(QQ+E&W @B#M*&+%+0F&Y[1TA7M^P+[0KY]E\A+BJFP^+]<([N,+
MD5R=UCS(\Y\A/U6E -? A8"]^I_P,]W^?P$X!W6?UU.LAV$HD_;N*BB>$?S9
M$H?8.18F:%^ZWO_(4/KYFW7R+V!,6.#WEGX9+\F;S5[5X6M[)<>2P?]Q\]NT
M!XI/0[](T^\LW!XA*ARJ)L[C-8"_2(F%R@YV2>/?1NUR=5XE<,+5:@F7,,N4
M%<'\L>2*T_DF!K',]\(9!';?_TE,-;9XQS:/RUEU7.I1D2U$"$J((P#ENJ5J
M@W@E7Q^>WQRC_R,*2G8. .TO^64 '\R7NN/_ +\=P^?B? SN"XTXC@<X8"$4
M[@OB#B,7N G=;[LNU!7>'SG78WY%_\ZV*[27DH.^M5.Z>_[(]<;Z_H][?*I-
M"()TS._9"F2A89Z )UN1;(M*AKU]Q?%XJD D9_Z=Z.LWSWE=/ZVZVH$V$<7J
M$_OW\HP_C((SR[QF+ EL+JQ,N+=-3F2.%ZN"VVVEL\1Z< &77BTFBIJT7G3E
M0U:Q02EE^X]DJ;:<'X7+SO+?>$\25.6[)X&8F)"_ /QBSL81),'N(&\C*O2Q
MOKADQKM0Y!:^XHTGFQ99'6T!/**9EB:_BO.G#B.-6(K6U@[[84F3V.^K2OUO
M<5756GJ8TQ=D=1T%F'J:*,IRD>0*0L%!DB_K[%.!(+M2"\TNZ\E9PR,>J'8"
M]0BLC.QG[,5PI&T#S?; \C3)5+%9E2F:[L%@!G5]Q:^2=G/X?#Q+H !Z[26Q
M+2];8_-R(QQT/?, _,ED&+:]2-S  :FNTF^S.]4@D-NL5G;77E$8[4TB[8K&
MUE]L 940%(W][M176S)=/(RSA47[7SCF[YUPXJL%K'UJ"@,O57D]1F4GBARD
M]%<<MUM-E0F=CWB<QU=)5D&S/U:H(+7$K5$N.U\C#@+ "NQ!5-5]:^@3E6Q&
M3IA_ 3:_O%13F7:G'5@/DXWF4#U(C7B9AUM_W;36&FF[$D3(3#54)E1'R93@
M&]"M^U2((H=P#YM;G#=W9%O?((@/5NF8_@40<NP\>K5<O-O>@L#3&,J%O".V
MP7PWT-(7'IO -<V#^>V&,&=[SU6D#ND(P>U3(_?U^+F%B]^!8Q=TCA41?/D0
M6MRQ'.[%^U90=^F?(E=>7E."V5K%]LH[;\%=+-&R-(DP)*LP)X"FA+LDJZHS
MUJDX$-VE@;G+%Y8VR:Q%7N<<X2BBF/]FX145XU?C),$6,4MB+Z>?<G$:;P'S
M^H:LE)RQ3N94!IY5)(:X*]!!%?.'J W-KSB6CT\<VX42._GJ1U,%'%3)E*4[
MS[Q;;?V;]):&,-(6[ >M.,B5_76U%MC .79_ 6F51'RI]JB<BAFCUL9S/):K
M!>'9LD6V8D>NFS\'I4NBB;^_4B,804D!]OR=<>]S2[A1ME:+&92]>PJ)V^&]
M?=F&9^NOFM&=VKX&KLM&%:Q?^C[!3G<++XC78E*%O-E#Q1SMHNHVF$H7RPWX
M_2G@Y6939)D9T56ZG>\2#'6XG+0,QF",-'\!JP37R?O+/Q_]\KV*QP0"T!41
M;AD VPY"-Q4T>8L*FUL6WB3BA/D,; S("<2B]?PC#DK5Q4]DZYX"5^[Z\&YM
MYG#02</LS[<'Z,ZUN13.E2QY=BR^U7HLF06[63&QDIIB01&RYX/-R<5$8@5\
MBE66W"9861?#%VRV@2U$Q!G!!#GSB#'@9DISR81.D2T"U+8&#G>9OX X%P!N
MWG@B3+94P=GOC/R=$XN5-\F?-3DH8RQ>>/5R=SS$B^C@)[,WLWS!0)%>DRX9
M1.Y6;8-JC.A6CB"GPX!HGWI9(Q24N^7N2Y?I,'P?\.4H-2C(.\>H&P6"!2=!
MF\].=RR7QBGZ%V#ZS5V;48=9EU+=2J'=E4:1GOFX=H<GNHC 2Y.ZF[.0UEG:
M4":6D$M")TZ)*D8/EY.T(<HBK +$44*^N6$YP\X5[*G&3O-"U)R':S&_T@Y4
M;REK\2J:UL19%$LM9*KV="[.*N),6?H1%%E>F4)>D0&*(^,,=8(E3N^'L53U
M7#(U_20A-O",,Q,\3@[FGSWA>D%,"XMDB]Z/]?E";%V#7T58RB)S'#S :$"&
MI</,QV+^02N'7N&]_@O&W<DP!3/M3SSU-54FA0=M7R^)#L,*V2$>9.' :8B]
MV@G_YK;X!]!R?Q &/ *)8,/=[6'!B"GV$ZW]U9-]B/%]I]MZ4C?1FW&OSC&F
MF'IW1+FJ (>I=75(A8BN).[OS)W*X7GUA+*3XWE!+3T'\F9_SJ[*\KITOBI5
M<?0LR@<YO?6/ C,/2)I>*@I/4!5#Q4&60^XR*,6S@5;8M'&7+4;%+YM)G&,D
MY6R$Y%1S(_1PAK6JGAS]KF7HGSM'J^/N>>[K1=AC_9.8SM+R9>$/3U4AW47F
MV8>A8!N/ \TVQ$IJ=.Z!L-BJDW<X1+%V^C<-;K%@EFD\9GBUB'#M53NQOB!K
MDCT,5TXPO&HS':5]<F3=$UDZ'S^44Z9M+5G'KXXH3!%QF('-!?R#D&ZZH>21
MJT5M6:)S)?3RM,[IQ)'"P'T?M-$).\#]"'V%M3?7\AZ$B]7[?>A!I9!8:)89
M-"2H5EB5F]DM*R ?:TE1U5<#K)M1KOQ<:T>%&C=I??; 7-8O.6U<X['Q$!@N
M6DG:(JS$@46%^I:[[><F%91LHW_#Z1:@AUJ&4J_?;*FM./&F!JT_,+L3I7;-
MPHK(>6-22J:DP!FW+4DE FQRU!JM?-+,"MRERR@'!NV,,2&[4[ G@,'[_7*5
MD>EM,Y^E&==$/"=#C)@^?%'<N*URQ3E\Q9"IF$2&-0K,RW)O0\/_XK?"ZT2$
M"@E36>!(T2A('(@&65.]XOT%*!!$,1^@4._[[%+<R)_P,M4AS$D'0PY>UPS#
M+K\5Q@Z"<MSEM*1H+!28:%\[5.YVE5+HL1@ 6->C*?630CR-N/UQ&I1_>GXO
M.4;T8KY]MJ\\;*@>Q9) OL/6&*DP11!WZBZ^O5KRHA.>ZFC-0DG^]N$<0 6<
M%NI#+K"@/0H$WIZ*_@9X"HY<G(EST,&[>;<$VA];J)COU?.5>\BX)_1MBPGN
M?QY%B?\9<X]S2^IO;7J6$3T5^@O>3RJ$.!,RB_T!EX+*8[M\IG&4R_3T]U_
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M%>:T5;?2,,@HOY*B6D+N)Y]54YCD2O<FG)99MY-NHZ8H/U!X>P]UB],4T+*
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M0(_-Q5E9%-?H8 L$M.4G3=JL62UQQ9U]K%LRB[W#1_)X%8GU5#*V\#&U$YO
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M2LS\INO\0WZO:JK8J#S.R'E,W#C;_.8:! HEU#A-6NN(^>W#DVGCZ+Y2[>]
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MQ8N/!*Y?#."$VL:9X1%/,E]@RN4Y4ZCPW5;>;-:J#1R')2?[?+(;RY,CA:P
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M%<*RS248NXBM?4RLC8&4(M0$X8 RUL1O;SYCFV[97*E/U!M4<; JT'R)AD
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MI5PN=E-;4RF9VRYY9Z1_*A7SD0$7RTJO/5G-@-G*)[ "-&W,\G^?O-NGU,:
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MP)\Q&=%+D]A#Y#UNR<K,A@).B5L,FXAE1!=A N)*BWZ5HTPLQ>W13F"$,6X
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MHX4&?"8,P&SH,H?_],':0.8$3[J ^XK)=7@PY+%TTVV)GRB&B18M9!LC+0.
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M$!)[%JO[LVRRXYN6FW%+5BG!P9WC187!%33"]XV6*W,WO(=/8:C3J=XW^0'
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MK9H;L3X'."78A+YV9D&>&#G,(&Q[DD9D$N>B(G/J&FMJ/,9]8LCDM9/.V.0
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M'#CK$OK*(":MEPSD1 QYW/;9T[)11!%0;N@]./!J4M[2$ZH$N90$UU\W$.&
M)8M3KHDS6FK"6GB:D!'"0AP$4H28]=YSZ@'3,Y,M.QZDZ=HQMTW4^,+T?S.Y
MO,N2FJ:9<8/!$F_DVW.)X@Q12G%R+V@Z+1#B>1,/'Y%+>AC%3B^??BH :E1;
M O,S%A4](7MP@Q<2OL#^'MS PH1'X=^QBNS NG&A?3;GB/Z]:L'I TO?=3-X
M9!1:(8HSA 3.=JL!L4")"KJM9'?LR-".HOS!I3"-/V)-5E_G(3F<(V]W\7]?
M/1Z._L>(28+F)I"+=/:T_=IDQ3)@4MF^B26\4D4LR(B=@NJ+WYUW6L*#^*UL
MTKCSYX:2QV%!>*'+IVY2F+E94!C>C>K1&:DH04DN9!,1=FYN?&'.'E3->U,P
M4$A [ELM^-*/*-^O8=EI9%%.^C  +?VG\W?7#\_"\T?'!,)?PV'9)#LN#/<9
M:LY))ZDAX&)G3 H35WKE6^>Z6R "93Z4BH=F\.'>8T).[&R C<!=:"V!_&^L
MWYJG*R]!D"(@OPZ':_N9@%'ND5&RGJ%>,DA')YZ',OCF^K<G')6LF,=A57?0
MIN)SXOD+0P9JEM72UN6 *<EA>W<M3IT$NK-D5JUA!K3:$YZ1B[=[X<_X3:U0
MB9+N =P3-SUF6<O+).$H*H-EX^USI1=_GK&/_]W%?MF;>#'%SSQ(0CA#CON'
MI'?V23O]8C/F-_GD;1^/UK\%W)>/BF]H_UG9>*,]I]AG_:[&0!CN_ UA7$+V
M!:#[.:^LQR3X_FD6&>N/B)&?YS,A3=2VVS0IE?\V[Y[D;VM_"\_8P_DMF,?<
MBG[,U^K#DNTT*A%DCTZ/^1P?,RDY1-F-$JI,8;_S+H)9A/SN-<K VHOK^A.1
M\W$1_WL/V'BV_[ZS=O#G#"AF92<\W$B^;;RRB!T07OSS7_1]X/L/^E8]#Z[]
M#J@S0$C9%N>;ZU'-"?O%WW$A 'FYW7D%+HFNE_Y5+&F^N-A"7P&BZG,SZBBP
MVQ)X1R#A"TD5+QPP%"(6;X'Y $3YK<N) WY;B8.'QVWACXRIU&'92<]8_9YB
M7AA;B[>+Y0#VGEL]+34EUJ]]9% )I90?](<_MO"XV\#2'EV5R-^=O 3-J7[0
M=QQ<"]*AEE#:AXQ#1"5&.!H[,CSL8+H!FGC%00F)#K/*AIFE$H(JN,K45"TS
M3.6H6KE53#ESII^HH8DYRZ>7X*KUK>=A&D 8$\QN&"EI9UN2TV,6]R\&=Z#!
M-I>DKQ?&ZV%%IYU5GYYGP75B"A;@ A; "81^W&77GP_C38MM\MHC.K7^OP3%
M_F^#=L>BZU>#NA8GEF_ON=[:<?8D?"/60R G_Y[;'I)%1,"5N'P;1<O [8[,
M?"^+('Y[+N\5)_ *J/PA/5>H:HV\YS<2UX6;/6S6A .GZ:E+ZP_@RRXZU"G(
M_4F *";5*9M&%T'*ZKGX1N_-NZ;/,8WT0(LO!89?QYHQF ^6=R*+]MO6;_1S
MIWZU0*-5=]SIT.U;1CR8B'CXL.<:*'7EFMZ_-\I;');\$2!P_,7LMH\M>CC'
M$4]#MR3E<T2\Q2KU]$S\BST9[-[;OPPS:JF" 9V;:LQP-9(&/8LPPW+8'*.*
M[1A.ADZ7CM2/&VQ0:2_/T/TKT*'3/'KC/95(UKM"]NC:;9$XUI*.*LACG]/#
MCTA2:2=#,_YN)!%A@0[FU8P\>ELP#PW$5VE:->U8]_=HNEZ;_O6.D3W(W:';
M4B([K0R+B4%#1MCRG? BW>7U\T]2IY9W2=5JR0I_6@]_P+4)E/-*MLWK/51&
MQ.1#6#F%&.9\]"&%@RH*,YR%![]3>//U9G68C>H+Z+_+HI& 9A)]SZ9#3W=I
M%#NL@Q)+;$5%ZL'OA"$G-;8:'*-\>7_[5C*^$J#K;5J60]"0][H59IPL$^,\
MB+1$?R3'RJ=_*CQ$=IW-N#(H^T"[G=XRWZ&D=!AUFO/^OORQ])]VJ2I,N0=C
M??"=)TVE8UXV7RTO? 46L3 <&)UBM))1O"SS& UP+U0TE;_O<5S4!:Y\[TJ\
MB>[+>/]-&>_1<P/6B=9H]A9?"FU("5>T&]%_+Y=1*',7OE&+QXI4KI_KFH!4
M;@!O,"K5<^,A$"R7D/ED$PSJ/+^VG8:&4BG.H!0#XOP2E %WAH692V:^8DU^
M\;Y&09;B_NX(_2A"<%MBD6:-_0AZ9H^S-G&W]',/G!LG U[GR37\OUC-PT;N
M:M[*SQ/IX9YIE94[>&,MA0:HJ/2*H3%BF4 .X.5(;IJ#=?%_1NIE9GA2%FH!
M?*?4;[_\"/H3$%!D$V%MHB^8U3%B/\?2="]RLR(TZ6"TB)T>DD1:P .9Y%/.
M3Y\Z6GWW,8%XMY"1WH$EVM7*VH',%COZ=@T*R6^@C8[+A_B4*2KK7C"4?C<J
M\>;GU]/24[0^O\CN+PRD.2!C(0*57>G$*ROH7FDO]E2[ULQCI176P!0,&)U0
M@!RE:3'YQLMPH8N&7]1#GA2VI# 0-1YP%_PKLN-=[]">%;*_^AFFG$4RT4%M
MYV./A-\5#*#&5J3.4;7OM4@A_DHK39QT*?_O0RZVV[,?9][\_C=72I%(.!AL
M'(4]XVLKSN<N> X4KL!M^E$J$%L$I/Y9&9%([=QH\:(!B8ZUP5;(W#B.(EQG
MQ$#])".E<.-:X]<G#V\=M[+N_IC/.-0H+C_ 4KG1NJKS9R.G[1V:R4GWZ[9Q
M!9"&H.'%4A$/^WGD IMWR\+R+]8-\'3BGI#A>C(MR,DG^4_W+E8>/'4B5T9*
M@RSDFN*V%#%V#NH"M142WX*X5GX9J7,0%'>P*2IOESMO!"C56E%3Z8_=6]W?
MMTDZ"SV+)($Y1:X2TBY,5V)L?YJ/0";$>CUV!J.V7>$&80C[4.F!XCS&<\2U
MGXFPA\T1]B1Z: YI7&"'J,J$G)POMA!%R/5S9-*V+)4I@@&9F+_;'=REHC*=
MMQ*\FAM*U XE[YNRTJ/9NM]UXL7EK)$ILX\D^RNE#.(1^)OSN+KG4&GNR%++
M5A4'JJ#/-#&L)UXCK*WY RU&W361X1!X?49BE@P1";)K&'AZTIV74?W^Z13)
M?#MX9=^P0(XUSM;?!)/,#FI#][CA;8UZN,M>I\Y-<E%FIH\16,E3/OO6:+:+
M%ENF)BZAI(#5]=L'C1Y!:\K#RWOV1(OS\&*GR_TJ-G;\ *FRCX0*ESX8R@J2
MI?1_=6Z1KJP$KTV5A0UFXB><J$EEJGAU=*NV8<79I<)$.4,=WOM6+T:-\"%!
M?C>H.(]T-ZZH3$\Y6J0)?4_J,O32^%*I36&478$U-Z-)-R4#J(TO_,GK\I'5
MGD.=Q"2CG01<OTZA</OCKG0S""$#.0=47H_"3"WNC9=;E+1@'D"H"4\HQ0H@
MH+>WPW^3G0:KRA%SN^_0)+M*H;T-=PZ[3-T*P#8(Y[50B$";ZAR-Y3L#)=-Z
MOL-8,'\3._X*".SC;_B,)7[++/_+OLDCO:T;C292[]7-]#XVT_V8GBXKL9@[
MH]5Z'X69&4F;2,4]Y/"LPQ=\JWB,@J#Z@7?:+NDP8!_CAOJ#YL/T>N[2?8L2
M22TZ(V*,A1>/ G?ZF/0'>Z4W^J8;;&R=91]RXYO-6=<<P_0CZ?G+P)^F^,K3
M'I*V>;Y6H3;73%5^3&_Z>-%*2T+\7I#(RG(4Y9]3RY&"^#_$3_MRD4:Z5YO8
M?Z&"Z*W^<++_[P@]\RS^,45C^M%$[ZXO7$-">K8VUL:*M <B>.7W-K1*"ZP1
MN5X<ND,!)J,SX;-K_P"1_6<799 M5#A3.KMARRY80*X5]8(&-E!R+X3M]V@=
M*OC,E'N_[S5[B^!]WB.RW+DA ,L ^=U[/ 1W[0](^%ULJ27#T8H-9-6,1'9V
M(2"::U<TWFMNU^)2W?@=D!Z&CO-.(,"%P%U!Y]YH8O&+"8T]=J"-]!3N+O,=
MQ7'L_N%8DH\H.J!L,K;E/&BIGYCE@!,PZ/W<ZL.#QOC!M$LG,3F'IH1 EY<=
MZ.,O6A N#%9&#E48'M3EF9FTHF?]!\ @V\Y*PBBM<<Z2M)"*P:5C#@95 ]5R
MPU5K+#9-DS_L&1A+7@4IG_BW _%L=./4XTR6D_J_HILFE0'6NAB*E,]2#I_H
M)-S4'FV=,AY7^RVM/BVHF9V;_J@E$ KUVCR>_^L]F;<@$#KP"NA>"C;TS'7Y
M30,A6=( +AS7>NX'"B J*D).[B]FO&*K,+ NY5'54$_S%!U8]D=-#G\RUB-#
MDPI,<XR47P-]' _!_"O2>\"EC-R)84Y><W:)G2U[2N7;:67VX7[)O,1BQ7=]
M5(F1'=&.7JEQ5 TA-%FNA&[0MA2G$1',Y0XW'7M_'SN>BY?$2VG)3<V5*)?*
M>])_*L6?!8+[RO,)!*6VR"(A-S5S?$1C8=#M;>"O*J*(:5:I*&->D&$A<R];
MV ;^S/1FZH9JFR[S>B=HHP 9=Y$\KE#T6NO6% .)A,<MZCTH6L<KD.$$K[Q1
M([JI%/X@\P_AU:4F. ? -S9T>6/>AA1VSH&UL<4C#<VZHMT._1?4K2T#U%"]
M*3@DJN69$TB(#I8A(ZNR1LFE7SX#%^W<<I:JW5<,.>9"FF>@[7#-;:W+<V36
MK^+'P-$DV^)Q7V=609P["\1\$8>.R6Q64NC4:\H1"3MIF_5K=2 7.R1ZK$8A
M#HN6@R7:M,4W58&E7YX[7C/C %DB!I1B5%)C0<:YP@FXT2-@ 2G(2-%Y!=Y%
M,A;O/I1>@#$,0<+C0HY&M,J_:W<-?)>=7H$"@0ZKRH_KE6SV);J4I87;;*QI
M(D[1/"G#O0IA,NMTI(W>734-IK-22LE5QF&I#TP7,V4Z"TF@1).Y44,2XEIX
M5\Q,1SOT:?LR>O#G9AXE( 4AQ&Z5VX+3R4M+W4P'52O/K:CHC=0[^VE),>IA
MJ+ ,?Z&Z1.;[8I,A%:'WYA_M5K[9ZWJ>6U4=[14F1_)LIHD^S-KRQ)C<)A%V
M,L4VHN*"2S/@\)7JCJJ5'IU6.I4#3P#Z1HP1J>0-DB2!B]1RR4_/<0PBFR<I
M+BU='K6[4#VII1Y;R\+EOW66>(E\]N41??0E:]QCC2@@LLJIAHB2/MK2)DI*
M>/3F"<F[\ 6"%H=LV!:(+V#270EP< U;__$X@78;=,B';\EH :\IH](4\[Q(
M;OE+-4"N+]QH\V$9XQ4@OSA.KET*+"9N^HF\/4UO,:<]^P%[*.9'XOF,#NK\
MKS6)\@.R4O\@Y)'0Z'L=0A41FCZHHY')+I_P>5!_HZK)7?)<RX-JKJ@L<S?%
MV(6L<;O]5^$ *[]P_-UP3KM&C,-ZTV>CE0$3A^X!L7SGML_+'$CJ?WX=J.*
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M<=94O79^^ZX&B6IH0M0Y![74A136X+$)CQ,80F>(1PBEX7A*CUF'V1;V[2N
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MU(MO0246R@TZ$UBW/&NLJZ9;2717:N(=ZPP%I-\H?:8Z+3TCVY.DRD* I^K
M"5P%DB8&NWYW3/%V'Y#9XTN#W$$$N*" W!BRF33 8IOE5C27&GQXG1G$IHDU
M0#8 138[>C%HY/X'V<P2'[=?@8]W0L(23+42L >-\76.KZN7]3_-%AXAU/N:
M^$VA&]_^O'UNX7+64)X3)S9)OT*_A41A+]L3XXGB># QWV=:6WMO>W^AH6,
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M1P,1Z61.=&_8*8(]BC)IOC9M,45(P/01=-4EY.YMJ*]+I!.?]V+=C6G65::
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M-U>P#QB81=N>7HS&"R'7^67Y')B !2Y5^$.D"+/<TL7#\/UW_&]R4HJ9UD+
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M.+Z+R?SS21C,>G\]^=M/__YO/_Y'K_<S(HC" +E@N@:W]X,OX/?KT0,8$!9
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M,LR\]^F^1WK-T;6EGP'AC8FWSP$9B4S<X>R9H?2\S.S! .*\C1!QA.+AW5N
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M?HFM.D-2/#VVL^!V.Y"-0WMQD#*1\',I'EW%\@7V-H*<13?2_/1_4$L#!!0
M   ( "M)?U8)4=2XDPT  *?#   5    <W)Z;BTR,#(R,3(S,5]C86PN>&UL
M[5UM;^,V$OY^P/T'7^ZSX[Q<>TW0;>&\+0QD8\-.VMX=#@M%HF/>RI)+2DF\
MA_[W#BG9D27Q378D*EF@Z":*9C0/GQ%?AC/4CS\_S_W.(R(4A\&'O</]@[T.
M"MS0P\'#A[TXFG9_V/OYI[_^Y<>_=;L?48"($R&O<[_L7%P-;CJ_G8VO.X.
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M1W1L^9JTW/8PL'=0UG#HJ]EFZQ$SGR<Q_6BY2] Q2&HVJA]$6WFU=A'8/J.
M3-PPU"CP1YC/-765!FT;@[0Y@)(BPP6=(V$<OD(OODLP*>[%R[3R5U*KIEG
MV-?-TS)*O5(@W9A939L#M-YY_(;"Z0SFW<$KPMX4P<DRGU-JT^]0[SFY3;,0
M>A^J[,$+ZK4I7:<H'1#&+G/[1OY9UT"F[W,M@=_'(!1Z]MYT;!.5&VMMR7M)
MT1\Y['EN7_7LI>JUJ/$RH'H^4%[RN-5-"09[,V!EAK+0]Q0//JIM&;I8&2Y0
ML=$GQC(R@#":P< )7Q$Y2+:[9)&U;0C2M9?.[J+D1TOI*\V8N1EJ=?O3D95?
MIU5>NQ6]F:7<B$FHN5W'D'&FC=5%DSFECLG$N%E$C^E#NWFCF07#F)&BG2'"
M@+&AJ4'!Q'F[\4';X*Z[[39:Y[ZX]MY7BY+"K+#ID1T&76Y0K+YP"1MH*=P_
MU/7S#RVJV-V;-]O1=[2Q,+'!T+;18*W3S^2VJ<7]35F_$W;K"%NO17W311T9
M&=7TS^]U!!)4-S;7UU*JM!4CNTZ!.:#-AE38K.&[31@*.$?!WGVZGFM-?NM:
MMN#KL?T 1T:$5@?R>$K_6GYT^=7+Z+UY@ZO.AA_0 VYC LP74(O,LEL]9+5/
M?4ZVQ:IG@M3U+7T3YYIS>O\]01C#=[VWPN6IJ1U2K5$#(."G*Q2C29C5&EB*
M36D4>-T#1LA/8(L8A2NGP>]/=PA.'EY$K$=YEN#ENMH(^L1S<CN9(')Q@;9^
MWQ2M*3FTC,DZ:]1V#1V[[?;V;85FC*PW=7@3MT#%\[!?2KCZ9[71=5A!&&=?
M@G#^957FBQ=%'Z60. $.97P"B6PXI4AI:VW$@7\3<W$2?PK0Q,NC3*-PC+8U
MB9K,O3 V(^FJZ5:"TC8^S='\!6&=4FZWVT;$&4B#_?P%?5I#UR@HL_4VXL9)
M-M Z;LH&J5#0.\.8SD8/T-361]!;AN( !>5GB#3-(W=H%%;B;WTA(G%/"=['
MD9:$I,C_/$U>OP0H_$*F.?(/.M\5G0*%X_*CE6\!$G2?H7E:-AQY+RBBGQO+
MJHP/#RY7U)B0=@#?#<BW[R)ORA%OJPS(<[&GJ@'>E@RZ2MG6JM<T'*@3G,SK
M\+02(A$*GZ<@3K(H5KR/'Q(,FXB?/QX:9+D4_"Y,?2]Z1#A,@COXG:Q#[)4?
M'QX>]XE]"1"V)HX,:J*8!T9H&J89L6)\\^:(HP1641#[M$_\\S&PJ3\V3OTU
M(,!DHQF@MW^@I9#[G;(@^%G_R&>"8+-_8IS]NS!"^!H.05,X+0FYWRH)0O=J
MTN="8/-^:ISWISD<#C:N# +>MTJ"T)?]XYT!@<W[F7'>;^<(3\-X^@M.?F2S
ME;NHD']FC?'AT4'_]"" PM;'N7E]O-'[<\I?L1L0*V.O.(A_V$--<'"PU7!A
M7 W/WMM] $CH[1?Y^K>\"INI"TZ=\>%Q#X>&$ Q;*R9/8850@R# 19X#\A^"
MY%"H$49Y -##X<$%PCFI'5A0Q5%-51P!@J/WH(H5$(XJ3)Z:MR2ZAG\.\7/R
M(U91Q*8T2-^K$[,0!D<)Y@_,*WFHN_ 0/^+D-2RR"TDUL5,%<)ST5AU,+!R=
MF#])KX1Z3-+,B_Y7N+A. B6-;%4 ##TT:/"1<+1A\F1-!ND (T_ ?[4(R-DK
M*\:^[!R.39ZB24*RZ'&6Q$BX4]TM!O*>]XEKMOP<OLV?GLFU.5ZLO,/IY'=-
MO.3P4CK5"&N.#T]ZN$E5@,11E,EC];:!_9_(P^KW"NO2X\/#7FU5A3 X2C!Y
MJ&9@H-X)ZM=]M#C -:.&BIN#/O+9TA=WNS_Y29RAM^RV<!S[^6.*ID4<1_GW
M*$E1\//'#.>(J[+F)^Z)E[Y0)O+TT]3S%H7>4)2EY6\V"ES]8KP.A;N.O+3,
MF#AX"UEC25H'R#"SR M\!:2JK:II2ZV*<#BW=<U/XTW45!7M9LOUA*&?_<*
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MHD3P7DT[ A <7\MR,_UEV^==MQ=\C2<A+%A;UKRJF%DV2CAJ,7LWDW<_XX9
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MJXZPGV;< CM2;JME0%Y+SSJK<;LOJ\&0'9I]ER;3):^X!PC-T_*@RCO/"ZJ
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M ^1>M &W?>_RF*14DN[==#92\FV[#PIN.+7:&9]UO \6=RS0:!;&>9)SM/*
MTI2\ZW5X]!5*SJIW:*18X^'>\KO HM6T-@U4WF38:V')!4\=,4S9U8)"[?'9
M@9G]I?#2H*-N4$&HT=QO*1A9B[G_[,#,L;R6N5]=:34-^12="WGEWI.-]>S
M]DLF$H5W;%JE?+C@V_+..IG[AGQ+O4UFR*]UNC5C13P[<,D77/-85[0B4@XT
M.*V8NVDY.W3)>F1>2P(6S+WTU\K8>W;HDM'&O(9X%+C@C"'>I;+/E=]R@F$X
M*7]N?LY7;!^8M>KFWM%!KA8;+CA9Z#5/=&8M @U9O0YTU#Q4T")QHS!L+K[R
M(O*+IQF"J369+Y(8UK5T0]@C3N (GBT'<7#[1QXNR+)'$P42ZW"'QN%2CD<0
M-ZL*HV(1EE<>GQUU>Y2OF 9OT (COUCDX-\1HJ,C#E:7#/3W7 0BYW%-GP!N
MK(Y>5>VQAZQ>%EPPWG)%A''99!! -0!GU1V@G8KER%RPN'*EI,%/311'*\(B
M8M71S9#J*MA<L+SN+XA[$LMN352; -!FC.G"JY-V:JR'3>.E2;>F42ZXJZ7"
M(TL*M8$?,^>N6A<I-;59;V#O@G4A9H\/4^7A'H7:,'9L/89;6R$U];D+TH7X
MND[TZ<K%0C>*E=T6Z+!Q/G@OZZ^+;9S[)4%&JQXHRN.#8:[DH7'!7'F78^ R
MQP@PW85OY%]\^[.\$@"S>J734$VJP%RP$1(K3IXA+!]*DAH R<V3A9JNA*AT
MQ"ZUUM0#2?$^2Z+@?K[ R2O=!LL'EZ 68+.:':*EQJ3([":^H^*E@R ("P'N
MXTF"YYX=9UEB2T;HH7@L(/5QN%B!E!I#)37'9Z<Z\LX-H2, -?&4?HC:NX>3
MV[=%2!YV>N"\5*%8$T2T>N.LQ"!CG5=%YH*1<832#(?D);EK+YTI!13PJ@ H
MJ\;%!NI2@^2"5;$ M]VSR+.<PPFYC<*>+]*8O#( M;I?:Z$[57 NF!>WI21O
M.,;"IWR8Y0&.U>#8%KH2X''![C? R!M.1LB+;M.,9$]>[7-$EV^<*N.S$ZOG
MU!9*$D-RP8['!B<SS MJ 30+80RM)ST!%HVV]VYM>A13.7/G7D2F<HG!G5<%
M"'0@.Y%<5?Q#$A>4"YFD6!)*C:[\2D"&H65-V78NYEQ=3U5 +ACW#&C*%:NX
M?I7)+. ZGKBX)4\V_Q-Y6.+CNUL.Y+/JHB/K[(S#,!N".;M<BK/*D("?-L,!
M?A@_D1T-=3Q R11[BUGH>Q%G?1&6!QP.O$16<W%10&0NB9!,,\76I"H5=XX2
ME@<<MD+.%/AE*$0,1$?R'_L*L;U>Z->,-$%:<]-"BOS/T^3U2YHM<*$A\J^*
M=N"G\?6 I8?B+R"?E4@0A>Z\PW)57DF.'L-F_^LD B))6%;A+?H0^L0Z,9AB
M1#N-(Q<"ZTZL<@>P7WA\=J%C _.4^SXL/5>P[@1?PPBE61*C1V])KW)XNQEA
M)1#,JO681Q5C2Z. 0X-IG\/\]P7('F>KS_&HWBX%,EFU&-;@EB6XP6=)TC0A
MCN(H($]ZDRO),)ZR'Z<1EA^?V<VL58-@,01S[W<\8R].X=1 ?>]A:N51O%L.
MY+(;4Z1.+5MT#89M#J7?R"OSDSP.R'9_>^",D(_"U\WJM\NR0E6 V9<^K8S&
M!>/U&I?4D7RKX/CLW(*[N)H21!+WUA ]0C28Z-'#V;(RLB6V:$$M8,[,E5 ]
MIV^6CIC:E$)QP0C-$5)JW136 U9L9Y^7DE]+9U58+ABDC6G-MIG!M/JT&J=;
MJ[$:5/Q OB"?'WE5@!4S1CM#DZ,8AQ-NIRP1I2.,7PF0&;(I*4^*8M+5%54%
MY$32? .J<F4FU*\SJ>&U6\^\@>\G>9REQ4F#S!M2UVY>%9APK'KBR\8*6UMB
M--J-XPV]7!%P,1O$P0UZ15%"O=4'Y,GU*9WORSO-Y^0186+=O4OP,)LAG"J%
M?&II'_@R8P$U=C[0!MJ)[/PM\"C%&VII'P:B(7-8C:.)-KUK[UB[1#F1T;\W
M'<N5/4-_>IAT+Z(C=Z/L9I(8\J]"6=I-]3: .:O! !K'/\-87)\)CFK+K9KI
M<+0=^5R)3&M[$7U>[XS%&1OEM2OT@/55[)JJ(;[U<(R"4;+T(I+);1@/_%F(
MBI##X61=@WMEK:EY .O:7<KY?O8[_8C-78-7Q-R2X&F!_' 2HJV9(PY&:$IR
M@R5X64OG39L&]*Y=6BKHNQU:%Z+DV"N'/,Y*6 _@V7WT1$F9-:"8N^073QYZ
M)U_!S..:(U&SN58,T(5XN:97V><'9BS)=:^R!<.();'&J^S>'$ [-'^='[AW
M/5[HW:#YBX)VP]VA#T:*\X/W8?VB:C=IFZ!$N>&@T9-^];Z,7UUT,)GQJY9/
M"<_=^?KIKK2 Q,&0?F)C"A';O%3J HYW8.NBHYVQP51GP%RLXTU(<JN\Y!D*
MKL+D*7]9AZFM)1&K4;D!0&+U-0NSNJQ)@PX7%%[P1^81P^.>Y50R'"75QF>7
M5H,4S&I/";P3OBCZ_5[/77@ULL[&7@+%";<30RZ4ERX[OI[S7]!3@.6()XHA
MM;FS?36C/^E-JXZ(FG*65EO(ULNMU62<"CU?L!Y5,9ASEI!$FH_($BM(PK#^
M.\!QST6*L90PA-;A']"<7$&'WBH!LAHZ#BGE3MCAC$-J553)W;Q#M-J>H)OP
M*YUT-82-2'C^ZKV%\WPN9'JK#,AMQ8F6V3WW&6;(RN&VW(D9]B_AK!^NN)EP
MQ'M0<#J151V?'VEQSR(OE0XGOWGDJ$C<H!<Y'"-)<@"N,Q:W!HAD]?)2C3+&
M?D(&R85<QT]9XO]^GZ8Y"FYR\APMG./#)*!/UGY#/^A?Q$Y,"O4!KF4S1GT-
M-@!H+B?#=3*?)S$5Y3G)O.AQU9&$60.$E4!BRW;!IH-*CLJ<+\=J*#^$WDL8
MA<PDN,QRX_-CJ[YNC=EF W'"SV+]4!=OL;Y:;OU%^8FZ&NT!;V;.N4*OC5;3
M67.8O77U(/<"81!Z>$E>*AY.Z.0AL=URZP 79AQU&CY35U^-['XAQNN"-T9%
ML&_>'/Y9QU8HKPQ ;;]3)U$"1W.*R%QP?.A A;9-"AWH4JN/@9X31.5L4]TE
M/\T\+#\^""L#8*MNXZW/#@KHQ(X&AFT=5$B2\PSAE#Q:E2T=L7*T#J8YZ_HH
MW=#S]]C,2:RVY^^9LN<OD5CC=M!\(F7UVY3S8P<];H\9%U9[0AL+-M%J]3\_
M=N,RA5(F-O9348T]D:2;5=L;GR;TRG8R&DP*VJ]2SH^=N$JAG5-VE4)E-78$
MEU$+Y$BIK989GYMZ[40/M?NRNG L)HYVPTG%)T]BV6"6'Y\;>NM.\[*G ,*%
M<VY%L'00!]] E,UOJE8:>5JD>BT!9X;NRI2-& +5L'79"*(+)U^K6K:]W'>I
M;K<R/&Y?ZP[QB+SF(YETN76 *3.G/T,3KP2($TD>F3)*S8N"6K#8VYY5);S7
M4%85DA/.]4;4Y<KT:$)O!I,]EJ_L!"@L5 ?_V&@,?A@_H*D7W<89L1.RYSQ&
M*9#:O4RVC%F.*[JQYXSX1!<B<,?!;A& 8^NI2"YK^^3N2ZP]S:$19FU/)RTH
MELX6M2P!',>87_+I%,4S%,Z?D)_CD.1!>HA\<<R L!+,CU:\_MB]=-<:H":]
MP?QW#V'L)U'\Z.'?Q23O%81^8R6Z5YE8CL3FO-IK[%6^(B_-,5U$[N-%GBDD
M N%5@2YBYF+3T,Y?C,.<+WQ+[4@WDOQ*T.\,);E2WO:+25=75!60Q+6^MZJR
MO4:;TYEL"3_2$<%^'25I&$^)"PKUI?V69%<H2GX<'AT</"),_14D^5256P J
MK#J$RX8(8U6J"XZC*1UY'KFB'+36U%X+ ,:JY[).37' <32EV6^_]%,GOPHS
M@J?P ^*J2%X5Q+?RHFT]'Y)Z:#C*Z#8@O2(M369!@SV&>99F7DR>AA29I215
M :75YRSJ^?VHH>'HK-MX@#)OY,I]DL3E$#^WZR1E/KZK4@V8<2Y#,5]7<B0<
M/77LC$^F7U[<TGXAD-RYK,$"/[D=N3F,V_.;SPE:^($ZGQ91;?=QY=)-I),:
MS0#Z'JQ,S9%Q]&K-F?X&K1-?;?F,JZF35QNP.I?D64F+8D <Y>G(S%?N;8:3
MC0\UUP=>4@.$=2YG,V=W)P/!85Q')KVM\,]R=U^??DEU@&$U(V(#72@AXCBW
M=GQ=O]EDTOVEVNZ:%@44_=Q-5Z3GZ$"+H2"9DQ3W-'X#MH><L 1>41#/JI&F
MWO&2+3V'W&[3TG%2"!0#L462A9T&QN?G/3JNU,'$T6*W1H'*_H*$484@ ^UO
MQ1./*!C6WT?+VQF?G_3I^%,?&D>UW=H.*A-S=>.OMA!5:P FJUDU&J]'^R X
MBBFWI(:#$BNBE>ESWDM4XH4#WJJ*MDQ)5<#BW.1T4<^I;@^-N=>YKO(4Q$Q3
MZ-HO84Q[[SVAS(O*'LZ==6K5!QS.[8GWM=( DKGT2@/XRAP%Y4=Y&M@I-CZ_
MM)KDM ;13,G-I4EB#C5Q[Q94 6F=,R9R>):B<")S4E?'D4OGK(?\U:$.)A=R
M&JUW17% .UE:6<F^>AGQ1US>  $"-:HV :"=,W[Q%5D/E88 SCISX @%:$Z_
M1LUSF]R0J[]SEYYFK0'&OFP%V@!T(>*S]K6FW8<]:DZ..W*;>]IHI>!O2598
MKV$*AN\F^#G9] 7.M%:K/N!P[J#.&1GU()E[LTAK2M\+N^\#-)Z8]D$8?%-H
M]<V-FJ^3N+"!K%(1;,;EDX]B#WK%,)8-C9JM <@>[.): ]01"*E/B\\_$HU:
MA-8 I'-WR?JTN ;HQ"-$S)W,[1O"?KBZE=W?QQP*-@V-V@,^>K#STP#1B0>,
M&F=^.W<D\YOH7+POL<[,;Y8>YRX2'9)KXR2FB2@DV8!%]8 ^!Q_@.9>KE _&
MW*M'-92U(YXT.HA9'O 8VFFJ9_65\\U6E "0N9>3;"C(E<@M_9J2!E]W:Z6H
M7*M*<Q+ME04\5NWP@N' V5:P$>@(597'^QQ*(K#V2H)P5DU"RO0*Y=<17"HG
M]TB9W*-2N$NK5]6-R=V27T?TIVOIK\X=? >7OW>2 -$1].EB/J4+VW'P$MYK
M**L*24?DIYOJ<F5'94)OTFAX'2X,C_E+%/JET4&\W+#*@J!6G7&E?9^Q[/!Q
MZ(CPY!&-PU>8?1\CSZ=3L"+EPEH@M-4;ZT;D*R#2$<#)4\/]XZTB]7LE87/2
MO[[.02&)V.S>[;5[#U<FG0\*WJ[BBN,++9G&F!^AOPPGH>]QG.]5JX*05B\F
M52B47E(*D+GPY"A36)GEG%\)@)DYV@FMZ/45I8I$HW7=@8ULXX/AQ:&9-:76
MP5"JJYJ'1 K*V(LB5@\=%X?NGA$I[?7/&A22"QZ[1K3E_A&QN=ID1T0M.^:V
M)\2+0ZOF=&G/5STA4ASF'&E;G4PN#JVZ033BF(/"!2_7+KW.+P[=.\,K;?#J
M(73A(1-'7)8.K=Y_:=[1J\%U]CT331&B%X=6W:PUZW0/F1//G8CFFX83\?C"
MU%O8-B?? I7$U;>+UW:OB/OX5LZ2R(M=B6\G[K5[ E8>;;I:;HJL<@X.?G@X
M4+$0MF]\?''6[>BB\KS(17[9%?GV;1$6Z2^XB5ZU?V-\<6(W5%:3?MEC6S--
M+MA"&Q-&_^]7E&;K4%71ADSG9\87=C-"=]#'M#)E+FW!=11.)EN?Y-]\[)8$
MV=[A3"$$ZX+=]<F?H2"G69)D!*0\!J1!!KJ^,;XP]%:W.#[![/C62X[&RYJ.
MTV7#CO.;-Y<]7E,M!JNF&1-_/5\]S0ID]I)]V"[D?"BEDEK^MPL" $.6-.6K
MF7T^Q;Q7!7?AC>T6S+MRS=)<!;++E%HF:,Y6YOE'\CQ+\A0.ZL\_8)@NAS$J
M7HL <<16?X6J@,+J-0"K6S,V+LI(S.5?J(AP%TXRA.*U )* !GE-F'"MAI+7
MUX(0B NFVZ?\)0V#T,/+2NI-62PCKP[LDLWX/KFWODLX<,*L6WV5 'KM5B)[
MZ3HDKPST&#+-JP=&BK7 49TB,B>>MNY AZ[L+PPJ4^][UYR5[W:^B)(E0EMO
M5,EW'Y)JL,K8S?.D.%H8ZZ 2,B?2+VQ)*HUK990&#NRF1VFD)2D@<RD74IQ5
M% ,_;90"/XQ'9(7F;$.V_@YSPWLW*3#PFLNNH*(7P7RV50+ &#HT23<(#,XX
MI%9%-9<303>MMM?L)OQVD<E PO-7[XTD@!(RO54&Y+:R^C*[YS[##%F=>$:[
MF-"6TI?-M\I!-S)C971G*A?@=N)-[>:0-XCB0-G6:>)SL*LTE*=!^53*T&[#
MJ^+&^)W(\_!.>I/MM=:9;B4-F]>1['*$T@R'?H:"XOQ/)!H]#<1G:&$E$-UN
MJEACHYQQYE9@PHF<%2OO"LG^H%(*.KP+>5ZZV!WLH7;B2?.55-)I>*L<]#A#
MKE[*J_$>FT+2JV([\2IY8]I=6;::\B]=;72$X)&OHD"\N%3+@&!6[7R,7LI8
M!/8EUO&,.(?"[_&K HG;I: C6$VFID8C2V8=[W;+L],]8X^$&]R$ZU>HN7Z9
MHDKC"\N/#AMTT93CUO%*MT,/0UY8?JC8J%.E$+2.Q[_M^=D/J>#5**)ON>2"
M2?NW@$>[EXAN>MR+Z=+^M'F*_,_3Y/5+@,*BQ\$_-AT-?AC?QEF8+0LAAI/R
M6HYU0A*4!NGMODQC1-E2P#I>07=IEB@"#^YC'R,H?(.*__Z&2$PB"@:O"'M3
MM!4CW,V,4E^N\87E9\7[,OLTI=:=-^H+3,16=?M&N! _9<&J (C<MM:UZRP"
MS$Z\45_9B%U[BS#SHF(_-D(IPJ\HN$OP79[E&)$-&@E,5MO)JK4%1ZR_QAZW
M#AU.O&_?=I(K)ZWT?A5 ^YQD)$P]PV&<AOZO7I2;7+Y4/@]LO\-M4_<,<OIK
MMX%.C0.]5W +"]K.ROL+R0M!\N[<>2%6ZK+F)0"=O^?ELDL2.1VWVSBQQGP6
M[T/<QVF&<WK]-,QF"#_/O'B+BZWAJ]R/.Q<(-&+50.SH9*R!4TXO[S8+W-KA
M&#8^Y!E&)A_?DI7]G4)/*9CJWZ^3E+QI^T^4C9"?3./P3Z%=U=@W@==WF BA
M(]HXW;%;([TQC,4PA(W]ZE>DG"C+2K>"@ ;LOLS;SXXKX)+3FW6\705?]0$_
M[%^&$W+5E>1Q!IP W]$-"G(:Z<&.EE"M#!#LQK"8NRVL@9^36L,QSTD>%32Z
M*@G6.?MOT/I2=! 'SPB;2:ZF\%DX'+[#WM4=<YQ^:3WIX%,^GWMXN0H^*[:A
M QA0K[!1A3F2%/?B9;IC^+3P*$G[#F!BY%1ZUT5OKZIL7&B?]]Y2S']VU!!=
M3J0K[%?ZLG,S&V3CZ<L$?4LO.6Z]-2,+LX2M_NJ=3E%L\78IP/F^',_/V<&:
M+-3&$AZJ*XKK^,PL!V(;VF6JA1RS2!1R717;6%8_DVS;=C-O2[O6AUZL;\I6
MUW1DH!O?E.U]"Y:=WGL9FMN4<>AR(3FAQOVF??\TL;N4W7=&W>ZAM4ATX3&A
MMH#I3?#:H^$7G*1&SOC\KX$V>W]U9*X_<@ESX<6CMN#N$CQ!(7'W6B,TV/<8
M7P,J>W_[8Z[O<0ES(FEGZZU(^9I%%WV/\36@LO>!:29WBAS"W,@JVMC^P)S6
M36T8]4D!^YV_\B*MFT@WTJJV1<U8'VSUY)JB@!;^RNN^$39U9)6UWZ<9ZXZM
M/EU3%-#"7WD_881-)Q+S:C2Z6;),*4H G/]M.]5#HKFDQ1T&H/!M<2-$% J_
MOT[B#'M^EGL1\1,ZDG7B;J497QZ\=U.K#4+-97YNW;GI;]-!GLT23/QDO\<@
MVZ[?U]9XI1EN*V-[18ZQ#M^YA*"SWD=GU1T$EDB6Y.ZV[Q\Y2KW2+_)OY\?=
M7G;9=6K:7KFA71Z8B4PV[89&M6K:#8V2H]$-K5M#5+-,Z9>'[\HEK5 ALY\P
M<!OS'NS$UN).:NO+0T-F[8:)TJER=5M 9/B=>-+Y?70FVYZ SO0JF4MA+4M$
M=VG2+]?V:C?/*HW'^*XGJ!H3QMQ!C3BI7QZ:\7MV9T? 16W,@]*8V_3EH:VD
MZ%P2A5Q7Q3;F]V>2;=M+4UO:92M*3US?I.E+UN'XYIS7Z\H ]/?]NEQT#.^6
MQEX[SZE#;ITWS+)XT&/^[O,=,-P/?SY-R:C<'!0U902]]3WNW,K(:$1S/SP%
M-7'B0.\'UOM^6^E YRY8E'@$VKN.7!_1=P;A($WS>8'G.]1[3F[3+)Q7!^5P
MLL+[]_7E7K<[<<QBS!-YK<R*NDD2<F()^S6)H)D(^OH(U&Z",/6O Z-]]QZB
M?4+S5%270!=N.+6"'87I[W<8H?LX0QBFW2Y[*NO;0+/;1G-W^BF?OEY<Z#89
MDC?A:QC RFUC/JU^&VCN_7F^X]ETGSXG;HK[Y;9T;&9N-.ZV).AK>LG1Z+;4
M09H@@DQT)5G^';"9,9+8NHP\9KRUO8?7VGTQ$4-P[[]5 D2UY?3#H(S#:554
M:Y>[=5EUXHJQ)KVR:\5NL[G<(!R^PM!\11M;"]DT2CPC1=5@*C=CT7)G)E*G
MP86KXXV4I1<_\=N1NJR)J@$IAB+GE/T8Y=S+=,:#Y<*%J2&=V9XP32M/-KEV
M?<VWB<#A+FO<LH#'Z@%2/E XVW4V$'<NEIJ$$(J.K20@2O3 B+F/ K-]#\&7
MV1@,\N;^=1&[S.H!T[^OA/8[TVG' >?],@V=F+$0&#<-G>XESS9$3F\CVNYC
MF%?04^G$^I 4#YM(3G&"6D#Z^SK$G>R=S959<.&JA".D]$ @K >LV#[%2<FO
MI;,J+!>N#HQIS95SG"GU:8WF:JU&\E@XD#,;Q,$->D51LB!2K[9ATH.=0FW@
MRJKGA<)P8BM2&9L+>?Y_03'"7@2R#H(YD)QFF!YO516I5!_@6DU<V5B5-="Y
MD#Y_$-%V4<#>&:RD%FA3K0%@K.\/U NVSW4X<.&V0M)'FX]=(*GW+D5\-2N!
M=^&FHGP^]@H$GH19"A*SF1%H6KD-@-WWQS$%.J])@_C.P[ IK%BSGKTWE Z"
M("R$N(\G"9X7BU?GAJXA'%+AT_'T(4G3:P_C)0A#N$]5+%D*M<>7%[4.D)R,
M!,#9-49 &?W*W>HKF]2CL _ V3]AB\:\3Z_3P/CRW.J^1IG3W0OX^B!=,.C<
MH G"(#.(/DA3E*7;&$KLY?Y;>"58JR6@P&JP54,]MT*KP<##&9]T'R[K?KRQ
MJ509$%C=H+89ES4 NF#-N?868>9%)+]B>2-*GJH?S!.<A7\6US>RL#+E-H T
MJW%A+<=A39SF<O;L30CE+U:;WXJ@;&,&$3N%'0I&L'.Z0<5_>4/6S-> H]ZN
MO289<<&HM-Z[WKYY<+9:[5?7[\E+C;S<F@#1JOM'RPE "9T+AB0^SD8[? !F
M]5394FTR8!JL0-SD:F&<YIB<#$<(#I#4:^,QB4)_":M&'F<C<@J,$6MUK=<
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M^)8#D<2U,&SH7\@7R(,"__K_ 5!+ P04    "  K27]6RS@>NSA[  "39P<
M%0   '-R>FXM,C R,C$R,S%?;&%B+GAM;.R]>W/D.)(G^/^9W7? ]:[95)N%
MJBJS9O:F>W=V+5(IU>I6F:&3E-4[5[;61D4@)&XSR&B2H4S5W7WWPX-O B#
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M*\+_ES3D5^*P1%1QP>LP)9R!X=0,1FZYD;26%S8>ZJ18694U"O7Y.V>D]A[
M<X:I,P594WW_G+S^L*.A9!_[H28=^\=?;^ES$%W%>9B_:98>RE( M%%KU[_W
MSTH0601E=>&N)@9J#5U=PM+0SPO@3GY$NQ3H%P%"7$>OWFM3!=!0YO/6^F$A
M3-6I37BI>A3H/>O"J?*L@S9;N>KRH&]2JS7NAVA68S\ON3)MXP+-JITTS]N:
MX[X>;0!)_WUH T)P,#V\KZ*3P,2U?@-"C6S<G11'[7U&]\#>B1DK0'FP<M:
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M*]+A^JI-]J62&PPQ?,%FXI.X/Y.@T5B[QA=00YIFYDPOT&EFPN .QB+6><Q
M7 CZ, B7-C@-P"L9YNW9T#MDBK"!ZOR*%V-L"U'6XVL+3A/N+[&6K^K4IK'7
MEH2Z1:34LN=B@Z>ZJ[5)Z,'NLNA;MG4=9>%FM;I1XMZ\WR-DP#NE<9B?4LIH
M<!U^XS]E@P\OF(0@<\V9=.^%/9>%A?,JBR._JC#!@F2_YP]$^$%->S3U4J8-
M0FG*-=+M-CW1W3W-*#/DA7WB(WVE42(:C+],$6?5]0SV1V,\Y]0*P:Z&3K!9
ML0KA=9&R,K'0;E1'ROK*"&51 "ND<S'ST])\SKM=PWQ:U(=WLW,JP-MW.+U
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M,3ZEM_*5BVR;AF)^/10!:90"Y)!9>U7( J4\4)F5Y^$<E01ND.,8*Z01-C9
M$L4"35UB6$ )B A, QZYG ;;_!1$_&'V];?0%!JA%P&E@%;O/G(X9!IE"2],
M?N7%T: _47M<M)LATX>Z&2]H./^8'()0]2:GC1 RUBO=;=$N!3S"NZ,%OB&^
M#1X;S+>1,^&0^8J_2_ZO-$CU<1.:<E!'P@H-N[TLBA!1!BDD8DY-P<Y?=7W?
M.E9=M..M3DNMF_6-EX$_YE1/OVXM;F@,2J*O VX-UQA,:X%;[(L98\U1+0H,
MQN"O#'HXLUL=]$ V80S9'&G*&!P_BX^("XF;_=6W8YB^;?:WFD=DK26AQADK
M*WJ;_J50@1LAQJ_+24'^D_@#PF@TT9Y(V',0]B1[OH?$[6$_12I[P,8L>ZRU
M1C%@H%F-:S-VT*;705C#8-LH/E7=[,NYZ^!(:!8&'PP';-&-AQV?L)*+)M8Q
MI2SFB.AH4Q=N.?KJR19DZF'0!F$P80$M18J8/U, @+H\Y%&_1N.!(7%5AMDB
MG>G/K#7H@;X)([VC>Q- 8,X:4QIL]O<TB*XR-O+1\IZ2Z6!1*P)YBJC7NW?*
MQHIR3\X+$UFZNK:*=&KHKCS/)T*H5/ZH41[T:'  -[USP '0C =[EN8-H+-_
MU2!G__CK _^:N&A'D^<T.+Z$VR#2'' ,E =9U)@U[KT!U2B"<J Q16&<]8@%
M).I5B 4>ED,N?>Y^5WM@,5 >"KD&C<W(13F<F*(R&G:'0-'"[A BG+&;T>WW
MS\GK#UE^3"5V^4\-W+)__?5RK4)H^1<(+%9:=+OP<GU[<[VY_WRS!H;:"(U
M(-7NKPH\[<Y"VXJH(N/O@C>.Y.SCB7ZFW_+'KS1ZI8/Y#\=7B;QM86FW]69&
M5=^*Y EY8O/?(-RMQ)$6V<1(J[P9#1>&T'C'3?Y(M^+$B?ST;D48RG[R;>O#
M!=0V&R(NB/:*R;S7'K\F,Q"XJLE#WM96SD)75I7?=-7;:V+I/YX#2SN '4O.
M#EK]XR3[YG 4K%-=OO*RL'0>9O+*SH";&IM-[/RGLV%G$[J3^-G$K5<,G8&8
M7O)Q,@UQ[E--,$^\2ER<T1V+DN= M*G\\H=67YB[R[;)*<[I[NK;EA5='_B_
MQG),7Y\OA#-8/(9]S>J(K(_("K%2?\YI_9_)S>%XXJ:%3((IC9IX<!*2G;@Z
M!&.$P_9*-^OC]H8$VH%[4^O!P^NJL ^'[G::R['+DWO  X QG[WWT(* \7*(
MM(9X+8"&\(;.@P"_T\QQ,/!MT/LRR%[8?"S<B70L@?!\&1L!MM%I)X8"_@0*
M.;!:3JDX&:SB]YI,(-^)@LDI"^)=]D=_B-%%F9D778@AT.(OE%\4H+OU*_OM
M,[VG_ 2K&0WVSIHP-E6A4<G*SD&2E;60HAI2U5-$.ZON4F$P<)2YI=!%4%B7
M5M;5L8Z">N)>B4>TLT>QF9#V$,:GZL=B%GG/ WXH@Y0Y79)S5;Y056VG.U7+
M>@BOB(V7LBH/R6IG<(^LY:J"L)H]"M*T1ZT3-0V0!:'FAU,6QFSM=ID<GL)8
MW&K(UD_94%2_60R0<@/Z=]%6%B?-\N374@+U%IA-5W2Q9=,/(#@J\O/=!6G^
M]I@&<<84X,]]F)-$&*4 4636O@NBHC01Q4FC/&JVB)ELP&2 !8BZ!+! $";^
M!Y-'#,CA<T ;Z&A@ 6H6B=GL\) )YG025EB"F54$K(FW].&%TOR6?V%X*-"+
M0,XF]'KW9A*R*!%E25E8,P* 3B,&VKXWA1AH>#3 #/I.DQ R:+3>1@<;C<O$
M!H[9X0QW %0J3+']>D^W-'SER=$&7PK2B\ FN=3IK4@"*7>8Z[+(3P0MI#QP
MYDHC;A1I*HV@F9!HX^&TY2>H'X*,[CZ%$<WR)#8=]=@(0:77&-*]]_:T+'_Q
MQ 7(H9301K<LBV<0$\"2:%CAJ)4_ PY$5JDSENR)"?S\<F0-'>>%(CI"=DM!
M,;"G7;>5B@+EX2H"PZ:J",8@=4^W*+-@-UMQQ+HM"Q(X9XS1/5N790E_SY?N
M_A+F+R])Q,. 'X-O.CKHRX,].J?7N#=)J8J21EG""F.\%C=*[Z\-O?.^WF 4
M&L))^W$W")#8O=TV1Z//Q;7&_LU=&M;6=CG6+P?%+86&O=CEQJ;@D9=!H-(<
M:H(Q1]?K+<8LVN563)G:IA-X\3F)[^G^%._X\JL]$,IE&=WIJ&(E"L4>.SNZ
MK<JD+M)*C)S:XSQ)"TD$FH': \9'![2U* H--2O6@G41T(&;ZHG5=<K\SK,(
MN"R3OSTF=S3=)^GA.DG%*UC9A[='IMC@T?0L]8,>X,W3(OT#LL;[L\U7EAM5
MKZH4B/RN55&]"(V5'U@1_@'D\W'?FP?WP'%&.O4/)F?DDN_>A>MK<>P_2_WG
MX5U:+;*D=T&.._"]@<[4O_0)-:-_Z;-IPN+D,HF86DDJS]#CW2U;]\0973^G
M5*C!]Q4^A.;G.-SJ@%JN.%K6NRW3%!= +BH@50UB(X5\N,%\YL,#*\&6-F.P
MVEKCH '5:K&#W)53CIHN'ZY+;>/=1KSI4'UTX"T?.UFP8RD[2WJG%^22/)#K
MNL59ZTOANO%17P-"L0ON ,P!?^UC,6CPV1V6C>PL)C;04U)VK@W_CV&6I^$3
M3R3P(4P>3D_5@R[5)\W<=Z@ R@&XV-3M@(8L8<*D*=UPPHAN -$Z,&?@C,J6
M1\"!I)5; .B\>?W#0Q[$;.72F\@,S @&Q<"BQ ;U[X7V%!+]J1?JZ ]C"%S$
MF!VNVC%C@*"RBQJ;M4\.BQ#7CJ=8M!QN* \H-UY)<#I9L >;+,.M.>\(5D9Q
M7B=I%=E9L6Z37@5I3'?WR5L0\=0HFWB]?0GIJ_SKOI+01D//5CT4]>9KCVX'
MEC435C6I2C:F)IN4R.I)53_9L+E+_07^\%S]#03. [0.WQ^O(X:#JG78KZEL
MG;1J';X+U&B=9%]+XD5[S\RHEI?RD4Y6[NV,@+. 9VU9\W"DVW ?TM:I2+R[
MI\^GB%?^YN15QU>-X%$GM(/1FW9<9%5S^V0N9HZUJMP;/[I$FXCL9VU\9U6;
M[!IMPO?0T[I-_/*>4UFC\YQ>4,;5:_H)$YA9Z+R33M_GF+-.*<]I^CCKH']^
M,\,9)X+G,N^#ZG'XU[D?MB]T=XHH?SA3F?\C^_#6^@N/XS6$IHVL#S 4;:S%
MO7V.HA[Y[JLF"TRV(D]OG3__*FI$O;L^J=>[\5.3NAPSO=)M&-.;G!Y&Y!AK
MB.(G66K:X9!GB8L1(8>*1=O.L<Q7U.L9&#>:)]N_W639B4UU3VD8/]_1-$QV
MOP01?RCMJ_B+"6:6\I!NTM*B_O8ODR-2D$A)(D571 BO"!.7!9#2=(\U[9X>
MF3XO/ <P\_E? QXAR@9Z-LZG]5_0K@".@F+/E[O@<%*LZ^&0Q.)KXHF:NZ+Y
MC+=5!X3@HEG-NO>C 7EY(HDA'OPA9K0 +'!&VI )&_"Q;H^A3M I%( LHTP7
M!!+<L%>[Q9;/>'@)TN$Q;T 8>L ;LD4]VC6DND.>E$0<YYPMXG]H#&C,ADQI
M _B89H4SY8!F!3(0PO +(YM]XV[)P#U237E 6N@T-L2\O]+F[2*Q*=O\M[@Z
M0_*7("9M(?SLE\;NZ4++V#<PJ0OK;V?K>/<YB8/Z-\T%^'!&0]>:(!,=.ENY
M!#8]2+$YLKM[B0C']?4\L_URCL-_%>;\B](76\SY]:((,W^#'<9I6RE':L%B
MKC#['.&5ID^)_3K P:)ZC2^RT1Z5^F.L X;0I5L-@$#+=4W@#K'.\FQ;0TQV
M$?SQ0L,<X5K%1L+FE&=Y()Z!-@Q)PZ* 8Y"%'2;:KXJ!I=@ :PCBK S&FR,A
M)BXO\B?J]D&8DE<NC3DPVJ*L.Q+:0@R$*N7!X69?;<)Q[WJ99,;G&LUB@!09
MT%][3IKL26<\$2+0P^%(,X8\+R8M;!#5I80-G&"VEOCB7+<=K"H$N574U$V]
M@7*WR,:N)8:-^K41RP8EL;V#M$-E4K3R!\Q#;)M*LVF0W%=#W9+JX;.W]=0#
M)PQQ GX4+]C[^<07<.P?8J-+'NO<Q(TEGHE:3M5 DL_-OAX] QFR4<S+9!7B
M%Z*2\N0RC$V/^0"Q8Z*E[$/B/<24RD2:S=&I)!,JA48@M4>R$3"%IN%'6EWP
MW>R=V:>7QB&=P9H!KC4D^6]]XI>#41TK6B/3-DHR?OJ3<<-S/QX#<P"B@5Q#
M*)P24UWXI<U^O=N%O-(@TAX>#DJ Q4:;M.XM=AIQ(T%5'/%@S;+AVZ&\,*UN
M%ZZ[2.O/ &(QWV,35*&,.Z('Q:'A/6R/MK6%:#U9YZU?BZ,<C,]EF0BV\)/+
MEOA3$AL2?$XLG]Q5U3)7V6ES70YB*^LC90.CR&P?O&DBY?5% 8^Q%'HJ]@FJ
M4CQA-R^&$ZDVD[*0!U(Z''0/H!8%@>V!TPSM"[VDNDSB+-Q1F6&QS#^_<=_:
ML*D'9YEE9>' @JM5!RDKX3>0?%I[3;(TDY9N6Y:F#4O]6X798]>P'K,'[H0!
M[>?3\S.-7VAX>*#;4QKRE 2WT=:<BVA "&J0&]*]"ZBZ/*D%5N3V]A(_+9!5
M/[2&%KA.L!ID%NZ,"1"_#>-M$K&1+_V;&=:*@E!05NG8;;&B#+_G]3=\P&I;
MM07299O4"IBS-.V4)8/<,.2.72QR/B?Y!QHE7]\Q.\H%ST#&=X<:P!88+E;U
MIIK%'JH8X>4> I,GH@+":VAL*: #W;W_VBL G,ZS6QC,T8EB(URNP6/6B4_M
M3A3+[]E6WSI]?YQ,)44-Z%126>5&I1^_9]UP/ ,N:3O0CDO+]MXT+KGTHII+
M52_*_:T9][+*T+AW0T^.]$LB!&2_T[=?(Q#S'>X#(8[:LA5\T?>2O/3OIR 2
M%XZOOFTIW67DW[_[9Z^&0RUJ=)'72T#&-=#:MC/>+4"N]];D>H](KO=6+?3>
M$W+9:6M#+K_FFEK4Z,BU!&1<R67;&>_G(M>'$^M4FF6L^J<P%FK>Q&$>!M%?
MBHP-,C1(1SE[>2@B.EC4;>-2E#1D22%,2NDBY@V!M!,L:]]'*"T)9?1>D)%C
MD(KD6D]E"VSK;Z!1V!6;+6*C -.*[D  G<M#K%EM![HK:]<Y@EXQ*+[W]>NV
M6E&B:B $Z@XKJ69H4*CN*T4UX&@Q<4ED6!'.'B%EN\^WR\(Z<+,OOKQ)[\/G
ME]P\H!I%X/913'KWE]RL-,]"6I3G*>^%!-Y0Z6C .8Z.%MCJ[/C  ,MRB\<=
M8'46,9%$3  L'#?430ZN*'T)3\_,%<D:]R _!3D_@WO[&.2FVUCV50"&5#C8
MU>VD:OK!LT1(X>;5W14IY0FO ">.8H)YK;P$E:U7WXYA$4:AL@HR9L(5DMUP
M"5<\SCTLWM,=/8B0>;'#4/TY*_ZNG7F.K0UU,+6QUGZ<K6LKMF?J0EE5"F/>
M.YOM/0OY5M/=Z2D*MZ6E?HW$UG >'J1AL3Q^_,; ]%PS]:+FSTDN@Z?#9,>^
MFJ2/2:V'9D!WE(=R.PX6:89R(F6+C#M$2)/'I-DS\$/Y7+8UX86;D<<5>BV'
M@8([*Q<QH8]Z?3,SR^OZ+Y-87F_X%,;AX72H;Z$_;&D<L&]OXB'..]<&[ '<
MK;7@3%45*>HBC4P.I*R.L/KPW(-GAD,[E)$H5[D73(B[.!N/>AS62SU^36;T
M4J(VC[V4M':^KF/UG8>7 C#<9R_50/E4+S4WQ)?R4L8>=ZP(/I^A:I5X]8VF
MV["XIMI?([XS;)F.K \R\^%(B[4[WB6WDV+!NR)E;067D\:J.%ELI\<RE=:\
MYJMV!3K6*_<$WB&EB9S+>.5I%"T-[]S11LTD.87?O?224\B-Y\Z&GG@S"6$[
M)MUC;5KOHWN-#9%@9AM4+L2#%^6&D63%#OBWX91JW%J\##<DB$V%6\.K< 8Z
MW.I?A4/DQ+ Q2EX8C$$G1P]C5@3I 6SN0TOQRW ?;I7S?N,!45<4]3BR9X<]
M;-JBOIPQ#AND.,\?L 7W0%$-M>'3PP5Q-OZHT!)O*I_;%O4K]&=DN(\W(3[N
M83W^Q?%8Q^Y<\VS\OV!GX[>!DTNH#FS:UNHQ8['A](&_&=9,?K3F>A:/YWQX
MJ\L4>=/7;'6[LW\C>_(W4-[-GMXRIK>TA>2%$"6MM%/-#_!7M9L%BX\0\17<
M-1U(.VV*=B)#[?3AK570JIU \R+-S3?]Z^0SD0WF,1#6[9^# QUX'K!=#/*Q
MC[9^O?2+[%^$_UWSIA\,$VV51'VC0]'1O3<Y%+T,BD+Y]IT%#LN""$BL=#1@
M4?.&'RP:AQ7U 8_M+M<ALMW?$[8B'K\FCR_)*6,SOL>OS.V^;6(J'T%C7S)?
MD;<2A=J*L+.CV_-,BI1B1,KQX MR]?<3OUUPPWHN%J]0%F\(<J @7K4?9R3K
M]'<V!H#M23A@KK4G 0TXJSV)A8&G[;%Y.'\=[G-*XTKA@90S-I((C-=;H6KW
MO&SWO10K7V3B+8V:IF:41>]_?/=/30M\8O< NG3DAH"6*[>7AM@$.E\=CE'R
M1FGK[=+AX7M0#(K(P_IWF[B4Z#[MBST^3["D\XXA1PH:@RT!U:(O))JLN#MO
M7\"?#;3T'WQ&7ED:<#&HUG: MSA,G:(RY@+1 (CN*M& !A#LRKT[]H&!7;1.
M.4"\=C7L9?$0V[2\@&8C#;+GE<W9[7-E6\(]&#MJ>[?6.=Y9;WDM\SGH1VSG
M;R\3A#7[;Z#G#0NB1/D [$(0 :'4+S3+P_AYP'VV2@$"N*U=%W?%7SWPFXI6
M[")%T820'3SH[#KEX#M9ZUZJ;O; MRA;4]/5L^V<\_KHSKS&;I>!6E!W-.OV
MW*OX,SF(OZ,M,E7-UUI1+M9V5LO'L6TX 5!?XE<+2'5+08&JIUVW24ZQ'\!2
M-V,+6@NVH16XIK2E'U-ZW?SIUB)^?X[*?9JNV[1%+Y[((M9J(-3J%ON^P'(-
M,Q!<-1!;96@8KQ8\UAQR7MY8$PC.F3P-J_O45;?.B"=3MPSYE'F^ >U:9FJ9
MV3W,JIF14)W7"-#/+-1*#1./:*F;%B.*TG',R1*_)R/B?XIEG]3;E!%@WL^<
MPP1%W3X+.!(Y,)<[!NB^9+FV,IMX%K,/ VEFFX<8&#/I5F6XW[=JU:VA527A
M[DPJM.Q?66.%R&N!)O7(M"QAYM45\+JC#@.=VXV+ L#R,N/(QEW@,:S'-. 7
MOCZ&V38-C\;[QV8AA">RE+H;K^T5$J0A@OMNEHL),C@E+TS84:T)&,]CZ7&D
M>REK81"Y/IHU.YC\GB%OA+[-.Y^?3P.11@M\ZQSFRH:66F#"7'QMU7[U0'[Q
MS";.+@TG")5( 9(L>#-<#J0/>9#F/A@N_\#OX!9"S7XG'^AS&,?BIX");>=/
M@RN;XRK>^=\85T6;J%OB+%980TYWMF76D,=U'ILRNOW^.7G]84=#.2RQ'^K1
MB/WCKU=Q'N9O\C.;?1F'J#H-,I8&&!',VO;V"45)4F.S*@SKCMVTKM6E92GR
M0J-=,8DL/"T&B2RP4M+  BCG-LF2R[V;>)M25O@CE?_]"^4)..AN_4K3X)FV
M\A7"3,C&Z'6>D[=1/0 VT2M>R2C5(]^5"OYQ14H=2:%D)XWIV<\.9^F9JI&"
MHI':*4]_)].&\6YDP2G&>!\"X\7YR">UYO&]5]^XM4;WJA& ]'LZG34+J)1\
MB<.\\"WR4EPA@^0=;/47J!';-1%CK%)C4*H:L=+CD!$H,"E5ZXVLR^ 8LF84
MK,WN:4;35[J[3M+K4WY**7\>DZ^?#+@?41=DXM41EIJV\5:DJ$8.UADI*R)[
M1B=9%2GK0DK/.H/)A7%IT[B]-"[4& >:KG4L?GL97,>"]RQ6$N7HF=T4X1B/
M";/P)L[3,,["K<A#N.""P>[S9[0NL&S/):?_E0HD+(.M5J320)U:\CRF]B,;
MM[;]E9?@>QCEQG YES_/^(H1')Y[MNY"8+\C1 N#Y&6-SAKC9Y[7E+\*R).S
M6OE$" W.(;K4N567](Q2"\6^A]!$O!IJ2+\+Z"-16KJWT?$L6F7'6V7/6T5X
MSQ\R,?M!]Y=P%)\M\G4<O_V>1LHD8S=QEJ<B."+;Y"\T?7P)XI:UK='!VHDB
M*'0.4\VI;;Y$>'^9:Z[2B0BE2,ZTZCK@YKS4"W?K0R=<5QZ6ST_O']89D??V
MT#TMFEN8;:XZBT^ S=1$TU?^2J+2XL])<:53&)<)=9M_OTPR_K[UO]+\GFZ3
MYSC\C9KN.RWX38RL40NTG,EA5HZPAN&*5-\I_2.OF+];3]XH?Q"UK'M%UH?D
M%.?(6:L FNQ+G%9_+D(&Q/R(;)L#C@<;]8LS4)M@:RGZG;?CDB[Y.DF+7_%R
MIJM7T(K\'ER<KHT7]'M%6 (_-&A\]'?F!VW;M5P+7I0K;_S[HSA\!O.-1C)/
MN ?#ZN79MED?;O8\BI\/[HPIK.6CCW1WVHK9IL)[N0A#W8NQM:7W!$(EQU<R
MNT*2'*4HV56R:+=,G'JI==L$OHNL;IV =I7?&U(B+6^RJU[B^UC?:EK'NT>:
M+I-/QNJSY["Y9-=^"VPAB=BBYI=7I/%M\<Z?^/J9[1.-:\^FY8R9AT8%C>/+
ML]P:<B#H;!M #NSTV[NU3UWYBV:+7[)3?.L<_)BAI0""+_CW%KMD!W;%RJ;Q
M^E>L&I?MA->F=2UGZ;"&.+=02$6?<&?AFAKAV_B74'Z/UTU\N5@"?7D$YY[M
MV,LBZD9IMV#O,B[Y?\B_)S\0=83%^0P;0,WWN[R^BWSCQI^[-1-M$O$T55#B
MSVF2+;+L-WWMC(87=6LM.93(+S8C0<17SVQQ[]1\_9FRD#O3"(]AGLWMI@PD
M.PN7=)VD>QKRFR*5$0NZ).77SL@EJ5MK29?4^&+ME^9S2'^2[1;3YX!Q?FF7
M9-=\M4LJ+T04<N?ME Q,F]LI&6AV%DZISL8+X9247SLCIZ1NK67W$ZLOGK]3
MLFN^_CSIDB_PHNB\G9*!:?/O(&IIYH=3TKZ9IISJ+;6/.*<6/CFQ65MWC'/+
MQJ\"SS,ES:(M/K0I=@ZKR/D)/]\[C:/9?AZ^5#%#Q7*HSJJ<DU=U;^=%7:MR
M-?M[]:_3VW[(R9['NG@A7S"[KQWI",[#X2IFWU@.UUF5<W*X[NV\J,-5KM1_
MKPYW>ML/.=SS6/,OY MF=[@C'8$?#M<^7@HIXLA: Y_<ZVRM"A9.B1-Q!!MG
M.7? S+^9F$R,P!E'WI]%_BM],- ]Y:_=L]]?)G&>!MO\%$0\=/[]D&>%UN:,
M\F*-:VV\&,]**])02]S+.<]L6?.TOV4SW89[2KZ[B<F_TB#-_HCN>'&\Q-SI
MM":X"$2'+'Z;K4_Y2Y+R"\E?XAU-.VF?L]8H<L_;HS'B%.8OYJ01-$1WW!B]
MXIQD07YBU9WJ"4V&9LSGX;]]Z 8'G[YJ3J>]=O!H7L?.Z:.Y'+_W.0;3EU49
M,):[#.JNPSGL=8QH6;SDB94N9WRQ=(8&K\/#I+L0N1)7Y%0UCOE>T$R-M.P]
MM-EP^62)RZ<Y<:FXV88^%$+Z7;B\E1JG^WL9SB9G84=7[_<U""+E;W?W0T@)
MWOT:&B;E@#<V7#'D?BF3_?T>7A7VL5U_!S><%W#V",/KO\UD_7X.O\XZ_B[&
M8/>>\2G+O_</KGC:9T[#QB__9IX+\'"H&.F5?E?CA0?#P>_2VWOES,_N[NGT
MQM;L./[;\;?8[A346WYDGWQEAKS26K_[,/O;^EMH2B%D%@/T2@/Z]S/-EL4;
MKH#\RDO_#TQLVW1#%X\V?0",H?+$\9%][6/"CR&M,*020\&04G\#ALKRY%=9
MVA,,Z;M!CR%]'\#,VNIS[T]TZ%BW7Q9R'J30M N18K8A2Y%?9;D>.(!6?!;Z
MBC*%NJA#O X%O;%8!P&_EQC5BFB=9:=#=5F%;MGP_TL2L6HBAIM[-D-<8G7A
M\O5S6%@XM>8":XK&GD1# W$W3NA :B4(U^+,=GPF-6_5!J]5R;-<.[@S=K9E
M@SM=S\_Y\?GJ=4K9#)9AF:V"(%V?^MOGZO@T+0GH]K@&A*M 2AU^+U[/LFUY
ML8L];X!48??9NCL31Q=U=B:"GI^K*UWWQ_ UW-%XAS'+:W_[7%V=IB4Q9GBE
M"K\73V?9M)79;R&-SG-3V)6B(-,Z%3_]OD=KLH9?.C ]7KOD1]$O5\W4=AA.
MS;<+4@LU964O4^U O@MC\N;I1:8Y>3C;A51K$H(XL)MXFQSH0\X<)]?P-I%/
MWPT<8QFE %V(6?LN<&5I4A4G97G-018,=V>R 9-]%B#JTL<"09CX'SR$&Y##
MYX#V&,[  LUA'"H/W.WPD GFPT0K+(&PX9YF;"C?OJSCW4?Z2J/DR!7BHU.<
MT<'S12MI0&;86=/;C2JD1 :DAAPI!)&/)9<Q"I,S#J#K,L<!<2#\^9G&- TB
MILYZ=PCC,,M3$21@RR!+>4 .V5K4!5PA)_#6EO2$1\L9ALDE)P!VV>2$/A ^
MK2-1+]VI=XT*Q0R$LJT D%'6-CFG?-'@#X9/H\UJ#4V[VHMCTL@-=UT>N8$.
MA$A7AV.4O%'Z@5%\'^89X[A:.0.7'.H I).+9;V=K$*6E,("@[JM0AQ>3;'O
M,<G92)7QF*\B=\.VN?5)\<<K9UQVN>8,2A"Z;8Z4#YWQ\VV299=!FK[MDY1O
M_F6///^0@62#DH#4&K:B"[A*@G 1TI(AOPHII.D>C"V0U+'$6)<PE@ #H<EC
M\$U>W1C8;NZ4 Z1 5\.>APV^%3>>4/>0[=7$1*RRN[OX5/8U+!H'-W][)3$0
MJ=T8;6(2=4?7154O<&G>IM7TN@TVL_2W6 #NW?N?W@G0\=_\]2;>L4E+'.:4
MU<VS06HWB,S% > WH&]_<[XL27@?\[)(^ST+*@Z!41N<E$ % \DNV8I;<\H5
MXRQM_GVSK:&\_V5*=V'>G!,-STMT,K C@E9SE<.5A5L36NS)RU3]D4</,W 4
MXX@9-7AX_QP<AN^?#DIB8[]EA26"5H1+X4^8YK3&.U;TX67%C3ZV0 _#K<^]
M$8^XAP]^M9[?B]/L^?7'.,&V.ZQ&.$?[$I^R4Q!MTIMXG]*_G]C<[2:GAX'I
MC5$*$.1F[;N(*4J3)"5U><(%5OQW'Y+\!76Z,[LUF,BW %:7!A:HPN3$X/1G
M0 Z?%]K)@A4S4"= "UCD(3O,4R K?"&?8MV&,>5*F48/*VDO3K.:UKB= G%)
M 3>LP038*#_.MWKHLS_CZD%OPNYM>ZUR77RA?D-79/CFFUFZ_5R'"J!V>%UL
M&EJ+DE*\\>@U$16(+3Z$;>"IUFVE=5MA74486EN7">O>%-:![14[H[*U>XP#
M2:O]9,#.@]]]_DCW-&4*,D7764;S3+D1DI5+2,.PZUP3:,(X5RO[.>1D#6([
M0-:QTFT-\-0:14TX@_-T<W6QD068,]RT>:,@V\^D-PJO$\9M<=%FR)OHQFQ+
M8:CQVM:6?N*ZH#AM&QJQ$8;IL4:=RQ#M!,#6\ R//JNA>1H*<XMN@Q^1+X-C
MF <1?V"R3/%YF63Y^I"D>?B;4&HPG[E#'8"CL(MEW1YKR-9)7+GTBC3E9\\"
M[C+LSF5?$1[-IA%!T[0C>KR2,S2[8ZXS+B>,MKWQO?Q%<0VBH8OZ-A_7++N)
MF8<(,OJ1RO_JAN>EO@8UGB_66A83:5+]KKRAUV1#-15==VZ0BB^2\I.D_";"
MO &^\?C0%12KD%WYR\)OK-AH5C=?JIW)B^8+8W6K@<U)EJ5I:Q)S!ARUFO5@
MPJV'MC%@8W^2/\#/KF3* ]9R5]^"0QC+? <TVZ;A<> 6VJ D>.H-DQ6:I!7<
MZ39D5J0AA9E]P\64+\RII'D0QAQ/W"B.SF.2A8,6P2?D& 2:.B7'(,J0C^%&
MG;YY<NCF>"SEV_&:0OW/-"=)94+$3=B:3/#C,,W]#&V&1<$]#>/LE/+W2N]I
MSD8FG@3M+HG"[1M;A)SBG/V6>1:J6ER[5@ U=7>QJ;_/6\F26IA(:2+%22F/
M,+.>W39+T\"FO\Z ;,UH<=!H-4E%027T%%+,@(L;X'93Q[8$SI2QH[5QJBCG
M^-\5I7NI-B>K_4K3I\1IEFBG/9\3EBN4[YXTVB/-!U6H,<P#59 ! 3I/%BJ3
M(T91\I6SL;ORO'SA26!N8DE) P/<JP*DQ@@[NZBKJB!5'2O2W^I:U=M5WY7K
M[C^N"H^&,].<P7@^_WRM&B HZZF6^ZA[UF-!W"7D6 0CWB$<(J51"OLNE19M
MVIM'F"QR-T%U\.C=O2DS)2SP SLA6Y_RER0-\S>K+-)] 8SI6%=GPVRL*NI!
MVNB1FGLQ U/"1#L!4V($"=>6V:%5(JC8'LJEW$&W!^F@1VOO%\)M\C_KT0+T
MD&R0TW6\X]FGH__CE(;9+MSRB9;%L[(#DJ"/S Y9H8Y!X@=E0H8TA=!?H 4Q
M!I(:EBCK/UMK!3&84&W&U2P/MY=\@I6^#=)#4QXR[%JC<>^<N2C7'0=02;"0
M\J"1TB;$].*A37"!OHMP&P9/_+74D&;KITP$BIF0/B"(<]- ;8,Q'JHALB(_
MI_PD[]=2%HL&HPWB6[!1+>+)E0$#L@PW! RP0J2&,R4\H((3!3[3&?=S_B35
MCNDS3Y$M4A2/ [_"!,G5W=E WPWR\T;C-BJ^#Y]?\LW^2T9E()ONU-U6&B%:
MUFR-+=2)D"6;/6'215CL4LC7@7Z:9:+(1;*_.#$# J4!&#&E%F#3Q8A"(<TU
MYG,DXCH^B:0"<<F>U!V&>OVT8=9=RL.9\K<[9DG.5E]7?S^%(H[4>< SU(0^
M$IJLM!\BRUK83[P>L0:O:H)V(?,9?!U^8];B^9&) +4;5P?1B<C!3?YBWETP
M2:%SJ]3>GD="PB^^Z(Q0JHI/BA9B[ C0@@M.OH.&-FRU80=XM21F/H.>%5;Y
M"SQ:7EF:(1^6B6G>7FMY-4Z8<#68A$ -*AQJB$6MV_:;4A"3&%T;K'CAW<Z;
MHRV>4D*)IT%&*,$TY[W@6QZC9MY5LQ5$NZVKL,'FXJT0:\Z#?+@\:V&+U!MY
MA\T-3>:;J(M":=RE4A=(->Z'1MVN\2.G5>>*++\7F[Y2_FK;>KM-3T%DN9GN
M5"%RABLKFZT3774OZ<LD5[Q"^21M4:4G8^58\XL_"9/20L*K0=0)RS8YK^R!
M/.>@6SZ?6%WOD9&D]H.OO@*T0=A@DQ7+JE=!T^JVFB;=&O11@+-]]J;@C=1#
M$#2/V"#X&S=RP^!P3F_0R%AQPZR-G\.GR/Y(T*(.-)]@MLQFCM[,A5-7,?L9
MX?CYNIN)37/"VAR1(,0?WV !2+-[@$+C. \Q$I6-:?Y6W8T>G"/J)C;--YG9
MY*9\MUG]:#//D#-M03#B<WXM%\:TUX3%1+,V,?LN/[C2OHLN,H!YN]Z8H_T>
M-"^H>[XB&4VU$>N5T3S#\4L30QL&*\'T(:,#&DK/ !3+,(GH9Q[$8(G"02)Z
M%[H@U7*(6F@)8-+&*E:AI,C,80J3J' .\0D*6 QBVX.H!''HY7SDZL%1J],1
MZ_PX'A5UH%-<$=3MH2]O0<7N-!791X])*^A4"ZHW=\G<IW;QWF4CG&:DS^D)
M1X!S>/A8,H&A:2NG6!&-VC*M97W8*FU8XKI%6HIZMC-JL.B!RFO2[_[W?VQM
MJQ7IR[S<%.U"S7HS=!&<3=X$M<&;9O.S?*S!@SW/?HHJEP%5)8TYD"JML1I
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MKHEV/43[&[!VP9 ^DK.SG?XF#T"/\G@$4$L#!!0    ( "M)?U9-X=L_;UD
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M[<B\("+^G9=$L,E,*QS<DG$P"L11'K+&0#=RM%8]55!%9BK'SYJ-N-8&'#A
M/TS7D2X/"2>51=]D96=008-@ N#'\2Q$-80<#= WA^UJ &;B[G-!\)1DP0A
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M\X1NMXO1%&4G>B/0TS+96;RZJG4Q/#FUQ4"J/F.5<3D>"L !NZQ'T4@1]OL
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M5P.>V\Y YI+7S[,T\R(?@.I^A2M-@1YL=Y"6]-7PF'+LO9/D+397BFM[\.F
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MDK_]'S+*7N--Z)I8L/H] 2O(_H_:TJX+%M47QE&!98SB:_R\'' %E%CD\I:
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M1_).0O7/B*"#X9<39--GUU\2*1ENAU(QY\<^YEJ?%6X_,.%LT2(% 6LL+&+
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M#RI!R#0:(?!)LKS1N2P]WH\J7QFU*&UY/Z#QMA@[=@3)$;L^.(Y&N%*SI!(
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M6U+^=\>"N55%LIN53']<P\N+G^$T[9++F3;.N&GH5J5D@SKV[SXHBT)]9C8
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M;VH=@" .("[Z"_<"91T6W'9,2E;I^M\OH/< [,M\%5&"[[:?[VXV#^,%(=<
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M59Q/V3+#: O(L2NV:0M8$YSC651HSISCHR/D?;C!N:^$%34W2W4!>*2FP,?
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M,V1P;W-A;2YH=&U02P$"% ,4    "  K27]64"6SXI]?   HB   $0
M        @ ':G00 9S0Y,3DS,V<P-&$P-"YJ<&=02P$"% ,4    "  K27]6
MPG13UR<? 0!N< $ $0              @ &H_00 9S0Y,3DS,V<Q,6$P,BYJ
M<&=02P$"% ,4    "  K27]6("/C^SJ\   7"0$ $0              @ '^
M' 8 9S0Y,3DS,V<V-F$V-BYJ<&=02P$"% ,4    "  K27]6 P2@SAI8   %
MH0  $0              @ %GV08 9S0Y,3DS,V<V-F(V-BYJ<&=02P$"% ,4
M    "  K27]67TYU]#C5 0"9*@( $0              @ &P,0< 9S0Y,3DS
M,V<X,6$X,2YJ<&=02P$"% ,4    "  K27]6C+%JO^1= 0!<K0$ $0
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M,V<X-V$X-RYJ<&=02P$"% ,4    "  K27]6S!K$U?GS  !O2 $ $0
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M,V<Y,6$P.2YJ<&=02P$"% ,4    "  K27]6!G^ 'DE- @ SG ( $0
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M,V<Y-&$P.2YJ<&=02P$"% ,4    "  K27]6-6I@+U7> 0!O- ( $0
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M,#(R,3(S,2YX<V102P$"% ,4    "  K27]6"5'4N),-  "GPP  %0
M        @ %(NR, <W)Z;BTR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @
M*TE_5C7-G;27/@  E><# !4              ( !#LDC '-R>FXM,C R,C$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( "M)?U;+.!Z[.'L  )-G!P 5
M      "  =@') !S<GIN+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  K
M27]63>';/V]9  "R^ 4 %0              @ %#@R0 <W)Z;BTR,#(R,3(S
?,5]P<F4N>&UL4$L%!@     ? !\ L0<  .7<)     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
